enrichment O

Relevance O
Nursing O
scholars O
and O
other O
health O
scientists O
who O
utilize O
epigenetic O
age O
acceleration O
to O
assess O
health O
risks O
may O
need O
to O
consider O
including O
psychosocial O
stressors O
in O
their O
studies O
as O
covariates O

The O
systematic O
review O
will O
evaluate O
characteristics O
of O
reported O
studies O
such O
as O
the O
source O
of O
DNA B-Gene
used O
, O
methods O
of O
quantifying O
DNA B-Gene
methylation O
and O
the O
participants O
' O
demographics O
( O
age O
, O
gender O
, O
race O
and O
adiposity O
) O

We O
here O
present O
epialleleR O
, O
a O
computational O
framework O
for O
sensitive O
detection O
, O
quantification O
, O
and O
visualization O
of O
mosaic O
epimutations O
in O
methylation O
sequencing O
data O

, O
those O
leveraging O
synthetic O
and O
chemical B-Chemical
biology O
and O
optogenetics O
) O
for O
examining O
precisely O
how O
epigenetic O
modifications O
at O
specific O
genomic O
sites O
affect O
disease B-Disease
processes O

1237 O
 O
Germline O
or O
somatic O
variation O
in O
the O
family O
of O
KMT2 B-Gene
lysine O
methyltransferases O
have O
been O
associated O
with O
a O
variety O
of O
congenital B-Disease
disorders I-Disease
and O
cancers B-Disease

Cellular O
reprogramming O
allows O
transitions O
of O
a O
mature O
cell O
between O
phenotypes O
, O
or O
identities O
, O
and O
represents O
one O
key O
driver O
of O
tumoral B-Disease
heterogeneity I-Disease

Studies O
in O
twins O
have O
demonstrated O
that O
genetics O
do O
not O
explain O
the O
totality O
of O
the O
pathogenesis O
of O
rheumatic B-Disease
diseases I-Disease

347 O
Purpose O
of O
review O
 O

As O
genomic O
studies O
have O
recently O
played O
a O
significant O
role O
in O
elucidating O
AD B-Disease
pathophysiology O
, O
a O
systematic O
review O
of O
findings O
from O
genome-wide O
linkage O
( O
GWL O
) O
, O
genome-wide O
association O
( O
GWA O
) O
, O
genome-wide O
expression O
( O
GWE O
) O
, O
and O
epigenome-wide O
association O

1122 O
 O
Primary B-Disease
Biliary I-Disease
Cholangitis I-Disease
( O
PBC B-Disease
) O
is O
a O
rare O
autoimmune O
disease O
of O
the O
liver O
, O
affecting O
mostly O
females O

In O
this O
study O
we O
performed O
an O
epigenome-wide O
association O
study O
(EWAS) O
to O
assess O
the O
association O
between O
levels O
of O
with O
genome-wide O
profiles O
in O
migrants O

Here O
we O
present O
a O
detailed O
protocol O
for O
using O
ME-Class2 O
to O
analyze O
genome-wide O
methylation O
( O
5mC B-Chemical
and O
/ O
or O
5hmC B-Chemical
) O
and O
expression O
data O

This O
results O
in O
the O
unregulated O
expression O
of O
critical O
viral B-Species
genes O
capable O
of O
redirecting O
cellular O
gene B-Gene
expression O

The O
accurate O
recognition O
of O
key O
epigenetic O
mechanisms O
in O
hemostasis B-Disease
would O
then O
contribute O
to O
identify O
new O
putative O
therapeutic O
targets O
, O
and O
develop O
innovative O
agents O
that O
could O
be O
helpful O
for O
preventing O
or O
managing O
a O
vast O
array O
of O
hemostasis B-Disease
disturbances O

Therefore O
, O
this O
review O
emphasizes O
on O
recent O
advances O
in O
epigenetic O
landscapes O
that O
could O
be O
targeted/explored O
using O
novel O
approaches O
as O
personalized O
treatment O
modalities O
for O
cancer B-Disease
containment O

B O
and O
T B-Gene
lymphocyte O
abnormalities O
, O
dysregulation O
of O
apoptosis O
, O
defects O
in O
the O
clearance O
of O
apoptotic O
materials O
, O
and O
various O
genetic O
and O
epigenetic O
factors O
are O
believed O
to O
contribute O
to O
the O
initiation O
and O
development O
of O
SLE B-Disease


564 O
Recent O
studies O
have O
identified O
both O
heritable O
DNA B-Chemical
methylation I-Chemical
effects O
and O
differential O
methylation O
in O
disease-discordant B-Disease
identical I-Disease
twins I-Disease

We O
hope O
this O
review O
will O
trigger O
a O
discussion O
about O
epigenetic O
toxicity O
that O
will O
lead O
to O
encouraging O
research O
advancements O

By O
combining O
data O
from O
the O
BLUEPRINT B-Gene
Epigenome I-Gene
Project I-Gene
with O
a O
novel O
analytical O
approach O
, O
these O
authors O
were O
able O
to O
measure O
the O
degree O
of O
transcriptional O
and O
epigenetic O
variability O
across O
a O
wide O
panel O
of O
samples O
and O
types O
of O
immune O
cell O

The O
article O
concludes O
by O
formulating O
the O
argument O
that O
this O
'epigenetic O
turn' O
in O
life O
sciences O
has O
some O
important O
implication O
for O
renewing O
epistemological O
basis O
of O
social O
sciences O

962 O
The O
transforming O
growth O
factor O
beta O
(TGF-Î²) O
family O
of O
ligands O
plays O
major O
roles O
in O
embryonic O
development O
, O
tissue O
homeostasis O
, O
adult O
immunity O
, O
and O
wound O
repair O

Ternary O
classification O
using O
only O
DNAm B-Gene
far O
exceeds O
the O
classification O
accuracy O
of O
simply O
assigning O
all O
classes O
as O
the O
most O
prevalent O
class O
( O
63 O

Recognizing O
the O
unmet O
need O
to O
establish O
novel O
therapeutic O
approaches O
for O
PD B-Disease
, O
especially O
those O
targeting O
the O
regulation O
of O
SNCA B-Gene
expression O
, O
we O
recently O
developed O
a O
CRISPR/dCas9-DNA-methylation-based B-Chemical
system O
to O
epigenetically O
modulate O
SNCA B-Gene
transcription O
by O
enriching O
methylation O
levels O

In O
the O
light O
of O
the O
fact O
that O
the O
epigenome O
is O
not O
only O
variable O
between O
individuals O
, O
but O
that O
it O
also O
varies O
between O
different O
tissues O
of O
the O
same O
individual O
and O
with O
the O
age O
of O
the O
individual O
, O
it O
is O
still O
a O
long O
journey O
to O
transit O
from O
the O
correlation O

edu O

852 O
IgA B-Chemical
nephropathy B-Disease
is O
the O
most O
common O
primary O
glomerulonephritis B-Disease
worldwide O

Epigenetics O
modify O
the O
expression O
of O
genes O
in O
the O
brain O
and O
body O
in O
response O
to O
circulating O
hormones O
and O
other O
mediators O
, O
which O
are O
activated O
to O
facilitate O
survival O
responses O
through O
a O
process O
called O
allostasis O

This O
review O
paper O
highlights O
major O
research O
publications O
that O
enhance O
our O
current O
understanding O
of O
the O
role O
of O
genetics O
, O
genomics O
, O
and O
epigenetics O
in O
osteoarthritis B-Disease

computational-epigenetics O

1412 O
Single-cell O
chromatin O
accessibility O
has O
emerged O
as O
a O
powerful O
means O
of O
understanding O
the O
epigenetic O
landscape O
of O
diverse O
tissues O
and O
cell O
types O
, O
but O
profiling O
cells O
from O
many O
independent O
specimens O
is O
challenging O
and O
costly O

227 O
The O
number O
of O
epigenetic O
studies O
is O
exponentially O
increasing O

121 O
The O
burgeoning O
field O
of O
epigenetics O
is O
making O
a O
significant O
impact O
on O
our O
understanding O
of O
brain O
evolution O
, O
development O
, O
and O
function O

Proximity O
ligation O
is O
induced O
between O
the O
random O
primer O
and O
the O
antibody O
by O
adding O
a O
connector O
DNA B-Chemical
with O
complementary O
sequences O
to O
the O
scaffold O
sequence O
of O
the O
random O
primer O
and O
the O
antibody-DNA O
probe O

They O
encode O
the O
four O
subunits O
and O
assembly O
factor O
of O
succinate B-Chemical
dehydrogenase I-Chemical
(SDH) B-Gene
, O
a O
mitochondrial O
enzyme O
involved O
both O
in O
the O
tricarboxylic B-Chemical
acid I-Chemical
cycle I-Chemical
and O
electron O
transport O
chain O

We O
also O
discuss O
how O
these O
epigenetic O
processes O
impact O
myelination O
and O
axonal O
regeneration O
, O
and O
facilitate O
the O
improvement O
of O
current O
preclinical O
therapeutics O
for O
functional O
nerve O
regeneration O
in O
neurodegenerative B-Disease
disorders I-Disease
or O
after O
injury O

Reduced-representation O
bisulfite O
sequencing O
and O
RNA-seq O
respectively O
identified O
3852 O
differentially O
methylated O
and O
1075 O
differentially O
expressed O
genes O
between O
laboratories O
, O
even O
in O
the O
absence O
of O
experimental O
intervention O

1052 O
Childhood O
socioeconomic O
position O
( O
SEP O
) O
is O
associated O
with O
the O
development O
of O
adult O
psychological O
outcomes O
, O
with O
DNA B-Chemical
methylation I-Chemical
( O
DNAm O
) O
as O
a O
mechanism O
to O
potentially O
explain O
these O
changes O

Epigenetics O
refers O
to O
the O
study O
of O
heritable O
changes O
in O
gene B-Gene
expression I-Gene
without O
alterations O
in O
DNA B-Gene
sequences I-Gene

The O
mechanisms O
, O
including O
genetic O
variations O
, O
copy-number O
variations O
, O
posttranscriptional O
variations O
, O
and O
epigenetic O
variations O
, O
can O
be O
detected O
using O
a O
variety O
of O
NGS O
methods O

, O

The O
strongest O
evidence O
that O
the O
age-related O
changes O
in O
DNA B-Chemical
methylation I-Chemical
play O
a O
role O
in O
aging O
comes O
from O
studies O
of O
anti-aging O
interventions O
( O
e O

Here O
, O
we O
assessed O
how O
the O
blood O
DNA B-Chemical
methylome O
of O
884 O
adults O
is O
affected O
by O
DNA B-Chemical
sequence O
variation O
, O
age O
, O
sex O
and O
139 O
factors O
relating O
to O
life O
habits O
and O
immunity O

415 O
Aims O
To O
develop O
a O
computational O
resource O
for O
viral B-Species
epigenomic O
methylation O
profiles O
from O
diverse O
diseases B-Disease

Next-generation O
sequencing O
(NGS) O
methods O
have O
been O
broadly O
used O
to O
identify O
these O
target O
sites O
and O
their O
patterns O

In O
this O
article O
, O
I O
review O
some O
of O
the O
conceptual O
issues O
and O
currently O
available O
software O
tools O
for O
the O
analysis O
of O
sequencing-based O
whole-genome O
epigenetics O
data O

Few O
methodologies O
integrate O
epigenetic O
based O
predictions O
of O
multiple O
approaches O
when O
combining O
profiles O
generated O
by O
different O
tools O

We O
show O
that O
each O
variable O
component O
in O
the O
k-mer O
landscape O
reflects O
a O
set O
of O
co-varying O
TFs O
, O
which O
are O
often O
known O
to O
physically O
interact O

138 O
Discoveries O
from O
the O
Human B-Species
Genome I-Species
Project I-Species
have O
invigorated O
discussions O
of O
epigenetic O
effects-modifiable O
chemical B-Chemical
processes O
that O
influence O
DNA's B-Gene
ability O
to O
give O
instructions O
to O
turn O
gene B-Gene
expression I-Gene
on O
or O
off-on O
health O
outcomes O

Post-translational O
histone B-Chemical
modifications O
are O
mainly O
studied O
by O
immunoprecipitation O
with O
high-throughput O
sequencing O
( O
ChIP-Seq O
) O

Psychotherapy O
could O
exert O
its O
therapeutic O
effect O
in O
idiopathic B-Disease
mental I-Disease
disorders I-Disease
through O
epigenetic O
mechanisms O

503 O
Cardiovascular B-Disease
diseases I-Disease
are O
the O
major O
cause O
of O
morbidity O
and O
mortality O
worldwide O

Multiple O
diverse O
epigenetic O
processes O
, O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modification I-Chemical
, O
and O
the O
expression O
of O
non-coding O
RNA B-Gene
molecules O
affect O
the O
expression O
of O
genes O
that O
produce O
important O
changes O
in O
cellular O
differentiation O
and O
function O
, O
influencing O
the O
health O
and O
adaptability O

Analysis O
of O
DNA B-Chemical
modification O
patterns O
relies O
increasingly O
on O
sequencing-based O
profiling O
methods O

Neither O
GWAS-based O
methodology O
nor O
state-of-the-art O
confounder O
adjustment O
methods O
completely O
remove O
bias O
and O
inflation O

201 O
Epigenetics O
studies O
the O
emergence O
of O
different O
phenotypes O
from O
a O
single O
genotype O

Transcriptomic O
studies O
have O
revealed O
that O
gene B-Gene
expression I-Gene
is O
coordinated O
to O
maintain O
neoblast O
pluripotency O
, O
and O
ensure O
correct O
lineage O
specification O
during O
differentiation O

Furthermore O
, O
we O
investigated O
whether O
these O
effects O
are O
mediated O
or O
not O
by O
changes O
in O
cellular O
composition O
, O
measured O
by O
deep O
immunophenotyping O

Here O
, O
we O
present O
an O
overview O
of O
the O
promises O
of O
epigenetics B-Chemical
in O
eventually O
treating O
IEMs B-Disease

We O
found O
that O
by O
integrating O
two O
enrichment-based O
methods O
that O
are O
complementary O
in O
nature O
( O
i O

We O
can O
predict O
active O
signaling O
pathways O
in O
K562 B-Species
single O
cells O
using O
the O
epigenetic O
data O
and O
confirm O
that O
the O
predicted O
results O
strongly O
correlate O
with O
actual O
active O
signaling O
pathways O
identified O
by O
RNA-seq B-Gene
results O

This O
epigenetic O
heterogeneity O
is O
of O
biological O
importance O
in O
normal O
functions O
such O
as O
tissue O
morphogenesis O
and O
can O
contribute O
to O
development O
or O
resistance O
of O
cancer B-Disease
, O
or O
other O
disease O
states O

de O
or O
markus O

This O
method O
combines O
bisulfite O
conversion O
with O
targeted O
amplification O
of O
regions O
of O
interest O
, O
transposome-mediated O
library O
construction O
and O
benchtop O
NGS O

Impact O
This O
approach O
provides O
novel O
insight O
into O
possible O
pleiotropic O
effects O
of O
genes O
involved O
in O
epigenetic O
processes O

Generating O
a O
unified O
view O
of O
spatial O
, O
temporal O
, O
genetic B-Gene
and O
epigenetic B-Gene
properties O
poses O
various O
challenges O
of O
data O
analysis O
, O
visualization O
, O
integration O
and O
mining O
, O
as O
well O
as O
of O
high O
performance O
computing O
and O
big O
data O
management O

1481 O
Epigenome-wide O
association O
studies O
represent O
one O
means O
of O
applying O
genome-wide O
assays O
to O
identify O
molecular O
events O
that O
could O
be O
associated O
with O
human B-Species
phenotypes O

Buddleja B-Species
officinalis I-Species
Maxim I-Species
, O
Gardenia B-Species
jasminoides I-Species
Ellis I-Species
, O
Curcuma B-Species
longa I-Species
L I-Species

We O
developed O
a O
software O
package O
called O
MethLAB O
( O
http//genetics O

We O
showcase O
our O
transfection O
protocol O
optimization O
using O
HEK293T B-Species
Lenti-Xâ¢ O
and O
breast B-Disease
cancer I-Disease
MCF-7 B-Species
cell O
lines O
, O
using O
a O
single-guide O
RNA-containing O
plasmid O

This O
review O
is O
the O
first O
of O
seven O
in O
this O
special O
issue O
of O
Integrative O
and O
Comparative O
Biology O
that O
addresses O
in O
detail O
these O
and O
other O
key O
topics O
in O
the O
study O
of O
epigenetics O

Pharmacological O
and O
genetic O
manipulation O
of O
epigenetic O
factors O
can O
, O
in O
turn O
, O
induce O
remarkable O
changes O
in O
neural O
cell O
identity O
and O
cognitive O
and O
behavioral O
phenotypes O

Faced O
with O
these O
two O
concerns O
, O
many O
turn O
away O
from O
epigenetics B-Chemical
altogether O
, O
refusing O
its O
novelty O
and O
supposed O
benefit O
for O
Indigenous B-Species
health O
equity O
and O
resisting O
the O
pull O
of O
postgenomics O

This O
review O
will O
discuss O
epigenetic O
studies O
in O
both O
suicidal B-Disease
ideation I-Disease
and O
behavior O

, O
kinking O

g O

A O
total O
of O
660,845 O
methylated O
cytosines O
were O
identified O
within O
the O
CpG B-Gene
context I-Gene
(CpGs) O
across O
the O
10 O
animals O
sequenced O
(5 O
N B-Species
and O
5 O
A B-Species
) O

Such O
effects O
are O
independent O
of O
the O
causative O
agent O
and O
there O
is O
no O
evidence O
at O
present O
that O
a O
germline-dependent O
epigenetic O
state O
can O
be O
reversed O

The O
procedure O
is O
tedious O
and O
time O
consuming O
, O
and O
one O
of O
the O
major O
limitations O
is O
the O
requirement O
for O
high O
amounts O
of O
starting O
material O
, O
usually O
millions O
of O
cells O

216 O
MicroRNAs B-Gene
(miRNAs) I-Gene
are O
short O
noncoding O
RNAs O
with O
gene O
regulatory O
functions O

We O
describe O
how O
large-scale O
epigenetic O
studies O
of O
twins O
can O
improve O
our O
understanding O
of O
how O
genetic O
, O
environmental O
and O
stochastic O
factors O
impact O
upon O
epigenetics O
, O
and O
how O
such O
studies O
can O
provide O
a O
comprehensive O
understanding O
of O
how O
epigenetic O
variation O
affects O
complex O
traits O

03 O
) O

il O
/ O
focs O
) O

In O
this O
paper O
, O
we O
hypothesize O
that O
the O
effects O
of O
parental O
nutritional O
status O
on O
fetal O
epigenetic O
programming O
are O
transgenerational O
and O
warrant O
further O
investigation O

Hence O
, O
adequate O
emphasis O
should O
be O
given O
to O
such O
factors O
in O
an O
individual O
's O
nutrition O
, O
especially O
early O
in O
life O

We O
applied O
HopLand O
to O
different O
types O
of O
single-cell O
transcriptomic O
data O

thermophila B-Species

1131 O
Epigenetic O
mechanisms O
represent O
potential O
molecular O
routes O
which O
could O
bridge O
the O
gap O
between O
genetic O
background O
and O
environmental O
risk O
factors O
contributing O
to O
the O
pathogenesis O
of O
pulmonary B-Disease
diseases I-Disease

Notably O
, O
these O
epigenetic O
changes O
are O
reversible O
, O
making O
them O
appealing O
targets O
for O
therapeutic O
and O
corrective O
interventions O

In O
this O
paper O
, O
we O
propose O
a O
model O
to O
explain O
individual O
differences O
in O
the O
development O
of O
the O
major O
forms O
of O
mental O
health O
problems O
that O
can O
be O
identified O
early O
in O
life O
through O
excesses O
and O
deficits O
in O
emotional O
attention O
, O
responsiveness O
and O
learning O
( O
i O

Conclusion O
 O
Existing O
epigenetic O
clocks O
require O
updates O
for O
full O
EPICv2 B-Gene
compatibility O

DNA O
methylation O
profiles O
at O
precancerous B-Disease
stages O
are O
basically O
inherited O
by O
the O
corresponding O
cancers B-Disease
developing O
in O
individual O
patients O

We O
also O
show O
that O
epigenetically O
driven O
effects O
are O
strongly O
enriched O
in O
repressed O
regions O
and O
near O
transcription O
start O
sites O
, O
whereas O
the O
genetically O
regulated O
CpGs O
are O
enriched O
in O
enhancers O

In O
recent O
years O
, O
evidence O
was O
derived O
that O
apart O
from O
5-methylcytosine B-Chemical
, O
the O
DNA B-Chemical
methylation/demethylation I-Chemical
cycle I-Chemical
includes O
three O
other O
oxidative O
derivatives O
of O
cytosine-5-hydroxymethylcytosine B-Chemical
( O
5hmC B-Chemical
) O
, O
5-formylcytosine B-Chemical
, O
and O

In O
this O
paper O
, O
we O
reviewed O
the O
literatures O
that O
has O
demonstrated O
that O
acupuncture O
could O
directly O
or O
indirectly O
affect O
epigenetics O
, O
in O
order O
to O
highlight O
the O
progress O
of O
acupuncture O
studies O
correlated O
to O
epigenetic O
regulations O

1333 O
For O
further O
resources O
related O
to O
this O
article O
, O
please O
visit O
the O
WIREs O
website O

406 O
Age-related O
changes O
in O
do O
occur O

Integrating O
histone B-Chemical
modification I-Chemical
information O
in O
the O
analysis O
of O
gene B-Gene
expression I-Gene
traits O
(eQTL O
mapping) O
has O
been O
shown O
to O
significantly O
enhance O
the O
prediction O
of O
eQTLs O

Importantly O
, O
these O
phenotypes O
persist O
in O
patients O
in O
remission O
and O
are O
found O
in O
all O
adipose O
depots O
explored O
including O
subcutaneous O
fat O

This O
Review O
summarizes O
epigenetic O
signatures O
obtained O
from O
human B-Species
tissues O
of O
relevance O
for O
metabolism-i O

For O
a O
year O
increase O
in O
extrinsic O
epigenetic O
age O
acceleration O
, O
age- O
and O
sex-adjusted O
relative O
risk O
ratios O
( O
95% O
CI O
) O
for O
being O
physically O
frail O
or O
pre-frail O
were O
1 O

385 O
Epigenetics O
is O
a O
major O
field O
of O
biomedical O
research O
, O
and O
epigenetic O
drug O
discovery O
shows O
great O
promise O
for O
new O
drugs O

Understanding O
the O
dynamic O
interaction O
between O
epigenetics O
and O
stress O
responses O
holds O
immense O
potential O
to O
engineer O
resilient O
crops O
that O
thrive O
in O
environments O
contaminated O
with O
heavy B-Chemical
metals I-Chemical
and O
metalloids B-Chemical

Here O
we O
review O
some O
of O
these O
techniques O
and O
discuss O
their O
potential O
clinical O
utility O

575 O
Autism B-Disease
spectrum I-Disease
disorders I-Disease
( O
ASD B-Disease
) O
have O
been O
increasing O
in O
prevalence O
over O
the O
last O
two O
decades O
, O
primarily O
because O
of O
increased O
awareness O
and O
diagnosis O

In O
fact O
, O
neuroepigenomics O
represents O
an O
effort O
to O
unify O
the O
research O
available O
on O
the O
molecular O
pathology O
of O
mental B-Disease
diseases I-Disease
, O
which O
has O
been O
carried O
out O
through O
several O
approaches O
ranging O
from O
interrogating O
single O
DNA B-Chemical
methylation I-Chemical
events O
and O
hydroxymethylation B-Chemical
patterns O

Although O
transformed O
cells O
are O
those O
in O
which O
DNA B-Chemical
methylation I-Chemical
disruption O
is O
more O
obvious O
, O
we O
observed O
that O
other O
common O
human O
diseases O
, O
such O
as O
neurological B-Disease
and O
autoimmune B-Disease
disorders I-Disease
, O
had O
their O
own O
distinct O
DNA B-Chemical
methylation I-Chemical
profiles O

Here O
, O
we O
present O
DamMet B-Gene
, O
an O
open-source O
software O
program O
retrieving O
maximum O
likelihood O
estimates O
of O
regional O
CpG B-Chemical
methylation I-Chemical
levels I-Chemical
from O
ancient O
DNA B-Chemical
sequencing O
data O

Designing O
and O
optimizing O
pyrosequencing O
assays O
correctly O
is O
vital O
for O
the O
interpretation O
of O
results O

789 O
AFLP O
or O
amplified O
fragment O
length O
polymorphism O
is O
a O
PCR-based O
molecular O
technique O
that O
uses O
selective O
amplification O
of O
a O
subset O
of O
digested O
DNA O
fragments O
from O
any O
source O
to O
generate O
and O
compare O
unique O
fingerprints O
of O
genomes O

Currently O
, O
fibromyalgia B-Disease
diagnosis O
is O
based O
exclusively O
on O
a O
comprehensive O
clinical O
assessment O
, O
according O
to O
2016 O
ACR O
criteria O
, O
but O
validated O
biological O
biomarkers O
associated O
with O
fibromyalgia B-Disease
have O
not O
yet O
been O
identified O

Although O
the O
exact O
mechanisms O
behind O
this O
cross O
talk O
remains O
elusive O
, O
microbiota B-Species
induced O
epigenetic O
mechanisms O
like O
DNA B-Gene
methylation I-Gene
and O
histone B-Gene
modifications I-Gene
may O
be O
key O

Several O
cost-effective O
reduced O
representation O
bisulfite O
sequencing O
approaches O
(RRBS) O
have O
been O
recently O
developed O
and O
applied O
to O
different O
organisms O
that O
lack O
a O
well O
annotated O
reference O
genome O

However O
, O
high-throughput O
design O
of O
primers O
for O
B- O
T- O
DNA B-Gene
amplification O
is O
hampered O
by O
limits O
in O
throughput O
and O
functionality O
of O
existing O
tools O
, O
requiring O
users O
to O
repeatedly O
perform O
specific O
tasks O
manually O

In O
cartilage B-Species
samples O
, O
overall O
sample O
correlations O
of O
methylation O
values O
between O
arrays O
were O
high O
( O
Pearson's O
r O
> O
0 O

180 O
 O
Much O
controversy O
surrounds O
the O
idea O
of O
transgenerational O
epigenetics O

understanding O

Here O
, O
we O
review O
the O
growing O
knowledge O
base O
of O
gene-regulatory O
mechanisms O
and O
describe O
their O
links O
to O
phenotype O
, O
proposing O
strategies O
to O
address O
widely O
recognized O
challenges O

Our O
analysis O
identified O
a O
methylation O
signature O
comprising O
21 O
genes O
for O
AD B-Disease
and O
a O
methylation O
signature O
comprising O
89 O
genes O
for O
DS B-Disease
, O
respectively O

However O
, O
the O
discovery O
of O
sequence-independent O
heritable O
DNA B-Chemical
changes O
( O
epigenetics O
) O
have O
helped O
us O
to O
explain O
the O
link O
between O
genes B-Gene
and O
the O
environment O

In O
this O
paper O
, O
we O
provide O
a O
brief O
review O
for O
the O
advances O
in O
the O
animal B-Species
miRNA B-Gene
target I-Gene
prediction O
methods O
and O
available O
resources O
to O
facilitate O
further O
study O
of O
miRNAs B-Gene
and O
their O
functions O

Environmental O
factors O
have O
the O
potential O
to O
alter O
the O
epigenome O
, O
allowing O
genes O
that O
are O
silenced O
to O
be O
activated O
and O
vice O
versa O

This O
feature O
has O
stimulated O
intensive O
research O
to O
identify O
predictive O
biomarkers O
of O
response O
and O
disentangle O
the O
molecular O
bases O
of O
their O
clinical O
efficacy O

Here O
in O
this O
review O
, O
we O
discuss O
developments O
in O
the O
field O
of O
AML B-Disease
biology O
and O
therapeutics O
, O
with O
a O
focus O
on O
advances O
in O
our O
understanding O
of O
how O
genetic O
and O
epigenetic O
determinants O
of O
AML B-Disease
have O
influenced O
prognostication O
and O
recent O
shifts O
in O
treatment O
paradigms O

436 O
Analogous O
to O
multicellular B-Species
organisms O
, O
social B-Species
insect I-Species
colonies O
are O
characterized O
by O
division O
of O
labor O
with O
queens O
and O
workers O
reflecting O
germline O
and O
soma O
, O
respectively O

However O
, O
conventional O
techniques O
for O
studying O
epigenetic O
or O
conformational O
modifications O
of O
chromosomes O
have O
inherent O
limitations O
and O
, O
therefore O
, O
new O
methods O
based O
on O
micro- O
and O
nanoscale O
devices O
have O
been O
sought O


Here O
we O
describe O
a O
protocol O
for O
the O
detection O
and O
quantification O
of O
epigenetic O
signaling O
DNA B-Gene
methylation I-Gene
modifications O
including O
, O
N6-methyladenine B-Chemical
( O
6mA B-Chemical
) O
, O
N4-methylcytosine B-Chemical
( O
4mC B-Chemical
) O
and O
C5-methylcytosine B-Chemical
( O
5mC B-Chemical
) O

Development O
and O
differentiation O
of O
T B-Gene
cells I-Gene
into O
functional O
subset O
cells O
including O
memory O
T B-Gene
cells I-Gene
are O
dynamic O
processes O
driven O
by O
environmental O
signals O

The O
pathogenesis O
of O
SLE B-Disease
has O
been O
intensively O
studied O
but O
remains O
unclear O

Both O
are O
bridges O
to O
link O
genotypes O
with O
phenotypes O
and O
important O
for O
understanding O
how O
weak O
selection O
and O
drift O
interact O
in O
the O
evolution O
of O
complex O
systems O

There O
are O
various O
epigenetic O
modifications O
involving O
mechanisms O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modification I-Chemical
, O
and O
noncoding O
RNA B-Gene
expression O
, O
all O
of O
which O
are O
inheritable O

Further O
, O
we O
provided O
evidence O
of O
a O
significant O
epigenetic O
etiology O
in O
isolated O
CoA B-Disease
development O

Variations O
of O
this O
method O
include O
bisulfite B-Chemical
sequencing O
, O
methylation-specific B-Chemical
PCR B-Chemical
, O
real-time B-Chemical
PCR-based I-Chemical
MethyLight I-Chemical
, O
and O
methylation-sensitive B-Chemical
high-resolution I-Chemical
melting I-Chemical
PCR I-Chemical

A O
total O
of O
71 O
children O
( O
mean O
[ O
SD O
] O
age O
, O
36 O

Two O
additional O
human-elephant B-Species
clocks O
were O
constructed O
by O
combining O
human B-Species
and O
elephant B-Species
samples O

Future O
investigations O
will O
be O
emphasized O
on O
molecular O
classification O
of O
NKTCL B-Disease
using O
integrated O
analysis O
of O
system O
biology O
, O
so O
as O
to O
optimize O
targeted O
therapeutic O
strategies O
of O
NKTCL B-Disease
in O
the O
era O
of O
precision O
medicine O

A O
large O
number O
of O
these O
markers O
arose O
in O
an O
attempt O
to O
better O
understand O
the O
molecular O
mechanisms O
involved O
in O
bladder B-Disease
carcinogenesis I-Disease
and O
tumor O
progression O
and O
how O
these O
may O
translate O
into O
diagnostic O
or O
prognostic O
tools O

Such O
effects O
on O
cellular O
and O
physiological O
phenotypic O
traits O
may O
result O
from O
external O
or O
environmental O
factors O
or O
be O
part O
of O
normal O
developmental O
program O

Using O
periosteal O
new O
bone O
formation O
as O
an O
example O
, O
various O
mechanisms O
and O
pathways O
are O
explored O
in O
which O
new O
bone O
can O
be O
formed O
under O
conditions O
of O
biological O
stress O
, O
particularly O
in O
bone O
microenvironments O
that O
involve O
inflammatory B-Disease
changes I-Disease

For O
a O
long O
time O
, O
it O
was O
believed O
the O
epigenetic O
information O
could O
not O
be O
transmitted O
from O
one O
generation O
to O
the O
next O
, O
however O
, O
recent O
evidence O
has O
demonstrated O
that O
these O
acquired O
changes O
can O
be O
transmitted O
across O
generations O
in O
different O
species O
, O
with O
implications O
also O
for O

Epigenetic O
mechanisms O
refer O
to O
environmentally O
sensitive O
modifications O
to O
DNA B-Chemical
and O
RNA B-Chemical
molecules O
that O
regulate O
gene B-Gene
transcription O
without O
altering O
the O
genetic O
sequence O
itself O

Blood O
samples O
from O
deceased O
alcohol O
abusers O
and O
age- O
and O
sex-matched O
controls O
were O
analyzed O
using O
the O
VISAGE B-Gene
enhanced I-Gene
tool O
for O
age O
prediction O
from O
somatic O
tissues O
that O
enables O
examination O
of O
44 O
CpGs B-Gene
within O
eight O
age O
markers O

These O
insights O
into O
neoblast B-Species
biology O
may O
be O
directly O
relevant O
to O
mammalian B-Species
stem O
cells O
and O
disease B-Disease

We O
hypothesized O
that O
the O
use O
of O
a O
newly O
developed O
, O
highly O
sensitive O
, O
and O
specific O
epigenetic O
test O
, O
PrecisionCHD B-Gene
, O
could O
decrease O
the O
costs O
of O
secondary O
prevention O

680 O
The O
series O
of O
events O
that O
allow O
the O
conversion O
from O
adherent O
epithelial B-Species
cells I-Species
into O
migratory O
cells O
is O
collectively O
known O
as O
epithelial-mesenchymal B-Disease
transition I-Disease
( O
EMT B-Disease
) O

Our O
objective O
was O
to O
determine O
whether O
significant O
epigenetic O
changes O
occur O
in O
isolated O
, O
non-syndromic O
CoA B-Disease

We O
examined O
the O
expression O
and O
epigenetics O
of O
GSTM3 B-Gene
in O
lens O
epithelial O
cells O
( O
LECs B-Species
) O
and O
lens O
cortex O
of O
ARC B-Disease
, O
and O
investigated O
the O
potential O
role O
of O
molecular O
changes O
in O
ARC B-Disease
pathogenesis O

The O
major O
fasciculi O
were O
segmented O
, O
and O
fractional O
anisotropy B-Chemical
, O
mean O
diffusivity O
and O
tract O
shape O
were O
calculated O

0 O
- O
fold O
change O
in O
methylation O
in O
versus O
controls O
with O
a O
FDR O
p-value O
â¤ O
0 O


The O
abundance O
and O
distribution O
of O
covalent O
histone B-Chemical
modifications O
in O
primary O
cancer B-Disease
tissues O
relative O
to O
normal O
cells O
is O
an O
important O
but O
largely O
uncharted O
area O
, O
although O
there O
is O
good O
evidence O
for O
a O
mechanistic O
role O
of O
cancer-specific B-Disease
alterations O
in O
histone B-Chemical
modifications O
in O

Such O
a O
method O
could O
also O
be O
used O
to O
elucidate O
the O
mechanisms O
underlying O
polymorphism-associated O
inter-individual O
differences O
in O
disease B-Disease
susceptibility I-Disease
and O
the O
mechanism O
of O
genomic B-Gene
imprinting I-Gene

668 O
 O
Animals B-Species
and O
plants B-Species
have O
biological O
clocks O
that O
help O
to O
regulate O
circadian O
cycles O
, O
seasonal O
rhythms O
, O
growth O
, O
development O
and O
sexual O
maturity O

Method O
of O
study O
 O
Review O
of O
research O
on O
the O
epigenetic O
regulation O
of O
T-cell B-Gene
subsets I-Gene

The O
second O
is O
primarily O
from O
the O
basic O
sciences O
, O
particularly O
molecular B-Gene
genetics I-Gene
, O
and O
regards O
epigenetics B-Gene
as O
a O
potentially O
important O
mechanism O
for O
organisms B-Species
exposed O
to O
variable O
environments O
across O
multiple O
generations O

Combined O
with O
the O
dependent O
adjustment O
for O
regional O
p-value O
combination O
and O
DMR O
annotation O
, O
we O
provide O
a O
method O
that O
may O
be O
applied O
to O
a O
variety O
of O
datasets O
for O
rapid O
DMR O
analysis O

395 O
Epigenetic O
modifications O
are O
gene B-Gene
regulatory O
mechanisms O
that O
allow O
rapid O
adaptation O
to O
the O
environment O

The O
inclusion O
of O
the O
epigenetic O
effect O
in O
the O
model O
helped O
to O
explain O
the O
residual O
and O
non-Mendelian O
variability O
of O
initial O
body O
weight O
in O
meat B-Species
quails I-Species

Such O
datasets O
can O
range O
from O
biological O
data O
, O
sensor O
data O
, O
medical O
diagnostics O
, O
or O
any O
other O
domain O
where O
labeling O
any O
instances O
of O
the O
minority O
class O
can O
be O
time-consuming O
or O
costly O
or O
the O
data O
may O
not O
be O
easily O
available O

Total O
number O
of O
SEMs O
was O
significantly O
higher O
in O
HCC B-Disease
tumor I-Disease
(median O
77,370 O
) O
than O
in O
peritumoral O
(median O
5,656 O
) O
tissues O
and O
correlated O
with O
tumor O
grade O

Finally O
, O
we O
review O
the O
medical O
applications O
of O
such O
integrative O
analyses O

Dr O

Deregulation O
of O
these O
processes O
result O
in O
lots O
of O
disease O
which O
are O
characterized O
by O
complex O
patterns O
of O
mutations O
and O
associated O
phenotypes O
affecting O
pre- O
and O
postnatal O
growth O
, O
development O
, O
and O
neurological O
function O

Despite O
the O
effects O
of O
childhood B-Disease
maltreatment I-Disease
and O
adversity O
on O
a O
wide O
range O
of O
adult O
physical O
and O
psychological O
negative O
outcomes O
, O
not O
all O
individuals O
respond O
similarly O

In O
our O
study O
we O
observed O
decrease O
in O
the O
level O
of O
DNA B-Gene
methylation I-Gene
under O
the O
influence O
of O
heat B-Chemical
stress I-Chemical
, O
especially O
after O
returning O
to O
control O
conditions O

1160Background O
Machine O
learning O
is O
a O
sub-field O
of O
artificial O
intelligence O
, O
which O
utilises O
large O
data O
sets O
to O
make O
predictions O
for O
future O
events O


We O
show O
that O
the O
chemical B-Chemical
inhibition O
of O
Erk B-Gene
signalling O
during O
EMT B-Disease
prevents O
the O
loss O
and O
gain O
of O
the O
H3K27ac B-Gene
mark O
at O
regulatory O
regions O
of O
epithelial O
and O
mesenchymal O
genes O
, O
respectively O
, O
and O
results O
in O
a O
transcriptome O
and O
epigenome O
closer O
to O

Looking O
forward O
, O
we O
describe O
additional O
challenges O
and O
future O
opportunities O
that O
will O
facilitate O
the O
improvement O
and O
broad O
adoption O
of O
single-cell O
omics O
in O
life O
science O
and O
medicine O

Conclusions O
 O
Quantum O
effects O
in O
DNA B-Gene
are O
prone O
to O
triggering O
and O
manipulation O
by O
external O
means O

These O
alterations O
were O
associated O
with O
either O
increased O
or O
decreased O
risk O
for O
cancer B-Disease
development O

Some O
investigators O
have O
been O
trying O
to O
illustrate O
the O
mechanism O
of O
acupuncture O
from O
an O
epigenetics O
perspective O
, O
which O
has O
shed O
new O
lights O
on O
the O
mechanisms O
and O
applications O
of O
acupuncture O

The O
laboratory O
mainly O
focuses O
on O
the O
analysis O
of O
epigenetic O
changes O
in O
neurodegenerative B-Disease
, O
autoimmune B-Disease
and O
inflammatory B-Disease
diseases O
as O
well O
as O
the O
alteration O
of O
the O
epigenetic O
profiles O
in O
function O
of O
environmental O
exposure O

Epigenetics O
is O
a O
gene B-Gene
regulation O
mechanism O
that O
does O
not O
depend O
on O
DNA B-Chemical
sequence O
but O
on O
chemical B-Chemical
modifications O
of O
DNA B-Chemical

The O
search O
to O
explain O
the O
molecular O
mechanism O
of O
NET O
dysfunction O
has O
focused O
on O
genetic O
variation O
in O
the O
SLC6A2 B-Gene
gene I-Gene
and O
remains O
inconclusive O

While O
key O
genes B-Gene
and O
signaling O
pathways O
that O
lead O
to O
the O
onset O
of O
sexual O
maturation O
are O
known O
, O
the O
molecular O
mechanisms O
that O
determine O
when O
an O
individual O
enters O
puberty B-Disease
are O
only O
beginning O
to O
be O
understood O

Hypermethylation O
of O
CpG O
loci O
located O
in O
promoters O
of O
genes O
regulating O
cholesterol O
metabolism O
 O
PCSK9 B-Gene
, O
LRP1 B-Gene
, O
ABCG1 B-Gene
, O
ANGPTL4 B-Gene
, O
SREBF1 B-Gene
and O
NR1H2 B-Gene
in O
hypercholesterolemic B-Disease
patients O
has O
been O
found O

With O
concomitant O
advances O
in O
extensive O
computational O
knowledge O
of O
the O
genomics O
and O
epigenomics O
of O
interindividual O
variations O
in O
drug O
responses O
, O
the O
boundaries O
toward O
development O
of O
personalized O
nanomedicines O
can O
be O
pushed O
further O

We O
present O
cfNOMe O
, O
a O
two-in-one O
method O
of O
measuring O
cfDNA B-Gene
cytosine B-Chemical
methylation O
and O
nucleosome O
occupancy O
in O
a O
single O
assay O
using O
non-disruptive O
enzymatic O
cytosine B-Chemical
conversion O
and O
a O
custom O
bioinformatic O
pipeline O

Collectively O
, O
these O
data O
identify O
potential O
molecular O
targets O
for O
Pb B-Chemical
- I-Chemical
induced O
metabolic O
diseases B-Disease
, O
and O
inform O
the O
design O
of O
more O
robust O
human B-Species
environmental O
epigenomics O
studies O

The O
SEM O
analysis O
provided O
valuable O
clues O
for O
further O
investigations O
in O
understanding O
the O
process O
of O
tumorigenesis O
in O
HCC B-Disease

Targeting O
epigenetic O
modulators O
associated O
with O
cancer B-Disease
stem I-Disease
cell I-Disease
survival O
can O
unlock O
a O
promising O
therapeutic O
approach O
in O
completely O
eradicating O
cancer B-Disease

Recently O
, O
it O
has O
become O
apparent O
that O
epigenetic O
mechanisms O
play O
an O
important O
role O
in O
gene B-Gene
regulation O

Additionally O
, O
our O
study O
confirmed O
that O
CRISPR/Cas9-mediated B-Gene
target O
methylation O
in O
a O
site-specific O
manner O
enabled O
the O
maintenance O
of O
gene O
silencing O
in O
vitro O
and O
in O
vivo O

These O
unbiased O
multi-omic O
results O
provide O
new O
evidence O
for O
germline B-Gene
mechanisms O
increasing O
risk O
of O
early O
leukaemogenesis B-Disease

Recent O
studies O
indicate O
that O
many O
filamentous O
fungal O
secondary O
metabolites O
are O
regulated O
by O
epigenetic O
modifications O
, O
which O
not O
only O
affect O
the O
titers O
of O
secondary O
metabolites O
, O
but O
also O
activate O
the O
cryptic O
gene B-Gene
clusters I-Gene

Environmental O
factors O
have O
been O
proposed O
to O
promote O
the O
development O
of O
malignancies B-Disease
by O
eliciting O
epigenetic O
changes O
; O
however O
, O
it O
is O
only O
with O
recent O
advances O
in O
epigenetics O
and O
epigenomics O
that O
target O
genes B-Gene
and O
the O
mechanisms O
underlying O
environmental O
influences O
are O
beginning O
to O
be O
elucidated O

This O
revealed O
that O
matrix O
factorization O
, O
latent O
variable O
analysis O
, O
and O
deep O
learning O
are O
potent O
strategies O

ChIP O
is O
also O
an O
exciting O
tool O
to O
study O
and O
compare O
chromatin O
states O
under O
normal O
and O
stress O
conditions O

The O
level O
of O
similarity O
accentuated O
over O
consecutive O
generations O
, O
indicating O
a O
mechanism O
of O
transgenerational O
plasticity O

Hence O
, O
our O
method O
is O
worth O
considering O
in O
HDMA B-Disease
studies O

4 O
years O
higher O
compared O
to O
the O
controls O
and O
this O
trend O
increased O
in O
older O
individuals O

In O
this O
Review O
, O
we O
discuss O
these O
varied O
technical O
challenges O
and O
solutions O
for O
sequencing O
ancient O
genomes O
and O
epigenomes O

org O
/ O
packages O
/ O
release O
/ O
bioc O
/ O
html O
/ O
/ O
ENmix B-Gene

This O
study O
queries O
the O
unicellular O
chlorophyte O
, O
Chlamydomonas B-Species
reinhardtii I-Species
using O
a O
three O
step O
" O
epigenetic B-Chemical
assay I-Chemical
" O
design O
to O
phenotypically O
track O
the O
variegation O
of O
a O
randomly O
integrated O
Paromomycin B-Chemical
resistance O
transgene B-Gene
( O
Pm B-Gene

Normal O
epigenetic O
states O
could O
be O
disrupted O
by O
detrimental O
mutations O
and O
expression O
alteration O
of O
regulators O
or O
by O
environmental O
factors O

nlm O

Genetic O
factors O
involve O
variation O
in O
the O
DNA B-Chemical
sequences O
of O
protein-coding O
genes B-Gene
, O
which O
directly O
contribute O
to O
phenotypic O
traits O
, O
and O
variation O
in O
noncoding O
sequences O
, O
which O
comprise O
98% O
of O
the O
genome O
and O
contain O
DNA B-Chemical
elements O
known O
to O
play O
a O
role O
in O
regulating O

This O
review O
summarizes O
the O
availability O
and O
accessibility O
of O
brain B-Disease
epigenetic O
and O
functional O
genomic O
data O
as O
a O
single O
resource O
to O
allow O
investigators O
to O
easily O
access O
available O
brain B-Disease
annotations O
and O
thus O
incorporate O
this O
wealth O
of O
information O
into O
their O
research O
to O
make O
important O
advances O
in O
the O
field O
of O

04 O
) O

Nevertheless O
, O
the O
implementation O
of O
epidrugs B-Chemical
in O
clinical O
practice O
is O
very O
scarce O
and O
mainly O
limited O
to O
haematological B-Disease
malignancies I-Disease

Results O
 O
Our O
new O
epigenetic O
gestational O
age O
clock O
showed O
higher O
precision O
and O
accuracy O
in O
predicting O
gestational O
age O
than O
previous O
gestational O
age O
clocks O
( O
R2 O
= O
0 O

This O
phenomenon O
has O
largely O
been O
studied O
in O
the O
context O
of O
chromatin B-Chemical
modification I-Chemical

It O
further O
provides O
a O
broad O
background O
on O
epigenetics O
with O
a O
focus O
on O
three-dimensional O
conformation O
of O
chromatin O

We O
show O
that O
the O
experimental O
data O
are O
compatible O
with O
the O
finite-size O
behavior O
of O
a O
self-attracting O
polymer B-Chemical

There O
are O
still O
many O
genes O
of O
unknown O
function O
in O
the O
chicken B-Species
genome O
yet O
to O
be O
characterized O

Conclusions O
 O
Novel O
therapeutic O
modalities O
leveraging O
epigenetics O
and O
epigenomics O
with O
increased O
precision O
are O
well O
positioned O
to O
advance O
the O
field O
and O
treat O
patients O
across O
disease O
areas O
in O
the O
coming O
years O

265 O
The O
epigenome O
has O
been O
heralded O
as O
a O
key O
'missing O
piece' O
of O
the O
aetiological O
puzzle O
for O
complex O
phenotypes O
across O
the O
biomedical O
sciences O

chromatin O

MethLAB O
tests O
for O
association O
between O
methylation O
and O
relevant O
phenotypes O
by O
fitting O
a O
separate O
linear O
model O
for O
each O
site O

The O
reviewed O
studies O
were O
challenging O
to O
compare O
due O
to O
poor O
transparency O
in O
reporting O
, O
and O
heterogeneous O
methodology O
, O
design O
, O
genome B-Gene
coverage I-Gene
, O
and O
statistical O
modelling O

Conclusion O
 O
Our O
study O
unveils O
a O
potential O
link O
between O
genetic O
, O
epigenetic O
, O
and O
transcriptional O
deregulation O
in O
CD4+ O
T O
cells O
of O
SSc B-Disease
patients O
, O
providing O
a O
novel O
integrated O
view O
of O
molecular O
components O
driving O
SSc B-Disease
pathogenesis O

the O

377 O
 O
Recent O
years O
have O
brought O
the O
interest O
of O
genetic O
research O
to O
the O
human B-Species
epigenome O

Here O
, O
we O
argue O
that O
fish B-Species
species I-Species
, O
which O
have O
been O
recently O
domesticated O
, O
can O
provide O
model O
systems O
to O
study O
epigenetic O
drivers O
in O
human B-Species
self-domestication O

The O
strong O
heritability O
of O
these O
conditions O
(in O
particular O
autism B-Disease
and O
schizophrenia B-Disease
) O
argues O
in O
favor O
of O
a O
genetic O
origin O

Such O
viruses O
involve O
human O
and O
animal O
pathogens O
including O
the O
etiologic O
agents O
of O
acute O
respiratory O
tract O
illnesses O
 O
severe O
acute O
respiratory O
syndrome O
coronavirus B-Disease
( O
SARS-CoV B-Species
) O
, O
Middle B-Disease
East I-Disease
respiratory I-Disease
syndrome I-Disease
coronavirus I-Disease
( O
MERS-CoV B-Species
) O
, O
and O
the O

Hereby O
, O
the O
molecular O
clock O
and O
the O
chromatin O
regulators O
controlling O
rhythmicity O
represent O
a O
unique O
scaffold O
mediating O
the O
crosstalk O
between O
the O
circadian O
and O
the O
immune O
systems O

Recent O
advances O
in O
single-cell O
DNA B-Chemical
methylome I-Chemical
profiling O
have O
presented O
opportunities O
to O
resolve O
this O
heterogeneity O
at O
the O
maximum O
resolution O

Our O
tool O
is O
integrated O
into O
Galaxy O
( O
http//galaxyproject O

627 O
Hematopoiesis O
is O
one O
of O
the O
best O
characterized O
biological O
systems O
but O
the O
connection O
between O
chromatin O
changes O
and O
lineage O
differentiation O
is O
not O
yet O
well O
understood O

Although O
methods O
for O
the O
isolation O
of O
MIC B-Gene
have O
been O
available O
for O
many O
years O
, O
cross-contamination O
and O
DNA B-Gene
degradation O
remain O
unresolved O

CB O
receptors O
interact O
with O
other O
compounds O
besides O
cannabidiol B-Chemical
and O
Î9-tetrahydrocannabinol B-Chemical
, O
like O
cannabinol B-Chemical
and O
Î8-tetrahydrocannabinol B-Chemical

Given O
that O
DNAm B-Gene
patterns O
in O
early O
life O
undergo O
rapid O
changes O
and O
have O
been O
linked O
to O
a O
wide O
range O
of O
health O
outcomes O
and O
environmental O
exposures O
, O
direct O
investigations O
of O
tissue-specific O
DNAm B-Gene
variation O
in O
pediatric O
samples O
may O
help O
inform O
the O
design O
and O
interpretation O
of O
DNAm B-Gene

57 O
% O
of O
the O
miRNAs O
) O
of O
the O
aberrantly O
methylated O
ncRNA O
promoters O

This O
is O
achieved O
by O
providing O
a O
survey O
of O
the O
following O
concepts O
 O
( O
i O
) O
factors O
influencing O
epigenetics O
, O
( O
ii O
) O
diseases B-Disease
arising I-Disease
from I-Disease
epigenetics O
, O
( O
iii O
) O
epigenetic O
enzymes O
as O
druggable O
targets O
along O
with O
coverage O
of O
existing O
FDA-approved O

These O
cells O
had O
a O
46 O
, O
XX B-Gene
karyotype O
, O
and O
no O
inactive O
X B-Gene
chromosomes O
were O
observed O
before O
passage O
20 O

Epigenetic O
processes O
may O
constitute O
one O
of O
these O
factors O
and O
have O
not O
yet O
been O
investigated O
in O
relation O
to O
childhood B-Disease
psychotic I-Disease
symptoms I-Disease

The O
results O
suggest O
the O
relevance O
of O
genetic O
and O
epigenetic O
processes O
for O
future O
theorizing O
regarding O
marital O
and O
family O
precursors O
of O
several O
forms O
of O
adult O
psychopathology B-Disease

Epigenetic O
abnormalities O
have O
been O
found O
to O
be O
causative O
factors O
in O
cancer B-Disease
, O
genetic O
disorders O
, O
and O
pediatric O
syndromes O

The O
methylation O
level O
of O
five O
studied O
demonstrated O
significant O
correlations O
with O
chronological O
age O
and O
an O
acceptable O
convergence O
of O
data O
obtained O
by O
the O
and O
array O

848 O
Current O
single-cell O
epigenome O
analyses O
are O
designed O
for O
single O
use O

We O
have O
organized O
the O
paper O
in O
two O
steps O
 O
first O
, O
we O
analyse O
value O
and O
functions O
of O
the O
concept O
of O
habit O
in O
Darwin O
's O
early O
works O
, O
notably O
in O
his O
Notebooks O
, O
and O
compare O
these O
views O
to O
his O
mature O
understanding O
of O
the O
concept O
in O
the O
Origin O
of O
Species B-Species

Environmental O
insults O
can O
reprogram O
the O
epigenome O
of O
the O
germline O
( O
sperm O
and O
eggs O
) O
, O
which O
transmits O
the O
susceptibility O
for O
disease B-Disease
to O
future O
generations O
through O
epigenetic O
transgenerational O
inheritance O

Here O
, O
we O
propose O
to O
model O
genetics O
( O
single B-Gene
nucleotide I-Gene
polymorphism I-Gene
( O
SNP B-Gene
) O
) O
, O
epigenetics O
( O
DNA B-Chemical
methylation I-Chemical
) O
, O
and O
gene B-Gene
expression I-Gene
data O
as O
a O
biological O
process O
to O
delineate O
phenotypic O
traits O
under O
the O
framework O
of O
causal O

Given O
the O
widespread O
distribution O
of O
epigenetic O
marks O
and O
miRNA B-Gene
target I-Gene
sites I-Gene
in O
the O
genome O
, O
the O
regulatory O
circuits O
linking O
both O
mechanisms O
are O
likely O
to O
have O
a O
major O
impact O
in O
genome O
transcription O
and O
cell O
physiology O

The O
concept O
of O
induced O
proximity O
has O
inspired O
the O
development O
of O
powerful O
tools O
for O
epigenetic O
research O

The O
reported O
relationships O
between O
epigenetic O
clocks O
and O
mental B-Disease
health I-Disease
are O
mostly O
correlational O
, O
and O
the O
mechanisms O
are O
poorly O
understood O

Although O
Pb B-Chemical
exposure O
ceased O
at O
3 O
weeks O
of O
age O
, O
we O
observed O
thousands O
of O
sex-specific O
differentially O
methylated O
cytosines O
in O
the O
blood O
and O
liver O
of O
Pb-exposed B-Chemical
animals O
at O
5 O
months O
of O
age O
, O
including O
44 O
genomically O
imprinted O
loci O

3D O
structure O
of O
genome O
also O
plays O
an O
important O
role O
in O
pathogenesis O
of O
various O
hereditary O
diseases B-Disease
and O
cancer B-Disease

Notably O
, O
SnapATAC O
is O
the O
only O
method O
able O
to O
analyze O
a O
large O
dataset O
( O
> O
80,000 O
cells O
) O

Availability O
and O
implementation O
 O
EpiCompare O
is O
freely O
available O
on O
the O
web O
at O
http//epigenome O

890 O
is O
an O
epigenetic O
modification O
that O
can O
alter O
gene O
expression O
, O
and O
the O
incidence O
can O
vary O
across O
developmental O
stages O
, O
, O
and O
sexes O

The O
growing O
list O
of O
examples O
of O
epigenetic O
phenomena O
that O
potentially O
impact O
speciation O
( O
i O

13/bioc/html/epidecodeR O

457Background O
Epigenetic O
mechanisms O
are O
informational O
cellular O
processes O
instructing O
normal O
and O
diseased O
phenotypes O

Although O
still O
a O
developing O
field O
, O
in O
the O
future O
, O
epigenetic O
modifications O
of O
gene B-Gene
expression I-Gene
may O
provide O
novel O
biomarkers O
to O
predict O
future O
susceptibility O
and/or O
onset O
of O
MDD B-Disease
, O
improve O
diagnosis O
, O
and O
aid O
in O
the O
development O
of O
epigenetics-based O
therapies O
for O
depression B-Disease

Implementation O
of O
a O
switched O
current O
integrator O
can O
potentially O
increase O
both O
accuracy O
and O
window O
for O
detection O
, O
within O
the O
frequency O
region O
of O
reactions O

We O
also O
discuss O
the O
systems O
biology O
approaches O
that O
enabled O
these O
discoveries O

Epigenetic O
clocks O
involve O
a O
complex O
transformation O
of O
DNA B-Chemical
methylome I-Chemical
data O
into O
estimated O
biological O
age O

Many O
fields O
in O
experimental O
biology O
and O
medicine O
employ O
transgenomic O
or O
otherwise O
genome-manipulated O
cells O
or O
organisms O
without O
considering O
the O
epigenetic O
consequences O
for O
the O
recipient O
genomes O

Recent O
findings O
 O
With O
the O
completion O
of O
the O
genome O
project O
in O
2003 O
, O
high O
expectations O
existed O
for O
the O
DNA B-Chemical
sequence I-Chemical
information O
to O
provide O
answers O
about O
the O
causative O
mutations O
for O
common O
diseases B-Disease

In O
the O
present O
study O
, O
we O
investigated O
the O
impact O
of O
the O
Sandwich B-Chemical
Model I-Chemical
combined O
with O
PRS B-Gene
in O
student O
learning O
, O
engagement O
and O
satisfaction O
by O
a O
randomised O
trial O
in O
a O
large O
undergraduate O
biomedical/medical O
sciences O
class O

Here O
, O
we O
discuss O
the O
current O
and O
future O
application O
of O
the O
emerging O
CRISPR B-Gene
toolbox O
toward O
predicting O
gene O
regulatory O
network O
behavior O
, O
improving O
stem O
cell O
disease B-Disease
modeling O
, O
dissecting O
the O
epigenetic O
code O
, O
reprogramming O
cell O
fate O
and O
treating O
diseases O
of O
gene O

An O
essential O
post-translational O
modification O
is O
the O
histone B-Chemical
acetylation/deacetylation-process I-Chemical
which O
is O
regulated O
by O
histone B-Chemical
acetyltransferases I-Chemical
( O
HATs B-Gene
) O
and O
histone B-Chemical
deacetylases I-Chemical
( O
HDACs B-Gene
) O

A O
suite O
of O
methods O
has O
been O
developed O
in O
recent O
years O
to O
minimise O
problems O
afflicting O
observational O
epidemiology O
, O
to O
strengthen O
causal O
inference O
and O
to O
provide O
greater O
insights O
into O
modifiable O
intra-uterine O
and O
early O
life O
risk O
factors O

By O
building O
on O
this O
knowledge O
, O
the O
present O
work O
provides O
a O
timely O
perspective O
highlighting O
the O
extraordinary O
potential O
of O
environmental O
epigenetic O
analyses O
as O
a O
promising O
source O
of O
rapid O
and O
sensible O
tools O
for O
pollution O
biomonitoring O
, O
using O
marine B-Species
invertebrates I-Species
as O
sentinel O
organisms O

1323 O
Epigenetics O
invites O
, O
by O
its O
specific O
characteristics O
, O
to O
reflect O
on O
a O
variety O
of O
questions O
relating O
to O
public O
policies O
in O
a O
logic O
of O
&#8220;sustainable O
health&#8221; O
but O
also O
of O
&#8220;lasting O
respect&#8221; O
for O
fundamental O
rights O

Epigenetic O
age O
does O
not O
only O
estimate O
chronological O
age O
but O
can O
also O
predict O
the O
risk O
of O
chronic B-Disease
diseases I-Disease
and O
mortality O

1310 O
During O
newt B-Species
lens O
regeneration O
a O
unique O
transdifferentiation O
event O
occurs O

been O

0 O
million O
children O
under O
18 O
in O
the O
United O
States O
, O
with O
an O
economic O
burden O
that O
is O
estimated O
to O
exceed O
that O
of O
tuberculosis B-Disease
and O
HIV/AIDS B-Disease
combined O

In O
this O
article O
, O
we O
first O
analyse O
the O
transformations O
of O
the O
concept O
of O
epigenetics O
, O
from O
Waddington B-Gene
to O
contemporary O
accounts O
, O
in O
order O
to O
identify O
its O
different O
meanings O
and O
traditions O
, O
and O
to O
come O
up O
with O
a O
typology O
of O
epigenetics O
throughout O
its O
history O

Furthermore O
, O
small O
non-coding O
RNA O
, O
termed O
microRNA B-Gene
( O
miRNA B-Gene
) O
bind O
to O
messenger B-Gene
RNA I-Gene
( O
mRNA B-Gene
) O
to O
regulate O
translation O

While O
many O
cancers B-Disease
are O
characterized O
by O
genetic O
and O
epigenetic O
modifications O
, O
it O
is O
far O
simpler O
to O
develop O
molecular O
tests O
that O
detect O
genetic O
rather O
than O
epigenetic O
changes O

Method O
 O
We O
conducted O
a O
scoping O
review O
based O
on O
a O
systematic O
literature O
search O
in O
PsycINFO O
, O
PubMed O
, O
and O
Embase O
databases O
for O
relevant O
abstracts O
using O
the O
terms O
attachment O
and O
epigenet B-Gene
* O

00 O
and O
when O
the O
genetic O
and O
epigenetic O
similarity O
of O
DZ B-Species
twins O
differs O
from O
0 O

However O
, O
biochemical O
relapse O
occurs O
in O
20-40% O
of O
advanced O
PCa B-Disease
treated O
with O
RT B-Chemical
either O
alone O
or O
in O
combination O
with O
adjuvant-hormonal O
therapy O

Urologic O
(prostate O
, O
bladder B-Disease
, O
kidney O
) O
, O
lung B-Disease
, O
breast B-Disease
and O
colorectal B-Disease
cancers O
are O
the O
most O
common O
and O
despite O
major O
advances O
in O
their O
characterization O
, O
this O
has O
seldom O
translated O
into O
biomarkers O
amenable O
for O
clinical O
practice O

682 O
Biochemical B-Chemical
, O
epigenetic O
, O
genetic O
, O
and O
imaging O
biomarkers O
are O
used O
to O
identify O
people O
at O
high O
risk O
for O
developing O
cancer B-Disease

I O
aim O
to O
examine O
a O
series O
of O
French O
medical O
treatises O
and O
clandestine O
manuscripts O
that O
outlined O
a O
mechanist O
theory O
of O
epigenesis O
, O
between O
the O
end O
of O
the O
seventeenth O
century O
and O
the O
1720s O
, O
to O
bring O
to O
light O
the O
strategies O
- O
often O
quite O
original O
- O
that O

In O
recent O
years O
, O
the O
epigenetic O
aspects O
of O
microtia B-Disease
have O
begun O
to O
receive O
attention O

We O
provide O
a O
historical O
perspective O
of O
these O
methods O
, O
brief O
procedural O
outline O
with O
emphasis O
on O
the O
computational O
tools O
used O
to O
meaningfully O
dissect O
information O

This O
review O
outlines O
the O
epigenetic O
therapeutic O
approach O
for O
cancer B-Disease
therapy O
using O
CRISPR/Cas B-Gene
, O
from O
the O
basic O
understanding O
of O
cancer B-Disease
epigenetics O
to O
potential O
applications O
of O
CRISPR/Cas B-Gene
in O
treating O
cancer B-Disease

Epigenetic O
mechanisms O
are O
crucial O
in O
the O
fine-tuning O
of O
gene B-Gene
expression I-Gene
to O
generate O
such O
transcriptional O
networks O

Finally O
, O
QEMSA B-Chemical
was O
applied O
to O
both O
genetic O
and O
epigenetic O
analysis O
of O
cancer B-Disease

A O
self-propagating O
epigenetic O
cycle O
has O
also O
been O
identified O

New O
advances O
in O
understanding O
how O
environmentally O
sensitive O
, O
yet O
highly O
heritable O
developmental O
processes O
are O
regulated O
have O
come O
from O
the O
field O
of O
epigenetics O

Second O
, O
it O
seems O
that O
rRNA B-Gene
genes I-Gene
also O
play O
a O
role O
in O
the O
maintenance O
of O
genome O
stability O
, O
where O
lower O
copy O
number O
of O
rRNA B-Gene
genes I-Gene
destabilizes O
the O
genome O


The O
articles O
also O
demonstrate O
that O
, O
in O
addition O
to O
genetic B-Gene
polymorphisms I-Gene
, O
epigenetics B-Gene
may O
also O
contribute O
to O
wide O
interindividual O
variations O
in O
drug B-Chemical
metabolism I-Chemical
and O
transport O

us O

We O
conclude O
with O
a O
series O
of O
suggestions O
on O
interpreting O
and O
reporting O
findings O
in O
these O
fields O
that O
we O
feel O
will O
help O
researchers O
harness O
this O
work O
to O
benefit O
disadvantaged O
groups O
while O
avoiding O
the O
inadvertent O
dissemination O
of O
new O
and O
old O
forms O
of O
stigma O
or O
prejudice O

230 O
Cancer B-Disease
immune O
evasion O
is O
one O
of O
the O
hallmarks O
of O
carcinogenesis B-Disease

Epigenome O
- O
wide O
conditional O
logistic O
regression O
analysis O
on O
the O
methionine B-Chemical
dependency O
phenotype O
highlighted O
several O
epigenome O
signatures O
related O
to O
cell O
cycle O
and O
division O
and O
responses O
to O
IR O
and O
ultraviolet O
light O

In O
this O
special O
report O
, O
current O
approaches O
and O
future O
challenges O
that O
lay O
ahead O
due O
to O
the O
enormous O
complexity O
are O
discussed O

 O

It O
is O
important O
to O
address O
the O
use O
of O
epigenetic O
pathways O
in O
new O
approaches O
to O
molecular O
diagnosis O
and O
novel O
targeted O
treatments O
across O
the O
clinical O
spectrum O


Such O
cell O
memory/transformation O
due O
to O
pain O
can O
cause O
an O
abnormality O
in O
a O
fundamental O
intracellular O
response O
, O
such O
as O
a O
change O
in O
the O
three-dimensional O
structure O
of O
DNA B-Gene
, O
transcription O
, O
or O
translation O

After O
a O
stint O
in O
the O
USA O
for O
her O
postdoc O
at O
University O
of O
California O
, O
San O
Francisco O
( O
UCSF O
) O
, O
Aydan O
was O
awarded O
the O
Sofja O
Kovalevskaja O
Award O
to O
move O
back O
to O
Europe O
in O
2018 O
to O
start O
her O
own O
lab O

During O
the O
last O
decades O
, O
huge O
advances O
on O
techniques O
to O
measure O
the O
level O
of O
DNA B-Gene
methylation I-Gene
have O
occurred O
; O
we O
have O
passed O
from O
measuring O
it O
with O
more O
rudimentary O
and O
expensive O
techniques O
to O
nowadays O
the O
ability O
to O
measure O
DNA B-Gene
methylation I-Gene
at O
a O
single-base O

an O

Increased O
understanding O
would O
also O
pave O
the O
way O
to O
developing O
innovative O
tests O
for O
better O
assessment O
of O
individual O
risk O
of O
bleeding B-Disease
or O
thrombosis B-Disease

Furthermore O
, O
epigenetic O
therapy O
has O
been O
suggested O
as O
a O
future O
possibility O
for O
T2DM B-Disease
treatment O

We O
also O
found O
that O
genes O
commonly O
believed O
to O
be O
silenced O
via O
hypermethylation B-Chemical
in O
cancers B-Disease
may O
still O
display O
highly O
variable O
methylation B-Chemical
levels O
among O
cancer B-Disease
cells O
, O
and O
should O
be O
considered O
while O
using O
them O
as O
epigenetic O
biomarkers O

Recently O
, O
in O
the O
context O
of O
expanding O
knowledge O
of O
the O
epigenome O
( O
DNA B-Gene
methylation I-Gene
, O
histone B-Gene
modifications I-Gene
, O
and O
noncoding B-Gene
RNAs I-Gene
) O
, O
its O
potential O
involvement O
in O
the O
onset O
and O
progression O
of O
AF B-Disease
pathophysiology I-Disease
has O
started O
to O
emerge O

In O
this O
study O
, O
we O
use O
pseudotime O
analysis O
to O
determine O
the O
functional O
form O
of O
these O
trajectories O

Taken O
together O
, O
these O
findings O
strongly O
suggest O
that O
to O
progress O
from O
ML B-Disease
to O
RC B-Disease
liposarcoma I-Disease
the O
cells O
have O
to O
overcome O
the O
epigenetic O
silencing O
restriction O
point O
in O
order O
to O
reset O
their O
new O
stem-like O
differentiation O
signature O

281 O
methylation O
is O
an O
epigenetic O
modification O
of O
molecule O
that O
plays O
a O
vital O
role O
in O
gene O
expression O
regulation O

1415 O
Stem B-Species
cells I-Species
determine O
homeostasis O
and O
repair O
of O
many O
tissues O
and O
are O
increasingly O
recognized O
as O
functionally O
heterogeneous O

While O
there O
is O
some O
degree O
of O
similarity O
between O
the O
nature O
and O
content O
of O
these O
areas O
and O
the O
abundant O
literature O
on O
ethical O
, O
legal O
and O
social O
issues O
in O
genetics B-Gene
, O
the O
potential O
implications O
of O
epigenetics B-Gene
ought O
not O
be O
conflated O
with O
the O
latter O

Moreover O
, O
we O
show O
that O
controlled O
redox B-Chemical
reactions O
allow O
for O
interconversion O
of O
these O
DNA-encoded B-Gene
layers O
of O
information O

In O
2017 O
, O
ShortCutsTV O
produced O
the O
English O
documentary O
' O
Are O
You O
What O
Your O
Mother O
Ate O
? O
The B-Disease
Agouti B-Species
Mouse I-Species
Study O
' O
based O
on O
his O
pioneering O
epigenetic O
research O

With O
the O
investigation O
of O
transgene B-Gene
silencing I-Gene
effects O
, O
however O
, O
it O
soon O
became O
clear O
that O
transgenes B-Gene
had O
helped O
us O
in O
a O
rather O
unexpected O
way O
to O
identify O
novel O
molecular O
pathways O
that O
were O
highly O
relevant O
to O
plant B-Species
development O
and O
evolution O

1489 O
An O
overwhelming O
number O
of O
research O
articles O
have O
reported O
a O
strong O
relationship O
of O
the O
microbiome B-Species
with O
cancer B-Disease

As O
epigenetic O
modifications O
found O
in O
DNA B-Chemical
and O
histones O
exhibit O
specific O
roles O
on O
various O
biological O
processes O
, O
also O
epitranscriptomic O
marks O
control O
gene O
expression O
patterns O
that O
are O
crucial O
for O
proper O
cell O
proliferation O
, O
differentiation O
and O
tissue O
development O

In O
plants B-Species
, O
epigenetic O
mechanisms O
can O
help O
to O
stabilize O
hybrid O
genomes O
and O
contribute O
to O
reproductive O
isolation O
, O
but O
the O
relationship O
between O
genetic O
and O
epigenetic O
changes O
in O
animal B-Species
hybrids O
is O
unclear O

Participants O
were O
recruited O
from O
3 O
Part O
C O
early O
intervention O
sites O
in O
a O
large O
southeastern O
US B-Species
city O

Understanding O
these O
mechanisms O
may O
allow O
prevention O
of O
Î²-cell B-Species
dedifferentiation O
or O
induction O
of O
cell O
redifferentiation O
for O
restoration O
of O
the O
functional O
Î²-cell B-Species
mass O

It O
is O
largely O
attributed O
to O
genetic O
, O
as O
well O
as O
epigenetic O
variations O
between O
individuals O
, O
which O
may O
be O
inherited O
or O
acquired O

This O
review O
summarizes O
recent O
evidence O
that O
supports O
the O
role O
of O
epigenetically O
mediated O
early O
life O
programming O
in O
the O
later O
onset O
of O
obesity B-Disease

Technically O
, O
the O
main O
challenge O
of O
PAT-ChIP O
is O
the O
preparation O
of O
good-quality O
chromatin O
from O
FFPE B-Chemical
samples O

miRNA O
genes O
can O
be O
epigenetically O
regulated O
by O
DNA B-Chemical
methylation I-Chemical
or O
specific O
histone B-Chemical
modifications I-Chemical

This O
is O
poised O
to O
change O
with O
the O
development O
of O
new O
tools O
and O
concerted O
efforts O
by O
researchers O
across O
disciplines O
that O
have O
led O
to O
a O
better O
understanding O
of O
epigenetic O
mechanisms O
and O
comprehensive O
maps O
of O
epigenomic O
variation O

In O
summary O
, O
this O
framework O
will O
be O
useful O
to O
better O
detect O
outlier-free O
genetic O
and O
epigenetic O
signatures O
in O
various O
complex B-Disease
diseases I-Disease
and O
their O
developmental O
stages O

In O
this O
review O
, O
we O
will O
discuss O
the O
roles O
of O
epigenetic O
mechanisms O
, O
including O
histone O
modifications O
, O
chromatin O
remodeling O
, O
and O
DNA B-Chemical
methylation I-Chemical
, O
in O
the O
maintenance O
and O
establishment O
of O
the O
myelination O
program O
during O
normal O
oligodendrocyte B-Species
development O
and O
regeneration O

g O

However O
, O
an O
exhaustive O
epitranscriptome O
's O
characterization O
, O
aimed O
to O
systematically O
classify O
all O
RNA B-Chemical
modifications O
and O
clarify O
rules O
, O
actors O
, O
and O
outcomes O
of O
this O
promising O
regulatory O
code O
, O
is O
currently O
not O
available O
, O
mainly O
hampered O
by O
lack O
of O
suitable O
detecting O
technologies O

Moreover O
, O
they O
can O
be O
monitored O
not O
only O
in O
the O
affected O
tissue O
, O
but O
also O
in O
body O
fluids O

1314 O
 O
Purpose O
 O
Glutathione B-Chemical
S-Transferase I-Chemical
Mu I-Chemical
3 I-Chemical
( O
GSTM3 B-Gene
) O
protects O
the O
lens O
from O
oxidative O
stress O
that O
contributes O
to O
age-related B-Disease
cataract I-Disease
( O
ARC B-Disease
) O
formation O

gov O
on O
"March O
17 O
, O
2023 O
" O
, O
using O
the O
following O
keywords O
 O
" O
osteoarthritis B-Disease
" O
in O
combination O
with O
any O
of O
these O
terms O
 O
" O
genetic B-Gene
( I-Gene
s I-Gene
) I-Gene
, O
" O
mutation B-Gene
( I-Gene
s I-Gene
) I-Gene
, O
" O
genomic B-Gene
( I-Gene
s I-Gene

Alterations O
in O
chromatin O
structure O
lead O
to O
inaccessibility O
of O
genomic O
DNA B-Gene
to O
various O
regulatory O
proteins O
such O
as O
transcription O
factors O
, O
which O
eventually O
modulates O
gene O
expression O

We O
also O
discuss O
the O
multiple O
challenges O
in O
developing O
compounds O
targeting O
epigenetic O
enzymes O
( O
named O
epidrugs O
) O
for O
epigenetic-based O
therapies O

The O
optimal O
duration O
and O
the O
dose O
necessary O
for O
a O
chemopreventive O
effect O
require O
further O
studies O

Now O
, O
also O
epigenomic O
biomarkers O
are O
at O
hand O
and O
together O
genetic O
and O
epigenetic O
biomarkers O
can O
indeed O
improve O
the O
predictability O
of O
drug B-Chemical
treatment O

The O
future O
perspectives O
of O
single-cell O
multi-omics O
analysis O
based O
on O
the O
transcriptome B-Gene
will O
also O
be O
discussed O

Furthermore O
, O
epigenetic-directed O
compounds O
may O
not O
only O
affect O
cancer B-Disease
cells O
but O
also O
immune O
cells O
in O
the O
tumor B-Disease
microenvironment I-Disease
, O
which O
could O
be O
beneficial O
for O
the O
clinical O
response O
to O
immunotherapy O

So O
far O
, O
studies O
of O
the O
epigenome O
have O
been O
scarce O
in O
nephrology O

1334 O
 O
Background O
 O
Lung B-Species
macrophages I-Species
are O
major O
participants O
in O
the O
pulmonary O
innate O
immune O
response O

harvard O

We O
review O
those O
models O
and O
suggest O
that O
impaired O
coherence O
might O
largely O
contribute O
to O
the O
progressive O
destabilization O
of O
the O
molecular O
and O
gene B-Gene
regulatory I-Gene
networks I-Gene
, O
thus O
connecting O
different O
non-genetic O
aspects O
of O
cancer B-Disease

208 O
Fifth O
International O
Cancer B-Disease
Epigenetics I-Disease
Conference O
, O
Beijing O
, O
China O
, O
21-23 O
October O
2016 O
This O
meeting O
reported O
many O
new O
findings O
in O
the O
field O
of O
cancer B-Disease
epigenetics I-Disease
, O
including O
basic O
science O
, O
translational O
and O
clinical O
studies O

Understanding O
the O
differential O
biological O
mechanisms O
contributing O
to O
risk O
vs O

To O
understand O
how O
genomics O
influence O
health O
disparities O
in O
the O
rheumatic B-Disease
diseases I-Disease
, O
further O
studies O
in O
different O
populations O
worldwide O
are O
needed O

seeks O

Gene O
regions O
of O
identified O
loci O
were O
enriched O
in O
nervous B-Disease
system I-Disease
development I-Disease
functions O

We O
consolidate O
evidence O
suggesting O
that O
although O
DNA B-Gene
methylation I-Gene
is O
likely O
present O
in O
some O
flatworm B-Species
lineages O
, O
it O
does O
not O
regulate O
neoblast O
function O
in O
Schmidtea B-Species
mediterranea I-Species

Consequently O
, O
there O
is O
a O
medical O
imperative O
to O
understand O
the O
link O
between O
epigenetic O
ageing O
, O
and O
healthspan O

We O
hypothesized O
that O
especially O
the O
insoluble O
, O
non-digestible O
particles O
that O
do O
not O
release O
a O
known O
hazardous O
chemical B-Chemical
can O
be O
underappreciated O
agents O
acting O
to O
affect O
the O
regulation O
inside O
macrophages B-Species
upon O
phagocytosis O

Methods O

Using O
a O
new O
codec O
, O
the O
decompression O
can O
be O
done O
on O
a O
graphical O
processing O
unit O
( O
GPU O
) O
making O
it O
fast O
enough O
to O
create O
the O
training O
batches O
during O
training O
, O
mitigating O
the O
need O
for O
saving O
preprocessed O
training O
examples O
to O
disk O

Findings O
 O
Recent O
evidence O
suggests O
a O
critical O
role O
of O
defined O
and O
tightly O
regulated O
neurodevelopmental O
programs O
running O
out O
of O
control O
in O
NDDs B-Disease
, O
most O
notably O
neuronal O
proliferation O
and O
migration O
, O
synapse O
formation O
and O
remodelling O
, O
as O
well O
as O
neural O
network O
configuration O
resulting O
in O

However O
, O
to O
date O
, O
gene B-Gene
discovery O
approaches O
have O
only O
mapped O
a O
minority O
of O
the O
heritability O
of O
these O
common O
diseases B-Disease
, O
and O
most O
disease-associated O
variants O
have O
been O
found O
to O
be O
non-coding O
, O
suggesting O
mechanisms O
of O
disease-association O
through O
transcriptional O
regulatory O
effects O

Conversely O
, O
metabolites O
and O
cofactors O
affect O
the O
expression O
and O
activity O
of O
epigenetic O
regulators O

1092 O
Epigenetic O
alterations O
in O
the O
pattern O
of O
DNA B-Chemical
and O
histone B-Chemical
modifications O
play O
a O
crucial O
role O
in O
cancer B-Disease
development O

, O
sparsely O
or O
moderately O
methylated O

Our O
genome-wide O
studies O
also O
revealed O
aberrant O
widespread O
hypermethylation O
that O
affected O
regulatory O
regions O
of O
the O
kidney B-Disease
genome O
in O
ccRCC B-Disease

Here O
, O
we O
provide O
a O
critical O
review O
of O
the O
major O
existing O
algorithms O
for O
correcting O
cell-type O
composition O
in O
the O
context O
of O
Illumina B-Chemical
Infinium I-Chemical
Methylation I-Chemical
Beadarrays I-Chemical
, O
with O
the O
aim O
of O
providing O
useful O
recommendations O
to O
the O
EWAS B-Disease
community O

Epigenetic O
mechanisms O
drive O
developmental O
processes O
and O
have O
also O
been O
shown O
to O
be O
tied O
to O
disease B-Disease
development O

Given O
the O
dynamic O
nature O
of O
the O
epigenome O
, O
longitudinal O
studies O
are O
indispensable O
for O
investigating O
smoking-induced B-Disease
methylation O
changes O
over O
time O

gain O

It O
could O
be O
helpful O
to O
the O
research O
about O
environmental O
epigenetic O
toxicology O

Genome-scale O
DNA B-Chemical
- I-Chemical
M I-Chemical
at O
ages O
10 O
and O
18 O
years O
in O
whole O
blood O
of O
325 O
subjects O
( O
n O
= O
140 O
females O
) O
in O
the O
( O
) O
birth O
cohort O
was O
analyzed O
using O
Illumina B-Chemical
Infinium I-Chemical
arrays I-Chemical

Such O
evidence O
can O
cast O
doubt O
on O
perceptions O
of O
justice O
in O
health O
, O
which O
in O
turn O
raises O
questions O
over O
the O
suitability O
of O
actions O
taken O
in O
pursuit O
of O
equity O

Epigenetics O
becomes O
a O
hot O
subject O
of O
research O
on O
the O
cardiac B-Disease
differentiation I-Disease
mechanism O
of O
stem B-Species
cells I-Species
providing O
new O
theories O
and O
Methods O
for O
stem B-Species
cell I-Species
application O
in O
developmental O
biology O
, O
genetics O
and O
regenerative O
medicine O

Communicated O
by O
Ramaswamy O
H O

629 O
The O
widespread O
application O
of O
ChIP-seq O
led O
to O
a O
growing O
need O
for O
consistent O
analysis O
of O
multiple O
epigenetics O
profiles O
, O
for O
instance O
, O
in O
human B-Species
studies O
where O
multiple O
replicates O
are O
a O
common O
element O
of O
design O

Understanding O
the O
functional O
role O
of O
these O
modifications O
in O
gene B-Gene
regulation O
, O
normal O
development O
, O
and O
pathological B-Disease
conditions I-Disease
requires O
the O
ability O
to O
localize O
these O
modifications O
in O
genomic O
DNA B-Gene

653 O
Methods O
to O
measure O
chromatin O
contacts O
at O
genomic O
regions O
bound O
by O
histone B-Chemical
modifications O
or O
proteins O
are O
important O
tools O
to O
investigate O
chromatin O
organization O

by O

Conclusions O
 O
Detection O
and O
comparison O
of O
epialleles O
within O
multiple O
tumour B-Disease
regions I-Disease
enables O
phylogenetic O
analyses O
, O
identification O
of O
differentially O
expressed O
epialleles O
, O
and O
provides O
a O
measure O
of O
epigenetic O
heterogeneity O

It O
constitutes O
a O
mechanism O
by O
which O
cell O
genome O
is O
regulated O
, O
allowing O
from O
a O
common O
genome O
of O
an O
individual O
to O
obtain O
all O
the O
different O
cell O
types O
that O
constitute O
the O
individual O

In O
parallel O
, O
studies O
of O
humans B-Species
and O
mice B-Species
, O
using O
high-throughput O
technologies O
, O
have O
revealed O
additional O
complexity O
in O
epigenetic O
processes O
, O
notably O
highlighting O
the O
importance O
of O
crosstalk O
between O
different O
epigenetic O
marks O

930 O
Transcriptional O
misregulation O
is O
involved O
in O
the O
development O
of O
many O
diseases O
, O
especially O
neoplastic B-Disease
transformation I-Disease

A O
number O
of O
studies O
exploring O
the O
cancer B-Disease
genome O
of O
brain B-Disease
tumors I-Disease
across O
ages O
using O
integrated O
genetics O
and O
epigenetics O
and O
next-generation O
sequencing O
technologies O
have O
recently O
emerged O

Computational O
analysis O
of O
differential O
DNA B-Gene
enrichment O
between O
conditions O
is O
important O
for O
identifying O
epigenetic O
alterations O
in O
disease B-Disease
compared O
to O
healthy O
controls O
and O
for O
revealing O
dynamic O
epigenetic O
modifications O
throughout O
normal O
and O
distorted O
cell O
differentiation O
and O
development O

935 O
As O
a O
potential O
link O
between O
genetic O
predisposition O
, O
environmental O
exposures O
, O
and O
food B-Disease
allergy I-Disease
outcomes O
, O
epigenetics O
has O
been O
a O
molecular O
variable O
of O
interest O
in O
ongoing O
efforts O
to O
understand O
food B-Disease
allergy I-Disease
mechanisms O
and O
outcomes O

849 O
 O
Epigenetic O
phenomena O
play O
a O
key O
role O
in O
regulating O
gene B-Gene
expression I-Gene

Differentially O
methylated O
positions O
and O
regions O
( O
DMPs O
and O
DMRs O
) O
were O
identified O
through O
linear O
regression O
analysis O

As O
evidence O
for O
germline O
non-genetic O
inheritance O
of O
phenotypes O
and O
diseases B-Disease
continues O
to O
grow O
in O
model O
organisms O
, O
there O
are O
fewer O
reports O
of O
this O
phenomenon O
in O
humans B-Species
, O
due O
to O
a O
variety O
of O
complications O
in O
evaluating O
this O
mechanism O
of O
inheritance O
in O
humans B-Species

This O
has O
led O
to O
considerable O
advances O
in O
the O
understanding O
of O
the O
basic O
biology O
and O
pathogenesis O
of O
brain B-Disease
tumors I-Disease
, O
including O
the O
most O
malignant O
and O
common O
variants O
in O
children O
 O
gliomas B-Disease
and O
medulloblastoma B-Disease

O O
wing O
to O
their O
involvement O
in O
these O
pathways O
and O
frequent O
occurrence O
in O
RCC B-Disease
, O
epigenetic O
alterations O
are O
regarded O
as O
potential O
biomarkers O
for O
the O
early O
detection O
of O
disease O
and O
for O
prediction O
of O
prognosis O
and O
treatment O
response O

Additional O
research O
is O
needed O
to O
evaluate O
if O
heritable O
effects O
of O
EDCs B-Chemical
are O
evident O
in O
aquatic B-Species
wildlife I-Species
, O
as O
has O
been O
demonstrated O
for O
terrestrial B-Species
mammals I-Species

establish O
that O
crucial O
SNPs O
linked O
to O
autoimmune B-Disease
disease I-Disease
are O
enriched O
in O
DNA B-Chemical
regions O
of O
CpG B-Chemical
demethylation O
that O
govern O
Treg B-Gene
cell I-Gene
development O
and O
function O

DNA O
methylation O
signatures O
associated O
with O
concurrent O
disease B-Disease
and O
with O
the O
development O
of O
asthma B-Disease
during O
childhood O
asthma B-Disease
have O
been O
identified O
, O
but O
their O
significance O
is O
not O
easily O
interpretable O

However O
, O
comparisons O
between O
these O
studies O
are O
routinely O
hampered O
by O
the O
lack O
of O
consistency O
in O
reporting O
sites O
of O
methylation B-Chemical
evaluated O

More O
specifically O
, O
we O
explore O
how O
further O
investigation O
of O
the O
ambiguous O
notions O
of O
epigenetic O
normality O
and O
epigenetic O
plasticity O
should O
play O
a O
role O
in O
shaping O
this O
emerging O
debate O

690 O
There O
is O
robust O
evidence O
of O
genetic O
susceptibility O
to O
Attention-Deficit B-Disease
Hyperactivity I-Disease
Disorder I-Disease
( O
ADHD O
) O
; O
however O
, O
there O
still O
remains O
significant O
variability O
that O
is O
not O
attributable O
to O
genetic O
factors O

We O
concluded O
that O
the O
integration O
of O
historical O
parental O
exposure O
to O
lead-contaminated B-Chemical
and O
current O
information O
about O
their O
offspring's O
environment O
are O
impacting O
plant B-Species
phenotypes O

The O
procedures O
introduced O
in O
the O
last O
few O
years O
dealt O
with O
this O
problem O
proponing O
successful O
strategies O
to O
obtain O
high-resolution O
ChIP B-Gene
profiles I-Gene
from O
FFPE B-Chemical
archival I-Chemical
samples I-Chemical

In O
conclusion O
, O
these O
results O
suggest O
that O
early O
conceptuses O
derived O
from O
IVP O
embryos O
exhibit O
epigenomic O
and O
transcriptomic O
changes O
that O
later O
affect O
its O
elongation O
and O
focal O
adhesion O
, O
impairing O
post-transfer O
survival O


Recent O
advances O
in O
epigenome O
engineering O
technologies O
allow O
now O
for O
the O
large-scale O
assessment O
of O
the O
functional O
relevance O
of O
DNA B-Gene
methylation O

1324 O
The O
epigenetic O
and O
physiological O
mechanisms O
that O
alter O
the O
structure O
of O
chromatin O
include O
the O
methylation O
of O
DNA B-Chemical
, O
changes O
in O
the O
histones B-Chemical
, O
and O
changes O
in O
RNA B-Chemical

Improvements O
in O
diagnostics O
and O
therapy O
of O
this O
common O
tumor B-Disease
are O
urgently O
required O
and O
need O
to O
be O
based O
on O
a O
better O
understanding O
of O
its O
biology O

Changes O
of O
DNA B-Gene
methylation O
levels O
and O
patterns O
have O
been O
widely O
studied O
in O
several O
diseases O
, O
especially O
cancer B-Disease
, O
where O
interest O
has O
focused O
on O
biomarkers O
for O
early O
detection O
of O
cancer B-Disease
development O
, O
accurate O
diagnosis O
, O
and O
response O
to O
treatment O
, O
but O
have O
also O
been O

We O
also O
use O
published O
data O
from O
redox O
proteomics O
to O
map O
out O
known O
intersections O
between O
oxidative B-Disease
stress I-Disease
and O
epigenetics O
that O
may O
signpost O
helpful O
directions O
for O
future O
investigation O

Based O
on O
the O
proposed O
model O
, O
we O
provided O
a O
method O
to O
stratify O
glioma B-Disease
patients O
according O
to O
their O
epigenomic O
state O

596 O
methylation O
at O
( O
) O
dinucleotides O
changes O
as O
a O
function O
of O
age O
in O
and O
models O
, O
a O
process O
that O
may O
contribute O
to O
development O

e O

Here O
we O
describe O
in-depth O
molecular O
mechanism O
underlying O
the O
most O
important O
RNA B-Gene
modifications O
with O
emerging O
roles O
in O
the O
nervous B-Disease
system I-Disease

Next O
, O
each O
primer O
pair O
is O
annotated O
with O
the O
number O
of O
cut O
sites O
in O
primers O
and O
amplicons O
, O
upstream O
and O
downstream O
genes B-Gene
, O
and O
CpG B-Gene
islands I-Gene
loci O

The O
mounting O
evidence O
points O
to O
a O
possible O
interaction O
between O
age-related O
epigenomic O
alterations O
and O
other O
aging O
hallmarks O
, O
like O

Availability O
and O
implementation O
 O
The O
source O
code O
and O
documentation O
manual O
for O
MammalMethylClock B-Gene
, O
and O
clock O
coefficient O

I O
inquire O
into O
the O
historical O
worth O
of O
the O
positions O
defended O
by O
these O
authors O
as O
well O
as O
into O
the O
connections O
existing O
between O
the O
history O
of O
epigenesis O
and O
that O
of O
materialism O
in O
the O
early O
modern O
era O

731 O
Diabetic B-Disease
nephropathy I-Disease
is O
one O
of O
the O
most O
prevalent O
microvascular O
complication O
in O
patients O
suffering O
from O
diabetes B-Disease
and O
is O
reported O
to O
be O
the O
major O
cause O
of O
renal O
failure O
when O
compared O
to O
any O
other O
kidney O
disease B-Disease

Circadian O
regulatory O
pathways O
result O
in O
rhythmic O
epigenetic O
modifications O
and O
the O
formation O
of O
circadian O
epigenomes O

As O
more O
datasets O
are O
being O
generated O
on O
the O
EPIC B-Chemical
platform O
, O
this O
clock O
will O
be O
valuable O
in O
studies O
using O
gestational O
age O
to O
assess O
neonatal O
development O

The O
epigenome O
may O
also O
harbour O
useful O
information O
about O
life-time O
exposures O
(measured O
or O
unmeasured O
) O
irrespective O
of O
their O
influence O
on O
health O
or O
disease B-Disease
, O
creating O
the O
potential O
for O
a O
person-specific O
biosocial O
archive O

Better O
understanding O
of O
DNA B-Gene
methylation I-Gene
in O
vertebrate B-Species
embryogenesis O
will O
provide O
insights O
for O
new O
treatment O
of O
DNA B-Gene
methylation-related I-Gene
human B-Disease
diseases I-Disease

PubMed O
database O
search O
yielded O
3051 O
hits O
on O
epigenetics O
and O
drugs B-Chemical
, O
starting O
in O
1992 O
and O
peaking O
in O
2016 O

Furthermore O
, O
we O
demonstrate O
that O
the O
stochastic O
evolution O
of O
age-associated O
DNA B-Chemical
methylation I-Chemical
patterns O
in O
BBA-seq B-Chemical
data O
enables O
epigenetic O
clocks O
for O
individual O
DNA B-Chemical
strands O

Nevertheless O
, O
it O
promises O
to O
provide O
novel O
insight O
needed O
for O
utilizing O
these O
alterations O
as O
potential O
diagnostic O
, O
prognostic O
markers O
, O
predict O
treatment O
efficacy O
, O
as O
well O
as O
therapeutic O
agents O

This O
review O
surveys O
the O
current O
state O
of O
computational O
tools O
developed O
for O
single-cell O
DNA B-Chemical
methylome I-Chemical
data O
analysis O

Pathway O
analysis O
showed O
increase O
in O
methylation O
of O
genes O
involved O
in O
antioxidant O
pathways O
including O
glutathione B-Chemical
and O
NRF2 B-Gene

input O

The O
widespread O
application O
of O
epigenome O
( O
eg O
, O
methylome O
) O
analyses O
will O
enhance O
our O
understanding O
of O
disease B-Disease
heterogeneity I-Disease
, O
epigenotypes O
( O
CpG B-Gene
island I-Gene
methylator I-Gene
phenotype I-Gene
, O
LINE-1 B-Gene
( O
long O
interspersed O
nucleotide O
element-1 O
; O
also O
called O
long O

Here O
, O
we O
review O
the O
promise O
and O
pitfalls O
of O
epigenetic O
drug B-Chemical
development O
to O
date O
and O
provide O
an O
outlook O
on O
recent O
advances O
and O
their O
promise O
for O
future O
therapeutic O
applications O

Such O
strategies O
can O
also O
be O
repurposed O
to O
normalize O
gene B-Gene
expression I-Gene
changes O
that O
occur O
secondary O
to O
the O
genetic O
defect O

The O
fields O
of O
genetic O
and O
environmental O
epidemiology O
primarily O
seek O
to O
identify O
genetic O
and O
environmental O
risk O
factors O
for O
disease O
, O
respectively O

985 O
methylation O
of O
sites O
is O
commonly O
measured O
using O
platforms O

The O
androgen B-Gene
receptor I-Gene
and O
its O
downstream O
effector O
pathways O
, O
central O
to O
prostate B-Disease
cancer I-Disease
initiation O
and O
progression O
, O
are O
subject O
to O
a O
multitude O
of O
epigenetic O
alterations O

Although O
hypermethylation O
of O
gene B-Gene
promoters O
is O
in O
turn O
associated O
with O
gene B-Gene
inactivation O
, O
the O
precise O
consequences O
of O
genome-wide O
hypomethylation O
are O
still O
debated O

404 O

Interestingly O
, O
recent O
studies O
have O
strengthened O
the O
knowledge O
of O
TDP-43 B-Gene
activity O
at O
the O
chromatin O
level O
and O
its O
implication O
in O
the O
regulation O
of O
DNA B-Chemical
transcription O
and O
stability O

In O
addition O
, O
his O
laboratory O
is O
interested O
in O
tumor B-Disease
biology O
, O
investigating O
somatic O
alterations O
in O
tumor B-Disease
tissue O
from O
the O
patients O
who O
have O
developed O
exposure-related B-Disease
cancers I-Disease

Hence O
, O
identification O
of O
epigenetic O
variations O
at O
candidate O
genes O
, O
or O
epigenetic O
signatures O
genome-wide O
by O
epigenome-wide O
association O
studies O
can O
aid O
in O
prompt O
diagnosis O
to O
prevent O
progression O
of O
complications O
and O
identification O
of O
much-needed O
new O
therapeutic O
targets O

The O
results O
of O
this O
analysis O
support O
those O
of O
epidemiological O
studies O
highlighting O
the O
importance O
of O
examining O
the O
construction O
of O
health O
during O
life O

389 O
Histone B-Chemical
modifications O
and O
DNA B-Chemical
methylation O
together O
govern O
promoter O
availability O
, O
thereby O
influencing O
gene O
expression O

In O
this O
review O
, O
we O
focus O
on O
the O
current O
understanding O
of O
the O
role O
of O
epigenetic O
marks O
and O
their O
three-dimensional O
nuclear O
organization O
in O
the O
developmental O
trajectory O
of O
distinct O
brain O
cell O
types O
to O
decipher O
the O
complex O
gene B-Gene
regulatory I-Gene
mechanisms I-Gene
that O
are O
disrupted O
in O
schizophrenia B-Disease

mpi-inf O

The O
use O
of O
MSP B-Gene
prompted O
the O
design O
of O
an O
ISFET B-Gene
weak O
inversion O
current O
mirror O
topology O
for O
differential O
sensing O
and O
reduction O
of O
drift O
and O
temperature O
sensitivities O

With O
progress O
of O
genome B-Gene
biology O
, O
the O
applicability O
of O
the O
nearly O
neutral O
theory O
has O
expanded O

Thus O
, O
this O
review O
focuses O
on O
the O
emerging O
area O
of O
pharmaco(epi)genomics O
, O
specifically O
highlighting O
epigenetic O
reprogramming O
during O
tumorigenesis O
and O
how O
epigenetic O
markers O
are O
targeted O
as O
a O
therapy O
( O
epidrugs B-Chemical
) O
and O
the O
clinical O
implications O
of O
this O
for O
cancer B-Disease
treatment O

Finally O
, O
we O
discuss O
the O
implications O
of O
mechanistic O
findings O
from O
model O
organisms O
for O
the O
emergent O
examples O
of O
parental O
effects O
in O
human B-Species
populations O

This O
review O
presents O
our O
perspective O
on O
the O
epigenome O
as O
a O
mediator O
for O
host-microbiota O
cross O
talk O
, O
as O
well O
as O
methodology O
to O
study O
epigenetics O
, O
the O
role O
of O
dysbiosis O
in O
disease O
, O
and O
how O
the O
gut O
microbiome-host O
axis O
may O
be O
used O
in O
personal O
medicine O

Because O
gene B-Gene
expression I-Gene
changes O
are O
critical O
in O
both O
normal O
development O
and O
disease B-Disease
progression I-Disease
, O
epigenetics O
is O
widely O
applicable O
to O
many O
aspects O
of O
biological O
research O

This O
would O
underlie O
an O
essential O
paradigm O
shift O
, O
and O
power O
the O
search O
for O
links O
between O
genomic O
and O
epigenomic O
features O
and O
physiology O

Epigenetics O
is O
able O
to O
provide O
answers O
to O
previously O
unanswered O
health-related O
questions O
and O
can O
explain O
differences O
in O
level O
of O
complexity O
between O
organisms O

The O
epigenome O
is O
susceptible O
to O
changes O
and O
can O
be O
shaped O
by O
nutritional O
states O
, O
especially O
in O
prenatal O
period O
through O
transgenerational O
mechanisms O
and O
in O
early O
postnatal O
life O
when O
critical O
developmental O
processes O
are O
taking O
place O

Recent O
work O
is O
now O
aiming O
to O
look O
further O
into O
the O
genome O
at O
the O
natural O
variation O
present O
in O
the O
epigenome O
, O
in O
DNA B-Chemical
methylation I-Chemical
as O
well O
as O
histone B-Chemical
modifications I-Chemical
, O
which O
both O
regulate O
gene O
expression O

Review O
of O
individual O
genes O
specific O
to O
poor-prognosis B-Disease
patients I-Disease
revealed O
the O
majority O
to O
be O
candidate O
tumor B-Gene
suppressors I-Gene
in O
other O
cancer B-Disease
types I-Disease

Translational O
tools O
like O
neuroimaging O
by O
PET B-Chemical
and O
magnetic O
resonance O
imaging O
provide O
the O
best O
way O
to O
link O
our O
current O
understanding O
of O
epigenetic O
changes O
with O
in O
vivo O
function O
in O
normal O
and O
diseased B-Disease
brains O

Recently O
, O
we O
have O
demonstrated O
that O
a O
semi-supervised O
peak O
calling O
approach O
( O
SPAN O
) O
allows O
for O
robust O
analysis O
of O
multiple O
epigenetic O
profiles O
while O
preserving O
individual O
sample O
statistics O

These O
few O
studies O
have O
reported O
significant O
epigenetic O
differences O
in O
various O
racial O
and O
ethnic O
groups O
that O
could O
account O
for O
the O
differences O
seen O
in O
tumor B-Disease
initiation I-Disease
, O
progression I-Disease
, O
aggressiveness I-Disease
, O
and O
outcome O
of O
these O
cancers B-Disease

6 O
Ã O
10-7 O
) O
to O
3 O

573Background O
The O
CRISPR-Cas B-Gene
systems O
have O
emerged O
as O
a O
robust O
genome O
editing O
tool O
useful O
in O
various O
fields O
of O
research O

As O
evidenced O
by O
the O
pandemic's O
disproportionate O
effects O
on O
people O
with O
low O
socioeconomic O
or O
poor O
health O
status O
, O
some O
pregnant O
women O
bore O
considerable O
physical O
and O
psychological O
stress O
which O
combined O
with O
other O
stress O
factors O
such O
as O
domestic O
violence O

Medulloblastoma O
is O
characterized O
by O
four O
major O
molecularly O
and O
histopathologically O
distinct O
groups O
, O
wingless O
( O
WNT B-Gene
) O
, O
sonic B-Gene
hedgehog I-Gene
( O
SHH B-Gene
) O
, O
group O
3 O
( O
G3 B-Gene
) O
, O
and O
group O
4 O
( O
G4 B-Gene
) O
, O
that O
, O
except O
for O

which O

elements O

solium B-Species
undergoes O
transcriptional O
and O
developmental O
regulation O
via O
epigenetics O
during O
its O
complex O
lifecycle O
and O
host O
interactions O

The O
analysis O
of O
the O
orthogonal O
dimension O
of O
the O
chromatin B-Chemical
space I-Chemical
identify O
32,662 O
chromatin B-Chemical
determinant O
regions O
( O
CDRs O
) O
, O
genomic O
regions O
with O
different O
epigenetic O
characteristics O
between O
the O
cell O
types O

The O
proposed O
14 O
AD B-Disease
epigenetic O
repositioning O
drugs O
have O
overlapping O
targets O
and O
miRs O
with O
known O
AD B-Disease
epigenetic O
targets O
and O
miRs O

Together O
with O
genetic O
prediction O
of O
appearance O
and O
biogeographic O
ancestry O
, O
epigenomic O
lifestyle O
prediction O
is O
expected O
to O
increase O
the O
ability O
of O
police O
to O
find O
unknown O
perpetrators O
of O
crime O
who O
are O
not O
identifiable O
using O
current O
forensic O
DNA B-Gene
profiling O

Alternations O
in O
epigenetic O
mechanisms O
may O
contribute O
to O
the O
incidence O
of O
aneuploidy B-Disease
as O
well O
as O
recurrent O
implantation O
failure O
of O
euploid O
embryos O

001 O
; O
and O
DNAm O
cystatin B-Chemical
C I-Chemical
, O
b(SE) O
= O
- O

Transcription O
is O
the O
first O
step O
in O
gene O
expression O
and O
is O
subject O
to O
multiple O
layers O
of O
regulation O
in O
which O
epigenetic O
mechanisms O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
tail I-Chemical
modifications I-Chemical
, O
and O
chromosomal B-Chemical
conformation I-Chemical
play O
an O
essential O
role O

758 O
Epigenome O
editing O
has O
emerged O
as O
a O
powerful O
technique O
for O
targeted O
manipulation O
of O
the O
chromatin O
and O
transcriptional O
landscape O
, O
employing O
designer O
DNA O
binding O
domains O
fused O
with O
effector O
domains O
, O
known O
as O
epi-editors O

This O
tool O
proves O
useful O
in O
predicting O
the O
role O
of O
H3K9ac B-Gene
and O
H3K27ac B-Gene
in O
associated O
gene O
expression O
after O
knocking O
down O
deacetylases O
FAM60A B-Gene
and O
SDS3 B-Gene
and O
N6-methyl-adenosine-associated B-Chemical
gene O
expression O
after O
knocking O
out O
the O
reader O
proteins O

Additionally O
, O
we O
highlight O
evidence O
for O
other O
types O
of O
epigenetic O
patterns O
to O
serve O
as O
exposure O
biomarkers O

In O
this O
review O
, O
we O
focus O
on O
epigenetic O
regulatory O
mechanisms O
in O
the O
TGF-Î² B-Chemical
signaling O
during O
mammalian B-Species
development O
and O
diseases O
and O
discuss O
the O
central O
role O
of O
the O
interaction O
between O
R-SMAD B-Gene
and O
various O
epigenetic O
regulators O
in O
this O
epigenetic O
regulation O

However O
, O
genetic O
factors O
are O
not O
enough O
to O
explain O
osteoporosis B-Disease
development O
and O
OVF B-Disease
occurrence O

Could O
the O
same O
be O
true O
for O
RNA B-Gene
? O
Joseph B-Gene
Martin I-Gene
discusses O

Genes O
that O
are O
affected O
include O
those O
involved O
in O
immune O
cell O
function O
and O
differentiation O
, O
TGFÎ² B-Gene
and O
Wnt B-Gene
pathways O
, O
extracellular O
matrix O
accumulation O
, O
transcription O
factors O
, O
and O
angiogenesis O

Although O
a O
significant O
amount O
of O
locus-specific O
methylation O
is O
epigenetically O
conserved O
, O
the O
majority O
of O
tissue-specific O
DNA B-Chemical
methylation O
is O
not O
conserved O
across O
the O
species B-Species
and O
tissue O
types O
that O
we O
investigated O

Finally O
, O
we O
discuss O
the O
therapeutic O
possibilities O
of O
their O
utilization O
for O
the O
betterment O
of O
immunotherapy O
in O
terms O
of O
diagnosis O
, O
progression O
, O
and O
cure O
for O
cancer B-Disease
patients O

We O
report O
a O
de O
novo O
deleterious O
mutation O
of O
( O
HIST1H1E B-Gene
; O
c O

166 O
Over O
the O
past O
25 O
years O
, O
the O
broad O
field O
of O
epigenetics O
and O
, O
over O
the O
past O
decade O
in O
particular O
, O
the O
emerging O
field O
of O
neuroepigenetics O
have O
begun O
to O
have O
tremendous O
impact O
in O
the O
areas O
of O
learned O
behavior O
, O
neurotoxicology O
, O
CNS B-Disease

350Background O

The O
current O
evidence O
supports O
the O
notion O
that O
genotype-dependent O
methylation O
may O
account O
, O
in O
part O
, O
for O
the O
mechanisms O
underlying O
observed O
G O
Ã O
E O
interactions O
in O
loci O
such O
as O
APOE B-Gene
, O
IL6 B-Gene
and O
ATP-binding B-Gene
cassette I-Gene
A1 I-Gene

Similar O
events O
may O
also O
affect O
other O
tumor B-Disease
suppressor I-Disease
genes O
, O
potentially O
being O
a O
significant O
contributor O
to O
cancer B-Disease
burden I-Disease

Multi-dimensional O
analysis O
using O
these O
approaches O
for O
spatial O
positioning O
and O
lineage O
tracing O
applications O
will O
be O
reviewed O

Scholars O
from O
many O
disciplines O
have O
formulated O
both O
optimistic O
and O
cautionary O
claims O
regarding O
its O
potential O
normative O
implications O

Still O
, O
in O
most O
cases O
, O
the O
mechanisms O
involved O
are O
poorly O
understood O

Johnson I-Gene

ca O
/ O
tools O
/ O
epivar O
; O
EpiVar B-Gene
Browser I-Gene
source O
code O
 O
https O
 O
/ O
/ O
github O

This O
technology O
allows O
us O
to O
identify O
structural O
changes O
in O
the O
genome O
that O
occur O
due O
to O
exposure O
to O
a O
wide O
variety O
of O
substances O
including O
alcohol B-Chemical
, O
tobacco B-Chemical
, O
and O
cannabis B-Chemical

Progress O
in O
the O
study O
of O
bromodomains O
, O
and O
the O
development O
of O
bromodomain B-Chemical
ligands O
, O
has O
been O
rapid O

helps O

g O

1316 O
is O
an O
important O
epigenetic O
modification O
that O
regulates O
development O
and O
plays O
a O
role O
in O
the O
pathophysiology O
of O
many O

Apart O
from O
epigenetic O
changes O
of O
islet O
Î² B-Gene
cells O
and O
glycometabolic O
tissues O
or O
organs O
, O
the O
inflammation-related O
epigenetics O
is O
also O
the O
core O
pathomechanism O
leading O
to O
Î²-cell B-Gene
dysfunction O
and O
insulin B-Chemical
resistance O

Thr146Hisfs*50 O
) O
, O
encoding O
H1 B-Gene
histone I-Gene
linker I-Gene
protein I-Gene
H1 I-Gene

770 O
Epigenetic O
gene B-Gene
regulation O
is O
a O
critical O
process O
controlling O
differentiation O
and O
development O
, O
the O
malfunction O
of O
which O
may O
underpin O
a O
variety O
of O
diseases B-Disease

identity O

In O
conclusion O
, O
we O
demonstrate O
that O
the O
plasticity O
of O
is O
impacted O
by O
myriad O
genetics O
and O
physiological O
factors O
, O
and O
that O
biomarkers O
are O
accurate O
predictors O
of O
age O
, O
sex O
and O
sterilization O
status O

Current O
research O
points O
towards O
a O
great O
future O
with O
novel O
drugs O
directed O
to O
the O
many O
complex O
multifactorial O
diseases B-Disease
of O
humans B-Species
, O
which O
are O
still O
often O
poorly O
understood O
and O
difficult O
to O
treat O

Hong O
and O
A O

The O
original O
concept O
of O
cancer B-Disease
epigenetics O
basically O
stands O
on O
the O
analysis O
of O
the O
epigenetic O
status O
in O
naturally O
occurring O
cancer B-Disease
cells O
; O
however O
, O
the O
rapidly O
emerging O
technology O
called O
epigenome O
editing O
would O
change O
this O
situation O
drastically O

In O
this O
review O
, O
I O
first O
discuss O
some O
of O
the O
circadian O
genes B-Gene
and O
regulatory O
proteins O

13Background O

886 O
Recently O
, O
the O
mechanisms O
underlying O
epigenetic O
dysregulation O
associated O
with O
neurodevelopmental B-Disease
disorders I-Disease
have O
attracted O
increasing O
attention O

18 O
], O
P O
= O
0 O

Conclusions O
 O
Our O
weighted O
optimization O
algorithm O
eDMR O
for O
calling O
DMRs O
extends O
an O
established O
DMR O
R O
pipeline O
( O
methylKit O
) O
and O
provides O
a O
needed O
resource O
in O
epigenomics O

These O
improvements O
to O
the O
ChIP-Seq O
method O
suit O
perfectly O
for O
large-scale O
epigenetic O
studies O
of O
clinical O
samples O
with O
limited O
cell O
numbers O
in O
a O
highly O
reproducible O
manner O

Localized O
low-risk O
PCa B-Disease
has O
an O
excellent O
prognosis O
thanks O
to O
effective O
local O
treatments O
; O
however O
, O
despite O
the O
incorporation O
of O
new O
therapeutic O
strategies O
, O
metastatic B-Disease
PCa I-Disease
remains O
incurable O
mainly O
due O
to O
disease O
heterogeneity O
and O
the O
development O
of O
resistance O
to O
therapy O

This O
chapter O
addresses O
epigenetics O
in O
the O
context O
of O
sex O
differences O
, O
discussing O
the O
intersection O
between O
genetics O
and O
gonadal B-Chemical
hormones I-Chemical
and O
their O
effect O
in O
the O
brain O
at O
discrete O
developmental O
periods O

ageing O
or O
disease O
) O

Evaluating O
epigenetics O
in O
ecotoxicological O
field O
studies O
is O
a O
second O
relatively O
new O
approach O

Here O
, O
we O
provide O
an O
integrated O
overview O
of O
( O
epi O
) O
genetic O
variants O
associated O
with O
asthma B-Disease
, O
focusing O
on O
efforts O
to O
link O
these O
disease O
associations O
to O
biological O
insight O
into O
asthma B-Disease
pathophysiology O
using O
state-of-the-art O
genomics O
methodology O

The O
application O
of O
molecular O
epigenetic O
data O
in O
advanced O
machine O
learning O
analysis O
to O
medicine O
is O
the O
focus O
of O
this O
review O

Other O
cell O
rejuvenation O
studies O
in O
old O
humans B-Species
and O
rodents B-Species
published O
afterwards O
will O
be O
very O
briefly O
mentioned O

Despite O
that O
exposure O
to O
potentially O
traumatizing O
events O
occurs O
in O
a O
large O
proportion O
of O
the O
general O
population O
, O
about O
80-90% O
of O
trauma-exposed O
individuals O
do O
not O
develop O
PTSD B-Disease
, O
suggesting O
an O
inter-individual O
difference O
in O
vulnerability O
to O
PTSD B-Disease

Epigenetic O
pathways O
like O
nucleosomes B-Chemical
remodeling O
, O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
and O
miRNA B-Gene
mediated O
genes O
play O
a O
crucial O
role O
in O
development O
of O
IPF B-Disease

In O
the O
case O
of O
the O
beef B-Species
cattle I-Species
dataset O
, O
the O
posterior O
estimate O
of O
transgenerational O
epigenetic O
variability O
was O
very O
low O
and O
a O
model O
comparison O
test O
indicated O
that O
a O
model O
that O
did O
not O
included O
it O
was O
the O
most O
plausible O

For O
instance O
, O
novel O
combinations O
of O
multiple O
representations O
, O
such O
as O
the O
addition O
of O
Z-values O
of O
similarity O
( O
fusion-Z O
) O
, O
lead O
to O
more O
robust O
representations O
of O
consensus O
SAS O
maps O

907 O
The O
tumor B-Disease
microenvironment I-Disease
( O
TME B-Disease
) O
comprises O
of O
components O
that O
exist O
within O
the O
immediate O
vicinity O
of O
tumor B-Disease
cells O
, O
including O
fibroblasts O
, O
immune O
cells O
, O
the O
extracellular O
matrix O
, O
and O
more O

Therefore O
, O
an O
improved O
understanding O
of O
variations O
at O
the O
single O
cell O
level O
are O
fundamental O
to O
understanding O
biology O
and O
developing O
new O
approaches O
to O
combating O
disease B-Disease

The O
Cochrane O
Risk O
of O
Bias O
Assessment O
Tool O
and O
Joanna O
Briggs O
Institute O
(JBI) O
Critical O
Appraisal O
tools O
will O
be O
used O
to O
assess O
the O
risk O
of O
bias O

doi O

1369 O
The O
sensitivity O
of O
chromatin B-Chemical
immunoprecipitation I-Chemical
( O
ChIP B-Chemical
) O
assays O
poses O
a O
major O
obstacle O
for O
epigenomic O
studies O
of O
low-abundance O
cells O

In O
blood O
, O
the O
contributive O
regions O
and O
genes B-Gene
identified O
by O
RE-VAE O
model O
were O
confirmed O
by O
tissue-specificity O
enrichment O
analysis O
with O
an O
independent O
tissue O
expression O
panel O

This O
article O
presents O
findings O
from O
a O
simulation O
study O
that O
examined O
the O
degree O
of O
bias O
in O
estimates O
of O
heritability O
and O
environmentality O
when O
the O
genetic O
and O
epigenetic O
similarity O
of O
MZ B-Species
twins I-Species
differs O
from O
1 O

Integration O
of O
epigenetic O
information O
represents O
yet O
another O
challenging O
molecular O
frontier O

Herein O
, O
we O
present O
a O
compromise O
between O
an O
extremely O
comprehensive O
study O
of O
a O
human B-Species
sample O
population O
with O
an O
intermediate O
level O
of O
resolution O
of O
CpGs B-Gene
at O
the O
genomic O
level O

95 O
Epigenetic O
modification O
are O
heritable O
changes O
in O
gene B-Gene
expression I-Gene
not O
encoded O
by O
the O
DNA B-Gene
sequence I-Gene
therefore O
playing O
a O
significant O
role O
in O
a O
broad O
range O
of O
biological O
processes O
and O
diseases B-Disease

The O
method O
relies O
on O
the O
availability O
of O
bisulfite B-Chemical
sequencing O
data O
from O
multiple O
samples O
of O
the O
two O
conditions O

Though O
the O
transformation O
ability O
of O
, O
and O
subsequent O
reliance O
on O
EWSR1-FLI1 B-Gene
had O
been O
previously O
described O
, O
the O
advent O
of O
genome-wide O
sequencing O
technologies O
allowed O
for O
the O
specific O
identification O
of O
genomic O
loci O
and O
genes O
targeted O
by O
EWSR1-FLI1 B-Gene

Besides O
, O
the O
effects O
of O
genome-wide O
polymorphisms O
in O
populations O
leading O
to O
variations O
in O
drug B-Chemical
response O
are O
also O
study O
subject O
of O
pharmaco-epigenomics O
and O
are O
being O
studied O
extensively O
in O
cancer B-Disease

As O
epigenetic O
modifiers O
are O
relatively O
early O
in O
development O
in O
paediatrics O
, O
there O
is O
a O
clear O
opportunity O
to O
shape O
the O
landscape O
of O
therapies O
targeting O
the O
epigenome O
in O
order O
that O
efficient O
and O
optimum O
plans O
for O
their O
evaluation O
in O
children O
and O
adolescents O
are O
developed O
in O
a O
timely O

This O
has O
resulted O
in O
both O
sparsity O
of O
investigations O
into O
disease-related B-Disease
changes O
in O
DNA B-Gene
methylation I-Gene
, O
a O
paucity O
of O
robust O
findings O
, O
and O
difficulties O
comparing O
studies O
in O
the O
same O
disease B-Disease

In O
view O
of O
the O
evidence O
available O
in O
animal B-Species
models O
, O
there O
is O
a O
need O
to O
evaluate O
epigenetic O
pain O
mechanisms O
in O
the O
context O
of O
human B-Species
and O
clinical O
studies O

692 O
The O
hygiene O
hypothesis O
(HH) O
proposed O
by O
Strachan O
in O
1989 O
was O
expanded O
to O
explain O
the O
inverse O
association O
between O
the O
occurrence O
of O
allergy O
disorders O
and O
the O
risk O
of O
infectious B-Disease
diseases I-Disease
and O
parasite B-Species
infestation O

1396 O
Welch O
et O
al O

Here O
, O
we O
review O
the O
development O
of O
these O
devices O
and O
explore O
their O
use O
in O
the O
study O
of O
DNA B-Gene
modifications O
, O
chromatin B-Gene
modifications O
and O
higher-order O
chromatin B-Gene
structures O

141 O
Epigenetic O
patterns O
in O
a O
cell O
control O
the O
expression O
of O
genes O
and O
consequently O
determine O
the O
phenotype O
of O
a O
cell O

Moreover O
, O
epigenetics O
implies O
overcoming O
classical O
dualist O
dichotomies O
such O
as O
nature-nurture O
, O
genotype-phenotype O
or O
pathogenesis-pathoplasty O

MOET O
embryos O

We O
conclude O
a O
genetic O
basis O
of O
inheritance O
cannot O
be O
ruled O
out O
and O
thus O
transgenerational O
epigenetic O
inheritance O
has O
not O
been O
adequately O
established O
by O
the O
original O
study O

Consistent O
large-scale O
differences O
in O
yield O
, O
sensitivity O
and O
specificity O
between O
the O
different O
kits O
could O
be O
identified O
, O
with O
Diagenode's B-Chemical
MethylCap I-Chemical
kit I-Chemical
as O
overall O
best O
performing O
kit O
under O
the O
tested O
conditions O

Aging O
may O
occur O
at O
different O
rates O
between O
and O
within O
species O
, O
especially O
or O
( O
it O
varies O
) O
among O
the O
long-lived O
ones O

the O

Contact O
 O
zhengjie@ntu O

GLINT O
, O
which O
does O
not O
require O
any O
programming O
proficiency O
, O
allows O
an O
easy O
execution O
of O
Epigenome-Wide B-Disease
Association I-Disease
Study I-Disease
analysis O
pipeline O
under O
different O
models O
while O
accounting O
for O
known O
confounders O
in O
methylation B-Chemical
data O

However O
, O
DNA B-Gene
co-methylation O
cluster O
has O
not O
been O
examined O
in O
depth O
, O
and O
co-methylation O
in O
multiple O
cancer B-Disease
types I-Disease
has O
never O
been O
studied O
previously O

Epigenomic O
modifications O
alter O
the O
structure O
of O
the O
chromatin O
and O
therefore O
regulate O
the O
transcriptional O
program O
of O
a O
cell O

The O
association O
between O
gene B-Gene
copy I-Gene
number I-Gene
variation O
, O
predicted O
MGMT B-Gene
methylation O
, O
and O
MGMT B-Gene
expression O
revealed O
a O
gene B-Gene
dosage O
effect O
on O
MGMT B-Gene
expression O
in O
lower B-Disease
grade I-Disease
glioma I-Disease
( O
World O
Health O
Organization O
grade O
II/III O
) O
that O
in O
contrast O
to O

We O
review O
a O
large O
body O
of O
research O
showing O
that O
differential O
DNA B-Gene
methylation I-Gene
is O
associated O
with O
changes O
in O
various O
external O
and O
internal O
factors O
, O
and O
propose O
that O
loci O
whose O
DNA B-Gene
methylation I-Gene
level O
is O
environmentally O
responsive O
could O
serve O
as O
markers O
to O
infer O
about O
ancient O
daily O

In O
this O
chapter O
, O
we O
summarized O
several O
popular O
methods O
for O
analyses O
of O
epigenetic O
modifications O
, O
including O
Methylated B-Chemical
DNA I-Chemical
Immunoprecipitation I-Chemical
Sequencing I-Chemical
( O
MeDIP-Seq B-Chemical
) O
for O
genome-wide O
DNA B-Chemical
methylation I-Chemical
analyses O
, O
Quantitative B-Chemical
Methylation I-Chemical


However O
there O
is O
dispute O
, O
contention O
, O
and O
caution O
as O
well O
as O
enthusiasm O
among O
these O
research O
communities O

This O
dynamic O
epigenetic O
layer O
responds O
to O
external O
environmental O
cues O
to O
influence O
the O
expression O
of O
genes O
associated O
with O
disease B-Disease
states I-Disease

Drugs O
with O
epigenetic O
mechanisms O
are O
already O
in O
use O
, O
with O
many O
more O
likely O
to O
be O
approved O
within O
the O
next O
few O
years O

However O
, O
analysis O
of O
such O
data O
often O
suffers O
from O
detecting O
the O
outliers O
of O
the O
samples O
, O
which O
subsequently O
affects O
the O
extraction O
of O
the O
true O
biological O
signals O
involved O
in O
the O
disease B-Disease

This O
converted O
DNA B-Gene
was O
then O
amplified O
via O
multiplex O
PCR O
with O
reverse O
primers O
containing O
a O
biotin B-Chemical
molecule O

The O
longer-lived O
BXD B-Species
strains O
had O
comparatively O
lower O
entropy O
at O
a O
given O
age O

Results O

Our O
model O
assumes O
that O
at O
each O
site O
, O
the O
methylation O
vector O
of O
all O
samples O
is O
linked O
to O
the O
set O
of O
fixed O
factors O
( O
covariates O
) O
and O
a O
set O
of O
latent O
factors O

evidence O

In O
addition O
, O
the O
possible O
biomedical O
and O
discovery O
research O
applications O
of O
single-molecule O
epigenomics O
will O
be O
highlighted O

Here O
, O
we O
will O
overview O
the O
current O
understanding O
of O
the O
causes O
and O
effects O
of O
the O
altered O
and O
heterogeneous O
epigenomic O
landscape O
in O
cancer B-Disease

We O
found O
statistically O
significant O
differential O
epigenetic O
heterogeneity O
(DEH) O
loci O
compared O
to O
normal O
controls O
and O
constructed O
co-epigenetic O
heterogeneity O
network O
and O
modules O

A O
growing O
body O
of O
research O
has O
been O
focusing O
on O
the O
role O
of O
epigenetics O
and O
metabolomics O
in O
response O
to O
mood O
stabilizers O
, O
especially O
lithium B-Chemical
salts I-Chemical

Our O
analysis O
suggests O
that O
epigenetic O
models O
of O
stress O
, O
trauma O
, O
and O
adversity O
therefore O
situate O
histories O
of O
oppression O
, O
inequality O
, O
and O
subjugation O
in O
discrete O
and O
gendered O
family O
relations O
, O
resulting O
in O
the O
temporal O
embedding O
of O
adversity O
during O
early O
life O

Here O
, O
my O
goal O
is O
to O
introduce O
some O
of O
the O
common O
goals O
and O
challenges O
shared O
by O
those O
pursuing O
this O
critical O
field O

CSCs O
are O
correlated O
with O
poor O
clinical O
outcome O
due O
to O
their O
contribution O
to O
chemotherapy B-Chemical
resistance O
and O
metastasis B-Disease

In O
addition O
, O
the O
implications O
of O
this O
theoretical O
framework O
for O
the O
current O
strategies O
of O
cancer B-Disease
treatment O
are O
discussed O
considering O
recent O
evidence O
of O
the O
molecular O
events O
underlying O
the O
epigenetic O
switches O
involved O
in O
the O
resistance O
of O
breast B-Disease
carcinomas I-Disease

1231 O
 O
Background O
 O
Mediation O
analysis O
is O
a O
powerful O
tool O
to O
identify O
factors O
mediating O
the O
causal O
pathway O
of O
exposure O
to O
health O
outcomes O

1443 O
Background O
Cancer B-Disease
treatments I-Disease
have O
substantially O
improved O
childhood O
cancer B-Disease
survival O
but O
are O
accompanied O
by O
long-term O
complications O
, O
notably O
chronic B-Disease
inflammatory I-Disease
diseases I-Disease

Recent O
findings O
on O
DNA B-Gene
methylation O
and O
hydroxymethylation O
, O
histone B-Gene
modifications O
, O
noncoding O
RNAs B-Gene
, O
and O
other O
epigenetic O
mechanisms O
were O
presented O
and O
discussed O

To O
demonstrate O
the O
potential O
of O
this O
technique O
, O
we O
constructed O
the O
first O
modern O
age O
profile O
of O
humpback B-Species
whales I-Species
off O
eastern O
Australia O
and O
compared O
the O
results O
to O
population O
structure O
5 O
decades O
earlier O

The O
term O
epigenetics O
refers O
to O
changes O
in O
gene B-Gene
expression I-Gene
that O
are O
not O
encoded O
in O
the O
DNA B-Gene
sequence I-Gene
, O
leading O
to O
remodeling O
of O
the O
chromatin O
and O
activation O
or O
inactivation O
of O
gene B-Gene
expression I-Gene

Given O
this O
, O
efforts O
aimed O
at O
understanding O
the O
molecular O
mechanisms O
underlying O
microglial B-Species
cell I-Species
functions O
hold O
great O
potential O
for O
the O
development O
of O
novel O
therapies O
for O
various O
conditions O
affecting O
the O
central B-Disease
nervous I-Disease
system I-Disease

Epigenetic O
clocks O
based O
on O
DNA B-Chemical
methylation I-Chemical
( O
DNAm B-Gene
) O
at O
specific O
CpG B-Gene
sites O
show O
a O
strong O
correlation O
with O
chronological O
age O
in O
humans B-Species
, O
and O
discrepancies O
between O
inferred O
and O
actual O
chronological O
age O
predict O
morbidity B-Disease
and O
mortality B-Disease

Quite O
the O
opposite O
, O
the O
ground O
for O
a O
re-racialization O
of O
social O
debates O
and O
the O
reinforcement O
of O
biological O
boundaries O
between O
groups O
are O
highlighted O
in O
the O
article O

However O
, O
the O
developed O
epi- O
drugs O
cause O
off-target O
gene B-Gene
and O
transposable O
elements O
activation O
; O
promote O
mutagenesis O
and O
carcinogenesis B-Disease
in O
normal O
cells O
, O
are O
the O
major O
hurdles O
regarding O
their O
clinical O
use O

Importantly O
, O
as O
the O
clinical O
pattern O
of O
PCa B-Disease
ranges O
from O
an O
indolent O
tumor O
to O
an O
aggressive O
disease O
, O
discovering O
specific O
targetable O
epigenetic O
molecules O
able O
to O
overcome O
and O
predict O
PCa B-Disease
radioresistance O
is O
urgently O
needed O

One O
method O
of O
modulating O
gene B-Gene
expression I-Gene
through O
environmental O
effects O
is O
via O
epigenetic O
modifications O

396 O

The O
role O
of O
tumor B-Disease
suppressors O
and O
oncogenes O
is O
well O
known O
in O
tumorigenesis O

Our O
findings O
pave O
the O
way O
to O
form O
personalized O
aging O
cards O
allowing O
the O
identification O
of O
specific O
genes B-Gene
related O
to O
CpG B-Chemical
sites I-Chemical
, O
as O
aging O
markers O
, O
and O
perhaps O
treatment O
of O
these O
targets O
in O
order O
to O
hinder O
undesirable O
age O
drifting O

The O
overall O
genesis O
of O
the O
Sandbox B-Disease
is O
described O
in O
the O
editorial O
NIGMS B-Gene
Sandbox I-Gene
[16] O
at O
the O
beginning O
of O
this O
Supplement O

Karl B-Gene

479 O
The O
variable O
predisposition O
of O
patients O
, O
both O
to O
disease B-Disease
susceptibility O
and O
drug B-Chemical
response O
, O
is O
well O
established O

The O
awareness O
of O
such O
alterations O
could O
improve O
our O
understanding O
of O
cancer B-Disease
dynamics O
and O
the O
identification O
of O
new O
therapeutic O
strategies O
and O
biomarkers O
to O
refine O
tumor B-Disease
classification O
and O
treatment O

Finally O
, O
we O
discuss O
existing O
challenges O
and O
opportunities O
for O
future O
development O

More O
recently O
there O
is O
mounting O
evidence O
indicating O
that O
epigenetic O
reprogramming O
in O
response O
to O
combined O
intrinsic O
and O
environmental O
exposures O
, O
might O
be O
particularly O
relevant O
due O
to O
its O
plasticity O
and O
potential O
application O
towards O
precision O
health O

These O
transcription O
factors O
were O
previously O
identified O
as O
activity-regulated O
genes O
, O
and O
their O
knockdown O
in O
dopaminergic B-Species
neurons O
reduced O
the O
effects O
of O
social O
experience O
on O
sleep O

In O
this O
study O
, O
we O
demonstrate O
the O
miniaturization O
of O
a O
methyltransferase B-Gene
assay O
using O
Echo B-Chemical
liquid I-Chemical
handlers O
and O
two O
different O
assay O
technologies O
 O
AlphaLISA B-Chemical
from O
PerkinElmer B-Chemical
and O
EPIgeneous B-Chemical
HTRF I-Chemical
from O
Cisbio B-Chemical

Previous O
studies O
identified O
candidate O
CREs O
(cCREs) O
using O
epigenetic O
features O
in O
one O
species B-Species
, O
making O
comparisons O
difficult O
between O
species B-Species

Because O
of O
the O
inherent O
flexibility O
of O
epigenetic O
regulation O
, O
a O
variety O
of O
biological O
phenomena O
can O
be O
traced O
back O
to O
evolutionary O
adaptations O
of O
few O
conserved O
molecular O
pathways O
that O
converge O
on O
chromatin B-Chemical

Advancements O
in O
high-throughput O
sequencing O
technologies O
have O
provided O
the O
opportunity O
to O
study O
the O
epigenetic O
mechanisms O
at O
genome-wide O
levels O

Without O
affecting O
the O
underlying O
DNA B-Chemical
sequence O
, O
epigenetic O
alterations O
impact O
gene B-Gene
expression O

These O
methods O
enable O
the O
quantification O
and O
localization O
of O
5hmC B-Chemical
in O
diverse O
biological O
samples O
and O
, O
in O
some O
cases O
, O
at O
the O
resolution O
of O
individual O
nucleotides O


Among O
194 O
patients O
with O
clinical O
features O
of O
an O
imprinting O
disorder B-Disease
but O
no O
molecular O
diagnosis O
, O
we O
found O
15 O
( O
8 O
% O
) O
with O
methylation O
anomalies O
, O
including O
missed O
and O
unexpected O
molecular O
diagnoses O

These O
results O
were O
not O
driven O
by O
differences O
in O
genetic O
diversity O
or O
population O
genetic O
structure O
, O
and O
many O
CpG B-Gene
sites I-Gene
fell O
within O
predicted O
transcription O
factor O
binding O
sites O
( O
TFBS B-Gene
) O
, O
with O
losses O
and O
gains O
of O
CpG B-Gene
sites I-Gene
altering O
predicted O
TFBS B-Gene

Fortunately O
, O
epigenetic O
phenomena O
are O
dynamic O
and O
rather O
quickly O
reversible O
with O
intensive O
lifestyle O
changes O

The O
main O
mechanisms O
of O
epigenetic O
control O
in O
mammals B-Species
are O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
and O
RNA B-Chemical
silencing I-Chemical

The O
journal O
with O
the O
highest O
h-index O
was O
Oncogene B-Gene
(h-index O
= O
38 O
) O

The O
extent O
to O
which O
DNA B-Gene
methylation I-Gene
in O
offspring O
is O
modified O
by O
these O
intrauterine O
exposures O
has O
not O
been O
presented O
in O
parallel O

In O
so O
doing O
, O
the O
paper O
considers O
the O
appearance O
and O
functions O
of O
epigenetics O
in O
evolutionary O
history-sketching O
a O
pathway O
by O
which O
epigenetic O
processes O
might O
have O
evolved O
via O
exaptation O
and O
then O
contributed O
to O
the O
later O
development O
and O
evolution O
of O
phenotypes O

794 O
Clinical O
relevance O
 O
A O
bibliometric O
analysis O
is O
a O
quantitative O
study O
that O
utilises O
methods O
such O
as O
citation O
analysis O
to O
evaluate O
research O
performance O

Epigenetics O
is O
a O
process O
involved O
in O
gene O
regulation O
, O
mediated O
via O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modification I-Chemical
, O
chromatin B-Chemical
remodeling I-Chemical
, O
and O
functional O
noncoding O
RNAs O
, O
which O
influences O
the O
accessibility O
of O
the O
underlying O
DNA B-Chemical
to O
transcriptional O
regulatory O

These O
are O
also O
windows O
of O
opportunity O
for O
interventions O
during O
the O
reproductive O
life O
cycle O
of O
women O
to O
improve O
maternal-child O
health O

By O
including O
environmental O
exposures O
as O
random O
effects O
, O
the O
authors O
found O
heritability O
estimates O
became O
more O
stable O
but O
not O
significantly O
different O

1375 O
Circadian B-Disease
rhythms I-Disease
refer O
to O
the O
endogenous O
rhythms O
that O
are O
generated O
to O
synchronize O
physiology O
and O
behavior O
with O
24-h O
environmental O
cues O

Studies O
show O
that O
bioactive O
nutrients O
and O
gut O
microbiota O
can O
alter O
either O
DNA B-Gene
methylation O
and O
histone B-Gene
signatures O
through O
a O
variety O
of O
mechanisms O

The O
significance O
of O
D'Arcy B-Gene
Thompson I-Gene
as O
a O
predecessor O
of O
the O
relational O
biology O
and O
of O
the O
epigenetic O
concepts O
of O
evolution O
is O
discussed O

In O
an O
effort O
to O
make O
these O
contributions O
more O
accessible O
to O
the O
nonspecialist O
, O
we O
group O
available O
chemical B-Chemical
approaches O
into O
those O
that O
allow O
the O
covalent O
structure O
of O
the O
protein O
and O
DNA B-Gene
components O
of O
chromatin O
to O
be O
manipulated O
, O
those O
that O
allow O
the O
activity O
of O
myriad O

We O
highlight O
the O
potential O
of O
small-molecule B-Chemical
inhibitors I-Chemical
targeting O
epigenetic O
regulators O
to O
amplify O
anti-tumor B-Disease
immune I-Disease
responses I-Disease

, O
durable O
changes O
in O
gene B-Gene
expression I-Gene
patterns O

However O
, O
clinical O
application O
has O
been O
hampered O
by O
in-stent O
restenosis B-Disease
( O
ISR B-Disease
) O

Conclusion O
 O
Bonferroni O
and O
Benjamini-Hochberg O
FDR O
are O
inappropriate O
for O
the O
EWAS B-Disease
replication O
phase O
, O
and O
methods O
that O
account O
for O
the O
underlying O
correlation O
need O
to O
be O
used O

It O
is O
well-known O
that O
during O
carcinogenesis B-Disease
, O
a O
site-specific O
DNA B-Gene
hypermethylation O
and O
a O
global O
DNA B-Gene
hypomethylation O
take O
place O

Efforts O
to O
examine O
epigenetic O
changes O
in O
health O
and O
disease B-Disease
have O
been O
hindered O
by O
the O
lack O
of O
high-throughput O
, O
quantitatively O
accurate O
methods O

161 O
 O
methylation O
, O
consisting O
on O
the O
covalent O
addition O
of O
a O
group O
in O
, O
plays O
a O
vital O
role O
for O
the O
development O
and O
correct O
functioning O
of O
cells O

372 O
microarrays O
have O
been O
the O
platform O
of O
choice O
for O
epigenome-wide O
association O
studies O
in O
epidemiology O
, O
but O
declining O
costs O
have O
rendered O
targeted O
sequencing O
a O
feasible O
alternative O

However O
, O
because O
of O
genetic O
diversity O
and O
the O
diploid O
nature O
of O
the O
human B-Species
genome O
, O
we O
hypothesize O
that O
using O
a O
generic O
reference O
could O
lead O
to O
incorrectly O
mapped O
reads O
and O
bias O
downstream O
results O

262 O
Age-associated O
DNA-methylation O
profiles O
have O
been O
used O
successfully O
to O
develop O
highly O
accurate O
biomarkers O
of O
age O
(epigenetic O
clocks O
) O
in O
humans O
, O
mice B-Species
, O
dogs B-Species
, O
and O
other O
species O

Hypermethylation O
in O
GSTM3 B-Gene
promoter O
and O
altered O
histone O
modification O
might O
have O
a O
role O
in O
the O
ARC B-Disease
formation O

Although O
defective O
gene B-Gene
regulation O
often O
affects O
oncogenic O
and O
tumour-suppressor O
networks O
, O
tumour B-Disease
immunogenicity O
and O
immune O
cells O
involved O
in O
antitumour O
responses O
may O
also O
be O
affected O
by O
epigenomic O
alterations O

Dysmyelination O
and O
remyelination O
failures O
after O
injury O
result O
in O
defective O
nerve O
conduction O
, O
impairing O
normal O
nervous B-Disease
system I-Disease
functions O

While O
reliable O
detection O
of O
cancer-specific B-Disease
epigenetic O
changes O
has O
proven O
to O
be O
technically O
challenging O
, O
a O
substantial O
progress O
has O
been O
made O
in O
developing O
the O
methodologies O
that O
allow O
an O
efficient O
and O
sensitive O
detection O
of O
epigenomic O
changes O
using O
the O
material O
originating O
from O
body O
fluids O

The O
concept O
that O
epigenetic O
memory O
and O
programming O
is O
directed O
by O
our O
diet O
has O
numerous O
implications O
for O
the O
interpretation O
of O
disease B-Disease
risk I-Disease
including O
their O
prevention O

Further O
, O
concordance O
rates O
in O
monozygotic O
twins O
are O
significantly O
higher O
compared O
to O
dizygotic O
sets O
while O
being O
significantly O
below O
50% O
for O
most O
autoimmune B-Disease
diseases I-Disease

Eight O
classes O
of O
medicinal O
products O
were O
discussed O
and O
prioritised O
based O
on O
the O
existing O
level O
of O
science O
to O
support O
early O
evaluation O
in O
children O
 O
inhibitors O
of O
menin B-Gene
, O
DOT1L B-Gene
, O
EZH2 B-Gene
, O
EED B-Gene
, O
BET B-Gene
, O
PRMT5 B-Gene
and O
LSD1 B-Gene
and O
a O

is O

However O
, O
the O
mechanisms O
by O
which O
nano-geometric O
cues O
dictate O
the O
osteogenic B-Disease
differentiation O
of O
stem B-Species
cells I-Species
remain O
unclear O

Moreover O
, O
exposure O
of O
monocytes O
to O
lipids B-Chemical
persistently O
alters O
their O
epigenetic O
makeup O
resulting O
in O
more O
proinflammatory O
cells O

Using O
a O
sub-sample O
of O
colon B-Disease
cancer I-Disease
- O
and O
healthy O
colon B-Disease
- O
samples O
from O
TCGA B-Gene
we O
show O
that O
Probe B-Gene
Lasso I-Gene
shifts O
DMR B-Gene
calling O
away O
from O
just O
probe-dense O
regions O
, O
and O
calls O
a O
range O
of O
DMR B-Gene
sizes O
ranging O
from O
tens-of-bases O
to O

These O
epigenetic O
modifications O
impact O
the O
ability O
of O
cis-regulatory O
sequences O
to O
maintain O
tissue-specific O
and O
inducible O
expression O
of O
genes O
that O
preserve O
health O

Epigenomic O
twin O
studies O
have O
great O
potential O
to O
contribute O
to O
our O
understanding O
of O
complex O
diseases O
, O
such O
as O
cancer B-Disease

They O
find O
substantial O
epigenetic O
variation O
among O
plant B-Species
individuals O

Hence O
, O
epigenetic O
changes O
can O
both O
impact O
on O
and O
be O
induced O
by O
lipids B-Chemical

The O
epigenetic O
effect O
was O
only O
significant O
for O
BW7 B-Gene

Fibrosis B-Disease
is O
the O
hallmark O
of O
SSc B-Disease
and O
contributes O
to O
its O
high O
mortality O

Nutrition O
can O
alter O
gene B-Gene
expression O
, O
as O
well O
as O
the O
susceptibility O
to O
disease B-Disease
, O
including O
cancer B-Disease
, O
through O
epigenetic O
changes O

Results O
 O
Our O
approach O
was O
more O
sensitive O
than O
FRS B-Gene
and O
PCE B-Gene
and O
had O
high O
generalizability O
across O
cohorts O

Even O
though O
these O
drugs O
showed O
some O
effect O
on O
several O
types O
of O
cancer B-Disease
, O
mild O
to O
severe O
adverse O
reactions O
have O
been O
observed O

Furthermore O
, O
the O
targetable O
nature O
of O
epigenetic O
modifications O
provides O
a O
unique O
opportunity O
to O
alter O
treatment O
paradigms O
and O
provide O
new O
therapeutic O
options O
for O
patients O
whose O
malignancies B-Disease
possess O
these O
aberrant O
epigenetic O
modifications O
, O
paving O
the O
way O
for O
new O
and O
personalized O
medicine O

The O
main O
disadvantage O
with O
DNA B-Gene
gene I-Gene
editing O
technologies O
is O
off-target O
DNA B-Gene
sequence I-Gene
alteration O
, O
which O
is O
not O
an O
issue O
with O
epigenetic O
editing O

An O
important O
future O
challenge O
in O
the O
field O
of O
epigenetics O
will O
be O
to O
describe O
how O
the O
environment O
affects O
both O
of O
these O
types O
of O
epigenetic O
change O
and O
to O
learn O
if O
interaction O
between O
them O
can O
determine O
healthy O
and O
disease B-Disease
phenotypes O
during O
lifetime O

We O
illustrate O
how O
scMET O
facilitates O
the O
characterization O
of O
epigenetically O
distinct O
cell O
populations O
and O
how O
it O
enables O
the O
formulation O
of O
novel O
hypotheses O
on O
the O
epigenetic O
regulation O
of O
gene B-Gene
expression I-Gene

Our O
work O
reveals O
a O
key O
role O
for O
TAD O
remodeling O
in O
epigenetic O
regulation O
of O
transcription O
and O
delivers O
the O
first O
tool O
for O
the O
community O
to O
perform O
dynamic O
analysis O
of O
TAD O
splits O
and O
mergers O
in O
numerous O
biological O
and O
disease B-Disease
models O

In O
patients O
with O
COPD B-Disease
, O
asthma B-Disease
and O
pulmonary B-Disease
arterial I-Disease
hypertension I-Disease
( O
PAH B-Disease
) O
, O
there O
is O
emerging O
evidence O
of O
aberrant O
epigenetic O
marks O
, O
mainly O
including O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical
which O
directly O
mediate O
reversible O
modifications O

We O
conclude O
that O
MBD-seq O
represents O
an O
excellent O
approach O
for O
large-scale O
MWAS O
and O
that O
increased O
utilization O
is O
likely O
to O
result O
in O
more O
discoveries O
, O
advance O
biological O
knowledge O
, O
and O
expedite O
the O
clinical O
translation O
of O
methylome-wide O
research O
findings O

452 O
Dysregulation O
of O
metabolism O
allows O
tumor O
cells O
to O
generate O
needed O
building O
blocks O
as O
well O
as O
to O
modulate O
epigenetic O
marks O
to O
support O
cancer B-Disease
initiation O
and O
progression O

We O
make O
an O
extensive O
analysis O
of O
the O
imputation O
performances O
of O
seven O
imputation O
methods O
on O
simulated O
missing O
completely O
at O
random O
( O
MCAR O
) O
, O
missing O
at O
random O
( O
MAR O
) O
and O
missing O
not O
at O
random O
( O
MNAR O
) O
methylation O
data O

e O

Comprehensive O
whole-genome O
DNA B-Chemical
methylation O
methods O
for O
a O
unbiased O
analysis O
based O
on O
either O
microarray O
or O
next-generation O
sequencing O
need O
to O
be O
evaluated O
in O
drug B-Chemical
toxicology O
in O
an O
intensive O
and O
systematic O
manner O

org O

Current O
therapeutic O
strategies O
, O
in O
particular O
for O
metastatic B-Disease
melanoma I-Disease
, O
do O
not O
give O
great O
results O
in O
terms O
of O
survival O

768 O
The O
aging O
process O
has O
been O
one O
of O
the O
most O
necessary O
research O
fields O
in O
the O
current O
century O
, O
and O
knowing O
different O
theories O
of O
aging O
and O
the O
role O
of O
different O
genetic O
, O
epigenetic O
, O
molecular O
, O
and O
environmental O
modulating O
factors O
in O
increasing O
the O
knowledge O
of O
aging O
mechanisms O

81 O
 O
Acute B-Disease
myeloid I-Disease
leukemia I-Disease
( O
AML B-Disease
) O
was O
one O
of O
the O
first O
cancers O
to O
be O
sequenced O
at O
the O
level O
of O
the O
whole O
genome O

1164 O
 O
Background O
 O

Comparison O
of O
different O
methylomes O
permits O
the O
discovery O
of O
differentially O
methylated O
regions O
that O
might O
be O
important O
in O
disease- O
or O
tissue-specific O
expression O

Notably O
, O
studies O
of O
pediatric O
brain B-Disease
tumors I-Disease
have O
identified O
unexpected O
oncogenic O
pathways O
implicated O
in O
tumorigenesis O

In O
total O
, O
3758 O
studies O
were O
included O
in O
the O
analysis O
, O
including O
3099 O
original O
articles O
, O
599 O
reviews O
, O
11 O
editorials O
, O
and O
49 O
early O
access O
articles O

We O
emphasize O
that O
no O
single O
approach O
can O
provide O
a O
complete O
view O
of O
the O
overall O
methylome B-Chemical
, O
and O
that O
combinations O
of O
several O
modalities O
applied O
to O
the O
same O
sample O
set O
will O
give O
the O
clearest O
picture O

1492 O
Soft B-Disease
tissue I-Disease
sarcoma I-Disease
( O
STS B-Disease
) O
comprise O
a O
large O
group O
of O
mesenchymal O
malignant O
tumors O
with O
heterogeneous O
cellular O
morphology O
, O
proliferative O
index O
, O
genetic O
lesions O
and O
, O
more O
importantly O
, O
clinical O
features O

To O
investigate O
the O
potential O
contribution O
of O
irradiation O
to O
these O
changes O
, O
we O
established O
two O
cell O
culture O
models O

Additionally O
, O
our O
cohort O
is O
unique O
in O
its O
large O
size O
, O
diversity O
, O
and O
focus O
on O
healthy O
donors O

CRISPR O
affinity O
purification O
in O
situ O
of O
regulatory O
elements O
showed O
that O
T-box B-Gene
transcription I-Gene
factor I-Gene
19 I-Gene
( O
TBX19 B-Gene
) O
, O
which O
is O
overexpressed O
uniquely O
in O
LCICs B-Disease
compared O
with O
non-LCICs B-Disease
and O
liver B-Species
progenitor I-Species
cells I-Species
, O
forms O
a O
complex O

Although O
the O
field O
has O
advanced O
over O
the O
past O
several O
decades O
, O
including O
being O
recognized O
by O
with O
its O
own O
Special O
Interest O
Group O
, O
recently O
renamed O
Epigenomics B-Gene
, O
we O
are O
excited O
about O
the O
opportunities O
for O
environmental O
epigenetic O
science O
in O
the O
next O
50 O
years O

53Interest O
in O
the O
field O
of O
epigenetics O
has O
increased O
rapidly O
over O
the O
last O
decade O
, O
with O
the O
term O
becoming O
more O
identifiable O
in O
biomedical O
research O
, O
scientific O
fields O
outside O
of O
the O
molecular O
sciences O
, O
such O
as O
ecology O
and O
physiology O
, O
and O
even O
mainstream O
culture O

012 O
; O
cg24241897 O
 O
coefficient O
= O
- O
0 O

Moreover O
, O
oleuropein B-Chemical
( O
OLP B-Chemical
) O
, O
an O
olive-derived O
polyphenol O
, O
also O
displayed O
similar O
epigenetic O
modulation O
and O
antiaging O
effects O

This O
study O
of O
complexity O
work O
and O
complexification O
shows O
that O
biosocial O
complexity O
is O
hardly O
a O
univocal O
enterprise O
in O
epigenetics O

Multiple O
cell O
surface O
and O
enzymatic O
markers O
have O
been O
characterized O
to O
identify O
CSCs B-Disease
within O
a O
heterogeneous O
tumor O
, O
and O
here O
we O
summarize O
ongoing O
preclinical O
and O
clinical O
efforts O
to O
therapeutically O
target O
these O
cells O
and O
improve O
patient O
outcomes O

To O
date O
, O
although O
several O
reports O
have O
demonstrated O
the O
occurrence O
of O
epigenetic O
alterations O
in O
a O
wide O
range O
of O
inflammatory B-Disease
rheumatic I-Disease
conditions I-Disease
, O
epigenomic O
information O
is O
rarely O
used O
in O
a O
clinical O
setting O

Because O
epigenetic O
alterations O
are O
principally O
reversible O
, O
this O
may O
offer O
new O
opportunities O
for O
treatment O
of O
IEM B-Disease
patients O

Indeed O
, O
there O
is O
evidence O
that O
many O
proteins O
and O
metabolites O
involved O
in O
epigenetic O
pathways O
are O
redox O
sensitive O

We O
conclude O
that O
sample O
heterogeneity O
masks O
DNA B-Gene
methylation I-Gene
signatures O
in O
subpopulations O
of O
cells O
and O
thus O
believe O
that O
beside O
a O
genetic O
evaluation O
, O
extensive O
epigenomic O
screening O
should O
become O
a O
standard O
procedure O
to O
ensure O
hiPSCs B-Species
state O
before O
they O
are O
used O
for O
genome O
editing O
and O

Our O
goal O
is O
to O
build O
a O
platform O
to O
discuss O
the O
ways O
in O
which O
future O
epidemiologic O
studies O
may O
benefit O
from O
including O
epigenetic O
measures O

We O
have O
, O
therefore O
, O
developed O
a O
method O
to O
quantitatively O
explore O
the O
extent O
to O
which O
DNA B-Chemical
methylation I-Chemical
levels O
can O
significantly O
reduce O
or O
even O
abolish O
the O
binding O
of O
certain O
transcription O
factors O
, O
resulting O
in O
reduced O
or O
non-expression O
of O
flanking O
genes B-Gene

Hybrids O
had O
predominantly O
intermediate O
methylation O
patterns O
( O
88 O

e O

A O
proof-of-principle O
interrogation O
of O
the O
epigenetic O
regulatory O
network O
is O
described O

S3EQ O
accurately O
generates O
both O
RNA O
- O
and O
ChIP-seq O
from O
a O
single O
sample O
, O
providing O
a O
clear O
advantage O
over O
existing O
methods O
which O
require O
two O
samples O

Here O
, O
we O
describe O
a O
protocol O
for O
sequencing O
multiple O
RRBS B-Chemical
libraries O
in O
a O
single O
sequencing O
reaction O
to O
generate O
base-resolution O
methylomes O

818 O
Epigenetic O
regulation O
is O
one O
of O
the O
most O
promising O
and O
expanding O
areas O
of O
cancer B-Disease
research O

Our O
work O
provides O
a O
comprehensive O
example O
of O
the O
role O
played O
by O
epigenetic O
mechanisms O
on O
gene B-Gene
network I-Gene
evolution O

Biologists O
should O
defend O
science O
against O
ideological O
and O
political O
interferences O

ac O

Thus O
, O
to O
maintain O
healthy O
human B-Species
physiology O
, O
host O
and O
microbiota B-Species
relationship O
should O
be O
in O
a O
balanced O
state O

The O
pathways O
enriched O
in O
the O
shared O
transcriptional O
association O
suggested O
links O
between O
epigenetic O
aging O
and O
metabolism O
, O
immunity O
, O
and O
autophagy O

Epigenome-wide O
analysis O
was O
performed O
from O
t0 O
and O
t1 O
saliva O
using O
the O
Illumina B-Chemical
EPIC I-Chemical
arrays O
that O
cover O
>860k O
probes O

We O
provide O
evidence O
that O
genetic O
changes O
from O
multiple O
sources O
do O
indeed O
occur O
in O
these O
experiments O
and O
explore O
several O
avenues O
by O
which O
these O
changes O
could O
be O
causal O
to O
the O
apparent O
inheritance O
of O
epigenetic O
changes O

A O
specific O
role O
of O
the O
circadian O
clock O
is O
to O
coordinate O
functions O
of O
the O
immune O
system O
both O
at O
steady-state O
and O
in O
response O
to O
infectious O
threats O

For O
example O
, O
when O
peak O
calling O
is O
done O
independently O
for O
each O
sample O
, O
small O
differences O
in O
signal O
strength/quality O
lead O
to O
a O
very O
different O
number O
of O
peaks O
for O
individual O
samples O
, O
making O
group-level O
analysis O
difficult O

Additionally O
, O
studies O
manipulating O
epigenetic O
enzymes O
in O
specific O
brain O
regions O
are O
beginning O
to O
build O
causal O
links O
between O
these O
epigenetic O
modifications O
and O
changes O
in O
addiction-related B-Disease
behavior O

We O
considered O
573 O
cases O
of O
low-grade B-Disease
glioma I-Disease
( O
LGG B-Disease
) O
and O
glioblastoma B-Disease
( O
GBM B-Disease
) O
from O
The B-Gene
Cancer I-Gene
Genome I-Gene
Atlas I-Gene
( O
TCGA B-Gene
) O

Epigenetic O
modifications O
may O
be O
the O
bridge O
connecting O
environmental O
factors O
and O
genetic O
factors O


Monitoring O
such O
epigenetic O
marks O
in O
response O
to O
toxicant O
exposure O
may O
in O
future O
provide O
a O
valuable O
tool O
for O
predicting O
adverse O
outcomes O
, O
but O
a O
more O
robust O
basis O
for O
Test O
Guideline O
recommendations O
is O
still O
needed O

Characterization O
of O
SNPs O
in O
the O
context O
of O
both O
inherited O
and O
acquired O
conditions O
, O
such O
as O
cancer B-Disease
, O
are O
a O
main O
focus O
of O
many O
genotyping O
procedures O

These O
severely O
affect O
the O
levels O
and O
distribution O
of O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
chromatin B-Chemical
accessibility I-Chemical
, O
and O
three-dimensional O
genome B-Chemical
interactions I-Chemical

The O
advent O
and O
refinement O
of O
novel O
assisted O
reproductive O
technology O
( O
ART B-Chemical
) O
laboratory O
techniques O
, O
including O
vitrification O
, O
dynamic O
culture O
systems O
, O
oocyte O
in O
vitro O
maturation O
, O
laser-assisted O
hatching O
, O
intracytoplasmic O
sperm O
injection O
, O
and O
preimplantation O
genetic O
testing O
for O
aneuploidy O

Therefore O
, O
an O
important O
gap O
in O
the O
field O
is O
the O
lack O
of O
a O
universal O
data O
harmonizer O
with O
the O
capability O
to O
arbitrarily O
integrate O
multi-modal O
datasets O

org O
) O
, O
a O
web O
- O
based O
platform O

93 O
 O
The O
association O
between O
air O
pollution O
and O
a O
wide-ranging O
spectrum O
of O
acute O
and O
chronic O
disorders-including O
cardiovascular B-Disease
diseases-is I-Disease
widely O
acknowledged O

However O
, O
the O
mechanistic O
link O
between O
epigenetic O
modifications O
and O
abnormalities O
in O
nutrition O
remains O
elusive O

g O

The O
most O
prominent O
evidence O
on O
the O
association O
between O
environment O
and O
autoimmunity O
has O
been O
reported O
in O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
, O
but O
similar O
mechanisms O
were O
proposed O
in O
rheumatoid B-Disease
arthritis I-Disease
, O
systemic B-Disease
sclerosis I-Disease
, O
and O
type B-Disease
1 I-Disease
diabetes I-Disease

The O
Encyclopedia O
of O
DNA B-Gene
Elements I-Gene
( O
ENCODE B-Gene
) O
project O
was O
one O
of O
the O
earliest O
producers O
of O
brain-derived B-Disease
epigenetic O
functional O
genomic O
data O
, O
albeit O
initially O
from O
only O
two O
cancerous B-Disease
brain B-Disease
cell O
lines O
for O
a O
limited O
number O
of O
epigenetic O
marks O

In O
this O
review O
, O
we O
will O
study O
what O
3D O
genome B-Gene
folding I-Gene
means O
in O
epigenetics O
, O
what O
types O
of O
3D O
genome B-Gene
structures I-Gene
there O
are O
, O
how O
they O
are O
formed O
, O
and O
how O
the O
technologies O
have O
developed O
to O
explore O
them O

However O
, O
understanding O
the O
functional O
and O
clinical O
consequences O
of O
the O
associated O
alleles O
has O
not O
followed O
the O
same O
pace O

This O
is O
mainly O
due O
to O
their O
crucial O
role O
in O
energetic O
balance O
, O
in O
modulating O
epigenetic O
programs O
and O
in O
influencing O
cell O
stress O
response O

A O
thoroughly O
epigenetic O
model O
of O
development O
and O
evolution O
was O
Waddington's O
aim O
when O
he O
introduced O
the O
term O
' O
epigenetics O
' O
in O
the O
1940s O
, O
but O
it O
has O
taken O
the O
modern O
development O
of O
molecular O
epigenetics O
to O
realize O
this O
aim O

We O
present O
scABC O
, O
an O
R B-Chemical
package O
for O
the O
unsupervised O
clustering O
of O
single-cell O
epigenetic O
data O
, O
to O
classify O
scATAC-seq O
data O
and O
discover O
regions O
of O
open O
chromatin O
specific O
to O
cell O
identity O

Other O
studies O
have O
reported O
increased O
cancer B-Disease
risk O
with O
skewed O
distributions O
of O
the O
normal O
pattern O
in O
cancer B-Disease
cases O
compared O
to O
controls O
, O
showing O
the O
promise O
of O
harnessing O
the O
normal O
variation O
in O
the O
epigenome O

Although O
evidence O
suggests O
that O
patterns O
of O
DNA B-Gene
methylation I-Gene
can O
describe O
ageing O
in O
plants B-Species
, O
predictions O
with O
epigenetic O
clocks O
have O
yet O
to O
be O
performed O

Recent O
advances O
 O
Methods O
for O
DNA B-Gene
methylation I-Gene
analysis O
differ O
in O
their O
coverage O
and O
sensitivity O
, O
and O
the O
method O
of O
choice O
depends O
on O
the O
intended O
application O
and O
desired O
level O
of O
information O

cancers O
and O
prediction O
of O
disease B-Disease

Herein O
, O
we O
report O
and O
discuss O
the O
formation O
of O
5-methylcytosine B-Chemical
-osmium I-Chemical
complexes O
that O
are O
used O
as O
the O
basis O
for O
a O
bisulfite-free O
chemical O
assay O
for O
DNA B-Chemical
methylation I-Chemical
analysis O

Similarly O
, O
the O
refinement O
and O
maturation O
of O
chromatin B-Chemical
immunoprecipitation I-Chemical
with O
next-generation O
sequencing O
( O
ChIP-seq B-Chemical
) O
has O
made O
possible O
genome-wide O
mapping O
of O
histone B-Chemical
modifications I-Chemical
, O
open O
chromatin B-Chemical
, O
and O
transcription O
factor O
binding O
sites O

To O
characterize O
epigenetic O
aging O
, O
genome-wide O
5mC B-Chemical
and O
5hmC B-Chemical
were O
measured O
in O
longitudinal O
blood O
samples O
( O
2 O
, O
4 O
, O
and O
10 O
months O
of O
age O
) O
from O
isogenic O
mice B-Species
using O
two O
sequencing O
methods O
- O
enhanced O
reduced O
representation O
bisulfite O
sequencing O
and O

202 O
The O
epigenetic O
and O
functional O
reprogramming O
of O
immune B-Gene
genes I-Gene
during O
induction O
of O
trained O
immunity O
is O
accompanied O
by O
the O
metabolic O
rewiring O
of O
cellular O
state O

1263 O
methylation O
represents O
one O
of O
the O
best O
characterized O
epigenetic O
modifications O

Hence O
, O
the O
need O
for O
finding O
early O
diagnosis O
and O
treatment O
options O
has O
been O
of O
great O
concern O

3 O
years O
in O
the O
control O
group O

We O
also O
conducted O
enrichment O
analysis O
based O
on O
the O
top O
DNAm B-Gene
signals O

Improved O
translational O
relevance O
also O
requires O
increased O
focus O
on O
volitional O
drug-intake O
models O
and O
standardization O
of O
opioid B-Chemical
exposure O
paradigms O

1260 O
The O
reversibility O
of O
epigenetic O
alterations O
makes O
them O
the O
attractive O
targets O
for O
therapeutic O
discovery O
; O
however O
, O
their O
potential O
remains O
untapped O
owing O
to O
a O
lack O
of O
mechanistic O
understanding O
, O
particularly O
for O
inflammatory B-Disease
skin I-Disease
disorders I-Disease

17 O
Epigenetics O
is O
likely O
to O
play O
a O
role O
in O
the O
mediation O
of O
the O
effects O
of O
genes B-Gene
and O
environment O
in O
risk O
for O
many O
non-communicable B-Disease
diseases I-Disease
( O
NCDs B-Disease
) O

Dietary O
intake O
has O
also O
presented O
significant O
influence O
on O
human B-Species
health O
and O
disease B-Disease
development O
and O
nutritional O
modifications O
have O
proven O
important O
in O
prevention O
, O
but O
also O
the O
treatment O
of O
disease B-Disease

464 O
Simian B-Species
virus I-Species
40 I-Species
(SV40) O
is O
one O
of O
the O
best-characterized O
members O
of O
the O
polyomavirus B-Species
family O
of O
small O
DNA O
tumor B-Disease
viruses I-Disease

In O
this O
review O
, O
we O
systematically O
summarize O
the O
recent O
developments O
of O
computational O
methods O
and O
software O
tools O
in O
high-throughput O
methylation O
data O
analysis O
with O
focus O
on O
two O
aspects O
 O
differential O
methylation O
analysis O
and O
tumor B-Disease
purity I-Disease
estimation O
in O
cancer B-Disease
studies O

1000 O
Integrating O
the O
genotype O
with O
epigenetic O
marks O
holds O
the O
promise O
of O
better O
understanding O
the O
biology O
that O
underlies O
the O
complex O
interactions O
of O
inherited O
and O
environmental O
components O
that O
define O
the O
developmental O
origins O
of O
a O
range O
of O
disorders B-Disease

We O
then O
will O
recapitulate O
some O
of O
the O
recent O
applications O
of O
ML O
to O
epigenomic O
analysis O

Selective O
recognition O
of O
PTMs O
is O
carried O
out O
by O
reader O
modules O
, O
which O
mediate O
the O
biological O
readout O
of O
epigenetic O
mechanisms O

Furthermore O
, O
correlation O
analysis O
identified O
17,500 O
possible O
DMP O
- O
DEG O
interaction O
pairs O
within O
a O
window O
of O
5 O
Mb O
, O
and O
utilizing O
PCHi-C O
data O
, O
we O
observed O
that O
212 O
CD4+ B-Species
T I-Species
cell-specific O
pairs O
of O
DMP O
- O
DEG O
also O
formed O
part O
of O
three-dimensional O
promoter-enhancer O

Here O
, O
we O
describe O
the O
importance O
of O
including O
epigenetics O
in O
genetic O
and O
environmental O
epidemiology O
studies O
, O
provide O
a O
conceptual O
framework O
when O
considering O
epigenetic O
data O
in O
population-based O
studies O
and O
touch O
upon O
the O
many O
challenges O
that O
lie O
ahead O

This O
allowed O
us O
to O
identify O
genes O
that O
were O
differentially O
methylated O
among O
the O
different O
specimens O
and O
link O
them O
to O
specific O
biochemical O
pathways O

Summary O
 O

R2 O
for O
epigenetic O
clocks O
based O
on O
the O
HorvathMammalMethylChip4 B-Gene
was O
higher O
and O
the O
MAD O
scaled O
to O
age O
range O
lower O
, O
compared O
with O
other O
DNAm B-Gene
quantification O
approaches O

What O
is O
lacking O
, O
however O
, O
is O
a O
clear O
demonstration O
of O
heritable O
transgenerational O
effects O
in O
aquatic B-Species
wildlife I-Species

Since O
its O
first O
description O
some O
150 O
years O
ago O
, O
its O
enigmatic O
clinical O
presentation O
has O
challenged O
clinicians O
and O
fascinated O
basic O
researchers O

Importantly O
, O
these O
epigenetic O
changes O
may O
be O
ideal O
targets O
for O
new O
personalized O
treatments O
as O
suggested O
by O
data O
in O
cancer B-Disease

Notably O
, O
the O
expression O
of O
several O
of O
these O
genes O
in O
hASCs B-Species
and O
PBMCs B-Species
such O
as O
tumor B-Disease
necrosis I-Disease
factor I-Disease
alpha I-Disease
( O
TNFA B-Gene
) O
and O
PR B-Gene
domain I-Gene
zinc I-Gene
finger I-Gene
protein I-Gene
16 I-Gene
( O
PRDM16 B-Gene
) O
were O
not O
restored O
to O

168 O
Epigenetic O
mechanisms O
play O
an O
important O
role O
in O
the O
regulation O
of O
cell O
type-specific O
gene O
activities O
, O
yet O
how O
epigenetic O
patterns O
are O
established O
and O
maintained O
remains O
poorly O
understood O

499 O
The O
study O
of O
epigenomics O
has O
advanced O
in O
recent O
years O
to O
span O
the O
regulation O
of O
a O
single O
genetic O
locus O
to O
the O
structure O
and O
orientation O
of O
entire O
chromosomes O
within O
the O
nucleus O

1040 O
Ewing B-Disease
sarcoma I-Disease
is O
a O
highly O
malignant O
tumor O
characterized O
by O
a O
chromosomal O
translocation O
that O
modifies O
the O
activity O
of O
an O
ETS B-Gene
family I-Gene
transcription I-Gene
factor I-Gene

Within O
the O
European O
Network O
for O
Human B-Disease
Congenital I-Disease
Imprinting I-Disease
Disorders I-Disease
we O
have O
discussed O
these O
issues O
and O
designed O
a O
nomenclature O
for O
naming O
imprinted O
DMRs O
as O
well O
as O
for O
reporting O
methylation B-Chemical
values O

He O
has O
also O
presented O
frequently O
at O
AACR O
conferences O
and O
chaired O
the O
special O
conference O
on O
' O
DNA B-Gene
Methylation I-Gene
, O
Imprinting O
and O
the O
Epigenetics O
of O
Cancer B-Disease
' O

There O
are O
a O
large O
number O
of O
putative O
mechanisms O
by O
which O
EEDs B-Chemical
can O
induce O
reproductive B-Disease
toxicity I-Disease
, O
and O
many O
studies O
have O
shown O
the O
involvement O
of O
epigenetics O

Here O
, O
we O
summarize O
the O
recent O
developments O
in O
comparative O
epigenomic O
analyses O
into O
three O
major O
directions O
, O
namely O
the O
comparisons O
across O
species B-Species
, O
the O
time-course O
of O
a O
biological O
process O
, O
and O
individuals O

Several O
studies O
have O
identified O
potential O
molecular O
mechanisms O
that O
contribute O
to O
early O
life O
epigenetic O
reprogramming O
, O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
microRNAs B-Gene
, O
and O
the O
homeostasis O
of O
the O
respiratory B-Species
mucosa I-Species
( O
epithelial B-Species
function I-Species
and O


We O
further O
applied O
a O
bivariate O
autoregressive O
latent O
trajectory O
model O
with O
structured O
residuals O
( O
ALT-SR O
) O
to O
evaluate O
the O
cross-lagged O
effect O
between O
DNA B-Gene
methylation O
of O
these O
CpGs O
and O
cardiometabolic B-Disease
traits O
( O
blood B-Disease
lipids I-Disease
, O
blood B-Disease
pressure I-Disease
, O
and O
body B-Disease
mass I-Disease

80 O
Epigenetics O
can O
be O
defined O
as O
stable O
, O
potentially O
heritable O
changes O
in O
the O
cellular O
phenotype O
caused O
by O
mechanisms O
other O
than O
alterations O
to O
the O
underlying O
DNA B-Gene
sequence I-Gene

Studies O
from O
these O
approaches O
have O
provided O
new O
insights O
into O
the O
molecular O
networks O
and O
processes O
involved O
in O
the O
mechanism O
of O
action O
of O
mood B-Chemical
stabilizers I-Chemical
, O
promoting O
a O
systems-level O
multiomics O
synergy O

A O
growing O
number O
of O
epigenetic O
studies O
in O
gastric B-Disease
cancer I-Disease
have O
provided O
lots O
of O
potential O
diagnostic O
and O
prognostic O
markers O
and O
therapeutic O
targets O

Accumulating O
evidence O
suggests O
that O
disturbances O
in O
DNA B-Gene
methylation O
, O
histone B-Gene
modifications O
and O
noncoding B-Gene
RNAs I-Gene
may O
contribute O
especially O
to O
altered O
differentiation O
and O
metastatic O
potential O

Polyamines O
are O
essential O
for O
many O
cellular O
functions O
and O
polyamine O
activity O
is O
increased O
in O
many O
autoimmune B-Disease
diseases I-Disease

gene B-Gene

Results O
 O
RPMM O
class O
membership O
was O
significantly O
associated O
with O
the O
CF B-Disease
disease I-Disease
status I-Disease
( O
P O
= O
0 O

Nearly O
all O
retinoblastomas B-Disease
are O
initiated O
through O
the O
biallelic O
inactivation O
of O
the O
retinoblastoma B-Disease
tumor I-Disease
susceptibility I-Disease
gene O
( O
RB1 B-Gene
) O

The O
modern O
societies O
are O
characterised O
by O
an O
ageing O
population O
, O
which O
represents O
challenges O
for O
the O
healthcare O
system O

In O
this O
article O
, O
the O
relevant O
patents O
on O
the O
strategies O
to O
develop O
safer O
anticancer B-Chemical
drugs I-Chemical
targeting O
epigenetic O
modulators O
, O
focusing O
on O
members O
and O
modifiers O
of O
the O
UHRF1 B-Gene
complex I-Gene
, O
are O
discussed O

An O
epigenome-wide O
association O
study O
for O
early-life O
exposure O
to O
hunger O
was O
performed O
in O
a O
subgroup O
( O
n O
= O
2221 O
) O
with O
whole O
blood O
DNA B-Chemical
methylation I-Chemical
data O

335 O
Epigenetic O
mechanisms O
are O
highly O
dynamic O
events O
that O
modulate O
gene B-Gene
expression O

139 O
Human B-Species
genetic O
variation O
is O
a O
major O
resource O
in O
forensics O
, O
but O
does O
not O
allow O
all O
forensically O
relevant O
questions O
to O
be O
answered O

DNA O
methylation O
at O
cytosine B-Chemical
residues O
is O
of O
particular O
interest O
for O
epigenetic O
studies O
as O
it O
has O
been O
demonstrated O
to O
be O
both O
a O
long O
lasting O
and O
a O
dynamic O
regulator O
of O
gene B-Gene
expression O

1346 O
Chromatin O
immunoprecipitation O
followed O
by O
next O
generation O
sequencing O
( O
ChIP-seq O
) O
is O
a O
technique O
of O
choice O
for O
studying O
protein-DNA O
interactions O

GeNemo O
returns O
a O
list O
of O
genomic O
regions O
with O
matching O
patterns O
to O
the O
input O
data O
, O
which O
may O
be O
viewed O
in O
the O
browser O
as O
well O
as O
downloaded O
in O
the O
BED O
file O
format O

Genotyping O
by O
sequencing O
( O
GBS O
) O
of O
the O
same O
animals O
was O
performed O
to O
detect O
single O
nucleotide O
polymorphisms O
( O
SNPs O
) O
at O
cytosines B-Chemical
in O
CpG B-Chemical
dinucleotides O
and O
remove O
them O
from O
the O
differential O
methylation O
analysis O

902 O
Neuropeptides B-Chemical
serve O
as O
neurohormones O
and O
local O
paracrine O
regulators O
that O
control O
neural O
networks O
regulating O
behavior O
, O
endocrine O
system O
and O
sensorimotor O
functions O

The O
quality O
of O
age O
predictions O
might O
particularly O
be O
influenced O
by O
lifetime O
adversities O
( O
chronic B-Disease
stress I-Disease
, O
trauma/post-traumatic B-Disease
stress I-Disease
disorder I-Disease
( O
PTSD B-Disease
) O
, O
violence O
, O
low O
socioeconomic O
status/education O
) O
, O
cancer B-Disease
, O
obesity B-Disease
and O
related O
diseases O
, O

The O
use O
of O
droplet O
digital O
PCR O
(ddPCR) O
to O
detect O
DNA B-Gene
methylation O
has O
recently O
emerged O

Both O
genetics O
and O
epigenetics O
contribute O
to O
determining O
the O
outcome O
of O
regulatory O
gene B-Gene
expression I-Gene
systems O

156 O
Hundreds O
of O
distinct O
chemical B-Chemical
modifications O
to O
DNA B-Gene
and O
histone B-Gene
amino O
acids O
have O
been O
described O

The O
singular O
dCas9 B-Gene
fusion O
offers O
a O
simple O
, O
reliable O
, O
and O
general O
tool O
for O
genome-wide O
screens O
, O
multiplexed O
editing O
, O
and O
potential O
therapeutics O

We O
created O
nuclease-resistant O
polyplexes O
with O
plasmid O
DNA B-Chemical
(pDNA) O
and O
post-translationally O
modified O
histone B-Chemical
3 B-Gene
(H3K4Me3) O
tail O
peptides O
known O
to O
signal O
transcriptional O
activation O
on O
chromosomal O
DNA B-Chemical

Plasma O
norepinephrine B-Chemical
( O
NE B-Chemical
) O
is O
often O
elevated O
in O
patients O
with O
POTS B-Disease
, O
resulting O
in O
consideration O
of O
dysfunction O
of O
the O
norepinephrine B-Chemical
transporter O
( O
NET B-Gene
) O
encoded O
by O
SLC6A2 B-Gene
gene O

Interestingly O
, O
metabolism O
and O
epigenetics O
are O
interconnected O

Discussion O
 O
The O
induction O
of O
methylome O
changes O
has O
been O
performed O
in O
plants B-Species
by O
several O
methods O
including O
chemical B-Chemical
drugs I-Chemical
treatment O
and O
tissue O
culture O

1333 O
Aberrant O
regulation O
of O
epigenetic O
mechanisms O
, O
including O
the O
two O
most O
common O
types O
; O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modification I-Chemical
have O
been O
implicated O
in O
common O
chronic O
progressive O
conditions O
, O
including O
Alzheimer B-Disease
disease I-Disease
, O
cardiovascular B-Disease
disease I-Disease
, O
and O


1129 O
The O
postural O
tachycardia O
syndrome O
( O
POTS O
) O
is O
characterised O
clinically O
by O
symptoms O
of O
light-headedness O
, O
palpitations O
, O
fatigue O
and O
exercise O
intolerance O
occurring O
with O
standing O
and O
relieved O
by O
lying O
down O

responses O

These O
factors O
affect O
how O
genes B-Gene
work O
; O
scientists O
now O
know O
that O
what O
matters O
as O
much O
as O
which O
genes B-Gene
you O
have O
( O
and O
what O
environments O
you O
encounter O
) O
is O
how O
your O
genes B-Gene
are O
affected O
by O
their O
contexts O

We O
evolved O
these O
genetic O
circuits O
under O
a O
fluctuating O
environment O
that O
alternatively O
selected O
for O
low O
and O
high O
protein B-Chemical
expression O
levels O

These O
reversible O
modifications O
include O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
acetylation I-Chemical
and O
RNA B-Chemical
interference I-Chemical

At O
individual O
CG B-Gene
dinucleotides I-Gene
(CpGs) O
the O
correlation O
of O
DNA B-Chemical
methylation I-Chemical
with O
chronological O
age O
was O
slightly O
higher O
for O
pyrosequencing O
and O
ddPCR O
as O
compared O
to O
BBA-seq O

The O
development O
of O
epigenetics O
provides O
a O
basis O
for O
the O
search O
for O
genetic O
markers O
associated O
with O
the O
major B-Gene
histocompatibility I-Gene
complex I-Gene

518 O
The O
genetic O
material O
of O
every O
organism O
exists O
within O
the O
context O
of O
regulatory O
networks O
that O
govern O
gene B-Gene
expression I-Gene
, O
collectively O
called O
the O
epigenome O

g O

969 O
Homocysteine B-Chemical
has O
a O
wide O
range O
of O
biological O
effects O

16 O
/ O
15 O


This O
study O
indicates O
that O
CpGs O
with O
different O
stabilities O
are O
involved O
in O
different O
functions O
and O
traits O
, O
and O
thus O
, O
they O
are O
potential O
indicators O
that O
can O
be O
applied O
for O
clinical O
epigenetic O
studies O
to O
outline O
underlying O
mechanisms O

This O
review O
aims O
to O
comprehensively O
analyze O
epigenetics O
' O
role O
in O
IgA B-Gene
nephropathy B-Disease
's I-Disease
development O
and O
suggest O
avenues O
for O
potential O
therapeutic O
interventions O

This O
approach O
could O
reach O
beyond O
the O
practitioners O
' O
eyeball O
' O
assessment O
or O
venerable O
markers O
derived O
from O
the O
physical O
examination O
and O
standard O
laboratory O
evaluation O

This O
module O
delivers O
learning O
materials O
on O
the O
analysis O
of O
bulk O
and O
single-cell O
ATAC-seq O
data O
in O
an O
interactive O
format O
that O
uses O
appropriate O
cloud O
resources O
for O
data O
access O
and O
analyses O

Epigenetic O
changes O
have O
also O
been O
linked O
to O
diabetes-related B-Disease
complications I-Disease

DNA O
methylation O
, O
which O
in O
mammals B-Species
takes O
place O
in O
the O
cytosines O
that O
precede O
a O
guanine B-Chemical
( O
CpG B-Gene
dinucleotide O
) O
, O
is O
the O
most O
well-characterized O
epigenetic O
mark O

Analysis O

However O
, O
if O
purpose-built O
clocks O
are O
necessary O
for O
meaningful O
predictions O
, O
then O
the O
utility O
of O
clocks O
and O
their O
application O
in O
the O
field O
needs O
to O
be O
considered O
in O
that O
context O

215 O
Epigenetic O
regulation O
plays O
a O
pivotal O
role O
in O
various O
biological O
and O
disease B-Disease
processes O

45 O
The O
prevalence O
of O
obesity B-Disease
and O
associated O
diseases O
has O
reached O
pandemic O
levels O

Using O
histone B-Chemical
marks O
, O
we O
also O
demonstrate O
how O
ViCAR B-Gene
improves O
on O
earlier O
approaches O
yielding O
increased O
signal-to-noise O

DMR O
analysis O
identified O
47 O
regions O
associated O
with O
the O
PD B-Disease

698Summary O
GLINT O
is O
a O
user-friendly O
command-line O
toolset O
for O
fast O
analysis O
of O
genome-wide O
DNA B-Chemical
methylation I-Chemical
data O
generated O
using O
the O
Illumina B-Chemical
human B-Species
methylation I-Chemical
arrays O

In O
this O
issue O
of O
Molecular O
Ecology O
, O
Herrera O
& O
Bazaga O
( O
2011 O
) O
provide O
one O
of O
the O
first O
attempts O
to O
truly O
address O
this O
question O
in O
an O
ecological O
setting O

In O
general O
, O
susceptibility O
to O
autoimmunity B-Disease
is O
associated O
with O
multiple O
risk O
factors O
, O
but O
the O
mechanism O
of O
the O
environmental O
component O
influence O
is O
poorly O
understood O

We O
now O
have O
an O
ever-growing O
number O
of O
reported O
epigenetic O
alterations O
in O
disease B-Disease
, O
and O
this O
offers O
a O
chance O
to O
increase O
sensitivity O
and O
specificity O
of O
future O
diagnostics O
and O
therapies O

Epigenetics O
is O
more O
and O
more O
emerging O
as O
a O
basis O
for O
cardiac B-Disease
malformations I-Disease

HCC B-Disease
and O
peritumoral O
tissues O
showed O
a O
different O
epigenetic O
profile O
, O
mainly O
characterized O
by O
loss O
of O
DNA B-Chemical
methylation I-Chemical
in O
HCC B-Disease

We O
caught O
up O
with O
Aydan O
over O
Zoom O
to O
hear O
more O
about O
her O
path O
from O
chemical B-Chemical
engineering O
to O
molecular B-Gene
genetics I-Gene
, O
her O
research O
and O
what O
it O
means O
to O
be O
awarded O
these O
prizes O

Recent O
findings O
involve O
epigenetic O
mechanisms O
in O
the O
origin O
of O
various O
diseases B-Disease

Researchers O
also O
prioritize O
testing O
the O
mechanisms O
and O
functions O
of O
miRNAs B-Gene
, O
circRNAs B-Gene
, O
and O
lncRNAs B-Gene

458 O
The O
deeper O
understanding O
of O
non-coding B-Gene
RNAs I-Gene
has O
recently O
changed O
the O
dogma O
of O
molecular O
biology O
assuming O
protein-coding B-Gene
genes I-Gene
as O
unique O
functional O
biological O
effectors O
, O
while O
non-coding B-Gene
genes I-Gene
as O
junk O
material O
of O
doubtful O
significance O

Multiplex O
design O
is O
challenging O
and O
cumbersome O
to O
define O
specific O
primers O
in O
an O
effective O
manner O
, O
and O
no O
suitable O
software O
tools O
are O
freely O
available O
for O
high-throughput O
primer O
design O
in O
a O
time-effective O
manner O
and O
to O
automatically O
annotate O
the O
resulting O
primers O
with O
known O
SNPs O
, O
CpG B-Chemical

For O
example O
, O
adverse O
exposures O
, O
such O
as O
precarious O
social O
and O
living O
conditions O
and O
related O
psychosocial O
stress O
among O
others O
, O
have O
been O
linked O
to O
specific O
genes B-Gene
being O
switched O
"on O
and O
off" O
through O
epigenetic O
mechanisms O

edu/ O
/EpiCompare/ O
/EpiCompare/ O

Among O
these O
, O
WGBS O
is O
considered O
the O
gold O
standard O

To O
translate O
research O
findings O
into O
clinical O
practice O
, O
interdisciplinary O
collaborations O
, O
technical O
and O
ethical O
considerations O
, O
and O
accessibility O
of O
resources O
and O
knowledge O
are O
crucial O


1073 O
Despite O
the O
success O
of O
genome-wide O
association O
studies O
( O
GWASs O
) O
in O
identifying O
loci O
associated O
with O
common B-Disease
diseases I-Disease
, O
a O
substantial O
proportion O
of O
the O
causality O
remains O
unexplained O

Chronic O
pain B-Disease
stimuli O
and O
intense O
pain B-Disease
have O
effects O
at O
a O
cellular O
and/or O
gene B-Gene
expression I-Gene
level O
, O
and O
will O
eventually O
induce O
" O
cellular O
memory O
due O
to O
pain B-Disease
" O
, O
which O
means O
that O
tissue O
damage O
, O
even O
if O
only O
transient O
, O
can O
elicit O
epigenetically O

The O
principles O
together O
with O
pros O
and O
cons O
are O
discussed O

We O
detail O
assays O
on O
studies O
of O
histone B-Chemical
modifications O
, O
DNA B-Chemical
methylation O
, O
3D O
chromatin O
structures O
and O
non-coding O
RNAs B-Gene

Analogously O
, O
epigenetic O
regulation O
is O
postulated O
to O
regulate O
caste O
differences O
in O
social O
insects B-Species

This O
knowledge O
constantly O
accumulates O
and O
is O
provided O
openly O
in O
the O
expanding O
hubs O
of O
information O
such O
as O
the O
USCS B-Gene
Genome I-Gene
Browser I-Gene

Recent O
technologies O
for O
high-throughput O
genome-wide O
analyses O
for O
epigenetic O
modifications O
are O
promising O
and O
potent O
tools O
for O
understanding O
the O
global O
dysregulation O
of O
cancer B-Disease
epigenetics O

The O
second O
contribution O
performed O
weighted O
gene B-Gene
coexpression I-Gene
network I-Gene
analysis O
and O
identified O
6 O
significant O
modules O
of O
at O
least O
30 O
CpG B-Gene
sites I-Gene
, O
including O
3 O
modules O
with O
topological O
differences O
pretreatment B-Chemical
and O
posttreatment B-Chemical

Here O
, O
we O
review O
the O
predictive O
biomarkers O
of O
12 O
epi-drugs B-Chemical
as O
well O
as O
the O
progress O
of O
combination O
therapy O
with O
chemotherapeutic B-Chemical
drugs O
or O
immunotherapy O

Instead O
, O
their O
clinical O
presentation O
is O
thought O
to O
result O
from O
the O
regulative O
interplay O
of O
a O
large O
number O
of O
genes B-Gene

The O
recent O
discovery O
of O
the O
sex O
determining O
region O
( O
SDR O
) O
of O
balsam O
poplar O
, O
Populus B-Species
balsamifera I-Species
, O
pinpointed O
13 O
genes O
with O
differentiated O
X O
and O
Y O
copies O

Contact O
 O
peter O

Environmental O
factors O
such O
as O
diet O
, O
gut B-Disease
microbiota I-Disease
, O
and O
infections O
have O
significant O
role O
in O
these O
epigenetic O
modifications O

Paternal O
contributions O
influenced O
by O
social O
structures O
including O
poor O
diet O
and O
stress O
influence O
the O
subsequent O
metabolic O
functioning O
of O
the O
child O

This O
review O
highlights O
traditional O
approaches O
as O
well O
as O
current O
advancements O
in O
the O
analysis O
of O
the O
gene B-Gene
expression I-Gene
data O
from O
cancer B-Disease
perspective O

EPIGENE O
is O
an O
open-source O
method O
and O
is O
freely O
available O
at O
 O
https//github O
. O

This O
narrative O
review O
summarizes O
current O
knowledge O
on O
the O
epigenetic O
basis O
of O
and O
describes O
studies O
in O
animal O
models O
and O
human O
subjects O
examining O
how O
the O
epigenome O
and O
transcriptome O
are O
modified O
by O
in O
the O
brain O

Most O
notable O
of O
these O
patterns O
are O
the O
valley O
patterns O
that O
are O
prevalently O
observed O
in O
assays O
such O
as O
ChIP B-Chemical
Sequencing I-Chemical
and O
bisulfite B-Chemical
sequencing I-Chemical

DNA O
methylation O
and O
microRNA O
have O
been O
proposed O
as O
biomarkers O
to O
predict O
islet B-Disease
Î² I-Disease
cell I-Disease
death I-Disease
, O
which O
needs O
further O
confirmation O
before O
any O
clinical O
application O
can O
be O
developed O

Here O
, O
we O
review O
our O
current O
knowledge O
of O
in O

Genetic O
predisposition O
- O
prenatal O
, O
perinatal O
and O
pediatric O
environmental O
influences O
- O
microbiome B-Species
aberration O
( O
dysbiosis O
) O
and O
immune B-Gene
dysregulation O
appear O
to O
be O
important O
elements O
in O
disease B-Disease
development O
, O
progression O
and O
maintenance O

Studies O
on O
the O
transcriptional O
regulation O
of O
adipogenesis O
highlight O
the O
importance O
of O
investigating O
adipocyte O
differentiation O
in O
vivo O
rather O
than O
drawing O
conclusions O
based O
on O
knockdown O
experiments O
in O
cell O
culture O

We O
consider O
what O
has O
historically O
been O
understood O
by O
the O
term O
"epigenetics" O
before O
turning O
to O
the O
advances O
in O
biochemistry O
, O
molecular O
biology O
, O
and O
genetics O
which O
have O
led O
to O
current-day O
definitions O
of O
the O
term O

In O
this O
chapter O
, O
we O
review O
the O
most O
recent O
findings O
in O
several O
molecular O
pathways O
linked O
with O
the O
pathogenesis O
of O
TLE B-Disease
that O
are O
controlled O
by O
epigenetic O
mechanisms O
highlighting O
their O
potential O
utility O
as O
biomarkers O
for O
upcoming O
treatment O
strategies O

Optimal O
execution O
and O
interpretation O
of O
data O
is O
fundamental O
for O
achieving O
accurate O
and O
reproducible O
results O

Discussion O

Recent O
molecular O
evidence O
shows O
that O
epialleles O
often O
display O
high O
levels O
of O
transgenerational O
instability O

maternal O

995 O
Personalized O
medicine O
aims O
to O
integrate O
a O
number O
of O
characteristics O
such O
as O
genetic O
and O
epigenetic O
variations O
, O
other O
biomarkers O
, O
clinical O
symptoms O
, O
and O
environmental O
factors O
in O
order O
to O
predict O
susceptibility O
to O
disease O
, O
aid O
in O
diagnosis O
, O
and O
identify O
efficacious O
treatments O
with O

Against O
this O
backdrop O
, O
comparative O
integrative O
biologists O
are O
particularly O
well-suited O
to O
understand O
epigenetic O
phenomena O
as O
a O
way O
for O
organisms O
to O
respond O
rapidly O
with O
modified O
phenotypes O
( O
relative O
to O
natural O
selection O
) O
to O
changes O
in O
the O
environment O

Exploration O
of O
DNA B-Gene
epigenetic O
patterns O
that O
regulate O
gene O
expression O
profiles O
could O
therefore O
provide O
the O
missing O
link O
between O
epigenomic O
state O
and O
FSD B-Disease
, O
and O
as O
such O
may O
offer O
a O
new O
biological O
framework O
for O
the O
multifactorial O
pathoetiology O
underlying O
FSD B-Disease

g O

However O
, O
the O
analysis O
of O
these O
complex O
omic O
data O
requires O
to O
face O
important O
analytic O
issues O

, O
the O
methylation O
did O
not O
differ O
between O
males O
and O
females O
at O
young O
age O
but O
age-related O
changes O
occurred O
in O
one O
sex O
but O
not O
the O
other O

Chromatin O
immunoprecipitation O
followed O
by O
sequencing O
( O
ChIP-seq O
) O
is O
the O
most O
widely O
used O
method O
to O
characterize O
where O
in O
the O
genome O
transcription O
factors O
, O
modified O
histones O
, O
modified O
nucleotides O
and O
chromatin O
binding O
proteins O
are O
found O
; O
bisulfite O
sequencing O
( O
BS-seq O
) O
and O

However O
, O
the O
exact O
regulatory O
mechanism O
between O
gene B-Gene
expression O
and O
methylation B-Chemical
is O
not O
precisely O
deciphered O

Differential O
methylation O
is O
now O
known O
to O
play O
a O
central O
role O
in O
the O
development O
and O
outcome O
of O
most O
if O
not O
all O
human B-Species
malignancies B-Disease

Because O
of O
these O
reasons O
, O
many O
of O
the O
global O
DNA B-Gene
methylation I-Gene
analysis O
methods O
are O
mainly O
performed O
at O
core O
facility O
, O
and O
laboratories O
with O
limited O
resources O
and O
expertise O
are O
not O
able O
to O
use O
these O
methods O

302 O
Epigenetics O
has O
an O
important O
role O
for O
the O
success O
of O
persistence O
in O
diverse O
host O
niches O

0 O
and O
an O
A260/230 O
ratio O
of O
2 O

0 O
and O
greater O

7 O
years O

Of O
these O
predictive O
sites O
, O
the O
average O
methylation B-Chemical
change O
over O
a O
lifetime O
was O
small O
( O
~ O
1 O

We O
discuss O
targeting O
of O
these O
enzymes O
for O
therapeutic O
gain O

The O
new O
procedure O
was O
used O
with O
two O
simulated O
data O
sets O
and O
with O
a O
beef B-Species
cattle I-Species
database O

The O
Drosophila B-Species
genetic O
system O
provides O
excellent O
models O
for O
such O
diseases B-Disease

1409 O
 O
Problem O
 O
Development O
of O
alternative O
CD4(+) B-Gene
T I-Gene
cells I-Gene
provides O
flexibility O
to O
the O
immune O
system O

These O
cells O
include O
conventional O
adult O
stem O
cells O
and O
a O
still O
poorly O
defined O
collection O
of O
cell O
types O
endowed O
with O
facultative O
phenotype O
and O
functional O
plasticity O

com O
/ O
dohlee O
/ O
prism O
) O

Preterm O
birth O
constitutes O
one O
of O
the O
major O
adverse O
events O
in O
human B-Species
development O

The O
most O
frequent O
keywords O
were O
" O
DNA B-Chemical
methylation I-Chemical
" O
and O
" O
LncRNA B-Gene
" O

459 O
Personalized O
medicine O
aims O
to O
deliver O
the O
right O
drug O
to O
a O
right O
patient O
at O
the O
right O
time O

298 O
constitutes O
the O
most O
studied O
epigenetic O
mechanism O
, O
regulating O
gene O
expression O
in O
several O
physiological O
and O
pathological O
states O

The O
central O
clock O
system O
controls O
peripheral O
clocks O
through O
a O
number O
of O
output O
cues O
that O
synchronize O
the O
system O
as O
a O
whole O

270 O
As O
a O
mechanism O
of O
epigenetic O
gene O
regulation O
, O
DNA B-Chemical
methylation I-Chemical
has O
crucial O
roles O
in O
developmental O
and O
differentiation O
programs O

Using O
the O
best-fitting O
two-factor O
solution O
that O
we O
identified O
, O
we O
obtained O
effects O
almost O
twice O
as O
large O
as O
those O
found O
by O
Fredrickson B-Gene
et I-Gene
al I-Gene


We O
methodically O
assessed O
the O
reprogramming O
efficiency O
of O
each O
line O
and O
then O
quantified O
the O
individual O
and O
demographic-specific O
variations O
in O
proteins O
and O
expression O

We O
tested O
different O
dCas9 B-Gene
orthologs O
( O
dCjCas9 B-Gene
, O
dNmCas9 B-Gene
, O
dSt1Cas9 B-Gene
, O
dFnCas9 B-Gene
, O
dSaCas9 B-Gene
and O
dSpCas9 B-Gene
) O
in O
C-terminal O
fusion O
with O
DNMT3A B-Gene
effector O
domain O
to O
find O
candidates O
that O
potentiate O
effector O
domain O
to O
perform O

One O
key O
problem O
is O
the O
inability O
of O
most O
DNA-packaging O
materials O
to O
release O
DNA B-Gene
and O
enable O
its O
efficient O
transcription O

Mutual O
correction O
of O
read1 O
and O
read2 O
can O
estimate O
the O
amplification O
and O
sequencing O
errors O
, O
and O
enables O
our O
developed O
computational O
pipeline O
, O
DSBS O
Analyzer O
( O
https//github O

Nevertheless O
, O
its O
impact O
in O
the O
field O
of O
cardiovascular B-Disease
disease I-Disease
( O
CVD B-Disease
) O
remains O
largely O
unexplored O

Information O
on O
the O
chronological O
age O
of O
a O
stain O
donor O
(or O
any O
sample O
donor O
) O
is O
elemental O
for O
forensic O
investigations O
in O
a O
number O
of O
aspects O
and O
has O
, O
therefore O
, O
been O
explored O
by O
researchers O
in O
some O
detail O

In O
fish B-Species
, O
studies O
on O
age-related O
DNA B-Gene
methylation I-Gene
changes O
are O
scarce O
and O
no O
epigenetic O
clocks O
have O
been O
constructed O

First O
, O
it O
uses O
a O
beta B-Chemical
distribution O
to O
characterize O
the O
bimodal O
and O
interval O
properties O
of O
the O
methylation B-Chemical
trait O
at O
a O
CpG B-Gene
site O

However O
, O
the O
role O
of O
DNA B-Gene
methylation O
in O
CVD B-Disease
etiology O
remains O
unclear O

The O
epigenome O
includes O
DNA B-Chemical
methylation O
, O
histone B-Chemical
modifications O
, O
and O
RNA-mediated O
processes O
, O
and O
disruption O
of O
this O
balance O
may O
cause O
several O
pathologies O
and O
contribute O
to O
obesity B-Disease
and O
type B-Disease
2 I-Disease
diabetes I-Disease
( O
T2D B-Disease
) O

Although O
the O
management O
of O
lupus B-Disease
patients O
has O
improved O
in O
the O
last O
years O
, O
several O
aspects O
still O
remain O
challenging O

These O
new O
approaches O
improve O
the O
assessment O
of O
epigenetic O
diversity O
in O
ecological O
settings O
and O
may O
provide O
functional O
insights O

In O
4 O

Integrative O
analyses O
identified O
candidate O
master O
regulators O
of O
Tmem O
cell O
differentiation O
, O
including O
the O
transcription O
factor O
FOXP1 B-Gene

This O
updated O
manuscript O
highlights O
these O
changes O
and O
improvements O

It O
includes O
environmental O
, O
nutritional O
, O
hormonal O
and O
physiological O
factors O
and O
influence O
of O
internal O
structural O
architecture O
of O
chromatin O
nucleosomes O
affecting O
DNA B-Gene
and O
histone B-Chemical
modifications O
in O
both O
male O
and O
female O
gametes O
, O
early O
embryogenesis O
and O
offspring O

Conclusion O
 O
This O
study O
reveals O
the O
potential O
mechanisms O
in O
SLE B-Disease
from O
epigenetic O
modifications O
and O
immune-cell O
infiltration O
, O
providing O
diagnostic O
biomarkers O
and O
therapeutic O
targets O
for O
SLE B-Disease

The O
other O
4 O
existing O
scores O
are O
experimental O
features O
( O
CTCF B-Gene
, O
DNase B-Chemical
I I-Chemical
, O
H3K4me3 B-Chemical
, O
RRBS B-Chemical
) O
commonly O
used O
in O
deep O
learning O
models O
for O
off-target O
activity O
prediction O

Pattern O
of O
DNA B-Chemical
methylation O
and O
expression O
of O
histone-modifying O
enzymes O
have O
been O
successfully O
used O
for O
risk O
stratification O

307 O
Purpose O
of O
review O
 O

The O
current O
objective O
is O
to O
review O
relevant O
studies O
of O
interest O
to O
behavioral O
scientists O
who O
study O
crime O
, O
and O
to O
translate O
admittedly O
challenging O
scientific O
information O
into O
text O
that O
is O
digestible O
to O
the O
average O
criminologist O

DNA O
methylation O
data O
were O
obtained O
from O
genomic O
DNA B-Chemical
extracted O
from O
the O
frontal O
cortex O
and O
blood O
samples O
of O
adult O
common B-Species
marmosets I-Species
as O
well O
as O
the O
frontal O
cortex O
of O
neonatal O
marmosets B-Species

Various O
epigenetic O
mechanisms O
may O
also O
be O
involved O
in O
the O
pathogenesis O
of O
preeclampsia B-Disease
and O
intrauterine B-Disease
growth I-Disease
restriction I-Disease

77 O
Epigenetics O
refers O
to O
the O
study O
of O
heritable O
changes O
in O
gene B-Gene
function I-Gene
that O
do O
not O
involve O
changes O
in O
the O
DNA B-Chemical
sequence I-Chemical

It O
contains O
regularly O
updated O
annotations O
from O
4 O
public O
databases O
 O
Blueprint B-Chemical
, O
RoadMap B-Chemical
, O
GENCODE B-Gene
and O
the O
UCSC B-Gene
Genome I-Gene
Browser I-Gene

In O
conclusion O
, O
although O
the O
importance O
of O
RASSF1A B-Gene
methylation O
to O
cancer B-Disease
has O
been O
established O
is O
included O
in O
several O
diagnostic O
panels O
, O
its O
diagnostic O
utility O
is O
still O
experimental O

Automation O
of O
chromatin B-Chemical
immunoprecipitation I-Chemical
assays O
is O
possible O
when O
the O
procedure O
is O
based O
on O
the O
use O
of O
magnetic B-Chemical
beads I-Chemical

In O
this O
chapter O
, O
we O
summarize O
the O
transformative O
single-cell O
epigenomic O
technologies O
that O
have O
deepened O
our O
understanding O
of O
the O
fundamental O
principles O
of O
gene B-Gene
regulation I-Gene

5% O
) O
genes O
are O
directly O
involved O
in O
epigenetic O
regulations O
and O
the O
majority O
of O
these O
genes O
belong O
to O
histone B-Chemical
writers O
, O
readers O
, O
and O
erasers O

Mutations O
that O
affect O
epigenetic O
mechanisms O
are O
common O
in O
cancer B-Disease

Experiments O
were O
now O
designed O
to O
assess O
the O
epigenetic O
consequences O
of O
inserting O
a O
5 O

Monozygotic O
twins O
discordant O
for O
any O
disease B-Disease
offer O
an O
ideal O
study O
design O
as O
they O
are O
matched O
for O
many O
factors O
, O
including O
genetic O
variation O
and O
this O
is O
a O
real O
advantage O
for O
epigenetics O
study O

Associations O
between O
greenness O
and O
biological O
aging O
measured O
by O
Horvath's B-Gene
and O
Hannum's B-Gene
DNAmAgeAC B-Gene
were O
less O
consistent O
, O
and O
depended O
on O
neighborhood O
socioeconomic O
status O

The O
genomic O
positions O
of O
valleys O
pinpoint O
locations O
of O
cis-regulatory O
elements O
such O
as O
enhancers O
and O
insulators O

These O
studies O
provide O
models O
for O
future O
cohort O
study O
design O
, O
potential O
perioperative O
drug B-Chemical
targets O
, O
and O
hypothesis O
development O

We O
used O
bioinformatics O
, O
network O
pharmacology O
and O
enrichment O
analysis O
to O
understand O
the O
effect O
of O
phytocannabinoids B-Chemical
in O
neuromodulation B-Disease

Approaches O
are O
also O
described O
for O
batch O
retrieval O
of O
genomic B-Chemical
information O
, O
performing O
more O
complex O
queries O
, O
and O
analyzing O
larger O
sets O
of O
experimental O
data O
, O
for O
example O
from O
next-generation O
sequencing B-Chemical
projects O

These O
strategies O
will O
be O
useful O
to O
perform O
large-scale O
, O
genome-wide O
DNA B-Gene
methylation I-Gene
analysis O

All O
genomic O
data O
from O
publicly O
funded O
projects O
are O
freely O
available O
in O
Internet-based O
databases O
, O
for O
download O
or O
searching O
via O
genome O
browsers O
such O
as O
Ensembl B-Gene
, O
Vega B-Gene
, O
NCBI's B-Gene
Map I-Gene
Viewer I-Gene
, O
and O
the O
UCSC B-Gene
Genome I-Gene
Browser I-Gene

Finally O
, O
we O
show O
that O
comparisons O
of O
the O
epigenetic O
landscape O
between O
species B-Species
can O
reveal O
elements O
with O
similar O
roles O
in O
regulation O
, O
even O
in O
the O
absence O
of O
genomic O
sequence O
alignment O

Results O
 O
In O
control O
animals O
, O
5319 O
age-dependent O
DMRs O
were O
identified O

In O
our O
opinion O
, O
filling O
the O
gaps O
in O
our O
understanding O
of O
the O
epigenetic O
mechanisms O
regulating O
the O
TCR B-Gene
repertoire I-Gene
will O
benefit O
the O
development O
of O
strategies O
that O
can O
modulate O
the O
TCR B-Gene
repertoire I-Gene
composition O
by O
leveraging O
the O
dynamic O
nature O
of O
epigenetic O
modifications O

It O
seems O
certain O
that O
comprehending O
the O
molecular O
mechanisms O
underlying O
epigenetic O
clocks O
, O
especially O
with O
regard O
to O
somatic O
stem O
cell O
aging O
, O
combined O
with O
applying O
single-cell O
epigenetic-age O
profiling O
technologies O
to O
aging O
and O
cancer B-Disease
cohorts O
, O
and O
the O
integration O
of O
existing O
and O
upcoming O

Accumulating O
evidence O
suggests O
that O
modern O
lifestyle O
characteristics O
such O
as O
the O
intake O
of O
energy-dense O
foods O
, O
adopting O
sedentary O
behavior O
, O
or O
exposure O
to O
environmental O
factors O
such O
as O
industrial O
endocrine B-Chemical
disruptors I-Chemical
all O
contribute O
to O
the O
rising O
obesity B-Disease
epidemic I-Disease

036 O
, O
SE O
= O
0 O

The O
more O
specific O
the O
testing O
procedures O
are O
, O
the O
less O
one O
can O
generalize O
to O
more O
naturalistic O
situations O
, O
including O
to O
human B-Species
clinical O
populations O

The O
interplay O
between O
epigenetics O
and O
environment O
directs O
the O
code O
into O
temporally O
distinct O
inflammatory B-Disease
responses I-Disease
, O
which O
can O
be O
acute B-Disease
or O
chronic B-Disease

Amongst O
all O
, O
bioinformatics O
plays O
a O
pivotal O
role O
in O
achieving O
epigenetics-related O
computational O
studies O

Many O
of O
the O
significant O
CpG B-Gene
sites I-Gene
(27/40 O
CpG B-Gene
sites I-Gene
) O
were O
located O
upstream O
of O
genes O
, O
and O
all O
such O
CpG B-Gene
sites I-Gene
with O
the O
exception O
of O
two O
were O
hypomethylated O
in O
PD B-Disease
subjects O

In O
this O
review O
, O
we O
explain O
briefly O
the O
history O
of O
epigenetics O
and O
we O
propose O
some O
examples O
of O
epigenetic O
and O
transgenerational O
effects O
demonstrated O
in O
humans B-Species
and O
animals B-Species

The O
direct O
effect O
is O
underestimated O
and O
, O
when O
the O
mediator O
is O
a O
biomarker O
of O
the O
exposure O
, O
as O
is O
true O
for O
smoking B-Chemical
, O
the O
indirect O
effect O
is O
overestimated O

( O
) O
review O
addresses O
one O
of O
the O
most O
fundamental O
questions O
in O
the O
fields O
of O
child O
psychology O
and O
psychiatry O
- O
How O
can O
adverse O
experiences O
shape O
development O
to O
a O
sufficient O
degree O
and O
in O
profound O
and O
enduring O
ways O
to O
create O
long O
term O
risk O
for O
later O
mental O
disorder B-Disease
and O

inhibited O
the O
epigenetic O
NRF2 B-Gene
/ I-Gene
KLOTHO I-Gene
suppressions O
in O
a O
gain O
of O
DNMT B-Gene
- I-Gene
sensitive I-Gene
manner O
in O
cultured O
renal B-Species
cells I-Species
, O
demonstrating O
a O
strong O
DNA-demethylating O
capacity O

Social O
and O
biographical O
conditions O
, O
as O
well O
as O
material O
exposures O
, O
all O
modulate O
our O
biology O
with O
consequences O
for O
risk O
predispositions O
and O
health O
conditions O

1371Background O
Methylation O
of O
cytosine B-Chemical
in O
genomic O
DNA B-Gene
is O
a O
well-characterized O
epigenetic O
modification O
involved O
in O
many O
cellular O
processes O
and O
diseases B-Disease

Some O
employ O
epigenetics O
to O
explain O
changes O
in O
gene B-Gene
expression I-Gene
, O
others O
use O
it O
to O
refer O
to O
transgenerational O
effects O
and/or O
inherited O
expression O
states O

We O
evaluated O
the O
association O
between O
Phase O
1 O
smoking O
status O
and O
rate O
of O
methylation B-Chemical
change O
, O
using O
generalized O
estimating O
equation O
models O

Some O
observations O
yielded O
a O
baseline O
for O
additional O
novel O
discoveries O
, O
occasionally O
facilitated O
by O
specific O
properties O
of O
some O
ciliates B-Species

Recent O
advances O
in O
the O
field O
of O
epigenetics O
extended O
the O
role O
of O
epigenetic O
mechanisms O
in O
controlling O
key O
biological O
processes O
such O
as O
genome O
imprinting O
and O
X-chromosome O
inactivation O

Epigenetic O
modification O
plays O
a O
central O
role O
in O
neurobiological O
and O
developmental O
processes O
, O
and O
disturbances O
to O
these O
processes O
can O
have O
implications O
for O
a O
range O
of O
mental B-Disease
health I-Disease
problems I-Disease

Epigenetics O
could O
explain O
the O
influence O
of O
factors O
such O
as O
the O
nutritional/metabolic O
status O
of O
the O
mother O
or O
the O
artificial O
environment O
of O
assisted O
reproductive O
technologies O

We O
confirm O
that O
the O
T O

432 O
Nutrition O
plays O
a O
key O
role O
in O
many O
aspects O
of O
health O
and O
dietary O
imbalances O
are O
major O
determinants O
of O
chronic O
diseases O
including O
cardiovascular B-Disease
disease I-Disease
, O
obesity B-Disease
, O
diabetes B-Disease
and O
cancer B-Disease

It O
will O
be O
important O
in O
the O
future O
to O
demonstrate O
that O
at O
least O
some O
of O
the O
age-related O
changes O
in O
DNA B-Gene
methylation I-Gene
directly O
lead O
to O
alterations O
in O
the O
transcriptome O
of O
cells/tissues O
that O
could O
potentially O
contribute O
to O
aging O

However O
, O
because O
there O
are O
so O
many O
techniques O
available O
, O
researchers O
are O
faced O
with O
the O
challenge O
of O
assessing O
the O
potential O
merits O
or O
limitations O
of O
each O
technique O
and O
selecting O
the O
appropriate O
method O
for O
their O
analysis O

He O
earned O
his O
B O

All O
contributions O
used O
the O
GAW20 O
real O
data O
set O
and O
employed O
either O
linear O
mixed O
effect O
(LME) B-Chemical
models O
or O
marginal O
models O
through O
generalized O
estimating O
equations O
(GEE) B-Chemical

Presented O
here O
is O
the O
"polyamine O
hypothesis" O
in O
which O
increased O
polyamine B-Chemical
synthesis O
competes O
with O
cellular O
methylation O
(epigenetic O
control) O
for O
SAM B-Chemical

Although O
direct O
evidence O
for O
epigenetic O
dysfunction O
in O
bipolar B-Disease
disorder I-Disease
is O
still O
limited O
, O
methodological O
technologies O
in O
epigenomic O
profiling O
have O
advanced O
, O
offering O
even O
single O
cell O
analysing O
and O
resolving O
the O
problem O
of O
cell O
heterogeneity O
in O
epigenetics O
research O

637 O
The O
analysis O
of O
epigenetic O
modifications O
in O
allergic B-Disease
diseases I-Disease
has O
recently O
attracted O
substantial O
interest O
because O
epigenetic O
modifications O
can O
mediate O
the O
effects O
of O
the O
environment O
on O
the O
development O
of O
or O
protection O
from O
allergic B-Disease
diseases I-Disease


562 O
 O
Cancer B-Disease
is O
a O
complex O
disease O
caused O
by O
the O
malignant O
cellular O
proliferation O
and O
metastasis O

Many O
of O
these O
epigenetic O
modifications O
have O
been O
reported O
to O
modulate O
atherosclerosis B-Disease
development O
and O
progression O
, O
ultimately O
contributing O
to O
stroke B-Disease
pathogenesis O

We O
also O
manually O
curated O
related O
biological O
and O
clinical O
information O
for O
each O
profile O
, O
allowing O
users O
to O
better O
browse O
and O
compare O
cfDNA B-Chemical
epigenomes O
at O
a O
specific O
stage O
( O
such O
as O
early- O
or O
metastasis-stage O
) O
of O
cancer B-Disease
development O

Identified O
epigenetic O
processes O
involved O
in O
human B-Species
disease B-Disease
include O
chromatin B-Chemical
remodeling O
, O
genomic B-Chemical
imprinting O
, O
X B-Gene
chromosome I-Gene
inactivation O
, O
and O
noncoding O
RNAs B-Gene
regulation O

However O
, O
successful O
whole-genome O
bisulphite O
sequencing O
( O
WGBS O
) O
of O
such O
serum O
samples O
has O
the O
potential O
to O
open O
biobanks O
for O
epigenetic O
analyses O
and O
deliver O
novel O
prediagnostic O
biomarkers O

Furthermore O
, O
epigenetics O
may O
play O
a O
major O
role O
in O
inflammatory B-Disease
responses I-Disease
following O
stroke B-Disease

As O
in O
many O
other O
omics O
experiments O
, O
the O
issue O
of O
missing O
values O
is O
an O
important O
one O
, O
and O
appropriate O
imputation O
techniques O
are O
important O
in O
avoiding O
an O
unnecessary O
sample O
size O
reduction O
as O
well O
as O
to O
optimally O
leverage O
the O
information O
collected O

We O
tested O
these O
genes O
for O
differential O
methylation O
using O
whole O
methylome O
sequencing O
of O
xylem B-Species
tissue O
of O
multiple O
individuals O
grown O
under O
field O
conditions O
in O
two O
common O
gardens O

Recently O
, O
however O
, O
ever-increasing O
evidence O
has O
associated O
epigenetic O
mechanisms O
, O
such O
as O
DNA B-Chemical
methylation I-Chemical
( O
DNAm B-Gene
) O
with O
age-onset O
pathologies O
, O
including O
cancer B-Disease
, O
cardiovascular B-Disease
disease I-Disease
, O
and O
Alzheimer's B-Disease
disease I-Disease

Recommendations O
for O
safeguards O
and O
guidelines O
on O
the O
use O
of O
epigenetics B-Chemical
with O
children O
and O
adolescents O
are O
outlined O
based O
on O
the O
identified O
issues O

Therefore O
, O
the O
objectives O
of O
this O
review O
were O
to O
( O
i O
) O
provide O
an O
overview O
of O
the O
literature O
on O
the O
association O
of O
prenatal O
exposure O
to O
psychotropics B-Chemical
and O
analgesics B-Chemical
with O
epigenetic O
outcomes O
, O
and O
( O
ii O
) O
suggest O
recommendations O
for O
future O
studies O
within O
prenatal O

Further O
implication O
of O
stochastic O
epigenetic O
variability O
in O
adaptation O
is O
found O
in O
bottlenecked O
invasive O
species B-Species
populations O
and O
populations O
using O
a O
bet-hedging O
strategy O

One O
goal O
is O
to O
provide O
an O
impetus O
to O
additionally O
investigate O
changes O
in O
DNA B-Gene
methylation I-Gene
as O
a O
possible O
consequence O
of O
an O
impaired O
methyl B-Chemical
group I-Chemical
metabolism O

This O
review O
discusses O
fetal O
programming O
mechanisms O
as O
well O
as O
maternal O
nutrition O
's O
impact O
on O
placental O
development O
and O
progeny O
heifer O
performance O
and O
reproduction O
owing O
to O
nutrient O
restriction O
, O
age O
, O
or O
production O
status O

We O
have O
developed O
a O
Bayesian O
model O
to O
infer O
which O
epialleles O
are O
present O
in O
multiple O
regions O
of O
the O
same O
tumour B-Disease

1379 O
 O
Understanding O
adipogenesis O
, O
the O
process O
of O
adipocyte O
development O
, O
may O
provide O
new O
ways O
to O
treat O
obesity B-Disease
and O
related O
metabolic O
diseases O

Effective O
targeted O
DNA B-Chemical
methylation I-Chemical
editing O
will O
continue O
to O
advance O
our O
fundamental O
understanding O
of O
the O
role O
of O
this O
modification O
in O
different O
genomic O
and O
cellular O
contexts O
, O
and O
further O
improvements O
may O
enable O
more O
accurate O
disease B-Disease
modeling I-Disease
and O
possible O
future O
treatments O

com O
/ O
FocusPaka B-Species
/ O
SIMD B-Gene

Novel O
genetic O
data O
have O
been O
obtained O
on O
the O
molecular O
bases O
of O
genetically O
complex O
AID B-Disease

This O
Review O
discusses O
emerging O
issues O
and O
strategies O
related O
to O
data O
integration O
in O
the O
era O
of O
next-generation O
genomics O

However O
, O
variation O
in O
DNA B-Gene
methylation I-Gene
increases O
with O
age O
, O
and O
there O
is O
no O
epigenetic O
clock O
specifically O
designed O
for O
adolescents O
and O
young O
adults O

The O
majority O
of O
such O
disorders B-Disease
have O
unknown O
underlying O
causes O

Some O
of O
these O
are O
key O
characteristics O
of O
human B-Species
carcinogens O
and O
have O
been O
considered O
for O
hazard O
identification O
of O
nanomaterials O

This O
method O
has O
been O
successfully O
used O
to O
detect O
changes O
in O
DNA B-Gene
methylation O
either O
occurring O
naturally O
or O
induced O
by O
various O
toxicants B-Chemical
and O
environmental O
factors O

We O
present O
a O
summary O
of O
the O
epidemiologic O
studies O
in O
NCI O
's O
grant O
portfolio O
( O
from O
January O
2005 O
through O
December O
2012 O
) O
and O
in O
the O
scientific O
literature O
published O
during O
the O
same O
period O
, O
irrespective O
of O
support O
from O
the O
NCI O

We O
found O
364 O
candidate O
obesity-regulating B-Disease
cis O
elements O
and O
genetic O
circuits O
in O
different O
cell O
types O

, O
the O
frequency O
and O
quality O
of O
maternal O
care O
modifying O
the O
brain O
and O
future O
behavior O
of O
the O
offspring O
each O
generation O
) O

Two O
specific O
types O
of O
epigenetic O
regulation O
established O
in O
early O
development O
include O
X-chromosome B-Gene
inactivation I-Gene
and O
genomic B-Gene
imprinting I-Gene
; O
they O
regulate O
gene O
expression O
in O
a O
dosage-dependent O
and O
parent-of-origin-specific O
manner O
, O
respectively O

We O
show O
that O
using O
a O
graph O
personalized O
genome O
represents O
a O
reasonable O
compromise O
between O
modified O
reference O
genomes O
and O
de O
novo O
assembled O
genomes O

79 O
Environmental O
epigenetics O
is O
increasingly O
employed O
to O
understand O
the O
health O
outcomes O
of O
communities O
who O
have O
experienced O
historical O
trauma O
and O
structural O
violence O

Over O
the O
past O
decade O
there O
has O
been O
remarkable O
progress O
in O
our O
knowledge O
of O
the O
importance O
of O
epigenetic O
events O
in O
the O
control O
of O
both O
normal O
cellular O
processes O
and O
abnormal O
events O
associated O
with O
tumor B-Disease
development I-Disease
and I-Disease
progression I-Disease

We O
previously O
demonstrated O
that O
human B-Species
adipose-derived I-Species
stem I-Species
cells I-Species
( O
hASCs B-Gene
) O
from O
CF B-Disease
of O
patients O
with O
CD B-Disease
exhibit O
dysfunctional O
phenotypes O
, O
including O
a O
pro-inflammatory O
profile O
, O
high O
phagocytic O
capacity O
, O
and O
weak O
immunosuppressive O
properties O

Furthermore O
, O
different O
predictors O
were O
often O
derived O
based O
on O
data O
from O
different O
types O
of O
arrays O
, O
where O
array O
differences O
and O
batch O
effects O
can O
make O
predictors O
difficult O
to O
compare O
across O
studies O

e O

He O
is O
the O
Founding O
Director O
of O
the O
Center O
for O
Environmental B-Disease
Health I-Disease
and O
Technology O
and O
Head O
of O
the O
Environmental B-Disease
Health I-Disease
Section O
at O
the O
Department O
of O
Epidemiology O

In O
addition O
, O
histone B-Chemical
modifications O
, O
nucleosome B-Chemical
remodeling O
, O
and O
micro B-Gene
RNA I-Gene
(miRNA) I-Gene
-mediated O
gene O
regulation O
are O
also O
fundamental O
to O
tumor B-Disease
genesis I-Disease

A O
characterization O
of O
lipid-associated O
genetic O
variants O
suggests O
that O
these O
variants O
exert O
their O
influence O
on O
lipid B-Chemical
levels O
through O
epigenetic O
changes O
in O
the O
liver B-Species

predictors O

We O
conclude O
by O
offering O
two O
examples O
of O
modern O
state-of-the-art O
integrated O
multi-omics O
studies O
of O
epigenetics O
in O
disease B-Disease
pathogenesis I-Disease
, O
one O
which O
sought O
to O
capture O
shared O
mechanisms O
among O
multiple O
diseases B-Disease
, O
and O
another O
which O
used O
epigenetic O
big O
data O
to O
better O
understand O
the O
pathogenesis O

62 O
between O
actual O
and O
predicted O
age O
across O
datasets O
(vs O

The O
replicated O
CpGs O
were O
further O
characterized O
by O
involvement O
in O
biological O
pathways O
to O
study O
their O
functional O
implications O
in O
aging B-Disease

This O
led O
to O
the O
conduct O
of O
epigenome-wide O
association O
studies O
(EWAS) O

, O
the O
REAL O
model O
) O

Heterogenization O
of O
housing O
conditions O
and O
of O
genetic B-Gene
makeup I-Gene
of O
experimental O
animals O
has O
been O
suggested O
as O
a O
possible O
method O
to O
increase O
the O
generalizability O
of O
results O

, O
histones B-Gene
) O
comprise O
the O
" O
cellular O
epigenome O
" O
; O
together O
these O
modifications O
play O
an O
important O
role O
in O
the O
regulation O
of O
gene B-Gene
expression O

In O
addition O
, O
the O
meeting O
highlighted O
some O
emerging O
aspects O
in O
the O
rapidly O
evolving O
field O
of O
epigenetics O

com O
/ O
harmancilab O
/ O
EpiSAFARI O

A O
small O
but O
significant O
subset O
of O
Pb-altered B-Chemical
genes O
exhibit O
basal O
sex O
differences O
in O
gene O
expression O
in O
the O
mouse B-Species
liver O

Our O
knowledge O
about O
spatial O
genome O
organization O
is O
relying O
on O
the O
advances O
in O
gene B-Gene
imaging O
technologies O
and O
the O
biochemical O
approaches O
based O
on O
the O
spatial O
dependent O
ligation O
of O
the O
genomic O
regions O

Although O
the O
inheritance O
of O
epigenetically O
controlled O
traits O
acquired O
through O
environmental O
impact O
is O
a O
matter O
of O
debate O
, O
it O
is O
well O
documented O
that O
environmental O
cues O
lead O
to O
epigenetic O
changes O
, O
including O
chromatin O
modifications O
, O
that O
affect O
cell O
differentiation O
or O
are O
associated O
with O
plant B-Species
acclimation O

299 O
Advances O
in O
our O
understanding O
of O
the O
epigenetic O
mechanisms O
that O
control O
gene B-Gene
expression O
in O
the O
central O
nervous O
system O
(CNS) O
and O
their O
role O
in O
neuropsychiatric B-Disease
disorders I-Disease
are O
paving O
the O
way O
for O
a O
potential O
new O
therapeutic O
approach O
that O
is O
focused O
on O
reversing O
the O

This O
is O
an O
unfortunate O
limitation O
that O
, O
thanks O
to O
an O
unprecedented O
pace O
of O
technological O
advancements O
especially O
in O
the O
sequencing O
technology O
field O
, O
is O
likely O
to O
be O
overcome O
soon O

( O

is O
highly O
heritable O
; O
however O
, O
epigenetics O
are O
considered O
relevant O
in O
potentially O
explaining O
the O
variance O
not O
accounted O
for O
by O
genetic O
influence O

We O
review O
here O
historical O
data O
on O
epigenetic O
modifications O
in O
PBC B-Disease
, O
present O
new O
data O
, O
and O
discuss O
possible O
links O
among O
X-chromosome B-Gene
abnormalities O
at O
a O
genetic O
and O
epigenetic O
level O
, O
PBC B-Disease
pathogenesis O
, O
and O
PBC B-Disease
sex O
imbalance O

590 O
Background O
DNA B-Gene
methylation I-Gene
microarrays O
are O
widely O
used O
in O
clinical O
epigenetics O
and O
are O
often O
processed O
using O
R B-Chemical
packages O
such O
as O
ChAMP B-Chemical
or O
RnBeads B-Chemical
by O
trained O
bioinformaticians O

Double O
-replication O
resulted O
in O
5,168 O
CpGs O
( O
39% O
age-methylated O
and O
61% O
age-demethylated O
) O
which O
were O
characterized O
by O
high O
concentration O
of O
age-methylated O
CpGs O
at O
1stExon B-Gene
and O
TSS200 B-Gene
and O
a O
dominant O
pattern O
of O
age-demethylated O
CpGs O
at O
other O
gene O
regions O
, O
and O

mutations O
, O
and O
aberrant O
epigenetic O
changes O
, O

Epigenetics O
may O
provide O
a O
link O
between O
genetic O
and O
environmental O
factors O
and O
behavior O

Here O
, O
we O
present O
the O
database O
for O
histone-modifying B-Chemical
enzymes I-Chemical
( O
dbHiMo O
; O
http//hme O

We O
examine O
the O
current O
state O
of O
DNA B-Gene
methylation I-Gene
studies O
in O
AS B-Disease
, O
IBD B-Disease
and O
psoriasis B-Disease
; O
the O
limitations O
of O
previous O
studies O
; O
and O
the O
best O
practices O
for O
DNA B-Gene
methylation I-Gene
studies O

Significant O
enrichment O
was O
observed O
for O
CpG B-Gene
islands O
, O
enhancers O
, O
and O
DNAse B-Gene
hypersensitivity I-Gene
sites I-Gene
( O
p O
< O
0 O

This O
review O
summarizes O
the O
chromatin O
alterations O
in O
lung B-Disease
cancer I-Disease
, O
focusing O
on O
the O
diagnostic O
and O
therapeutic O
approaches O
targeting O
epigenetic O
modifications O
that O
could O
help O
to O
reduce O
the O
high O
case-fatality O
rate O
of O
this O
dreadful O
disease O

A O
better O
understanding O
of O
these O
mechanisms O
has O
implications O
for O
treatment O
of O
memory O
disorders O
caused O
by O
normal O
aging O
or O
diseases O
including O
schizophrenia B-Disease
, O
Alzheimer's B-Disease
, O
depression B-Disease
, O
and O
drug B-Chemical
addiction O

However O
, O
the O
complexity O
, O
high-dimensionality O
, O
sparsity O
, O
and O
noise O
associated O
with O
these O
data O
pose O
challenges O
for O
extensive O
integrative O
analyses O

We O
base O
our O
hypothesis O
on O
theoretical O
and O
experimental O
studies O
showing O
quantum O
phenomena O
to O
be O
active O
in O
double-stranded B-Gene
DNA I-Gene
, O
even O
under O
ambient O
conditions O

Karlsson O
earned O
a O
PhD O
in O
toxicology O
at O
the O
Department O
of O
Pharmaceutical B-Chemical
Bioscience I-Chemical
, O
Uppsala O
University O
, O
and O
has O
also O
worked O
at O
Centre O
of O
Molecular B-Chemical
Medicine I-Chemical
, O
Karolinska O
Institute O
, O
as O
well O
as O
Harvard O
University O
School O
of O
Public O
Health O

The O
resulting O
large-scale O
data O
sets O
promise O
to O
contribute O
towards O
a O
more O
precise O
and O
complete O
understanding O
of O
gene B-Gene
regulation O
and O
to O
yield O
insights O
into O
the O
interplay O
between O
genomes O
and O
the O
environment O

Fifty O
six O
papers O
examined O
body O
size O
, O
37 O
nutrition O
and O
17 O
SEP O

In O
cross-sectional O
analyses O
adjusting O
for O
lifetime O
experience O
of O
neglect O
, O
lifetime O
experience O
of O
abuse O
was O
associated O
with O
DNAm O
for O
four O
( O
) O
sites O
( O
 O
coefficient O
= O
0 O

586 O
Cytosine B-Chemical
methylation O
in O
DNA B-Chemical
constitutes O
an O
important O
epigenetic O
layer O
of O
transcriptional O
and O
regulatory O
control O
in O
many O
eukaryotes B-Species


In O
this O
article O
, O
the O
complexity O
of O
epigenetic O
processes O
and O
the O
current O
level O
of O
proof O
for O
their O
involvement O
in O
CNS B-Disease
disorders I-Disease
are O
discussed O

This O
has O
led O
to O
, O
apart O
from O
better O
understanding O
of O
the O
disease B-Disease
biology O
, O
the O
development O
of O
epigenetic O
drugs O
, O
such O
as O
histone B-Chemical
deacetylase I-Chemical
inhibitors I-Chemical
that O
are O
already O
used O
in O
clinical O
trials O
in O
MM B-Disease
with O
promising O
results O

The O
SLFN12 B-Gene
gene I-Gene
plays O
a O
pivotal O
role O
in O
the O
onset O
of O
HT B-Disease
, O
suggesting O
that O
the O
methylation B-Chemical
status O
of O
this O
gene O
could O
serve O
as O
a O
potential O
epigenetic O
indicator O
for O
HT B-Disease

Results O
 O
Early O
life O
trauma O
and O
earlier O
age O
at O
menarche O
independently O
predicted O
accelerated O
aging O
based O
on O
one O
of O
the O
four O
epigenetic O
clocks O
, O
DNAm B-Gene
GrimAge I-Gene
, O
though O
early O
life O
trauma O
was O
not O
associated O
with O
age O
of O
menarche O

1372 O
The O
functional O
impact O
of O
aberrant O
DNA B-Gene
methylation I-Gene
and O
the O
widespread O
alterations O
in O
DNA B-Gene
methylation I-Gene
in O
cancer B-Disease
development I-Disease
have O
led O
to O
the O
development O
of O
a O
variety O
of O
methods O
to O
characterize O
the O
DNA B-Gene
methylation I-Gene
patterns O

Through O
simulations O
, O
we O
demonstrated O
that O
the O
MRF B-Gene
had O
improved O
power O
over O
other O
existing O
methods O
in O
detecting O
rare O
variants O
of O
relatively O
large O
effect O
, O
especially O
when O
the O
sample O
size O
is O
small O

1301 O
Aim O
 O
To O
identify O
epigenetically O
regulated O
network O
of O
genes O
in O
peripheral O
blood O
mononuclear O
cells O
significant O
for O
rheumatoid B-Disease
arthritis I-Disease
( O
RA B-Disease
) O

DNAm O
of O
hematopoietic B-Species
cells O
was O
compared O
globally O
across O
the O
450K B-Chemical
array O
and O
through O
site-specific O
linear O
modeling O

In O
bacteria B-Species
, O
genome-wide O
mapping O
of O
methylated O
and O
unmethylated O
loci O
is O
now O
feasible O

003 O
), O
p O
= O

In O
contrast O
, O
the O
epigenetic O
model O
of O
aging O
straightforwardly O
explains O
both O
biologic O
phenomena O

As O
for O
metabolomic O
profiling O
, O
abnormal O
amino B-Chemical
acids I-Chemical
metabolism O
plays O
an O
important O
role O
on O
disease O
progression O
of O
NKTCL B-Disease

However O
, O
it O
is O
possible O
that O
with O
more O
longitudinal O
studies O
and O
better O
characterised O
cohorts O
, O
both O
predictive O
and O
protective O
links O
between O
epigenetic O
processes O
and O
ADHD B-Disease
will O
be O
revealed O

With O
the O
benefits O
of O
high O
efficiency O
and O
sensitivity O
in O
DPI O
analysis O
, O
the O
system O
provides O
great O
promise O
in O
studying O
epigenetic O
regulation O
during O
various O
biological O
processes O

Methyl O
groups O
play O
essential O
roles O
in O
numerous O
cellular O
functions O
such O
as O
DNA B-Gene
methylation O
, O
nucleotide- O
and O
protein O
biosynthesis O

Additional O
evidence O
indicates O
that O
SNCA B-Gene
promoter O
polymorphisms O
increases O
alpha-synuclein B-Gene
expression O
and O
increases O
susceptibility O
to O
sporadic B-Disease
PD I-Disease

We O
also O
hypothesize O
that O
the O
"embedding" O
partly O
occurs O
because O
of O
epigenetic O
changes O
, O
i O

However O
, O
CLIA B-Chemical
was O
introduced O
in O
1988 O
, O
before O
the O
advent O
of O
genome-wide O
profiling O
and O
associated O
computational O
analysis O

We O
found O
that O
the O
Horvath B-Gene
, O
Hannum B-Gene
, O
Levine B-Gene
and O
GrimAge B-Gene
epigenetic O
clocks O
tend O
to O
agree O
in O
direction O
of O
effects O
, O
but O
vary O
in O
size O

Pharmacological O
regulation O
of O
histone B-Chemical
acetylation I-Chemical
level O
has O
been O
investigated O
as O
one O
potential O
clinical O
strategy O

epihet O
is O
available O
at O
https//bioconductor O

Specifically O
, O
this O
manuscript O
reviews O
 O
array O
comparative O
genome B-Gene
hybridisation O
; O
single O
nucleotide O
polymorphism B-Gene
arrays O
; O
microarray O
technology O
, O
used O
to O
study O
epigenetics B-Disease
; O
and O
methodology O
applied O
in O
proteomics O

, O
case O
vs O
control O
; O
treatments O
vs O
placebo O
, O
accuracy O
is O
not O
crucial O

The O
characterization O
of O
epigenetic O
age O
prediction O
variation O
provides O
useful O
metrics O
to O
contextualize O
the O
relevance O
of O
epigenetic O
age O
alterations O


The O
greatest O
number O
of O
retrieved O
publications O
were O
published O
in O
the O
journal O
, O
" O
Arteriosclerosis O
, O
Thrombosis O
, O
and O
Vascular O
Biology O
" O
( O
62 O
, O
3 O

These O
modifications O
are O
dynamic O
, O
potentially O
heritable O
, O
and O
can O
be O
induced O
by O
environmental O
stimuli O
or O
drugs B-Chemical

s O
claimed O
hedonic O
and O
eudaimonic O
dimensions O

Epigenetic O
processes O
are O
such O
as O
histone B-Chemical
methylation I-Chemical
, O
acetylation B-Chemical
, O
ubiquitination B-Chemical
, O
sumoylation B-Chemical
, O
phosphorylation B-Chemical
, O
ADP B-Chemical
ribosylation I-Chemical
, O
DNA B-Chemical
methylation I-Chemical
and O
non-coding O
RNAs B-Gene
interactions O
associated O
with O
structural O
changes O
in O

857 O
Epigenetic O
modifications O
play O
a O
key O
role O
in O
cellular O
development O
and O
tumorigenesis B-Disease

output-and O

7 O
Food B-Disease
allergy I-Disease
is O
a O
global O
health O
problem O
, O
particularly O
in O
developed O
countries O

In O
addition O
, O
we O
present O
a O
simple O
procedure O
for O
the O
calculation O
of O
the O
inverse O
of O
this O
matrix O
( O
T-1 O
 O
) O
and O
a O
Gibbs B-Chemical
sampler I-Chemical
algorithm O
that O
obtains O
posterior O
estimates O
of O
all O
the O
unknowns O
in O
the O
model O


The O
epigenome O
refers O
to O
the O
chemical B-Chemical
modifications O
on O
both O
DNA B-Gene
and O
the O
structural O
proteins O
that O
package O
DNA B-Gene
into O
the O
nucleus O
, O
which O
together O
regulate O
gene B-Gene
expression O
in O
specific O
cell O
types O
, O
conditions O
, O
and O
developmental O
stages O

We O
show O
the O
potential O
of O
epigenetic O
changes O
for O
various O
clinical O
applications O
 O
as O
diagnostic O
tools O
, O
to O
assess O
tolerance O
following O
immunotherapy O
or O
possibly O
predict O
the O
success O
of O
therapy O
at O
an O
early O
time O
point O

Their O
advantages O
and O
disadvantages O
will O
also O
be O
discussed O

This O
review O
highlights O
the O
current O
knowledge O
on O
emerging O
approaches O
in O
TE/RM O
with O
a O
focus O
on O
the O
effect O
of O
materials O
and O
topography O
on O
the O
epigenetic O
expression O
pattern O
in O
cells O
with O
potential O
impacts O
on O
modulating O
regenerative O
biology O

Among O
the O
different O
genome-wide O
analysis O
, O
epigenomics O
is O
the O
most O
under-investigated O
"omic" O
approach O
requiring O
more O
critical O
and O
speculative O
discussion O
about O
approaches O
, O
methods O
and O
experimental O
designs O

1365 O
may O
be O
regulated O
by O
genetic O
variants O
within O
a O
genomic O
region O
, O
referred O
to O
as O
methylation O
quantitative O
trait O
loci O
( O
mQTLs O
) O

580 O
Introduction O
Epigenetics O
has O
recently O
emerged O
as O
a O
potential O
mechanism O
by O
which O
adverse O
environmental O
stimuli O
can O
result O
in O
persistent O
changes O
in O
gene B-Gene
expression I-Gene

Drawing O
on O
these O
principles O
, O
this O
paper O
contains O
an O
outline O
of O
an O
embodied O
coactive O
systems O
framework O
for O
understanding O
how O
individual O
psychological O
structures O
develop O
as O
a O
product O
of O
socially O
distributed O
coactions O
that O
occur O
among O
elements O
of O
the O
extended O
person-environment O
system O

1148 O
methylation O
is O
an O
epigenetic O
modification O
involved O
in O
organism O
development O
and O
cellular O
differentiation O

The O
role O
of O
the O
epigenome O
, O
specifically O
, O
the O
methylome O
has O
been O
increasingly O
highlighted O
and O
has O
been O
implicated O
in O
many O
cellular O
and O
developmental O
processes O
such O
as O
embryonic O
reprogramming O
, O
cellular O
differentiation O
, O
imprinting O
, O
X B-Gene
chromosome I-Gene
inactivation O
, O
genomic O
stability O

with O

A O
total O
of O
2178 O
research O
articles O
were O
identified O
, O
which O
subsequently O
reduced O
to O
67 O
unique O
articles O
relevant O
to O
the O
field O

regulatory O

From O
a O
quantitative O
genetics O
perspective O
, O
the O
estimation O
of O
variance O
components O
is O
achieved O
by O
means O
of O
the O
information O
provided O
by O
the O
resemblance O
between O
relatives O

638 O
Somatic O
mutations O
accumulating O
over O
a O
patient O
's O
lifetime O
are O
well-defined O
causative O
factors O
that O
fuel O
carcinogenesis B-Disease

There O
has O
been O
limited O
ability O
to O
identify O
and O
characterize O
the O
functional O
components O
of O
this O
huge O
and O
largely O
misunderstood O
part O
of O
the O
human B-Species
genome O
that O
, O
for O
decades O
, O
was O
ignored O
as O
" O
Junk B-Gene
" I-Gene
DNA I-Gene

Depression O
that O
starts O
in O
childhood O
is O
increasing O
in O
frequency O
, O
likely O
due O
both O
to O
evolutionary O
trends O
and O
to O
increased O
recognition O
of O
the O
disorder B-Disease

of O

1348 O
Epigenetic O
changes O
have O
been O
identified O
as O
a O
major O
driver O
of O
fundamental O
metabolic O
pathways O

Here O
we O
discuss O
asthma B-Disease
epigenetics O
within O
a O
developmental O
perspective O
based O
on O
our O
recent O
demonstration O
that O
the O
epigenetic O
trajectory O
to O
childhood B-Disease
asthma I-Disease
begins O
at O
birth O

Whereas O
the O
role O
of O
DNA B-Chemical
methylation I-Chemical
in O
MEI B-Disease
remains O
unclear O
, O
insights O
from O
genome-wide O
studies O
suggest O
that O
a O
previously O
underappreciated O
fraction O
of O
mammalian B-Species
genomes I-Species
bypass O
epigenetic O
reprogramming O
during O
development O

We O
studied O
both O
postulated O
channels O
by O
sequencing O
methylomes O
and O
genomes O
of O
Baltic B-Species
three-spined I-Species
sticklebacks I-Species
( O
Gasterosteus B-Species
aculeatus I-Species
) O
along O
a O
salinity O
cline O

ca O
Supplementary O
information O
 O
Supplementary O
data O
are O
available O
at O
Bioinformatics O
online O

Apart O
from O
the O
central O
role O
of O
genetic O
abnormalities O
, O
epigenetic O
aberrations O
have O
also O
been O
shown O
to O
be O
important O
players O
in O
the O
development O
of O
MM B-Disease
, O
and O
a O
lot O
of O
research O
during O
the O
past O
decades O
has O
focused O
on O
the O
ways O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical

02 O
) O

In O
consequence O
, O
novel O
therapeutic O
strategies O
aimed O
at O
reversing O
aberrant O
epigenetic O
marks O
in O
cancer B-Disease
cells O
have O
been O
developed O
and O
used O
in O
recent O
molecular O
studies O
and O
clinical O
trials O

Thus O
, O
the O
study O
on O
epigenetics O
opens O
a O
wide O
window O
for O
the O
discovery O
of O
newer O
drugs O

Recent O
findings O
 O
Chromatin O
is O
the O
physical O
expression O
of O
the O
epigenome O
and O
has O
a O
memory O
function O
on O
the O
level O
of O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modification I-Chemical
and O
3-dimensional O
( O
3D O
) O
organization O

1151 O
The O
global O
pandemic O
of O
obesity B-Disease
and O
type B-Disease
2 I-Disease
diabetes I-Disease
is O
often O
causally O
linked O
to O
marked O
changes O
in O
diet O
and O
lifestyle O
; O
namely O
marked O
increases O
in O
dietary O
intakes O
of O
high O
energy O
diets O
and O
concomitant O
reductions O
in O
physical O
activity O
levels O

442 O
Motivation O
DNA B-Gene
methylation-based I-Gene
predictors O
of O
various O
biological O
metrics O
have O
been O
widely O
published O
and O
are O
becoming O
valuable O
tools O
in O
epidemiologic O
studies O
of O
epigenetics O
and O
personalized O
medicine O


We O
also O
discuss O
future O
needs O
in O
this O
area O
including O
exploration O
of O
epigenomic O
variation O
between O
individuals O
, O
single-cell O
epigenomics O
, O
environmental O
epigenomics O
, O
exploration O
of O
the O
use O
of O
surrogate O
tissues O
, O
and O
improved O
technologies O
for O
epigenome O
manipulation O

Inactivation O
of O
a O
histone B-Chemical
H3 I-Chemical
deacetylase I-Chemical
led O
to O
pleiotropic O
activation O
and O
overexpression O
of O
more O
than O
75 O
% O
of O
the O
biosynthetic O
genes O

Since O
histones B-Chemical
influence O
gene B-Gene
expression O
and O
the O
program O
of O
embryo B-Species
development O
, O
these O
epigenetic O
changes O
likely O
contribute O
to O
the O
risk O
of O
adult B-Disease
disease I-Disease
onset O
not O
just O
in O
the O
directly O
affected O
offspring O
, O
but O
for O
multiple O
generations O
to O
come O

Although O
most O
of O
the O
observed O
epigenetic O
variation O
was O
additive O
and O
had O
a O
strong O
genetic O
component O
, O
we O
also O
found O
a O
small O
percentage O
of O
non-additive O
, O
potentially O
stochastic O
, O
methylation O
differences O
that O
might O
act O
as O
an O
evolutionary O
bet-hedging O
strategy O
and O
increase O
fitness O
under O
environmental O
instability O

This O
finding O
was O
further O
validated O
on O
the O
epigenomic O
level O
by O
examining O
H3K27 B-Chemical
acetylation O
profiles O

Longitudinal O
studies O
are O
crucial O
to O
elucidate O
exposure-epigenome O
interactions O
and O
develop O
prevention O
strategies O

In O
NRF2 B-Gene
knockout O
and O
KLOTHO B-Gene
knockdown O
D-gal B-Chemical
mice O
, O
OLP B-Chemical
exhibited O
reduced O
antiaging O
effects O
with O
KLOTHO B-Gene
displaying O
a O
prominent O
gene O
effect O
and O
effect O
size O
; O
consistently O
in O
KLOTHO B-Gene
knockdown O
mice O
, O
the O
antiaging O
effects O
of O

We O
employ O
a O
novel O
tree-based O
depth-penalization O
mechanism O
in O
order O
to O
capture O
the O
higher O
regulatory O
impact O
of O
closer O
neighbors O
in O
the O
regulatory O
network O

By O
using O
two O
recently O
developed O
computational O
algorithms O
( O
i O

From O
memory O
formation O
to O
immune O
function O
, O
the O
experience-dependent O
plasticity O
of O
epigenetic O
modifications O
to O
micro- O
and O
macro-social O
environments O
may O
contribute O
to O
the O
process O
of O
learning O
from O
comfort O
, O
pain B-Disease
, O
and O
stress B-Disease
to O
better O
survive O
in O
whatever O
circumstances O
life O
has O
in O
store O

The O
literature O
indicates O
that O
EDC B-Chemical
exposure O
to O
the O
parents O
induces O
developmental O
, O
physiological O
, O
endocrinological O
, O
and O
behavioral O
changes O
as O
well O
as O
increased O
mortality O
of O
offspring O
raised O
in O
clean O
environments O

Using O
pathway O
analysis O
, O
multiple O
canonical O
pathways O
plausibly O
linked O
to O
neuronal B-Disease
function I-Disease
were O
over-represented O

The O
balance O
between O
5hmC B-Chemical
and O
its O
precursor O
, O
5-methylcytosine B-Chemical
( O
5mC B-Chemical
) O
, O
has O
emerged O
as O
a O
determinant O
of O
key O
processes O
including O
cell O
fate O
specification O
, O
and O
alterations O
involving O
these O
bases O
have O
been O
implicated O
in O
the O
pathogenesis O
of O
various O

We O
pose O
that O
it O
is O
essential O
that O
the O
goal O
of O
the O
specific O
experiment O
conducted O
is O
clearly O
defined O
and O
that O
the O
decision O
to O
balance O
between O
standardization O
and O
generalization O
must O
be O
made O
based O
on O
the O
specific O
needs O
to O
meet O
the O
intended O
goal O

With O
the O
advent O
of O
new O
technologies O
we O
are O
just O
starting O
to O
unravel O
the O
cancer B-Disease
epigenome O
and O
latest O
mechanistic O
findings O
provide O
the O
first O
clue O
as O
to O
how O
altered O
epigenetic O
patterns O
might O
occur O
in O
different O
cancers B-Disease

In O
contrast O
, O
substantial O
changes O
to O
our O
environment O
as O
part O
of O
our O
modern O
life O
style O
have O
not O
only O
led O
to O
a O
significant O
reduction O
of O
certain O
infectious B-Disease
diseases I-Disease
but O
also O
seen O
the O
exponential O
increase O
in O
complex O
traits O
including O
obesity B-Disease
and O
multifactorial O
diseases B-Disease
such O
as O


Therefore O
a O
robust O
, O
powerful O
, O
high-throughput O
, O
optimized O
, O
and O
methylation-specific O
primer O
design O
tool O
with O
great O
accuracy O
will O
be O
very O
useful O

Here O
, O
we O
present O
an O
overview O
of O
the O
multifaceted O
roles O
of O
DNA B-Gene
methylation I-Gene
in O
prokaryotes B-Species
and O
suggest O
research O
directions O
and O
tools O
which O
can O
enable O
us O
to O
better O
understand O
the O
contribution O
of O
DNA B-Gene
methylation I-Gene
to O
prokaryotic B-Species
genome O
evolution O
and O
adaptation O

The O
ultimate O
goal O
is O
to O
apply O
the O
knowledge O
and O
the O
technology O
generated O
by O
this O
research O
towards O
genetically O
based O
strategies O
for O
the O
development O
of O
personalised O
nutrition O
and O
medicine O

These O
DMPs O
and O
DEGs O
are O
enriched O
in O
functional O
categories O
related O
to O
inflammation B-Disease
and O
T B-Gene
cell I-Gene
biology O

938 O
Epidemiological O
research O
since O
the O
1980s O
has O
highlighted O
the O
consequences O
of O
early O
life O
adversity O
, O
particularly O
during O
gestation O
and O
early O
infancy O
, O
for O
adult O
health O
( O
the O
" O
Barker O
hypothesis O
" O
) O

Finally O
, O
prediction O
results O
can O
be O
readily O
visualized O
and O
further O
explored O
in O
the O
WashU B-Gene
Epigenome I-Gene
Browser I-Gene

The O
DNA B-Gene
methylation I-Gene
pattern O
can O
be O
the O
cause O
or O
consequence O
of O
high O
blood O
lipids B-Chemical

Although O
it O
has O
long O
been O
known O
that O
in O
vitro O
conditions O
induce O
variation O
at O
several O
levels O
, O
most O
studies O
using O
such O
conditions O
rely O
on O
the O
assumption O
that O
in O
vitro O
cultured O
plant B-Species
cells/tissues O
mostly O
conform O
genotypically O
and O
phenotypically O

In O
this O
review O
, O
we O
first O
discuss O
the O
rationale O
and O
premise O
behind O
profiling O
epigenomes O
for O
precision O
medicine O

Prenatal O
or O
infant O
exposure O
was O
strongly O
associated O
with O
depressive B-Disease
symptoms I-Disease

Recent O
evidences O
also O
suggest O
that O
miRNAs B-Gene
can O
directly O
modulate O
gene O
transcription O
in O
the O
nucleus O
through O
the O
recognition O
of O
specific O
target O
sites O
in O
promoter O
regions O

PAT-ChIP O
therefore O
represents O
a O
versatile O
procedure O
and O
diagnostic O
tool O
for O
the O
analysis O
of O
epigenetic O
alterations O
in O
cancer B-Disease
and O
potentially O
other O
diseases O

Haystack O
is O
a O
bioinformatics O
pipeline O
to O
identify O
hotspots O
of O
epigenetic O
variability O
across O
different O
cell-types O
, O
cell-type O
specific O
cis-regulatory O
elements O
, O
and O
associated O
transcription O
factors O

In O
this O
review O
, O
we O
have O
discussed O
the O
current O
knowledge O
on O
the O
role O
of O
epigenetic O
mechanisms O
( O
primarily O
DNAme B-Chemical
and O
histone B-Chemical
modifications O
) O
in O
acute B-Disease
and O
chronic B-Disease
kidney I-Disease
diseases I-Disease
, O
and O
their O
translational O
potential O
to O
identify O
much O
needed O
new O
therapies O

1493 O
The O
global O
burden O
of O
breast B-Disease
cancer I-Disease
( O
BC O
) O
is O
increasing O
significantly O

In O
particular O
, O
these O
cells O
show O
accumulation O
of O
H3K4me3 B-Chemical
and O
H3K27Ac B-Chemical
epigenetic O
marks O
on O
multiple O
immune O
gene B-Gene
promoters O
and O
associated O
enhancers O

534 O
Purpose O
of O
review O
 O

Across O
plant O
and O
animal O
species B-Species
, O
recent O
studies O
have O
revealed O
the O
roles O
of O
mRNA B-Gene
cytosine B-Chemical
methylation I-Chemical
in O
several O
fundamental O
biological O
processes O

Psychiatry O
has O
learned O
that O
diseases O
with O
strong O
genetic O
predisposition O
, O
such O
as O
schizophrenia B-Disease
, O
show O
a O
concordance O
of O
around O
50% O
between O
monozygotic B-Species
twins O
, O
thus O
evidencing O
the O
importance O
of O
the O
genetic B-Gene
background O
and O
the O
presence O
of O
environmental O
variables O
that O
stimulate O

The O
first O
is O
primarily O
medically O
based O
and O
views O
epigenetic O
mechanisms O
as O
pathways O
for O
disease B-Disease
( O
e O

Recent O
advances O
in O
genomics O
have O
placed O
them O
back O
at O
the O
center O
of O
genome O
dynamics O

Thus O
, O
technological O
advances O
in O
the O
field O
of O
epigenetics O
may O
provide O
innovative O
targets O
to O
develop O
new O
stroke B-Disease
therapies O


1470 O
The O
impact O
of O
large O
and O
complex O
epigenomic O
datasets O
on O
biological O
insights O
or O
clinical O
applications O
is O
limited O
by O
the O
lack O
of O
accessibility O
by O
easy O
, O
intuitive O
, O
and O
fast O
tools O

Finally O
, O
we O
discuss O
possible O
mechanisms O
that O
may O
explain O
transgenerational O
inheritance O
, O
including O
transmission O
of O
an O
epigenetic O
blueprint O
, O
which O
may O
predispose O
offspring O
to O
specific O
epigenetic O
patterning O

, O
" O
the O
epigenetics O
of O
cancer B-Disease
" O
) O

At O
the O
moment O
, O
epigenetic O
biomarkers O
for O
RCC B-Disease
are O
not O
being O
used O
in O
clinical O
practice O
, O
but O
targeted O
epigenetic O
therapies O
are O
under O
investigation O

Accordingly O
, O
a O
novel O
method O
that O
enables O
examination O
of O
allelic O
methylation B-Chemical
and O
hydroxymethylation B-Chemical
status O
and O
also O
overcomes O
the O
drawbacks O
of O
conventional O
methods O
is O
needed O

The O
eye O
is O
likely O
to O
provide O
a O
valuable O
model O
for O
validating O
biomarkers O
of O
ageing O
at O
molecular O
, O
epigenetic O
, O
cellular O
and O
clinical O
levels O

This O
is O
likely O
to O
happen O
because O
of O
the O
current O
biopolitical O
context O
in O
which O
scientific O
findings O
are O
translated O

Analysis O
of O
patient O
samples O
, O
however O
, O
is O
hampered O
by O
technical O
limitations O
in O
the O
study O
of O
chromatin B-Gene
structure I-Gene
from O
pathology O
archives O
that O
usually O
consist O
of O
heavily O
fixed O
, O
paraffin-embedded O
material O

He O
has O
authored O
over O
100 O
peer-reviewed O
manuscripts O
, O
book O
chapters O
and O
review O
articles O
, O
and O
is O
on O
the O
editorial O
board O
of O
several O
journals O
in O
his O
field O

365 O
Environmental O
stress O
is O
ubiquitous O
in O
modern O
societies O
and O
can O
exert O
a O
profound O
and O
cumulative O
impact O
on O
cell O
function O
and O
health O
phenotypes O

872 O
In O
recognition O
of O
Canada's O
longstanding O
interest O
in O
epigenetics O
- O
and O
a O
particular O
linguistic O
interjection O
- O
the O
inaugural O
'Epigenetics, O
Eh!' O
conference O
was O
held O
between O
4-7 O
May O
2011 O
in O
London, O
ntarioO O

It O
is O
recognized O
that O
environmental O
factors O
and O
individual O
lifestyles O
play O
important O
roles O
in O
disease B-Disease
susceptibility I-Disease
, O
but O
the O
link O
between O
these O
external O
risk O
factors O
and O
our O
genetics B-Gene
has O
been O
unclear O

If O
epigenetic O
inheritance O
is O
indeed O
as O
common O
as O
the O
data O
suggest O
, O
this O
finding O
has O
potentially O
important O
implications O
for O
evolutionary O
theory O
and O
our O
understanding O
of O
how O
evolution O
and O
adaptation O
progress O

Small O
molecules B-Chemical
are O
promising O
therapeutic O
approaches O
to O
target O
the O
epigenetic-metabolomic O
crosstalk O
in O
cancer B-Disease

In O
this O
chapter O
, O
we O
discuss O
the O
interplay O
between O
these O
three O
key O
elements O
, O
reveal O
how O
epigenetic O
modifications O
may O
mediate O
genetic O
susceptibility O
of O
food B-Disease
allergies I-Disease
, O
and O
explain O
why O
epigenetic O
modifications O
may O
be O
the O
key O
in O
environmental O
factors O
mediated-gene O
expression O
, O
leading O

Survival O
advantages O
may O
be O
induced O
by O
cancer B-Disease
therapies O
and O
also O
occur O
as O
a O
result O
of O
inherent O
cell O
and O
microenvironmental O
factors O

001 O
), O
placenta O
( O
Max O
F O
P O
< O
0 O

Our O
work O
highlights O
the O
contribution O
of O
machine O
learning O
in O
the O
identification O
of O
potential O
epigenetic O
targets O
and O
offers O
a O
novel O
approach O
for O
epigenetic O
drug B-Chemical
discovery O
and O
development O


497 O
Epilepsy B-Disease
affects O
over O
50 O
million O
individuals O
globally O
, O
making O
it O
the O
most O
prevalent O
chronic O
and O
serious O
neurological O
condition O

Selection O
or O
engineering O
of O
populations O
of O
extracellular B-Chemical
vesicles I-Chemical
and O
epigenetic O
editing O
represent O
novel O
tools O
for O
modulation O
of O
the O
cellular O
phenotype O
and O
responses O
, O
although O
further O
technological O
improvements O
are O
required O

Epigenetic O
changes O
are O
reversible O
and O
include O
key O
processes O
of O
DNA B-Chemical
methylation I-Chemical
, O
chromatin B-Chemical
modifications I-Chemical
, O
nucleosome B-Chemical
positioning I-Chemical
, O
and O
alterations O
in O
noncoding O
RNA B-Chemical
profiles O

The O
first O
submodule O
is O
devoted O
to O
transcriptomics O
analysis O
with O
the O
RNA B-Gene
sequencing I-Gene
data O
, O
the O
second O
submodule O
focuses O
on O
epigenetics O
analysis O
using O
the O
DNA B-Gene
methylation I-Gene
data O
, O
and O
the O
third O
submodule O
integrates O
the O
two O
methods O
for O
a O
deeper O
biological O
understanding O

Among O
the O
environmental O
factors O
that O
can O
influence O
genetic O
activity O
are O
parenting O
styles O
, O
diets O
, O
and O
social O
statuses O

association O

g O

The O
methods O
used O
in O
this O
study O
have O
shown O
sensitivity O
of O
between O
60-70% O
based O
on O
positions O
also O
methylated O
in O
colorectal B-Disease
cancer I-Disease
cell I-Disease
lines I-Disease


CHANCE O
is O
available O
at O
https//github O

Human O
studies O
have O
included O
the O
theory-driven O
approach O
of O
candidate-gene B-Gene
studies I-Gene
(CGS) O
, O
as O
well O
as O
the O
increasingly O
popular O
exploratory O
approach O
of O
epigenome-wide B-Gene
association I-Gene
studies I-Gene
(EWAS) O

AD B-Disease
can O
be O
classified O
into O
familial B-Disease
AD I-Disease
( O
FAD B-Disease
) O
and O
sporadic B-Disease
AD I-Disease
( O
SAD B-Disease
) O
based O
on O
heritability O
and O
into O
early O
onset O
AD B-Disease
( O
EOAD B-Disease
) O
and O
late O
onset O
AD B-Disease
( O
LOAD B-Disease
) O
based O
on O
age O
of O
onset O

Generation O
of O
enormous O
amounts O
of O
data O
has O
driven O
the O
need O
for O
more O
advanced O
storage O
solutions O
and O
shared O
access O
through O
a O
range O
of O
public O
repositories O


89 O
Ecological O
Epigenetics O
studies O
the O
relationship O
between O
epigenetic O
variation O
and O
ecologically O
relevant O
phenotypic O
variation O

The O
biosynthetic O
pathway O
of O
SLs O
that O
are O
derived O
from O
carotenoids B-Chemical
was O
partially O
decrypted O
based O
on O
the O
identification O
of O
mutants O
from O
a O
variety O
of O
plant B-Species
species I-Species

Percutaneous O
coronary O
intervention O
( O
PCI O
) O
has O
been O
a O
significant O
breakthrough O
for O
its O
treatment O

1190 O
 O
Gastric B-Disease
cancer I-Disease
( O
GC B-Disease
) O
remains O
a O
major O
cause O
of O
mortality O
despite O
declining O
rate O
in O
the O
world O

We O
also O
describe O
several O
of O
the O
bioinformatic O
tools O
used O
to O
properly O
analyze O
methylome-sequencing O
data O

Different O
factors O
are O
examined O
to O
optimize O
the O
MIC B-Chemical
purification O

scATAC-seq O
data O
analysis O
presents O
unique O
methodological O
challenges O

In O
this O
chapter O
we O
provide O
information O
on O
various O
epigenetic O
mechanisms O
and O
their O
role O
in O
carcinogenesis B-Disease
, O
in O
particular O
, O
epigenetic O
modifications O
causing O
genetic O
changes O
and O
the O
potential O
clinical O
impact O
of O
epigenetic O
research O
in O
the O
future O

patterns O

306 O
Systemic B-Disease
lupus I-Disease
erythematosus I-Disease
( O
SLE B-Disease
) O
is O
an O
autoimmune O
disease O
with O
multiple O
organ O
involvement O

In O
addition O
to O
their O
abilities O
to O
reactivate O
genes O
, O
including O
tumour B-Disease
suppressors O
, O
that O
have O
acquired O
DNA B-Chemical
methylation O
during O
carcinogenesis B-Disease
, O
they O
induce O
the O
expression O
of O
thousands O
of O
transposable O
elements O
including O
endogenous O
retroviruses O
and O
latent O
cancer B-Disease
testis I-Disease
antigens O
normally O
silenced O

From O
this O
context O
, O
the O
consideration O
of O
health O
risk O
with O
respect O
to O
epigenetics B-Gene
, O
it O
is O
argued O
, O
demands O
a O
more O
inclusive O
concept O
of O
health O
when O
used O
in O
discussions O
of O
inequities O

1045 O
Epigenetic O
inheritance O
is O
a O
phenomenon O
whereby O
stochastic O
or O
signal-induced O
changes O
to O
parental O
germline O
epigenome O
modulate O
phenotypic O
output O
in O
one O
or O
more O
subsequent O
generations O
, O
independently O
of O
mutations O
in O
the O
genomic O

Previously O
believed O
to O
be O
of O
no O
biological O
relevance O
, O
microRNAs B-Gene
regulate O
processes O
fundamental O
to O
human B-Species
health O
and O
disease B-Disease

1242 O
 O
Hepatocellular B-Disease
carcinoma I-Disease
( O
HCC B-Disease
) O
results O
from O
accumulation O
of O
both O
genetic O
and O
epigenetic O
alterations O

The O
selection O
comprised O
original O
research O
articles O
published O
in O
the O
English O
language O
between O
the O
OARSI O
congresses O
of O
2022 O
and O
2023 O

Inspired O
by O
the O
biological O
processes O
of O
gene B-Gene
regulation O
and O
epigenetics O
, O
epiNet O
captures O
biological O
organisms O
' O
ability O
to O
alter O
their O
regulatory O
topologies O
according O
to O
environmental O
stimulus O

812 O
Emerging O
studies O
suggest O
that O
dietary O
components O
can O
affect O
gene B-Gene
expression I-Gene
through O
epigenetic O
mechanisms O

Epigenetic O
pathways O
mediate O
cellular O
adaptation O
, O
and O
are O
therefore O
a O
potential O
target O
of O
oxidative B-Chemical
stress I-Chemical

Finally O
, O
a O
selected O
group O
of O
transgenic O
clones O
responsive O
to O
HDACi O
sodium B-Chemical
butyrate I-Chemical
, O
when O
tested O
in O
a O
gradient O
plate O
format O
showed O
similarity O
in O
phenotype O
to O
the O
plant-derived O
compound O
cinnamic B-Chemical
acid I-Chemical

Here O
, O
we O
perform O
WGBS O
using O
the O
Accel-NGS B-Chemical
library I-Chemical
preparation I-Chemical
kit I-Chemical
on O
ultralow O
amounts O
of O
DNA B-Gene
from O
long-term O
archived O
samples O
with O
diverse O
pretreatments O
from O
the O
Janus B-Chemical
Serum I-Chemical
Bank I-Chemical

About O
30% O
of O
newly O
diagnosed O
PCa B-Disease
patients O
receive O
with O
a O
curative O
intent O

Although O
the O
main O
application O
is O
designed O
for O
Illumina B-Species
DNA B-Gene
methylation I-Gene
array I-Gene
data O
analysis O
, O
we O
made O
the O
accessory O
modules O
suitable O
for O
other O
kinds O
of O
data O
analysis O
as O
well O

The O
primary O
limitation O
in O
ion-semiconductor O
sequencing O
is O
base O
calling O
of O
repeated O
nucleotides O
known O
as O
homopolymers O

1188 O
Chronic O
stressors O
, O
during O
developmental O
sensitive O
periods O
and O
beyond O
, O
contribute O
to O
the O
risk O
of O
developing O
psychiatric O
conditions O
, O
including O
major B-Disease
depressive I-Disease
disorder I-Disease
( O
MDD B-Disease
) O

In O
the O
present O
work O
, O
we O
link O
the O
current O
body O
of O
knowledge O
and O
earlier O
pre-genomic O
concepts O
in O
order O
to O
propose O
a O
new O
definition O
of O
epigenetics B-Gene
that O
is O
faithful O
to O
its O
regulatory O
nature O

88 O
) O
with O
a O
threshold O
value O
of O
0 O


In O
this O
review O
, O
we O
summarize O
the O
central O
mechanisms O
by O
which O
epigenetics O
and O
metabolism O
reciprocally O
modulate O
each O
other O
in O
cancer B-Disease
and O
elaborate O
upon O
and O
update O
the O
major O
contributions O
of O
the O
interplays O
between O
epigenetic O
aberrations O
and O
metabolic O
rewiring O
to O
cancer B-Disease
initiation O
and O

Interestingly O
, O
this O
epigenetic O
variation O
is O
significantly O
correlated O
with O
long-term O
differences O
in O
herbivory O
, O
but O
only O
weakly O
with O
herbivory-related O
DNA B-Gene
sequence I-Gene
variation I-Gene
, O
which O
suggests O
that O
besides O
habitat O
, O
substrate O
and O
genetic O
variation O
, O
epigenetic O
variation O
may O
be O
an O
additional O
, O

613 O
Studies O
on O
" O
epigenetic O
inheritance O
" O
or O
" O
transgenerational O
epigenetic O
inheritance O
" O
have O
emerged O
at O
ever-increasing O
numbers O
in O
the O
last O
years O
, O
in O
plant B-Species
as O
well O
as O
animal B-Species
systems O
and O
in O
diverse O
contexts O
ranging O
from O
stress B-Disease
adaptation I-Disease
to O
behavioral O
studies O

In O
this O
introduction O
, O
the O
authors O
present O
the O
basics O
of O
epigenetics O
in O
a O
way O
that O
is O
designed O
to O
make O
this O
exciting O
field O
accessible O
to O
a O
wide O
readership O

1312Tweetable O
There O
is O
growing O
evidence O
of O
a O
role O
of O
environmental O
exposures O
in O
the O
pathogenesis O
and O
epigenetics O
of O
suicidal O
behavior O
in O
older O
age O

EPIIC O
( O
Epigenetic O
Impact O
of O
Childbirth O
) O
is O
an O
international O
, O
interdisciplinary O
research O
collaboration O
with O
expertise O
in O
the O
fields O
of O
genetics O
, O
physiology O
, O
developmental O
biology O
, O
epidemiology O
, O
medicine O
, O
midwifery O
, O
and O
nursing O

A O
growing O
list O
of O
studies O
show O
that O
environmental O
stimuli O
can O
affect O
aging O
and O
longevity O
through O
conserved O
pathways O
which O
, O
in O
turn O
, O
modulate O
chromatin B-Chemical
states O

We O
profiled O
six O
histone O
modifications O
( O
H3K4me1 B-Chemical
, O
H3K4me3 B-Chemical
, O
H3K27ac B-Chemical
, O
H3K36me3 B-Chemical
, O
H3K9me3 B-Chemical
, O
H3K27me3 B-Chemical
) O
, O
identified O
chromatin O
states O
using O
a O
hidden O
Markov O
model O
, O
produced O
a O
novel O
quantitative O

36 O
Inheritance O
of O
genomic B-Chemical
DNA I-Chemical
underlies O
the O
vast O
majority O
of O
biological O
inheritance O
, O
yet O
it O
has O
been O
clear O
for O
decades O
that O
additional O
epigenetic O
information O
can O
be O
passed O
on O
to O
future O
generations O

Although O
most O
algorithms O
used O
in O
machine O
learning O
were O
developed O
as O
far O
back O
as O
the O
1950s O
, O
the O
advent O
of O
big O
data O
in O
combination O
with O
dramatically O
increased O
computing O
power O
has O
spurred O
renewed O
interest O
in O
this O
technology O
over O
the O
last O
two O
decades O

This O
article O
gives O
an O
account O
of O
a O
journey O
that O
started O
with O
the O
analysis O
of O
transgene-related O
silencing O
events O
and O
that O
led O
to O
the O
discovery O
of O
a O
new O
molecular O
world O
of O
small O
RNAs O
and O
epigenetic O
marks O
that O
regulate O
plant B-Species
gene B-Gene
expression O
and O
adaptation O
to O
environmental O
changes O

We O
first O
applied O
DBSCAN O
algorithm O
to O
eliminate O
outliers O
, O
and O
then O
used O
Limma B-Chemical
statistical O
method O
to O
determine O
differentially O
methylated O
genes B-Gene

Currently O
, O
the O
epigenetic O
regulation O
has O
been O
considered O
as O
the O
most O
important O
mechanism O
during O
hematopoietic B-Disease
differentiation I-Disease
, O
resulting O
in O
a O
specific O
epigenomic O
landscape O
in O
the O
hematopoietic B-Disease
stem/progenitor I-Disease
cells O

In O
this O
article O
, O
we O
reviewed O
the O
literature O
investigating O
the O
involvement O
of O
epigenetic O
mechanisms O
, O
noncoding O
RNAs O
and O
metabolomic O
modifications O
in O
bipolar B-Disease
disorder I-Disease
and O
the O
mechanism O
of O
action O
and O
clinical O
efficacy O
of O
mood B-Chemical
stabilizers I-Chemical

In O
this O
review O
, O
several O
natural O
compounds B-Chemical
and O
their O
studies O
about O
miRNA-related B-Gene
action O
mechanism O
were O
summarized O

While O
there O
is O
still O
more O
work O
to O
be O
done O
to O
fully O
characterize O
the O
mechanistic O
pathways O
linking O
social O
exposures O
to O
epigenetic O
changes O
and O
health O
outcomes O
, O
the O
body O
of O
work O
presented O
in O
this O
special O
issue O
represents O
solid O
progress O
toward O
this O
goal O

The O
initial O
search O
provided O
174 O
articles O
, O
and O
95 O
were O
used O

Systemic O
autoimmune O
diseases O
include O
rheumatoid B-Disease
arthritis I-Disease
, O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
, O
systemic B-Disease
sclerosis I-Disease
, O
Sjogren B-Disease
syndrome I-Disease
, O
polymyositis B-Disease
, O
and O
dermatomyositis B-Disease

NAc O

153 O
Background O
Advances O
in O
omics O
and O
computational O
Artificial O
Intelligence O
(AI) O
have O
been O
said O
to O
be O
key O
to O
meeting O
the O
objectives O
of O
precision O
cardiovascular B-Disease
medicine O

We O
demonstrate O
the O
effectiveness O
of O
the O
approach O
in O
a O
simulation O
study O
and O
on O
a O
real O
epigenomic O
data O
set O
from O
the O
ENCODE B-Chemical
project O

 O

complex O

403 O
Despite O
growing O
appreciation O
of O
the O
importance O
of O
epigenetics O
in O
breast B-Disease
cancer I-Disease
, O
our O
understanding O
of O
epigenetic O
alterations O
of O
non-coding O
RNAs O
( O
ncRNAs O
) O
in O
breast B-Disease
cancer I-Disease
remains O
limited O

human O

026 O
) O

4 O
 O
Epigenetic O
modifications O
of O
histones O
( O
methylation B-Chemical
, O
acetylation B-Chemical
, O
phosphorylation B-Chemical
, O
etc O

dogma O

Recent O
studies O
have O
found O
that O
epigenetic O
modulation O
of O
memory O
processes O
leads O
to O
surprisingly O
robust O
and O
persistent O
extinction O

These O
results O
revealed O
, O
for O
the O
first O
time O
, O
the O
epigenetic O
mechanism O
by O
which O
nanotopography O
directs O
stem B-Species
cell I-Species
fate O

Due O
emphasis O
should O
be O
given O
to O
epigenetic O
mechanisms O
in O
the O
pharmacotherapy O
, O
psychotherapy O
and O
nutritional O
management O
of O
these O
disorders B-Disease

Based O
on O
such O
an O
interoperation O
, O
Illumina B-Chemical
's I-Chemical
Infinium I-Chemical
platform O
is O
quite O
amenable O
to O
usage O
in O
a O
clinical B-Disease
setting I-Disease
for I-Disease
diagnostic I-Disease
work O

Here O
, O
we O
discuss O
how O
epigenomic O
therapies O
might O
be O
used O
to O
ameliorate O
DS-related B-Disease
phenotypes O
with O
a O
particular O
focus O
on O
the O
CRISPR-Cas B-Gene
9 I-Gene
system O
for O
targeted O
epigenomic O
engineering O
in O
DS B-Disease

Focussing O
on O
the O
5hmC B-Chemical
mark O
we O
demonstrate O
, O
by O
directly O
comparing O
with O
alternative O
sequencing O
strategies O
, O
that O
this O
platform O
can O
successfully O
generate O
genome O
wide O
5hmC B-Chemical
patterns O
from O
as O
little O
as O
500 O
ng O
of O
genomic O
DNA B-Chemical
in O
less O
than O
4 O
days O

To O
summarize O
how O
enzymatic O
rather O
than O
chemical B-Chemical
approaches O
can O
be O
leveraged O
to O
localize O
and O
resolve O
different O
cytosine B-Chemical
modifications O
in O
a O
non-destructive O
manner O

We O
performed O
epigenome-wide O
association O
studies O
to O
assess O
the O
effect O
of O
IRs B-Gene
and O
methionine-dependency-oriented O
analysis O
by O
carrying O
out O
epigenome-wide O
conditional O
logistic O
regression O

Our O
tool O
will O
be O
useful O
for O
highly O
sensitive O
epigenetic O
studies O
based O
on O
a O
small O
quantity O
of O
sample O

We O
confirmed O
that O
tissue-specific O
differentially O
methylated O
regions O
are O
strongly O
associated O
with O
tissue-specific O
regulatory O
elements O

001 O
) O
and O
a O
2 O

870 O
Systemic B-Disease
sclerosis I-Disease
( O
SSc B-Disease
) O
is O
an O
autoimmune O
disease O
with O
unknown O
etiology O
, O
characterized O
by O
vasculopathy O
, O
inflammation O
, O
and O
extensive O
fibrosis O
in O
the O
skin O
and O
organs O

By O
projecting O
all O
the O
trajectories O
into O
a O
2-dimensional O
plane O
of O
dimensions O
i O
and O
j O
, O
we O
can O
approximately O
calculate O
the O
quasi-potential O
U(xi,xj,â) O
= O
- O
ln O
P(xi,xj,â) O
, O
where O
P(xi,xj,â) O
is O
the O
estimated O
probability O
of O
an O
equilibrium O
steady O
state O
or O

Altogether O
, O
we O
propose O
an O
affordable O
single O
CG B-Gene
- I-Gene
resolution O
technique O
well O
suited O
for O
large O
- O
scale O
epigenome B-Disease
studies O

390 O
The O
field O
of O
epigenetics O
is O
now O
on O
a O
geometric O
rise O
, O
driven O
in O
a O
large O
part O
by O
the O
realization O
that O
modifiers O
of O
chromatin O
are O
key O
regulators O
of O
biological O
processes O
in O
vivo O

It O
is O
characterized O
by O
the O
deposition O
of O
two O
forms O
of O
aggregates O
within O
the O
brain O
, O
the O
amyloid B-Chemical
Î² I-Chemical
plaques O
and O
tau B-Chemical
neurofibrillary I-Chemical
tangles O

12 O
showed O
the O
poorest O
performance O
and O
provided O
artificially O
lower O
CpG O
methylation O
levels O
when O
5-methylcytosine B-Chemical
is O
read O
as O
guanine B-Chemical
(first O
read O
of O
PBAT-seq O
and O
second O
read O
of O
MethylC-seq O
) O

Paternal O
consumption O
of O
such O
dietary O
compounds O
could O
not O
only O
benefit O
the O
fathers O
but O
their O
offspring O
as O
well O

9 O
% O
and O
an O
order O
of O
magnitude O
lower O
runtime O
than O
the O
kernel O
SVM B-Gene

583 O
Recent O
technological O
advances O
in O
sequencing O
DNA B-Chemical
and O
RNA B-Chemical
modifications O
using O
high-throughput O
platforms O
have O
generated O
vast O
epigenomic O
and O
epitranscriptomic O
datasets O
whose O
power O
in O
transforming O
life O
science O
is O
yet O
fully O
unleashed O

Because O
individual O
genotypes O
and O
epigenetic O
signal O
tracks O
are O
not O
directly O
accessible O
, O
and O
rather O
aggregated O
in O
the O
portal O
output O
, O
no O
identifiable O
data O
is O
released O
, O
yet O
the O
interface O
allows O
for O
dynamic O
genotype-epigenome O
interrogation O

Finally O
, O
we O
conclude O
by O
presenting O
a O
typology O
of O
the O
different O
conceptions O
of O
epigenetics B-Chemical
throughout O
time O
, O
and O
analyse O
the O
connections O
between O
them O

Finally O
, O
we O
examine O
in O
vitro O
studies O
that O
model O
the O
impact O
of O
asthma-associated B-Disease
exposures O
on O
the O
epigenome O

These O
alterations O
support O
the O
transcriptional O
program O
crucial O
for O
the O
acquisition O
and O
maintenance O
of O
cancer B-Disease
hallmarks I-Disease

, O
heavy B-Chemical
metals I-Chemical
, O
particulate B-Chemical
air I-Chemical
pollution I-Chemical
, O
bisphenol B-Chemical
A I-Chemical
, O
hydroquinone B-Chemical
, O
and O
pentachlorophenol B-Chemical
metabolites I-Chemical
) O

Epigenetics O
is O
the O
study O
of O
biochemical O
modifications O
to O
DNA B-Chemical
and O
to O
histones B-Chemical
, O
the O
proteins O
that O
provide O
stability O
to O
DNA B-Chemical

Here O
we O
highlight O
a O
flurry O
of O
recent O
activity O
to O
identify O
the O
mRNA B-Gene
profiles O
from O
thousands O
of O
single-cells O
as O
well O
as O
chromatin B-Chemical
accessibility O
and O
histone B-Chemical
marks O
on O
single O
to O
few O
hundreds O
of O
cells O

In O
addition O
, O
several O
significant O
brain-development O
related O
pathways O
, O
e O

We O
also O
discuss O
the O
background O
of O
and O
challenges O
in O
the O
analysis O
of O
each O
molecular O
layer O
and O
integration O
of O
multiple O
levels O
of O
omics O
data O
, O
as O
well O
as O
how O
microchip-based O
methodologies O
benefit O
these O
fields O

Regarding O
sequence O
dependency O
, O
charge O
localization O
, O
shown O
to O
favor O
guanines B-Chemical
, O
could O
influence O
or O
even O
direct O
epigenetic O
changes O
, O
e O

Here O
, O
we O
describe O
methods O
for O
introducing O
a O
chemical-inducible O
epigenome O
remodeling O
tool O
( O
CiDER O
) O
, O
based O
on O
an O
engineered O
split-TET2 B-Gene
enzyme O
, O
into O
mammalian B-Species
cells O
and O
quantifying O
the O
chemical O
inducible O
production O
of O
5-hydroxymethylcytosine B-Chemical
( O
5hmC B-Chemical
) O

Understanding O
mechanisms O
that O
underlie O
increased O
psychosis B-Disease
risk O
is O
of O
great O
importance O
for O
the O
development O
of O
novel O
preventive O
approaches O
and O
early O
interventions O

Furthermore O
, O
these O
changes O
mediated O
by O
DNA B-Gene
methylation I-Gene
inhibitors O
can O
also O
alter O
the O
function O
of O
immune O
cells O
relevant O
to O
acquired O
immunity O

Understanding O
how O
CD B-Chemical
shapes O
the O
functionality O
of O
hASCs B-Gene
is O
critical O
for O
investigating O
the O
complex O
pathophysiology O
of O
this O
disease O
, O
as O
well O
as O
for O
the O
success O
of O
cell-based O
therapies O

Lastly O
, O
it O
seems O
intuitive O
that O
germline- O
and O
context-dependent O
epigenetic O
modifications O
interact O
, O
resulting O
in O
the O
individual O
variation O
observed O
in O
behaviors O
, O
but O
until O
now O
this O
hypothesis O
has O
never O
been O
tested O
experimentally O

Taken O
together O
, O
we O
conclude O
that O
presently O
, O
the O
evidence O
suggesting O
that O
acquired O
epigenetic O
marks O
are O
passed O
to O
the O
subsequent O
generation O
remains O
limited O

Ultimately O
, O
the O
information O
gained O
by O
further O
research O
may O
improve O
the O
clinical O
guidelines O
for O
the O
use O
of O
such O
drugs O
in O
patients O
of O
reproductive O
age O

1467 O
The O
multiple O
species O
concepts O
currently O
in O
use O
by O
the O
scientific O
community O
( O
e O

The O
goals O
of O
his O
work O
include O
a O
mechanistic O
understanding O
of O
individual O
susceptibility O
to O
exposure-related B-Disease
cancers I-Disease

1064 O
Epigenetic O
marks O
change O
during O
fetal O
development O
, O
adult O
life O
, O
and O
aging O

However O
, O
current O
publications O
have O
been O
limited O
by O
the O
use O
of O
global O
or O
targeted O
methods O
of O
measuring O
DNA B-Gene
methylation I-Gene

org O
/ O
groups O
/ O
biolabs O
/ O
tools O
/ O
span O
- O
peak O
- O
analyzer O
and O
https O
 O
/ O
/ O
research O

1322 O
 O
Several O
recent O
studies O
have O
highlighted O
the O
biological O
complexity O
of O
multiple B-Disease
myeloma I-Disease
( O
MM B-Disease
) O
that O
arises O
as O
a O
result O
of O
several O
disrupted O
cancer O
pathways O

Specifically O
, O
aging O
is O
associated O
with O
profound O
epigenetic O
changes O
, O
resulting O
in O
alterations O
of O
gene B-Gene
expression I-Gene
and O
disturbances O
in O
broad O
genome B-Gene
architecture I-Gene
and O
the O
epigenomic B-Gene
landscape I-Gene

This O
short O
review O
highlights O
key O
epigenetic O
players O
in O
the O
regulation O
of O
aging O
, O
as O
well O
as O
both O
future O
goals O
and O
challenges O
to O
the O
utilization O
of O
epigenetic O
strategies O
to O
delay O
and O
reverse O
the O
main O
diseases B-Disease
of I-Disease
aging I-Disease

The O
proposed O
MRF O
has O
two O
major O
advantages O
over O
existing O
approaches O

As O
more O
accurate O
and O
powerful O
tools O
for O
epigenetic O
analysis O
become O
available O
for O
application O
in O
a O
broader O
range O
of O
plant B-Species
species I-Species
, O
analysis O
of O
the O
epigenetic O
landscape O
of O
plant B-Species
cell I-Species
cultures I-Species
may O
turn O
out O
to O
be O
crucial O
for O
understanding O
variant O
phenotypes O

Because O
of O
their O
importance O
, O
a O
great O
number O
of O
different O
statistical O
algorithms O
, O
which O
adjust O
for O
cell-type O
composition O
, O
have O
been O
proposed O

MeDIP O
uses O
an O
antibody O
raised O
against O
5-methylcytosine B-Chemical
to O
capture O
methylated O
fragments O
of O
DNA B-Gene
, O
which O
are O
subsequently O
sequenced O
to O
envisage O
the O
methylome O
landscape O

This O
disagreement O
on O
a O
clear O
definition O
has O
made O
communication O
difficult O
, O
synthesis O
of O
epigenetic O
research O
across O
fields O
nearly O
impossible O
, O
and O
has O
in O
many O
ways O
biased O
methodologies O
and O
interpretations O

Finally O
, O
we O
replaced O
Fredrickson B-Gene
et O
al O

Studies O
were O
included O
if O
they O
described O
epigenetic O
and/or O
transcriptional O
regulation O
of O
OCG B-Gene
in O
a O
specific O
skeletal B-Disease
disorder I-Disease
, O
and O
quantified O
alterations O
in O
OCG B-Gene
by O
any O
well-described O
experimental O
method O

It O
will O
first O
, O
show O
that O
genetic O
modifications O
causing O
major O
alterations O
in O
polygenic O
phenotypes O
often O
hit O
targets O
within O
an O
array O
of O
' O
candidate B-Gene
genes I-Gene
' O
, O
second O
, O
present O
new O
methods O
that O
include O
mutations O
of O
all O
effect O
sizes O
, O
and O
help O
exhaustively O
describe O
the O
molecular O

We O
generated O
novel O
DNA B-Gene
methylation I-Gene
data O
from O
n O
= O
94 O
blood B-Species
samples O
, O
from O
which O
we O
extracted O
leucocyte B-Species
DNA B-Gene
, O
using O
a O
custom O
methylation B-Chemical
array I-Chemical
( O
HorvathMammalMethylChip40 B-Chemical
) O

1118 O
Inflammatory B-Disease
bowel I-Disease
disease I-Disease
( O
IBD B-Disease
) O
represents O
heterogeneous O
and O
relapsing O
intestinal O
conditions O
with O
a O
severe O
impact O
on O
the O
quality O
of O
life O
of O
individuals O
and O
a O
continuously O
increasing O
prevalence O

The O
role O
of O
5mC B-Chemical
in O
transcriptional O
repression O
is O
well O
established O
for O
a O
few O
hundred O
genes B-Gene
through O
methylation O
of O
their O
promoters O

However O
, O
the O
relatively O
modest O
risk O
association O
and O
the O
studies O
in O
twins O
have O
suggested O
a O
role O
for O
environmental O
and O
epigenetic O
factors O
, O
as O
well O
as O
genetic-epigenetic O
interaction O

Yet O
, O
the O
clinical O
use O
for O
solid O
tumors O
of O
approved O
epigenetic O
drugs O
is O
meager O

, O
early O
life O
and O
ancestral O
environments O
) O
on O
the O
presence O
of O
health O
indicators O

AD O
related O
target O
proteins O
, O
epigenetic O
targets O
, O
enriched O
pathways O
, O
and O
functional O
categories O
of O
the O
proposed O
repositioning O
were O
also O
studied O

1075 O
We O
surveyed O
current O
trends O
in O
epigenetics O
in O
general O
and O
epigenetics O
of O
HIV B-Disease
infection I-Disease
and O
AIDS B-Disease
in O
particular O
to O
pinpoint O
promising O
areas O
for O
translational O
research O

Epigenetic O
modifications O
provide O
a O
potential O
association O
with O
the O
environmental O
factors O
and O
altered O
gene B-Gene
expression I-Gene
that O
might O
cause O
disease B-Disease
phenotypes O

Defined O
as O
multivariate O
regression O
models O
, O
these O
DNA B-Gene
methylation-based I-Gene
biomarkers O
of O
age O
or O
mortality O
risk O
are O
useful O
in O
species B-Species
conservation O
efforts O
and O
in O
preclinical O
studies O

Linear O
mixed O
models O
were O
used O
to O
examine O
DNA-M B-Gene
changes O
between O
pre- O
and O
post-adolescence O
and O
whether O
the O
changes O
were O
gender-specific O

From O
this O
view O
, O
genes B-Gene
and O
environment O
, O
biology O
and O
culture O
, O
cognition O
and O
emotion O
, O
self O
and O
other O
, O
and O
so O
forth O
are O
inseparable O
as O
causal O
processes O
in O
the O
development O
of O
action O
and O
experience O

Therefore O
, O
our O
results O
were O
implemented O
as O
a O
freely O
accessible O
web O
application O

The O
fundamentals O
of O
molecular O
genetics O
, O
and O
the O
recent O
advances O
in O
the O
field O
, O
are O
important O
for O
clinicians O
to O
understand O
, O
as O
they O
provide O
a O
foundation O
for O
critical O
appraisal O
of O
the O
literature O
, O
unprecedented O
insights O
into O
the O
pathogenesis O
of O
the O
disorder B-Disease
, O
and O
reveal O

Epigenetic O
alterations O
are O
associated O
with O
inflammation O
and O
cardiovascular B-Disease
disease I-Disease
in O
patients O
with O
chronic B-Disease
kidney I-Disease
disease I-Disease

This O
is O
a O
very O
brief O
review O
of O
some O
early O
discoveries O
, O
and O
by O
no O
means O
is O
a O
complete O
account O
of O
the O
history O
of O
epigenetics B-Disease

A O
revised O
populationist O
approach O
is O
proposed O
and O
supported O
by O
paleoanthropologic O
evidence O
that O
reflects O
a O
picture O
of O
emerging O
suitability O
for O
bipedalism O
that O
is O
driven O
by O
natural O
genetic B-Gene
divergence O

ViCAR O
is O
a O
practical O
and O
powerful O
tool O
to O
explore O
epigenetic O
marks O
and O
3D O
genome B-Gene
interactomes O

Both O
novel O
and O
repurposed O
drugs O
are O
employed O
in O
AD B-Disease
clinical O
trials O
due O
to O
their O
epigenetic O
effects O
, O
as O
well O
as O
increasing O
number O
of O
natural O
compounds O

345 O
and O
are O
two O
critical O
aspects O
of O
the O
epigenetic O
landscape O
that O
contribute O
significantly O
to O

There O
is O
experimental O
evidence O
for O
the O
involvement O
of O
DNA B-Gene
methylation I-Gene
and O
histone B-Gene
modifications I-Gene
in O
the O
pathogenesis O
of O
drusen B-Disease
formation I-Disease
, O
a O
central O
hallmark O
of O
AMD B-Disease

177 O
The O
celebrated O
1917 O
work O
" O
On O
Growth O
and O
Form O
" O
of O
D'Arcy O
W O

e O

, O
early-life O
adversity O
and O
psychiatric B-Disease
disorder I-Disease
in O
epigenetic O
studies O
of O
suicidality B-Disease

This O
review O
covers O
the O
latest O
applications O
of O
epigenetic O
therapies O
for O
treatment O
of O
B O
cell O
, O
T O
cell O
, O
and O
Hodgkin B-Disease
lymphomas I-Disease
, O
highlighting O
key O
clinical O
trial O
results O
with O
monotherapies O
and O
combination O
therapies O
from O
the O
main O
classes O
of O
epigenetic O
therapies O
, O
including O

Methylation O
arrays O
were O
used O
for O
the O
analysis O

018 O
, O
SE O
= O
0 O

Contact O
elior O

Finally O
, O
we O
show O
supporting O
evidence O
that O
there O
are O
common O
strategies O
of O
reprogramming O
between O
newt B-Species
somatic O
cell O
in O
transdifferentiation O
and O
oocytes O
after O
somatic O
cell O
nuclear O
transfer O

Preterm O
birth O
is O
a O
profound O
environmental O
stressor O
that O
is O
closely O
associated O
with O
alterations O
in O
connectivity O
of O
neural O
systems O
and O
long-term O
neuropsychiatric B-Disease
impairment I-Disease

In O
this O
review O
we O
discuss O
how O
current O
knowledge O
relating O
to O
disease B-Disease
progression O
, O
mutational O
profile O
and O
therapeutic O
potential O
is O
progressing O
and O
increasing O
understanding O
of O
myeloid B-Species
malignancies O

Importantly O
, O
interventions O
that O
clear O
senescent O
cells O
have O
achieved O
marked O
improvements O
in O
healthspan O
and O
lifespan O
in O
mice B-Species

Although O
Lamarckism O
fell O
out O
of O
favour O
soon O
after O
the O
publication O
of O
Darwin B-Gene
's I-Gene
work O
on O
natural O
selection O
and O
evolution O
, O
the O
concept O
of O
transmission O
of O
acquired O
characteristics O
has O
recently O
gained O
renewed O
attention O
and O
has O
led O
to O
some O
rethinking O
of O
the O
standard O
evolutionary O
model O

Two O
systems O
to O
evaluate O
threshold O
cycles O
were O
developed O
, O
based O
on O
the O
Derivative B-Gene
method O
and O
a O
new O
proposed O
3-point O
exponential O
evaluation O
aim O
to O
reduce O
detection O
time O
simultaneously O

Historically O
, O
global O
DNA B-Gene
hypomethylation O
was O
first O
revealed O
in O
1983 O
, O
and O
, O
after O
a O
decade O
, O
silencing O
of O
a O
tumor B-Disease
suppressor I-Disease
gene O
by O
regional O
DNA B-Gene
hypermethylation O
was O
reported O

8% O

Both O
genetic O
and O
environmental O
factors O
determine O
the O
timing O
of O
puberty O

, O
excitation-inhibition O
coupling O
and O
activity-dependent O
plasticity O
) O

This O
led O
to O
evaluation O
and O
approval O
of O
the O
cytotoxic O
( O
cell O
killing O
) O
drug O
hydroxyurea B-Chemical
to O
treat O
sickle B-Disease
cell I-Disease
disease I-Disease

1360 O
The O
use O
of O
epigenetic O
biomarkers O
in O
cancer B-Disease
management O
relies O
on O
the O
availability O
of O
robust O
assays O
and O
evidence O
that O
these O
markers O
are O
able O
to O
segregate O
clinically O
significant O
groups O
of O
patients O

Inherited O
and O
acquired O
genetic O
mutations O
as O
well O
as O
epigenetic O
aberrations O
are O
known O
to O
be O
important O
contributors O
to O
the O
development O
and O
progression O
of O
breast B-Disease
cancer I-Disease

Given O
that O
epigenetic O
modifications O
are O
sensitive O
to O
environment O
, O
stable O
, O
and O
reversible O
, O
epigenetic O
studies O
in O
psychiatry O
could O
represent O
a O
promising O
approach O
to O
better O
understanding O
and O
treating O
disease B-Disease

Expected O
outcome O
is O
that O
this O
approach O
can O
provide O
insights O
into O
how O
to O
preserve O
health O
and O
reduce O
the O
impact O
of O
ageing B-Disease
diseases I-Disease
in O
humans B-Species


Finally O
, O
we O
highlight O
the O
potential O
therapeutic O
opportunities O
for O
hematological B-Disease
malignancies I-Disease
and O
solid B-Disease
tumors I-Disease
by O
targeting O
this O
epigenetic-metabolic O
circuit O

Epigenetic O
modifications O
which O
generally O
occur O
during O
the O
beginning O
stages O
of O
the O
disease B-Disease
are O
responsible O
for O
the O
metabolic O
memory O
effect O

This O
wealth O
of O
data O
has O
the O
potential O
to O
improve O
patient O
care O
, O
through O
personalized O
medicine O
and O
the O
identification O
of O
novel O
drug O
targets O

Besides O
, O
the O
most O
important O
clinical O
uses O
of O
Epigenetics B-Chemical
studies O
are O

with O

Previous O
studies O
have O
linked O
physiological O
features O
to O
coding O
DNA B-Gene
sequence I-Gene
, O
regulatory O
DNA B-Gene
sequence I-Gene
, O
and O
epigenetic O
state O
, O
but O
few O
have O
disentangled O
their O
relative O
contributions O
or O
unambiguously O
distinguished O
causative O
effects O
( O
' O
drivers O
' O
) O
from O
correlations O

Throughout O
I O
support O
the O
view O
that O
the O
Baldwin O
effect O
and O
genetic B-Gene
assimilation I-Gene
, O
even O
if O
they O
are O
quite O
close O
, O
should O
not O
be O
conflated O
, O
and O
that O
drawing O
a O
line O
between O
these O
concepts O
is O
helpful O
in O
order O
to O
better O
understand O
where O
epigenetic B-Gene
inheritance I-Gene

We O
update O
on O
the O
most O
current O
clinical O
studies O
focusing O
on O
epigenetic O
changes O
involved O
in O
bacterial-host O
interactions O
and O
their O
putative O
role O
as O
biomarkers O
or O
drug B-Chemical
targets O
to O
improve O
precision O
medicine O
and O
personalized O
therapy O
in O
critical B-Disease
illness I-Disease
and O
transplantation O
setting O


The O
activation O
of O
these O
immune-related O
pathways O
positively O
associated O
with O
prognosis O
in O
certain O
cancer B-Disease
types O
, O
most O
notably O
melanoma B-Disease
, O
head O
and O
neck O
, O
and O
cervical B-Disease
cancers O

To O
overcome O
this O
limitation O
, O
it O
would O
be O
useful O
to O
acquire O
reliable O
signals O
from O
multiple O
epigenetic O
marks O
in O
the O
same O
single O
cell O

Here O
, O
we O
give O
a O
historical O
overview O
of O
the O
epigenomics O
field O
and O
how O
epigenetic O
modifications O
can O
affect O
embryo O
development O
and O
disease B-Disease
etiology I-Disease

to O

Studies O
have O
demonstrated O
that O
epigenetic O
regulation O
, O
an O
integral O
part O
of O
the O
TGF-Î² B-Chemical
signaling O
, O
enables O
cells O
to O
sense O
and O
respond O
to O
TGF-Î² B-Chemical
signaling O
in O
a O
cell O
context-dependent O
manner O

A O
sensitivity O
analyses O
corroborated O
the O
performance O
of O
the O
original O
cutoff O
for O
various O
optimization O
criteria O
and O
for O
most O
data O
preprocessing O
methods O

Besides O
, O
it O
requires O
very O
small O
quantities O
of O
DNA B-Gene
and O
no O
prior O
genome O
information O

This O

Alterations O
of O
oncogenic O
signaling O
pathways O
janus B-Chemical
kinase-signal I-Chemical
transducer I-Chemical
and I-Chemical
activator I-Chemical
of I-Chemical
transcription I-Chemical
( O
JAK-STAT B-Gene
) O
, O
nuclear B-Chemical
factor-ÎºB I-Chemical
( O
NF-ÎºB B-Gene
) O
, O
mitogen-activated B-Chemical
protein I-Chemical
kinase I-Chemical
( O
MAPK B-Gene

Real-world O
pilots O
to O
test O
the O
reliability O
of O
these O
analyses O
are O
indicated O

This O
overall O
loss O
of O
DNA B-Chemical
methylation I-Chemical
has O
been O
proposed O
as O
a O
valid O
biomarker O
for O
cancer B-Disease

Obesity B-Disease
is O
associated O
with O
extensive O
gene B-Gene
expression I-Gene
changes O
in O
tissues O
throughout O
the O
body O

Recent O
technological O
advances O
offer O
a O
better O
understanding O
of O
the O
underlying O
epigenetic O
alterations O
during O
carcinogenesis B-Disease
and O
provide O
insight O
into O
the O
discovery O
of O
putative O
epigenetic O
biomarkers O
for O
detection O
, O
prognosis O
, O
risk O
assessment O
, O
and O
disease O
monitoring O

We O
discuss O
controversial O
issues O
regarding O
developmental O
changes O
in O
, O
such O
as O
the O
age O
at O
which O
develops O
and O
becomes O
established O
, O
and O
its O
causal O
direction O
, O
i O

Here O
we O
review O
evidence O
suggesting O
that O
epigenetic O
therapeutics B-Chemical
can O
deactivate O
immunosuppressive O
gene B-Gene
expression O
or O
reprogram O
tumor O
cells O
to O
activate O
antigen O
presentation O
mechanisms O

We O
posit O
that O
addressing O
these O
challenges O
will O
require O
the O
collaboration O
of O
biologists O
from O
different O
disciplines O
and O
a O
focus O
on O
the O
exploration O
of O
data O
and O
phenomena O
without O
preconceived O
limits O
on O
potential O
mechanisms O
or O
outcomes O

In O
this O
review O
, O
we O
outline O
the O
major O
transcriptomic O
and O
epigenetic O
processes O
and O
the O
respective O
datasets O
that O
are O
most O
relevant O
for O
studying O
the O
periconceptional O
period O

To O
illustrate O
the O
composability O
of O
these O
elements O
, O
Jacob B-Gene
and I-Gene
Monod I-Gene
linked O
phenotypic O
diversity O
to O
the O
architectures O
of O
regulatory O
circuits O

The O
Epigenomics O
resource O
also O
provides O
the O
user O
with O
a O
unique O
interface O
that O
allows O
for O
intuitive O
browsing O
and O
searching O
of O
data O
sets O
based O
on O
biological O
attributes O

Finally O
, O
the O
potential O
functions O
of O
aberrantly O
methylated O
ncRNAs O
were O
predicted O
, O
suggestiong O
that O
ncRNAs O
and O
coding O
genes B-Gene
cooperatively O
mediate O
pathway O
dysregulation O
during O
the O
development O
and O
progression O
of O
breast B-Disease
cancer I-Disease

genome-wide O

To O
discuss O
recent O
advances O
in O
the O
field O
of O
DNA B-Gene
methylation I-Gene
and O
their O
impact O
on O
our O
understanding O
of O
the O
role O
of O
this O
epigenetic O
mechanism O
in O
cancer B-Disease
development I-Disease
, O
as O
well O
as O
their O
implications O
for O
biomarker O
discovery O
and O
therapy O

In O
cross-sectional O
epigenome-wide O
analyses O
, O
we O
investigated O
associations O
of O
lifetime O
abuse O
and O
neglect O
with O
DNAm B-Gene
at O
baseline O

In O
addition O
, O
we O
describe O
Chromatin B-Chemical
State I-Chemical
Discovery I-Chemical
and O
Characterization O
( O
ChromHMM B-Chemical
) O
methodology O
to O
integrate O
data O
from O
these O
individual O
analyses O
, O
plus O
that O
from O
RNA-seq B-Gene
analysis O
of O
gene O
expression O
, O
to O
obtain O
the O
most O
comprehensive O
overall O
assessment O
of O
epigenetic O
programming O

Here O
, O
we O
review O
major O
model O
systems O
for O
transgenerational O
epigenetic O
inheritance O
via O
the O
germline O
in O
multicellular O
organisms O

However O
, O
since O
methylation B-Chemical
data O
is O
more O
sensitive O
to O
confounding O
, O
e O

Epigenetics O
provides O
distinctly O
different O
discursive O
possibilities O
than O
previous O
frameworks O
 O
firstly O
, O
it O
offers O
one O
distinct O
molecular O
mechanism O
for O
how O
ACEs B-Chemical
work O
, O
lending O
" O
molecular O
credibility O
" O
to O
epidemiological O
findings O
; O
secondly O
, O
it O
raises O
the O
possibility O
of O
reversing O
the O
negative O

The O
further O
use O
of O
epigenetics B-Gene
for O
diagnosis B-Disease
and O
therapy O
is O
warranted O

956 O
Epigenomics O
encompasses O
analyses O
of O
a O
variety O
of O
different O
epigenetic O
parameters O
which O
, O
collectively O
, O
make O
up O
the O
epigenetic O
programming O
that O
dictates O
cell O
fate O
and O
function O

Children O
with O
developmental O
delays O
are O
at O
a O
heightened O
risk O
of O
experiencing O
mental O
health O
challenges O
, O
and O
this O
risk O
is O
exacerbated O
among O
racially O
minoritized O
children O
who O
face O
disproportionate O
adversity O

Biologically O
, O
these O
changes O
manifest O
as O
blunted O
immune O
responses O
, O
decreased O
bone O
marrow O
cellularity O
, O
and O
increased O
risk O
of O
myeloid B-Disease
diseases I-Disease

Here O
, O
we O
report O
that O
natural O
and O
D-galactose B-Chemical
( O
D-gal B-Chemical
) O
- O
induced O
aging O
kidneys O
display O
marked O
suppression O
of O
antiaging O
factor O
NRF2 B-Gene
( O
nuclear O
factor O
erythroid-derived O
2-like O
2 O
) O
and O
KLOTHO B-Gene
, O
accompanied O
by O
upregulations O
of O
DNA B-Gene

These O
processes O
affect O
gene B-Gene
transcription O
, O
DNA B-Gene
replication O
and O
DNA B-Gene
repair O
, O
comprehending O
epigenetics O
as O
a O
key O
factor O
in O
understanding O
Aging B-Disease
and O
developing O
new O
avenues O
for O
delaying O
Aging B-Disease
, O
clinical O
advancements O
in O
ameliorating O
aging-related B-Disease
diseases I-Disease
and O
rejuvenating O
health O

Bioinformatics O
is O
an O
effective O
approach O
for O
epigenomic O
profiling O

A O
decrease O
in O
the O
level O
of O
DNA B-Gene
methylation I-Gene
in O
such O
specific O
sites O
suggests O
that O
under O
the O
influence O
of O
heat B-Chemical
stress I-Chemical
we O
observe O
active O
demethylation O
phenomenon O
rather O
than O
passive O
demethylation O
, O
which O
is O
not O
locus O
specific O

0 O
License O

6mA B-Chemical
, O
4mC B-Chemical
, O
5mC B-Chemical
) O
in O
parallel O
with O
acquisition O
of O
primary O
sequence O
data O
, O
based O
on O
analysis O
of O
the O
kinetics O
of O
DNA B-Chemical
synthesis O
reactions O

405 O
Epigenetic O
testing O
is O
one O
of O
the O
most O
significant O
new O
technologies O
to O
provide O
insight O
into O
the O
behavioral O
and O
environmental O
factors O
that O
influence O
the O
development O
and O
reconfiguration O
of O
the O
human B-Species
genetic B-Gene
code I-Gene

1185 O
Epigenetics O
refers O
to O
molecular O
factors O
and O
processes O
around O
DNA B-Chemical
that O
can O
affect O
genome O
activity O
and O
gene B-Gene
expression O
independent O
of O
DNA B-Chemical
sequence O


275 O
Epigenetics O
is O
a O
new O
branch O
of O
genetics O
which O
studies O
reversible O
and O
heritable O
changes O
of O
gene B-Gene
function O
that O
do O
not O
involve O
alterations O
in O
DNA B-Chemical
sequence O
of O
nucleus O

In O
fact O
, O
recent O
studies O
demonstrated O
that O
some O
drugs B-Chemical
and O
early O
interventions O
are O
effective O
at O
preventing O
epigenetic B-Disease
disorders I-Disease

126 O
The O
involvement O
of O
epigenetic O
processes O
in O
the O
origin O
and O
progression O
of O
cancer B-Disease
is O
now O
widely O
appreciated O

Moreover O
, O
we O
show O
that O
the O
pseudotime O
trajectory O
can O
be O
modeled O
with O
respect O
to O
time O
, O
using O
a O
sum O
of O
two O
exponentials O
, O
with O
coefficients O
that O
are O
close O
to O
the O
timescales O
of O
human B-Species
age-associated O
mortality B-Disease

Additionally O
, O
the O
methods O
used O
for O
their O
detection O
and O
important O
associations O
with O
genetic O
variations O
in O
the O
context O
of O
CVD B-Disease
were O
summarized O

In O
this O
review O
, O
we O
will O
identify O
and O
discuss O
current O
ethical O
, O
legal O
and O
social O
issues O
of O
epigenetics B-Gene
research O
in O
the O
context O
of O
personalized O
medicine O

plant B-Species

Policies O
of O
government O
and O
the O
private O
sector O
, O
particularly O
at O
the O
local O
, O
community O
level O
, O
can O
create O
a O
supporting O
environment O
for O
such O
interventions O

Acknowledging O
the O
latest O
developments O
in O
ancient B-Disease
DNA I-Disease
research O
, O
we O
further O
discuss O
paleoepigenomic O
approaches O
as O
the O
only O
means O
to O
infer O
epigenetic O
changes O
in O
the O
past O

To O
date O
, O
few O
programs O
exist O
for O
regional O
analysis O
of O
enriched O
or O
whole-genome O
bisulfate O
conversion O
sequencing O
data O
, O
even O
though O
such O
data O
are O
increasingly O
common O

Here O
we O
discuss O
the O
evidence O
in O
favor O
of O
a O
genetic O
and O
epigenetic O
basis O
for O
sexually O
dimorphic O
behavior O
, O
as O
a O
consequence O
of O
underlying O
differences O
in O
the O
regulation O
of O
genes B-Gene
that O
drive O
brain O
function O

Gene B-Gene
-specific I-Gene
methylation O
analysis O
by O
sequencing O
of O
bisulfite-treated O
genomic O
DNA B-Gene
has O
been O
instrumental O
in O
understanding O
how O
DNA B-Gene
methylation O
affects O
gene O
transcription O

Once O
in O
this O
region O
, O
the O
self-activating O
genetic O
circuit O
can O
exhibit O
epigenetic O
switching O
, O
which O
starts O
competing O
with O
genetic O
adaptation O

There O
was O
an O
increase O
in O
the O
frequency O
of O
C O
to O
T O
(thymine) B-Chemical
transitions O
at O
the O
CHH O
positions O
in O
the O
progeny O
of O
cold O
stressed O
plants O
; O
because O
this O
type O
of O
mutations O
is O
often O
due O
to O
the O
deamination O
of O
the O
methylated O
cytosines B-Chemical
, O
it O
can O

Known O
imprinted O
regions O
are O
enriched O
among O
epigenetically O
regulated O
loci O
, O
but O
we O
also O
observe O
several O
novel O
genomic O
regions O
( O
e O

Within O
the O
scope O
of O
this O
current O
review O
, O
the O
most O
sought O
after O
epigenetic O
changes O
of O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modification I-Chemical
are O
thoroughly O
scrutinized O
to O
understand O
their O
close O
functional O
association O
with O
the O
broad O
spectrum O
of O
suicide B-Disease
phenotype I-Disease

We O
will O
present O
the O
importance O
of O
chicken B-Species
in O
poultry O
epigenetics O
and O
in O
genomic O
studies O
that O
trace O
back O
to O
their O
ancestor O
, O
the O
last O
link O
between O
human B-Species
and O
chicken B-Species
in O
the O
tree O
of O
life O


There O
have O
been O
numerous O
diseases O
, O
exposures O
and O
lifestyle O
factors O
investigated O
with O
EWAS O
, O
with O
several O
significant O
associations O
now O
identified O

The O
behavioral O
phenotypes O
associated O
with O
drug B-Chemical
exposure O
are O
reviewed O
in O
depth O

The O
excitement O
in O
modern O
molecular O
biology O
surrounding O
the O
impact O
exerted O
by O
the O
environment O
on O
development O
of O
the O
phenotype O
is O
focused O
largely O
on O
mechanism O
and O
has O
not O
incorporated O
questions O
asked O
( O
and O
answers O
provided O
) O
by O
early O
philosophers O
, O
biologists O
, O
and O
psychologists O

And O
the O
combined O
utilization O
of O
epigenetic O
medications O
with O
immune O
checkpoint O
inhibitors O
that O
focus O
on O
immune O
checkpoint O
molecules O
[ O
e O

Epigenetic O
mutations O
are O
emerging O
as O
critical O
components O
of O
disease B-Disease
progression O
, O
with O
mutations O
in O
genes O
controlling O
chromatin O
regulation O
and O
methylation/acetylation O
status O

Embodiment O
provides O
a O
basis O
for O
epigenetics O
across O
generations O
and O
for O
epigenetic O
( O
qualitative O
discontinuous O
) O
change O
across O
ontogeny O

As O
better O
targeted O
therapies O
are O
importantly O
needed O
for O
CVID B-Disease
, O
improved O
understanding O
of O
the O
genetic O
and O
epigenetic O
basis O
for O
the O
development O
of O
CVID B-Disease
presents O
the O
most O
promising O
venue O
for O
improvement O

We O
anticipate O
that O
BECon O
will O
enable O
biological O
interpretation O
of O
blood-based O
human B-Species
DNA B-Gene
methylation I-Gene
results O
, O
in O
the O
context O
of O
brain O

7 O
- O
1 O
0 O

Although O
the O
advent O
of O
genome-wide O
DNA B-Chemical
methylation I-Chemical
profiling O
in O
primary O
disease B-Disease
tissue O
has O
provided O
a O
manifold O
resource O
for O
biomarker O
development O
, O
only O
a O
tiny O
fraction O
of O
DNA B-Chemical
methylation-based I-Chemical
assays O
have O
reached O
clinical O
testing O

The O
majority O
of O
epigenetic O
analyses O
of O
eating O
disorders B-Disease
investigated O
methylation O
at O
candidate O
genes O
( O
n O
= O
13 O
) O
, O
focusing O
on O
anorexia B-Disease
and O
bulimia B-Disease
nervosa I-Disease
in O
very O
small O
samples O
with O
considerable O
sample O
overlap O
across O
published O
studies O

Utilizing O
open O
source O
tools O
, O
we O
here O
describe O
a O
comprehensive O
computational O
methodology O
to O
thoroughly O
analyze O
DNA B-Gene
methylation O
patterns O
during O
tumor B-Disease
evolution O
based O
on O
bisulfite O
converted O
sequencing O
data O
, O
including O
intra-tumor B-Disease
methylation O
heterogeneity O

Next O
, O
we O
detail O
research O
findings O
from O
the O
rapidly O
progressing O
field O
of O
epigenetics O
and O
epigenomics O
, O
highlighting O
ways O
in O
which O
our O
emerging O
understanding O
in O
these O
areas O
could O
guide O
future O
intervention O
and O
research O
efforts O
in O
public O
health O

However O
, O
association O
analyses O
based O
on O
methylation O
array O
data O
are O
susceptible O
to O
batch/slide O
effects O
, O
which O
can O
lead O
to O
inflated O
false O
positive O
rates O
or O
reduced O
statistical O
powerResults O
 O
We O
use O
multiple O
DNA B-Chemical
methylation O
datasets O
based O
on O
the O
popular O
Illumina B-Chemical
Infinium I-Chemical

in O


A O
total O
of O
37,363 O
cGCPs O
was O
identified O
in O
the O
six O
datasets O
; O
approximately O
38% O
of O
the O
cGCPs O
were O
positively O
correlated O

This O
technique O
is O
widely O
used O
in O
plants B-Species
for O
taxonomy O
, O
genetic O
diversity O
, O
phylogenetic O
analysis O
, O
construction O
of O
high-resolution O
genetic O
maps O
, O
and O
positional O
cloning O
of O
genes B-Gene
, O
to O
determine O
relatedness O
among O
cultivars O
and O
varietal O
identity O
, O
etc O

Several O
epigenetic O
clocks O
accurately O
predict O
chronological O
age O
using O
methylation O
levels O
at O
age O
associated O
GpG-sites O


38 O
or O
the O
latest O
HCS B-Chemical
v2 I-Chemical

Thus O
, O
with O
continued O
careful O
attention O
to O
fundamental O
biological O
and O
pharmacologic O
considerations O
( O
reviewed O
herein O
) O
, O
there O
is O
potential O
that O
rational O
, O
molecular-targeted O
, O
safe O
and O
highly O
potent O
disease-modifying O
therapy O
can O
be O
realized O
for O
patients O
with O
sickle B-Disease
cell I-Disease
disease I-Disease
, O

Computer O
- O
aided O
knowledge O
discovery O
for O
epigenetic O
implications O
of O
current O
approved O
or O
investigational O
drugs O
was O
performed O
by O
querying O
information O
from O
multiple O
publicly O
available O
gold O
- O
standard O
sources O
to O
( O
i O
) O
identify O
enzymes O
involved O
in O
classical O
epigenetic O
processes O
, O
( O
ii O
) O
screen O
original O

642 O
 O
Introduction O
 O
It O
is O
understood O
that O
cancer B-Disease
is O
a O
clonal O
disease O
initiated O
by O
a O
single O
cell O
, O
and O
that O
metastasis B-Disease
, O
which O
is O
the O
spread O
of O
cancer B-Disease
from O
the O
primary O
site O
, O
is O
also O
initiated O
by O
a O
single O
cell O

1247 O
Borderline B-Disease
Personality I-Disease
Disorder I-Disease
( O
BPD B-Disease
) O
is O
a O
major O
mental O
illness O
with O
a O
lifetime O
prevalence O
of O
approximately O
1-3% O
, O
characterized O
by O
a O
persistent O
pattern O
of O
instability O
in O
relationships O
, O
mood O
, O
impulse O
regulation O
, O
and O
sense O
of O
self O

The O
pro-regenerative O
transcriptional O
program O
is O
likely O
silenced O
or O
repressed O
in O
adult O
neural O
cells O
including O
neurons O
and O
myelinating O
cells O
in O
the O
central O
and O
peripheral O
nervous O
systems O
limiting O
the O
capacity O
for O
repair O
after O
injury O

These O
types O
of O
sensitization O
effects O
are O
amenable O
to O
clinical O
attempts O
at O
amelioration O
and O
prevention O
, O
and O
provide O
treatment O
targets O
and O
strategies O
to O
minimize O
the O
likelihood O
of O
illness B-Disease
progression O
to O
treatment O
resistance O

10 O
, O
p O
= O

Various O
stimuli O
, O
including O
microbial O
infection B-Disease
, O
can O
induce O
the O
epigenetic O
reprogramming O
of O
innate O
immune O
cells O
and O
HSCs B-Gene
, O
which O
can O
result O
in O
an O
augmented O
response O
to O
secondary O
stimulation O

To O
date O
, O
although O
genetic O
studies O
reported O
several O
susceptibility O
genes O
with O
PD B-Disease
, O
few O
of O
them O
were O
replicated O
and O
the O
pathogenesis O
of O
PD B-Disease
remains O
to O
be O
clarified O

In O
this O
review O
, O
we O
introduce O
novel O
NGS O
technologies O
and O
their O
application O
to O
unraveling O
epigenetic O
memories O
that O
are O
key O
in O
trained B-Disease
immunity I-Disease
and O
summarize O
the O
recent O
findings O
in O
trained B-Disease
immunity I-Disease

The O
highly O
specialized O
nuclear O
proteins O
in O
sperm B-Species
create O
a O
chromatin O
structure O
that O
is O
at O
least O
six O
times O
denser O
than O
histone B-Chemical
bound O
DNA B-Gene

172 O
In O
many O
aspects O
of O
life O
, O
epigenetics O
, O
or O
the O
altering O
of O
phenotype O
without O
changes O
in O
sequences O
, O
play O
an O
essential O
role O
in O
biological O
function O

We O
identified O
9112 O
and O
3929 O
DMPs O
and O
DEGs O
, O
respectively O

Epigenetic O
modification O
of O
phenotype O
( O
molecular O
, O
cellular O
, O
morphological O
, O
physiological O
, O
and O
behavioral O
) O
can O
be O
highly O
variable O
depending O
upon O
ancestral O
environmental O
exposure O
and O
can O
contribute O
to O
apparent O
" O
random O
" O
noise O
in O
collected O
datasets O

Mapping O
of O
chromatin O
state O
, O
chromatin O
accessibility O
dynamics O
, O
and O
higher-order O
chromatin O
structure O
enables O
a O
new O
level O
of O
understanding O
of O
cell O
fate O
determination O
, O
identity O
and O
function O
in O
normal O
growth O
and O
development O
, O
disease B-Disease
resistance I-Disease
, O
and O
yield O

Major O
reprogramming O
takes O
place O
in O
primordial O
germ O
cells O
, O
in O
which O
parental O
imprints O
are O
erased O
and O
totipotency O
is O
restored O

12 O
All O
animals O
have O
evolved O
solutions O
to O
manage O
their O
genomes O
, O
enabling O
the O
efficient O
organization O
of O
meters O
of O
DNA B-Chemical
strands O
in O
the O
nucleus O
and O
allowing O
for O
nuanced O
regulation O
of O
gene O
expression O
while O
keeping O
transposable O
elements O

Of O
note O
, O
studies O
investigating O
the O
epigenetic O
control O
of O
the O
onset O
of O
puberty O
suggest O
that O
epigenetic O
repression O
of O
key O
inhibitory O
loci O
may O
play O
a O
fundamental O
role O
in O
the O
initiation O
of O
puberty O

This O
allows O
users O
to O
analyse O
data O
from O
the O
Infinium B-Chemical
Human I-Chemical
Methylation I-Chemical
BeadChip I-Chemical
in O
the O
easiest O
possible O
way O

showed O

To O
date O
, O
there O
exists O
no O
technique O
which O
can O
successfully O
monitor O
the O
epigenomics O
of O
CSC B-Species

85 O
( O
sensitivity O
 O
0 O

Areas O
covered O
 O
In O
this O
review O
, O
we O
summarize O
the O
role O
of O
methylation O
changes O
, O
histone O
modifications O
, O
and O
non-coding O
RNAs O
in O
the O
pathogenesis O
of O
GC B-Disease
and O
how O
these O
signatures O
can O
be O
used O
as O
diagnostic O
and O
therapeutic O
targets O
in O
clinical O
management O

and O

5 O
- O
month O
( O
P O
< O
0 O

Conclusion O
 O
These O
data O
highlight O
sex-dependent O
miRNA B-Gene
and O
mRNA B-Gene
patterning O
in O
the O
placenta B-Species
and O
provide O
insight O
into O
a O
potential O
mechanism O
for O
observed O
sex O
differences O
in O
outcomes O

Targeting O
PRMT1 B-Gene
using O
furamidine B-Chemical
, O
a O
selective O
pharmacologic O
inhibitor O
, O
suppressed O
TBX19 B-Gene
- O
induced O
mitochondrial O
fission O
, O
leading O
to O
a O
profound O
loss O
of O
self-renewal O
potential O
and O
tumor-initiating O
capacity O
of O
LCICs B-Disease

The O
4th O
intron O
is O
strongly O
methylated B-Chemical
in O
both O
sexes O
and O
the O
5th O
intron O
is O
unmethylated B-Chemical
in O
both O
sexes O

Lastly O
, O
animal O
models O
of O
neurodegenerative B-Disease
disorders I-Disease
are O
generated O
by O
over-expression O
of O
causal O
genes O
, O
further O
supporting O
the O
conclusion O
that O
increased O
gene O
expression O
is O
related O
to O
pathogenesis O

It O
can O
also O
change O
dynamically O
in O
response O
to O
developmental O
cues O
or O
environmental O
stimuli O
, O
and O
is O
an O
important O
regulator O
for O
developmental O
switch O
and O
cell O
fate O
determination O

Several O
genes O
, O
including O
those O
related O
to O
adrenal B-Disease
and O
ovarian B-Species
steroidogenesis O
as O
well O
as O
those O
associated O
with O
hormonal O
response O
to O
gonadotrophins B-Chemical
, O
androgens B-Chemical
and O
insulin B-Chemical
, O
have O
been O
demonstrated O
to O
be O
associated O
with O
PCOS B-Disease

The O
resulting O
datasets O
are O
conveniently O
formatted O
to O
allow O
easy O
alignment O
of O
significant O
hits O
to O
genes B-Gene
and O
genetic O
features O
, O
however O
; O
methods O
that O
parse O
significant O
hits O
into O
discreet O
differentially O
methylated B-Chemical
regions O
( O
DMRs O
) O
remain O
a O
challenge O
to O
implement O

These O
approaches O
offer O
the O
possibility O
to O
identify O
disease B-Disease
mechanisms O
, O
discover O
novel O
diagnostic O
biomarkers O
, O
and O
develop O
new O
therapeutic O
strategies O

The O
histone B-Chemical
modification I-Chemical
valleys O
detected O
by O
EpiSAFARI O
exhibit O
high O
conservation O
, O
transcription O
factor O
binding O
and O
they O
are O
enriched O
in O
nascent O
transcription O

Therefore O
, O
it O
is O
necessary O
to O
decipher O
and O
better O
understand O
the O
genetic O
determinants O
of O
their O
regulation O
at O
different O
levels O

786 O
 O
Summary O
 O
The O
tidyCoverage O
R B-Chemical
package O
provides O
a O
framework O
for O
intuitive O
investigation O
of O
collections O
of O
genomic O
tracks O
over O
genomic O
features O
, O
relying O
on O
the O
principle O
of O
tidy O
data O
manipulation O

This O
review O
provides O
an O
update O
on O
the O
association O
of O
suboptimal O
nutritional O
environment O
and O
the O
high O
propensity O
to O
produce O
adult-onset B-Disease
chronic I-Disease
illnesses I-Disease
with O
a O
particular O
focus O
on O
modifications O
in O
genome B-Gene
functions I-Gene
that O
occur O
without O
alterations O
to O
the O
DNA B-Gene
sequence I-Gene

Additionally O
, O
bisulfite B-Chemical
fails O
to O
resolve O
5mC B-Chemical
from O
5hmC B-Chemical

This O
chapter O
mainly O
focuses O
on O
T1D-related B-Disease
DNA B-Gene
methylation I-Gene
, O
histone B-Gene
modification I-Gene
, O
and O
non-coding B-Gene
RNA I-Gene
, O
as O
well O
as O
their O
possible O
translational O
potential O
in O
the O
early O
diagnosis O
and O
treatment O
of O
T1D B-Disease

722 O
The O
protein O
interactome O
mediates O
crucial O
functions O
in O
transcription O
, O
chromatin O
remodeling O
, O
and O
higher-order O
structural O
organization O

While O
this O
article O
focuses O
on O
current O
literature O
and O
primary O
research O
findings O
in O
lung B-Disease
cancer I-Disease
, O
the O
principles O
we O
describe O
here O
apply O
to O
the O
discovery O
and O
development O
of O
epigenetic O
biomarkers O
for O
other O
types O
of O
cancer B-Disease

In O
this O
review O
, O
we O
propose O
that O
planarians B-Species
represent O
a O
unique O
and O
effective O
system O
to O
study O
the O
epigenetic O
regulation O
of O
these O
processes O
in O
an O
in O
vivo O
context O

In O
vitro O
plant O
cell O
and O
tissue O
culture O
methodologies O
are O
important O
for O
many O
ongoing O
plant O
propagation O
and O
breeding O
programmes O
as O
well O
as O
for O
cutting-edge O
research O
in O
several O
plant O
model O
species B-Species


The O
experiences O
of O
life O
trauma O
, O
post-traumatic O
stress O
, O
and O
discrimination O
may O
be O
associated O
with O
accelerated O
epigenetic O
aging O
that O
can O
be O
consistently O
detected O
using O
different O
epigenetic O
clocks O

Targeting O
these O
epigenetic O
alterations O
will O
enhance O
our O
understanding O
of O
the O
biological O
basis O
of O
addiction B-Disease
and O
might O
even O
yield O
more O
effective O
anti-addiction B-Chemical
therapies O

Therefore O
, O
elucidating O
the O
dysregulated O
epigenetic O
mechanisms O
in O
the O
immune O
system O
is O
crucial O
for O
understanding O
the O
pathogenesis O
of O
SLE B-Disease

Next O
we O
describe O
chromatin B-Chemical
immunoprecipitation-based I-Chemical
techniques O
( O
ChIP B-Chemical
) O
for O
study O
of O
the O
epigenome O

After O
further O
adjustment O
for O
smoking O
and O
chronic B-Disease
disease I-Disease
, O
the O
association O
with O
physical O
frailty O
remained O
significant O

Finally O
, O
the O
review O
describes O
current O
methods O
for O
the O
integration O
of O
multiple O
molecular O
biology O
platforms O

The O
results O
of O
quantitative O
reverse O
transcription B-Gene
PCR I-Gene
, O
immunohistochemistry O
and O
DNA B-Gene
methylation I-Gene
analysis O
confirmed O
the O
potential O
of O
these O
genes O
as O
biomarkers O

Tumor O
plasticity O
is O
controlled O
by O
genetic O
and O
epigenetic O
changes O
of O
crucial O
genes B-Gene
involved O
in O
cancer B-Disease
cell I-Disease
survival O
, O
growth O
and O
metastasis O

We O
also O
describe O
how O
recent O
advances O
in O
molecular O
biology O
beyond O
the O
operon O
model-namely O
, O
programmable O
DNA O
- O
and O
RNA O
- O
binding O
molecules O
as O
well O
as O
models O
of O
epigenetic O
and O
posttranslational O
regulation-are O
expanding O
the O
synthetic O
biology O
toolkit O
and O
enabling O
the O
design O
of O
more O
complex O

These O
interactions O
make O
combined O
epigenetic B-Chemical
therapy I-Chemical
and O
immunotherapy B-Chemical
an O
attractive O
approach O
to O
circumvent O
the O
limitations O
of O
immunotherapy B-Chemical
alone O

It O
then O
provides O
a O
series O
of O
easily O
interpretable O
figures O
for O
visualizing O
the O
signal O
and O
epigenetic O
state O
patterns O
of O
the O
cCREs O
clusters O
during O
the O
cell O
differentiation O

706 O
Background O
High O
surrounding O
greenness O
has O
many O
health B-Disease
benefits O
and O
might O
contribute O
to O
slower O
biological O
aging O

15 O
to O
0 O

361 O
Our O
paper O
explores O
the O
value-laden O
and O
epistemic O
resources O
that O
scientists O
working O
in O
epigenetics O
and O
developmental O
programming O
of O
health O
and O
disease B-Disease
(DOHaD) I-Disease
mobilise O
to O
produce O
scientific O
representations O
of O
pregnancy O
and O
parenthood O
, O
which O
in O
turn O
imagine O
norms O
, O
values O
, O
and O

Methods O
 O
Here O
, O
we O
undertook O
module- O
and O
region-based O
DNA B-Gene
methylation I-Gene
analyses O
of O
incident O
CVD B-Disease
in O
the O
Women B-Disease
's I-Disease
Health I-Disease
Initiative I-Disease
( O
WHI B-Disease
) O
and O
Framingham B-Disease
Heart I-Disease
Study I-Disease
Offspring I-Disease
Cohort I-Disease
( O
FHS B-Disease
) O
in O
order O
to O

The O
goal O
of O
this O
minireview O
is O
to O
summarize O
pharmacological O
strategies O
to O
modify O
the O
epigenetic O
landscape O
of O
cancer B-Disease
cells O

Here O
, O
we O
identified O
lineage-specific O
DNA B-Gene
methylation I-Gene
signatures O
of O
six O
immune O
cell O
types O
from O
human B-Species
peripheral I-Species
blood I-Species
and O
determined O
their O
relationship O
to O
other O
epigenetic O
and O
transcriptomic O
patterns O

DNA O
methylation O
patterns O
in O
orthopteroids B-Species
share O
a O
number O
of O
characteristics O
with O
those O
of O
hymenopteran B-Species
insects I-Species
, O
although O
methylation O
levels O
are O
much O
higher O
, O
and O
extend O
to O
introns O
and O
repeat O
elements O

recorded O

Following O
this O
, O
the O
included O
studies O
were O
analysed O
for O
citations O
, O
journals O
, O
keywords O
, O
authors O
, O
and O
countries O
, O
using O
the O
Bibliometrix O
package O
in O
R O
Studio O

36 O
; O
P O
= O

The O
methyl O
group O
is O
derived O
from O
an O
essential O
molecule O
in O
the O
cell O
, O
S-adenosylmethionine B-Chemical
( O
SAM B-Chemical
) O

g O

Our O
EWAS O
identified O
570 O
CpG B-Gene
sites O
where O
methylation B-Chemical
variability O
was O
significantly O
associated O
with O
age O
(P O
< O
1 O

469 O
methylation O
is O
a O
chemically O
reversible O
epigenetic O
modification O
that O
regulates O
the O
chromatin O
structure O
and O
gene O
expression O
, O
and O
thereby O
takes O
part O
in O
various O
cellular O
processes O
like O
embryogenesis O
, O
genomic O
imprinting O
, O
X-chromosome O
inactivation O
, O
and O
genome O
stability O

present O
novel O
techniques O
for O
the O
integration O
of O
single-cell O
RNA-seq O
datasets O
across O
multiple O
platforms O
, O
individuals O
, O
and O
species B-Species

The O
level O
of O
DNA B-Gene
methylation O
of O
specific O
genomic O
regions O
correlates O
with O
chromatin O
condensation O
, O
the O
level O
of O
gene B-Gene
expression O
, O
and O
in O
some O
cases O
genome O
stability O
and O
the O
frequency O
of O
homologous O
recombination O

In O
recent O
years O
, O
there O
has O
been O
a O
great O
deal O
of O
research O
on O
the O
epigenomic O
profile O
of O
GC B-Disease
, O
and O
epigenetic O
alterations O
seem O
to O
play O
a O
more O
important O
role O
than O
genetic O
factors O

830 O
for O
the O
discriminating O
model O
, O
outperforming O
inverse O
docking O
in O
predicting O
protein-ligand O
interactions O

851 O
The O
epigenetic O
modification O
of O
nucleic B-Chemical
acids I-Chemical
represents O
one O
of O
the O
most O
significant O
areas O
of O
study O
in O
the O
field O
of O
nucleic B-Chemical
acids I-Chemical
because O
it O
makes O
gene B-Gene
regulation O
more O
complex O
and O
heredity O
more O
complicated O
, O
thus O
indicating O
its O
profound O
impact O

on O

Charge O
delocalization O
can O
directly O
alter O
DNA B-Gene
recognition O
by O
proteins O
or O
indirectly O
by O
DNA B-Gene
structural O
changes O

Same O
were O
the O
reasons O
for O
ineffective O
and O
imprecise O
results O

In O
the O
IOW O
cohort O
, O
after O
controlling O
for O
technical O
variation O
and O
cell O
compositions O
at O
both O
pre- O
and O
post-adolescence O
, O
15,532 O
cytosine-phosphate-guanine B-Chemical
( O
CpG B-Chemical
) O
sites O
( O
of O
400,825 O
CpGs O
, O
3 O

This O
enables O
us O
to O
identify O
the O
mutual O
constitution O
of O
' O
prototypes O
' O
( O
i O

Epigenetic O
alterations O
comprise O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modification I-Chemical
, O
and O
microRNAs B-Gene
dysregulated O
expression O
and O
they O
play O
a O
significant O
role O
in O
the O
differentiation O
and O
proliferation O
properties O
of O
TC B-Disease

1367 O
 O
A O
discussion O
of O
the O
recent O
transition O
to O
a O
new O
geological O
epoch O
, O
the O
Anthropocene B-Disease
, O
opens O
this O
article O

We O
also O
found O
no O
significant O
increase O
in O
deamination O
, O
measured O
by O
C B-Gene
> I-Gene
T I-Gene
transitions O
, O
previously O
considered O
a O
result O
of O
crosslinking O
DNA B-Gene
by O
formalin B-Chemical
fixation O
and O
a O
barrier O
to O
the O
use O
of O
FFPE O
in O
methylation O
studies O

Intervention O
 O
Participants O
received O
either O
iPCIT O
( O
a O
telehealth O
therapeutic O
intervention O
focused O
on O
enhancing O
the O
parent-child O
relationship O
and O
addressing O
behavioral O
challenges O
in O
young O
children O
) O
or O
referrals O
as O
usual O


Genes O
encoding O
epigenetic O
regulators O
are O
often O
mutated O
in O
cancer B-Disease
, O
underscoring O
their O
central O
roles O
in O
carcinogenesis O

3 O
Ã O
10-6 O
) O
compared O
to O
those O
who O
were O
CHIP- B-Gene
/ O
AgeAccelHG- O

For O
the O
majority O
of O
DNA B-Gene
methylation I-Gene
sites O
, O
interindividual O
variation O
in O
whole O
blood O
is O
not O
a O
strong O
predictor O
of O
interindividual O
variation O
in O
the O
brain O
, O
although O
the O
relationship O
with O
cortical O
regions O
is O
stronger O
than O
with O
the O
cerebellum O

"omics" O

In O
doing O
that O
, O
we O
developed O
a O
highly O
accurate O
epigenetic O
clock O
, O
which O
predicts O
the O
age O
of O
multiple O
tissues O
with O
higher O
accuracy O

At O
the O
cellular O
level O
, O
aberrant O
epigenetic O
changes O
associated O
with O
environmental O
exposures O
may O
deregulate O
key O
cellular O
processes O
( O
including O
transcriptional O
control O
, O
DNA B-Gene
repair O
, O
cell O
cycle O
control O
, O
and O
carcinogen O
detoxification O
) O
, O
which O
can O
be O
further O
modulated O
by O
environmental O
stressors O

Finally O
, O
considering O
that O
the O
addition O
of O
different O
parts O
of O
saffron B-Species
flowers I-Species
is O
one O
of O
the O
most O
widespread O
adulterations O
, O
by O
analyzing O
the O
DNA B-Gene
of O
the O
different O
parts O
of O
the O
flower O
( O
styles O
, O
stamens O
and O
tepals O
) O
at O
the O
genetic O
and O
epigenetic O

Basic O
Protocol O
 O
Query O
the O
portal O
Support O
Protocol O
1 O
 O
Batch O
downloading O
Support O
Protocol O
2 O
 O
Using O
the O
cart O
to O
download O
files O
Support O
Protocol O
3 O
 O
Visualize O
data O
Alternate O
Protocol O
 O
Query O
building O
and O
programmatic O
access O

A O
special O
case O
of O
imprinting O
occurs O
during O
X B-Gene
chromosome I-Gene
inactivation O
in O
females O
, O
where O
one O
of O
the O
two O
X B-Gene
chromosomes I-Gene
is O
silenced O
, O
to O
achieve O
dosage O
compensation O
between O
the O
sexes O

are O

His O
model O
of O
genetic O
assimilation O
was O
based O
on O
the O
idea O
of O
differential O
levels O
of O
hereditary O
responsiveness O
to O
environmental O
variations O
, O
giving O
the O
genome B-Gene
a O
leading O
role O
and O
paving O
the O
way O
for O
critics O
of O
his O
conceptions O

220 O
The O
biological O
and O
medical O
importance O
of O
epigenetics O
is O
nowtaken O
for O
granted O
, O
but O
the O
significance O
of O
one O
aspect O
of O
it O
â O
epigenetic O
inheritance O
â O
is O
less O
widely O
recognized O

Compared O
with O
gene B-Gene
regulatory O
elements O
, O
epigenetic O
modifications O
are O
able O
to O
change O
to O
dynamically O
respond O
to O
signals O
from O
physical O
, O
biological O
and O
social O
environments O

As O
a O
case O
study O
, O
we O
discuss O
the O
development O
of O
models O
for O
11 O
sets O
of O
inhibitors O
of O
histone B-Chemical
deacetylases I-Chemical
( O
HDACs B-Gene
) O
, O
which O
are O
one O
of O
the O
major O
epigenetic O
target O
families O
that O
have O
been O
screened O

There O
is O
now O
increasing O
evidence O
, O
both O
in O
animals B-Species
and O
humans B-Species
, O
that O
such O
developmental O
plasticity O
is O
mediated O
in O
part O
by O
epigenetic B-Chemical
mechanisms O

1402 O
We O
present O
TADsplimer O
, O
the O
first O
computational O
tool O
to O
systematically O
detect O
topologically O
associating O
domain O
( O
TAD O
) O
splits O
and O
mergers O
across O
the O
genome O
between O
Hi-C O
samples O

Conclusions O
 O
The O
proposed O
method O
has O
higher O
power O
, O
sufficient O
false O
discovery O
rate O
control O
, O
and O
precise O
mediation O
effect O
estimation O

A O
prominent O
advantage O
of O
this O
step O
is O
that O
it O
would O
enable O
researchers O
to O
harness O
the O
reversibility O
of O
epigenetic O
modifications O
for O
their O
druggability O


85 O
Epigenetics O
has O
the O
potential O
to O
revolutionize O
diagnosis O
and O
treatment O
in O
psychiatry O
, O
especially O
child O
psychiatry O
, O
as O
it O
may O
offer O
the O
opportunity O
for O
early O
detection O
and O
prevention O
, O
as O
well O
as O
development O
of O
new O
treatments O

g O

056 O
), O
p O
= O

Epigenetics O
may O
be O
the O
missing O
molecular O
evidence O
of O
the O
importance O
of O
using O
preventive O
strategies O
at O
the O
policy O
level O
to O
reduce O
the O
incidence O
and O
prevalence O
of O
common O
diseases B-Disease


Using O
generalized O
dissimilarity O
modelling O
and O
multiple O
matrix O
regression O
, O
we O
found O
that O
genome-wide O
epigenetic O
differentiation O
is O
strongly O
correlated O
with O
environmental O
divergence O
, O
even O
after O
controlling O
for O
the O
underlying O
genetic B-Gene
structure I-Gene

High-throughput O
bisulfite O
sequencing O
methods O
, O
such O
as O
reduced-representation O
bisulfite O
sequencing O
( O
RRBS O
) O
or O
whole O
genome O
bisulfite O
sequencing O
( O
WGBS O
) O
, O
provide O
an O
opportunity O
to O
identify O
the O
genomic O
regions O
of O
disordered O
or O
heterogeneous O
DNA O
methylation O
, O
which O
might O
be O
associated O
with O

Increased O
risk O
of O
AD B-Disease
is O
associated O
with O
certain O
polymorphic O
variants O
of O
the O
APOE B-Gene
gene O
, O
as O
well O
as O
some O
other O
, O
less O
affecting O
genes O

This O

When O
the O
scope O
of O
the O
analysis O
is O
to O
detect O
regions O
of O
the O
genome B-Gene
with O
different O
methylation B-Chemical
patterns O
between O
two O
or O
more O
conditions O
, O
e O

Previous O
predictors O
of O
epigenetic O
gestational O
age O
were O
based O
on O
DNA B-Chemical
methylation I-Chemical
data O
from O
the O
Illumina B-Chemical
HumanMethylation I-Chemical
27 I-Chemical
K I-Chemical
or O
450 B-Chemical
K I-Chemical
array O
, O
which O
have O
subsequently O
been O
replaced O
by O
the O
Illumina B-Chemical
MethylationEPIC I-Chemical

nlm O

Here O
, O
we O
review O
recent O
studies O
that O
revealed O
such O
deeply O
conserved O
CREs O
do O
exist O
, O
discuss O
the O
difficulties O
associated O
with O
their O
identification O
and O
describe O
new O
approaches O
that O
will O
facilitate O
this O
search O

For O
quantifying O
miRNAs B-Gene
, O
digital O
back-end O
processing O
circuits O
were O
considered O
toward O
a O
fully O
portable O
platform O
that O
can O
carry O
out O
real-time O
monitoring O
of O
DNA B-Gene
amplification O
reactions O

Epigenetics O
is O
the O
study O
of O
stable O
and O
heritable O
changes O
in O
gene B-Gene
expression I-Gene
that O
occur O
independently O
of O
the O
primary O
DNA B-Gene
sequence I-Gene

Metabolic O
syndrome B-Disease
, O
obesity B-Disease
, O
heart B-Disease
disease I-Disease
, O
and O
hypertension B-Disease
in O
adulthood O
have O
all O
been O
linked O
to O
unwanted O
epigenetic O
programing O
in O
embryos O
and O
fetuses O

We O
will O
discuss O
examples O
focusing O
on O
kidney B-Disease
diseases I-Disease
, O
specifically O
on O
IgA B-Disease
nephropathy I-Disease

We O
cover O
both O
basic O
data O
processing O
and O
analysis O
steps O
, O
as O
well O
as O
more O
advanced O
data O
integration O
methods O

and O
M O

874 O
Epigenetic O
mechanisms O
are O
processes O
that O
affect O
gene B-Gene
expression I-Gene
and O
cellular O
functions O
without O
involving O
changes O
in O
the O
DNA B-Chemical
sequence I-Chemical

Conclusions O
 O
Comparison O
of O
all O
modeling O
approaches O
indicated O
a O
need O
for O
bias O
correction O
in O
marginal O
models O
and O
similar O
power O
for O
each O
method O
, O
with O
quadratic O
inference O
functions O
providing O
a O
minor O
decrement O
in O
power O
compared O
to O
generalized O
estimating O
equations O
and O
linear O
mixed-effects O
models O

Understanding O
the O
interplay O
between O
genetic O
and O
nongenetic O
components O
provides O
deep O
insights O
into O
disease B-Disease
pathogenesis O
and O
promotes O
personalized O
strategies O
for O
people O
healthcare O

Finally O
, O
recently O
developed O
artificial O
transcription-factor O
( O
ATF B-Gene
) O
targeting O
tools O
may O
provide O
flexible O
manipulation O
of O
DNA B-Chemical
methylation I-Chemical
events O
in O
specific O
gene B-Gene
regions O
, O
revealing O
the O
functional O
consequences O
of O
particular O
DNA B-Chemical
methylation I-Chemical
events O


35 O
Epigenetics O
research O
in O
evolutionary O
biology O
encompasses O
a O
variety O
of O
research O
areas O
, O
from O
regulation O
of O
gene B-Gene
expression O
to O
inheritance O
of O
environmentally O
mediated O
phenotypes O

mpg O

255 O
The O
human B-Species
genome O
gives O
rise O
to O
different O
epigenomic O
landscapes O
that O
define O
each O
cell O
type O
and O
can O
be O
deregulated O
in O
disease B-Disease

We O
demonstrate O
the O
novelty O
and O
reliability O
of O
our O
method O
by O
plotting O
the O
potential O
landscapes O
of O
a O
few O
published O
models O
of O
GRN B-Gene

Aim O


As O
epigenetic O
modifications O
are O
reversible O
and O
can O
be O
potentially O
targeted O
by O
pharmacological O
and O
dietary O
interventions O
, O
a O
series O
of O
epigenetic O
drugs O
have O
been O
developed O
, O
including O
DNA B-Chemical
methyltransferase I-Chemical
inhibitors I-Chemical
( O
nucleoside B-Chemical
analogs I-Chemical
, O
small O
molecules O
, O

However O
, O
there O
are O
no O
detailed O
studies O
of O
their O
performances O
under O
different O
missing O
data O
mechanisms O
- O
( O
completely O
) O
at O
random O
or O
not O
- O
and O
different O
representations O
of O
DNA B-Chemical
methylation I-Chemical
levels O
( O
Î² B-Gene
and O
M-value B-Gene
) O

We O
then O
present O
the O
unique O
advantage O
of O
long-read O
sequencing O
in O
detecting O
base O
modifications O
in O
native O
DNA O
and O
highlight O
the O
respective O
strengths O
and O
weaknesses O
of O
PacBio B-Chemical
and O
Nanopore B-Chemical
sequencing O
for O
this O
application O

Further O
, O
AVPC B-Disease
is O
shown O
to O
evolve O
from O
a O
CRPC-Ad B-Disease
phenotype O

As O
new O
methylation O
microarrays O
are O
developed O
and O
older O
models O
discontinued O
, O
existing O
epigenetic O
clocks O
might O
become O
obsolete O

Single-cell O

Following O
PRISMA O
guidelines O
, O
two O
independent O
authors O
conducted O
a O
search O
within O
PubMed O
and O
Web O
of O
Science O
and O
identified O
18 O
journal O
articles O
and O
conference O
abstracts O
addressing O
anorexia B-Disease
nervosa I-Disease
( O
n O
= O
13 O
) O
, O
bulimia B-Disease
nervosa I-Disease
( O
n O
= O
6 O
) O
, O
and O

Conclusions O
 O
In O
patients O
with O
invasive O
urothelial B-Disease
carcinoma I-Disease
, O
we O
found O
differential O
methylation O
in O
patients O
with O
better O
and O
worse O
prognosis O
after O
cystectomy O

Moreover O
, O
evidence O
exists O
, O
at O
least O
from O
animal B-Species
models O
, O
that O
such O
epigenetic O
programming O
should O
be O
viewed O
as O
a O
transgenerational O
phenomenon O

Chirality O
-induced O
spin O
selectivity O
filters O
electrons O
for O
their O
spin O
along O
DNA B-Species
and O
, O
thus O
, O
is O
not O
only O
an O
indicator O
for O
quantum O
coherence O
but O
can O
potentially O
affect O
DNA B-Species
binding O
properties O

1264 O
Bipolar B-Disease
disorder I-Disease
(BD) O
is O
a O
severe O
mental O
disorder O
characterized O
by O
recurrent O
episodes O
of O
mania O
and O
depression O

This O
library O
allows O
easy O
integration O
of O
new O
formats O
and O
rapid O
prototyping O
of O
new O
functionalities O
with O
a O
focus O
on O
the O
analysis O
of O
genomic O
regions O
and O
features O

For O
example O
, O
poor O
prenatal O
diet O
and O
exposure O
to O
maternal O
distress O
during O
pregnancy O
are O
linked O
to O
epigenetic O
changes O
, O
which O
may O
cause O
health O
problems O
in O
the O
offspring O

However O
, O
the O
significance O
of O
the O
close O
connection O
between O
metabolism O
and O
epigenetics O
in O
the O
context O
of O
cancer B-Disease
has O
not O
been O
fully O
deciphered O

ChIP O
followed O
by O
microarray O
or O
next-generation O
sequencing O
enables O
the O
precise O
genomic O
localization O
of O
protein-DNA O
interactions O


Results O
 O
A O
comprehensive O
and O
integrated O
web O
resource O
ViralEpi B-Gene
v1 O

Although O
only O
a O
few O
studies O
have O
assessed O
the O
impacts O
of O
EDCs B-Chemical
on O
mtDNA B-Gene
methylation O
, O
the O
current O
review O
provides O
reasons O
to O
consider O
mtDNA B-Gene
epigenetic O
disruption O
as O
a O
mechanism O
of O
action O
of O
EDCs B-Chemical
and O
reviews O
potential O
limitations O
related O
to O
currently O
available O
evidence O

Further O
, O
although O
studies O
are O
still O
scarce O
, O
various O
environmental O
factors O
( O
e O

Nineteen O
studies O
were O
included O

In O
addition O
, O
human B-Species
studies O
are O
usually O
confounded O
with O
genetic O
and O
environmental O
heterogeneity O
and O
it O
is O
very O
difficult O
to O
derive O
causality O

Based O
on O
this O
, O
this O
article O
summarizes O
the O
most O
relevant O
and O
recent O
studies O
on O
epigenetic O
alterations O
in O
placenta O
, O
adipose O
tissue O
and O
maternal O
blood O
associated O
with O
GDM B-Disease
in O
order O
to O
provide O
the O
reader O
with O
a O
general O
overview O
of O
the O
subject O
and O
indicate O
future O
research O
topics O

Together O
, O
these O
data O
indicate O
that O
targeting O
domain-specific O
BET O
mechanisms O
may O
be O
an O
effective O
and O
safer O
strategy O
to O
reduce O
cocaine-induced B-Disease
neurobehavioral I-Disease
adaptations O

Such O
advances O
have O
enabled O
the O
sequencing O
of O
specimens O
of O
up O
to O
1 O
million O
years O
old O
, O
which O
, O
owing O
to O
their O
extensive O
DNA B-Gene
damage O
and O
contamination O
, O
were O
previously O
not O
amenable O
to O
genetic O
analyses O

In O
this O
work O
, O
Reduced B-Chemical
Representation I-Chemical
Bisulphite I-Chemical
Sequencing I-Chemical
( O
RRBS B-Chemical
) O
profiling O
of O
the O
taurine B-Species
Angus I-Species
( O
A O
) O
and O
indicine B-Species
Nellore I-Species
( O
N O
) O
cattle B-Species
breeds O
was O
applied O
to O
identify O
methylation O
differences O
between O
the O
two O

This O
paper O
reviews O
recent O
researches O
that O
highlight O
the O
links O
between O
CTCF B-Gene
, O
epigenetics O
and O
diseases B-Disease

Statistical O
methods O
such O
as O
mediation O
analysis O
, O
high-dimensional O
instrumental O
variable O
regression O
, O
sparse O
signal O
recovery O
, O
and O
compositional O
data O
regression O
provide O
potential O
frameworks O
for O
integrative O
analysis O
of O
these O
high-dimensional O
genomic O
data O

marabousymposium O

In O
contrast O
to O
genetic O
changes O
, O
which O
are O
difficult O
to O
reverse O
, O
epigenetic O
aberrations O
can O
be O
pharmaceutically O
reversible O

However O
, O
this O
was O
not O
completely O
the O
case O

We O
propose O
a O
regression O
model O
for O
the O
joint O
effect O
of O
SNPs O
, O
methylation O
, O
gene O
expression O
, O
and O
their O
nonlinear O
interactions O
on O
the O
outcome O
and O
develop O
a O
variance O
component O
score O
test O
for O
any O
arbitrary O
set O
of O
regression O
coefficients O

We O
also O
discuss O
the O
implications O
of O
the O
inheritance O
of O
histone B-Chemical
modifications O
and O
small B-Chemical
RNA I-Chemical
for O
embryogenesis O
in O
metazoans B-Species
, O
with O
a O
particular O
focus O
on O
insights O
gained O
from O
genome-wide O
studies O

The O
types O
of O
analyses O
we O
have O
undertaken O
provide O
insights O
into O
the O
relationships O
between O
immune B-Chemical
modulation I-Chemical
and O
cancer B-Disease
etiology O
and O
progression O
, O
offering O
clues O
into O
ways O
of O
therapeutically O
manipulating O
the O
immune B-Chemical
system I-Chemical
to O
promote O
immune B-Chemical
recognition I-Chemical
and O
immunotherapy B-Chemical

36 O
], O
P O
= O
0 O

We O
review O
genetic O
studies O
in O
BPD B-Disease
, O
with O
a O
focus O
on O
limitations O
and O
challenges O
and O
future O
directions O

DNA B-Gene
, O
for O
example O
, O
combines O
remarkable O
longevity O
with O
high O
data O
storage O
densities O
and O
has O
been O
demonstrated O
as O
a O
means O
for O
preserving O
digital O
information O

Epigenetics O
is O
considered O
to O
play O
an O
important O
role O
in O
etiology O
of O
complex O
traits O
and O
diseases O
, O
and O
DNA B-Gene
methylation I-Gene
is O
one O
of O
the O
major O
forms O
of O
epigenetic O
modifications O

New O
technologies O
as O
detection O
of O
circulating O
nucleic O
acids O
including O
microRNAs B-Gene
to O
early O
detect O
breast B-Disease
cancer I-Disease
are O
emerging O

Epigenetic O
modifications O
are O
the O
main O
modulators O
of O
gene O
expression O
or O
protein O
translation O
in O
response O
to O
environmental O
stimuli O
and O
pathophysiological O
conditions O

youtube O

We O
demonstrate O
that O
within O
individual O
BBA-seq O
reads O
the O
DNA B-Gene
methylation O
at O
neighboring O
CpGs O
is O
not O
coherently O
modified O
, O
but O
reveals O
a O
stochastic O
pattern O

Additionally O
, O
an O
update O
on O
the O
detection O
of O
epigenetic O
variation O
in O
plant B-Species
cell I-Species
cultures I-Species
will O
be O
provided O
and O
discussed O
in O
the O
light O
of O
recent O
progress O
in O
the O
plant B-Species
epigenetics I-Species
field O

Consequently O
, O
the O
categorically O
defined O
entities O
of O
ID B-Disease
, O
ADHD B-Disease
and O
ASD B-Disease
are O
increasingly O
viewed O
as O
disorders O
on O
a O
multidimensional O
continuum O
of O
molecular O
and O
cellular O
deficiencies O
in O
neurodevelopment O

There O
is O
, O
however O
, O
no O
consensus O
about O
the O
optimal O
thresholds O
for O
filtering O
bisulfite B-Chemical
sequencing I-Chemical
data O
with O
implications O
for O
the O
reproducibility O
of O
findings O
in O
epigenetic O
epidemiology O

632 O
The O
sequence O
of O
the O
human B-Species
genome O
represents O
our O
genetic O
blueprint O

They O
mainly O
arise O
from O
heterogeneity O
at O
the O
individual O
and O
tissue O
level O
and O
require O
future O
strategies O
in O
order O
to O
reinforce O
the O
biological O
relevance O
of O
epigenetic O
data O
and O
its O
translational O
use O
in O
psychiatry B-Disease

The O
Environmental O
Risk O
(E-Risk) O
Longitudinal O
Twin O
Study O
cohort O
of O
2,232 O
children O
( O
1,116 O
twin O
pairs O
) O
was O
assessed O
for O
age-12 O
psychotic B-Disease
symptoms I-Disease
and O
24 O
monozygotic B-Species
twin I-Species
pairs I-Species
discordant O
for O
symptoms O
were O
identified O
for O
methylomic O
comparison O

The O
identification O
of O
spatially O
and O
temporally O
tuned O
epigenetic O
modification O
of O
genetic O
loci O
during O
memory O
storage O
has O
revealed O
the O
remarkably O
input-responsive O
, O
target-specific O
, O
and O
long-term O
nature O
of O
epigenetic O
regulation O
, O
but O
the O
underlying O
mechanisms O
have O
remained O
elusive O


The O
present O
review O
is O
an O
extensive O
search O
in O
public O
databases O
, O
such O
as O
Google O
Scholar O
, O
Scopus O
, O
the O
Web O
of O
Science O
, O
and O
PubMed O
, O
to O
collect O
all O
the O
literature O
about O
the O
neurobiological O
roles O
of O
cannabis B-Chemical
extract I-Chemical
, O
cannabidiol B-Chemical
, O

It O
indeed O
provides O
new O
opportunities O
for O
diagnostic O
tools O
and O
innovative O
therapeutic O
targets O
in O
order O
to O
improve O
the O
prognosis O
of O
patients O
affected O
by O
these O
rare O
tumors O
, O
in O
particular O
in O
the O
context O
of O
metastatic O
diseases B-Disease
associated O
with O
SDHB B-Gene
mutations O


We O
also O
identified O
a O
set O
of O
18 O
genes O
epigenetically O
active O
and O
consistently O
expressed O
in O
the O
thyroid B-Disease
that O
are O
likely O
highly O
relevant O
to O
thyroid B-Disease
function O

001 O
, O
were O
also O
associated O
with O
lower O
birthweight O
, O
independent O
of O
gestational O
length O

, O
disease B-Disease
susceptibility I-Disease
) O

Only O
2,749 O
age-related O
differentially O
methylated O
CpG O
sites O
were O
seen O
within O
PNS B-Disease
females O

1328 O
 O
Despite O
the O
development O
of O
novel O
therapeutic O
approaches O
and O
improved O
clinical O
management O
, O
survival O
from O
metastatic B-Disease
disease I-Disease
remains O
poor O

327 O
The O
identification O
of O
potential O
epigenetic O
targets O
for O
a O
known O
bioactive O
compound O
is O
essential O
and O
promising O
as O
more O
and O
more O
epigenetic O
drugs O
are O
used O
in O
cancer B-Disease
clinical I-Disease
treatment I-Disease
and O
the O
availability O
of O
chemogenomic O
data O
related O
to O
epigenetics O
increases O

The O
recent O
characterization O
of O
epigenetic O
modifications O
of O
DNA B-Chemical
and O
RNA B-Chemical
using O
chemical O
labelling O
strategies O
has O
promoted O
the O
discovery O
of O
these O
modifications O
, O
and O
the O
newly O
developed O
single-base O
or O
single-cell O
resolution O
mapping O
strategies O
have O
enabled O
large-scale O
epigenetic O
studies O
in O
eukaryotes B-Species

Epigenetic O
regulation O
lies O
at O
the O
heart O
of O
these O
interactions O
and O
mediates O
the O
lasting O
effects O
of O
the O
environment O
on O
gene B-Gene
regulation O

Also O
, O
in O
response O
to O
environmental O
cues O
, O
cells O
can O
induce O
epigenetic O
transcriptional O
memory O
to O
poise O
inducible O
genes O
for O
faster O
induction O
in O
the O
future O

Social O
scientists O
' O
understanding O
of O
epigenetics O
, O
thus O
, O
appears O
in O
part O
to O
be O
socially O
constructed O
, O
i O

1491 O
The O
complexity O
of O
the O
human B-Species
brain O
emerges O
from O
a O
long O
and O
finely O
tuned O
developmental O
process O
orchestrated O
by O
the O
crosstalk O
between O
genome B-Gene
and O
environment O

388 O
Age O
is O
a O
fundamental O
aspect O
of O
animal O
ecology O
, O
but O
is O
difficult O
to O
determine O
in O
many O
species B-Species

The O
most O
common O
epigenetic O
alterations O
are O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modification I-Chemical

e O

597 O
Cancer B-Disease
epigenomic-environment O
is O
a O
core O
center O
of O
a O
tumor's O
genetic O
and O
epigenetic O
configuration O

Significant O
differential O
methylation O
at O
a O
subset O
of O
imprinted O
loci O
was O
identified O
in O
both O
genders O
, O
and O
non-CpG B-Chemical
methylation O
occurred O
only O
in O
male O
gonocytes B-Species

Active O
domains O
behave O
as O
pure O
polymer O
coils O
, O
while O
inactive O
and O
repressed O
domains O
both O
lie O
at O
the O
coil-globule O
crossover O

We O
demonstrate O
EpiExplorer O
's O
utility O
by O
describing O
a O
hypothesis-generating O
analysis O
of O
DNA B-Chemical
hydroxymethylation I-Chemical
in O
relation O
to O
public O
reference O
maps O
of O
the O
human B-Species
epigenome O

1205 O
During O
the O
past O
decades O
, O
life O
expectancy O
of O
subjects O
with O
Down B-Disease
syndrome I-Disease
( O
DS B-Disease
) O
has O
greatly O
improved O
, O
but O
age-specific O
mortality O
rates O
are O
still O
important O
and O
DS B-Disease
subjects O
are O
characterized O
by O
an O
acceleration O
of O
the O
ageing O
process O
, O
which O
affects O
particularly O

Recent O
work O
has O
demonstrated O
that O
the O
epigenome O
is O
already O
rejuvenated O
by O
the O
maturation O
phase O
of O
somatic O
cell O
reprogramming O
, O
which O
suggests O
full O
reprogramming O
is O
not O
required O
to O
reverse O
ageing O
of O
somatic O
cells O

We O
investigate O
the O
impact O
of O
exposure O
misclassification O
in O
such O
investigations O

We O
propose O
the O
role O
of O
epigenetic O
factors O
and O
non-coding O
RNAs B-Gene
(ncRNAs) I-Gene
as O
potential O
biomarkers O
and O
drugs O
in O
DCM B-Disease
diagnosis O
and O
treatment O
, O
providing O
a O
new O
perspective O
and O
understanding O
of O
epigenomics O
in O
DCM B-Disease

Current O
data O
suggest O
the O
importance O
of O
genetics O
and O
epigenetics O
in O
the O
appearance O
of O
PCOS B-Disease

Nevertheless O
, O
findings O
from O
studies O
conducted O
so O
far O
have O
only O
explained O
a O
small O
proportion O
of O
the O
observed O
variability O
, O
suggesting O
that O
factors O
other O
than O
DNA B-Gene
variants I-Gene
could O
be O
involved O

11 O
 O
Infertility B-Disease
is O
a O
complex O
pathophysiological O
condition O

Epigenetic O
mechanisms O
provide O
new O
directions O
and O
therapeutic O
strategies O
for O
the O
research O
and O
treatment O
of O
peripheral B-Disease
T-cell I-Disease
lymphoma I-Disease

An O
enhanced O
understanding O
of O
posttranscriptional O
mechanisms O
would O
help O
to O
clarify O
some O
remaining O
enigmatic O
issues O
in O
primary O
and O
secondary O
hemostasis B-Disease
, O
which O
cannot O
be O
thoughtfully O
explained O
by O
genetics B-Gene
or O
biochemistry O
alone O

The O
role O
of O
epigenetics O
in O
these O
and O
other O
CVDs B-Disease
is O
currently O
under O
intense O
scrutiny O
, O
and O
we O
can O
expect O
important O
insights O
to O
emerge O
, O
including O
novel O
biomarkers O
and O
new O
approaches O
to O
enable O
precision O
medicine O

He O
served O
as O
the O
Principal O
Investigator O
for O
all O
DNA B-Gene
methylation I-Gene
data O
production O
for O
the O
Cancer B-Disease
Genome I-Disease
Atlas I-Disease
( O
TCGA B-Disease
) O
and O
led O
many O
TCGA B-Disease
analysis O
efforts O

On O
the O
basis O
of O
bacterial O
artificial O
chromosome O
array-based O
methylated O
CpG O
island O
amplification O
data O
, O
indicators O
for O
carcinogenetic O
risk O
estimation O
have O
been O
established O
using O
liver O
tissue O
specimens O
from O
patients O
with O
hepatitis B-Disease
virus I-Disease
infection I-Disease
, O
chronic B-Disease
hepatitis I-Disease
and O
liver B-Disease

An O
examination O
of O
epigenetic O
pathways O
, O
operating O
at O
the O
nexus O
of O
genomics O
and O
human B-Species
behaviour O
, O
sheds O
new O
light O
on O
shared O
parental O
responsibility O
for O
the O
intergenerational O
origins O
of O
obesity B-Disease

MiRNAs O
also O
play O
a O
role O
in O
the O
pathogenesis O
of O
these O
diseases O
and O
several O
known O
miRNAs O
that O
are O
involved O
in O
these O
diseases O
have O
also O
been O
shown O
to O
play O
a O
role O
in O
CD8+ B-Gene
regulation O

Epigenetic O
marks O
, O
which O
are O
labile O
chemical B-Chemical
marks O
with O
diverse O
functions O
, O
form O
a O
layer O
of O
biological O
information O
that O
sits O
at O
the O
interface O
of O
genetics O
and O
the O
environment O

g O

Thus O
, O
modulating O
epigenetics O
in O
combination O
with O
immunotherapy O
might O
be O
a O
promising O
therapeutic O
option O
to O
improve O
the O
success O
of O
this O
therapy O

Furthermore O
, O
we O
suggest O
that O
both O
typical O
and O
novel O
antidepressant B-Chemical
treatments O
may O
exert O
positive O
influence O
through O
similar O
, O
activity-dependent O
pathways O

Additionally O
, O
we O
found O
three O
regions O
( O
associated O
with O
the O
genes O
SLC9A1 B-Gene
, O
SLC1A5 B-Gene
, O
and O
TNRC6C B-Gene
) O
whose O
methylation O
associates O
with O
CVD B-Disease
risk O

8 O
( O
3 O
) O

Behavioural O
genomics O
is O
beginning O
to O
demonstrate O
links O
to O
biological O
mechanisms O
through O
regulation O
of O
gene B-Gene
expression I-Gene
, O
which O
directs O
the O
proteome O
and O
influences O
the O
personal O
phenotype O

Methylation-based O
sample O
classification O
was O
performed O
using O
the O
recursively O
partitioned O
mixture O
model O
( O
RPMM B-Gene
) O
and O
was O
tested O
against O
sample O
case-control O
status O

A O
growing O
body O
of O
evidence O
implicates O
epigenetic O
aberrations O
in O
this O
intractable O
disease O
, O
including O
specific O
modifications O
affecting O
the O
three O
main O
cell O
types O
involved O
in O
SSc B-Disease
pathogenesis O
 O
immune O
cells O
, O
endothelial O
cells O
and O
fibroblasts O

We O
explore O
the O
predictions O
and O
hypotheses O
that O
arise O
from O
this O
definition O

Genetic O
and O
environmental O
factors O
have O
been O
shown O
to O
trigger O
SLE B-Disease

We O
discuss O
prospects O
for O
clinical O
translation O
of O
genetic O
findings O
and O
future O
directions O
for O
research O

Conclusion O
 O
The O
use O
of O
our O
tool O
in O
a O
clinical O
setting O
could O
better O
identify O
patients O
at O
high O
risk O
for O
a O
heart B-Disease
attack I-Disease

Subsequently O
, O
we O
created O
an O
extensive O
dataset O
of O
over O
1300 O
study O
findings O
in O
which O
epigenetic O
clocks O
were O
utilized O
in O
blood O
tissue O
of O
human B-Species
subjects O
to O
assess O
the O
relationship O
between O
these O
clocks O
and O
numeral O
environmental O
exposures O
and O
human B-Species
traits O

We O
anticipate O
that O
the O
development O
of O
CRISPR B-Gene
based O
technology O
will O
continue O
to O
explore O
novel O
methods O

In O
this O
paper O
, O
we O
will O
summarize O
the O
major O
concepts O
of O
cancer B-Disease
epigenetics O
, O
placing O
emphasis O
on O
history O

The O
goal O
of O
the O
Epigenomics O
of O
Plants B-Species
International O
Consortium O
is O
to O
crack O
this O
second O
code O
, O
and O
ultimately O
master O
its O
control O
, O
to O
help O
catalyze O
a O
new O
green O
revolution O

Our O
hope O
is O
that O
this O
review O
serves O
as O
a O
primer O
for O
anthropologists O
and O
human B-Species
biologists O
interested O
in O
incorporating O
epigenetic B-Gene
data O
into O
their O
research O
programs O

This O
study O
presents O
the O
first O
genome-wide O
mapping O
of O
epigenetic O
differences O
in O
hematopoietic O
cells O
across O
the O
late O
gestational O
period O

Conclusion O
 O
Childhood B-Disease
hunger I-Disease
is O
a O
risk O
factor O
for O
depressive B-Disease
symptoms I-Disease
and O
CVD B-Disease
at O
older O
age O

In O
this O
review O
, O
we O
perform O
a O
critical O
analysis O
of O
methods O
with O
the O
explicit O
aim O
of O
harmonizing O
data O
, O
as O
opposed O
to O
case-specific O
integration O

The O
UPM B-Gene
more O
faithfully O
models O
epigenetic O
aging O
than O
the O
time O
linear O
approach O
while O
methylated O
sites O
accelerate O
and O
decelerate O
jointly O

A O
total O
of O
1848 O
publications O
related O
to O
epigenetics B-Gene
and O
atherosclerosis B-Disease
were O
found O

, O
the O
abundance O
of O
CpG O
sites O
) O
in O
three O
microbial O
surveillance O
genes O
 O
Toll-like B-Gene
receptors I-Gene
( O
TLRs O
) O
1B B-Gene
( O
TLR1B B-Gene
) O
, O
2A B-Gene
( O
TLR2A B-Gene
) O
, O
and O
4 B-Gene
( O
TLR4 B-Gene
) O
varied O
between O
native O
and O
introduced O

MSREqPCR O
provides O
high O
multiplexing O
capabilities O
also O
when O
starting O
with O
limited O
amount O
of O
DNA-like B-Chemical
cfDNA B-Chemical
to O
validate O
many O
targets O
in O
a O
time- O
and O
cost-effective O
manner O

DNA O
methylation O
at O
birth O
has O
proven O
to O
be O
an O
accurate O
predictor O
of O
gestational O
age O

To O
reduce O
the O
complexity O
, O
we O
developed O
a O
package O
, O
called O
Snapshot O
, O
for O
clustering O
and O
visualizing O
candidate O
cis-regulatory O
elements O
( O
cCREs O
) O
based O
on O
their O
epigenetic O
signals O
during O
cell O
differentiation O

ox O

Here O
, O
we O
developed O
a O
simple O
method O
to O
determine O
allelic O
hydroxymethylation B-Chemical
status O
and O
identified O
novel O
sequence- O
and O
parent-of-origin-dependent O
allele-specific O
hydroxymethylation B-Chemical
sites O

410Background O
Genetic O
and O
epigenetic O
dysregulation O
of O
is O
widely O
linked O
up O
with O
abnormal O
proliferation O
and/or O
epithelial-to-mesenchymal O
transition O
, O
in O
different O

This O
review O
aimed O
to O
provide O
an O
overview O
of O
the O
most O
recent O
findings O
of O
key O
epitranscriptomic O
modifications O
in O
both O
coding O
and O
nonâcoding O
RNAs O

Epigenetic O
dysregulation O
was O
also O
observed O
in O
several O
tumor B-Disease
suppressor I-Disease
genes O
and O
miRNAs O
in O
lung B-Disease
cancer I-Disease
patients O
, O
suggesting O
the O
important O
role O
of O
these O
changes O
in O
cancer B-Disease
initiation O
and O
progression O

Besides O
the O
global O
hypomethylation O
on O
lupus B-Disease
T B-Gene
and O
B B-Gene
cells O
, O
the O
gene B-Gene
specific O
and O
site-specific O
methylation O
has O
been O
identified O
and O
documented O
to O
be O
responsible O
for O
SLE B-Disease

Peaks O
predicted O
to O
be O
co-localized O
by O
only O
a O
very O
small O
number O
of O
tools O
, O
discovered O
to O
be O
only O
marginally O
overlapping O
, O
or O
found O
to O
represent O
significant O
outliers O
to O
the O
approximation O
model O
are O
removed O
from O
the O
results O
, O
providing O
concise O
and O
high O
quality O
epigenetic O
datasets O

Epigenetics O
is O
the O
study O
of O
how O
changes O
in O
the O
environment O
and O
behavior O
can O
have O
an O
impact O
on O
gene B-Gene
function I-Gene


1454 O
Several O
studies O
of O
the O
developmental O
origins O
of O
health O
and O
disease B-Disease
and O
metabolic O
programming O
have O
identified O
links O
between O
early O
nutrition O
, O
epigenetic O
processes O
and O
long-term O
illness O

omics O

In O
conclusion O
, O
there O
are O
major O
quality O
differences O
between O
kits O
for O
- O
based O
capturing O
of O
, O
with O
the O
kit O
performing O
best O
under O
the O
used O
settings O

Lifestyle O
modifications O
including O
dietary O
interventions O
hold O
an O
immense O
promise O
to O
manage O
and O
prevent O
these O
diseases B-Disease

All O
the O
indications O
are O
that O
future O
research O
will O
continue O
to O
reveal O
new O
epigenetic O
targets O
and O
mechanisms O
that O
will O
advance O
the O
prospects O
for O
selective O
epigenetic O
therapy O
for O
IBD B-Disease
and O
other O
complex O
diseases O

We O
performed O
an O
epigenome-wide O
association O
study O
( O
EWAS O
) O
on O
CVD B-Disease
in O
a O
longitudinal O
sample O
of O
Swedish B-Species
twins O
( O
535 O
individuals O
) O

Results O
 O
With O
regioneR O
we O
provided O
an O
R O
package O
allowing O
to O
assess O
the O
statistical O
significance O
of O
pairwise O
associations O
between O
genomic O
region O
sets O
using O
permutation O
tests O


Understanding O
the O
genetic O
basis O
and O
therefore O
physiologic O
key O
mechanisms O
of O
sexual O
function O
and O
dysfunction O
has O
the O
potential O
for O
improved O
treatments O
( O
i O

The O
purpose O
of O
this O
article O
is O
to O
add O
to O
the O
conversation O
about O
avoiding O
this O
unintended O
outcome O
by O
( O
1 O
) O
discussing O
the O
importance O
of O
cognitive O
processing O
and O
issue O
frames O
, O
( O
2 O
) O
describing O
framing O
challenges O
associated O
with O
communicating O
about O
developmental O
origins O
of O
health O
and O

The O
immune O
cells O
involved O
in O
anti-tumor B-Disease
responses O
and O
the O
immunogenicity O
of O
tumors O
may O
also O
be O
affected O
by O
epigenomic O
changes O

There O
is O
currently O
no O
consensus O
concerning O
the O
pathogenesis O
and O
etiology O
of O
microtia O
; O
genetic O
and O
environmental O
factors O
may O
play O
a O
role O

We O
analysed O
the O
relationship O
between O
genetic O
background O
and O
methylation O
patterns O
in O
natural O
hybrids O
of O
two O
genetically O
divergent O
fish O
species O
with O
different O
mating O
systems O
, O
Kryptolebias B-Species
hermaphroditus I-Species
( O
self-fertilizing O
) O
and O
K O

1261 O
Cancer B-Disease
was O
initially O
considered O
to O
be O
an O
exclusively O
genetic O
disease O
, O
but O
an O
interplay O
of O
dysregulated O
genetic O
and O
epigenetic O
mechanisms O
is O
now O
known O
to O
contribute O
to O
the O
cancer B-Disease
phenotype O

173 O
Purpose O
of O
review O
 O
To O
summarize O
recently O
developed O
next O
generation O
sequencing-based O
methods O
to O
study O
epigenomics O
and O
epitranscriptomics O

Genes O
involved O
in O
estrogen B-Chemical
metabolism O
were O
also O
hypermethylated O
while O
genes O
involved O
in O
the O
EGFR B-Gene
pathway O
were O
found O
to O
be O
hypomethylated O

The O
purpose O
of O
this O
review O
is O
to O
outline O
the O
contribution O
of O
epigenetic O
mechanisms O
to O
genomic O
function O
, O
particularly O
in O
the O
development O
of O
complex O
behavioral O
phenotypes O
, O
focusing O
on O
the O
sensitive O
periods O

820 O
Chromatin B-Chemical
immunoprecipitation O
, O
DNase B-Chemical
I I-Chemical
hypersensitivity O
and O
transposase-accessibility O
assays O
combined O
with O
high-throughput O
sequencing O
enable O
the O
genome-wide O
study O
of O
chromatin B-Chemical
dynamics O
, O
transcription O
factor O
binding O
and O
gene O
regulation O

146 O
as O
a O
multivalent O
eukaryotic O
transcription O
factor O
plays O
a O
diverse O
range O
of O
roles O
in O
regulation O
of O
various O
genes O
through O
the O
binding O
of O
its O
11 O
fingers O
to O
consensus O
sites O
or O
various O
proteins O

We O
are O
beginning O
to O
understand O
how O
genetic O
variation O
and O
epigenetic O
events O
alter O
requirements O
for O
and O
responses O
to O
foods O
in O
our O
diet O
( O
the O
field O
of O
nutrigenetics/nutrigenomics O
and O
epigenetics O
) O

Found O
in O
0 O

Analysis O
of O
methylation O
status O
of O
certain O
genomic O
sites O
can O
predict O
an O
individual O
's O
age O
at O
death O
and O
reconstruct O
some O
phenotypic O
features O
, O
as O
it O
was O
done O
for O
the O
Denisovan B-Species
genome O
, O
and O
even O
to O
elucidate O
unfavorable O
environmental O
factors O
that O
had O
affected O
this O
archaic O
individual O

Charge O
transfer O
via O
quantum O
tunneling O
mediated O
by O
overlapping O
orbitals O
results O
in O
charge O
delocalization O
along O
several O
neighboring O
bases O
, O
which O
can O
even O
be O
extended O
by O
classical O
( O
non-quantum O
) O
electron O
hopping O

The O
purpose O
of O
this O
study O
was O
to O
examine O
whether O
epigenetic O
age O
during O
pregnancy O
was O
associated O
with O
gestational O
length O
and O
birthweight O

We O
describe O
an O
experimental O
design O
to O
meet O
these O
requirements O
, O
the O
experimental O
results O
obtained O
, O
and O
the O
operating O
parameters O
established O

A O
move O
to O
recognize O
human B-Species
existence O
everywhere O
as O
contextualized O
in O
environments O
that O
impinge O
on O
body O
functioning O
throughout O
life O
opens O
up O
a O
discussion O
of O
the O
embodiment O
of O
trauma B-Disease
followed O
by O
six O
illustrative O
examples O
from O
the O
newly O
recognized O
field O
of O
environmental B-Chemical
epigenetics O

Environmental O
factors O
, O
somatic O
mutations O
and O
ageing O
contribute O
to O
epigenetic O
changes O
that O
may O
constitute O
early O
hallmarks O
or O
causal O
factors O
of O
disease B-Disease

Thus O
, O
understanding O
the O
molecular O
mechanisms O
operated O
by O
methamphetamine B-Chemical
represents O
a O
wide O
window O
to O
understand O
both O
the O
addicted O
brain O
and O
a O
variety O
of O
neuropsychiatric B-Disease
disorders I-Disease

1445 O
inhibitors O
have O
become O
the O
mainstay O
for O
treatment O
of O
certain O

The O
technique O
does O
not O
require O
special O
equipment O
and O
is O
independent O
of O
prior O
knowledge O
about O
the O
genome B-Gene

The O
epialleleR O
is O
freely O
available O
at O
https//github O
. O
com O
/ O
epiallele O
/ O
epialleleR O
. O

744 O
The O
novel O
genome-wide O
assays O
of O
epigenetic O
marks O
have O
resulted O
in O
a O
greater O
understanding O
of O
how O
genetics O
and O
the O
environment O
interact O
in O
the O
development O
and O
inheritance O
of O
diabetes B-Disease

We O
will O
further O
evaluate O
how O
recent O
technological O
advances O
may O
enable O
us O
to O
unravel O
the O
molecular O
mechanisms O
underlying O
these O
phenomena O
, O
which O
will O
be O
crucial O
for O
understanding O
heritability O
in O
health O
and O
disease B-Disease

At O
present O
, O
however O
, O
it O
is O
unclear O
how O
best O
to O
adjust O
for O
cell-type O
heterogeneity O
, O
as O
this O
may O
also O
largely O
depend O
on O
the O
type O
of O
tissue O
and O
phenotype O
being O
considered O

520 O
Aydan O
Bulut-Karslioglu O
is O
a O
Group O
Leader O
at O
the O
Max O
Planck O
Institute O
for O
Molecular O
Genetics O
, O
Germany O
, O
where O
her O
research O
focuses O
on O
the O
epigenetic O
and O
metabolic O
mechanisms O
regulating O
embryonic O
development O

The O
potential O
roles O
of O
non-coding O
RNAs O
(ncRNAs) O
such O
as O
microRNAs B-Gene
(miRNAs) I-Gene
in O
moderating O
or O
mediating O
the O
impact O
of O
severe B-Disease
stress I-Disease
and I-Disease
trauma I-Disease
are O
increasingly O
gaining O
attention O

Here O
, O
we O
want O
to O
provide O
general O
guidelines O
on O
how O
to O
design O
studies O
on O
epigenetic O
inheritance O
in O
plants B-Species
and O
to O
consider O
critical O
points O
during O
data O
analysis O
and O
interpretation O

Users O
can O
download O
it O
from O
https//github O

Here O
we O
suggest O
that O
exceptional O
90-year O
old O
siblings O
have O
adopted O
a O
range O
of O
behaviours O
and O
life-styles O
which O
have O
contributed O
to O
their O
ageing-well-phenotype O
and O
which O
link O
with O
important O
public O
health O
messages O

Proper O
epigenetic O
regulation O
is O
essential O
for O
normal O
differentiation O
in O
embryogenesis O
and O
development O

We O
tested O
the O
hypothesis O
that O
5hmC B-Chemical
changes O
with O
age O
, O
but O
in O
a O
direction O
opposite O
to O
5-methylcytosine B-Chemical
( O
5mC B-Chemical
) O
, O
potentially O
playing O
a O
distinct O
role O
in O
aging O

In O
the O
long O
term O
, O
adversity O
during O
childhood O
, O
by O
inducing O
these O
epigenetic O
changes O
, O
predisposes O
some O
individuals O
in O
developing O
mental B-Disease
health I-Disease
problems I-Disease
in O
adulthood O

This O
analysis O
demonstrated O
an O
unequal O
distribution O
of O
differentially O
methylated O
regions O
across O
the O
human B-Species
genome O

This O
model O
also O
predicted O
the O
altered O
CG O
methylation O
pattern O
of O
mutant O
oocytes O
having O
perturbed O
histone O
modification O
, O
was O
applicable O
to O
cross-species O
prediction O
of O
the O
CG O
methylation O
pattern O
of O
human B-Species
oocytes O
, O
and O
identified O
the O
epigenetic O
crosstalk O
potentially O
important O
in O
other O
cell O
types O

DNA O
methylation B-Chemical
and O
demethylation B-Chemical
is O
a O
key O
mechanism O
of O
genome B-Gene
programming O
and O
reprogramming O


These O
effects O
occur O
via O
chemical O
structural O
interactions O
with O
epigenetic O
enzymes O
, O
through O
interactions O
with O
DNA B-Gene
repair I-Gene
mechanisms O

Development O
of O
epigenome O
editing O
tools O
enables O
a O
functional O
dissection O
of O
the O
link O
between O
altered O
epigenetic O
changes O
and O
disease B-Disease
outcomes I-Disease

These O
recommendations O
may O
improve O
the O
quality O
, O
comparability O
, O
and O
clinical O
relevance O
of O
such O
studies O

This O
interplay O
opens O
an O
exciting O
possibility O
to O
manipulate O
the O
epigenetic O
pattern O
and O
to O
develop O
novel O
AMD B-Disease
therapies O
by O
physical O
, O
pharmacological O
or O
genetic O
interventions O

We O
hypothesized O
that O
CNFs B-Disease
and O
PNFs B-Disease
are O
epigenetically O
distinct O
tumor O
types O
that O
exhibit O
differential O
signaling O
due O
to O
genome-wide O
and O
site-specific O
methylation O
events O

Application O
of O
this O
model O
to O
DNA B-Gene
methylation I-Gene
data O
measured O
across O
broad O
age O
ranges O
, O
from O
before O
birth O
to O
old O
age O
, O
and O
from O
two O
tissue O
types O
, O
suggests O
a O
universal O
logarithmic O
trend O
characterizes O
epigenetic O
ageing O
across O
entire O
lifespans O

In O
addition O
to O
influencing O
how O
doctors O
treat O
diseases O
, O
discoveries O
about O
behavioral O
epigenetics O
are O
likely O
to O
alter O
how O
biologists O
think O
about O
evolution O
, O
because O
some O
epigenetic O
effects O
of O
experience O
appear O
to O
be O
transmissible O
from O
generation O
to O
generation O

In O
contrast O
, O
the O
other O
~60% O
of O
CHIP O
carriers O
who O
were O
AgeAccelHG- O
were O
not O
at O
increased O
risk O
of O
these O
outcomes O

The O
dynamic O
interplay O
between O
the O
life O
, O
social O
, O
and O
behavioral O
sciences O
often O
remains O
underappreciated O
and O
underutilized O
in O
addressing O
complex O
diseases B-Disease
and I-Disease
disorders O
and O
in O
developing O
effective O
remediation O
strategies O

Both O
simulation O
and O
real-data O
analysis O
show O
the O
outperformance O
of O
adaptive O
SMCCA O
in O
terms O
of O
feature O
selection O
over O
conventional O
SMCCA O
and O
SMCCA O
with O
fixed O
weights O

Among O
the O
most O
promising O
of O
such O
biomarkers O
is O
DNA B-Chemical
methylation-based I-Chemical
biological O
age O

Further O
computational O
analyses O
identified O
a O
distinct O
set O
of O
transcription O
factor O
motifs O
enriched O
at O
distal O
regulatory O
regions O
that O
are O
epigenetically O
remodelled O
by O
ERK B-Gene
signalling O

According O
to O
the O
World O
Health O
Organization O
, O
asthma B-Disease
affects O
>7 O

It O
is O
in O
this O
intersection O
where O
the O
science O
of O
epigenetics B-Gene
plays O
a O
crucial O
role O

This O
epigenetic O
articulation O
makes O
ACEs B-Gene
attractive O
for O
new O
actors O
in O
science O
and O
society O


Here O
, O
we O
investigate O
the O
impact O
of O
the O
context O
of O
genetic O
and O
epigenetic O
alterations O
and O
tumor B-Disease
type I-Disease
on O
the O
classification O
and O
report O
on O
technical O
aspects O
, O
such O
as O
robustness O
of O
cutoff O
definition O
and O
preprocessing O
of O
the O
data O

However O
, O
recent O
data O
show O
that O
, O
in O
patients O
with O
BWS B-Disease
or O
RSS B-Disease
, O
including O
those O
conceived O
with O
the O
help O
of O
ART B-Chemical
the O
DNA B-Gene
methylation I-Gene
defect O
involves O
imprinted O
loci O
other O
than O
11p15 B-Gene

Although O
epigenome-wide O
association O
study O
attracts O
increasing O
attention O
, O
currently O
, O
it O
has O
a O
fundamental O
problem O
in O
that O
each O
cell O
within O
one O
individual O
has O
a O
unique O
, O
time-varying O
epigenome O

113 O
Cancer B-Disease
disparities O
in O
incidence O
and O
death O
rates O
exist O
among O
various O
racial O
and O
ethnic O
groups O

Several O
methods O
have O
been O
proposed O
to O
deal O
with O
mediation O
in O
high-dimensional O
settings O
, O
including O
methods O
that O
incorporate O
dimensionality O
reduction O
techniques O
to O
the O
mediation O
algorithm O

We O
start O
by O
presenting O
the O
well-elucidated O
mechanisms O
of O
plant B-Species
gbM B-Gene
establishment O
and O
maintenance O

In O
this O
review O
, O
we O
discuss O
what O
is O
currently O
understood O
in O
the O
field O
and O
suggest O
areas O
for O
future O
research O
which O
may O
lead O
to O
the O
development O
of O
novel O
preventative O
or O
therapeutic O
interventions O
for O
NAFLD B-Disease

1463 O
Mitochondrial B-Chemical
dynamics O
play O
vital O
roles O
in O
the O
tumorigenicity B-Disease
and O
malignancy O
of O
various O
types O
of O
cancers O
by O
promoting O
the O
tumor-initiating O
potential O
of O
cancer O
cells O
, O
suggesting O
that O
targeting O
crucial O
factors O
that O
drive O
mitochondrial B-Chemical
dynamics O
may O
lead O
to O

io O

There O
was O
a O
single O
significant O
( O
P O
= O
1 O

For O
combinations O
of O
any O
two O
of O
the O
methods O
, O
we O
derived O
the O
pool-adjacent-violators O
algorithm O
( O
PAVA O
) O
exact O
constrained O
MLE O
in O
analytical O
form O

Cancer B-Disease
and O
pulmonary B-Disease
arterial I-Disease
hypertension I-Disease
have O
been O
shown O
to O
undergo O
metabolic O
reprogramming O
, O
which O
is O
accompanied O
by O
increased O
lactate B-Chemical
production O

In O
this O
way O
, O
they O
can O
contribute O
to O
heritable O
phenotypic O
variation O
in O
natural O
and O
experimental O
populations O
independent O
of O
DNA B-Chemical
sequence O

As O
expected O
, O
sequencing O
read O
depth O
, O
group O
size O
, O
and O
the O
magnitude O
of O
DNA B-Chemical
methylation I-Chemical
difference O
between O
groups O
all O
impacted O
upon O
statistical O
power O

These O
studies O
highlight O
that O
in O
time O
loosening O
of O
epigenetic O
control O
increase O
the O
propensity O
of O
joint O
tissues O
to O
engage O
an O
osteoarthritis B-Disease
disease I-Disease
phenotype I-Disease

Methods O
 O
Interacting O
partners O
of O
the O
AD B-Disease
epigenetic O
proteins O
were O
identified O
from O
the O
extensive O
human B-Species
interactome O
to O
construct O
Epigenetic O
Protein-Protein O
Interaction O
Network O
( O
EP-PPIN O
) O

All O
EpiExplorer B-Gene
analyses O
are O
performed O
dynamically O
within O
seconds O
, O
using O
an O
efficient O
and O
versatile O
text O
indexing O
scheme O
that O
we O
introduce O
to O
bioinformatics O

In O
this O
review O
, O
our O
group O
assessed O
the O
published O
evidence O
on O
the O
tumorigenic O
role O
of O
epigenomics O
in O
Hurthle B-Disease
cell I-Disease
neoplasms I-Disease
( O
HCN B-Disease
) O
, O
highlighting O
the O
yet O
limited O
, O
heteregeneous O
and O
non-validated O
data O
preventing O
its O
current O
use O
in O
clinical O
practice O
, O

EGFR B-Gene
expression O
was O
confirmed O
to O
be O
elevated O
in O
six O
bladder B-Disease
cancer I-Disease
cell O
lines O

Hyper- O
and O
hypo-methylation O
events O
of O
specific O
regulatory O
elements O
( O
such O
as O
promoters O
and O
enhancers O
) O
are O
sometimes O
thought O
to O
be O
correlated O
with O
expression O
of O
nearby O
genes O

Recent O
advances O
in O
sequencing O
technologies O
and O
the O
development O
of O
techniques O
that O
profile O
epigenetic O
marks O
and O
chromatin O
accessibility O
using O
reagents O
that O
can O
be O
used O
in O
any O
has O
catapulted O
epigenomic O
studies O
in O
diverse O
animal O
, O
shedding O
light O
on O
the O
multitude O
of O
epigenomic O

We O
review O
the O
epigenetics O
of O
orthopteroid B-Species
insects O
, O
focussing O
on O
recent O
research O
on O
locusts B-Species
and O
termites B-Species
, O
two O
groups O
which O
display O
high O
levels O
of O
phenotypic O
plasticity O
, O
and O
for O
which O
genome B-Gene
sequences I-Gene
have O
become O
available O
in O
recent O
years O

We O
systematically O
reviewed O
over O
500 O
studies O
from O
the O
past O
5 O
years O
to O
identify O
trends O
in O
the O
frequency O
of O
epigenetic O
inheritance O
due O
to O
differences O
in O
reproductive O
mode O
and O
germline O
development O

Intriguing O
as O
it O
is O
, O
this O
hypothesis O
requires O
further O
study O
, O
as O
does O
the O
distinctly O
uneven O
historiography O
of O
the O
Famine O
in O
relation O
to O
the O
Irish B-Species
mental I-Species
hospitals I-Species

A O
total O
of O
25,765 O
of O
these O
were O
differentially O
methylated O
( O
DMCs O
) O

74 O
Neurodevelopmental B-Disease
disorders I-Disease
, O
such O
as O
autism B-Disease
, O
are O
complex O
entities O
that O
can O
be O
caused O
by O
biological O
and O
social O
factors O

We O
also O
proposed O
the O
future O
directions O
of O
synthetic O
epigenetics O
for O
the O
development O
of O
engineered O
smart O
crops O
that O
can O
actively O
monitor O
and O
respond O
to O
internal O
and O
external O
cues O
throughout O
their O
life O
cycles O

With O
the O
latest O
advances O
in O
cancer B-Disease
research O
, O
there O
is O
a O
greater O
need O
to O
explore O
and O
understand O
the O
biology O
, O
timing O
of O
dissemination O
, O
and O
origin O
of O
DCCs O
during O
tumor B-Disease
progression O

Another O
contribution O
used O
a O
variance-component O
LME O
to O
depict O
the O
proportion O
of O
heritability O
resulting O
from O
a O
genetic O
and O
shared O
environment O

We O
speculate O
that O
this O
process O
might O
contribute O
to O
making O
aging O
the O
main O
risk O
factor O
for O
many O
cancers B-Disease

Conclusions O
741 O
Acknowledgements O
741 O
SUMMARY O
 O
Investigating O
the O
features O
and O
implications O
of O
epigenetic O
mechanisms O
across O
the O
breadth O
of O
organisms O
and O
ecosystems O
is O
important O
for O
understanding O
the O
ecological O
relevance O
of O
epigenetics O

This O
review O
specifically O
focuses O
on O
these O
techniques O
, O
such O
as O
EM-seq O
to O
study O
DNA B-Chemical
methylation I-Chemical
, O
CUT&RUN O
, O
and O
CUT&Tag O
to O
study O
histone/transcription O
factor--DNA O
interactions O
, O
ATAC-seq O
to O
study O
chromatin O
accessibility O
, O
Hi-C O
to O
explore O
3D O
genome O
architecture O
and O

In O
this O
review O
, O
we O
argue O
that O
selected O
insects B-Species
can O
be O
used O
as O
models O
for O
human B-Species
diseases B-Disease
with O
an O
epigenetic O
component O
because O
the O
underlying O
molecular O
mechanisms O
( O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
acetylation I-Chemical
and O
the O
expression O
of O
microRNAs B-Gene
) O

Of O
particular O
interest O
to O
both O
evolutionary O
and O
behavioral O
biologists O
is O
the O
newly O
emerging O
field O
of O
epigenetics O
and O
behavior O

760 O
Epigenetic O
modifications O
are O
heritable O
yet O
reversible O
, O
essential O
for O
normal O
physiological O
functions O
and O
biological O
development O

Although O
many O
factors O
complicate O
the O
interpretation O
of O
epigenetic O
variation O
in O
human B-Species
disease B-Disease
, O
cell-specific O
methylation O
patterns O
and O
the O
cellular O
heterogeneity O
present O
in O
peripheral O
blood O
and O
tissue O
biopsies O
are O
anticipated O
to O
cause O
the O
most O
problems O

To O
unfold O
the O
complex O
etiology O
of O
schizophrenia B-Disease
, O
it O
is O
important O
to O
understand O
the O
interplay O
between O
genetic O
and O
nongenetic O
factors O

The O
down-regulation O
of O
GLDC B-Gene
was O
closely O
linked O
to O
promoter O
methylation O

However O
, O
the O
direction O
of O
causation O
for O
these O
associations O
is O
not O
always O
clear O
, O
and O
investigations O
to-date O
have O
often O
failed O
to O
replicate O
at O
the O
level O
of O
individual O
loci O

We O
also O
discuss O
the O
advantages O
and O
challenges O
of O
using O
epigenetic O
biomarkers O
as O
an O
indicator O
of O
toxicant B-Chemical
exposure O
, O
using O
measures O
that O
can O
be O
taken O
to O
improve O
risk O
assessment O
, O
and O
our O
perspectives O
on O
the O
future O
role O
of O
epigenetics O
in O
toxicology O

We O
describe O
the O
multifactorial O
variance O
of O
methylation O
at O
these O
CpGs O
and O
show O
that O
high-fat B-Chemical
diet I-Chemical
augments O
the O
age-related O
changes O

Here O
we O
will O
review O
how O
dietary O
factors O
modulate O
the O
establishment O
and O
maintenance O
of O
epigenetic O
marks O
, O
thereby O
influencing O
gene B-Gene
expression I-Gene
and O
, O
hence O
, O
disease B-Disease
risk I-Disease
and O
health O

Evidence O
suggests O
that O
early-life O
adversity O
can O
become O
biologically O
embedded O
and O
has O
the O
potential O
to O
influence O
health O
outcomes O
decades O
later O


Moreover O
, O
some O
unique O
epigenetic O
mechanisms O
have O
been O
evolved O
in O
plants B-Species

In O
this O
review O
, O
we O
discuss O
some O
of O
the O
recent O
advances O
in O
cancer B-Disease
genomic O
and O
epigenomic O
research O

We O
then O
describe O
the O
epigenetic O
editing O
toolkit O
focusing O
on O
CRISPR-based B-Gene
technologies O
, O
and O
highlight O
its O
achievements O
, O
drawbacks O
and O
promise O

Third O
, O
genes O
that O
were O
both O
DE B-Gene
and O
DM B-Gene
were O
subjected O
to O
hierarchical O
clustering O
and O
functional O
enrichment O
analysis O

The O
aim O
of O
this O
review O
is O
to O
examine O
what O
we O
know O
about O
the O
potential O
for O
using O
blood B-Chemical
samples O
in O
ecological O
epigenetic O
studies O

s O
psychometric O
data O
with O
random O
numbers O
and O
continued O
to O
find O
very O
large O
numbers O
of O
apparently O
statistically O
significant O
effects O

Results O
demonstrated O
that O
p6mA B-Chemical
outperformed O
other O
existing O
predictors O
using O
different O
datasets O

1342 O
Epigenetic O
changes O
can O
provide O
a O
pathway O
for O
organisms O
to O
respond O
to O
local O
environmental O
conditions O
by O
influencing O
gene B-Gene
expression I-Gene

While O
the O
earliest O
approaches O
were O
nonspecific O
and O
were O
at O
best O
useful O
for O
quantification O
of O
total O
methylated B-Chemical
cytosines I-Chemical
in O
the O
chunk O
of O
DNA B-Chemical
, O
this O
field O
has O
seen O
considerable O
progress O
and O
development O
over O
the O
past O
decades O

Recently O
, O
epigenetic O
changes O
such O
as O
alteration O
of O
methylation B-Chemical
status O
or O
modification O
of O
non-coding O
RNAs B-Gene
have O
been O
suggested O
as O
correlated O
to O
possible O
deleterious O
effects O
leading O
to O
different O
thyroid B-Disease
disorders I-Disease
in O
susceptible O
individuals O

Despite O
the O
increase O
in O
use O
, O
marijuana B-Chemical
's O
effect O
on O
aging B-Disease
remains O
understudied O
and O
understanding O
the O
effects O
of O
marijuana B-Chemical
on O
molecular O
aging B-Disease
may O
provide O
novel O
insights O
into O
the O
role O
of O
marijuana B-Chemical
in O
the O
aging B-Disease
process O

Network O
pharmacology O
analysis O
of O
8 O
phytocannabinoids O
revealed O
an O
interaction O
with O
10 O
(out O
of O
60 O
) O
targets O
related O
to O
neurodegenerative B-Disease
diseases I-Disease
, O
with O
enrichment O
of O
ErbB B-Gene
and O
PI3K-Akt B-Gene
signalling O
pathways O
which O
helps O
in O
ameliorating O
neuro-inflammation O
in O
various O
neurodegenerative B-Disease

Small O
molecule O
inhibitors O
of O
histone B-Chemical
deacetylases I-Chemical
, O
histone B-Chemical
methylation I-Chemical
, O
and O
DNA B-Chemical
methylation I-Chemical
are O
potentially O
important O
for O
preventing O
T1D B-Disease
or O
in O
the O
reprogramming O
of O
insulin-producing O
cells O

epigenetic O

By O
applying O
FOCS B-Gene
to O
2630 O
samples O
taken O
from O
ENCODE B-Gene
, O
Roadmap B-Gene
Epigenomics I-Gene
, O
FANTOM5 B-Gene
, O
and O
a O
new O
compendium O
of O
GRO-seq B-Gene
samples O
, O
we O
provide O
extensive O
enhancer-promotor O
maps O
( O
http//acgt O

We O
also O
highlight O
the O
knowledge O
gaps O
that O
need O
to O
be O
investigated O
for O
understanding O
the O
entire O
role O
of O
DNA B-Gene
methylation I-Gene
in O
plant B-Species
pathogen I-Species
interactions O

In O
this O
review O
, O
we O
summarize O
the O
emerging O
insights O
on O
lncRNA O
expression O
and O
functional O
role O
in O
cancer O
, O
focusing O
on O
the O
evolutionary O
conserved O
and O
abundantly O
expressed O
metastasis-associated O
lung B-Disease
adenocarcinoma I-Disease
transcript O
1 O
( O
MALAT1 B-Gene
) O
that O
currently O
represents O
the O
best O

926 O
Prostate B-Disease
cancer I-Disease
is O
a O
major O
health O
burden O
within O
the O
ever-increasingly O
aging O
US B-Species
population O

We O
investigated O
the O
genome-wide O
DNA B-Chemical
methylation I-Chemical
profile O
in O
69 O
pairs O
of O
HCC B-Disease
and O
adjacent O
non-cancerous O
liver O
tissues O
using O
the O
Infinium B-Chemical
HumanMethylation I-Chemical
450K I-Chemical
BeadChip I-Chemical
array O

We O
show O
that O
current O
enhancer-promoter O
inference O
methods O
produce O
a O
high O
rate O
of O
false O
positive O
links O

Some O
aberrant O
genomic O
imprinting O
was O
also O
observed O
in O
these O
cells O

Differentially O
methylated O
genes O
are O
involved O
in O
many O
relevant O
oncologic B-Disease
pathways O
, O
including O
EGFR B-Gene
and O
antioxidant O
pathways O
, O
that O
may O
be O
a O
target O
for O
therapy O
or O
chemoprevention O

Predictive O
genetic O
panels O
for O
these O
adolescents O
presenting O
with O
a O
very O
severe O
disease B-Disease
course O
, O
and/or O
families O
with O
high O
penetrance O
of O
disease B-Disease
will O
be O
of O
benefit O

Using O
evolutionary O
principles O
, O
it O
is O
also O
possible O
to O
interpret O
" O
sunsetting O
" O
of O
modified O
phenotypes O
when O
environmental O
conditions O
result O
in O
a O
disappearance O
of O
the O
epigenetic O
modification O
of O
gene B-Gene
regulation O

The O
quantitative O
analysis O
of O
DNA B-Gene
methylation I-Gene
patterns O
has O
the O
potential O
to O
serve O
as O
diagnostic O
and O
prognostic O
biomarkers O
, O
however O
, O
there O
is O
currently O
a O
lack O
of O
consensus O
regarding O
the O
optimal O
methodologies O
to O
quantify O
methylation B-Gene
status O

Potential O
transcription O
factors O
binding O
to O
GSTM3 B-Gene
promoter O
were O
detected O
by O
electrophoretic O
mobility O
shift O
assay O

In O
this O
light O
, O
we O
discuss O
a O
multi-tiered O
approach O
to O
animal O
experimentation O
, O
in O
which O
standardization O
and O
generalizability O
are O
each O
given O
precedence O
during O
different O
phases O
of O
a O
project O
, O
depending O
upon O
the O
goal O
of O
the O
experiment O

any O

All O
designs O
were O
fabricated O
in O
unmodified O
CMOS O
with O
performance O
assessed O
based O
on O
functionality O
as O
well O
as O
pH-resolution B-Chemical
required O
in O
practice O

This O
review O
describes O
recent O
advances O
in O
our O
knowledge O
of O
status O
in O
and O
the O
therapeutic O
potential O
of O
inhibitors O

435dupC O
; O
p O

Our O
results O
provide O
new O
insights O
into O
genetic O
regulation O
of O
blood B-Disease
pressure I-Disease
in O
terms O
of O
likely O
causal O
genes B-Gene
and O
involved O
biological O
pathways O
offering O
opportunities O
for O
future O
translation O
into O
clinical O
practice O

Tools O
used O
routinely O
to O
determine O
prognosis O
have O
not O
changed O
over O
the O
past O
decade O
; O
classification O
remains O
largely O
morphology O
based O
; O
and O
patients O
continue O
to O
be O
exposed O
to O
potentially O
toxic O
therapy O
with O
no O
indication O
of O
the O
likelihood O
of O
response O

Data O
analysis O
was O
conducted O
May O
2023 O
to O
April O
2024 O

Molecular O
profiling O
of O
AML B-Disease
through O
targeted O
sequencing O
panels O
and O
cytogenetics O
has O
become O
a O
mainstay O
in O
risk-stratifying O
AML B-Disease
patients O
and O
guiding O
clinicians O
toward O
optimal O
therapies O
for O
their O
patients O

, O
, O
, O
, O
, O
, O
, O
and O
) O
, O
which O
have O
the O
capacity O
to O
adopt O
at O
least O
one O
conformation O
that O
self-templates O
over O
long O
biological O
timescales O

In O
conclusion O
, O
we O
introduced O
and O
implemented O
a O
VAE O
model O
to O
represent O
large-scale O
epigenomics O
data O

Although O
the O
potential O
adverse O
effects O
of O
environmental O
chemicals B-Chemical
are O
known O
to O
the O
scientific O
community O
, O
regulatory O
agencies O
, O
and O
the O
public O
, O
little O
is O
known O
about O
the O
mechanistic O
basis O
by O
which O
these O
chemicals B-Chemical
can O
induce O
long-term O
or O
transgenerational O
effects O

During O
ontogenesis O
, O
the O
DNA B-Chemical
methylome I-Chemical
undergoes O
both O
programmed O
changes O
and O
those O
induced O
by O
environmental O
and O
endogenous O
factors O

patients O

A O
nascent O
area O
of O
research O
focuses O
on O
the O
utility O
of O
epigenetic O
marks O
in O
capturing O
this O
intersection O
of O
genes B-Gene
and O
environment O
, O
as O
epigenetic O
mechanisms O
are O
both O
tightly O
linked O
to O
the O
genome B-Gene
and O
environmentally O
responsive O

The O
Adverse O
Outcome O
Pathway O
( O
AOP O
) O
framework O
has O
the O
potential O
to O
demonstrate O
, O
by O
way O
of O
an O
inference- O
and O
science-based O
analysis O
, O
the O
causal O
relationship O
between O
chemical B-Chemical
exposures I-Chemical
, O
epigenome B-Gene
, O
and O
adverse B-Disease
health I-Disease
outcomes I-Disease

Having O
a O
similar O
conceptual O
framework O
to O
systems O
biology O
, O
the O
holistic O
MPE O
approach O
enables O
us O
to O
link O
potential O
etiological O
factors O
to O
specific O
molecular O
pathology O
, O
and O
gain O
novel O
pathogenic O
insights O
on O
causality O

The O
current O
review O
provides O
an O
introduction O
and O
overview O
of O
epigenetics O
with O
a O
particular O
focus O
on O
preclinical O
and O
clinical O
studies O
relevant O
to O
major B-Disease
depressive I-Disease
disorder I-Disease
( O
MDD B-Disease
) O

199 O
The O
most O
exciting O
recent O
advance O
for O
achieving O
durable O
management O
of O
advanced O
human B-Species
cancers B-Disease
is O
immunotherapy O
, O
especially O
the O
concept O
of O
immune O
checkpoint O
blockade O

29 O
, O
p O
= O

, O
SALL1 B-Gene
, O
WNT5Î± B-Gene
, O
LRP1b B-Gene
, O
CDH2 B-Gene
) O
in O
patients O
' O
liquid-biopsies O
was O
clinically O
significant O
showing O
high O
positive O
correlation O
in O
the O
pre-B B-Disease
ALL I-Disease
cases O
( O
p-value O
< O
0 O

The O
Personalized O
Lifestyle O
Medicine O
Institute O
presented O
Jirtle B-Gene
with O
the O
Research O
and O
Innovation O
Leadership O
Award O
in O
2019 O

1086Waddington's O
epigenetic O
landscape O
is O
a O
powerful O
metaphor O
for O
development O

The O
potential O
reversibility O
of O
epigenetic O
changes O
suggests O
that O
they O
could O
be O
modulated O
by O
nutrition O
and O
bioactive O
food O
compounds O

Several O
polymorphisms O
that O
mediate O
the O
HPA B-Gene
axis O
, O
neurotransmission O
, O
immune O
response O
, O
brain O
development O
, O
serotonin B-Chemical
synthesis O
, O
and O
other O
processes O
were O
found O

23 O
Allergic B-Disease
diseases I-Disease
are O
on O
the O
rise O
in O
the O
Western O
world O
and O
well-known O
allergy-protecting O
and O
-driving O
factors O
such O
as O
microbial O
and O
dietary O
exposure O
, O
pollution O
and O
smoking O
mediate O
their O
influence O
through O
alterations O
of O

The O
most O
potent O
compound O
inhibits O
binding O
of O
CREBBP B-Gene
to O
chromatin O
in O
U2OS B-Species
cells O

Small O
- O
molecule O
inhibitors O
of O
these O
epigenetic O
modifying O
enzymes O
are O
known O
as O
epigenetic O
drugs O
( O
epi-drugs O
) O
, O
which O
can O
cause O
programmed O
death O
of O
tumor B-Disease
cells I-Disease
by O
affecting O
the O
cell O
cycle O
, O
angiogenesis O
, O
proliferation O
, O
and O
migration O

There O
is O
emerging O
evidence O
that O
epigenetic O
variants O
of O
functional O
and/or O
agronomic O
importance O
exist O
in O
CWR B-Gene
gene I-Gene
pools O

Recently O
, O
new O
classes O
of O
epigenetic O
inhibitors O
have O
appeared O
in O
literatures O

Because O
epigenetic O
mechanisms O
are O
potentially O
reversible O
, O
unraveling O
the O
epigenetic O
contribution O
to O
the O
etiology O
of O
NPDs B-Disease
is O
key O
to O
the O
design O
of O
future O
therapeutic O
strategies O

Genes O
with O
differential O
methylation O
(DMGs) O
were O
identified O
and O
underwent O
functional O
annotation O
via O
the O
databases O
of O
Gene B-Gene
Ontology I-Gene
and O
Kyoto B-Gene
Encyclopedia I-Gene
of I-Gene
Genes I-Gene
and I-Gene
Genomes I-Gene

Epidemiologic O
studies O
evaluating O
social O
, O
behavior O
, O
family O
, O
and O
environmental O
factors O
have O
helped O
understand O
social O
inequality O
and O
develop O
the O
area O
of O
social O
epigenomics O

1487 O
 O
RASSF1A B-Gene
, O
one O
of O
the O
eight O
isoforms O
of O
the O
RASSF1 B-Gene
gene I-Gene
, O
is O
a O
tumor B-Disease
suppressor I-Disease
gene O
that O
influences O
tumor B-Disease
initiation I-Disease
and O
development O

, O
BDNF B-Gene
) O
extracellular B-Chemical
matrix I-Chemical
proteins I-Chemical
( O
e O

At O
the O
cellular O
level O
, O
ageing O
is O
associated O
with O
reduced O
function O
, O
altered O
gene B-Gene
expression I-Gene
and O
a O
perturbed O
epigenome O

Specifically O
, O
intergenic O
ncRNAs O
were O
observed O
to O
comprise O
a O
majority O
( O
51 O

Recent O
studies O
indicate O
that O
the O
TME B-Gene
imposes O
metabolic O
constraints O
on O
immune O
cells O
, O
inducing O
them O
to O
attain O
a O
tolerogenic O
state O
, O
incompetent O
of O
mounting O
effective O
tumor B-Disease
eradication O

Epigenetics O
plays O
a O
significant O
role O
, O
and O
several O
epigenetic O
interventions O
can O
modulate O
lifespan O

faba O
) O
seedlings O
exposed O
to O
CdCl2 B-Chemical
treatment O
and O
to O
post-cadmium O
recovery O
water O
incubations O
were O
tested O
with O
respect O
to O
H2O2 B-Chemical
production O
, O
DNA B-Gene
double-strand O
breaks O
( O
Î³-phosphorylation O
of O
H2AX B-Gene
histones O
) O
, O
chromatin O
morphology O
, O
histone O

278 O
Crop B-Species
wild I-Species
relatives I-Species
( O
CWRs B-Species
) O
are O
recognized O
as O
the O
best O
potential O
source O
of O
traits O
for O
crop O
improvement O

Herein O
we O
review O
the O
most O
promising O
epigenetic O
detection O
, O
diagnostic O
, O
prognostic O
and O
predictive O
biomarkers O
for O
the O
most O
common O
cancers B-Disease

However O
, O
the O
observed O
alteration O
in O
DNA B-Gene
methylation O
of O
MIR29B2CHG B-Gene
had O
a O
non-significant O
effect O
on O
age O
estimation O
with O
the O
VISAGE B-Gene
age O
prediction O
model O

We O
previously O
described O
a O
proof-of-principle O
technique O
that O
enabled O
high O
cell O
throughput O
; O
however O
, O
it O
produced O
only O
low-coverage O
profiles O
and O
was O
a O
difficult O
protocol O
that O
required O
custom O
sequencing O
primers O
and O
recipes O
and O
frequently O
produced O
libraries O
with O
excessive O
adapter O
contamination O

become O

The O
key O
findings O
underscore O
the O
pivotal O
role O
of O
epigenetic O
studies O
in O
understanding O
and O
enhancing O
IMF O
deposition O
in O
beef B-Species
cattle I-Species
, O
with O
implications O
for O
precision O
livestock O
farming O
and O
ethical O
livestock O
management O

g O

develop O
CRISPRoff B-Gene
, O
a O
programmable O
epigenetic O
memory O
writer O
capable O
of O
establishing O
specific O
gene O
silencing O
programs O
that O
are O
stably O
maintained O
across O
cell O
division O
and O
differentiation O

A O
further O
review O
of O
the O
scientific O
basis O
for O
the O
relevance O
of O
epigenetics O
is O
found O
in O
the O
accompanying O
article O
by O
Philibert B-Gene
and O
Erwin B-Gene
in O
this O
issue O

There O
were O
230 O
significantly O
differentially-methylated O
CpG B-Chemical
loci O
in O
258 O
genes B-Gene

This O
review O
focuses O
on O
the O
increasingly O
important O
role O
that O
chemistry B-Chemical
plays O
in O
this O
burgeoning O
field O

Differential O
transcription O
and O
CpG B-Chemical
methylation O
patterns O
were O
compared O
between O
transgenomic O
and O
nontransgenomic O
cell O
clones O
by O
using O
gene O
chip O
microarray O
systems O

1361 O
Aging B-Disease
and O
cancer B-Disease
are O
clearly O
associated O
processes O
, O
at O
both O
the O
epidemiological O
and O
molecular O
level O

Although O
there O
is O
substantial O
heterogeneity O
in O
how O
race O
is O
conceptualized O
and O
interpreted O
across O
studies O
, O
we O
observe O
practices O
that O
may O
unwittingly O
encourage O
typological O
thinking O
, O
including O
 O
using O
DNA B-Chemical
methylation I-Chemical
as O
a O
novel O
marker O
of O
racial O
classification O
; O
neglect O
of O
variation O
and O

Currently O
, O
there O
are O
limited O
studies O
using O
machine O
learning O
applied O
to O
epigenetics O

Current O
approaches O
such O
as O
epigenetics O
and O
gene-environment O
interactions O
were O
used O
to O
identify O
candidate O
biomarkers O
for O
anxiety B-Disease
disorders I-Disease
to O
assess O
determinants O
of O
disease O

This O
research O
area O
is O
emerging O
and O
demonstrated O
great O
variance O
in O
findings O
with O
no O
clear O
patterns O
identified O
across O
studies O

In O
contrast O
, O
extensive O
and O
transgenerationally O
heritable O
repatterning O
of O
DNA B-Chemical
methylation I-Chemical
at O
all O
three O
kinds O
of O
genomic O
loci O
were O
reproducibly O
detected O

The O
epigenome O
was O
rejuvenated O
to O
a O
similar O
extent O
, O
including O
H3K9me3 B-Chemical
levels O
and O
the O
DNA B-Chemical
methylation I-Chemical
ageing O
clock O

nuclei O

Here O
we O
have O
developed O
the O
first O
"maturation O
phase O
transient O
reprogramming" O
(MPTR) O
method O
, O
where O
reprogramming O
factors O
are O
selectively O
expressed O
until O
this O
rejuvenation O
point O
then O
withdrawn O

As O
a O
result O
, O
interest O
in O
placental B-Chemical
epigenetics O
generally O
, O
and O
changes O
occurring O
in O
placenta-associated B-Disease
disease I-Disease
, O
has O
intensified O
over O
recent O
years O

Emerging O
findings O
on O
epigenetic O
changes O
associated O
with O
adverse O
early O
experiences O
are O
also O
reviewed O

The O
iPCIT O
group O
had O
a O
slower O
pace O
of O
aging O
( O
Î² O
= O
0 O

However O
, O
just O
like O
any O
drug B-Chemical
irrational O
usage O
may O
lead O
to O
unforeseen O
negative O
effects O

Here O
, O
we O
present O
a O
detailed O
step-by-step O
ChIP B-Chemical
assay O
to O
investigate O
epigenetic O
chromatin O
marks O
during O
vegetative O
and O
reproductive O
development O
in O
cereals B-Species


Findings O
from O
89 O
systematic O
reviews O
of O
moderate O
to O
high O
quality O
suggest O
that O
childhood-onset O
depressive B-Disease
disorders I-Disease
have O
neurobiological O
, O
genetic O
, O
environmental O
, O
and O
epigenetic O
roots O
consistent O
with O
a O
diathesis-stress O
theory O
of O
depression B-Disease


1336 O
 O
Background O
 O
DNA B-Gene
methylation I-Gene
is O
an O
important O
epigenetic O
modification O
critical O
in O
regulation O
and O
transgenerational O
inheritance O

181 O
Multiple O
genetic O
and O
epigenetic O
events O
characterize O
tumor B-Disease
progression I-Disease
and O
define O
the O
identity O
of O
the O
tumors B-Disease

This O
Review O
discusses O
some O
of O
the O
key O
statistical O
challenges O
and O
algorithms O
associated O
with O
drawing O
inferences O
from O
DNA B-Chemical
methylation I-Chemical
data O
, O
including O
cell-type O
heterogeneity O
, O
feature O
selection O
, O
reverse O
causation O
and O
system-level O
analyses O
that O
require O
integration O
with O
other O
data O
types O
such O
as O
gene B-Gene

1230 O
 O
Endometriosis B-Disease
is O
a O
common O
reproductive O
disease O
with O
a O
heterogeneous O
presentation O

SLC6A4 B-Gene
is O
confirmed O
as O
a O
relevant O
biomarker O
of O
early O
adversity O
exposures O
, O
and O
epigenetic O
mechanisms O
occurring O
at O
this O
gene O
appear O
to O
play O
a O
critical O
role O
for O
programming O

In O
this O
paper O
, O
the O
reader O
can O
find O
one O
of O
the O
widest O
compilations O
of O
the O
landmarks O
and O
epistemic O
considerations O
of O
the O
knowledge O
of O
epigenetics O
across O
the O
history O
of O
biology O
from O
the O
earliest O
epigenetic O
formulation O
to O
genetic O
determinism O
until O
the O
present O

We O
also O
compare O
tissue-specific O
and O
pan-tissue O
clock O
performance O

Research O
on O
these O
diverse O
forms O
of O
inheritance O
challenges O
the O
notion O
that O
there O
is O
some O
special O
form O
of O
ethical O
concern O
that O
falls O
on O
germline O
interventions O
in O
general O
, O
and O
on O
interventions O
to O
the O
nuclear O
genome B-Gene
within O
the O
germline O
in O
particular O

Epigenetic O
regulatory O
mechanisms O
are O
a O
heritable O
change O
in O
a O
sequence O
of O
stable O
but O
reversible O
gene B-Gene
function I-Gene
modification I-Gene
yet O
do O
not O
affect O
the O
DNA B-Gene
primary I-Gene
sequence I-Gene
directly O

Method O
availability O
 O
https//github O

CHIP O
was O
strongly O
associated O
with O
epigenetic O
age O
acceleration O
, O
defined O
as O
the O
residual O
after O
regressing O
epigenetic O
clock O
age O
on O
chronological O
age O
, O
in O
several O
clocks O
, O
ranging O
from O
1 O

 O


510 O
Our O
social O
environment O
, O
from O
the O
microscopic O
to O
the O
macro-social O
, O
affects O
us O
for O
the O
entirety O
of O
our O
lives O

It O
thus O
constitutes O
a O
valuable O
reservoir O
of O
information O
for O
personalized O
medicine O
, O
which O
is O
aimed O
at O
customizing O
health-care O
interventions O
based O
on O
the O
unique O
characteristics O
of O
each O
individual O

Here O
we O
review O
recent O
literature O
in O
this O
area O
, O
and O
discuss O
some O
important O
issues O
raised O
by O
these O
innovative O
analyses O

1209Background O
DNA B-Chemical
methylation I-Chemical
(global O
and O
gene-specific O
) O
has O
been O
reported O
as O
an O
epigenetic O
mechanism O
that O
could O
be O
involved O
in O
the O
pathogenesis O
of O
type B-Disease
2 I-Disease
diabetes I-Disease
mellitus I-Disease
(T2DM) I-Disease

Here O
, O
we O
show O
that O
infection O
of O
the O
male O
lineage O
with O
the O
common O
human O
parasite O
Toxoplasma B-Species
results O
in O
transgenerational O
behavioral O
changes O
in O
offspring O
in O
a O
sex-dependent O
manner O

Besides O
, O
the O
phenomenon O
of O
methylation B-Chemical
of O
genes O
and O
the O
presence O
of O
specific O
microRNA B-Gene
(miRNA I-Gene
) I-Gene
could O
take O
part O
in O
PCOS B-Disease
aetiology O

iFACE O
is O
based O
on O
time O
series O
analysis O
of O
intraindividual O
variation O
of O
a O
single O
pair O
of O
genetically O
related O
subjects O


31 O
verO O
the O
past O
70 O
years O
, O
the O
study O
of O
epigenetics O
has O
evolved O
from O
a O
research O
curiosity O
for O
outsiders O
to O
one O
of O
the O
most O
hyped O
biological O
concepts O

, O
Carthamus B-Species
tinctorius I-Species
L I-Species

With O
the O
utilization O
of O
constructs O
often O
with O
large O
sizes O
and O
the O
wide O
array O
of O
cell O
types O
used O
to O
read O
out O
the O
effect O
of O
epigenetic O
editing O
in O
different O
biological O
applications O
, O
it O
is O
evident O
that O
ongoing O
optimalization O
of O
transfection O
protocols O
tailored O
to O
each O
specific O
experimental O
setup O
is O

, O
assessing O
causality O
or O
establishing O
reference O
epigenomes O
) O
but O
also O
in O
the O
ethical O
and O
social O
sphere O
( O

The O
combination O
of O
immune-checkpoint O
inhibition O
with O
epigenetic O
therapy O
is O
one O
such O
strategy O
that O
is O
being O
tested O
in O
clinical O
trials O
, O
encompassing O
a O
variety O
of O
cancer B-Disease
types I-Disease

The O
time O
has O
come O
to O
turn O
these O
findings O
into O
clinically O
meaningful O
biomarkers O
, O
capable O
of O
detecting O
tumors O
through O
noninvasive O
approaches O
, O
establishing O
the O
clinical O
relevance O
of O
each O
bladder B-Disease
cancer I-Disease
and O
predicting O
response O
to O
therapy O

However O
, O
only O
pan-BET B-Chemical
inhibitors I-Chemical
, O
small O
molecules O
that O
bind O
to O
both O
bromodomains O
( O
BD1 O
and O
BD2 O
) O
with O
all O
BET O
proteins O
, O
have O
been O
investigated O
in O
animal O
models O
of O
SUD B-Disease

1140 O
With O
the O
availability O
of O
high-quality O
full O
genome O
polymorphism O
( O
SNPs O
) O
data O
, O
it O
becomes O
feasible O
to O
study O
the O
past O
demographic O
and O
selective O
history O
of O
populations O
in O
exquisite O
detail O

Furthermore O
, O
ENCODE B-Gene
data O
can O
be O
freely O
visualized O
or O
downloaded O
for O
additional O
analyses O

1434 O
Whether O
and O
how O
epigenetic O
mechanisms O
and O
the O
microbiome O
play O
a O
role O
in O
mammalian B-Species
adaptation O
raised O
considerable O
attention O
and O
controversy O
, O
mainly O
because O
they O
have O
the O
potential O
to O
add O
new O
insights O
into O
the O
Modern B-Chemical
Synthesis I-Chemical

The O
application O
of O
ChIP B-Chemical
to O
genome-wide O
chromatin O
studies O
using O
real O
archival O
samples O
represents O
an O
unprecedented O
opportunity O
to O
conduct O
retrospective O
clinical O
studies O
thanks O
to O
the O
possibility O
of O
accessing O
large O
cohorts O
of O
samples O
and O
their O
associated O
diagnostic O
records O

94 O
) O

1163Background O
Following O
gene B-Gene
duplication O
, O
retained O
paralogs O
undergo O
functional O
divergence O
, O
which O
is O
reflected O
in O
changes O
in O
DNA B-Gene
sequence O
and O
expression O
patterns O

However O
, O
navigating O
this O
growing O
toolbox O
of O
methods O
for O
5hmC B-Chemical
detection O
can O
be O
challenging O

Conclusions O
 O
Epigenetic O
modifications O
related O
to O
globalization O
may O
crucially O
contribute O
to O
explain O
current O
and O
future O
patterns O
of O
NCDs B-Disease
, O
and O
thus O
deserve O
attention O
from O
environmental O
researchers O
, O
public O
health O
experts O
, O
policy O
makers O
, O
and O
concerned O
citizens O

Our O
approach O
using O
the O
bacterial B-Species
artificial I-Species
chromosome I-Species
array-based O
methylated O
CpG O
island O
amplification O
method O
has O
revealed O
that O
DNA B-Gene
methylation I-Gene
alterations O
correlated O
with O
the O
future O
development O
of O
more O
malignant O
cancers B-Disease
are O
already O
accumulated O
at O
the O
precancerous O
stage O
in O
the O
kidney B-Disease

Then O
, O
we O
discuss O
the O
CRISPR B-Gene
based O
methods O
for O
targeted O
transcriptional O
regulation O
, O
epigenome O
editing O
, O
and O
RNA B-Gene
editing O

Various O
cytokines O
, O
transcription O
factors O
, O
and O
other O
regulatory O
molecules O
have O
been O
found O
to O
be O
differentially O
methylated O
in O
CD8+ B-Gene
T I-Gene
cells O
in O
autoimmune B-Disease
diseases I-Disease

Despite O
the O
triumphs O
of O
modern O
genetics O
, O
and O
the O
disproval O
of O
Lysenkoism B-Disease
, O
recent O
years O
have O
seen O
a O
' O
re-thinking O
' O
of O
this O
doctrine O
in O
Russia O

The O
authors O
believe O
that O
the O
use O
of O
continuous O
multidimensional O
data O
, O
such O
as O
those O
regarding O
gut B-Species
microbiota I-Species
, O
or O
binary O
multidimensional O
systems O
properly O
transformed O
into O
a O
continuous O
variable O
, O
such O
as O
the O
epigenetic B-Gene
clock I-Gene
, O
offer O
an O
advantageous O
scenario O
for O
the O
design O
of O

952 O
for O
the O
epigenetic O
target O
prediction O
task O

Our O
algorithm O
takes O
the O
spatial O
distribution O
of O
CpGs B-Gene
into O
account O
for O
the O
enrichment O
assay O
, O
allowing O
for O
optimization O
of O
the O
definition O
of O
empirical O
regions O
for O
differential O
methylation B-Chemical

Thus O
, O
chromatin O
structure O
has O
become O
a O
principal O
focus O
in O
recent O
genomics O
researches O
that O
strive O
to O
characterize O
regulatory O
functions O
of O
DNA B-Gene
variants O
related O
to O
diseases B-Disease
or O
other O
traits O

Epigenome-wide O
DNA B-Chemical
methylation O
was O
examined O
via O
Illumina B-Chemical
MethylationEPIC I-Chemical
( O
850 O
K O
) O
array O

9 O

519 O
 O
Background O
 O

Epigenetic O
priming O
during O
fetal O
development O
and O
early O
childhood O
likely O
plays O
an O
important O
role O
in O
IgE B-Gene
-mediated I-Gene
type-I B-Disease
hypersensitivity I-Disease

The O
current O
review O
focuses O
on O
the O
emergence O
of O
data O
that O
support O
the O
role O
of O
DNA B-Gene
methylation O
and O
demethylation O
, O
and O
its O
molecular O
mediators O
in O
memory B-Disease
formation O

We O
demonstrate O
through O
a O
simulation O
study O
that O
our O
approach O
has O
a O
superior O
performance O
compared O
to O
BSmooth B-Gene

Epigenetic O
mechanisms O
may O
be O
responsible O
for O
age-related O
tactical O
shifts O

The O
molecular O
mechanism O
conferring O
to O
the O
"latent" O
damages O
at O
distal O
tissues O
, O
however O
, O
remains O
elusive O

Covariates O
were O
maternal O
sociodemographic O
variables O
, O
gestational O
age O
at O
blood O
sample O
collection O
, O
and O
pre-pregnancy O
body O
mass O
index O

DNA O
methylation O
is O
stably O
inherited O
by O
offspring O
and O
spontaneous O
epialleles O
are O
rare O

Unlike O
epigenetic O
clocks O
that O
constrain O
the O
functional O
form O
of O
methylation O
changes O
with O
time O
, O
pseudotime O
analysis O
orders O
samples O
along O
a O
path O
, O
based O
on O
similarities O
in O
a O
latent O
dimension O
, O
to O
provide O
an O
unbiased O
trajectory O

Our O
source O
code O
will O
be O
made O
publicly O
available O
at O
 O
https//bitbucket O

While O
the O
mechanism O
of O
how O
haploinsufficiency O
of O
HIST1H1E B-Gene
causes O
autism B-Disease
is O
entirely O
unknown O
, O
our O
report O
underscores O
the O
importance O
of O
further O
study O
of O
the O
function O
of O
this O
protein O
and O
other O
histone O
linker O
proteins O
in O
brain O
development O

Epigenetics O
is O
defined O
as O
any O
heritable O
- O
at O
least O
through O
one O
mitotic O
cell O
division O
- O
change O
in O
phenotype O
or O
trait O
that O
is O
not O
the O
result O
of O
a O
change O
in O
genomic O
DNA O
sequence O
, O
and O
it O
forms O
the O
basis O
that O
mediates O
the O
environmental O
impact O
on O
diabetes B-Disease
susceptibility O

However O
, O
the O
research O
results O
of O
the O
last O
twenty O
years O
or O
so O
have O
cast O
doubt O
on O
the O
validity O
of O
the O
clinical O
categories O
set O
out O
in O
dsm B-Disease
iii I-Disease

In O
this O
umbrella O
review O
, O
we O
systematically O
searched O
the O
extant O
literature O
for O
genetic O
, O
epigenetic O
, O
and O
neurobiological O
factors O
that O
contribute O
to O
a O
childhood O
onset O
of O
depression B-Disease

With O
the O
development O
of O
drugs O
that O
target O
the O
specific O
epigenetic O
mechanisms O
involved O
in O
the O
regulation O
of O
gene B-Gene
expression O
, O
development O
and O
utilization O
of O
epigenetic O
tools O
are O
an O
appropriate O
and O
effective O
approach O
that O
can O
be O
clinically O
applied O
to O
the O
treatment O
of O
various O
diseases B-Disease

1425 O
Introduction O
Activity O
landscapes O
are O
valuable O
tools O
for O
exploring O
systematically O
the O
structure-activity O
relationships O
(SAR) O
of O
chemical B-Chemical
databases O

Investigators O
have O
detected O
alterations O
at O
multiple O
levels O
of O
biological O
organization O
in O
offspring O
exposed O
to O
EDCs B-Chemical
through O
the O
blood O
or O
germ O
line O
of O
the O
parents O
, O
suggesting O
that O
generational O
consequences O
of O
EDCs B-Chemical
are O
evident O

Herein O
we O
introduce O
a O
novel O
approach O
for O
epigenetic O
quantitative O
structure-activity O
relationship O
( O
QSAR B-Chemical
) O
modelling O
using O
conformal O
prediction O

Here O
, O
we O
review O
current O
scientific O
knowledge O
regarding O
genomic O
imprinting O
in O
livestock B-Species
species I-Species
and O
evaluate O
how O
this O
information O
can O
be O
used O
in O
modern O
livestock B-Species
improvement O
programmes O

In O
natural O
systems O
, O
small O
effect O
sizes O
relative O
to O
noise O
necessitates O
large O
sampling O
efforts O
to O
detect O
differences O

of O

Finally O
, O
we O
consider O
the O
potential O
future O
application O
of O
epigenetic O
editing O
to O
the O
study O
and O
treatment O
of O
specific O
disease B-Disease
conditions I-Disease

, O
bacteria B-Species
) O
against O
plasmids O
and O
viruses O

1074 O
The O
full O
breadth O
of O
the O
field O
 O
The O
2016 O
EMBO O
Chemical B-Chemical
Biology I-Chemical
Conference O
, O
covering O
topics O
from O
tool O
development O
to O
biological O
applications O
and O
from O
computational O
drug O
design O
to O
synthetic O
chemistry O
, O
took O
place O
in O
Heidelberg O
from O
31st O
August O
to O
3rd O
September O

The O
most O
common O
variation O
in O
the O
human B-Species
genome O
is O
the O
SNP O
, O
which O
occurs O
throughout O
the O
genome O
, O
both O
within O
coding O
and O
noncoding O
regions O

) O
Research O
Workshop O
, O
" O
Using O
Nutrigenomics O
and O
Metabolomics O
in O
Clinical O
Nutrition O
Research O
, O
" O
was O
held O
on O
January O
21 O
, O
2012 O
, O
in O
Orlando O
, O
Florida O

Yet O
, O
both O
these O
different O
epistemological O
aspects O
of O
epigenetics B-Gene
still O
coexist O

These O
epigenetic O
effects O
add O
to O
wanted O
and O
unwanted O
drug B-Chemical
effects O
, O
contributing O
to O
mechanisms O
of O
drug B-Chemical
resistance O
or O
disease-related B-Disease
and O
unrelated O
phenotypes O

This O
review O
summarizes O
these O
technologies O
and O
insights O
from O
recent O
studies O
, O
describes O
the O
complex O
relationship O
between O
epigenetic O
components O
and O
gene B-Gene
regulation I-Gene
, O
and O
highlights O
caveats O
and O
promises O
of O
the O
emerging O
field O
of O
epigenome O
editing O
, O
including O
applications O
for O
translational O
purposes O
, O
such O

This O
review O
discusses O
our O
current O
understanding O
of O
the O
role O
epigenetic O
processes O
play O
in O
asthma B-Disease
pathogenesis I-Disease
, O
focusing O
on O
genome-wide O
, O
population-based O
studies O

267 O
Epigenetics O
has O
drawn O
much O
attention O
as O
a O
mechanism O
of O
transcriptional O
regulation O
involving O
modifications O
to O
genomic O
DNA B-Chemical
and O
histone B-Chemical
, O
without O
changes O
to O
nucleotide O
sequences O

Stem O
Cells O
2018 O
; O
36 O
 O
1697 O
- O
1708 O

In O
the O
spirit O
of O
integrative O
, O
humanistic O
medicine O
, O
treatments O
that O
" O
open O
windows O
of O
plasticity O
" O
allow O
targeted O
behavioral O
interventions O
to O
redirect O
brain O
and O
body O
functions O
and O
behavior O
in O
healthier O
directions O

Expert O
opinion O
 O
Epigenetic O
alterations O
take O
place O
before O
most O
genetic O
aberrations O
observed O
in O
GC B-Disease
and O
may O
have O
an O
initiating O
role O
in O
the O
pathogenesis O
of O
GC B-Disease

In O
order O
to O
evaluate O
Cd(II) B-Chemical
-mediated O
epigenetic O
changes O
involved O
in O
transcription O
and O
in O
the O
assembly O
of O
nucleosomes O
during O
the O
S-phase O
of O
the O
cell O
cycle O
, O
the O
acetylation O
of O
histone B-Gene
H3 I-Gene
on O
lysine O
5 O
(H3K56Ac) O
was O
investigated O
by O
immunofluorescence O

Available O
data O
suggest O
that O
anxiety B-Disease
disorders I-Disease
are O
highly O
complex O
and O
polygenic O

The O
first O
study O
demonstrating O
that O
skin O
fibroblasts O
from O
healthy O
centenarians O
can O
be O
rejuvenated O
by O
cell O
reprogramming O
was O
published O
in O
2011 O
and O
will O
be O
discussed O
in O
some O
detail O

781 O
The O
eukaryotic B-Species
epigenome O
has O
an O
instrumental O
role O
in O
determining O
and O
maintaining O
cell O
identity O
and O
function O

1250 O
The O
rising O
prevalence O
of O
obesity B-Disease
over O
the O
past O
decades O
coincides O
with O
the O
rising O
awareness O
that O
a O
detailed O
understanding O
of O
both O
adipose B-Species
tissue I-Species
biology O
and O
obesity-associated B-Disease
remodeling O
is O
crucial O
for O
developing O
therapeutic O
and O
preventive O
strategies O

Additionally O
, O
a O
cohort O
study O
showed O
that O
exposure O
to O
NO2 B-Chemical
was O
associated O
with O
significant O
hypomethylation O

To O
discover O
co-opted O
TEs O
, O
and O
distinguish O
them O
from O
noisy O
genomic O
elements O
, O
we O
argue O
that O
comparative O
epigenomic O
methods O
will O
also O
be O
important O

Conclusions O
 O
Early O
trauma O
and O
early O
menarche O
appear O
to O
exert O
independent O
effects O
on O
DNAm B-Gene
GrimAge I-Gene
, O
which O
has O
been O
shown O
to O
be O
the O
strongest O
epigenetic O
predictor O
of O
mortality O
risk O

336 O
Mutations O
in O
epigenetic O
regulators O
are O
prevalent O
in O
cancer B-Disease
, O
but O
their O
functional O
impact O
is O
poorly O
delineated O
aside O
from O
disrupting O
differentiation O

Recent O
findings O
 O
Epigenetics O
describes O
three O
major O
phenomena O
 O
DNA B-Gene
modification O
via O
methylation B-Chemical
, O
histone B-Gene
sidechain I-Gene
modifications O
, O
and O
short O
noncoding O
RNA B-Gene
sequences O
which O
work O
in O
concert O
to O
regulate O
gene B-Gene
transcription I-Gene
in O
a O
heritable O
fashion O

237 O
Axonal O
regeneration O
relies O
on O
the O
expression O
of O
regenerative O
associated O
genes O
within O
a O
coordinated O
transcriptional O
programme O
, O
which O
is O
finely O
tuned O
as O
a O
result O
of O
the O
activation O
of O
several O
regenerative O
signalling O
pathways O

Epigenetic O
therapies O
include O
epi-drugs O
, O
combinatorial O
therapy O
, O
nanocarriers O
, O
plant-derived O
products O
that O
are O
being O
used O
for O
changing O
the O
epigenetic O
pattern O
to O
reverse O
gene B-Gene
expression O

A O
better O
understanding O
of O
this O
conservation O
is O
imperative O
for O
effective O
design O
and O
interpretation O
of O
human B-Species
environmental O
epigenetics O
studies O

It O
is O
now O
clear O
, O
however O
, O
that O
epigenomic O
signature O
is O
also O
largely O
perturbed O
in O
many O
malignancies B-Disease

1013Purpose O
of O
review O
Following O
a O
life-threatening O
traumatic O
exposure O
, O
about O
10% O
of O
those O
exposed O
are O
at O
considerable O
risk O
for O
developing O
posttraumatic B-Disease
stress I-Disease
disorder I-Disease
( O
PTSD B-Disease
) O
, O
a O
severe O
and O
disabling O
syndrome O
characterized O
by O
uncontrollable O
intrusive O
memories O
, O
nightmares O

Many O
CpG B-Gene
sites I-Gene
show O
significant O
tissue-independent O
correlations O
with O
age O
which O
allowed O
us O
to O
develop O
a O
multi-tissue O
predictor O
of O
age O
in O
the O
mouse B-Species

Moving O
these O
initial O
findings O
from O
the O
lab O
into O
a O
clinical O
setting O
where O
they O
can O
be O
used O
to O
measure O
male O
infertility B-Disease
though O
requires O
a O
platform O
that O
is O
stable O
and O
robust O
against O
batch O
effects O
that O
can O
occur O
between O
sample O
runs O

Empirical O
studies O
to O
investigate O
the O
role O
of O
epigenetics O
in O
trans-generational O
gene B-Gene
regulation O
and O
disease B-Disease
require O
appropriate O
model O
organisms O

New O
datasuggest O
that O
not O
only O
is O
it O
ubiquitous O
, O
but O
both O
the O
generationand O
the O
transmission O
of O
epigenetic O
variations O
may O
be O
affectedby O
developmental O
conditions O

Initially O
, O
the O
use O
of O
this O
system O
was O
focused O
on O
the O
study O
of O
protein-coding O
genes O
but O
, O
recently O
, O
a O
number O
of O
CRISPR-Cas9-based B-Gene
tools O
have O
been O
developed O
to O
study O
non-coding O
transcriptional O
regulatory O
elements O

152 O
Epigenetic O
modification O
has O
been O
implicated O
in O
a O
wide O
range O
of O
diseases O
and O
the O
ability O
to O
modulate O
such O
systems O
is O
a O
lucrative O
therapeutic O
strategy O
in O
drug O
discovery O

This O
makes O
5hmC B-Chemical
a O
potential O
contributor O
to O
epigenetically O
mediated O
responses O
to O
environmental O
factors O

We O
call O
the O
combined O
algorithm O
which O
uses O
DHS B-Chemical
data O
and O
robust O
partial O
correlations O
for O
inference O
, O
EpiDISH O
( O
Epigenetic O
Dissection O
of O
Intra-Sample O
Heterogeneity O
) O

underlying O

Several O
concepts O
have O
revolutionized O
our O
way O
of O
appraising O
neuropsychiatric B-Disease
disorders I-Disease
( O
NPDs B-Disease
) O

The O
reversible O
nature O
of O
epigenetic O
modifications O
holds O
promise O
for O
future O
therapeutic O
strategies O
in O
obesity B-Disease
and O
T2D B-Disease

648 O
Computer-based O
approaches O
represent O
a O
powerful O
tool O
which O
helps O
to O
identify O
and O
optimize O
lead O
structures O
in O
the O
process O
of O
drug O
discovery O

578 O
 O
Barker O
et O
al O

At O
present O
, O
only O
six O
agents O
in O
two O
epigenetic O
target O
classes O
have O
been O
approved O
by O
the O
, O
limited O
to O
treatment O
of O
hematological B-Disease
malignancies I-Disease

DNA B-Gene
methylation I-Gene
is O
the O
major O
form O
of O
epigenetic O
modifications O
through O
which O
the O
cell O
regulates O
the O
gene O
expression O
and O
silencing O

All O
the O
studies O
remain O
in O
the O
pre-clinical O
stage O

The O
alteration O
of O
DNA B-Chemical
methylation I-Chemical
patterns O
has O
been O
found O
to O
be O
related O
to O
many O
diseases O
, O
including O
cancer B-Disease

This O
critical O
step O
allows O
repeated O
experiments O
with O
the O
same O
single O
cell O

A O
plethora O
of O
studies O
have O
emphasized O
the O
importance O
of O
analyzing O
epigenetics O
data O
through O
genome-wide O
studies O
and O
high-throughput O
approaches O
, O
thereby O
providing O
key O
insights O
towards O
epigenetics-based O
diseases O
such O
as O
cancer B-Disease

Epigenetic O
therapy O
aims O
at O
the O
purging O
of O
the O
latent O
reservoir O
by O
switching O
on O
transcription O
of O
silent O
HIV B-Species
genomes O

Here O
we O
describe O
an O
optimized O
ChIP-seq O
method-STAR O
(Small-scale O
TELP-Assisted O
Rapid O
) O
ChIP-seq O
- O
that O
allows O
the O
detection O
of O
histone B-Chemical
modifications O
using O
only O
a O
few O
hundred O
cells O

Interdisciplinary O
collaboration O
and O
good O
public O
communication O
regarding O
epigenetic O
risk O
will O
be O
important O
to O
advance O
the O
return O
of O
results O
framework O
for O
epigenetic O
science O

Hence O
, O
it O
's O
an O
essential O
part O
of O
high-dimensional O
mediation O
analysis O
( O
HDMA O
) O
to O
adjust O
for O
the O
potential O
confounders O

While O
females O
and O
males O
show O
no O
significant O
differences O
in O
predicted O
DNA B-Gene
methylation I-Gene
age O
, O
ovariectomy B-Chemical
results O
in O
significant O
age O
acceleration O
in O
females O

Data O
were O
processed O
using O
the O
Bioconductor O
package O
Minfi O

Genome O
engineering O
technologies O
use O
highly O
specific O
DNA-targeting O
tools O
to O
precisely O
deposit O
epigenetic O
changes O
in O
a O
locus-specific O
manner O
, O
creating O
diverse O
epigenome O
editing O
platforms O

In O
this O
commentary O
, O
we O
propagate O
the O
idea O
of O
a O
widespread O
follow-up O
use O
of O
epigenome B-Chemical
editing I-Chemical
technology O
in O
EWAS B-Gene
studies O

hPTM B-Gene

It O
has O
become O
increasingly O
clear O
, O
however O
, O
that O
different O
investigators O
ascribe O
different O
definitions O
to O
the O
term O

[Formula O
 O
see O
text O

Thereafter O
, O
using O
specific O
antibody O
directed O
against O
the O
protein O
of O
interest O
the O
covalently O
cross-linked O
DNA B-Chemical
is O
pulled O
down O
together O
with O
Protein B-Gene
A I-Gene
or O
G B-Gene
carrying O
beads O
that O
bind O
the O
Fc O
fragment O
of O
the O
antibody O

In O
this O
review O
, O
we O
will O
outline O
the O
adaption O
of O
current O
GRS B-Gene
approaches O
to O
methylation B-Chemical
data O
and O
highlight O
occurring O
challenges O

1216 O
RNA B-Chemical
modifications O
are O
emerging O
players O
in O
the O
field O
of O
post-transcriptional O
regulation O
of O
gene O
expression O
, O
and O
are O
attracting O
a O
comparable O
degree O
of O
research O
interest O
to O
DNA B-Chemical
and O
histone B-Chemical
modifications O
in O
the O
field O
of O
epigenetics O

Areas O
covered O
 O
This O
paper O
highlights O
different O
approaches O
for O
conducting O
SAR O
analysis O
of O
datasets O
with O
a O
particular O
focus O
on O
the O
activity O
landscape O
methodology O

289 O
Human B-Species
health O
tends O
to O
mirror O
gradients O
in O
social O
standing O
related O
to O
class O
, O
ethnicity O
and O
race O

960 O
As O
omics O
technologies O
, O
including O
genomics O
, O
epigenomics O
, O
transcriptomics O
, O
T B-Gene
cell I-Gene
receptor-repertorie I-Gene
profiling O
, O
proteomics O
, O
metabolomics O
and O
microbiomics O
, O
have O
provided O
valuable O
insights O
into O
CAR B-Gene
T I-Gene
cell I-Gene
therapy O
, O
in O
our O
recent O
review O
, O
we O
discuss O

CUT&RUN O
is O
now O
being O
widely O
used O
for O
characterizing O
the O
epigenetic O
landscape O
in O
many O
cell O
types O
as O
it O
utilizes O
far O
less O
cell O
numbers O
when O
compared O
to O
Chromatin B-Chemical
Immunoprecipitation-sequencing I-Chemical
( O
ChIP-seq B-Chemical
) O
, O
thereby O
making O
it O
a O
powerful O
tool O
for O
researchers O

Several O
studies O
have O
indicated O
an O
epigenetic O
basis O
for O
the O
carcinogenic B-Disease
effects I-Disease
of O
circadian O
disruption O

Based O
on O
these O
profiles O
, O
we O
confirm O
that O
CNFs O
and O
PNFs O
are O
epigenetically O
distinct O
tumors O
with O
broad O
differences O
in O
higher-order O
chromatin O
states O
and O
specific O
methylation O
events O
altering O
genes O
involved O
in O
key O
biological O
and O
cellular O
processes O
, O
such O
as O
inflammation O
, O
signaling O

These O
limitations O
call O
for O
studies O
that O
combine O
data O
from O
postmortem O
human B-Species
brain I-Species
tissue O
and O
animal B-Species
models O
, O
assess O
longitudinal O
epigenetic O
changes O
in O
living O
subjects O
, O
and O
examine O
dimensional O
phenotypes O
in O
addition O
to O
diagnoses O

g O

These O
sites O
were O
enriched O
for O
CpGs O
under O
genetic O
influence O
, O
suggesting O
that O
a O
substantial O
proportion O
of O
DNAm B-Chemical
covariation O
between O
tissues O
can O
be O
attributed O
to O
genetic O
variation O

03 O
), O
but O
not O
associated O
with O
physical O
activity O
( O
Î² O
= O

tidyCoverage O
emerges O
as O
a O
valuable O
tool O
, O
contributing O
to O
the O
advancement O
of O
epigenomics O
research O
by O
promoting O
consistency O
, O
reproducibility O
, O
and O
accessibility O
in O
data O
analysis O

In O
this O
review O
, O
we O
make O
a O
brief O
summary O
of O
important O
progress O
achieved O
in O
plant B-Species
epigenetics O
field O
in O
China O
over O
the O
past O
several O
decades O
and O
give O
a O
brief O
outlook O
on O
future O
research O
prospects O

The O
current O
review O
is O
an O
update O
of O
the O
previously O
published O
paper O
, O
describing O
the O
most O
recent O
advances O
in O
the O
epigenetics O
of O
diabetes B-Disease

) O

5 O
to O
10 O

We O
conclude O
by O
discussing O
the O
importance O
of O
establishing O
community O
standards O
to O
maximize O
the O
possibility O
of O
integrative O
computational O
analyses O
, O
such O
as O
was O
clearly O
beneficial O
for O
the O
human B-Species
ENCODE B-Gene
project O

We O
then O
review O
the O
current O
literature O
on O
how O
epigenetic O
clocks O
relate O
to O
specific O
aspects O
of O
mental B-Disease
health I-Disease
, O
such O
as O
stress B-Disease
, O
medications B-Chemical
, O
substance B-Chemical
use I-Chemical
, O
health O
behaviors O
, O
and O
symptom O
clusters O


mpg O

The O
findings O
of O
our O
work O
might O
provide O
insight O
into O
future O
AD B-Disease
epigenetic-therapeutics O

Numerous O
studies O
have O
highlighted O
the O
role O
of O
genetic O
and O
epigenetic O
factors O
in O
this O
disease B-Disease

We O
introduce O
the O
BISulfite-seq B-Chemical
Command I-Chemical
line I-Chemical
User I-Chemical
Interface I-Chemical
Toolkit I-Chemical
( O
BISCUIT B-Chemical
) O
and O
its O
companion O
R/Bioconductor B-Chemical
package O
, O
biscuiteer B-Chemical
, O
for O
simultaneous O
extraction O
of O
genetic O
and O
epigenetic O
information O
from O
bulk O
and O
single-cell O

In O
this O
Perspective O
, O
we O
revisit O
the O
Waddington B-Gene
diagram O
in O
light O
of O
the O
emerging O
recognition O
that O
plasticity O
is O
part O
and O
parcel O
of O
adult O
regeneration O

001 O
) O

levels O

This O
review O
discusses O
the O
diabetic B-Disease
retinopathy I-Disease
, O
its O
pathogenesis O
, O
current O
treatment O
options O
, O
need O
of O
finding O
novel O
treatment O
options O
, O
and O
different O
epigenetic O
alterations O
associated O
with O
DR B-Disease

539 O
Epigenetics O
is O
one O
of O
the O
most O
rapidly O
expanding O
fields O
in O
biology O
, O
which O
plays O
important O
roles O
in O
environmental B-Chemical
pollutant-induced I-Chemical
neurotoxicity B-Disease

Allele O
- O
specific O
expression O
has O
been O
thought O
to O
be O
restricted O
to O
a O
few O
specific O
classes O
of O
genes B-Gene

Availability O
and O
implementation O
 O
The O
bigwig-loader O
installation O
instructions O
and O
source O
code O
can O
be O
accessed O
at O
https//github O

There O
are O
many O
convergent O
regulatory O
networks O
and O
signaling O
mechanisms O
between O
development O
and O
regeneration O


Here O
, O
we O
performed O
promoter-wide O
DNA B-Chemical
methylation I-Chemical
analysis O
of O
lymphoblastoid B-Species
cell I-Species
lines I-Species
( O
LCLs O
) O
derived O
from O
two O
pairs O
of O
monozygotic O
twins O
discordant O
for O
BD B-Disease

Conclusion O
 O
Gestational O
epigenetic O
age O
acceleration O
or O
deceleration O
was O
not O
related O
to O
more O
favorable O
or O
unfavorable O
factors O
in O
one O
direction O
in O
the O
investigated O
tissues O
, O
and O
the O
relative O
epigenetic O
age O
differed O
between O
tissues O
of O
the O
same O
person O

Establishing O
such O
links O
between O
environmental O
exposures O
and O
modifiable O
molecular O
changes O
ultimately O
holds O
promise O
to O
inform O
interventional O
efforts O
toward O
alleviating O
the O
environmentally O
mediated O
onset O
of O
obesity B-Disease

Current O
knowledge O
on O
cardiac O
epitranscriptomics O
, O
albeit O
limited O
still O
, O
indicates O
that O
the O
impact O
of O
epitranscriptomic O
editing O
in O
the O
heart O
, O
in O
both O
physiological O
and O
pathological B-Disease
conditions I-Disease
, O
holds O
untapped O
potential O
for O
the O
development O
of O
novel O
targeted O
therapeutic O
approaches O
in O
a O
dynamic O

Thus O
, O
novel O
pathogenic O
mechanisms O
and O
putative O
biomarkers O
may O
be O
detectable O
in O
peripheral O
blood O
, O
sputum O
, O
nasal O
and O
buccal O
swabs O
or O
lung O
tissue O

Cellular O
senescence O
, O
mediated O
by O
telomere B-Gene
attrition I-Gene
, O
is O
in O
a O
class O
by O
itself O
, O
having O
recently O
been O
validated O
as O
a O
primary O
regulator O
of O
aging B-Disease

Critical O
knowledge O
gaps O
and O
research O
needs O
are O
discussed O
and O
advances O
in O
epigenomics O
that O
may O
help O
in O
understanding O
the O
functional O
relevance O
of O
epigenetic O
alterations O

More O
than O
60 O
susceptible O
genes O
or O
loci O
of O
T1D B-Disease
have O
been O
identified O

In O
this O
review O
, O
we O
highlight O
selected O
, O
well-characterized O
relationships O
between O
epigenetic O
factors O
and O
transcriptional O
cell O
fate O
regulators O
during O
the O
initial O
stages O
of O
mouse B-Species
development O

The O
q-value O
threshold O
was O
calculated O
using O
moderated O
Student's O
t-test O
followed O
by O
Benjamini-Hochberg B-Chemical
multiple O
test O
correction O
FDR O

With O
emphasis O
on O
the O
insights O
obtained O
from O
transcriptomic O
analyses O
for O
porcine B-Species
immunity O
, O
we O
also O
discuss O
the O
experimental O
design O
in O
pig B-Species
immunity O
research O
and O
the O
value O
of O
the O
newly O
published O
porcine B-Species
genome B-Gene
assembly I-Gene
in O
using O
the O
pig B-Species
as O
a O
model O
for O


CRISPR-Cas9 O
technology O
has O
already O
led O
to O
the O
discovery O
of O
new O
paradigms O
in O
gene B-Gene
regulation I-Gene
and O
, O
as O
new O
CRISPR-based O
tools O
and O
methods O
continue O
to O
be O
developed O
, O
promises O
to O
transform O
our O
knowledge O
of O
the O
gene B-Gene
regulatory I-Gene
code I-Gene
and O
our O
ability O
to O

Here O
, O
we O
review O
a O
number O
of O
case O
studies O
that O
cover O
different O
aspects O
of O
epigenetic B-Disease
drug I-Disease
discovery O
spanning O
from O
sequencing O
of O
epigenetic B-Disease
modifications O
, O
assays O
development O
over O
screening O
to O
medicinal O
chemistry O
, O
in O
vivo O
testing O
and O
clinical O
application O

Our O
results O
highlight O
that O
old O
females O
may O
display O
a O
lower O
degree O
of O
biological O
ageing O
than O
males O

We O
collected O
buccal O
swabs O
from O
217 O
canids O
( O
207 O
domestic B-Species
dogs I-Species
and O
10 O
grey B-Species
wolves I-Species
) O
and O
used O
targeted O
bisulphite B-Chemical
sequencing O
to O
measure O
methylomes O

This O
review O
will O
explore O
new O
insights O
into O
the O
established O
therapeutic O
paradigms O
targeting O
, O
inflammation O
and O
with O
the O
focus O
on O
recent O
clinical O
developments O

First-in-class O
compounds O
have O
successfully O
transitioned O
to O
clinical O
investigation O
, O
importantly O
also O
in O
solid B-Disease
tumors I-Disease
and O
pediatric B-Disease
malignancies I-Disease

The O
model O
borrows O
information O
from O
all O
tumour B-Disease
regions O
to O
leverage O
greater O
statistical O
power O

923 O
 O
Reduced O
representation O
bisulfite O
sequencing O
( O
RRBS O
) O
is O
an O
effective O
technique O
for O
profiling O
genome-wide O
DNA B-Chemical
methylation I-Chemical
patterns I-Chemical
in O
eukaryotes B-Species

edu O

1437 O
Collectively O
, O
the O
dsDNA O
tailed O
bacteriophages O
( O
Caudovirales B-Species
) O
contain O
the O
largest O
chemical B-Chemical
diversity O
of O
naturally O
occurring O
deoxynucleotides B-Chemical
in O
DNA B-Chemical
observed O
to O
date O

This O
review O
briefly O
explains O
the O
molecular O
nature O
of O
the O
individual O
regulatory O
process O
that O
constitute O
epigenetics O
, O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
chromatin B-Chemical
remodeling I-Chemical
, O
transcriptional O
control O
, O
and O
noncoding O
RNAs O

Altered O
biological O
processes O
and O
functions O
included O
 O
neuromotor B-Disease
damage I-Disease
, O
malformation O
of O
major O
brain B-Disease
structures I-Disease
, O
brain B-Disease
growth I-Disease
, O
neuroprotection O
, O
neuronal O
development O
and O
de-differentiation O
, O
and O
cranial O
sensory O
neuron O
development O

Within O
the O
viral O
genome O
nucleosomes O
are O
organized O
for O
the O
expression O
of O
appropriate O
genes O
with O
relevant O
histone B-Chemical
modifications O
particularly O
histone B-Chemical
acetylation O

We O
also O
discuss O
how O
these O
findings O
lead O
to O
improved O
understanding O
of O
the O
molecular O
basis O
of O
CVID B-Disease
and O
possible O
future O
directions O
to O
pursue O

jetbrains O

This O
review O
presents O
the O
evidence O
on O
the O
impact O
of O
epigenomic O
readers O
, O
writers O
, O
and O
erasers O
in O
both O
ischemic B-Disease
and I-Disease
hemorrhagic I-Disease
stroke I-Disease
pathophysiology O

His O
research O
combines O
experimental O
model O
systems O
, O
computational O
and O
omics O
tools O
, O
and O
epidemiological O
studies O
to O
investigate O
the O
influence O
of O
environmental O
exposures O
on O
wildlife O
and O
human B-Species
health O
, O
and O
underlying O
molecular O
mechanisms O

Aberrant O
epigenetic O
regulation O
has O
been O
previously O
implicated O
in O
other O
rheumatological B-Disease
disorders I-Disease

This O
knowledge O
can O
help O
developing O
' O
epigenetics O
drugs' O
for O
complex O
diseases O
like O
cancers B-Disease

50 O
Epigenetics O
refers O
to O
the O
study O
of O
heritable O
changes O
in O
that O
occur O
without O
a O
change O
in O

05 O
) O
in O
genes O
implicated O
in O
cell O
signaling O
, O
growth O
, O
and O
development O

The O
substantial O
overlap O
in O
genetically O
identified O
pathogenic O
pathways O
has O
been O
demonstrated O
between O
these O
diseases B-Disease

Methylation-Sensitive-Random O
Amplified O
Polymorphic O
DNA-Polymerase O
Chain O
Reaction O
(MS-RAPD-PCR) O
is O
a O
restriction O
enzyme O
digestion O
and O
PCR-based O
method O
for O
the O
analysis O
of O
methylation O
changes O

An O
account O
of O
the O
recognition O
and O
routinization O
of O
epigenetics B-Chemical
follows O
, O
in O
which O
an O
unexamined O
assumption O
of O
genetic B-Gene
determinism O
is O
debunked O

A O
comprehensive O
understanding O
of O
the O
pertinent O
changes O
in O
the O
epigenetic O
makeup O
of O
suicide B-Disease
phenotype I-Disease
exhibits O
a O
characteristic O
signature O
with O
the O
possibility O
of O
using O
it O
as O
a O
biomarker O
to O
help O
predict O
the O
risk O
factors O
associated O
with O
suicide B-Disease

g O

Inspired O
by O
the O
dynamic O
, O
biological O
regulation O
of O
(epi)genetic O
information O
, O
we O
herein O
present O
how O
binary O
data O
can O
undergo O
controlled O
changes O
when O
encoded O
in O
synthetic O
DNA B-Gene
strands I-Gene

Designs O
and O
analyses O
of O
such O
studies O
raise O
many O
statistical O
challenges O

363 O
B O
is O
a O
codirector O
of O
the O
Cancer B-Disease
Biology I-Disease
Program I-Disease
at O
The O
at O
and O
the O
and O
Professor O
of O
Oncology B-Disease
and O
Medicine O

Recent O
studies O
have O
demonstrated O
that O
the O
population O
of O
CSCs B-Species
and O
the O
progression O
of O
cancer B-Disease
are O
increased O
by O
the O
deregulation O
of O
different O
epigenetic O
pathways O
having O
effects O
on O
gene B-Gene
expression I-Gene
patterns O
and O
key O
pathways O
connected O
with O
cell O
proliferation O
and O
survival O

906 O
Increasing O
evidence O
suggests O
an O
association O
between O
gene B-Gene
expression I-Gene
and O
clinical B-Disease
pain I-Disease

These O
"persisters" O
represent O
a O
pool O
of O
slow-growing O
cells O
that O
can O
either O
re-expand O
when O
treatment B-Chemical
is I-Chemical
discontinued O
or O
acquire O
permanent O
resistance B-Disease

Emerging O
studies O
report O
a O
theoretical O
role O
of O
endocrine O
disruptors O
, O
intestinal B-Disease
dysbiosis I-Disease
and O
Advanced B-Chemical
Glycation I-Chemical
End I-Chemical
products I-Chemical
( O
AGEs B-Chemical
) O
in O
PCOS B-Disease

In O
this O
article O
, O
we O
discuss O
the O
link O
between O
the O
environment O
, O
DNA B-Gene
methylation I-Gene
and O
allergic B-Disease
disease I-Disease
, O
as O
well O
as O
questions O
of O
causality O
inherent O
to O
analyses O
of O
DNA B-Gene
methylation I-Gene

And O
, O
if O
the O
public O
policies O
also O
have O
a O
direct O
impact O
on O
fundamental O
freedoms O
, O
other O
factors O
also O
play O
a O
decisive O
role O
in O
this O
regard O
, O
accentuating O
the O
specificity O
of O
genetic B-Gene
data O

A O
critical O
discussion O
of O
all O
the O
recent O
findings O
on O
this O
topic O
is O
also O
included O

Epigenetic O
biomarkers O
provide O
an O
opportunity O
to O
understand O
liver B-Disease
cancer I-Disease
etiology O
and O
evaluate O
novel O
epigenetic O
inhibitors O
for O
treatment O


Coronavirus B-Disease
disease I-Disease
2019 I-Disease
( O
COVID-19 B-Disease
) O
, O
an O
emerging O
disease O
with O
a O
quick O
rise O
in O
infected O
cases O
and O
deaths O
, O
was O
recently O
identified O
causing O
a O
worldwide O
pandemic O

to O

Spinal O
cord O
injury B-Disease
patients O
often O
have O
increased O
risk O
of O
developing O
persistent O
neuropathic B-Disease
pain I-Disease
and O
other O
neurodegenerative B-Disease
conditions I-Disease
beyond O
the O
primary O
lesion O
center O
later O
in O
their O
life O

Furthermore O
, O
mediation O
analysis O
was O
performed O
to O
evaluate O
whether O
the O
cross-lagged O
effects O
had O
causal O
impacts O
on O
CVD B-Disease

experimental O
designs O
, O
settings O
, O
techniques O
) O
and O
' O
stereotypes O
' O
( O
i O

We O
found O
no O
differential O
gene O
expression O
in O
sperm B-Species
cells I-Species
of O
the O
two O
groups O
(adjusted O
P-value>0 O

Cancer O
cells O
employ O
multiple O
mechanisms O
to O
avoid O
immune O
recognition O
and O
suppress O
antitumor O
immune O
responses O

598 O
Swine B-Species
performance O
in O
the O
face O
of O
disease B-Disease
challenge I-Disease
is O
becoming O
progressively O
more O
important O

Transient O
methylation B-Chemical
levels O
, O
along O
with O
the O
reversible O
inhibition O
of O
the O
desired O
genes B-Gene
, O
by O
some O
epigenetic O
editing O
techniques O
, O
limit O
their O
further O
application O
in O
functional O
and O
therapeutic O
studies O
of O
critical O
regulators O
in O
the O
cancer B-Disease
epigenome O

Clinical O
trials O
are O
warranted O
to O
determine O
the O
specific O
foods O
, O
dietary O
patterns O
, O
and O
dietary O
supplements O
that O
will O
normalize O
or O
lower O
epigenetic O
aging O
across O
the O
life O
course O

Methods O
 O
We O
used O
a O
case-control O
study O
design O
with O
a O
fractionated O
irradiation O
regimen O
on O
four O
cancerous O
cell O
lines O
representative O
of O
HCC B-Disease
( O
HepG2 B-Species
) O
, O
melanoma B-Disease
( O
MeWo B-Species
and O
MeWo-LC1 B-Species
, O
which O
exhibit O
opposed O
methionine B-Chemical
dependency O
phenotypes O
) O

Using O
this O
information O
, O
we O
highlight O
specific O
examples O
where O
neutrophil B-Species
oxidants O
react O
with O
epigenetic B-Gene
pathway I-Gene
components O

These O
modifications O
are O
maintained O
by O
the O
dynamic O
activity O
of O
various O
modifying O
and O
demodifying O
enzymes O
, O
the O
activities O
of O
which O
can O
be O
influenced O
by O
metabolites O
and O
other O
environmental O
cues O

The O
gold O
standard O
for O
assaying O
genome-wide O
DNA B-Chemical
methylation I-Chemical
at O
single-base O
resolution O
is O
whole-genome O
bisulfite B-Chemical
sequencing I-Chemical
(WGBS) I-Chemical

We O
have O
performed O
extensive O
user O
testing O
throughout O
the O
development O
of O
this O
resource O
, O
and O
new O
features O
and O
improvements O
are O
continuously O
being O
implemented O
based O
on O
the O
results O

Cleavage O

In O
the O
current O
study O
, O
we O
report O
that O
overexpression O
of O
mitochondrial O
fission O
factor B-Gene
( O
MFF B-Gene
) O
, O
which O
is O
upregulated O
significantly O
in O
liver B-Disease
cancer-initiating I-Disease
cells I-Disease
( O
LCIC B-Disease
) O
, O
promotes O
mitochondrial O
fission O
and O
enhances O
stemness O
and O
tumor-initiating O
capability O

In O
1940 O
, O
Waddington B-Gene
coined O
the O
term O
" O
epigenetic O
landscape O
" O
as O
a O
metaphor O
for O
pluripotency O
and O
differentiation O
, O
but O
methylation B-Chemical
landscapes O
have O
not O
yet O
been O
rigorously O
computed O

792 O
The O
Epigenomics O
database O
at O
the O
National O
Center O
for O
Biotechnology O
Information O
(NCBI) O
is O
a O
new O
resource O
that O
has O
been O
created O
to O
serve O
as O
a O
comprehensive O
public O
resource O
for O
whole-genome O
epigenetic O
data O
sets O
(www O

To O
study O
early O
and O
unbiased O
epigenetic O
predictors O
of O
longevity O
prospectively O
, O
a O
birth O
cohort O
would O
be O
ideal O

After O
completing O
her O
undergraduate O
degree O
in O
chemical O
engineering O
, O
Aydan O
shifted O
focus O
to O
molecular O
biology O
for O
her O
Master O
's O
degree O
and O
epigenetics B-Disease
during O
her O
PhD O
in O
Thomas B-Gene
Jenuwein I-Gene
's O
lab O

Conclusion O
 O
This O
discovery O
provides O
new O
insight O
on O
the O
epigenetic O
regulation O
in O
cancers B-Disease
and O
leads O
to O
potential O
new O
direction O
for O
epigenetic O
biomarker O
and O
cancer B-Disease
drug O
discovery O

Epigenomics O
is O
the O
study O
of O
genome-wide O
epigenetic O
modifications O

Here O
we O
provide O
an O
intellectual O
framework O
for O
interpreting O
these O
findings O
and O
how O
they O
can O
interact O
with O
each O
other O

Social O
experience O
altered O
the O
epigenetic O
landscape O
in O
clusters O
of O
genes O
involved O
in O
transcription O
and O
neural O
function O

Despite O
decades O
of O
research O
, O
stroke B-Disease
continues O
to O
be O
classified O
as O
a O
leading O
cause O
of O
death O
and O
disability O
worldwide O
with O
limited O
clinical O
interventions O

However O
, O
people O
differ O
strikingly O
in O
their O
susceptibility O
to O
develop O
signs O
and O
symptoms O
of O
mental B-Disease
illness I-Disease
after O
traumatic O
stress O

Next O
, O
hierarchical O
clustering O
technique O
was O
applied O
to O
detect O
gene B-Gene
modules O

Long O
thought O
to O
be O
an O
inexorable O
road O
toward O
decline O
and O
diseases B-Disease
, O
aging O
is O
in O
fact O
remarkably O
plastic O

DNA O
methylation O
array O
data O
are O
commonly O
used O
in O
the O
prediction O
of O
methylation O
age O

We O
summarize O
current O
studies O
of O
modifications O
using O
the O
Nanopore B-Chemical
sequencer O
, O
detection O
tools O
using O
statistical O
tests O
or O
machine O
learning O
, O
and O
applications O
of O
this O
technology O
, O
such O
as O
analyses O
of O
open O
chromatin O
, O
DNA B-Chemical
replication O
, O
and O
RNA B-Chemical
metabolism O

The O
implications O
of O
stochastic O
epigenetic O
variability O
are O
multifold O
 O
by O
affecting O
development O
and O
subsequently O
phenotype O
, O
random O
changes O
in O
epigenetic O
marks O
may O
provide O
additional O
phenotypic O
diversity O
, O
which O
can O
help O
natural O
populations O
when O
facing O
fluctuating O
environments O

Such O
scenario O
demands O
new O
therapeutic O
approaches O
to O
fight O
against O
this O
devastating O
dementia B-Disease

45 O
% O
of O
the O
lncRNAs B-Gene
and O
51 O

Strong O
correlations O
existed O
between O
human B-Species
and O
marmoset B-Species
DNA B-Gene
methylation I-Gene
data O

Among O
the O
most O
critical O
of O
these O
processes O
are O
epigenetic O
mechanisms O
, O
which O
serve O
to O
link O
the O
cellular O
environment O
with O
genomic O
material O

The O
more O
effective O
therapeutic O
approaches O
with O
minimal O
or O
no O
side O
effects O
for O
SLE B-Disease
patients O
are O
hard O
to O
develop O
, O
mainly O
due O
to O
the O
complexity O
of O
the O
disease O

This O
review O
highlights O
the O
significance O
of O
environmental O
temperature O
on O
epigenetic O
control O
of O
phenotypic O
variation O
, O
with O
the O
aim O
of O
furthering O
our O
understanding O
of O
how O
epigenetics O
might O
help O
or O
hinder O
species' B-Species
adaptation O
to O
climate O
change O

However O
, O
it O
may O
be O
important O
to O
consider O
the O
interplay O
between O
maternal O
and O
paternal O
influences O
as O
well O
as O
the O
experimental O
dissociation O
between O
experience-dependent O
and O
germline B-Species
transmission O
when O
exploring O
the O
role O
of O
epigenetic O
variation O
within O
the O
germline B-Species
as O
a O
mediator O
of O
these O
effects O

In O
this O
paper O
, O
we O
propose O
a O
novel O
formulation O
of O
SMCCA O
, O
called O
adaptive O
SMCCA O
, O
to O
overcome O
the O
problem O
by O
introducing O
adaptive O
weights O
when O
combining O
pairwise O
covariances O

Epigenetic O
modification O
of O
DNA B-Chemical
and O
DNA-associated O
histone B-Chemical
proteins O
has O
been O
demonstrated O
to O
control O
cell O
phenotype O
and O
regulate O
the O
renewal O
and O
pluripotency O
of O
stem O
cell O
populations O

Zygote O
microinjection O
of O
total O
small O
RNA O
from O
sperm O
of O
infected O
mice B-Species
partially O
recapitulates O
the O
behavioral O
phenotype O
of O
naturally O
born O
offspring O
, O
suggesting O
an O
epigenetic O
mechanism O
of O
behavioral O
inheritance O
in O
the O
first O
generation O

Experiments O
performed O
on O
four O
epigenetic O
datasets O
and O
several O
known O
datasets O
show O
that O
an O
imbalanced O
dataset O
can O
have O
similar O
accuracy O
as O
a O
regular O
learner O
on O
a O
balanced O
dataset O

43 O
) O

Here O
we O
describe O
how O
digestion O
of O
genomic O
plant B-Species
DNA O
with O
restriction O
enzymes O
, O
subsequent O
bisulfite O
conversion O
of O
unmethylated O
cytosines O
, O
and O
final O
DNA O
sequencing O
allow O
for O
the O
examination O
of O
genome-wide O
genetic O
and O
epigenetic O
variation O
in O
plants B-Species
without O
the O
need O
for O
a O
reference O

The O
growing O
interest O
in O
5hmC B-Chemical
, O
as O
well O
as O
in O
the O
Ten-Eleven B-Gene
Translocation I-Gene
( O
TET B-Gene
) O
family O
enzymes O
that O
catalyze O
its O
generation O
and O
further O
oxidation O
to O
5-formylcytosine B-Chemical
( O
5fC B-Chemical
) O
and O
5-carboxycytosine B-Chemical
( O
5caC B-Chemical

Additionally O
, O
several O
studies O
have O
characterized O
the O
effects O
of O
aging O
across O
the O
methylome O
in O
a O
wide O
variety O
of O
tissues O
from O
humans B-Species
and O
mice B-Species

However O
, O
current O
technologies O
in O
DPI B-Chemical
profiling O
still O
suffer O
from O
high O
cell O
demands O
, O
low O
detection O
sensitivity O
, O
and O
large O
reagent O
consumption O

The O
interplay O
between O
the O
epigenome O
and O
metabolome O
contributes O
to O
a O
biological O
system O
that O
is O
responsive O
to O
the O
tumor B-Disease
microenvironment I-Disease
and O
possesses O
a O
wealth O
of O
unknown O
biomarkers O
and O
targets O
of O
cancer B-Disease
therapy I-Disease

These O
findings O
could O
be O
of O
particular O
relevance O
for O
studies O
of O
complex O
neuropsychiatric B-Disease
traits O
, O
which O
often O
rely O
on O
proxy O
tissues O

In O
addition O
, O
they O
are O
involved O
in O
the O
control O
of O
plant B-Species
architecture O
by O
inhibiting O
bud O
outgrowth O
as O
well O
as O
many O
other O
morphological O
and O
developmental O
processes O
together O
with O
other O
plant B-Species
hormones O
such O
as O
auxins B-Chemical
and O
cytokinins B-Chemical

We O
present O
an O
overview O
of O
epigenetic O
regulation O
and O
a O
summary O
of O
reported O
evidence O
of O
environmental O
toxicants B-Chemical
as O
epigenetic O
disruptors O

While O
it O
is O
well O
recognized O
that O
methylation O
is O
tissue O
specific O
, O
a O
frequent O
limitation O
for O
many O
studies O
is O
that O
sampling-specific O
tissues O
may O
require O
sacrificing O
individuals O
, O
something O
which O
is O
generally O
undesirable O
and O
sometimes O
impossible O

Results O

We O
show O
that O
pseudotime O
analysis O
can O
be O
applied O
to O
DNA B-Gene
methylation I-Gene
in O
human B-Species
blood O
and O
brain O
tissue O
and O
find O
that O
it O
is O
highly O
correlated O
with O
the O
epigenetic O
states O
described O
by O
the O
Epigenetic B-Gene
Pacemaker I-Gene

The O
intricate O
pathological O
mechanisms O
of O
DCM B-Disease
cause O
diastolic O
dysfunction O
, O
followed O
by O
impaired O
systolic O
function O
in O
the O
late O
stages O

We O
explored O
the O
application O
of O
epigenetic O
clocks O
to O
measure O
the O
efficacy O
of O
interventions O
focusing O
on O
rejuvenation O

The O
modules O
begin O
with O
data O
collection O
and O
preprocessing O
, O
with O
further O
downstream O
analysis O
performed O
in O
a O
Vertex O
AI O
Jupyter O
notebook O
instance O
with O
an O
R O
kernel O

Transcriptional O
changes O
due O
to O
environmental O
factors O
are O
also O
involved O
in O
the O
progression O
of O
IPF B-Disease

Epigenetics O
, O
or O
the O
study O
of O
heritable O
( O
mitotically O
and/or O
meiotically O
) O
changes O
in O
gene O
activity O
that O
are O
not O
brought O
about O
by O
changes O
in O
the O
DNA B-Gene
sequence I-Gene
, O
can O
explain O
some O
types O
of O
ill O
health B-Disease
in O
offspring O
, O
which O
have O
been O
exposed O
to O
stressors O

Such O
divergent O
research O
foci O
can O
occasionally O
render O
the O
umbrella O
term O
" O
epigenetics B-Disease
" O
ambiguous O

There O
is O
a O
great O
deal O
of O
interest O
regarding O
the O
biological O
embedding O
of O
childhood B-Disease
trauma I-Disease
and O
social O
exposures O
through O
epigenetic O
mechanisms O
, O
including O
DNA B-Chemical
methylation I-Chemical
( O
DNAm B-Chemical
) O
, O
but O
a O
comprehensive O
understanding O
has O
been O
hindered O

This O
article O
demonstrates O
that O
this O
emphasis O
on O
the O
environment O
and O
on O
so-called O
Lamarckian O
inheritance O
, O
in O
addition O
to O
other O
factors O
, O
reflects O
an O
interdisciplinary O
power O
struggle O
with O
genetics O
, O
in O
which O
epigenetics O
appears O
to O
grant O
the O
social O
sciences O
a O
higher O
epistemic O
status O

Here O
, O
we O
review O
the O
contribution O
of O
dietary O
factors O
to O
the O
epigenetic O
changes O
observed O
in O
complex O
diseases O
and O
suggest O
future O
steps O
to O
better O
address O
this O
issue O
, O
focusing O
on O
neurobehavioral O
, O
neuropsychiatric O
and O
neurodegenerative O
disorders O
, O
cardiovascular B-Disease
diseases I-Disease
, O
obesity B-Disease

Differentially O
methylated O
region-representational O
difference O
analysis O
( O
DMR-RDA O
) O
is O
a O
sensitive O
and O
powerful O
PCR-based O
technique O
that O
isolates O
DNA B-Chemical
fragments O
that O
are O
differentially O
methylated O
between O
two O
otherwise O
identical O
genomes O

Historical O
studies O
implicated O
epigenetic O
alterations O
, O
particularly O
DNA B-Chemical
methylation I-Chemical
, O
in O
OA B-Disease
pathogenesis O
; O
however O
, O
recent O
technological O
advances O
have O
resulted O
in O
numerous O
epigenome-wide O
studies O
examining O
in O
detail O
epigenetic O
modifications O
in O
OA B-Disease

We O
also O
define O
the O
different O
types O
of O
mechanisms O
that O
have O
been O
found O
to O
mediate O
epigenetic O
inheritance O
and O
to O
regulate O
whether O
epigenetic O
information O
persists O
for O
one O
or O
many O
generations O

 O

We O
integrate O
these O
published O
methods O
into O
a O
single O
R O
function O
to O
produce O
158 O
previously O
published O
predictors O
for O
chronological O
age O
, O
biological O
age O
, O
exposures O
, O
lifestyle O
traits O
and O
serum O
protein O
levels O
using O
both O
classical O
and O
principal O
component-based O
methods O

1128 O
 O
Neuromuscular B-Disease
disorders I-Disease
( O
NMDs B-Disease
) O
include O
several O
hereditary O
or O
acquired O
conditions O
that O
impair O
the O
neuromuscular B-Disease
system I-Disease
and O
muscle O
function O
[ O

Further O
analyses O
in O
the O
same O
tissues O
revealed O
many O
DMCs O
( O
including O
non-CGs O
) O
and O
DMIs O
, O
which O
were O
highly O
correlated O
with O
the O
expression O
of O
genes O
involved O
in O
tissue O
development O

979 O
Purpose O
of O
review O
 O

Furthermore O
, O
we O
exploit O
the O
functional O
nature O
of O
the O
data O
and O
the O
spatial O
correlation O
across O
sites O
by O
assuming O
some O
Gaussian B-Chemical
processes O
on O
the O
fixed O
and O
latent O
coefficient O
vectors O
, O
respectively O

For O
example O
, O
variants O
in O
BABAM1 B-Gene
were O
confirmed O
as O
a O
susceptibility O
locus O
for O
squamous B-Disease
cell I-Disease
lung I-Disease
, O
overall O
breast B-Disease
, O
estrogen B-Chemical
receptor I-Chemical
( O
ER B-Gene
) O
- O
negative O
breast B-Disease
, O
and O
overall O
prostate B-Disease
, O
and O
overall O
serous B-Disease
ovarian I-Disease

Finally O
, O
the O
Review O
underscores O
the O
great O
potential O
of O
this O
field O
to O
enhance O
the O
effectiveness O
and O
safety O
of O
drug B-Chemical
treatments I-Chemical
through O
personalized O
medicine O

Finally O
, O
only O
germline-dependent O
epigenetic O
modifications O
can O
be O
truly O
transgenerational O

They O
study O
variation O
of O
DNA B-Gene
methylation I-Gene
in O
a O
wild O
population O
of O
the O
rare O
, O
long-lived O
violet O
Viola B-Species
cazorlensis I-Species
, O
and O
they O
use O
these O
data O
to O
explore O
interrelations O
between O
environmental O
, O
genetic O
and O
epigenetic O
variation O
, O
and O
in O
particular O
the O
extent O
to O
which O

This O
tool O
may O
be O
helpful O
in O
age O
assessment O
of O
adolescents O
and O
young O
adults O

This O
paper O
briefly O
summarizes O
the O
development O
of O
genomics O
, O
epigenomics O
, O
transcriptomics O
, O
proteomics O
and O
metabolomics O
, O
highlights O
the O
composition O
and O
function O
of O
multi-omics O
platforms O
as O
well O
as O
the O
applications O
of O
multi-omics O
technology O
, O
and O
prospects O
future O
applications O
of O
multi-omics O
in O
synthetic O
biology O

Site O
-specific O
DNA B-Gene
methylation I-Gene
differences O
were O
observed O
at O
age O
10 O
between O
monozygotic O
twins O
discordant O
for O
age-12 O
psychotic B-Disease
symptoms I-Disease

For O
example O
, O
exclusively O
H3K9me3 B-Chemical
marked O
segments O
are O
enriched O
, O
while O
poised O
and O
active O
states O
are O
rare O

Such O
genome-wide O
DNA B-Chemical
methylation I-Chemical
profiling O
has O
now O
firmly O
established O
the O
clinical O
relevance O
of O
translational O
epigenetics O

Together O
, O
our O
methods O
enable O
generalizable O
, O
versatile O
multimodal O
profiles O
for O
reconstructing O
comprehensive O
epigenome O
and O
transcriptome O
landscapes O
and O
analyzing O
the O
regulatory O
interplay O
at O
single-cell O
level O

This O
study O
provides O
insight O
into O
the O
roles O
of O
non-CpG B-Chemical
methylation I-Chemical
as O
an O
epigenetic O
code O
in O
the O
mammalian B-Species
brain I-Species
genome O

The O
fraction O
of O
such O
genes B-Gene
with O
a O
common O
proportionality O
coefficient O
increased O
with O
an O
increase O
in O
the O
robustness O
of O
the O
evolved O
network O

Based O
on O
the O
sequence O
context O
information O
available O
in O
, O
we O
also O
computed O
scores O
for O
off-target O
sites O

Recent O
preclinical O
and O
clinical O
studies O
show O
a O
therapeutic O
benefit O
of O
epigenetically O
active O
drugs O
for O
breast B-Disease
cancer I-Disease
entities O
that O
are O
still O
difficult O
to O
treat O
(triple O
negative O
, O
UICC O
stage O
IV O
) O

824 O
) O
and O
precise O
( O
2 O
) O

Analyses O
of O
genomic O
variations O
in O
many O
organisms O
have O
provided O
insights O
into O
phenotypic O
traits O
, O
evolution O
and O
disease B-Disease
, O
and O
are O
transforming O
medicine O

The O
metadata O
model O
captures O
the O
details O
of O
the O
experiments O
, O
raw O
and O
processed O
data O
files O
, O
and O
processing O
pipelines O
in O
human O
and O
machine-readable O
form O
and O
enables O
the O
user O
to O
search O
for O
specific O
data O
either O
using O
a O
web O
browser O
or O
programmatically O
via O
REST O
API O

A O
number O
of O
studies O
have O
performed O
molecular O
characterization O
of O
these O
different O
microglial B-Species
activation O
states O
over O
the O
last O
years O
making O
use O
of O
"omics" O
technologies O
, O
that O
is O
transcriptomics O
, O
proteomics O
and O
, O
less O
frequently O
, O
epigenomics O
profiling O

Finally O
, O
we O
conclude O
with O
insights O
from O
evolutionary O
psychobiology O
suggesting O
positive O
selection O
for O
discrete O
NDD-associated B-Disease
traits O

Given O
the O
dynamic O
and O
potentially O
reversible O
nature O
of O
the O
different O
types O
of O
epigenetic O
marks O
, O
environmental O
epigenetics O
constitutes O
a O
promising O
venue O
for O
developing O
fast O
and O
sensible O
biomonitoring O
programs O

Another O
genome-wide O
association O
study O
reports O
that O
single O
nucleotide O
polymorphisms O
mapping O
to O
the O
class O
II O
MHC B-Gene
region O
on O
chromosome O
6 O
contribute O
to O
lymphomagenesis B-Disease

To O
help O
researchers O
understand O
some O
of O
the O
misconceptions O
in O
the O
field O
and O
to O
communicate O
the O
science O
accurately O
to O
each O
other O
and O
the O
lay O
audience O
, O
here O
we O
review O
the O
basis O
for O
many O
of O
the O
assumptions O
made O
about O
what O
are O
currently O
referred O
to O
as O
epigenetic O
processes O

Epigenetic O
studies O
further O
report O
encouraging O
findings O
about O
the O
use O
of O
methylation B-Chemical
changes O
as O
diagnostic O
markers O
of O
disease B-Disease
phenotype O
and O
predictive O
tools O
of O
progression O
and O
response O
to O
treatment O

Much O
of O
this O
research O
examined O
epigenetic O
effects O
following O
exposure O
to O
toxicants O
, O
nutritional O
changes O
or O
infectious B-Disease
disease I-Disease
in O
those O
animals B-Species
directly O
exposed O
, O
or O
in O
the O
offspring O
they O
produced O

6 O
years O
across O
datasets O
(vs O

655 O

008 O
, O
- O
0 O

The O
robustness O
and O
plasticity O
are O
concerned O
with O
changeability O
of O
a O
biological O
system O
against O
external O
perturbations O

Like O
earlier O
models O
of O
temperament O
, O
the O
REAL O
constructs O
are O
defined O
in O
terms O
of O
how O
the O
child O
responds O
to O
environmental O
conditions O

Microbes O
have O
been O
observed O
more O
commonly O
in O
the O
body O
fluids O
like O
urine O
, O
stool O
, O
mucus O
of O
people O
with O
cancer B-Disease
compared O
to O
the O
healthy O
controls O

Moreover O
, O
compared O
to O
separate O
observations O
or O
single O
snapshots O
, O
spatial O
dimension O
and O
lineage O
time O
tracing O
can O
provide O
a O
more O
multifaceted O
understanding O
of O
the O
micro-environment O
and O
dynamic O
processes O

, O
MMPs O
, O
collagen O
, O
integrins O
) O
, O
IGFBP2 B-Gene
and O
NF-ÎºB B-Gene
signaling O
pathways O
, O
phospholipid O
metabolism O
, O
cytokines O
( O
e O

To O
support O
this O
claim O
, O
we O
reanalysed O
GEO O
datasets O
with O
an O
improved O
QC O
pipeline O
that O
reduced O
test-statistic O
inflation O
parameter O
lambda O
from O
the O
original O
mean/median O
of O
20 O

Two O
new O
research O
fields O
have O
recently O
been O
trying O
to O
give O
some O
answers O
 O
nutrigenomics B-Gene
and O
nutrigenetics B-Gene

( O
2017 O
) O
reveal O
a O
role O
for O
active O
DNA B-Chemical
demethylation I-Chemical
in O
allowing O
axon O
regeneration O
to O
occur O
in O
the O
mature O
nervous O
system O
following O
axonal O
injury B-Disease

e O

RNA O
interference O
, O
histone B-Chemical
modification I-Chemical
, O
DNA B-Chemical
methylation I-Chemical
and O
chromatin B-Chemical
remodelling I-Chemical
are O
epigenetic O
processes O
that O
control O
gene B-Gene
expression I-Gene
without O
causing O
mutations O
in O
the O
DNA B-Chemical

We O
argue O
that O
Darwin's B-Species
lasting O
and O
multifaceted O
interest O
in O
the O
notion O
of O
habit O
, O
throughout O
his O
intellectual O
life O
, O
is O
both O
conceptually O
and O
methodologically O
relevant O

With O
the O
emergence O
of O
CRISPR-based B-Gene
epigenomic O
editing O
, O
it O
is O
now O
possible O
to O
investigate O
the O
direct O
role O
of O
locus-specific O
epigenetic O
alterations O
in O
metastatic B-Disease
progression O

443Background O
The O
functional O
impact O
of O
genetic O
variation O
has O
been O
extensively O
surveyed O
, O
revealing O
that O
genetic O
changes O
correlated O
to O
phenotypes O
lie O
mostly O
in O
non-coding O
genomic O
regions O

88%) O
showed O
statistically O
significant O
DNA-M B-Gene
changes O
from O
pre-adolescence O
to O
post-adolescence O
invariant O
to O
gender O
(false O
discovery O
rate O
(FDR) O
= O
0 O

this O

However O
, O
growing O
evidence O
shows O
that O
alterations O
in O
molecular O
mediators O
associated O
with O
the O
diagnosis O
of O
CMPs B-Disease
are O
not O
always O
correlated O
with O
genetic O
mutations O
, O
suggesting O
that O
additional O
mechanisms O
, O
such O
as O
epigenetics O
, O
may O
play O
a O
role O
in O
the O
onset O
or O
progression O
of O

It O
requires O
minimal O
efforts O
to O
build O
and O
is O
well-documented O
via O
a O
complete O
docXygen O
guide O
, O
online O
documentation O
and O
tutorials O

In O
this O
article O
, O
we O
review O
some O
current O
strategies O
to O
unravel O
these O
translational O
gaps O
as O
well O
as O
prospects O
for O
the O
implementation O
of O
genetic O
and O
epigenetic O
methods O
into O
novel O
clinical O
practice O

Whether O
directly O
or O
indirectly O
, O
arsenic B-Chemical
modulates O
epigenetic O
gene B-Gene
regulation O
and O
our O
understanding O
of O
the O
direct O
effect O
of O
this O
modulation O
on O
chromatin B-Gene
structure I-Gene
is O
limited O

The O
tight O
control O
of O
all O
these O
mechanisms O
defines O
the O
final O
cellular O
character O

ChIP-S3EQ O

Then O
, O
a O
comparison O
will O
be O
made O
between O
the O
principles O
of O
the O
cumulative O
theory O
of O
aging O
and O
the O
basic O
facts O
underlying O
the O
epigenetic O
model O
of O
aging O
, O
including O

While O
the O
majority O
of O
genetic O
, O
epigenetic O
, O
and O
gene O
expression O
analyses O
to O
date O
have O
focused O
on O
targeted O
genes B-Gene
and O
hypotheses O
, O
large-scale O
consortia O
are O
now O
well-positioned O
to O
better O
understand O
interactions O
of O
environment O
and O
biology O
with O
much O
more O
statistical O
power O

MeDeCom O
is O
based O
on O
constrained O
non-negative O
matrix O
factorization O
with O
a O
new O
biologically O
motivated O
regularization O
function O

To O
characterize O
enactments O
of O
biosocial O
complexity O
, O
the O
article O
develops O
the O
concepts O
of O
complexity O
work O
and O
complexification O

5 O
by O
whole-genome O
shotgun O
bisulfite O
sequencing O


664 O
The O
Epigenomics O
resource O
at O
the O
National O
Center O
for O
Biotechnology O
Information O
( O
NCBI O
) O
has O
been O
created O
to O
serve O
as O
a O
comprehensive O
public O
repository O
for O
whole-genome O
epigenetic O
data O
sets O
( O
www O

This O
body O
of O
work O
has O
linked O
the O
biological O
aging O
of O
MSC B-Species
to O
changes O
in O
their O
epigenetic O
signatures O
affecting O
growth O
, O
lifespan O
, O
self-renewal O
and O
multi-potential O
, O
due O
to O
deregulation O
of O
processes O
such O
as O
cellular O
senescence B-Disease
, O
oxidative B-Chemical
stress I-Chemical
, O
DNA B-Gene

Advances O
in O
Machine O
Learning O
( O
ML O
) O
are O
critical O
to O
realize O
this O
promise O

, O
environmental O
pollution O
and O
food O
additives O

Summary O
 O
Recent O
conceptual O
advances O
in O
the O
field O
of O
DNA B-Gene
methylation I-Gene
and O
the O
advent O
and O
rapid O
development O
of O
new O
technologies O
in O
epigenomics O
have O
started O
to O
unravel O
the O
mechanisms O
underlying O
aberrant O
DNA B-Gene
methylation I-Gene
in O
cancer B-Disease
cells I-Disease
and O
identify O
novel O
targets O
for O

528 O
Motivation O
Epigenetic O
data O
are O
invaluable O
when O
determining O
the O
regulatory O
programs O
governing O
a O
cell O

Nutritional O
imbalances O
are O
associated O
with O
noncommunicable B-Disease
diseases I-Disease

We O
show O
empirically O
that O
the O
epigenomic O
data O
normalized O
by O
our O
method O
, O
compared O
to O
existing O
methods O
, O
can O
better O
capture O
real O
biological O
variation O
, O
such O
as O
impact O
on O
gene B-Gene
expression I-Gene
regulation I-Gene

Transcription O
factor O
binding O
site O
enrichment O
revealed O
enrichment O
of O
transcription O
factors O
related O
to O
critical O
developmental O
processes O
and O
sex O
determination O
such O
as O
SRY B-Gene
and O
ESR1 B-Gene

8 O
Why O
do O
we O
grow O
up O
to O
have O
the O
traits O
we O
do O
? O
Most O
20th O
century O
scientists O
answered O
this O
question O
by O
referring O
only O
to O
our O
genes B-Gene
and O
our O
environments O

With O
evidence O
that O
95% O
of O
cases O
of O
spontaneous O
preterm O
birth O
are O
intractable O
to O
current O
interventions O
, O
our O
best O
hope O
in O
resolving O
this O
problem O
may O
lie O
in O
new O
, O
innovative O
ideas O

1214Background O
Body O
size O
, O
nutrition O
and O
socioeconomic O
position O
( O
SEP O
) O
in O
early O
life O
have O
been O
associated O
with O
a O
wide O
range O
of O
long-term O
health O
effects O

Whole-genome O
bisulfite O
sequencing O
( O
WGBS O
) O
, O
such O
as O
MethylC-seq O
and O
post-bisulfite O
adaptor O
tagging O
sequencing O
( O
PBAT-seq O
) O
, O
uses O
the O
power O
of O
high-throughput O
DNA B-Chemical
sequencers O
and O
provides O
genome-wide O
DNA B-Chemical
methylation O
profiles O
at O
single-base O
resolution O

DNA B-Chemical
N6-methyladenine I-Chemical
( O
6mA O
) O
, O
which O
is O
a O
prevalent O
epigenetic O
modification O
, O
plays O
important O
roles O
in O
a O
series O
of O
biological O
processes O


842 O
There O
are O
functional O
benefits O
to O
exercise O
in O
muscle O
, O
even O
when O
performed O
late O
in O
life O
, O
but O
the O
contributions O
of O
epigenetic O
factors O
to O
late-life O
exercise O
adaptation O
are O
poorly O
defined O

It O
can O
also O
use O
different O
hierarchies O
of O
cell O
types O
to O
highlight O
the O
epigenetic O
history O
specific O
to O
any O
particular O
cell O
lineage O

Materials O
and O
methods O
 O
GLDC B-Gene
expression O
and O
epigenetics O
were O
investigated O
using O
GC B-Disease
cell I-Disease
lines I-Disease
and O
tissues O

Extensive O
research O
provides O
evidence O
that O
epigenetic O
alterations O
are O
critical O
for O
SSc B-Disease
pathogenesis O

Moreover O
, O
our O
findings O
indicate O
that O
offspring O
would O
thrive O
in O
the O
heterogeneous O
lead B-Chemical
environment O
if O
they O
did O
not O
experience O
lead B-Chemical
pollution O
in O
the O
past O
, O
their O
progeny O
will O
avoid O
lead B-Chemical
toxicity O
by O
reducing O
underground O
biomass O
allocation O

harvard O

560 O
Fetal B-Disease
exposure O
to O
prenatal O
stress O
can O
have O
significant O
consequences O
on O
short- O
and O
long-term O
health O

The O
three O
major O
classes O
of O
epigenetic O
effectors O
are O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
post-translational I-Chemical
modifications I-Chemical
( O
such O
as O
acetylation B-Chemical
, O
methylation B-Chemical
or O
phosphorylation B-Chemical
) O
and O
small O
noncoding O
RNAs B-Chemical
( O
most O
notably O
microRNAs B-Chemical
) O

Many O
other O
non-canonical O
players O
, O
such O
as O
chromatin B-Chemical
regulators O
and O
noncoding O
RNAs O
, O
are O
also O
involved O
in O
regulating O
gene B-Gene
expression I-Gene

In O
this O
Review O
, O
we O
discuss O
recent O
evidence O
in O
support O
of O
a O
novel O
concept O
whereby O
cell-intrinsic O
damage O
that O
accumulates O
during O
ageing O
and O
cell-extrinsic O
changes O
in O
ageing O
stem O
cell O
niches O
and O
the O
blood O
result O
in O
modifications O
of O
the O
stem O
cell O
epigenome O

Future O
examinations O
of O
epigenetic O
mechanisms O
in O
these O
insects B-Species
will O
benefit O
from O
comparison O
of O
tissues O
from O
aged-matched O
individuals O
from O
alternative O
morphs O
, O
and O
adequate O
biological O
replication O

Epigenetic O
modification O
of O
chromatin O
plays O
a O
pivotal O
role O
in O
regulating O
gene O
expression O
during O
cell O
differentiation O

Current O
genetic O
and O
epigenetic O
studies O
are O
finally O
shedding O
light O
on O
the O
biomolecular O
mechanisms O
linked O
to O
the O
core O
pathogenetic O
alterations O
in O
schizophrenia B-Disease
, O
rather O
than O
just O
their O
symptoms O

Epigenetics O
is O
an O
evolving O
field O
and O
could O
be O
highly O
relevant O
to O
many O
paediatric B-Disease
cancers I-Disease
; O
the O
biology O
is O
multifaceted O
and O
new O
targets O
are O
frequently O
emerging O

1109 O
Urothelial B-Disease
carcinoma I-Disease
of O
the O
bladder O
is O
one O
of O
the O
most O
common O
malignancies O
in O
the O
industrialized O
world O
, O
mainly O
caused O
by O
smoking O
and O
occupational O
exposure O
to O
chemicals B-Chemical

194 O
Growing O
cancer B-Disease
incidence O
and O
mortality O
worldwide O
demands O
development O
of O
accurate O
biomarkers O
to O
perfect O
detection O
, O
diagnosis O
, O
prognostication O
and O
monitoring O

514 O
 O
Background O
 O
Modulating O
the O
epigenome O
has O
long O
been O
considered O
a O
potential O
opportunity O
for O
therapeutic O
intervention O
in O
numerous O
disease O
areas O
with O
several O
approved O
therapies O
marketed O
, O
primarily O
for O
cancer B-Disease

Various O
protocols O
are O
available O
for O
genome-wide O
bisulfite O
sequencing O
and O
here O
I O
describe O
an O
optimized O
method O
based O
on O
Post O
Bisulfite O
Adapter O
Tagging O
( O
PBAT O
) O
for O
low O
amounts O
of O
DNA B-Chemical
or O
cells O
, O
with O
as O
little O
as O
50 O
cells O
as O
minimum O
requirement O
, O
and O
with O
the O

We O
also O
discuss O
what O
dictates O
whether O
the O
presence O
of O
an O
altered O
nucleobase O
is O
defined O
as O
damage B-Disease
or O
a O
natural O
modification O

These O
primers O
, O
mainly O
those O
developed O
on O
matK B-Gene
, O
were O
able O
to O
recognize O
saffron B-Species
and O
the O
adulterant O
species O
and O
also O
in O
mixtures O
with O
very O
low O
percentages O
of O
adulterant O

epigenomics O

Here O
, O
we O
generate O
a O
large O
single-cell O
DNA O
methylation O
and O
transcriptome O
dataset O
from O
mouse B-Species
peripheral O
blood O
samples O
, O
spanning O
a O
broad O
range O
of O
ages O

Our O
novel O
CHO B-Species
- I-Species
specific I-Species
CpG B-Gene
island I-Gene
microarray O
will O
provide O
valuable O
information O
in O
future O
studies O
of O
cellular O
processes O
associated O
with O
productivity O
and O
product O
characteristics O

g O

Indeed O
, O
several O
epigenetic O
biomarkers O
have O
been O
successfully O
developed O
and O
applied O
in O
traditional O
model O
organisms O
( O
e O

While O
the O
benzoxazinone B-Chemical
series O
showed O
low O
affinity O
for O
the O
CREBBP B-Gene
bromodomain O
, O
expansion O
of O
the O
dihydroquinoxalinone B-Chemical
series O
resulted O
in O
the O
first O
potent O
inhibitors O
of O
a O
bromodomain O
outside O
the O
BET B-Gene
family O


647 O
Hydroxymethylcytosine B-Chemical
(hmC O
or O
5-hmC O
) O
is O
a O
nitrogen O
base O
occurring O
as O
a O
result O
of O
cytosine B-Chemical
methylation O
followed O
by O
replacing O
a O
methyl B-Chemical
group O
with O
a O
hydroxyl B-Chemical
group O
through O
active O
oxidation O

Further O
, O
it O
may O
allow O
the O
gradual O
achievement O
of O
whole O
body O
rejuvenation O

Most O
reports O
of O
this O
process O
evaluate O
the O
association O
of O
a O
lifetime O
exposure O
in O
ancestors O
with O
changes O
in O
DNA B-Gene
methylation I-Gene
or O
small O
RNA B-Gene
expression I-Gene
in O
germ O
cells O
, O
as O
well O
as O
the O
association O
between O
ancestral O
experiences O
and O
the O
inheritance O
of O
a O
phenotype O
in O
descendants O
, O

Supporting O
functional O
relevance O
of O
this O
largely O
unknown O
regulatory O
mechanism O
, O
several O
human O
diseases B-Disease
have O
been O
associated O
directly O
to O
RNA B-Gene
modifications O
or O
to O
RBPs B-Gene
that O
may O
play O
as O
effectors O
of O
epitranscriptomic O
marks O

1435 O
 O
Non-alcoholic B-Disease
fatty I-Disease
liver I-Disease
disease I-Disease
( O
NAFLD B-Disease
) O
is O
estimated O
to O
affect O
24 O
% O
of O
the O
global O
adult O
population O

Conclusion O
 O
Adolescent O
transition O
is O
associated O
with O
changes O
in O
DNA-M B-Gene
at O
more O
than O
15K O
CpGs O

The O
aim O
of O
the O
study O
was O
to O
investigate O
the O
DNA B-Gene
methylation I-Gene
profile O
in O
peripheral O
leukocytes O
associated O
with O
elevated O
LDL-cholesterol B-Chemical
level O
in O
overweight O
and O
obese O
individuals O

1010 O
Research O
involving O
ancient O
DNA B-Chemical
(aDNA) I-Chemical
has O
experienced O
a O
true O
technological O
revolution O
in O
recent O
years O
through O
advances O
in O
the O
recovery O
of O
aDNA B-Chemical
and O
, O
particularly O
, O
through O
applications O
of O
high-throughput O
sequencing O

We O
use O
a O
' O
pan-mammalian B-Species
' O
microarray O
that O
provides O
a O
common O
platform O
for O
assaying O
the O
methylome O
across O
mammalian B-Species
clades O


Based O
on O
these O
insights O
, O
we O
propose O
a O
method O
, O
EPISTRUCTURE O
, O
for O
the O
inference O
of O
ancestry O
from O
methylation B-Chemical
data O
, O
without O
the O
need O
for O
genotype B-Gene
data O

Here O
we O
describe O
the O
online O
tool O
EpiAnnotator O
for O
performing O
enrichment O
analyses O
on O
epigenomic O
data O
in O
a O
fast O
and O
user-friendly O
way O

292 O
The O
future O
of O
drug O
design O
and O
the O
development O
of O
new O
therapeutics O
will O
rely O
on O
our O
ability O
to O
unravel O
the O
complexities O
of O
the O
epigenome O
in O
normal O
and O
disease B-Disease
states O

We O
also O
showed O
that O
our O
proposed O
model O
is O
particularly O
efficient O
when O
the O
number O
of O
columns O
is O
much O
greater O
than O
the O
number O
of O
rows-which O
is O
usually O
the O
case O
in O
methylation B-Chemical
data O
analysis O

This O
study O
exhaustively O
reviews O
the O
current O
research O
advancements O
in O
understanding O
of O
dysbiosis O
linked O
with O
colon O
 B-Disease
, O
lung O
 B-Disease
, O
ovarian O
 B-Disease
, O
breast O
 B-Disease
cancers O
and O
insights O
into O
the O
potential O
molecular O
targets O
of O
the O
microbiome O
promoting O
carcinogenesis O
, O
the O
epigenetic O
alterations O

A O
total O
of O
408 O
patients O
met O
all O
inclusion O
criteria O

1087 O
verO O
the O
past O
two O
decades O
, O
a O
growing O
interest O
on O
the O
research O
of O
the O
biological O
basis O
of O
human B-Species
longevity O
has O
emerged O
, O
in O
order O
to O
clarify O
the O
intricacy O
of O
biological O
and O
environmental O
factors O
affecting O
( O
together O
with O
stochastic O
factors O
) O
the O
quality O
and O

Metabolism O
produces O
various O
metabolites O
that O
are O
substrates O
, O
cofactors O
, O
or O
inhibitors O
of O
epigenetic O
enzymes O

62 O
years O

At O
present O
, O
DNA B-Gene
methylation I-Gene
is O
the O
most O
promising O
biological O
biomarker O
applied O
for O
age O
assessment O

263 O
Shortly O
after O
gene B-Gene
transfer I-Gene
technologies O
had O
been O
established O
for O
different O
plant B-Species
species I-Species
, O
the O
first O
reports O
emerged O
about O
transgenes O
showing O
unexpected O
segregation O
patterns O
due O
to O
unstable O
expression O

Here O
, O
we O
review O
operational O
definitions O
of O
transgenerational O
inheritance O
and O
the O
processes O
of O
epigenetic O
programing O
during O
early O
development O

Here O
, O
we O
discuss O
our O
understanding O
of O
the O
interplay O
that O
exists O
between O
genetic O
and O
epigenetic O
mechanisms O
in O
these O
disorders O
, O
highlighting O
the O
nascent O
field O
of O
epigenetic O
epidemiology O
- O
which O
focuses O
on O
analyzing O
relationships O
between O
the O
epigenome O
and O
environmental O
exposures O
, O
development O
and O

However O
, O
our O
understanding O
of O
the O
genetic O
architecture O
of O
BPD B-Disease
is O
very O
limited O

Addressing O
DNA B-Gene
methylation O
status O
of O
drug-metabolizing O
enzymes O
and O
transporters O
( O
DMET B-Gene
) O
is O
challenging O
and O
might O
provide O
answers O
in O
relation O
to O
interindividual O
differences O
in O
pharmacokinetics O
and O
pharmacodynamics O

Four O
activity-related O
transcription O
factors O
are O
required O
in O
dopaminergic B-Species
neurons O
for O
the O
effects O
of O
social O
environment O
on O
sleep O

Hence O
, O
epigenetics O
research O
may O
help O
to O
understand O
the O
mechanisms O
leading O
to O
suicidal B-Disease
ideation I-Disease
and O
behavior O

Among O
many O
epigenetic O
mechanisms O
, O
covalent O
modifications O
such O
as O
acetylation B-Chemical
and O
methylation B-Chemical
of O
lysine B-Chemical
residues O
on O
core O
histones B-Gene
emerged O
as O
a O
major O
mechanism O
in O
epigenetic O
regulation O

However O
, O
Waddington O
referred O
first O
to O
the O
notion O
in O
the O
late O
1930s O

1117 O
Considered O
to O
be O
a O
field O
that O
is O
continuously O
growing O
, O
epitranscriptomics O
analyzes O
the O
modifications O
that O
occur O
in O
RNA B-Gene
transcripts I-Gene
and O
their O
downstream O
effects O

Epigenetic O
alterations O
are O
innovative O
cancer B-Disease
biomarkers O
owing O
to O
stability O
, O
frequency O
, O
reversibility O
and O
accessibility O
in O
body O
fluids O
, O
entailing O
great O
potential O
of O
assay O
development O
to O
assist O
in O
patient O
management O

Among O
other O
factors O
, O
primary O
chromatin B-Chemical
structure O
and O
epigenetics O
may O
influence O
off-target O
activity O

This O
method O
is O
cost-effective O
, O
requires O
simple O
and O
basic O
instrumentation O
, O
and O
therefore O
can O
easily O
be O
performed O
in O
any O
laboratory O
with O
basic O
setup O
having O
a O
regular O
DNA B-Chemical
thermal I-Chemical
cycler I-Chemical
and O
DNA B-Chemical
gel I-Chemical
electrophoresis I-Chemical
system O

880 O
 O
Patients O
suffering O
from O
psychiatric B-Disease
disorders I-Disease
have O
a O
life O
span O
burden O
, O
which O
represents O
an O
enormous O
human O
, O
family O
, O
social O
, O
and O
economical O
cost O

In O
this O
study O
, O
we O
identified O
examples O
of O
epigenetic O
patterns O
associated O
with O
ELA O
experiences O
of O
threat O
and O
deprivation O
that O
were O
already O
observable O
in O
youth O

PCOS O
is O
a O
polygenic O
and O
multifactorial O
hormonal O
and O
metabolic O
dysfunction O

These O
findings O
have O
revealed O
that O
the O
epigenetic O
modification O
of O
nucleic B-Chemical
acids I-Chemical
has O
considerable O
significance O
in O
various O
areas O
from O
methodology O
to O
clinical B-Disease
medicine I-Disease
and O
even O
in O
biomedical O
applications O

Among O
the O
epigenetic O
targets O
are O
the O
writer O
and O
eraser O
enzymes O
that O
are O
, O
respectively O
, O
responsible O
for O
the O
reversible O
introduction O
and O
removal O
of O
structural O
modifications O
in O
the O
nucleosome O

To O
make O
the O
functionality O
accessible O
to O
biologists O
, O
and O
to O
facilitate O
reproducible O
analysis O
, O
we O
have O
also O
developed O
a O
web-based O
interface O
providing O
an O
expertly O
guided O
and O
customizable O
way O
of O
utilizing O
the O
methodology O

Stem O
Cells O
Translational O
Medicine O
2019 O
; O
8 O
 O
75 O
- O
81 O

We O
will O
address O
considerations O
for O
all O
steps O
required O
to O
plan O
and O
conduct O
an O
analysis O
of O
DNA B-Gene
methylation O
, O
from O
appropriate O
sample O
collection O
, O
to O
the O
most O
commonly O
used O
methods O
for O
laboratory O
analyses O
of O
locus-specific O
and O
genome-wide O
approaches O
, O
and O
recommendations O
for O
statistical O
analyses O

However O
, O
with O
the O
rise O
of O
epigenetics O
, O
science O
and O
the O
public O
understanding O
of O
science O
is O
leaving O
an O
era O
in O
which O
the O
DNA B-Gene
sequence I-Gene
was O
thought O
to O
be O
" O
destiny O
" O
and O
entering O
an O
era O
where O
the O
environment O
shapes O
the O
biology O
and O
behavior O
of O
individuals O
and O

Again O
, O
these O
pathway O
maps O
are O
miscellaneous O
without O
an O
obvious O
relationship O
to O
epigenetic O
inheritance O

On O
the O
basis O
of O
EWAS1 B-Gene

Here O
, O
we O
utilize O
a O
quantitative O
molecular O
marker O
of O
aging O
( O
known O
as O
the O
epigenetic O
clock O
) O
to O
demonstrate O
that O
trisomy B-Disease
21 I-Disease
significantly O
increases O
the O
age O
of O
blood O
and O
brain O
tissue O
( O
on O
average O
by O
6 O

Based O
on O
Fisherian O
p-values O
, O
we O
set O
a O
threshold O
for O
methylation O
differences O
" O
worth O
further O
scrutiny O
" O

Genetic O
factors O
are O
not O
associated O
with O
distinct O
psychiatric B-Disease
disorders I-Disease
, O
but O
rather O
diverse O
clinical O
phenotypes O

We O
then O
describe O
the O
techniques O
that O
have O
been O
used O
to O
investigate O
DNA B-Gene
methylation O
in O
marine B-Species
fishes I-Species
to O
date O
and O
highlight O
some O
new O
techniques O
that O
hold O
great O
promise O
for O
future O
studies O

This O
eliminates O
tip O
costs O
and O
reduces O
the O
risk O
of O
reagent B-Chemical
carryover O

ALEA O
provides O
a O
customizable O
pipeline O
of O
command O
line O
tools O
for O
allele-specific O
analysis O
of O
next-generation O
sequencing O
data O
( O
ChIP-seq O
, O
RNA-seq O
, O
etc O

The O
metastatic O
cascade O
comprises O
a O
complex O
range O
of O
molecular O
events O
that O
cannot O
be O
explained O
by O
genetic O
aberrations O
alone O
; O
dynamic O
, O
epigenetic O
regulatory O
mechanisms O
are O
now O
being O
implicated O
as O
key O
drivers O
of O
successful O
metastasis B-Disease

We O
used O
the O
enhancer O
and O
promoter O
regions O
as O
the O
annotation O
features O
and O
ChIP-seq B-Gene
signal I-Gene
values O
in O
these O
regions O
as O
the O
feature O
values O

Ï O
= O
0 O

290 O
 O
The O
"CpG O
Island O
Methylator O
Phenotype O
" O
( O
CIMP O
) O
has O
been O
found O
to O
be O
a O
useful O
concept O
in O
stratifying O
several O
types O
of O
human O
cancer B-Disease
into O
molecularly O
and O
clinically O
distinguishable O
subgroups O

The O
present O
review O
provides O
a O
contextual O
background O
to O
CCS B-Gene
research O
and O
a O
theoretical O
framework O
discussing O
the O
potential O
uses O
of O
this O
novel O
epigenomic O
biomarker O
within O
sport O
and O
exercise O
science O
and O
medicine O

For O
complete O
details O
on O
the O
use O
and O
execution O
of O
this O
protocol O
, O
please O
refer O
to O
Loukas B-Gene
et O
al O

In O
this O
review O
, O
we O
highlight O
key O
findings O
from O
the O
stress O
, O
MDD B-Disease
, O
and O
learning O
and O
memory O
fields O
to O
propose O
a O
model O
where O
stress O
regulates O
downstream O
cellular O
functioning O
through O
activity-dependent O
epigenetic O
changes O

In O
recent O
years O
, O
multi-omics O
research O
and O
the O
analysis O
of O
differential O
epigenetic O
marks O
in O
AD B-Disease
subjects O
have O
contributed O
to O
our O
understanding O
of O
AD B-Disease
; O
however O
, O
the O
impact O
of O
epigenetic O
research O
is O
yet O
to O
be O
seen O

In O
the O
present O
article O
, O
we O
have O
described O
and O
advocated O
the O
epigenetic O
role O
in O
Aging B-Disease
and O
associated O
diseases O

DNA O
methylation O
refers O
to O
CpG B-Chemical
islands I-Chemical
, O
generally O
leading O
to O
tumour B-Disease
suppressor I-Disease
gene B-Gene
transcriptional I-Gene
silencing O

Adjustment O
for O
baseline O
outcome O
provided O
greater O
power O
and O
more O
accurate O
control O
of O
Type B-Disease
I I-Disease
error O
rates O
than O
computation O
of O
a O
pre-to-post O
change O
score O

The O
intricate O
interplay O
between O
these O
factors O
offers O
insights O
into O
genetic O
and O
epigenetic O
mechanisms O
in O
IEIs B-Disease

This O
paper O
reviews O
all O
existing O
risk O
factors O
affecting O
DDH B-Disease
incidence O
, O
along O
with O
candidate O
genes O
associated O
with O
genetic O
or O
epigenetic O
etiology O
of O
DDH B-Disease
in O
various O
studies O

g O

Recent O
advances O
in O
the O
field O
of O
epigenetics O
suggest O
that O
epigenetic O
factors O
such O
as O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical
, O
as O
well O
as O
regulatory O
processes O
involving O
non-coding O
RNA B-Gene
are O
associated O
with O
the O
long-term O
sequelae O
of O
CT B-Disease

Traditionally O
, O
it O
has O
been O
thought O
that O
such O
differences O
are O
due O
largely O
to O
hormonal O
regulation O
; O
however O
, O
there O
are O
also O
genetic O
and O
epigenetic O
effects O
caused O
by O
the O
inheritance O
and O
unequal O
dosage O
of O
genes B-Gene
located O
on O
the O
X B-Gene
and O
Y B-Gene
chromosomes O

The O
resulting O
pathways O
were O
found O
to O
be O
representative O
of O
well-established O
molecular O
events O
known O
to O
occur O
in O
response O
to O
arsenic B-Chemical
exposure O

Elucidating O
these O
complex O
biosocial O
loops O
is O
one O
of O
the O
main O
challenges O
animating O
epigenetics O

See O
related O
article O
by O
Luebeck O
et O
al O

g O

These O
considerations O
suggest O
that O
epidemiological O
approaches O
will O
remain O
fruitful O
as O
we O
enter O
the O
decade O
of O
the O
epigenome O

Large O
numbers O
of O
individually O
sequenced O
libraries O
are O
costly O

Over O
his O
entire O
life O
Darwin B-Species
has O
modified O
and O
reassessed O
his O
views O
on O
habits O
as O
many O
times O
as O
required O
by O
evidence O
 O
his O
work O
on O
this O
notion O
may O
represent O
the O
paradigm O
of O
a O
habit O
of O
good O
scientific O
research O
methodology O

Using O
data O
from O
four O
cohorts O
, O
we O
trained O
and O
tested O
epigenetic O
scores O
( O
EpiScores O
) O
for O
953 O
plasma O
proteins O
, O
identifying O
109 O
scores O
that O
explained O
between O
1% O
and O
58% O
of O
the O
variance O
in O
protein O
levels O
after O
adjusting O
for O
known O
protein O
quantitative O
trait O
loci O
( O

367 O
Interactions O
of O
drugs O
with O
the O
classical O
epigenetic O
mechanism O
of O
DNA B-Gene
methylation I-Gene
or O
histone B-Gene
modification I-Gene
are O
increasingly O
being O
elucidated O
mechanistically O
and O
used O
to O
develop O
novel O
classes O
of O
epigenetic O
therapeutics O

minary@cs O

Here O
, O
we O
summarize O
data O
supporting O
different O
molecular O
mechanisms O
that O
could O
mediate O
the O
primarily O
tumor B-Disease
suppressive I-Disease
function O
of O
macroH2A B-Gene

Not O
only O
innate O
system O
cells O
, O
such O
as O
macrophages O
, O
monocytes O
, O
and O
natural O
killer O
cells O
, O
but O
also O
bone O
marrow O
hematopoietic O
stem O
cells O
( O
HSCs B-Gene
) O
have O
been O
found O
to O
gain O
memories O
upon O
transient O
stimulation O
, O
leading O
to O
the O
enhancement O
of O
responses O
to O
secondary O

Notably O
, O
KMT2A-fusions B-Gene
are O
prevalent O
in O
70% O
of O
infant B-Disease
leukaemias I-Disease
but O
fail O
to O
phenocopy O
short O
latency O
leukaemogenesis B-Disease
in O
mammalian B-Species
models I-Species
, O
suggesting O
additional O
factors O
are O
necessary O
for O
transformation O

Since O
life O
is O
a O
complex O
regulatory O
system O
in O
which O
the O
regulation O
of O
gene B-Gene
mutations I-Gene
, O
epigenetic O
alterations O
, O
abnormal O
gene B-Gene
expression I-Gene
as O
well O
as O
anomalous O
variations O
in O
signal O
pathway O
are O
related O
with O
the O
occurrence O
and O
development O
of O
diseases B-Disease
, O
it O
is O
obvious O

Oxidation O
products O
of O
5mC B-Chemical
are O
now O
thought O
to O
be O
intermediates O
in O
active O
demethylation O
as O
well O
as O
epigenetic O
marks O
in O
their O
own O
rights O

Microbiomics O
involves O
a O
remarkable O
potential O
to O
understand O
ancient O
biology O
, O
disease B-Disease
, O
and O
stress O

1354 O
Post-traumatic B-Disease
stress I-Disease
disorder I-Disease
( O
PTSD B-Disease
) O
is O
a O
psychiatric O
disorder O
that O
can O
develop O
following O
exposure O
to O
or O
witnessing O
of O
a O
( O
potentially O
) O
threatening O
event O

Among O
different O
methodological O
approaches O
tested O
to O
date O
, O
the O
methylation-sensitive O
analysis O
of O
carefully O
selected O
markers O
( O
sites O
) O
has O
brought O
the O
most O
promising O
results O
by O
providing O
prediction O
accuracies O
of O
Â±3-4 O
years O
, O
which O
can O
be O
comparable O
to O
, O
or O
even O
surpass O

There O
is O
considerable O
discordance O
for O
psychotic B-Disease
symptoms I-Disease
between O
monozygotic B-Species
twins I-Species
, O
indicating O
that O
child-specific O
non-genetic O
factors O
must O
be O
involved O

This O
Review O
highlights O
advances O
from O
the O
past O
5 O
years O
in O
the O
field O
of O
epigenetics O
and O
their O
application O
to O
inflammatory B-Disease
rheumatic I-Disease
diseases I-Disease
, O
delineating O
the O
future O
lines O
of O
development O
for O
a O
rational O
use O
of O
epigenetic O
information O
in O
clinical O
settings O
and O
in O
personalized O
medicine O

Through O
extensive O
optimization O
for O
sensitivity O
and O
multimodality O
resolution O
, O
we O
demonstrate O
that O
uCoTarget O
enables O
simultaneous O
detection O
of O
five O
histone O
modifications O
( O
H3K27ac B-Chemical
, O
H3K4me3 B-Chemical
, O
H3K4me1 B-Chemical
, O
H3K36me3 B-Chemical
, O
and O
H3K27me3 B-Chemical
) O

Second O
, O
insights O
from O
human B-Species
biology O
are O
examined O
regarding O
some O
epigenetic O
factors O
and O
disease B-Disease
etiology O

392Background O
Diseases B-Disease
are O
complex O
phenotypes O
often O
arising O
as O
an O
emergent O
property O
of O
a O
non-linear O
network O
of O
genetic O
and O
epigenetic O
interactions O

In O
the O
last O
few O
years O
, O
epigenetic O
mechanisms O
were O
increasingly O
put O
forward O
in O
this O
context O
because O
of O
their O
pivotal O
role O
in O
gene-environment O
interactions O

g O

We O
specially O
focus O
on O
the O
influence O
of O
ITSs B-Gene
and O
some O
experimental O
aspects O
of O
the O
ChIP B-Chemical
technique O
on O
ChIP B-Chemical
analyses O



into O

Beyond O
forward O
cellular O
differentiation O
( O
cell O
programming O
) O
, O
terminally O
differentiated O
cells O
are O
reverted O
to O
a O
pluripotent O
or O
even O
totipotent O
state O
, O
that O
is O
, O
cellular O
reprogramming O

Alterations O
in O
epigenetic O
profiling O
may O
provide O
important O
insights O
into O
the O
etiology O
and O
natural O
history O
of O
cancer B-Disease

There O
are O
several O
molecular O
techniques O
used O
to O
screen O
methylation O
of O
DNA O
; O
here O
, O
we O
focus O
on O
the O
most O
common O
technique O
, O
methylation-sensitive-AFLP B-Chemical
( O
MS-AFLP B-Chemical
) O
, O
which O
is O
used O
to O
identify O
genome-wide O
methylation O
patterns O


Despite O
these O
shortcomings O
, O
the O
study O
of O
DNA B-Gene
and O
histone B-Chemical
modifications O
in O
chromatin O
extracted O
from O
diseased O
and O
control O
brain O
tissue O
is O
likely O
to O
provide O
valuable O
insight O
into O
the O
genomic O
risk O
architecture O
of O
schizophrenia B-Disease
, O
particularly O
in O
the O
large O
majority O
of O
cases O
for O
which O

A O
special O
emphasis O
in O
how O
they O
could O
be O
used O
as O
targets O
for O
the O
development O
and O
use O
of O
novel O
drugs O
in O
cancer B-Disease
therapy I-Disease
is O
delineated O

838 O
Over O
the O
last O
years O
, O
epigenetic O
changes O
, O
including O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical
detected O
in O
early O
tumorigenesis B-Disease
and O
cancer B-Disease
progression I-Disease
, O
have O
been O
proposed O
as O
biomarkers O
for O
cancer B-Disease
detection I-Disease
, O
tumor B-Disease
prognosis I-Disease

The O
best O
known O
and O
most O
studied O
epigenetic O
mark O
in O
DNA O
is O
5-methylcytosine B-Chemical
( O
5mC B-Chemical
) O
, O
generated O
by O
a O
methyltransferase O
that O
uses O
SAM B-Chemical
as O
methyl O
donor O
, O
usually O
in O
CpG B-Gene
contexts O

A O
substantial O
drop O
in O
promoter O
methylation O
signal O
of O
the O
follow-up/post-treatment O
patients O
was O
also O
noted O
(p-value O
< O
0 O

Replication O
of O
findings O
was O
attempted O
in O
the O
comparable O
Avon B-Disease
Longitudinal I-Disease
Study I-Disease
of I-Disease
Parents I-Disease
and I-Disease
Children I-Disease
(ALSPAC) I-Disease
cohort O

Disruption O
of O
these O
processes O
is O
now O
understood O
to O
be O
a O
major O
contributor O
to O
cancer B-Disease
development O
and O
progression O
, O
and O
recent O
efforts O
have O
attempted O
to O
pharmacologically O
reverse O
such O
altered O
epigenetics O

The O
side O
chain O
of O
this O
series O
binds O
in O
an O
induced-fit O
pocket O
forming O
a O
cation-Ï O
interaction O
with O
R1173 B-Gene
of O
CREBBP B-Gene

However O
, O
the O
functions O
and O
morphologies O
of O
each O
cell O
are O
different O
, O
and O
the O
factors O
that O
determine O
them O
are O
the O
genes B-Gene
and O
proteins O
expressed O
in O
the O
cells O

400 O
We O
examined O
the O
usefulness O
of O
commercially O
available O
DNA O
methylation O
arrays O
designed O
for O
the O
human B-Species
genome O
( O
Illumina O
HumanMethylation450 O
and O
MethylationEPIC O
) O
for O
high-throughput O
epigenome O
analysis O
of O
the O
common B-Species
marmoset I-Species
, O
a O

The O
microflora B-Species
hypothesis O
(MH) O
suggests O
that O
gut B-Species
microbial I-Species
dysbiosis O
in O
early O
life O
might O
trigger O
hypersensitivity B-Disease
disorders I-Disease

1368 O
Prostate B-Disease
cancer I-Disease
( O
PCa B-Disease
) O
is O
the O
most O
commonly O
diagnosed O
malignant O
neoplasm O
in O
men O
in O
the O
Western O
world O

We O
also O
identified O
AXIN1 B-Gene
, O
GRIK2 B-Gene
, O
CAMK4 B-Gene
, O
TRAF1 B-Gene
as O
hypomethylated O
genes O
with O
enhanced O
expression O
after O
loading O
that O
maintained O
their O
hypomethylated O
status O
even O
during O
unloading O
where O
muscle B-Species
mass I-Species
returned O
to O
control O
levels O
, O
indicating O
a O
memory O
of O
these O
genes O

mechanisms O

The O
concept O
and O
biomarkers O
of O
biological O
age O
have O
been O
established O
, O
notably O
clocks O

112 O
The O
field O
described O
as O
' O
epigenetics O
' O
has O
captured O
the O
imagination O
of O
scientists O
and O
the O
lay O
public O

Rapid O
development O
in O
the O
sequencing O
technology O
also O
enabled O
the O
establishment O
of O
these O
genome-wide O
studies O

DNA O
methylation B-Chemical
, O
an O
epigenetic O
factor O
, O
is O
used O
for O
model O
training O
in O
many O
studies O

But O
recent O
discoveries O
in O
the O
emerging O
field O
of O
behavioral O
epigenetics O
have O
revealed O
factors O
at O
the O
interface O
between O
genes B-Gene
and O
environments O
that O
also O
play O
crucial O
roles O
in O
development O

715 O
As O
an O
individual O
becomes O
addicted O
to O
a O
drug B-Chemical
of I-Chemical
abuse O
, O
nerve O
cells O
within O
the O
brain O
's O
reward O
circuitry O
adapt O
at O
the O
epigenetic O
level O
during O
the O
course O
of O
repeated O
drug B-Chemical
exposure O

Waddington O
in O
the O
context O
of O
studies O
on O
development O

Conclusions O
 O
Taken O
together O
, O
our O
results O
highlight O
a O
number O
of O
important O
considerations O
and O
practical O
implications O
in O
the O
design O
and O
interpretation O
of O
EWAS O
analyses O
performed O
in O
pediatric O
peripheral O
tissues O

, O
genetic O
load O
) O
on O
substance B-Disease
abuse I-Disease
as O
well O
as O
a O
main O
effect O
of O
CSA B-Gene
on O
substance B-Disease
abuse I-Disease
in O
adulthood O

713 O
The O
origin O
of O
epigenetics O
has O
been O
traditionally O
traced O
back O
to O
Conrad B-Gene
Hal I-Gene
Waddington's I-Gene
foundational O
work O
in O
1940s O

Adolescents O
who O
are O
affected O
by O
mental B-Disease
health I-Disease
conditions I-Disease
are O
at O
risk O
of O
suicide B-Disease
and O
social O
and O
academic O
impairments O

We O
surveyed O
the O
genotypes O
and O
DNA B-Gene
methylomes O
of O
237 O
neonates O
and O
found O
1423 O
punctuate O
regions O
of O
the O
methylome O
that O
were O
highly O
variable O
across O
individuals O
, O
termed O
variably O
methylated O
regions O
( O
VMRs O
) O
, O
against O
a O
backdrop O
of O
homogeneity O

968 O
Brain B-Disease
development I-Disease
is O
a O
life-long O
process O
that O
encompasses O
several O
critical O
periods O
of O
transition O
, O
during O
which O
significant O
cognitive O
changes O
occur O

It O
is O
well O
established O
that O
some O
of O
these O
microbes O
are O
the O
causative O
agents O
, O
whereas O
others O
may O
encourage O
the O
formation O
of O
tumours B-Disease
, O
but O
very O
little O
is O
known O
about O
how O
these O
microbial O
communications O
causing O
change O
at O
gene B-Gene
and O
epigenome O
level O
and O
trigger O
as O
well O
as O

184 O
Adult O
tissue O
stem O
cells O
have O
a O
pivotal O
role O
in O
tissue O
maintenance O
and O
regeneration O
throughout O
the O
lifespan O
of O
multicellular B-Species
organisms I-Species

In O
summary O
, O
our O
study O
provides O
a O
baseline O
dataset O
and O
essential O
information O
for O
DNA B-Gene
methylation I-Gene
profiles O
of O
cattle B-Species

recently O

219 O
A O
plethora O
of O
preclinical O
evidences O
suggests O
that O
pharmacological O
targeting O
of O
epigenetic O
dysregulation O
is O
a O
potent O
strategy O
to O
combat O
human O
diseases B-Disease

Such O
stresses O
include O
malnutrition O
, O
which O
may O
be O
associated O
with O
type B-Disease
2 I-Disease
diabetes I-Disease
, O
and O
mental O
stress O
, O
which O
may O
be O
associated O
with O
neurodevelopmental B-Disease
disorders I-Disease

Availability O
and O
implementation O
 O
http//sigseeker O

However O
, O
it O
is O
still O
a O
cost-prohibitive O
technology O
for O
a O
typical O
laboratory O
due O
to O
the O
required O
sequencing O
depth O

Discussion O
 O
Organizing O
epigenetic O
information O
into O
the O
topology O
of O
a O
qualitative O
AOP O
network O
may O
help O
describe O
how O
a O
system O
will O
respond O
to O
epigenetic O
modifications O
caused O
by O
environmental O
chemical B-Chemical
exposures O

2 O
million O
CpGs O
tested O
for O
ASM O
, O
mQTL O
, O
and O
genotype-independent O
effects O
, O
we O
identify O
~32% O
as O
being O
genetically O
regulated O
( O
ASM O
or O
mQTL O
) O
and O
~14% O
as O
being O
putatively O
epigenetically O
regulated O

We O
also O
outline O
what O
is O
currently O
understood O
about O
the O
public's O
understanding O
and O
opinion O
of O
epigenetics B-Gene
, O
DOHaD B-Gene
, O
and O
their O
relation O
to O
NCDs B-Disease

environmental O

When O
comparing O
with O
other O
open-source O
target O
identification O
tools O
, O
it O
was O
found O
that O
only O
our O
tool O
was O
able O
to O
accurately O
predict O
all O
the O
targets O
corresponding O
to O
each O
compound O

1257 O
Transcriptional O
and O
epigenetic O
dynamics O
of O
the O
genome O
occur O
during O
early O
development O
in O
mammals B-Species

Pro O
- O
angiogenic O
factors O
that O
are O
secreted O
by O
tumors O
will O
trigger O
the O
sprouting O
of O
nearby O
existing O
blood O
vessels O
towards O
themselves O
and O
therefore O
researchers O
have O
developed O
targeted O
therapy O
towards O
these O
pro-angiogenic O
proteins O
to O
inhibit O
angiogenesis O

Using O

934 O
There O
are O
over O
28 O
million O
CpG B-Gene
sites I-Gene
in O
the O
human B-Species
genome I-Species

Graphical O
Abstract O

The O
molecular O
mechanisms O
involved O
in O
prostate B-Disease
cancer I-Disease
are O
diverse O
and O
heterogeneous O


1473 O
Sub-Saharan B-Species
African I-Species
( O
SSA B-Species
) O
migrants O
in O
Europe O
experience O
psychosocial O
stressors O
, O
such O
as O
perceived O
discrimination B-Disease
( O
PD B-Disease
) O

This O
mini-review O
puts O
recent O
developments O
in O
age O
estimation O
via O
(epi)genetic O
methods O
in O
the O
context O
of O
the O
requirements O
and O
goals O
of O
forensic O
genetics O
and O
highlights O
paths O
to O
follow O
in O
the O
future O
of O
forensic O
genomics O

22 O
, O
p O
= O

This O
toolkit O
has O
been O
coopted O
to O
support O
the O
dynamic O
nature O
of O
genomes O
in O
lineages O
across O
the O
eukaryotic B-Species
tree I-Species
of I-Species
life I-Species

, O
due O
to O
noise O
during O
development O
or O
environmental O
variations O

Although O
these O
disorders O
differ O
in O
their O
underlying O
causes O
and O
pathophysiologies O
, O
many O
involve O
the O
dysregulation O
of O
restrictive O
element O
1-silencing O
transcription O
factor O
( O
REST B-Gene
) O
, O
which O
acts O
via O
epigenetic O
mechanisms O
to O
regulate O
gene O
expression O

We O
look O
for O
similarities O
and O
differences O
between O
two O
epigenetic O
models O
, O
by O
Turing B-Gene
and O
Edelman B-Gene
, O
as O
they O
are O
realized O
in O
Game B-Chemical
of I-Chemical
Life I-Chemical
objects O

These O
changes O
affecting O
the O
expression O
of O
certain O
genes O
, O
without O
however O
modifying O
DNA B-Gene
sequences O
, O
particularly O
interfere O
with O
the O
functioning O
of O
systems O
regulating O
response O
to O
stress O

The O
improved O
understanding O
of O
the O
epigenetic O
underpinnings O
of O
islet O
cell O
differentiation O
, O
function O
and O
breakdown O
, O
as O
well O
as O
the O
development O
of O
innovative O
tools O
for O
their O
manipulation O
, O
is O
key O
to O
islet O
cell O
biology O
and O
the O
discovery O
of O
novel O
approaches O
to O
therapies O
for O

86 O
) O
and O
high O
repeatability O
( O
PCC O
> O
0 O

Our O
findings O
suggest O
that O
DNAm B-Gene
can O
classify O
ternary O
smoking O
status O
with O
close O
to O
65% O
accuracy O

1451 O
Aim O
 O
A O
systematic O
multimolecule O
drug O
design O
procedure O
is O
proposed O
for O
promoting O
hepatogenesis B-Disease
and O
liver B-Disease
regeneration O

We O
apply O
these O
recommendations O
for O
imprinted O
DMRs O
that O
are O
commonly O
assayed O
in O
clinical O
laboratories O
and O
show O
how O
they O
support O
standardized O
database O
submission O

Supplementary O
information O
 O
Supplementary O
data O
are O
available O
at O
Bioinformatics O
online O

To O
this O
end O
, O
epigenetics O
aims O
to O
discover O
the O
molecular O
mechanisms O
that O
explain O
how O
different O
nutrients B-Chemical
and O
hormones B-Chemical
, O
environmental O
changes O
, O
and O
emotional O
, O
social O
and O
cognitive O
experiences O
modify O
gene B-Gene
expression O
and O
behaviors O
, O
even O
permanently O
so O

6 O
and O
above O

The O
area O
of O
redifferentiation O
strategy O
leads O
to O
the O
creation O
of O
new O
definitions O
of O
RAIR B-Disease
TC I-Disease
including O
persistent O
non O
radioiodine-avid O
patients O
and O
'true' O
RAIR B-Disease
TC I-Disease
patients O

A O
selection O
of O
the O
major O
recent O
advances O
in O
this O
area O
will O
be O
reviewed O
, O
focusing O
on O
the O
important O
emerging O
themes O
that O
are O
relevant O
to O
these O
diseases O
including O
inflammatory B-Disease
bowel I-Disease
disease I-Disease
( O
IBD B-Disease
) O

The O
large O
body O
of O
data O
support O
the O
role O
of O
epigenetic O
mechanisms O
in O
neurological B-Disease
function O
of O
both O
human B-Species
and O
animals B-Species

492 O
Convincing O
evidence O
accumulated O
over O
the O
last O
decades O
demonstrates O
the O
crucial O
role O
of O
epigenetic O
modifications O
for O
mammalian B-Species
genome O
regulation O
and O
its O
flexibility O

different O

Epigenetic O
conceptions O
of O
aging O
gained O
currency O
with O
the O
development O
of O
methylation B-Chemical
clocks I-Chemical
beginning O
in O
2013 O

An O
EpigenART O
competition O
included O
ten O
artists O
, O
creating O
a O
unique O
opportunity O
for O
artists O
and O
scientists O
to O
interact O
and O
explore O
their O
individual O
interpretations O
of O
this O
scientific O
discipline O

subsets O

Finally O
, O
we O
provide O
a O
perspective O
as O
to O
how O
decoding O
the O
genetic O
and O
epigenetic O
basis O
of O
asthma B-Disease
has O
the O
potential O
to O
transform O
clinical O
management O
of O
asthma B-Disease
and O
to O
predict O
the O
risk O
of O
asthma B-Disease
development O

This O
includes O
elucidating O
the O
differences O
in O
gene B-Gene
expression I-Gene
that O
are O
mediated O
through O
programming O
of O
the O
genome B-Gene
through O
epigenetic O
chromatin O
modifications O

First O
, O
knowledge O
on O
the O
molecular O
processes O
involved O
in O
tumor B-Disease
progression I-Disease
contributes O
to O
molecularize O
medicine O
, O
extending O
genomic O
medicine O

Furthermore O
, O
we O
highlight O
some O
of O
the O
recent O
marker O
validation O
studies O
and O
established O
markers O
that O
are O
currently O
commercially O
available O
for O
assisting O
in O
clinical O
management O
of O
different O
cancers B-Disease

Feature O
-based O
modeling O
quantifies O
the O
effect O
of O
cytosine B-Chemical
methylation I-Chemical
( O
5mC B-Chemical
) O
on O
binding O
free O
energy O
in O
a O
position-specific O
manner O

Genomic O
imprinting O
refers O
to O
epigenetic O
marking O
of O
genes O
that O
results O
in O
monoallelic O
expression O
depending O
on O
the O
parental O
origin O

Conclusions O
 O
Software O
updates O
in O
the O
Illumina B-Chemical
HiSeq I-Chemical
platform O
can O
affect O
the O
outputs O
from O
low-diversity O
sequencing O
libraries O
such O
as O
WGBS B-Chemical
libraries O

Research O
in O
this O
field O
is O
needed O
to O
identify O
biomarkers O
that O
can O
be O
used O
for O
early O
detection O
of O
the O
disease B-Disease
as O
well O
as O
new O
approaches O
to O
its O
treatment O

Recent O
efforts O
by O
ENCODE B-Gene
, O
the O
NIH B-Gene
Roadmap I-Gene
and O
the O
International B-Gene
Human I-Gene
Epigenome I-Gene
Consortium I-Gene
( O
IHEC B-Gene
) O
have O
made O
significant O
advances O
towards O
assembling O
reference O
epigenomic O
maps O
of O
various O
tissues O

However O
, O
50 O

This O
is O
partly O
attributable O
to O
the O
preterm O
immune O
system O
, O
which O
differs O
from O
that O
of O
the O
term O
neonate O
in O
cell O
composition O
and O
function O

We O
focus O
on O
schizophrenia B-Disease
, O
major B-Disease
depressive I-Disease
disorder I-Disease
, O
post-traumatic B-Disease
stress I-Disease
disorder I-Disease
, O
anorexia B-Disease
nervosa I-Disease
, O
and O
substance B-Disease
dependence I-Disease
as O
examples O
that O
highlight O
the O
ways O
in O
which O
social O
environmental O
exposures O
, O
mediated O
through O
epigenetic O
processes O
, O

EpiProfile O
2 O

Microfluidics O
and O
microfabrication O
have O
played O
a O
central O
role O
in O
the O
range O
of O
new O
techniques O
, O
and O
will O
likely O
continue O
to O
impact O
their O
further O
development O
towards O
routine O
single-cell O
epigenetic O
analysis O

Hence O
, O
this O
review O
aims O
to O
shed O
light O
and O
discuss O
the O
current O
state O
of O
epigenetics O
research O
in O
the O
diagnosis O
and O
management O
of O
BC B-Disease

1325 O
 O
Background O
 O
Epigenetics O
can O
contribute O
to O
lipid B-Disease
disorders I-Disease
in O
obesity B-Disease

885 O
As O
the O
basic O
units O
of O
life O
, O
cells O
present O
dramatic O
heterogeneity O
which O
, O
although O
crucial O
to O
an O
organism O
's O
behavior O
, O
is O
undetected O
by O
bulk O
analysis O

We O
found O
moderate O
differential O
expression O
between O
testes O
of O
differentially O
fed O
boars O
with O
a O
high O
FDR O
of O
0 O

The O
present O
review O
aims O
to O
provide O
an O
overview O
of O
current O
research O
focused O
on O
the O
epigenetic O
mechanisms O
that O
regulate O
gene B-Gene
expression O
in O
the O
cyclical O
endometrium B-Species
and O
discuss O
the O
technical O
and O
clinical O
perspectives O
regarding O
this O
topic O

618 O
Epigenetic O
processes O
are O
known O
to O
have O
powerful O
roles O
in O
organ O
development O
across O
biology O

However O
, O
clear O
and O
unequivocal O
guidelines O
on O
how O
to O
approach O
this O
in O
the O
clinical O
setting O
have O
not O
been O
developed O

Most O
GRS O
approaches O
can O
directly O
be O
transferred O
to O
methylation B-Chemical
data O

In O
particular O
, O
histone B-Chemical
modifications I-Chemical
have O
a O
role O
in O
the O
regulation O
of O
gene B-Gene
expression I-Gene
pertinent O
to O
activation O
of O
fibroblasts B-Species
to O
myofibroblasts B-Species
, O
governing O
their O
fate O

129 O
Ageing O
is O
defined O
by O
the O
decline O
in O
the O
biological O
and O
physiological O
functions O
over O
time O
, O
which O
leads O
to O
health O
problems O
and O
increases O
risks O
of O
diseases B-Disease

416 O
Aim O
To O
show O
that O
an O
increased O
correlation O
between O
after O
selection O
through O
an O
epigenome-wide O
association O
studies O
(EWAS) O
might O
translate O
into O
biased O
replication O
results O

Given O
the O
potential O
side O
effects O
associated O
with O
pan-BET B-Chemical
inhibitors O
, O
safer O
and O
more O
selective O
strategies O
are O
needed O
to O
advance O
BET B-Gene
therapeutics O
as O
a O
potential O
treatment O
for O
SUD B-Disease

The O
inclusion O
of O
leukemia B-Disease
epigenomes O
in O
the O
healthy O
hematological O
chromatin O
sample O
space O
gives O
us O
insights O
on O
the O
healthy O
cell O
types O
that O
are O
more O
epigenetically O
similar O
to O
the O
disease O
samples O

1217 O
The O
application O
of O
epigenetics O
to O
the O
study O
of O
behavioral O
and O
socio-emotional O
development O
in O
humans B-Species
has O
revealed O
that O
DNA B-Gene
methylation I-Gene
could O
be O
a O
potential O
marker O
of O
adversity O
exposure O
and O
long-lasting O
programming O
of O
health O
and O
disease B-Disease

The O
diversity O
in O
eukaryotic B-Species
genome O
architectures O
and O
the O
dynamic O
processes O
are O
only O
possible O
due O
to O
the O
well-developed O
epigenetic O
toolkit O
, O
which O
probably O
existed O
in O
the O
Last B-Species
Eukaryotic I-Species
Common I-Species
Ancestor I-Species
( O
LECA O
) O

The O
clarification O
of O
aberrant O
methylation O
of O
target O
genes B-Gene
, O
which O
play O
important O
roles O
in O
the O
initiation O
and O
progression O
of O
COPD B-Disease
, O
will O
provide O
new O
disease-specific O
biomarker O
and O
targets O
for O
early O
diagnosis O
and O
therapy O

This O
expansion O
of O
knowledge O
, O
which O
is O
very O
much O
ongoing O
, O
has O
been O
made O
possible O
by O
the O
availability O
of O
evermore O
sensitive O
and O
precise O
molecular O
tools O

358 O
The O
genetic O
and O
epigenetic O
material O
originating O
from O
tumour B-Disease
that O
can O
be O
found O
in O
body O
fluids O
of O
individuals O
with O
cancer B-Disease
harbours O
tumour-specific O
alterations O
and O
represents O
an O
attractive O
target O
for O
biomarker O
discovery O

1304 O

In O
this O
study O
, O
we O
focus O
on O
the O
current O
research O
of O
the O
epigenetics O
of O
breast B-Disease
cancer I-Disease
, O
especially O
on O
the O
potential O
of O
epigenetics O
for O
clinical O
application O
in O
diagnostics O
, O
risk O
stratification O
and O
therapy O

However O
, O
the O
direct O
relationship O
is O
still O
unknown O

Our O
model O
, O
which O
estimates O
age O
based O
on O
DNA B-Chemical
methylation I-Chemical
at O
329 O
unique O
CpG B-Gene
sites O
, O
has O
a O
median O
absolute O
error O
of O
3 O

ChIPseeker O
is O
a O
Bioconductor O
package O
for O
performing O
these O
analyses O
among O
variable O
epigenomic O
datasets O

In O
this O
review O
, O
we O
summarize O
the O
existing O
literature O
on O
dietary O
micronutrients O
, O
bioactive O
compounds O
, O
and O
food-borne O
mycotoxins O
that O
affect O
DNA B-Gene
methylation I-Gene
patterns O
and O
identify O
their O
potential O
in O
the O
onset O
and O
treatment O
of O
cancer B-Disease

Intracellular O
events O
observed O
to O
change O
with O
age O
included O
the O
methylation O
of O
bivalent O
chromatin O
domains O
, O
and O
targets O
of O
polycomb B-Gene
repressive I-Gene
complexes I-Gene

EPIGENE O
- O
predicted O
TUs O
show O
an O
enrichment O
of O
RNA B-Chemical
Polymerase I-Chemical
II I-Chemical
at O
the O
transcription O
start O
site O
and O
in O
gene O
body O
indicating O
that O
they O
are O
indeed O
transcribed O

40 O
years O
respectively O
, O
suggesting O
that O
developmental O
state O
correlates O
with O
DNAm B-Gene
age O

Cancer O
cells O
reprogram O
their O
metabolism O
to O
meet O
the O
high O
bioenergetic O
and O
biosynthetic O
demands O
for O
vigorous O
proliferation O

precision O

In O
this O
current O
opinion O
paper O
, O
we O
argue O
that O
understanding O
the O
dynamic O
interplay O
between O
the O
genome B-Gene
acquired O
at O
conception O
and O
environmental O
exposures O
throughout O
life O
requires O
pregnancy O
and O
birth O
cohorts O
, O
and O
that O
greater O
Canadian O
national O
commitment O
to O
the O
infrastructure O
needed O
for O
sustaining O
such O

g O

8% O
, O
a O
Matthews B-Chemical
correlation I-Chemical
coefficient I-Chemical
of O
0 O

More O
recently O
, O
chemical B-Chemical
modifications I-Chemical
of O
RNA B-Chemical
molecules I-Chemical
- O
the O
so-called O
epitranscriptome O
- O
have O
been O
found O
to O
regulate O
various O
aspects O
of O
RNA B-Chemical
function O
and O
homeostasis O

Analyses O
of O
epigenetic O
modification O
is O
of O
great O
significance O
in O
providing O
more O
accurate O
information O
for O
the O
risk O
assessment O
and O
management O
of O
harmful O
factors O

Current O
methods O
for O
estimating O
humpback B-Species
age O
cannot O
be O
applied O
to O
all O
individuals O
and O
populations O

243 O
Acupuncture O
has O
been O
widely O
used O
for O
treating O
diseases B-Disease
since O
the O
ancient O
days O
in O
China O
, O
but O
the O
mechanism O
by O
which O
acupuncture O
exerts O
such O
powerful O
roles O
is O
unclear O

Despite O
the O
tissue-specific O
nature O
of O
DNA B-Gene
methylation I-Gene
, O
the O
inaccessibility O
of O
human B-Species
brain O
samples O
necessitates O
the O
frequent O
use O
of O
surrogate O
tissues O
such O
as O
blood O
, O
in O
studies O
of O
associations O
between O
DNA B-Gene
methylation I-Gene
and O
brain O
function O
and O
health O

Methods O
 O
Participants O
were O
premenopausal O
women O
( O
N O
= O
183 O
) O

Our O
SMC O
framework O
readily O
accounts O
for O
a O
wide O
range O
of O
heritable O
genomic O
markers O
, O
thus O
paving O
the O
way O
for O
next-generation O
inference O
of O
evolutionary O
history O
by O
combining O
information O
from O
several O
genetic O
and O
epigenetic O
markers O

Among O
the O
four O
identified O
frequent O
clusters O
, O
two O
of O
them O
separate O
the O
tumor B-Disease
sample O
from O
normal O
sample O
in O
10 O
out O
of O
11 O
cancer B-Disease
types O
, O
which O
indicates O
that O
consistent O
epigenetic O
landscape O
changes O
exist O
in O
multiple O
cancer B-Disease
types O

790 O
Epigenetics O
is O
currently O
the O
focus O
of O
intense O
research O
interest O
across O
a O
broad O
range O
of O
disciplines O
due O
to O
its O
importance O
in O
a O
multitude O
of O
biological O
processes O
and O
disease B-Disease
states I-Disease

This O
is O
an O
access O
pattern O
needed O
to O
create O
training O
batches O
for O
typical O
machine O
learning O
models O
on O
epigenetics O
data O

989 O
Epigenetic O
memory O
allows O
organisms O
to O
stably O
alter O
their O
transcriptional O
program O
in O
response O
to O
developmental O
or O
environmental O
stimuli O

05 O
) O

836 O
The O
for O
Breast B-Disease
Development I-Disease
and O
Cancer B-Disease
( O
) O
meeting O
on O
' O
Methods O
in O
Mammary B-Species
Gland I-Species
Development O
and O
Cancer B-Disease
' O
has O
become O
an O
annual O
international O
rendezvous O
for O
scientists O
with O
interests O
in O
the O
normal O
and O
neoplastic O
breast B-Disease

970 O
Genetics O
is O
often O
referred O
to O
as O
the O
blueprint O
of O
life O
, O
but O
it O
tells O
only O
part O
of O
the O
story O

793 O
Epigenetic O
potential O
, O
defined O
as O
the O
capacity O
for O
epigenetically-mediated O
phenotypic O
plasticity O
, O
may O
play O
an O
important O
role O
during O
range O
expansions O

This O
communication O
provides O
an O
introduction O
to O
the O
fundamentals O
of O
epigenetics O
and O
then O
reviews O
how O
some O
of O
the O
latest O
advances O
in O
this O
technology O
can O
now O
be O
used O
to O
assess O
the O
consumption O
of O
alcohol B-Chemical
and O
tobacco B-Chemical

Our O
aims O
here O
were O
to O
build O
an O
epigenetic O
gestational O
age O
clock O
specific O
for O
the O
EPIC B-Chemical
array O
and O
to O
evaluate O
its O
precision O
and O
accuracy O
using O
the O
embryo O
transfer O
date O
of O
newborns O
from O
the O
largest O
EPIC-derived B-Chemical
dataset O
to O
date O
on O
assisted O
reproductive O
technologies O
( O
ART B-Disease

Exploring O
the O
whole O
spectrum O
of O
mutations O
controlling O
complex O
traits O
is O
made O
possible O
by O
the O
combination O
of O
genetic O
, O
genomic O
and O
epigenomic O
approaches O

Recent O
evidence O
has O
revealed O
that O
discrete O
populations O
of O
adult O
cells O
can O
retain O
the O
ability O
to O
adopt O
alternative O
cell O
fates O
in O
response O
to O
environmental O
cues O

Dysregulation O
the O
stage O
of O
formation O
of O
the O
preosteoclast O
from O
late O
monocyte O
was O
noted O
in O
rheumatoid B-Disease
arthritis I-Disease
and O
fracture O
, O
whereas O
dysregulation O
at O
stage O
of O
formation O
of O
late O
monocyte O
from O
early O
monocyte O
was O
noted O
in O
osteopetrosis B-Disease
and O
spondyloarthritis B-Disease

631 O
is O
a O
chronic O
and O
recurrent O
inflammatory O
skin O
disease O
, O
involving O
the O
rapid O
proliferation O
and O
abnormal O
differentiation O
of O
and O
activation O
of O

provides O
evidence O
for O
this O
mode O
of O
inheritance O
in O
mice B-Species
by O
using O
a O
CRISPR/Cas9-based B-Gene
epigenetic O
editing O
technique O
to O
modify O
DNA B-Gene
methylation B-Chemical
levels O
at O
specific O
promoters O
and O
then O
demonstrating O
the O
inheritance O
of O
the O
gain O
in O
methylation B-Chemical
in O
offspring O

The O
aetiopathogenesis O
of O
these O
conditions O
and O
disorders O
involves O
an O
interaction O
between O
both O
genetic O
and O
environmental O
risk O
factors O
on O
the O
developmental O
trajectory O

They O
are O
associated O
with O
DNA B-Gene
but O
without O
altering O
the O
DNA B-Gene
sequence O

003 O
; O
cg27152686 O
 O
coefficient O
= O
- O
0 O

For O
instance O
, O
regenerants O
were O
particularly O
affected O
by O
the O
inheritance O
of O
root-specific O
epigenetic O
imprints O
, O
which O
were O
associated O
with O
an O
increased O
accumulation O
of O
salicylic B-Chemical
acid I-Chemical
in O
leaves O
and O
accelerated O
plant O
senescence O

At O
this O
threshold O
, O
we O
were O
able O
to O
confirm O
previously-found O
CpG B-Gene
sites I-Gene
that O
stratify O
with O
respect O
to O
sex O

In O
this O
review O
we O
consider O
the O
potential O
, O
and O
the O
limitations O
, O
of O
epigenetic O
variation O
in O
crop O
improvement O

974 O
Obesity B-Disease
is O
caused O
by O
a O
combination O
of O
hereditary O
and O
environmental O
factors O

Individual O
life O
courses O
can O
no O
longer O
be O
regarded O
as O
discrete O
, O
bounded O
, O
life O
histories O
, O
with O
clearly O
defined O
beginning O
and O
end O
points O

1480 O
Social O
and O
behavioral O
research O
in O
public O
health O
is O
often O
intimately O
tied O
to O
profound O
, O
but O
frequently O
neglected O
, O
biological O
influences O
from O
underlying O
genetic B-Gene
, O
environmental O
, O
and O
epigenetic B-Gene
events O

In O
this O
review O
, O
we O
outline O
the O
recent O
development O
of O
a O
variety O
of O
CRISPR-based B-Gene
epigenetic O
editors O
for O
targeted O
DNA B-Chemical
methylation/demethylation O
, O
histone O
modification O
, O
and O
three-dimensional O
DNA B-Chemical
conformational O
change O
, O
highlighting O
their O
relative O
performance O
and O
impact O
on O
gene B-Gene
regulation O

1306 O
The O
production O
of O
germ B-Species
cells I-Species
in O
vitro O
would O
open O
important O
new O
avenues O
for O
stem B-Gene
biology I-Gene
and O
human B-Species
medicine O
, O
but O
the O
mechanisms O
of O
germ B-Species
cell I-Species
differentiation O
are O
not O
well O
understood O

Additionally O
, O
environmental O
factors O
like O
nutrition O
or O
maternal O
behavior O
in O
early O
childhood O
are O
able O
to O
induce O
epigenetic O
changes O

This O
review O
summarizes O
the O
major O
epigenetically O
induced O
changes O
in O
radioresistant-like O
PCa B-Disease
cells O
and O
describes O
recently O
reported O
targeted O
epigenetic O
therapies O
in O
pre-clinical O
and O
clinical O
settings O

The O
potential O
use O
of O
these O
small O
molecules O
in O
inducing O
iPSCs B-Gene
and O
new O
ways O
to O
identify O
small O
molecules O
of O
higher O
potency O
and O
fewer O
side O
effects O
are O
also O
discussed O

We O
utilize O
multi-omics O
data O
from O
diverse O
human B-Species
tissue/cells O
to O
identify O
shared O
features O
across O
eleven O
existing O
epigenetic O
clocks O

EWAS O
aim O
to O
systematically O
identify O
epigenetic O
variants O
across O
the O
genome O
that O
associate O
with O
complex O
phenotypes O

One O
example O
used O
a O
porcine B-Species
model O
to O
investigate O
the O
effect O
that O
feeding O
males O
a O
diet O
supplemented O
with O
micronutrients B-Chemical
had O
on O
liver B-Gene
DNA I-Gene
methylation I-Gene
and O
muscle B-Gene
mass I-Gene
in O
grand-offspring O
(the O
transgenerational O
F2 O
generation O
) O

While O
these O
advances O
enable O
us O
to O
explore O
frontiers O
of O
chromatin O
biology O
and O
better O
understand O
cell O
lineage O
relationships O
, O
they O
pose O
new O
challenges O
in O
data O
processing O
and O
interpretation O

The O
model O
projected O
that O
for O
a O
commercial O
insurer O
with O
one O
million O
members O
, O
full O
adoption O
of O
PrecisionCHD B-Chemical
as O
the O
primary O
method O
of O
initial O
CHD B-Disease
assessment O
would O
save O
approximately O
$113 O

of O

Enacting O
complexity O
in O
this O
research O
means O
dissecting O
multiple O
so-called O
biosocial O
processes O
of O
health B-Disease
differentiation O
in O
the O
face O
of O
stressful O
experiences O

Finally O
, O
we O
found O
that O
~40% O
of O
CHIP B-Disease
carriers O
had O
acceleration O
>0 O
in O
both O
Hannum B-Gene
and O
GrimAge B-Gene
( O
referred O
to O
as O
AgeAccelHG+ B-Gene
) O

These O
dynamic O
elements O
interact O
to O
determine O
the O
normal O
level O
of O
expression O
or O
methylation O
status O
of O
the O
constituent O
genes O
in O
the O
genome O

Using O
this O
strategy O
, O
we O
generated O
high-quality O
epigenomic O
profiles O
of O
histone B-Chemical
modifications O
or O
DNA B-Chemical
methylation O
in O
10-1000 O
cells O

Finally O
, O
we O
review O
the O
literature O
on O
histone B-Chemical
modifications O
and O
non-coding O
RNA B-Gene
involvement O
in O
brain B-Disease
sexual I-Disease
differentiation I-Disease
and O
their O
perturbation O
by O
EDCs B-Chemical

We O
looked O
for O
epigenome O
signatures O
at O
the O
locus O
and O
single-probe O
(CpG B-Chemical
dinucleotide) I-Chemical
levels O
and O
through O
enrichment O
analyses O
of O
gene B-Gene
ontologies I-Gene
(GO) I-Gene

Epigenetic O
age O
is O
believed O
to O
be O
one O
of O
the O
most O
accurate O
metrics O
of O
biological O
age O

In O
this O
paper O
, O
we O
argue O
that O
the O
impetus O
to O
create O
new O
biomedical O
interventions O
to O
manipulate O
and O
reverse O
epigenetic O
variants O
is O
likely O
to O
garner O
more O
attention O
than O
effective O
social O
and O
public O
health O
interventions O
and O
therefore O
also O
to O
garner O
a O
greater O
share O
of O
limited O
public O
resources O

To O
the O
best O
of O
our O
knowledge O
, O
this O
survey O
is O
the O
first O
EWAS O
for O
PD B-Disease
in O
first O
generation O
SSA B-Species
migrants O

We O
evaluated O
performance O
using O
an O
independent O
validation O
data O
set O
consisting O
of O
18-year-old O
individuals O
, O
where O
we O
obtained O
a O
median O
absolute O
deviation O
of O
just O
below O
0 O

Nevertheless O
, O
as O
we O
gain O
more O
knowledge O
, O
we O
realize O
that O
the O
DNA-protein B-Gene
interactions O
are O
not O
driven O
by O
a O
" O
one O
size O
fits O
all O
" O
rule O

This O
new O
simulator O
provides O
direct O
validation O
of O
DamMet B-Gene
predictions O

1363 O
is O
an O
essential O
modification O
that O
plays O
a O
crucial O
role O
in O
genome O
regulation O
during O
differentiation O
and O
development O
, O
and O
is O
disrupted O
in O
a O
range O
of O

These O
have O
implications O
for O
investigating O
the O
link O
of O
the O
phenomena O
to O
human B-Species
diabetes B-Disease
, O
providing O
a O
new O
perspective O
on O
environmentally O
triggered O
diabetes B-Disease
risk O


However O
, O
due O
to O
confounding O
and O
other O
limitations O
, O
identification O
of O
causal O
risk O
factors O
has O
proved O
challenging O
and O
published O
findings O
are O
often O
not O
reproducible O

1031 O
Posttraumatic B-Disease
stress I-Disease
disorder I-Disease
( O
PTSD B-Disease
) O
is O
a O
stress-related O
psychiatric O
disorder O
that O
is O
thought O
to O
emerge O
from O
complex O
interactions O
among O
traumatic O
events O
and O
multiple O
genetic O
factors O

In O
addition O
to O
latent O
reservoir O
purging O
, O
epigenetic O
research O
offers O
alternative O
therapeutic O
tools O
as O
well O
; O
although O
not O
aimed O
at O
the O
elimination O
of O
the O
virus O
, O
targeted O
silencing O
of O
HIV B-Disease
transcription O
by O
epigenetic O
regulators O
may O
help O
HAART B-Chemical
to O
minimize O
virus O
replication O

Distinct O
chromatin O
alterations O
occur O
in O
all O
stages O
of O
lung B-Disease
cancer I-Disease
, O
including O
initiation O
, O
growth O
, O
and O
metastasis O

In O
this O
minireview O
, O
we O
will O
focus O
on O
reviewing O
the O
fundamentals O
and O
applications O
of O
machine O
learning O
methods O
which O
are O
regularly O
used O
in O
epigenetics O
filed O
and O
explain O
their O
features O

320 O
serves O
to O
mark O
as O
either O
a O
directed O
epigenetic O
signaling O
modification O
or O
in O
response O
to O
lesions O

Finally O
, O
epigenetic O
change O
partially O
mediated O
the O
effect O
of O
CSA B-Chemical
on O
antisocial O
characteristics O

Alteration O
in O
DNA B-Gene
methylation I-Gene
has O
been O
implicated O
in O
aging O
, O
as O
well O
as O
aging-related O
conditions O
such O
as O
cancer B-Disease
, O
as O
well O
as O
cardiovascular B-Disease
, O
neurodegenerative B-Disease
, O
and O
autoimmune B-Disease
diseases I-Disease

77 O
per O
decade O
in O
M O
value O
, O
equivalent O
to O
a O
Î² O
value O
change O
of O
0 O

The O
protocol O
implements O
a O
semiautomated O
platform O
to O
reduce O
technical O
variability O
and O
improve O
signal-to-noise O
ratio O
as O
well O
as O
reduce O
hands-on O
time O
, O
thus O
allowing O
large-scale O
epigenetic O
studies O
of O
clinical O
samples O
with O
limited O
cell O
numbers O

This O
view O
ignores O
the O
fact O
that O
environmental O
factors O
affect O
gene B-Gene
expression I-Gene
mainly O
through O
signaling O
cascades O
and O
the O
activation O
or O
repression O
of O
transcription O
factors O
, O
which O
recruit O
chromatin O
regulators O

In O
our O
analysis O
, O
we O
found O
that O
epigenetic O
proteins O
DNMT3A B-Gene
, O
HDAC2 B-Gene
, O
KDM6A B-Gene
, O
and O
TET2 B-Gene
are O
highly O
mutated O
in O
variety O
of O
cancers B-Disease

26 O
), O
with O
the O
highest O
estimate O
for O
BW7 B-Gene

The O
new O
procedure O
, O
that O
we O
named O
enhanced O
PAT-ChIP O
( O
EPAT-ChIP O
) O
, O
was O
then O
applied O
at O
genome-wide O
level O
using O
an O
archival O
sample O
of O
invasive O
breast B-Disease
carcinoma I-Disease
to O
investigate O
H3K4me3 B-Chemical
, O
a O
lowly O
abundant O
histone O
modification O
, O
and O

Even O
though O
both O
hypo- O
- O
and O
hypermethylation-mediated O
abnormalities O
are O
prevalent O
in O
the O
cancer B-Disease
genome O
, O
the O
field O
of O
cancer B-Disease
epigenetics O
has O
been O
more O
focused O
on O
targeting O
hypermethylation O


We O
discuss O
some O
of O
the O
requirements O
, O
merits O
, O
and O
challenges O
that O
should O
be O
considered O
when O
choosing O
a O
methylome B-Chemical
technology O
to O
ensure O
that O
it O
will O
be O
informative O

Using O
high-throughput O
array O
and O
sequencing O
technologies O
, O
these O
studies O
identified O
several O
loci O
associated O
with O
the O
disease B-Disease

This O
reflects O
the O
fact O
that O
TDP-43 B-Gene
functions O
are O
particularly O
complex O
and O
broad O
in O
a O
great O
variety O
of O
human O
cells O

DNA O
methylation O
and O
histone O
acetylation O
are O
subject O
to O
modification O
by O
several O
classes O
of O
'epigenetic O
modifiers' O
, O
some O
of O
which O
are O
in O
clinical O
use O
or O
in O
preclinical O
development O

udel O

Epigenetic O
mechanisms O
, O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
act O
at O
the O
interface O
of O
genetic O
and O
environmental O
risk O
and O
protective O
factors O

1189 O
Epigenetic O
inheritance O
has O
been O
proposed O
to O
contribute O
to O
adaptation O
and O
acclimation O
via O
two O
information O
channels O
 O
( O
i O
) O
inducible O
epigenetic O
marks O
that O
enable O
transgenerational O
plasticity O
and O
( O
ii O
) O
noninducible O
epigenetic O
marks O
resulting O
from O
random O
epimutations O
shaped O
by O
selection O

Moreover O
, O
as O
epigenetic O
modifications O
are O
highly O
plastic O
and O
responsive O
to O
the O
environment O
, O
there O
is O
much O
excitement O
around O
the O
theme O
of O
epigenetic O
therapeutics O
, O
including O
not O
only O
new O
drugs O
but O
also O
more O
informed O
patient O
advice O
on O
lifestyle O
choices O
and O
their O
impact O
on O
pathology O

384 O
Interindividual O
variability O
of O
DNA B-Gene
methylation I-Gene
is O
a O
mechanism O
of O
the O
epigenetic O
drift O
in O
aging O

A O
significant O
part O
of O
how O
hormones B-Chemical
affect O
DNA B-Gene
transcription O
is O
via O
epigenetic O
modifications O
of O
DNA B-Gene
and/or O
the O
chromatin B-Gene
in O
which O
it O
is O
entwined O

23%) O
, O
( O
485 O
, O
26 O

However O
, O
the O
demand O
for O
its O
accurate O
quantification O
might O
vary O
across O
studies O

These O
protocols O
include O
DNA B-Chemical
probe I-Chemical
amplification O
and O
labeling O
; O
tissue B-Species
fixation O
; O
preservation O
and O
preparation O
for O
hybridization O
; O
hybridization O
of O
the O
DNA B-Chemical
probes I-Chemical
with O
genomic O
DNA B-Chemical
in O
the O
tissue B-Species
; O
and O
post-hybridization O
tissue B-Species
sample O
processing O

He O
trained O
for O
his O
PhD O
with O
Dr O
Piet O
Borst O
, O
The O
Netherlands O
Cancer O
Institute O
, O
and O
as O
a O
postdoc O
with O
Dr O
Anton O
Berns O
, O
The O
Netherlands O
Cancer O
Institute O
, O
and O
with O
Dr O
Rudolf O
Jaenisch O
, O
at O
the O
Whitehead O
Institute O
for O
Biomedical O
Research O
in O
Cambridge O
, O
MA O

Dr O
Kelsey's O
laboratory O
mainly O
investigates O
susceptibility O
to O
smoking-related O
lung B-Disease
cancer I-Disease
and O
studies O
multi-racial O
and O
ethnic O
populations O

Furthermore O
, O
the O
efficiencies O
for O
the O
predictions O
are O
above O
80% O
for O
most O
data O
sets O
and O
above O
90% O
for O
four O
data O
sets O
at O
different O
significant O
levels O

DNA O
methylation O
is O
the O
most O
abundant O
epigenetic O
modification O
among O
vertebrates B-Species
and O
is O
essential O
to O
mammalian B-Species
development O

With O
the O
discovery O
and O
development O
of O
the O
orthologous O
CRISPR-Cas B-Gene
systems O
, O
their O
genome O
editing O
efficiency O
have O
improved O

1029Epigenetics O
is O
revealing O
how O
"nature O
is O
nurtured", O
with O
environmental O
factors O
such O
as O
nutrition O
, O
environmental O
neurotoxicants O
, O
and O
psychological O
stress O
influencing O
DNA B-Gene
expression O

Experimental O
evidences O
for O
the O
proportionality O
of O
the O
variances O
over O
genes B-Gene
are O
also O
discussed O


1219 O
Epigenetics O
includes O
a O
complex O
set O
of O
processes O
that O
alter O
gene O
activity O
without O
modifying O
the O
DNA B-Chemical
sequence I-Chemical
, O
which O
ultimately O
determines O
how O
the O
genetic O
information O
common O
to O
all O
the O
cells O
of O
an O
organism O
is O
used O
to O
generate O
different O
cell O
types O


This O
review O
examines O
recent O
studies O
of O
the O
ASD B-Disease
epigenome O
, O
detailing O
common O
gene O
pathways O
found O
to O
be O
differentially O
methylated O
in O
people O
with O
ASD B-Disease
, O
and O
considers O
how O
these O
discoveries O
may O
inform O
our O
understanding O
of O
ASD B-Disease
etiology O

We O
also O
discuss O
examples O
of O
epigenetic O
alterations O
of O
T B-Gene
cells I-Gene
in O
autoimmune B-Disease
diseases I-Disease

Such O
approaches O
will O
substantially O
increase O
the O
field's O
ability O
to O
establish O
the O
precise O
epigenetic O
mechanisms O
underlying O
drug B-Chemical
addiction B-Disease
, O
and O
could O
lead O
to O
novel O
treatments O
for O
addictive O
disorders B-Disease

Furthermore O
, O
knockout O
of O
the O
putative O
6mA O
methylase O
NO08G00280 B-Gene
by O
genome O
editing O
leads O
to O
changes O
in O
methylation O
patterns O
that O
are O
correlated O
with O
changes O
in O
the O
expression O
of O
molybdenum B-Chemical
cofactor I-Chemical
, O
sulfate B-Chemical
transporter I-Chemical
, O
glycosyl B-Chemical

Epigenetic O
processes O
thus O
conceived O
generate O
substantial O
subject-specific O
structural O
variation O
, O
for O
instance O
, O
in O
growing O
brain B-Species
networks O

1290 O
 O
Possible O
phenotypic O
impairments O
associated O
with O
maternal O
stress O
during O
gestation O
in O
beef B-Species
cattle I-Species
may O
be O
explained O
by O
epigenetic O
effects O

It O
has O
been O
suggested O
that O
epigenetics O
may O
underlie O
the O
observation O
that O
some O
individuals O
appear O
to O
age O
faster O
than O
others O

Pooling O
DNA B-Chemical
prior O
to O
library O
preparation O
may O
be O
an O
efficient O
way O
to O
reduce O
costs O
and O
increase O
sample O
size O
, O
yet O
there O
are O
to O
date O
no O
recommendations O
in O
ecological O
epigenetics O
research O

One O
of O
the O
most O
striking O
outcomes O
of O
the O
recent O
surge O
of O
sequencing-based O
studies O
on O
neurodevelopmental B-Disease
disorders I-Disease
( O
NDDs B-Disease
) O
is O
the O
emergence O
of O
chromatin B-Chemical
regulation O
as O
one O
of O
the O
two O
domains O
most O
affected O
by O
causative O
mutations O
or O
Copy B-Gene
Number I-Gene

the O
emerging O
field O
of O
epigenetics O
as O
related O
to O
psychology O
is O
reviewed O

With O
fixed O
models O
, O
transcription B-Gene
factors I-Gene
functionally O
active O
in O
the O
regulation O
of O
gene B-Gene
expression I-Gene
and O
affected O
by O
epigenetic O
DNA B-Chemical
methylation I-Chemical
can O
be O
identified O
and O
subsequently O
confirmed O

However O
, O
looking O
at O
specific O
genes O
requires O
bespoke O
coding O
for O
which O
wet-lab O
biologists O
or O
clinicians O
are O
not O
trained O

We O
show O
a O
trade-off O
between O
either O
minimizing O
the O
adaptation O
time O
or O
increasing O
the O
robustness O
of O
the O
phenotype O
to O
biochemical O
noise O

Conclusions O
 O
We O
have O
developed O
a O
muscle-specific O
epigenetic O
clock O
that O
predicts O
age O
with O
better O
accuracy O
than O
the O
pan-tissue O
clock O

Epigenetic O
changes O
are O
fundamental O
for O
the O
regulatory O
physiological O
processes O
that O
regulate O
gene O
activity O
; O
therefore O
, O
these O
changes O
are O
altered O
in O
response O
to O
environmental O
factors O
or O
disease B-Disease
states I-Disease
, O
but O
, O
in O
many O
circumstances O
, O
they O
are O
also O
believed O
to O
contribute O
to O

Method O
 O
Using O
the O
Illumina O
850K O
BeadChip O
, O
we O
conducted O
a O
genome-wide O
DNAm O
assessment O
on O
10 O
matched O
pairs O
of O
HT B-Disease
sufferers I-Disease
and O
healthy O
individuals O

Their O
application O
in O
some O
skin B-Disease
diseases I-Disease
and O
cosmetic O
research O
and O
development O
is O
also O
summarized O

0 O
, O
we O
have O
added O
more O
distinctive O
features O

In O
this O
minireview O
, O
we O
discuss O
recent O
advances O
in O
transcriptional O
and O
epigenomic O
regulation O
of O
adipogenesis O
, O
with O
a O
focus O
on O
factors O
and O
mechanisms O
shared O
by O
both O
white B-Species
adipogenesis I-Species
and O
brown B-Species
adipogenesis I-Species

Epigenetic O
alterations O
, O
frequently O
associated O
with O
molecular O
variations O
in O
PCa B-Disease
, O
contribute O
to O
the O
acquisition O
of O
a O
radioresistant O
phenotype O

In O
particular O
, O
DNA B-Gene
changes O
caused O
by O
psychological B-Disease
trauma I-Disease
can O
be O
transmitted O
from O
generation O
to O
generation O
, O
validating O
the O
psychoanalytic O
concept O
of O
intergenerational O
transmission O
of O
trauma O

Trichostatin B-Chemical
A B-Chemical
, O
a O
histone O
deacetyltransferase O
inhibitor O
( O
HDACi O
) O
, O
leads O
to O
AMP B-Gene
Î²-defensin I-Gene
2 I-Gene
( O
HBD2 B-Gene
) O
gene O
up-regulation O
in O
human O
epithelial O
cells O
suggesting O
a O
useful O
' O
epi-therapy O
' O
for O
Escherichia B-Species
coli I-Species
- O

We O
calculate O
the O
stability O
of O
the O
phenotypic O
states O
both O
for O
cooperative O
binding O
feedback O
and O
dimer O
binding O
feedback O
, O
resulting O
in O
non-linear O
decay O

Secondary O
analyses O
explored O
the O
effects O
of O
type O
of O
trauma O
( O
abuse O
and O
neglect O
) O
and O
adult O
chronic B-Disease
stress I-Disease
status O
( O
caregiver O
of O
child O
with O
autism B-Disease
and O
non-caregiver O
) O

183 O
Polygenic O
approaches O
often O
access O
more O
variance O
of O
complex O
traits O
than O
is O
possible O
by O
single O
variant O
approaches O

Finally O
, O
we O
make O
specific O
suggestions O
for O
future O
research O
on O
MS-AFLP B-Gene
and O
identify O
questions O
that O
are O
most O
compelling O
and O
tractable O
in O
the O
short O
term O

Changes O
of O
epigenetic O
marks O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
and O
non-coding O
RNA B-Gene
's O
can O
induce O
changes O
in O
gene B-Gene
transcription I-Gene
leading O
to O
physiological O
long-term O
changes O
or O
even O
transgenerational O
inheritance O

862 O
 O
Primary O
malignant O
brain O
tumors O
remain O
a O
disproportionate O
cause O
of O
morbidity O
and O
mortality O
in O
humans B-Species

This O
review O
will O
present O
the O
role O
of O
epigenetic O
abnormalities O
in O
MM B-Disease
and O
how O
these O
can O
affect O
specific O
pathways O
, O
and O
focus O
on O
the O
potential O
of O
novel O
' O
epidrugs B-Chemical
' O
as O
future O
treatment O
modalities O
for O
MM B-Disease

In O
females O
, O
EEDs B-Disease
can O
affect O
uterine B-Disease
development O
and O
the O
expression O
levels O
of O
reproduction-related O
genes B-Gene
, O
ultimately O
reducing O
female O
fertility O
and O
the O
normal O
development O
of O
the O
fetus O

Users O
input O
their O
functional O
genomic O
data O
in O
the O
Browser O
Extensible O
Data O
( O
BED O
) O
, O
Peaks O
, O
and O
bigWig O
formats O
, O
and O
may O
search O
for O
data O
in O
any O
of O
the O
three O
formats O

To O
bridge O
this O
gap O
, O
we O
developed O
a O
tool O
for O
mapping O
and O
quantification O
of O
methylation B-Chemical
differences O
at O
candidate O
genomic O
features O
of O
interest O
, O
without O
using O
coding O

Menin O
inhibitors O
should O
be O
moved O
rapidly O
into O
paediatric O
development O
, O
in O
view O
of O
their O
biological O
rationale O
, O
strong O
preclinical O
activity O
and O
ability O
to O
fulfil O
an O
unmet O
clinical O
need O

Using O
genome-wide O
DNA B-Chemical
methylation I-Chemical
data O
measured O
in O
a O
large O
collection O
of O
Scottish B-Species
old O
individuals O
, O
we O
performed O
discovery O
association O
analysis O
to O
identify O
age-methylated O
CpGs O
and O
replicated O
them O
in O
two O
independent O
Danish B-Species
cohorts O

In O
contrast O
to O
genetic O
studies O
, O
which O
estimate O
the O
effects O
of O
structural O
changes O
in O
, O
and O
transcriptomic O
studies O
, O
which O
measure O
genomic O
outputs O
, O
epigenetic O
studies O
can O
access O
states O
of O
regulation O
of O
genome O
function O
in O
particular O
cells O
and O
in O
response O
to O
specific O
stimuli O

Some O
questions O
may O
instead O
be O
addressable O
via O
epigenomics O
, O
as O
the O
epigenome O
acts O
as O
an O
interphase O
between O
the O
fixed O
genome B-Gene
and O
the O
dynamic O
environment O

The O
analysis O
of O
these O
modifications O
provides O
a O
thorough O
insight O
into O
the O
cardiovascular B-Disease
system I-Disease
from O
its O
development O
to O
its O
further O
functioning O

558 O
Considerable O
epidemiological O
, O
experimental O
and O
clinical O
data O
have O
amassed O
showing O
that O
the O
risk O
of O
developing O
disease O
in O
later O
life O
is O
dependent O
on O
early O
life O
conditions O
, O
mainly O
operating O
within O
the O
normative O
range O
of O
developmental O
exposures O

The O
systemic O
and O
pervasive O
occurrence O
of O
DNA B-Gene
methylation O
throughout O
the O
genome O
defines O
cellular O
identity O
and O
therefore O
requires O
genome-wide O
assays O
to O
fully O
appreciate O
and O
discern O
differential O
patterns O
of O
methylation O
that O
influence O
aspects O
of O
phenotypic O
plasticity O
including O
susceptibility O
to O
common O
complex O
disease B-Disease

Emerging O
evidence O
suggests O
that O
epigenetic O
regulation O
is O
an O
additional O
essential O
component O
of O
HSC B-Gene
development O

Thus O
, O
an O
altered O
functionality O
of O
the O
endocrine O
, O
immune O
, O
nervous O
and O
cardiovascular O
systems O
is O
observed O
in O
the O
progeny O

Areas O
of O
agreement O
 O

Recent O
in O
vitro O
studies O
suggest O
that O
vitamin B-Chemical
C I-Chemical
at O
physiological O
concentrations O
, O
combined O
with O
hypomethylating B-Chemical
agents I-Chemical
may O
act O
synergistically O
to O
cause O
DNA B-Gene
demethylation O
through O
active O
and O
passive O
mechanisms O
, O
respectively O

We O
then O
carried O
out O
epigenome-wide O
association O
studies O
( O
EWAS O
) O
to O
test O
the O
association O
between O
methylation O
at O
each O
site O
and O
cleft B-Disease
subtype I-Disease
( O
cleft B-Disease
lip I-Disease
only I-Disease
( O
CLO O
) O
n O
= O
50 O
; O
cleft B-Disease
palate I-Disease
only I-Disease
( O
CPO O
) O
n O

Epigenetic O
changes O
may O
be O
responsible O
for O
'metabolic O
memory' O
and O
development O
of O
micro- O
and O
macrovascular O
complications O
of O
diabetes B-Disease

In O
Drosophila B-Species
, O
TADs O
are O
biochemically O
defined O
by O
epigenetic O
marks O
, O
this O
suggesting O
that O
the O
3D O
arrangement O
may O
be O
the O
" O
missing O
link O
" O
between O
epigenetics O
and O
gene B-Gene
activity I-Gene

858 O
Viewing O
recurrent O
depression B-Disease
as O
a O
potentially O
progressive O
illness O
may O
help O
transform O
treatment O
toward O
earlier O
, O
more O
consistent O
intervention O
and O
prevention O

Here O
, O
we O
review O
whether O
altered O
epigenetic O
landscapes O
are O
merely O
a O
consequence O
of O
chromatin B-Chemical
modifier/remodeler I-Chemical
aberrations O
or O
a O
hallmark O
of O
cancer B-Disease
etiology O

In O
this O
technical O
commentary O
, O
we O
argue O
that O
the O
method O
used O
in O
the O
original O
study O
inherently O
amplifies O
the O
likelihood O
of O
genetic O
changes O
that O
thereafter O
lead O
to O
the O
heritability O
of O
epigenetic O
changes O

We O
now O
know O
of O
more O
than O
150 O
RNA B-Chemical
modifications O
and O
the O
true O
potential O
of O
a O
few O
of O
these O
is O
currently O
emerging O
as O
the O
consequence O
of O
a O
leap O
in O
detection O
technology O
, O
principally O
associated O
with O
high-throughput O
sequencing O

Recent O
advances O
in O
our O
understanding O
of O
epigenetics O
have O
pointed O
out O
that O
epigenetic O
alterations O
also O
play O
an O
important O
role O
in O
neurodevelopment O
and O
may O
increase O
the O
risk O
to O
psychiatric B-Disease
disorders I-Disease

While O
it O
is O
known O
that O
intergenerational O
trauma O
can O
be O
transmitted O
through O
attachment O
relationships O
, O
a O
new O
branch O
of O
genetics O
( O
epigenetics O
) O
has O
emerged O
to O
study O
the O
interaction O
between O
human O
behavior O
and O
changes O
in O
DNA B-Gene
expression O

These O
epigenetic O
modifications O
are O
usually O
analyzed O
by O
microscopy O
or O
by O
chromatin B-Chemical
immunoprecipitation I-Chemical
( O
ChIP B-Chemical
) O

Our O
results O
show O
that O
prenatal O
arsenic B-Chemical
exposure O
can O
alter O
DNA B-Gene
methylation I-Gene
in O
artery B-Species
and O
placenta B-Species
but O
not O
in O
HUVEC B-Species

The O
developmental O
systems O
perspective O
offers O
a O
distinctive O
, O
coherent O
, O
integrative O
way O
to O
understand O
the O
relationships O
between O
evolution O
, O
epigenetics B-Disease
, O
development O
, O
and O
the O
effects O
of O
experienced O
contexts O

Relapse O
after O
treatment O
has O
been O
previously O
explained O
using O
the O
cancer B-Disease
stem I-Disease
cell I-Disease
model O
and O
the O
clonal B-Disease
evolution I-Disease
model O

In O
addition O
to O
describing O
suggested O
troubleshooting O
workflows O
, O
these O
methods O
include O
four O
important O
updates O
which O
should O
facilitate O
widespread O
implementation O
of O
the O
technique O
 O
( O
1 O
) O
additionally O
optimized O
reaction O
conditions O
; O
( O
2 O
) O
redesigned O
quality O
controls O
which O
can O
be O
performed O
prior O
to O
resource-consumptive O
deep O

gevry@usherbrooke O

332 O
The O
escalating O
threat O
of O
heavy B-Chemical
metal I-Chemical
and O
metalloid B-Chemical
stress O
on O
plant B-Species
ecosystems O
requires O
innovative O
strategies O
to O
strengthen O
plant B-Species
resilience O
and O
ensure O
agricultural O
sustainability O

Summary O
 O
Epigenetic O
studies O
in O
the O
eating O
disorders O
corroborate O
the O
idea O
that O
eating O
disorder O
cause O
is O
multifactorial O
, O
and O
identify O
markers O
that O
could O
help O
inform O
our O
understanding O
of O
illness O
staging O
and O
subtyping O
that O
may O
explain O
the O
commonly O
progressive O
course O
of O
these O
disorders O
, O

Alterations O
in O
the O
metabolic O
processes O
can O
lead O
to O
epigenetic O
and O
genetic O
perturbations O
, O
causative O
for O
diverse O
disorders O
, O
accelerated O
aging O
, O
and O
various O
age-related O
diseases B-Disease

In O
genome-wide O
association O
studies O
, O
only O
a O
small O
proportion O
of O
heritability O
is O
explained O
by O
genetic O
variants O
identified O
to O
date O
, O
which O
has O
prompted O
researchers O
in O
bioinformatics O
and O
biostatistics O
to O
take O
into O
account O
nonlinear O
relationships O
due O
to O
gene-environment O
or O
gene-gene O
interactions O

We O
introduce O
platforms O
for O
mapping O
genome-wide O
chromatin B-Chemical
accessibility O
, O
nucleosome B-Chemical
occupancy O
, O
DNA-binding B-Chemical
proteins O
, O
and O
DNA B-Chemical
methylation B-Chemical
, O
primarily O
focusing O
on O
the O
integration O
of O
DNA B-Chemical
methylation B-Chemical
and O
chromatin B-Chemical
immunoprecipitation-sequencing B-Chemical
technologies O
into O

However O
, O
dysregulation O
of O
epigenetic O
patterns O
causes O
diseases O
like O
cancer B-Disease
, O
diabetes B-Disease
, O
neurological B-Disease
disorder I-Disease
, O
infectious B-Disease
diseases I-Disease
, O
autoimmunity B-Disease
etc O

We O
anticipate O
that O
JMnorm B-Gene
will O
enhance O
integrative O
and O
comparative O
epigenomics O

Here O
we O
show O
that O
seemingly O
minor O
experimental O
variations O
, O
even O
under O
normal O
baseline O
conditions O
, O
can O
have O
a O
significant O
impact O
on O
epigenome O
outcome O
measures O
and O
data O
interpretation O

 O

We O
have O
also O
analyzed O
the O
selected O
probes O
for O
their O
biological O
relevance O

In O
addition O
, O
epigenetic O
marks O
are O
potentially O
heritable O

344 O
methylation O
is O
one O
of O
the O
best-known O
epigenetic O
modifications O
in O

In O
this O
scenario O
, O
mitochondrial B-Species
function O
(or O
dysfunction O
) O
and O
mitochondrial B-Species
DNA B-Gene
have O
emerged O
as O
major O
players O

However O
, O
no O
clear O
pathogenic O
genes B-Gene
have O
so O
far O
been O
identified O

Here O
, O
we O
review O
recent O
developments O
in O
conventional O
active O
site O
and O
allosteric O
inhibitors O
, O
peptidomimetics O
, O
and O
novel O
proteolysis-targeted O
chimera O
( O
PROTAC O
) O
technology O
that O
have O
deepened O
our O
understanding O
of O
transcriptional O
processes O
and O
led O
to O
promising O
preclinical O
compounds O
for O
therapeutic O

Computational O
predictions O
indicate O
that O
one-twentieth O
of O
all O
drugs O
might O
potentially O
interact O
with O
human B-Species
histone B-Gene
deacetylase I-Gene
, O
which O
was O
prospectively O
experimentally O
verified O
for O
the O
compound O
with O
the O
highest O
predicted O
interaction O
probability O

Such O
integration O
allowed O
highly O
sensitive O
tests O
starting O
with O
100 O
cross-linked O
cells O
for O
ChIP B-Chemical
or O
500 O
pg O
of O
genomic O
DNA B-Chemical
for O
MeDIP B-Chemical
(compared O
to O
10(6)-10(7) O
cells O
for O
ChIP B-Chemical
and O
1-10 O
Î¼g O
of O
DNA B-Chemical
for O
MeDIP B-Chemical
in O
conventional O

To O
investigate O
how O
various O
study O
variables O
influence O
power O
to O
identify O
DNA B-Gene
methylation I-Gene
differences O
between O
groups O
, O
we O
developed O
a O
framework O
for O
simulating O
bisulfite O
sequencing O
data O

1404DNA O
methylation O
( O
DNAm O
) O
is O
a O
mechanism O
for O
rapid O
acclimation O
to O
environmental O
conditions O

Sirtuins O
, O
a O
family O
of O
nicotine B-Chemical
adenine I-Chemical
dinucleotide I-Chemical
( O
NAD+ B-Chemical
) O
-dependent O
enzymes O
, O
are O
involved O
in O
the O
cell O
metabolism O
and O
can O
regulate O
many O
cellular O
functions O
including O
DNA B-Gene
repair O
, O
inflammatory B-Disease
response O
, O
cell O
cycle O
or O
apoptosis O

Despite O
well-characterized O
associations O
between O
aberrant O
DNA B-Gene
methylation I-Gene
changes O
and O
gene B-Gene
expression O
, O
evidence O
for O
a O
causal O
relationship O
in O
this O
context O
has O
been O
difficult O
to O
obtain O

This O
has O
resulted O
in O
an O
exponential O
increase O
of O
450k O
data O
in O
recent O
years O
and O
triggered O
the O
development O
of O
numerous O
integrated O
analysis O
pipelines O
and O
stand-alone O
packages O

1176 O
Recent O
insights O
in O
evolutionary O
biology O
have O
shed O
light O
on O
epigenetic O
variation O
that O
interacts O
with O
genetic O
variation O
to O
convey O
heritable O
information O

Importantly O
, O
our O
data O
suggested O
that O
DNA B-Gene
methylation I-Gene
might O
play O
an O
important O
role O
in O
repressing O
key O
parasitism-related O
genes O
, O
including O
genes O
encoding O
excretion-secretion O
proteins O
, O
thereby O
raising O
the O
possibility O
of O
targeting O
DNA B-Gene
methylation I-Gene
processes O
as O
a O
useful O
strategy O
in O
therapeutics O

Carefully O
selected O
core O
STR B-Gene
loci O
form O
the O
basis O
of O
intelligence-led O
DNA B-Chemical
databases O
that O
provide O
investigative O
leads O
by O
linking O
unsolved O
crime O
scenes O
and O
criminals O
through O
their O
matched O
STR B-Gene
profiles O

Signals O
from O
the O
local O
environment O
or O
a O
history O
of O
signals O
can O
drive O
these O
variations O
, O
and O
tissues O
have O
many O
cell O
types O
that O
play O
separate O
roles O

Recent O
advances O
in O
"omics"-namely O
genomics B-Gene
and O
epigenetics O
, O
metabolomics O
, O
and O
proteomics O
- O
now O
provide O
exciting O
approaches O
and O
tools O
that O
can O
be O
used O
for O
the O
first O
time O
to O
address O
this O
gap O

However O
, O
the O
extent O
to O
which O
observed O
epigenetic O
variation O
occurs O
independently O
of O
genetic O
influences O
remains O
uncertain O
, O
due O
to O
the O
widespread O
impact O
of O
genetics O
on O
epigenetic O
variation O
and O
the O
limited O
availability O
of O
comprehensive O
( O
epi O
) O
genomic O
resources O
from O
most O
species B-Species

Application O
of O
these O
enzymes O
in O
sequencing O
can O
be O
accomplished O
by O
relying O
on O
their O
natural O
activity O
, O
exploiting O
their O
ability O
to O
discriminate O
between O
cytosine B-Chemical
modification I-Chemical
states O
, O
reacting O
them O
with O
functionalized O
substrate O
analogs O
to O
introduce O
chemical O
handles O
, O
or O
engineering O
the O
DNA-modifying O

Herein O
, O
we O
summarize O
the O
current O
understanding O
of O
MRD B-Gene
biology O
in O
solid O
tumors B-Disease
, O
with O
a O
focus O
on O
epigenetics O
and O
pluripotency O
, O
presenting O
an O
overall O
view O
of O
the O
direction O
the O
field O
is O
taking O
to O
reach O
the O
goal O
of O
reducing O
cancer-related B-Disease
mortalities O
that O

1232 O
Clonal O
hematopoiesis O
of O
indeterminate O
potential O
(CHIP) O
is O
a O
common O
precursor O
state O
for O
blood O
cancers O
that O
most O
frequently O
occurs O
due O
to O
mutations O
in O
the O
DNA-methylation O
modifying O
enzymes O
DNMT3A B-Gene
or O
TET2 B-Gene

We O
identified O
BRG1 B-Gene
, O
BAF155 B-Gene
, O
and O
BAF60a B-Gene
expression O
as O
strongly O
correlating O
with O
iPSC B-Species
reprogramming O
efficiency O

cancer B-Disease

However O
, O
the O
methylome O
has O
not O
yet O
been O
fully O
described O
in O
archival O
formalin-fixed B-Chemical
paraffin I-Chemical
embedded I-Chemical
( O
FFPE B-Chemical
) O
samples O
in O
the O
context O
of O
matched O
fresh-frozen B-Chemical
( O
FF B-Chemical
) O
tumor B-Disease
material O
at O
base-pair O
resolution O
using O
a O
targeted O
approach O

This O
has O
been O
addressed O
by O
including O
cellular O
heterogeneity O
obtained O
through O
cytology O
at O
the O
time O
of O
collection O
or O
by O
using O
cellular O
deconvolution O
algorithms O
built O
on O
epigenetic O
data O
from O
specific O
cell O
types O

It O
may O
be O
used O
as O
a O
tool O
to O
help O
the O
study O
of O
6mA B-Chemical
distribution O
pattern O

Dynamic O
and O
latent O
epigenetic O
alterations O
are O
incorporated O
in O
AD B-Disease
pathological O
pathways O
and O
present O
valuable O
reversible O
targets O
for O
AD B-Disease
and O
other O
neurological O
disorders O

In O
this O
review O
we O
will O
provide O
an O
overview O
on O
"mitochondrial O
epigenetics" O
state O
of O
the O
art O
, O
by O
summarizing O
the O
involvement O
of O
mitochondrial O
function O
and O
of O
mitochondria-nucleus O
communication O
in O
regulating O
nuclear O
epigenome O
, O
as O
well O
as O
the O
key O
aspects O
of O
the O
epigenetic O
marks O

It O
has O
been O
observed O
that O
misregulation O
of O
epigenetic O
processes O
has O
been O
associated O
with O
human B-Species
disease B-Disease

solium B-Species
genome O

Studies O
have O
revealed O
key O
roles O
of O
epigenetic O
processes O
in O
regulating O
immune O
cell O
function O
and O
mediating O
antitumour B-Disease
immunity O

In O
particular O
, O
the O
nutritional O
environment O
in O
which O
the O
fetus O
or O
infant O
develops O
influences O
the O
risk O
of O
metabolic B-Disease
disorders I-Disease
in O
offspring O

The O
emerging O
tools O
of O
epigenetics O
can O
be O
used O
as O
preventive O
, O
diagnostic O
, O
and O
therapeutic O
markers O


By O
exploring O
these O
challenges O
, O
among O
others O
, O
the O
field O
of O
epigenetic O
chemical B-Chemical
biology O
will O
increase O
its O
potential O
for O
clinical O
benefit O
, O
and O
more O
effective O
strategies O
targeting O
the O
aberrant O
epigenome O
in O
cancer B-Disease
are O
likely O
to O
be O
developed O
both O
in O
haematological B-Disease
and O
solid O

e O

Early O
techniques O
for O
interrogating O
the O
role O
of O
DNA B-Gene
methylation I-Gene
in O
the O
regulation O
of O
gene B-Gene
transcription I-Gene
lack O
specificity O
and O
, O
where O
more O
specific O
techniques O
such O
and O
ZNFs B-Gene
and O
TALEs B-Gene
have O
been O
developed O
, O
they O
are O
limited O
by O
their O
extensive O
cost O
and O
labor O

17 O
to O
3 O

DNAm O
in O
preterm O
and O
term O
hematopoietic O
cells O
conformed O
to O
previously O
identified O
DNAm O
signatures O
of O
fetal O
liver O
and O
bone O
marrow O
, O
respectively O

calibration O
of O
sample-specific O
peak O
calling O
parameters O
by O
leveraging O
manual O
annotation O

Epigenomics O
has O
emerged O
as O
a O
key O
player O
in O
our O
rapidly O
evolving O
understanding O
of O
osteoarthritis B-Disease

birds B-Species
also O
lost O
more O
CpG B-Gene
sites I-Gene
in O
TLR1B B-Gene
, O
gained O
more O
CpG B-Gene
sites I-Gene
in O
TLR2A B-Gene
, O
and O
lost O
fewer O
CpG B-Gene
sites I-Gene
in O
TLR4 B-Gene
compared O
to O
native O
birds B-Species

ChIP-S3EQ O
performance O
was O
comparable O
to O
ChIP-seq O
, O
while O
RNA-S3EQ O
generated O
an O
almost O
identical O
expression O
profile O
to O
nuclear-enriched O
and O
whole O
cell O
RNA-seq O

Current O
evidence O
supports O
the O
notion O
that O
early O
infancy O
is O
characterized O
by O
heightened O
susceptibility O
to O
airway O
genetic B-Gene
reprogramming I-Gene
in O
response O
to O
the O
first O
exposures O
in O
life O
, O
some O
of O
which O
can O
have O
life-long O
consequences O

The O
double-replicated O
CpGs O
were O
characterized O
by O
distribution O
over O
gene B-Gene
regions O
and O
location O
in O
relation O
to O
CpG O
islands O

521 O
Background O
Epigenetic O
modifications O
, O
including O
CG B-Chemical
methylation I-Chemical
( O
a O
major O
form O
of O
DNA B-Chemical
methylation I-Chemical
) O
and O
histone B-Chemical
modifications I-Chemical
, O
interact O
with O
each O
other O
to O
shape O
their O
genomic O
distribution O
patterns O

Recent O
research O
has O
reported O
the O
role O
of O
epigenetic O
alterations O
in O
the O
mechanism O
of O
BC B-Disease
pathogenesis O
and O
its O
hallmarks O
include O
drug B-Chemical
resistance O
and O
stemness O
features O

protects O
against O
diseases O
like O
epilepsy B-Disease
, O
depression B-Disease
, O
and O
Parkinson's B-Disease
by O
modifying O
DNA B-Gene
and O
mitochondrial B-Gene
DNA I-Gene
in O
the O
hippocampus O

Mass O
spectrometry O
( O
MS O
) O
has O
emerged O
as O
the O
most O
powerful O
and O
versatile O
tool O
for O
the O
comprehensive O
, O
unbiased O
and O
quantitative O
analysis O
of O
histone B-Chemical
proteoforms O

The O
aim O
of O
this O
review O
is O
to O
provide O
guidance O
for O
those O
assessing O
macroH2A's B-Gene
potential O
as O
biomarker O
or O
therapeutic O
intervention O
point O

Epigenetic O
changes O
are O
a O
novel O
therapeutic O
target O
due O
to O
their O
specificity O
and O
potential O
for O
reversal O

Methods O
 O
A O
literature O
search O
of O
PubMed O
was O
performed O
using O
the O
criteria O
 O
" O
osteoarthritis B-Disease
" O
and O
one O
of O
the O
following O
terms O
" O
genetic(s) O
, O
genomic(s) O
, O
epigenetic(s) O
, O
polymorphism O
, O
noncoding O
ribonucleic B-Chemical
acid I-Chemical
( O
RNA B-Chemical
) O
, O
microRNA B-Gene

The O
effect O
of O
ionizing B-Chemical
radiations I-Chemical
(IRs) I-Chemical
is O
well O
known O
regarding O
their O
ability O
to O
induce O
genetic O
alterations O
; O
however O
, O
their O
impact O
on O
the O
epigenome O
landscape O
in O
cancer B-Disease
, O
notably O
at O
the O
CpG B-Gene
dinucleotide I-Gene
resolution I-Gene
, O
remains O
to O
be O
further O

1110 O
modifications O
, O
such O
as O
guide O
numerous O
critical O
biological O
processes O
, O
yet O
epigenetic O
information O
has O
not O
routinely O
been O
collected O
as O
part O
of O
sequence O
analyses O

003 O
, O
SE B-Gene
= O
0 O

From O
the O
whole O
embryo O
to O
the O
gene B-Gene
; O
2 O

Herein O
, O
we O
show O
that O
CRISPR/dCas9-mediated B-Gene
histone O
epigenetic O
modification O
systems O
efficiently O
reprogramed O
the O
expression O
of O
target O
genes O
in O
A O

Cells O
of O
the O
endocrine O
organs O
, O
which O
include O
pituitary B-Species
, O
thyroid B-Species
, O
thymus B-Species
, O
pancreas B-Species
ovary B-Species
and O
testes B-Species
, O
have O
been O
shown O
to O
be O
susceptible O
to O
epigenetic B-Chemical
alteration I-Chemical
, O
leading O
to O
both O
local O
and O
systemic O
changes O
often O
resulting O

At O
this O
region O
, O
5mC B-Chemical
and O
5hmC B-Chemical
levels O
both O
decreased O
with O
age O

330Chemical O
biology O
approaches O
are O
a O
powerful O
means O
to O
functionally O
characterize O
epigenetic O
regulators O
such O
as O

82 O
Epidemiology O
is O
the O
branch O
of O
science O
that O
investigates O
the O
causes O
and O
distribution O
of O
disease O
in O
populations O
in O
order O
to O
provide O
preventative O
measures O
and O
promote O
human O
health O

of O

1349 O
Our O
understanding O
of O
RNA B-Chemical
modifications O
has O
been O
growing O
rapidly O
over O
the O
last O
decade O

mean O
level O
of O
DNA B-Gene
methylation O
and O
difference O
between O
groups O
) O
parameters O

This O
allows O
them O
to O
serve O
as O
protein-based O
epigenetic O
elements O
that O
are O
readily O
broadcast O
through O
mitosis O
and O
meiosis O

However O
, O
the O
individual O
methylation O
profile O
within O
each O
allele O
has O
not O
yet O
been O
examined O
at O
the O
whole-genome O
level O

1449 O
A O
study O
in O
this O
issue O
demonstrates O
that O
epigenome-modifying O
drugs O
used O
in O
cancer B-Disease
chemotherapy I-Disease
induce O
transcription O
from O
thousands O
of O
previously O
unannotated O
transcription O
start O
sites O
, O
most O
of O
which O
are O
derived O
from O
ancient O
endogenous O
retroviruses B-Species
( O
ERVs I-Species
) O

Interestingly O
, O
the O
molecular O
clock O
coordinates O
transcriptional-translational O
feedback O
loops O
which O
orchestrate O
daily O
oscillations O
in O
expression O
of O
many O
genes O
involved O
in O
cellular O
functions O

com O
/ O
NIGMS B-Gene
/ O
NIGMS B-Gene
- O
Sandbox O

However O
, O
analysis O
of O
single-cell O
methylome O
data O
is O
challenging O
due O
to O
data O
sparsity O
and O
moderate O
correlation O
with O
transcript O
level O

Regulation O
of O
the O
Î³-globin B-Gene
to O
Î²-globin B-Gene
switch O
is O
achieved O
by O
chromatin O
remodeling O
at O
the O
HBB B-Gene
locus O
on O
chromosome O
11 O
and O
interactions O
of O
major O
DNA O
binding O
proteins O
, O
such O
as O
KLF1 B-Gene
and O
BCL11A B-Gene
in O
the O
proximal O
promoters O
of O
the O
globin B-Gene

104 O
is O
reconfigured O
during O
male O
reproduction O
in O
, O
but O
little O
is O
known O
regarding O
the O
mechanisms O
controlling O
these O
epigenetic O
dynamics O

50 O

Given O
the O
complex O
pathophysiology O
of O
cardiovascular B-Disease
diseases I-Disease
, O
an O
experimental O
approach O
capable O
of O
identifying O
multiple O
signaling O
networks O
activated O
in O
the O
heart B-Species
upon O
pathological O
conditions O
could O
be O
particularly O
effective O
to O
identify O
new O
diagnostic O
, O
prognostic O
or O
therapeutic O
targets O

Ethanol B-Chemical
metabolism O
globally O
increases O
donor O
substrates O
for O
histone O
acetylation O
and O
histone O
and O
DNA B-Gene
methylation O
, O
and O
this O
chapter O
discusses O
how O
this O
can O
further O
impact O
epigenetic O
programming O
of O
the O
adolescent O
brain O

We O
will O
discuss O
four O
overlapping O
but O
distinct O
major O
categories O
under O
ML O
 O
dimensionality O
reduction O
, O
unsupervised O
methods O
, O
supervised O
methods O
, O
and O
deep O
learning O
( O
DL O
) O

Epigenetics O
explains O
how O
the O
environment-our O
zip O
code-literally O
gets O
under O
our O
skin O
, O
creates O
biological O
changes O
that O
increase O
our O
vulnerability O
for O
disease O
, O
and O
even O
children O
's O
prospects O
for O
social O
success O
, O
over O
their O
life O
course O
and O
into O
future O
generations O

By O
exploiting O
differential O
kinetics O
of O
hydrolytic O
deamination O
reactions O
of O
cytosine B-Chemical
and O
its O
naturally O
occurring O
derivatives O
, O
we O
demonstrate O
how O
multiple O
layers O
of O
information O
can O
be O
stored O
in O
a O
single O
DNA B-Chemical
template O

However O
, O
all O
analyses O
have O
been O
correlational O
in O
nature O
and O
, O
as O
these O
studies O
have O
focussed O
on O
children O
and O
adolescents O
, O
DNAm B-Gene
has O
been O
based O
on O
peripheral O
tissue O
( O
cord B-Chemical
blood I-Chemical
, O
whole B-Chemical
blood I-Chemical
, O
buccal B-Chemical
cells I-Chemical
) O


As O
with O
other O
cell O
types O
and O
populations O
, O
endocrine O
cells O
are O
susceptible O
to O
tumour B-Disease
development I-Disease
, O
which O
in O
turn O
may O
have O
resulted O
from O
aberration O
of O
epigenetic O
control O

In O
this O
field O
, O
the O
uterus B-Disease
is O
seen O
as O
a O
micro-environment O
in O
which O
new O
generations O
can O
take O
shape O

detection O
of O
reversed O
letters O
and O
identify O
the O
most O
significant O
age-related O
cognitive O
indices O

These O
ambiguities O
can O
be O
eliminated O
by O
robust O
methods O
that O
directly O
characterize O
the O
existence O
and O
genomic O
locations O
of O
combinations O
of O
chromatin O
features O
in O
very O
small O
inputs O
of O
cells O
or O
ideally O
, O
single O
cells O

ChIPseeker O
is O
a O
freely O
available O
open-source O
package O
that O
may O
be O
found O
at O
https//www O

The O
purpose O
of O
this O
review O
is O
to O
provide O
an O
overview O
of O
the O
studies O
suggesting O
that O
epigenetic O
changes O
introduced O
by O
the O
social O
environment O
then O
manifest O
as O
psychological B-Disease
consequences I-Disease

Combination O
of O
DAC B-Chemical
with O
Bcl2 B-Gene
inhibitor O
venetoclax B-Chemical
provides O
more O
effective O
epigenetic O
therapy O
for O
lung B-Disease
cancer I-Disease

Most O
machine O
learning O
approaches O
developed O
so O
far O
aim O
at O
finding O
DNA B-Gene
sequences O
responsible O
for O
the O
CG B-Chemical
methylation I-Chemical
patterns O
and O
were O
not O
tailored O
for O
studying O
the O
epigenetic O
crosstalk O

The O
muscle B-Species
clock I-Species
outperformed O
the O
pan-tissue B-Species
clock I-Species
, O
with O
a O
median O
error O
of O
only O
4 O

, O
enhancers O
and O
insulators O
) O
and O
even O
within O
each O
class O
( O
e O

This O
review O
covers O
recent O
developments O
in O
the O
field O
and O
future O
prospects O

1193Background O
DNA B-Gene
methylation I-Gene
is O
a O
highly O
studied O
epigenetic O
signature O
that O
is O
associated O
with O
regulation O
of O
gene B-Gene
expression O
, O
whereby O
genes B-Gene
with O
high O
levels O
of O
promoter B-Gene
methylation I-Gene
are O
generally O
repressed O

Conclusion O
An O
adapted O
FLoSS O
from O
data O
collectable O
postnatally O
may O
be O
a O
feasible O
tool O
to O
study O
unbiased O
epigenetic O
predictors O
for O
longevity O

004 O
; O
cg08671764 O
 O
coefficient O
= O
0 O

Notably O
, O
these O
projects O
have O
found O
that O
approximately O
80% O
of O
human B-Species
DNA B-Gene
was O
biochemically O
active O
in O
at O
least O
one O
epigenomic O
assay O
while O
only O
approximately O
10% O
of O
the O
sequence O
displayed O
signs O
of O
purifying O
selection O

The O
analysis O
of O
data O
from O
subjects O
influenced O
by O
radiation B-Chemical
, O
cancer B-Disease
, O
and O
exercise-based O
interventions O
shows O
that O
despite O
being O
good O
predictors O
of O
chronological O
age O
, O
neither O
a O
pathological O
state O
like O
breast B-Disease
cancer I-Disease
, O
a O
hazardous O
environmental O
factor O
( O
radiation B-Chemical
) O

982 O
To O
date O
, O
how O
epigenetic O
changes O
are O
regulated O
during O
liver B-Species
regeneration O
remains O
unclear O

depression O
with O
diabetes B-Disease
or O
cardiovascular B-Disease
disease I-Disease


362 O
Epigenetics O
is O
the O
study O
of O
heritable O
changes O
in O
gene B-Gene
expression I-Gene
that O
occur O
independent O
of O
the O
DNA B-Gene
sequence I-Gene

These O
techniques O
for O
genome-wide O
profiling O
of O
chromatin B-Chemical
provide O
powerful O
and O
efficient O
tools O
to O
study O
the O
epigenome O

There O
are O
different O
types O
of O
epigenetic O
mechanisms O
 O
histone B-Chemical
modification I-Chemical
, O
non-coding O
RNAs B-Gene
and O
DNA B-Chemical
methylation I-Chemical

Altered O
DNA B-Gene
methylation I-Gene
in O
cancer B-Disease
was O
identified O
in O
1983 O

The O
seemingly O
natural O
capability O
of O
cancer B-Disease
to O
adapt O
dynamically O
in O
a O
Darwinian O
manner O
is O
a O
primary O
reason O
for O
therapeutic O
failures O

839 O
Current O
genome-wide O
ChIP-seq O
experiments O
on O
different O
epigenetic O
marks O
aim O
at O
unraveling O
the O
interplay O
between O
their O
regulation O
mechanisms O

832 O
Immunotherapy O
has O
brought O
new O
hope O
for O
cancer B-Disease
patients O
in O
recent O
times O

Intriguingly O
, O
the O
observed O
scaling O
laws O
lack O
consistent O
interpretation O
in O
polymer B-Chemical
physics O

Therefore O
, O
we O
address O
the O
impact O
of O
some O
epigenetic O
modifiers O
on O
T-cell B-Species
activation O
and O
differentiation O
, O
and O
discuss O
possible O
synergies O
with O
T B-Species
cell-based O
immunotherapeutic O
strategies O

376 O
How O
evolution O
can O
be O
facilitated O
by O
epigenetic O
mechanisms O
has O
received O
refreshed O
attention O
recently O

498 O

797 O
 O
methylation O
is O
an O
essential O
epigenetic O
modification O
involved O
in O
regulating O
the O
expression O
of O
genomes O

The O
epigenetic O
age O
can O
now O
be O
extrapolated O
from O
one O
of O
several O
epigenetic O
clocks O
, O
which O
are O
based O
on O
age-related O
changes O
in O
DNA B-Gene
methylation I-Gene
levels O
at O
specific O
multiple O
CpG B-Gene
sites I-Gene

Rather O
than O
investigating O
genetic O
and O
epigenetic O
factors O
independently O
, O
an O
integrative O
etiological O
research O
paradigm O
based O
on O
the O
combination O
of O
genomic O
, O
transcriptomic O
, O
and O
epigenomic O
analyses O
is O
required O

However O
, O
at O
the O
current O
time O
, O
their O
impact O
on O
overall O
expense O
for O
CHD B-Disease
care O
is O
poorly O
understood O

research O

Here O
, O
we O
review O
the O
role O
of O
epigenetic O
mechanisms O
in O
cancer B-Disease
metastasis I-Disease
, O
explore O
recent O
developments O
in O
technologies O
for O
epigenomic O
investigation O
, O
and O
highlight O
the O
emerging O
applications O
of O
epigenomic O
editing O
technologies O
in O
the O
clinical O
management O
of O
cancer B-Disease

Systematical O
studies O
of O
clinical O
and O
pathological O
mechanisms O
and O
identification O
of O
optimal O
therapeutic O
targets O
through O
integrative O
analysis O
of O
multi-omics O
data O
from O
different O
levels O
and O
resources O
have O
become O
an O
important O
research O
direction O
of O
precision O
medicine O
, O
which O
would O
provide O
innovative O
perspectives O
on O
disease B-Disease
study O
and O
new O

The O
semiautonomous O
platform O
reduces O
technical O
variability O
, O
improves O
signal-to-noise O
ratios O
, O
and O
drastically O
reduces O
labor O

A O
teaching O
session O
on O
epigenetics O
was O
delivered O
either O
as O
a O
traditional O
lecture O
( O
C-group O
) O
or O
as O
a O
PRS-including O
Sandwich-based O
session O
( O
S-group O
) O

With O
the O
advances O
of O
high-throughput O
technologies O
and O
the O
accumulation O
of O
enormous O
amount O
of O
data O
, O
method O
development O
for O
analyzing O
these O
data O
has O
gained O
tremendous O
interests O
in O
the O
fields O
of O
computational O
biology O
and O
bioinformatics O

Recent O
studies O
have O
shown O
clear O
sexual O
dimorphism O
both O
in O
programming O
trajectories O
and O
in O
response O
to O
a O
given O
environmental O
insult O

A O
few O
computational O
methods O
have O
been O
proposed O
for O
quantitative O
modeling O
of O
landscape O
; O
however O
, O
to O
model O
and O
visualize O
the O
landscape O
of O
a O
high O
dimensional O
gene B-Gene
regulatory I-Gene
system I-Gene
with O
realistic O
details O
is O
still O
challenging O

These O
methods O
have O
been O
used O
to O
generate O
base-resolution O
maps O
of O
5mC B-Chemical
and O
its O
oxidation O
derivatives O
in O
genomic O
samples O

ChIP O
has O
been O
widely O
applied O
to O
assess O
the O
abundance O
of O
various O
epigenetic O
regulators O
, O
including O
modified O
histones O
, O
in O
various O
regions O
of O
cellular O
and O
viral O
chromatin O

Epigenetic O
mechanisms O
, O
including O
DNA B-Chemical
methylation I-Chemical
, O
chromatin B-Chemical
remodeling I-Chemical
, O
and O
non-coding O
RNA B-Gene
, O
are O
the O
link O
between O
environmental O
stimuli O
and O
disease B-Disease
onset I-Disease
on O
a O
permissive O
genetic O
background O
in O
autoimmune B-Disease
and O
chronic B-Disease
inflammatory I-Disease
diseases I-Disease

22 O
 O
Proteolysis O
targeting O
chimeras O
( O
PROTACs B-Chemical
) O
are O
heterobifunctional O
molecules O
and O
allow O
selective O
protein O
degradation O
by O
addressing O
the O
natural O
ubiquitin B-Gene
proteasome I-Gene
system O

Vital O
to O
address O
these O
enduring O
questions O
will O
be O
determining O
the O
role O
of O
epigenetic O
processes O
, O
or O
non-sequence-based O
features O
of O
the O
genome B-Gene
, O
that O
are O
not O
only O
critical O
for O
the O
regulation O
of O
transcriptional O
responses O
to O
hypoxia B-Disease
but O
heritable O
across O
generations O

Their O
beauty O
made O
them O
an O
object O
of O
scientia O
amabilis O
, O
and O
their O
manifold O
reactions O
made O
them O
attractive O
for O
college O
experiments O
and O
finally O
challenged O
causal O
analyses O
at O
the O
cellular O
level O

Nicolas O
Malebranche's O
role O
in O
disseminating O
this O
paradigm O
, O
particularly O
in O
the O
milieu O
of O
the O
AcadÃ©mie O
Royale O
des O
Sciences O
during O
the O
years O
when O
Bernard B-Gene
Le I-Gene
Bouyer I-Gene
de I-Gene
Fontenelle I-Gene
was O
its O
secretary O
, O
has O
been O
studied O
in O
detail O
, O
especially O
by O
Jacques O



72 O
 O
Bisulfite O
sequencing O
is O
a O
powerful O
technique O
to O
detect O
5-methylcytosine B-Chemical
in O
DNA B-Chemical
that O
has O
immensely O
contributed O
to O
our O
understanding O
of O
epigenetic O
regulation O
in O
plants B-Species
and O
animals B-Species

The O
transcriptional O
significance O
of O
potential O
epigenetic O
biomarker O
genes O
was O
corroborated O
through O
qRT-PCR O

This O
is O
a O
very O
promising O
and O
sustainable O
resolution O
to O
the O
obesity B-Disease
pandemic O

To O
start O
, O
four O
and O
five O
published O
transcriptomic O
and O
epigenomic O
datasets O
, O
respectively O
, O
were O
processed O
for O
data O
integration O

We O
also O
focus O
on O
problems O
and O
future O
perspectives O
in O
the O
development O
of O
fluorescent O
probes O
for O
epigenetics O

More O
broadly O
, O
an O
examination O
of O
the O
epigenetics O
of O
obesity B-Disease
reveals O
a O
two-way O
dynamic O
between O
social O
processes O
and O
genomic O
health O
information O

We O
compared O
the O
proposed O
method O
with O
the O
existing O
method O
consisting O
of O
PS-based O
confounding O
adjustment O
, O
SIS O
, O
minimax O
concave O
penalty O
( O
MCP B-Chemical
) O
variable O
selection O
, O
and O
classical O
joint-significance O
testing O

Key O
to O
these O
changes O
is O
the O
transition O
from O
the O
maternal O
environment O
of O
the O
oocyte O
to O
an O
embryonic-driven O
developmental O
expression O
programme O
, O
a O
process O
termed O
the O
maternal-to-zygotic O
transition O
( O
MZT O
) O

1387 O
Secondary O
metabolites O
of O
filamentous B-Species
fungi I-Species
are O
important O
sources O
of O
new O
drugs O
, O
and O
their O
biosynthetic O
processes O
are O
regulated O
by O
numerous O
factors O

With O
the O
use O
of O
whole-genome O
methylation O
sequencing O
, O
the O
data O
described O
herein O
substantiate O
an O
increasingly O
compromised O
DNA B-Gene
methylation I-Gene
profile O
as O
sperm B-Species
ages O
and O
, O
for O
the O
first O
time O
, O
also O
demonstrate O
a O
generational O
correlation O
in O
sperm B-Species
and O
blastocyst B-Species
of O

Loss O
of O
tissue O
homeostasis O
during O
post-reproductive O
lifespan O
is O
caused O
, O
at O
least O
in O
part O
, O
by O
a O
decline O
in O
stem O
cell O
function O
and O
is O
associated O
with O
an O
increased O
incidence O
of O
diseases B-Disease

However O
, O
very O
few O
studies O
have O
evaluated O
this O
from O
the O
perspective O
of O
epigenetics O

197 O
Epigenetic O
modifications O
are O
responsible O
for O
the O
stable O
maintenance O
of O
cellular O
phenotypes O
and O
consist O
of O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical

Epigenome O
editing O
is O
a O
promising O
approach O
for O
durable O
gene O
regulation O
, O
with O
many O
applications O
in O
basic O
research O
including O
the O
investigation O
of O
the O
regulatory O
functions O
and O
logic O
of O
chromatin O
modifications O
and O
cellular O
reprogramming O

Notably O
, O
though O
, O
we O
found O
that O
termination O
of O
resulted O
in O
a O
loss O
of O
regulation O
of O
the O
transcriptome O

The O
presented O
hypothesis O
might O
serve O
to O
understand O
and O
structure O
new O
findings O
into O
a O
more O
encompassing O
view O
of O
the O
genesis O
of O
degenerative B-Disease
diseases I-Disease
and O
may O
inspire O
novel O
approaches O
for O
their O
study O
and O
therapy O

regulate O

Epigenetic O
modifications O
can O
occur O
during O
periods O
of O
illness O
; O
these O
may O
persist O
and O
potentially O
influence O
allograft O
outcomes O

7 O
cells O

Exploiting O
functional O
annotation O
of O
RRBS B-Gene
loci O
739 O
IV O

As O
knowledge O
of O
epigenetic O
programming O
expands O
, O
a O
growing O
body O
of O
literature O
in O
social O
sciences O
and O
humanities O
is O
exploring O
the O
implications O
of O
this O
new O
field O
of O
study O
for O
contemporary O
societies O

We O
mainly O
focus O
on O
studies O
that O
have O
used O
small O
molecules O
to O
interfere O
with O
epigenome-modifying O
enzymes O
, O
such O
as O
DNA B-Chemical
methyltransferase I-Chemical
, O
histone B-Chemical
acetyltransferase I-Chemical
, O
and O
histone B-Chemical
methyltransferase I-Chemical

The O
eligible O
studies O
assessed O
human B-Species
prenatal O
exposure O
to O
psychotropics B-Chemical
or O
analgesics B-Chemical
, O
with O
epigenetic O
analyses O
of O
offspring O
tissue O
as O
an O
outcome O

The O
development O
of O
computational O
tools O
to O
enable O
testing O
and O
analysis O
of O
high-throughput-sequencing O
data O
is O
essential O
to O
modern O
genomics O
research O

Population O
studies O
, O
formalmodels O
, O
and O
research O
on O
genomic O
and O
ecological O
stressesall O
suggest O
that O
epigenetic O
inheritance O
is O
important O
in O
both O
micro-and O
macroevolutionary O
change O

The O
alterations O
in O
normal O
DNA B-Gene
methylation O
and O
histone B-Gene
acetylation/deacetylation O
patterns O
lead O
to O
deregulated O
transcription O
and O
chromatin O
organization O
resulting O
in O
altered O
gene B-Gene
expression O
profiles O
that O
facilitates O
tumor B-Disease
development O
and O
progression O

01 O
) O
in O
PNS O
cows O
relative O
to O
Controls O
at O
5 O
years O
of O
age O

Here O
, O
we O
suggest O
a O
methodology O
to O
probe O
into O
past O
environments O
, O
using O
reconstructed O
premortem O
DNA B-Chemical
methylation I-Chemical
maps O
of O
ancient O
individuals O

One O
interesting O
case O
is O
the O
heterodox O
readers O
of O
Malebranche O
, O
which O
use O
some O
of O
his O
own O
arguments O
( O
notably O
on O
the O
physiology O
of O
brain B-Disease
traces I-Disease
and O
the O
laws O
of O
nature O
) O
both O
against O
preexistence O
and O
to O
support O
epigenesis O

777 O
The O
field O
of O
epigenetics O
has O
exploded O
over O
the O
last O
two O
decades O
, O
revealing O
an O
astonishing O
level O
of O
complexity O
in O
the O
way O
genetic O
information O
is O
stored O
and O
accessed O
in O
eukaryotes B-Species

Acceleration O
of O
epigenetic O
clocks O
was O
also O
significantly O
related O
to O
mortality O
, O
cardiovascular B-Disease
disease I-Disease
, O
cancer B-Disease
and O
diabetes B-Disease

Most O
Jumonji B-Gene
C I-Gene
domain-containing O
(JMJD) B-Gene
proteins O
are O
histone B-Chemical
lysine I-Chemical
demethylases O
(KDM) O
and O
therefore O
epigenetic O
regulators O

A O
detail O
experimental O
protocol O
for O
MS-RAPD-PCR B-Gene
is O
described O
in O
this O
chapter O

Epidemiological O
studies O
demonstrating O
excessive O
paternal O
transmission O
provided O
the O
earliest O
evidence O
of O
epigenetic O
deregulation O
in O
psoriatic B-Disease
disease I-Disease
, O
however O
few O
studies O
have O
examined O
its O
molecular O
mechanisms O

By O
contrast O
, O
knockout O
of O
the O
candidate O
demethylase O
NO06G02500 B-Gene
results O
in O
increased O
6mA B-Chemical
levels O
and O
reduced O
growth O

Epigenetic O
mechanisms O
are O
essential O
for O
maintaining O
specific O
patterns O
of O
gene B-Gene
expression O
and O
normal O
development O
and O
growth O
of O
living O
individuals O

767 O
, O
= O
3 O

The O
focus O
of O
this O
review O
will O
be O
to O
discuss O
the O
chemical B-Chemical
methodologies O
that O
have O
been O
developed O
to O
detect O
the O
cytosine B-Chemical
derivatives O
in O
the O
genomic B-Gene
DNA I-Gene

Epigenetics O
seems O
to O
play O
a O
crucial O
role O
and O
could O
represent O
the O
link O
between O
environmental O
factors O
, O
that O
we O
are O
constantly O
exposed O
to O
, O
and O
risk O
factors O
for O
nephrolithiasis B-Disease

Finally O
, O
we O
demonstrate O
the O
added O
value O
of O
EpiDISH B-Gene
in O
an O
EWAS B-Disease
of O
smoking O


For O
the O
ART-conceived O
newborns O
, O
the O
dataset O
had O
detailed O
information O
on O
the O
embryo O
transfer O
date O
and O
the O
specific O
ART O
procedure O
used O
for O
conception O

by O
age O
and O
tissue O
, O
it O
is O
more O
complex O
to O
find O
appropriate O
external O
weights O

92 O
Background O
Longitudinal O
data O
and O
repeated O
measurements O
in O
epigenome-wide O
association O
studies O
(EWAS) O
provide O
a O
rich O
resource O
for O
understanding O
epigenetics O

e O

1380 O
Coronaviruses B-Species
(CoVs) I-Species
are O
highly O
diverse O
single-stranded O
RNA O
viruses O
owing O
to O
their O
susceptibility O
to O
numerous O
genomic O
mutations O
and O
recombination O

PTSD B-Disease

In O
this O
piece O
, O
we O
evaluate O
1 O
) O
the O
possible O
roles O
of O
epigenomes O
and O
microbiomes O
in O
animal B-Species
adaptation O
, O
2 O
) O
advances O
in O
the O
retrieval O
of O
paleoepigenome O
and O
paleomicrobiome O
data O
using O
ancient O
DNA B-Gene
techniques O
, O
and O
3 O
) O
the O
plasticity O
of O
either O

Of O
interest O
here O
is O
the O
recent O
shift O
in O
focus O
from O
genetic O
to O
epigenetic/epigenomic O
research O
and O
the O
emergence O
and O
extension O
of O
resource O
provision O
to O
support O
this O
both O
at O
local O
and O
global O
scale O

1317 O
Over O
the O
past O
decade O
, O
major O
technological O
and O
analytical O
advancements O
have O
propelled O
efforts O
toward O
identifying O
the O
molecular O
mechanisms O
that O
govern O
human B-Species
adaptation O
to O
high O
altitude O

1172 O
The O
impact O
of O
epigenetics O
on O
the O
differentiation O
of O
memory O
T B-Gene
( O
Tmem B-Gene
) O
cells O
is O
poorly O
defined O

As O
a O
first O
instance O
of O
EPICO O
, O
we O
implemented O
the O
BLUEPRINT B-Gene
Data I-Gene
Analysis I-Gene
Portal I-Gene
( O
BDAP B-Gene
) O

, O
brain O
) O

This O
research O
provides O
a O
solid O
foundation O
for O
further O
detailed O
investigation O
of O
these O
themes O
, O
all O
of O
which O
will O
be O
important O
data O
to O
help O
inform O
future O
public O
health O
messages O
regarding O
epigenetic O
concepts O

Here O
, O
we O
review O
the O
omics O
approaches O
used O
in O
these O
studies O
and O
resulting O
discoveries O

Furthermore O
, O
several O
shared O
functional O
categories O
and O
enriched O
pathways O
were O
obtained O
for O
these O
drugs O
with O
FDA B-Chemical
approved I-Chemical
epigenetic I-Chemical
drugs I-Chemical
and O
known O
AD B-Disease
drugs O

1179 O
Substantial O
progress O
has O
been O
made O
in O
identifying O
genetic O
loci O
associated O
with O
multifactorial O
disorders O
, O
including O
variants O
that O
seem O
to O
impact O
outcomes O
following O
solid O
organ O
transplantation O

Post-traumatic O
stress O
disorder B-Disease
( O
PTSD B-Disease
) O
is O
a O
debilitating O
disorder O
affecting O
approximately O
8% O
of O
the O
world O
's O
population O
during O
their O
lifetime O
, O
and O
typically O
develops O
after O
exposure O
to O
a O
traumatic O
event O

1255 O
Squamous B-Disease
cell I-Disease
carcinoma I-Disease
( O
SCC B-Disease
) O
of O
the O
oral B-Disease
and O
oropharyngeal B-Disease
region O
is O
the O
sixth O
most O
common O
malignancy O
in O
the O
world O
today O

Data O
on O
total O
and O
annual O
publications O
citations O
impact O
factors O
Hirsch O
( O
H O
) O
- O
index O
citation O
times O
most O
prolific O
authors O
and O
frequently O
published O
journals O
were O
collected O
for O
quantitative O
and O
qualitative O
comparison O

Although O
the O
study O
by O
Herrera O
& O
Bazaga O
( O
2011 O
) O
raises O
at O
least O
as O
many O
new O
questions O
as O
it O
answers O
, O
it O
is O
a O
pioneering O
example O
of O
how O
epigenetics O
can O
be O
incorporated O
into O
ecological O
field O
studies O
, O
and O
it O
illustrates O
the O
value O
and O
potential O
novel O

Recent O
human B-Species
brain O
imaging O
studies O
have O
examined O
differences O
in O
activity O
in O
the O
nucleus B-Gene
accumbens I-Gene
between O
controls O
and O
patients O
with O
chronic B-Disease
pain I-Disease
, O
and O
have O
revealed O
that O
the O
nucleus B-Gene
accumbens I-Gene
plays O
a O
role O
in O
predicting O
the O
value O
of O
a O
noxious O
stimulus O

The O
associated O
transcriptional O
changes O
suggest O
that O
environmentally O
induced O
5hmC B-Chemical
alterations O
play O
a O
role O
in O
epigenetically O
mediated O
genome O
flexibility O

In O
the O
subsequent O
method O
, O
the O
protocol O
to O
carry O
out O
a O
MS-AFLP O
analysis O
of O
saffron B-Species
DNA B-Gene
methylation I-Gene
patterns I-Gene
is O
described O

Lysenkoism O
was O
applied O
to O
agriculture O
during O
the O
Stalin O
era O
with O
disastrous O
consequences O

In O
this O
paper O
, O
by O
taking O
advantage O
of O
our O
laboratory O
's O
research O
on O
the O
DNA B-Chemical
methylation I-Chemical
maintenance I-Chemical
gene O
, O
OsMET1-2 B-Gene
in O
rice B-Species
, O
we O
have O
integrated O
our O
innovative O
findings O
in O
the O
education O
curriculum O
, O
and O
built O
a O
comprehensive O
teaching O
system O
on O

Nanomedicine O
, O
the O
application O
of O
nanotechnology O
in O
medicine O
, O
has O
a O
potential O
to O
advance O
the O
identification O
of O
diagnostic O
and O
prognostic O
biomarkers O
and O
the O
delivery O
of O
right O
drug B-Chemical
to O
disease B-Disease
sites O

DGW O
uses O
Dynamic O
Time O
Warping O
to O
adaptively O
rescale O
and O
align O
genomic O
distances O
which O
allows O
to O
group O
regions O
of O
interest O
with O
similar O
shapes O
, O
thereby O
capturing O
the O
structure O
of O
epigenomic O
marks O

This O
article O
draws O
on O
a O
multi-sited O
ethnography O
of O
epigenetic O
knowledge O
production O
in O
the O
United O
States O
and O
Canada O
to O
document O
how O
scientists O
conceptualize O
, O
model O
, O
and O
measure O
these O
experiences O
and O
their O
effects O
on O
children O
's O
neurodevelopmental O
and O
behavioral O
health O

It O
is O
therefore O
imperative O
to O
incorporate O
into O
" O
precision O
medicine O
" O
a O
better O
understanding O
of O
how O
these O
differences O
affect O
the O
efficacy O
of O
pharmacological O
, O
behavioral O
and O
psychosocial O
interventions O

In O
particular O
, O
members O
of O
the O
Wnt B-Gene
and O
TGF-beta B-Gene
pathways O
, O
pro-apoptotic O
genes O
such O
as O
APAF-1 B-Gene
and O
negative O
cell-cycle O
regulators O
such O
as O
KILLIN B-Gene
have O
been O
shown O
to O
be O
epigenetically O
silenced O
in O
numerous O
studies O
in O
ccRCC B-Disease

g O


It O
should O
be O
noted O
that O
the O
study O
of O
the O
role O
of O
epigenetics O
in O
food B-Disease
allergy I-Disease
is O
still O
in O
its O
infancy O
, O
and O
lags O
behind O
research O
on O
epigenetics O
in O
other O
fields O
such O
as O
cancer B-Disease
and O
autoimmune B-Disease
diseases I-Disease

Despite O
their O
remarkable O
genetic O
heterogeneity O
and O
complexity O
of O
pathophysiological O
mechanisms O
, O
NDDs B-Disease
display O
an O
overlap O
in O
their O
phenotypic O
features O
, O
a O
considerable O
degree O
of O
comorbidity O
as O
well O
as O
sharing O
of O
genetic O
and O
environmental O
risk O
factors O

164 O
Phenotypic O
variation O
arises O
from O
interactions O
between O
environmental O
and O
genetic O
variation O
, O
and O
the O
emergence O
of O
such O
variation O
is O
, O
in O
part O
, O
mediated O
by O
epigenetic O
mechanisms O
 O
factors O
that O
modify O
gene B-Gene
expression O
but O
do O
not O
change O
the O
gene B-Gene
sequence O
, O
per O
se O

A O
combination O
approach O
is O
critical O
for O
successful O
utilisation O
of O
any O
epigenetic O
modifiers O
( O
e O

In O
this O
primer O
, O
we O
briefly O
review O
the O
epigenetic O
basis O
of O
human B-Species
disease B-Disease
and O
discuss O
how O
recent O
discoveries O
in O
this O
field O
could O
be O
translated O
into O
clinical O
diagnosis O
, O
prevention O
, O
and O
treatment O

We O
delineate O
a O
set O
of O
generic O
questions O
that O
are O
useful O
across O
a O
broad O
range O
of O
investigations O
and O
discuss O
the O
implications O
of O
choosing O
different O
statistical O
measures O
and O
null O
models O

The O
heritability O
of O
these O
modifications O
provides O
a O
memory O
of O
cell O
identity O
and O
function O

Here O
, O
we O
briefly O
review O
the O
current O
knowledge O
of O
how O
epigenetic O
regulation O
contributes O
to O
subset O
specification O
, O
differentiation O
and O
memory O
development O
in O
T B-Species
cells I-Species

Uncovering O
the O
human B-Species
epigenome O
can O
lead O
us O
to O
better O
understand O
the O
dynamics O
of O
DNA B-Gene
methylation I-Gene
in O
disease B-Disease
progression I-Disease
which O
can O
further O
assist O
in O
cancer B-Disease
prevention I-Disease

Therefore O
, O
this O
paper O
mainly O
reviews O
the O
epigenetic O
changes O
in O
the O
pathogenesis O
of O
peripheral B-Disease
T-cell I-Disease
lymphoma I-Disease
and O
the O
advancement O
of O
epigenetic-targeted O
drugs O
in O
the O
treatment O
of O
peripheral B-Disease
T-cell I-Disease
lymphoma I-Disease
( O
PTCL B-Disease
) O

1285 O
Well-differentiated O
thyroid B-Disease
cancer I-Disease
accounts O
for O
the O
majority O
of O
endocrine O
malignancies O
and O
, O
in O
general O
, O
has O
an O
excellent O
prognosis O

Conversely O
, O
genetic O
adaptation O
was O
favored O
in O
a O
slowly O
fluctuating O
environment O
because O
it O
maximized O
the O
phenotypic O
robustness O
to O
biochemical O
noise O
during O
the O
constant O
environment O
between O
transitions O
, O
even O
if O
this O
resulted O
in O
slower O
adaptation O

This O
relationship O
is O
increasingly O
coming O
into O
focus O
as O
it O
is O
of O
fundamental O
importance O
for O
differentiation O
, O
aging O
, O
and O
cancer B-Disease

To O
improve O
risk O
stratification O
for O
CHD B-Disease
, O
we O
developed O
a O
novel O
integrated O
genetic-epigenetic O
tool O

The O
identification O
of O
5hmC B-Chemical
separately O
from O
5mC B-Chemical
initially O
posed O
a O
challenge O
given O
that O
legacy O
epigenetic O
sequencing O
technologies O
could O
not O
discriminate O
between O
these O
two O
most O
abundant O
modifications O
, O
a O
significant O
blind O
spot O
considering O
their O
potentially O
functionally O
opposing O
roles O

It O
is O
dynamically O
changed O
during O
germline O
development O

Recent O
findings O
 O
Epigenetics O
is O
a O
new O
frontier O
in O
cancer B-Disease
research O
with O
tremendous O
impact O
on O
our O
thinking O
and O
understanding O
of O
biological O
phenomena O
and O
complex O
diseases O
, O
notably O
cancer B-Disease

The O
action O
of O
Pax B-Gene
factors O
on O
gene O
expression O
is O
also O
exerted O
through O
recruitment O
of O
chromatin O
remodelling O
complexes O
that O
introduce O
either O
activating O
or O
repressive O
chromatin O
marks O

( O
3 O
) O
Results O
 O
After O
deduplication O
, O
we O
identified O
198 O
potentially O
related O
citations O

Search O
, O
BLAST B-Gene
, O
Alignment O
and O
Profile O
based O
prediction O

Many O
histone B-Chemical
modification I-Chemical
enzymes O
and O
DNMTs B-Gene
are O
up-regulated O
in O
cancer B-Disease
cells O
, O
and O
contribute O
to O
malignant O
transformation O

Methods O
 O
Genome-wide O
DNA B-Chemical
methylation I-Chemical
analysis O
of O
newborn O
blood O
DNA B-Chemical
was O
performed O
in O
24 O
isolated O
, O
non-syndromic O
CoA B-Disease
cases O
and O
16 O
controls O
using O
the O
Illumina B-Chemical
HumanMethylation450 I-Chemical
BeadChip I-Chemical
arrays O

Anti-DNA B-Chemical
, O
anti-phospholipid B-Chemical
, O
and O
anti-Ro/SSA B-Chemical
autoantibodies O
are O
thought O
to O
be O
pathogenic O
for O
glomerulonephritis B-Disease
, O
recurrent B-Disease
thrombosis I-Disease
and O
miscarriages O
, O
and O
neonatal B-Disease
lupus I-Disease
, O
respectively O

We O
performed O
gene B-Gene
chip I-Gene
microarray I-Gene
profiling O
and O
found O
that O
talc B-Chemical
alone O
, O
and O
especially O
with O
oestrogen B-Chemical
, O
has O
induced O
a O
substantially O
more O
prominent O
gene B-Gene
expression I-Gene
change O
than O
titanium B-Chemical
dioxide I-Chemical
; O
the O
affected O
genes O
were O
involved O
in O
pathways O
of O

Based O
on O
this O
historical O
reconstruction O
, O
in O
Â§4 O
, O
I O
examine O
what O
modern O
epigenetics B-Gene
can O
bring O
to O
the O
picture O
and O
under O
what O
conditions O
epigenetic B-Gene
inheritance I-Gene
might O
be O
seen O
as O
strengthening O
the O
causal O
relationship O
between O
adaptability O
and O
adaptation O

We O
estimated O
technical O
noise O
and O
intra-subject O
variation O
using O
two O
datasets O
with O
repeated O
sampling O

A O
canonical O
feature O
of O
extinction O
is O
that O
the O
original O
response O
is O
temporarily O
suppressed O
, O
but O
returns O
under O
various O
conditions O

1060Purpose O
of O
review O
To O
summarize O
is O
to O
review O
recent O
progress O
in O
' B-Chemical
genomic I-Chemical
' O
science O
and O
how O
this O
may O
be O
applied O
to O
the O
perioperative O
environment O

Although O
most O
studies O
found O
significant O
differences O
in O
DNA B-Gene
methylation I-Gene
upon O
medication O
exposure O
, O
almost O
no O
differences O
were O
persistent O
across O
studies O
for O
similar O
medications O
and O
sequencing O
methods O

https O
 O
/ O
/ O
doi O

In O
this O
context O
it O
is O
important O
for O
clinicians O
to O
understand O
the O
principles O
of O
epigenetic O
mechanisms O
and O
how O
these O
principles O
relate O
to O
human B-Species
health O
and O
disease B-Disease

They O
are O
also O
burdened O
by O
relevant O
side O
effects O

g O

In O
this O
review O
, O
we O
will O
consider O
the O
current O
evidence O
that O
early-life O
environmental O
signals O
can O
have O
long-term O
effects O
on O
the O
epigenome O

We O
discuss O
the O
concepts O
of O
gene B-Gene
and O
epigenetic O
editing O
, O
and O
the O
advantages O
and O
disadvantages O
of O
current O
and O
upcoming O
gene-based O
therapies O
for O
treatment O
of O
IEMs B-Disease

ca O
or O
sjones@bcgsc O

Finally O
, O
we O
identified O
232 O
novel O
TUs O
in O
and O
43 O
novel O
cell-specific O
TUs O
all O
of O
which O
were O
supported O
by O
ChIP-seq O
and O
data O

, O
Cum O
Laude O
, O
from O
the O
University O
of O
Leiden O
, O
The O
Netherlands O

1352 O
Embryo/fetal O
nutrition O
and O
the O
environment O
in O
the O
reproductive O
tract O
influence O
the O
subsequent O
risk O
of O
developing O
adult O
diseases O
and O
disorders O
, O
as O
formulated O
in O
the O
Barker B-Disease
hypothesis I-Disease

Similar O
to O
genetic O
mutations O
, O
epigenetic O
modifications O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
and O
RNA B-Chemical
interference I-Chemical
can O
influence O
gene B-Gene
expression I-Gene
and O
therefore O
may O
cause O
behavioral O
and O
neuronal O
changes O
observed O
in O
mental B-Disease
disorders I-Disease

1408 O
Two O
recent O
reports O
in O
Nature O
highlight O
a O
novel O
mechanism O
of O
immunoevasion O
that O
relies O
on O
the O
SET B-Gene
domain I-Gene
bifurcated I-Gene
histone I-Gene
lysine I-Gene
methyltransferase I-Gene
1 I-Gene
( O
SETDB1 B-Gene
) O
- O
dependent O
epigenetic O
suppression O
of O
endogenous O
retroelements O
in O
melanoma B-Disease

1234Background O
and O
objective O
High-throughput O
Next O
Generation O
Sequencing O
tools O
have O
generated O
immense O
quantity O
of O
genome-wide O
methylation O
and O
expression O
profiling O
data, O
resulting O
in O
an O
unprecedented O
opportunity O
to O
unravel O
the O
epigenetic O
regulatory O
mechanisms O
underlying O
cancer B-Disease

We O
will O
discuss O
the O
spread O
and O
amplitude O
of O
the O
potential O
gene B-Gene
expression I-Gene
changes O
controlled O
by O
5mC B-Chemical
at O
enhancers O
, O
and O
how O
these O
may O
contribute O
to O
the O
determination O
of O
cell O
identities O
during O
development O

The O
history O
of O
epigenetics B-Disease
is O
briefly O
reviewed O
, O
together O
with O
the O
key O
issues O
in O
the O
field O
today O

This O
review O
discusses O
the O
potential O
for O
epigenomic O
drugs B-Chemical
to O
impact O
on O
the O
germline O
epigenome O
and O
subsequent O
offspring O
and O
aims O
to O
foster O
further O
examination O
into O
the O
possible O
effects O
of O
these O
drugs B-Chemical
on O
gametes O

Despite O
their O
shapes O
reminiscent O
of O
an O
entangled O
yarn O
, O
the O
rapid O
development O
of O
molecular O
and O
next-generation O
sequencing O
technologies O
( O
NGS O
) O
has O
revealed O
that O
mammalian B-Species
genomes O
are O
highly O
organized O
in O
a O
hierarchical O
order O
that O
delicately O
affects O
transcription O
activities O

Expert O
opinion O
 O
Despite O
significant O
interests O
in O
targeting O
epigenetic O
modifiers O
as O
a O
therapeutic O
route O
, O
certain O
classes O
of O
target O
proteins O
are O
heavily O
studied O
while O
some O
are O
less O
characterized O

Because O
epigenetic O
mechanisms O
link O
gene B-Gene
regulation O
to O
environmental O
cues O
and O
developmental O
trajectories O
, O
their O
contribution O
to O
asthma B-Disease
and O
allergy B-Disease
pathogenesis O
is O
under O
active O
investigation O

One O
of O
these O
burgeoning O
fields O
is O
the O
study O
of O
the O
epigenome O

In O
conclusion O
, O
the O
research O
identified O
risk O
and O
protective O
factors O
associated O
with O
epigenetic O
aging O
pre- O
and O
post-trauma O
exposure O
, O
with O
implications O
for O
health O
and O
well-being O
among O
individuals O
exposed O
to O
trauma O

Loss O
of O
this O
regulation O
contributes O
to O
many O
diseases B-Disease

Areas O
timely O
for O
developing O
research O
 O
Metanalysis O
through O
integration O
of O
multiple O
datasets O
and O
platforms O
will O
enable O
a O
holistic O
understanding O
of O
the O
epigenome O
in O
ageing O
and O
its O
relevance O
to O
disease B-Disease

Consistent O
shifts O
in O
DNAm O
between O
preterm O
and O
term O
cells O
were O
observed O
at O
25 O
CpG O
sites O
, O
with O
many O
of O
these O
sites O
located O
in O
genes O
involved O
in O
growth O
and O
proliferation O
, O
hematopoietic B-Disease
lineage I-Disease
commitment O
, O
and O
the O
cytoskeleton O

The O
availability O
of O
next-generation O
sequencing O
has O
enabled O
the O
profiling O
of O
methylation B-Chemical
marks O
at O
an O
unprecedented O
scale O

Taken O
together O
incorporating O
epigenetic O
studies O
in O
ecotoxicology O
context O
presents O
a O
promising O
tool O
for O
development O
of O
sensitive O
biomarkers O
for O
environmental O
stress O
assessment O

1256 O
More O
than O
7 O
million O
individuals O
have O
been O
conceived O
by O
Assisted B-Disease
Reproductive I-Disease
Technologies I-Disease
( O
ART B-Disease
) O
and O
there O
is O
clear O
evidence O
that O
ART B-Disease
is O
associated O
with O
a O
range O
of O
adverse O
early O
life O
outcomes O
, O
including O
rare O
imprinting B-Disease
disorders I-Disease

Additionally O
, O
other O
inhibitors O
of O
epigenetic O
processes O
, O
such O
as O
histone B-Chemical
deacetylases I-Chemical
, O
methylases B-Chemical
and O
demethylases B-Chemical
, O
can O
elicit O
similar O
effects O
either O
individually O
or O
in O
combinations O
with O
DNA B-Chemical
methylation I-Chemical
inhibitors O

We O
thus O
demonstrate O
that O
DXM B-Chemical
can O
robustly O
find O
allelic O
subpopulation O
methylation O
profiles O
that O
may O
contribute O
to O
disease B-Disease
progression I-Disease
using O
bisulfite O
sequencing O
data O
of O
any O
heterogeneous O
sample O

Whole-genome O
sequencing O
has O
made O
it O
possible O
to O
identify O
secondary O
genetic O
lesions O
following O
RB1 B-Gene
inactivation O

In O
addition O
, O
fibroblasts O
produced O
youthful O
levels O
of O
proteins O
, O
and O
showed O
partial O
functional O
rejuvenation O
of O
their O
migration O
speed O

We O
also O
provide O
insights O
into O
the O
mechanism O
of O
action O
of O
the O
drugs O
under O
investigation O
and O
their O
potential O
impact O
on O
disease-modifying B-Disease
pathways O

A O
growing O
body O
of O
work O
has O
shown O
that O
epigenetic O
drugs O
, O
specifically O
DNA B-Chemical
methyltransferase I-Chemical
inhibitors I-Chemical
, O
can O
upregulate O
immune O
signaling O
in O
epithelial B-Disease
cancer I-Disease
cells I-Disease
through O
demethylation O
of O
endogenous O
retroviruses O
and O
cancer B-Disease
testis I-Disease
antigens I-Disease

Results O
 O
Here O
we O
show O
that O
our O
bimodal O
distribution O
model O
and O
weighted O
cost O
function O
for O
optimized O
regional O
methylation B-Chemical
analysis O
provides O
accurate O
boundaries O
of O
regions O
harboring O
significant O
epigenetic O
modifications O

1072 O
RNA B-Chemical
modifications O
have O
recently O
become O
the O
focus O
of O
attention O
due O
to O
their O
extensive O
regulatory O
effects O
in O
a O
vast O
array O
of O
cellular O
networks O
and O
signaling O
pathways O

1484 O
For O
many O
years O
cancer B-Disease
research O
has O
focused O
on O
genetic O
defects O
, O
but O
during O
the O
last O
decade O
epigenetic O
deregulation O
has O
been O
increasingly O
recognized O
as O
a O
hallmark O
of O
cancer B-Disease

Active O
work O
includes O
several O
studies O
of O
individual O
susceptibility O
to O
cancer B-Disease

This O
review O
focuses O
on O
recently O
discovered O
mechanisms O
, O
and O
challenges O
prevailing O
views O
on O
the O
dynamics O
, O
position O
and O
functions O
of O
epigenetic O
marks O

To O
illustrate O
this O
interplay O
of O
biology O
and O
experience O
, O
we O
summarize O
key O
findings O
from O
the O
growing O
field O
of O
epigenetics O
and O
child O
mental O
health O
, O
arguing O
that O
epigenetic O
processes O
might O
mediate O
the O
relationship O
between O
environmental O
adversity O
and O
the O
major O
neurodevelopmental O
systems O
of O
REAL B-Species

Various O
multifactorial O
diseases B-Disease
often O
contain O
changed O
epigenetic O
signatures O
at O
many O
loci O
, O
so O
tools O
for O
simultaneously O
targeting O
different O
loci O
would O
significantly O
facilitate O
the O
understanding O
of O
disease B-Disease
pathogenesis O


4%) O

Similar O
DMPs B-Gene
were O
not O
found O
at O
age O
5 O

The O
scholarship O
presented O
in O
these O
volumes O
suggests O
that O
rigorous O
, O
relational O
developmental O
theory-predicated O
research O
about O
the O
plastic O
, O
mutually O
influential O
relations O
among O
individual O
and O
ecological O
processes O
will O
enable O
developmental O
science O
to O
better O
describe O
, O
explain O
, O
and O
optimize O
the O
fundamental O
relational O
process O
of O

Here O
, O
we O
discuss O
the O
optimal O
execution O
of O
population-based O
studies O
of O
epigenetic O
variation O
, O
which O
will O
contribute O
to O
the O
emerging O
field O
of O
' O
epigenetic O
epidemiology O
' O
and O
emphasize O
the O
importance O
of O
establishing O
a O
causal O
role O
in O
pathology O
for O
disease-associated B-Disease
epigenetic O
changes O

Furthermore O
, O
the O
constraint O
of O
samples O
size O
, O
inherent O
to O
the O
study O
of O
preimplantation B-Disease
embryo I-Disease
development I-Disease
, O
was O
put O
in O
perspective O
with O
the O
various O
molecular O
platforms O
described O

By O
the O
hypothesis O
put O
forward O
here O
, O
we O
would O
like O
to O
foster O
research O
on O
" O
Quantum B-Disease
Epigenetics I-Disease
" O
at O
the O
interface O
of O
medicine O
, O
biology O
, O
biochemistry O
, O
and O
physics O
to O
investigate O
the O
potential O
epigenetic O
impact O
of O
quantum O
physical O
principles O
on O
( O
human B-Species
) O
life O

Direct O
effects O
of O
autonomous O
motivation O
on O
DNA B-Gene
methylation I-Gene
did O
not O
persist O
when O
these O
indirect O
effects O
were O
included O
( O
Î² O
= O

1476 O
Molecular O
genetics O
is O
changing O
our O
understanding O
of O
the O
developmental O
translation O
of O
genotype O
to O
phenotype O
between O
and O
within O
different O
phylogenetic O
groups O

Advances O
in O
genetics O
have O
identified O
novel O
pathways O
and O
targets O
that O
operate O
in O
numerous O
diseases B-Disease
, O
paving O
the O
way O
for O
' O
precision O
medicine O
' O

Systematic O
identification O
of O
the O
valleys O
provides O
novel O
information O
for O
delineating O
the O
annotation O
of O
regulatory O
elements O

These O
results O
highlight O
the O
potential O
of O
machine O
learning-based O
imputation O
methods O
to O
advance O
personalized O
epigenomics O

Locus O
Overlap O
Analysis O
( O
LOLA O
) O
provides O
easy O
and O
automatable O
enrichment O
analysis O
for O
genomic O
region O
sets O
, O
thus O
facilitating O
the O
interpretation O
of O
functional O
genomics O
and O
epigenomics O
data O

In O
this O
review O
, O
we O
will O
explore O
these O
issues O
, O
with O
a O
particular O
focus O
on O
the O
potential O
role O
of O
paternally O
induced O
maternal O
investment O
, O
highlight O
the O
literature O
illustrating O
the O
transgenerational O
impact O
of O
paternal O
experiences O
, O
and O
discuss O
the O
evidence O
supporting O
the O
role O
of O
epigenetic O

These O
same O
neurobiological O
processes O
are O
responsible O
for O
determining O
the O
heterogeneous O
features O
of O
complex O
epileptic B-Disease
disease I-Disease
states O

Although O
not O
somatically O
heritable O
, O
epigenetic O
modifications O
in O
neurons B-Species
are O
dynamic O
and O
reversible O
, O
which O
makes O
them O
good O
targets O
for O
therapeutic B-Disease
intervention I-Disease

Recently O
, O
a O
profound O
understanding O
of O
epigenetics O
in O
the O
pathophysiology O
of O
DCM B-Disease
has O
been O
broadened O
owing O
to O
advanced O
high-throughput O
technologies O
, O
which O
assist O
in O
developing O
potential O
therapeutic O
strategies O

1482 O
The O
diversity O
of O
brain O
cell O
types O
was O
one O
of O
the O
earliest O
observations O
in O
modern O
neuroscience O
and O
continues O
to O
be O
one O
of O
the O
central O
concerns O
of O
current O
neuroscience O
research O

05 O
) O
, O
with O
multiple O
sites O
located O
within O
ACOT7 B-Gene
( O
4 O
sites O
) O
, O
EPX B-Gene
( O
5 O
sites O
) O
, O
EVL B-Gene
( O
3 O
sites O
) O
, O
KSR1 B-Gene
( O
4 O
sites O
) O
, O
ZFPM1 B-Gene
( O
3 O
sites O
) O
, O
and O
ZNF862 B-Gene
( O
3 O
sites O

The O
knowledge O
upon O
which O
these O
claims O
are O
based O
is O
beginning O
to O
expand O

Secondly O
, O
we O
explore O
how O
epigenetics O
narrows O
definitions O
of O
colonial O
harm O
through O
the O
optic O
of O
molecular O
trauma O
, O
reproducing O
conditions O
in O
which O
Indigenous O
people O
are O
made O
intelligible O
through O
a O
lens O
of O
" O
damaged O
" O
bodies O

He O
received O
the O
2018 O
Northern O
Communities O
Health B-Disease
Foundation I-Disease
Visiting O
Professorship O
Award O
at O
the O
University O
of O
Adelaide O
, O
Australia O

As O
an O
integrator O
of O
genetic O
and O
environmental O
inputs O
, O
and O
because O
of O
advances O
in O
measurement O
techniques O
that O
are O
highly O
reproducible O
and O
provide O
sequence O
information O
, O
the O
epigenome O
is O
a O
rich O
source O
of O
potential O
biosignatures O
of O
cardiovascular B-Disease
health O
and O
disease O

However O
, O
are O
cell O
type-specific O
and O
associated O
with O
epigenetic O
regulation O
, O
although O
their O
dependency O
on O
remains O
to O
be O
elucidated O

In O
isogenic O
lineages O
and O
asexually O
reproducing O
organisms O
, O
poor O
or O
absent O
genetic B-Gene
diversity I-Gene
can O
hence O
be O
tolerated O

We O
further O
applied O
our O
method O
to O
a O
study O
of O
congenital B-Disease
heart I-Disease
defects I-Disease
with O
83 O
cardiac O
tissue O
samples O
and O
identified O
two O
mQTL O
regions O
, O
MRPS10 B-Gene
and O
PSORS1C1 B-Gene
, O
which O
were O
colocalized O
with O
expression O
QTL O
in O
cardiac O
tissue O

While O
these O
arrays O
offer O
a O
convenient O
and O
relatively O
robust O
assessment O
of O
the O
probed O
sites O
they O
only O
allow O
interrogation O
of O
2-4% O
of O
all O
CpG B-Gene
sites O
in O
the O
human B-Species
genome O

Further O
improvements O
are O
likely O
by O
combining O
genetic B-Gene
selection O
with O
epigenetic B-Gene
selection O
or O
manipulation O

B-Chemical O
smium I-Chemical
in O
the O
oxidized O
state O
reacts O
with O
C5-methylated B-Chemical
pyrimidines I-Chemical
in O
the O
presence O
of O
a O
bipyridine B-Chemical
ligand I-Chemical
to O
give O
a O
stable O
ternary O
complex O

Finally O
, O
our O
work O
suggests O
that O
optimal O
time O
windows O
exist O
for O
rejuvenating O
the O
transcriptome O
and O
the O
epigenome O

This O
article O
discusses O
the O
history O
behind O
the O
multitude O
of O
definitions O
that O
have O
been O
employed O
since O
the O
conception O
of O
epigenetics B-Chemical
, O
analyzes O
the O
components O
of O
these O
definitions O
, O
and O
offers O
solutions O
for O
clarifying O
the O
field O
and O
mitigating O
the O
problems O
that O
have O
arisen O
due O
to O
these O

With O
the O
information O
deduced O
from O
our O
method O
, O
we O
can O
predict O
transcription O
factor O
binding O
status O
in O
promoter O
regions O
to O
further O
investigate O
how O
a O
particular O
gene B-Gene
is O
regulated O
by O
a O
specific O
group O
of O
transcription O
factors O
organized O
in O
a O
particular O
pattern O

Environmental O
xenobiotics B-Chemical
can O
interfere O
with O
the O
natural O
process O
of O
epigenetic O
aging O

Thus O
, O
future O
research O
should O
go O
beyond O
the O
study O
of O
epigenetic O
mechanisms O
at O
the O
level O
of O
the O
gene B-Gene
and O
devote O
additional O
investigation O
of O
epigenetic O
outcomes O
at O
the O
level O
of O
both O
the O
individual O
organism O
and O
how O
it O
affects O
the O
evolution O
of O
populations O

Even O
so O
, O
our O
understanding O
of O
the O
underlying O
sources O
of O
epigenetic O
variability O
remains O
limited O

To O
mimic O
this O
natural O
genetic O
experiment O
using O
drugs O
, O
one O
guiding O
observation O
was O
that O
is O
increased O
during O
recovery O
of O
bone O
marrow O
from O
extreme O
stress O

Nutrients O
can O
influence O
the O
epigenetic O
status O
through O
several O
mechanisms O
, O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
and O
miRNA-dependent B-Gene
gene I-Gene
silencing I-Gene

In O
that O
regard O
, O
the O
application O
of O
paradigms O
in O
epigenomics O
to O
study O
transcription O
in O
microglia B-Species
has O
provided O
significant O
insights O
into O
the O
molecular O
mechanisms O
that O
control O
the O
ontogeny O
and O
functions O
of O
these O
cells O

To O
date O
, O
most O
studies O
focusing O
on O
the O
roles O
of O
miRNAs B-Gene
in O
PTSD B-Disease
have O
, O
however O
, O
been O
completed O
in O
animals B-Species
, O
using O
cross-sectional O
study O
designs O
and O
focusing O
almost O
exclusively O
on O
subjects O
with O
susceptible O
phenotypes O


In O
addition O
to O
genes O
and O
promoters O
, O
CandiMeth O
can O
analyse O
methylation O
differences O
at O
long O
and O
short O
interspersed O
nuclear O
elements O

g O

Here O
, O
I O
present O
and O
review O
various O
algorithms O
that O
may O
be O
used O
for O
purposes O
of O
deconvolving O
epigenomic O
data O
from O
admixed O
samples O
to O
yield O
estimates O
that O
may O
be O
factored O
into O
downstream O
analyses O

Structural O
and O
computational O
studies O
reveal O
that O
an O
internal O
hydrogen B-Chemical
bond I-Chemical
stabilizes O
the O
protein-bound O
conformation O
of O
the O
dihydroquinoxalinone B-Chemical
series O

Transcription O
factors O
(TFs) O
that O
regulate O
neurogenesis B-Disease
and O
neuron B-Disease
plasticity I-Disease
, O
including O
Egr1 B-Gene
, O
Klf4 B-Gene
, O
and O
Myc B-Gene
, O
are O
significantly O
upregulated O

This O
article O
examines O
these O
three O
issues O
, O
noting O
the O
rapid O
expansion O
of O
research O
based O
on O
EMR-sourced O
clinical O
data O
, O
the O
large O
number O
of O
data O
protection O
models O
that O
can O
apply O
to O
genetic B-Gene
data O
( O
including O
point-of-use O
prohibitions O
on O
discrimination O
and O
confidentiality O
) O
, O
and O
the O

We O
believe O
that O
EPAT-ChIP O
will O
facilitate O
the O
application O
of O
chromatin O
studies O
to O
archived O
pathology O
samples O
, O
thus O
contributing O
to O
extend O
the O
current O
understanding O
of O
cancer B-Disease
epigenomes O
and O
enabling O
the O
identification O
of O
clinically O
useful O
tumor O
biomarkers O

uk O
/ O
bloodbrain O
/ O
) O

1284 O
Strigolactones B-Chemical
(SLs) O
represent O
an O
important O
new O
plant B-Species
hormone O
class O
marked O
by O
their O
multifunctional O
role O
in O
plant B-Species
and O
rhizosphere O
interactions O

We O
would O
therefore O
recommend O
aiming O
for O
a O
high O
initial O
coverage O
of O
individual O
libraries O
( O
15Ã O
) O
in O
future O
studies O

The O
stability O
and O
permanence O
of O
these O
metabolic O
processes O
, O
fueling O
the O
supplementation O
of O
methyl B-Chemical
groups I-Chemical
, O
seem O
to O
be O
important O
criteria O
to O
prevent O
deficiencies O
and O
erosion O
of O
the O
methylome B-Gene

One O
important O
DNA B-Chemical
methylation I-Chemical
pathway O
reduces O
the O
abilities O
of O
transcription O
factors O
to O
bind O
to O
gene O
promoter O
regions O

Here O
, O
we O
outline O
emerging O
areas O
of O
epigenetic O
aging O
research O
that O
prioritize O
biological O
understanding O
and O
clinical O
application O

Many O
more O
fascinating O
examples O
of O
epigenetic O
plasticity O
lie O
outside O
the O
realm O
of O
model O
organisms O
and O
have O
so O
far O
been O
only O
sporadically O
investigated O
at O
a O
molecular O
level O
; O
however O
, O
recent O
progress O
on O
sequencing O
technology O
and O
genome O
editing O
tools O
have O
begun O
to O
blur O
the O
lines O
between O

The O
present O
review O
offers O
a O
comprehensive O
overview O
of O
available O
studies O
of O
miRNAs B-Gene
in O
PTSD B-Disease
and O
discusses O
the O
current O
challenges O
, O
pitfalls O
, O
and O
future O
perspectives O
of O
this O
field O

accelerated O

We O
examine O
research O
on O
the O
potential O
role O
of O
DNA B-Gene
methylation I-Gene
, O
histone B-Gene
modifications I-Gene
, O
and O
non-coding B-Gene
RNAs I-Gene
in O
the O
regulation O
of O
gene B-Gene
expression I-Gene
in O
these O
insects B-Species

Here O
we O
consider O
how O
gene B-Gene
expression I-Gene
in O
neurons B-Species
is O
regulated O
by O
specific O
patterns O
of O
action O
potential O
firing O
, O
with O
an O
emphasis O
on O
new O
information O
on O
epigenetic O
regulation O
of O
gene B-Gene
expression I-Gene

In O
this O
issue O
of O
The O
EMBO O
Journal O
, O
van O
Steenwyk O
and O
colleagues O
( O
2020 O
) O
provide O
important O
new O
insights O
into O
how O
one O
form O
of O
paternal O
experience O
( O
early-life B-Disease
stress I-Disease
or O
trauma B-Disease
) O
may O
impact O
sperm O
epigenetics O
via O
circulating O
factors O
, O
presenting O

We O
discuss O
the O
difficulties O
of O
working O
with O
ancient B-Chemical
DNA I-Chemical
in O
particular O
utilizing O
paleoepigenomic O
approaches O
, O
and O
assess O
new O
paleoepigenomic O
data O
, O
which O
might O
be O
helpful O
in O
future O
studies O

In O
this O
review O
, O
we O
discuss O
four O
basic O
regulatory O
mechanisms O
implicated O
in O
complex O
genetic O
diseases O
, O
such O
as O
cancer B-Disease
, O
neurological B-Disease
disorders I-Disease
, O
heart B-Disease
disease I-Disease
, O
diabetes B-Disease
, O
and O
many O
others O

Tumor-intrinsic O
epigenetic O
and O
genetic O
aberrations O
cooperate O
and O
interact O
with O
microenvironmental O
cells O
to O
shape O
the O
transcriptome O
at O
different O
phases O
of O
lymphoma B-Disease
evolution O
, O
and O
intraclonal O
heterogeneity O
can O
now O
be O
characterized O
by O
single-cell O
profiling O

Fluorescent O
in O
situ O
hybridization O
using O
specific O
fluorescent O
DNA B-Chemical
and O
RNA B-Chemical
probes O
in O
cells O
and O
tissues O
with O
the O
spatially O
preserved O
nuclear O
and O
genome O
architecture O
( O
3D-FISH O
) O
provides O
a O
powerful O
tool O
for O
the O
further O
advancement O
of O
our O
knowledge O
about O
genome O
structure O
and O

Recently O
, O
epigenetic-based O
biomarkers O
have O
brought O
to O
light O
new O
insights O
into O
the O
clinical O
management O
of O
bladder B-Disease
cancer I-Disease

in O

Seven O
of O
37 O
cytosines B-Gene
assayed O
for O
methylation B-Chemical
level O
in O
humpback B-Species
skin O
had O
significant O
age-related O
profiles O

The O
prenatal O
and O
perinatal O
periods O
are O
thought O
to O
be O
important O
times O
for O
epigenetic O
marking O

associated O

The O
application O
of O
these O
tools O
is O
illustrated O
through O
a O
series O
of O
case O
studies O
that O
highlight O
how O
the O
molecular O
precision O
afforded O
by O
chemistry B-Chemical
is O
being O
used O
to O
establish O
causal O
biochemical O
relationships O
at O
the O
heart O
of O
epigenetic O
regulation O

In O
a O
previous O
study O
, O
this O
resemblance O
was O
described O
as O
a O
function O
of O
the O
epigenetic O
variance O
component O
and O
a O
reset O
coefficient O
that O
indicates O
the O
rate O
of O
dissipation O
of O
epigenetic O
marks O
across O
generations O

We O
found O
that O
more O
than O
10 O
years O
post-treatment O
, O
CCS O
treated O
with O
TBI/HSCT O
showed O
an O
altered O
DNA B-Gene
methylation I-Gene
signature O
in O
T B-Species
cell I-Species
, O
particularly O
at O
genes O
controlling O
immune O
and O
inflammatory O
processes O
and O
oxidative O
stress O

From O
among O
the O
probes O
on O
the O
methylation O
arrays O
, O
we O
selected O
those O
available O
for O
the O
common B-Species
marmoset I-Species

The O
appropriate O
transition O
of O
immune O
cells O
into O
diverse O
functional O
states O
, O
which O
is O
crucial O
for O
immunity O
, O
involves O
complex O
and O
well-regulated O
changes O
in O
transcriptional O
program O

Conclusions O
 O
Our O
results O
indicate O
that O
obese O
individuals O
with O
hypercholesterolemia B-Disease
present O
specific O
DNA B-Gene
methylation I-Gene
profile I-Gene
in O
genes O
related O
to O
lipids B-Chemical
transport O
and O
metabolism O


1159 O
Epigenetic O
alterations O
are O
a O
hallmark O
of O
aging O
and O
age-related O

Such O
DNA B-Chemical
methylation I-Chemical
alterations O
may O
confer O
vulnerability O
to O
further O
genetic O
and O
epigenetic O
alterations O
, O
generate O
more O
malignant O
cancers B-Disease
, O
and O
thus O
determine O
patient O
outcome O

lineage O
- O
specific O
regulatory O
elements O

of O

For O
disease B-Disease
, O
the O
generated O
DNA B-Gene
methylation I-Gene
fingerprints O
show O
that O
, O
during O
tumorigenesis B-Disease
, O
human B-Species
cancer I-Species
cells I-Species
underwent O
a O
progressive O
gain O
of O
promoter O
CpG-island B-Gene
hypermethylation I-Gene
and O
a O
loss O
of O
CpG B-Gene
methylation I-Gene
in O
non-CpG-island B-Gene

In O
this O
Review O
, O
we O
discuss O
the O
latest O
insights O
into O
the O
role O
of O
DNA B-Gene
methylation I-Gene
, O
histone B-Gene
modifications I-Gene
and O
non-coding B-Gene
RNAs I-Gene
in O
SSc B-Disease
and O
how O
these O
epigenetic O
alterations O
affect O
disease O
features O

A O
promising O
new O
approach O
is O
to O
introduce O
Deep O
Learning O
(DL) O
for O
the O
generation O
and O
simultaneous O
computation O
of O
novel O
genomic O
features O
tuned O
to O
the O
classification O
task O

These O
modifications O
strongly O
depend O
on O
the O
environment O
, O
could O
be O
reversible O
and O
are O
potentially O
transmittable O
to O
daughter O
cells O

Genetic O
and O
epigenetic O
epidemiologic O
studies O
may O
assist O
in O
the O
identification O
of O
critical O
protective O
and O
pathogenic O
pathways O

Two O
plausible O
explanations O
are O
discussed O

We O
present O
Coordinate B-Gene
Covariation I-Gene
Analysis I-Gene
( O
COCOA B-Gene
) O
, O
a O
computational O
framework O
that O
uses O
covariation O
of O
epigenetic O
signals O
across O
individuals O
and O
a O
database O
of O
region O
sets O
to O
annotate O
epigenetic O
heterogeneity O

Small O
RNA B-Chemical
sequencing O
of O
sperm O
reveals O
significant O
transcriptional O
differences O
of O
infected O
animals O
compared O
to O
controls O

The O
coherent O
behaviour O
of O
certain O
cellular O
subsystems O
has O
been O
theoretically O
predicted O
for O
a O
long O
time O
to O
have O
a O
general O
role O
in O
coordinating O
biological O
processes O

, O
pairs O
of O
compounds O
with O
high O
structural O
similarity O
but O
high O
differences O
in O
potency O
) O
of O
DNMTi B-Chemical
available O
in O
a O
public O
database O
suggest O
that O
it O
is O
feasible O
to O
develop O
predictive O
models O
for O
non-nucleoside O
DNMTi B-Chemical
using O
approaches O
such O
as O
quantitative O
structure-activity O
relationships O
and O
that O

Remarkably O
, O
epigenetic O
therapies O
combined O
with O
chemotherapies O
or O
hormone-based O
therapies O
represent O
the O
most O
promising O
strategy O

We O
also O
found O
that O
transcription O
factors O
in O
specific O
enhancer-promoter O
loop O
formation O
were O
also O
associated O
with O
metastasis B-Disease

In O
conclusion O
, O
we O
identified O
epigenetic O
signatures O
for O
cigarette B-Chemical
smoking I-Chemical
that O
may O
have O
been O
missed O
in O
cross-sectional O
analyses O
, O
providing O
insight O
into O
the O
epigenetic O
effect O
of O
smoking O
and O
highlighting O
the O
importance O
of O
longitudinal O
analysis O
in O
understanding O
the O
dynamic O
human O
epigenome O

, O
rs9388766 O
 O
OR O
= O
1 O

reprogramming O

Dysregulation O
can O
occur O
at O
any O
stage O
; O
however O
, O
the O
formation O
of O
committed O
osteoclasts B-Species
from O
preosteoclasts B-Species
is O
the O
most O
common O
target O

Here O
we O
define O
many O
of O
the O
problems O
with O
current O
epigenomic O
studies O
and O
propose O
solutions O
that O
can O
be O
applied O
to O
allow O
this O
and O
other O
disease B-Disease
-omics O
studies O
to O
achieve O
their O
potential O
for O
generating O
valuable O
insights O

Traditionally O
, O
liver B-Disease
cirrhosis I-Disease
, O
proteomic O
biomarkers O
, O
and O
the O
presence O
of O
hepatitis B-Species
viruses I-Species
have O
been O
used O
for O
the O
detection O
and O
diagnosis O
of O
liver B-Disease
cancer I-Disease

In O
this O
review O
, O
we O
shall O
summarize O
data O
from O
principal O
studies O
evaluating O
the O
impact O
of O
major O
genetic O
, O
epigenetic O
and O
environmental O
factors O
on O
the O
appearance O
of O
this O
female B-Disease
disorder I-Disease

Recent O
work O
has O
convincingly O
linked O
the O
accumulation O
of O
senescent O
cells O
in O
aged O
tissues O
to O
a O
decline O
in O
health O
and O
a O
limit O
of O
lifespan O
, O
primarily O
through O
" O
inflammaging B-Disease
" O

Specifically O
, O
AIKYATAN-CNN O
achieved O
40% O
higher O
validation O
rate O
versus O
CSIANN O
and O
the O
same O
accuracy O
as O
RFECS O

While O
the O
study O
of O
epigenetics O
has O
been O
most O
broadly O
applied O
to O
neoplastic B-Disease
diseases I-Disease
, O
the O
role O
of O
the O
epigenome O
in O
a O
wide O
range O
of O
disease O
processes O
including O
autoimmune B-Disease
, O
allergic B-Disease
, O
and O
inflammatory B-Disease
processes O
is O
increasingly O
being O
recognized O

Methods O
are O
provided O
for O
identifying O
genomic O
locus O
and O
sequence O
information O
using O
gene B-Gene
names I-Gene
or O
codes O
, O
identifiers O
for O
DNA B-Chemical
and O
RNA B-Chemical
molecules O
and O
proteins O
; O
also O
from O
karyotype O
bands O
, O
chromosomal O
coordinates O
, O
sequences O
, O
motifs O
, O
and O
matrix-based O
patterns O

147 O
During O
the O
late O
1940s O
and O
1950s O
, O
a O
pseudo-scientific O
concept O
based O
on O
Marxist-Leninist O
ideology O
became O
internationally O
known O
as O
'Lysenkoism O
' O

896 O
We O
show O
that O
epigenome- O
- O
and O
transcriptome- O
wide O
association O
studies O
( O
EWAS O
and O
TWAS O
) O
are O
prone O
to O
significant O
inflation O
and O
bias O
of O
test O
statistics O
, O
an O
unrecognized O
phenomenon O
introducing O
spurious O
findings O
if O
left O
unaddressed O

Conclusions O
 O
CandiMeth O
( O
RRIDSCR_017974 O
; O
Biotools O
CandiMeth O
) O
allows O
rapid O
, O
quantitative O
analysis O
of O
methylation O
at O
user-specified O
features O
without O
the O
need O
for O
coding O
and O
is O
freely O
available O
at O
https//github O
.com O

So O
far O
, O
identification O
of O
relies O
primarily O
on O
time-consuming O
and O
expensive O
experimental O
approaches O

Epigenetic O
DNA B-Chemical
modifications O
involve O
changes O
in O
the O
gene B-Gene
activity O
but O
not O
in O
the O
DNA B-Chemical
sequence O

In O
the O
present O
study O
, O
we O
evaluate O
the O
epigenome-wide O
association O
of O
arsenic B-Chemical
exposure O
in O
utero O
and O
DNA B-Gene
methylation I-Gene
in O
placenta O
( O
n O
= O
37 O
) O
, O
umbilical O
artery O
( O
n O
= O
45 O
) O
and O
human B-Species
umbilical I-Species
vein I-Species
endothelial I-Species
cells I-Species

This O
yields O
an O
extremely O
efficient O
Conditional O
Expectation O
Maximization O
algorithm O
, O
alternating O
between O
the O
two O
sets O
while O
increasing O
the O
overall O
likelihood O

In O
this O
study O
, O
we O
developed O
a O
targeted O
epigenetic O
clock O
purposely O
optimized O
for O
the O
measurement O
of O
biological O
age O

Groups O
of O
cCREs O
displaying O
similar O
patterns O
of O
regulatory O
activity O
in O
human B-Species
and O
mouse B-Species
cell O
types O
, O
obtained O
by O
joint O
clustering O
on O
esRP B-Gene
scores O
, O
harbor O
distinctive O
transcription O
factor O
binding O
motifs O
that O
are O
similar O
between O
species O

The O
sample O
consisted O
of O
77 O
women O
from O
the O
Los O
Angeles O
, O
CA O
, O
area O
enrolled O
in O
the O
Healthy B-Disease
Babies I-Disease
Before I-Disease
Birth I-Disease
study O

g O

A O
prior O
drawback O
of O
MBD-seq O
is O
the O
relatively O
large O
amount O
of O
genomic B-Chemical
DNA I-Chemical
( O
ideally O
>1 O
Âµg O
) O
required O
to O
obtain O
high-quality O
data O


We O
applied O
uCoTarget O
to O
the O
in O
vitro O
generation O
of O
hematopoietic B-Disease
stem/progenitor I-Disease
cells I-Disease
( O
HSPCs O
) O
from O
human B-Species
embryonic I-Species
stem I-Species
cells I-Species
, O
presenting O
multimodal O
epigenomic O
profiles O
in O
26,418 O
single O
cells O

Unraveling O
the O
molecular O
basis O
of O
epigenetic O
memory O
dictated O
by O
protein O
and O
RNA B-Chemical
factors O
in O
conjunction O
with O
epigenetic O
marks O
that O
are O
erased O
and O
re-established O
during O
embryogenesis/development O
during O
the O
formation O
of O
somatic O
, O
stem O
and O
disease B-Disease
cells O
will O
have O
far O
reaching O
implications O
to O

We O
end O
with O
a O
discussion O
of O
key O
areas O
for O
future O
research O
to O
advance O
understanding O
of O
the O
role O
of O
epigenetics O
in O
the O
legacy O
effects O
of O
stress B-Disease
and I-Disease
trauma I-Disease

The O
organisation O
of O
the O
human B-Species
genome O
within O
three-dimensional O
space O
, O
known O
as O
chromosome O
conformation O
, O
has O
recently O
been O
shown O
as O
a O
dynamic O
epigenetic O
regulator O
of O
gene B-Gene
expression I-Gene
, O
facilitating O
the O
interaction O
of O
distal O
genomic O
regions O
due O
to O
tight O
and O
regulated O
packaging O
of O
chromosomes O

A O
complete O
semiautomated O
, O
microscaled O
H3K27ac B-Gene
ChIP-Seq O
procedure O
including O
cell O
fixation O
, O
chromatin O
shearing O
, O
immunoprecipitation O
, O
and O
sequencing O
library O
preparation O
, O
for O
batch O
of O
48 O
samples O
for O
cell O
number O
inputs O
less O
than O
100,000 O
cells O
is O
described O
in O
detail O

However O
, O
epigenetics O
is O
such O
a O
new O
field O
that O
in O
most O
of O
these O
areas O
the O
impact O
is O
more O
in O
the O
category O
of O
fascinating O
implications O
as O
opposed O
to O
established O
facts O

465 O
Epigenetics O
is O
the O
heritable O
phenotypic O
changes O
without O
altering O
the O
genotype O

This O
study O
examined O
the O
impact O
of O
prenatal O
transportation O
stress O
on O
DNA B-Gene
methylation I-Gene
of O
lymphocytes O
of O
Brahman B-Species
cows I-Species
over O
the O
first O
5 O
years O
of O
life O

Novel O
approaches O
to O
researching O
preterm B-Disease
birth I-Disease
are O
currently O
underway O
, O
building O
upon O
our O
prior O
discoveries O
and O
probing O
into O
the O
unknown O
on O
multiple O
fronts O

Genetic O
variation O
in O
iron B-Chemical
regulatory O
genes O
may O
to O
lesser O
extent O
also O
influence O
Mn B-Chemical
levels O
and O
toxicity O

By O
focusing O
on O
modulating O
gene B-Gene
regulation O
mediated O
by O
cell O
type-specific O
enhancers O
, O
there O
is O
hope O
that O
normal O
epigenetic O
patterning O
in O
an O
affected O
tissue O
could O
be O
restored O
with O
fewer O
side O
effects O
than O
observed O
with O
treatments O
employing O
relatively O
nonspecific O
inhibitors O
such O
as O
epigenetic O

Pharmacogenetic O
and O
pharmacoepigenetic O
studies O
are O
required O
for O
the O
proper O
evaluation O
of O
efficacy O
and O
safety O
issues O
in O
clinical O
trials O
with O
epigenetic B-Chemical
drugs O

Understanding O
the O
precise O
role O
of O
DNA B-Gene
hypomethylation O
is O
not O
only O
crucial O
from O
a O
mechanistic O
point O
of O
view O
but O
also O
for O
the O
development O
of O
pharmacological O
agents O
that O
can O
reverse O
the O
hypomethylated O
state O
of O
the O
DNA B-Gene

The O
future O
will O
see O
the O
increasing O
success O
of O
combining O
epigenetic B-Chemical
drugs O
with O
other O
therapies O

The O
15 O
newly O
considered O
scores O
consist O
of O
13 O
freshly O
computed O
nucleosome B-Chemical
occupancy/positioning I-Chemical
scores O
and O
2 O
experimental O
features O
( O
MNase B-Chemical
and O
DRIP B-Chemical
) O

Despite O
advances O
in O
our O
knowledge O
of O
psychopathic O
individuals O
, O
the O
construct O
remains O
complex O
and O
is O
hampered O
by O
a O
lack O
of O
integration O
across O
a O
range O
of O
fundamental O
domains O

Currently O
, O
no O
disease-modifying O
agent O
is O
approved O
for O
the O
treatment O
of O
AD B-Disease

However O
, O
the O
main O
impact O
of O
epigenetic O
modifications O
, O
including O
persistent O
lysine B-Chemical
methylation O
of O
the O
H3 B-Gene
histone O
, O
is O
exerted O
during O
retinal B-Disease
embryonic I-Disease
development O

g O

411 O
Epigenetic O
mechanisms O
such O
as O
DNA B-Chemical
methylation I-Chemical
modulate O
gene B-Gene
expression I-Gene
in O
a O
complex O
fashion O
are O
consequently O
recognized O
as O
among O
the O
most O
important O
contributors O
to O
phenotypic O
variation O
in O
natural O
populations O
of O
plants B-Species
, O
animals B-Species
, O
and O
microorganisms B-Species

No O
associations O
were O
observed O
for O
the O
remaining O
EAA B-Chemical
estimates O

Such O
work O
will O
significantly O
advance O
our O
understanding O
of O
how O
opioids B-Chemical
cause O
persistent O
changes O
to O
brain O
function O
and O
will O
provide O
a O
platform O
on O
which O
to O
develop O
interventions O
for O
treating O
opioid B-Chemical
addiction B-Disease

1474Gene O
body O
methylation O
(gbM) O
is O
a O
widely O
conserved O
epigenetic O
feature O
of O
plant B-Species
genomes O

reliably O

Research O
predating O
2009 O
and O
animal B-Species
studies O
were O
excluded O
in O
order O
to O
review O
the O
current O
state O
of O
research O
in O
humans B-Species

In O
this O
chapter O
we O
will O
cover O
all O
the O
main O
technologies O
available O
, O
with O
a O
special O
emphasis O
on O
the O
microarray O
technology O
, O
as O
it O
supposes O
a O
perfect O
choice O
taking O
into O
account O
its O
price O
as O
well O
as O
the O
amount O
of O
cytosines B-Chemical
interrogated O
, O
the O
compatibility O
with O

phenotypes O
are O
highly O
variable O
, O
and O
gene O
expression O
patterns O
cannot O
be O
explained O
by O
trisomy O
alone O
, O
implicating O
epigenetics O
in O
pathophysiology O

Among O
the O
protective O
factors O
, O
a O
sense O
of O
psychological O
organisational O
membership O
at O
the O
start O
of O
the O
paramedicine O
course O
as O
measured O
at O
baseline O
significantly O
reduced O
epigenetic B-Disease
age I-Disease
at O
baseline O
and O
post-trauma B-Disease
exposure I-Disease

However O
, O
the O
mechanisms O
by O
which O
early O
environmental O
insults O
can O
have O
long-term O
effects O
on O
offspring O
are O
relatively O
unclear O

In O
this O
chapter O
we O
summarize O
how O
the O
circadian B-Gene
clock I-Gene
is O
involved O
in O
neuronal B-Gene
functions O
and O
depressive-like B-Disease
behavior I-Disease
and O
propose O
that O
potential O
strategies O
for O
antidepressant B-Chemical
therapy I-Chemical
by O
incorporating O
circadian B-Gene
genomic I-Gene
and O
epigenetic B-Gene
rewiring I-Gene
of O
neuronal B-Gene

Research O
suggests O
that O
epigenetic O
processes O
can O
be O
manipulated O
in O
the O
future O
to O
treat O
or O
prevent O
epilepsy B-Disease
as O
epigenetics O
has O
been O
shown O
to O
have O
a O
profound O
influence O
on O
how O
genes O
are O
expressed O
in O
epilepsy B-Disease

Understanding O
the O
impact O
of O
parenting O
interventions O
on O
biological O
markers O
associated O
with O
these O
risks O
is O
crucial O
for O
mitigating O
long-term O
health O
disparities O

Tyrosine O
kinase O
inhibitors O
classically O
prescribed O
in O
this O
setting O
can O
fail O
due O
to O
primary O
or O
acquired O
resistance O
or O
the O
necessity O
of O
drug O
withdrawal O
because O
of O
serious O
or O
moderate O
but O
chronic O
and O
deleterious O
adverse O
effects O

Further O
, O
we O
develop O
a O
DNAm O
classifier O
which O
performs O
well O
in O
discriminating O
current O
from O
former O
smokers O
( O
agnostic O
LASSO B-Chemical
model O
AUC O
in O
external O
validation O
data O
 O
0 O

1289/EHP8793 O

], O
and O
also O
a O
novel O
non O
iterative O
approximation O
using O
Lagrange B-Gene
multipliers I-Gene

In O
this O
review O
, O
we O
compare O
the O
different O
FFPE-ChIP O
techniques O
, O
highlighting O
their O
strengths O
, O
limitations O
, O
common O
features O
, O
and O
peculiarities O
, O
as O
well O
as O
pitfalls O
and O
caveats O
related O
to O
ChIP O
studies O
in O
FFPE O
samples O
, O
in O
order O
to O
facilitate O
their O
application O

The O
preclinical O
evidence O
for O
efficacy O
of O
pharmacological O
approaches O
that O
target O
epigenetics O
in O
the O
CNS B-Disease
and O
the O
particular O
challenges O
of O
this O
approach O
are O
also O
examined O

differentiation O

This O
approach O
can O
be O
used O
with O
any O
genomic O
or O
biological O
data O
set O
applied O
to O
medicine O

In O
spite O
of O
significant O
research O
focused O
on O
understanding O
the O
etiological O
mechanisms O
, O
search O
for O
diagnostic O
biomarker(s) O
and O
disease-modifying O
therapy O
is O
still O
on O

557 O
Spectacular O
advances O
in O
the O
throughput O
of O
DNA B-Gene
sequencing O
have O
allowed O
genome-wide O
analysis O
of O
epigenetic O
features O
such O
as O
methylation B-Chemical
, O
nucleosome B-Chemical
position O
and O
post-translational B-Chemical
modification O
, O
chromatin B-Chemical
accessibility O
and O
connectivity O
, O
and O
transcription B-Gene
factor I-Gene
binding O

It O
is O
even O
applicable O
to O
genomes O
that O
have O
high O
complexity O
and O
a O
large O
size O
, O
being O
the O
method O
of O
choice O
for O
the O
analysis O
of O
plant B-Species
non-model I-Species
systems I-Species

Drugs O
targeting O
DNA B-Gene
and O
histone B-Gene
modifications O
are O
under O
development O
with O
some O
such O
as O
5-azacytidine B-Chemical
, O
decitabine B-Chemical
, O
vorinostat B-Chemical
, O
and O
panobinostat B-Chemical
already O
approved O
by O
the O
and O
( O
) O
and O
the O

Here O
, O
the O
evidence O
of O
the O
epigenetic O
correlates O
of O
prenatal O
adversities O
, O
NICU-related O
environment O
and O
development O
of O
preterm O
infants O
is O
systematically O
reviewed O

CSCs O
are O
a O
subpopulation O
of O
bulk O
tumors O
, O
with O
stem O
cell-like O
properties O
and O
tumorigenic O
capabilities O
, O
having O
the O
abilities O
of O
self-renewal O
and O
differentiation O
, O
thereby O
being O
able O
to O
generate O
heterogeneous O
lineages O
of O
cancer O
cells O
and O
lead O
to O
resistance O
toward O
anti-tumor B-Chemical
treatments O

Two O
measures O
of O
performance O
are O
usually O
reported O
, O
the O
R2 O
of O
the O
association O
between O
the O
predicted O
and O
chronological O
age O
, O
and O
the O
mean/median O
absolute O
deviation O
( O
MAD O
) O
of O
estimated O
age O
from O
chronological O
age O
, O
and O
we O
argue O
that O
only O
the O
MAD O
reflects O
accuracy O

, O
) O
, O
and O
neural O
network O
function O
( O
e O

This O
manuscript O
describes O
the O
development O
of O
a O
resource O
module O
that O
is O
part O
of O
a O
learning O
platform O
named O
``NIGMS O
Sandbox O
for O
Cloud-based O
Learning O
'' O
https//github O

Results O
 O
Despite O
several O
promising O
findings O
of O
differential O
epigenetic O
profiles O
in O
individuals O
with O
psychotic B-Disease
disorders I-Disease
in O
the O
studies O
published O
to O
date O
, O
the O
knowledge O
of O
the O
role O
of O
epigenetic O
processes O
in O
psychotic B-Disease
disorder I-Disease
remains O
very O
limited O
, O
and O
should O
be O
interpreted O

Our O
protocol O
provides O
a O
comprehensive O
overview O
of O
flow O
cytometry O
analysis O
following O
transfection O
not O
just O
to O
improve O
transfection O
efficiency O
but O
also O
to O
assess O
the O
expression O
level O
of O
the O
utilized O
construct O


In O
recent O
years O
, O
a O
growing O
number O
of O
studies O
have O
reported O
the O
identification O
of O
novel O
transcriptional O
and O
epigenomic O
regulators O
of O
adipogenesis O

1108 O
Alterations O
in O
DNA B-Chemical
methylation I-Chemical
, O
which O
are O
associated O
with O
DNA B-Gene
methyltransferase I-Gene
abnormalities O
and O
result O
in O
silencing O
of O
tumor-related O
genes B-Gene
and O
chromosomal O
instability O
, O
are O
involved O
even O
in O
precancerous B-Disease
changes I-Disease
in O
various O
organs O

Here O
, O
we O
will O
summarize O
and O
discuss O
epigenetic O
patterns O
in O
autoimmune/inflammatory B-Disease
disorders I-Disease
, O
underlying O
molecular O
alterations O
and O
their O
effects O
on O
gene B-Gene
expression I-Gene
and O
immune O
phenotypes O

1022 O
Aim O
 O
To O
explore O
potential O
abnormal O
epigenetic O
modifications O
and O
immune-cell O
infiltration O
in O
tissues O
from O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
( O
SLE B-Disease
) O
patients O

Conclusion O
 O
dsm-5 B-Chemical
provides O
a O
range O
of O
possibilities O
for O
classifying O
psychiatric B-Disease
disorders I-Disease
at O
symptom O
level O

66E-08 O
) O

, O
modification O
of O
cytosines B-Chemical
in O
CpG B-Gene
dinucleotides O

To O
avoid O
confusion O
surrounding O
nomenclature O
, O
special O
care O
is O
needed O
to O
communicate O
results O
accurately O
, O
especially O
between O
scientists O
and O
other O
health O
care O
professionals O

916 O
We O
describe O
a O
suite O
of O
predictive O
models O
, O
coined O
FAST(m)C B-Gene
, O
for O
nonreference O
, O
cost-effective O
exploration O
and O
comparative O
analysis O
of O
context-specific O
DNA B-Chemical
methylation I-Chemical
levels O

These O
results O
will O
provide O
the O
key O
to O
understanding O
the O
mechanism O
underlying O
allelic O
heterogeneity O

Here O
we O
review O
single O
molecule O
epigenomic O
methods O
under O
development O
to O
overcome O
these O
limitations O
, O
the O
technical O
challenges O
associated O
with O
single O
molecule O
methods O
and O
their O
potential O
application O
to O
single O
cells O

Chromatin-modifying O
proteins O
are O
emerging O
as O
essential O
components O
of O
the O
epigenetic O
machinery O
, O
which O
establishes O
the O
nuclear O
landscape O
that O
ultimately O
determines O
the O
final O
identity O
and O
functional O
specialization O
of O
adult O
cells O

Epigenetic O
multiplexing O
approaches O
such O
as O
Multiplexed B-Chemical
Error-robust I-Chemical
FISH I-Chemical
( O
MERFISH B-Chemical
) O
, O
introduced O
by O
Lu B-Gene
et I-Gene
al I-Gene

The O
intra-clonal O
behaviors O
were O
highly O
stereotypic O
, O
conserved O
under O
the O
stress O
of O
transplantation O
, O
inflammation B-Disease
, O
and O
genotoxic B-Chemical
injury O
, O
and O
associated O
with O
distinctive O
transcriptional O
, O
DNA B-Gene
methylation O
, O
and O
chromatin O
accessibility O
patterns O

Hallmarks O
of O
ageing O
include O
the O
accumulation O
of O
molecular O
damage O
, O
failure O
of O
quality O
control O
systems O
, O
metabolic O
changes O
and O
alterations O
in O
epigenome O
stability O

The O
construction O
of O
the O
epigenetic O
clock O
involved O
the O
utilization O
of O
different O
machine-learning O
models O
, O
including O
linear O
models O
, O
deep O
neural O
networks O
( O
DNN O
) O
, O
and O
gradient-boosted O
decision O
trees O
( O
GBDT O
) O

stress B-Disease

Through O
the O
interaction O
of O
these O
modifications O
a O
" O
histone B-Chemical
code" I-Chemical
is O
emerging O
wherein O
individual O
memories O
leave O
unique O
memory O
traces O
at O
the O
molecular O
level O
with O
distinct O
time O
courses O

is O

ca O

319 O
The O
aim O
of O
this O
review O
is O
to O
summarize O
an O
evolution O
of O
thinking O
about O
the O
epigenetic O
basis O
of O
human B-Species
cancer B-Disease
, O
from O
the O
earliest O
studies O
of O
altered O
DNA B-Gene
methylation I-Gene
in O
cancer B-Disease
to O
the O
modern O
comprehensive O
epigenomic O
era O

These O
findings O
suggest O
a O
potential O
epigenetic O
germline O
inheritance O
of O
paternal O
effects O

Here O
, O
we O
discuss O
some O
recent O
advances O
in O
the O
regulation O
of O
trained O
immunity O
, O
with O
a O
particular O
focus O
on O
the O
mechanistic O
role O
of O
a O
novel O
class O
of O
long O
non-coding O
RNAs O
in O
the O
establishment O
of O
epigenetic O
marks O
on O
trained O
immune O
gene B-Gene
promoters I-Gene

Our O
results O
validate O
the O
use O
of O
the O
EpiDISH B-Gene
algorithm O
in O
estimating O
the O
effect O
of O
cellular O
heterogeneity O
in O
EWAS B-Disease
and O
showed O
DNA B-Chemical
methylation O
generally O
underestimates O
the O
epithelial O
cell O
content O
obtained O
from O
cytology O

We O
further O
replicated O
some O
of O
the O
identified O
epigenetic O
field O
defects O

Future O
work O
will O
reveal O
if O
the O
approach O
of O
epigenome O
editing O
fulfills O
its O
great O
promise O
in O
basic O
research O
and O
clinical O
applications O

Finally O
, O
we O
observe O
that O
impaired O
global O
chromatin B-Chemical
decondensation O
often O
coincides O
with O
chemical B-Chemical
inhibition O
of O
allogeneic O
T-cell B-Species
activation O

com/ O
/KHanghoj/ O
/DamMet/ O
along/ O
with/ O
a/ O
manual/ O
and/ O
tutorial/ O

Song O
, O
E O

In O
comparison O
, O
bisulfite B-Chemical
barcoded I-Chemical
amplicon I-Chemical
sequencing I-Chemical
( O
BBA-seq O
) O
gave O
slightly O
lower O
correlation O
between O
chronological O
age O
and O
DNA B-Chemical
methylation I-Chemical
at O
individual O
CpGs O
, O
while O
the O
age-predictions O
were O
overall O
relatively O
accurate O

It O
discusses O
psychological O
and O
pharmacological O
interventions O
that O
can O
counteract O
epigenetic O
changes O
induced O
by O
CT B-Chemical
and O
the O
need O
to O
establish O
longitudinal O
assessment O
after O
CT B-Chemical
for O
developing O
more O
effective O
diagnostics O
and O
treatment O
strategies O
based O
on O
epigenetic O
targets O

Accumulating O
evidence O
has O
revealed O
that O
these O
mechanisms O
are O
critical O
components O
of O
ongoing O
physiology O
and O
function O
in O
the O
adult O
nervous B-Disease
system I-Disease
, O
and O
are O
essential O
for O
many O
cognitive O
processes O
, O
including O
learning O
and O
memory O

Therefore O
, O
their O
study O
is O
crucial O
for O
the O
better O
understanding O
of O
cellular O
functions O
in O
eukaryotes B-Species

We O
leverage O
other O
established O
computational O
methods O
to O
screen O
for O
these O
regions O
within O
a O
new O
R B-Chemical
package I-Chemical
called O
DAMEfinder O

Detecting O
mQTLs O
may O
provide O
insights O
into O
the O
underlying O
mechanism O
of O
how O
genotypic O
variations O
may O
influence O
the O
disease B-Disease
risk I-Disease

This O
review O
summarizes O
the O
contemporary O
studies O
in O
epigenetic O
mechanisms O
in O
IMF O
regulation O
, O
high-resolution O
epigenomic O
mapping O
, O
single-cell O
epigenomics O
, O
multi-omics O
integration O
, O
epigenome O
editing O
approaches O
, O
longitudinal O
studies O
in O
cattle B-Species
growth O
, O
environmental O
epigenetics O
, O
machine O
learning O
in O
epigenetics O


Because O
SETDB1 B-Gene
is O
highly O
expressed O
by O
the O
stem O
cell O
compartment O
, O
these O
findings O
delineate O
an O
innovative O
strategy O
for O
restoring O
cancer B-Disease
stem O
cell O
immunosurveillance O

Cross O
- O
comparison O
to O
other O
open-resource O
genomic O
data O
at O
UCSC O
facilitates O
interpretation O
of O
the O
biological O
significance O
of O
the O
data O
and O
the O
design O
of O
wet-lab O
assays O
to O
further O
explore O
methylation B-Chemical
changes O
and O
their O
consequences O
for O
the O
candidate O
genes B-Gene

heterogeneity O

Over O
the O
past O
decades O
, O
studies O
on O
epigenetic O
information O
, O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
chromatin B-Chemical
accessibility I-Chemical
, O
and O
chromatin B-Chemical
conformation I-Chemical
have O
shown O
that O
these O
properties O
play O
a O
fundamental O
role O
in O
gene B-Gene
regulation I-Gene

Ultimately O
, O
the O
best O
model O
for O
precision O
medicine O
in O
complex O
, O
multifactorial O
diseases O
such O
as O
psychiatric B-Disease
illnesses I-Disease
will O
likely O
involve O
integrated O
methodology O
that O
combines O
information O
from O
multiple O
sources O
including O
biologic O
, O
clinical O
, O
and O
environmental O
data O

Beyond O
genetic O
alterations O
, O
lymphoid B-Disease
tumors I-Disease
also O
show O
widespread O
epigenomic O
changes O

634 O
Current O
trends O
in O
Higher O
Education O
Pedagogies O
include O
an O
ongoing O
discussion O
about O
active O
learning O
strategies O

128 O
The O
term O
epigenetics O
was O
coined O
in O
1942 O
by O
C O


For O
a O
specific O
site O
, O
the O
array O
methylation O
correlation O
coefficient O
differed O
between O
, O
, O
and O
whole O
blood O
, O
reflecting O
the O
difference O
in O
methylation O
variance O
between O
cell O
types O

RnBeads O

By O
contrast O
, O
sites O
of O
lineage-specific O
hypermethylation O
were O
restricted O
mostly O
to O
adaptive B-Disease
immune I-Disease
cells O

Many O
principles O
from O
nucleotide B-Chemical
sequencing O
and O
transcriptomics O
can O
be O
applied O
to O
other O
high-throughput O
molecular O
biology O
techniques O

EPIGENE O
outperformed O
the O
existing O
RNA-seq-based O
approaches O
in O
TU O
prediction O
precision O
across O
human B-Species
cell I-Species
lines I-Species

In O
this O
article O
, O
we O
review O
the O
current O
knowledge O
of O
and O
recent O
insights O
into O
the O
role O
of O
epigenetic O
factors O
in O
the O
development O
of O
, O
with O
emphasis O
on O

Due O
to O
the O
limited O
sample O
size O
and O
the O
high O
coincidence O
of O
prematurity O
and O
multiple O
births O
, O
the O
relationship O
between O
cause O
of O
preterm B-Disease
birth I-Disease
and O
DNAm B-Gene
could O
not O
be O
evaluated O

In O
this O
review O
, O
we O
will O
discuss O
and O
summarize O
recent O
advances O
in O
PROTAC B-Chemical
discovery O
with O
focus O
on O
epigenetic O
targets O

DNA O
methylation O
has O
a O
demonstrated O
role O
in O
the O
genome O
stability O
and O
protection O
, O
regulation O
of O
gene O
expression O
and O
many O
other O
aspects O
of O
genome O
function O
and O
maintenance O

While O
there O
are O
a O
variety O
of O
methods O
to O
perform O
genome-wide O
analyses O
of O
DNA B-Gene
methylation I-Gene
in O
model O
organisms O
, O
this O
is O
still O
a O
challenging O
task O
for O
non-model O
organisms O
without O
a O
reference O
genome O

The O
precise O
role O
of O
epigenetic O
abnormalities O
is O
important O
for O
understanding O
tumorigenesis B-Disease
and O
the O
establishment O
of O
brain B-Disease
tumor I-Disease
treatment O
strategies O

In O
parallel O
, O
we O
discuss O
the O
potential O
of O
combining O
epigenetic O
drugs B-Chemical
with O
existing O
anticancer O
regimens O
as O
a O
promising O
strategy O
for O
overcoming O
cancer B-Disease
drug I-Disease
resistance I-Disease

procedure O

Members O
of O
the O
International O
Human B-Species
Epigenome I-Species
Consortium O
( O
IHEC O
) O
Bioethics O
Workgroup O
considered O
the O
potential O
ethical O
, O
legal O
, O
and O
social O
issues O
( O
ELSI O
) O
involved O
in O
returning O
epigenetic B-Gene
research O
results O
and O
incidental O
findings O
in O
order O
to O
produce O
a O
set O
of O
' O

532 O
Motivation O
Characterizing O
cancer B-Disease
subclones O
is O
crucial O
for O
the O
ultimate O
conquest O
of O
cancer B-Disease

Materials O
& O
methods O
 O
Young O
pubertal O
and O
mature O
rats B-Species
were O
exposed O
perinatally O
to O
vehicle O
or O
environmental O
xenobiotic O
2,2',4,4'-tetrabromodiphenyl B-Chemical
ether I-Chemical

Accumulating O
evidence O
has O
been O
suggesting O
that O
epigenetic O
control O
is O
a O
key O
factor O
to O
initiate O
and O
sustain O
the O
regenerative O
transcriptional O
response O
and O
that O
it O
might O
contribute O
to O
regenerative O
success O
versus O
failure O

This O
review O
consolidates O
key O
findings O
of O
chromatin O
state O
changes O
in O
senescence O
including O
histone B-Chemical
modifications I-Chemical
, O
histone B-Chemical
variants I-Chemical
, O
DNA B-Chemical
methylation I-Chemical
and O
changes O
in O
three-dimensional O
genome O
organization O

In O
this O
work O
, O
we O
provide O
thorough O
reviews O
and O
discussions O
on O
the O
statistical O
method O
developments O
and O
data O
analysis O
strategies O
for O
using O
epigenetic O
profiles O
, O
in O
particular O
, O
to O
construct O
diagnostic O
models O

A O
similar O
comprehensive O
approach O
to O
decoding O
the O
epigenetic O
readouts O
from O
chemical B-Chemical
challenges O
in O
vivo O
would O
yield O
new O
paradigms O
for O
monitoring O
and O
assessing O
environmental O
exposure O
in O
model O
systems O
and O
humans B-Species

Furthermore O
, O
the O
mean O
/ O
median O
number O
of O
methylome-wide O
significant O
findings O
was O
reduced O
by O
65,688 O
/ O
57,805 O
loci O
after O
more O
thorough O
QC B-Chemical

The O
donor O
's O
epigenome O
may O
also O
impact O
transplant O
survival O
, O
and O
initial O
research O
has O
demonstrated O
that O
peritransplant O
conditions O
induce O
rapid O
epigenetic O
modification O
within O
the O
allograft O

The O
primary O
objective O
of O
this O
article O
is O
to O
provide O
an O
overview O
of O
the O
current O
methods O
for O
assaying O
DNA B-Gene
methylation O
, O
the O
most O
commonly O
studied O
epigenetic O
modification O

Epigenetics O
, O
an O
emerging O
scientific O
research O
area O
â O
, O
shows O
how O
environmental O
influences O
affect O
gene B-Gene
expressions O
and O
explains O
how O
early O
experiences O
can O
impact O
throughout O
life O

903 O
Elastic O
net O
type O
regression O
methods O
have O
become O
very O
popular O
for O
prediction O
of O
certain O
outcomes O
in O
epigenome-wide O
association O
studies O
( O
EWAS O
) O

In O
this O
paper O
, O
we O
propose O
an O
efficient O
Linear O
Model O
of O
Coregionalisation O
with O
informative O
Covariates O
( O
LMCC O
) O
to O
predict O
missing O
values O
based O
on O
observed O
values O
and O
covariates O

The O
strongest O
patterns O
of O
differential O
methylation O
( O
mostly O
male-biased O
) O
are O
found O
in O
the O
putative O
promoter O
and O
the O
first O
intron O

Interference O
in O
any O
of O
these O
interconnected O
mechanisms O
can O
result O
in O
DNA B-Gene
breakage O
and O
lead O
to O
the O
activation O
of O
repair O
pathways O

It O
is O
highly O
complex O
, O
with O
genetic O
and O
environmental O
influences O

Our O
results O
demonstrate O
that O
AERNs O
are O
more O
adept O
at O
controlling O
multiple O
opposing O
trajectories O
when O
applied O
to O
a O
chaos O
control O
task O
within O
a O
conservative O
dynamical O
system O
, O
suggesting O
that O
AERNs O
are O
an O
interesting O
area O
for O
further O
investigation O

The O
findings O
suggest O
that O
in O
the O
standard O
biometric O
model O
when O
or O
twin O
similarity O
differs O
from O
1 O

Availability O
and O
implementation O
 O
EpiSAFARI B-Gene
is O
publicly O
available O
at O
https//github O

With O
this O
aim O
, O
we O
first O
made O
extensive O
usage O
of O
a O
normal O
human B-Species
colon B-Species
specimen O
fixed O
at O
controlled O
conditions O
( O
24 O
h O
, O
48 O
h O
, O
and O
72 O
h O
) O
to O
mimic O
the O
variability O
of O
tissue O
fixation O
that O
is O
most O
frequently O
found O
in O
archived O
samples O


341 O
Epigenomic O
profiling O
, O
by O
revealing O
genome-wide O
distributions O
of O
epigenetic O
modifications O
, O
generated O
a O
large O
amount O
of O
structural O
information O
about O
the O
chromosomes O

659Introduction O
Schizophrenia B-Disease
is O
a O
major O
psychiatric O
disorder O
that O
afflicts O
about O
1% O
of O
the O
world's O
population O
, O
falling O
into O
the O
top O
10 O
medical O
disorders O
causing O
disability O

Family O
clusters O
of O
nonagenarian O
and O
centenarian O
siblings O
, O
who O
show O
both O
exceptional O
age-span O
and O
health-span O
, O
are O
likely O
to O
have O
inherited O
facilitatory O
gene B-Gene
groups O
, O
but O
also O
have O
nine O
decades O
of O
life O
experiences O
and O
behaviours O
which O
have O
interacted O
with O
their O
genetic O
profiles O

Current O
and O
future O
areas O
of O
research O
in O
this O
field O
seek O
to O
expand O
these O
lines O
of O
evidence O
to O
other O
environmental O
exposures O
, O
to O
determine O
their O
specificity O
, O
and O
to O
develop O
predictive O
algorithms O
and O
methylation O
scores O
that O
can O
be O
used O
to O
evaluate O
early-life O
risk O
factors O
for O
health O
outcomes O

When O
we O
controlled O
for O
multiple O
statistical O
testing O
, O
neither O
of O
these O
associations O
survived O
correction O
( O
both O
P O
â¥ O
0 O

Questions O
that O
are O
being O
raised O
in O
this O
review O
are O
the O
precise O
phenotype O
of O
the O
disorder B-Disease
in O
question O
, O
and O
also O
the O
trait O
versus O
state O
debate O
and O
how O
these O
concepts O
are O
being O
implemented O
in O
a O
variety O
of O
study O
designs O

Different O
conditions O
of O
chromatin B-Chemical
extraction O
were O
tested O
applying O
either O
diverse O
sonication O
protocols O
or O
heat-mediated O
limited O
reversal O
of O
crosslinking O
( O
LRC O
) O

All O
three O
JMJD1 B-Gene
proteins O
are O
capable O
of O
removing O
dimethyl B-Chemical
and O
monomethyl B-Chemical
marks O
from O
lysine B-Chemical
9 O
on O
histone B-Chemical
H3 B-Chemical
and O
might O
also O
demethylate O
histone B-Chemical
H4 B-Chemical
on O
arginine B-Chemical
3 O
and O
nonhistone O
proteins O

Alterations O
to O
the O
epigenome O
are O
thought O
to O
capture O
and O
mediate O
the O
effects O
of O
genetic O
and O
environmental O
risk O
factors O
on O
complex B-Disease
disease I-Disease

solium B-Species
genome O
in O
the O
cysticercus B-Disease
stage O
is O
epigenetically O
modified O
by O
DNA B-Chemical
methylation O
in O
a O
pattern O
similar O
to O
that O
of O
other O
invertebrate B-Species
genomes O
, O
i O

Epigenetic O
modifiers O
, O
chromatin O
remodelers O
and O
non-coding O
RNAs O
are O
integral O
contributors O
to O
the O
regulatory O
networks O
involved O
in O
cancer B-Disease
metabolism O
, O
facilitating O
malignant O
transformation O

DNA B-Chemical

Another O
interesting O
finding O
that O
resulted O
from O
the O
genome O
project O
was O
that O
the O
perceived O
level O
of O
complexity O
of O
humans B-Species
was O
not O
accompanied O
with O
a O
relative O
increase O
in O
the O
number O
of O
genes B-Gene
when O
compared O
to O
'lower O
species' B-Species

795 O
The O
notion O
that O
biological O
memories O
of O
environmental O
experiences O
can O
be O
embedded O
in O
the O
human B-Species
genome B-Gene
and O
even O
transmitted O
transgenerationally O
is O
increasingly O
relevant O
in O
the O
postgenomic O
world O
, O
particularly O
in O
molecular O
epigenetics O
, O
where O
the O
genome B-Gene
is O
conceptualized O
as O
porous O

However O
, O
for O
the O
subset O
of O
patients O
with O
very-early O
onset O
IBD B-Disease
, O
several O
causal O
mutations O
have O
been O
found O

678Background O
One O
of O
the O
fascinating O
aspects O
of O
epigenetic O
regulation O
is O
that O
it O
provides O
means O
to O
rapidly O
adapt O
to O
environmental O
change O

The O
discovery O
of O
pharmacoepigenetics B-Chemical
provides O
a O
new O
way O
to O
solve O
this O
problem O

Metabolic O
reprogramming O
and O
epigenetic O
modifications O
have O
been O
extensively O
linked O
; O
furthermore O
, O
posttranslational O
modifications O
of O
histones B-Gene
caused O
by O
metabolites O
play O
a O
vital O
role O
in O
epigenetic O
alterations O

The O
current O
approach O
requires O
extensive O
computation O
of O
features O
over O
the O
genome B-Gene

Localized O
functional O
domains O
within O
chromosomes O
, O
known O
as O
topologically O
associating O
domains O
( O
TADs O
) O
, O
have O
been O
recently O
highlighted O

JBR O
was O
designed O
for O
efficient O
data O
processing O
, O
resulting O
in O
fast O
viewing O
and O
analysis O
of O
multiple O
replicates O
, O
up O
to O
thousands O
of O
tracks O

The O
precise O
mechanism O
of O
aggregation O
remains O
unknown O
, O
but O
increased O
expression O
of O
aggregation-prone O
proteins O
can O
lead O
to O
their O
aggregation O

Despite O
the O
limited O
data O
available O
in O
the O
literature O
to O
date O
, O
mainly O
due O
to O
the O
novelty O
of O
the O
topic O
, O
the O
intriguing O
interplay O
of O
the O
mitochondrial B-Chemical
epigenetic I-Chemical
changes O
in O
both O
physiological B-Disease
and I-Disease
pathological I-Disease
conditions I-Disease
will O
also O
be O
presented O

Here O
, O
we O
describe O
an O
established O
MeDIP B-Chemical
protocol O
and O
tiling O
array O
hybridization O
method O
for O
profiling O
methylation O
of O
testicular B-Species
germ I-Species
cells I-Species

This O
review O
aims O
to O
summarize O
evidence O
supporting O
the O
link O
between O
the O
circadian B-Gene
clock I-Gene
and O
redox B-Chemical
metabolism O
, O
focusing O
on O
possible O
connections O
through O
epigenetic O
mechanisms O

However O
, O
screening O
for O
potentially O
malignant B-Disease
disease I-Disease
is O
typically O
confounded O
by O
difficulty O
in O
discriminating O
between O
reactive/inflammatory O
lesions O
vs O
those O
lesions O
that O
are O
premalignant O
in O
nature O

While O
there O
has O
been O
enormous O
progress O
made O
, O
there O
are O
still O
gaps O
in O
knowledge O
which O
includes O
, O
the O
identity O
of O
unique O
epigenetic O
memory O
factors O
( O
EMFs B-Gene
) O
and O
epigenome O
coding O
enzymes/co-factors/scaffolding O
proteins O
involved O
in O
the O
assembly O
of O
defined O
" O
epigenetic O
memorysomes O
" O

This O
review O
first O
summarizes O
the O
epigenetic O
targets O
, O
including O
metastable O
epialleles O
and O
imprinting O
genes B-Gene
, O
by O
which O
the O
environmental O
factors O
can O
modify O
the O
epigenome O

New O
tools O
available O
for O
epigenomic O
analysis O
offer O
the O
opportunity O
to O
capture O
epigenetic O
variation O
and O
integrate O
it O
into O
advanced O
(epi)breeding O
programmes O

We O
also O
observed O
main O
effects O
of O
CSA B-Chemical
and O
genetic B-Gene
load I-Gene
on O
depression B-Disease
and O
on O
antisocial O
characteristics O

environmental O
epigenetics O
studies O
rely O
on O
surrogate O
tissues O
, O
such O
as O
blood B-Species
, O
to O
assess O
the O
effects O
of O
environment O
on O
disease-relevant B-Disease
but O
inaccessible O
target O
tissues O

We O
observe O
expression-level O
reductions O
in O
multiple O
replicates O
sorted O
for O
the O
lowest O
expression O
that O
persist O
for O
several O
days O
, O
even O
after O
lifting O
the O
selection O
pressure O

03 O
) O
and O
less O
DNAm-derived O
CRP B-Chemical
( O
Î² O
= O
0 O

Since O
the O
1950s O
, O
the O
contribution O
of O
key O
scientists O
( O
Mary B-Gene
Lyon I-Gene
and O
Eduardo B-Gene
Scarano I-Gene
) O
, O
as O
well O
as O
the O
discussions O
at O
the O
international O
conference O
of O
Gif-sur-Yvette O
( O
1957 O
) O
paved O
the O
way O
for O
three O
fundamental O
shifts O
of O
focus O
 O
1 O

Yet O
many O
epigenetic O
traits O
are O
instead O
linked O
to O
self-perpetuating O
changes O
in O
the O
individual O
or O
collective O
activity O
of O
proteins B-Gene

This O
resource O
will O
benefit O
future O
studies O
aiming O
to O
investigate O
sex O
specific O
epigenetic O
signatures O
and O
further O
our O
understanding O
of O
the O
role O
of O
in O
sex O
differences O
in O

We O
examine O
whether O
an O
epigenetic O
modification O
, O
trimethylation O
of O
histone B-Chemical
H3 I-Chemical
at I-Chemical
lysine I-Chemical
27 I-Chemical
( O
H3K27me3 B-Chemical
) O
, O
could O
be O
a O
factor O
in O
the O
evolution O
of O
expression O
patterns O
after O
gene B-Gene
duplication I-Gene

Each O
locus O
had O
at O
least O
2 O

A O
number O
of O
chemical B-Chemical
and O
physical O
factors O
, O
along O
with O
proposed O
infectious O
agents O
or O
aging O
, O
are O
involved O
in O
the O
etiopathogenesis O
of O
autoimmune B-Disease
diseases I-Disease
through O
epigenetic O
changes O

Here O
we O
review O
how O
the O
field O
has O
evolved O
over O
the O
last O
few O
decades O
and O
reflect O
on O
some O
of O
the O
recent O
advances O
that O
are O
changing O
our O
understanding O
of O
biology O

Recent O
research O
activities O
on O
the O
discovery O
and O
development O
of O
novel O
epigenetic O
therapeutics O
have O
passed O
successfully O
, O
whereas O
epigenetic O
effects O
of O
non-epigenetic O
drugs O
or O
epigenetically O
induced O
changes O
in O
the O
targets O
of O
common O
drugs O
have O
not O
yet O
received O
the O
necessary O
systematic O
attention O
in O
the O
context O

We O
built O
a O
machine O
learning O
model O
named O
epiNet O
to O
predict O
CG B-Gene
methylation I-Gene
patterns O
based O
on O
other O
epigenetic O
features O
, O
such O
as O
histone B-Chemical
modifications I-Chemical
, O
but O
not O
DNA B-Chemical
sequence I-Chemical

In O
doing O
so O
, O
we O
demonstrate O
that O
it O
is O
essential O
that O
future O
research O
explores O
the O
public O
's O
awareness O
and O
understanding O
of O
epigenetics B-Gene
and O
epigenetic B-Gene
concepts O

260Genome O
architecture O
varies O
considerably O
among O
eukaryotes B-Species
in O
terms O
of O
both O
size O
and O
structure O
( O
e O

Hence O
, O
we O
provided O
a O
reliable O
and O
robust O
epigenomic O
profiling O
approach O
for O
small O
cell B-Species
numbers O
and O
single O
cells B-Species

The O
investigation O
of O
PTMs O
and O
variants O
in O
the O
context O
of O
clinical O
samples O
has O
highlighted O
their O
importance O
as O
biomarkers O
for O
patient O
stratification O
and O
as O
key O
players O
in O
aberrant O
epigenetic O
mechanisms O
potentially O
targetable O
for O
therapy O

Moreover O
, O
in O
rare O
cases O
of O
PD B-Disease
, O
duplication O
or O
triplication O
of O
SNCA B-Gene
gene O
leads O
to O
alpha-synuclein B-Chemical
accumulation O
, O
with O
triplication O
producing O
a O
more O
severe O
phenotype O
than O
duplication O
, O
suggesting O
that O
SNCA B-Gene
expression O
level O
determines O
the O
severity O
of O
the O
pathology O

The O
present O
paper O
focuses O
on O
recent O
research O
suggesting O
a O
direct O
correlation O
between O
psychological B-Disease
trauma I-Disease
and O
DNA B-Gene
modifications O

Every O
protein O
in O
the O
synapse O
undergoes O
some O
form O
of O
turnover O
, O
some O
with O
half-lives O
of O
only O
hours O

Dysregulation O
of O
TGF-Î² B-Chemical
signaling O
pathway O
leads O
to O
severe O
diseases O

1436 O
Aim O
 O
Hypotheses O
about O
what O
phenotypes O
to O
include O
in O
causal O
analyses O
, O
that O
in O
turn O
can O
have O
clinical O
and O
policy O
implications O
, O
can O
be O
guided O
by O
hypothesis-free O
approaches O
leveraging O
the O
epigenome O
, O
for O
example O

Research O
studies O
show O
that O
epigenetic O
signaling O
contributes O
to O
human B-Species
disease O
, O
tumorigenesis O
and O
aging O

291 O
 O
Significant O
advances O
in O
our O
understanding O
of O
the O
biology O
of O
renal B-Disease
cell I-Disease
carcinoma I-Disease
( O
RCC B-Disease
) O
have O
been O
achieved O
in O
recent O
years O

We O
conclude O
by O
assessing O
some O
opportunities O
, O
challenges O
, O
and O
techniques O
for O
epigenetic O
research O
in O
both O
model O
and O
non-model O
plants O
, O
in O
particular O
for O
advancing O
understanding O
of O
the O
regulation O
of O
genome O
function O
by O
epigenetic O
mechanisms O

Technological O
advancements O
in O
high-throughput O
genome O
sequencing O
and O
functional O
genomics O
have O
unraveled O
the O
complexities O
of O
epigenetic O
regulation O
in O
response O
to O
heavy B-Chemical
metal I-Chemical
and O
metalloid B-Chemical
contamination O

Mechanistically O
, O
treatment O
of O
lung B-Disease
cancer I-Disease
cells O
or O
lung B-Disease
cancer I-Disease
xenografts O
with O
DAC B-Chemical
induced O
the O
conversion O
of O
the O
FBW7 B-Gene
gene I-Gene
from O
a O
methylated O
form O
to O
an O
unmethylated O
form O
, O
which O
was O
associated O
with O
the O
increased O
expression O
of O
FBW7 B-Gene

On O
the O
other O
hand O
, O
BBA-seq O
revealed O
that O
neighboring O
CpGs O
tend O
to O
be O
stochastically O
modified O
at O
murine B-Species
age-associated O
regions O

We O
built O
an O
epigenetic O
gestational O
age O
clock O
using O
Lasso O
regression O
trained O
on O
755 O
randomly O
selected O
non-ART O
newborns O
from O
the O
Norwegian B-Species
Study I-Species
of I-Species
Assisted I-Species
Reproductive I-Species
Technologies I-Species
(START) I-Species
- O
a O
substudy O
of O
the O
Norwegian B-Species
Mother I-Species
, O
Father O
, O
and O
Child O

More O
sensitive O
and O
specific O
biomarkers O
for O
an O
early O
diagnosis O
as O
well O
as O
for O
monitoring O
disease B-Disease
activity O
and O
tissue O
damage O
are O
needed O

In O
this O
review O
, O
we O
summarize O
and O
analyze O
recent O
epigenomic O
advances O
in O
three O
major O
crops O
epigenomics O
and O
discuss O
possibilities O
and O
challenges O
for O
future O
research O
in O
the O
field O

Leveraging O
closed O
submicroliter O
reaction O
volumes O
and O
a O
superhydrophobic O
interface O
, O
DMF-ChIP-seq O
presented O
higher O
sensitivity O
in O
peak O
enrichment O
than O
other O
current O
methods O
, O
with O
high O
accuracy O
( O
Pearson B-Chemical
Correlation I-Chemical
Coefficient I-Chemical
( O
PCC B-Chemical
) O
> O
0 O

Critical O
studies O
on O
epigenetics O
are O
emerging O
within O
a O
separate O
space O
of O
bioethical O
and O
biopolitical O
investigations O
and O
claims O
, O
with O
scholars O
from O
various O
epistemological O
standpoints O
utilizing O
distinct O
yet O
complementary O
analytical O
approaches O

84-0 O

We O
evaluate O
whether O
DNA-methylation B-Gene
mediates O
smoking-birth B-Chemical
weight O
relationship O
in O
the O
Norwegian B-Species
Mother I-Species
and I-Species
Child I-Species
Study I-Species
birth O
cohort O

I O
focus O
my O
review O
on O
integrative O
approaches O
for O
genome-wide O
genetic O
variants O
and O
gene O
expression O
data O
, O
methods O
for O
joint O
analysis O
of O
genetic O
and O
epigenetic O
variants O
, O
and O
methods O
for O
analysis O
of O
microbiome O
data O

422 O
The O
legal O
system O
has O
been O
preparing O
for O
an O
explosion O
of O
epigenetic B-Gene
issues O
in O
public O
health O
, O
environmental O
regulation O
and O
litigation O

These O
clocks O
can O
identify O
people O
at O
high O
risk O
of O
developing O
kidney B-Disease
problems I-Disease
even O
before O
symptoms O
appear O

We O
found O
that O
the O
methylation O
status O
of O
2 O
consecutive O
CpG B-Gene
sites I-Gene
showed O
deviation O
from O
equilibrium O
frequency O
toward O
concordant O
linkage O
(both O
methylated O
or O
both O
unmethylated O
) O
in O
germline B-Species
cells I-Species

There O
were O
no O
differences O
between O
EAA B-Gene
of O
primary/metastatic O
tumor O
paired O
samples O
, O
suggesting O
that O
the O
observed O
effect O
is O
not O
due O
to O
tissue O
migration O
or O
ectopic O
location O

The O
results O
provide O
absolute O
quantitation O
of O
cytosine B-Chemical
methylation O
with O
base O
specificity O

Herein O
, O
we O
provide O
a O
review O
of O
epigenetics O
and O
epigenomics O
in O
metabolic O
memory O
of O
diabetic B-Disease
complications I-Disease
covering O
the O
current O
basic O
research O
, O
clinical O
data O
, O
and O
translational O
implications O

Yet O
, O
research O
on O
the O
development O
of O
epigenetic O
biomarkers O
often O
pulls O
in O
a O
direction O
that O
departs O
from O
a O
view O
of O
biological O
determinants O
of O
health O
embedded O
in O
their O
social O
and O
material O
environment O

genes O

, O
in O
terms O
of O
mating O
and O
reproduction O
) O
but O
costly O
for O
older O
people O
in O
deprived O
communities O
who O
would O
benefit O
from O
investing O
in O
grandchildren O

In O
the O
current O
review O
, O
we O
discuss O
the O
main O
approaches O
used O
exclusively O
to O
study O
the O
genetics O
and O
epigenetics O
of O
essential B-Disease
hypertension I-Disease
, O
the O
biomarkers O
identified O
, O
their O
clinical O
utility O
and O
the O
difficulties O
to O
be O
overcome O

Given O
the O
increase O
in O
use O
and O
legalization O
, O
these O
findings O
provide O
novel O
insight O
on O
the O
effect O
of O
marijuana B-Chemical
use O
on O
the O
aging O
process O
as O
captured O
through O
blood O
DNA B-Gene
methylation O

008 O
) O
compared O
to O
heavy O
drinkers O
( O
Î² O
= O
0 O

org/ O

Here O
we O
highlight O
how O
the O
changes O
in O
genome B-Gene
architecture I-Gene
in O
diverse O
eukaryotes B-Species
are O
regulated O
by O
epigenetic O
processes O
, O
such O
as O
DNA B-Chemical
elimination O
, O
genome B-Gene
rearrangements O
, O
and O
adaptive O
changes O
to O
genome B-Gene
architecture I-Gene

Improved O
understanding O
, O
by O
clinicians O
and O
physician-scientists O
in O
our O
field O
, O
of O
the O
concepts O
presented O
in O
both O
parts O
of O
this O
review O
will O
advance O
diagnosis O
and O
therapy O
for O
diseases O
of O
the O
head O
and O
neck O

The O
analysis O
of O
the O
genes B-Gene
proximal O
to O
the O
differentially O
methylated O
sites O
suggested O
that O
biological O
processes O
potentially O
impacted O
include O
immune B-Disease
response I-Disease
, O
neuron B-Disease
migration I-Disease
and O
ensheathment O
, O
peptide B-Chemical
signaling O
, O
adaptive O
thermogenesis O
, O
and O
tissue O
development O


Epigenetics O
is O
the O
expansion O
of O
classical O
genetics O
, O
the O
corresponding O
experimental O
courses O
of O
which O
have O
not O
been O
integrated O
into O
the O
current O
teaching O
system O

Similarly O
, O
accurate O
models O
should O
be O
able O
to O
guide O
the O
rational O
screening O
of O
compound B-Chemical
libraries I-Chemical

Once O
DCCs B-Gene
exit O
dormancy O
, O
they O
become O
metastatic O
and O
the O
survival O
rates O
of O
the O
patients O
inevitably O
decrease O

How O
the O
molecular O
signaling O
associated O
with O
growth O
is O
synchronized O
with O
signaling O
associated O
with O
exercise O
is O
poorly O
understood O

Most O
importantly O
, O
we O
provide O
proof O
of O
principle O
that O
the O
DNA B-Gene
methylation I-Gene
fingerprints O
obtained O
might O
be O
useful O
for O
translational O
purposes O
by O
showing O
that O
we O
are O
able O
to O
identify O
the O
tumor B-Disease
type I-Disease
origin I-Disease
of I-Disease
cancers I-Disease
of I-Disease
unknown I-Disease
primary I-Disease
origin I-Disease

This O
review O
highlights O
the O
potential O
of O
epigenetics O
as O
a O
tool O
for O
predicting O
treatment O
efficacy O
and O
personalizing O
medicine O
for O
psychiatric B-Disease
disorders I-Disease

552 O
 O
Background O
 O
Epigenome-wide O
association O
studies O
using O
DNA B-Chemical
methylation I-Chemical
have O
the O
potential O
to O
uncover O
novel O
biomarkers O
and O
mechanisms O
of O
cardiovascular B-Disease
disease I-Disease
( O
CVD B-Disease
) O
risk O

primary B-Disease

3 O
, O
Bioconductor B-Chemical
3 O

For O
example O
, O
there O
is O
a O
high O
negative O
correlation O
between O
promoter O
CpG O
methylation O
and O
CD3D B-Gene
expression O
in O
renal B-Disease
and O
thyroid B-Disease
cancers O
, O
but O
not O
in O
brain B-Disease
tumors O

This O
will O
provide O
much-needed O
information O
which O
will O
prepare O
health O
professionals O
for O
the O
introduction O
of O
epigenetic O
testing O
into O
future O
healthcare O

 O

Future O
studies O
should O
focus O
on O
refined O
measurement O
and O
definition O
of O
prenatal B-Disease
stress I-Disease
and O
its O
timing O
, O
ideally O
also O
incorporating O
genomic O
as O
well O
as O
longitudinal O
information O

However O
, O
when O
describing O
these O
scientific O
advances O
as O
' O
epigenetic O
' O
, O
we O
encounter O
the O
problem O
that O
this O
term O
means O
different O
things O
to O
different O
people O
, O
starting O
within O
the O
scientific O
community O
and O
amplified O
in O
the O
popular O
press O

441 O
Completion O
of O
the O
human B-Species
genome O
a O
decade O
ago O
laid O
the O
foundation O
for O
 O
using O
genetic O
information O
in O
assessing O
risk O
to O
identify O
individuals O
and O
populations O
that O
are O
likely O
to O
develop O
cancer B-Disease
, O
and O
designing O
treatments O
based O
on O
a O
person O
's O
genetic O
profiling O
( O
precision O

The O
conceptual O
MER-Net O
is O
aimed O
at O
linking O
metabolomic O
and O
epigenomic O
networks O
through O
observation O
of O
biological O
processes O
, O
omics O
data O
acquisition O
, O
analysis O
of O
network O
information O
, O
and O
integration O
with O
validated O
database O
knowledge O

Better O
understanding O
of O
these O
modifications O
is O
relevant O
from O
the O
perspective O
that O
they O
may O
be O
reversible O
and O
, O
therefore O
, O
offer O
potential O
for O
novel O
treatment O
strategies O

It O
also O
helps O
the O
user O
better O
visualize O
the O
methylation B-Chemical
data O

Epigenomic O
analysis O
has O
quickly O
become O
a O
big O
data O
science O
, O
posing O
tremendous O
challenges O
on O
its O
translation O
into O
knowledge O

extracranial O

The O
package O
, O
test O
data O
and O
usage O
instructions O
are O
available O
online O
at O
http//www O

This O
review O
provides O
a O
brief O
overview O
of O
epigenetics O
, O
focusing O
on O
their O
association O
with O
the O
genesis O
of O
cancers B-Disease
, O
and O
we O
look O
forward O
to O
the O
application O
of O
epigenetics O
in O
cancer B-Disease
clinical O
diagnosis O
and O
treatment O

Six O
studies O
calculated O
epigenetic O
age O
, O
with O
a O
small O
number O
revealing O
an O
elevated O
significant O
association O
with O
childhood O
SEP B-Disease

Integrating O
historical O
work O
, O
ethnographic O
observation O
, O
and O
insights O
from O
philosophical O
practice-oriented O
conceptual O
analysis O
, O
we O
detail O
the O
distinctive O
epistemic O
goals O
the O
epimutation O
concept O
fulfils O
in O
medicine O
, O
plant B-Species
biology O
and O
toxicology O

34 O
Epigenetic O
mechanisms O
inducing O
phenotypic O
changes O
without O
altering O
the O
genome O
are O
increasingly O
recognized O
as O
key O
factors O
modulating O
expression O
and O
, O
consequently O
, O
cell O
functions O
[ O

The O
entire O
on-chip O
process O
of O
sonication O
and O
IP O
took O
only O
1 O
h O

Our O
article O
introduces O
EE B-Chemical
into O
bioethics O
by O
translating O
knowledge O
from O
science O
to O
ethics O
and O
by O
comparing O
the O
risks O
of O
EE B-Chemical
with O
those O
of O
GE B-Gene

Transgenerational O
epigenetic O
inheritance O
is O
defined O
as O
heritable O
information O
passed O
from O
parents O
to O
their O
offspring O
without O
changing O
the O
DNA B-Gene
sequence I-Gene

The O
event O
was O
held O
in O
Strasbourg O
, O
France O
and O
represents O
the O
city O
's O
second O
time O
hosting O
the O
IMGC O

In O
this O
review O
, O
we O
provide O
an O
overview O
of O
epigenetics O
drug O
targets O
, O
focus O
on O
approaches O
used O
for O
initial O
hit O
identification O
, O
and O
describe O
the O
subsequent O
role O
of O
structure-guided O
chemistry B-Chemical
optimisation O
of O
initial O
hits O
to O
clinical O
candidates O

Our O
simulations O
show O
that O
the O
use O
of O
covariates O
can O
significantly O
improve O
the O
accuracy O
of O
imputed O
values O
, O
especially O
in O
cases O
where O
missing O
data O
contain O
some O
relevant O
information O
about O
the O
explanatory O
variable O

Due O
to O
accessibility O
of O
the O
ddPCR O
technology O
and O
its O
accuracy O
on O
high- O
as O
well O
as O
low-DNA O
input O
samples O
, O
we O
propose O
the O
use O
of O
this O
approach O
for O
studies O
involving O
degraded O
FFPE O
samples O

This O
is O
particularly O
meaningful O
for O
neurological B-Disease
studies O
in O
animal B-Species
models O
, O
in O
which O
baseline O
parameters O
between O
experimental O
groups O
are O
difficult O
to O
control O

Such O
strategies O
may O
distort O
relationships O
between O
functionally O
correlated O
epigenetic O
features O
and O
hinder O
biological O
interpretation O

Relevant O
articles O
were O
selected O
, O
and O
additional O
sources O
were O
located O
from O
ancestry O
searches O
of O
reference O
lists O

Whereas O
the O
underlying O
molecular O
sources O
of O
interindividual O
variability O
remain O
poorly O
understood O
, O
recent O
work O
by O
Ecker B-Gene
et O
al O

Lactylation O
is O
found O
in O
different O
pathophysiological B-Disease
states O
and O
leads O
to O
diverse O
biological O
effects O
; O
however O
, O
only O
a O
few O
mechanisms O
of O
lactylation O
have O
been O
illustrated O

1400 O
Epigenetic O
memory O
is O
an O
essential O
process O
of O
life O
that O
governs O
the O
inheritance O
of O
predestined O
functional O
characteristics O
of O
normal O
cells O
and O
the O
newly O
acquired O
properties O
of O
cells O
affected O
by O
cancer B-Disease
and O
other O
diseases O
from O
parental O
to O
progeny O
cells O

This O
easy-to-perform O
method O
can O
be O
used O
to O
analyze O
the O
methylome O
of O
bladder B-Disease
cancer I-Disease
or O
urothelial O
cells O
shed O
in O
the O
urine O
to O
elucidate O
the O
evolution O
of O
bladder B-Disease
carcinogenesis I-Disease
and/or O
identify O
epigenetic O
signatures O
of O
chemicals B-Chemical
known O
to O
cause O
this O
malignancy O

Finally O
, O
we O
tuned O
, O
trained O
, O
and O
evaluated O
both O
random O
forest O
and O
neural O
network O
classifiers O
on O
the O
resulting O
dataset O

Epigenetics O
is O
central O
to O
cellular O
differentiation O
, O
a O
process O
that O
regulates O
heritable O
and O
long-lasting O
alterations O
in O
gene B-Gene
expression I-Gene
without O
changing O
the O
DNA B-Gene
sequence I-Gene

This O
review O
will O
focus O
on O
the O
potential O
of O
vitamin B-Chemical
C I-Chemical
to O
optimize O
the O
outcome O
of O
epigenetic O
therapy O
in O
cancer B-Disease
patients O
and O
alternatively O
to O
act O
as O
a O
therapeutic O
at O
high O
doses O

, O
hypoxia O
, O
malnutrition O
and O
placental O
insufficiency O
) O
permanently O
modify O
the O
physiological O
systems O
of O
the O
progeny O
, O
predisposing O
them O
to O
premature O
ageing O
and O
chronic O
disease B-Disease
during O
adulthood O

Moreover O
, O
besides O
the O
genetic O
causes O
of O
IEMs B-Disease
, O
it O
is O
increasingly O
recognized O
that O
their O
clinical O
phenotypes O
are O
associated O
with O
epigenetic O
changes O

27 O
[ O
0 O

Following O
Breusch-Pagan B-Disease
test O
of O
heteroscedasticity O
, O
we O
showed O
that O
a O
linear O
regression O
model O
, O
where O
the O
residuals O
were O
used O
in O
a O
mixed O
effect O
model O
with O
a O
random O
intercept O
, O
properly O
estimated O
the O
change O
of O
interindividual O
variability O
over O
time O

Herein O
, O
we O
highlight O
emerging O
paradigms O
for O
linking O
epigenetic O
machinery O
and O
processes O
with O
neurological B-Disease
disease I-Disease
states O
, O
including O
how O
( O
1 O
) O
mutations O
in O
genes B-Gene
encoding I-Gene
epigenetic O
factors O
cause O
disease B-Disease
, O
( O
2 O
) O
genetic O
variation O
in O
genes B-Gene
encoding I-Gene

com O
/ O
pinellolab O
/ O
haystack_bio O

Recent O
advances O
in O
deep O
learning O
technologies O
, O
a O
sub-discipline O
of O
machine O
learning O
that O
requires O
less O
user O
input O
but O
more O
data O
and O
processing O
power O
, O
has O
provided O
even O
greater O
promise O
in O
assisting O
physicians O
to O
achieve O
accurate O
diagnoses O

991 O
Different O
epigenetic O
alterations O
(DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
chromatin B-Chemical
remodeling I-Chemical
, O
noncoding O
RNA B-Gene
dysregulation O
) O
are O
associated O
with O
the O
phenotypic O
expression O
of O
complex O
disorders B-Disease
in O
which O
genomic O
, O
epigenomic O
, O
proteomic O
, O
and O

Disease B-Disease
status I-Disease
does O
not O
change O
DNAm B-Gene
age O
of O
eutopic O
endometrium O
, O
but O
the O
effect O
of O
ectopic O
status O
was O
profound O
 O
- O
16 O

Recent O

Improved O
technologies O
and O
accumulating O
studies O
have O
been O
extending O
our O
understanding O
of O
the O
roles O
of O
DNA B-Gene
methylation I-Gene
to O
various O
genomic O
contexts O
including O
gene O
bodies O
, O
repeat O
sequences O
and O
transcriptional O
start O
sites O


A O
common O
theme O
for O
the O
successful O
inhibition O
of O
these O
enzymes O
in O
a O
potent O
and O
selective O
manner O
is O
the O
targeting O
of O
the O
cofactors O
present O
in O
the O
active O
site O
, O
namely O
zinc B-Chemical
and O
iron B-Chemical
cations O
, O
S-adenosylmethione B-Chemical
, O
nicotinamide B-Chemical
adenine I-Chemical

204 O
We O
introduce O
the O
special O
section O
on O
" O
Genetics B-Gene
and O
Epigenetics B-Gene
in O
Family O
Context O

In O
addition O
, O
the O
evolutionary O
role O
of O
epigenetically O
inherited O
phenotypes O
is O
a O
relatively O
recent O
but O
promising O
field O

Moreover O
, O
TNF B-Gene
methylation O
was O
positively O
associated O
with O
lifetime O
physical O
activity O
( O
Î² O
= O

The O
sizable O
amount O
of O
processed O
data O
also O
comes O
with O
challenges O
regarding O
data O
management O
and O
assessment O
for O
effective O
biomarker O
exploration O
to O
be O
further O
applied O
in O
prospective O
clinical B-Disease
trials I-Disease

As O
such O
, O
this O
emergence O
of O
epigenetic O
studies O
is O
somewhat O
" O
old O
wine O
in O
new O
bottles O
" O
and O
represents O
a O
reformulation O
of O
the O
old O
debate O
of O
preformationism O
versus O
epigenesis O
- O
one O
resolved O
in O
the O
1800s O

Haystack O
is O
generally O
applicable O
to O
any O
epigenetic O
mark O
and O
provides O
an O
important O
tool O
to O
investigate O
the O
mechanisms O
underlying O
epigenetic O
switches O
during O
development O

Non O
-genetic O
factors O
, O
including O
diet O
, O
physical O
activity O
, O
health O
habits O
, O
and O
psychosocial O
factors O
contribute O
approximately O
50% O
of O
the O
variability O
in O
human B-Species
lifespan O
with O
another O
25% O
explained O
by O
genetic O
differences O

Each O
exposure O
has O
effects O
that O
may O
persist O
across O
the O
life O
course O
and O
in O
some O
instances O
may O
be O
transmitted O
to O
offspring O
via O
epigenetic O
inheritance O

The O
proposed O
primer O
design O
( O
methylation-independent O
primers O
with O
amplification O
of O
solely O
the O
converted O
DNA B-Chemical
target O
) O
will O
allow O
for O
methylation O
detection O
, O
independent O
of O
bisulfite B-Chemical
conversion O
efficiency O

The O
molecular O
determinants O
of O
these O
phenotypic O
transitions O
are O
only O
emerging O
from O
recent O
studies O
that O
reveal O
how O
dynamic O
chromatin O
states O
can O
generate O
flexible O
epigenetic O
landscapes O
, O
which O
confer O
on O
cells O
the O
ability O
to O
retain O
partial O
pluripotency O
and O
adapt O
to O
environmental O
changes O

As O
such O
, O
he O
was O
among O
the O
few O
scientists O
in O
the O
mid-twentieth O
century O
to O
develop O
an O
elaborated O
concept O
of O
the O
environment O
that O
would O
fully O
embrace O
its O
constructive O
role O
both O
in O
development O
and O
evolution O

Concerning O
heredity O
, O
both O
narrowly O
epigenetic O
and O
broader O
'exogenetic' O
systems O
of O
inheritance O
play O
important O
roles O
in O
the O
construction O
of O
phenotypes O

The O
survey O
included O
questions O
on O
knowledge O
of O
epigenetics B-Chemical
and O
perceptions O
of O
epigenetic B-Chemical
concepts O
for O
self O
and O
for O
children O

of O

Conclusions O
Despite O
these O
inconclusive O
results O
, O
the O
hypothesis O
that O
the O
early O
life O
environment O
can O
impact O
DNAm O
, O
potentially O
persisting O
into O
adult O
life O
, O
was O
supported O
by O
some O
studies O
and O
warrants O
further O
investigation O

06 O
to O
0 O

398 O
Multi-omics O
( O
genomics B-Gene
, O
transcriptomics B-Gene
, O
epigenomics B-Gene
, O
proteomics B-Gene
, O
metabolomics B-Gene
, O
etc O

736 O
The O
pathological O
hallmark O
of O
neurodegeneration O
is O
presence O
of O
intra- O
and O
extra O
neuronal O
inclusion O
bodies O
such O
as O
Lewy B-Disease
bodies I-Disease
in O
Parkinson's B-Disease
disease I-Disease
, O
senile O
plaques O
and O
neurofibrillary O
tangles O
in O
Alzheimer's B-Disease
disease I-Disease

One O
human B-Species
and O
two O
animal B-Species
studies O
found O
persistent O
changes O
from O
in O
utero O
exposure O
to O
Mn B-Chemical
but O
whether O
these O
changes O
have O
functional O
effects O
remains O
unknown O

However O
, O
we O
also O
identify O
novel O
associations O
between O
methylomes O
and O
sex O
, O
weight O
, O
and O
sterilization O
status O
, O
leading O
to O
accurate O
models O
that O
predict O
these O
factors O

Here O
, O
we O
describe O
the O
critical O
issues O
of O
this O
new O
branch O
of O
bioinformatics O
, O
oriented O
at O
the O
comprehension O
of O
the O
three-dimensional O
genome O
architecture O
, O
which O
we O
call O
'Nucleome O
Bioinformatics O
' O
, O
looking O
beyond O
the O
currently O
available O
tools O
and O
methods O
, O
and O
highlight O
yet O
unaddressed O
challenges O
and O

DNA O
methylation O
patterns O
depend O
on O
the O
genotype B-Gene
and O
can O
be O
reshaped O
by O
environmental O
conditions O
, O
while O
transgenerational O
epigenetic O
inheritance O
has O
been O
reported O
in O
various O
species B-Species

Contact O
 O
lpinello@mgh O

In O
addition O
, O
the O
development O
of O
epigenetic O
clocks O
provides O
a O
new O
dimension O
in O
which O
to O
investigate O
diseases B-Disease
at O
the O
molecular O
level O

Dr O
Laird O
published O
the O
first O
demonstration O
of O
the O
causal O
role O
for O
DNA B-Gene
methylation I-Gene
in O
oncogenesis B-Disease
(Cell O
, O
1995 O
) O
[ O
1 O
] O

Finally O
, O
MSRE-HTPrimer O
selects O
resulting O
primer O
pairs O
for O
all O
target O
sequences O
based O
on O
a O
custom O
quality O
matrix O
defined O
by O
the O
user O

This O
is O
the O
first O
epigenetic O
age O
estimation O
method O
for O
a O
wild O
animal O
species B-Species
and O
the O
approach O
we O
took O
for O
developing O
it O
can O
be O
applied O
to O
many O
other O
nonmodel O
organisms O

Women O
are O
portrayed O
as O
predominantly O
to O
blame O
for O
the O
intergenerational O
transmission O
of O
obesity B-Disease
, O
due O
to O
gender O
norms O
emphasising O
maternal O
responsibility O
during O
early-life O
events O

Herein O
, O
we O
suggest O
exploring O
the O
genetic O
and O
epigenetic O
patterns O
related O
to O
ageing O
and O
correlate O
them O
with O
the O
ageing-related O
phenotype O
of O
the O
biological O
entities O
in O
order O
to O
establish O
mechanistic O
links O
and O
map O
the O
molecular O
pathways O

neuronal O

We O
have O
identified O
an O
additional O
epigenetic O
stratification O
category O
, O
the O
" O
Outlier B-Disease
Methylation I-Disease
Phenotype I-Disease
" O
( O
OMP O
) O

10 O
Ã O
10-5 O
( O
8 O

The O
present O
review O
is O
focused O
on O
recent O
developments O
in O
the O
area O
and O
a O
brief O
discussion O
of O
the O
future O
prospects O
and O
challenges O

I O
briefly O
outline O
some O
methods O
by O
which O
we O
can O
measure O
DNA B-Gene
methylation I-Gene
before O
I O
examine O
studies O
that O
have O
compared O
DNA B-Gene
methylation I-Gene
patterns O
across O
different O
tissues O
and O
, O
finally O
, O
examine O
how O
useful O
blood B-Species
samples I-Species
may O
be O
for O
ecological O
studies O
of O
DNA B-Gene

The O
field O
of O
epigenetics O
in O
eating B-Disease
disorders I-Disease
remains O
in O
its O
infancy O

Currently O
, O
we O
utilize O
mainly O
genetic B-Gene
biomarkers O
for O
optimization O
of O
drug B-Chemical
therapy O
, O
although O
many O
rare O
genetic B-Gene
variants O
are O
not O
taken O
into O
consideration O

561 O
The O
epigenomic O
era O
has O
revealed O
a O
well-connected O
network O
of O
molecular O
processes O
that O
shape O
the O
chromatin O
landscape O

Analyses O
of O
subpathways O
did O
not O
reveal O
gene B-Gene
subsets O
that O
contributed O
disproportionately O
to O
susceptibility O

In O
this O
article O
, O
we O
integrated O
the O
overlapping O
weighting O
( O
OW O
) O
technique O
into O
HDMA O
workflow O
and O
proposed O
a O
concise O
and O
powerful O
high-dimensional O
mediation O
analysis O
procedure O
consisting O
of O
OW O
confounding O
adjustment O
, O
sure O
independence O
screening O
( O
SIS O
) O
, O
de-biased O
Lasso O
penalization O
, O

We O
demonstrate O
that O
by O
using O
specific O
combinations O
of O
epigenomes O
we O
can O
detect O
developmental O
lineage-specific O
enhancers O

Areas O
covered O
 O
This O
article O
focuses O
on O
the O
concepts O
and O
drug B-Chemical
discovery I-Chemical
aspects O
of O
epigenomics O

Bisulfite O
amplicon O
NGS O
showed O
good O
precision O
, O
whilst O
the O
lower O
precision O
of O
qPCR O
and O
dPCR O
analysis O
precluded O
discrimination O
of O
differences O
of O
< O
25% O
in O
methylation O
status O

Here O
, O
we O
report O
the O
adaptation O
of O
the O
recently O
developed O
oxidative B-Chemical
bisulfite I-Chemical
( O
oxBS B-Chemical
) O
chemistry O
to O
specifically O
detect O
both O
5mC B-Chemical
and O
5hmC B-Chemical
in O
a O
single O
workflow O
using O
450K B-Chemical
BeadChips I-Chemical
, O
termed O
oxBS-450K B-Chemical

To O
examine O
the O
impact O
of O
an O
individual O
's O
sex O
, O
ancestry O
, O
and O
age O
on O
iPSC B-Species
reprogramming O
, O
we O
created O
a O
novel O
sex O
and O
ancestry O
balanced O
cohort O
of O
240 O
iPSC B-Species
lines O
derived O
from O
human B-Species
dermal I-Species
fibroblasts I-Species
( O
DF O
) O
from O
80 O
heathy O

mainly O

In O
diseases B-Disease
of O
the O
lung B-Disease
, O
microRNAs B-Gene
have O
been O
implicated O
in O
developmental O
programming O
, O
as O
drivers O
of O
disease O
, O
potential O
therapeutic O
targets O
, O
and O
clinical O
biomarkers O
; O
however O
, O
several O
obstacles O
must O
be O
overcome O
for O
us O
to O
fully O
realize O
their O
potential O
therapeutic O

There O
is O
increasing O
evidence O
that O
transcriptional O
reprogramming O
caused O
by O
epigenetic O
modifications O
can O
be O
passed O
from O
parents O
to O
offspring O

These O
mechanisms O
of O
activity-dependent O
regulation O
of O
gene B-Gene
expression I-Gene
are O
important O
in O
neural O
development O
, O
plasticity O
, O
and O
in O
neurological B-Disease
and I-Disease
psychological I-Disease
disorders I-Disease

There O
have O
been O
extensive O
studies O
on O
the O
roles O
of O
DNA B-Gene
methylation I-Gene
in O
cancers O
, O
and O
several O
cancer O
drugs O
were O
developed O
targeting O
this O
process O

As O
molecular O
epigenetic O
mechanisms O
often O
control O
gene B-Gene
expression O
, O
even O
across O
generations O
, O
they O
may O
impact O
many O
evolutionary O
processes O

235 O
It O
has O
become O
clear O
that O
in O
addition O
to O
the O
there O
is O
another O
layer O
of O
information O
, O
termed O
, O
that O
can O
influence O
phenotypes O
and O
traits O

aging O
phenotype O
) O
stems O
from O
genetic O
or O
environmental O
factors O
or O
as O
a O
combination O
between O
the O
two O
( O
epigenetics O
) O

This O
is O
a O
critical O
obstacle O
since O
genetics O
can O
pave O
the O
way O
for O
identifying O
new O
treatment O
targets O
and O
developing O
preventive O
and O
disease-modifying O
pharmacological O
treatments O
which O
are O
currently O
lacking O

We O
observed O
that O
tissue O
exposed O
to O
perfluorocarbon B-Chemical
showed O
no O
significant O
DNA B-Gene
methylation I-Gene
differences O
when O
compared O
to O
unprocessed O
tissue O
, O
while O
formalin B-Chemical
processing O
altered O
the O
quality O
and O
reliability O
of O
the O
data O
produced O
on O
the O
DNA B-Gene
methylation I-Gene
array O
platform O

In O
addition O
, O
the O
cancer B-Disease
epigenome O
dictates O
the O
response O
of O
a O
cancer B-Disease
cell O
to O
therapeutic O
intervention O
and O
, O
therefore O
its O
knowledge O
, O
will O
allow O
to O
predict O
response O
to O
different O
therapeutic O
approaches O

Twenty-eight O
( O
82% O
) O
of O
these O
new O
genes B-Gene
were O
successfully O
replicated O
by O
transcriptome-wide O
association O
analyses O
in O
a O
large O
independent O
cohort O
( O
n O
= O
~220,000 O
) O

Compared O
to O
SRA01/04 O
, O
HLEB3 O
displayed O
lower O
acetylated B-Chemical
H3 I-Chemical
and O
higher O
trimethylated B-Chemical
H3K9 I-Chemical
levels O

 O

We O
conclude O
that O
Fredrickson B-Gene
et I-Gene
al I-Gene

Results O
 O
Among O
the O
most O
predictive O
factors O
of O
epigenetic O
age O
deviations O
in O
single O
tissues O
were O
child O
sex O
, O
birth O
length O
, O
maternal O
smoking O
during O
pregnancy O
, O
maternal O
mental O
disorders B-Disease
until O
childbirth O
, O
delivery O
mode O
and O
parity O

Although O
the O
causal O
role O
of O
genetic O
mutations O
on O
cancer B-Disease
development O
has O
been O
established O
in O
vivo O
, O
similar O
evidence O
for O
epigenetic O
alterations O
is O
limited O

Clinical O
behavior O
ranges O
from O
the O
spontaneous O
regression O
of O
localized O
, O
asymptomatic O
tumors O
, O
as O
well O
as O
metastasized O
tumors O
in O
infants O
, O
to O
rapid O
progression O
and O
resistance O
to O
therapy O

Besides O
the O
widely O
used O
PCR B-Chemical
technique O
, O
there O
are O
several O
alternative O
approaches O
for O
genomic O
DNA B-Chemical
amplification O
suitable O
for O
supporting O
the O
detection O
of O
genomic O
variation O

Types O
of O
environmental O
exposure O
under O
consideration O
include O
hypnotic B-Chemical
drugs I-Chemical
and O
medicines O
( O
i O

This O
dependence O
on O
SE-driven B-Gene
transcription O
to O
maintain O
chemoresistance B-Disease
offers O
an O
Achilles' O
heel O
for O
chemoresistance B-Disease

We O
also O
demonstrate O
the O
presence O
of O
correlations O
between O
cognitive O
, O
phenotypic O
and O
epigenetic O
age O
accelerations O
that O
suggests O
a O
deep O
connection O
between O
cognitive O
performance O
and O
aging O
status O
of O
an O
individual O

Next O
, O
findings O
from O
the O
nondental O
literature O
are O
drawn O
on O
to O
elaborate O
the O
pathways O
and O
mechanisms O
that O
link O
the O
socio-exposome O
with O
gene B-Gene
expression-or O
the O
biological O
embedding O
of O
social O
experiences O
through O
epigenetics B-Gene

In O
addition O
, O
ChIP O
analyses O
of O
telomeres B-Gene
should O
be O
properly O
controlled O

Epigenetic O
studies O
that O
incorporate O
well-characterized O
patient O
tissue O
samples O
( O
including O
affected O
tissues O
and O
peripheral O
blood O
) O
, O
similar O
to O
those O
relevant O
to O
gene B-Gene
expression I-Gene
studies O
, O
along O
with O
genetic O
and O
epidemiological O
information O
, O
can O
be O
the O
first O
step O
in O
developing O
appropriate O
functional O
assays O

The O
talks O
were O
mainly O
focused O
on O
questions O
of O
the O
generation O
, O
maintenance O
, O
flexibility O
and O
erasure O
of O
DNA B-Gene
methylation I-Gene
patterns O
in O
context O
of O
other O
epigenetic O
signals O
like O
histone B-Chemical
tail I-Chemical
modifications O
and O
ncRNAs B-Gene

Cellular O
responses O
to O
cadmium B-Chemical
( O
II O
) O
toxicity O
seem O
to O
be O
composed O
of O
a O
series O
of O
interlinked O
biochemical O
reactions O
, O
which O
, O
via O
generation O
of O
ROS B-Chemical
and O
DNA B-Gene
damage-induced O
replication O
stress O
, O
ultimately O
activate O
signal O
factors O
engaged O
in O
cell O
cycle O
control O
pathways O
, O

Here O
, O
we O
leverage O
epigenome-wide O
data O
to O
study O
links O
between O
the O
DNA B-Chemical
methylation I-Chemical
( O
DNAm B-Gene
) O
signatures O
of O
the O
circulating O
proteome O
and O
incident O
diseases B-Disease

In O
this O
review O
, O
we O
will O
critically O
evaluate O
the O
role O
of O
epigenetic O
mechanisms O
in O
Î³-globin B-Gene
gene I-Gene
regulation O
and O
discuss O
data O
generated O
in O
tissue O
culture O
, O
pre-clinical O
animal O
models O
, O
and O
clinical O
trials O
to O
support O
drug B-Chemical
development O
to O
date O

This O
highlights O
the O
importance O
of O
continuing O
research O
development O
to O
further O
advance O
the O
existing O
knowledge O
on O
epigenetics O
and O
BC B-Disease
carcinogenesis O
to O
overcome O
the O
current O
challenges O

Emerging O
evidence O
suggests O
that O
epigenetic O
modifications O
may O
explain O
these O
lasting O
effects O

Using O
powerful O
epigenetic-based O
therapies O
for O
cancer B-Disease
cells O
, O
the O
aberrantly O
regulated O
epigenome O
can O
be O
restored O
to O
a O
more O
normal O
state O
through O
epigenetic O
reprogramming O

We O
demonstrate O
the O
utility O
of O
Snapshot O
using O
data O
from O
a O
consortium O
project O
for O
ValIdated O
Systematic O
IntegratiON O
( O
VISION O
) O
of O
epigenomic O
data O
in O
hematopoiesis B-Disease

Thus O
, O
we O
provide O
a O
novel O
discovery O
tool O
for O
the O
identification O
of O
significant O
associations O
that O
warrant O
to O
be O
tested O
for O
functional O
interdependence O

331 O
Sperm B-Species
, O
eggs O
and O
embryos O
are O
made O
up O
of O
more O
than O
genes B-Gene
, O
and O
there O
are O
indications O
that O
changes O
to O
non-genetic O
structures O
in O
these O
elements O
of O
the O
germline O
can O
also O
be O
inherited O

00 O
or O
0 O

We O
identified O
34 O
novel O
genes O
for O
blood B-Disease
pressure I-Disease
, O
supported O
by O
more O
than O
one O
source O
of O
biological O
evidence O

47 O
The O
past O
decade O
has O
seen O
an O
explosion O
of O
articles O
in O
scientific O
journals O
involving O
non-genetic O
influences O
on O
phenotype O
through O
modulation O
of O
gene B-Gene
function O
without O
changes O
in O
gene B-Gene
sequence O

Members O
from O
the O
three O
families O
of O
epigenetic O
proteins O
(readers O
, O
writers O
, O
and O
erasers O
) O
have O
been O
shown O
to O
be O
druggable O
using O
small-molecule B-Chemical
inhibitors I-Chemical

Mutations O
in O
chromatin O
modifiers-proteins O
that O
shape O
the O
epigenomic O
landscape O
through O
remodeling O
and O
regulation O
of O
post-translational O
modifications O
on O
chromatin O
- O
are O
very O
frequent O
and O
often O
define O
specific O
glioma B-Disease
subtypes O

We O
argue O
that O
using O
epigenetic O
biomarkers O
could O
reveal O
a O
broad O
range O
of O
health O
and O
life-style O
related O
information O
, O
therefore O
it O
is O
necessary O
to O
develop O
adequate O
safeguards O
to O
protect O
the O
privacy O
of O
the O
individuals O
under O
scrutiny O

) O

462 O
Indicine B-Species
and O
taurine B-Species
subspecies O
present O
distinct O
morphological O
traits O
as O
a O
consequence O
of O
environmental O
adaptation O
and O
artificial O
selection O

Advantages O
of O
cfDNA B-Chemical
as O
analytical O
target O
have O
evoked O
a O
burst O
of O
sophisticated O
techniques O
, O
providing O
clinically O
relevant O
information O

1003 O
The O
discovery O
of O
5-hydroxymethylcytosine B-Chemical
( O
5hmC B-Chemical
) O
as O
a O
common O
DNA B-Gene
modification O
in O
mammalian B-Species
genomes O
has O
ushered O
in O
new O
areas O
of O
inquiry O
regarding O
the O
dynamic O
epigenome O


73 O
Everyone O
has O
heard O
of O
' O
epigenetics B-Gene
' O
, O
but O
the O
term O
means O
different O
things O
to O
different O
researchers O

Path O
models O
evaluated O
whether O
early O
life O
trauma O
predicted O
early O
pubertal O
timing O
and O
thereby O
, O
adult O
epigenetic O
age O
acceleration O
( O
indexed O
via O
four O
epigenetic O
clocks O
 O
Horvath B-Gene
DNAm B-Gene
Age I-Gene
, O
Hannum B-Gene
DNAm B-Gene
Age I-Gene
, O
DNAm B-Gene
PhenoAge I-Gene
, O
and O

800 O
Epigenetics O
is O
the O
study O
of O
heritable O
, O
reversible O
gene B-Gene
expression I-Gene
patterns O
that O
do O
not O
originate O
from O
alterations O
in O
the O
DNA B-Chemical
sequence O

has O

Our O
findings O
imply O
that O
epigenetic O
enzymes O
can O
function O
as O
sensors O
to O
gauge O
the O
availability O
of O
metabolites O
and O
influence O
cell O
fate O
decisions O

Importantly O
, O
a O
plethora O
of O
studies O
demonstrated O
that O
especially O
JMJD1A B-Gene
and O
JMJD1C B-Gene
are O
overexpressed O
in O
various O
tumors B-Disease
, O
stimulate O
cancer B-Disease
cell O
proliferation O
and O
invasion O
, O
and O
facilitate O
efficient O
tumor B-Disease
growth O

There O
were O
a O
total O
of O
240 O
genes O
differentially O
methylated O
by O
MethylMix B-Chemical
criteria O

If O
epigenetic O
mechanisms O
point O
to O
the O
deep O
socio-environmental O
embeddedness O
of O
our O
health O
, O
we O
conclude O
, O
future O
designs O
and O
methods O
of O
this O
research O
may O
require O
an O
improved O
methodological O
consideration O
of O
a O
biosocial O
perspective O

Here O
, O
we O
attempt O
to O
provide O
a O
broad O
overview O
of O
chromatin O
regulation O
, O
as O
it O
relates O
to O
central B-Disease
nervous I-Disease
system I-Disease
( O
CNS B-Disease
) O
function O
, O
with O
specific O
emphasis O
on O
the O
modes O
of O
histone B-Chemical
posttranslational I-Chemical
modifications I-Chemical
, O
chromatin O
remodeling O
, O

Assays O
for O
human B-Species
age O
have O
recently O
been O
developed O
based O
on O
age-induced O
changes O
in O
DNA B-Chemical
methylation O
of O
specific O
genes B-Gene

Finally O
, O
the O
authors O
provide O
some O
suggestions O
for O
future O
directions O

However O
, O
many O
existing O
epigenetic O
clocks O
are O
weakly O
correlated O
with O
each O
other O
, O
suggesting O
they O
may O
capture O
different O
biological O
processes O


This O
report O
presents O
selected O
highlights O
of O
this O
meeting O
which O
illustrate O
how O
recent O
advances O
in O
mammalian B-Species
genetic O
approaches O
have O
improved O
our O
ability O
to O
decipher O
complex O
biological O
mechanisms O

587 O
Epigenetic O
modifications O
, O
including O
and O
, O
determine O
the O
way O
is O
packaged O
within O
the O
nucleus O
and O
regulate O
cell-specific O
expression O

DNA O
methylation O
and O
other O
epigenetic O
marks O
are O
firmly O
entwined O
with O
allergic B-Disease
disease I-Disease
, O
a O
link O
that O
may O
hold O
the O
basis O
for O
future O
allergic B-Disease
disease I-Disease
diagnosis O
and O
treatment O

and O

We O
present O
a O
protocol O
for O
genome-wide O
comparative O
analysis O
of O
DNA-IP B-Chemical
sequencing O
data O
to O
identify O
statistically O
significant O
differential O
sequencing O
coverage O
between O
two O
conditions O
by O
considering O
variation O
across O
replicates O

743 O
Cellular O
processes O
that O
control O
transcription O
of O
genetic O
information O
are O
critical O
for O
cellular O
function O
, O
and O
are O
often O
implicated O
in O
psychiatric O
and O
neurological O
disease B-Disease
states I-Disease

Szyf O
received O
his O
PhD O
from O
the O
Hebrew O
University O
and O
did O
his O
postdoctoral O
fellowship O
in O
genetics O
at O
Harvard O
Medical O
School O
, O
joined O
the O
Department O
of O
Pharmacology O
and O
Therapeutics O
at O
McGill O
University O
in O
Montreal O
in O
1989 O
and O
is O
a O
fellow O
of O
the O
Royal O
Society O
of O
Canada O

It O
includes O
changes O
related O
to O
telomere B-Gene
shortening O
, O
cell O
senescence O
and O
epigenetic O
modifications O

As O
a O
result O
, O
epigenome O
editing O
has O
helped O
to O
uncover O
the O
causal O
relationships O
between O
epigenetic O
marks O
and O
gene B-Gene
expression I-Gene

BDAP O
provides O
a O
desktop O
for O
the O
comparative O
analysis O
of O
epigenomes O
of O
hematopoietic B-Disease
cell I-Disease
types I-Disease
based O
on O
results O
, O
such O
as O
the O
position O
of O
epigenetic O
features O
, O
from O
basic O
analysis O
pipelines O

Cancer O
diagnosis O
is O
complex O
because O
the O
majority O
of O
malignant O
tumors O
present O
with O
long O
periods O
of O
latency O
and O
lack O
of O
clinical O
presentation O
at O
early O
stages O

1287 O
Recent O
genome-wide O
association O
studies O
uncovered O
part O
of O
blood B-Chemical
pressure's I-Chemical
heritability O

356 O
This O
article O
describes O
ethnography O
as O
a O
research O
method O
and O
outlines O
how O
it O
excels O
in O
capturing O
the O
salient O
experiences O
of O
individuals O
among O
diverse O
communities O
in O
their O
own O
words O

Despite O
the O
overall O
promise O
of O
early O
approaches O
, O
however O
, O
these O
drugs O
have O
been O
plagued O
by O
poor O
pharmacokinetic O
and O
safety/tolerability O
profiles O
due O
in O
large O
part O
to O
off-target O
effects O
and O
a O
lack O
of O
specificity O

We O
observed O
an O
interactive O
effect O
of O
child O
sex O
abuse B-Disease
( O
CSA B-Disease
) O
and O
biological O
parent O
psychopathology B-Disease
( O
i O

various O

We O
investigated O
the O
cross-sectional O
relationship O
between O
two O
such O
estimates O
of O
biological O
age O
and O
objectively O
measured O
sedentary O
and O
walking O
behavior O
in O
older O
people O

1329 O
The O
development O
of O
chromatin O
immunoprecipitation O
( O
ChIP O
) O
with O
massively O
parallel O
DNA B-Chemical
sequencing I-Chemical
( O
ChIP-seq O
) O
technologies O
has O
promoted O
generation O
of O
large-scale O
epigenomics O
data O
, O
providing O
us O
unprecedented O
opportunities O
to O
explore O
the O
landscape O
of O
epigenomic O
profiles O
at O
scales O

However O
, O
to O
develop O
effective O
strategies O
for O
engagement O
, O
it O
is O
important O
to O
understand O
the O
public O
's O
understanding O
of O
the O
relevant O
concepts O

1005 O
 O
Objective O
 O
Epigenetics O
has O
been O
described O
as O
one O
of O
the O
most O
exciting O
areas O
of O
contemporary O
biology O
, O
and O
research O
has O
begun O
to O
explore O
whether O
epigenetic O
modifications O
are O
influenced O
by O
psychological O
processes O

Simulations O
show O
that O
the O
proposed O
methodology O
outperforms O
existing O
analysis O
methods O
that O
either O
ignore O
the O
correlation O
between O
DNA B-Gene
methylation I-Gene
profiles I-Gene
at O
neighbouring O
CpG B-Gene
sites I-Gene
or O
do O
not O
correct O
for O
errors O

mammals I-Species
, O
for O
example O
, O
become O
, O
insulin B-Chemical
, O
and O
to O
store O
fat O

Here O
, O
we O
outline O
in O
detail O
the O
tools O
and O
steps O
needed O
to O
analyze O
genome-wide O
transcription O
factor O
binding O
and O
histone O
modification O
data O
( O
chromatin O
immunoprecipitation O
, O
ChIP-seq O
) O
, O
as O
well O
as O
chromatin O
accessibility O
data O
( O
assay O
for O
transposase-accessible O
chromatin O
, O
ATAC-seq O

Thus O
, O
the O
proposed O
protocol O
is O
an O
attractive O
option O
for O
adequately O
powered O
and O
cost-effective O
methylome-wide O
investigations O
using O
( O
very O
) O
low O
amounts O
of O
DNA B-Gene

This O
analysis O
is O
intended O
to O
assist O
practitioners O
and O
observers O
of O
genetics O
and O
epigenetics O
in O
recognizing O
and O
moving O
beyond O
the O
conceptual O
legacies O
of O
negative O
definition O

Finally O
, O
our O
model O
reproduced O
previous O
results O
of O
increased O
epigenetic O
age O
acceleration O
in O
cancer B-Disease
patients O
and O
in O
survivors O
treated O
with O
radiation B-Chemical
therapy I-Chemical
, O
and O
no O
changes O
from O
exercise-based O
interventions O

DNA O
methylation O
stands O
out O
as O
a O
tracer O
of O
cell O
identity O
and O
memory O
, O
as O
neoplasms O
show O
epigenetic O
imprints O
of O
their O
cellular O
origin O
and O
proliferative O
history O
, O
which O
can O
be O
quantified O
by O
an O
epigenetic O
mitotic O
clock O

Numerous O
environmental O
toxicants O
are O
classified O
as O
endocrine O
disrupting O
chemicals O
( O
EDCs B-Chemical
) O

Exposure O
to O
inorganic B-Chemical
arsenic I-Chemical
has O
been O
implicated O
in O
many O
diseases O
ranging O
from O
acute B-Disease
toxicities I-Disease
to O
malignant B-Disease
transformations I-Disease

Future O
research O
should O
address O
the O
limitations O
of O
this O
study O
by O
using O
racially O
diverse O
samples O

In O
vitro O
and O
cell O
type-specific O
studies O
have O
demonstrated O
that O
epithelial O
and O
stromal O
cells O
undergo O
particular O
epigenetic O
changes O
that O
modulate O
their O
transcriptional O
networks O
to O
accomplish O
their O
function O
during O
decidualization O
and O
implantation O

In O
pace O
with O
the O
rapid O
increase O
in O
interest O
in O
epigenetic O
research O
, O
the O
range O
of O
methods O
has O
greatly O
expanded O
over O
the O
past O
decade O

Existing O
therapeutic O
strategies O
have O
had O
limited O
success O
; O
they O
have O
poor O
effects O
on O
core O
cognitive O
impairment B-Disease
and O
long-term O
disability B-Disease

Importantly O
, O
molecular O
mechanisms O
of O
bioactive O
dietary O
components O
should O
be O
investigated O
in O
greater O
detail O
in O
human B-Species
intervention O
studies O

These O
observations O
suggest O
the O
involvement O
of O
epigenetic O
mechanisms O

Studies O
examining O
spatial O
patterns O
of O
genetic O
and O
epigenetic O
variation O
can O
provide O
valuable O
insights O
into O
how O
ecological O
and O
population O
processes O
contribute O
to O
epigenetic O
divergence O
across O
heterogeneous O
landscapes O

Here O
, O
we O
review O
key O
facts O
on O
the O
involvement O
of O
epigenetic O
modifications O
in O
allergic B-Disease
diseases I-Disease
and O
summarize O
and O
critically O
evaluate O
the O
lessons O
learned O
from O
epigenome-wide O
association O
studies O

981 O
The O
Barker B-Disease
hypothesis O
of O
' O
foetal B-Disease
origin I-Disease
of I-Disease
adult I-Disease
diseases I-Disease
' O
has O
led O
to O
emphasize O
the O
concept O
of O
' O
developmental O
programming O
' O
, O
based O
on O
the O
crucial O
role O
of O
epigenetic O
factors O

It O
features O
studies O
conducted O
on O
models O
representing O
many O
different O
cancers B-Disease
, O
and O
includes O
mechanistic O
reports O
conducted O
using O
appropriate O
in O
vitro O
models O
, O
studies O
that O
analyzed O
human B-Species
cancer I-Disease
patients-derived O
specimens O
, O
clinical O
trials O
and O
, O
additionally O
, O
studies O
involving O
bioinformatics O
, O
metabolomics O
, O

While O
there O
has O
been O
some O
research O
exploring O
the O
public's O
understanding O
of O
genetic O
and O
environmental O
susceptibility O
to O
disease O
, O
limited O
research O
exists O
on O
public O
opinion O
and O
understanding O
of O
epigenetics B-Gene
and O
epigenetic B-Gene
concepts O

1211 O
Epigenetic O
processes O
are O
complex O
regulatory O
transcriptional O
pathways O
that O
underpin O
fundamental O
physiology O
and O
are O
implicated O
in O
the O
aetiology O
of O
many O
diseases B-Disease

44%) O

Specifically O
, O
the O
EpiVar O
Browser O
allows O
a O
user O
to O
navigate O
an O
epigenetic O
dataset O
from O
a O
cohort O
of O
individuals O
and O
enables O
direct O
exploration O
of O
genotype-chromatin O
phenotype O
relationships O

It O
is O
proposed O
that O
increased O
polyamine B-Chemical
activity O
can O
cause O
disruption O
of O
cellular O
methylation O
, O
which O
can O
lead O
to O
abnormal O
expression O
of O
previously O
sequestered O
genes O
and O
disruption O
of O
other O
methylation-dependent O
cellular O
processes O

Overall O
, O
we O
identify O
an O
important O
epigenetic O
role O
for O
a O
number O
of O
largely O
unstudied O
genes O
in O
muscle B-Disease
hypertrophy/memory I-Disease

The O
regulatory O
system O
consists O
of O
a O
genome-wide O
"backbone" O
within O
which O
its O
specific O
genes O
are O
differentially O
expressed O
by O
the O
local O
epigenetic O
landscapes O
of O
cells O
and O
tissues O
within O
which O
they O
reside O
, O
thereby O
explaining O
its O
holistic O
nature O

Furthermore O
, O
the O
binary O
sequel O
of O
methylated B-Chemical
and O
non-methylated B-Chemical
CpGs O
in O
individual O
reads O
can O
be O
used O
for O
single-read O
predictions O
, O
which O
may O
reflect O
heterogeneity O
in O
epigenetic B-Disease
aging I-Disease

90 O
, O
p O
< O
4 O

Herein O
, O
we O
review O
recent O
studies O
on O
the O
application O
of O
epigenome-modifying O
small O
molecules B-Chemical
in O
enhancing O
reprogramming O
and O
functionally O
replacing O
some O
reprogramming O
factors O

51The O
understanding O
of O
epigenetic O
mechanisms O
is O
necessary O
for O
assessing O
the O
potential O
impacts O
of O
epigenetics O
on O
plant B-Species
growth O
, O
development O
and O
reproduction O
, O
and O
ultimately O
for O
the O
response O
of O
these O
factors O
to O
evolutionary O
pressures O
and O
crop B-Species
breeding O
programs O

Conclusions O
A O
sufficiently O
advanced O
universal O
harmonizer O
has O
major O
medical O
implications O
, O
such O
as O
( O
i O
) O
identifying O
dysregulated O
biological O
pathways O
responsible O
for O
a O
disease O
is O
a O
powerful O
diagnostic O
tool O
; O
( O
2 O
) O
investigating O
these O
pathways O
further O
allows O
the O
biological O
community O
to O
better O

Indeed O
also O
in O
the O
field O
of O
epigenetics O
, O
virtual O
screening O
(VS) O
studies O
and O
structure-based O
approaches O
have O
been O
applied O
to O
identify O
novel O
chemical B-Chemical
modulators O
of O
epigenetic O
targets O
as O
well O
as O
to O
predict O
the O
binding O
mode O
of O
active O
ligands O
and O
to O
study O
the O
protein O
dynamics O

1194Childhood O
maltreatment O
, O
occurring O
in O
up O
to O
20-30% O
of O
the O
population O
, O
remains O
far O
too O
common O
, O
and O
incorporates O
a O
range O
of O
active O
and O
passive O
factors O
, O
from O
abuse O
, O
to O
neglect O
, O
to O
the O
impacts O
of O
broader O
structural O
and O
systemic O
adversity O

Here O
we O
report O
a O
robust O
, O
high-throughput O
targeted O
, O
quantitative O
mass O
spectrometry O
( O
MS O
) O
method O
to O
rapidly O
profile O
modifications O
of O
the O
core B-Chemical
histones I-Chemical
of O
chromatin O
that O
compose O
the O
epigenetic O
landscape O
, O
enabling O
comparisons O
among O
cells O
with O
differing O
genetic O
backgrounds O
, O

In O
fact O
, O
epitranscriptomics O
aims O
at O
identifying O
and O
characterizing O
all O
functionally O
relevant O
changes O
involving O
both O
non-substitutional O
chemical B-Chemical
modifications O
and O
editing O
events O
made O
to O
the O
transcriptome O

Additional O
molecular O
functions O
modulated O
by O
these O
drugs O
included O
other O
enzyme O
interactions O
, O
whereas O
modulation O
of O
ion O
channels O
or O
G-protein-coupled O
receptors O
were O
underrepresented O

Interrogating O
the O
interaction O
of O
genetic O
and O
environmental O
influences O
raised O
new O
challenges O
of O
statistical O
power O
, O
which O
were O
not O
easily O
bested O
by O
the O
addition O
of O
subjects O

In O
this O
paper O
, O
we O
propose O
a O
Statistical O
Inferences O
with O
( O
SIMD O
) O
to O
infer O
the O
methylation O
level O
for O
each O

As O
a O
consequence O
population-level O
differences O
(for O
example O
, O
secular O
trends O
or O
differences O
between O
administrative O
areas O
) O
can O
be O
entirely O
explicable O
by O
causal O
factors O
that O
appear O
to O
account O
for O
only O
a O
small O
proportion O
of O
individual-level O
risk O

Here O
, O
we O
introduce O
two O
methods O
for O
bisulfite-based O
DNA B-Chemical
methylation I-Chemical
analyses O
using O
small O
samples O
such O
as O
germ B-Species
cells I-Species
 O
bisulfite O
Sanger O
sequencing O
at O
a O
specific O
locus O
and O
high-throughput O
bisulfite O
sequencing O
at O
the O
whole O
genome O
level O

Annotation O
, O
comparison O
, O
visualization O
, O
and O
interpretation O
of O
epigenomic O
datasets O
remain O
key O
aspects O
of O
computational O
biology O

Therefore O
, O
stage-specific O
epigenetic O
changes O
can O
be O
used O
as O
powerful O
and O
reliable O
tools O
for O
early O
diagnosis O
of O
lung B-Disease
cancer I-Disease
and O
to O
monitor O
patient O
prognosis O

Using O
next-generation O
sequencing O
, O
we O
investigated O
three O
pairs O
of O
matched O
FFPE O
and O
FF O
samples O
to O
determine O
the O
extent O
of O
their O
similarity O

Furthermore O
, O
we O
can O
postulate O
that O
such O
variations O
exist O
between O
transformed O
macrophage-like O
cell O
lines O
and O
primary O
macrophages O
obtained O
from O
healthy O
volunteers O


407 O
The O
Great O
Irish B-Disease
Famine I-Disease
( O
1845-52 O
) O
saw O
the O
Irish B-Species
population O
fall O
by O
20% O
as O
one O
million O
people O
died O
and O
another O
million O
emigrated O

Current O
trends O
in O
osteoarthritis B-Disease
genetics O
research O
involve O
meta-analyses O
of O
various O
cohorts O
to O
explore O
the O
impact O
of O
gene B-Gene
variants O
on O
osteoarthritis-related B-Disease
outcomes O
, O
such O
as O
pain O

These O
drugs O
may O
fulfil O
the O
need O
for O
newer O
and O
more O
effective O
drugs O
for O
treating O
these O
disorders B-Disease

Findings O
revealed O
significant O
epigenetic O
effects O
in O
an O
assortment O
of O
genes O
that O
are O
implicated O
in O
the O
etiology O
of O
depression B-Disease
, O
suicidality B-Disease
, O
callous-unemotional B-Disease
traits I-Disease
, O
and O
chronic B-Disease
and I-Disease
intergenerational I-Disease
aggressive I-Disease
behavior I-Disease

Indeed O
, O
this O
tendency O
to O
always O
look O
forward O
, O
with O
minimal O
concern O
or O
regard O
of O
what O
has O
gone O
before O
, O
has O
led O
to O
the O
present O
situation O
in O
which O
" O
true O
" O
epigenetic O
studies O
are O
believed O
to O
consist O
of O
one O
of O
two O
schools O

The O
protocol O
requires O
4 O
d O
from O
the O
start O
to O
the O
end O
of O
the O
PAT-ChIP B-Chemical
procedure O

This O
knowledge O
has O
shaped O
what O
we O
classify O
as O
nephrolithiasis B-Disease
, O
a O
condition O
that O
is O
now O
recognized O
as O
systemic O

In O
total O
we O
identified O
765 O
unique O
publications O
, O
which O
eventually O
reduced O
to O
380 O
of O
relevance O
to O
the O
field O
as O
judged O
by O
two O
assessors O

speaks O

Summary O
 O
Structured O
investigation O
of O
epigenetic O
events O
, O
their O
causes O
and O
effects O
on O
immune O
phenotypes O
in O
autoimmune/inflammatory B-Disease
, O
will O
improve O
our O
understanding O
of O
disease O
, O
deliver O
new O
diagnostic O
tools O
and O
treatment O
options O

Introduction O
of O
more O
advanced O
approaches O
to O
DNA B-Gene
methylation I-Gene
analysis O
, O
such O
as O
microarray O
platforms O
and O
massively O
parallel O
sequencing O
, O
has O
brought O
us O
closer O
to O
unveiling O
the O
whole O
methylome O

Although O
current O
efforts O
concentrate O
on O
long-lived O
resting O
memory O
CD4+ B-Gene
T-cells I-Gene
, O
dormant O
HIV B-Species
proviruses O
also O
reside O
in O
other O
cell O
types O

This O
article O
describes O
main O
provisions O
of O
the O
chromosome O
territory O
theory O
and O
current O
trends O
toward O
further O
development O
of O
human B-Species
genetics O
based O
on O
the O
new O
knowledge O
about O
the O
role O
of O
chromosome O
territories O

179 O
 O
Purpose O
of O
review O
 O
Epigenetic O
mechanisms O
of O
transcriptional O
regulation O
in O
atherosclerosis B-Disease
have O
gained O
an O
increasing O
interest O
in O
recent O
years O

As O
the O
( O
) O
celebrates O
its O
50th O
Anniversary O
this O
year O
, O
we O
have O
come O
together O
to O
review O
and O
summarize O
the O
seminal O
advances O
in O
the O
field O
of O

Aging O
, O
in O
fact O
, O
is O
one O
of O
the O
most O
relevant O
risk O
factors O
for O
a O
wide O
range O
of O
maladies B-Disease
, O
and O
molecular O
surrogates O
of O
this O
phenotype O
could O
enable O
better O
patients O
stratification O

08 O
years O
( O
EEAA B-Disease
, O
p O
< O
3 O

Further O
research O
into O
how O
epigenetic O
mechanisms O
affect O
the O
health O
and O
production O
traits O
of O
domestic B-Species
livestock I-Species
and O
their O
offspring O
is O
important O
to O
elucidate O

Greatest O
efforts O
were O
invested O
in O
studying O
DNA B-Gene
methylation I-Gene
in O
comparison O
to O
histone B-Chemical
modifications I-Chemical
and O
miRNA B-Gene
studies O

These O
studies O
provide O
a O
new O
insight O
into O
action O
mechanism O
by O
which O
natural B-Chemical
compound I-Chemical
exerts O
its O
bioactivity O
and O
a O
novel O
treatment O
strategy O
, O
demonstrating O
natural B-Chemical
compound I-Chemical
a O
promising O
remedy O
for O
clinical O
treatments O

Discussion O
 O
This O
systematic O
review O
will O
evaluate O
published O
literature O
, O
assessing O
the O
link O
between O
DNA B-Gene
methylation I-Gene
and O
T2DM B-Disease

Paternal O
actions O
, O
embedded O
within O
a O
structural O
network O
of O
the O
social O
determinants O
of O
health O
, O
operate O
both O
pre-conception O
to O
induce O
epigenetic O
changes O
to O
the O
spermatozoa B-Species
and O
during O
the O
gestational O
period O
to O
influence O
developmental O
programming O

identification O
of O
disease O
biomarkers O
and O
ii O

526 O
Various O
different O
classes O
of O
RNAs B-Gene
contained O
in O
sperm O
cells O
have O
emerged O
as O
causal O
vectors O
for O
the O
transmission O
of O
acquired O
information O
from O
father O
to O
offspring O

03-1 O

271 O
Epigenetics O
is O
the O
study O
of O
the O
heritable O
changes O
on O
gene B-Gene
expression I-Gene
that O
are O
responsible O
for O
the O
regulation O
of O
development O
and O
that O
have O
an O
impact O
on O
several O
diseases B-Disease

DNA O
methylation B-Chemical
, O
histone B-Chemical
modification O
, O
and O
RNA B-Chemical
regulation O
are O
some O
of O
the O
mechanisms O
involved O
in O
epigenetic O
modification O

699 O
 O
Genetic O
studies O
have O
attempted O
to O
elucidate O
causal O
mechanisms O
for O
the O
development O
of O
complex B-Disease
disease I-Disease
, O
but O
genome-wide O
associations O
have O
been O
largely O
unsuccessful O
in O
establishing O
these O
links O

Our O
results O
show O
that O
EPIGENE B-Gene
can O
identify O
genome-wide O
TUs O
in O
an O
unbiased O
manner O

However O
, O
there O
is O
still O
a O
vast O
gap O
between O
genetics O
and O
biology O
that O
needs O
to O
be O
bridged O

) O

The O
pathways O
connecting O
social O
, O
environmental O
, O
and O
structural O
factors O
and O
various O
health O
outcomes O
have O
been O
illuminated O
by O
the O
emergence O
of O
epigenetic O
and O
epigenomic O
research O
, O
further O
bolstering O
the O
value O
of O
population O
health O
perspectives O
in O
supporting O
clinical O
practice O
, O
community-based O
programs O
, O
and O

We O
identified O
two O
DMPs O
associated O
with O
PD B-Disease

Several O
environmental O
factors O
( O
eg O
, O
smoking O
, O
air O
pollution O
) O
have O
been O
associated O
with O
altered O
mtDNA B-Gene
methylation O
in O
a O
handful O
of O
mechanistic O
studies O
and O
in O
observational O
human B-Species
studies O

These O
findings O
suggest O
that O
biological O
age O
, O
as O
measured O
by O
these O
epigenetic O
indices O
, O
could O
indicate O
risk O
for O
adverse O
pregnancy B-Disease
outcomes I-Disease

Epidemiological O
and O
laboratory O
studies O
suggest O
that O
paternal O
nutritional O
and O
toxicological O
exposures O
as O
well O
as O
paternal O
age O
and O
phenotypic O
variation O
can O
lead O
to O
variations O
in O
offspring O
and O
, O
in O
some O
cases O
, O
grand-offspring O
development O

Tost O
has O
an O
H-index O
of O
50 O
and O
is O
the O
author O
or O
co-author O
of O
more O
than O
195 O
publications O

We O
examine O
disruption O
of O
these O
processes O
by O
endocrine-disrupting B-Chemical
chemicals I-Chemical
( O
EDCs B-Chemical
) O
in O
an O
age-, O
sex-, O
and O
region-specific O
manner O
, O
focusing O
on O
how O
perinatal O
EDCs B-Chemical
act O
through O
epigenetic O
mechanisms O
to O
reprogram O
DNA B-Gene
methylation I-Gene
and O
sex O
steroid O

Pharmacokinetics O
and O
biodistribution O
of O
these O
carriers O
are O
controlled O
by O
a O
complex O
array O
of O
interrelated O
core O
and O
interfacial O
physicochemical O
and O
biological O
factors O

We O
present O
the O
first O
systematic O
review O
synthesising O
the O
literature O
investigating O
childhood O
SEP B-Disease
and O
DNAm B-Gene

869 O
gene B-Gene
segments O
analyzed O
, O
transcriptional O
activities O
were O
up- O
or O
downregulated O
in O
the O
transgenomic O
cell O
clones O

Epialleles O
offer O
an O
additional O
source O
of O
variation O
that O
can O
affect O
phenotypic O
diversity O
beyond O
changes O
to O
nucleotide B-Chemical
sequence I-Chemical

1226 O
 O
Background O
 O
Suicide O
results O
in O
over O
800,000 O
deaths O
every O
year O
, O
making O
it O
a O
major O
public O
health O
concern O
worldwide O

Lysenkoism O
was O
a O
neo-Lamarckian O
idea O
, O
claiming O
that O
in O
crop O
plants O
, O
such O
as O
wheat B-Species
, O
environmental O
influences O
are O
heritable O
via O
all O
cells O
of O
the O
organism O

He O
has O
been O
awarded O
10 O
patents O
related O
to O
DNA B-Gene
methylation I-Gene
technology O
by O
the O
United O
States O
Patent O
and O
Trademark O
Office O
, O
one O
of O
which O
is O
the O
basis O
for O
the O
first O
US O
FDA-approved O
blood-based O
DNA B-Gene
methylation I-Gene
assay O
for O
cancer B-Disease
( O
Epi O
proColon O
) O

Studies O
measuring O
epigenetic O
markers O
either O
at O
the O
same O
time O
as O
, O
or O
after O
, O
the O
early O
life O
exposure O
and O
have O
a O
measure O
of O
body O
size O
, O
nutrition O
or O
SEP O
in O
early O
life O
( O
up O
to O
12 O
years O
) O
, O
written O
in O
English O
and O
from O
a O
community-dwelling O
participants O
were O


This O
indicates O
that O
, O
from O
a O
father O
's O
perspective O
, O
preconception O
is O
a O
valuable O
window O
of O
opportunity O
to O
start O
potential O
nutritional O
interventions O
with O
these O
BFCs B-Chemical
to O
maximize O
sperm O
epigenetic O
integrity O
and O
promote O
adequate O
fetal O
growth O
and O
development O
, O
thus O
preventing O
chronic B-Disease

Despite O
impressive O
recent O
progress O
, O
including O
single O
cell O
transcriptome O
and O
epigenome O
profiling O
as O
well O
as O
anatomical O
methods O
, O
we O
still O
lack O
a O
complete O
census O
or O
taxonomy O
of O
brain O
cell O
types O

641 O
Unlike O
genomes O
, O
which O
are O
static O
throughout O
the O
lifespan O
of O
an O
organism O
, O
DNA B-Chemical
methylomes I-Chemical
are O
dynamic O

This O
chapter O
provides O
a O
broad O
overview O
of O
the O
major O
genomic O
databases O
and O
browsers O
, O
and O
describes O
various O
approaches O
and O
the O
latest O
resources O
for O
searching O
them O

Recently O
, O
interest O
has O
been O
growing O
in O
transferring O
GRS B-Gene
approaches O
to O
DNA B-Chemical
methylation I-Chemical
data O
( O
methylation B-Chemical
risk I-Chemical
scores I-Chemical
, O
MRS B-Gene
) O
, O
which O
can O
be O
used O
1 O
) O
as O
biomarkers O
for O
environmental O
exposures O
, O
2 O
) O
in O
association O

By O
and O
large O
, O
these O
challenges O
have O
been O
successfully O
met O
by O
the O
introduction O
by O
statutes O
such O
as O
the O
Genetic B-Gene
Information I-Gene
Nondiscrimination I-Gene
Act I-Gene
( O
GINA B-Gene
) O

discuss O
available O
evidence O
suggesting O
that O
postnatal O
environmental O
risk O
factors O
contribute O
to O
psychotic B-Disease
disorders I-Disease
via O
epigenetic O
mechanisms O

The O
power O
to O
detect O
between-group O
differences O
in O
methylation O
using O
bisulfite-sequencing O
approaches O
is O
influenced O
by O
both O
experimental O
( O

975Waddington O
is O
usually O
acknowledged O
as O
a O
biologist O
who O
proposed O
a O
more O
subtle O
concept O
of O
environment O
than O
the O
one O
generally O
in O
currency O
during O
the O
rise O
of O
the O
Modern O
Synthesis O

Recent O
attempts O
to O
reconcile O
neo-Darwinism B-Disease
and O
neo-Lamarckism B-Disease
in O
a O
unified O
theory O
of O
molecular O
evolution O
give O
epigenetic B-Gene
mechanisms O
and O
microbiome B-Species
a O
prominent O
role O

Recent O
studies O
demonstrate O
that O
this O
link O
between O
mental B-Disease
health I-Disease
and O
aging O
is O
reflected O
in O
epigenetic O
clocks O
, O
aging O
biomarkers O
based O
on O
DNA B-Chemical
methylation I-Chemical

The O
reproducibility O
of O
childhood B-Disease
trauma I-Disease
DNAm B-Gene
studies O
, O
and O
the O
field O
of O
social O
epigenetics O
in O
general O
, O
may O
be O
improved O
by O
increasing O
sample O
sizes O
, O
standardizing O
variables O
, O
making O
use O
of O
effect O
size O
thresholds O
, O
collecting O
longitudinal O
and O
intervention O
samples O
, O
appropriately O

The O
DNAm O
profiling O
across O
the O
genome O
indicated O
an O
overall O
reduction O
in O
methylation O
in O
HT B-Disease
subjects O
in O
comparison O
with O
their O
healthy O
counterparts O

Williams O
suggests O
that O
multiple O
, O
redundant O
clocks O
might O
influence O
organismal O
aging O

However O
, O
dissection O
of O
the O
embryos B-Species
at O
around O
the O
periimplantation O
stages O
is O
not O
easy O
, O
and O
this O
impedes O
in O
vivo O
analysis O
of O
the O
kinetics O
of O
XCI B-Gene

This O
study O
aims O
to O
investigate O
how O
DNAm O
and O
gene O
expression O
are O
coordinated O
across O
different O
human B-Species
tissues O
and O
developmental O
stages O
, O
as O
well O
as O
the O
biological O
significance O
of O
such O
correlations O

In O
this O
study O
, O
target O
site O
prediction O
tools O
for O
two O
major O
epigenetic O
mechanisms O
comprising O
histone B-Chemical
modification I-Chemical
and O
DNA B-Chemical
methylation I-Chemical
are O
reviewed O

1444 O
Hormones B-Chemical
are O
essential O
regulators O
of O
many O
behaviors O

Recent O
evidence O
suggests O
an O
important O
role O
for O
epigenetic O
regulation O
in O
the O
emergence O
of O
neuropsychiatric B-Disease
disease I-Disease

He O
then O
worked O
for O
2 O
years O
at O
the O
National B-Disease
Heart I-Disease
and I-Disease
Lung I-Disease
Institute I-Disease
of O
the O
NIH O

Here O
, O
we O
introduce O
HopLand O
, O
a O
pseudotime O
recovery O
method O
using O
continuous O
Hopfield B-Gene
network I-Gene
to O
map O
cells O
to O
a O
Waddington's B-Species
epigenetic I-Species
landscape I-Species

As O
expected O
, O
we O
found O
that O
DNA B-Gene
methylomes O
are O
strongly O
associated O
with O
age O
, O
enabling O
the O
construction O
of O
epigenetic O
clocks O

856 O
The O
social O
environment O
plays O
a O
considerable O
role O
in O
determining O
major O
psychiatric B-Disease
disorders I-Disease

We O
construct O
tests O
for O
candidate O
models O
determined O
by O
different O
combinations O
of O
SNPs B-Gene
, O
DNA B-Chemical
methylation I-Chemical
, O
gene B-Gene
expression I-Gene
, O
and O
interactions O
and O
further O
propose O
an O
omnibus O
test O
to O
accommodate O
different O
models O

In O
an O
exploratory O
study O
we O
report O
the O
use O
of O
AI O
and O
epigenomics O
to O
achieve O
important O
objectives O
of O
precision O
cardiovascular B-Disease
medicine I-Disease

In O
this O
opinion O
, O
encompassing O
both O
basic O
and O
clinical O
viewpoints O
, O
we O
focus O
on O
selected O
IEIs O
with O
mutations O
in O
transcription O
factors O
that O
interact O
with O
epigenetic O
enzymes O

Here O
we O
describe O
the O
enzymes O
that O
control O
the O
epigenetic O
state O
of O
the O
cell O
, O
how O
they O
are O
affected O
in O
cancer B-Disease
and O
how O
this O
knowledge O
can O
be O
exploited O
to O
treat O
cancer B-Disease
with O
a O
new O
arsenal O
of O
selective O
therapies O

But O
the O
EWAS B-Gene
software O
has O
lagged O
behind O
compared O
with O
genome-wide B-Gene
association I-Gene
study I-Gene
( O
GWAS B-Gene
) O

The O
recent O
identification O
of O
5-hydroxymethylcytosine B-Chemical
(5hmC) I-Chemical
, O
which O
is O
enriched O
in O
the O
brain B-Disease
( O
tenfold O
over O
peripheral O
tissues O
) O
, O
raises O
new O
questions O
as O
to O
the O
role O
of O
this O
base O
in O
mediating O
epigenetic O
effects O
in O
the O
brain B-Disease

that O

For O
25% O
of O
all O
CpGs B-Gene
we O
observed O
medium O
to O
large O
common O
epigenetic O
variation O

SIGNIFICANCE O
 O
These O
findings O
show O
that O
TBX19 B-Gene
/ O
PRMT1 B-Gene
complex-mediated O
upregulation O
of O
MFF B-Gene
promotes O
mitochondrial O
fission O
and O
tumor-initiating O
capacity O
in O
liver B-Disease
cancer I-Disease
cells O
, O
identifying O
PRMT1 B-Gene
as O
a O
viable O
therapeutic O
target O
in O

( O

HbF O
induction O
even O
by O
stress O
ultimately O
involves O
chromatin O
remodeling O
of O
the O
gene O
for O
HbF O
( O
HBG B-Gene
) O
, O
therefore O
, O
a O
logical O
alternative O
approach O
is O
to O
directly O
inhibit O
epigenetic O
enzymes O
that O
repress O
HBG B-Gene
- O
implicated O
enzymes O
include O
DNA B-Chemical
methyltransferase I-Chemical

Advances O
in O
high-throughput O
technologies O
, O
like O
gene B-Gene
expression I-Gene
profiling O
, O
next-generation O
sequencing O
, O
proteomics O
, O
and O
metabolomics O
, O
have O
enabled O
detailed O
molecular O
characterization O
of O
various O
tumors B-Disease

Several O
lines O
of O
evidence O
garnered O
over O
the O
past O
decades O
suggest O
that O
epigenetic O
alterations O
, O
mostly O
encompassing O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
tail I-Chemical
modifications I-Chemical
, O
and O
generation O
of O
microRNAs B-Gene
, O
play O
an O
important O
, O
though O
still O
incompletely O
explored O
, O
role O
in O

In O
addition O
to O
promoter O
polymorphisms O
, O
epigenetic O
modification O
can O
alter O
downstream O
gene B-Gene
expression I-Gene

One O
method O
that O
permits O
methylome O
analysis O
is O
methylated O
DNA O
immunoprecipitation O
( O
MeDIP O
) O
combined O
with O
next-generation O
sequencing O
( O
MeDIP-seq O
) O

We O
identified O
67,604 O
age-associated O
CpG B-Gene
sites I-Gene
reaching O
genome-wide O
significance O
of O
FWER O
<0 O

We O
then O
discuss O
, O
noting O
the O
general O
themes O
, O
four O
studies O
across O
taxa O
that O
demonstrate O
characteristics O
that O
increase O
the O
inferences O
that O
can O
be O
made O
from O
MS-AFLP B-Chemical
data O
; O
we O
suggest O
that O
future O
MS-AFLP B-Chemical
studies O
should O
incorporate O
these O
methods O
and O
techniques O

Throughout O
this O
cycle O
, O
the O
endometrium O
exhibits O
different O
transcriptional O
networks O
according O
to O
the O
genes B-Gene
expressed O
in O
each O
phase O

Following O
this O
, O
we O
pay O
attention O
to O
key O
discoveries O
in O
the O
field O
of O
epigenetics O
that O
have O
emerged O
from O
the O
study O
of O
unusual O
and O
enigmatic O
phenomena O
in O
plants B-Species


We O
also O
present O
a O
new O
method O
for O
determining O
the O
number O
of O
linear O
terms O
to O
interpret O
as O
cell-mixture O
effects O
and O
demonstrate O
robustness O
to O
the O
choice O
of O
this O
parameter O

e O

miRNAs O
have O
been O
found O
to O
actively O
regulate O
a O
variety O
of O
cellular O
processes O
, O
including O
cell O
proliferation O
, O
death O
, O
and O
metabolism O

For O
BMI O
at O
age O
10 O
years O
, O
the O
association O
was O
gender-specific O

This O
review O
aims O
to O
present O
an O
overview O
of O
current O
epigenetic O
mechanisms O
involved O
in O
the O
pathogenesis O
of O
SLE B-Disease
, O
and O
discuss O
their O
potential O
roles O
in O
clinical O
and O
pharmacological O
applications O

635 O
There O
are O
four O
major O
hypotheses O
( O
H1 O
, O
H2 O
, O
H3 O
, O
and O
H4 O
) O
as O
to O
the O
source O
of O
missing O
heritability O

All O
analyses O
were O
performed O
using O
primary O
alveolar O
macrophages O
from O
human B-Species
subjects O
collected O
via O
bronchoalveolar O
lavage O

We O
describe O
a O
large-scale O
coordinated O
study O
of O
allelic O
and O
non-allelic O
effects O
on O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
mark I-Chemical
deposition I-Chemical
, O
and O
gene B-Gene
expression I-Gene
, O
detecting O
the O
interrelations O
between O
epigenetic O
and O
functional O
features O
at O
unprecedented O
resolution O

While O
a O
number O
of O
reference-based O
deconvolution O
algorithms O
have O
emerged O
, O
their O
potential O
remains O
underexplored O
and O
a O
comparative O
evaluation O
of O
these O
algorithms O
beyond O
tissues O
such O
as O
blood B-Disease
is O
still O
lacking O

It O
is O
currently O
unclear O
to O
what O
extent O
the O
observed O
phenotypic O
heterogeneity O
reflects O
the O
underlying O
molecular O
pathophysiology O
; O
in O
particular O
, O
the O
molecular O
and O
clinical O
diversity O
of O
multilocus O
methylation B-Chemical
defects O
remains O
uncertain O

Cancer O
-induced O
metabolic O
changes O
alter O
the O
epigenetic O
landscape O
, O
especially O
modifications O
on O
histones B-Chemical
and O
DNA B-Chemical
, O
thereby O
promoting O
malignant B-Disease
transformation I-Disease
, O
adaptation O
to O
inadequate O
nutrition O
, O
and O
metastasis B-Disease

However O
, O
in O
the O
last O
20 O
years O
, O
more O
powerful O
and O
affordable O
tools O
to O
interrogate O
the O
genetic O
and O
epigenetic O
determinants O
of O
male B-Disease
infertility I-Disease
have O
accelerated O
the O
number O
of O
new O
discoveries O
in O
the O
characterization O
of O
male B-Disease
infertility I-Disease

02 O
( O
1 O

 O
Assessing O
whether O
epigenetic O
alterations O
mediate O
associations O
between O
environmental O
exposures O
and O
health O
outcomes O
is O
increasingly O
popular O

The O
MLML2R O
package O
is O
freely O
available O
at O
https//CRAN O

Combining O
both O
topics O
, O
epigenetic O
machinery O
plays O
a O
central O
role O
in O
generating O
an O
immunosuppressive O
environment O
for O
cancer B-Disease
growth I-Disease
, O
which O
creates O
a O
barrier O
for O
immunotherapy O
to O
be O
successful O

house-keeping O
genes B-Gene
versus O
differentiation-related O
genes B-Gene

differential O

This O
commingling O
of O
life O
courses O
may O
prove O
problematic O
to O
unravel O
; O
nevertheless O
, O
this O
review O
aims O
to O
consider O
the O
potential O
consequences O
for O
bioarchaeological O
interpretations O

This O
package O
, O
called O
S3V2-IDEAS O
, O
can O
be O
used O
to O
identify O
epigenetic O
states O
for O
multiple O
features O
, O
or O
identify O
discretized O
signal O
intensity O
levels O
and O
a O
master O
peak O
list O
across O
different O
cell O
types O
for O
a O
single O
feature O

Sparse O
multiple O
canonical O
correlation O
analysis O
(SMCCA) O
is O
a O
multivariate O
model O
widely O
used O
to O
extract O
contributing O
features O
from O
each O
data O
while O
maximizing O
the O
cross-modality O
correlation O

1169Pharmacoepigenetics O
is O
an O
emerging O
field O
, O
which O
can O
be O
studied O
by O
several O
approaches O

Because O
experimental O
studies O
using O
extant O
animals O
can O
hardly O
be O
done O
over O
evolutionary O
timescales O
, O
we O
propose O
that O
advances O
in O
ancient O
DNA B-Chemical
techniques O
provide O
a O
valid O
alternative O

We O
suggest O
ways O
through O
which O
epigenetic O
mechanisms O
might O
contribute O
to O
alter O
developmental O
trajectories O
in O
preterm B-Disease
infants I-Disease

They O
can O
bind O
to O
target O
messenger B-Chemical
RNA I-Chemical
(mRNA) I-Chemical
transcripts O
of O
protein-coding O
genes O
and O
negatively O
control O
their O
translation O
or O
cause O
mRNA B-Chemical
degradation O

Despite O
identification O
of O
multiple O
gene B-Gene
loci I-Gene
associated O
with O
AF B-Disease
, O
thus O
far O
none O
has O
led O
to O
a O
therapy O
, O
indicating O
additional O
contributors O
to O
pathology O

Entropy O
increases O
with O
age O

ncbi O

e O

epigenetic O

Using O
a O
recently O
published O
set O
of O
epigenomes O
from O
four O
individual O
donors O
, O
we O
show O
that O
transfer O
learning O
across O
individuals O
allows O
eDICE O
to O
successfully O
predict O
individual-specific O
epigenetic O
variation O
even O
in O
tissues O
that O
are O
unmapped O
in O
a O
given O
donor O

This O
work O
represents O
initial O
steps O
toward O
broadly O
accessible O
integrative O
analysis O
of O
epigenomic O
data O
across O
international O
consortia O

This O
is O
the O
first O
study O
to O
report O
the O
role O
of O
epigenetic O
modification O
of O
SLC6A4 B-Gene
in O
BD B-Disease
using O
an O
unbiased O
approach O
, O
which O
provides O
an O
insight O
for O
its O
pathophysiology O

Discrimination O
is O
assessed O
by O
AUC B-Gene
, O
whilst O
classification O
accuracy O
is O
assessed O
by O
accuracy O
and O
kappa O
, O
derived O
from O
confusion O
matrices O

Herein O
, O
I O
propose O
a O
new O
candidate O
for O
an O
aging O
clock O
, O
based O
on O
epigenetics O
and O
the O
state O
of O
chromosome B-Chemical
methylation I-Chemical
, O
particularly O
in O
stem B-Species
cells I-Species

Such O
meiotic O
epigenetic O
inheritance O
(MEI) O
is O
fairly O
common O
in O
yeast B-Species
, O
plants B-Species
and O
nematodes B-Species
, O
but O
its O
extent O
in O
mammals B-Species
has O
been O
much O
debated O

1296 O
Reversible O
, O
spatial O
, O
and O
temporal O
regulation O
of O
metabolic O
reprogramming O
and O
epigenetic O
homeostasis O
are O
prominent O
hallmarks O
of O
carcinogenesis B-Disease

Given O
the O
recent O
advent O
of O
ChIP-seq O
in O
planarians B-Species
, O
we O
propose O
future O
avenues O
of O
research O
that O
will O
identify O
the O
genomic O
targets O
of O
these O
complexes O
allowing O
for O
a O
clearer O
picture O
of O
how O
neoblast B-Gene
processes O
are O
coordinated O
at O
the O
epigenetic O
level O

His O
research O
focus O
is O
the O
genetics O
and O
epigenetics O
of O
complex O
autoimmune O
and O
inflammatory O
diseases O
, O
including O
lupus B-Disease
and O
systemic B-Disease
vasculitis I-Disease

1143 O
 O
Atherosclerosis B-Disease
is O
a O
pathological O
vascular O
state O
caused O
by O
the O
interaction O
of O
environmental O
and O
hereditary O
factors O

Recent O
findings O
 O
Investigations O
of O
the O
associations O
between O
DNAm O
and O
childhood B-Disease
trauma I-Disease
are O
commonly O
performed O
using O
candidate O
gene O
approaches O
, O
specifically O
involving O
genes O
related O
to O
neurological O
and O
stress O
pathways O

Results O

These O
results O
support O
the O
potential O
of O
our O
targeted O
epigenetic O
clock O
as O
a O
new O
marker O
of O
biological O
age O
and O
open O
its O
evaluation O
in O
large O
cohorts O
to O
further O
promote O
the O
assessment O
of O
biological O
age O
in O
healthcare O
practice O

However O
, O
the O
exact O
etiology O
is O
largely O
unknown O

Epigenetic O
modifications O
of O
the O
genome O
, O
such O
as O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical
, O
have O
been O
reported O
to O
play O
a O
role O
in O
some O
skin B-Disease
diseases I-Disease
or O
cancer B-Disease

The O
development O
of O
chemoresistance B-Disease
involves O
several O
polygenic O
, O
progressive O
mechanisms O
at O
the O
molecular O
and O
cellular O
levels O
, O
as O
well O
as O
both O
genetic O
and O
epigenetic O
heterogeneities O

In O
this O
report O
, O
we O
demonstrate O
a O
simple O
microfluidic O
device O
that O
integrates O
sonication O
and O
immunoprecipitation O
( O
IP O
) O
for O
epigenetic O
assays O
, O
such O
as O
chromatin O
immunoprecipitation O
( O
ChIP O
) O
and O
methylated O
DNA B-Chemical
immunoprecipitation O
( O
MeDIP O
) O

The O
genome-wide O
distribution O
of O
methylation B-Chemical
diversifies O
rapidly O
in O
different O
lineages O
, O
and O
DNA B-Chemical
methylation I-Chemical
is O
lost O
altogether O
surprisingly O
frequently O

Epigenetic O
changes O
( O
DNA B-Gene
methylation I-Gene
, O
histone B-Gene
modifications I-Gene
and O
non-coding B-Gene
RNAs I-Gene
) O
are O
present O
ubiquitously O
in O
virtually O
all O
types O
of O
human B-Species
malignancies B-Disease
and O
may O
appear O
in O
early O
cancer B-Disease
development I-Disease
, O
and O
thus O
they O
provide O
particularly O
attractive O
markers O
with O

, O
physical O
activity O
, O
diet O
, O
and O
smoking O
) O
and O
health-related O
motivation O
from O
the O
perspective O
of O
self-determination O
theory O

The O
techniques O
were O
evaluated O
for O
linearity O
, O
accuracy O
and O
precision O

Due O
to O
its O
complex O
pathogenesis O
, O
the O
treatment O
means O
of O
DR B-Disease
are O
very O
limited O

41 O
% O
and O
sensitivity O
of O
70 O
% O

A O
limited O
number O
of O
studies O
in O
domestic B-Species
animals I-Species
have O
examined O
epigenetic O
transgenerational O
inheritance O
in O
the O
absence O
of O
continued O
exposures O

Published O
evaluation O
tools O
, O
however O
, O
allow O
testing O
for O
predefined O
hypotheses O
only O

As O
an O
example O
, O
we O
discuss O
possible O
rewiring O
effects O
of O
the O
cancer-associated B-Disease
genetic O
, O
structural O
, O
and O
posttranscriptional O
variations O
on O
the O
protein-protein O
interaction O
( O
PPI O
) O
network O
centered O
around O
P53 B-Gene
protein O

Adolescence O
-related O
factors O
and O
environmental O
exposure O
factors O
were O
assessed O
on O
their O
association O
with O
DNA-M B-Gene
changes O

The O
periconception O
period O
and O
early O
embryogenesis O
are O
associated O
with O
widespread O
epigenetic O
remodeling O
, O
which O
can O
be O
influenced O
by O
ART B-Chemical
, O
with O
effects O
on O
the O
developmental O
trajectory O
in O
utero O
, O
and O
potentially O
on O
health O
throughout O
life O

One O
can O
expect O
that O
still O
further O
associations O
will O
emerge O
with O
additional O
aging O
research O
, O
but O
to O
what O
end O
? O
Prediction O
of O
age O
was O
an O
important O
first O
step O
, O
but-in O
our O
view-the O
focus O
must O
shift O
from O
chasing O
increasingly O
accurate O
age O
computations O
to O
understanding O
the O
links O
between O
the O

As O
conserved O
regulatory O
mechanisms O
in O
gene O
expression O
, O
epigenetic O
mechanisms O
participate O
in O
almost O
all O
the O
important O
biological O
processes O
ranging O
from O
basal O
development O
to O
environmental O
response O


Here O
, O
we O
review O
the O
recent O
links O
that O
indicate O
DNA B-Gene
methylation I-Gene
( O
both O
5mC B-Chemical
and O
5hmC B-Chemical
) O
is O
highly O
dynamic O
and O
that O
perturbations O
in O
this O
modification O
may O
contribute O
to O
behaviors O
related O
to O
psychiatric B-Disease
disorders I-Disease
and O
hold O
clinical O
relevance O

Our O
aim O
is O
to O
provide O
researchers O
with O
conceptual O
tools O
to O
sensibly O
design O
their O
studies O
and O
to O
interpret O
their O
results O
in O
the O
admissible O
framework O

Cartilage O
has O
been O
the O
most O
widely O
studied O
tissue O
in O
OA B-Disease
, O
and O
differential O
methylation O
of O
genes O
involved O
in O
inflammation O
, O
cell O
cycle O
, O
TGFÎ² B-Gene
, O
and O
HOX B-Gene
genes O
have O
been O
confirmed O
several O
times O

There O
was O
no O
association O
with O
DNAm-derived O
IL-6 B-Gene
( O
Î² O
= O
0 O

1196 O
In O
recent O
years O
, O
a O
greater O
understanding O
has O
emerged O
of O
the O
role O
epigenetic O
mechanisms O
play O
in O
the O
brain O
, O
not O
only O
during O
development O
, O
but O
also O
in O
mature O
neurons O
involved O
in O
long-term O
memory O

The O
understanding O
of O
these O
modifications O
and O
their O
significance O
in O
the O
management O
of O
BC B-Disease
carcinogenesis O
is O
challenging O
and O
requires O
further O
attention O

Because O
the O
environment O
induces O
epiallelic O
change O
, O
removing O
the O
causative O
factor O
can O
reverse O
a O
context-dependent O
epigenetic O
state O

Early O
diagnosis O
of O
GC B-Disease
is O
critical O
in O
terms O
of O
prognosis O
, O
and O
aberrations O
at O
the O
molecular O
level O
, O
especially O
epigenetic O
alterations O
, O
manifest O
much O
earlier O
than O
histological O
findings O

10 O
) O
discovered O
between O
preterm O
and O
term O
infants O
compared O
to O
the O
<1000 O
prematurity-DM O
sites O
identified O
in O
white B-Species
blood I-Species
cell I-Species
populations O

It O
then O
examines O
examples O
from O
the O
current O
literature O
of O
genomic O
, O
epigenomic O
, O
transcriptomic O
, O
and O
proteomic O
discoveries O
and O
biomarkers O
that O
may O
help O
to O
understand O
risk O
and O
resilience O
in O
the O
aftermath O
of O
trauma B-Disease
, O
predictors O
of O
traumatic B-Disease
exposure I-Disease
risk O
, O
and O
potential O

593 O
Introduction O
Tendon O
is O
a O
composite O
material O
with O
a O
well-ordered O
hierarchical O
structure O
exhibiting O
viscoelastic O
properties O
designed O
to O
transfer O
force O

English-language O
articles O
without O
time O
limits O
were O
retrieved O

This O
chapter O
focuses O
on O
the O
causes O
and O
impact O
of O
DNA B-Gene
hypomethylation I-Gene
in O
the O
development O
of O
cancer B-Disease
and O
describes O
the O
possible O
ways O
to O
pharmacologically O
target O
it O
, O
especially O
by O
using O
a O
naturally O
occurring O
physiologic O
agent O
S-adenosylmethionine B-Chemical
( O
SAM B-Chemical
) O

269 O
 O
Cancer B-Disease
is O
a O
set O
of O
diseases O
that O
exhibit O
not O
only O
genetic O
mutations O
but O
also O
a O
profoundly O
distorted O
epigenetic O
landscape O

522 O
Interindividual O
differences O
in O
expression O
of O
ADME B-Gene
genes I-Gene
are O
controlled O
by O
both O
genetic O
and O
epigenetic O
factors O

Finally O
, O
we O
discuss O
clinical O
implications O
, O
unanswered O
questions O
, O
and O
future O
directions O
for O
human B-Species
development O
in O
epigenetics B-Gene
research O

297 O
Understanding O
pharmacogenetic O
differences O
in O
drug O
response O
and O
tolerability O
has O
been O
an O
important O
area O
of O
research O
in O
personalized O
medicine O
, O
but O
the O
clinical O
utility O
of O
pharmacogenetics O
testing O
has O
not O
been O
established O

This O
pipeline O
is O
very O
simple O
and O
can O
be O
applied O
to O
a O
wide O
variety O
of O
cells O
, O
including O
cancer B-Disease
cells I-Disease

Recent O
large-scale O
genomic O
studies O
have O
shown O
that O
mutations O
in O
players O
of O
the O
epigenetic O
machinery O
and O
concomitant O
perturbation O
of O
epigenomic O
patterning O
are O
frequent O
events O
in O
tumors B-Disease

446 O
 O
Background O
 O
On O
a O
tide O
of O
big O
data O
, O
machine O
learning O
is O
coming O
to O
its O
day O

834 O
The O
rate/quality O
of O
human B-Species
aging O
and O
the O
development/progression O
of O
diseases O
depend O
on O
a O
complex O
interplay O
among O
genetics O
, O
epigenetics O
and O
environment O

The O
original O
implementation O
has O
been O
enhanced O
in O
two O
important O
ways O
 O
we O
introduced O
a O
fast O
, O
variational O
inference O
approach O
that O
enables O
the O
quantification O
of O
Bayesian O
posterior O
confidence O
measures O
on O
the O
model O
, O
and O
we O
adapted O
the O
method O
to O
use O
several O
observation O
models O
, O
making O
it O
suitable O

44 O
 O
Aging B-Disease
is O
associated O
with O
a O
wide O
range O
of O
human O
disorders O
, O
including O
cancer B-Disease
, O
diabetes B-Disease
, O
cardiovascular B-Disease
, O
and O
neurodegenerative B-Disease
diseases I-Disease

Combining O
SNPs O
and O
SMPs O
while O
accounting O
for O
site- O
and O
region-level O
epimutation O
processes O
, O
we O
provide O
new O
estimates O
of O
the O
glacial O
age O
bottleneck O
and O
post-glacial O
population O
expansion O
of O
the O
European B-Species
A I-Species

Conclusions O
 O
These O
results O
support O
a O
hypothesis O
that O
epigenetic O
changes O
, O
specifically O
DNA B-Chemical
methylation I-Chemical
at O
a O
multitude O
of O
gene B-Gene
loci I-Gene
in O
lung B-Species
macrophages I-Species
, O
may O
participate O
, O
at O
least O
in O
part O
, O
in O
driving O
dysfunctional O
innate O
immune O
cells O
in O
the O

Exploring O
neuro-epigenetics O
and O
systems O
pharmacology O
of O
major O
and O
minor O
phytocannabinoid B-Chemical
combinations O
can O
lead O
to O
success O

One O
of O
the O
concerns O
raised O
is O
that O
MZ B-Species
twins O
are O
not O
100% O
genetically O
and O
epigenetically O
similar O
because O
they O
show O
variations O
in O
their O
genomes O
and O
epigenomes O
leading O
to O
inaccurate O
estimates O
of O
heritability O


There O
were O
1535 O
DEG O
and O
6360 O
DMG O
, O
with O
490 O
overlapped O
genes O
, O
whose O
expression O
profiles O
at O
days O
13 O
and O
16 O
resulted O
in O
three O
main O
clusters O

A O
second O
research O
axis O
investigates O
novel O
technologies O
for O
the O
analysis O
of O
mutations O
of O
clinical O
relevance O
present O
at O
very O
low O
proportions O
in O
the O
analyzed O
samples O
and O
their O
impact O
on O
treatment O
management O

The O
efficacy O
of O
these O
cell-based O
interventions O
may O
be O
amplified O
with O
adjunctive O
epigenetic B-Chemical
modifications O

Mollusks O
in O
particular O
, O
are O
a O
large O
group O
of O
invertebrates O
, O
with O
several O
species O
important O
for O
ecosystem O
function O
, O
human O
economy O
and O
health O

Disruptions O
in O
epigenetic O
processes O
can O
lead O
to O
altered O
gene B-Gene
function O
and O
cellular O
neoplastic B-Disease
transformation I-Disease

New O
research O
highlights O
how O
the O
cell O
cycle O
can O
influence O
DNA B-Gene
methylation I-Gene
dynamics O
observed O
during O
male O
gametogenesis O
and O
may O
induce O
epigenetic O
variation O
in O
clonally O
propagated O
plants B-Species

Investigative O
Ophthalmology O
& O
Visual O
Science O
was O
the O
most O
published O
journal O
with O
185 O
articles O
, O
and O
Proceedings O
of O
the O
National O
Academy O
of O
Sciences O
of O
the O
United O
States O
of O
America O
was O
the O
most O
cited O
journal O
, O
with O
8727 O
citations O

ME-Class2 O
further O
illuminated O
how O
synergistic O
changes O
in O
5mC B-Chemical
and O
5hmC B-Chemical
potentially O
contribute O
to O
gene O
silencing O
and O
activation O

Materials O
& O
methods O
 O
Minimally O
adjusted O
epigenome-wide O
association O
studies O
( O
EWAS O
) O
using O
ALSPAC O
data O
were O
performed O
for O
example O
conditions O
, O
dysmenorrhea B-Disease
and O
heavy B-Disease
menstrual I-Disease
bleeding I-Disease
( O
HMB B-Disease
) O

Over O
the O
years O
, O
the O
study O
of O
epigenetic O
processes O
has O
increased O
, O
and O
novel O
therapeutic O
approaches O
have O
emerged O

Whole O
blood O
samples O
for O
DNA B-Chemical
methylation I-Chemical
assay O
were O
obtained O
during O
the O
second O
trimester O
( O
15 O

A O
restricted O
number O
of O
SEMs O
resulted O
to O
be O
shared O
by O
more O
than O
90% O
of O
HCC B-Disease
tumor I-Disease
samples O
and O
never O
present O
in O
peritumoral O
tissue O

In O
other O
behavioral O
experiments O
, O
RVX-208 B-Chemical
treatment O
did O
not O
alter O
distance O
traveled O
, O
anxiety-like O
behavior O
, O
or O
novel O
object O
recognition O
memory O

In O
this O
model O
, O
a O
switch O
in O
the O
vascular O
landscape O
from O
a O
normal O
to O
a O
pro-angiogenic O
signature O
and O
the O
silencing O
of O
region O
mark O
the O
progression O
from O
to O
in O
concert O
with O
the O
acquisition O
by O
the O
latter O
of O
the O
over-expression O
of O
/ O

These O
cumulative O
epigenetic O
alterations O
in O
stem O
cells O
might O
be O
the O
cause O
of O
the O
deregulation O
of O
developmental O
pathways O
seen O
during O
ageing O

We O
used O
epigenome-wide O
DNA O
methylation O
( O
IlluminaHumanMethylation450 O
BeadChip O
) O
in O
cord O
blood O
and O
mid-childhood O
peripheral O
blood O
to O
investigate O
pre- O
and O
post-natal O
methylation O
marks O
associated O
with O
mid-childhood O
( O
age O
6 O

As O
such O
, O
the O
epigenome O
is O
an O
attractive O
candidate O
for O
mediating O
long-term O
responses O
to O
cellular O
stimuli O
, O
such O
as O
environmental O
effects O
modifying O
disease B-Disease
risk I-Disease

Recently O
, O
DNA B-Gene
methylation I-Gene
has O
attracted O
much O
attention O
due O
to O
the O
discovery O
of O
5-hydroxymethyl-cytosine B-Chemical
and O
its O
role O
in O
epigenetic O
reprogramming O
and O
pluripotency O

908 O
Given O
the O
availability O
of O
genomic O
data O
, O
there O
have O
been O
emerging O
interests O
in O
integrating O
multi-platform O
data O

g O

883 O
Inheritance O
of O
biological O
information O
to O
future O
generations O
depends O
on O
the O
replication O
of O
and O
the O
principle O
of O
distribution O
of O

The O
fundamental O
functions O
of O
ChIPseeker O
, O
including O
data O
preparation O
, O
annotation O
, O
comparison O
, O
and O
visualization O
, O
are O
explained O
in O
this O
article O

As O
researchers O
more O
precisely O
define O
the O
epigenetic O
landscape O
that O
regulates O
disease B-Disease
progression I-Disease
in O
each O
of O
these O
cases O
, O
therapeutics O
can O
be O
designed O
to O
specifically O
target O
the O
molecules O
that O
mediate O
these O
epigenetic O
processes O

His O
lab O
currently O
works O
on O
epigenetic O
mechanisms O
of O
gene O
regulation O
in O
cancer B-Disease
and O
other O
diseases B-Disease

Here O
, O
we O
review O
these O
concepts O
and O
discuss O
recent O
results O
based O
on O
next-generation O
sequencing O
( O
NGS O
) O
approaches O
that O
have O
shed O
light O
on O
the O
mechanisms O
that O
underlie O
the O
emergence O
of O
NPDs B-Disease
, O
highlighting O
the O
importance O
of O
epigenetic O
phenomena O

This O
review O
discusses O
current O
evidence O
for O
transgenerational O
epigenetic O
inheritance O
, O
confounding O
issues O
associated O
with O
its O
study O
, O
and O
the O
biological O
relevance O
of O
altered O
epigenetic O
states O
for O
subsequent O
generations O

Finally O
, O
EDCs O
have O
been O
shown O
to O
disrupt O
several O
modulators O
of O
mtDNA B-Gene
methylation O
, O
including O
DNA B-Gene
methyltransferases O
and O
the O
mitochondrial B-Gene
transcription I-Gene
factor I-Gene
A/nuclear I-Gene
respiratory I-Gene
factor I-Gene
1 I-Gene
pathway O

Finally O
, O
recent O
studies O
of O
pharmacological O
inhibitors O
of O
epigenetic O
modifier O
enzymes O
demonstrate O
their O
potential O
applicability O
as O
novel O
treatment O
modalities O
for O
psoriasis B-Disease

, O
disease B-Disease
) O
, O
and O
extrinsic O
( O
e O

Downstream O
bioinformatics O
analyses O
were O
performed O
to O
identify O
correlating O
differentially O
methylated O
CpG O
positions O
( O
DMPs O
) O
and O
differentially O
expressed O
genes O
( O
DEGs O
) O
, O
which O
were O
then O
confirmed O
utilizing O
previously O
published O
promoter O
capture O
Hi-C O
( O
PCHi-C O
) O
data O

Lastly O
, O
we O
pose O
examples O
of O
relevant O
scientific O
questions O
worth O
exploring O

The O
aim O
of O
this O
article O
was O
to O
present O
a O
broad O
perspective O
on O
the O
current O
state O
of O
knowledge O
in O
a O
relatively O
new O
and O
complex O
field O
of O
"attachment O
and O
epigenetic O
processes O

More O
recently O
, O
expression O
and O
epigenetic O
studies O
in O
IBD B-Disease
are O
increasingly O
being O
reported O
, O
and O
have O
shown O
that O
many O
effects O
seem O
to O
be O
highly O
cell-type O
specific O


Mutagen O

Childhood O
abuse O
, O
but O
not O
neglect O
, O
predicted O
faster O
epigenetic O
aging O
; O
results O
did O
not O
differ O
by O
chronic B-Disease
stress I-Disease
status O

Epigenome O
editing O
, O
the O
most O
promising O
derivative O
technology O
of O
genome O
editing O
, O
can O
modify O
the O
epigenetic O
states O
at O
the O
pre-defined O
genomic O
locus O
using O
the O
programmable O
effectors O
, O
consisting O
of O
various O
epigenetic O
factors O
combined O
with O
site-specific O
DNA-binding B-Gene
domains I-Gene

In O
the O
brain O
, O
there O
are O
pathways O
including O
" O
positive O
regulation O
of O
glial B-Species
cell I-Species
differentiation I-Species
" O

We O
found O
that O
a O
multi-layer O
perceptron O
network O
fed O
by O
the O
338 O
probes O
selected O
by O
applying O
both O
expert O
choice O
and O
Boruta O
results O
in O
the O
best O
performance O
, O
achieving O
an O
out-of-sample O
accuracy O
of O
82 O

There O
is O
an O
urgent O
need O
to O
identify O
and O
validate O
the O
specificity O
and O
regulatory O
mechanisms O
of O
inflammatory O
cell O
epigenetics O
in O
depth O

Materials O
& O
methods O
 O
Using O
machine O
learning O
techniques O
and O
datasets O
from O
the O
Framingham B-Disease
Heart I-Disease
Study I-Disease
( O
FHS O
) O
and O
Intermountain B-Disease
Healthcare I-Disease
( O
IM O
) O
, O
we O
developed O
and O
validated O
an O
integrated O
genetic-epigenetic O
model O
for O
predicting O
3-year O
incident O
CHD B-Disease

Advances O
over O
the O
past O
10 O
years O
have O
allowed O
large-scale O
assessment O
of O
one O
epigenetic O
mark O
in O
particular O
, O
DNA B-Chemical
methylation I-Chemical
, O
in O
human B-Species
populations O
, O
and O
the O
examination O
of O
DNA B-Chemical
methylation I-Chemical
is O
becoming O
increasingly O
common O
in O
psychological O
studies O

Conclusions O
 O
EPAT-ChIP O
procedure O
improves O
the O
efficiency O
of O
chromatin O
isolation O
from O
FFPE O
samples O
allowing O
the O
study O
of O
long O
time-fixed O
specimens O
( O
72 O
h O
) O
, O
as O
well O
as O
the O
investigation O
of O
low O
distributed O
epigenetic O
marks O
( O
e O

1174 O
Infectious B-Disease
disease I-Disease
is O
still O
a O
major O
threat O
in O
the O
world O
today O

06 O
; O
95 O
% O
CI O
= O
1 O

Moreover O
, O
targeting O
epigenetic O
reader O
proteins O
, O
such O
as O
bromodomain B-Gene
proteins I-Gene
, O
emerged O
as O
a O
new O
field O
in O
drug O
development O
and O
the O
first O
studies O
underscored O
the O
potential O
of O
these O
drugs O
not O
only O
in O
malignant B-Disease
and O
inflammatory B-Disease
conditions O
but O
also O
in O
autoimmune B-Disease

This O
short O
review O
aims O
at O
summarizing O
the O
role O
of O
epigenetics O
in O
multiple O
aspects O
of O
biology O
and O
medicine O
, O
including O
development O
, O
cancer B-Disease
, O
non-tumoral O
diseases O
, O
environmentally O
induced O
phenotypic O
changes O
, O
and O
also O
in O
inheritance O
and O
evolution O

Here O
, O
we O
describe O
computational O
pipelines O
for O
analysis O
of O
bulk O
mepigenomic O
profiling O
data O
, O
including O
whole-genome O
bisulfite O
sequencing O
( O
WGBS O
) O
to O
detect O
DNA O
methylation O
patterns O
, O
chromatin O
immunoprecipitation-sequencing O
( O
ChIP-seq O
) O
to O
detect O
genomic O
patterns O
of O
either O
specific O
histone O

8 O
to O
7 O

Quality O
assessment O
revealed O
a O
high O
risk O
of O
bias O
in O
domains O
pertaining O
to O
randomization O
, O
allocation O
concealment O
, O
blinding O
of O
outcome O
assessors O
and O
determination O
of O
sample O
size O

33 O
 O
Purpose O
of O
review O
 O

The O
contains O
two O
subdomains O
and O
four O
of O
the O
nine O
factors O
have O
an O
additional O
domain O
, O
the O
( O
) O

However O
, O
the O
epigenome O
and O
metabolome O
are O
both O
highly O
complex O
and O
dynamic O
biological O
networks O
in O
vivo O

Using O
the O
term O
epimutation O
as O
exemplar O
, O
we O
analyze O
the O
paradoxical O
like-but-unlike O
structure O
of O
a O
term O
that O
must O
simultaneously O
connect O
with O
but O
depart O
from O

As O
nutrients O
like O
folic B-Chemical
acid I-Chemical
and O
vitamin B-Chemical
B(12) I-Chemical
can O
influence O
an O
individual's O
epigenome O
, O
especially O
early O
in O
life O
, O
abnormal O
intakes O
of O
such O
agents O
may O
be O
involved O
in O
the O
pathogenesis O
of O
the O
idiopathic B-Disease
mental I-Disease
disorders I-Disease

Several O
whole-epigenome O
profiling O
technologies O
such O
as O
MethylC-seq B-Chemical
reduced O
representation O
bisulfite O
sequencing O
( O
RRBS B-Chemical
) O
and O
the O
Infinium B-Chemical
Human I-Chemical
methylation I-Chemical
450 I-Chemical
K I-Chemical
bead I-Chemical
chip I-Chemical
are O
now O
available O
allowing O
for O
the O
identification O
of O
epigenetic O
drivers O

30 O
 O
Psychosocial O
stress-especially O
when O
chronic O
, O
excessive O
, O
or O
occurring O
early O
in O
life-has O
been O
associated O
with O
accelerated O
aging O
and O
increased O
disease B-Disease
risk O

It O
describes O
nine O
emerging O
areas O
of O
discussion O
, O
relating O
to O
( O
1 O
) O
the O
impact O
of O
epigenetics O
on O
the O
nature O
versus O
nurture O
dualism O
, O
( O
2 O
) O
the O
potential O
resulting O
biologization O
of O
the O
social O
, O
( O
3 O
) O
the O
meaning O
of O
epigenetics O
for O
public O
health O

We O
present O
DGW B-Gene
, O
an O
open O
source O
software O
package O
for O
simultaneous O
alignment O
and O
clustering O
of O
multiple O
epigenomic O
marks O

Emerging O
insights O
from O
cancer B-Disease
genome O
sequencing O
and O
chromatin B-Gene
biology O
have O
identified O
leveraged O
opportunities O
for O
development O
of O
chromatin-directed B-Chemical
small I-Chemical
molecules I-Chemical
as O
cancer B-Disease
therapies O

At O
12 O
months O
of O
age O
, O
blood O
was O
collected O
and O
assayed O
for O
and O
maternally O
reported O
infant O
temperament O
was O
assessed O
using O
the O
Infant O
Behavior O
Questionnaire O
in O
67 O
mother-infant O
dyads O

This O
relationship O
reflects O
plastic O
responses O
made O
by O
the O
developing O
organism O
as O
an O
evolved O
strategy O
to O
cope O
with O
immediate O
or O
predicted O
circumstances O
, O
to O
maximize O
fitness O
in O
the O
context O
of O
the O
range O
of O
environments O
potentially O
faced O

We O
also O
discuss O
how O
the O
combined O
use O
of O
genome O
and O
epigenome O
editing O
tools O
permits O
investigators O
to O
uncover O
novel O
molecular O
pathways O
involved O
in O
the O
pathophysiology O
and O
etiology O
conferred O
by O
risk O
variants O
associated O
with O
aging O
and O
aging-related O
disease B-Disease

Authors O
of O
the O
present O
paper O
review O
recent O
progress O
of O
researches O
on O
acupuncture O
therapy O
in O
resisting O
MI B-Disease
from O
1 O
) O
improving O
cardiovascular O
function O
and O
promoting O
angiogenesis O
, O
and O
2 O
) O
protecting O
myocardial O
cells O
from O
further O
injury O
and O
reducing O
cellular O
apoptosis O
at O
different O
pathological O
stages O

Conclusion O
 O
Identifying O
the O
biological O
processes O
whereby O
the O
negative O
effects O
of O
trauma O
are O
passed O
across O
generations O
and O
defining O
groups O
at O
high O
risk O
is O
a O
key O
step O
to O
breaking O
the O
intergenerational O
transmission O
of O
the O
effects O
of O
mental B-Disease
disorders I-Disease

Focusing O
on O
the O
amygdala O
, O
prefrontal O
cortex O
and O
hippocampus O
, O
we O
review O
studies O
investigating O
the O
epigenetic O
consequences O
of O
adolescent O
ethanol B-Chemical
exposure O

field O

Thus O
, O
the O
DNA B-Chemical
methylation I-Chemical
patterns O
identified O
across O
the O
largest O
spectrum O
of O
samples O
, O
tissues O
, O
and O
diseases B-Disease
reported O
to O
date O
constitute O
a O
baseline O
for O
developing O
higher-resolution O
DNA B-Chemical
methylation I-Chemical
maps O
and O
provide O
important O
clues O
concerning O
the O
contribution O
of O
CpG B-Chemical

The O
GSTM3 B-Gene
expression O
declined O
in O
hydrogen B-Chemical
peroxide-treated I-Chemical
HLE B-Species
cell O
lines O

987 O
Metabolic O
pathways O
must O
be O
adapted O
to O
support O
cell O
processes O
required O
for O
transformation O
and O
cancer B-Disease
progression O

1389 O
 O
Importance O
 O
Although O
scientific O
and O
technological O
discoveries O
have O
improved O
the O
health O
of O
the O
US O
population O
overall O
, O
racial O
and O
ethnic O
minority O
( O
American B-Species
Indian I-Species
and I-Species
Alaska I-Species
Native I-Species
, O
Asian B-Species
, O
Black B-Species
or I-Species
African I-Species
American I-Species
, O
Hispanic B-Species
or I-Species

DNA O
methyltransferases O
are O
crucial O
in O
disease B-Disease
pathogenesis I-Disease
by O
mediating O
methylation O
of O
DNA B-Gene
in O
specific O
promoters O
, O
regulating O
expression O
of O
specific O
pathways O

particularly O

Single O
-trait O
genetic O
analyses O
were O
performed O
using O
mixed O
models O
with O
random O
epigenetic O
effects O

Although O
important O
methodological O
advances O
have O
been O
conducted O
in O
the O
previous O
years O
, O
key O
challenges O
such O
as O
the O
development O
of O
sensitivity O
analyses O
, O
dealing O
with O
mediator-mediator O
interactions O
, O
including O
environmental O
mixtures O
as O
exposures O
, O
or O
the O
integration O
of O
different O
omic O
data O
should O
be O
the O
focus O
of O

721 O
( O
) O
overwrites O
information O
about O
multiple O
extrinsic O
factors O
on O
the O
genome O

Strikingly O
, O
they O
are O
plastic O
and O
respond O
to O
environmental O
signals O
, O
including O
diet O

genome O

It O
is O
increasingly O
recognised O
that O
the O
study O
of O
DNA B-Gene
methylation I-Gene
(DNAm) B-Gene
patterns O
along O
the O
genome O
- O
so-called O
'epialleles' O
- O
offers O
greater O
insight O
into O
epigenetic O
dynamics O
than O
conventional O
analyses O
which O
examine O
DNAm B-Gene
marks O
individually O

Integrating O
various O
components O
of O
the O
epigenome O
into O
multi-omics O
measurements O
allows O
for O
studying O
cellular O
heterogeneity O
at O
different O
time O
scales O
and O
for O
discovering O
new O
layers O
of O
molecular O
connectivity O
between O
the O
genome O
and O
its O
functional O
output O

Here O
, O
we O
discuss O
the O
impact O
of O
pathogen-induced O
DNA B-Chemical
methylation I-Chemical
modifications O
on O
a O
host O
's O
transcriptome O
reprogramming O
and O
genome O
stability O
, O
as O
part O
of O
the O
plant B-Species
's O
defense O
mechanisms O

Epigenetic O
alterations O
can O
significantly O
impact O
the O
expression O
and O
function O
of O
these O
critical O
genes O
, O
contributing O
to O
the O
initiation O
and O
progression O
of O
cancer B-Disease

We O
generated O
deep O
epigenomes O
comprising O
genome-wide O
profiles O
of O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
DNA B-Chemical
accessibility I-Chemical
, O
and O
coding O
and O
non-coding O
RNA B-Chemical
expression O
in O
naive O
, O
central- O
, O
effector- O
, O
and O
terminally O
differentiated O
CD45RA+ B-Gene

Maternal O
nutrient O
status O
can O
cause O
epigenetic O
alterations O
to O
the O
genome O
of O
the O
developing O
fetus O
, O
which O
potentially O
can O
impact O
future O
generations O

23 O
, O
p O
= O

The O
epigenome O
is O
sensitive O
to O
metabolic O
changes O

gov O

Mapping O
the O
gene B-Gene
regulatory O
networks O
(GRNs) O
underlying O
cell O
states O
provides O
attractive O
opportunities O
to O
mechanistically O
understand O
this O
heterogeneity O

In O
addition O
, O
we O
propose O
a O
specific O
pipeline O
to O
accurately O
perform O
these O
studies O

It O
is O
of O
great O
significance O
to O
study O
its O
pathogenesis O
and O
targeted O
therapy O

The O
effect O
of O
ascorbate B-Chemical
is O
unique O
as O
other O
antioxidants O
failed O
to O
promote O
plasma O
cell O
differentiation O

310 O
The O
universality O
of O
DNA B-Chemical
methylation I-Chemical
as O
an O
epigenetic O
regulatory O
mechanism O
belongs O
to O
all O
biological O
kingdoms O

1132 O
Given O
the O
tissue-specific O
nature O
of O
epigenetic O
processes O
, O
the O
assessment O
of O
disease-relevant B-Disease
tissue O
is O
an O
important O
consideration O
for O
epigenome-wide O
association O
studies O
( O
EWAS O
) O

It O
demonstrates O
that O
health O
cannot O
be O
understood O
in O
terms O
of O
immediate O
environmental O
circumstances O
alone O

We O
conclude O
that O
multifaceted O
studies O
of O
GSE B-Gene
based O
on O
theories O
of O
personality O
development O
should O
be O
undertaken O

infant O

In O
particular O
, O
epigenetics O
links O
developmental O
biology O
and O
genetics O
, O
as O
well O
as O
many O
other O
areas O
of O
knowledge O

These O
processes O
are O
controlled O
by O
a O
fine-tuned O
chemical B-Chemical
cross I-Chemical
talk I-Chemical
between O
the O
host O
and O
microbiota B-Species

Users O
need O
to O
upload O
sets O
of O
selected O
and O
background O
regions O

The O
cumulative O
DNA B-Gene
damage O
theory O
of O
aging O
postulates O
that O
as O
an O
animal O
ages O
, O
toxic O
reactive O
oxygen B-Chemical
species O
generated O
as O
byproducts O
of O
the O
mitochondria O
during O
respiration O
induce O
a O
random O
and O
progressive O
damage O
in O
genes O
thus O
leading O
cells O
to O
a O
progressive O
functional O
decline O

461 O
In O
this O
article O
, O
we O
outline O
the O
two O
dominant O
concepts O
of O
personalized O
medicine O
put O
forward O
by O
epigenetics B-Gene
in O
the O
field O
of O
oncology B-Disease

The O
identification O
of O
epigenetic O
marks O
that O
are O
transmitted O
to O
the O
next O
generations O
is O
of O
primary O
importance O
for O
their O
use O
in O
breeding O
and O
for O
the O
development O
of O
new O
cultivars O
with O
a O
broad-spectrum O
of O
tolerance/resistance O
to O
abiotic O
and O
biotic O
stresses O

In O
this O
context O
, O
epitranscriptomic O
modifications O
offer O
a O
novel O
and O
promising O
therapeutic O
avenue O
, O
based O
on O
the O
fineâtuning O
of O
regulatory O
cascades O
, O
necessary O
for O
cardiac O
function O

In O
this O
regard O
, O
epigenetics O
represents O
a O
great O
opportunity O
for O
the O
integration O
of O
public O
policy O
measures O
aimed O
to O
create O
healthier O
living O
environments O

These O
differences O
disappeared O
when O
comparing O
delayed O
processed O
cells O
due O
to O
a O
drastic O
change O
in O
expression O
levels O
of O
atopy-related B-Disease
genes O
in O
delayed O
processed O
CD4+ O
T-cells O
from O
atopic B-Disease
donors O

922 O
Azusa O
Inoue O
is O
a O
Team O
Leader O
at O
RIKEN O
Center O
for O
Integrative O
Medical O
Sciences O
( O
IMS O
) O
in O
Japan O

By O
using O
these O
patterns O
, O
the O
emergence O
of O
diseases B-Disease
could O
be O
prognosticated O

To O
bridge O
this O
gap O
, O
we O
introduce O
ViCAR O
( O
viewpoint O
HiCAR O
) O
, O
for O
the O
direct O
antibody-based O
capture O
of O
chromatin O
interactions O
at O
folded O
G4s B-Gene

Epigenetics O
is O
the O
study O
of O
heritable O
changes O
in O
gene B-Gene
expression I-Gene
independent O
of O
underlying O
DNA B-Chemical
( O
DeoxyriboNucleic B-Chemical
Acid I-Chemical
) O
sequence O
, O
which O
not O
only O
affect O
this O
generation O
but O
will O
be O
passed O
to O
subsequent O
generations O

D O

1358 O
Tremendous O
advances O
in O
Next O
Generation O
Sequencing O
( O
NGS O
) O
and O
high-throughput O
omics O
methods O
have O
brought O
us O
one O
step O
closer O
towards O
mechanistic O
understanding O
of O
the O
complex B-Disease
disease I-Disease
at O
the O
molecular O
level O

To O
extend O
a O
healthy O
lifespan O
and O
possibly O
reverse O
some O
facets O
of O
aging O
and O
aging-related O
diseases O
, O
it O
will O
be O
crucial O
to O
comprehend O
global O
and O
locus-specific O
epigenomic O
modifications O
and O
recognize O
corresponding O
regulators O
of O
health O
and O
longevity O

484 O
 O
Methylation B-Chemical
induces O
epigenetic O
silencing O
of O
tumor B-Disease
suppressor I-Disease
genes O
in O
human B-Species
lung I-Species
cancer I-Disease

Indeed O
, O
microbes O
within O
the O
human O
gut O
may O
play O
a O
significant O
role O
in O
the O
regulation O
of O
various O
elements O
of O
" O
gut-brain O
axis O
" O
, O
via O
their O
influence O
on O
inflammatory O
cytokines O
and O
production O
of O
antimicrobial O
peptides O
that O
affect O
the O
epigenome O
through O
their O
involvement O
in O
generating O

Moreover O
, O
we O
show O
why O
germline O
EE B-Gene
is O
not O
effective O
and O
reject O
the O
position O
of O
strong O
epigenetic O
determinism O

Currently O
, O
available O
therapies O
provide O
only O
symptomatic O
relief O
and O
unable O
to O
treat O
the O
underlying O
pathophysiology O
of O
diabetic B-Disease
nephropathy I-Disease

This O
study O
evaluates O
the O
epigenetic O
impact O
of O
preterm B-Disease
birth I-Disease
in O
isolated O
hematopoietic O
cell O
populations O
, O
reducing O
the O
concern O
of O
cell O
composition O
differences O

approach O

Global O
alterations O
to O
the O
DNA B-Chemical
methylation I-Chemical
landscape O
contribute O
to O
alterations O
in O
the O
transcriptome O
and O
deregulation O
of O
cellular O
pathways O

444 O
In O
1961 O
, O
Jacob B-Gene
and O
Monod I-Gene
proposed O
the O
operon O
model O
of O
gene O
regulation O

Using O
this O
method O
, O
we O
analyzed O
chromatin B-Chemical
immunoprecipitation I-Chemical
( O
ChIP B-Chemical
) O
- O
and O
RNA B-Chemical
- I-Chemical
sequencing I-Chemical
data O
from O
the O
nucleus B-Species
accumbens I-Species
( O
NAc B-Species
) O
of O
the O
same O
animal O

004 O
), O
negatively O
associated O
with O
smoking O
( O
Î² O
= O
- O

15 O
( O
SD O
2 O

Some O
basic O
approaches O
to O
the O
study O
of O
epigenetics B-Gene
are O
reviewed O

These O
results O
highlight O
a O
great O
need O
for O
the O
inclusion O
of O
the O
proteomic O
characterization O
of O
epigenetic O
mechanisms O
in O
the O
study O
of O
gene/disease O
associations O
in O
psychiatric B-Disease
disorders I-Disease

Finally O
, O
we O
discuss O
how O
fundamental O
insights O
gained O
by O
NGS O
, O
particularly O
the O
discovery O
of O
widespread O
allele-specific O
epigenetic O
variation O
in O
the O
human B-Species
genome O
, O
have O
the O
potential O
to O
significantly O
contribute O
to O
the O
understanding O
of O
human B-Species
common O
complex O
diseases B-Disease

409 O
The O
past O
decade O
of O
life O
sciences O
research O
has O
been O
driven O
by O
progress O
in O
genomics O

More O
specifically O
, O
I O
present O
a O
protocol O
based O
on O
an O
adaptation O
of O
the O
CIBERSORT B-Gene
algorithm I-Gene
, O
previously O
developed O
for O
gene-expression O
, O
to O
methylation O
data O

We O
first O
prioritised O
genes O
based O
on O
coding O
consequences O
, O
multilayer O
molecular O
associations O
, O
blood B-Disease
pressure-associated I-Disease
expression O
levels O
, O
and O
coregulation O
evidence O

Embodiment O
means O
that O
biological O
, O
psychological O
, O
and O
behavioral O
attributes O
of O
the O
person O
, O
in O
fusion O
with O
the O
contexts O
of O
human O
development O
, O
have O
a O
temporal O
parameter O

What O
prompted O
Akenside O
to O
take O
such O
a O
bold O
step O
? O
Faced O
with O
a O
scarcity O
of O
biographical O
sources O
, O
Akenside O
's O
major O
poem O
on O
The O
Pleasures O
of O
Imagination O
( O
1744 O
) O
suggests O
how O
the O
poet O
had O
been O
thinking O
about O
reproductive O
processes O
in O
innovative O
contexts O
and O

894 O
The O
reprogramming O
of O
human B-Species
induced I-Species
pluripotent I-Species
stem I-Species
cells I-Species
( O
hiPSCs B-Species
) O
proceeds O
in O
a O
stepwise O
manner O
with O
reprogramming O
factors O
binding O
and O
epigenetic O
composition O
changes O
during O
transition O
to O
maintain O
the O
epigenetic O
landscape O
, O
important O
for O
pluripotency O

We O
developed O
an O
R/Bioconductor O
package O
, O
epihet O
, O
to O
calculate O
the O
intra-tumoral B-Disease
epigenetic O
heterogeneity O
and O
to O
perform O
differential O
epigenetic O
heterogeneity O
analysis O

Our O
results O
suggest O
that O
there O
is O
variation O
in O
DNA B-Gene
methylation I-Gene
associated O
with O
suicide B-Disease
attempt I-Disease
that O
may O
offer O
novel O
highlights O
into O
the O
molecular O
mechanisms O
linked O
to O
suicide B-Disease
attempt I-Disease
associated O
with O
schizophrenia B-Disease

He O
has O
authored O
or O
coauthored O
more O
than O
370 O
publications O

Conclusions O
 O
Our O
comprehensive O
computational O
analysis O
helps O
the O
CRISPR-Cas9 B-Gene
community O
better O
understand O
the O
relationship O
between O
epigenetic O
features O
and O
CRISPR-Cas9 B-Gene
off-target O
activity O

A O
research O
agenda O
to O
definitively O
establish O
the O
relationship O
between O
biomarkers O
of O
ageing O
and O
ocular O
parameters O
is O
proposed O

01 O
)-year O
decrease O
in O
GrimAge B-Gene
acceleration O

Neither O
concept O
has O
yet O
identified O
a O
specific O
mechanism O
to O
explain O
aging's O
emergence O
and O
acceleration O
during O
mid-life O
and O
beyond O

Using O
ChIP-seq O
on O
mini-INTACT O
purified O
dopaminergic O
nuclei O
, O
we O
identified O
epigenetic O
signatures O
in O
socially O
isolated O
and O
socially O
enriched O
Drosophila B-Species
males O

Major O
challenges O
include O
how O
to O
determine O
the O
clinical O
validity O
and O
actionability O
of O
epigenetic O
results O
, O
and O
considerations O
related O
to O
environmental O
exposures O
and O
epigenetic O
marks O
, O
including O
circumstances O
warranting O
the O
sharing O
of O
results O
with O
family O
members O
and O
third O
parties O

Conclusions O
 O
This O
year O
few O
studies O
have O
identified O
new O
genetic O
variants O
contributing O
to O
OA B-Disease
susceptibility O
, O
but O
a O
focus O
has O
been O
on O
refining O
risk O
loci O
or O
their O
functional O
validation O

Although O
the O
molecular O
mechanisms O
responsible O
for O
the O
etiology O
of O
most O
diseases O
are O
unknown O
, O
there O
is O
evidence O
of O
both O
genetic O
and O
environmental O
factors O
that O
could O
influence O
this O
development O

We O
followed-up O
our O
statistical O
analyses O
with O
a O
literature O
review O
in O
order O
to O
inform O
the O
proposed O
disease B-Disease
implications I-Disease
for O
the O
loci O
we O
uncovered O

Other O
steps O
have O
also O
been O
adapted O
from O
existing O
techniques O
to O
optimize O
their O
use O
for O
PAT-ChIP-seq B-Chemical


The O
high O
dependence O
on O
tissues O
with O
epigenetic O
marks O
compels O
scientists O
to O
refine O
their O
sampling O
procedures O
, O
and O
in O
this O
review O
, O
we O
will O
focus O
on O
findings O
obtained O
from O
brain O
tissue O

Methods O
 O
In O
a O
subsets O
( O
ASSET O
) O
meta-analytic O
approach O
, O
we O
investigated O
associations O
of O
genetic O
variants O
related O
to O
epigenetic O
mechanisms O
with O
risks O
of O
breast B-Disease
, O
lung B-Disease
, O
colorectal B-Disease
, O
ovarian B-Disease
and O
prostate B-Disease
carcinomas I-Disease
using O
51,724 O
cases O
and O

Given O
its O
medical O
utility O
, O
in O
recent O
years O
it O
has O
become O
apparent O
that O
there O
is O
a O
need O
to O
develop O
methods O
for O
the O
analysis O
of O
DNA B-Gene
methylation O
using O
different O
approaches O
 O
global O
, O
locus-specific O
, O
or O
genome-wide O

This O
emerging O
field O
has O
revolutionized O
our O
understanding O
of O
epigenetics O
in O
IgA B-Disease
nephropathy I-Disease
research O

Population O
health O
represents O
a O
unifying O
paradigm O
for O
understanding O
systematic O
variations O
in O
health O
and O
related O
factors O
, O
informing O
integrated O
action O
, O
and O
reducing O
health O
disparities O

post-traumatic B-Disease

Emphasis O
is O
given O
in O
this O
article O
, O
through O
the O
use O
of O
case O
studies O
, O
to O
socially O
disadvantaged O
communities O
that O
are O
often O
under-represented O
in O
scientific O
literature O

In O
this O
chapter O
we O
discuss O
the O
methods O
available O
and O
provide O
a O
protocol O
to O
quantify O
DNA B-Chemical
methylation I-Chemical
status O
of O
CpG B-Gene
sites I-Gene
in O
candidate O
genes O
, O
which O
can O
readily O
be O
applied O
to O
most O
pharmacogenetics O
laboratories O

Yet O
while O
memories O
may O
last O
a O
lifetime O
, O
neurons O
are O
dynamic O
structures O

The O
covalent O
modifications O
of O
chromatin O
, O
which O
include O
methylation O
and O
acetylation O
, O
on O
DNA B-Gene
nucleotide O
bases O
, O
histone B-Gene
proteins O
and O
RNA B-Gene
are O
derived O
from O
intermediates O
of O
one-carbon B-Chemical
metabolism O
and O
central O
metabolism O

This O
is O
particularly O
relevant O
in O
the O
plant B-Species
kingdom O
, O
where O
most O
species O
are O
sessile O
and O
exposed O
to O
increasing O
habitat O
fluctuations O
due O
to O
global O
warming O

Taking O
the O
example O
of O
the O
epigenetics O
of O
cardiovascular B-Disease
diseases I-Disease
, O
this O
paper O
illustrates O
how O
common O
understandings O
of O
epigenetic O
biomarkers O
strongly O
lean O
toward O
considering O
them O
as O
mere O
targets O
for O
molecular O
intervention O
, O
rather O
than O
as O
correlates O
of O
a O
complex O
biological O
and O
social O

We O
critically O
evaluate O
current O
knowledge O
on O
causal O
epigenetic O
aberrations O
and O
examine O
to O
what O
extent O
the O
prioritization O
of O
(epi)genetic O
deregulations O
can O
be O
assessed O
in O
cancer B-Disease
as O
some O
type O
of O
genetic O
lesion O
characterizing O
solid O
cancer B-Disease
progression O

Ultimately O
this O
critical O
appraisal O
could O
lead O
to O
a O
reconfiguration O
of O
research O
and O
health O
services O
agendas O
, O
towards O
more O
equitable O
responsibilities O
across O
genders O
for O
preventing O
obesity B-Disease

Since O
arsenic B-Chemical
is O
non-mutagenic O
, O
the O
mechanism O
by O
which O
arsenic B-Chemical
causes O
carcinogenesis B-Disease
is O
via O
alterations O
in O
epigenetic-regulated O
gene B-Gene
expression O

541 O
Epigenetic O
clocks O
, O
developed O
using O
DNA B-Chemical
methylation I-Chemical
data O
, O
have O
been O
widely O
used O
to O
quantify O
biological O
aging O
in O
multiple O
tissues/cells O

To O
resolve O
the O
limitation O
and O
to O
offer O
an O
easily O
accessible O
solution O
for O
researchers O
, O
we O
developed O
methylR B-Gene
a O
graphical O
tool O
that O
can O
analyze O
not O
only O
the O
raw O
data O
but O
also O
performs O
different O
downstream O
analyses O
with O
a O
few O
mouse O
clicks O

After O
the O
proposal O
of O
the O
histone B-Chemical
code O
in O
the O
2000s O
, O
alterations O
of O
histone B-Chemical
methylation I-Chemical
were O
also O
identified O
in O
cancers B-Disease

This O
problem O
can O
be O
alleviated O
by O
chromatin-based O
approaches O
due O
to O
a O
correlation O
between O
modifications O
and O
transcription O

We O
summarize O
these O
novel O
findings O
in O
pediatric O
brain B-Disease
tumors I-Disease
, O
which O
also O
are O
put O
in O
the O
context O
of O
the O
evolving O
notion O
of O
molecular O
pathology O
, O
now O
a O
mandated O
tool O
for O
proper O
classification O
and O
therapy O
assignment O
in O
the O
clinical O
setting O

This O
review O
summarizes O
epigenetic O
mechanisms O
identified O
in O
ageing O
healthy O
tendon B-Species

The O
study O
of O
epigenetics O
in O
Plasmodium B-Species
falciparum I-Species
started O
to O
flourish O
in O
recent O
years O
due O
to O
improvement O
of O
genomic O
technologies O

tumorigenesis B-Disease

This O
data O
can O
be O
used O
to O
design O
drugs O
against O
diseases O
linked O
to O
epigenetic O
modifications O

However O
, O
interactions O
between O
diet O
and O
the O
epigenome O
continue O
throughout O
life O
and O
likely O
contribute O
to O
the O
onset O
and O
progression O
of O
various O
complex O
diseases B-Disease

Computer O
-aided O
drug O
design O
techniques O
( O
CADD B-Chemical
) O
encompass O
a O
large O
variety O
of O
methods O
which O
are O
subdivided O
into O
structure O
- O
based O
( O
SBDD B-Chemical
) O
and O
ligand O
- O
based O
drug O
design O
( O
LBDD B-Chemical
) O
methods O

Therefore O
, O
preventive O
and O
preemptive O
medicine O
is O
possible O
for O
disorders O
caused O
by O
alterations O
in O
programming O
during O
fetal O
and O
early O
periods O

In O
this O
issue O
of O
Developmental O
Cell O
, O
Wang O
and O
colleagues O
( O
2019 O
) O
employed O
transcriptomic O
and O
epigenomic O
profiling O
to O
explore O
how O
Uhrf1 B-Gene
, O
an O
epigenetic O
regulator O
of O
DNA B-Chemical
methylation I-Chemical
, O
functions O
in O
liver B-Disease
regeneration I-Disease
using O
a O
mouse B-Species
model O

Targeted O
methylation O
polymerase B-Gene
chain I-Gene
reaction I-Gene
(PCR)-based O
analyses O
are O
among O
the O
most O
universal O
and O
commonly O
used O
techniques O
in O
research O

The O
major O
contributing O
countries O
were O
the O
China B-Species
( O
522 O
, O
28 O

In O
this O
chapter O
, O
we O
attempt O
to O
discuss O
the O
mechanisms O
underpinning O
the O
metabolic O
and O
epigenetic O
interplay O
in O
immune O
cells O
of O
the O
TME B-Disease
and O
how O
modulating O
these O
events O
can O
boost O
the O
application O
of O
existing O
anticancer B-Chemical
immunotherapy I-Chemical

The O
reversal O
of O
DNA B-Gene
methylation O
, O
or O
DNA B-Gene
demethylation O
, O
is O
mediated O
by O
the O
ten-eleven B-Gene
translocation I-Gene
( O
TET B-Gene
) O
protein O
family O
of O
dioxygenases O

7 O
cell O
line O
to O
examine O
the O
effect O
of O
three O
environmental O
stressors O
( O
UV B-Chemical
radiation I-Chemical
, O
Hypoxia B-Disease
and O
fasting O
) O
on O
their O
expression O

This O
review O
highlights O
recent O
advances O
in O
locus-specific O
and O
whole-genome O
analysis O
of O
, O
with O
a O
specific O
focus O
on O
epigenetic O
phenomena O
and O
their O
clinical O
value O

Moreover O
, O
impaired O
DNA B-Gene
methylation O
on O
the O
inactive O
X-chromosome B-Gene
was O
suggested O
to O
explain O
, O
at O
least O
in O
part O
, O
the O
female O
prevalence O
of O
the O
disease B-Disease

We O
applied O
our O
CHO B-Species
- I-Species
specific O
CpG B-Gene
island I-Gene
microarray O
to O
investigate O
the O
effect O
of O
butyrate B-Chemical
treatment O
on O
differential O
DNA B-Gene
methylation I-Gene
in O
CHO B-Species
cultures O
in O
a O
time-dependent O
approach O

Expert O
opinion O
 O
Knowledge O
of O
the O
mechanisms O
by O
which O
epigenetic O
modifications O
participate O
in O
complex B-Disease
disorders I-Disease
would O
not O
only O
help O
scientists O
find O
novel O
therapeutic O
strategies O
but O
could O
also O
aid O
in O
implementing O
preventive O
care O
measures O
at O
gestation O

In O
particular O
, O
starting O
with O
low-input O
DNA B-Chemical
can O
result O
in O
low-diversity O
libraries O

It O
calculates O
an O
ASM B-Gene
score O
for O
all O
CpG B-Gene
sites O
or O
pairs O
in O
the O
genome O
of O
each O
sample O
, O
and O
then O
quantifies O
the O
change O
in O
ASM B-Gene
between O
conditions O

Identifying O
differential O
methylations O
can O
help O
to O
study O
genomic O
regions O
associated O
with O
diseases B-Disease

We O
observed O
significant O
tissue O
overlap O
in O
the O
genes B-Gene
mapping O
to O
differentially O
methylated O
cytosines O

The O
meeting O
was O
centered O
on O
the O
contribution O
of O
epigenetics O
to O
gene B-Gene
expression O
, O
DNA B-Gene
damage O
and O
repair O
, O
and O
the O
role O
of O
environmental O
factors O

660 O
Environmental O
research O
and O
public O
health O
in O
the O
21st O
century O
face O
serious O
challenges O
such O
as O
increased O
air O
pollution O
and O
global O
warming O
, O
widespread O
use O
of O
potentially O
harmful O
chemicals O
including O
pesticides B-Chemical
, O
plasticizers B-Chemical
, O
and O
other O
endocrine O
disruptors O
, O
and O
radical O
changes O

The O
emergence O
of O
single-cell O
epigenomic O
technologies O
has O
introduced O
the O
exciting O
possibility O
of O
linking O
genetic O
and O
transcriptional O
heterogeneity O
in O
the O
context O
of O
cancer B-Disease
biology O

The O
use O
of O
personalized O
medicine O
approaches O
in O
psychiatry B-Disease
is O
underdeveloped O
, O
but O
has O
a O
profound O
potential O
for O
improving O
prevention O
and O
treatment O

Furthermore O
, O
constant O
epigenetic O
changes O
due O
to O
hyper O
or O
hypomethylation O
could O
efficiently O
serve O
as O
effective O
biomarkers O
of O
cancer B-Disease
diagnosis O
and O
therapeutic O
development O

After O
identifying O
some O
important O
conceptual O
and O
methodological O
flaws O
in O
their O
argument O
, O
we O
report O
the O
results O
of O
a O
series O
of O
reanalyses O
of O
their O
dataset O

org/ O

org O
/ O
packages O
/ O
ChIPseeker O

These O
growth O
disorders O
are O
caused O
by O
abnormal O
DNA B-Chemical
methylation I-Chemical
in O
the O
11p15 O
imprinted O
region O
encompassing O
many O
imprinted O
genes O
, O
such O
as O
IGF2 B-Gene

The O
focus O
of O
this O
chapter O
is O
to O
provide O
the O
methodologies O
that O
have O
been O
developed O
to O
detect O
the O
in O
the O
genomic O
DNA B-Gene

773 O
The O
management O
of O
radioiodine B-Chemical
refractory I-Chemical
thyroid B-Disease
cancers I-Disease
( O
RAIR B-Disease
TC I-Disease
) O
is O
challenging O
for O
the O
clinician O

A O
multiplicity O
of O
genes O
was O
shown O
to O
be O
differentially O
expressed O
in O
immediately O
processed O
CD4+ O
T-cells O
from O
atopic B-Disease
versus O
healthy O
subjects O

his O

This O
indicates O
that O
epigenetic O
age O
deviations O
associate O
with O
distinct O
, O
tissue O
specific O
, O
factors O
during O
the O
gestational B-Disease
and I-Disease
perinatal I-Disease
period O

A O
number O
of O
different O
quantitative O
approaches O
have O
also O
been O
established O
to O
map O
the O
DNA B-Gene
epigenomes O
with O
single-base O
resolution O
, O
as O
represented O
by O
the O
bisulfite-based B-Chemical
methods O
, O
such O
as O
classical O
bisulfite B-Chemical
sequencing O
, O
pyrosequencing O
etc O

DNA O
methylation O
was O
measured O
in O
21 O
human B-Species
cartilage O
samples O
using O
the O
both O
450K B-Chemical
and O
EPIC B-Chemical
arrays O

in O
J O
Autoimmun O
8351-61 O
, O
2017 O
) O
, O
providing O
novel O
therapeutic O
potential O
as O
novel O
treatment O
targets O
for O
psoriasis B-Disease

Advancements O
in O
genome-wide O
sequencing O
has O
broadened O
the O
view O
of O
the O
human B-Species
methylome O
and O
revealed O
the O
organization O
of O
the O
human B-Species
genome O
into O
large-scale O
methylation O
domains O
that O
footprint O
over O
neurologically O
important O
genes B-Gene
involved O
in O
embryonic O
development O

Â© O
2016 O
AACR O

Here O
we O
describe O
a O
novel O
approach O
, O
sciPlex-ATAC-seq O
, O
which O
uses O
unmodified B-Chemical
DNA B-Chemical
oligos I-Chemical
as O
sample-specific O
nuclear O
labels O
, O
enabling O
the O
concurrent O
profiling O
of O
chromatin O
accessibility O
within O
single O
nuclei O
from O
virtually O
unlimited O
specimens O
or O
experimental O
conditions O

4 O
mmol/L B-Chemical

We O
summarise O
this O
progress O
and O
highlight O
resulting O
key O
findings O
about O
the O
complexity O
of O
eukaryotic B-Species
DNA B-Gene
methylation I-Gene
, O
its O
role O
in O
metazoan B-Species
genome O
evolution O
, O
epigenetic O
reprogramming O
, O
and O
its O
close O
ties O
with O
histone B-Chemical
modifications I-Chemical
in O
the O
context O
of O

Conclusions O
 O
Whilst O
the O
reported O
metadata O
provides O
useful O
insight O
into O
the O
plausible O
involvement O
of O
epigenetic O
glitches O
in O
leukemogensis B-Disease
, O
our O
findings O
strengthen O
the O
remarkable O
functional O
consequences O
of O
dysregulated O
Wnt B-Gene
signaling I-Gene
genes I-Gene
in O
the O
hematological B-Disease
malignancies I-Disease
besides O

This O
review O
aims O
to O
analyze O
the O
epigenetic O
alterations O
putatively O
induced O
by O
chemical O
exposures O
and O
involved O
in O
the O
onset O
of O
frequent O
thyroid O
diseases O
such O
as O
thyroid B-Disease
cancer I-Disease
, O
autoimmune B-Disease
thyroiditis I-Disease
and O
disruption O
of O
fetal O
thyroid O
homeostasis O

001 O
) O
higher O
average O
in O
GrimAge B-Chemical
acceleration O
( O
GAA O
) O
using O
generalized O
estimating O
equations O
, O
respectively O

Chromatin O
-associated O
marks O
are O
informative O
to O
uncover O
altered O
regulatory O
regions O
and O
transcription O
factor O
networks O
contributing O
to O
the O
development O
of O
distinct O
lymphoid B-Disease
tumors I-Disease

49 O
The O
heart O
is O
the O
first O
organ O
to O
be O
functional O
in O
the O
fetus O

Identified O
pathways O
emphasize O
the O
importance O
of O
this O
period O
of O
transition O
on O
epigenetic O
state O
of O
genes O
relevant O
to O
cell O
growth O
and O
immune O
system O
development O

Current O
evidence O
points O
toward O
opioids B-Chemical
promoting O
higher O
levels O
of O
permissive O
histone B-Chemical
acetylation I-Chemical
and O
lower O
levels O
of O
repressive O
histone B-Chemical
methylation I-Chemical
as O
well O
as O
alterations O
to O
DNA B-Chemical
methylation I-Chemical
patterns O
and O
noncoding O
RNA B-Chemical
expression O
throughout O
the O
brain's O
reward O

Advanced O
literature O
searches O
were O
done O
on O
PubMed/MEDLINE O
, O
Scopus O
and O
Google O
Scholar O

These O
enzymatic O
activities O
include O
methylation O
by O
DNA B-Chemical
methyltransferases O
, O
oxidation O
of O
5mC B-Chemical
by O
TET B-Gene
family I-Gene
enzymes O
, O
hypermodification O
of O
5hmC B-Chemical
by O
glucosyltransferases O
, O
and O
the O
generation O
of O
transition O
mutations O
from O
cytosine B-Chemical
to O
uracil B-Chemical
by O

These O
molecular O
alterations O
include O
multiple O
cancer-driving O
mutations O
, O
gene B-Gene
fusions I-Gene
, O
amplification O
, O
deletion O
, O
and O
post-translational O
modifications O
, O
among O
others O

Thus O
, O
epigenetic O
characterization O
of O
the O
various O
HIV B-Species
- I-Species
infected O
host O
cells O
and O
host O
cell-dependent O
HIV B-Species
latency O
mechanisms O
is O
a O
promising O
research O
area O
and O
may O
facilitate O
the O
development O
of O
cell O
type-specific O
epigenetic O
drugs O

I O
claim O
in O
particular O
that O
 O
( O
i O
) O
if O
sociologists O
want O
to O
investigate O
race O
in O
a O
postgenomic O
world O
they O
should O
pay O
more O
attention O
to O
this O
novel O
plastic O
and O
biosocial O
view O
of O
race O
; O
and O
( O
ii O
) O
there O
are O
no O
reasons O
to O
believe O
that O
an O

, O
AKT1 B-Gene
and O
CTNNB1 B-Gene

However O
, O
the O
details O
of O
how O
the O
methylation B-Chemical
profiles O
change O
remain O
largely O
unknown O

In O
this O
article O
, O
we O
propose O
a O
methylation O
random O
field O
( O
MRF O
) O
method O
to O
detect O
mQTLs O
by O
testing O
the O
association O
between O
the O
methylation O
level O
of O
a O
CpG B-Chemical
site I-Chemical
and O
a O
set O
of O
genetic O
variants O
within O
a O
genomic O
region O

Whereas O
telomeres O
and O
subtelomeres O
cannot O
be O
differentiated O
by O
microscopy O
techniques O
, O
telomeres O
and O
ITSs O
might O
not O
be O
differentiated O
in O
ChIP O
analyses O

We O
hypothesized O
that O
changes O
in O
hASCs B-Species
are O
a O
consequence O
of O
epigenetic O
modifications O

DNA O
methylation O
is O
a O
common O
epigenetic O
modification O
that O
regulates O
gene O
expression O
, O
and O
aberrant O
DNA O
methylation O
patterns O
are O
considered O
a O
hallmark O
of O
cancer B-Disease

Atrial O
remodeling O
includes O
changes O
in O
ion B-Chemical
channel I-Chemical
expression O
and O
function O
, O
structural O
alterations O
, O
and O
neural O
remodeling O
, O
which O
create O
an O
arrhythmogenic O
milieu O
resulting O
in O
AF B-Disease
initiation O
and O
maintenance O

The O
epigenetic O
status O
of O
cells O
plays O
a O
crucial O
role O
in O
determining O
their O
differentiation O
state O
and O
proper O
function O
within O
multicellular O
organisms O

The O
objective O
of O
this O
work O
is O
to O
discuss O
the O
epigenome O
as O
a O
modifier O
of O
exposure O
effects O
and O
risk O
, O
perspectives O
for O
integrating O
toxicoepigenetic O
data O
into O
an O
AOP O
framework O
, O
tools O
for O
the O
exploration O
of O
epigenetic O
toxicity O
, O
and O
integration O
of O
AOP-guided O
epigenetic O
information O

In O
this O
paper O
, O
we O
argue O
that O
the O
identification O
and O
assignment O
of O
moral O
epigenetic O
responsibilities O
should O
reflect O
the O
rich O
diversity O
and O
complexity O
of O
epigenetic O
mechanisms O
, O
and O
not O
rely O
solely O
on O
a O
gross O
comparison O
between O
epigenetics O
and O
genetics O

While O
participants O
' O
recognition O
of O
epigenetic O
terms O
and O
phrases O
was O
high O
, O
their O
understanding O
was O
limited O

Its O
importance O
lies O
in O
the O
fact O
that O
methyl B-Chemical
group I-Chemical
metabolic O
pathways O
are O
crucial O
for O
the O
successful O
conversion O
of O
dietary O
nutrients O
into O
the O
basic O
building O
blocks O
to O
carry O
out O
any O
cellular O
methylation O
reaction O

1094 O
The O
past O
decade O
has O
seen O
the O
emergence O
of O
immunotherapy O
as O
a O
prime O
approach O
to O
cancer B-Disease
treatment O
, O
revolutionizing O
the O
management O
of O
many O
types O
of O
cancer B-Disease

Understanding O
the O
extent O
of O
epigenetic O
changes O
occurring O
in O
RCC B-Disease
and O
the O
mechanisms O
by O
which O
they O
influence O
disease O
progression O
and O
treatment O
response O
, O
as O
well O
as O
knowledge O
of O
current O
research O
on O
biomarkers O
and O
treatments O
, O
is O
crucial O
to O
successful O
clinical O
translation O
of O
epigenetics O
in O

Accumulating O
evidence O
indicates O
that O
oxidative O
stress O
and O
redox O
balance O
are O
under O
circadian O
control O
and O
feedback O
on O
the O
clock O
system O

1413 O
The O
role O
of O
epigenetic O
processes O
in O
the O
control O
of O
gene B-Gene
expression I-Gene
has O
been O
known O
for O
a O
number O
of O
years O

Greenness O
metrics O
were O
associated O
with O
significantly O
lower O
DNAmAgeAC B-Gene
based O
on O
GrimAge B-Gene
acceleration O
, O
suggesting O
slower O
biological O
aging O
with O
higher O
greenness O
based O
on O
both O
NDVI B-Gene
and O
EVI B-Gene
in O
300-2,000m O
buffer O
areas O

Elucidating O
its O
pathogenic O
mechanism O
is O
one O
of O
the O
major O
challenges O
that O
we O
face O
currently O

This O
approach O
can O
be O
sensitive O
to O
the O
dynamic O
interaction O
between O
biological O
predisposition O
and O
environmental O
influences O
, O
and O
is O
potentially O
more O
informative O
than O
an O
approach O
using O
static O

Despite O
the O
well-known O
deleterious O
health O
effects O
of O
arsenic B-Chemical
exposure O
, O
the O
molecular O
mechanisms O
in O
arsenic-mediated B-Chemical
carcinogenesis O
are O
not O
fully O
understood O

This O
article O
will O
discuss O
the O
general O
features O
of O
placental O
DNA B-Chemical
methylation I-Chemical
and O
will O
describe O
current O
technologies O
for O
profiling O
genome-wide O
DNA B-Chemical
methylation I-Chemical
patterns O
in O
this O
tissue O
, O
the O
approaches O
to O
data O
analysis O
and O
some O
of O
the O
major O
findings O
from O
recent O
studies O

Accumulating O
evidence O
has O
shown O
that O
high O
levels O
of O
SNCA B-Gene
are O
causative O
for O
the O
development O
of O
PD B-Disease

Integration O
of O
data O
from O
multiple O
modalities O
, O
including O
molecular O
profiling O
of O
genes B-Gene
and O
gene B-Gene
products O
, O
epigenetic O
landscape O
, O
cellular O
morphology O
, O
connectivity O
, O
and O
physiology O
, O
will O
be O
essential O
for O
a O
meaningful O
and O
broadly O
useful O
definition O
of O
brain O
cell O
types O

Under O
physiological O
conditions O
or O
adaptive O
states O
, O
these O
cells O
cooperate O
to O
support O
tissue O
and O
organ O
homeostasis O
, O
and O
to O
promote O
growth O
or O
compensatory O
regeneration O

274 O
 O
Purpose O
of O
review O
 O
Epigenetic O
changes O
can O
be O
highly O
influenced O
by O
environmental O
factors O
and O
have O
in O
turn O
been O
proposed O
to O
influence O
chronic B-Disease
disease I-Disease

Adapted O
FLoSS B-Gene
â¥7 O
as O
a O
marker O
of O
exceptional O
longevity O
occurred O
in O
3 O

Adipogenesis O
is O
controlled O
by O
coordinated O
actions O
of O
lineage-determining O
transcription O
factors O
and O
epigenomic O
regulators O

Third O
, O
we O
claim O
that O
the O
classical O
opposition O
between O
epigenesis B-Gene
and O
preformationism O
as O
ways O
of O
thinking O
about O
the O
developmental O
process O
is O
part O
of O
the O
history O
of O
epigenetics B-Gene
and O
has O
contributed O
to O
its O
current O
various O
meanings O

Using O
methylation B-Chemical
data O
, O
six O
artificial O
intelligence O
( O
AI O
) O
platforms O
including O
deep O
learning O
( O
DL O
) O
was O
used O
for O
CoA B-Chemical
detection O

Therefore O
, O
the O
role O
of O
epigenetics O
in O
the O
pathogenesis O
of O
COPD B-Disease
has O
attracted O
much O
attention O

Moreover O
, O
the O
introduction O
of O
epigenetics B-Chemical
into O
the O
regulatory O
mechanism O
in O
has O
provided O
more O
objective O
and O
scientific O
support O
for O
theories O
and O
brought O
new O
opportunities O
for O
the O
improvement O
of O
studies O

Further O
, O
we O
evaluated O
the O
AI O
analysis O
of O
DNA B-Gene
methylation I-Gene
for O
the O
prediction O
of O
CoA B-Chemical

Despite O
the O
important O
role O
these O
types O
of O
effects O
play O
in O
biology O
, O
the O
molecular O
mediators O
of O
this O
non-genetic O
transmission O
of O
information O
are O
just O
now O
beginning O
to O
be O
deciphered O

ChIP O
can O
be O
widely O
used O
to O
determine O
the O
presence O
of O
particular O
histones O
with O
posttranslational O
modifications O
at O
specific O
genomic O
regions O
or O
whether O
and O
where O
specific O
DNA-binding O
proteins O
including O
transcription O
factors O
interact O
with O
candidate O
target O
genes O

We O
propose O
that O
MER-Net O
can O
serve O
as O
a O
tool O
to O
guide O
integrated O
metabolomics O
and O
epigenomics O
research O
or O
can O
be O
modified O
to O
answer O
other O
complex O
biological O
and O
clinical B-Disease
questions I-Disease
using O
multiomics O
data O

detecting O

Parallel O
GSEA O
performed O
on O
matched O
transcriptomic O
samples O
determined O
that O
a O
substantially O
reduced O
subset O
of O
these O
pathways O
are O
enriched O
and O
that O
not O
all O
chemically-induced B-Chemical
methylation O
results O
in O
a O
downstream O
alteration O
in O
gene B-Gene
expression O

Furthermore O
, O
JBR O
includes O
the O
capability O
for O
peak O
optimization O
, O
i O


The O
enriched O
DNA B-Chemical
fragments O
can O
be O
amplified O
and O
hybridized O
to O
tiling O
arrays O
covering O
CpG B-Gene
islands O
, O
promoters O
, O
or O
the O
entire O
genome B-Gene

After O
that O
, O
we O
investigated O
the O
significant O
signal O
pathways O
and O
epigenetic O
modifications O
in O
the O
core O
GWGENs B-Gene
to O
identify O
potential O
biomarkers O
as O
drug O
targets O

The O
current O
state O
of O
knowledge O
of O
epigenetics O
has O
evolved O
as O
our O
understanding O
of O
DNA B-Gene
methylation I-Gene
, O
chromatin B-Gene
modifications I-Gene
, O
and O
noncoding B-Gene
RNA I-Gene
, O
and O
their O
effects O
on O
gene O
expression O
increased O

) O
that O
takes O
the O
raw O
sequencing O
data O
and O
produces O
separate O
allelic O
tracks O
ready O
to O
be O
viewed O
on O
genome O
browsers O

253 O
Biological O
phenomena O
defined O
as O
having O
an O
" O
epigenetic O
" O
component O
( O
according O
to O
various O
definitions O
) O
have O
been O
extensively O
studied O
in O
plant B-Species
systems O
and O
illuminated O
many O
mechanisms O
by O
which O
gene B-Gene
expression I-Gene
is O
regulated O
and O
patterns O
of O
expression O
inherited O
through O
cell O
divisions O

The O
only O
in O
vivo O
study O
reporting O
that O
a O
number O
of O
organs O
of O
old O
progeric B-Disease
mice B-Species
can O
be O
rejuvenated O
by O
cyclic O
partial O
reprogramming O
will O
also O
be O
described O
in O
some O
detail O

Equally O
important O
is O
the O
possibility O
to O
investigate O
epigenetic O
modifications O
of O
ancient O
genomes O
, O
which O
has O
allowed O
to O
obtain O
previously O
inaccessible O
information O
on O
gene B-Gene
expression O
, O
nucleosome O
positioning O
, O
and O
DNA B-Chemical
methylation O

05 O
[ O
95% O
CI O
- O
0 O

1326 O
Allopolyploidy O
has O
played O
a O
prominent O
role O
in O
organismal O
evolution O
, O
particularly O
in O
angiosperms B-Species

A O
precise O
therapeutic O
strategy O
is O
complicated O
by O
poor O
understanding O
of O
the O
pathological O
changes O
in O
epilepsy B-Disease
thus O
, O
30% O
of O
TLE B-Disease
patients O
are O
resistant O
to O
drug B-Chemical
therapy O

Such O
insight O
is O
crucial O
to O
enable O
development O
of O
evidence-based O
therapeutic O
options O

740 O
Drug B-Chemical
resistance O
, O
either O
intrinsic O
or O
acquired O
, O
represents O
a O
major O
hurdle O
to O
achieving O
optimal O
therapeutic O
outcomes O
during O
cancer B-Disease
treatment O

943 O
Aging O
of O
organisms O
begins O
from O
a O
single O
cell O
at O
the O
molecular O
level O

Although O
this O
research O
field O
is O
still O
young O
, O
these O
comprehensive O
data O
support O
not O
only O
a O
role O
for O
epigenetics O
in O
disease B-Disease
development I-Disease
, O
but O
also O
epigenetic O
alterations O
as O
a O
response O
to O
disease B-Disease

Most O
studies O
predominantly O
focus O
on O
the O
innate O
immune O
system O

This O
novel O
ASM B-Gene
score O
compares O
favorably O
to O
current O
methods O
that O
also O
screen O
for O
ASM B-Gene

Here O
we O
present O
a O
novel O
framework O
for O
reference-based O
inference O
, O
which O
leverages O
cell-type O
specific O
( O
DHS O
) O
information O
from O
the O
to O
construct O
an O
improved O
reference O
database O

We O
propose O
a O
set O
of O
parameters O
to O
be O
collected O
in O
disaster O
settings O
to O
assess O
the O
long-term O
outcomes O
of O
famine O
 O
PALTEM O
( O
parameters O
to O
assess O
long-term O
effects O
of O
) O

Furthermore O
, O
the O
development O
, O
synthesis O
, O
and O
future O
perspectives O
of O
selective O
class O
IIa O
inhibitors B-Chemical
will O
be O
highlighted O

918 O
We O
are O
at O
an O
inflection O
point O
in O
our O
study O
of O
the O
human B-Species
genome O
as O
it O
relates O
to O
neurodegenerative B-Disease
disease I-Disease

The O
study O
sample O
size O
ranged O
from O
96 O
to O
1163 O
and O
most O
study O
populations O
had O
a O
mean O
age O
under O
50 O
and O
included O
predominantly O
White B-Species
male O
participants O

In O
this O
chapter O
, O
we O
review O
the O
recent O
advances O
in O
the O
field O
of O
" O
computational O
epigenetics O
" O
, O
including O
computational O
methods O
for O
processing O
different O
types O
of O
epigenetic O
data O
, O
prediction O
of O
chromatin B-Chemical
states O
, O
and O
study O
of O
protein B-Chemical
dynamics O

1340 O
Alzheimer's B-Disease
disease I-Disease
( O
AD B-Disease
) O
is O
the O
most O
common O
type O
of O
dementia O
in O
the O
elderly O

Conclusion O
 O
The O
iCloneViz O
approach O
can O
be O
used O
for O
analysis O
of O
clonal O
evolution O
and O
mutational O
dynamics O
of O
multi-omic O
data O
sets O

778 O
Epigenetics O
is O
the O
process O
by O
which O
gene B-Gene
expression I-Gene
is O
regulated O
by O
events O
other O
than O
alterations O
of O
the O
genome O

However O
, O
aberrant O
epigenetic O
control O
plays O
a O
key O
role O
in O
pathogenesis O
of O
disease B-Disease

We O
put O
a O
special O
focus O
on O
the O
discussion O
of O
molecular O
mechanisms O
underlying O
environmentally O
induced O
alterations O
in O
DNA B-Gene
hydroxymethylation B-Chemical
patterns O
and O
their O
impact O
on O
genetic O
dysfunction B-Disease

Appropriate O
construct O
designs O
were O
used O
to O
demonstrate O
that O
the O
cis-spread O
of O
heterochromatin O
could O
be O
interfered O
with O
a O
stronger O
euchromatic O
barrier O
( O
TUB2 B-Gene
promoter O
) O

The O
discovery O
that O
what O
our O
genes B-Gene
do O
depends O
in O
part O
on O
our O
experiences O
has O
shed O
light O
on O
how O
Nature O
and O
Nurture O
interact O
at O
the O
molecular O
level O
inside O
of O
our O
bodies O

and O

list@mpi-inf O

We O
first O
demonstrate O
our O
method O
with O
a O
chemical B-Chemical
epigenomics O
screen O
, O
in O
which O
we O
identify O
drug-altered O
distal O
regulatory O
sites O
predictive O
of O
compound- B-Chemical
and O
dose-dependent O
effects O
on O
transcription O

wustl O

While O
genetic O
risk O
of O
disease B-Disease
is O
currently O
unmodifiable O
, O
there O
is O
hope O
that O
epigenetic O
risk O
may O
be O
reversible O
and O
or O
modifiable O

At O
the O
same O
time O
, O
the O
methylation O
level O
of O
three O
CpG B-Gene
sites I-Gene
showed O
a O
weak O
relationship O
with O
age O
and O
exhibited O
a O
low O
concordance O
between O
the O
data O
obtained O
from O
the O
two O
technologies O

Moreover O
, O
precise O
genome O
editing O
technologies O
such O
as O
CRISPR/Cas B-Gene
has O
proven O
their O
efficacy O
in O
epigenome O
editing O
, O
including O
the O
alteration O
of O
epigenetic O
markers O
, O
such O
as O
DNA B-Chemical
methylation I-Chemical
or O
histone B-Chemical
modification I-Chemical

966 O
Recent O
efforts O
have O
posited O
the O
utility O
of O
transcriptomic-based O
approaches O
to O
understand O
chemical-related B-Chemical
perturbations O
in O
the O
context O
of O
human B-Species
health O
risk O
assessment O

Currently O
, O
the O
regulation O
of O
gene B-Gene
activity O
by O
epigenetic O
mechanisms O
is O
suggested O
to O
be O
a O
key O
player O
in O
mediating O
the O
link O
between O
adverse O
early-life O
events O
and O
adult O
neurobehavioral B-Disease
outcomes O

Here O
, O
we O
examine O
and O
synthesize O
the O
impacts O
of O
climate O
change O
on O
freshwater O
ecosystems O
, O
exploring O
the O
potential O
role O
of O
epigenetic O
mechanisms O
in O
both O
short- O
and O
long-term O
adaptation O
of O
species B-Species

936 O
Aging O
involves O
a O
diverse O
set O
of O
biological O
changes O
accumulating O
over O
time O
that O
leads O
to O
increased O
risk O
of O
morbidity O
and O
mortality O

879 O
Spatial O
genome O
organization O
in O
the O
cell O
nucleus O
plays O
a O
crucial O
role O
in O
the O
control O
of O
genome O
functions O

512 O
Liquid B-Chemical
chromatography-tandem I-Chemical
mass I-Chemical
spectrometry I-Chemical
( O
LC-MS/MS B-Chemical
) O
is O
a O
widely O
used O
technique O
in O
the O
global O
analysis O
of O
epigenetic O
DNA B-Gene
modifications O

Anthropologists O
and O
human B-Species
biologists O
are O
interested O
in O
epigenetics O
specifically O
, O
as O
it O
provides O
a O
potential O
link O
between O
the O
environment O
and O
the O
genome B-Gene
, O
as O
well O
as O
a O
new O
layer O
of O
complexity O
for O
the O
study O
of O
human B-Species
biological O
variation O

We O
focus O
on O
the O
relevance O
of O
DNA B-Gene
methylation I-Gene
, O
a O
well O
characterized O
epigenetic O
modification O
of O
the O
genome O
, O
as O
a O
biomarker O
and O
underlying O
mechanism O
of O
atherosclerosis B-Disease

Commissioning O

Here O
, O
we O
first O
found O
that O
IF B-Chemical
for O
3 O
months O
caused O
modulation O
of O
H3K9 B-Gene
trimethylation I-Gene
( O
H3K9me3 B-Gene
) O
in O
the O
cerebellum B-Species
, O
which O
in O
turn O
orchestrated O
a O
plethora O
of O
transcriptomic O
changes O
involved O
in O
robust O
metabolic O
switching O
processes O
commonly O

To O
date O
, O
there O
is O
almost O
no O
ethical O
debate O
about O
, O
whereas O
the O
discussions O
about O
GE O
are O
voluminous O

However O
, O
this O
approach O
overlooks O
a O
number O
of O
confounding O
factors O
, O
including O
the O
presence O
of O
sequencing O
errors O
and O
true O
variants O

In O
contrast O
to O
population-averaged O
analyses O
, O
single-molecule O
approaches O
potentially O
allow O
the O
mapping O
of O
epigenetic O
linkage O
between O
distantly O
located O
genomic O
regions O
, O
the O
locus-specific O
analysis O
of O
repetitive O
DNA B-Gene
elements O
, O
as O
well O
as O
determination O
of O
allele-specific O
DNA B-Gene
modification O
patterns O

An O
analysis O
of O
the O
change O
in O
methylation O
between O
cord O
blood O
and O
mid-childhood O
DNA O
( O
Î-DNAm O
) O
identified O
395 O
methylation O
marks O
in O
272 O
genes O
associated O
with O
mid-childhood O
IgE B-Chemical
( O
FDR O
< O
0 O

g O

e O

1150 O
Therapeutic O
interventions O
aimed O
at O
inducing O
fetal B-Gene
hemoglobin I-Gene
and O
reducing O
the O
concentration O
of O
sickle B-Gene
hemoglobin I-Gene
is O
an O
effective O
approach O
to O
ameliorating O
acute O
and O
chronic O
complications O
of O
sickle B-Disease
cell I-Disease
disease I-Disease
, O
exemplified O
by O
the O
long-term O
use O
of O

Herein O
, O
we O
investigated O
GLDC B-Gene
expression O
and O
its O
promoter O
methylation O
in O
gastric B-Disease
cancer I-Disease
( O
GC B-Disease
) O

1001 O
A O
growing O
number O
of O
inconsistencies O
have O
accumulated O
within O
the O
genetically O
deterministic O
paradigm O
of O
the O
origin O
of O
cancer B-Disease

Materials O
& O
methods O
 O
382 O
placentas O
from O
the O
extremely O
low O
gestational O
age O
newborns O
( O
ELGAN O
) O
cohort O
were O
evaluated O
for O
expression O
levels O
of O
37,268 O
mRNAs O
and O
2,102 O
miRNAs O
using O
genome-wide O
RNA-sequencing O

In O
a O
subset O
of O
patients O
with O
congenital B-Disease
neurodevelopmental I-Disease
disorders I-Disease
, O
clear O
diagnosis O
can O
be O
achieved O
using O
DNA B-Gene
sequence-based I-Gene
analysis O
to O
identify O
changes O
in O
the O
DNA B-Gene
sequence I-Gene
( O
genetic O
variation O
) O

First O
, O
2 O
studies O
are O
summarized O
, O
one O
a O
candidate O
gene B-Gene
study O
and O
the O
other O
an O
epigenome-wide O
association O
study O
in O
which O
DNAm B-Gene
was O
reported O
to O
( O
partially O
) O
mediate O
the O
link O
between O
adversity O
and O
child O
development O

While O
epigenetics O
continues O
to O
be O
a O
burgeoning O
research O
area O
in O
neuroscience O
, O
unaddressed O
issues O
related O
to O
data O
reproducibility O
across O
laboratories O
remain O

Epi-drugs O
include O
histone B-Chemical
methylation I-Chemical
inhibitors I-Chemical
, O
histone B-Chemical
demethylation I-Chemical
inhibitors I-Chemical
, O
histone B-Chemical
deacetylation I-Chemical
inhibitors I-Chemical
, O
and O
DNA B-Chemical
methylation I-Chemical
inhibitors I-Chemical


In O
addition O
to O
many O
tools O
directly O
for O
data O
analysis O
, O
advanced O
computational O
approaches O
, O
such O
as O
deep O
learning O
, O
have O
recently O
become O
promising O
to O
deeply O
mine O
the O
data O
structures O
and O
identify O
important O
regulators O
from O
complex O
functional O
genomics O
data O

BROCKMAN O
represents O
each O
sample O
as O
a O
vector O
of O
epigenomic-mark-associated O
DNA B-Chemical
word I-Chemical
frequencies O
, O
and O
decomposes O
the O
resulting O
matrix O
to O
find O
hidden O
structure O
in O
the O
data O
, O
followed O
by O
unsupervised O
grouping O
of O
samples O
and O
identification O
of O
the O
TFs O
that O
distinguish O

With O
rapid O
aging O
of O
the O
world O
population O
, O
the O
need O
to O
elucidate O
the O
underlying O
mechanisms O
is O
pressing O
, O
now O
more O
so O
than O
ever O

The O
first O
group O
of O
theories O
can O
be O
indicated O
as O
referring O
to O
the O
gene-centric B-Gene
paradigm I-Gene

Microtia B-Disease
is O
a O
congenital O
malformation O
of O
the O
external O
and O
middle O
ear O
caused O
by O
the O
abnormal O
development O
of O
the O
first O
and O
second O
and O
the O
first O

952 O
Inherited O
information O
not O
encoded O
in O
the O
can O
regulate O
a O
variety O
of O
complex O
phenotypes O

211 O
Epigenetic O
modifications O
direct O
the O
way O
DNA B-Gene
is O
packaged O
into O
the O
nucleus O
, O
making O
genes O
more O
or O
less O
accessible O
to O
transcriptional O
machinery O
and O
influencing O
genomic O
stability O

Thousands O
of O
tracks O
are O
available O
, O
reflecting O
data O
on O
a O
variety O
of O
tissues O
, O
cell O
types O
and O
cell O
lines O
from O
the O
human B-Species
and O
mouse B-Species
genomes O

In O
the O
brain O
, O
epigenetic O
processes O
translate O
information O
from O
transient O
cellular O
impulses O
and O
adjustments O
in O
neuronal O
activity O
into O
long-lasting O
impacts O
on O
gene B-Gene
expression I-Gene

The O
organizing O
committee O
, O
led O
by O
Niall O
Dillon O
of O
the O
Medical O
Research O
Council O
Clinical O
Sciences O
Centre O
( O
London O
, O
UK O
) O
, O
consisted O
of O
several O
distinguished O
researchers O
in O
the O
fields O
of O
epigenetics O
and O
chromatin O
organization O
from O
across O
the O
UK O

Human O
DNA B-Gene
methylation I-Gene
studies O
require O
careful O
considerations O
for O
design O
and O
analysis O
including O
population O
and O
tissue O
selection O
, O
population O
stratification O
, O
cell O
heterogeneity O
, O
confounding O
, O
temporality O
, O
sample O
size O
, O
appropriate O
statistical O
analysis O
, O
and O
validation O
of O
results O

Highlights O
include O
reference O
epigenome O
maps O
for O
a O
wide O
variety O
of O
human B-Species
cells O
and O
tissues O
, O
the O
development O
of O
new O
technologies O
for O
epigenetic O
assays O
and O
imaging O
, O
the O
identification O
of O
novel O
epigenetic O
modifications O
, O
and O
an O
improved O
understanding O
of O
the O
role O
of O
epigenetic O
processes O

Besides O
, O
both O
saliva O
and O
the O
buccal O
sample O
showed O
pathways O
related O
to O
circadian B-Disease
rhythm I-Disease
, O
although O
these O
findings O
were O
not O
FDR O
significant O

e O


The O
numbers O
and O
effect O
sizes O
of O
differentially O
methylated O
regions O
( O
DMRs O
) O
post-bariatric O
were O
more O
pronounced O
in O
AT O
( O
SAT O
 O
12,865 O
DMRs O
from O
-11 O

Despite O
the O
current O
relative O
lack O
of O
robust O
data O
, O
such O
studies O
may O
facilitate O
the O
development O
of O
interventions O
that O
ultimately O
decrease O
the O
significant O
morbidity O
and O
mortality O
of O
this O
highly O
vulnerable O
population O

Imputation O
accuracy O
is O
lower O
for O
mid-range O
Î²-values O
, O
while O
it O
is O
generally O
more O
accurate O
for O
values O
at O
the O
extremes O
of O
the O
Î²-value O
range O

1175 O
 O
Background O
 O
The O
epigenome O
may O
be O
an O
important O
interface O
between O
environmental O
chemical B-Chemical
exposures O
and O
human B-Species
health O

We O
summarize O
the O
up-to-date O
findings O
and O
discuss O
the O
implications O
of O
various O
studies O
and O
point O
to O
new O
avenues O
of O
research O
on O
PCOS B-Disease
in O
the O
rapidly O
developing O
field O
of O
epigenetics O
and O
epigenomics O

326 O
Fetal O
exposures O
can O
induce O
epigenetic O
modifications O
, O
particularly O
DNA B-Chemical
methylation I-Chemical
, O
potentially O
predisposing O
individuals O
to O
later O
health O
issues O

We O
found O
several O
cases O
of O
Parkinson's B-Disease
disease I-Disease
with O
epigenetic O
abnormality O
in O
SNCA B-Gene
gene I-Gene

Thanks O
to O
single-molecule O
DNA B-Chemical
sequencing O
technologies O
, O
genome-wide O
identification O
of O
methylated O
DNA B-Chemical
is O
becoming O
feasible O
on O
a O
large O
scale O
, O
providing O
the O
possibility O
to O
investigate O
more O
deeply O
the O
presence O
, O
variability O
, O
and O
roles O
of O
DNA B-Chemical
methylation O

Evolutionary O
theory O
provides O
a O
unique O
way O
to O
gain O
new O
insights O
into O
epigenetic O
ageing O
and O
health O

The O
meeting O
covered O
a O
diverse O
range O
of O
topics O
and O
brought O
together O
scientists O
carrying O
out O
fundamental O
research O
on O
epigenetic O
mechanisms O
and O
also O
researchers O
who O
are O
exploring O
the O
role O
of O
epigenetics O
in O
human O
diseases B-Disease
and O
its O
clinical O
applications O

the O

Late-life O
PoWeR O
from O
22-24 O
months O
of O
age O
modestly O
but O
significantly O
attenuates O
an O
age-associated O
shift O
toward O
promoter O
hypermethylation O

435dupC O
at O
the O
3' O
end O
of O
the O
mRNA B-Gene
leads O
to O
a O
frameshift O
and O
truncation O
of O
the O
positive O
charge O
in O
the O
carboxy-terminus O
of O
the O
protein O

These O
advancements O
in O
the O
understanding O
of O
the O
physiopathology O
of O
schizophrenia B-Disease
provide O
exciting O
new O
perspectives O
for O
treatments O

860 O
Early O
developmental O
environment O
can O
influence O
long-term O
health O
through O
reprogramming O
of O
the O
epigenome O

We O
used O
targeted O
bisulfite O
sequencing O
to O
amplify O
48 O
CpGs O
from O
four O
genes O
in O
muscle O
samples O
and O
applied O
penalized O
regressions O
to O
predict O
age O

Human O
and O
experimental O
animal O
studies O
have O
highlighted O
the O
link O
between O
alterations O
in O
the O
early O
life O
environment O
and O
increased O
risk O
of O
obesity B-Disease
and O
metabolic O
disorders B-Disease
in O
later O
life O

These O
life O
history O
stages O
are O
somewhat O
arbitrary O
, O
with O
many O
traits O
spanning O
conventional O
divisions O
, O
but O
each O
period O
tends O
to O
have O
its O
own O
characteristic O
ethologies O
and O
particular O
contribution O
to O
neural O
and O
behavioral O
phenotypes O

We O
close O
by O
considering O
various O
ethical O
, O
legal O
, O
and O
social O
issues O
posed O
by O
recent O
developments O
in O
public O
health O
genomics O
; O
these O
include O
policies O
to O
regulate O
access O
to O
personal O
genomic O
information O
, O
the O
need O
to O
enhance O
genetic B-Gene
literacy O
in O
both O
health O
professionals O
and O
the O
public O
, O

cn O
or O
http//www O

The O
system O
can O
thereby O
reduce O
costs O
by O
allowing O
for O
reduced O
reaction O
volumes O
, O
limiting O
the O
number O
of O
expensive O
reagents O
such O
as O
enzymes O
, O
magnetic O
beads O
, O
antibodies O
, O
and O
hands-on O
time O
required O

Moreover O
, O
negative O
definition O
casts O
the O
genetic-epigenetic O
relationship O
as O
an O
either/or O
binary O
, O
overshadowing O
continuities O
and O
connections O

Recent O
use O
and O
each O
additional O
day O
of O
recent O
use O
were O
associated O
with O
a O
20-month O
( O
P O
< O
0 O

This O
approach O
let O
us O
to O
distinguish O
different O
cells O
types O
based O
on O
their O
epigenomic O
profiles O
, O
thus O
recapitulating O
important O
aspects O
of O
human B-Species
hematopoiesis O

The O
goal O
of O
this O
study O
is O
to O
develop O
and O
demonstrate O
a O
more O
detailed O
clonality O
approach O
by O
utilizing O
integrative O
genomics O

DNA B-Gene
of O
the O
same O
individuals O
were O
used O
for O
pooled O
and O
individual O
epigenomic O
libraries O
and O
sequenced O
with O
equivalent O
resources O
per O
individual O

Stem O
cell O
lineage O
commitment O
and O
differentiation O
are O
regulated O
by O
an O
intricate O
range O
of O
host O
and O
environmental O
factors O
of O
which O
epigenetic O
influence O
is O
considered O
vital O

By O
formulating O
a O
single O
reaction O
variable O
representing O
the O
birth O
and O
death O
of O
molecules O
, O
including O
transcription O
, O
translation O
and O
decay O
, O
we O
calculate O
the O
escape O
time O
from O
the O
phenotypic O
states O
attained O
from O
autocatalytic O
synthesis O
through O
a O
Fokker-Planck O
formulation O
and O
integration O
of O
an O
effective O

In O
terms O
of O
novel O
features O
, O
15 O
of O
the O
epigenetic O
scores O
are O
newly O
considered O

Increasing O
efforts O
have O
been O
made O
over O
the O
past O
2 O
decades O
to O
identify O
and O
modify O
environmental O
risk O
factors O
among O
persons O
who O
are O
susceptible O
to O
disease B-Disease
because O
of O
their O
genotype B-Gene
and O
to O
integrate O
genetic B-Gene
information O
and O
other O
biological O
variables O
with O
information O
about O
individual-level O
risk O
factors O
and O

Changes O
in O
many O
ocular O
tissues O
can O
be O
measured O
directly O
, O
easily O
and O
objectively O
in O
vivo O
( O
e O

The O
purpose O
of O
this O
review O
was O
to O
present O
and O
summarize O
the O
association O
between O
aberrant O
DNA B-Gene
methylation I-Gene
of O
immune O
cells O
and O
SLE B-Disease
, O
the O
possible O
mechanisms O
of O
immune O
dysfunction O
caused O
by O
DNA B-Gene
methylation I-Gene
, O
and O
to O
better O
understand O
the O
roles O
of O
aberrant O

87 O
) O
, O
p O
= O

Being O
the O
first O
software O
of O
its O
kind O
, O
we O
anticipate O
that O
EpiProfile O
2 O

Additionally O
, O
results O
demonstrate O
that O
different O
risk O
and O
protective O
factors O
influence O
epigenetic O
aging O
at O
different O
times O

epigenetic O

359Summary O
Epigenetic O
modifications O
reflect O
key O
aspects O
of O
transcriptional O
regulation O
, O
and O
many O
epigenomic O
datasets O
have O
been O
generated O
under O
different O
biological O
contexts O
to O
provide O
insights O
into O
regulatory O
processes O

The O
observations O
provide O
further O
insights O
into O
the O
characteristics O
of O
these O
effects O
and O
can O
improve O
existing O
adjustment O
approaches O

Genetic O
predisposition O
, O
as O
well O
as O
aging O
, O
contribute O
to O
epigenetic O
variability O
, O
and O
several O
environmental O
factors O
, O
including O
exercise O
and O
diet O
, O
further O
interact O
with O
the O
human B-Species
epigenome O

We O
first O
applied O
a O
variety O
of O
exploratory O
and O
confirmatory O
factor O
analysis O
techniques O
to O
their O
self-reported O
well-being O
data O

357 O
 O
The O
55th O
Annual O
Canadian O
Society O
for O
Molecular O
Biosciences O
Conference O
on O
Epigenetics O
and O
Genomic O
Stability O
in O
Whistler O
, O
Canada O
, O
14-18 O
March O
2012 O
, O
brought O
together O
31 O
speakers O
from O
different O
nationalities O

The O
authors O
summarize O
the O
presentations O
, O
which O
highlight O
how O
the O
complex O
interactions O
between O
genes B-Gene
and O
environment O
may O
in O
part O
be O
mediated O
through O
epigenetic O
changes O
and O
how O
information O
about O
nutritional O
and O
other O
environmental O
stimuli O
can O
be O
transmitted O
to O
the O
next O
generation O

1345 O
 O
Recent O
studies O
have O
described O
numerous O
environmentally-induced O
disruptions O
of O
the O
epigenome O
( O
epimutations O
) O
in O
mammals B-Species

, O

However O
, O
this O
phenomenon O
uses O
a O
novel O
approach O
that O
accurately O
maps O
DNA B-Gene
quantity O
into O
shifts O
in O
relative O
band O
position O

Recent O
advances O
revealed O
that O
ZIPs B-Gene
modulate O
epigenetics O

In O
this O
review O
, O
we O
briefly O
outline O
some O
principles O
of O
epigenetics O
, O
focusing O
on O
highlighting O
important O
considerations O
unique O
to O
studies O
to O
guide O
psychologists O
in O
incorporating O
into O
a O
project O

The O
Fragment O
CpG-plot O
is O
able O
to O
monitor O
data O
quality O
based O
on O
inherent O
sequence O
data O
characteristics O
, O
and O
is O
therefore O
a O
cost-efficient O
tool O
for O
experimental O
optimization O
, O
but O
also O
to O
monitor O
quality O
throughout O
routine O
applications O

Technological O
advances O
in O
the O
study O
of O
chromosome O
conformation O
mean O
a O
new O
class O
of O
biomarker-the O
chromosome O
conformation O
signature O
(CCS)-can O
identify O
chromosomal O
interactions O
across O
several O
genomic O
loci O
as O
a O
collective O
marker O
of O
an O
epigenomic O
state O

941 O
Centromeres O
represent O
the O
basis O
for O
kinetochore O
formation O
, O
and O
are O
essential O
for O
proper O
chromosome O
segregation O
during O
mitosis O

Distal O
regulatory O
elements O
, O
such O
as O
enhancers O
, O
play O
a O
major O
role O
in O
specifying O
cell-specific O
transcription O
patterns O
in O
both O
normal O
and O
diseased B-Disease
tissues O
, O
suggesting O
that O
enhancers O
may O
be O
prime O
targets O
for O
therapeutic O
intervention O

We O
provide O
a O
theoretical O
basis O
for O
why O
cooperative O
TF B-Gene
binding O
- O
and O
any O
associated O
epigenomic O
mark O
- O
is O
inherently O
more O
variable O
than O
non-cooperative O
binding O

If O
aging O
is O
not O
a O
stochastic O
process O
of O
attrition O
but O
is O
centrally O
orchestrated O
, O
it O
is O
reasonable O
to O
suspect O
that O
the O
timing O
of O
senescence O
is O
also O
influenced O
by O
one O
or O
more O
biological O
clocks O

Whereas O
chemical O
processes O
like O
DNA B-Gene
methylation O
or O
histone B-Gene
modifications O
are O
well-accepted O
epigenetic O
mechanisms O
, O
we O
herein O
propose O
the O
existence O
of O
an O
additional O
quantum O
physics O
layer O
of O
epigenetics O

Our O
work O
supports O
the O
existence O
of O
heritable O
stress O
response O
in O
plants B-Species
and O
demonstrates O
that O
genetic B-Gene
changes I-Gene
prevail O

684 O
 O
Over O
the O
past O
two O
decades O
, O
epigenetics O
has O
evolved O
into O
a O
key O
concept O
for O
understanding O
regulation O
of O
gene B-Gene
expression I-Gene

Results O
 O
A O
total O
of O
551 O
families O
contributed O
to O
adapted O
FLoSS B-Gene
, O
with O
a O
mean O
score O
of O
-0 O

16 O
Accumulating O
epidemiological O
, O
clinical O
, O
and O
experimental O
evidence O
supports O
the O
conclusion O
of O
a O
critical O
role O
of O
epigenetic O
factors O
in O
immune O
programming O

This O
work O
involves O
the O
use O
of O
an O
epidemiologic O
approach O
to O
characterize O
epigenetic O
and O
genetic O
alteration O
of O
genes O
in O
the O
causal O
pathway O
for O
malignancy B-Disease

Multiple O
studies O
support O
the O
conclusion O
that O
environmental O
challenges O
, O
such O
as O
a O
maternal O
low-protein O
diet O
, O
can O
change O
one-carbon O
amino O
acid O
metabolism O
and O
, O
thus O
, O
alter O
histone O
and O
DNA B-Chemical
epigenetic O
modifications O

The O
sensitivity/specificity O
was O
15/93% O
in O
and O
31/89% O
in O
for O
, O
and O
sensitivity/specificity O
was O
41/74% O
in O
and O
69/55% O
in O
for O

DNA O
methylation O
age O
acceleration O
was O
significantly O
higher O
in O
AT B-Gene
compared O
to O
blood O
, O
but O
remained O
unaffected O
after O
surgery O

during O

This O
review O
describes O
detailed O
steps O
to O
perform O
cell O
fixation O
, O
chromatin O
shearing O
, O
immunoprecipitation O
, O
and O
sequencing O
library O
preparation O
for O
a O
batch O
of O
48-96 O
samples O
with O
small O
cell O
numbers O

1430 O
Recent O
sequencing O
technologies O
enable O
joint O
quantification O
of O
promoters O
and O
their O
enhancer O
regions O
, O
allowing O
inference O
of O
enhancer-promoter O
links O

com O
/ O
watch?v=IRy_uUWyrEw O

Further O
research O
on O
lactylation B-Chemical
would O
provide O
us O
with O
a O
better O
understanding O
of O
the O
cross O
talk O
between O
metabolomics O
and O
epigenomics O

After O
a O
ligand O
binds O
, O
the O
conformational O
change O
in O
the O
receptor O
initiates O
changes O
in O
cell O
signaling O
cascades O
( O
membrane O
receptors O
) O
or O
direct O
alternations O
in O
DNA B-Gene
transcription O
( O
steroid O
receptors O
) O

These O
approaches O
have O
the O
potential O
to O
increase O
resolution O
of O
epigenetic O
changes O
to O
the O
single O
base O
level O
in O
multiple O
disease B-Disease
states I-Disease
or O
across O
a O
population O
of O
individuals O

We O
suggest O
that O
future O
research O
in O
environmental O
epigenetics O
focus O
on O
establishing O
the O
reversibility O
of O
stress-induced B-Disease
epigenetic O
modifications O
, O
and O
also O
on O
identifying O
positive O
epigenetic O
effects O
of O
environmental O
enrichment O

The O
promising O
newer O
approaches O
may O
provide O
reliable O
means O
of O
early O
and O
more O
specific O
diagnosis O
and O
help O
identify O
therapeutic O
interventions O
for O
LOAD B-Disease

We O
present O
the O
current O
state O
of O
knowledge O
and O
show O
that O
integrative O
approaches O
are O
necessary O
to O
further O
understand O
the O
causal O
pathways O
between O
environmental O
influences O
, O
epigenetic O
modification O
, O
and O
neuronal O
function O

Some O
investigations O
have O
shown O
that O
epigenetic O
phenomena O
changes O
occur O
in O
the O
cardiac B-Disease
differentiation O
of O
stem B-Species
cells I-Species

In O
addition O
, O
the O
early O
appearance O
and O
ubiquity O
of O
epigenetic O
changes O
in O
virtually O
all O
steps O
of O
tumor B-Disease
development I-Disease
and I-Disease
progression I-Disease
in O
most O
, O
if O
not O
all O
, O
human B-Species
neoplasms B-Disease
, O
make O
them O
attractive O
targets O
for O
biomarker O
discovery O
and O
targeted O
prevention O

As O
such O
, O
epigenetic O
drugs O
comprise O
an O
important O
new O
field O
in O
cancer B-Disease
therapy O
; O
however O
, O
drug O
development O
is O
a O
high-cost O
and O
time-consuming O
procedure O

Recent O
papers O
argue O
that O
epigenetic O
marks O
acquired O
through O
experience O
are O
passed O
to O
offspring O
, O
but O
as O
in O
much O
of O
the O
field O
of O
epigenetics O
, O
there O
is O
lack O
of O
precision O
in O
the O
definitions O
and O
perhaps O
too O
much O
eagerness O
to O
translate O
animal B-Species
research O
to O
humans B-Species

between O

453 O
Transgenerational O
epigenetic O
inheritance O
in O
mammals B-Species
remains O
a O
controversial O
phenomenon O

Most O
of O
epigenetic O
studies O
on O
DNA B-Chemical
methylation I-Chemical
of O
target O
genes O
in O
lung B-Disease
diseases I-Disease
mainly O
demonstrated O
the O
correlation O
of O
DNA B-Chemical
methylation I-Chemical
of O
target O
genes O
with O
the O
levels O
of O
other O
corresponding O
factors O
, O
with O
the O
specificity O
of O
clinical O
phenomes O
, O
and O

health O

gov O
/ O
epigenomics O
) O

They O
result O
from O
a O
combination O
of O
genetic O
factors O
and O
environmental O
insults O
, O
and O
their O
etiology O
finds O
roots O
in O
the O
neurodevelopmental O
period O


Supplementary O
information O
 O

1252 O
The O
epigenetic O
modifications O
of O
human B-Species
telomeres O
play O
a O
relevant O
role O
in O
telomere O
functions O
and O
cell O
proliferation O

We O
carried O
out O
an O
epigenome-wide O
association O
study O
of O
physical B-Disease
frailty I-Disease
, O
as O
defined O
by O
the O
Fried B-Disease
phenotype I-Disease

Expression O
of O
GSTM3 B-Gene
decreased O
in O
ARC B-Disease
lens O
tissues O
compared O
to O
that O
in O
the O
controls O
, O
which O
correlated O
with O
the O
hypermethylation O
of O
GSTM3 B-Gene
promoter O

Larger O
cohorts O
will O
be O
required O
with O
international O
collaborations O
to O
strengthen O
this O
research O
area O

This O
review O
first O
summarizes O
the O
different O
mechanisms O
by O
which O
the O
environment O
can O
model O
the O
epigenome O
 O
receptor O
signalling O
, O
energy O
metabolism O
and O
signal O
mechanotransduction O
from O
extracellular O
matrix O
to O
chromatin O

This O
article O
is O
part O
of O
the O
theme O
issue O
'Developing O
differences O
 O
early-life O
effects O
and O
evolutionary O
medicine O
' O

The O
role O
played O
by O
epigenetic O
mechanisms O
in O
the O
pathogenesis O
of O
childhood B-Disease
asthma I-Disease
is O
understood O
only O
in O
part O

DNA O
methylation O
at O
single-base O
resolution O
in O
regions O
of O
high O
CpG B-Chemical
density O
was O
measured O
on O
24 O
individual O
hypothalamus B-Species
samples O
using O
reduced O
representation O
bisulfite B-Chemical
sequencing O

While O
gaining O
a O
deeper O
understanding O
of O
how O
DNA B-Gene
and O
histone B-Chemical
modifications O
, O
together O
with O
multiple O
classes O
of O
ncRNAs B-Gene
, O
act O
to O
functionalize O
our O
genome O
, O
participants O
were O
also O
provided O
with O
a O
glimpse O
of O
the O
astounding O
complexity O
of O
chromatin B-Chemical
structure O
, O
challenging O
existing O

We O
successfully O
demonstrated O
that O
this O
system O
is O
efficient O
in O
modifying O
individual O
histone B-Chemical
post-translational I-Chemical
modifications O

705Gene O
body O
methylation O
(gbM) O
is O
an O
epigenetic O
mark O
where O
gene O
exons O
are O
methylated O
in O
the O
context O
only O
, O
as O
opposed O
to O
and O
contexts O
( O
where O
H O
stands O
for O
, O
, O
or O
) O

119 O
 O
Epigenetic O
modifications O
are O
dynamic O
mechanisms O
involved O
in O
the O
regulation O
of O
gene B-Gene
expression I-Gene

364 O
Epigenetic O
modulations O
underlie O
critical O
developmental O
processes O
and O
contribute O
to O
determining O
adult O
phenotype O

1082 O
The O
problem O
of O
preterm B-Disease
birth I-Disease
continues O
to O
pose O
one O
of O
the O
most O
significant O
research O
challenges O
that O
we O
face O
due O
to O
its O
immense O
scope O
and O
complexity O

1276 O
In O
the O
past O
few O
fears O
, O
there O
has O
been O
a O
nascent O
convergence O
of O
scientific O
understanding O
of O
human B-Species
disease B-Disease
with O
epigenetic O

The O
Fat B-Species
Mass I-Species
and I-Species
Obesity I-Species
( O
FTO B-Gene
) O
locus O
, O
the O
strongest O
genetic O
risk O
factor O
for O
human B-Disease
obesity I-Disease
, O
is O
an O
enriched O
site O
for O
hibernator B-Species
pARs B-Gene

However O
, O
the O
entire O
picture O
of O
the O
epigenetic O
crosstalk O
regulating O
the O
CG B-Gene
methylation I-Gene
pattern O
is O
unknown O
especially O
in O
cells O
that O
are O
available O
only O
in O
a O
limited O
number O
, O
such O
as O
mammalian B-Species
oocytes I-Species

This O
review O
will O
explore O
recent O
genetic O
and O
epigenetic O
approaches O
to O
anxiety B-Disease
disorders I-Disease
explaining O
differential O
susceptibility O
risk O

We O
discuss O
the O
interplay O
between O
epigenetics O
and O
DNA B-Gene
sequence I-Gene
variation O
as O
well O
as O
the O
implications O
of O
epigenetics O
for O
cellular O
memory O
and O
plasticity O

These O
changes O
are O
the O
result O
of O
a O
complex O
cross-talk O
between O
several O
molecular O
mechanisms O
that O
is O
in O
turn O
orchestrated O
by O
genetic O
and O
environmental O
factors O

226 O
 O
Epigenetic O
changes O
caused O
by O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical
play O
important O
roles O
in O
the O
regulation O
of O
various O
cellular O
processes O
and O
development O

g O

140 O
Society O
prizes O
the O
rapid O
translation O
of O
basic O
biological O
science O
into O
ways O
to O
prevent O
human O
illness B-Disease

The O
emerging O
field O
of O
epigenetics O
is O
beginning O
to O
reveal O
how O
genotypic O
expression O
can O
be O
mediated O
by O
an O
array O
of O
variables O
including O
external O
environmental O
exposure O
, O
inter-individual O
developmental O
variation O
, O
and O
by O
the O
genome O
itself O

02 O
, O
1 O

Summary O

7% O
) O
% O
) O

Epigenetics O
, O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modification I-Chemical
, O
and O
post-transcriptional O
regulation O
of O
miRNAs B-Gene
, O
is O
the O
study O
of O
heritable O
changes O
in O
gene B-Gene
expression I-Gene
that O
do O
not O
include O
DNA B-Chemical
sequence I-Chemical
alterations O

Integration O
of O
chromatin O
conformation O
datasets O
is O
one O
of O
the O
latest O
efforts O
in O
deciphering O
schizophrenia B-Disease
risk O
, O
allowing O
the O
identification O
of O
genes O
in O
contact O
with O
regulatory O
variants O
across O
100s O
of O
kilobases O

Epigenetic O
processes O
serve O
critical O
roles O
in O
development O
and O
operate O
as O
intermediaries O
that O
connect O
the O
genome B-Gene
to O
the O
rest O
of O
the O
world O

It O
has O
been O
proposed O
that O
up O
to O
88% O
of O
obese O
adults O
have O
NAFLD B-Disease
, O
and O
with O
global O
obesity O
rates O
increasing O
, O
this O
disease O
is O
set O
to O
become O
even O
more O
prevalent O

Biomedical O
text O
and O
numerical O
data O
mining O
are O
both O
considered O
, O
the O
first O
dealing O
with O
automated O
methods O
for O
analyzing O
research O
content O
and O
information O
extraction O
, O
and O
the O
second O
( O
broadly O
) O
with O
pattern O
recognition O
and O
prediction O

The O
most O
commonly O
used O
approach O
infers O
the O
methylation O
state O
of O
a O
given O
genomic O
region O
on O
the O
basis O
of O
the O
amount O
of O
nucleotide O
mis-incorporations O
observed O
at O
CpG B-Chemical
dinucleotide I-Chemical
sites O

Here O
we O
review O
the O
methods O
that O
have O
permitted O
us O
glimpses O
of O
the O
colon B-Disease
cancer I-Disease
methylome O
and O
outline O
future O
directions O
that O
will O
eventually O
lead O
researchers O
to O
identify O
the O
altered O
epigenetic O
patterns O
in O
cancer B-Disease
cells O

These O
epigenomic O
data O
can O
be O
analyzed O
by O
a O
large O
number O
of O
bioinformatics O
tools O
and O
software O

We O
argue O
that O
attention O
to O
phenotype O
nuance O
, O
progressing O
to O
association O
with O
epigenetic O
marks O
and O
then O
causal O
analyses O
of O
the O
epigenetic O
mechanism O
, O
will O
enable O
clearer O
evaluation O
of O
the O
evolutionary O
path O

Aberrant O
DNA B-Gene
methylation I-Gene
has O
unique O
characteristics O
different O
from O
point O
mutations O
and O
is O
utilized O
as O
a O
diagnostic O
target O

Thus O
, O
the O
intertwined O
links O
between O
the O
circadian O
clock O
and O
epigenetics O
may O
point O
to O
novel O
approaches O
for O
antidepressant B-Chemical
treatments O
, O
epigenetic O
therapy O
, O
and O
chronotherapy O

The O
presence O
in O
the O
same O
cell O
compartment O
of O
two O
nuclei O
with O
distinctly O
different O
structural O
and O
functional O
properties O
provides O
an O
ideal O
model O
system O
to O
explore O
mechanisms O
of O
genome O
maintenance O

We O
extended O
the O
model-based O
analyses O
of O
EpiMix O
to O
cis-regulatory O
elements O
within O
protein-coding B-Gene
genes I-Gene
, O
distal O
enhancers O
, O
and O
genes B-Gene
encoding I-Gene
microRNAs B-Gene
and I-Gene
long I-Gene
non-coding I-Gene
RNAs I-Gene
( O
lncRNAs B-Gene
) O

This O
article O
discusses O
the O
current O
status O
, O
challenges O
and O
research O
opportunities O
in O
GWAS B-Gene
and O
EWAS B-Gene

Epigenetic O
mechanisms O
are O
sure O
to O
play O
a O
pivotal O
role O
in O
what O
is O
essentially O
an O
acquired O
phenotype O

His O
research O
findings O
include O
the O
report O
of O
a O
close O
link O
between O
DNA B-Gene
methylation I-Gene
and O
BRAF B-Gene
mutation I-Gene
in O
colorectal B-Disease
cancer I-Disease
( O
Nature O
Genetics O
, O
2006 O
) O
[ O
2 O
] O
, O
the O
discovery O
that O
embryonic B-Species
stem I-Species
cell I-Species
polycomb B-Gene
repressor I-Gene
targets O

The O
workflow O
described O
here O
enables O
significant O
gene O
and O
methylation-specific O
pathways O
to O
be O
identified O
from O
whole O
blood O
samples O
of O
individuals O
exposed O
to O
environmentally O
relevant O
chemical B-Chemical
levels O

This O
article O
examines O
the O
epigenetic O
impact O
of O
adversity O
during O
childhood O
and O
its O
behavioral O
consequences O
on O
mental B-Disease
health I-Disease

In O
general O
, O
it O
can O
be O
stated O
that O
behavior O
and O
environment O
will O
finally O
take O
on O
a O
leading O
role O
in O
human B-Species
development O
through O
epigenetic O
mechanisms O

Although O
several O
disease-modifying O
immunotherapeutic O
agents O
are O
in O
clinical O
development O
, O
many O
have O
failed O
due O
to O
the O
lack O
of O
efficacy O
or O
serious O
adverse O
events O

From O
the O
therapeutic O
viewpoint O
, O
DNA B-Gene
demethylating I-Gene
agents O
have O
been O
approved O
for O
the O
treatment O
of O
myelodysplastic B-Disease
syndrome I-Disease
and O
histone B-Chemical
deacetylase I-Chemical
inhibitors O
for O
the O
treatment O
of O
cutaneous B-Disease
T-cell I-Disease
lymphoma I-Disease

07 O
/ O
1 O

Second O
, O
there O
is O
a O
discussion O
of O
( O
1 O
) O
the O
" O
tissue O
issue O
, O
" O
( O
2 O
) O
maximizing O
the O
interpretability O
of O
candidate O
gene B-Gene
and O
epigenome-wide O
approaches O
, O
and O
( O
3 O
) O
the O
need O
for O
examining O
DNAm B-Gene
as O
a O
potential O
biomarker O
for O
mental B-Disease

799 O
Personalized O
medicine O
, O
which O
involves O
modifying O
treatment O
strategies O
/ O
drug B-Chemical
dosages O
based O
on O
massive O
laboratory O
/ O
imaging O
data O
, O
faces O
large O
statistical O
and O
study O
design O
problems O


A O
better O
understanding O
of O
the O
molecular O
basis O
for O
epigenetic O
memory O
will O
play O
a O
central O
role O
in O
improving O
diagnostics O
and O
prognostics O
of O
disease B-Disease
states I-Disease
and O
aid O
the O
development O
of O
targeted O
therapeutics O
of O
complex O
diseases B-Disease

In O
this O
review O
, O
we O
mainly O
focus O
on O
base O
modification O
detection O
in O
the O
DNA B-Gene
and O
RNA B-Gene
of O
mammals B-Species
using O
the O
Nanopore B-Chemical
sequencer O

In O
this O
article O
, O
we O
review O
recent O
findings O
on O
the O
role O
of O
epigenetic O
factors O
in O
eating B-Disease
disorders I-Disease
, O
address O
methodological O
issues O
that O
need O
to O
be O
considered O
when O
interpreting O
research O
findings O
, O
and O
comment O
on O
possible O
clinical O
applications O

Our O
work O
provides O
a O
foundation O
for O
single-cell O
and O
sparse O
data O
epigenetic O
age O
predictors O
, O
validates O
their O
functionality O
and O
highlights O
epigenetic O
heterogeneity O
during O
ageing O

15Given O
the O
increasing O
research O
activity O
on O
epigenetics O
to O
monitor O
human B-Species
diseases B-Disease
and O
its O
connection O
with O
lifestyle O
and O
environmental O
expositions O
, O
the O
field O
of O
epigenetics O
has O
attracted O
a O
great O
deal O
of O
interest O
also O
at O
the O
ethical O
and O
societal O
level O

However O
, O
three O
areas O
of O
development O
suggest O
where O
epigenetic O
data O
protection O
may O
prove O
problematic O

1376 O
 O
Aging O
is O
associated O
with O
impairments O
in O
hematopoietic B-Species
stem I-Species
cell I-Species
( O
HSC B-Gene
) O
function O
and O
an O
increased O
risk O
of O
leukemogenesis B-Disease

Epigenetic O
alterations O
can O
arise O
from O
downstream O
activation O
of O
cellular O
pathways O
through O
both O
extracellular O
stimulation O
and O
genetic-associated O
changes O
, O
impacting O
epigenetic O
enzymes O
or O
their O
interactors O

There O
is O
growing O
interest O
in O
the O
potential O
role O
of O
epigenetic O
mechanisms O
in O
disease B-Disease
susceptibility I-Disease
and O
data O
are O
emerging O
on O
the O
role O
of O
epigenetics O
in O
the O
maturation O
of O
the O
immune B-Gene
system I-Gene
in O
early O
life O

003 O
; O
and O
DNAm O
cystatin B-Chemical
C I-Chemical
, O
b(SE) O
= O
2 O

The O
persistence O
of O
these O
neuroadaptations O
is O
mediated O
in O
part O
by O
epigenetic O
remodeling O
of O
gene B-Gene
expression I-Gene
programs O
in O
discrete O
brain O
regions O

Dysregulated O
epigenetic O
changes O
can O
alter O
gene B-Gene
expression O
and O
impair O
cellular O
functions O
in O
immune O
cells O
, O
resulting O
in O
autoreactive B-Disease
immune O
responses O

891Background O
Aging O
is O
defined O
as O
a O
biological O
and O
physical O
complex O
process O
that O
is O
characterized O
by O
the O
increase O
in O
susceptibility O
to O
diseases O
and O
eventually O
death O

Now O
, O
it O
is O
established O
that O
aberrant O
epigenetic O
alterations O
are O
involved O
in O
cancer B-Disease
development O
and O
progression O
, O
along O
with O
mutations O
and O
chromosomal O
losses O

Overall O
, O
neuromuscular B-Disease
disorder I-Disease
epigenetic O
biomarkers O
have O
a O
strong O
potential O
for O
clinical O
applications O
in O
the O
near O
future O
Dysregulation O
of O
the O
epigenome O
is O
associated O
with O
the O
onset O
and O
progression O
of O
several O
diseases O
, O
including O
cancer B-Disease
, O
autoimmune B-Disease
, O
cardiovascular B-Disease
, O

Materials O
and O
methods O
 O

Although O
in O
its O
infancy O
, O
research O
in O
this O
area O
potentially O
unifies O
several O
pathophysiological O
processes O
underpinning O
abnormal O
pain O
processing O
and O
opens O
up O
a O
different O
avenue O
for O
the O
development O
of O
novel O
analgesics B-Chemical

More O
broadly O
, O
it O
allows O
for O
proper O
treatment O
of O
correlated O
responses O
within O
clusters O

E O


We O
aimed O
to O
identify O
epigenetic O
marks O
of O
DNA B-Chemical
methylation I-Chemical
in O
the O
brain O
and O
peripheral O
tissues O
to O
elucidate O
the O
potential O
pathophysiological O
mechanism O
of O
POD B-Disease

However O
, O
while O
these O
tools O
are O
advancing O
our O
ability O
to O
understand O
and O
manipulate O
this O
regulatory O
layer O
of O
the O
genome B-Gene
, O
they O
still O
possess O
a O
variety O
of O
limitations O
in O
efficacy O
, O
implementation O
, O
and O
targeting O
specificity O

Additionally O
, O
they O
increase O
the O
risk O
of O
mortality O

However O
, O
few O
computational O
pipelines O
are O
available O
to O
the O
public O
to O
perform O
systematic O
DNA B-Gene
methylation I-Gene
analysis O

The O
DNA B-Gene
repair I-Gene
mechanisms O
again O
are O
influenced O
by O
the O
chromatin B-Gene
structure I-Gene

Increasing O
evidence O
suggests O
that O
epigenetic O
factors O
and O
mechanisms O
serve O
as O
important O
mediators O
of O
the O
pathogenic O
processes O
that O
lead O
to O
irrevocable O
neural O
injury B-Disease
and O
of O
countervailing O
homeostatic O
and O
regenerative O
responses O

Here O
, O
we O
discuss O
the O
epigenetic O
processes O
of O
innate O
immune O
cells O
during O
serious B-Disease
infections I-Disease
with O
systemic B-Disease
inflammation I-Disease
in O
four O
stages O
 O
homeostasis O
, O
incitement O
, O
evolution O
, O
and O
resolution O

scMET O
can O
identify O
highly O
variable O
features O
that O
drive O
epigenetic O
heterogeneity O
, O
and O
perform O
differential O
methylation O
and O
variability O
analyses O

Epigenetic O
control O
has O
also O
been O
implicated O
in O
the O
modulation O
of O
biological O
timekeeping O
, O
and O
cellular O
metabolism O
and O
epigenetic O
state O
seem O
to O
be O
closely O
linked O

The O
analyses O
revealed O
the O
involvement O
of O
both O
coding O
and O
non O
coding O
RNAs O
(SNORDs O
located O
in O
DLK1-DIO3 B-Gene
region O
) O
and O
support O
a O
model O
of O
stepwise O
progression O
mainly O
driven O
by O
epigenetic O
changes O
involving O
tumour B-Disease
vascular I-Disease
supply I-Disease
and O
tumoral B-Disease
cellular I-Disease
component I-Disease

g O

However O
, O
the O
precise O
molecular O
mechanisms O
remain O
to O
be O
elucidated O

The O
pathophysiology O
of O
ADs B-Disease
is O
multifaceted O
and O
involves O
intricate O
connections O
among O
biological O
elements O
, O
environmental O
stimuli O
, O
and O
psychological O
mechanisms O

Their O
application O
to O
analyze O
the O
SAR O
of O
DNA B-Gene
methyltransferase I-Gene
( O
DNMT B-Gene
) O
inhibitors O
, O
which O
are O
attractive O
compounds O
as O
potential O
epi-drugs O
or O
epi-probes O
, O
provides O
useful O
information O
to O
identify O
pharmacophoric O
regions O
and O
plan O
the O
development O
of O
predictive O
models O
and O
virtual O
screening O

Here O
, O
we O
provide O
a O
detailed O
protocol O
for O
the O
design O
, O
construction O
, O
and O
utilization O
of O
a O
transient O
, O
CRISPR-based B-Gene
DNA B-Chemical
methylation-editing I-Chemical
system O
in O
mammalian B-Species
cells I-Species

Autoimmune B-Disease
/ I-Disease
inflammatory I-Disease
disorders I-Disease
can O
be O
stratified O
along O
a O
spectrum O
based O
on O
the O
primary O
involvement O
of O
innate O
vs O

His O
expertise O
is O
in O
cellular O
and O
molecular O
biology O

We O
then O
( O
II O
) O
compare O
EE O
and O
GE O
and O
suggest O
that O
the O
severity O
of O
risks O
of O
novel O
gene B-Gene
technologies O
depends O
on O
three O
factors O
 O
( O
i O
) O
the O
choice O
of O
an O
ex O
vivo O
versus O
an O
in O
vivo O
editing O
approach O
, O
( O
ii O
) O
the O
time O
of O

In O
recent O
years O
, O
CRISPR-Cas9 B-Gene
systems O
have O
been O
employed O
to O
unearth O
this O
complexity O
and O
provide O
new O
insights O
on O
the O
contribution O
of O
chromatin B-Chemical
dysregulation O
in O
the O
development O
of O
genetic B-Disease
diseases I-Disease
, O
as O
well O
as O
new O
tools O
to O
prevent O
or O
reverse O
this O

Methods O
 O
DNA B-Gene
samples O
exacted O
from O
CD4+ B-Gene
T I-Gene
cells I-Gene
of O
48 O
SSc B-Disease
patients O
and O
16 O
healthy O
controls O
were O
hybridized O
on O
MethylationEPIC B-Chemical
BeadChip I-Chemical
array O

Trial O
registration O
 O
ClinicalTrials O

LOAD O
cases O
are O
more O
prevalent O
with O
genetically O
complex O
architecture O

Illumina O
methylation O
arrays O
are O
useful O
for O
epigenome O
research O
using O
the O
common B-Species
marmoset I-Species

Our O
data O
suggest O
that O
for O
the O
majority O
of O
the O
genome O
, O
a O
blood-based O
EWAS O
for O
disorders O
where O
brain O
is O
presumed O
to O
be O
the O
primary O
tissue O
of O
interest O
will O
give O
limited O
information O
relating O
to O
underlying O
pathological O
processes O

and O

Promising O
results O
from O
microRNA B-Gene
(miRNA) I-Gene
profiling O
and O
hypermethylation O
of O
selected O
genes O
have O
raised O
hopes O
of O
identifying O
new O
biomarkers O

How O
ascorbate B-Chemical
affects O
the O
immune O
system O
at O
the O
cellular O
and O
molecular O
levels O
remained O
unclear O

1351 O
methylation O
exerts O
critical O
effects O
on O
gene-expression O
regulation O
in O
normal O
cells O
, O
and O
alterations O
on O
the O
normal O
methylation O
patterns O
characterize O
, O
and O
likely O
contribute O
, O
to O
development O
and O
progression O

First O
, O
a O
summary O
of O
the O
epigenetic O
landscape O
of O
oral B-Disease
health I-Disease
is O
presented O

98 O
About O
80 O
% O
of O
brain B-Disease
disorders I-Disease
have O
a O
genetic B-Gene
basis O

Among O
them O
, O
49 O
regions O
could O
be O
validated O
with O
similar O
methylation O
changes O
in O
blood O
from O
independent O
individuals O

Combined O
treatment O
with O
DAC B-Chemical
and O
a O
Bcl2 B-Gene
inhibitor O
, O
venetoclax B-Chemical
, O
exhibited O
strong O
synergistic O
potency O
against O
lung B-Disease
cancer I-Disease
without O
normal O
tissue O
toxicity O

Epigenetic O
mechanisms O
, O
especially O
DNA B-Chemical
methylation I-Chemical
( O
DNAm B-Gene
) O
, O
are O
a O
possible O
process O
how O
these O
adverse O
environmental O
events O
could O
be O
biologically O
embedded O

624 O
Numerous O
preclinical O
and O
clinical O
trials O
, O
with O
older O
as O
well O
as O
some O
newer O
drugs O
, O
have O
demonstrated O
the O
targeting O
of O
aberrant O
epigenetic O
marks O
to O
be O
a O
viable O
means O
of O
preventing O
and O
treating O
certain O
human O
disorders O
, O
including O
myelodysplastic B-Disease
and I-Disease

143 O
 O
Lymphoid B-Disease
neoplasms I-Disease
represent O
a O
heterogeneous O
group O
of O
disease O
entities O
and O
subtypes O
with O
markedly O
different O
molecular O
and O
clinical O
features O

Our O
results O
highlight O
concordant O
loci O
for O
EAA B-Disease
in O
humans B-Species
and O
mice B-Species
, O
and O
demonstrate O
a O
tight O
coupling O
between O
the O
metabolic O
state O
and O
epigenetic O
aging O

DNA O
methylation O
profiling O
was O
the O
focus O
of O
the O
majority O
of O
studies O
, O
but O
several O
studies O
also O
measured O
microRNA B-Gene
profiles O

Thus O
, O
in O
this O
study O
, O
we O
developed O
an O
in O
silico O
epigenetic O
panel O
and O
performed O
a O
comparative O
analysis O
of O
epigenetic O
modifiers O
in O
the O
RNA-seq O
results O
of O
32 O
human B-Species
tissues O

EZH2 B-Gene
and O
EED B-Gene
) O
and O
exploration O
of O
the O
optimum O
combination O
(s O
) O
should O
be O
supported O
by O
preclinical O
research O
and O
, O
where O
possible O
, O
molecular O
biomarker O
validation O
in O
advance O
of O
clinical O
translation O

The O
newly O
developed O
clock O
uses O
200 O
cytosine-phosphate-guanine B-Chemical
dinucleotides I-Chemical
to O
estimate O
chronological O
age O
in O
skeletal O
muscle O
, O
16 O
of O
which O
are O
in O
common O
with O
the O
353 O
cytosine-phosphate-guanine B-Chemical
dinucleotides I-Chemical
of O
the O
pan-tissue O
clock O

Moreover O
, O
upregulated O
circulating O
miR-361-5p B-Gene
, O
miR-889 B-Gene
, O
miR-576-3p B-Gene
may O
be O
useful O
biomarkers O
to O
discriminate O
tuberculosis B-Disease
patients O

717 O
Forensic O
genetics O
developed O
from O
protein-based O
techniques O
a O
quarter O
of O
a O
century O
ago O
and O
became O
famous O
as O
" O
DNA B-Chemical
fingerprinting O
," O
this O
being O
based O
on O
restriction O
fragment O
length O
polymorphisms O
( O
RFLPs O
) O
of O
high-molecular-weight O
DNA B-Chemical

Specifically O
, O
we O
give O
details O
about O
the O
protocol O
, O
discuss O
the O
pros O
and O
cons O
of O
these O
methodologies O
, O
and O
give O
practical O
tips O
for O
achieving O
optimal O
results O
and O
for O
troubleshooting O

59 O
( O
95% O
CI O
 O
0 O

uCoTarget O
reveals O
establishment O
of O
pairing O
of O
HSPC O
enhancers O
( O
) O
and O
promoters O
( O
) O
and O
engagement O
priming O
for O
activation O
along O
the O
HSPC O
path O

However O
, O
the O
association O
of O
epigenetic O
dysfunction O
with O
disease B-Disease
and O
the O
development O
of O
therapeutic O
agents O
for O
treatment O
are O
slow O

1149 O
Nonviral O
gene B-Gene
delivery I-Gene
has O
seen O
limited O
clinical O
application O
due O
in O
part O
to O
the O
inefficiency O
with O
which O
most O
nonviral O
vehicles O
navigate O
the O
intracellular O
gene B-Gene
delivery I-Gene
pathway O

These O
diseases B-Disease
compromise O
healthspan O

To O
study O
these O
dynamics O
, O
we O
developed O
quantitative O
models O
that O
measure O
the O
effect O
of O
multiple O
factors O
on O
DNA B-Gene
methylomes O
including O
, O
age O
, O
sex O
, O
weight O
, O
and O
genetics O

cancers I-Disease

0 O
to O
become O
a O
popular O
software O
and O
be O
widely O
used O
in O
epigenome-wide O
associated O
studies O
in O
the O
future O

223 O
Epigenome O
editing O
refers O
to O
the O
directed O
alteration O
of O
chromatin O
marks O
at O
specific O
genomic O
loci O
by O
using O
targeted O
EpiEffectors O
which O
comprise O
designed O
DNA O
recognition O
domains O
( O
, O
, O
or O

It O
also O
provides O
an O
interface O
between O
environment O
and O
the O
genotype B-Gene
leading O
to O
functional O
plasticity O
of O
the O
genome B-Gene

We O
review O
here O
the O
progress O
made O
in O
this O
field O
and O
discuss O
open O
questions O
in O
epigenetic O
regulation O
and O
its O
stability O
, O
methods O
to O
increase O
the O
specificity O
of O
epigenome O
editing O
, O
and O
improved O
delivery O
methods O
for O
targeted O
EpiEffectors O

This O
finding O
may O
assist O
in O
classifying O
endometriosis B-Disease
into O
distinct O
subtypes O
that O
may O
be O
clinically O
relevant O

We O
outline O
experimental O
protocols O
and O
best O
practices O
for O
the O
cellular O
characterization O
and O
use O
of O
" O
chemical B-Chemical
probes I-Chemical
" O
that O
selectively O
inhibit O
protein O
methyltransferases B-Gene
, O
many O
of O
which O
methylate O
histones B-Gene
to O
regulate O
heritable O
gene B-Gene
expression I-Gene
patterns I-Gene

their O

CFEA O
provides O
a O
comprehensive O
and O
timely O
resource O
to O
the O
scientific O
community O
and O
supports O
the O
development O
of O
liquid B-Chemical
biopsy-based I-Chemical
biomarkers O
for O
various O
human B-Species
diseases O

Methylation O
studies O
evolved O
rapidly O
from O
low O
resolution O
global O
to O
targeted O
analyses O
of O
known O
psoriatic B-Disease
disease I-Disease
susceptibility O
loci O
such O
as O
HLA-C*0602 B-Gene

These O
epigenetic O
modifications O
influence O
how O
DNA B-Gene
is O
transcribed O
without O
altering O
its O
sequence O

In O
a O
healthy O
cohort O
, O
the O
most O
variable O
CpG B-Gene
sites I-Gene
are O
responsible O
for O
accelerated O
and O
decelerated O
epigenetic O
aging O
, O
relative O
to O
chronological O
age O

Dr O
. O

There O
are O
two O
critical O
periods O
of O
epigenetic O
reprogramming O
 O
gametogenesis O
and O
early O
preimplantation O
development O

This O
review O
is O
focused O
on O
the O
results O
from O
human B-Species
studies O
highlighting O
the O
causal O
role O
of O
epigenetic O
mechanisms O
in O
mediating O
the O
link O
between O
the O
adversity O
during O
early O
development O
, O
from O
prenatal O
stages O
through O
infancy O
, O
and O
adult O
neuropsychiatric B-Disease
outcomes O

In O
this O
review O
, O
we O
highlight O
the O
evidence O
that O
epigenetic O
modifications O
, O
specifically O
histone O
modifications O
, O
within O
key O
brain O
reward O
regions O
are O
correlated O
with O
addiction B-Disease

Psychopathy B-Disease
is O
a O
personality O
disorder O
associated O
with O
repeat O
displays O
of O
antisocial O
behaviour O
, O
and O
is O
associated O
with O
the O
disproportionate O
imposition O
of O
harm O
on O
communities O

These O
findings O
unveil O
a O
novel O
mechanism O
underlying O
mitochondrial O
fission-mediated O
cancer B-Disease
stemness O
and O
suggest O
that O
regulation O
of O
mitochondrial O
fission O
via O
inhibition O
of O
PRMT1 B-Gene
may O
be O
an O
attractive O
therapeutic O
option O
for O
liver B-Disease
cancer I-Disease
treatment O

Exciting O
epigenetic O
discoveries O
have O
been O
found O
in O
addiction B-Disease
, O
early O
life O
stress O
, O
neurodegeneration B-Disease
, O
post-traumatic B-Disease
stress I-Disease
disorder I-Disease
, O
and O
depression B-Disease

The O
area O
under O
curve O
( O
AUC O
) O
value O
for O
the O
SLFN12 B-Gene
gene I-Gene
among O
HT B-Disease
patients O
was O
0 O

In O
this O
review O
, O
we O
focus O
on O
the O
prodynorphin B-Gene
gene I-Gene
as O
a O
model O
for O
the O
in-depth O
epigenetic O
and O
transcriptional O
analysis O
of O
expression O
of O
the O
neuropeptide B-Gene
genes I-Gene

However O
, O
to O
our O
knowledge O
, O
the O
two O
methods O
have O
not O
yet O
been O
compared O

Additionally O
, O
disturbed O
methylation O
patterns O
and O
cell-type O
specific O
marks O
were O
identified O
as O
potential O
mediators O
of O
genetic O
risk O
in O
RA B-Disease

We O
then O
review O
the O
short-comings O
of O
MS-AFLP B-Chemical
and O
suggest O
alternative O
techniques O
that O
might O
address O
some O
of O
these O
limitations O

For O
example O
, O
in O
Down B-Disease
syndrome I-Disease
, O
duplication O
of O
the O
21(st) O
chromosome O
, O
which O
contains O
the O
amyloid B-Chemical
beta I-Chemical
precursor I-Chemical
protein I-Chemical
( O
APP B-Gene
) O
gene O
, O
leads O
to O
accumulation O
of O
amyloid B-Chemical
beta I-Chemical
and O
Alzheimer's B-Disease
disease I-Disease
pathology O
and O

1421 O
Inflammation B-Disease
is O
a O
fundamental O
biologic O
process O
that O
is O
evolutionally O
conserved O
by O
a O
germ O
line O
code O

epigenetics B-Chemical

In O
addition O
, O
the O
large O
clusters O
of O
histone B-Chemical
valleys O
are O
found O
to O
be O
enriched O
at O
the O
promoters O
of O
the O
developmentally O
associated O
genes B-Gene

130 O
Recent O
findings O
in O
epigenetics O
have O
been O
attracting O
much O
attention O
from O
social O
scientists O
and O
bioethicists O
because O
they O
reveal O
the O
molecular O
mechanisms O
by O
which O
exposure O
to O
socioenvironmental O
factors O
, O
such O
as O
pollutants B-Chemical
and O
social O
adversity O
, O
can O
influence O
the O
expression O
of O
genes B-Gene

439 O
Mortality O
and O
morbidity O
from O
cardiovascular B-Disease
diseases I-Disease
( O
CVDs B-Disease
) O
represents O
a O
huge O
burden O
to O
society O

845 O
Autoimmune B-Disease
diseases I-Disease
are O
usually O
complex O
and O
multifactorial O
, O
characterized O
by O
aberrant O
production O
of O
autoreactive O
immune O
cells O
and/or O
autoantibodies O
against O
healthy O
cells O
and O
tissues O

7 O
and O
several O
freely O
available O
Python O
packages O

We O
discuss O
critical O
components O
of O
single-cell O
DNA O
methylome O
data O
analysis O
, O
including O
data O
preprocessing O
, O
quality O
control O
, O
imputation O
, O
dimensionality O
reduction O
, O
cell O
clustering O
, O
supervised O
cell O
annotation O
, O
cell O
lineage O
reconstruction O
, O
gene B-Gene
activity I-Gene
scoring I-Gene
, O
and O
integration O
with O
transcriptome O
data O

Epigenetic O
regulation O
provides O
a O
plausible O
explanation O
for O
the O
nongenetic O
paternal O
transmission O
of O
disease B-Disease
susceptibility I-Disease

The O
central O
role O
of O
histone B-Chemical
post-translational I-Chemical
modifications O
in O
epigenetics O
related O
biological O
processes O
has O
revitalized O
mass O
spectrometry O
based O
investigations O

wustl O

While O
data O
on O
genotoxicity O
are O
collected O
through O
standardized O
guideline O
tests O
, O
data O
collected O
on O
epigenetic O
effects O
is O
far O
less O
uniform O

66%) O

But O
what O
benefits O
have O
flown O
from O
the O
honeybee B-Species
genome O
project O
? O
What O
does O
the O
annotated O
genomic O
assembly O
mean O
for O
the O
study O
of O
behavioural O
complexity O
and O
organismal O
function O
in O
honeybees B-Species
? O
Here O
, O
I O
discuss O
several O
lines O
of O
research O
that O
have O
arisen O
from O
this O

No O
doubt O
, O
this O
important O
goal O
has O
been O
successfully O
achieved O
owing O
to O
the O
high O
quality O
of O
presented O
epidemiological O
and O
experimental O
studies O
and O
engaging O
discussions O
of O
many O
yet O
to O
be O
published O
results O

CVD O
and O
its O
associated O
pathologies O
remain O
the O
leading O
cause O
of O
death O
in O
Western B-Species
populations O
due O
to O
the O
limited O
regenerative O
capacity O
of O
the O
heart O

application O

Memory O
involves O
read-write O
systems O
that O
enable O
self-propagation O
and O
mitotic O
inheritance O
of O
cis-acting O
epigenetic O
marks O
to O
induce O
stable O
changes O
in O
transcription O

1398 O
Schizophrenia B-Disease
is O
a O
chronic O
mental O
illness O
with O
a O
substantial O
genetic O
component O

Using O
an O
online O
questionnaire O
, O
this O
study O
investigated O
the O
Australian B-Species
public O
's O
understanding O
, O
views O
, O
and O
opinions O
of O
epigenetics B-Gene
and O
related O
concepts O
, O
including O
the O
concepts O
of O
the O
developmental O
origins O
of O
health O
and O
disease B-Disease
( O
DOHaD B-Disease
) O
and O
the O
first O
1000 O

001 O
), O
and O
HUVEC B-Species
( O
Max O
F O
P O
= O
0 O

547 O
Motivation O
The O
interpretation O
of O
transcriptional O
dynamics O
in O
single-cell O
data O
, O
especially O
pseudotime O
estimation O
, O
could O
help O
understand O
the O
transition O
of O
gene B-Gene
expression I-Gene
profiles I-Gene

The O
influences O
of O
nutrients O
and O
bioactive O
food O
components O
on O
epigenetic O
phenomena O
such O
as O
methylation O
and O
various O
types O
of O
modifications O
have O
been O
extensively O
investigated O

A O
deep O
understanding O
of O
these O
mechanisms O
will O
help O
in O
properly O
coordinating O
future O
individual O
treatments O
of O
osteoporosis B-Disease
and O
OVF B-Disease

Epigenetic O
therapy O
using O
DAC B-Chemical
should O
be O
an O
attractive O
strategy O
for O
lung B-Disease
cancer I-Disease
therapy O

Here O
, O
we O
detail O
existing O
and O
emerging O
methods O
for O
the O
detection O
, O
quantification O
, O
and O
localization O
of O
5hmC B-Chemical
at O
global O
, O
locus-specific O
, O
and O
base O
resolution O
levels O

The O
observed O
methylation O
index O
, O
sensitivity O
and O
specificity O
of O
selected O
molecular O
markers O
( O
viz O

Human O
DNA B-Gene
Methylation I-Gene
Microarray O
(from O
Agilent B-Chemical
Technologies I-Chemical
) O
containing O
27,627 O
probes O
for O
CpG B-Gene
islands I-Gene
was O
used O
for O
screening O
of O
DNA B-Gene
methylation I-Gene
status O
in O
10 O
selected O
samples O

, O
DNA B-Gene
methylation I-Gene
) O
can O
influence O
gene O
expression O
changes O
and O
is O
known O
to O
occur O
as O
a O
molecular O
response O
to O
some O
chemical B-Chemical
exposures O

120Predicting O
differentially O
expressed O
genes B-Gene
(DEGs) O
from O
epigenetics O
signal O
data O
is O
the O
key O
to O
understand O
how O
epigenetics O
controls O
cell O
functional O
heterogeneity O
by O
gene B-Gene
regulation O

At O
present O
, O
silenced O
HIV B-Species
genomes O
, O
the O
latent O
HIV B-Species
reservoir O
, O
is O
a O
major O
obstacle O
for O
a O
curative O
treatment O
of O
AIDS B-Disease
patients O

We O
explain O
how O
the O
use O
of O
several O
combinations O
of O
barcoded O
adapters O
for O
the O
creation O
of O
highly O
multiplexed O
libraries O
allows O
the O
inclusion O
of O
up O
to O
144 O
different O
samples/individuals O
in O
only O
one O
sequencing O
lane O

In O
this O
review O
, O
we O
summarize O
the O
basics O
of O
epigenome O
editing O
and O
cancer B-Disease
epigenetics O
, O
followed O
by O
the O
current O
examples O
of O
cancer B-Disease
induction O
and O
suppression O
with O
the O
transcriptional O
control O
and O
epigenome O
editing O
technologies O

5-hmC B-Chemical
is O
considered O
to O
be O
one O
of O
the O
forms O
of O
epigenetic O
modification O
and O
is O
suggested O
as O
an O
intermediate O
step O
in O
a O
semi-active O
loss O
of O
DNA B-Chemical
methylation I-Chemical
mark O

Given O
these O
assumptions O
, O
we O
propose O
a O
Bayesian O
mixed O
model O
methodology O
that O
allows O
the O
estimation O
of O
epigenetic O
variance O
from O
a O
genealogical O
and O
phenotypic O
database O

984 O
Childhood O
psychotic O
symptoms O
are O
associated O
with O
increased O
rates O
of O
schizophrenia B-Disease
, O
other O
psychiatric O
disorders O
, O
and O
suicide O
attempts O
in O
adulthood O
; O
thus O
, O
elucidating O
early O
risk O
indicators O
is O
crucial O
to O
target O
prevention O
efforts O

The O
field O
of O
epigenetic O
inheritance O
is O
entering O
an O
exciting O
phase O
, O
in O
which O
we O
are O
beginning O
to O
understand O
the O
mechanisms O
by O
which O
non-genetic O
information O
is O
transmitted O
to O
, O
and O
deciphered O
by O
, O
subsequent O
generations O
to O
maintain O
essential O
environmental O
information O
without O
permanently O
altering O
the O

Once O
the O
human B-Species
epigenome O
has O
been O
fully O
mapped O
, O
identification O
of O
the O
effects O
of O
all O
deleterious O
environmental O
exposures O
according O
to O
duration O
of O
exposure O
and O
time O
period O
will O
be O
a O
complex O
undertaking O
, O
requiring O
collaborative O
epidemiologic O
studies O

These O
genetic O
and O
epigenetic O
changes O
in O
luminal B-Disease
A I-Disease
, O
luminal B-Disease
B I-Disease
, O
ERBB2/HER2-enriched B-Disease
, O
basal-like B-Disease
, O
and O
normal-like B-Disease
breast B-Disease
cancer I-Disease
subtypes O
are O
discussed O
in O
this O
chapter O

MethQTLs O
were O
readily O
detected O
in O
neonatal O
methylomes O
, O
and O
genotype O
alone O
best O
explained O
â¼25% O
of O
the O
VMRs O

Importantly O
, O
the O
new O
and O
innovative O
techniques O
including O
the O
CRISPR-Cas9 B-Gene
system O
have O
recently O
been O
adopted O
in O
epigenetic O
engineering O
of O
plant B-Species
genomes O
, O
facilitating O
the O
efforts O
for O
epibreeding O

Here O
we O
synthesize O
nearly O
a O
century O
of O
research O
on O
the O
ciliate O
genus O
Paramecium B-Species
that O
highlights O
the O
shortcomings O
of O
our O
prevailing O
notions O
on O
the O
nature O
of O
species O

A O
substantial O
minority O
of O
patients O
are O
unresponsive O
to O
current O
therapies O
, O
so O
there O
is O
an O
urgent O
need O
to O
develop O
more O
broadly O
effective O
, O
accessible O
, O
and O
tolerable O
therapies O

Such O
broad O
and O
high-resolution O
coverage O
investigations O
of O
the O
epigenome O
provide O
unprecedented O
opportunities O
to O
analyze O
DNA B-Chemical
methylation I-Chemical
patterns O
, O
which O
are O
correlated O
with O
tumorigenesis B-Disease
, O
tumor B-Disease
evolution I-Disease
, O
and O
tumor B-Disease
progression I-Disease

This O
review O
identified O
key O
putative O
markers O
that O
may O
be O
targeted O
for O
personalized O
clinical O
decision-making O
and O
provide O
important O
insights O
concerning O
candidate O
mechanisms O
that O
might O
underpin O
the O
early O
onset O
of O
depression B-Disease

These O
profiles O
measure O
epigenetic O
activity O
at O
the O
nucleotide O
resolution O
and O
they O
exhibit O
distinctive O
patterns O
as O
they O
fluctuate O
along O
the O
genome B-Gene

The O
honeybee B-Species
genome O
project O
helped O
pioneer O
advances O
in O
social O
insect O
molecular O
biology O
, O
and O
fuelled O
breakthrough O
research O
into O
the O
role O
of O
flexible O
epigenomic O
control O
systems O
in O
linking O
genotype B-Gene
to O
phenotype O

785 O
Knowledge O
of O
the O
fundamental O
epigenetic O
mechanisms O
governing O
gene B-Gene
expression O
and O
cellular O
phenotype O
are O
sufficiently O
advanced O
that O
novel O
insights O
into O
the O
epigenetic O
control O
of O
chronic B-Disease
liver I-Disease
disease I-Disease
are O
now O
emerging O

Recently O
, O
a O
series O
of O
approaches O
to O
study O
epigenetic O
reprogramming O
during O
transdifferentiation O
have O
been O
performed O

Multifactorial O
etiology O
, O
of O
which O
the O
candidate O
genes B-Gene
have O
been O
studied O
the O
most O
, O
poses O
a O
challenge O
in O
understanding O
this O
disorder B-Disease

21 O
Epigenetics O
, O
defined O
as O
'the O
study O
of O
mitotically O
and/or O
meiotically O
heritable O
changes O
in O
gene B-Gene
function I-Gene
that O
cannot O
be O
explained O
by O
changes O
in O
DNA B-Gene
sequence I-Gene
', O
has O
emerged O
as O
a O
promissory O
yet O
controversial O
field O
of O
scientific O
inquiry O
over O
the O
past O
decade O

We O
also O
highlight O
current O
challenges O
and O
future O
potential O
for O
epigenetics-based B-Chemical
therapies O

In O
eukaryotes B-Species
, O
DNA B-Gene
wraps O
on O
a O
histone B-Chemical
octamer O
( O
two O
copies O
of O
H2A B-Gene
, O
H2B B-Gene
, O
H3 B-Gene
and O
H4 B-Gene
) O
to O
form O
nucleosome O
, O
the O
fundamental O
unit O
of O
chromatin O

Therefore O
, O
the O
aim O
of O
this O
paper O
was O
to O
provide O
insight O
and O
synthesis O
into O
the O
intricate O
relationship O
between O
epigenetic O
mechanisms O
and O
IMF O
deposition O
in O
beef B-Species
cattle I-Species

It O
may O
caused O
by O
specific O
or O
multiple O
physical O
and O
physiological O
factors O
, O
including O
abnormalities O
in O
homeostasis O
, O
hormonal O
imbalances O
and O
genetic B-Disease
alterations I-Disease

Data O
holdings O
have O
also O
increased O
dramatically O
since O
the O
initial O
publication O
describing O
the O
NCBI O
Epigenomics O
resource O
and O
currently O
consist O
of O
>3700 O
viewable O
and O
downloadable O
data O
tracks O
from O
955 O
biological O
sources O
encompassing O
five O
well-studied O
species B-Species

N-terminal O
fusions O
showed O
better O
results O
for O
both O
Cas9 B-Gene
orthologs O
, O
SaCas9 B-Gene
and O
SpCas9 B-Gene
, O
so O
it O
can O
be O
used O
as O
universal O
approach O
for O
linking O
different O
effector O
domains O
in O
order O
to O
obtain O
highly O
active O
fusions O

611 O
The O
advent O
of O
functional O
genomics O
powered O
by O
high-throughput O
sequencing O
has O
given O
us O
a O
new O
appreciation O
of O
the O
genomic O
sequences O
that O
lie O
outside O
the O
canonical O
promoter-coding O
sequence O
box O

By O
considering O
the O
biological O
drivers O
of O
cell O
identity O
, O
such O
as O
networks O
of O
genes B-Gene
and O
gene B-Gene
regulatory O
elements O
, O
we O
propose O
a O
definition O
of O
cell O
type O
that O
emphasizes O
self-stabilizing O
regulation O

Here O
, O
we O
explored O
the O
varied O
osteogenic O
behaviors O
of O
human B-Species
adipose-derived I-Species
stem I-Species
cells I-Species
( O
hASCs B-Gene
) O
on O
titanium B-Chemical
dioxide I-Chemical
( O
TiO2 B-Chemical
) O
nanotube O
arrays O
of O
different O
diameters O

1355 O
The O
Special O
Issue O
State-of-the-Art O
Molecular O
Genetics O
and O
Genomics O
in O
Germany O
focuses O
on O
German O
researchers O
and O
their O
international O
peers O
, O
covering O
their O
recent O
advances O
in O
genetics O
, O
genomics O
, O
epigenetics O
, O
and O
cytogenetics/cytogenomics O
in O
relation O
to O
prokaryotic O
and O
eukaryotic O

In O
May O
2011 O
, O
the O
Canadian B-Species
Conference I-Species
on I-Species
Epigenetics I-Species
 O
Epigenetics B-Gene
Eh I-Gene
! O
was O
held O
in O
London B-Species
, O
Canada I-Species

Although O
epigenetic O
abnormalities O
are O
thought O
to O
be O
a O
symptom O
of O
cell O
tumorigenesis B-Disease
and O
malignant O
events O
that O
impact O
tumor B-Disease
growth O
and O
drug B-Chemical
resistance O
, O
physicians O
believe O
that O
related O
processes O
might O
be O
a O
key O
therapeutic O
target O
for O
cancer B-Disease
treatment O
and O
prevention O
due O
to O

66 O
Epigenetic O
mechanisms O
- O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
post-translational I-Chemical
modifications O
and O
changes O
in O
nucleosome B-Chemical
positioning I-Chemical
- O
regulate O
gene O
expression O
, O
cellular O
differentiation O
and O
development O
in O
almost O
all O
tissues O
, O
including O
the O
brain O

We O
will O
try O
to O
answer O
these O
two O
questions O
and O
determine O
the O
links O
between O
them O
by O
examining O
public O
health O
challenges O
and O
the O
questions O
raised O
by O
recent O
progress O
in O
biology O
, O
especially O
epigenetics B-Gene

175 O
Quantifying O
the O
relative O
importance O
of O
genomic O
and O
epigenomic O
modulators O
of O
phenotype O
is O
a O
focal O
challenge O
in O
comparative O
physiology O
, O
but O
progress O
is O
constrained O
by O
availability O
of O
data O
and O
analytic O
methods O

In O
this O
review O
, O
we O
investigated O
the O
structure O
, O
function O
, O
and O
regulation O
of O
chemoresistance-related O
SEs O
and O
their O
contributions O
to O
the O
chemotherapy O
via O
regulation O
of O
the O
formation O
of O
cancer B-Disease
stem I-Disease
cells I-Disease
, O
cellular O
plasticity O
, O
the O
microenvironment O
, O
genes B-Gene
associated I-Gene
with I-Gene

This O
review O
explores O
the O
nature O
of O
epigenetic O
modification O
in O
disease B-Disease
and O
the O
emerging O
evidence O
for O
epigenetic O
influences O
on O
allograft O
survival O

the O

While O
we O
cannot O
provide O
a O
step-by-step O
guide O
that O
fits O
all O
experimental O
setups O
and O
questions O
addressed O
, O
we O
explain O
frequent O
misconceptions O
and O
often O
overlooked O
pitfalls O

We O
developed O
a O
method O
to O
screen O
for O
genomic O
regions O
that O
exhibit O
loss O
or O
gain O
of O
ASM O
in O
samples O
from O
two O
conditions O
(treatments O
, O
diseases B-Disease
, I-Disease
etc O

processes I-Disease

From O
this O
perspective O
, O
we O
first O
review O
the O
state O
of O
high-throughput O
biological O
data O
acquisition O
( O
i O

509Background O

Genetics O
alone O
cannot O
explain O
sporadic O
cancer B-Disease
and O
cancer B-Disease
development O
in O
individuals O
with O
no O
family O
history O
or O
a O
weak O
family O
history O
of O
cancer B-Disease

10971037 O

The O
overarching O
aim O
is O
to O
integrate O
the O
evidence O
which O
suggests O
epigenetic O
inheritance O
modulates O
lifespan/longevity O
with O
the O
main O
evolutionary O
theories O
of O
ageing O

Among O
these O
methods O
, O
epigenetic O
regulation O
and O
epigenetic O
signatures O
are O
regarded O
as O
an O
important O
hurdle O
to O
overcome O
during O
reprogramming O
and O
differentiation O

We O
obtained O
a O
DNA B-Chemical
methylation I-Chemical
fingerprint O
of O
1628 O
human B-Species
samples O
in O
which O
we O
interrogated O
1505 O
CpG B-Gene
sites I-Gene

Here O
, O
we O
present O
a O
review O
of O
these O
methods O
and O
their O
promise O
to O
influence O
our O
studies O
on O
the O
epigenome O
for O
endocrine O
research O
and O
perhaps O
to O
uncover O
novel O
therapeutic O
options O
in O
disease B-Disease
states I-Disease

In O
recent O
years O
, O
with O
the O
in-depth O
study O
of O
the O
epigenetics O
of O
SSc B-Disease
( O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modification I-Chemical
, O
and O
non-coding O
RNA B-Gene
) O
, O
the O
DNA B-Chemical
methylation I-Chemical
and O
miRNA B-Gene
has O
been O
the O
most O
widely O
studied O

com O
/ O
p O
/ O
edmr O
/ O

This O
, O
coupled O
with O
its O
intentionally O
general O
nature O
, O
makes O
its O
interpretation O
for O
epigenetic O
assays O
non-trivial O

Conclusions O
 O
People O
who O
are O
biologically O
older O
, O
as O
indexed O
by O
greater O
extrinsic O
epigenetic O
age O
acceleration O
, O
are O
more O
likely O
to O
be O
physically O
frail O


1266 O
 O
Background O
 O
Pancreatic B-Disease
cancer I-Disease
's O
poor O
prognosis O
is O
caused O
by O
distal O
metastasis O
, O
which O
is O
associated O
with O
epigenetic O
changes O

1 O
 O
Neuromuscular B-Disease
disorders I-Disease
are O
a O
heterogeneous O
group O
of O
conditions O
affecting O
the O
neuromuscular O
system O

1120 O
There O
is O
a O
growing O
recognition O
of O
the O
importance O
of O
identifying O
both O
trans-diagnostic O
risk O
factors O
across O
the O
major O
disorders O
that O
onset O
early O
in O
childhood O
, O
as O
well O
as O
precise O
vulnerabilities O
that O
differentiate O
among O
specific O
disorders O

the O
relationship O
between O
genes B-Gene
and O
behavior O
is O
reconsidered O
in O
terms O
of O
epigenetic O
mechanisms O
acting O
after O
birth O
and O
not O
only O
prenatally O
, O
as O
traditionally O
held O

A O
progressive O
understanding O
of O
normal O
bone O
metabolism O
and O
the O
role O
of O
epigenetic O
mechanisms O
in O
multifactorial O
osteopathy B-Disease
can O
help O
us O
better O
understand O
the O
etiology O
of O
the O
disease O
and O
convert O
this O
information O
into O
clinical O
practice O

Studies O
have O
shown O
that O
epigenetic O
dysregulation O
is O
associated O
with O
multiple O
steps O
during O
carcinogenesis B-Disease

There O
were O
14 O
regions O
differentially O
methylated O
in O
the O
lip O
tissue O
from O
children O
with O
CLO B-Disease
and O
CLP B-Disease
, O
with O
one O
region O
( O
near O
KIAA0415 B-Gene
) O
showing O
up O
in O
both O
the O
blood O
and O
lip O
EWAS O

Prior O
studies O
have O
attempted O
to O
identify O
functional O
genomic O
aberrations O
by O
integrating O
multi-omics O
measurements O
in O
cancer B-Disease
samples O
with O
community-curated O
biological O
pathway O
networks O

448 O
Type O
2 O
diabetes B-Disease
( O
T2D B-Disease
) O
is O
caused O
by O
an O
inherited O
predisposition O
to O
pancreatic B-Species
islet I-Species
Î²-cell I-Species
failure O
, O
which O
is O
manifested O
under O
cellular O
stress O
induced O
by O
metabolic B-Chemical
overload I-Chemical

It O
reveals O
from O
the O
single-cell O
data O
the O
combinatorial O
regulatory O
interactions O
among O
genes B-Gene
that O
control O
the O
dynamic O
progression O
through O
successive O
cell O
states O

Although O
we O
lacked O
statistical O
power O
to O
conduct O
the O
most O
rigorous O
possible O
analyses O
, O
these O
results O
suggest O
that O
epigenetic O
potential O
may O
play O
a O
role O
in O
house B-Species
sparrow I-Species
range O
expansions O
, O
but O
additional O
work O
will O
be O
critical O
to O
elucidating O
how O
epigenetic O
potential O
affects O
gene B-Gene
expression I-Gene

Prenatal O
stress-associated O
epigenetic O
changes O
have O
also O
been O
linked O
to O
child O
health O
including O
internalizing O
problems O
, O
neurobehavioral O
outcomes O
and O
stress O
reactivity O

There O
is O
growing O
literature O
discussing O
the O
most O
promising O
opportunities O
, O
as O
well O
as O
arising O
ethical O
, O
legal O
and O
social O
issues O
( O
ELSI O
) O

The O
mechanism(s) O
that O
distinguish O
transgenerational O
and O
non-transgenerational O
epimutations O
have O
not O
been O
delineated O

Epigenetics O
has O
been O
implicated O
in O
the O
pathogenesis O
of O
systemic B-Disease
sclerosis I-Disease
( O
SSc B-Disease
) O

The O
development O
of O
epigenetic O
drugs O
requires O
a O
detailed O
knowledge O
of O
the O
processes O
that O
govern O
chromatin B-Chemical
regulation O

investigate O

In O
each O
of O
these O
diseases B-Disease
, O
genes B-Gene
that O
play O
a O
role O
in O
the O
proliferation O
or O
activation O
of O
CD8+ B-Gene
T I-Gene
cells I-Gene
have O
been O
found O
to O
be O
affected O
by O
epigenetic O
modifications O

425 O
This O
article O
compares O
two O
different O
bodies O
of O
theories O
concerning O
the O
role O
of O
the O
genome B-Gene
in O
life O
processes O

Through O
the O
practice O
of O
this O
course O
, O
students O
have O
a O
deeper O
understanding O
of O
the O
important O
role O
of O
epigenetic B-Chemical
modifications I-Chemical
, O
their O
scientific O
research O
capabilities O
have O
been O
greatly O
improved O
, O
thereby O
strongly O
supporting O
the O
cultivation O
of O
top O
innovative O
talents O
among O
the O
students O

Conclusions O
 O
Analysis O
of O
the O
existing O
data O
suggests O
that O
certain O
key O
genes O
and O
pathways O
may O
be O
the O
underlying O
cause O
of O
congenital B-Disease
microtia I-Disease

Here O
, O
we O
present O
this O
approach O
's O
implementation O
, O
centered O
around O
the O
JBR B-Gene
genome I-Gene
browser I-Gene
, O
a O
stand-alone O
tool O
that O
allows O
for O
accessible O
and O
streamlined O
annotation O
, O
analysis O
and O
visualization O

Challenges O
for O
the O
field O
include O
( O
1 O
) O
no O
clear O
consensus O
yet O
regarding O
disease-associated B-Disease
changes O
, O
( O
2 O
) O
the O
lack O
of O
cell-specific O
chromatin B-Chemical
assays O
which O
makes O
it O
difficult O
to O
ascribe O
epigenetic O
alterations O
to O
specific O
cell O
populations O
, O
and O
( O
3 O
) O
lack O
of O

Among O
the O
66 O
sites O
differentially O
methylated O
between O
groups O
exposed O
to O
inflammatory O
signals O
and O
control O
, O
most O
sites O
were O
over-methylated O
in O
the O
challenged O
group O
and O
included O
sites O
in O
the O
promoter O
regions O
of O
genes O
SIRT3 B-Gene
and O
NRBP1 B-Gene

We O
discuss O
challenges O
and O
barriers O
to O
advancing O
cardiometabolic B-Disease
epigenetics O
research O
, O
along O
with O
the O
opportunities O
for O
novel O
preventive O
strategies O
, O
targeted O
therapies O
, O
and O
personalized O
medicine O
approaches O
that O
may O
arise O
from O
a O
better O
understanding O
of O
epigenetic O
processes O

88 O
years O
( O
p O
= O
4 O

We O
provide O
recommendations O
for O
future O
studies O

This O
calls O
for O
more O
emphasis O
on O
individual O
assessment O
and O
diagnostics O
in O
both O
clinical O
practice O
and O
scientific O
research O

stress O

This O
review O
brings O
the O
essential O
knowledge O
on O
cardiac B-Disease
biology O
of O
development O

Restricting O
the O
analysis O
to O
CpGs B-Gene
shared O
between O
450 O
K O
and O
EPIC O
did O
not O
reduce O
the O
precision O
of O
the O
clock O

961 O
Nanostructured O
materials O
can O
direct O
stem B-Species
cell I-Species
lineage O
commitment O
solely O
by O
their O
various O
, O
but O
controllable O
, O
geometric O
cues O
, O
which O
would O
be O
very O
important O
for O
their O
future O
application O
in O
bone B-Disease
tissue I-Disease
engineering O
and O
bone B-Disease
regeneration O

Since O
some O
epigenetic O
changes O
are O
significant O
in O
abnormalities O
such O
as O
cancers B-Disease
and O
neurodegenerative B-Disease
diseases I-Disease
, O
the O
initial O
changes O
, O
dynamic O
and O
reversible O
properties O
, O
and O
diagnostic O
potential O
of O
epigenomic O
phenomena O
are O
subject O
to O
epigenome-wide O
association O
studies O
( O
EWAS O
) O
for O

Under O
such O
conditions O
, O
the O
two O
types O
of O
variances O
in O
the O
gene B-Gene
expression I-Gene
levels O
, O
i O

EpiAnnotator O
is O
an O
R O
Package O
accompanied O
by O
a O
web O
interface O

In O
recent O
years O
, O
epigenetic O
chromatin O
modifications O
have O
been O
implicated O
in O
CNS B-Disease
myelination O
and O
functional O
nerve O
restoration O

For O
many O
years O
, O
natural O
compounds O
have O
been O
used O
to O
treat O
various O
neurodegenerative B-Disease
diseases I-Disease
, O
but O
the O
use O
of O
such O
compounds O
as O
epigenetic O
modulators O
to O
reverse O
or O
treat O
neurological B-Disease
diseases I-Disease
are O
not O
well O
studied O

Given O
the O
potential O
and O
variety O
of O
computational O
implementations O
(epigenetic O
clocks B-Gene
), O
we O
here O
present O
a O
systematic O
review O
of O
such O
clocks O

This O
is O
now O
changing O
, O
as O
more O
and O
more O
ecologists O
learn O
about O
epigenetic O
processes O
and O
their O
potential O
ecological O
and O
evolutionary O
relevance O
, O
and O
a O
new O
research O
field O
of O
ecological O
epigenetics O
is O
beginning O
to O
take O
shape O

However O
, O
despite O
publication O
of O
multiple O
positive O
evaluations O
, O
the O
use O
of O
MBD-seq B-Gene
for O
MWAS B-Disease
is O
often O
fiercely O
criticized O

While O
Vargas O
' O
general O
idea-invoking O
epigenetic O
effects O
as O
an O
explanation O
of O
Kammerer O
's O
findings-remains O
attractive O
, O
at O
least O
two O
key O
aspects O
of O
his O
model O
need O
to O
be O
revised O

However O
, O
the O
main O
focus O
is O
emphasized O
on O
various O
epigenetic O
modifications O
particularly O
DNA B-Gene
methylation I-Gene
which O
are O
responsible O
for O
the O
initiation O
and O
progression O
of O
diabetic B-Disease
retinopathy I-Disease
and O
the O
use O
of O
different O
epigenetic O
inhibitors O
as O
a O
novel O
therapeutic O
option O
for O
DR B-Disease

This O
review O
will O
explore O
the O
interplay O
between O
epigenetics O
and O
aging O
, O
and O
how O
epigenetic O
reprogramming O
can O
be O
harnessed O
for O
age O
reversal O

Overlapping O
genes O
in O
comparison O
1 O
were O
involved O
in O
processes O
like O
limb O
morphogenesis O
and O
phenotypes O
like O
abnormal O
jaw O
morphology O
and O
hypopigmentation B-Disease

Altered O
methylome O
signatures O
were O
found O
in O
several O
cell O
types O
in O
RA B-Disease
, O
first O
of O
all O
RA B-Disease
synovial O
fibroblasts O
, O
and O
contribute O
to O
the O
intrinsic O
fibroblast O
activation O

All O
these O
results O
demonstrate O
that O
adaptive O
SMCCA O
are O
well O
suited O
for O
detecting O
three-way O
or O
multiway O
correlations O
and O
thus O
can O
find O
widespread O
applications O
in O
multiple O
omics O
and O
imaging O
data O
integration O

Recent O
observations O
( O
Boettiger B-Gene
et I-Gene
al I-Gene

Finally O
, O
we O
will O
discuss O
the O
application O
of O
proteomic O
methods O
in O
the O
diagnosis O
and O
prognosis O
of O
cancer B-Disease
based O
on O
epigenetic O
biomarkers O
and O
comment O
on O
their O
future O
impact O
on O
cancer B-Disease
epigenetics O

Machine O
Learning O
( O
ML O
) O
algorithms O
are O
particularly O
suited O
for O
epigenomic O
data O
analyses O
due O
to O
their O
flexibility O
and O
ability O
to O
learn O
underlying O
hidden O
structures O

While O
many O
epigenetic O
features O
have O
correlated O
relationships O
, O
most O
existing O
data O
normalization O
approaches O
analyze O
each O
feature O
independently O

The O
objective O
of O
this O
review O
paper O
is O
to O
summarise O
the O
current O
evidence O
supporting O
the O
interplay O
among O
DNA B-Chemical
methylation I-Chemical
, O
genetic O
variants O
, O
and O
environmental O
factors O
, O
specifically O
( O
1 O
) O
the O
association O
between O
SNP B-Gene
and O
DNA B-Chemical
methylation I-Chemical
; O
( O
2 O
) O

450Background O
Epigenetic O
heterogeneity O
within O
a O
tumour O
can O
play O
an O
important O
role O
in O
tumour O
evolution O
and O
the O
emergence O
of O
resistance O
to O
treatment O

Accumulating O
evidence O
shows O
that O
epigenetic O
remodeling O
plays O
a O
central O
role O
in O
mediating O
the O
transcriptional O
program O
for O
immune O
cell O
activation O
and O
immunological O
memory O

In O
such O
cases O
, O
one O
can O
impute O
the O
low-coverage O
( O
array-based O
) O
methylation O
data O
using O
the O
high-density O
information O
provided O
by O
the O
WGBS B-Chemical
samples O

Herein O
, O
we O
review O
the O
findings O
on O
epigenetics O
associated O
with O
psoriasis B-Disease
, O
and O
discuss O
future O
perspectives O
in O
this O
field O

We O
show O
that O
the O
field O
of O
epigenetics O
and O
epigenomics O
could O
serve O
to O
link O
molecular O
regulatory O
mechanisms O
with O
disease B-Disease
development I-Disease
and O
disease B-Disease
manifestation I-Disease
which O
could O
contribute O
to O
PCOS B-Disease
prevention O
and O
treatment O
and O
eventually O
promote O
reproductive O
health O
in O
fertile O
age O
women O

Epigenetic O
modifications O
mediate O
the O
biological O
effects O
of O
several O
environmental O
factors O
on O
gene O
expression O
; O
however O
, O
no O
information O
is O
available O
on O
the O
effects O
of O
IF B-Chemical
on O
the O
epigenome O

Concurrently O
, O
immune O
cells O
undergo O
significant O
metabolic O
reprogramming O
during O
immune O
response O

Genomic O
amplification O
of O
the O
MYCN B-Gene
oncogene O
has O
been O
used O
to O
predict O
outcome O
in O
neuroblastoma B-Disease
for O
over O
30 O
years O
, O
however O
, O
recent O
methodological O
advances O
including O
miRNA O
and O
mRNA O
profiling O
, O
comparative O
genomic O
hybridization O
( O
array-CGH O
) O
, O
and O
whole-genome O
sequencing O
have O

Yet O
, O
on O
close O
inspection O
, O
there O
is O
an O
inconsistency O
in O
Waddington's O
theoretical O
positioning O

Then O
an O
overview O
of O
the O
epigenetic O
changes O
in O
response O
to O
maternal O
environment O
during O
the O
vulnerability O
time O
windows O
, O
gametogenesis O
, O
early O
development O
, O
placentation O
and O
foetal O
growth O
, O
and O
postnatal O
period O
, O
is O
described O
, O
with O
the O
specific O
example O
of O
overnutrition O
and O
food O
deprivation O

EpiAnnotator's O
web O
interface O
is O
accessible O
at O
http//computational-epigenomics O

Most O
epigenetic O
studies O
have O
addressed O
long-term O
effects O
of O
environmental O
stressors O
on O
a O
small O
number O
of O
epigenetic O
marks O
, O
at O
the O
pan-genomic O
or O
individual O
gene B-Gene
level O
, O
in O
humans B-Species
and O
animal B-Species
models O

165 O
Epigenomics O
is O
the O
study O
of O
the O
physical O
modifications O
, O
associations O
and O
conformations O
of O
genomic O
DNA B-Gene
sequences O
, O
with O
the O
aim O
of O
linking O
these O
with O
epigenetic O
memory O
, O
cellular O
identity O
and O
tissue-specific O
functions O

We O
also O
conducted O
a O
Grey B-Disease
literature I-Disease
search O
, O
such O
as O
Google B-Chemical
Scholar I-Chemical

Given O
the O
individualized O
traits O
of O
epigenetic B-Chemical
biomarkers O
, O
epigenetic B-Chemical
considerations O
would O
significantly O
refine O
personalized O
nanomedicine O

456 O
 O
methylation O
is O
an O
epigenetic O
modification O
with O
a O
very O
long O
evolutionary O
history O

In O
germ O
cells O
and O
the O
developing O
embryo O
, O
genome-wide O
epigenetic O
reprogramming O
drives O
the O
erasure O
and O
reestablishment O
of O
correct O
epigenetic O
patterns O
at O
critical O
developmental O
time O
periods O
and O
in O
specific O
cell O
types O

Our O
method O
is O
based O
on O
a O
combinatorial O
genome O
segmentation O
solely O
using O
information O
on O
combinations O
of O
epigenetic O
marks O

More O
recently O
, O
there O
has O
been O
one O
genome-wide O
linkage O
study O
and O
a O
genome-wide O
association O
study O
( O
GWAS O
) O
of O
subclinical B-Disease
BPD I-Disease
traits O
and O
a O
first O
GWAS O
in O
a O
relatively O
modest O
sample O
of O
patients O
fulfilling O
full O
diagnostic O
criteria O
for O
the O
disorder O

, O
blood B-Disease
and O
brain B-Disease
) O

1101 O
Data O
from O
both O
bulk O
and O
single-cell O
whole-genome O
DNA B-Chemical
methylation I-Chemical
experiments O
are O
under-utilized O
in O
many O
ways O

aestivum O

Nature O
's O
second O
code O
is O
enigmatic O
and O
must O
be O
deciphered O
if O
we O
are O
to O
fully O
understand O
and O
optimize O
the O
genetic O
potential O
of O
crop B-Species
plants I-Species

Thus O
, O
this O
combination O
can O
correctly O
classify O
control O
samples O
and O
potentially O
identify O
epigenetically O
abnormal O
spermatozoa O
samples O
in O
the O
male O
partners O
of O
couples O
undergoing O
RPL B-Disease

This O
biological O
risk O
is O
complemented O
by O
alterations O
in O
the O
functional O
regulation O
of O
genes B-Gene
via O
environmentally O
induced O
epigenetic O
changes O
, O
including O
prior O
childhood O
and O
adult O
trauma B-Disease
exposure O

657 O
, O
and O
an O
area O
under O
the O
ROC O
curve O
of O
0 O

The O
majority O
of O
signals O
involve O
noncoding O
genetic O
variation O
, O
of O
which O
a O
large O
part O
is O
related O
to O
gene B-Gene
expression I-Gene
changes O

for O

The O
development O
of O
accurate O
computational O
approaches O
for O
analyzing O
complex O
epigenetic O
profiles O
is O
essential O
for O
disentangling O
the O
mechanisms O
underlying O
cellular O
development O
, O
and O
the O
intricate O
interaction O
networks O
determining O
and O
sensing O
chromatin O
modifications O
and O
DNA B-Chemical
methylation I-Chemical
to O
control O
gene B-Gene
expression I-Gene

Machine O
learning O
algorithms O
have O
accelerated O
studies O
in O
precision O
medicine O
targeting O
epigenetics B-Disease
diseases I-Disease

Results O
implicate O
maternal O
prenatal O
stress O
as O
a O
source O
of O
epigenetic O
mechanisms O
that O
affect O
fetal O
brain O
development O
and O
program O
risk O
for O
emotional O
dysregulation O
and O
mental O
disorders B-Disease
over O
a O
lifetime O
and O
across O
generations O

The O
presence O
of O
confounding O
in O
observational O
studies O
is O
inevitable O

Moreover O
, O
the O
contribution O
of O
the O
hereditary O
component O
decreases O
in O
the O
advanced O
, O
later O
onset O
forms O
of O
these O
chronic O
diseases O
including O
AMD B-Disease

Future O
studies O
should O
incorporate O
dose- O
and O
time-dependent O
study O
designs O
and O
also O
investigate O
the O
persistence O
of O
effects O
following O
cessation O
of O
exposure O
, O
considering O
the O
dynamic O
nature O
of O
most O
epigenetic O
alterations O

Thus O
, O
nutrition O
represents O
a O
promising O
tool O
to O
be O
used O
not O
only O
in O
cancer B-Disease
prevention O
, O
but O
hopefully O
also O
in O
cancer B-Disease
treatment O

We O
will O
focus O
on O
the O
use O
of O
MS B-Chemical
in O
the O
discovery O
and O
mapping O
of O
histone B-Chemical
modifications O
and O
how O
novel O
proteomic O
approaches O
are O
being O
utilized O
to O
identify O
and O
study O
chromatin-associated O
proteins O
and O
multi-subunit O
complexes O

However O
, O
many O
types O
of O
high-throughput O
data O
are O
based O
on O
genomic B-Gene
regions I-Gene

Epigenetic O
clocks O
, O
which O
measure O
changes O
in O
a O
few O
hundred O
specific O
CpG O
sites O
, O
can O
accurately O
predict O
chronological O
age O
in O
a O
variety O
of O
species O
, O
including O
humans B-Species

processes O

distribution O
of O
sequences O
within O
the O
genome O
, O
elimination O
of O
DNA B-Chemical
during O
formation O
of O
somatic O
nuclei O
) O

In O
addition O
, O
we O
applied O
this O
analysis O
to O
the O
transitional O
zone O
between O
methylated O
and O
unmethylated O
regions O
and O
to O
the O
cells O
undergoing O
epigenetic O
reprogramming O

The O
strict O
redundancy O
of O
each O
morphostasis O
regulatory O
cycle O
requires O
sensitive O
dependence O
upon O
initial O
conditions O
to O
avoid O
initiating O
deterministic O
chaos O
behavior O

Finally O
, O
we O
will O
discuss O
how O
current O
knowledge O
may O
aid O
us O
in O
early O
detection O
and O
improved O
management O
of O
PTSD B-Disease
patients O

Unlike O
the O
genome O
, O
the O
epigenome B-Gene
is O
highly O
variable O
between O
cells O
and O
is O
dynamic O
and O
plastic O
in O
response O
to O
cellular O
stress B-Disease
and O
environmental O
cues O

There O
were O
differentially O
methylated O
genes O
in O
5-yr-old B-Species
cows I-Species
that O
contributed O
similarly O
to O
altered O
gene B-Gene
pathways I-Gene
in O
both O
treatment O
groups O

The O
perturbations O
are O
either O
genetic O
, O
i O

to O

96 O
 O
Abnormal O
gene B-Gene
regulation O
as O
a O
consequence O
of O
flawed O
epigenetic O
mechanisms O
may O
be O
central O
to O
the O
initiation O
and O
persistence O
of O
many O
human B-Species
diseases B-Disease

Sequencing O
technologies O
that O
detect O
modification O
coupled O
with O
mass B-Chemical
spectrometry I-Chemical
to O
discover O
new O
adducts O
is O
a O
powerful O
tactic O
to O
study O
bacterial B-Species
epigenetics O
, O
which O
is O
poised O
to O
make O
novel O
and O
far-reaching O
discoveries O
that O
link O
biological O
significance O
and O
the O
bacterial B-Species
epigenome O

Most O
early O
genetic O
studies O
in O
BPD B-Disease
were O
non-replicated O
association O
studies O
in O
small O
samples O
, O
focused O
on O
single O
candidate O
genes O

We O
also O
compared O
methylation O
in O
the O
blood O
to O
methylation O
in O
the O
lip O
or O
palate O
tissue O
using O
genome-wide O
data O
from O
the O
same O
150 O
children O
and O
conducted O
an O
EWAS O
of O
CLO B-Disease
compared O
to O
CLP B-Disease
in O
lip O
tissue O

We O
introduce O
the O
term O
bio-ethnography O
to O
refer O
to O
research O
designs O
that O
integrate O
both O
of O
these O
methodologies O
into O
a O
single O
research O
project O

Specifically O
, O
we O
focus O
on O
the O
development O
of O
dual O
hybrids O
to O
exploit O
multitargeting O
of O
key O
epigenetic O
molecules O
deregulated O
in O
cancer O
; O
the O
study O
of O
epigenetic-synthetic O
lethality O
interactions O
as O
a O
mechanism O
to O
address O
loss-of-function O
mutations O
, O
and O
the O
combination O
of O
epidrugs B-Chemical

Smoking O
and O
adverse O
childhood O
experience O
score O
were O
associated O
with O
both O
conditions O
in O
the O
hypothesis-testing O
phase O

We O
have O
experimentally O
validated O
primer O
pairs O
designed O
by O
our O
pipeline O
and O
shown O
a O
very O
high O
success O
rate O
of O
primer O
pairs O
 O
out O
of O
190 O
primer O
pairs O
, O
71 O
% O
could O
be O
successfully O
validated O

A O
novel O
concept O
in O
ecotoxicological O
epigenetics O
is O
the O
induction O
of O
transgenerational O
stress O
resistance O
upon O
chemical B-Chemical
exposure O
, O
as O
demonstrated O
in O
rice B-Species
exposed O
to O
metals B-Chemical


To O
overcome O
this O
hurdle O
, O
we O
designed O
a O
split-TET2 B-Gene
enzyme O
to O
enable O
temporal O
control O
of O
5-methylcytosine B-Chemical
( O
5mC B-Chemical
) O
oxidation O
and O
subsequent O
remodeling O
of O
epigenetic O
states O
in O
mammalian B-Species
cells O
by O
simply O
adding O
chemicals O

505 O
 O
Melanoma B-Disease
is O
the O
most O
aggressive O
form O
of O
skin B-Disease
cancer I-Disease
and O
advanced O
stages O
are O
inevitably O
resistant O
to O
conventional O
therapeutic O
agents O


The O
publication O
" O
Oxidative B-Chemical
Stress I-Chemical
and O
Diabetic B-Disease
Complications I-Disease
" O
was O
cited O
2370 O
times O

619 O
The O
epigenetic O
trajectory O
of O
DNA B-Chemical
methylation I-Chemical
profiles O
has O
a O
nonlinear O
relationship O
with O
time O
, O
reflecting O
rapid O
changes O
in O
DNA B-Chemical
methylation I-Chemical
early O
in O
life O
that O
progressively O
slow O
with O
age O

571 O
Detection O
in O
blood O
of O
the O
genetic O
and O
epigenetic O
changes O
present O
in O
metastatic B-Disease
cancers I-Disease
is O
opening O
up O
new O
possibilities O
in O
molecular O
diagnostics O

Finally O
, O
we O
demonstrated O
that O
RE-VAE O
model O
could O
detect O
cancer B-Disease
cell I-Disease
lines I-Disease
with O
similar O
epigenomics O
profiles O

We O
provide O
an O
overview O
of O
the O
current O
state O
of O
the O
field O
and O
vision O
for O
deriving O
the O
epigenomics O
of O
autoimmunity B-Disease

Correlation O
analyses O
of O
TF O
binding O
sequences O
and O
methylation O
or O
hydroxymethylation O
between O
three O
mouse B-Species
strains O
revealed O
the O
involvement O
of O
Pax5 B-Gene
in O
strain-specific O
methylation O
and O
hydroxymethylation O
in O
exon O
7 O
of O
Pdgfrb B-Gene

608 O
There O
have O
been O
considerable O
advances O
in O
uncovering O
the O
complex O
genetic O
mechanisms O
that O
underlie O
nervous B-Disease
system I-Disease
disease I-Disease
pathogenesis O
, O
particularly O
with O
the O
advent O
of O
exome O
and O
whole O
genome O
sequencing O
techniques O

Taking O
into O
account O
that O
IR B-Disease
results O
from O
a O
complex O
interplay O
between O
genes O
and O
the O
environment O
and O
that O
epigenetic O
marks O
are O
reversible O
, O
disentangling O
the O
relationship O
between O
IR B-Disease
and O
epigenetics O
will O
provide O
new O
tools O
to O
improve O
the O
management O
and O
prevention O
of O
IR B-Disease

Epigenetic O
alterations O
contribute O
significantly O
to O
the O
development O
and O
progression O
of O
gastric B-Disease
tumors I-Disease

ca O
and O
the O
github O
repository O
at O
https//github O

In O
this O
study O
, O
we O
utilized O
CRISPR/Cas9-mediated O
the O
homology-directed O
repair O
( O
HDR O
) O
pathway O
following O
double-strand O
breaks O
( O
DSBs O
) O
information O
to O
target O
de O
novo O
methylation O
of O
the O
vital O
epigenetic O
biomarker O
, O
O6-methylguanine-DNA B-Chemical
methyltransferase I-Chemical
( O
MGMT B-Gene
) O

05 O

This O
has O
invigorated O
research O
and O
raised O
many O
new O
questions O
concerning O
the O
heritability O
of O
disease B-Disease
risk O
and O
the O
ability O
to O
adapt O
to O
novel O
environments O

Differences O
detected O
in O
the O
array O
were O
validated O
with O
pyrosequencing O

 O

Our O
recently O
developed O
computational O
framework O
, O
MAPLE O
, O
addresses O
these O
challenges O
using O
supervised O
learning O
models O

This O
knowledge O
can O
possibly O
be O
used O
to O
revolutionize O
animal O
breeding O
and O
to O
increase O
human B-Species
and O
animal B-Species
health O
worldwide O

Studying O
genetic O
variation O
in O
DMET B-Gene
genes O
in O
relation O
to O
drug B-Chemical
response O
has O
been O
the O
main O
focus O
of O
pharmacogenetics O
laboratories O
; O
it O
is O
, O
however O
, O
expected O
that O
epigenetic O
modifications O
will O
play O
a O
role O
in O
drug B-Chemical
responses O
as O
well O

Nevertheless O
, O
there O
are O
very O
few O
examples O
of O
epigenetic O
biomarkers O
implemented O
in O
the O
clinical O
setting O

We O
then O
develop O
uCoTargetX O
, O
an O
expansion O
of O
uCoTarget O
to O
simultaneously O
measure O
transcriptome O
and O
multiple O
epigenome O
targets O

716 O
Introduction O
Gastric B-Disease
cancer I-Disease
( O
GC B-Disease
) O
is O
the O
fifth O
most O
common O
malignancy O
in O
the O
world O
and O
accounts O
for O
7 O

es O

001 O
) O
and O
a O
1-month O
( O
P O
< O
0 O

Methods O
 O
PubMed O
and O
Web O
of O
Science O
databases O
were O
interrogated O
from O
January O
1995 O
up O
to O
December O
2012 O
using O
combinations O
of O
search O
terms O
, O
including O
" O
epigenetic O
" O
, O
" O
microRNA B-Gene
" O
and O
" O
DNA B-Chemical
methylation I-Chemical
" O
cross O
referenced O
with O
" O
depression B-Disease
" O

The O
third O
part O
will O
apply O
both O
models O
to O
two O
natural O
processes O
, O
namely O
, O
the O
setting O
of O
the O
aging O
clock O
in O
the O
mammalian B-Species
zygote O
and O
the O
changes O
in O
the O
aging O
clock O
along O
successive O
generations O
in O
mammals B-Species

The O
emerging O
evidence O
of O
epigenetic O
inheritance O
mechanisms O
is O
changing O
the O
concept O
of O
how O
and O
what O
information O
can O
be O
transferred O
across O
generations O
, O
rising O
as O
a O
promising O
theory O
to O
explain O
how O
psychiatric-related B-Disease
information O
can O
be O
inherited O

BPD O
has O
a O
complex O
, O
multifactorial O
etiology O
, O
resulting O
from O
an O
interaction O
among O
genetic O
and O
environmental O
substrates O
, O
and O
has O
moderate O
to O
high O
heritability O
based O
on O
twin O
and O
family O
studies O

555 O
Mood B-Disease
stabilizers O
are O
the O
cornerstone O
in O
treatment O
of O
mood B-Disease
disorders I-Disease
, O
but O
their O
use O
is O
characterized O
by O
high O
interindividual O
variability O

An O
important O
characteristic O
of O
epigenetic O
changes O
is O
that O
they O
can O
be O
produced O
in O
response O
to O
environmental O
cues O
and O
passed O
on O
to O
later O
generations O
, O
potentially O
facilitating O
later O
genetic O
adaptation O

Better O
understanding O
of O
the O
interplay O
between O
multiple O
environmental O
and O
genetic O
factors O
involved O
in O
the O
patogenesis O
of O
bipolar B-Disease
disorder I-Disease
could O
provide O
relevant O
information O
for O
treatment O
of O
patients O
with O
this O
complex O
disorder O

These O
methods O
differ O
by O
their O
genomic O
CpG B-Chemical
coverage O
, O
resolution O
, O
quantitative O
accuracy O
, O
cost O
, O
and O
software O
for O
analyzing O
the O
data O

The O
studies O
link O
early-life O
exposures O
, O
structural O
inequities O
, O
and O
behavioral O
factors O
and O
interventions O
to O
epigenetic O
changes O
, O
and O
in O
some O
studies O
, O
later O
health B-Disease
outcomes I-Disease

Here O
we O
present O
three O
methods O
for O
the O
detection O
of O
DNA B-Gene
methylation O
in O
plant B-Species
tissues O
 O
high B-Chemical
performance I-Chemical
liquid I-Chemical
chromatography I-Chemical
, O
methylation-sensitive B-Chemical
restriction I-Chemical
digest I-Chemical
followed O
by O
quantitative B-Chemical
PCR I-Chemical
and O
bisulfite B-Chemical
conversion I-Chemical
followed O
by O
single O

Epigenetic O
modifications O
sit O
'on O
top O
of O
' O
the O
genome O
and O
affect O
how O
DNA B-Gene
is O
compacted O
into O
chromatin O
and O
transcribed O
into O
ribonucleic B-Chemical
acid I-Chemical
( O
RNA B-Gene
) O

Aberrant O
epigenetic O
signatures O
are O
a O
hallmark O
of O
complex O
multifactorial O
diseases O
( O
including O
neoplasms O
and O
malignancies O
such O
as O
leukemias B-Disease
, O
lymphomas B-Disease
, O
sarcomas B-Disease
, O
and O
breast B-Disease
, O
lung B-Disease
, O
prostate B-Disease
, O
liver B-Disease
, O
and O
colorectal B-Disease
cancers I-Disease

Reported O
are O
major O
enhancements O
to O
CloneViz O
, O
which O
now O
provides O
capabilities O
enabling O
a O
formal O
tumor B-Disease
multi-dimensional O
clonality O
analysis O
by O
integrating O
 O
i O
) O
DNA B-Chemical
mutations O
, O
ii O
) O
RNA B-Chemical
expressed O
mutations O
, O
and O
iii O
) O
DNA B-Chemical
methylation O
data O

Our O
focus O
is O
on O
bromodomains O
, O
which O
bind O
to O
acetylated B-Chemical
lysine I-Chemical
residues O

Epigenetic O
mechanisms O
, O
particularly O
DNA B-Chemical
methylation I-Chemical
and O
miRNA B-Gene
expression O
, O
attract O
increasing O
attention O
as O
potential O
links O
between O
the O
genetic O
and O
environmental O
determinants O
of O
health O
and O
disease B-Disease

However O
, O
although O
evolution O
by O
natural O
selection O
requires O
new O
heritable O
traits O
to O
be O
produced O
and O
transmitted O
, O
it O
does O
not O
prescribe O
, O
per O
se O
, O
the O
mechanisms O
by O
which O
this O
is O
operated O

However O
, O
although O
recent O
attempts O
to O
standardize O
have O
been O
made O
, O
fixation O
and O
storage O
conditions O
of O
clinical O
specimens O
are O
still O
extremely O
variable O
and O
can O
affect O
the O
success O
of O
chromatin B-Gene
studies O

uk O

These O
studies O
have O
highlighted O
methylation O
changes O
in O
specific O
candidate O
genes O
as O
associated O
with O
T O
regulatory O
cell O
activity O
as O
well O
as O
differential O
methylation O
of O
Type B-Disease
1 I-Disease
and O
Type B-Disease
2 I-Disease
cytokine O
genes O
associated O
with O
various O
food B-Disease
allergies I-Disease


This O
results O
in O
a O
state O
of O
viral B-Disease
mimicry I-Disease
in O
which O
treated O
cells O
mount O
an O
innate O
immune O
response O
by O
turning O
on O
viral B-Disease
defence I-Disease
genes B-Gene
and O
potentially O
expressing O
neoantigens B-Gene

The O
Research O
to O
Accelerate O
Cures O
and O
Equity O
( O
RACE O
) O
for O
Children O
Act O
FDARA O
amendments O
to O
section O
505B O
of O
the O
FD&C O
Act O
was O
implemented O
in O
August O
2020 O
, O
and O
as O
there O
are O
many O
epigenetic O
targets O
on O
the O
FDA O
Paediatric O
Molecular O
Targets O
List O
, O
clinical O
evaluation O

Third O
, O
tools O
from O
epidemiology O
are O
examined O
that O
may O
aid O
bioarchaeologists O
to O
better O
cope O
with O
some O
of O
the O
inherent O
limitations O
of O
skeletal O
samples O
to O
better O
measure O
and O
quantify O
the O
expressions O
of O
skeletal O
stress O
markers O

515 O
Health O
problems O
associated O
with O
aging O
are O
a O
major O
public O
health O
concern O
for O
the O
future O

Next O
, O
we O
discuss O
how O
new O
techniques O
for O
single-cell O
epigenomics O
, O
such O
as O
single-cell O
ATAC-seq O
and O
single-cell O
DNA B-Chemical
methylation I-Chemical
profiling O
, O
can O
be O
used O
to O
decipher O
gene O
regulatory O
programmes O

The O
three O
major O
risk O
factors O
in O
prostate B-Disease
cancer I-Disease
 O
age O
, O
geographic O
ancestry O
, O
and O
environment O
are O
all O
influenced O
by O
epigenetics O
and O
additional O
significant O
insight O
is O
required O
to O
gain O
an O
understanding O
of O
the O
underlying O
mechanisms O

There O
has O
been O
significant O
progress O
in O
the O
field O
of O
suicide B-Disease
epigenetics O
, O
with O
emerging O
findings O
in O
the O
brain-derived B-Gene
neurotrophic I-Gene
factor I-Gene
and O
hypothalamic-pituitary-adrenal B-Gene
axis I-Gene
genes O

In O
the O
case O
of O
epigenetics O
, O
complexification O
entails O
a O
reconfiguration O
of O
postgenomic O
experimental O
systems O
in O
ways O
that O
some O
actors O
deem O
' O
better O
' O
at O
enacting O
health B-Disease
as O
a O
biosocial O
process O

These O
regions O
harbor O
distant O
regulatory O
elements O
, O
enhancers O
, O
super-enhancers O
, O
insulators O
, O
alternative O
promoters O
, O
and O
sequences O
that O
transcribe O
as O
noncoding O
RNAs B-Chemical
( O
ncRNAs B-Chemical
) O
such O
as O
miRNAs B-Gene
and O
long O
ncRNAs B-Gene

Recently O
, O
methylation O
has O
been O
demonstrated O
to O
be O
required O
for O
early O
embryogenesis O

It O
offers O
a O
powerful O
, O
yet O
versatile O
and O
easily O
extensible O
interface O
to O
read O
, O
write O
and O
manipulate O
multiple O
genomic B-Disease
file I-Disease
formats O

Specifically O
, O
we O
focus O
on O
the O
role O
epigenetics O
may O
play O
in O
multigenerational O
and O
transgenerational O
transmission O
of O
environmentally O
induced O
health B-Disease
effects I-Disease

Therefore O
, O
it O
may O
be O
more O
beneficial O
to O
target O
specific O
repeat O
elements O
depending O
upon O
their O
chromosomal O
location O
, O
rather O
than O
analyzing O
overall O
methylation O
levels O

If O
confirming O
the O
hypothesis O
, O
such O
studies O
challenge O
our O
fundamental O
understanding O
of O
evolution O
by O
natural O
selection O
; O
therefore O
they O
require O
particular O
rigor O
in O
design O
and O
great O
care O
in O
data O
analysis O

Here O
we O
summarize O
the O
knowledge O
gained O
from O
genome-wide O
localization O
profiling O
of O
different O
epigenetic O
features O
, O
and O
discuss O
hypotheses O
emerging O
from O
the O
analysis O
of O
these O
' O
descriptive O
' O
epigenetic O
maps O

Despite O
our O
efforts O
, O
we O
still O
need O
to O
refine O
our O
hypothesis O
generation O
process O
to O
obtain O
real O
knowledge O
from O
a O
neuroepigenomic O
framework O
, O
to O
avoid O
the O
creation O
of O
more O
noise O
on O
this O
innovative O
point O
of O
view O
; O
this O
may O
help O
us O
to O
definitively O
unravel O
the O
molecular O

33 O
weeks O
and O
has O
similar O
properties O
to O
the O
recently O
described O
human B-Species
epigenetic I-Species
clock I-Species

Mass O
spectrometry O
( O
MS O
) O
has O
emerged O
as O
a O
versatile O
technology O
for O
the O
analysis O
of O
histones B-Chemical
, O
contributing O
to O
the O
dissection O
of O
hPTMs B-Chemical
, O
with O
special O
strength O
in O
the O
identification O
of O
novel O
marks O
and O
in O
the O
assessment O
of O
modification O
cross O
talks O

, O
from O
0 O

Discussion O
 O
Until O
recently O
, O
efforts O
to O
apply O
epigenomic O
data O
in O
toxicology O
and O
risk O
assessment O
were O
restricted O
by O
an O
incomplete O
understanding O
of O
epigenomic O
variability O
across O
tissue O
types O
and O
populations O

The O
goal O
of O
this O
review O
is O
to O
present O
current O
epigenetic O
findings O
in O
livestock O
species O
( O
cattle B-Species
, O
pigs B-Species
, O
sheep B-Species
and O
poultry B-Species
) O

Altogether O
, O
functional O
work O
suggests O
that O
the O
effects O
of O
gbM B-Gene
, O
if O
any O
, O
must O
be O
relatively O
small O
, O
but O
there O
is O
nonetheless O
evidence O
that O
it O
is O
shaped O
by O
natural O
selection O

1156 O
 O
Schizophrenia B-Disease
is O
a O
major O
clinical O
problem O
and O
represents O
a O
major O
risk O
factor O
for O
suicide O

This O
project O
is O
an O
interdisciplinary O
, O
cross-organizational O
effort O
to O
provide O
a O
guided O
learning O
module O
for O
integrating O
transcriptomics O
and O
epigenetics O
data O
analysis O
protocols O
into O
a O
comprehensive O
analysis O
pipeline O
for O
users O
to O
implement O
in O
their O
own O
work O
, O
utilizing O
the O
cloud O
computing O
infrastructure O
on O
Google O
Cloud O

The O
mechanistic O
uncertainty O
of O
intraovarian O
PRP B-Gene
notwithstanding O
, O
at O
least O
two O
other O
major O
challenges O
confront O
this O
controversial O
intervention O

This O
paper O
explores O
the O
views O
of O
epigenetic O
researchers O
about O
some O
of O
these O
discussions O

Pediatricians O
must O
be O
aware O
of O
these O
mechanisms O
and O
their O
consequences O
, O
seeking O
to O
prevent O
them O
and O
thus O
promote O
the O
health O
, O
well-being O
, O
and O
quality O
of O
life O
of O
children O
, O
contributing O
to O
their O
full O
development O

By O
assessing O
the O
epigenetic O
factors O
involved O
in O
cGCPs B-Gene
, O
we O
discovered O
novel O
regulatory O
mechanisms O
of O
positive O
cGCPs B-Gene
distinct O
from O
negative O
cGCPs B-Gene
, O
which O
were O
related O
to O
multiple O
factors O
, O
such O
as O
H3K27me3 B-Chemical
, O
CTCF B-Gene
, O
and O
JARD2 B-Gene

This O
resulted O
in O
a O
mean O
predicted O
age O
of O
1 O

26 O
; O
95% O
CI O
, O
0 O

This O
will O
allow O
new O
levels O
of O
understanding O
of O
cell O
fate O
decisions O
, O
identity O
, O
and O
function O
in O
normal O
development O
, O
physiology O
, O
and O
disease B-Disease

Targeted O
next-generation O
bisulfite O
sequencing O
was O
used O
to O
validate O
selected O
differentially O
methylated O
CpGs O

0 O
supports O
label-free O
and O
isotopic O
labeling O
, O
different O
organisms B-Species
, O
known O
sequence O
mutations O
in O
diseases B-Disease
, O
different O
derivatization O
strategies O
, O
and O
unusual O
PTMs O
( O
such O
as O
acyl-derived O
modifications O
) O

This O
is O
crucial O
for O
the O
initiation O
of O
appropriate O
effector O
mechanisms O
to O
protect O
against O
various O
pathogens O
such O
as O
bacteria B-Species
, O
viruses B-Species
, O
tumors B-Disease
, O
and O
parasites B-Species

On O
the O
recovered O
DNA O
, O
new O
markers O
were O
developed O
based O
on O
the O
sequence O
of O
the O
plastid O
genes O
matK B-Gene
and O
rbcL B-Gene

Chemotherapeutics B-Chemical
induce O
epigenetic O
reprogramming O
in O
cancer B-Disease
cells O
, O
converting O
a O
transient O
transcriptional O
state O
into O
a O
stably O
resistant O
one O

Conclusions O
Functional O
and O
correlative O
studies O
are O
now O
needed O
to O
elucidate O
the O
potential O
links O
between O
germline B-Gene
genotype I-Gene
, O
epigenetic O
function O
, O
and O
cancer B-Disease
etiology I-Disease

Candidate O
gene B-Gene
association I-Gene
studies I-Gene
( O
CGASs B-Gene
) O
along O
with O
genome-wide B-Gene
association I-Gene
studies I-Gene
( O
GWASs B-Gene
) O
and O
genome-wide B-Gene
linkage I-Gene
analyses I-Gene
( O
GWLAs B-Gene
) O
have O
found O
numerous O
genes O
and O
loci O
with O
susceptible O
DDH B-Disease
association O

Epigenetic O
clock O
(eAge) O
algorithms O
utilize O
DNA B-Gene
methylation I-Gene
to O
estimate O
the O
age O
and O
risk O
factors O
for O
diseases B-Disease
as O
well O
as O
analyze O
the O
impact O
of O
various O
interventions O

Scalable O
single-cell O
CUT&Tag O
can O
be O
combined O
with O
distinct O
platforms O
to O
distinguish O
cellular O
identity O
, O
epigenetic O
features O
and O
even O
spatial O
chromatin O
profiling O

We O
perform O
simulations O
and O
real O
data O
analysis O
to O
compare O
different O
approaches O
, O
and O
provide O
recommendations O
for O
data O
analysis O

The O
final O
product O
is O
a O
start-to-finish O
tutorial O
for O
the O
researchers O
with O
limited O
experience O
in O
multi-omics O
to O
integrate O
transcriptomics O
and O
epigenetics O
data O
analysis O
into O
a O
comprehensive O
pipeline O
to O
perform O
their O
own O
biological O
research O

The O
former O
emphasizes O
the O
social O
, O
technical O
, O
and O
material O
work O
that O
goes O
into O
the O
production O
of O
mixed O
biological O
and O
social O
representations O
of O
stress B-Disease
in O
epigenetics B-Gene

The O
comprehensive O
analyses O
undertaken O
in O
this O
study O
reveal O
a O
molecular O
framework O
for O
understanding O
how O
IF B-Gene
impacts O
the O
metabolo-epigenetic O
axis O
of O
the O
brain O
and O
will O
serve O
as O
a O
valuable O
resource O
for O
future O
research O

87 O
As O
a O
final O
function O
of O
various O
epigenetic O
mechanisms O
, O
chromatin O
regulation O
is O
a O
transcription O
control O
process O
that O
especially O
demonstrates O
active O
interaction O
with O
genetic O
elements O

However O
, O
the O
study O
of O
Kammerer O
's O
original O
publications O
reveals O
that O
there O
are O
substantial O
misunderstandings O
in O
Vargas O
' O
treatment O
of O
the O
subject O


1083 O
The O
study O
of O
heritable O
genetic O
changes O
that O
do O
not O
implicate O
alterations O
in O
the O
DNA B-Gene
sequence O
- O
epigenetics O
- O
represents O
one O
of O
the O
most O
prolific O
and O
expanding O
fields O
in O
plant B-Species
biology O
during O
the O
last O
two O
decades O

1280 O
Over O
the O
past O
40 O
years O
a O
global O
discourse O
on O
population O
obesity B-Disease
has O
emerged O
, O
with O
moral O
outrage O
surrounding O
the O
rise O
in O
childhood B-Disease
obesity I-Disease
during O
this O
time O

As O
the O
complex O
mechanisms O
of O
epigenetic O
modification O
has O
been O
increasingly O
discovered O
, O
they O
are O
more O
closely O
related O
to O
the O
occurrence O
and O
development O
of O
cancer B-Disease

The O
Famine O
occurred O
at O
a O
time O
when O
the O
Irish B-Species
asylums O
were O
growing O
rapidly O
anyway O
, O
so O
its O
precise O
effects O
on O
mental O
health O
are O
difficult O
although O
not O
impossible O
to O
study O

49 O
; O
P O
= O

001 O
; O
DNAm O
PAI-1 O
, O
b O
( O
SE O
) O
= O
- O

614 O
Anne O
Ferguson-Smith O
and O
Marisa O
Bartolomei O
look O
back O
at O
the O
life O
and O
science O
of O
, O
a O
pioneer O
in O
genomic O
imprinting O
and O
epigenetics O

18 O
, O
p O
= O

639 O
Inborn B-Disease
errors I-Disease
of I-Disease
immunity I-Disease
( O
IEIs B-Disease
) O
comprise O
a O
variety O
of O
immune O
conditions O
leading O
to O
infections O
, O
autoimmunity O
, O
allergy O
, O
and O
cancer O

Our O
results O
indicate O
that O
the O
models O
reported O
herein O
have O
considerable O
potential O
to O
identify O
small O
molecules B-Chemical
with O
epigenetic O
activity O

g O

has O

We O
show O
that O
fasting O
and O
UV B-Chemical
radiation O
reduced O
the O
viability O
of O
RAW264 B-Species

897 O
Alterations O
in O
DNA B-Gene
methylation I-Gene
are O
seen O
in O
cancers B-Disease
and O
have O
also O
been O
examined O
in O
clear B-Disease
cell I-Disease
renal I-Disease
cell I-Disease
carcinoma I-Disease
(ccRCC) I-Disease

As O
a O
result O
, O
minimal O
DNA B-Gene
methylation I-Gene
changes O
during O
developmental O
stages O
drive O
severe O
phenotypes O
, O
as O
observed O
in O
germ-line O
imprinting O
disorders O
, O
while O
genome-wide O
alterations O
occurring O
in O
somatic O
cells O
are O
linked O
to O
cancer B-Disease
onset I-Disease
and I-Disease
progression I-Disease

725 O
methylation O
is O
an O
important O
epigenetic O
modification O
that O
regulates O
temporal O
and O
spatial O
expression O
of O
genes O
for O
controlling O
cell O
fate O
and O
differentiation O

Epigenetics O
provides O
a O
promising O
avenue O
for O
both O
targeted O
individual O
intervention O
and O
public O
health O
messaging O

380 O
Mapping O
genome-wide O
DNA B-Chemical
- I-Chemical
protein O
interactions O
( O
DPIs O
) O
provides O
insights O
into O
the O
epigenetic O
landscape O
of O
complex O
biological O
systems O
and O
elucidates O
the O
mechanisms O
of O
epigenetic O
regulation O
in O
biological O
progress O

843 O
and O
modifications O
have O
important O
functions O
, O
including O
the O
regulation O
of O
gene O
expression O

powerful O

Although O
genome O
wide O
association O
studies O
( O
GWAS O
) O
, O
and O
studies O
on O
twins O
demonstrate O
the O
genetic/hereditary O
component O
to O
these O
complex O
diseases O
, O
including O
AMD B-Disease
, O
this O
contribution O
is O
much O
less O
than O
100 O
% O

However O
, O
only O
results O
of O
HLA B-Gene
phenotyping O
have O
been O
taken O
over O
to O
routine O
clinical O
practice O

Blood O
cells O
and O
tumor B-Disease
tissue I-Disease
were O
the O
most O
commonly O
used O
biospecimens O
in O
these O
studies O
, O
although O
buccal B-Species
cells I-Species
, O
cervical B-Species
cells I-Species
, O
sputum B-Species
, O
and O
stool B-Species
samples I-Species
were O
also O
used O

Epigenetic O
mechanisms O
are O
important O
in O
predisposing O
ageing O
tendon O
to O
injury O

A O
data O
science O
approach O
is O
used O
to O
synthesize O
current O
knowledge O
on O
the O
pharmacological O
implications O
of O
epigenetic O
regulation O
of O
gene B-Gene
expression I-Gene

Importantly O
we O
now O
know O
that O
environmental O
stimuli O
influence O
epigenetic O
marks O
, O
which O
in O
the O
context O
of O
neuroendocrinology O
can O
lead O
to O
behavioral O
changes O

These O
datasets O
are O
able O
to O
be O
directly O
integrated O
with O
one O
another O
as O
well O
as O
with O
existing O
snmC-seq2 B-Gene
datasets O
with O
little O
discernible O
bias O

Meanwhile O
, O
contemporary O
developments O
in O
epigenetics O
have O
opened O
new O
outlooks O
for O
understanding O
the O
molecular O
basics O
of O
IMF B-Gene
regulation O
, O
and O
it O
has O
become O
a O
key O
area O
of O
research O
for O
world O
scholars O

However O
, O
research O
in O
human B-Species
subjects O
is O
still O
limited O

Here O
, O
we O
provide O
a O
comprehensive O
review O
of O
growing O
epigenetic O
features O
involved O
in O
AF B-Disease
pathogenesis O
and O
summarize O
the O
emerging O
epigenomic O
targets O
for O
therapy O
that O
have O
been O
explored O
in O
preclinical O
models O
of O
AF B-Disease

As O
well O
as O
being O
potential O
biomarkers O
for O
epilepsy B-Disease
diagnosis O
, O
epigenetic O
changes O
can O
also O
be O
used O
as O
prognostic O
indicators O
of O
treatment O
response O

In O
addition O
to O
containing O
up O
to O
five O
times O
more O
information O
than O
the O
coding O
genome O
, O
the O
cis-regulatory O
genome O
also O
acts O
as O
a O
major O
reservoir O
of O
disease-associated B-Disease
polymorphic I-Disease
variation I-Disease

620 O
It O
is O
important O
for O
large-scale O
epigenomic O
studies O
to O
determine O
and O
explore O
the O
nature O
of O
hidden O
confounding O
variation O
, O
most O
importantly O
cell O
composition O

We O
performed O
high-resolution O
genome-wide O
DNA B-Gene
methylome O
profiling O
using O
the O
MethylationEPIC B-Chemical
BeadChip I-Chemical
on O
baseline O
conditions O
, O
irradiated O
cell O
lines O
( O
cumulative O
dose O
of O
10 O
Gy O
) O
, O
and O
non-irradiated O
counterparts O

Many O
differentially O
methylated O
genes O
were O
found O
to O
encode O
transfer B-Gene
RNAs I-Gene
( O
tRNAs B-Gene
) O
related O
to O
or O

The O
authors O
hold O
that O
future O
studies O
on O
the O
underlying O
mechanisms O
of O
acupuncture O
therapy O
in O
the O
prevention O
and O
treatment O
of O
MI B-Disease
from O
epigenetics O
may O
be O
a O
new O
approach O
and O
a O
new O
direction O

RRBS O
loci O
as O
genome-wide O
epigenetic O
markers O
739 O
III O

We O
hypothesize O
that O
environmental O
factors O
(including O
social O
adversity O
, O
diet O
, O
lack O
of O
physical O
activity O
and O
pollution O
) O
can O
become O
" O
embedded O
" O
in O
the O
biology O
of O
humans B-Species

The O
evaluation O
is O
based O
on O
the O
cumulative O
distribution O
function O
and O
the O
statistical O
significance O
in O
differential O
expression O
of O
genes O
grouped O
by O
the O
number O
of O
'epi-marks' O

However O
, O
androgen B-Chemical
deprivation I-Chemical
therapy I-Chemical
is O
not O
curative O
, O
and O
patients O
will O
progress O
to O
castrate-resistant B-Disease
disease I-Disease
( O
CRPC B-Disease
) O

55 O
Epigenetic O
modifications O
offer O
compelling O
evidence O
of O
the O
environmental O
etiology O
of O
complex O
diseases B-Disease

Autoimmune O
diseases B-Disease
now O
include O
almost O
100 O
conditions O
and O
are O
estimated O
to O
cumulatively O
affect O
up O
to O
5% O
of O
the O
world O
population O
with O
a O
healthcare O
expenditure O
superior O
to O
cancer B-Disease
worldwide O

This O
article O
summarizes O
the O
concept O
and O
development O
of O
epigenetics O
, O
as O
well O
as O
the O
process O
and O
principle O
of O
epigenetic O
modifications O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modification I-Chemical
, O
and O
non-coding O
RNA O

726 O
Freshwater B-Species
ecosystems O
are O
amongst O
the O
most O
threatened O
ecosystems O
on O
Earth O

419 O
Epigenetic O
regulation O
of O
gene O
expression O
refers O
to O
heritable O
factors O
that O
are O
functionally O
relevant O
genomic O
modifications O
but O
that O
do O
not O
involve O
changes O
in O
DNA O
sequence O

s O

To O
explore O
the O
role O
epigenetic O
inheritance O
plays O
in O
evolution O
, O
we O
subject O
isogenic O
wild-type O
yeast B-Species
cells O
expressing O
PGAL1-YFP B-Gene
( O
yellow O
fluorescent O
protein O
) O
to O
selection O
by O
daily O
sorting O
based O
on O
reporter O
expression O

The O
idea O
that O
epigenetic O
mechanisms O
mediate O
the O
life-long O
effects O
of O
perinatal O
adversity O
has O
attractive O
potential O
implications O
for O
early O
detection O
, O
prevention O
, O
and O
intervention O
in O
mental B-Disease
health I-Disease
disorders I-Disease
will O
be O
discussed O

Recently O
, O
TCGA B-Gene
analysis O
of O
a O
large O
cohort O
of O
ccRCC B-Disease
samples O
demonstrated O
that O
aberrant O
hypermethylation O
correlated O
with O
the O
stage O
and O
grade O
in O
kidney B-Disease
cancer I-Disease

508 O
Environmental O
epigenetics O
has O
become O
a O
site O
of O
growing O
attention O
related O
to O
the O
intergenerational O
effects O
of O
stress O
, O
trauma O
, O
and O
adversity O

We O
conclude O
with O
a O
discussion O
of O
social O
epigenetics O
as O
a O
mechanistic O
link O
to O
health B-Disease
inequalities I-Disease
and O
provide O
suggestions O
for O
future O
social O
epigenetics O
research O
on O
health B-Disease
inequalities I-Disease

[ O
Qu B-Gene
, O
J B-Gene

central O

In O
order O
to O
summarize O
current O
knowledge O
and O
to O
facilitate O
the O
potential O
coordination O
of O
future O
research O
activities O
, O
the O
first O
international O
workshop O
on O
the O
epigenetics O
of O
OA B-Disease
was O
held O
in O
Amsterdam O
in O
October O
2015 O

We O
also O
introduce O
the O
epiBED O
format O
for O
single-molecule O
analysis O
of O
coupled O
epigenetic O
and O
genetic O
information O
, O
facilitating O
the O
study O
of O
cellular O
and O
tissue O
heterogeneity O
from O
DNA B-Gene
methylation I-Gene
sequencing O

We O
review O
the O
current O
knowledge O
in O
the O
field O
regarding O
epigenetic O
regulation O
of O
microglial O
identity O
and O
function O
, O
provide O
an O
exemplary O
analysis O
that O
demonstrates O
the O
advantages O
of O
performing O
joint O
transcriptomic O
and O
epigenomic O
profiling O
of O
single O
microglial O
cells O
and O
discuss O
how O
comprehensive O
epigenetic O
analyses O

In O
contrast O
, O
the O
less O
common O
poorly O
differentiated O
thyroid B-Disease
carcinoma I-Disease
( O
PDTC O
) O
and O
anaplastic B-Disease
thyroid I-Disease
carcinoma I-Disease
( O
ATC O
) O
are O
two O
of O
the O
most O
aggressive O
human O
malignancies O

In O
contrast O
, O
evolutionary O
dynamics O
of O
tissue-specific O
are O
best O
explained O
by O
the O
maintenance O
or O
turnover O
of O
binding O
sites O
for O
important O
transcription O
factors O

It O
has O
been O
demonstrated O
that O
the O
genes O
encoding O
for O
miRNAs B-Gene
undergo O
the O
same O
regulatory O
epigenetic O
processes O
of O
protein O
coding O
genes O

We O
will O
conduct O
a O
narrative O
synthesis O
of O
data O
, O
and O
if O
there O
are O
an O
adequate O
number O
of O
sufficiently O
homogenous O
studies O
, O
we O
will O
consider O
performing O
a O
meta-analysis O

( O
Maas B-Disease
model B-Disease
) O
, O
weighted O
scores O
from O
a O
LASSO B-Gene
model I-Gene
of O
candidate O
smoking O
CpGs O
from O
the O
literature O
( O
candidate O
CpG O
LASSO B-Gene
model I-Gene
) O
, O
and O
weighted O
scores O
from O
a O
LASSO B-Gene
model I-Gene
supplied O
with O
genome-wide O
450K O
data O
( O
agnostic O

We O
show O
the O
value O
of O
computer O
simulations O
to O
experiment O
with O
and O
propose O
generalizations O
of O
broader O
scope O
with O
novel O
testable O
predictions O

Histone O
modifications O
, O
DNA B-Chemical
methylation I-Chemical
, O
chromatin O
remodeling O
, O
nucleosome O
positioning O
, O
regulation O
by O
non-coding O
RNAs O
and O
precisely O
microRNAs O
are O
influential O
epigenetic O
marks O
in O
the O
field O
of O
progressive B-Disease
cancer I-Disease
sub-types I-Disease

44 O
and O
7 O

This O
review O
explores O
how O
epigenetics B-Chemical
induce O
and O
regulate O
critical O
periods O
, O
and O
also O
discusses O
how O
early O
environmental O
interactions O
prime O
a O
system O
towards O
a O
particular O
health O
outcome O
and O
influence O
susceptibility O
to O
disease B-Disease
or O
cognitive O
impairment B-Disease
throughout O
life O

Biological O
age O
was O
estimated O
using O
two O
measures O
of O
DNA B-Gene
methylation-based I-Gene
age O
acceleration-extrinsic O
and O
intrinsic O
epigenetic O
age O
acceleration O

657 O
The O
evolutionary O
history O
of O
modern B-Species
humans I-Species
means O
much O
more O
than O
their O
demographic O
past O

However O
, O
further O
research O
is O
needed O
, O
including O
additional O
studies O
, O
replication O
, O
validation O
, O
and O
application O
beyond O
clinical B-Disease
settings I-Disease

Technical O
challenges O
include O
tissue O
specificity O
issues O
, O
limited O
coverage O
of O
current O
methylation B-Chemical
arrays O
and O
confounding O
factors O
like O
cell O
composition O
variability O


com O
/ O
guanjue O
/ O
Snapshot O

Conclusions O
Our O
exhaustive O
experiments O
using O
an O
array O
of O
ML O
tools O
validate O
the O
need O
for O
a O
model O
that O
is O
not O
only O
expressive O
but O
can O
scale O
with O
increasing O
data O
volumes O
and O
diversity O

91-0 O

We O
further O
consider O
imputation O
performances O
on O
the O
popular O
Î²- O
and O
M-value O
representations O
of O
methylation O
levels O

Gefitinib B-Chemical
, O
a O
tyrosine B-Chemical
kinase I-Chemical
inhibitor I-Chemical
of O
EGFR B-Gene
, O
is O
useful O
as O
an O
anti-fibrosis B-Disease
agent O
in O
preclinical O
models O

cancers B-Disease

882Social O
epigenomics O
is O
an O
area O
of O
science O
that O
evaluates O
why O
and O
how O
different O
social O
factors O
and O
processes O
affect O
different O
components O
of O
the O
epigenome O

1300 O
In O
complex O
multicellular O
systems O
, O
gene B-Gene
expression I-Gene
is O
regulated O
at O
multiple O
stages O
through O
interconnected O
complex O
molecular O
pathways O
and O
regulatory O
networks O


Here O
, O
we O
combine O
comparative O
phylogenomics O
with O
large-scale O
human B-Species
genome B-Gene
data O
to O
uncover O
candidate O
cis O
elements O
regulating O
mammalian B-Species
obesity B-Disease

In O
this O
study O
, O
we O
constructed O
a O
6mA O
predictor O
, O
p6mA O
, O
from O
a O
series O
of O
sequence-based O
features O
, O
including O
physicochemical O
properties O
, O
position-specific O
triple-nucleotide O
propensity O
( O
PSTNP O
) O
, O
and O
electron-ion O
interaction O
pseudopotential O
( O
EIIP O
) O

We O
identified O
the O
CpG O
site O
cg19647197 O
within O
the O
CCDC53 B-Gene
gene I-Gene
, O
which O
is O
characterized O
by O
hypomethylation O
of O
WBC B-Species
in O
the O
attempters B-Disease
compared O
to O
the O
non-attempters B-Disease

Evaluations O
in O
real O
datasets O
show O
that O
this O
approach O
improves O
estimate O
precision O
and O
comparability O
across O
studies O

disease B-Disease

Furthermore O
, O
there O
is O
circumstantial O
evidence O
that O
a O
subset O
of O
antipsychotic O
drugs O
, O
including O
the O
atypical O
, O
Clozapine B-Chemical
, O
interfere O
with O
chromatin B-Gene
remodeling I-Gene
mechanisms O

The O
aim O
of O
this O
review O
was O
to O
synthesize O
general O
trends O
concerning O
the O
associations O
between O
human B-Species
epigenetic O
clocks O
and O
these O
investigated O
factors O

7 O
% O
of O
the O
28 O

The O
large O
number O
of O
differentially O
methylated O
cytosines O
between O
hybrids O
and O
parental O
species B-Species
(n O
= O
5,800 O
) O
suggests O
that O
hybridization O
may O
play O
a O
role O
in O
increasing O
genetic O
and O
epigenetic O
variation O

Typically O
, O
researchers O
analyzed O
genomic O
DNA B-Chemical
( O
gDNA B-Chemical
) O
to O
measure O
the O
amount O
of O
RASSF1A B-Gene
promoter O
methylation O

In O
recent O
years O
, O
an O
increasing O
number O
of O
studies O
documented O
potential O
links O
between O
parental O
care O
and O
epigenetic O
mechanisms O


This O
latter O
epigenetic O
defect O
is O
associated O
with O
an O
increased O
risk O
of O
tumors O
such O
as O
nephroblastoma B-Disease

Considerable O
work O
is O
being O
devoted O
to O
understanding O
the O
mechanisms O
of O
action O
of O
both O
asbestos B-Chemical
and O
arsenic B-Chemical
including O
their O
ability O
to O
affect O
promoter O
methylation O
and O
gene B-Gene
silencing O
in O
carcinogenesis B-Disease

Species B-Species
differences O
need O
to O
be O
considered O
when O
interpreting O
results O
from O
various O
models O

Environ O

001 O
) O
higher O
GAA B-Gene
, O
respectively O

DNA O
methylation O
has O
been O
well O
studied O
in O
human B-Species
and O
model O
organisms O
, O
but O
only O
limited O
data O
exist O
in O
economically O
important O
animals O
like O
cattle B-Species

Future O
studies O
on O
the O
role O
of O
these O
factors O
in O
psychopathological B-Disease
conditions I-Disease
, O
subphenotypes O
and O
endophenotypes O
may O
greatly O
benefit O
by O
using O
more O
precise O
clinical O
data O
and O
a O
combined O
approach O
with O
multiple O
research O
tools O
incorporated O
into O
a O
single O
study O

Recent O
findings O
 O
Common O
polymorphisms O
in O
the O
Mn B-Chemical
transporter O
genes O
SLC30A10 B-Gene
and O
SLC39A8 B-Gene
seem O
to O
have O
a O
large O
impact O
on O
intracellular O
Mn B-Chemical
levels O
and O
, O
in O
turn O
, O
neurotoxicity B-Disease

Investigators O
can O
interact O
with O
EpiCompare O
by O
investigating O
Roadmap B-Gene
Epigenomics I-Gene
data O
, O
or O
uploading O
their O
own O
data O
for O
comparison O

Conclusion O
 O
Progress O
in O
treating O
human B-Species
disease O
in O
general O
will O
require O
close O
collaboration O
with O
experts O
in O
bioinformatics O

We O
discuss O
one O
approach O
for O
methylation-based O
biomarker O
assay O
development O
that O
describes O
the O
discovery O
at O
a O
genome-scale O
level O
, O
which O
addresses O
some O
of O
the O
practical O
considerations O
for O
design O
of O
assays O
that O
can O
be O
implemented O
in O
the O
clinic O

Here O
, O
we O
discuss O
how O
cellular O
reprogramming O
mediated O
by O
driver O
genes B-Gene
in O
STS B-Disease
can O
profoundly O
reshape O
the O
molecular O
and O
morphological O
features O
of O
a O
transformed O
cell O
and O
lead O
to O
erroneous O
interpretation O
of O
its O
cell-of-origin O

Furthermore O
, O
epihet O
can O
implement O
a O
biological O
network O
analysis O
workflow O
for O
transforming O
cancer-specific B-Disease
differential O
epigenetic O
heterogeneity O
loci O
into O
cancer-related B-Disease
biological O
function O
and O
clinical O
biomarkers O

In O
this O
chapter O
, O
we O
provide O
an O
overview O
of O
recent O
advances O
on O
high-dimensional O
mediation O
analysis O
, O
with O
application O
to O
two O
DNA B-Chemical
methylation I-Chemical
data O

Computational O
models O
using O
DNA B-Gene
methylation I-Gene
data O
can O
create O
" O
epigenetic O
clocks O
" O
which O
are O
proposed O
to O
reflect O
" O
biological O
" O
aging O

231 O
Cytosine B-Chemical
DNA B-Gene
methylation I-Gene
( O
5-methylcytsone B-Chemical
, O
5mC B-Chemical
) O
is O
the O
major O
DNA B-Gene
modification O
found O
in O
the O
genomes O
of O
animals B-Species
and O
plants B-Species

Genetic O
factors O
are O
important O
in O
determining O
bone O
mass O
and O
structure O
, O
as O
well O
as O
any O
predisposition O
for O
bone O
degradation O
and O
OVF B-Disease

com O
/ O
tianguolangzi O
/ O
DSBS O
) O
, O
to O
accurately O
identify O
SNV B-Gene
and O
DNA B-Chemical
methylation I-Chemical

A O
critical O
issue O
is O
to O
pinpoint O
the O
( O
neuro O
) O
biological O
mechanisms O
underlying O
the O
susceptibility O
to O
stress-related O
disorder O
such O
as O
PTSD B-Disease
, O
which O
develops O
in O
the O
minority O
of O
~ O
15 O
% O
of O
individuals O
exposed O
to O
trauma O

The O
pathophysiology O
of O
POTS B-Disease
is O
complicated O
and O
poorly O
understood O

Here O
, O
we O
develop O
double O
strand O
bisulfite O
sequencing O
( O
DSBS O
) O
for O
genome-wide O
accurate O
identification O
of O
SNVs O
and O
DNA B-Chemical
methylation I-Chemical
simultaneously O
at O
a O
single-base O
resolution O
by O
using O
one O
dataset O

The O
enrichment O
analysis O
based O
on O
the O
1000 O
top O
hit O
( O
p O
< O
0 O

1024 O
Genetic B-Gene
and O
epigenetic O
contributions O
to O
various O
diseases B-Disease
and O
biological O
processes O
have O
been O
well-recognized O

This O
review O
stands O
as O
an O
update O
on O
epigenetic O
alterations O
induced O
by O
occupational O
and O
environmental O
human O
carcinogens B-Disease
that O
were O
previously O
and O
recently O
classified O
as O
Group O
1 O
by O
the O
International O
Agency O
for O
Research O
on O
Cancer O

He O
was O
the O
inaugural O
recipient O
of O
the O
Epigenetic B-Chemical
Medicine I-Chemical
Award I-Chemical
in O
2008 O
and O
received O
the O
STARS B-Chemical
Lecture I-Chemical
Award I-Chemical
in O
Nutrition B-Disease
and I-Disease
Cancer I-Disease
from O
the O
in O
2009 O

predator O
cues O
, O
chemicals B-Chemical
, O
parasites O
) O
can O
induce O
intergenerational O
effects O
on O
the O
phenotype O
( O
life-history O
traits O
, O
morphology O
, O
behaviour O
) O
of O
several O
mollusk B-Species
taxa O

In O
this O
review O
, O
we O
discuss O
recently O
emerging O
methods O
to O
map O
GRNs O
from O
single-cell O
transcriptomics O
data O
, O
tackling O
the O
challenge O
of O
increased O
noise O
levels O
and O
data O
sparsity O
compared O
with O
bulk O
data O
, O
alongside O
increasing O
data O
volumes O

This O
does O
not O
come O
with O
alterations O
in O
the O
base O
sequence O
( O
' O
genetic B-Gene
code O
' O
) O

progress O

In O
this O
study O
, O
we O
explored O
the O
feasibility O
of O
constructing O
a O
minimized O
epigenetic O
clock O
utilizing O
data O
acquired O
through O
the O
iPlex B-Chemical
MassARRAY I-Chemical
technology O

Hence O
, O
time-of-day O
dependent O
variables O
are O
found O
in O
the O
physiology O
of O
immune B-Disease
cells I-Disease
, O
host-parasite B-Disease
interactions I-Disease
, O
inflammatory B-Disease
processes I-Disease
, O
or O
adaptive O
immune B-Disease
responses I-Disease

However O
, O
only O
recently O
has O
it O
been O
possible O
to O
map O
selected O
RNA B-Chemical
modifications I-Chemical
at O
single-nucleotide O
resolution O
, O
which O
has O
created O
a O
number O
of O
exciting O
hypotheses O
about O
the O
biological O
function O
of O
RNA B-Chemical
modifications I-Chemical
, O
culminating O
in O
the O
proposition O
of O
the O
' O
epitranscriptome O

g O

Among O
the O
three O
genes O
we O
obtained O
as O
candidate O
regions O
showing O
distinct O
difference O
of O
DNA O
methylation O
between O
one O
of O
the O
two O
pairs O
, O
hypermethylation O
of O
SLC6A4 B-Gene
, O
encoding O
HTT B-Gene
, O
in O
the O
bipolar B-Disease
twin O
was O
only O
confirmed O
by O
bisulfite B-Chemical
sequencing O

In O
this O
review O
, O
we O
summarize O
human B-Species
studies O
which O
have O
investigated O
genome-wide O
DNA B-Gene
methylation I-Gene
in O
the O
offspring O
in O
relation O
to O
maternal O
smoking B-Chemical
and O
one-carbon B-Chemical
micronutrient I-Chemical
exposure I-Chemical
during O
pregnancy O

Finally O
, O
we O
discuss O
what O
the O
future O
may O
hold O
in O
terms O
of O
method O
development O
and O
translational O
potential O

This O
review O
aims O
to O
dissect O
the O
interface O
of O
personalized O
medicine O
with O
nanomedicine O
and O
epigenetics O

Although O
more O
stable O
, O
the O
epigenetic O
marks O
in O
adulthood O
are O
also O
dynamic O
and O
modifiable O
by O
environmental O
factors O
including O
diet B-Chemical

This O
especially O
refers O
to O
the O
idea O
- O
common O
in O
colonial O
humoralism O
and O
epigenetics B-Disease
- O
that O
different O
types O
of O
bodies O
are O
in O
balance O
and O
closely O
linked O
with O
particular O
local O
environments O
and O
lifestyles O

Thus O
, O
such O
orphan O
target O
proteins O
are O
not O
yet O
druggable O
with O
limited O
report O
of O
active O
modulators O

Over O
the O
past O
two O
decades O
, O
more O
than O
100 O
imprinted O
mammalian B-Species
genes B-Gene
have O
been O
identified O
, O
while O
considerable O
advances O
have O
been O
made O
in O
elucidating O
the O
molecular O
mechanisms O
governing O
imprinting O

DXM B-Chemical
does O
not O
require O
prior O
knowledge O
of O
the O
number O
of O
subpopulations O
or O
types O
of O
cells O
to O
expect O

The O
cell-specific O
epigenomics O
and O
transcriptional O
patterns O
identified O
serve O
as O
a O
foundation O
for O
future O
studies O
on O
immune O
dysregulation O
in O
diseases B-Disease
and O
aging O

scMET O
is O
a O
hierarchical O
Bayesian O
model O
which O
overcomes O
sparsity O
, O
sharing O
information O
across O
cells O
and O
genomic O
features O
to O
robustly O
quantify O
genuine O
biological O
heterogeneity O

Here O
, O
we O
develop O
BROCKMAN B-Gene
( O
Brockman B-Gene
Representation I-Gene
Of I-Gene
Chromatin I-Gene
by I-Gene
K-mers I-Gene
in I-Gene
Mark-Associated I-Gene
Nucleotides I-Gene
) O
, O
an O
approach O
to O
infer O
variation O
in O
transcription O
factor O
( O
TF O
) O
activity O
across O
samples O
through O
unsupervised O
analysis O
of O
the O
variation O
in O

686Background O

e O

years O

Finally O
, O
we O
summarize O
the O
current O
technologies O
best O
suited O
to O
capturing O
mtDNA B-Gene
methylation O
, O
and O
how O
a O
move O
towards O
whole O
epigenome O
sequencing O
of O
mtDNA B-Gene
may O
help O
to O
advance O
our O
current O
understanding O
of O
the O
field O

Epigenetic O
features O
include O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
non-coding O
RNAs B-Gene
, O
and O
chromatin B-Chemical
structure I-Chemical

Renu O
A O
Kowluru O
from O
the O
Kresge O
Eye O
Institute O
, O
Wayne O
State O
University O
, O
Detroit O
, O
USA O
, O
had O
the O
most O
citations O
with O
1,690 O
and O
the O
highest O
h-index O
( O
h-index O
= O
23 O
) O

Areas O
covered O
 O
We O
present O
an O
overview O
of O
the O
major O
epigenetic O
mechanisms O
and O
their O
effects O
on O
the O
expression O
of O
drug B-Chemical
metabolizing I-Chemical
enzymes O
and O
drug B-Chemical
transporters O
, O
as O
well O
as O
the O
epigenetic O
status O
of O
drug B-Chemical
protein I-Chemical
targets O
affecting O
therapy O
response O

He O
was O
recently O
appointed O
as O
Guest O
Professor O
at O
Central O
South O
University O
in O
Changsha O
, O
China O

633 O
Relational O
developmental O
systems O
' O
theories O
emphasize O
that O
any O
facet O
of O
individual O
structure O
or O
function O
is O
embodied O
with O
other O
features O
of O
the O
individual O
and O
with O
the O
characteristics O
of O
his O
or O
her O
proximal O
and O
distal O
ecology O
, O
including O
culture O
and O
history O

Presented O
herein O
is O
a O
novel O
, O
unifying O
mechanism O
with O
empirical O
evidence O
that O
describes O
how O
aging O
becomes O
continuous O
with O
development O

Larger O
sample O
sizes O
, O
replication O
, O
genetic-epigenetic O
analyses O
and O
longitudinal O
assays O
are O
now O
needed O
to O
establish O
the O
role O
of O
epigenetic O
variants O
in O
disease B-Disease

Altering O
the O
structure O
of O
the O
chromatin O
, O
DNA B-Gene
methylation I-Gene
has O
the O
potential O
to O
down-regulate O
gene O
expression O

First O
, O
we O
constructed O
a O
p300-dCas9 B-Gene
system O
and O
demonstrated O
the O
activation O
of O
a O
EGFP B-Gene
fluorescent O
reporter O

Although O
recent O
advances O
in O
next O
generation O
sequencing O
technology O
allow O
researchers O
to O
map O
epigenetic O
modifications O
across O
the O
genome O
, O
such O
experiments O
are O
often O
time-consuming O
and O
cost O
prohibitive O

This O
phenomenon O
has O
risen O
concern O
for O
human O
health O
as O
the O
preservation O
of O
homeostasis O
is O
essential O
for O
development O
and O
for O
maintaining O
psychological O
and O
physiological O
wellbeing O

, O
M O

However O
, O
much O
like O
the O
GWAS B-Gene
studies O
, O
EWAS B-Gene
are O
likely O
to O
require O
large O
international O
consortium-based O
approaches O
to O
reach O
the O
numbers O
of O
subjects O
, O
and O
statistical O
and O
scientific O
rigor O
, O
required O
for O
robust O
findings O

Conclusion O
 O
Misclassification O
correction O
plus O
cautious O
interpretation O
are O
recommended O
for O
mediation O
analyses O
in O
the O
presence O
of O
exposure O
misclassification O

Although O
the O
hunt O
for O
genetic O
alterations O
in O
head O
and O
neck O
cancer B-Disease
has O
continued O
in O
the O
past O
two O
decades O
, O
with O
unequivocal O
proof O
of O
a O
genetic O
role O
in O
multistage O
head O
and O
neck O
carcinogenesis B-Disease
, O
epigenetic O
alteration O
in O
association O
with O
promoter O
CpG B-Chemical
islands I-Chemical

It O
is O
generally O
believed O
that O
early O
life O
constitutes O
a O
period O
during O
which O
there O
is O
increased O
sensitivity O
to O
the O
regulatory O
effects O
of O
epigenetic O
mechanisms O

Genome-wide O
association O
studies O
( O
GWAS O
) O
have O
helped O
to O
understand O
the O
genetic O
basis O
and O
pathogenesis O
of O
inflammatory B-Disease
bowel I-Disease
disease I-Disease
( O
IBD B-Disease
) O

provides O

Numerous O
studies O
supporting O
this O
hypothesis O
are O
reviewed O
, O
and O
potential O
research O
techniques O
to O
study O
these O
transgenerational O
epigenetic O
effects O
are O
offered O

Our O
evaluation O
indicated O
that O
these O
two O
signatures O
could O
lead O
to O
high O
classification O
accuracy O
values O
( O
92% O
and O
70% O
) O
for O
these O
two O
diseases B-Disease

60 O
Understanding O
epigenetic O
processes O
holds O
immense O
promise O
for O
medical O
applications O

1268 O
Rhabdomyosarcoma B-Disease
is O
the O
most O
common O
soft-tissue O
sarcoma O
of O
childhood O
, O
and O
despite O
clinical O
advances O
, O
subsets O
of O
these O
patients O
continue O
to O
suffer O
high O
levels O
of O
morbidity O
and O
mortality O
associated O
with O
their O
disease O

In O
addition O
to O
acquisition O
of O
resistance-conferring O
genetic O
mutations O
, O
accumulating O
evidence O
suggests O
an O
intimate O
involvement O
of O
the O
epigenetic O
machinery O
in O
this O
process O
as O
well O

1173 O
Even O
under O
homogenous O
conditions O
clonal O
cells O
can O
assume O
different O
distinct O
states O
for O
generations O
to O
follow O
, O
also O
known O
as O
epigenetic O
inheritance O

We O
developed O
a O
package O
that O
reduces O
noise O
while O
normalizing O
the O
epigenomic O
data O
by O
a O
novel O
normalization O
method O
, O
followed O
by O
integrative O
dimensional O
reduction O
by O
learning O
and O
assigning O
epigenetic O
states O

1483 O
 O
Protein B-Chemical
biomarkers O
have O
been O
identified O
across O
many O
age-related O
morbidities B-Disease

Echo O
liquid O
handlers O
can O
transfer O
compounds O
, O
samples O
, O
reagents O
, O
and O
beads O
in O
submicroliter O
volumes O
to O
high-density O
assay O
formats O
using O
only O
acoustic O
energy-no O
contact O
or O
tips O
required O

In O
an O
attempt O
to O
address O
this O
deficit O
, O
the O
current O
chapter O
will O
first O
describe O
methods O
of O
identifying O
and O
characterizing O
functional O
elements O
of O
the O
cis-regulatory O
genome O
at O
a O
genome-wide O
level O
using O
databases O
such O
as O
ENCODE O
, O
the O
UCSC O
browser O
, O
and O
NCBI O

1468 O
Cancer B-Disease
is O
an O
important O
factor O
threatening O
human O
life O
and O
health O
; O
in O
recent O
years O
, O
its O
morbidity O
and O
mortality O
remain O
high O
and O
demosntrate O
an O
upward O
trend O

1139 O
The O
idea O
that O
epigenetic O
determinants O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
or O
RNA B-Chemical
can O
be O
passed O
to O
the O
next O
generation O
through O
meiotic O
products O
( O
gametes O
) O
is O
long O
standing O

Supplementary O
information O
 O
Supplementary O
data O
are O
available O
at O
Bioinformatics O
online O

Although O
this O
line O
of O
research O
offers O
an O
exciting O
outlook O
for O
future O
epigenetic O
research O
in O
PTSD B-Disease
, O
important O
limitations O
include O
the O
tissue O
specificity O
of O
epigenetic O
modifications O
, O
the O
phenomenologic O
definition O
of O
the O
disorder O
, O
and O
the O
challenge O
of O
translating O
molecular O
evidence O
across O
species B-Species

1043 O
The O
analysis O
of O
cytosine B-Chemical
methylation I-Chemical
provides O
a O
new O
way O
to O
assess O
and O
describe O
epigenetic O
regulation O
at O
a O
whole-genome O
level O
in O
many O
eukaryotes B-Species

These O
findings O
, O
when O
coupled O
with O
the O
data O
emerging O
from O
the O
various O
different O
livestock B-Species
genome B-Gene
projects O
, O
have O
major O
implications O
for O
the O
future O
of O
animal B-Species
breeding O
, O
health O
and O
management O

platelet-rich B-Chemical
plasma I-Chemical
(PRP) O
is O
claimed O
to O
restore O
the O
fertility O
potential O
by O
improving O
reserve O
, O
an O
effect O
perhaps O
mediated O
epigenetically O
by O
platelet-discharged O
regulatory O
elements O
rather O
than O
gonadotropin-activated O
G-protein O
coupled O
receptors O
, O
as O
with O
stimulated O
in O
vitro O

Both O
genetic O
and O
environmental O
factors O
impact O
epigenetic O
marks O
, O
generating O
phenotypic O
variation O
that O
ranges O
from O
normal O
variation O
to O
human B-Disease
disease I-Disease

Part O
of O
the O
focus O
of O
this O
research O
has O
been O
on O
epigenetic O
events O
, O
which O
are O
increasingly O
being O
recognized O
for O
their O
importance O
in O
gene B-Gene
regulation I-Gene
and O
cancer B-Disease
progression I-Disease

This O
review O
puts O
recent O
discoveries O
in O
the O
epigenetics O
of O
non-model O
invertebrates B-Species
in O
historical O
context O
, O
and O
describes O
new O
insight O
into O
the O
patterning O
and O
functions O
of O
DNA B-Chemical
methylation I-Chemical
and O
other O
highly O
conserved O
epigenetic O
modifications O

This O
article O
reviews O
the O
potential O
contributions O
and O
problems O
of O
epigenetic O
research O
in O
child O
psychiatry O

This O
conference O
represented O
the O
current O
state O
of O
the O
epigenetics O
community O
with O
cancer B-Disease
/ I-Disease
oncology I-Disease
as O
a O
key O
driver O

In O
this O
review O
we O
provide O
an O
overview O
of O
the O
epigenetic O
landscape O
and O
discuss O
the O
potential O
for O
redox B-Chemical
regulation O

Among O
them O
the O
most O
important O
are O
the O
nonspecific O
nature O
of O
cancer B-Disease
mutations O
and O
the O
non-cell-autonomous O
factors O
of O
cancer B-Disease
initiation O
and O
progression O

While O
the O
pathogenesis O
of O
IgE-mediated B-Disease
food I-Disease
allergy I-Disease
is O
quite O
straightforward O
, O
the O
factors O
that O
lead O
to O
the O
development O
of O
food B-Disease
allergies I-Disease
at O
any O
age O
in O
children O
and O
adults O
are O
unclear O

of O

Epigenetics O
play O
a O
central O
role O
in O
controlling O
changes O
in O
gene B-Gene
expression I-Gene
during O
aging O

From O
cytoplasmic O
inheritance O
to O
the O
epigenetics O
mechanisms O

Infection O
is O
a O
leading O
cause O
of O
morbidity O
and O
mortality O
, O
especially O
in O
preterm O
infants O
, O
but O
it O
remains O
unclear O
why O
neonates O
are O
so O
susceptible O
or O
what O
mediates O
differential O
risk O

1215 O
The O
cover O
of O
a O
recent O
issue O
of O
Science O
et O
SantÃ© O
, O
the O
INSERM O
magazine O
, O
asked O
the O
following O
question O
concerning O
epigenetics O
 O
â O
What O
is O
the O
exact O
role O
played O
by O
the O
? O
â O

Novel O
epigenetically O
regulated O
CpG O
sites O
include O
ABCG4 B-Gene
, O
ANGPTL4 B-Gene
, O
AP2A2 B-Gene
, O
AP2M1 B-Gene
, O
AP2S1 B-Gene
, O
CLTC B-Gene
, O
FGF19 B-Gene
, O
FGF1R B-Gene
, O
HDLBP B-Gene
, O
LIPA B-Gene
, O
LMF1 B-Gene
, O
LRP5 B-Gene
, O
LSR B-Gene

org O
/db O
, O
is O
expected O
to O
become O
a O
valuable O
resource O
for O
transcriptional O
and O
epigenetic O
regulation O
studies O

Î² O
values O
, O
which O
represent O
the O
levels O
of O
DNA B-Chemical
methylation I-Chemical
, O
were O
normalized O
via O
an O
appropriate O
pipeline O

Conclusions O
 O
Integration O
of O
epigenetic O
findings O
into O
biopsychosocial O
models O
of O
the O
etiology O
of O
psychotic B-Disease
disorders I-Disease
eventually O
may O
yield O
important O
insights O
into O
the O
biological O
underpinnings O
of O
the O
onset O
and O
course O
of O
psychotic B-Disease
disorders I-Disease

With O
the O
advent O
of O
high-throughput O
methods O
-- O
including O
genome-wide O
association O
( O
GWA B-Gene
) O
studies O
, O
chromatin O
immunoprecipitation O
followed O
by O
sequencing O
( O
ChIP-seq B-Gene
) O
and O
RNA B-Gene
sequencing I-Gene
( O
RNA-seq B-Gene
) O
-- O
acquisition O
of O
genome-scale O
data O
has O
never O
been O
easier O

Here O
we O
review O
available O
techniques O
and O
future O
possibilities O
, O
arguing O
that O
the O
full O
potential O
of O
single-cell O
epigenetic O
studies O
will O
be O
realized O
through O
parallel O
profiling O
of O
genomic O
, O
transcriptional O
, O
and O
epigenetic O
information O

The O
situated O
perspective O
of O
individual O
researchers O
provides O
in O
fact O
evidence O
for O
a O
conflictual O
(moral O
and O
epistemic) O
economy O
of O
gendered O
engagements O
with O
parental O
figurations O
in O
DOHaD B-Disease
and O
epigenetic O
research O
, O
and O
consequently O
suggests O
a O
more O
fine-grained O
, O
as O
well O
as O
conflictual O

The O
association O
of O
CCSs O
with O
gene B-Gene
expression I-Gene
patterns I-Gene
suggests O
that O
there O
are O
likely O
to O
be O
CCSs O
that O
respond O
, O
or O
regulate O
the O
response O
, O
to O
exercise O
and O
related O
stimuli O

Dysregulation O
of O
these O
processes O
has O
been O
observed O
in O
many O
psychiatric B-Disease
disorders O
, O
and O
evidence O
suggests O
that O
they O
may O
also O
be O
involved O
in O
suicidal B-Disease
behaviors O

Experimental O
evidence O
also O
supports O
a O
role O
of O
epigenetic O
modifications O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
acetylation/methylation I-Chemical
, O
and O
microRNA B-Gene
expression O
in O
Î³-globin B-Gene
gene I-Gene
silencing O
during O
development O

438 O
The O
study O
of O
epigenetics O
, O
or O
chemical B-Chemical
modifications O
to O
the O
genome O
that O
may O
alter O
gene B-Gene
expression O
, O
is O
a O
growing O
area O
of O
interest O
for O
social O
scientists O

An O
informative O
subset O
of O
studies O
that O
examined O
candidate O
gene B-Gene
by O
environment O
(GxE) O
predictors O
of O
these O
psychiatric B-Disease
problems I-Disease
in O
individuals O
maltreated O
as O
children O
is O
reviewed O
, O
together O
with O
extant O
genome O
wide O
association O
studies O
(GWAS) O

Here O
, O
we O
review O
emerging O
evidence O
that O
epigenetics O
contributes O
to O
the O
machinery O
that O
can O
alter O
DNA B-Gene
structure O
, O
gene B-Gene
expression O
, O
and O
cellular O
differentiation O
during O
physiological O
and O
pathological O
bone B-Disease
remodeling O

In O
recent O
years O
, O
epigenetic O
modifications O
have O
been O
shown O
to O
play O
an O
important O
role O
in O
the O
fate O
of O
CD8+ B-Gene
T I-Gene
cells O

Neuroblastoma B-Disease

696Background O
Long-term O
stored O
serum O
is O
considered O
challenging O
for O
epigenomic O
analyses O
 O
as O
there O
are O
no O
cells O
, O
circulating O
DNA B-Gene
is O
scarce O
, O
and O
amplification O
removes O
epigenetic O
signals O

The O
present O
review O
aims O
at O
overviewing O
the O
effect O
of O
DNA B-Gene
methylation O
on O
etiology O
, O
pathogenesis O
, O
pathophysiological O
changes O
, O
and O
complications O
of O
COPD B-Disease

These O
alterations O
lead O
to O
transcriptional O
changes O
that O
ultimately O
define O
the O
phenotype O
and O
function O
of O
a O
given O
cell O

Characterization O
of O
these O
methylation O
events O
is O
critical O
to O
understand O
the O
molecular O
consequences O
of O
chemical B-Chemical
exposures O

O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O

Thus O
, O
it O
is O
important O
to O
understand O
the O
relationship O
between O
predictive O
clock O
sites O
and O
aging B-Disease
biology I-Disease

To O
outline O
in O
more O
detail O
the O
lentivirus-CRISPR/dCas9 B-Chemical
system O
used O
in O
these O
experiments O
, O
this O
protocol O
describes O
how O
to O
produce O
, O
purify O
, O
and O
concentrate O
lentiviral B-Chemical
vectors O
and O
to O
highlight O
their O
suitability O
for O
epigenome- O
and O
genome-editing O
applications O
using O
hiPSCs B-Species
and O

As O
the O
understanding O
of O
epigenetic O
processes O
improves O
, O
so O
will O
the O
ability O
to O
use O
these O
data O
in O
the O
clinic O
to O
improve O
patient O
care O

898 O
The O
occurrence O
and O
progression O
of O
diseases B-Disease
are O
strongly O
associated O
with O
a O
combination O
of O
genetic B-Gene
, O
lifestyle O
, O
and O
environmental O
factors O

O O

151 O
 O
Genomic B-Chemical
predisposition O
fails O
to O
fully O
explain O
the O
onset O
of O
complex B-Disease
diseases I-Disease
, O
which O
is O
well O
illustrated O
by O
the O
largely O
incomplete O
concordance O
among O
monozygotic B-Species
twins I-Species

This O
review O
details O
cellular O
, O
molecular O
and O
epigenetic O
mechanisms O
related O
to O
ageing O
within O
the O
eye O
, O
and O
describes O
ocular O
parameters O
that O
can O
be O
directly O
measured O
clinically O
and O
which O
might O
be O
of O
value O
in O
ageing O
research O
as O
the O
translational O
" O
window O
to O
the O
rest O
of O
the O
body O


Here O
we O
describe O
RNA-seq O
, O
H3K9ac B-Chemical
, O
H3K27ac B-Chemical
and O
H3K27me3 B-Chemical
ChIP-seq O
, O
and O
ATAC-seq O
in O
dorsal B-Species
root I-Species
ganglia I-Species
( O
DRG B-Species
) O
after O
sciatic B-Species
nerve I-Species
or O
dorsal B-Species
column I-Species
axotomy I-Species
, O
to O

The O
three O
most O
age-informative O
cytosine B-Chemical
markers O
were O
selected O
for O
a O
humpback B-Species
epigenetic O
age O
assay O

This O
introductory O
chapter O
, O
largely O
based O
on O
my O
personal O
perception O
, O
aims O
at O
integrating O
work O
presented O
in O
this O
special O
issue O
of O
JEM O
into O
a O
broader O
historical O
context O
up O
to O
current O
research O

Treatment O
of O
DNA B-Gene
with O
bisulfite B-Chemical
converts O
cytosine B-Chemical
to O
uracil B-Chemical
while O
leaving O
5-methylcytosine B-Chemical
intact O
, O
allowing O
for O
single-nucleotide O
resolution O
information O
about O
the O
methylated O
areas O
of O
DNA B-Gene

733 O
Advances O
in O
genomic O
technology O
have O
enabled O
a O
greater O
understanding O
of O
the O
genetics O
of O
common O
immune-mediated O
diseases O
such O
as O
ankylosing B-Disease
spondylitis I-Disease
( O
AS O
) O
, O
inflammatory B-Disease
bowel I-Disease
disease I-Disease
( O
IBD O
) O
and O
psoriasis B-Disease

Suicidal O
behavior O
is O
the O
product O
of O
the O
interaction O
of O
many O
risk O
factors O
, O
such O
as O
genetics O
and O
environmental O
factors O

Only O
few O
of O
the O
association O
signals O
correspond O
to O
nonsynonymous O
coding O
variation O
with O
a O
clear O
effect O
on O
protein B-Chemical
function I-Chemical

a O

Here O
, O
we O
review O
the O
state O
of O
the O
science O
of O
epigenetics O
associated O
with O
environmental O
stimuli O
and O
cancer B-Disease
risk I-Disease
, O
highlighting O
key O
developments O
in O
the O
field O

Greenness O
was O
also O
inversely O
associated O
with O
three O
of O
the O
eight O
components O
of O
GrimAge O
, O
specifically O
, O
DNA B-Gene
methylation-based I-Gene
surrogates O
of O
serum B-Chemical
cystatin-C I-Chemical
, O
serum B-Chemical
growth I-Chemical
differentiation I-Chemical
factor I-Chemical
15 I-Chemical
, O
and O
smoking B-Chemical
pack I-Chemical

miRNAs O
expression O
, O
similarly O
to O
that O
of O
protein-coding B-Gene
genes I-Gene
, O
is O
regulated O
by O
multiple O
transcriptional O
networks O
as O
well O
as O
the O
epigenetic O
machinery O

59 O
Epigenetic O
mechanisms O
are O
believed O
to O
play O
an O
important O
role O
in O
disease O
, O
development O
and O
ageing O
with O
early O
life O
representing O
a O
window O
of O
particular O
epigenomic O
plasticity O

Enrichment O
of O
hypomethylated O
CpG B-Gene
islands I-Gene
was O
observed O
for O
artery O
while O
hypermethylation O
of O
open O
sea O
regions O
were O
present O
in O
placenta B-Species
relative O
to O
prenatal O
arsenic B-Chemical
exposure O

Despite O
this O
, O
it O
has O
not O
been O
possible O
to O
determine O
the O
causes O
of O
the O
epigenetic O
characteristics O
of O
GDM B-Disease
, O
highlighting O
the O
need O
for O
integral O
and O
longitudinal O
studies O

Several O
genomic O
and O
epigenomic O
studies O
of O
CVID B-Disease
have O
recently O
been O
carried O
out O
on O
cohorts O
of O
sporadic O
cases O
of O
CVID B-Disease


However O
, O
much O
less O
has O
been O
said O
about O
the O
authors O
who O
argued O
against O
this O
doctrine O
prior O
to O
the O
appearance O
of O
the O
relevant O
pieces O
by O
Pierre-Louis B-Gene
Moreau I-Gene
de I-Gene
Maupertuis I-Gene
, O
Georges-Louis B-Gene
Leclerc I-Gene
, O
Comte O
de O
Buffon B-Gene
, O
and O
Denis B-Gene
Diderot I-Gene

We O
find O
that O
the O
local O
chromatin O
environment O
of O
the O
reporter O
has O
a O
significant O
effect O
on O
the O
observed O
phenotype O

Genome O
- O
wide O
profiling O
revealed O
differential O
methylation O
in O
3791 O
of O
> O
480,000 O
CpG's O
examined O
in O
transgenomic O
versus O
nontransgenomic O
clones O

Here O
, O
we O
report O
for O
the O
first O
time O
an O
analysis O
of O
autosomal O
sex O
differences O
in O
DNAme B-Gene
using O
the O
Illumina B-Chemical
EPIC I-Chemical
array I-Chemical
in O
human B-Species
whole I-Species
blood I-Species
by O
performing O
a O
discovery O
( O
n O
= O
1171 O
) O
and O
validation O
( O
n O
= O
2471 O
) O

Availability O
and O
implementation O
 O
regioneReloaded O
is O
an O
R O
package O
released O
under O
an O
Artistic-2 O

No O
CpG B-Gene
reached O
epigenome-wide O
significance O
after O
multiple O
testing O
correction O

We O
found O
that O
reanalysis O
of O
the O
same O
single O
cell O
is O
feasible O
, O
provides O
confirmation O
of O
the O
epigenetic O
signals O
, O
and O
allows O
application O
of O
statistical O
analysis O
to O
identify O
reproduced O
reads O
using O
data O
sets O
generated O
only O
from O
the O
single O
cell O

Our O
review O
provides O
an O
overview O
of O
an O
exciting O
and O
controversially O
discussed O
field O
in O
developmental O
and O
molecular O
biology O

Whole O
- O
exome O
sequencing O
studies O
identify O
recurrent O
somatic O
gene O
mutations O
, O
involving O
RNA B-Gene
helicases I-Gene
, O
tumor B-Disease
suppressors I-Disease
, O
JAK-STAT B-Gene
pathway I-Gene
molecules O
, O
and O
epigenetic B-Gene
modifiers I-Gene

immunotherapy B-Chemical

Targeting O
epigenetic O
mechanisms O
in O
paediatric B-Disease
malignancy I-Disease
has O
in O
most O
circumstances O
yet O
to O
reach O
or O
extend O
beyond O
clinical O
proof O
of O
concept O
, O
as O
many O
targets O
do O
not O
yet O
have O
available O
investigational O
drugs O
developed O

The O
knowledge O
obtained O
from O
such O
studies O
will O
elucidate O
the O
mechanisms O
of O
epigenetic O
changes O
and O
, O
through O
the O
identification O
and O
characterization O
of O
DNA B-Gene
methylation I-Gene
markers O
and O
disease-specific B-Disease
methylation I-Disease
patterns O
, O
will O
help O
improve O
the O
diagnosis O
and O
treatment O
options O
for O
patients O

The O
concept O
that O
environmental O
influences O
can O
cause O
stable O
, O
heritable O
changes O
in O
gene B-Gene
expression I-Gene
has O
been O
embraced O
with O
such O
enthusiasm O
that O
the O
study O
of O
epigenetics O
has O
found O
its O
place O
in O
virtually O
every O
medical O
biology O
field O

Female O
participants O
without O
children O
were O
more O
likely O
to O
recognize O
the O
term O
epigenetics B-Gene
, O
while O
age O
also O
had O
an O
impact O

However O
, O
the O
links O
between O
epigenetic O
modifications O
and O
health B-Disease
outcomes I-Disease
are O
often O
correlative O
and O
do O
not O
distinguish O
between O
cause O
and O
effect O
or O
common-cause O
relationships O

1478 O
The O
acquisition O
of O
reproductive O
competence O
is O
organized O
and O
activated O
by O
steroid B-Chemical
hormones I-Chemical
acting O
upon O
the O
hypothalamus O
during O
critical O
windows O
of O
development O

468 O
 O
Renal B-Disease
cell I-Disease
carcinoma I-Disease
( O
RCC B-Disease
) O
is O
characterized O
by O
an O
infrequent O
number O
of O
somatic O
mutations O

For O
each O
individual O
, O
CD4+ B-Gene
T-cells I-Gene
were O
isolated O
from O
the O
first O
blood B-Chemical
sample I-Chemical
within O
2 O
h O
(immediate) O
or O
from O
the O
second O
blood B-Chemical
sample I-Chemical
after O
24 O
h O
storage O
(delayed) O

Availability O
and O
implementation O
 O
The O
EPM O
is O
available O
at O
https//pypi O

It O
is O
an O
ortholog O
of O
Arabidopsis B-Species
genes O
ARR16 B-Gene
and O
ARR17 B-Gene

This O
review O
considers O
how O
epigenetic O
factors O
may O
affect O
rates O
of O
ageing O
of O
muscle O
and O
bone O
and O
provides O
an O
overview O
of O
current O
understanding O
in O
this O
area O

Further O
, O
the O
chicken B-Species
model O
organism O
has O
aided O
in O
our O
understanding O
of O
human B-Species
disease B-Disease

This O
software O
is O
accompanied O
by O
a O
set O
of O
precomputed O
tracks O
, O
which O
may O
be O
used O
as O
a O
valuable O
resource O
for O
functional O
annotation O
of O
the O
human B-Species
genome O

Moreover O
, O
we O
found O
that O
upregulated O
genes O
, O
which O
were O
located O
in O
switched O
compartments O
, O
changed O
contact O
domains O
, O
and O
metastasis-specific O
enhancer-promoter O
loops O
, O
were O
related O
to O
cancer B-Disease
metastasis I-Disease
and O
poor O
prognosis O
of O
patients O
with O
pancreatic B-Disease
cancer I-Disease

However O
, O
the O
low O
efficiency O
and O
slow O
kinetics O
of O
reprogramming O
related O
to O
producing O
these O
cells O
and O
underlying O
safety O
issues O
, O
such O
as O
viral O
integration O
and O
genetic O
and O
epigenetic O
abnormalities O
of O
iPSCs B-Species
, O
hamper O
the O
further O
application O
of O
iPSCs B-Species
in O
laboratory O
and O
clinical O

232 O
 O
methylation O
controls O
several O
cellular O
processes O
, O
from O
early O
development O
to O
old O
age O
, O
including O
biological O
responses O
to O
endogenous O
or O
exogenous O
stimuli O
contributing O
to O
transition O

We O
propose O
the O
hypothesis O
that O
PbRR9 B-Gene
has O
a O
direct O
, O
epigenetically O
mediated O
, O
role O
in O
poplar B-Species
sex O
determination O

Although O
the O
mechanisms O
are O
still O
largely O
unknown O
, O
especially O
in O
humans B-Species
, O
the O
new O
research O
methods O
are O
now O
gradually O
available O
, O
and O
the O
animal B-Species
models O
can O
provide O
more O
in-depth O
study O
of O
mechanisms O

cepbrowser O

Thus O
, O
using O
binned O
libraries O
, O
based O
on O
a O
common O
set O
of O
responses O
to O
known O
drugs O
, O
a O
cost-effective O
high-throughput O
screening O
strategy O
for O
epigenetically O
active O
compounds O
from O
plants B-Species
or O
other O
sources O
is O
described O

Although O
the O
field O
is O
still O
in O
its O
early O
days O
, O
this O
chapter O
will O
discuss O
the O
current O
standing O
of O
epigenetic O
research O
into O
ADHD B-Disease

We O
also O
summarize O
state O
of O
the O
art O
techniques O
for O
evaluating O
the O
epigenome O
, O
environmental O
epigenetic O
analysis O
, O
and O
the O
emerging O
field O
of O
epigenome O
editing O

579 O
We O
have O
developed O
a O
database O
called O
dbEM O
( O
database O
of O
Epigenetic B-Disease
Modifiers I-Disease
) O
to O
maintain O
the O
genomic O
information O
of O
about O
167 O
epigenetic O
modifiers/proteins O
, O
which O
are O
considered O
as O
potential O
cancer B-Disease
targets O

Genome O
- O
wide O
analysis O
, O
using O
arrays O
and O
high O
- O
throughput O
sequencing O
, O
has O
enabled O
assessment O
of O
large O
fractions O
of O
the O
methylome B-Chemical
, O
but O
each O
protocol O
comes O
with O
unique O
advantages O
and O
disadvantages O

This O
may O
contribute O
to O
the O
development O
of O
drug B-Chemical
resistance O
and O
unwanted O
side O
effects O

Although O
our O
understanding O
of O
metabolism O
in O
pAML B-Disease
is O
still O
in O
its O
infancy O
, O
greater O
insights O
into O
these O
processes O
and O
their O
( O
epigenetic O
) O
modulation O
may O
pave O
the O
way O
toward O
novel O
treatment O
options O

Whilst O
some O
studies O
have O
implicated O
a O
defect O
in O
the O
SLC6A2 B-Gene
gene O
, O
the O
cause O
of O
reduced O
SLC6A2 B-Gene
expression O
and O
function O
remains O
unclear O

Especially O
, O
in O
pediatric O
high-grade O
brain O
tumors O
, O
such O
as O
diffuse O
midline O
glioma B-Disease
, O
H3K27M-altered B-Gene
and O
posterior O
fossa O
group O
A-ependymoma B-Disease
, O
epigenetic O
changes O
predominate O
, O
along O
with O
changes O
in O
expression O
of O
known O
oncogenes O
and O
tumor O
suppressor O
genes O
induced O
by O

Maximising O
the O
impact O
of O
RRBS O
in O
plants B-Species
741 O
VI O

In O
this O
paper O
, O
we O
explore O
the O
relation O
between O
DNA B-Gene
methylation I-Gene
and O
transcription O
and O
characterize O
in O
detail O
the O
histone B-Chemical
modifications I-Chemical
for O
specific O
DNA B-Gene
methylation I-Gene
levels O
using O
a O
stochastic O
approach O

It O
is O
shown O
that O
standard O
quantitative O
genetic O
modeling O
based O
on O
analyses O
of O
interindividual O
phenotypic O
variation O
misclassifies O
the O
variation O
generated O
by O
nonlinear O
epigenetic O
processes O
as O
being O
due O
to O
specific O
environmental O
influences O

Here O
, O
we O
explored O
the O
epigenetic O
patterns O
of O
ncRNAs O
in O
breast B-Disease
cancers I-Disease
using O
published O
sequencing-based O
methylome O
data O
, O
primarily O
focusing O
on O
the O
two O
most O
commonly O
studied O
ncRNA O
biotypes O
, O
long O
ncRNAs O
and O
miRNAs O

We O
suppose O
that O
epigenetic O
mechanisms O
may O
induce O
higher O
rates O
of O
obesity B-Disease
in O
subjects O
who O
suffer O
from O
mood B-Disease
disorders I-Disease

Recent O
discovery O
of O
mutations O
affecting O
epigenetic O
regulators O
reinforces O
the O
importance O
of O
these O
changes O
in O
the O
pathophysiology O
of O
ccRCC B-Disease
and O
points O
to O
the O
potential O
of O
epigenetic O
modulators O
in O
the O
treatment O
of O
this O
malignancy O

1079Background O
Functional O
genomic O
and O
epigenomic O
research O
relies O
fundamentally O
on O
sequencing O
based O
methods O
like O
ChIP-seq O
for O
the O
detection O
of O
DNA-protein O
interactions O

Here O
we O
provide O
a O
detailed O
explanation O
of O
the O
methodology O
used O
, O
the O
choice O
of O
reagents O
and O
the O
troubleshooting O
steps O
required O
to O
establish O
a O
robust O
chromatin O
preparation O
procedure O

behavior O

In O
this O
context O
, O
we O
will O
discuss O
about O
molecules O
of O
intermediary O
energy O
metabolism O
affecting O
chromatin B-Gene
modifier I-Gene
actions O
, O
nutrition-triggered O
epigenetic O
memory O
in O
pre- O
and O
postnatal O
phases O
of O
life O
; O
and O
epigenetic O
programming O
of O
immune B-Gene
cells I-Gene
by O
vitamin B-Chemical
D I-Chemical

In O
order O
to O
maximize O
the O
use O
of O
structure-activity O
relationships O
there O
is O
a O
clear O
need O
to O
develop O
robust O
and O
accurate O
models O
to O
understand O
the O
underlying O
structure-activity O
relationship O

differentiation O
of O
shades O
( O
campimetry O
) O
; O
2 O

Examples O
of O
recent O
findings O
relating O
to O
the O
role O
of O
epigenetic O
modifications O
in O
complex O
disease O
and O
outcomes O
are O
derived O
from O
research O
into O
type B-Disease
1 I-Disease
diabetes I-Disease
, O
pain B-Disease
, O
and O
the O
hypoxic B-Disease
response I-Disease

For O
example O
, O
mapping O
of O
open O
chromatin B-Chemical
regions O
, O
post-translational O
histone B-Chemical
modifications O
and O
DNA B-Chemical
methylation O
across O
a O
whole O
genome O
is O
now O
feasible O
, O
and O
new O
non-coding O
regulatory O
RNAs B-Gene
can O
be O
sensitively O
identified O
via O
RNA B-Gene
sequencing O

Studies O
on O
cross-sectional O
data O
have O
discovered O
a O
change O
in O
methylation B-Chemical
variability O
in O
association O
with O
age O

Here O
, O
we O
review O
the O
alterations O
of O
lipid B-Chemical
metabolism O
and O
epigenetics O
in O
PCa B-Disease
, O
before O
focusing O
on O
the O
mechanisms O
that O
connect O
them O

986 O

In O
this O
review O
, O
we O
discuss O
how O
the O
genome O
, O
epigenome O
, O
and O
transcriptome O
of O
MZ B-Species
twins O
can O
be O
studied O
in O
an O
integrative O
manner O
from O
this O
perspective O

Being O
able O
to O
quantify O
to O
which O
extent O
epigenomic O
processes O
are O
mediators O
of O
the O
association O
between O
environmental O
exposures O
and O
diseases B-Disease
is O
of O
interest O
for O
epidemiologic O
research O

Importantly O
, O
all O
of O
the O
major O
epigenetic O
mechanisms O
in O
mammalians B-Species
also O
occur O
in O
plants B-Species

Our O
proposed O
method O
is O
therefore O
designed O
to O
provide O
a O
dynamic O
assessment O
to O
investigate O
functionally O
active O
transcription B-Gene
factors I-Gene

1121 O
Epigenetic O
alterations O
, O
such O
as O
changes O
in O
DNA B-Chemical
methylation I-Chemical
, O
histones/chromatin O
structure O
, O
nucleosome O
positioning O
, O
and O
expression O
of O
non-coding O
RNAs O
, O
are O
recognized O
among O
key O
characteristics O
of O
carcinogens O
; O
they O
may O
occur O
independently O
or O
concomitantly O
with O
genotoxic O
effects O

Eventually O
, O
harnessing O
epigenetic O
strategies O
presents O
a O
promising O
trajectory O
toward O
sustainable O
agriculture O
in O
the O
face O
of O
escalating O
environmental O
challenges O

Phytocannabinoids O
interact O
with O
cannabinoid O
and O
non-cannabinoid O
receptors O
(GPCR O
, O
ion O
channels O
, O
and O
PPAR B-Gene
) O
to O
improve O
various O
neurodegenerative B-Disease
diseases I-Disease

Possible O
mechanisms O
of O
epigenetic O
modifications O
and O
their O
role O
on O
physiology O
and O
adaptation O
as O
well O
as O
the O
incidence O
of O
intergenerational O
and O
transgenerational O
inheritance O
are O
discussed O

Our O
model O
MGMT-STP27 B-Gene
allows O
prediction O
of O
the O
methylation O
status O
of O
the O
MGMT B-Gene
promoter O
using O
data O
from O
the O
Illumina's B-Chemical
Human I-Chemical
Methylation I-Chemical
BeadChips I-Chemical
( O
HM-27K B-Chemical
and O
HM-450K B-Chemical
) O
that O
is O
publically O
available O
for O
many O
cancer B-Disease
data O

Finally O
, O
DNA B-Gene
methylation O
of O
the O
same O
site O
was O
also O
higher O
in O
the O
postmortem O
brains O
of O
BD B-Disease
patients O

To O
this O
end O
, O
we O
have O
implemented O
a O
computational O
pipeline O
to O
systematically O
study O
epigenetic O
variability O
and O
uncover O
regulatory O
DNA O
sequences O


We O
found O
a O
distinct O
DNA B-Gene
methylation I-Gene
landscape O
in O
hASCs B-Species
from O
patients O
with O
CD B-Disease
, O
leading O
to O
changes O
in O
the O
expression O
of O
differentially O
methylated O
genes O
involved O
in O
immune O
response O
, O
metabolic O
, O
cell O
differentiation O
, O
and O
development O
processes O

We O
develop O
a O
theoretical O
description O
of O
such O
crosses O
and O
model O
the O
relationship O
between O
epiallelic B-Gene
instability O
, O
recombination B-Gene
, O
parent-of-origin B-Gene
effects O
, O
as O
well O
as O
transgressive B-Gene
segregation O
and O
their O
joint O
impact O
on O
phenotypic B-Disease
variation O
across O
generations O

This O
strategy O
represents O
an O
innovative O
, O
groundbreaking O
approach O
, O
improving O
the O
conservation O
and O
management O
of O
natural O
resources O
in O
the O
oceans O

To O
date O
, O
our O
knowledge O
about O
the O
role O
of O
epigenetic O
processes O
in O
schizophrenia B-Disease
is O
limited O
and O
based O
on O
analyses O
of O
small O
numbers O
of O
samples O
obtained O
from O
a O
range O
of O
different O
cell O
and O
tissue O
types O

EpiProfile O
2 O

Conclusion O
 O
These O
results O
demonstrate O
that O
epigenetic O
aging O
is O
dynamic O
and O
changes O
after O
exposure O
to O
trauma B-Disease

The O
findings O
of O
several O
studies O
have O
shown O
that O
instituting O
tight O
glycemic O
control O
in O
diabetic B-Disease
patients I-Disease
does O
not O
immediately O
benefit O
the O
progression O
of O
retinopathy B-Disease
, O
and O
the O
benefits O
of O
good O
control O
persist O
beyond O
the O
period O
of O
good O
glycemic O
control O

on O

So O
far O
, O
the O
best O
investigated O
externally O
visible O
characteristics O
are O
eye O
, O
hair O
and O
skin O
colour O
, O
as O
well O
as O
geographic O
ancestry O
and O
age O

It O
reintroduces O
long O
forgotten O
exclusionary O
and O
stereotypic O
perspectives O
on O
indigenous O
and O
mestizos O
, O
and O
biologizes O
as O
well O
as O
racializes O
social-cultural O
differences O
among O
human B-Species
groups O


In O
isogenic O
KMT2C B-Gene
KO O
hPSCs O
, O
we O
found O
genome-wide O
differences O
in O
histone O
modifications O
at O
active O
and O
poised O
enhancers O
, O
leading O
to O
gene O
expression O
profiles O
akin O
to O
mesendoderm B-Species
rather O
than O
mesoderm B-Species
highlighted O
by O
a O
significant O
increase O
in O
NODAL B-Gene
expression O
and O

Last O
but O
not O
least O
we O
have O
discussed O
the O
limitations O
, O
different O
uses O
of O
CRISPR/Cas9 B-Gene
and O
dCas9 B-Gene
in O
the O
area O
of O
genetic O
engineering O

These O
include O
cell O
type O
, O
age O
, O
the O
timing O
of O
experience O
, O
sex O
, O
and O
DNA B-Gene
sequence I-Gene

These O
epigenetic O
marks O
include O
DNA B-Chemical
methylation I-Chemical
at O
CpG B-Gene
dinucleotides O
, O
covalent O
modifications O
of O
, O
and O
noncoding B-Gene
RNAs I-Gene
( O
ncRNAs B-Gene
) O

liu O

The O
influence O
of O
the O
periconceptional O
milieu O
on O
the O
epigenetic O
profile O
of O
the O
developing O
embryo O
has O
become O
a O
popular O
research O
focus O
in O
the O
quest O
to O
understand O
the O
effects O
of O
environment O
, O
nutrition O
and O
assisted O
reproduction O
technology O
on O
human B-Species
development O
and O
health O

33 O

Indeed O
, O
progress O
in O
understanding O
gene B-Gene
regulation O
at O
promoter O
regions O
and O
chromatin O
organization O
in O
health O
and O
disease B-Disease
has O
been O
substantial O

Â© O
2016 O
Wiley O
Periodicals O
, O
Inc O

Revealing O
diet-epigenetic O
relationships O
has O
the O
potential O
to O
transform O
nutrition O
science O
by O
increasing O
our O
fundamental O
understanding O
of O
 O
( O
i O
) O
the O
role O
of O
nutrients O
in O
biological O
systems O
, O
( O
ii O
) O
the O
resilience O
of O
living O
organisms O
in O
responding O
to O
environmental O
perturbations O
, O
and O
( O

These O
data O
provide O
a O
molecular O
basis O
for O
exercise O
as O
a O
therapy O
to O
attenuate O
skeletal B-Disease
muscle I-Disease
aging I-Disease

The O
knowledge O
gained O
from O
these O
recent O
molecular O
, O
cellular O
, O
genomic O
, O
and O
epigenomic O
analyses O
are O
now O
being O
integrated O
to O
identify O
new O
therapeutic O
approaches O
that O
can O
help O
save O
lives O
and O
vision O
in O
children O
with O
retinoblastoma B-Disease
, O
with O
fewer O
long-term O
side O
effects O

In O
my O
view O
, O
further O
studies O
are O
needed O
to O
understand O
the O
toxicity O
of O
these O
treatments O
in O
order O
to O
improve O
survival O
of O
melanoma B-Disease
patients O

RVX-208 B-Chemical
produced O
a O
distinct O
transcriptional O
response O
in O
stimulated O
primary O
neurons O
compared O
to O
JQ1 B-Chemical
but O
had O
little O
effect O
on O
gene O
expression O
in O
non-stimulated O
neurons O

The O
MAC B-Chemical
contamination O
ratio O
in O
purified O
MIC B-Chemical
is O
about O
0 O

The O
method O
can O
acquire O
at O
least O
five O
epigenetic O
marks O
 O
H3K27ac B-Gene
, O
H3K27me3 B-Gene
, O
mediator B-Gene
complex I-Gene
subunit I-Gene
1 I-Gene
, O
a O
DNA B-Chemical
modification I-Chemical
, O
and O
a O
DNA-interacting B-Chemical
protein I-Chemical

553 O
The O
Illumina O
HumanMethylation450 O
BeadChip O
has O
become O
a O
popular O
platform O
for O
interrogating O
DNA B-Gene
methylation I-Gene
in O
epigenome-wide O
association O
studies O
(EWAS) O
and O
related O
projects O
as O
well O
as O
resource O
efforts O
such O
as O
the O
International B-Disease
Cancer I-Disease
Genome I-Disease
Consortium I-Disease
(ICGC) O
and O
the O


Epigenetic O
signatures O
( O
DNA B-Chemical
methylation I-Chemical
, O
mRNA B-Gene
and O
microRNA B-Gene
expression I-Gene
, O
etc O
) O
may O
serve O
as O
biomarkers O
for O
risk O
stratification O
, O
early O
detection O
, O
and O
disease B-Disease
classification I-Disease
, O
as O
well O
as O
targets O
for O
therapy O
and O
chemoprevention O

A O
pharmacoepigenetic O
approach O
may O
help O
to O
elucidate O
and O
revert O
such O
phenomena O

In O
this O
review O
, O
we O
briefly O
introduce O
the O
epigenetics O
regulation O
and O
update O
the O
relevant O
progress O
in O
DCM B-Disease

Background O
 O
The O
number O
of O
studies O
on O
epigenetics O
in O
eye B-Disease
diseases I-Disease
has O
exceeded O
5,000 O
, O
but O
the O
progress O
and O
scope O
of O
epigenetic O
research O
on O
eye B-Disease
diseases I-Disease
remain O
unclear O

Materials O
& O
methods O
 O
Genome-wide O
microarray O
data O
including O
three O
hepatic B-Disease
conditions I-Disease
are O
obtained O
from O
the O
GEO B-Gene
database O
( O
GSE15238 O
) O

, O
GluR2 B-Gene
, O
GLRA2 B-Gene
, O
and O
GLRA3 B-Gene
) O
, O
growth O
factors O
( O
e O

We O
hypothesize O
that O
events O
during O
the O
intrapartum O
period O
- O
specifically O
the O
use O
of O
synthetic B-Chemical
oxytocin I-Chemical
, O
antibiotics B-Chemical
, O
and O
cesarean B-Disease
section I-Disease
- O
affect O
the O
epigenetic O
remodeling O
processes O
and O
subsequent O
health O
of O
the O
mother O
and O
offspring O

Our O
method O
provides O
intuitive O
maps O
of O
epigenetic O
patterns O
across O
multiple O
levels O
of O
organization O
, O
e O

36 O

This O
article O
describes O
the O
ethical O
issues O
associated O
with O
use O
of O
epigenetic O
testing O
for O
alcohol B-Chemical
, O
tobacco B-Chemical
, O
and O
cannabis B-Chemical
and O
the O
implications O
of O
this O
technology O

To O
enhance O
scientific O
rigor O
, O
we O
conclude O
that O
strict O
adherence O
to O
protocols O
is O
necessary O
for O
the O
execution O
and O
interpretation O
of O
epigenetic O
studies O
and O
that O
protocol-sensitive O
epigenetic O
changes O
, O
amongst O
naive O
animals B-Species
, O
may O
confound O
experimental O
results O

Moreover O
, O
additional O
research O
on O
non-genetic O
inheritance O
draws O
attention O
to O
a O
variety O
of O
means O
whereby O
differences O
can O
be O
inherited O
in O
offspring O
generations O
that O
do O
not O
rely O
on O
differences O
in O
germline O
structures O

In O
addition O
, O
an O
increasing O
number O
of O
non-coding O
RNAs B-Gene
with O
regulatory O
activity O
on O
gene O
expression O
have O
been O
identified O

1344Background O
DNA B-Gene
methylation I-Gene
profiling O
reveals O
important O
differentially O
methylated O
regions O
(DMRs) O
of O
the O
genome O
that O
are O
altered O
during O
development O
or O
that O
are O
perturbed O
by O
disease B-Disease

Epigenetic O
regulators O
therefore O
likely O
play O
a O
crucial O
role O
in O
cardiomyocyte O
homeostasis O
and O
facilitate O
the O
cellular O
adaption O
to O
various O
internal O
and O
external O
stimuli O
, O
responding O
to O
different O
intercellular O
and O
extracellular O
cues O

1273 O
(DNAm) O
plays O
a O
determining O
role O
in O
neural O
cell O
fate O
and O
provides O
a O
molecular O
link O
between O
early-life O
stress O
and O

273 O
Over O
the O
past O
two O
decades O
, O
advances O
in O
genetic O
technologies O
have O
posed O
unexpected O
challenges O
to O
the O
ethical O
and O
legal O
framework O
guiding O
the O
application O
of O
the O
most O
recent O
advances O
in O
healthcare O
technologies O

52 O
Cardiomyopathies B-Disease
(CMPs) O
are O
a O
heterogeneous O
group O
of O
myocardial O
diseases O
accountable O
for O
the O
majority O
of O
cases O
of O
heart B-Disease
failure I-Disease
(HF) O
and/or O
sudden B-Disease
cardiac I-Disease
death I-Disease
(SCD) O
worldwide O

Molecular O
biomarkers O
capable O
of O
identifying O
the O
subset O
of O
lesions O
likely O
to O
progress O
to O
cancer B-Disease
are O
required O
to O
eliminate O
this O
clinical O
diagnostic O
dilemma O

Further O
studies O
should O
be O
dedicated O
to O
strength O
these O
preliminary O
findings O
, O
in O
larger O
multicenter O
cohorts O
, O
to O
identify O
reliable O
directions O
for O
biomarker O
research O
and O
clinical O
practice O

Now O
, O
however O
, O
theoretical O
and O
experimental O
studies O
have O
illuminated O
the O
possible O
roles O
that O
epigenetic O
information O
could O
play O
in O
evolution O
and O
we O
are O
on O
the O
cusp O
of O
testing O
this O
concept O
in O
ecologically O
relevant O
settings O

We O
illustrate O
the O
utility O
of O
our O
method O
in O
large-scale O
EWAS O
and O
TWAS O
meta-analyses O
of O
age O
and O
smoking O

971 O
Although O
epidemiological O
studies O
support O
the O
role O
of O
environment O
in O
a O
wide O
range O
of O
human B-Species
cancers O
, O
the O
precise O
mechanisms O
by O
which O
environmental O
exposures O
promote O
cancer B-Disease
development O
and O
progression O
remain O
poorly O
understood O

Furthermore O
, O
the O
global O
content O
of O
specific O
epigenetic O
modifications O
and O
the O
gene B-Gene
expression I-Gene
of I-Gene
non-coding I-Gene
RNAs I-Gene
and O
epigenetic O
modifiers O
vary O
according O
to O
the O
menstrual O
cycle O
phase O

However O
, O
evidence O
demonstrates O
that O
the O
mutation O
of O
genes O
accounts O
for O
only O
a O
small O
portion O
of O
CHD B-Disease
cases O
, O
whereas O
the O
aberrant O
expression O
regulated O
by O
epigenetic O
modification O
plays O
a O
predominant O
role O
in O
the O
pathogenesis O
of O
CHD B-Disease

Even O
if O
Lamarckism O
is O
not O
back O
, O
epigenetic O
inheritance O
might O
be O
appealing O
for O
evolutionary O
biologists O
because O
it O
could O
potentiate O
two O
neglected O
mechanisms O
 O
the O
Baldwin O
effect O
and O
genetic O
assimilation O


In O
this O
review O
article O
, O
we O
will O
provide O
a O
critical O
overview O
of O
the O
MS-based O
approaches O
that O
can O
be O
employed O
to O
study O
histone B-Chemical
PTMs O
and O
variants O
in O
clinical B-Disease
samples O
, O
with O
a O
strong O
focus O
on O
the O
latest O
advances O
in O
this O
area O
, O
such O
as O
the O
analysis O
of O

We O
then O
study O
three O
path-specific O
effects O
 O
the O
direct O
effect O
of O
SNPs B-Gene
on O
the O
outcome O
, O
the O
effect O
mediated O
through O
expression B-Gene
, O
and O
the O
effect O
through O
methylation B-Chemical

The O
recent O
development O
of O
CRISPR/catalytically B-Gene
dead I-Gene
CRISPR/Cas9 I-Gene
(dCas9)-based I-Gene
targeted O
DNA B-Chemical
methylation I-Chemical
editing O
tools O
has O
enabled O
new O
insights O
into O
the O
roles O
and O
functional O
relevance O
of O
this O
modification O
, O
including O
its O
importance O
at O
regulatory O
regions O
and O
the O
role O
of O

As O
such O
, O
these O
cells O
carry O
with O
them O
the O
potential O
to O
influence O
the O
phenotype O
of O
all O
successive O
cell O
types O
as O
the O
organism O
grows O
, O
differentiates O
and O
ages O

Genetics O
seems O
to O
play O
a O
major O
role O
in O
susceptibility O
to O
Mn B-Chemical
toxicity O
and O
should O
therefore O
be O
considered O
in O
risk O
assessment O

Since O
some O
of O
the O
epigenetic O
modifications O
can O
be O
reversed O
, O
they O
could O
be O
used O
as O
potential O
therapeutic O
targets O

Change O
in O
gene B-Gene
expression O
due O
to O
these O
epigenetic O
modifications O
are O
responsible O
for O
new O
traits O
in O
different O
organisms O
leading O
to O
various O
diseases O
including O
cancer B-Disease
, O
diabetic B-Disease
kidney I-Disease
disease I-Disease
( O
DKD B-Disease
) O
, O
diabetic B-Disease
nephropathy I-Disease
( O
DN B-Disease
) O
and O
renal B-Disease

Professor O
Randy B-Gene
Jirtle I-Gene
joined O
the O
in O
1977 O
and O
headed O
the O
Epigenetics B-Disease
and I-Disease
Imprinting I-Disease
Laboratory O
until O
2012 O

Furthermore O
, O
evidence O
shows O
that O
parental O
behavior O
and O
diet O
can O
affect O
the O
phenotype O
of O
subsequent O
generations O
via O
epigenetic O
transmission O
mechanisms O

Challenges O
and O
opportunities O
in O
the O
field O
are O
discussed O
in O
this O
chapter O

I O
show O
that O
Erikson's O
psychosocial O
approach O
requires O
close O
attention O
to O
the O
role O
of O
the O
community O
in O
the O
formation O
of O
individual O
identity O
and O
to O
the O
importance O
of O
the O
stage O
of O
generativity O
as O
an O
often O
overlooked O
component O
in O
understanding O
both O
identity O
and O
the O
whole O
Eriksonian O
life O
cycle O

We O
hope O
that O
this O
series O
sparks O
a O
larger O
discussion O
of O
issues O
faced O
by O
underrepresented O
scientists O
and O
ways O
the O
scientific O
community O
can O
foster O
diversity O
and O
better O
support O
underrepresented O
scientists O

38 O
The O
field O
of O
tissue O
engineering O
and O
regenerative O
medicine O
( O
TE/RM O
) O
involves O
regeneration O
of O
tissues O
and O
organs O
using O
implantable O
biomaterials O

regarding O

The O
basic O
idea O
is O
that O
the O
cytopathic O
effect O
of O
the O
replicating O
virus B-Disease
and O
the O
immune O
system O
may O
eliminate O
the O
reactivated O
cells O
, O
whereas O
HAART B-Chemical
may O
block O
the O
infection O
of O
new O
target O
cells O

The O
metabolism-induced O
recoding O
of O
epigenetics O
in O
cancer B-Disease
depends O
strongly O
on O
nutrient O
availability O
for O
tumor O
cells O

org O
/ O
packages O
/ O
BPRMeth O

1253 O
Modern O
epigenetics O
emerged O
about O
40 O
years O
ago O

64 O
 O
Purpose O
of O
review O
 O
The O
purpose O
of O
this O
review O
is O
to O
provide O
an O
update O
of O
recent O
advances O
in O
the O
established O
role O
of O
different O
layers O
of O
epigenetic O
control O
mechanism O
that O
are O
used O
by O
joint O
cells O
to O
ensure O
tissue O
homeostasis O
and O
cope O
with O
changing O
microenvironment O
( O
e O

Â© O
2019 O
Wiley O
Periodicals O
, O
Inc O

Striking O
new O
evidence O
implicates O
the O
dysregulation O
of O
epigenetic O
mechanisms O
in O
neurodegenerative B-Disease
disorders I-Disease
and O
diseases O

It O
has O
recently O
been O
found O
that O
some O
of O
the O
chromatin B-Chemical
modulatory I-Chemical
machinery O
essential O
for O
proper O
development O
plays O
a O
previously O
unappreciated O
role O
in O
the O
pathogenesis O
of O
cardiac B-Disease
disease I-Disease
in O
adults O

1183 O
verO O
the O
last O
several O
decades O
, O
several O
lines O
of O
evidence O
have O
shown O
that O
epigenetic O
modifications O
modulate O
phenotype O
and O
mediate O
an O
organism B-Species
's I-Species
response O
to O
environmental O
stimuli O

A O
key O
property O
of O
epigenetic O
marks O
is O
that O
they O
can O
be O
inherited O
along O
mitotic O
cell O
lineages O
, O
and O
epigenetic O
differences O
that O
occur O
during O
early O
development O
can O
have O
lasting O
consequences O
on O
the O
organismal O
phenotypes O

Endometriosis B-Disease
may O
result O
from O
the O
migration O
of O
shed O
endometrium B-Species
to O
the O
peritoneal B-Species
cavity I-Species

More O
research O
in O
epigenetics O
is O
needed O
that O
will O
enhance O
our O
understanding O
of O
the O
determinants O
of O
cancer B-Disease
across O
various O
diverse O
populations O
and O
ultimately O
reduce O
cancer B-Disease
health O
disparities O

Taken O
together O
, O
we O
describe O
alternative O
targeted O
methods O
for O
epigenetic O
age O
predictions O
that O
provide O
new O
perspectives O
for O
aging-intervention O
studies O
in O
mice B-Species

edu O
/ O
conneely O
/ O
MethLAB O
) O
using O
R B-Chemical
, O
an O
open O
source O
statistical O
language O
that O
can O
be O
edited O
to O
suit O
the O
needs O
of O
the O
user O

We O
built O
predictive O
models O
with O
high O
accuracy O
for O
small B-Chemical
molecules I-Chemical
' O
epigenetic O
target O
profiling O
through O
a O
systematic O
comparison O
of O
the O
machine O
learning O
models O
trained O
on O
different O
molecular O
fingerprints O

After O
passage O
60 O
, O
most O
cells O
displayed O
the O
46 O
, O
XX O
karyotype O
again O
with O
a O
mosaic O
ratio O
of O
97 O
 O
3 O

Second O
, O
an O
epigenome-wide O
association O
study O
( O
EWAS O
) O
on O
1011 O
longitudinal O
samples O
( O
385 O
individuals O
followed O
up O
to O
18 O
years O
) O
was O
performed O
to O
identify O
age-varying O
methylation O
sites O
using O
these O
methods O

But O
while O
this O
" O
policy O
translation O
" O
of O
epigenetics O
introduces O
new O
arguments O
in O
favor O
of O
public O
health O
strategies O
and O
policy-making O
, O
a O
more O
" O
clinical O
translation O
" O
of O
epigenetics O
is O
also O
emerging O

Importantly O
tracking O
epigenetic O
states O
and O
profiling O
the O
epigenome O
within O
cells O
require O
the O
use O
of O
epigenetic O
methodologies O
and O
subsequent O
data O
analysis O

scATAC-seq O
experiments O
sample O
DNA O
, O
which O
, O
due O
to O
low O
copy O
numbers O
( O
diploid O
in O
humans B-Species
) O
, O
lead O
to O
inherent O
data O
sparsity O
( O
1-10% O
of O
peaks O
detected O
per O
cell O
) O
compared O
to O
transcriptomic O
( O
scRNA-seq O
) O
data O
( O
10-45% O
of O

Practice O
implications O
 O
Advanced O
practice O
psychiatric O
nurses O
will O
benefit O
from O
an O
expanded O
knowledge O
base O
in O
neuroscience O
and O
epigenetics B-Chemical
that O
informs O
and O
explains O
the O
scientific O
rationale O
for O
our O
integrated O
practice O

Furthermore O
, O
accumulating O
genetic O
and O
pathological O
evidence O
implicates O
microglial B-Species
cell I-Species
activity O
in O
the O
etiology O
of O
numerous O
neurodegenerative B-Disease
diseases I-Disease
and O
psychiatric B-Disease
disorders I-Disease

Conclusion O
 O
Epigenetic O
modification O
of O
gene B-Gene
expression I-Gene
provides O
a O
mechanism O
for O
understanding O
the O
link O
between O
long-term O
effects O
of O
adverse O
life O
events O
and O
the O
changes O
in O
gene B-Gene
expression I-Gene
that O
are O
associated O
with O
depression B-Disease

Recent O
strides O
in O
this O
field O
encompass O
identifying O
specific O
epigenetic O
markers O
associated O
with O
stress O
resilience O
, O
developing O
tools O
for O
editing O
the O
epigenome O
, O
and O
integrating O
epigenetic O
data O
into O
breeding O
programs O
for O
stress-resistant O
crops O

Differential O
expression O
analysis O
was O
used O
to O
identify O
differences O
in O
the O
expression O
based O
on O
the O
sex O
of O
the O
fetus O

Epigenetics O
is O
strongly O
influenced O
by O
environmental O
factors O
, O
including O
known O
cardiovascular B-Disease
risk I-Disease
factors I-Disease
such O
as O
smoking B-Chemical
, O
obesity B-Disease
, O
and O
low O
physical O
activity O

007 O
) O

It O
is O
hoped O
that O
an O
understanding O
of O
this O
area O
will O
lead O
to O
interventions O
that O
might O
prevent O
or O
reduce O
rates O
of O
musculoskeletal B-Disease
ageing I-Disease
in O
later O
life O

As O
such O
, O
maintenance O
of O
cardiac B-Disease
homeostasis I-Disease
is O
paramount O
for O
its O
physiological O
function O
and O
its O
capacity O
to O
respond O
to O
environmental O
stimuli O

As O
such O
, O
any O
observed O
phenotypic O
changes O
including O
organ O
development O
, O
aging O
, O
and O
the O
occurrence O
of O
disease B-Disease
could O
be O
driven O
by O
epigenetic O
mechanisms O
in O
the O
presence O
of O
stable O
cellular O
DNA B-Gene
sequences O

Morphostasis O
evolved O
in O
humans B-Species
to O
ensure O
the O
nurturing O
of O
dependent O
offspring O
during O
the O
first O
decade O
of O
young O
adulthood O
when O
peak O
parental O
vitality O
prevails O
in O
the O
absence O
of O
aging B-Disease

Together O
with O
techniques O
in O
which O
cell O
lineage O
is O
recorded O
, O
this O
multilayered O
information O
will O
provide O
insights O
into O
a O
cell O
's O
past O
history O
and O
its O
future O
potential O

The O
melanogenesis B-Disease
pathway I-Disease
was O
differentially O
methylated O
in O
artery O
( O
Max B-Gene
F I-Gene
P I-Gene
< O
0 O

By O
analyzing O
2,239 O
samples O
with O
both O
DNAm O
and O
gene B-Gene
expression I-Gene
data O
in O
the O
same O
human B-Species
subjects O
obtained O
from O
six O
published O
datasets O
, O
we O
evaluated O
the O
correlations O
between O
gene B-Gene
and O
CpG O
pairs O
( O
GCPs O
) O
at O
cis-regions O
and O
compared O
significantly O
correlated O
GCPs O

301 O
 O
Gene B-Gene
expression I-Gene
in O
individual O
cells O
is O
epigenetically O
regulated O
by O
DNA B-Chemical
modifications O
, O
histone B-Chemical
modifications O
, O
transcription B-Gene
factors I-Gene
, O
and O
other O
DNA-binding O
proteins O

The O
Toxicant B-Chemical
Exposures O
and O
Responses O
by O
Genomic B-Gene
and O
Epigenomic B-Gene
Regulators I-Gene
of O
Transcription I-Gene
(TaRGET O
II) O
consortium O
was O
established O
by O
the O
to O
address O
the O
utility O
of O
surrogate O
tissues O
as O
proxies O
for O

556 O
Epigenetic O
mechanisms O
, O
which O
include O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modification I-Chemical
, O
and O
microRNA B-Gene
(miRNA) I-Gene
, O
can O
produce O
heritable O
phenotypic O
changes O
without O
a O
change O
in O
DNA B-Chemical
sequence I-Chemical

24 O
Epigenetics O
is O
a O
term O
that O
encompasses O
a O
variety O
of O
regulatory O
processes O
that O
are O
able O
to O
crosstalk O
in O
order O
to O
influence O
gene B-Gene
expression O
and O
cell O
phenotype O
in O
response O
to O
environmental O
cues O

These O
long-lasting O
increases O
in O
pathological O
responsivity O
appear O
to O
be O
mediated O
by O
epigenetic O
mechanisms O
involving O
alterations O
in O
chemical B-Chemical
marks O
placed O
on O
DNA B-Gene
and O
histories O

adult O

Aging O
is O
an O
inevitable O
outcome O
of O
life O
, O
characterized O
by O
a O
progressive O
decline O
in O
tissue O
and O
organ O
function O

g O

These O
are O
in O
the O
path O
to O
become O
the O
dominant O
assays O
for O
genome-wide O
analysis O
of O
TFs B-Gene
and O
chromatin B-Chemical
modifications O
in O
bulk O
, O
single-cell O
, O
and O
spatial O
genomic O
applications O

1033 O
Susceptibility O
to O
psychiatric B-Disease
disorders I-Disease
seems O
to O
be O
influenced O
by O
environmental O
disturbances O
throughout O
all O
stages O
of O
life O

001 O
) O
, O
which O
suggested O
an O
impending O
role O
of O
minimally O
invasive O
liquid-biopsy O
approach O
in O
the O
diagnosis O
and/or O
therapeutic O
monitoring O
of O
pediatric O
leukemia B-Disease

Crohn B-Disease
's I-Disease
disease I-Disease
( O
CD B-Disease
) O
is O
characterized O
by O
persistent O
inflammation O
and O
ulceration O
of O
the O
small O
or O
large O
bowel O
, O
and O
expansion O
of O
mesenteric O
adipose O
tissue O
, O
termed O
creeping O
fat O
( O
CF B-Disease
) O

Analyzing O
simulated O
and O
real O
data O
sets O
, O
we O
provide O
in-depth O
assessments O
of O
epialleleR B-Gene
performance O
and O
show O
that O
linkage O
to O
epihaplotype B-Gene
data O
is O
necessary O
to O
detect O
low-level O
methylation B-Chemical
events O

Thus O
, O
a O
number O
of O
bioinformatic O
tools O
have O
been O
developed O
to O
infer O
heterogeneous O
tumor B-Disease
populations O
based O
on O
genomic O
signatures O
such O
as O
mutations O
and O
copy O
number O
variations O

MIRA O
is O
based O
on O
the O
ability O
of O
the O
methyl-binding B-Chemical
domain I-Chemical
( O
MBD B-Gene
) O
proteins O
, O
the O
MBD2B B-Gene
/ O
MBD3L1 B-Gene
complex O
, O
to O
specifically O
bind O
methylated B-Chemical
CpG I-Chemical
dinucleotides I-Chemical

Cells O
of O
a O
multicellular O
organism O
have O
the O
same O
genetic O
information O
, O
yet O
they O
show O
structural O
and O
functional O
differences O
owing O
to O
differential O
expression O
of O
their O
genes B-Gene

Of O
all O
the O
rheumatic B-Disease
diseases I-Disease
, O
SSc B-Disease
carries O
the O
highest O
all-cause O
mortality O
rate O
and O
represents O
an O
unmet O
medical O
need O

Epigenetic O
plasticity O
enables O
an O
organism O
to O
respond O
to O
developmental O
and O
environmental O
signals O
without O
genetic O
changes O

Metabolomics O
, O
the O
study O
of O
metabolism O
at O
whole-body O
level O
, O
involves O
assessment O
of O
the O
total O
repertoire O
of O
small O
molecules O
present O
in O
a O
biological O
sample O
, O
shedding O
light O
on O
interactions O
between O
gene B-Gene
expression I-Gene
, O
protein O
expression O
, O
and O
the O
environment O

The O
analysis O
was O
performed O
at O
seven O
time O
points O
, O
taking O
into O
account O
the O
control O
conditions O
, O
heat B-Disease
stress I-Disease
, O
and O
recovery O
to O
control O
conditions O
after O
the O
stress O
treatment O
was O
discontinued O

We O
also O
discuss O
the O
efforts O
that O
are O
being O
made O
to O
increase O
the O
efficiency O
of O
current O
protocols O
and O
address O
the O
potential O
for O
the O
use O
of O
these O
cells O
in O
disease B-Disease
modelling O
, O
drug B-Chemical
discovery O
and O
regenerative O
medicine O

In O
the O
final O
sections O
of O
the O
paper O
we O
briefly O
outline O
some O
further O
implications O
of O
epigenetics B-Gene
for O
medicine B-Disease
and O
for O
the O
nature/nurture O
debate O

Recently O
, O
important O
roles O
of O
various O
epigenetic O
mechanisms O
have O
been O
identified O
in O
the O
pathogenesis O
of O
diabetes B-Disease
and O
its O
complications O

Furthermore O
, O
the O
potential O
targets O
provided O
by O
the O
epigenome O
for O
the O
development O
of O
future O
diagnostics O
, O
preventive O
strategies O
, O
and O
therapy O
for O
cardiovascular B-Disease
disease I-Disease
are O
reviewed O

These O
modifications O
are O
dynamic O
, O
with O
cellular O
machinery O
identified O
to O
modulate O
and O
interpret O
the O
marks O

Based O
on O
this O
, O
we O
have O
developed O
a O
new O
approach O
for O
epigenetic O
age O
predictions O
based O
on O
the O
binary O
sequel O
of O
methylated B-Chemical
and O
non-methylated B-Chemical
sites O
in O
individual O
reads O
, O
which O
reflects O
heterogeneity O
in O
epigenetic O
aging O
within O
a O
sample O

Here O
, O
we O
focus O
on O
recent O
advances O
in O
our O
understanding O
of O
the O
genetics O
and O
epigenetics O
of O
RCC B-Disease
, O
and O
the O
potential O
for O
such O
knowledge O
to O
provide O
novel O
markers O
and O
therapeutic O
targets O

Moreover O
, O
examining O
the O
environmental O
, O
genetic O
, O
and O
epigenetic O
factors O
that O
promote O
resilience O
to O
trauma B-Disease
may O
lead O
to O
important O
advances O
in O
the O
field O

Epigenetic O
abnormalities O
can O
be O
causally O
involved O
in O
cancer B-Disease
development I-Disease
(driver) O
and O
can O
also O
be O
present O
as O
a O
passenger O

In O
recent O
years O
, O
the O
development O
of O
sequencing O
technology O
has O
provided O
new O
means O
of O
exploring O
the O
complex O
pathogenesis O
of O
IBD B-Disease

Recent O
findings O
 O
A O
substantial O
portion O
of O
the O
variance O
explaining O
differential O
risk O
responses O
to O
trauma B-Disease
exposure I-Disease
may O
be O
explained O
by O
differential O
inherited O
and O
acquired O
genetic O
and O
epigenetic O
risk O

Different O
mechanisms O
could O
contribute O
to O
the O
development O
of O
its O
typical O
clinical O
features O
( O
i O

However O
, O
it O
has O
only O
recently O
gained O
major O
scientific O
interest O
when O
it O
was O
measured O
on O
photosynthetic O
complexes O
at O
physiological O
temperatures O
and O
confirmed O
to O
have O
a O
direct O
effect O
over O
the O
dynamics O
of O
the O
energy O
transfer O

PU O

Profiling O
DNA B-Chemical
methylation O
across O
the O
genome O
is O
critical O
to O
understanding O
the O
influence O
of O
epigenetics O
in O
normal O
biology O
and O
disease O
, O
such O
as O
cancer B-Disease


1 O
binding O
sites O
were O
associated O
with O
lineage-specific O
hypo- O
and O
hypermethylation B-Chemical
in O
different O
cell O
types O
, O
suggesting O
that O
it O
regulates O
DNA B-Chemical
methylation I-Chemical
in O
a O
context-dependent O
manner O

Drug O
discovery O
undertakings O
have O
focused O
mainly O
on O
the O
role O
of O
genomics B-Gene
in O
carcinogenesis B-Disease
, O
with O
the O
focus O
turning O
to O
the O
epigenome B-Gene
recently O

We O
argue O
that O
the O
integration O
of O
ethnographic O
findings O
into O
epigenomics O
will O
significantly O
improve O
disparities-focused O
study O
designs O
within O
environmental O
epigenomics O
by O
identifying O
and O
contextualizing O
the O
most O
salient O
dimensions O
of O
the O
'environment' O
that O
are O
affecting O
local O
communities O

DNA O
methylation O
patterns O
are O
susceptible O
to O
change O
in O
response O
to O
environmental O
stimuli O
such O
as O
diet O
or O
toxins O
, O
whereby O
the O
epigenome O
seems O
to O
be O
most O
vulnerable O
during O
early O
life O

com O
/ O
sjthursby O
/ O
CandiMeth B-Chemical

A O
number O
of O
phenotypic O
studies O
have O
documented O
the O
role O
of O
histone O
modification O
and O
chromatin O
remodelling O
complexes O
in O
regulating O
distinct O
neoblast O
processes O
, O
and O
we O
focus O
on O
four O
important O
examples O
of O
planarian B-Species
epigenetic O
regulators O
 O
Nucleosome B-Chemical
Remodeling I-Chemical
Deacetylase I-Chemical
( O

Two O
contributions O
investigated O
treatment O
response O

Understanding O
and O
interpretation O
of O
the O
role O
for O
epigenetic O
modifications O
in O
the O
human B-Species
genome O
has O
progressed O
rapidly O
over O
the O
past O
decade O
with O
the O
advancement O
of O
microarray-based O
and O
sequence-based O
technologies O

1220 O
Periodontitis B-Disease
is O
a O
chronic O
multifactorial O
inï¬ammatory O
disease O
associated O
with O
microbial O
dysbiosis O
and O
characterized O
by O
progressive O
destruction O
of O
the O
periodontal O
tissues O

Here O
we O
show O
that O
the O
two O
methods O
are O
highly O
correlated O
in O
saliva O
and O
buccal O
samples O
( O
R O
= O
0 O

1428 O
has O
become O
a O
global O
epidemic O
that O
has O
a O
negative O
impact O
on O
population O
health O
and O
the O
economy O
of O
nations O

, O
H3K4me3 B-Gene
) O
and O
the O
analysis O
of O
multiple O
histone B-Chemical
marks O
from O
low O
amounts O
of O
starting O
material O

This O
review O
presents O
a O
summary O
of O
the O
literature O
on O
childhood B-Disease
trauma I-Disease
and O
DNAm B-Gene
, O
highlights O
issues O
in O
the O
field O
, O
and O
proposes O
some O
potential O
solutions O

This O
review O
addresses O
recent O
findings O
examining O
DNA B-Gene
methylation I-Gene
, O
histone B-Gene
modifications I-Gene
and O
miRNA B-Gene
changes O
in O
aging O
MSC B-Species
populations O

ngsplusplus O

org/ O
/ewas/ O

Information O
gained O
from O
GWAS B-Gene
and O
EWAS B-Gene
has O
potential O
applications O
in O
cancer B-Disease
control O
and O
treatment O

Based O
on O
the O
current O
knowledge O
, O
this O
review O
provides O
a O
brief O
overview O
of O
the O
highly O
interconnected O
relationship O
between O
nutrition O
, O
metabolism O
, O
changes O
in O
epigenetic O
modifications O
, O
cancer B-Disease
, O
and O
aging O



com O
/ O
james O
- O
e O
- O
barrett O

On O
the O
other O
hand O
, O
pain B-Disease
is O
a O
multidimensional O
experience O
with O
sensory-discriminative O
and O
motivational-affective O
components O

807 O
Intravenously O
injected O
nanoparticulate O
drug O
carriers O
provide O
a O
wide O
range O
of O
unique O
opportunities O
for O
site-specific O
targeting O
of O
therapeutic O
agents O
to O
many O
areas O
within O
the O
vasculature O
and O
beyond O

He O
is O
now O
Professor O
of O
Epigenetics O
in O
the O
Department O
of O
Biological O
Sciences O
at O
North O
Carolina O
State O
University O
, O
Raleigh O
, O
NC O
, O
USA O

We O
have O
found O
three O
overlap O
genes O
that O
show O
significant O
DNA B-Gene
methylation I-Gene
changes O
, O
both O
in O
obesity B-Disease
and O
depression B-Disease

Dominated O
by O
an O
informational O
myth O
and O
a O
mechanistic O
Cartesian O
body/mind O
and O
form/substance O
dualism O
, O
this O
considers O
the O
genome B-Gene
as O
an O
ensemble O
of O
discrete O
units O
of O
information O
governing O
human B-Species
body O
and O
behavior O
, O
and O
remains O
hegemonic O
in O
life O
sciences O
and O
in O
the O
public O
imagination O

Blood O
samples O
showed O
also O
pathways O
related O
to O
immune O
function O

We O
anticipate O
that O
epigenetic O
information O
organized O
into O
AOP O
frameworks O
can O
be O
consistently O
used O
to O
support O
biological O
plausibility O
and O
to O
identify O
data O
gaps O
that O
will O
accelerate O
the O
pace O
at O
which O
epigenetic O
information O
is O
applied O
in O
chemical B-Chemical
evaluation O
and O
risk-assessment O
paradigms O

Recent O
findings O
show O
that O
the O
onset O
and O
development O
of O
these O
illnesses O
cannot O
be O
well O
described O
by O
the O
one-gene O
one-disease O
approach O

148 O
The O
temporal O
coding O
of O
action O
potential O
activity O
is O
fundamental O
to O
nervous O
system O
function O

Although O
many O
experiments O
have O
been O
designed O
to O
measure O
genome-wide O
DNA B-Chemical
methylation I-Chemical
levels O
at O
high O
resolution O
, O
the O
meaning O
of O
these O
different O
DNA B-Chemical
methylation I-Chemical
levels O
on O
transcription O
factor O
binding O
abilities O
remains O
poorly O
understood O

Such O
factors O
may O
alter O
the O
DNA B-Gene
methylation I-Gene
pattern O
and O
may O
explain O
the O
partly O
high O
deviations O
between O
epigenetic O
age O
and O
chronological O
age O
in O
single O
cases O
(despite O
of O
low O
mean O
absolute O
deviations O
) O
that O
can O
also O
be O
observed O
with O
" O
epigenetic O
clocks O
" O
comprising O
a O

1012 O
Current O
research O
on O
triple-negative B-Disease
breast I-Disease
cancer I-Disease
( O
TNBC B-Disease
) O
has O
resulted O
in O
delineation O
into O
the O
quadruple-negative B-Disease
breast I-Disease
cancer I-Disease
( O
QNBC B-Disease
) O
subgroup O

We O
have O
also O
compiled O
the O
preclinical O
and O
clinical O
status O
of O
these O
epigenetic O
modulators O
in O
different O
cancers B-Disease

Allohexaploidization O
is O
a O
critical O
step O
leading O
to O
the O
formation O
of O
common O
wheat O
as O
a O
new O
species O
, O
Triticum B-Species
aestivum I-Species
, O
as O
well O
as O
for O
bestowing O
its O
remarkable O
adaptability O

402 O
Nonlinear O
epigenetic O
processes O
are O
conceived O
of O
in O
terms O
of O
self-organizing O
dynamic O
models O
of O
biological O
pattern O
formation O

Epigenetic O
mechanisms O
like O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical
are O
essential O
for O
multiple O
physiological O
processes O
like O
development O
, O
establishment O
of O
tissue O
identity O
, O
imprinting O
, O
X-chromosome B-Gene
inactivation I-Gene
, O
chromosomal O
stability O
and O
gene B-Gene
transcription I-Gene
regulation I-Gene

He O
has O
served O
on O
the O
American O
Association O
for O
Cancer B-Disease
Research I-Disease
Board O
of O
Directors O
, O
and O
is O
an O
associate O
editor O
of O
Cancer B-Disease
Research I-Disease

& O

The O
current O
review O
provides O
insights O
into O
the O
plausible O
chromosomal O
, O
genetic O
and O
epigenetic O
alterations O
, O
which O
may O
result O
into O
infertile B-Disease
phenotype I-Disease

One O
approach O
is O
to O
identify O
significantly O
overlapping O
gene B-Gene
sets I-Gene
, O
which O
works O
well O
for O
gene-centric O
data O

and O

Consequently O
, O
targeting O
the O
enzymatic O
machinery O
that O
controls O
the O
epigenetic O
regulation O
of O
the O
genome O
has O
emerged O
as O
an O
attractive O
new O
strategy O
for O
therapeutic O
intervention O

Furthermore O
, O
we O
identify O
significant O
differences O
in O
age-acceleration O
dependent O
on O
the O
lipid B-Chemical
content O
of O
the O
diet O

In O
the O
IOW O
cohort O
, O
body O
mass O
index O
( O
BMI O
) O
at O
age O
10 O
years O
, O
age O
of O
growth O
spurt O
, O
nonsteroidal B-Chemical
drugs I-Chemical
use O
, O
and O
current O
smoking O
status O
showed O
statistically O
significant O
associations O
with O
DNA-M B-Gene
changes O
at O
15 O
CpGs O
on O
14 O
genes O
such O

Immune O
cells O
are O
no O
exception O
, O
as O
they O
also O
present O
a O
functional O
clock O
dictating O
transcriptional O
rhythms O

We O
conclude O
by O
highlighting O
several O
priority O
directions O
for O
advancing O
population-based O
epigenomic O
and O
epigenetic O
understandings O
of O
food B-Disease
allergy I-Disease

10 O
years O
old O

RNA O
samples O
from O
8 O
testes O
of O
boars B-Species
that O
received O
either O
a O
diet O
enriched O
in O
methylating B-Chemical
micronutrients I-Chemical
or O
a O
control O
diet O
were O
analyzed O
by O
microarray O
analysis O

1014 O
 O
Background O
 O
Recent O
computational O
advances O
in O
ancient O
DNA B-Chemical
research O
have O
opened O
access O
to O
the O
detection O
of O
ancient O
DNA B-Chemical
methylation O
footprints O
at O
the O
genome-wide O
scale O

A O
cryptic O
lineage O
of O
earthworms B-Species
had O
developed O
arsenic B-Chemical
tolerance O
in O
the O
field O
, O
concurrent O
with O
specific O
DNA B-Gene
methylation I-Gene
patterns O

This O
work O
, O
coupled O
with O
previous O
related O
findings O
, O
suggests O
that O
induction O
of O
ERVs B-Gene
, O
rather O
than O
direct O
effects O
on O
specific O
genes O
, O
may O
have O
a O
central O
role O
in O
the O
cellular O
responses O
to O
such O
agents O
and O
, O
in O
turn O
, O
their O
therapeutic O
efficacy O

These O
trends O
in O
divergence O
of O
expression O
and O
upstream O
regions O
are O
especially O
pronounced O
for O
transcription O
factors O

Ever O
use O
and O
cumulative O
marijuana-years B-Chemical
were O
calculated O
from O
the O
baseline O
visit O
to O
Y15 O
and O
Y20 O
, O
and O
recent O
marijuana B-Chemical
use O
( O
both O
any O
and O
number O
of O
days O
of O
use O
in O
the O
last O
30 O
days O
) O
were O
calculated O
at O
Y15 O
and O
Y20 O

767 O
 O
DNA B-Gene
methylation I-Gene
is O
a O
stable O
epigenetic O
mechanism O
that O
has O
important O
roles O
in O
the O
normal O
function O
of O
a O
cell O
and O
therefore O
also O
in O
disease B-Disease
etiology I-Disease

The O
latter O
underlines O
how O
complexity O
can O
be O
assembled O
differently O
across O
distinct O
configurations O
of O
experimental O
work O

The O
acquired O
knowledge O
may O
in O
the O
future O
serve O
as O
a O
solid O
foundation O
for O
developing O
newer O
, O
increasingly O
effective O
methods O
of O
treating O
psoriasis B-Disease

Taking O
advantage O
of O
the O
reversibility O
of O
epigenetic O
alterations O
, O
drugs O
targeting O
epigenetic O
regulators O
and O
readers O
have O
been O
developed O
for O
restoration O
of O
normal O
pattern O
of O
the O
epigenome O
, O
and O
some O
have O
already O
demonstrated O
clinical O
benefits O

Thus O
, O
for O
the O
first O
time O
, O
we O
can O
identify O
age-associated O
molecular O
changes O
that O
appear O
to O
track O
the O
exponential O
dynamics O
of O
mortality B-Disease
risk I-Disease

In O
this O
review O
, O
we O
discuss O
current O
findings O
in O
mitochondrial B-Chemical
epigenetics O
as O
well O
as O
its O
potential O
role O
as O
a O
regulator O
of O
mitochondria B-Chemical
within O
the O
brain B-Disease

by O

There O
are O
a O
number O
of O
studies O
that O
have O
found O
promising O
associations O
between O
a O
variety O
of O
biomarkers O
and O
clinical O
response O
to O
psychopharmacological B-Chemical
treatment O
in O
various O
psychiatric B-Disease
disorders I-Disease

The O
quality O
of O
algorithm O
is O
important O
, O
but O
is O
not O
in O
itself O
a O
guarantee O
of O
the O
quality O
of O
a O
specific O
data O
analysis O

1277 O
Recent O
studies O
implicate O
mitochondrial B-Chemical
dysfunction I-Chemical
in O
the O
development O
and O
progression O
of O
numerous O
chronic O
diseases O
, O
which O
may O
be O
partially O
due O
to O
modifications O
in O
mitochondrial B-Chemical
DNA I-Chemical
( O
mtDNA B-Gene
) O

Such O
work O
may O
bring O
insights O
into O
the O
potential O
role O
of O
epigenetic O
in O
adaptation O
and O
evolution O
in O
mollusks B-Species

Methods O

Here O
, O
we O
describe O
a O
protocol O
for O
a O
versatile O
DNA B-Chemical
methylation I-Chemical
enrichment I-Chemical
method O
, O
the O
Methylated B-Chemical
CpG I-Chemical
Island I-Chemical
Recovery I-Chemical
Assay I-Chemical
( O
MIRA B-Chemical
) O
, O
which O
enables O
analysis O
of O
the O
DNA B-Chemical
methylation I-Chemical
status O
in O
individual O

The O
candidate O
genes O
were O
annotated O
using O
ensemble O
and O
their O
expression O
was O
further O
tested O
in O
vitro O
using O
the O
murine B-Species
RAW I-Species
264 I-Species

However O
, O
although O
variations O
in O
DNAm O
are O
frequently O
found O
in O
stress-related O
genes B-Gene
, O
unsupervised O
epigenome-wide O
association O
studies O
( O
EWAS O
) O
have O
shown O
limited O
reproducibility O
both O
between O
studies O
and O
in O
relating O
these O
changes O
to O
exposures O

As O
a O
biological O
phenomenon O
, O
it O
is O
underpinned O
by O
the O
dysregulation O
of O
a O
myriad O
of O
complex O
processes O

Existing O
software O
tools O
facilitate O
primer O
design O
, O
primer O
quality O
control O
or O
visualization O
of O
primer O
localization O

e O

Aberrant O
DNA B-Gene
methylation I-Gene
is O
implicated O
in O
immune B-Disease
dysfunction I-Disease
, O
inflammation B-Disease
, O
and O
insulin B-Disease
resistance I-Disease

Despite O
numerous O
advances O
in O
treatment O
, O
long-term O
survival O
from O
this O
disease B-Disease
remains O
poor O

A O
recent O
publication O
illustrates O
the O
influence O
of O
TEs B-Gene
epigenetic O
control O
on O
the O
expression O
of O
a O
neighboring O
gene B-Gene
crucial O
for O
reproduction O

482 O
There O
is O
mounting O
evidence O
in O
the O
literature O
that O
mesenchymal B-Species
stromal/stem I-Species
cell I-Species
(MSC) O
like O
populations O
derived O
from O
different O
tissues O
, O
undergo O
epigenetic O
changes O
during O
aging O
, O
leading O
to O
compromised O
connective O
tissue O
integrity O
and O
function O

Conclusions O
 O
In O
sum O
, O
we O
present O
several O
epigenetic O
associations O
with O
incident O
CVD B-Disease
which O
reveal O
disease O
mechanisms O
related O
to O
development O
and O
monocyte O
biology O

533 O
enrichment O
followed O
by O
sequencing O
( O
) O
is O
a O
versatile O
tool O
in O
molecular O
biology O
with O
a O
wide O
variety O
of O
applications O

in O
Nature O
529(7586)418-422, O
2016) O
provide O
access O
to O
structural O
features O
of O
these O
domains O
with O
unprecedented O
resolution O
thanks O
to O
super-resolution O
experiments O

Over O
the O
last O
decade O
, O
there O
has O
been O
a O
tremendous O
advancement O
in O
understanding O
the O
science O
of O
epigenetics O
, O
as O
well O
as O
a O
rise O
in O
public O
interest O
in O
learning O
more O
about O
the O
influence O
of O
diet O
and O
lifestyle O
choices O
on O
the O
health O
of O
an O
individual O

Although O
, O
the O
mechanism O
of O
epigenetics O
in O
cancer B-Disease
largely O
remains O
unexplored O

This O
further O
demonstrates O
the O
ability O
of O
our O
strategy O
to O
take O
full O
advantage O
of O
molecular-level O
information O
as O
well O
as O
protein-level O
information O
in O
molecular O
activity O
prediction O

Epitranscriptomics O
has O
recently O
emerged O
as O
an O
exciting O
, O
new O
field O
for O
understanding O
the O
fundamental O
mechanisms O
underlying O
RNA B-Chemical
modifications O
and O
their O
impact O
on O
gene B-Gene
expression O

1 O
in O
this O
issue O
of O
Cell O
, O
now O
allows O
researchers O
to O
study O
the O
epigenomic O
regulation O
of O
gene O
expression O
in O
a O
tissue-region O
specific O
manner O

Ensuing O
phenotypic O
changes O
allow O
genetically O
identical O
cells O
to O
express O
diverse O
and O
frequently O
adaptive O
phenotypes O

Additionally O
, O
several O
recent O
studies O
have O
renewed O
interest O
in O
the O
use O
of O
pharmacological O
doses O
of O
vitamin B-Chemical
C I-Chemical
injected O
intravenously O
to O
selectively O
kill O
tumor B-Disease
cells I-Disease

The O
phenotypic O
variation O
regulated O
by O
the O
stress O
legacy O
affects O
the O
growth O
performance O
, O
biomass O
allocation O
strategy O
, O
and O
even O
the O
behaviour O
of O
D B-Species

de O

Cancer O
stem O
cells O
are O
an O
important O
subpopulation O
of O
tumor B-Disease
cells O
that O
regulate O
tumor B-Disease
plasticity O
and O
determine O
therapeutic O
resistance O

988Objectives O
Schizophrenia B-Disease
spectrum I-Disease
disorders I-Disease
and O
bipolar B-Disease
spectrum I-Disease
disorders I-Disease
are O
the O
product O
of O
both O
heritable O
and O
non-heritable O
factors O
, O
the O
impact O
of O
which O
converges O
at O
different O
biological O
levels O

We O
present O
a O
benchmarking O
framework O
that O
is O
applied O
to O
10 O
computational O
methods O
for O
scATAC-seq O
on O
13 O
synthetic O
and O
real O
datasets O
from O
different O
assays O
, O
profiling O
cell O
types O
from O
diverse O
tissues O
and O
organisms O

DNA O
methylation O
age O
distribution O
is O
wider O
than O
technically O
expected O
, O
indicating O
epigenetic O
age O
heterogeneity O
and O
functional O
differences O

Advantages O
of O
the O
described O
method O
include O
amplification-insensitive O
detection O
, O
5-hydroxymethylcytosine B-Chemical
complexation O
, O
and O
visualization O
through O
methylation-specific O
in O
situ O
hybridization O

Despite O
accumulating O
evidence O
for O
the O
significance O
of O
global O
DNA B-Gene
methylation I-Gene
reprogramming O
in O
certain O
cancer B-Disease
types O
including O
myeloid B-Disease
malignancies I-Disease
, O
none O
of O
the O
bioinformatic O
tools O
are O
designed O
to O
exploit O
subclonally O
reprogrammed O
methylation O
patterns O
to O
reveal O
constituent O
populations O
of O

Here O
, O
we O
focus O
on O
the O
interplay O
between O
metabolic O
rewiring O
and O
epigenetic O
landscape O
in O
the O
context O
of O
tumourigenesis B-Disease
and O
highlight O
recent O
advances O
in O
the O
use O
of O
small-molecule B-Chemical
drug I-Chemical
targets O
for O
therapy O

To O
set O
the O
scene O
, O
we O
begin O
with O
a O
short O
background O
of O
how O
the O
field O
of O
epigenetics O
has O
evolved O
, O
with O
a O
particular O
focus O
on O
plant B-Species
epigenetics O

Combined O
with O
NGS O
technology O
, O
live O
imaging O
systems O
can O
now O
be O
used O
to O
track O
epigenetic O
events O
and O
clarify O
their O
casual O
and O
spatiotemporal O
relationships O
to O
cell O
differentiation O
and O
embryonic O
development O

the O

unique O

epigenetics B-Chemical

Meanwhile O
, O
STR B-Gene
multiplexes O
have O
been O
developed O
and O
made O
commercially O
available O
which O
simultaneously O
amplify O
up O
to O
30 O
STR B-Gene
loci O
from O
as O
little O
as O
15 O
cells O
or O
fewer O

We O
further O
used O
epidecodeR O
to O
explore O
the O
effectiveness O
of O
demethylase O
FTO B-Gene
inhibitors O
and O
histone-associated O
modifications O
in O
drug B-Disease
abuse I-Disease
in O
animals B-Species

114 O
The O
stage O
and O
molecular O
pathology-dependent O
prognosis O
of O
breast B-Disease
cancer I-Disease
, O
the O
limited O
treatment O
options O
for O
triple-negative B-Disease
carcinomas I-Disease
, O
as O
well O
as O
the O
development O
of O
resistance O
to O
therapies O
illustrate O
the O
need O
for O
improved O
early O
diagnosis O
and O
the O
development O
of O
new O

738 O
There O
is O
a O
growing O
perception O
that O
DNA B-Gene
methylation I-Gene
may O
be O
influenced O
by O
exogenous O
and O
endogenous O
parameters O

A O
literature O
search O
was O
conducted O
for O
the O
most O
pertinent O
articles O
on O
the O
epigenetic O
effects O
of O
famine O

871 O
Sponsored O
by O
the O
New O
York O
Academy O
of O
Sciences O
, O
the O
Warren O
Alpert O
Medical O
School O
of O
Brown O
University O
and O
the O
University O
of O
Massachusetts O
Boston O
, O
" O
Behavioral O
Epigenetics O
" O
was O
held O
on O
October O
29-30 O
, O
2010 O
at O
the O
University O
of O
Massachusetts O
Boston O
Campus O
Center O
, O
Boston O

846 O
 O
There O
is O
considerable O
excitement O
about O
the O
potential O
for O
epigenetic O
information O
to O
contribute O
to O
heritable O
variation O
in O
many O
species B-Species

Remarkably O
, O
abnormal O
neuronal O
activity O
and O
depression-like B-Disease
behavior I-Disease
appear O
in O
animals O
lacking O
elements O
of O
the O
molecular O
clock O

Histone B-Chemical
acetylation I-Chemical
status O
is O
considered O
a O
potential O
diagnostic O
biomarker O
for O
depression B-Disease
, O
while O
inhibitors O
of O
histone B-Gene
deacetylases I-Gene
( O
HDACs B-Gene
) O
have O
garnered O
interest O
as O
novel O
therapeutics O

The O
UHRF1 B-Gene
complex O
includes O
HDAC1 B-Gene
, O
Tip60 B-Gene
, O
G9a B-Gene
, O
and O
maintenance O
and O
de O
novo O
DNMTs B-Gene

Within O
the O
fields O
of O
genetics O
and O
its O
sub-field O
epigenetics O
, O
both O
prime O
examples O
of O
complex O
data O
, O
machine O
learning O
methods O
are O
on O
the O
rise O
, O
as O
the O
field O
of O
personalised O
medicine O
is O
aiming O
for O
treatment O
of O
the O
individual O
based O
on O
their O
genetic O
and O
epigenetic O
profiles O

Examples O
of O
such O
modifications O
include O
DNA B-Gene
methylation I-Gene
, O
histone B-Gene
modifications I-Gene
, O
noncoding B-Gene
RNAs I-Gene
, O
and O
chromatin B-Gene
architecture I-Gene

The O
direction O
of O
DNAm B-Gene
change O
with O
gestational O
age O
at O
these O
prematurity-DM B-Disease
sites O
followed O
known O
patterns O
of O
hematopoietic B-Species
differentiation O
, O
suggesting O
that O
term O
hematopoietic B-Species
cell O
populations O
are O
more O
epigenetically O
mature O
than O
their O
preterm O
counterparts O

In O
summary O
, O
we O
endeavored O
to O
depict O
the O
current O
understanding O
of O
the O
coordination O
between O
these O
fundamental O
abnormalities O
more O
comprehensively O
and O
provide O
new O
perspectives O
for O
utilizing O
metabolic O
and O
epigenetic O
targets O
for O
cancer B-Disease
treatment O

160 O
 O
Epigenetics O
, O
broadly O
defined O
as O
the O
regulation O
of O
gene B-Gene
expression I-Gene
without O
alteration O
of O
the O
genome O
, O
has O
become O
a O
field O
of O
tremendous O
interest O
in O
neuroscience B-Disease
, O
neurology B-Disease
, O
and O
psychiatry B-Disease

This O
need O
motivated O
us O
to O
develop O
a O
tool O
that O
allows O
investigators O
to O
easily O
identify O
regions O
with O
epigenetic O
features O
unique O
to O
specific O
epigenomes O
that O
they O
choose O
, O
making O
detection O
of O
common O
regulatory O
elements O
and/or O
cell O
type-specific O
regulatory O
elements O
an O
interactive O
and O
dynamic O
experience O

Further O
studies O
are O
needed O
to O
determine O
if O
these O
alterations O
in O
DNA B-Gene
methylation I-Gene
mediate O
the O
effect O
of O
prenatal O
arsenic B-Chemical
exposure O
and O
health O
outcomes O
later O
in O
life O

These O
observations O
indicate O
that O
innate O
and O
adaptive O
immune O
lineages O
are O
specified O
by O
distinct O
epigenetic O
mechanisms O
via O
combinatorial O
and O
context-dependent O
use O
of O
key O
transcription O
factors O

However O
, O
the O
accuracy O
and O
consistency O
of O
WGBS B-Gene
outputs O
in O
relation O
to O
the O
operating O
conditions O
of O
high-throughput O
sequencers O
have O
not O
been O
explored O

The O
database O
incorporates O
11,576 O
HMEs O
identified O
from O
603 O
proteomes O
including O
483 O
fungal B-Species
, O
32 O
plants B-Species
and O
51 O
metazoan B-Species
species O

Remarkably O
, O
epigenetic-sensitive O
drugs O
may O
aid O
to O
counteract O
MDR B-Disease
in O
clinical O
setting O

org O

An O
R O
package O
MethylMix O
was O
used O
to O
perform O
an O
analysis O
incorporating O
both O
methylation O
and O
gene B-Gene
expression I-Gene
data O
on O
all O
samples O
, O
as O
well O
as O
a O
subset O
analysis O
comparing O
patients O
surviving O
less O
than O
2 O
years O
and O
patients O
surviving O
more O
than O
2 O
years O

We O
consider O
the O
case O
where O
relatively O
few O
samples O
are O
processed O
via O
an O
expensive O
high-density O
whole O
genome O
bisulfite O
sequencing O
( O
WGBS O
) O
strategy O
and O
a O
larger O
number O
of O
samples O
is O
processed O
using O
more O
affordable O
low-density O
, O
array-based O
technologies O

Here O
, O
protocols O
are O
provided O
for O
four O
different O
epigenomic O
methods O
including O
whole-genome O
bisulfite O
sequencing O
( O
WGBS O
) O
to O
assess O
DNA O
methylation O
patterns O
, O
chromatin O
immunoprecipitation-sequencing O
( O
ChIP-seq O
) O
to O
assess O
genomic O
patterns O
of O
either O
specific O
histone O
modifications O
or O
bound O
transcription O

Recent O
findings O
 O
Complementary O
approaches O
uncovered O
close O
links O
between O
circulating O
lipids B-Chemical
and O
epigenetic O
mechanisms O
at O
multiple O
levels O

We O
searched O
multiple O
databases O
to O
produce O
a O
systematic O
review O
on O
the O
role O
of O
epigenetic O
mechanisms O
in O
tendon B-Disease
ageing I-Disease

The O
purpose O
of O
this O
article O
is O
to O
introduce O
basic O
concepts O
in O
epigenetics O
and O
their O
recent O
applications O
to O
the O
study O
of O
osteoarthritis B-Disease
development O
and O
progression O

As O
the O
relationship O
between O
DNA B-Gene
methylation O
, O
histone B-Chemical
modifications O
, O
and O
gene B-Gene
expression O
is O
elucidated O
, O
an O
important O
aspect O
to O
investigate O
is O
how O
the O
epigenetic O
status O
regulates O
the O
cell O
through O
differential O
expression O
of O
genes O

Our O
review O
highlights O
the O
importance O
of O
integrative O
approaches O
involving O
genomics O
and O
systems O
biology O
perspective O
in O
elucidating O
AD B-Disease
pathophysiology O

Maternal O
factors O
, O
including O
nutrition O
, O
smoking O
and O
toxin O
exposure O
, O
can O
alter O
CB B-Gene
DNA I-Gene
methylation I-Gene
patterns O
, O
associated O
with O
conditions O
from O
obesity B-Disease
to O
neurodevelopmental B-Disease
disorders I-Disease

In O
this O
review O
, O
we O
focus O
on O
the O
challenges O
and O
opportunities O
of O
clinical O
epigenomics O
in O
cardiovascular B-Disease
disease I-Disease

We O
show O
evidence O
for O
specific O
ART-associated O
variation O
in O
methylation B-Chemical
around O
birth O
, O
most O
of O
which O
occurred O
independently O
of O
embryo O
culturing O

This O
review O
discusses O
recent O
advances O
in O
unravelling O
this O
interplay O
with O
a O
particular O
focus O
on O
promising O
approaches O
and O
methods O
that O
will O
be O
able O
to O
establish O
causal O
relationships O

1258 O

The O
origin O
of O
epigenetic O
variance O
can O
be O
attributed O
to O
genetic O
, O
environmental O
, O
or O
stochastic O
factors O

Most O
importantly O
, O
and O
in O
agreement O
with O
previous O
results O
from O
genome-wide O
clocks O
, O
epigenetic O
age O
was O
significantly O
higher O
and O
lower O
than O
expected O
in O
models O
of O
increased O
( O
persons O
with O
Down B-Disease
syndrome I-Disease
, O
n O
= O
62 O
) O
and O
decreased O
( O
centenarians O
, O
n O
= O
106 O

7 O
% O
of O
all O
cancer-related B-Disease
deaths O

The O
ultimate O
goal O
of O
chrono-epigenetics O
is O
to O
predict O
disease B-Disease
risk O
, O
age O
of O
onset O
and O
disease B-Disease
dynamics O
from O
within O
individual-specific O
temporal O
dynamics O
of O
epigenomes O

This O
suggests O
that O
MBD-seq O
provides O
similar O
information O
about O
the O
methylome O
and O
classifies O
methylation O
status O
somewhat O
more O
accurately O

Drugs O
causing O
epigenetic O
modifications O
have O
been O
shown O
to O
induce O
the O
cardiac B-Disease
differentiation I-Disease
of O
stem B-Species
cells I-Species

Although O
this O
finding O
is O
in O
line O
with O
the O
prevailing O
opinion O
of O
rapid O
genomic O
instability O
associated O
with O
nascent O
plant O
allopolyploidy O
, O
its O
relevance O
to O
speciation O
of O
T B-Species

The O
redirected O
cellular O
expression O
is O
a O
consequence O
of O
either O
indirect O
epigenetic O
regulation O
where O
cellular O
signaling O
or O
transcriptional O
dysregulation O
occurs O
or O
direct O
epigenetic O
regulation O
where O
epigenetic O
cofactors O
such O
as O
histone B-Chemical
deacetylases I-Chemical
are O
targeted O

e O

By O
introducing O
Tn5 B-Chemical
transposase-assisted I-Chemical
fragmentation O
, O
2cChIP-seq O
reliably O
captured O
genomic O
regions O
with O
histone B-Chemical
modification I-Chemical
at O
the O
single-cell O
level O
in O
about O
100 O
cells O

We O
specifically O
address O
(i O
) O
queen B-Species
versus O
worker B-Species
caste O
differentiation O
, O
(ii O
) O
queen B-Species
versus O
worker B-Species
caste O
differences O
, O
and O
(iii O
) O
division O
of O
labor O
among O
workers B-Species

It O
has O
stimulated O
a O
large O
body O
of O
research O
, O
facilitated O
by O
the O
concurrent O
development O
of O
new O
techniques O
in O
genetics O
, O
neuro-imaging O
and O
neuropsychology O

Availability O
and O
implementation O
 O
The O
Haystack B-Gene
pipeline I-Gene
is O
implemented O
as O
an O
open-source O
, O
multiplatform O
, O
Python O
package O
called O
haystack_bio O
freely O
available O
at O
https//github O

Source O
code O
, O
tests O
, O
code O
examples O
and O
documentation O
are O
available O
via O
the O
website O
at O
http//www O

e O

We O
also O
illustrate O
its O
coupling O
to O
an O
implemented O
"shotgun" O
workflow O
, O
by O
which O
heavy O
arginine-labeled O
histone B-Chemical
peptides O
, O
produced O
upon O
Arg-C B-Chemical
digestion O
, O
are O
qualitatively O
and O
quantitatively O
analyzed O
in O
an O
LC-MS/MS B-Chemical
system O
that O
combines O
ultrahigh-pressure O
liquid O
chromatography O

While O
the O
application O
focus O
relates O
to O
cancer B-Disease
research O
, O
the O
methods O
are O
equally O
relevant O
to O
broader O
issues O
of O
epigenetics B-Gene
and O
redox B-Chemical
science O
in O
this O
special O
forum O

This O
will O
potentially O
lead O
to O
the O
identification O
of O
useful O
biomarkers O
and O
the O
development O
of O
novel O
pharmacotherapies O

The O
review O
also O
considers O
various O
modifications O
of O
this O
technique O
and O
novel O
developments O
in O
detection O
of O
polymorphism O

Here O
, O
we O
discuss O
modes O
of O
epigenetic O
inheritance O
and O
the O
molecular O
basis O
of O
epigenetic O
transcriptional O
memory O

1130 O
The O
technology O
of O
tissue O
differentiation O
from O
human B-Species
pluripotent I-Species
stem I-Species
cells I-Species
has O
attracted O
attention O
as O
a O
useful O
resource O
for O
regenerative O
medicine O
, O
disease B-Disease
modeling O
and O
drug B-Chemical
development O

67 O
 O
It O
is O
now O
appreciated O
that O
both O
genetic O
alteration O
, O
e O

The O
strategy O
we O
present O
here O
opens O
a O
window O
to O
reconstruct O
previously O
inaccessible O
aspects O
of O
the O
lives O
of O
past O
individuals O

Analysis O
of O
knockout O
mice B-Species
revealed O
critical O
roles O
for O
JMJD1 B-Gene
proteins O
in O
fertility B-Disease
, O
obesity B-Disease
, O
metabolic B-Disease
syndrome I-Disease
, O
and O
heart B-Disease
disease I-Disease

711 O
Ageing O
is O
the O
gradual O
decline O
in O
organismal O
fitness O
that O
occurs O
over O
time O
leading O
to O
tissue O
dysfunction O
and O
disease B-Disease

108 O
The O
concept O
of O
epigenetics O
has O
evolved O
since O
Waddington O
defined O
it O
from O
the O
late O
1930s O
as O
the O
study O
of O
the O
causal O
mechanisms O
at O
work O
in O
development O

1229 O
Developmental O
plasticity O
is O
a O
key O
driver O
of O
the O
extraordinary O
ecological O
success O
of O
insects B-Species

We O
compared O
methylation O
frequencies O
of O
RASSF1A B-Gene
in O
gDNA B-Chemical
and O
cfDNA B-Chemical
in O
various O
cancer B-Disease
types O

Here O
, O
we O
describe O
how O
insights O
into O
the O
natural O
reactivities O
of O
these O
DNA-modifying B-Chemical
enzymes O
can O
be O
leveraged O
to O
convert O
them O
into O
powerful O
biotechnological O
tools O

Therefore O
, O
their O
study O
is O
becoming O
an O
issue O
of O
major O
interest O

Amino O
acid O
metabolism O
is O
deregulated O
in O
many O
cancers O
, O
with O
changes O
in O
branched-chain O
amino O
acid O
metabolism O
specifically O
affecting O
cancer O
cell O
state O
as O
well O
as O
systemic O
metabolism O
in O
individuals O
with O
malignancy O

While O
it O
is O
now O
possible O
to O
draw O
direct O
connections O
between O
specific O
DNA B-Gene
sequences I-Gene
and O
specific O
physical O
features O
and O
to O
predict O
disease B-Disease
risk I-Disease
, O
the O
effects O
of O
certain O
genes B-Gene
can O
be O
masked O
by O
a O
process O
called O
" O
epigenetics O

Despite O
improvements O
in O
our O
understanding O
of O
molecular O
and O
cell O
biology O
, O
high O
attrition O
rates O
in O
drug O
development O
continue O
, O
speaking O
to O
the O
difficulties O
of O
developing O
unequivocal O
methods O
to O
predict O
the O
efficacy O
and O
safety O
of O
drugs O

1182 O
The O
growing O
epidemic O
of O
obesity O
and O
diabetes B-Disease
, O
the O
aging O
population O
as O
well O
as O
prevalence O
of O
drug B-Chemical
abuse O
has O
led O
to O
significant O
increases O
in O
the O
rates O
of O
the O
closely O
associated O
acute O
and O
chronic O
kidney B-Disease
diseases I-Disease
, O
including O
diabetic B-Disease

However O
further O
exploration O
is O
needed O

The O
software O
uses O
an O
intelligent O
retention O
time O
prediction O
trained O
on O
the O
analyzed O
samples O
to O
enable O
accurate O
peak O
detection O

Therefore O
, O
this O
study O
has O
two O
aims O
 O
1 O
) O
to O
identify O
a O
best O
performing O
kit O
for O
MBD-based O
enrichment O
using O
independent O
validation O
data O
, O
and O
2 O
) O
to O
evaluate O
whether O
quality O
evaluation O
can O
also O
be O
performed O
solely O
based O
on O
the O
characteristics O
of O
the O
generated O
sequences O

These O
approaches O
have O
enabled O
the O
measurement O
of O
cytosine B-Chemical
methylation O
from O
specific O
loci O
at O
restricted O
regions O
to O
single-base-pair O
resolution O
on O
a O
genome-scale O
level O

In O
this O
chapter O
, O
we O
report O
a O
possible O
alternative O
use O
of O
epigenetics O
by O
applying O
methylation-sensitive O
amplified O
fragment O
length O
polymorphisms O
( O
MS-AFLP O
) O
to O
saffron B-Species
traceability O

These O
results O
provide O
insight O
on O
shared O
adaptive O
mechanisms O
of O
the O
epigenome O
in O
cancerous B-Disease
cell I-Disease
lines I-Disease
in O
response O
to O
IR B-Chemical

Recent O
genome-wide O
epigenetic O
studies O
in O
disease-discordant B-Disease
monozygotic O
twins O
emphasize O
the O
power O
of O
this O
design O
to O
successfully O
identify O
epigenetic O
changes O
associated O
with O
complex O
traits O

Despite O
recent O
, O
major O
, O
technical O
advances O
aiming O
to O
elucidate O
its O
genetic O
component O
, O
the O
discovered O
biomarkers O
up O
to O
now O
were O
reported O
to O
have O
only O
small O
effects O
, O
explaining O
consequently O
a O
tiny O
fraction O
of O
its O
phenotypic O
variance O
and O
resulting O
in O
a O
large O
proportion O
of O
missing O

In O
this O
chapter O
, O
epigenetic-mediated O
genetics-lifestyle-environment O
interactions O
within O
specific O
diseases B-Disease
and O
different O
ethnic O
groups O
are O
systematically O
discussed O
, O
and O
data O
sources O
, O
computational O
models O
, O
and O
translational O
platforms O
for O
systems O
medicine O
research O
are O
sequentially O
presented O

A O
variety O
of O
experimental O
approaches O
to O
generate O
genome-wide O
or O
whole-genome O
DNA B-Chemical
methylation I-Chemical
data O
have O
emerged O
in O
recent O
years O

1417 O
Methyl B-Chemical
group I-Chemical
metabolism O
belongs O
to O
a O
relatively O
understudied O
field O
of O
research O

But O
at O
the O
same O
time O
, O
it O
provides O
hope O
because O
it O
tells O
us O
that O
a O
concerted O
focus O
on O
using O
public O
policy O
to O
improve O
our O
social O
, O
physical O
, O
and O
economic O
environments O
can O
ultimately O
change O
our O
biology O
and O
the O
trajectory O
of O
health O
and O
social O
success O
into O
future O
generations O

Those O
data O
show O
that O
ddPCR B-Chemical
can O
be O
used O
for O
methylation O
analysis O
on O
FFPE B-Chemical
samples O
with O
a O
wide O
range O
of O
DNA B-Gene
input O
and O
that O
the O
precision O
of O
the O
assay O
depends O
largely O
on O
the O
total O
amount O
of O
amplifiable O
DNA B-Gene
fragments O

Furthermore O
, O
upcoming O
high-throughput O
epigenomic O
studies O
, O
which O
will O
add O
greatly O
to O
our O
knowledge O
concerning O
the O
impact O
of O
epigenetic O
modifications O
on O
pig B-Species
immune O
response O
, O
are O
listed O
in O
this O
review O

 O

In O
this O
review O
, O
the O
early O
history O
has O
also O
been O
emphasized O
in O
order O
to O
underscore O
the O
transformation O
of O
the O
science O
of O
epigenetics O
from O
a O
phenomenon O
to O
a O
modern O
field O
of O
intense O
research O

Ultimately O
, O
both O
genetic O
biomarkers O
and O
epigenetic O
mechanisms O
should O
be O
taken O
into O
consideration O
in O
predicting O
drug B-Chemical
response O
in O
the O
course O
of O
successful O
personalized O
therapy O

takes O

Such O
epigenomic O
studies O
represent O
a O
broader O
category O
of O
disease B-Disease
-omics O
, O
which O
suffer O
from O
multiple O
problems O
in O
design O
and O
execution O
that O
severely O
limit O
their O
interpretability O

Despite O
the O
promise O
of O
immunotherapy B-Chemical
, O
most O
patients O
do O
not O
have O
a O
response O
or O
become O
resistant O
to O
treatment O


877 O
Aim O
strongly O
influences O
, O
with O
current O
and O
never O
smokers O
exhibiting O
different O

We O
found O
that O
pooling O
effectively O
captures O
similar O
genome-wide O
and O
global O
methylation B-Chemical
signals O
as O
individual O
libraries O
, O
highlighting O
that O
pooled O
libraries O
are O
representative O
of O
the O
global O
population O
signal O

It O
also O
illustrates O
the O
potential O
role O
of O
epigenetic O
alterations O
as O
indicators O
for O
carcinogen B-Chemical
exposure O
and O
for O
identification O
of O
carcinogens B-Chemical
, O
especially O
those O
with O
non-genotoxic O
mechanisms O
of O
action O

scMET O
is O
available O
at O
https//github O

We O
emphasize O
methodological O
considerations O
such O
as O
power O
to O
detect O
methylation O
signals O
, O
exposure O
assessment O
, O
control O
of O
sources O
of O
variability O
, O
causal O
inference O
and O
the O
role O
of O
observed O
methylation O
changes O
in O
mediating O
downstream O
outcomes O
in O
the O
offspring O

The O
study O
of O
ecological O
epigenomics O
holds O
great O
promise O
to O
better O
understand O
the O
linkages O
between O
genotype B-Gene
, O
phenotype O
, O
and O
the O
environment O
and O
to O
explore O
mechanisms O
of O
phenotypic O
plasticity O

Indeed O
, O
the O
flexibility O
of O
epigenetic O
effects O
and O
stability O
of O
genetic O
coding O
lead O
to O
gene B-Gene
regulation I-Gene
complexity O
in O
response O
signals O

Conclusions O
 O
After O
duplication O
, O
a O
histone O
modification O
can O
be O
associated O
with O
a O
particular O
fate O
of O
paralogs O
 O
H3K27me3 B-Chemical
is O
linked O
to O
lower O
expression O
divergence O
yet O
higher O
coding O
sequence O
divergence O

1113 O
 O
Background O
 O
Advanced O
biological O
aging O
, O
as O
measured O
by O
epigenetic O
aging O
indices O
, O
is O
associated O
with O
early O
mortality O
and O
morbidity O

Results O
 O
EWASs O
revealed O
shared O
GO O
annotation O
pathways O
associated O
with O
increased O
methylation O
signatures O
for O
several O
biological O
processes O
in O
response O
to O
IRs O
, O
including O
blood O
circulation O
, O
plasma O
membrane-bounded O
cell O
projection O
organization O
, O
cell O
projection O
organization O
, O
multicellular O
organismal O
process O
, O
developmental O
process O
, O

The O
purpose O
of O
this O
study O
is O
to O
bring O
forth O
an O
overview O
of O
the O
relevant O
parameters O
that O
need O
to O
be O
collected O
to O
assess O
the O
long-term O
and O
transgenerational O
health O
outcomes O
of O
famine B-Disease

1055 O
In O
the O
post-genomic O
era O
, O
epigenetic O
factors-literally O
those O
that O
are O
" O
over O
" O
or O
" O
above O
" O
genetic O
ones O
and O
responsible O
for O
controlling O
the O
expression O
and O
function O
of O
genes B-Gene
- I-Gene
have O
emerged O
as O
important O
mediators O
of O
development O
and O
aging O
; O
gene-gene O
and O

Methylated O
DNA B-Chemical
immunoprecipitation O
followed O
by O
sequencing O
( O
MeDIP-seq O
) O
is O
one O
of O
the O
major O
tools O
used O
in O
whole-genome O
epigenetic O
studies O

Such O
techniques O
now O
allow O
genome-wide O
analyses O
of O
epigenetic O
regulation O
and O
help O
to O
advance O
our O
understanding O
of O
how O
epigenetic O
regulatory O
mechanisms O
affect O
cellular O
and O
genome O
function O

The O
current O
limitations O
associated O
with O
epigenetic O
profiling O
and O
therapeutics O
in O
liver B-Disease
disease I-Disease
are O
discussed O
, O
as O
is O
the O
intriguing O
possibility O
that O
environmental-induced O
epigenetic O
changes O
may O
become O
stable O
and O
heritable O

Latest O
generation O
techniques O
now O
allow O
high-resolution O
investigations O
of O
the O
entire O
genome O
, O
the O
proteome O
and O
the O
cellular O
metabolome O
, O
as O
well O
as O
epigenetic O
modifications O
and O
associated O
gene B-Gene
expression I-Gene
profiles I-Gene

Intriguingly O
, O
it O
appears O
that O
transcription O
factors O
and O
chromatin-modifying O
coregulator O
complexes O
are O
the O
key O
regulatory O
components O
that O
coordinate O
both O
signaling-induced O
transcriptional O
and O
epigenetic O
alterations O
in O
adipocytes B-Species

Epi-drugs O
, O
DNA B-Chemical
methyl I-Chemical
transferase I-Chemical
( O
DNMT B-Gene
) O
inhibitors O
and O
histone B-Chemical
deacetylase I-Chemical
( O
HDAC B-Gene
) O
inhibitors O
are O
the O
best O
examples O
of O
epigenetic O
therapies O
with O
clinical O
applicability O

EMT O
is O
employed O
during O
embryonic O
development O
such O
as O
for O
gastrulation O
and O
neural O
crest O
migration O
and O
is O
misused O
in O
diseases O
, O
such O
as O
cancer B-Disease
metastasis I-Disease

Using O
permissive O
cutoffs O
, O
modified O
reference O
genomes O
are O
found O
to O
alter O
approximately O
1% O
of O
peak O
calls O
while O
de O
novo O
assembled O
genomes O
alter O
up O
to O
5% O
of O
peaks O

The O
application O
of O
epigenetic O
theory O
in O
filamentous B-Species
fungi I-Species
is O
becoming O
a O
new O
strategy O
for O
fungal B-Species
strain O
improvement O
and O
a O
powerful O
method O
to O
obtain O
novel O
natural O
products O

We O
suggest O
that O
studies O
of O
should O
be O
designed O
to O
address O
these O
questions O

It O
has O
become O
a O
multi-faceted O
notion O
with O
different O
meanings O
, O
depending O
on O
the O
disciplinary O
context O
it O
is O
used O

There O
is O
anticipation O
that O
DNA B-Gene
methylation O
may O
close O
gaps O
in O
our O
understanding O
of O
disease B-Disease
etiology O
, O
and O
how O
certain O
risk O
factors O
affect O
health O
and O
disease B-Disease
, O
but O
also O
that O
it O
has O
potential O
as O
a O
biomarker O
for O
disease B-Disease

The O
developmental O
potency O
of O
stem B-Species
cells I-Species
and O
their O
embryonic O
counterparts O
is O
directly O
determined O
by O
metabolic B-Chemical
rewiring I-Chemical

Subsequently O
, O
an O
antibody O
against O
an O
epigenetic O
marker O
and O
control O
IgG B-Chemical
, O
each O
labeled O
with O
different O
DNA B-Chemical
probes O
, O
are O
bound O
to O
the O
respective O
targets O
in O
the O
same O
single O
cell O

Due O
to O
the O
vast O
range O
of O
genes O
affecting O
epigenetic O
dysregulation O
, O
we O
aim O
to O
provide O
a O
selective O
review O
of O
the O
disorders B-Disease
caused O
by O
aberrant O
histone B-Chemical
modifications O
, O
with O
particular O
emphasis O
on O
enzymes O
regulating O
histone B-Chemical
acetylation O
and O
methylation O
, O
in O
order O

Genome-wide O
analyses O
such O
as O
microarrays O
and O
next-generation O
sequencing O
technologies O
have O
been O
used O
to O
assess O
large O
fractions O
of O
the O
methylome B-Chemical

First O
, O
our O
pipeline O
designs O
all O
possible O
PCR O
primer O
pairs O
and O
oligos O
, O
followed O
by O
filtering O
for O
SNPs O
loci O
and O
repeat O
regions O

In O
this O
chapter O
, O
some O
of O
the O
well-known O
processes O
of O
epigenetics O
, O
such O
as O
chromosome O
organization O
, O
DNA B-Chemical
methylation I-Chemical
, O
and O
effects O
of O
transcriptional O
factors O
are O
reviewed O
along O
with O
studies O
examining O
the O
role O
of O
these O
processes O
in O
the O
pathophysiology O
of O
ADHD B-Disease

On O
the O
one O
hand O
, O
as O
a O
critic O
of O
population O
genetics O
, O
Waddington B-Gene
never O
stopped O
claiming O
that O
natural O
selection O
acts O
on O
phenotypes O
and O
that O
the O
phenotype O
is O
the O
outcome O
of O
both O
the O
genome B-Gene
and O
the O
environment O

The O
number O
of O
such O
biomedical O
resources O
is O
increasing O
constantly O
and O
mining O
these O
large O
and O
diverse O
data O
sets O
continues O
to O
present O
real O
challenges O

Finally O
, O
the O
authors O
outline O
the O
potential O
for O
misuse O
of O
this O
technology O
and O
suggest O
that O
well-informed O
policy O
could O
play O
a O
critical O
role O
in O
shaping O
the O
optimal O
implementation O
of O
epigenetic B-Chemical
technologies O

To O
fast-track O
exploration O
, O
we O
generated O
epidecodeR B-Gene
implemented O
in O
R B-Gene
, O
which O
allows O
biologists O
to O
quickly O
survey O
whether O
an O
epigenomic O
or O
epitranscriptomic O
status O
of O
their O
interest O
potentially O
influences O
gene B-Gene
expression I-Gene
responses O

stresses O

Clinical O
studies O
are O
needed O
to O
evaluate O
the O
optimum O
doses O
of O
dietary O
compounds O
, O
the O
safety O
profile O
of O
dosages O
, O
to O
establish O
the O
most O
efficient O
way O
of O
administration O
, O
and O
bioavailability O
, O
in O
order O
to O
maximize O
the O
beneficial O
effects O
already O
discovered O
, O
and O
to O
ensure O
replicability O

There O
are O
statistical O
challenges O
unique O
to O
DNA B-Gene
methylome I-Gene
data O
and O
also O
multiple O
features O
, O
which O
can O
be O
exploited O
to O
increase O
power O

142 O
Denis O
Noble O
discusses O
Conrad B-Gene
Waddington's I-Gene
classic O
paper O
, O
" O
The O
genetic O
assimilation O
of O
the O
bithorax B-Disease
phenotype I-Disease
" O
, O
published O
in O
Evolution O
in O
1956 O

In O
addition O
, O
we O
show O
how O
genome-wide O
methylation O
detection O
arrays O
and O
high-throughput O
sequencing O
have O
provided O
immense O
insight O
into O
ovarian B-Disease
cancer-specific I-Disease
methylation O
signatures O
that O
may O
serve O
as O
diagnostic O
biomarkers O
or O
predict O
patient O
response O
to O
epigenetic B-Chemical
therapy I-Chemical

Moving O
forward O
an O
integrative O
analysis O
of O
genomic O
, O
transcriptomic O
and O
epigenomic O
data O
, O
with O
the O
latter O
two O
coming O
from O
specific O
cell O
types O
, O
will O
provide O
an O
understanding O
that O
has O
been O
missed O
from O
genetics O
alone O

Computational O
studies O
using O
these O
methods O
have O
provided O
important O
insights O
into O
the O
epigenetic O
regulatory O
mechanisms O

Current O
clinical O
trials O
are O
testing O
this O
combination O
therapy O
as O
a O
potent O
new O
cancer B-Disease
management O
strategy O

Beyond O
their O
actions O
on O
hormonal O
pathways O
, O
EDC B-Chemical
exposure O
is O
associated O
with O
elevated O
oxidative O
stress O
, O
which O
may O
occur O
through O
or O
result O
in O
mitochondrial O
dysfunction O

1485 O
Comparative O
analysis O
of O
epigenomes O
offers O
new O
opportunities O
to O
understand O
cellular O
differentiation O
, O
mutation O
effects O
and O
disease B-Disease
processes I-Disease

In O
this O
paper O
we O
review O
existing O
research O
in O
the O
field O
of O
imaging O
epigenetics O
, O
outline O
important O
caveats O
and O
considerations O
, O
and O
suggest O
a O
set O
of O
guidelines O
for O
researchers O
conducting O
this O
work O

1439Background O
Several O
independent O
research O
groups O
have O
shown O
that O
alterations O
in O
human B-Species
sperm O
methylation B-Gene
profiles I-Gene
correlate O
with O
decreased O
fecundity O
and O
an O
increased O
risk O
of O
poor O
embryo O
development O

08 O
) O
and O
negatively O
associated O
with O
smoking O
( O
Î² O
= O
- O

Moving O
forward O
, O
studies O
must O
leverage O
advanced O
chromatin O
analysis O
and O
next-generation O
sequencing O
approaches O
combined O
with O
bioinformatics O
pipelines O
to O
identify O
novel O
gene B-Gene
networks I-Gene
regulated O
by O
particular O
epigenetic O
modifications O

For O
the O
other O
, O
we O
showed O
preliminary O
evidence O
for O
monocyte-specific O
effects O
and O
statistical O
links O
to O
cumulative O
exposure O
to O
traditional O
cardiovascular O
risk O
factors O

Epigenetic O
regulation O
explains O
how O
, O
starting O
from O
a O
unique O
genome O
, O
the O
pluripotent O
embryo O
can O
generate O
a O
variety O
of O
tissues O
and O
maintain O
their O
identity O
throughout O
development O

We O
consider O
data O
from O
a O
panel O
of O
Arabidopsis B-Species
epigenetic O
recombinant O
inbred O
lines O
and O
explore O
estimates O
of O
the O
number O
of O
quantitative O
trait O
loci O
for O
plant O
height O
that O
resulted O
from O
a O
manipulation O
of O
DNA B-Chemical
methylation I-Chemical
levels I-Chemical
in O
one O
of O
the O
two O
isogenic O

Studying O
gene B-Gene
regulatory O
mechanisms O
within O
the O
immune B-Disease
system I-Disease
is O
a O
promising O
avenue O
for O
enhancing O
our O
understanding O
of O
immune B-Disease
cells I-Disease
and O
the O
immune B-Disease
system I-Disease
as O
a O
whole O

787 O
( O
P O
= O
3 O

Further O
, O
the O
basic O
notion O
that O
what O
is O
near-random O
at O
one O
level O
may O
be O
almost O
entirely O
predictable O
at O
a O
higher O
level O
is O
an O
emergent O
property O
of O
many O
systems O
, O
from O
particle O
physics O
to O
the O
social O
sciences O

We O
have O
made O
substantial O
usability O
improvements O
to O
user O
interfaces O
, O
enhanced O
functionality O
, O
made O
identification O
of O
data O
tracks O
of O
interest O
easier O
and O
created O
new O
tools O
for O
preliminary O
data O
analyses O

013 O
; O
DNAm O
ADM B-Gene
, O
b(SE) O
= O
- O
13 O

In O
this O
study O
, O
we O
present O
a O
systematic O
comparison O
of O
genome-wide O
DNAm O
patterns O
between O
matched O
pediatric O
buccal O
epithelial O
cells O
( O
BECs O
) O
and O
peripheral O
blood O
mononuclear O
cells O
( O
PBMCs O
) O
, O
two O
of O
the O
most O
widely O
used O
peripheral O
tissues O
in O
human B-Species
epigenetic O

EpiProfile O
is O
freely O
available O
at O
https//github O

133 O
In O
1956 O
, O
in O
his O
Principles O
of O
Embryology O
, O
Conrad B-Gene
Hal I-Gene
Waddington I-Gene
explained O
that O
the O
word O
" O
epigenetics O
" O
should O
be O
used O
to O
translate O
and O
update O
Wilhelm B-Gene
Roux I-Gene
' O
German O
notion O
of O
" O
Entwicklungsmechanik O
" O
( O
1890 O
) O
to O

To O
define O
the O
extent O
of-and O
molecular O
basis O
for-heterogeneity O
, O
we O
overlaid O
functional O
, O
transcriptional O
, O
and O
epigenetic O
attributes O
of O
hematopoietic B-Species
stem I-Species
cells I-Species
( O
HSCs B-Species
) O
at O
a O
clonal O
level O
using O
endogenous O
fluorescent B-Chemical
tagging O

Conclusions O
 O
Our O
study O
extends O
the O
limited O
literature O
of O
comparative O
epigenomics O
and O
suggests O
a O
new O
paradigm O
for O
epigenetic O
conservation O
without O
genetic O
conservation O
through O
analysis O
of O
transcription O
factor O
binding O
sites O

Variants O
in O
L3MBTL3 B-Gene
were O
associated O
with O
colorectal B-Disease
, O
overall O
breast B-Disease
, O
ER-negative B-Disease
breast I-Disease
, O
clear B-Disease
cell I-Disease
ovarian I-Disease
, O
and O
overall O
and O
aggressive O
prostate B-Disease
cancer I-Disease
risk O
( O
e O

Among O
these O
approaches O
, O
transcriptomic O
analysis O
provides O
knowledge O
of O
the O
molecular O
linkages O
between O
genetic O
information O
and O
the O
proteome O
, O
leading O
to O
a O
comprehensive O
understanding O
of O
biological O
processes O
and O
diseases B-Disease

Mis- O
and O
overinterpretation O
of O
epigenetic O
data O
foster O
genetic O
denialism O
( O
" O
We O
can O
control O
our O
genes B-Gene
" O
) O
and O
epigenetic O
determinism O
( O
" O
You O
are O
what O
your O
parents O
ate O
" O
) O

Potential O
drug B-Chemical
targets O
began O
to O
emerge O
; O
however O
, O
independent O
validation O
studies O
are O
lacking O

This O
perspective O
describes O
recent O
advances O
in O
the O
discovery O
of O
epigenetic O
biomarkers O
in O
lung B-Disease
cancer I-Disease
, O
specifically O
those O
that O
result O
in O
the O
methylation O
of O
DNA B-Gene
at O
CpG B-Chemical
sites O

We O
extract O
a O
biologically O
relevant O
latent O
space O
of O
LUAD B-Disease
and O
LUSC B-Disease
samples O

932 O
 O
Background O
 O

Preterm O
infants O
are O
hospitalized O
in O
the O
Neonatal O
Intensive O
Care O
Unit O
( O
NICU O
) O
where O
they O
are O
exposed O
to O
life-saving O
yet O
pain-inducing O
procedures O
and O
to O
protective O
care O

We O
examine O
previous O
studies O
that O
have O
attempted O
to O
predict O
treatment O
efficacy O
through O
epigenetics O
, O
provide O
an O
experimental O
model O
, O
and O
note O
the O
potential O
challenges O
at O
each O
stage O


The O
advance O
of O
these O
tests O
to O
the O
clinical O
routine O
will O
depend O
on O
rigorous O
, O
extensive O
, O
and O
independent O
validation O
in O
well-annotated O
cohort O
of O
patients O
and O
commercial O
development O
of O
clinical O
routine-friendly O
and O
adequate O
procedures O

We O
use O
information O
from O
whole O
genome O
and O
targeted O
bisulfite O
sequencing O
from O
910 O
samples O
to O
perform O
genotype-dependent O
analyses O
of O
allele-specific O
methylation O
( O
ASM O
) O
and O
non-allelic O
methylation O
( O
mQTL O
) O

Currently O
available O
in O
silico O
methods O
have O
facilitated O
the O
identification O
, O
positioning O
and O
quantitative O
comparisons O
of O
individual O
modification O
sites O

, O
DNA B-Gene
extraction O
to O
generation O
of O
MeDIP-seq B-Gene
library O
, O
can O
be O
completed O
within O
3-5 O
d O

This O
review O
offers O
a O
comprehensive O
overview O
of O
the O
current O
state O
of O
knowledge O
on O
epigenetic O
processes O
implicated O
in O
cardiovascular B-Disease
and I-Disease
metabolic I-Disease
diseases I-Disease
, O
highlighting O
the O
potential O
of O
DNA B-Chemical
methylation I-Chemical
as O
a O
precision O
medicine O
biomarker O
and O
examining O
the O
impact O
of O
social O

Referring O
to O
huge O
amounts O
of O
epigenetic O
data O
coming O
from O
biological O
experiments O
and O
clinic O
, O
machine O
learning O
can O
help O
in O
detecting O
epigenetic O
features O
in O
genome O
, O
finding O
correlations O
between O
phenotypes O
and O
modifications O
in O
histone B-Chemical
or O
genes B-Gene
, O
accelerating O
the O
screen O
of O
lead O
compounds O

950 O
Over O
the O
past O
30 O
years O
, O
a O
plethora O
of O
pathogenic O
mutations O
affecting O
enhancer O
regions O
and O
epigenetic O
regulators O
have O
been O
identified O

These O
differences O
in O
protein O
expression O
rates O
were O
quantified O
by O
the O
development O
of O
a O
noncompartmentalized O
cellular O
kinetics O
model O

Thus O
, O
the O
concept O
of O
redifferentiation O
strategy O
, O
which O
involves O
treating O
patients O
with O
one O
or O
more O
drugs O
capable O
of O
restoring O
radioiodine B-Chemical
sensitivity O
for O
RAIR B-Disease
TC I-Disease
, O
has O
emerged O

Behavioral O
epigenetics O
shows O
that O
our O
behavior O
could O
have O
long-term O
effects O
on O
the O
regulation O
of O
the O
genome B-Gene
function O

In O
fact O
, O
these O
changes O
form O
the O
basis O
of O
the O
so O
called O
" O
epigenetic O
clocks O
" O
, O
which O
translate O
the O
genomic B-Chemical
methylation I-Chemical
profile I-Chemical
into O
an O
" O
epigenetic O
age O
" O

Because O
of O
these O
central O
roles O
, O
there O
is O
the O
potential O
for O
epigenetics O
to O
play O
a O
role O
in O
crop O
improvement O
strategies O
including O
the O
selection O
for O
favorable O
epigenetic O
states O
, O
creation O
of O
novel O
epialleles O
, O
and O
regulation O
of O
transgene B-Gene
expression O

Formerly O
restricted O
to O
the O
analysis O
of O
only O
limited O
amounts O
of O
genetic O
information O
, O
aDNA O
studies O
have O
now O
progressed O
to O
whole-genome O
sequencing O
for O
an O
increasing O
number O
of O
ancient O
individuals O
and O
extinct B-Species
species I-Species
, O
as O
well O
as O
to O
epigenomic O
characterization O

Here O
, O
we O
describe O
an O
alternative O
epigenome O
profiling O
approach O
, O
named O
TOP-seq O
, O
which O
is O
based O
on O
covalent O
tagging O
of O
individual O
unmodified O
CG O
sites O
followed O
by O
non-homologous O
priming O
of O
the O
DNA B-Chemical
polymerase I-Chemical
action O
at O
these O
sites O
to O
directly O
produce O
adjoining O
regions O

248 O
It O
has O
been O
widely O
described O
that O
cancer B-Disease
genomes O
have O
frequent O
alterations O
to O
the O
epigenome O
, O
including O
epigenetic O
silencing O
of O
various O
tumor B-Disease
suppressor I-Disease
genes B-Gene
with O
functions O
in O
almost O
all O
cancer-relevant B-Disease
signalling O
pathways O
, O
such O
as O
apoptosis O
, O
cell O

We O
examined O
genome-wide O
DNA B-Chemical
methylation O
and O
gene O
expression O
profiles O
of O
hippocampal O
tissues O
from O
wild-type B-Species
rats I-Species
housed O
in O
three O
independent O
laboratories O
using O
nearly O
identical O
conditions O

gov O
/ O
epigenomics O
) O

are O
among O
the O
most O
frequently-used O
adulterants O
in O
saffron B-Chemical
spice O

Epigenetic O
modifications O
are O
related O
to O
methylation O
of O
CpG B-Gene
DNA I-Gene
islands O
, O
post-translational O
modifications O
of O
, O
and O
non-coding O
RNAs B-Gene

765 O
External O
constraints O
, O
such O
as O
development O
, O
disease O
, B-Disease
and O
environment O
, O
can O
induce O
changes O
in O
epigenomic O
patterns O
that O
may O
profoundly O
impact O
the O
health O
trajectory O
of O
fetuses O
and O
neonates O
into O
adulthood O
, O
influencing O
conditions O
like O
obesity B-Disease

studies O

At O
the O
same O
time O
, O
upregulation O
of O
MIR29B2CHG B-Gene
expression O
may O
have O
a O
biological O
function O
, O
which O
merits O
further O
studies O


com O
/ O
imbbLab O
/ O
EPIGENE B-Gene

For O
the O
three O
methods O
combination O
, O
we O
implemented O
both O
the O
iterative O
method O
by O
Qu B-Gene
et I-Gene
al I-Gene

980 O
The O
interaction O
between O
the O
gut O
and O
its O
eventual O
trillions O
of O
microbe B-Species
inhabitants O
during O
microbial O
colonization O
, O
represents O
a O
critical O
time O
period O
for O
establishing O
the O
overall O
health O
and O
wellbeing O
of O
an O
individual O

, O
the O
450HM B-Gene
and O
MethylationEPIC B-Gene
) O

Beyond O
their O
role O
in O
cell O
differentiation O
, O
interactions O
of O
the O
organism B-Species
with O
the O
environment O
are O
also O
often O
encoded O
into O
permanent O
or O
semi-permanent O
epigenetic O
marks O
and O
affect O
cellular O
behavior O
and O
organismal O
health O

The O
next O
steps O
for O
this O
field O
will O
entail O
transitioning O
from O
correlative O
studies O
to O
causal O
ones O

In O
the O
absence O
of O
SNP O
information O
, O
our O
method O
relies O
only O
on O
reads O
to O
quantify O
ASM O

Genetic B-Disease
predispositions I-Disease
have O
been O
demonstrated O
to O
have O
a O
substantial O
role O
in O
the O
unbalanced O
energy O
metabolism O
seen O
in O
obesity B-Disease

703 O
Motivation O
Functional O
genomics O
experiments O
generate O
genomewide O
signal O
profiles O
that O
are O
dense O
information O
sources O
for O
annotating O
the O
regulatory O
elements O

It O
is O
the O
combined O
application O
of O
technological O
advances O
to O
probe O
epigenetic O
modifications O
at O
a O
genome-wide O
scale O
and O
methodological O
advances O
aimed O
at O
causal O
inference O
( O
including O
Mendelian B-Gene
randomization I-Gene
and O
integrative O
genomics O
) O
that O
will O
elucidate O
the O
interplay O
between O
circulating O
lipids B-Chemical
and O

The O
DEGs B-Gene
were O
significantly O
regulated O
by O
DMPs B-Chemical
and/or O
differentially O
expressed O
miRNAs B-Gene

In O
addition O
, O
epigenetics O
seems O
to O
be O
involved O
in O
complex O
phenomena O
such O
as O
X B-Gene
monosomy O
or O
abnormalities O
in O
the O
process O
of O
X B-Gene
chromosome O
inactivation O
, O
which O
have O
been O
reported O
in O
PBC B-Disease
and O
appear O
to O
influence O
its O
sex O
imbalance O
and O
pathogenesis O

However O
, O
the O
interplay O
between O
these O
factors O
has O
only O
recently O
been O
started O
to O
be O
unraveled O


6 O
 O
Epigenetic O
mechanisms O
comprising O
of O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
and O
gene B-Gene
silencing I-Gene
by O
RNA B-Chemical
interference I-Chemical
have O
been O
strongly O
linked O
to O
the O
development O
and O
progression O
of O
various O
diseases B-Disease

Immune O
activation O
due O
to O
infection O
can O
also O
modulate O
brain O
function O
, O
but O
whether O
this O
experience O
can O
be O
passed O
down O
to O
offspring O
remains O
unknown O

Our O
study O
examines O
genetic O
elements O
conserved O
across O
non-hibernating O
mammals B-Species
to O
identify O
genome-wide O
patterns O
of O
accelerated O
evolution O
in O
hibernators B-Species
from O
different O
clades O

Thus O
, O
our O
aim O
was O
to O
develop O
gene B-Gene
delivery I-Gene
polyplexes O
capable O
of O
initiating O
their O
own O
transcription O
upon O
arrival O
in O
the O
nucleus O

We O
next O
discuss O
how O
this O
trajectory O
may O
be O
affected O
by O
prenatal O
environmental O
exposures O

Studying O
patient O
subgroups O
is O
needed O
in O
order O
to O
extract O
more O
comparable O
and O
reproducible O
epigenetic O
findings O
in O
suicide B-Disease

Furthermore O
, O
a O
significant O
proportion O
of O
common O
DNA B-Chemical
methylation I-Chemical
is O
at O
least O
partially O
genetically O
driven O
and O
thus O
may O
be O
observed O
similarly O
across O
tissues O

[ O
BMB O
Reports O
2024 O
; O
57(5) O
 O
216-231 O
] O

hirsutism B-Disease
, O
acne B-Disease
, O
oligo-amenorrhea B-Disease
, O
alopecia B-Disease
) O

14 O
viruses O
including O
members O
of O
the O
, O
, O
, O
and O
families O
are O
presently O
the O
subject O
of O
intense O
interest O
with O
respect O
to O
the O
role O
that O
epigenetics O
plays O

and O

0 O


There O
is O
an O
association O
between O
adverse O
environmental O
stimuli O
, O
such O
as O
early O
life O
stress O
, O
and O
epigenetic O
modification O
of O
gene B-Gene
expression O

191Tweetable O
This O
article O
reviews O
machine O
learning O
models O
that O
leverages O
epigenomic O
data O
for O
predicting O
multifactorial O
diseases B-Disease
and O
symptoms O
as O
well O
as O
how O
such O
models O
can O
be O
utilized O
to O
explore O
new O
research O
questions O

Millions O
of O
people O
worldwide O
are O
chronically O
exposed O
to O
arsenic B-Chemical
through O
drinking O
water O
and O
food O

Such O
variability O
poses O
a O
challenge O
in O
successfully O
targeting O
all O
tumor B-Disease
subpopulations O
at O
the O
same O
time O

HAART O
itself O
affects O
the O
epigenotype O
of O
host O
cells O

Multiple O
lines O
of O
evidence O
indicate O
that O
early O
life O
exposure O
to O
environmental O
chemicals B-Chemical
at O
relatively O
low O
concentrations O
could O
have O
lasting O
effects O
on O
individual O
and O
population O
health O

Screening O
the O
DNA B-Gene
methylome O
offers O
an O
attractive O
alternative O
as O
methylation O
can O
be O
thought O
of O
as O
a O
proxy O
for O
the O
combined O
influences O
of O
genetics O
and O
environment O

Evaluating O
and O
interpreting O
the O
association O
between O
genomic B-Chemical
regions I-Chemical
and O
their O
features O
has O
become O
a O
common O
and O
challenging O
analysis O
in O
genomic B-Chemical
and O
epigenomic B-Chemical
studies O

These O
methods O
, O
although O
promising O
and O
innovative O
, O
can O
present O
several O
technical O
and O
analytical O
pitfalls O

The O
metabolic O
memory O
phenomena O
(persistent O
effect O
of O
a O
glycemic B-Chemical
insult I-Chemical
even O
after O
retrieved O
) O
associated O
with O
it O
has O
increased O
the O
risk O
of O
developing O
the O
complication O
even O
after O
the O
termination O
of O
the O
glycemic B-Chemical
insult I-Chemical

Given O
the O
progress O
of O
genomic O
discovery O
in O
anorexia B-Disease
nervosa I-Disease
, O
with O
the O
identification O
of O
the O
first O
genome-wide O
significant O
locus O
, O
as O
well O
as O
animated O
discussion O
of O
epigenetic O
mechanisms O
in O
linking O
environmental O
factors O
with O
disease O
onset O
, O
our O
goal O
was O
to O
conduct O
a O

The O
ascertainment O
and O
use O
of O
these O
marks O
to O
identify O
at-risk O
patient O
populations O
, O
refine O
diagnostic O
criteria O
, O
and O
provide O
prognostic O
and O
predictive O
factors O
to O
guide O
treatment O
decisions O
are O
of O
growing O
clinical O
relevance O

In O
addition O
, O
resistance O
to O
contaminating O
cells O
makes O
DNA B-Gene
methylation I-Gene
useful O
in O
genome-wide O
screening O
of O
biomarkers O
for O
various O
clinicopathologic O
characteristics O

g O

The O
creation O
of O
more O
specific O
and O
effective O
epigenetic O
therapies O
, O
however O
, O
requires O
a O
more O
complete O
understanding O
of O
epigenomic O
landscapes O

We O
find O
that O
DNAm B-Gene
can O
classify O
ternary O
smoking O
status O
with O
reasonable O
accuracy O
, O
including O
when O
applied O
to O
external O
data O

992 O
In O
recent O
decades O
, O
the O
developmental O
sciences O
have O
undergone O
a O
relational O
turn O

O O
ngoing O
research O
in O
the O
field O
of O
epigenetics O
has O
resulted O
in O
the O
resolutory O
role O
of O
various O
epigenetic O
markers O
and O
their O
inhibition O
using O
specific O
inhibitors O
to O
arrest O
their O
key O
cellular O
functions O
in O
in-vitro O
and O
pre-clinical O
studies O

Accelerated O
execution O
and O
integrated O
semi-supervised O
peak O
calling O
make O
JBR O
and O
SPAN O
next-generation O
visualization O
and O
analysis O
tools O
for O
multi-sample O
epigenetic O
data O

Identification O
and O
comparison O
of O
the O
epigenomic O
landscape O
has O
challenged O
our O
understanding O
of O
the O
regulation O
of O
phenotype O

To O
redirect O
future O
novel O
experimental O
or O
theoretical O
efforts O
, O
it O
is O
crucial O
to O
compile O
all O
significant O
issues O
that O
could O
impact O
human B-Species
and O
ecological O
benefit O
in O
the O
most O
precise O
and O
accurate O
manner O

Here O
, O
we O
studied O
molecular O
changes O
conferring O
abnormal O
functionality O
at O
distal O
spinal O
cord O
( O
T12 O
) O
beyond O
the O
lesion O
center O
( O
T10 O
) O
by O
combining O
next-generation O
sequencing O
( O
RNA O
- O
and O
bisulfite O
sequencing O
) O
, O
super-resolution O
microscopy O
, O
and O
immunofluorescence O
staining O
at O

Applying O
PRISM B-Gene
for O
two O
AML B-Disease
samples O
, O
we O
demonstrate O
that O
PRISM B-Gene
could O
infer O
the O
evolutionary O
history O
of O
malignant O
samples O
from O
an O
epigenetic O
point O
of O
view O

Conclusions O
 O
VAEs O
can O
distinguish O
the O
original O
subtypes O
from O
manually O
mixed O
methylation B-Chemical
data I-Chemical
frame I-Chemical
with O
the O
encoded O
features O
of O
latent O
space O

New O
insight O
into O
these O
mechanisms O
has O
come O
from O
the O
study O
of O
small O
RNAs B-Gene
, O
which O
have O
emerged O
as O
regulators O
that O
can O
confer O
sequence O
specificity O
to O
DNA B-Chemical
- I-Chemical
and O
chromatin-modifying O
processes O

NGS-based O
studies O
have O
provided O
detailed O
and O
comprehensive O
views O
of O
epigenetic O
modifications O
for O
the O
genomes O
of O
many O
species B-Species
and O
cell O
types O

This O
article O
argues O
that O
considering O
the O
impact O
of O
the O
socio-exposome O
in O
the O
biological O
profiling O
for O
precision O
oral O
health O
applications O
is O
necessary O
to O
ensure O
that O
definitions O
of O
biological O
risk O
do O
not O
override O
social O
ones O

695 O
Despite O
decades O
of O
investigation O
into O
the O
genetics O
of O
autism B-Disease
spectrum I-Disease
disorder I-Disease
( O
ASD B-Disease
) O
, O
a O
current O
consensus O
in O
the O
field O
persists O
that O
ASD B-Disease
risk O
is O
too O
heterogeneous O
to O
be O
diagnosed O
by O
a O
single O
set O
of O
genetic O
variants O

Our O
new O
model O
translates O
the O
capabilities O
of O
state-of-the-art O
epigenetic O
clocks O
to O
the O
EPICv2 O
platform O
and O
is O
cross-compatible O
with O
older O
microarrays O

But O
these O
categories O
seem O
to O
be O
less O
distinct O
than O
was O
at O
first O
assumed O

1077 O
Epigenetic O
changes O
in O
stroke B-Disease
may O
revolutionize O
cell-based O
therapies O
aimed O
at O
reducing O
ischemic B-Disease
stroke I-Disease
risk O
and O
damage O

To O
explore O
possible O
relationships O
and O
linkages O
between O
Cd(II)-induced B-Chemical
oxidative I-Chemical
stress I-Chemical
and O
the O
consequent O
damage O
at O
the O
genomic O
level O
(followed O
by O
DNA B-Gene
replication I-Gene
stress I-Gene
), O
root O
apical O
meristem O
(RAM) O
cells O
in O
broad B-Species
bean I-Species
( O

We O
conclude O
that O
DNAm B-Gene
age O
of O
ectopic B-Disease
lesions I-Disease
suggests O
a O
distinct O
developmental O
origin O
for O
a O
subset O
of O
lesions O

Also O
, O
several O
of O
the O
epigenetic O
drugs B-Chemical
currently O
approved O
as O
anticancer O
agents O
affect O
the O
expression O
of O
miRNAs B-Gene
and O
this O
might O
explain O
part O
of O
their O
mechanism O
of O
action O

We O
show O
that O
equal O
epigenetic O
age O
in O
different O
subjects O
can O
result O
from O
variable O
contribution O
size O
of O
the O
same O
CpG B-Gene
sites I-Gene
to O
the O
total O
epigenetic O
age O

927 O
Targeting O
epigenetic O
mechanisms O
during O
initial O
learning O
or O
memory O
retrieval O
can O
lead O
to O
persistent O
memory O

In O
performance O
comparisons O
, O
EpiSAFARI B-Gene
performs O
favorably O
in O
terms O
of O
accuracy O

Here O
, O
we O
discuss O
the O
latest O
technological O
advances O
in O
the O
CRISPR-based B-Gene
genome O
and O
epigenome O
editing O
toolbox O
, O
and O
provide O
insight O
into O
how O
these O
synthetic O
biology O
tools O
could O
facilitate O
aging O
research O
by O
establishing O
in O
vitro O
cell O
and O
in O
vivo O
animal O
models O
to O
dissect O
genetic O

Small O
molecule O
modulators O
of O
key O
epigenetic O
targets O
will O
be O
central O
in O
the O
study O
of O
these O
intricate O
networks O
as O
well O
as O
providing O
highly O
useful O
start O
points O
for O
drug O
discovery O
efforts O

Here O
, O
we O
describe O
an O
open-source O
, O
optimized O
method O
for O
determining O
empirically O
based O
DMRs O
( O
eDMR O
) O
from O
high-throughput O
sequence O
data O
that O
is O
applicable O
to O
enriched O
whole-genome O
methylation O
profiling O
datasets O
, O
as O
well O
as O
other O
globally O
enriched O
epigenetic O
modification O
data O

1347 O
The O
eye O
and O
visual O
system O
are O
valuable O
in O
many O
areas O
of O
translational O
research O
such O
as O
stem B-Chemical
cell I-Chemical
therapy O
, O
transplantation O
research O
and O
gene B-Gene
therapy O

Our O
user-friendly O
graphical O
software O
quickly O
estimates O
the O
strength O
and O
quality O
of O
immunoprecipitations O
, O
identifies O
biases O
, O
compares O
the O
user O
's O
data O
with O
ENCODE O
's O
large O
collection O
of O
published O
datasets O
, O
performs O
multi-sample O
normalization O
, O
checks O
against O
quantitative O
PCR-validated O
control O
regions O
, O
and O
produces O

Vis O
Ã  O
vis O
other O
species O
, O
the O
human B-Species
brain O
displays O
unique O
functional O
and O
morphological O
features O
that O
result O
from O
this O
extensive O
developmental O
process O
that O
is O
, O
unsurprisingly O
, O
highly O
vulnerable O
to O
both O
genetically O
and O
environmentally O
induced O
alterations O

e O

We O
show O
that O
postgenomic O
research O
on O
health B-Disease
disparities I-Disease
in O
Latin B-Species
America I-Species
reintroduces O
old O
colonial O
views O
about O
the O
relations O
between O
race O
, O
environment O
, O
and O
social O
status O

To O
overcome O
this O
challenge O
, O
we O
built O
the O
Cistrome O
database O
, O
a O
collection O
of O
ChIP-seq O
and O
chromatin O
accessibility O
data O
( O
DNase-seq O
and O
ATAC-seq O
) O
published O
before O
January O
1 O
, O
2016 O
, O
including O
13 O
366 O
human B-Species
and O
9953 O
mouse B-Species
samples O

Using O
only O
15 O
ng O
of O
DNA B-Chemical
as O
input O
, O
there O
is O
minimal O
loss O
in O
data O
quality O
, O
achieving O
93% O
of O
the O
coverage O
of O
WGB-seq O
( O
with O
standard O
amounts O
of O
input O
DNA B-Chemical
) O
at O
similar O
false/positive O
rates O

Second O
, O
and O
drawing O
from O
a O
set O
of O
interviews O
( O
N O
= O
15 O
) O
, O
we O
describe O
a O
tension O
between O
this O
dominant O
, O
objectifying O
molecular O
discourse O
and O
the O
perspective O
of O
individual O
scientists O

1204 O
Environmental B-Chemical
endocrine I-Chemical
disruptors I-Chemical
( O
EEDs B-Chemical
) O
seriously O
endanger O
human B-Species
health O
by O
interfering O
with O
the O
normal O
function O
of O
reproductive O
systems O

We O
also O
discuss O
current O
treatment O
regimens O
targeting O
these O
factors O
and O
other O
promising O
inhibitors O
in O
clinical O
trials O

Therefore O
, O
there O
is O
a O
strong O
need O
for O
new O
research O
comprising O
translational O
and O
cross-species B-Species
approaches O
that O
use O
longitudinal O
designs O
for O
studying O
trajectories O
of O
change O
contrasting O
susceptible O
and O
resilient O
subjects O

Discoveries O
of O
the O
dynamic O
nature O
of O
the O
epigenome B-Gene
and O
its O
variable O
sensitivity O
towards O
change O
in O
numerous O
phenomena O
add O
further O
complexity O
to O
the O
assessment O
of O
health B-Disease
inequalities I-Disease

This O
infrastructure O
facilitates O
the O
extraction O
and O
manipulation O
of O
genomic O
coverage O
track O
data O
across O
individual O
or O
multiple O
sets O
of O
thousands O
of O
genomic O
loci O

Despite O
the O
wide O
variety O
of O
analytical O
techniques O
that O
have O
been O
developed O
to O
detect O
DNA B-Gene
modifications O
, O
their O
investigation O
at O
the O
single-genome O
level O
is O
only O
beginning O
to O
emerge O

Density O
curves O
comparing O
these O
studies O
indicated O
these O
heritability O
estimates O
were O
similar O

To O
accomplish O
an O
era O
of O
gene-environment-wide O
interaction O
studies O
, O
it O
is O
necessary O
to O
launch O
a O
national O
human B-Species
epigenome B-Gene
project O

We O
propose O
that O
malfunctions O
detected O
in O
these O
mechanisms O
are O
not O
necessarily O
independent O
, O
since O
these O
malfunctions O
are O
often O
found O
associated O
with O
the O
same O
disease B-Disease
and O
targeting O
the O
same O
gene B-Gene
, O
group O
of O
genes B-Gene
, O
or O
functional O
pathway O

Outside O
of O
biomedicine O
, O
social O
scientists O
have O
long O
recognized O
the O
impact O
of O
the O
social O
and O
physical O
environment O
on O
individuals O
and O
populations O
but O
have O
not O
usually O
connected O
these O
effects O
with O
changes O
in O
underlying O
biology O

identify O

A O
spike-in O
strategy O
based O
on O
SILAC B-Chemical
can O
be O
used O
to O
overcome O
this O
limitation O
and O
profile O
hPTMs B-Gene
across O
multiple O
samples O

evaluation O
of O
the O
arithmetic O
correctness O
and O
3 O

Phenotypic O
plasticity O
via O
epigenetic O
potential O
might O
be O
selectively O
advantageous O
at O
the O
time O
of O
initial O
introduction O
or O
during O
spread O
into O
new O
areas O
, O
enabling O
introduced O
organisms O
to O
cope O
rapidly O
with O
novel O
challenges O

He O
is O
known O
for O
his O
groundbreaking O
studies O
linking O
environmental O
exposures O
early O
in O
life O
to O
the O
development O
of O
adult O
diseases B-Disease
through O
changes O
in O
the O
epigenome O
and O
for O
determining O
the O
evolutionary O
origin O
of O
genomic O
imprinting O
in O
mammals B-Species

se O

This O
system O
is O
applied O
to O
cells O
with O
the O
triplication O
of O
the O
SNCA B-Gene
locus O
and O
reduces O
the O
SNCA-mRNA B-Gene
and O
protein O
levels O
by O
about O
30% O
through O
the O
targeted O
DNA B-Chemical
methylation O
of O
SNCA B-Gene
intron O
1 O

Some O
transcriptomic O
and O
epigenomic O
changes O
were O
shared O
between O
talc B-Chemical
and O
titanium B-Chemical
dioxide I-Chemical
, O
however O
, O
it O
is O
especially O
interesting O
that O
each O
of O
the O
two O
particles O
of O
similar O
size O
and O
insoluble O
nature O
has O
also O
induced O
a O
specific O
pattern O
of O
gene B-Gene
expression I-Gene
and O

, O
Large-scale O
screening O
has O
been O
instrumental O
in O
identifying O
genes O
and O
pathways O
susceptible O
to O
epigenetic O
control O
, O
particularly O
in O
the O
context O
of O
adipogenesis O
and O
metabolic O
homeostasis O
; O
Single-cell O
RNA O
sequencing O
( O
scRNA-seq O
) O
provides O
a O
high-resolution O
view O
of O
gene O
expression O
patterns O
at O
the O
individual O


This O
article O
is O
part O
of O
a O
discussion O
meeting O
issue O
' O
Frontiers O
in O
epigenetic O
chemical B-Chemical
biology O
' O

Further O
analysis O
highlights O
the O
importance O
of O
cGCPs B-Gene
for O
their O
cellular O
functions O
and O
potential O
roles O
in O
complex O
traits O
and O
human B-Disease
diseases I-Disease

This O
review O
will O
provide O
an O
overview O
of O
the O
major O
epigenetic O
pathways O
and O
modern O
techniques O
for O
their O
study O
, O
before O
focusing O
on O
experimental O
evidence O
supporting O
a O
strong O
role O
for O
epigenetics O
in O
selected O
psychiatric O
disorders O
such O
as O
depression B-Disease
, O
schizophrenia B-Disease
, O
and O
drug B-Disease
addiction I-Disease

The O
ways O
in O
which O
these O
epigenetic O
mechanisms O
influence O
liver O
physiology O
and O
disease O
will O
be O
considered O
in O
detail O
, O
particularly O
in O
the O
context O
of O
cancer B-Disease
, O
fibrosis B-Disease
, O
and O
nonalcoholic B-Disease
steatohepatitis I-Disease

In O
the O
last O
decade O
, O
an O
exciting O
boom O
of O
experimental O
research O
has O
brought O
to O
light O
the O
pivotal O
biological O
functions O
of O
long B-Species
non-coding I-Species
RNAs I-Species
( O
lncRNAs B-Gene
) O
, O
representing O
more O
than O
the O
half O
of O
the O
whole O
non-coding O
transcriptome O
, O
along O
with O
their O

1251 O
 O
Background O
 O
Recent O
innovations O
in O
single-cell O
Assay B-Chemical
for I-Chemical
Transposase I-Chemical
Accessible I-Chemical
Chromatin I-Chemical
using I-Chemical
sequencing I-Chemical
( O
scATAC-seq B-Chemical
) O
enable O
profiling O
of O
the O
epigenetic O
landscape O
of O
thousands O
of O
individual O
cells O

The O
newest O
version O
, O
HumanMethylationEPIC B-Gene
, O
quantifies O
the O
DNA B-Chemical
methylation I-Chemical
level O
of O
850,000 O
CpG B-Gene
sites O
, O
while O
the O
previous O
versions O
, O
HumanMethylation450 B-Gene
and O
HumanMethylation27 B-Gene
, O
measured O
>450,000 O
and O
27,000 O
loci O
, O
respectively O

B-Protein O
I-Protein O
S-Protein O
C-Protein O
U-Protein O
I-Protein O
T-Protein O
is O
particularly O
suited O
for O
processing O
data O
from O
single-cell O
DNA B-Chemical
methylation I-Chemical
assays O
, O
with O
its O
excellent O
scalability O
, O
efficiency O
, O
and O
ability O
to O
greatly O
enhance O
mappability O
, O
a O
key O
challenge O
for O
single-cell O
studies O

Identification O
of O
functionally O
relevant O
epigenetic O
biomarkers O
in O
human B-Species
specimens O
has O
the O
potential O
to O
improve O
prediction O
of O
drug B-Chemical
responses O
based O
on O
patient's O
epigenetic O
profiles O

, O
adipose B-Species
tissue I-Species
, O
skeletal B-Species
muscle I-Species
, O
pancreatic B-Species
islets I-Species
, O
liver B-Species
, O
and O
blood-in B-Species
relation O
to O
obesity B-Disease
and O
T2D B-Disease

Previous O
research O
has O
looked O
at O
the O
rate O
at O
which O
spontaneous O
epialleles O
arise O
but O
it O
is O
currently O
unknown O
how O
they O
are O
maintained O
across O
generations O

This O
impact O
is O
thought O
to O
be O
in O
large O
part O
mediated O
by O
the O
action O
of O
glucocorticoid B-Chemical
stress I-Chemical
hormones I-Chemical
, O
primarily O
cortisol B-Chemical
in O
humans B-Species

In O
this O
review O
, O
the O
three O
major O
epigenetic O
mechanisms O
are O
described O
 O
covalent O
DNA B-Chemical
modification O
, O
histone B-Chemical
protein I-Chemical
modification O
, O
and O
regulation O
by O
noncoding O
RNA B-Gene

regulatory O

366 O
 O
Cancer B-Disease
genome O
analyses O
have O
revealed O
that O
the O
enzymes O
involved O
in O
epigenetic O
gene O
regulation O
are O
frequently O
deregulated O
in O
cancer B-Disease

In O
this O
review O
, O
we O
discuss O
various O
fluorescent O
probes O
for O
detection O

Despite O
these O
essential O
roles O
, O
centromeres B-Species
are O
not O
defined O
by O
specific O
DNA B-Gene
sequences I-Gene
, O
but O
by O
epigenetic O
means O

05 O

282 O
Epigenetic O
targets O
are O
of O
significant O
importance O
in O
drug O
discovery O
research O
, O
as O
demonstrated O
by O
the O
eight O
approved O
epigenetic O
drugs O
for O
treatment O
of O
cancer B-Disease
and O
the O
increasing O
availability O
of O
chemogenomic O
data O
related O
to O
epigenetics O

1307 O
methylation O
( O
) O
that O
occurs O
on O
promoter O
regions O
is O
primarily O
considered O
to O
repress O
gene O
expression O

Finally O
we O
discuss O
the O
crucial O
areas O
requiring O
a O
greater O
understanding O
of O
these O
processes O
, O
in O
order O
to O
piece O
together O
a O
global O
picture O
of O
the O
changing O
epigenetic O
landscape O
in O
MSC B-Species
during O
aging O

The O
molecular O
mechanisms O
of O
suicidal O
behavior O
in O
psychosis B-Disease
remain O
poorly O
investigated O
, O
although O
it O
has O
been O
hypothesized O
that O
epigenetic O
processes O
are O
involved O
in O
the O
etiology O
of O
both O
psychosis B-Disease
and O
suicidality O

Our O
tool O
is O
available O
from O
the O
Galaxy O
ToolShed O
, O
GitHub O
repository O
, O
and O
also O
as O
a O
Docker O
image O

Concurrent O
methylation O
pattern O
changes O
in O
blood O
and O
AT O
, O
particularly O
in O
immune-related O
genes B-Gene
, O
suggest O
blood O
DNA B-Chemical
methylation O
mirrors O
AT O
's O
inflammatory O
state O
post-bariatric O
surgery B-Disease

As O
programs O
scale O
to O
evaluate O
many O
new O
targets O
related O
to O
epigenetic O
expression O
, O
new O
tools O
and O
techniques O
are O
required O
to O
enable O
efficient O
and O
reproducible O
high-throughput O
epigenetic O
screening O

The O
theories O
discussed O
are O
divided O
into O
epigenetic O
and O
genetic O
ones O
, O
with O
the O
latter O
further O
classified O
into O
gene-based O
and O
genome-based O
hypotheses O

Ever O
use O
of O
marijuana B-Chemical
and O
each O
additional O
marijuana-year B-Chemical
were O
associated O
with O
a O
6-month O
( O
P O
< O
0 O

417Background O
Premature O
infants O
are O
highly O
vulnerable O
to O
infection B-Disease

These O
biomarkers O
include O
neuroimaging O
, O
electrophysiology O
, O
peripheral O
serum B-Chemical
, O
and O
plasma B-Chemical
biomarkers O
, O
and O
variations O
in O
genomics O
, O
epigenetics O
, O
proteomics O
, O
and O
metabolomics O

One O
question O
that O
is O
particularly O
intriguing O
ecologists O
is O
to O
what O
extent O
epigenetic O
variation O
is O
an O
additional O
, O
and O
hitherto O
overlooked O
, O
source O
of O
natural O
variation O
in O
ecologically O
important O
traits O

Finally O
we O
demonstrated O
that O
LIPC B-Gene
, O
looped O
to O
metastasis-specific B-Disease
enhancers O
, O
could O
promote O
pancreatic B-Disease
cancer I-Disease
metastasis I-Disease

640 O
 O
Epigenetics O
is O
a O
rapidly O
developing O
science O
that O
has O
gained O
a O
lot O
of O
interest O
in O
recent O
years O
due O
to O
the O
correlation O
between O
characteristic O
epigenetic O
marks O
and O
cardiovascular B-Disease
diseases I-Disease
( O
CVDs B-Disease
) O

1027 O
Acute B-Disease
leukemias I-Disease
are O
hematologic O
malignancies O
with O
aggressive O
behavior O
especially O
in O
adult O
population O

567 O
Modern O
biomedical O
scientists O
are O
often O
trapped O
in O
silos O
of O
knowledge O
and O
practice O
, O
such O
as O
those O
who O
study O
brain O
structure O
, O
function O
and O
behavior O
, O
on O
the O
one O
hand O
, O
and O
body O
systems O
and O
disorders O
, O
on O
the O
other O

Additionally O
, O
we O
discovered O
that O
high O
efficiency O
iPSC B-Species
reprograming O
is O
negatively O
correlated O
with O
donor O
age O
, O
positively O
correlated O
with O
African B-Species
American I-Species
descent O
, O
and O
uncorrelated O
with O
donor O
sex O

DNA O
methylation O
is O
a O
major O
epigenetic O
mechanism O
that O
is O
most O
intensively O
studied O
in O
the O
context O
of O
gene B-Gene
regulation O
and O
unscheduled O
silencing O
in O
cancer B-Disease
cells O

In O
addition O
, O
concrete O
and O
sustainable O
innovation O
in O
cancer B-Disease
treatment O
ought O
to O
integrate O
epigenome B-Gene
targeting I-Gene
drugs O
with O
classic O
therapies O
such O
as O
chemotherapy B-Chemical
and O
immunotherapy B-Chemical

This O
review O
, O
therefore O
, O
aims O
to O
acquaint O
the O
cardiovascular B-Disease
community O
with O
the O
rapidly O
advancing O
and O
evolving O
field O
of O
epigenetics O
and O
its O
implications O
in O
cardiovascular B-Disease
precision O
medicine O

Accumulating O
researches O
have O
revealed O
the O
association O
between O
DCM B-Disease
and O
various O
epigenetic O
regulatory O
mechanisms O
, O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
non-coding O
RNAs B-Gene
, O
and O
other O
epigenetic O
molecules O

549 O
Epigenetics O
acts O
as O
an O
interface O
between O
environmental/exogenous O
factors O
, O
cellular O
responses O
, O
and O
pathological O
processes O

Recently O
, O
RNA B-Chemical
modifications O
(epitranscriptomics) O
have O
been O
shown O
to O
hold O
enormous O
potential O
in O
shaping O
cellular O
transcriptomes O

Reflecting O
these O
age-related O
epigenetic O
changes O
, O
Nfic B-Gene
RNA O
expression O
in O
blood O
decreased O
with O
age O
, O
suggesting O
that O
age-related O
regulation O
of O
this O
gene O
may O
be O
driven O
by O
5hmC B-Chemical
, O
not O
canonical O
DNA B-Chemical
methylation O

645 O
Epigenetic O
modifications O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
post-translational O
chromatin O
modifications O
and O
non-coding O
RNA-mediated O
mechanisms O
are O
responsible O
for O
epigenetic O
inheritance O

transcription O

Troubling O
from O
a O
communications O
perspective O
, O
however O
, O
is O
the O
tendency O
in O
framing O
the O
science O
to O
hold O
mothers O
almost O
uniquely O
culpable O
for O
their O
offspring O
's O
later O
disease B-Disease
risk I-Disease

Further O
research O
on O
the O
(epi)genetic O
and O
molecular O
defects O
in O
spermatogenesis O
and O
sperm O
function O
is O
necessary O
to O
improve O
the O
diagnosis O
and O
to O
develop O
more O
personalized O
treatments O
of O
men O
with O
idiopathic B-Disease
infertility I-Disease

DNA O
methylation O
changes O
are O
observed O
in O
both O
hereditary O
and O
sporadic O
forms O
, O
and O
combining O
DNA B-Chemical
methylation I-Chemical
analysis O
with O
mutational O
screening O
holds O
the O
potential O
for O
better O
diagnostic O
and O
prognostic O
accuracy O

The O
source O
code O
and O
documentation O
are O
freely O
available O
through O
Bioconductor O
 O
http//www O

While O
in O
most O
reports O
genetic O
variation O
has O
been O
found O
to O
occur O
at O
relatively O
modest O
frequencies O
, O
variation O
in O
DNA B-Chemical
methylation I-Chemical
patterns I-Chemical
seems O
to O
be O
much O
more O
frequent O
and O
in O
some O
cases O
it O
has O
been O
directly O
implicated O
in O
phenotypic O
variation O

The O
results O
provided O
a O
potential O
strategy O
of O
ARC O
management O
by O
manipulating O
epigenetic O
changes O

To O
address O
this O
issue O
we O
compared O
five O
analytical O
methods O
 O
( O
i O
) O
MethyLight B-Chemical
qPCR O
, O
( O
ii O
) O
MethyLight B-Chemical
digital B-Chemical
PCR I-Chemical
( O
dPCR B-Chemical
) O
, O
methylation-sensitive B-Chemical
and O
-dependent O
restriction O
enzyme O
( O
MSRE/MDRE B-Chemical
) O
digestion O
followed O
by O

550 O
Postnatal O
environmental O
factors O
, O
such O
as O
early O
life O
adversity O
, O
cannabis B-Chemical
use O
, O
and O
social O
stressors O
are O
associated O
with O
increased O
risk O
for O
psychotic B-Disease
disorders I-Disease

012 O
, O
were O
each O
associated O
with O
shorter O
gestational O
length O

This O
paper O
describes O
a O
method O
to O
reuse O
the O
same O
single O
cell O
for O
iterative O
epigenomic O
analyses O

Analyses O
were O
intent-to-treat O
and O
used O
path O
analysis O

Next O
, O
we O
followed O
up O
the O
prioritised O
genes B-Gene
in O
multilayer O
studies O
of O
genomics O
, O
epigenomics O
, O
and O
transcriptomics O
, O
functional O
enrichment O
, O
and O
their O
potential O
suitability O
as O
drug O
targets O

1456 O
 O
Aims O
 O

This O
review O
discusses O
the O
evidence O
on O
aberrantly O
methylated O
RASSF1A B-Gene
in O
gDNA B-Chemical
and O
cfDNA B-Chemical
from O
different O
cancer B-Disease
types O
and O
its O
utility O
for O
early O
cancer B-Disease
diagnosis O
, O
prognosis O
, O
and O
surveillance O

In O
a O
landmark O
paper O
in O
Nature O
, O
Elaine O
Fuchs O
and O
colleagues O
show O
that O
memory O
of O
inflammation O
is O
not O
restricted O
to O
the O
hematopoietic B-Disease
lineage O
( O
Naik O
et O
al O

750 O
Evolutionary O
change O
is O
a O
product O
of O
selection O

However O
, O
the O
recent O
development O
of O
epigenetic O
editing O
technologies O
now O
enables O
researchers O
to O
move O
beyond O
inferred O
conclusions O
, O
towards O
explicit O
causal O
reasoning O
, O
through O
' O
programing O
' O
precise O
chromatin B-Chemical
perturbations O
in O
single O
cells O

Past O
decades O
have O
made O
tremendous O
progress O
in O
deciphering O
the O
regulatory O
relationships O
involved O
by O
correlating O
aggregated O
(epi)genomics O
profiles O
with O
global O
perturbations O

Although O
extensive O
correlative O
data O
exist O
supporting O
the O
notion O
that O
epigenetic O
mechanisms O
such O
as O
DNA B-Chemical
methylation I-Chemical
underlie O
biological O
embedding O
, O
causal O
data O
are O
lacking O

This O
study O
provides O
an O
elementary O
analysis O
of O
multiple O
regulators O
of O
epigenetics O
and O
their O
roles O
associated O
with O
the O
pathology O
of O
IPF B-Disease

Recent O
advances O
in O
clustered B-Gene
regularly I-Gene
interspaced I-Gene
palindromic I-Gene
repeats I-Gene
(CRISPR) I-Gene
/ I-Gene
Cas-based I-Gene
epigenome O
editing O
technologies O
have O
enabled O
researchers O
to O
site-specifically O
program O
epigenetic O
modifications O
to O
endogenous O
DNA B-Chemical
and O
histones B-Chemical
and O
to O
manipulate O
the O
architecture O
of O
native O


1208 O
Aim O
The O
contribution O
of O
miRNAs B-Gene
as O
epigenetic O
regulators O
of O
sexually O
dimorphic O
gene O
expression O
in O
the O
placenta O
is O
unknown O

However O
, O
the O
effect O
of O
the O
Sandwich O
Model O
in O
learning O
gain O
and O
student O
attitudes O
was O
not O
dependent O
on O
PRS O
incorporation O
per O
se O
and O
students O
seemed O
to O
favour O
non-PRS O
activities O
over O
PRS O
, O
as O
evidenced O
by O
their O
feedback O

Functional O
classifications O
furthermore O
indicated O
that O
several O
major O
signaling O
systems O
such O
as O
the O
Wnt/Î²-catenin B-Gene
pathway I-Gene
were O
affected O
by O
butyrate B-Chemical
treatment O

We O
argue O
that O
, O
since O
Waddington O
, O
epigenetics O
, O
as O
an O
integrative O
research O
area O
, O
has O
been O
used O
to O
bridge O
the O
gap O
between O
different O
biological O
fields O

628 O
Interindividual O
differences O
in O
chromatin O
states O
at O
a O
locus O
( O
epialleles O
) O
can O
result O
in O
gene O
expression O
changes O
that O
are O
sometimes O
transmitted O
across O
generations O

Current O
single-cell O
methods O
that O
produce O
high O
quality O
methylomes O
are O
expensive O
and O
low O
throughput O
without O
the O
aid O
of O
extensive O
automation O

Micronutrients O
such O
as O
betaine B-Chemical
, O
choline B-Chemical
, O
folate B-Chemical
, O
and O
methionine B-Chemical
serve O
as O
cofactors O
or O
methyl O
donors O
for O
one-carbon O
metabolism O
and O
other O
DNA B-Gene
methylation O
reactions O

Comparisons O
between O
species O
revealed O
that O
at O
a O
minimum O
11-37% O
of O
tissue-specific O
DNA B-Gene
methylation I-Gene
patterns O
are O
conserved O
, O
a O
phenomenon O
that O
we O
define O
as O
epigenetic O
conservation O

Custom O
approaches O
were O
used O
for O
the O
integration O
of O
the O
multi-omic O
datasets O

Studies O
have O
linked O
allele-specific O
genetic O
changes O
to O
gene B-Gene
expression O
, O
DNA B-Chemical
methylation O
, O
and O
histone B-Chemical
marks O
but O
these O
investigations O
have O
only O
been O
carried O
out O
in O
a O
limited O
set O
of O
samples O

However O
, O
numerous O
studies O
have O
demonstrated O
that O
lactate B-Chemical
serves O
metabolic O
and O
nonmetabolic O
functions O
in O
physiological O
processes O
and O
multiple O
diseases B-Disease

The O
1,200 O
genes O
that O
differ O
appear O
at O
first O
glance O
insufficient O
to O
describe O
what O
makes O
us O
 B-Species
human O
and O
them O
 B-Species
apes O

We O
review O
studies O
that O
used O
MS-AFLP B-Gene
to O
address O
ecological O
questions O
, O
that O
describe O
which O
taxa O
have O
been O
investigated O
, O
and O
that O
identify O
general O
trends O
in O
the O
field O

methodologies O

Childhood O
trauma O
is O
defined O
in O
a O
wide O
range O
of O
ways O
in O
several O
societal O
contexts O

We O
identified O
a O
'bowing' O
pattern O
specific O
to O
FFPE B-Chemical
samples O
categorized O
by O
a O
lower O
CG B-Gene
proportion O
at O
the O
start O
of O
sequence O
reads O

Specifically O
, O
we O
incorporate O
heat B-Chemical
shock I-Chemical
treatment O
for O
increased O
transfection O
efficiency O
of O
the O
MCF-7 B-Species
cell I-Species
line I-Species

Further O
, O
we O
discuss O
the O
improvement O
in O
the O
development O
of O
natural O
ingredients O
with O
low O
toxicity O
and O
low O
side O
effects O
as O
epi-drugs B-Chemical


1356 O
Epigenetics O
is O
a O
field O
of O
biomedicine O
that O
expanded O
tremendously O
during O
the O
1980s O

com O
/ O
c3g O
/ O
epivar-browser O
; O
bw-merge-window O
tool O
source O
code O
 O
https O
 O
/ O
/ O
github O

, O
neural O
tube O
development O
, O
are O
detected O
by O
our O
model O
, O
demonstrating O
imaging O
epigenetic O
association O
may O
be O
overlooked O
by O
conventional O
SMCCA B-Chemical

Epigenetic O
variance O
, O
and O
specifically O
differential O
DNA B-Chemical
methylation I-Chemical
, O
have O
emerged O
as O
areas O
of O
particularly O
high O
interest O
to O
ASD B-Disease
, O
as O
the O
epigenetic O
markers O
from O
specific O
chromatin O
loci O
collectively O
can O
reflect O
influences O
of O
multiple O
genetic O
and O
environmental O
factors O
and O
can O
also O

We O
also O
review O
innovative O
methods O
and O
technologies O
that O
enable O
the O
characterization O
of O
individual O
epigenetic O
modifications O
and O
more O
widespread O
epigenomic O
states O
at O
high O
resolution O

g O

This O
can O
obviously O
be O
problematic O
if O
methylation O
patterns O
in O
the O
blood B-Chemical
do O
not O
reflect O
that O
in O
the O
relevant O
tissue O

These O
recent O
advances O
allow O
researchers O
to O
obtain O
virtually O
any O
cell O
type O
found O
in O
the O
human B-Species
brain O
, O
making O
it O
possible O
to O
produce O
and O
study O
functional O
neurons O
in O
laboratory O
conditions O
for O
both O
scientific O
and O
medical O
purposes O

This O
study O
highlights O
the O
importance O
of O
epigenomic O
changes O
for O
Tmem O
cell O
biology O
and O
demonstrates O
the O
value O
of O
epigenetic O
data O
for O
the O
identification O
of O
lineage O
regulators O

Indeed O
, O
diseases O
such O
as O
cancer B-Disease
can O
occur O
in O
the O
offspring O
due O
to O
epigenetically-inherited O
gene B-Gene
expression I-Gene
profiles I-Gene
induced O
by O
stress O
experienced O
by O
the O
parent O

353 O
analysis O
has O
become O
an O
integral O
part O
of O
biomedical O
research O

Histone O
modification O
alters O
the O
level O
of O
gene O
expression O
by O
regulating O
the O
acetylation O
status O
of O
lysine B-Chemical
residues O
on O
the O
promoter O
surrounding O
histones O
, O
often O
leading O
to O
the O
silencing O
of O
tumour B-Disease
suppressor I-Disease
genes O
or O
the O
overexpression O
of O
proto-oncogenes O
in O
lymphoma B-Disease

In O
the O
case O
of O
large O
, O
repetitive O
, O
or O
not-yet-sequenced O
genomes O
characterised O
by O
a O
high O
level O
of O
DNA B-Chemical
methylation I-Chemical
, O
the O
NGS O
analysis O
of O
bisulphite B-Chemical
pre-treated I-Chemical
DNA B-Chemical
is O
expensive O
and O
time O
consuming O
, O
and O
moreover O
, O
in O
some O
cases O

In O
addition O
, O
miRNAs B-Gene
can O
themselves O
repress O
key O
enzymes O
that O
drive O
epigenetic O
remodeling O
, O
generating O
regulatory O
circuits O
that O
have O
a O
significant O
effect O
in O
the O
transcriptional O
landscape O
of O
the O
cell O

Epigenetic O
(DNA O
methylation O
) O
datasets O
inherently O
come O
with O
few O
differentially O
DNA B-Chemical
methylated I-Chemical
regions O
(DMR O
) O
and O
with O
a O
higher O
number O
of O
non-DMR O
sites O

Plus O
, O
convolutional O
neural O
networks O
( O
CNN O
) O
provide O
the O
best-in-class O
accuracy O
, O
superior O
to O
the O
vanilla O
variant O

to O

876 O
 O
Manifold O
internal O
and O
external O
factors O
may O
influence O
brain O
function O
in O
the O
long O
run O
, O
including O
genetic O
predispositions O
as O
well O
as O
epigenetic O
and O
environmental O
factors O
[ O

Methods O
 O
To O
identify O
the O
differentially O
methylated O
genes O
, O
genome-wide O
DNA B-Chemical
methylation I-Chemical
microarray O
analysis O
was O
performed O
in O
leukocytes O
of O
obese B-Disease
individuals I-Disease
with O
high O
LDL-cholesterol B-Chemical
( O
LDL-CH O
, O
â¥ O
3 O

25 O
% O
would O
be O
expected O
to O
do O
so O
if O
the O
regression O
process O
was O
really O
able O
to O
identify O
independent O
differential O
gene B-Gene
expression I-Gene
effects O

com O
/ O
JD2112 O
/ O
methylr B-Chemical
; O
Webserver O
 O
https O
 O
/ O
/ O
methylr B-Chemical

In O
this O
review O
, O
I O
discuss O
how O
these O
epigenetic O
modifications O
contribute O
to O
the O
disordered O
energy O
metabolism O
in O
obesity B-Disease
and O
to O
what O
degree O
lifestyle O
and O
weight O
reduction O
strategies O
and O
pharmacological O
drugs O
can O
restore O
energy O
balance O
by O
restoring O
normal O
epigenetic O
profiles O

of O

Understanding O
the O
biology O
of O
RNA B-Gene
modifications O
represents O
one O
of O
the O
next O
frontiers O
in O
molecular O
biology O

The O
GNP B-Chemical
efficiently O
generated O
SERS O
for O
structural O
functional O
molecular O
epigenetics O
and O
nuclear O
proteomics O
in O
preclinical O
models O
of O
breast B-Disease
and O
lung B-Disease
CSCs O

Recent O
data O
based O
on O
profiling O
of O
the O
DNA B-Gene
methylome I-Gene
of O
PCOS B-Disease
in O
different O
tissues O
provided O
consistent O
molecular O
evidence O
in O
support O
of O
epidemiological O
findings O
on O
disease O
comorbidity O
suggesting O
a O
possible O
autoimmune O
basis O
in O
the O
pathogenesis O
of O
the O
disease O

regulations O

No O
reviews O
have O
been O
published O
on O
SE-related B-Gene
mechanisms O
in O
the O
cancer B-Disease
chemoresistance I-Disease

Furthermore O
, O
we O
provide O
a O
brief O
guideline O
for O
base-calling O
and O
data O
analysis O
of O
multiplexed O
RRBS B-Chemical
libraries O

Genome O
and O
epigenome O
editing O
technologies O
can O
be O
applied O
to O
many O
aspects O
of O
aging O
research O
and O
offer O
the O
potential O
to O
develop O
novel O
therapeutics O
against O
age-related B-Disease
diseases I-Disease

821 O
 O
Background O
 O
Epigenetics O
has O
recently O
evolved O
from O
a O
collection O
of O
diverse O
phenomena O
to O
a O
defined O
and O
far-reaching O
field O
of O
study O

Understanding O
how O
, O
or O
if O
, O
DNA B-Gene
methylation I-Gene
in O
blood O
reflect O
DNA B-Gene
methylation I-Gene
patterns O
in O
other O
tissues O
is O
therefore O
of O
utmost O
importance O
if O
we O
are O
to O
make O
inferences O
about O
how O
observed O
differences O
in O
methylation B-Gene
or O
temporal O
changes O
in O
methylation B-Gene
can O
contribute O

The O
approaches O
presented O
here O
constitute O
the O
forefront O
of O
epigenetics O
research O
at O
the O
single-cell O
level O
using O
classic O
and O
innovative O
methods O
to O
dissect O
epigenetics O
mechanisms O
from O
the O
limited O
material O
available O
in O
a O
single O
cell O

Contact O
 O
twang O
@ O
genetics O

More O
recently O
, O
these O
successful O
study O
designs O
have O
been O
applied O
to O
the O
investigation O
of O
intermediate O
traits O
that O
relate O
to O
and O
inform O
our O
understanding O
of O
clinical B-Disease
syndromes I-Disease
and O
to O
exploration O
of O
the O
epigenome O
, O
the O
higher-order O
structure O
of O
DNA B-Gene
that O
dictates O
the O
expression O
of O

In O
addition O
, O
by O
using O
an O
expanded O
dataset O
from O
both O
sample O
types O
, O
we O
confirmed O
our O
previous O
finding O
that O
age O
has O
strong O
, O
non-linear O
negative O
correlation O
with O
epithelial O
cell O
proportion O
in O
both O
sample O
types O

Data O
emerging O
from O
the O
world O
's O
behavioral O
epigenetics O
laboratories O
support O
the O
idea O
that O
a O
person O
's O
genes B-Gene
alone O
cannot O
determine O
if O
, O
for O
example O
, O
he O
or O
she O
will O
end O
up O
shy O
, O
suffering O
from O
cardiovascular B-Disease
disease I-Disease
, O
or O
extremely O
smart O

1144 O
 O
Background O
 O
The O
a-theoretical O
approach O
to O
psychiatric B-Disease
disorders I-Disease
, O
introduced O
via O
dsm B-Chemical
iii I-Chemical
, O
has O
had O
a O
tremendous O
impact O

cs O

Nutrition O
, O
among O
many O
other O
environmental O
factors O
, O
is O
a O
key O
player O
that O
can O
induce O
epigenetic O
changes O
not O
only O
in O
the O
directly O
exposed O
organisms O
but O
also O
in O
subsequent O
generations O
through O
the O
transgenerational O
inheritance O
of O
epigenetic O
traits O

Herein O
, O
the O
authors O
highlight O
genes O
with O
observed O
epigenetic O
modifications O
that O
are O
associated O
with O
more O
aggressive O
 B-Disease
TNBC/QNBC O
pathogenesis O
and O
possible O
interventions O

Chronic O
hyperglycemia B-Disease
induces O
epigenetic O
changes O
in O
multiple O
organs O
, O
contributing O
to O
diabetic B-Disease
complications O

Here O
, O
we O
describe O
our O
methods O
for O
dissecting O
the O
periimplantation O
stage O
embryo O
and O
subsequent O
procedures O
for O
RNA-FISH O
and O
immunostaining O

Alteration O
of O
chromatin O
is O
now O
recognized O
to O
be O
deregulated O
in O
many O
cancers B-Disease

impact O

These O
concepts O
are O
critically O
evaluated O
and O
an O
integrated O
perspective O
is O
provided O
on O
the O
basis O
of O
the O
recent O
application O
of O
nanoscience O
approaches O
to O
nanocarrier O
design O
and O
engineering O

This O
group O
was O
at O
high O
risk O
of O
all-cause O
mortality O
( O
hazard O
ratio O
2 O

Rejuvenation O
by O
reprogramming O
is O
a O
young O
but O
rapidly O
expanding O
subfield O
in O
the O
biology O
of O

Although O
GRN B-Gene
subcircuits O
involved O
in O
ancient O
developmental O
processes O
are O
expected O
to O
be O
at O
least O
partially O
conserved O
, O
identification O
of O
CREs O
that O
are O
conserved O
across O
phyla O
has O
remained O
elusive O

alba B-Species
(at O
the O
time O
of O
study O
), O
and O
to O
identify O
epigenetic O
variations O
related O
to O
stress O
, O
probably O
caused O
by O
different O
and O
changing O
pedoclimatic O
conditions O
, O
to O
which O
the O
poplar B-Species
stands O
have O
been O
exposed O

This O
can O
have O
direct O
consequences O
for O
the O
developing O
fetus O
and O
potentially O
even O
long-term O
health O
implications O

Recent O
discoveries O
of O
5-methylcytosine B-Chemical
( O
5mC B-Chemical
) O
oxidation O
derivatives O
including O
5-hydroxymethylcytosine B-Chemical
( O
5hmC B-Chemical
) O
, O
5-formylcytsine B-Chemical
( O
5fC B-Chemical
) O
, O
and O
5-carboxycytosine B-Chemical
( O
5caC B-Chemical
) O
in O
mammalian B-Species
genome O

O O
ngoing O
efforts O
include O
studies O
of O
paternal O
epigenetic O
inheritance O
in O
the O
ERC-funded O
project O
PATER O


At O
their O
most O
basic O
level O
, O
relational O
and O
systems O
approaches O
analyze O
the O
developmental O
origins O
of O
order O
and O
variability O
not O
in O
terms O
of O
sets O
of O
separable O
causal O
forces O
but O
instead O
in O
analyses O
of O
relations O
between O
causal O
systems O

Sampling O
of O
the O
overproduced O
compounds O
led O
to O
the O
isolation O
of O
ten O
compounds O
of O
which O
four O
contained O
new O
structures O
, O
including O
the O
cyclic O
peptides O
arbumycin B-Chemical
and O
arbumelin B-Chemical
, O
the O
diterpenoid O
arbuscullic B-Chemical
acid I-Chemical
A I-Chemical
, O
and O
the O
meroterpenoid O

We O
also O
found O
a O
substantial O
mediating O
role O
for O
epigenetic O
regulation O
of O
the O
prioritised O
genes B-Gene

Lower O
level O
of O
GSTM3 B-Gene
was O
detected O
in O
HLEB3 B-Species
than O
in O
SRA01/04 B-Species
, O
while O
HLEB3 B-Species
displayed O
hypermethylation O
of O
GSTM3 B-Gene
and O
SRA01/04 B-Species
did O
not O

486 O
Epigenetics O
refers O
to O
a O
heritable O
change O
in O
the O
pattern O
of O
gene B-Gene
expression I-Gene
that O
is O
mediated O
by O
a O
mechanism O
specifically O
not O
due O
to O
alterations O
in O
the O
primary O
nucleotide O
sequence O

This O
review O
questions O
the O
fact O
that O
the O
epigenetic O
context O
in O
which O
a O
genetic O
alteration O
arises O
has O
to O
be O
taken O
into O
account O
as O
a O
key O
determinant O
of O
STS B-Disease
tumor I-Disease
initiation I-Disease
and I-Disease
progression I-Disease

1206 O
 O
This O
special O
issue O
of O
the O
Journal O
of O
Eukaryotic B-Species
Microbiology I-Species
( O
JEM O
) O
summarizes O
achievements O
obtained O
by O
generations O
of O
researchers O
with O
ciliates B-Species
in O
widely O
different O
disciplines O

We O
also O
highlight O
unique O
aspects O
of O
single-cell O
DNA B-Chemical
methylome I-Chemical
data O
analysis O
and O
discuss O
how O
techniques O
common O
to O
other O
single-cell O
omics O
data O
analyses O
can O
be O
adapted O
to O
analyze O
DNA B-Chemical
methylomes I-Chemical

While O
the O
evidence O
supporting O
this O
hypothesis O
is O
limited O
and O
primarily O
based O
on O
the O
epigenetic O
profiling O
of O
psychotic B-Disease
patients O
and O
animal B-Species
models O
, O
further O
investigation O
in O
this O
area O
is O
warranted O
and O
may O
bring O
exciting O
results O

Results O
from O
in O
vitro O
experiments O
showed O
that O
two O
clocks O
( O
Levine B-Gene
and I-Gene
Lin I-Gene
) O
were O
accelerated O
in O
accordance O
with O
two O
hallmarks O
of O
aging-cellular O
senescence B-Disease
and O
mitochondrial B-Disease
dysfunction I-Disease

234 O
Epigenetics O
, O
defined O
as O
inheritable O
and O
reversible O
phenomena O
that O
affect O
gene B-Gene
expression I-Gene
without O
altering O
the O
underlying O
base O
pair O
sequence O
has O
been O
shown O
to O
play O
an O
important O
role O
in O
the O
etiopathogenesis O
of O
obesity B-Disease

However O
, O
genetic O
and O
epigenetic O
risk O
factors O
may O
affect O
different O
populations O
disproportionally O
and O
further O
exacerbate O
health O
disparities O

In O
this O
Review O
, O
we O
discuss O
the O
examples O
of O
MEI B-Gene
in O
mammals B-Species
, O
including O
mammalian B-Species
epigenome O
reprogramming O
, O
and O
the O
molecular O
mechanisms O
of O
MEI B-Gene
in O
vertebrates B-Species
in O
general O

Recent O
studies O
have O
shown O
that O
epigenetic O
mechanisms O
, O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
play O
a O
key O
role O
in O
adapting O
plants B-Species
to O
stress B-Disease
conditions I-Disease

Alterations O
in O
the O
normal O
methylation O
levels O
of O
DNA B-Gene
may O
contribute O
to O
the O
development O
of O
pathological O
conditions O
like O
cancer B-Disease

These O
associations O
remained O
significant O
after O
accounting O
for O
baseline O
DNAm O
score O
, O
child O
demographics O
, O
and O
symptom O
severity O
, O
and O
were O
independent O
of O
predicted O
buccal O
epithelial O
cell O
proportion O
for O
both O
DunedinPACE B-Gene
and O
CRP B-Chemical

Conclusions O
 O
Our O
findings O
reveal O
systematic O
patterns O
in O
slide O
effects O

Since O
then O
, O
the O
number O
of O
studies O
of O
epigenetic O
effects O
of O
chemicals B-Chemical
has O
nearly O
doubled O

Although O
the O
nature O
of O
the O
genetic O
control O
of O
adaptive O
behaviours O
in O
insects B-Species
is O
a O
major O
unresolved O
problem O
it O
is O
now O
understood O
that O
epigenetic O
mechanisms O
, O
bound O
by O
genetic O
constraints O
, O
are O
prime O
drivers O
of O
plasticity O
arising O
from O
both O
developmental O
and O
experience-dependent O
events O

In O
general O
, O
most O
methods O
require O
a O
DNA B-Gene
amplification O
step O
to O
provide O
the O
amounts O
of O
DNA B-Gene
needed O
for O
the O
SNP B-Gene
detection O
step O

1203 O
In O
search O
of O
transmittable O
epigenetic O
marks O
we O
investigated O
gene B-Gene
expression I-Gene
in O
testes O
and O
sperm O
cells O
of O
differentially O
fed O
F0 O
boars O
from O
a O
three O
generation O
pig B-Species
feeding O
experiment O
that O
showed O
phenotypic O
differences O
in O
the O
F2 O
generation O

1384 O
The O
understanding O
of O
the O
relationship O
between O
epigenetic O
alterations O
, O
their O
effects O
on O
gene O
expression O
and O
the O
knowledge O
that O
these O
epigenetic O
alterations O
are O
reversible O
, O
have O
opened O
up O
new O
therapeutic O
pathways O
for O
treating O
various O
diseases O
, O
including O
cancer B-Disease

Our O
method O
classifies O
both O
the O
directionality O
of O
DMRs O
and O
their O
genome-wide O
distribution O
, O
and O
we O
have O
observed O
that O
shows O
clinical O
relevance O
through O
correct O
stratification O
of O
two O
Acute B-Disease
Myeloid I-Disease
Leukemia I-Disease
( O
AML B-Disease
) O
tumor O
sub-types O

Many O
cancers B-Disease
may O
remain O
asymptomatic O
until O
relatively O
late O
stages O
; O
in O
managing O
the O
disease O
, O
efforts O
should O
be O
focused O
on O
early O
detection O
, O
accurate O
prediction O
of O
disease B-Disease
progression O
, O
and O
frequent O
monitoring O

This O
review O
will O
critically O
evaluate O
inherited O
epigenetic O
effects O
from O
an O
evolutionary O
perspective O

1308 O
Recent O
progress O
in O
interpreting O
comprehensive O
genetic O
and O
epigenetic O
profiles O
for O
human B-Species
cellular O
states O
has O
contributed O
new O
insights O
into O
the O
developmental O
origins O
of O
disease B-Disease
, O
elucidated O
novel O
signalling O
pathways O
and O
enhanced O
drug B-Chemical
discovery O
programs O

New O
classes O
of O
epigenetic O
therapies O
promise O
low O
toxicity O
and O
may O
work O
synergistically O
with O
other O
cancer B-Disease
treatments O
to O
overcome O
drug B-Chemical
resistance O
mechanisms O

He O
has O
been O
elected O
as O
a O
member O
of O
the O
American O
Society O
for O
Clinical O
Investigation O
, O
and O
has O
received O
numerous O
awards O
, O
including O
the O
Edmund O
L O
Dubois O
, O
MD O
, O
Memorial O
Lectureship O
Award O
from O
the O
American O
College O
of O
Rheumatology O
in O
recognition O
for O
his O
work O
in O

621 O
The O
development O
of O
new O
blood O
vessels O
from O
pre-existing O
vasculature O
is O
called O
angiogenesis B-Disease

DNA O
methylation O
valleys O
exhibit O
elevated O
conservation O
and O
high O
transcription O
factor O
binding O

1166 O
 O
Introduction O
 O
Fatty B-Disease
liver I-Disease
disease I-Disease
, O
defined O
by O
the O
presence O
of O
liver B-Chemical
fat I-Chemical
infiltration I-Chemical
, O
is O
part O
of O
a O
cluster O
of O
disorders O
that O
occur O
in O
the O
context O
of O
metabolic B-Disease
syndrome I-Disease

Especially O
, O
DNA B-Gene
methylation I-Gene
is O
responsible O
for O
organizing O
the O
genome B-Species
into O
transcriptionally O
silent O
and O
active O
regions O

By O
using O
streptavidin-coated B-Chemical
quantum I-Chemical
dots I-Chemical
(QDs) I-Chemical
as O
nanotethers O
to O
gather O
biotin-labeled B-Chemical
DNA B-Gene
into O
electrophoretic O
nanoassemblies O
, O
the O
QD B-Chemical
surface I-Chemical
charge I-Chemical
is O
modulated O
and O
transformed O
into O
electrophoretic O
mobility O
shifts O
using O
standard O
agarose B-Chemical

For O
EE B-Disease
, O
techniques O
similar O
to O
genome B-Gene
editing I-Gene
( O
GE B-Gene
) O
techniques O
are O
used O

The O
diseases O
induced O
by O
hyperhomocysteinemia B-Disease
(HHcy) I-Disease
are O
called O
homocysteine-related B-Disease
diseases I-Disease

Epigenetic O
therapies O
hold O
promise O
for O
a O
wide O
range O
of O
biological O
applications O
, O
from O
cancer B-Disease
treatment O
to O
the O
establishment O
of O
induced B-Gene
pluripotent I-Gene
stem I-Gene
cells I-Gene

However O
, O
there O
is O
evidence O
that O
in O
the O
uremic B-Disease
milieu O
, O
several O
features O
such O
as O
inflammation B-Disease
, O
dyslipidaemia B-Disease
, O
hyperhomocysteinaema B-Disease
, O
oxidative B-Chemical
stress I-Chemical
as O
well O
as O
vitamin B-Chemical
and O
nutritional O
deficiencies O
may O
affect O
the O
epigenome O
, O
and O
impact O

Hibernator O
pARs O
are O
disproportionately O
located O
near O
human B-Species
obesity B-Disease
susceptibility O
genes B-Gene
compared O
to O
random O
conserved O
regions O
, O
hibernator O
ARs O
that O
are O
not O
parallel O
, O
and O
non-hibernator O
pARs O

Although O
conception O
is O
the O
critical O
moment O
for O
making O
decisions O
regarding O
gene B-Gene
mapping O
and O
fetal B-Disease
health O
, O
studies O
have O
shown O
that O
perinatal O
nursing O
care O
practices O
also O
affect O
the O
genetic B-Gene
remodeling O
processes O
and O
the O
subsequent O
health O
of O
the O
mother O
and O
her O
offspring O

Of O
these O
15,532 O
CpGs O
, O
10,212 O
CpGs O
( O
66 O
% O
) O
were O
replicated O
in O
the O
ALSPAC B-Gene
cohort I-Gene

08 O
to O
0 O

It O
is O
generally O
accepted O
that O
the O
central O
pathogenesis O
of O
psoriasis B-Disease
is O
a O
T B-Gene
cell-dominant I-Gene
immune O
disorder O
affected O
by O
multiple O
factors O
including O
genetic O
susceptibility O
, O
environmental O
factors O
, O
innate O
and O
adaptive O
immune O
responses O
, O
etc O

As O
these O
samples O
contain O
a O
mix O
of O
white B-Species
blood I-Species
cells I-Species
and O
buccal B-Species
epithelial I-Species
cells I-Species
that O
can O
vary O
within O
a O
population O
, O
this O
cellular O
heterogeneity O
may O
confound O
EWAS B-Disease

1198 O
Psoriasis B-Disease
is O
an O
inflammatory O
disease O
of O
the O
skin O
that O
is O
sometimes O
accompanied O
by O
an O
auto-inflammatory O
arthritis O
called O
psoriatic O
arthritis O
( O
PsA B-Disease
) O

Epigenetic O
diversity O
may O
provide O
an O
additional O
layer O
of O
variation O
within O
CWR B-Species
and O
can O
contribute O
novel O
epialleles O
for O
key O
traits O
for O
crop O
improvement O

Instead O
, O
we O
find O
that O
the O
method O
based O
on O
robust O
partial O
correlations O
is O
generally O
more O
robust O
across O
a O
range O
of O
different O
tissue O
types O
and O
for O
realistic O
noise O
levels O

1383 O
A O
recent O
study O
( O
Sulkowski B-Gene
et O
al O

Distinct O
histone B-Chemical
modifications O
are O
linked O
with O
specific O
chromatin B-Chemical
structures O
and O
intranuclear O
positioning O
, O
thereby O
impacting O
and O
, O
which O
in O
turn O
are O
related O
to O
gene B-Gene
expression I-Gene
and O

171 O
Immune O
cells O
are O
capable O
of O
sensing O
various O
signals O
in O
the O
microenvironment O
and O
turning O
on O
specific O
immune O
functions O
in O
response O

1265 O
Purpose O
of O
review O
 O
Global O
epigenetic O
reprogramming O
of O
the O
parental O
genomes O
after O
fertilization O
ensures O
the O
establishment O
of O
genome O
organization O
permissive O
for O
cell O
specialization O
and O
differentiation O
during O
development O

The O
implication O
is O
that O
healthy O
lifestyle O
modifications O
designed O
to O
prevent O
colorectal B-Disease
cancer I-Disease
should O
be O
adopted O
early O
in O
life O

1311 O
Myeloid B-Disease
malignancy I-Disease
is O
a O
broad O
term O
encapsulating O
myeloproliferative B-Disease
neoplasms I-Disease
( O
MPN B-Disease
) O
, O
myelodysplastic B-Disease
syndrome I-Disease
( O
MDS B-Disease
) O
and O
acute B-Disease
myeloid I-Disease
leukaemia I-Disease
( O
AML B-Disease
) O


We O
found O
a O
few O
loci O
where O
both O
the O
transcriptional O
changes O
and O
epigenetic O
changes O
occurred O
in O
the O
pathways O
involving O
immune O
and O
inflammatory O
signalling O

495 O
In O
mice B-Species
, O
epiblast O
cells O
found O
both O
the O
germ-line O
and O
somatic O
lineages O
in O
the O
developing O
embryo O

Despite O
several O
new O
disease-associated O
factors O
have O
been O
discovered O
based O
on O
single O
omics O
data O
analysis O
, O
identification O
of O
disease B-Disease
targets O
by O
integrative O
analysis O
of O
multi-omics O
data O
is O
still O
growing O

1070Motivation O
Next-generation O
sequencing O
methods O
continue O
improving O
the O
annotation O
of O
genomes O
in O
part O
by O
determining O
the O
distribution O
of O
features O
such O
as O
epigenetic O
marks O

We O
then O
discuss O
investigations O
that O
have O
implemented O
epigenome-wide O
approaches O
aimed O
at O
genome-wide O
profiling O
and O
discovery O

PRISM O
adopts O
DNA B-Gene
methyltransferase I-Gene
1-like I-Gene
hidden O
Markov O
model-based O
in O
silico O
proofreading O
for O
the O
correction O
of O
erroneous O
methylation O
patterns O

Methods O
 O
To O
advance O
the O
practical O
applicability O
of O
the O
smoking-associated O
methylation O
signals O
, O
we O
used O
machine O
learning O
methodology O
to O
train O
a O
classifier O
for O
smoking O
status O
prediction O

Epigenetic O
modifications O
encompass O
processes O
including O
DNA B-Chemical
methylation I-Chemical
, O
covalent O
histone B-Chemical
modifications I-Chemical
, O
and O
RNA-mediated B-Chemical
regulation O

Cannabidomics O
studies O
show O
wide O
variability O
of O
metabolites O
across O
different O
strains O
and O
varieties O
, O
which O
determine O
their O
medicinal O
and O
abusive O
usage O
, O
which O
is O
very O
important O
for O
its O
quality O
control O
and O
regulation O

These O
social O
differences O
become O
embodied O
as O
physiological O
and O
health O
differences O

Quantifying O
Waddington B-Gene
's I-Gene
epigenetic O
landscape O
by O
mathematical O
modeling O
would O
be O
useful O
for O
understanding O
the O
mechanisms O
of O
cell O
fate O
determination O

We O
investigated O
how O
sex O
differences O
influenced O
the O
relationship O
between O
age O
and O
chronological O
age O
using O
sex-specific O
epigenetic O
clocks O

Further O
, O
this O
review O
also O
includes O
epigenetic O
drugs B-Chemical
under O
development O
in O
preclinical O
and O
clinical O
stages O

Epigenetic O
inactivation O
of O
RASSF1A B-Gene
was O
detected O
in O
various O
cancer B-Disease
types O
and O
led O
to O
significant O
interest O
; O
current O
research O
on O
RASSF1A B-Gene
promoter O
methylation O
focuses O
on O
its O
roles O
as O
an O
epigenetic O
tumor O
biomarker O

1299 O
It O
is O
becoming O
increasingly O
evident O
that O
epigenetic O
mechanisms O
that O
act O
on O
and O
regulate O
chromatin O
structure O
play O
a O
key O
role O
in O
the O
development O
, O
adaptation O
, O
and O
survival O
of O
the O
malaria B-Disease
parasite I-Disease
within O
its O
human B-Species
host I-Species

While O
DNA B-Gene
is O
the O
same O
in O
all O
the O
parts O
of O
the O
plant O
, O
the O
epigenetic O
state O
can O
vary O
according O
to O
the O
organ O
and/or O
tissue O
of O
origin O
, O
making O
it O
possible O
to O
discriminate O
the O
stigmas O
from O
the O
other O
parts O
of O
saffron B-Species
flower I-Species

Likewise O
, O
JMJD1B B-Gene
appears O
to O
be O
a O
tumor O
suppressor O
in O
acute B-Disease
myeloid I-Disease
leukemia I-Disease
, O
but O
a O
tumor O
promoter O
in O
other O
cancers O

This O
may O
be O
a O
way O
of O
understanding O
the O
successes O
to O
date O
of O
plasma-based B-Chemical
rejuvenation O

The O
ultimate O
aim O
of O
genomic O
studies O
in O
any O
human B-Species
disease B-Disease
is O
to O
understand O
its O
pathogenesis O
, O
thereby O
enabling O
the O
prediction O
of O
the O
evolution O
of O
the O
disease B-Disease
to O
establish O
new O
treatments O
and O
address O
the O
development O
of O
personalized O
therapies O

to O

Findings O
support O
significant O
associations O
between O
attachment-related O
dimensions O
and O
epigenetic O
status O
in O
studies O
which O
considered O
different O
populations O
, O
age O
ranges O
, O
attachment O
measures O
and O
peripheral O
tissues O

Ectopic O
endometriotic B-Disease
tissue O
exhibits O
decelerated O
DNAm B-Gene
age O
, O
similar O
to O
that O
observed O
in O
teratomas B-Disease
composed O
of O
multipotent O
tissue O
, O
but O
distinct O
from O
eutopic O
tissue O

To O
address O
this O
critical O
issue O
, O
we O
developed O
a O
novel O
framework O
for O
identifying O
methylation O
signatures O
using O
consecutive O
adaptation O
of O
a O
well-known O
outlier O
detection O
algorithm O
, O
density O
based O
clustering O
of O
applications O
with O
reducing O
noise O
( O
DBSCAN B-Chemical
) O
followed O
by O
hierarchical O
clustering O

Accurate O
measurements O
of O
normal O
and O
altered O
DNA B-Gene
methylation I-Gene
patterns O
are O
important O
to O
understand O
its O
role O
in O
regulating O
gene B-Gene
expression I-Gene
and O
cell O
phenotype O

Chance O
events O
- O
such O
as O
a O
particular O
lifelong O
smoker O
living O
unharmed O
to O
100 O
years O
- O
are O
averaged O
out O
at O
the O
group O
level O

525 O
Motivation O
Epigenetic O
clocks O
are O
prediction O
methods O
based O
on O
DNA B-Chemical
methylation I-Chemical
levels O
in O
a O
given O
species O
or O
set O
of O
species O

Although O
these O
factors O
were O
originally O
thought O
to O
act O
in O
a O
long O
time O
domain O
only O
, O
it O
is O
now O
clear O
that O
they O
can O
also O
be O
highly O
dynamic O
, O
changing O
over O
minutes O

We O
briefly O
review O
the O
current O
understanding O
of O
genetic O
and O
epigenetic O
causes O
of O
male O
infertility B-Disease
and O
how O
findings O
may O
be O
translated O
into O
a O
practical O
component O
for O
the O
diagnosis O
and O
treatment O
of O
male O
infertility B-Disease

Interestingly O
, O
they O
also O
show O
the O
highest O
similarity O
in O
expression O
patterns O
and O
upstream O
regulatory O
regions O
, O
while O
paralogous O
pairs O
where O
only O
one O
gene O
is O
an O
H3K27me3 B-Chemical
target O
show O
the O
highest O
divergence O
in O
expression O
patterns O
and O
upstream O
regulatory O
sequence O

We O
quantified O
DNA B-Chemical
methylation O
in O
matched O
DNA B-Chemical
samples O
isolated O
from O
whole O
blood O
and O
4 O
brain O
regions O
(prefrontal O
cortex O
, O
entorhinal O
cortex O
, O
superior O
temporal O
gyrus O
, O
and O
cerebellum O
) O
from O
122 O
individuals O

1146 O
Epigenetic O
changes O
are O
one O
underlying O
cause O
for O
cancer B-Disease
development O
and O
often O
due O
to O
dysregulation O
of O
enzymes O
modifying O
DNA B-Chemical
or O
histones B-Chemical

In O
this O
chapter O
, O
we O
mainly O
focus O
on O
how O
various O
epigenetic O
modifications O
play O
a O
key O
role O
in O
neurodegenerative B-Disease
diseases I-Disease
, O
their O
mechanism O
of O
action O
, O
and O
how O
it O
acts O
as O
a O
potential O
therapeutic O
target O
for O
epigenetic B-Chemical
drugs I-Chemical
to O
treat O
these O

In O
this O
article O
, O
we O
discuss O
the O
underlying O
concepts O
of O
epigenetics B-Disease
and O
address O
its O
current O
and O
potential O
applicability O
for O
primary O
care O
providers O

Such O
transcriptional O
programs O
are O
mediated O
by O
heritable O
regulation O
of O
the O
function O
of O
enhancers O
and O
promoters O


Second O
, O
I O
show O
that O
Waddington B-Gene
's I-Gene
own O
view O
of O
epigenetics B-Gene
has O
changed O
over O
time O
and O
I O
analyze O
how O
these O
changes O
appear O
through O
his O
many O
representations O
( O
both O
schematic O
or O
metaphorical O
images O
) O
of O
the O
relationships O
between O
genetic B-Gene
signals I-Gene
and O
developmental O
processes O

Cord O
blood B-Chemical
(CB) O
DNA B-Chemical
methylation O
provides O
a O
unique O
window O
into O
the O
fetal O
epigenome O
, O
reflecting O
the O
intrauterine O
environment O
's O
impact O

Considerable O
epidemiological O
, O
experimental O
and O
clinical O
data O
have O
been O
amassed O
showing O
that O
the O
risk O
of O
developing O
disease O
in O
later O
life O
is O
dependent O
on O
early O
life O
conditions O
, O
mainly O
operating O
within O
the O
normative O
range O
of O
developmental O
exposures O

However O
, O
the O
original O
family O
longevity O
selection O
score O
( O
FLoSS B-Gene
) O
focuses O
on O
populations O
of O
elderly O
only O

Conclusion O
 O
These O
results O
point O
toward O
a O
crucial O
role O
of O
criticality O
to O
enhance O
the O
system O
responsivity O
, O
resulting O
in O
both O
energy O
transitions O
and O
structural O
rearrangements O

In O
this O
study O
, O
we O
employed O
multiple O
integrated O
bioinformatic O
approaches O
to O
identify O
the O
probable O
epigenetic O
factors O
, O
molecular O
pathways O
, O
and O
functionalities O
associated O
with O
mda-9 B-Gene
dysregulation O
during O
cancer B-Disease
progression O

An O
ability O
to O
access O
and O
utilize O
these O
information O
sources O
will O
become O
essential O
to O
informing O
the O
future O
design O
of O
experiments O
and O
subsequent O
determination O
of O
the O
role O
of O
epigenetics B-Gene
in O
health O
and O
disease B-Disease
and O
will O
form O
a O
critical O
step O
in O
our O
development O
of O
personalized O
medicine O

Environmental O
factors O
may O
change O
the O
expression O
of O
genes O
through O
epigenetic O
mechanisms O
, O
thus O
inducing O
individuals O
with O
susceptible O
genes O
to O
develop O
T1D B-Disease
; O
however O
, O
the O
underlying O
mechanisms O
remain O
poorly O
understood O

com O
/ O
en O
/ O
epiannotator O

Then O
, O
we O
discuss O
recent O
advances O
in O
the O
identification O
of O
novel O
epigenetic O
biomarkers O

This O
approach O
is O
likely O
to O
reap O
rewards O
in O
terms O
of O
understanding O
the O
pathophysiology O
of O
DS B-Disease
, O
especially O
when O
combined O
with O
animal O
models O
, O
but O
significant O
technical O
and O
ethical O
challenges O
must O
be O
overcome O
for O
clinical O
translation O

719 O
Epigenetic O
and O
genetic O
alterations O
contribute O
to O
cancer B-Disease
initiation O
and O
progression O

preferred O

While O
a O
non-retrograde O
menstruation O
origin O
of O
ectopic O
tissue O
is O
certain O
in O
these O
cases O
, O
we O
explored O
the O
use O
of O
DNA B-Gene
methylation I-Gene
age O
( O
DNAm B-Gene
age I-Gene
) O
to O
distinguish O
between O
retrograde O
and O
non-retrograde O
tissue O
origin O
in O
endometriosis B-Disease

Knowledge O
of O
these O
factors O
is O
of O
great O
relevance O
for O
the O
interpretation O
of O
DNA-methylation B-Gene
data O
for O
the O
estimation O
of O
chronological O
age O
in O
forensic O
casework O

Computational O
tools O
have O
been O
developed O
apace O
with O
these O
epigenome O
methods O
to O
better O
enable O
accurate O
interpretation O
of O
the O
profiling O
data O

of O

However O
, O
the O
premature O
rush O
to O
take O
murine B-Species
epigenetic O
findings O
in O
these O
directions O
makes O
impossible O
demands O
on O
prospective O
parents O
and O
triggers O
serious O
social O
and O
ethical O
questions O

The O
intent O
of O
this O
review O
is O
to O
elaborate O
upon O
well-supported O
examples O
of O
epigenetic O
precision O
medicine O
and O
how O
the O
field O
is O
moving O
forward O
, O
primarily O
in O
the O
context O
of O
aberrant O
DNA B-Gene
methylation I-Gene

Epigenetic O
processes O
, O
such O
as O
DNA B-Gene
methylation O
and O
histone B-Gene
posttranslational I-Gene
modifications O
, O
instruct O
the O
cell/tissue O
to O
correctly O
interpret O
external O
signals O
and O
adjust O
its O
functions O
accordingly O

Head O
and O
neck O
cancers O
are O
a O
group O
of O
malignancies O
with O
diverse O
biological O
behaviors O
and O
a O
strong O
, O
well-established O
association O
with O
environmental O
effects O

It O
has O
been O
hypothesized O
that O
epigenetic O
switches O
first O
evolved O
as O
a O
mechanism O
of O
bet-hedging O
and O
adaptation O
, O
but O
the O
evolutionary O
trajectories O
and O
conditions O
by O
which O
an O
epigenetic O
switch O
can O
outcompete O
adaptation O
through O
genetic O
mutation O
remain O
unknown O

Little O
is O
known O
about O
whether O
easily O
accessible O
tissues O
, O
such O
as O
whole O
blood O
, O
can O
be O
used O
to O
address O
questions O
about O
interindividual O
epigenomic O
variation O
in O
inaccessible O
tissues O
, O
such O
as O
the O
brain O

Epigenetic O
heritability O
was O
0 O

However O
, O
in O
the O
past O
, O
insufficient O
differentiation O
between O
cellular O
and O
cell-free O
DNA B-Gene
may O
have O
confounded O
analyses O
of O
genome-wide O
methylation O
levels O
in O
aging O
cells O

Overall O
, O
we O
suggest O
that O
epigenetics O
could O
provide O
new O
insights O
into O
a O
more O
comprehensive O
interpretation O
of O
mental B-Disease
illness I-Disease
and O
might O
eventually O
improve O
the O
nosology O
, O
treatment O
, O
and O
prevention O
of O
psychiatric B-Disease
disorders I-Disease

Objectives O
 O
To O
analyze O
how O
worldwide O
changes O
in O
movements O
of O
goods O
, O
persons O
and O
lifestyles O
( O
globalization O
) O
may O
affect O
the O
" O
epigenetic O
landscape O
" O
of O
populations O
and O
through O
this O
have O
an O
impact O
on O
NCDs B-Disease


We O
discuss O
clinical O
trials O
and O
promising O
preclinical O
data O
of O
potential O
future O
targets O

There O
is O
, O
however O
, O
a O
third O
, O
and O
separate O
, O
school O
based O
on O
the O
historical O
literature O
and O
debates O
and O
regards O
epigenetics B-Chemical
as O
more O
of O
a O
perspective O
than O
a O
phenomenon O

In O
crop O
breeding O
, O
the O
decrease O
in O
genetic O
diversity O
due O
to O
artificial O
selection O
of O
conventional O
breeding O
methods O
has O
been O
a O
long-standing O
concern O

784Purpose O
To O
assess O
the O
genetic O
and O
epigenetic O
status O
of O
parthenogenetic O
human B-Species
embryonic I-Species
stem I-Species
cells I-Species
(phESCs) I-Species

Gene O
- O
based O
studies O
have O
focused O
on O
finding O
the O
genes B-Gene
that O
cause O
microtia B-Disease
and O
on O
gene B-Gene
function O
defects O

We O
review O
epigenetic O
changes O
in O
acute B-Disease
leukemia I-Disease
in O
relation O
to O
what O
is O
known O
about O
their O
mechanism O
of O
action O
, O
their O
prognostic O
role O
and O
their O
potential O
use O
as O
therapeutic O
targets O
, O
with O
important O
implications O
for O
precision O
medicine O

Nevertheless O
, O
DNA B-Gene
methylation I-Gene
in O
prokaryotes B-Species
plays O
a O
pivotal O
role O
in O
many O
cellular O
processes O
such O
as O
defense O
systems O
against O
exogenous O
DNA B-Gene
, O
cell O
cycle O
dynamics O
, O
and O
gene B-Gene
expression I-Gene
, O
including O
virulence B-Disease

In O
separate O
covariate-adjusted O
linear O
regression O
models O
, O
higher O
early O
second O
trimester O
GrimAgeAccel O
, O
b(SE) O
= O
- O

The O
opposition O
to O
all O
forms O
of O
non-genetic O
inheritance O
that O
prevailed O
at O
the O
time O
of O
the O
rise O
of O
the O
Modern O
Synthesis O
helps O
to O
explain O
why O
the O
Baldwin O
effect O
was O
understood O
as O
an O
insignificant O
mechanism O
during O
the O
second O
half O
of O
the O
twentieth O
century O

In O
this O
chapter O
, O
an O
iterative O
VS O
approach O
using O
both O
SBDD O
and O
LBDD O
methods O
, O
which O
was O
successful O
in O
identifying O
Spindlin1 B-Gene
inhibitors O
, O
will O
be O
described O

However O
, O
identifying O
mediator O
and O
moderator O
effects O
in O
the O
interrelationship O
between O
these O
parameters O
was O
problematic O
owing O
to O
heterogeneous O
methodologies O

Although O
researchers O
have O
focused O
on O
genetic O
or O
environmental O
contributions O
to O
the O
disease O
, O
we O
still O
lack O
a O
scientific O
framework O
that O
joins O
molecular O
and O
clinical O
findings O

S O

From O
a O
methodological O
point O
of O
view O
, O
we O
suggest O
that O
Darwin O
's O
plastic O
approach O
to O
habits O
, O
from O
his O
early O
writings O
up O
to O
the O
mature O
works O
, O
can O
provide O
today O
's O
evolutionary O
scientists O
with O
a O
viable O
methodological O
model O
to O
address O
the O
challenging O
task O
of O
extending O

characterized O

Availability O
and O
implementation O
 O
Online O
portal O
 O
https//computationalgenomics O

Ultimately O
, O
it O
is O
this O
proper O
annotation O
that O
determines O
the O
quality O
of O
expression O
patterns O
required O
to O
ensure O
and O
shape O
the O
phenotypic O
integrity O
and O
function O
of O
a O
highly O
specialized O
cell O
type O

Despite O
the O
great O
diagnostic O
advances O
made O
in O
the O
past O
decade O
, O
the O
use O
of O
traditional O
diagnostic O
procedures O
only O
enables O
the O
tissue O
of O
origin O
to O
be O
determined O
in O
â¼30% O
of O
patients O
with O
CUP B-Disease

Our O
findings O
provide O
a O
first O
attempt O
at O
identifying O
the O
missing O
links O
between O
ML B-Gene
and O
RC B-Gene
liposarcomas B-Disease
, O
that O
may O
also O
have O
broader O
applications O
in O
other O
clinico-pathological O
settings O
characterised O
by O
a O
spectrum O
of O
progression O

Accumulating O
evidence O
indicates O
that O
patient-specific O
clonal O
composition O
impinges O
significantly O
on O
cellular O
processes O
, O
such O
as O
gene B-Gene
regulation I-Gene
and O
metabolism O

( O
Brassicaceae B-Species
) O
under O
the O
influence O
of O
heat B-Disease
stress I-Disease

Conclusions O
 O
The O
results O
of O
the O
analysis O
provide O
guidelines O
for O
the O
most O
suitable O
imputation O
approaches O
for O
DNA B-Gene
methylation I-Gene
data O
under O
different O
representations O
of O
DNA B-Gene
methylation I-Gene
levels O
and O
different O
missing O
data O
mechanisms O

The O
activities O
of O
the O
nuclear O
enzymes O
, O
histone B-Gene
deacetylases I-Gene
, O
are O
increasingly O
being O
recognized O
as O
potential O
targets O
for O
pharmacologically O
inducing O
stem O
cell O
differentiation O
and O
dedifferentiation O

Thus O
, O
innovative O
treatments O
are O
required O
to O
extend O
the O
asymptomatic O
phase O
of O
MRD B-Disease
after O
the O
initial O
therapeutic O
intervention O

This O
new O
approach O
first O
uses O
a O
hidden O
Markov O
model O
( O
HMM O
) O
to O
identify O
DM O
CG O
sites O
accounting O
for O
spatial O
correlation O
across O
CG O
sites O
and O
variation O
across O
samples O
, O
and O
then O
summarizes O
identified O
sites O
into O
regions O

196 O
Inferring O
the O
chronological O
and O
biological O
age O
of O
individuals O
is O
fundamental O
to O
population O
ecology O
and O
our O
understanding O
of O
ageing O
itself O
, O
its O
evolution O
, O
and O
the O
biological O
processes O
that O
affect O
or O
even O
cause O
ageing O

Understanding O
methamphetamine B-Chemical
toxicity O
is O
key O
beyond O
the O
field O
of O
drug O
abuse O
since O
it O
allows O
getting O
an O
insight O
into O
the O
molecular O
mechanisms O
which O
operate O
in O
a O
variety O
of O
neuropsychiatric B-Disease
disorders I-Disease

Next-generation O
sequencing O
techniques O
have O
provided O
us O
an O
exciting O
toolkit O
of O
genome-wide O
assays O
that O
can O
be O
used O
to O
predict O
and O
annotate O
enhancers O

In O
addition O
to O
genetic O
regulation O
of O
these O
processes O
, O
compelling O
evidence O
suggests O
that O
environmental O
conditions O
produce O
persistent O
changes O
in O
development O
through O
epigenetic O
mechanisms O

Design O
 O

However O
, O
we O
currently O
lack O
an O
understanding O
of O
how O
common O
various O
epigenetic O
inheritance O
types O
are O
, O
and O
how O
they O
impact O
phenotypes O

Genes B-Gene
associated O
with O
poor B-Disease
prognosis I-Disease
were O
individually O
queried O

Although O
it O
is O
widely O
appreciated O
that O
transcription O
factors O
and O
developmental O
signaling O
pathways O
play O
a O
crucial O
role O
in O
cell O
fate O
specification O
at O
the O
onset O
of O
development O
, O
it O
is O
increasingly O
clear O
that O
their O
function O
is O
tightly O
connected O
to O
the O
underlying O
epigenetic O
status O
of O
the O

COSMIC O
, O
CCLE O
and O
1000-genome O
project O

We O
propose O
that O
estimates O
obtained O
from O
GWAS B-Gene
underestimate O
heritability O
by O
not O
taking O
into O
account O
non-DNA O
(epigenetic) O
sources O
of O
heritability O

We O
use O
the O
game O
to O
explore O
issues O
in O
symbiopoiesis O
and O
evo-devo O
, O
where O
we O
explore O
a O
fractal O
hypothesis O
 O
that O
self-similarity O
exists O
at O
different O
levels O
( O
cells O
, O
organisms O
, O
ecological O
communities O
) O
as O
a O
result O
of O
homologous O
interactions O
of O
two O
as O
processes O

In O
particular O
, O
research O
has O
focused O
on O
imprinted O
genes B-Gene
influencing O
foetal O
growth O
and O
development O
, O
which O
are O
associated O
with O
economically O
important O
production O
traits O
in O
cattle B-Species
, O
sheep B-Species
and O
pigs B-Species

O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O
O O

These O
systems O
allow O
precise O
modulation O
of O
gene B-Gene
expression I-Gene
over O
time O
and O
offer O
a O
means O
to O
deactivate O
epi-editors O
, O
thereby O
reducing O
off-target O
effects O
associated O
with O
prolonged O
expression O

The O
way O
the O
DNA B-Gene
code O
is O
translated O
into O
function O
depends O
not O
only O
on O
its O
sequence O
but O
also O
on O
the O
interaction O
with O
environmental O
factors O

However O
, O
generating O
these O
predictors O
from O
original O
source O
software O
and O
web O
servers O
is O
complex O
and O
time O
consuming O

There O
were O
2,637 O
CpG B-Gene
sites I-Gene
differentially O
methylated O
( O
P O
< O
0 O

1271 O
As O
an O
important O
content O
of O
alternative O
and O
complementary O
medicine O
, O
acupuncture O
therapy O
has O
been O
proved O
to O
be O
effective O
in O
relieving O
myocardial B-Disease
ischemia I-Disease
( O
MI B-Disease
) O

Diabetes B-Disease
could O
lead O
to O
multiple O
complications O
including O
retinopathy B-Disease
, O
nephropathy B-Disease
, O
and O
cardiovascular B-Disease
disease I-Disease
that O
greatly O
increase O
morbidity O
and O
mortality O

Thus O
the O
need O
for O
biomarkers O
in O
RCC B-Disease
is O
urgent O

Most O
importantly O
, O
the O
epigenetic O
footprint O
of O
immune-related O
pathways O
is O
associated O
with O
the O
patient O
outcome O
, O
underscoring O
the O
crucial O
need O
to O
understand O
this O
process O

Such O
epigenetic O
modifications O
therefore O
provide O
a O
rapid O
and O
global O
approach O
to O
mine O
the O
chemical B-Chemical
diversity O
of O
endophytic B-Species
fungi I-Species

Existing O
methods O
, O
such O
as O
BATMAN B-Gene
and O
MEDIPS B-Gene
, O
analyze O
MeDIP-seq B-Chemical
data O
by O
dividing O
the O
whole O
genome O
into O
equal O
length O
windows O
and O
assume O
that O
each O
CpG B-Gene
of O
the O
same O
window O
has O
the O
same O
methylation B-Chemical
level O

While O
the O
number O
of O
reported O
epigenetic O
inheritance O
phenomena O
across O
phyla O
is O
exponentially O
growing O
, O
much O
remains O
to O
be O
elucidated O
about O
their O
mechanistic O
underpinnings O
, O
and O
their O
significance O
for O
organismal O
homeostasis O
and O
adaptation O

Similarly O
, O
no O
definitive O
, O
validated O
criteria O
exist O
for O
predicting O
which O
dysplastic O
lesions O
are O
most O
likely O
to O
progress O
to O
cancer B-Disease
over O
time O

05 O
) O
between O
maternal O
infection O
or O
sex O
groups O

1248Background O
Non-communicable B-Disease
diseases I-Disease
( O
NCDs B-Disease
) O
are O
increasing O
worldwide O

In O
this O
Review O
, O
we O
present O
the O
latest O
data O
on O
strategies O
using O
epigenetics O
and O
other O
molecular O
biomarkers O
to O
guide O
therapeutic O
decisions O
involving O
patients O
with O
CUP B-Disease
, O
and O
we O
highlight O
areas O
warranting O
further O
research O
to O
engage O
the O
medical O
community O
in O
this O
unmet O
need O

As O
proof O
of O
functional O
conservation O
, O
mammalian B-Species
epigenetic O
drugs B-Chemical
demonstrably O
interfered O
with O
stress-induced B-Disease
gene B-Gene
silencing O

In O
addition O
, O
they O
have O
the O
ability O
to O
potentially O
expand O
the O
range O
of O
screening O
conditions O
from O
often O
limited O
amounts O
of O
valuable O
sample O
, O
as O
well O
as O
reduce O
the O
usage O
of O
expensive O
reagents B-Chemical

Although O
much O
work O
has O
been O
done O
, O
much O
is O
still O
unknown O

) O
sheds O
light O
on O
the O
characterization O
of O
this O
phenomenon O
in O
a O
complex O
biological O
scenario O

Different O
epigenetic O
modifications O
, O
such O
as O
mutations O
in O
DNA B-Gene
methyltransferase I-Gene
and O
somatic O
mutations O
in O
core B-Gene
histone I-Gene
genes O
that O
lead O
to O
a O
global O
loss O
of O
the O
histone B-Chemical
modifications I-Chemical
, O
have O
innumerable O
relationships O

effects O

This O
chain O
of O
consequences O
has O
motivated O
attempts O
to O
computationally O
model O
the O
influence O
of O
and O
in O
and O
investigate O
their O
intrinsic O
interdependency O

Most O
DMCs O
clustered O
in O
CpG O
stretches O
nearby O
genes O
involved O
in O
cellular O
and O
anatomical O
structure O
morphogenesis O

Emerging O
evidence O
is O
consistent O
with O
the O
idea O
that O
epigenetic O
processes O
are O
involved O
in O
embedding O
the O
impact O
of O
early-life O
experience O
in O
the O
genome B-Gene
and O
mediating O
between O
social O
environments O
and O
later O
behavioral O
phenotypes O

This O
review O
proposes O
that O
epigenomic O
processes O
are O
involved O
in O
shaping O
patterns O
of O
adaptation O
to O
high O
altitude O
by O
influencing O
adaptive O
potential O
and O
phenotypic O
variability O
under O
conditions O
of O
limited O
oxygen B-Chemical
supply O

This O
increased O
epigenetic O
stochasticity O
appears O
to O
be O
mediated O
by O
large-scale O
changes O
in O
DNA B-Chemical
methylation I-Chemical
and O
chromatin O
in O
domains O
associated O
with O
the O
nuclear O
lamina O

To O
provide O
a O
primer O
on O
epigenomic O
research O
for O
fish B-Species
biologists O
, O
we O
start O
by O
describing O
fundamental O
aspects O
of O
epigenetics O
, O
focusing O
on O
the O
most O
widely O
studied O
and O
most O
well O
understood O
of O
the O
epigenetic O
marks O
 O
DNA B-Chemical
methylation I-Chemical

We O
finally O
look O
forward O
to O
the O
application O
of O
single-cell O
multi-omics O
and O
perturbation O
techniques O
that O
will O
likely O
play O
important O
roles O
for O
GRN B-Gene
inference O
in O
the O
future O

Well O
thought O
out O
experimental O
designs O
that O
include O
complementary O
gene B-Gene
expression I-Gene
studies O
, O
and O
the O
improvement O
of O
genomics O
resources O
for O
the O
target O
group O
, O
promise O
to O
maximize O
the O
effect O
of O
future O
RRBS B-Gene
studies O

Key O
knowledge O
gaps O
are O
concerned O
with O
the O
causality O
of O
the O
relation O
between O
epigenetic O
and O
phenotypic O
changes O
, O
the O
persistence O
of O
transgenerational O
effects O
, O
the O
implications O
at O
population O
level O
and O
the O
costs O
of O
tolerance O

We O
present O
emerging O
information O
on O
the O
epigenetic O
control O
of O
the O
polarity O
axis O
, O
a O
central O
feature O
of O
epithelial O
architecture O
created O
by O
the O
orderly O
distribution O
of O
multiprotein O
complexes O
at O
cell-cell O
and O
cell-extracellular O
matrix O
contacts O
and O
altered O
upon O
cancer B-Disease
onset I-Disease
( O
with O
apical O
polarity O

649 O
( O
) O
is O
an O
essential O
epigenetic O
mark O
associated O
with O
transcriptional O
silencing O

This O
information O
is O
obtained O
from O
public O
resources O
viz O

752 O
Metabolites B-Chemical
control O
epigenetic O
mechanisms O
, O
and O
conversly O
, O
cell O
metabolism O
is O
regulated O
at O
the O
epigenetic O
level O
in O
response O
to O
changes O
in O
the O
cellular O
environment O

We O
present O
the O
first O
EPIC-based O
predictor O
of O
gestational O
age O
and O
demonstrate O
its O
robustness O
and O
precision O
in O
ART B-Disease
and O
non-ART B-Disease
newborns O

Despite O
milestones O
in O
understanding O
the O
specific O
genetic O
causes O
of O
the O
syndrome B-Disease
, O
the O
major O
symptoms O
of O
DS B-Disease
- O
not O
least O
those O
related O
to O
neurocognitive O
function O
- O
are O
incurable O

Conclusions O
 O
p6mA B-Chemical
can O
predict O
the O
methylation O
status O
of O
DNA B-Chemical
adenines O
, O
using O
only O
sequence O
files O

Additional O
advantages O
of O
this O
method O
over O
other O
methods O
for O
DNA B-Gene
methylation I-Gene
analysis O
are O
that O
it O
requires O
very O
less O
amount O
of O
DNA B-Gene
and O
can O
screen O
DNA B-Gene
methylation I-Gene
changes O
globally O
at O
genome-wide O
level O
with O
high O
sensitivity O

Imprint O
marks O
are O
then O
re-established O
during O
spermatogenesis O
or O
oogenesis O
, O
depending O
on O
gender O

We O
derive O
a O
kernel O
smoothed O
EM-algorithm O
, O
capable O
of O
analyzing O
an O
entire O
chromosome O
at O
once O
, O
and O
to O
simultaneously O
correct O
for O
experimental O
errors O
arising O
from O
either O
the O
pre-treatment O
steps O
or O
from O
the O
sequencing O
stage O
and O
to O
take O
into O
account O
spatial O
correlations O
between O
DNA B-Gene

Although O
still O
in O
the O
early O
phase O
, O
epigenetic O
modifications O
, O
particularly O
DNA B-Chemical
methylation I-Chemical
and O
microRNAs B-Chemical
, O
might O
have O
potential O
for O
assisting O
in O
the O
stratification O
of O
patients O
for O
treatment O
and O
complement O
or O
replace O
in O
the O
future O
biochemical O
or O
clinical O
tests O

Thus O
, O
we O
believe O
that O
studying O
epigenetics O
can O
provide O
previously O
unknown O
causes O
for O
dementia B-Disease
and O
other O
neurodegenerative B-Disease
disorders I-Disease

With O
advances O
in O
modern O
health O
care O
, O
the O
average O
age O
of O
the O
general O
population O
is O
ever O
increasing O

Specifically O
, O
we O
describe O
how O
( O
epi O
) O
genetic O
machinery O
can O
affect O
chromatin O
status O
during O
hematopoiesis O
, O
leading O
to O
an O
altered O
metabolic O
profile O
, O
and O
focus O
on O
the O
potential O
value O
of O
targeting O
epigenetic O
abnormalities O
in O
precision O
and O
combination O
therapy O
for O
pAML B-Disease

Therefore O
, O
in O
the O
present O
study O
, O
we O
comprehensively O
review O
the O
current O
status O
of O
the O
epigenetic O
clocks O
and O
their O
associations O
across O
the O
human B-Species
phenome O

These O
"big O
data" O
(epigenetic O
clocks O
and O
microbiota B-Species
) O
can O
help O
tailor O
treatment O
plans O
by O
pinpointing O
patients O
likely O
to O
experience O
rapid O
declines O
or O
those O
who O
might O
not O
need O
overly O
aggressive O
therapies O

) O
specimens O
were O
collected O
from O
different O
monoclonal O
stands O
in O
the O
Maltese B-Species
archipelago I-Species
, O
and O
their O
DNA B-Gene
was O
processed O
by O
means O
of O
an O
innovative O
approach O
where O
MSAP B-Chemical
analysis O
was O
followed O
by O
NGS B-Chemical

Methylomes O
are O
also O
affected O
by O
genetics O
, O
and O
we O
observe O
multiple O
associations O
between O
SNP B-Gene
loci O
and O
methylated O
CpGs B-Gene

Purpose O
- O
built O
clocks O
for O
specific O
tissues O
age O
ranges O
or O
phenotypes O
may O
perform O
better O
for O
their O
specific O
purpose O

From O
the O
mid-seventies O
, O
the O
state O
of O
understanding O
started O
changing O

374 O
 O
Epigenetic O
reprogramming O
underlies O
specification O
of O
immune O
cell O
lineages O
, O
but O
patterns O
that O
uniquely O
define O
immune O
cell O
types O
and O
the O
mechanisms O
by O
which O
they O
are O
established O
remain O
unclear O

mapping O

The O
SigSeeker O
peak-calling O
ensemble O
uses O
multiple O
tools O
to O
identify O
peaks O
, O
and O
with O
user-defined O
thresholds O
for O
peak O
overlap O
and O
signal O
strength O
it O
retains O
only O
those O
peaks O
that O
are O
concordant O
across O
multiple O
tools O


The O
protocol O
is O
easily O
adaptable O
and O
can O
be O
used O
to O
produce O
high O
titer O
lentiviruses B-Species
for O
in O
vitro O
and O
in O
vivo O
applications O

Some O
genetic O
and O
epigenetic O
aspects O
and O
lifestyle O
changes O
seem O
to O
be O
involved O
in O
PCOS B-Disease
development O

MethLAB O
features O
a O
graphical O
user O
interface O
(GUI) O
with O
a O
menu-driven O
format O
designed O
to O
efficiently O
read O
in O
and O
manipulate O
array-based O
methylation O
data O
in O
a O
user-friendly O
manner O

Preliminary O
studies O
suggest O
that O
epigenetic O
mechanisms O
may O
explain O
why O
the O
damage O
takes O
place O
in O
some O
patients B-Disease
only O
or O
at O
a O
given O
time O

Previously O
, O
the O
diagnosis O
of O
complex O
genetic O
diseases B-Disease
has O
conventionally O
been O
done O
based O
on O
the O
non-molecular O
characteristics O
like O
kind O
of O
tumor B-Disease
tissue O
, O
pathological O
characteristics O
, O
and O
clinical O
phase O

Epigenetic O
changes O
can O
be O
seen O
from O
the O
very O
early O
stages O
in O
tumorigenesis B-Disease
and O
dysregulation O
of O
the O
epigenome O
has O
an O
increasingly O
acknowledged O
pathogenic O
role O

Then O
we O
review O
the O
epigenetics O
changes O
in O
response O
to O
environmental O
challenge O
during O
critical O
developmental O
windows O
, O
gametogenesis O
, O
embryogenesis O
, O
and O
fetal O
and O
postnatal O
period O
, O
with O
the O
specific O
example O
of O
diabetic B-Disease
susceptibility I-Disease

Through O
the O
analysis O
of O
such O
a O
model O
, O
we O
identified O
key O
genes B-Gene
and O
regulatory O
interactions O
driving O
the O
transition O
of O
cell O
states O

This O
chemical-inducible B-Chemical
epigenome O
remodeling O
tool O
will O
find O
broad O
use O
in O
interrogating O
cellular O
systems O
without O
altering O
the O
genetic O
code O
, O
as O
well O
as O
in O
probing O
the O
epigenotype-phenotype O
relations O
in O
various O
biological O
systems O

The O
TF B-Gene
paralogs O
tested O
vary O
in O
their O
methylation B-Chemical
sensitivity O
, O
for O
which O
we O
provide O
a O
structural O
rationale O

Different O
reports O
lately O
showed O
that O
a O
fundamental O
mechanism O
such O
as O
imprinting O
is O
likely O
to O
be O
closely O
linked O
to O
the O
dynamics O
of O
TEs B-Gene
epigenetic O
control O

The O
current O
gold O
standard O
to O
assess O
and O
quantitively O
map O
DNA B-Gene
methylation O
is O
bisulfite B-Chemical
sequencing O

To O
facilitate O
the O
uptake O
of O
the O
socio-exposome O
in O
multiomics O
oral B-Disease
health I-Disease
studies O
and O
subsequent O
interventions O
, O
3 O
pertinent O
facets O
are O
discussed O

187 O
Epigenetics B-Disease
researchers O
in O
developmental O
, O
cell O
, O
and O
molecular O
biology O
greatly O
diverge O
in O
their O
understanding O
and O
definitions O
of O
epigenetics O

This O
review O
highlights O
results O
from O
the O
most O
recent O
transcriptome O
research O
, O
and O
the O
meta-analyses O
performed O
, O
in O
the O
context O
of O
pig B-Species
immunity O

18 O
, O
p O
= O

The O
aims O
of O
this O
study O
were O
to O
examine O
the O
relationship O
between O
preterm B-Disease
birth I-Disease
and O
DNAm B-Gene
, O
and O
to O
investigate O
factors O
that O
contribute O
to O
variance O
in O
DNAm B-Gene

for O

Concerning O
development O
, O
it O
cements O
the O
vision O
of O
a O
reactive O
genome B-Gene
strongly O
coupled O
to O
its O
environment O

g O

This O
approach O
has O
the O
potential O
to O
accelerate O
analyses O
that O
would O
otherwise O
require O
a O
lengthy O
multi-step O
approval O
process O
and O
provides O
a O
generalizable O
strategy O
to O
facilitate O
responsible O
access O
to O
sensitive O
epigenomics O
data O

Although O
patterns O
of O
CHH-methylation O
showed O
little O
association O
with O
age O
, O
both O
and O
CHG-methylation O
contexts O
were O
strongly O
associated O
with O
ageing O
, O
largely O
becoming O
hypomethylated O
with O
age O

Humpback O
whales B-Species
exemplify O
this O
as O
they O
have O
a O
lifespan O
comparable O
to O
humans O
, O
mature O
sexually O
as O
early O
as O
4 O
years O
and O
have O
no O
reliable O
visual O
age O
indicators O
after O
their O
first O
year O

In O
the O
current O
study O
, O
we O
will O
aim O
to O
discuss O
the O
role O
of O
epigenomic O
mechanisms O
in O
aging O
and O
the O
most O
recent O
developments O
in O
epigenetic O
diagnostic O
biomarkers O
, O
which O
have O
the O
potential O
to O
focus O
efforts O
on O
reversing O
the O
destructive O
signs O
of O
aging O
and O
extending O
the O

The O
hypothesis O
that O
epigenetic O
mechanisms O
may O
link O
such O
nutritional O
imbalances O
with O
altered O
disease B-Disease
risk I-Disease
has O
been O
gaining O
acceptance O
over O
recent O
years O

Although O
most O
mental B-Disease
diseases I-Disease
are O
influenced O
by O
genetic O
and O
environmental O
factors O
, O
finding O
genetic O
biomarkers O
that O
predict O
treatment O
efficacy O
has O
been O
challenging O

7 O
) O
, O
a O
significant O
difference O
compared O
with O
healthy B-Disease
controls I-Disease

Inside O
these O
territories O
, O
chromosomes B-Gene
are O
folded O
in O
a O
hierarchical O
set O
of O
topological O
structures O
, O
called O
compartments O
, O
topologically O
associated O
domains O
and O
loops O

Dr O
Karl O
Kelsey O
, O
MD O
, O
MOH O
is O
a O
Professor O
of O
Epidemiology O
and O
Pathology O
and O
Laboratory O
Medicine O
at O
Brown O
University O

This O
review O
summarizes O
the O
impact O
of O
epigenetics O
on O
the O
development O
of O
psoriasis B-Disease
and O
highlights O
challenges O
for O
the O
future O

New O
tools O
furnished O
by O
advances O
in O
basic O
science O
and O
translational O
medicine O
could O
help O
achieve O
this O
goal O

804 O
Deoxyribonucleic B-Chemical
acid I-Chemical
(DNA) O
is O
the O
blueprint O
on O
which O
life O
is O
based O
and O
transmitted O
, O
but O
the O
way O
in O
which O
chromatin O
- O
a O
dynamic O
complex O
of O
nucleic O
acids O
and O
proteins O
- O
is O
packaged O
and O
behaves O
in O
the O
cellular O
nucleus O
has O
only O

First O
, O
validation O
of O
automated O
ChIP-seq O
assays O
using O
antibodies O
directed O
against O
various O
histone B-Chemical
modifications O
was O
shown O
, O
followed O
by O
optimization O
of O
the O
automated O
protocols O
to O
perform O
chromatin O
immunoprecipitation O
and O
library O
preparation O
starting O
with O
low O
cell O
numbers O

483 O
High-throughput O
genomic O
sequencing O
and O
quantitative O
mass O
spectrometry O
(MS)-based O
proteomics O
technology O
have O
recently O
emerged O
as O
powerful O
tools O
, O
increasing O
our O
understanding O
of O
chromatin O
structure O
and O
function O

Finally O
, O
findings O
were O
validated O
through O
a O
machine O
learning O
approach O
with O
two O
additional O
datasets O
from O
day O
15 O
embryos O

The O
information O
gained O
can O
be O
used O
to O
promote O
health O
but O
it O
also O
raises O
a O
variety O
of O
ethical O
, O
legal O
, O
and O
social O
issues O

The O
epigenotyping O
procedure O
that O
we O
describe O
provides O
an O
important O
first O
step O
to O
epigenetic O
quantitative O
trait O
loci O
mapping O
in O
genetically O
identical O
individuals O

1471 O
Epigenetic O
modulators O
play O
significant O
roles O
in O
carcinogenesis B-Disease

The O
method O
described O
here O
helps O
to O
overcome O
those O
challenges O

A O
problem O
arises O
with O
these O
behavioral O
definitions O
when O
considering O
the O
potential O
for O
persistent O
memory O
of O
extinction O

08 O
) O

A O
record O
of O
this O
paper O
's O
transparent O
peer O
review O
process O
is O
included O
in O
the O
Supplemental O
Information O

However O
, O
we O
still O
know O
little O
about O
the O
spatial O
distribution O
of O
epigenetic O
variation O
in O
natural O
systems O
, O
how O
it O
relates O
to O
the O
distribution O
of O
genetic O
variation O
and O
the O
environmental O
structure O
of O
the O
landscape O
, O
and O
the O
processes O
that O
generate O
and O
maintain O
it O

We O
identified O
methylation O
sites O
associated O
with O
IgE B-Gene
using O
covariate-adjusted O
robust O
linear O
regressions O

Recent O
technological O
developments O
have O
enabled O
base-pair O
resolution O
of O
various O
epigenomic O
features O
, O
leading O
to O
new O
insights O
into O
epigenetic O
regulation O

We O
benchmark O
DXM B-Chemical
's O
performance O
and O
demonstrate O
improvement O
over O
existing O
methods O

Artificial O
C/T O
SNP O
creation O
via O
bisulfite B-Chemical
modification O
permits O
measurement O
of O
DNA B-Chemical
methylation O
locally O
and O
globally O
in O
real O
time O

By O
characterizing O
environmentally O
dependent O
epigenetic O
variation O
in O
natural O
populations O
, O
we O
will O
enhance O
our O
understanding O
of O
developmental O
, O
ecological O
, O
and O
evolutionary O
phenomena O

Recent O
work O
shows O
how O
molecular O
"noise" O
can O
shape O
the O
architecture O
of O
this O
landscape O
and O
how O
universal O
properties O
of O
cell O
fate O
commitment O
can O
be O
distilled O
from O
careful O
consideration O
of O
its O
geometry O

Supported O
by O
validation O
using O
mass O
spectrometry O
and O
pyrosequencing O
, O
we O
demonstrate O
reproducible O
( O
R(2) O
> O
0 O

For O
policy O
makers O
, O
rather O
than O
controlling O
this O
complex O
range O
of O
determinants O
of O
health O
, O
isolating O
and O
targeting O
maternal O
body O
and O
responsibilising O
mothers O
for O
the O
control O
of O
this O
micro-environment O
might O
seem O
feasible O

Our O
method O
provides O
an O
analytical O
approach O
to O
study O
the O
relationship O
between O
epigenomic O
changes O
and O
cell O
lineage O
differentiation O

134 O
 O
The O
nearly O
neutral O
theory O
emphasizes O
the O
interaction O
of O
drift O
and O
weak O
selection O
in O
evolution O

These O
observed O
associations O
may O
be O
modified O
by O
alcohol B-Chemical
consumption O

, O
replace O
or O
augment O
self-reported O
adherence O
) O

Although O
some O
of O
these O
issues O
remain O
controversial O
, O
this O
review O
mainly O
focuses O
on O
promising O
data O
that O
support O
the O
developing O
field O
of O
Nutritional B-Disease
Epigenetics I-Disease

Epigenetic O
mechanisms O
are O
adaptations O
made O
to O
our O
genome O
in O
response O
to O
our O
environment O
which O
include O
tags O
placed O
on O
and O
removed O
from O
the O
DNA B-Gene
itself O
to O
how O
our O
DNA B-Gene
is O
packaged O
, O
affecting O
how O
our O
genes B-Gene
are O
read O
, O
transcribed O
, O
and O
interact O

We O
introduce O
BS-Seeker3 O
, O
an O
extensively O
improved O
and O
optimized O
implementation O
of O
BS-Seeker2 O
that O
leverages O
the O
available O
computational O
power O
of O
a O
standard O
bioinformatics O
lab O

811 O
Epigenetic O
alterations O
, O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
and O
noncoding O
RNA B-Gene
expression O
, O
have O
been O
reported O
to O
play O
a O
major O
role O
in O
the O
genesis O
of O
lung B-Disease
cancer I-Disease

1049 O
Efforts O
have O
been O
directed O
to O
redesign O
crops O
with O
increased O
yield O
, O
stress O
adaptability O
, O
and O
nutritional O
value O
through O
synthetic O
biology-the O
application O
of O
engineering O
principles O
to O
biology O

Macrophages O
are O
the O
first O
immune O
cells O
to O
engage O
and O
clear O
particles O
of O
various O
nature O

46Background O
Previous O
studies O
have O
traditionally O
attributed O
the O
initiation O
of O
cancer B-Disease
cells I-Disease
to O
genetic B-Gene
mutations I-Gene
, O
considering O
them O
as O
the O
fundamental O
drivers O
of O
carcinogenesis B-Disease

When O
Waddington B-Gene
mentioned O
it O
in O
1956 O
, O
the O
notion O
of O
epigenetics B-Gene
was O
not O
yet O
popular O
, O
as O
it O
would O
become O
from O
the O
1980s O

It O
is O
recognized O
that O
the O
incidence O
of O
tendon B-Disease
injury I-Disease
increases O
with O
age O
, O
suggesting O
a O
deterioration O
in O
homeostatic O
mechanisms O
or O
reparative O
processes O

The O
study O
of O
aberrant O
DNA B-Gene
methylation I-Gene
patterns O
, O
such O
as O
hypermethylation O
of O
CpG B-Gene
islands I-Gene
and O
global O
genomic O
hypomethylation O
, O
are O
common O
issues O
in O
the O
studies O
on O
all O
types O
of O
cancer B-Disease
, O
and O
as O
in O
other O
areas O
of O
molecular O
oncology O
, O

Genes O
such O
as O
DNA B-Gene
methyltransferase I-Gene
3A I-Gene
( O
DNMT3A B-Gene
) O
, O
ten B-Gene
eleven I-Gene
translocation I-Gene
methylcytosine I-Gene
dioxygenase I-Gene
2 I-Gene
( O
TET2 B-Gene
) O
, O
additional B-Gene
sex I-Gene
combs-like I-Gene
1 I-Gene
( O
ASXL1 B-Gene
) O
, O
enhancer B-Gene
of I-Gene

Gene O
ontology O
clusters O
regarding O
, O
e O

Epigenetics O
can O
be O
defined O
as O
reversible O
heritable O
changes O
to O
chromatin O
that O
can O
alter O
gene B-Gene
expression I-Gene
without O
altering O
the O
gene's B-Gene
DNA I-Gene
sequence I-Gene

Importantly O
, O
ART B-Chemical
- I-Chemical
associated I-Chemical
epigenetic O
variation O
at O
birth O
largely O
resolves O
by O
adulthood O
with O
no O
direct O
evidence O
that O
it O
impacts O
on O
development O
and O
health O

Therefore O
, O
psychoanalysis O
, O
which O
has O
proven O
to O
reduce O
the O
intergenerational O
transmission O
of O
trauma O
from O
a O
behavioral O
perspective O
, O
can O
play O
a O
positive O
role O
in O
regulating O
DNA B-Gene
changes O
caused O
by O
environmental O
stress O

In O
accordance O
with O
the O
notion O
of O
global O
methylation O
reprogramming O
, O
our O
preliminary O
observations O
on O
acute B-Disease
myeloid I-Disease
leukemia I-Disease
( O
AML B-Disease
) O
samples O
implied O
the O
existence O
of O
subclonally O
occurring O
focal O
methylation O
aberrance O
throughout O
the O
genome O

including O

Cutaneous O
(CNF) O
and O
plexiform B-Disease
neurofibromas I-Disease
(PNF) O
share O
nearly O
identical O
histology O
, O
but O
maintain O
different O
growth O
rates O
and O
risk O
of O
malignant B-Disease
conversion I-Disease

The O
model O
reported O
the O
lowest O
epigenetic O
age O
acceleration O
in O
normal O
populations O
, O
as O
well O
as O
the O
lowest O
variation O
across O
technical O
replicates O
and O
repeated O
samples O
from O
the O
same O
subjects O

The O
patterns O
revealed O
show O
this O
epigenetic O
mark O
to O
be O
critical O
in O
tissue-type O
definition O
and O
stemness O
, O
particularly O
around O
transcription O
start O
sites O
that O
are O
not O
within O
a O

Regulation O
of O
non-coding O
RNAs O
associated O
with O
the O
target O
proteins O
of O
these O
drugs B-Chemical
was O
also O
studied O

Single-cell O

Originally O
prepared O
for O
the O
Organisation O
of O
Economic O
Cooperation O
and O
Development O
( O
OECD O
) O
, O
this O
detailed O
review O
evaluates O
the O
potential O
role O
of O
chemical-induced B-Chemical
epigenetic O
modifications O
to O
endocrine O
signaling O
pathways O
during O
sensitive O
windows O
of O
exposure O
as O
a O
mechanism O
of O
endocrine O
disruption O
, O
along O
with O

Comparing O
age-related O
DMCs O
and O
DHMRs O
, O
1,854 O
annotated O
genes O
showed O
both O
differential O
5mC B-Chemical
and O
5hmC B-Chemical
, O
including O
one O
gene O
- O
Nfic B-Gene
- O
at O
five O
CpGs O
in O
the O
same O
250 O
bp O
chromosomal O
region O

Recent O
evidence O
from O
molecular O
approaches O
has O
provided O
new O
insights O
about O
how O
environmental O
exposures O
cause O
persistent O
alterations O
in O
the O
regulation O
of O
gene B-Gene
expression I-Gene
, O
particularly O
by O
so-called O
epigenetic O
mechanisms O

Moreover O
, O
the O
Nanopore B-Chemical
sequencer O
detects O
modifications O
on O
long O
DNA B-Gene
and O
RNA B-Gene
molecules O

Characterization O
of O
robustness O
and O
plasticity O
of O
phenotypes O
is O
a O
basic O
issue O
in O
evolutionary O
and O
developmental O
biology O

This O
renewed O
interest O
has O
been O
concomitant O
with O
methodological O
progress O
enabling O
, O
for O
example O
, O
high O
coverage O
and O
single O
base O
resolution O
profiling O
of O
the O
mammalian B-Species
methylome B-Chemical
in O
small O
numbers O
of O
cells O

Our O
analysis O
offers O
both O
a O
state-of-the-art O
overview O
of O
the O
computational O
techniques O
developed O
so O
far O
and O
a O
heterogeneous O
picture O
of O
performances O
, O
which O
can O
be O
helpful O
in O
orienting O
future O
research O

Although O
replication O
is O
required O
, O
these O
results O
are O
consistent O
with O
a O
biologically O
based O
model O
of O
temperament O
, O
create O
new O
avenues O
for O
hypothesis-driven O
research O
into O
epigenetic O
pathways O
that O
underlie O
individual O
differences O
in O
temperament O
, O
and O
demonstrate O
that O
infant O
temperament O
has O
a O
widespread O
epigenetic O
signature O

However O
, O
although O
multiple O
frameworks O
have O
been O
developed O
to O
facilitate O
access O
to O
these O
tools O
, O
comparatively O
little O
effort O
has O
been O
made O
at O
implementing O
low-level O
programming O
libraries O
to O
increase O
the O
speed O
and O
ease O
of O
their O
development O

sg O

epidecodeR O
is O
available O
for O
downloading O
as O
an O
R O
package O
at O
https//bioconductor O

Now O
the O
time O
has O
come O
that O
we O
may O
apply O
similar O
approaches O
in O
social O
epigenomics O
because O
technologies O
of O
determining O
methylation O
 B-Chemical
, O
histone O
 O
, O
and O
noncoding O
RNA O
 B-Gene
profiling O
are O
well O
developed O

These O
findings O
highlight O
gene O
regulatory O
mechanisms O
at O
both O
cell-specific O
and O
systemic O
levels O
that O
may O
be O
involved O
in O
fetal O
immune O
system O
maturation O

663 O
In O
the O
last O
decade O
, O
the O
development O
of O
high-throughput O
sequencing O
methodologies O
has O
significantly O
improved O
the O
gathering O
of O
genomic O
information O
and O
consequent O
under-standing O
of O
the O
genetic O
and O
epigenetic O
background O
of O
complex O
and O
monogenetic O
endocrine O
disorders O
[ O

The O
study O
enrolled O
a O
cohort O
of O
relatively O
healthy O
individuals O
, O
and O
their O
methylation O
levels O
of O
eight O
specific O
CpG O
dinucleotides O
in O
genes O
SLC12A5 B-Gene
, O
LDB2 B-Gene
, O
FIGN B-Gene
, O
ACSS3 B-Gene
, O
FHL2 B-Gene
, O
and O
EPHX3 B-Gene
were O
evaluated O
using O
the O

uk O
/ O
mosaics O

Comprehension O
and O
relevant O
alterations O
in O
these O
epigenetic O
modifications O
can O
lead O
to O
new O
therapeutic O
avenues O
of O
age-delaying O
contrivances O

and O

Taken O
together O
, O
these O
studies O
highlight O
the O
need O
for O
future O
research O
evaluating O
mtDNA B-Gene
epigenetic O
disruption O
by O
EDCs B-Chemical
and O
to O
detail O
specific O
mechanisms O
responsible O
for O
such O
disruptions O

011 O
) O
, O
with O
nondrinkers O
exhibiting O
a O
higher O
GAA B-Gene
( O
Î² O
= O
0 O

1442 O
 O
Depression B-Disease
is O
a O
highly O
prevalent O
, O
disabling O
, O
and O
often O
chronic O
illness O
that O
places O
substantial O
burdens O
on O
patients O
, O
families O
, O
healthcare O
systems O
, O
and O
the O
economy O

While O
epigenetic O
marks O
can O
be O
inherited O
independently O
of O
genetic O
sequences O
in O
some O
species B-Species
, O
there O
is O
little O
evidence O
that O
such O
" O
transgenerational O
inheritance O
" O
is O
a O
general O
phenomenon O

328 O
The O
growing O
interest O
in O
epigenetic O
probes O
and O
drug O
discovery O
, O
as O
revealed O
by O
several O
epigenetic O
drugs O
in O
clinical O
use O
or O
in O
the O
lineup O
of O
the O
drug O
development O
pipeline O
, O
is O
boosting O
the O
generation O
of O
screening O
data O

Nuclease O

Alongside O
, O
technological O
advancements O
allow O
for O
the O
analysis O
of O
these O
mechanisms O
with O
high O
resolution O
up O
to O
the O
single-cell O
level O


The O
software O
is O
available O
at O
 O
https//hyperbrowser O

Although O
there O
are O
adequate O
animal O
models O
for O
some O
of O
the O
core O
dimensions O
of O
BPD B-Disease
, O
there O
is O
a O
lack O
of O
translational O
research O
including O
data O
from O
animal O
models O
in O
BPD B-Disease

The O
markers O
- O
BCAS4 B-Gene
, O
CG06379435 B-Gene
, O
VE_8 B-Gene
, O
and O
ZC3H12D B-Gene
- O
were O
amplified O
together O
and O
then O
sequenced O
via O
pyrosequencing O

These O
methods O
have O
been O
used O
to O
generate O
base-resolution O
maps O
of O
5mC B-Chemical
and O
its O
oxidation O
derivatives O
in O
genomic O
samples O

1061 O
Dynamic O
epigenetic O
reprogramming O
occurs O
during O
mammalian B-Species
germ O
cell O
development O
, O
although O
the O
targets O
of O
this O
process O
, O
including O
DNA B-Chemical
demethylation O
and O
de O
novo O
methylation O
, O
remain O
poorly O
understood O

418Motivation O
With O
the O
increasing O
amount O
of O
genomic O
and O
epigenomic O
data O
in O
the O
public O
domain O
, O
a O
pressing O
challenge O
is O
to O
integrate O
these O
data O
to O
investigate O
the O
role O
of O
epigenetic O
mechanisms O
in O
regulating O
gene B-Gene
expression I-Gene
and O
maintenance O
of O
cell-identity O

477 O
It O
has O
been O
estimated O
that O
the O
heritable O
component O
of O
bipolar B-Disease
disorder I-Disease
ranges O
between O
80 O
and O
90% O

5 O
% O
of O
CpG B-Gene
sites O
showed O
poor O
correlation O
( O
r O
< O
0 O

Analysis O
of O
DNA B-Chemical
methylation I-Chemical
profiles O
revealed O
several O
loci O
engaged O
in O
plasma O
lipoprotein O
formation O
and O
metabolism O
, O
cholesterol B-Chemical
efflux O
and O
reverse O
transport O
, O
triglycerides B-Chemical
degradation O
and O
fatty O
acids O
transport O
and O
Î²-oxidation O

430 O
Atrial B-Disease
fibrillation I-Disease
(AF) O
is O
the O
most O
common O
cardiac O
arrhythmia O
and O
an O
important O
cause O
of O
morbidity O
and O
mortality O
globally O

Major O
conclusions O
 O
Nature O
offers O
a O
suite O
of O
enzymes O
with O
biological O
roles O
in O
cytosine B-Chemical
modification O
in O
organisms O
spanning O
from O
bacteriophages B-Species
to O
mammals B-Species

For O
the O
first O
time O
, O
the O
" O
color-specificity O
" O
of O
both O
the O
persistence O
length O
and O
the O
mean O
interaction O
energy O
are O
estimated O
, O
leading O
to O
important O
differences O
between O
epigenetic O
states O

Although O
the O
majority O
of O
work O
examining O
how O
epigenetic O
modifications O
contribute O
to O
addiction B-Disease
has O
focused O
on O
psychostimulants O
such O
as O
cocaine B-Chemical
, O
research O
into O
opioid-induced O
changes O
to O
the O
epigenetic O
landscape O
is O
emerging O

In O
particular O
, O
the O
addition O
of O
functional O
domains O
encoding O
epigenetic O
effectors O
and O
chromatin O
modifiers O
to O
the O
CRISPR/Cas B-Gene
ribonucleoprotein I-Gene
complex I-Gene
opens O
the O
possibility O
to O
introduce O
targeted O
epigenomic O
modifications O
in O
plants B-Species
in O
an O
easily O
programmable O
manner O

As O
a O
cofactor O
for O
epigenetic O
enzymes O
, O
ascorbate B-Chemical
facilitates O
TET2/3-mediated B-Gene
DNA B-Chemical
modification O
and O
demethylation O
of O
multiple O
elements O
at O
the O
Prdm1 B-Gene
locus O

Initially O
, O
age-predictors O
for O
mice B-Species
were O
trained O
for O
genome-wide O
DNA B-Chemical
methylation I-Chemical
profiles O
and O
we O
have O
recently O
described O
a O
targeted O
assay O
based O
on O
pyrosequencing O
of O
DNA B-Chemical
methylation I-Chemical
at O
only O
three O
age-associated O
genomic O
regions O

Advances O
in O
understanding O
of O
cancer B-Disease
biology O
, O
genomics O
, O
epigenomics O
, O
and O
immunology O
have O
resulted O
in O
development O
of O
several O
therapeutic O
options O
that O
expand O
cancer B-Disease
care O
beyond O
traditional O
chemotherapy B-Chemical
or O
radiotherapy B-Chemical
, O
including O
individualized O
treatment O
strategies O
, O
novel O

These O
comparisons O
indicate O
that O
the O
quality O
of O
our O
ensemble O
technique O
exceeds O
that O
of O
single O
tool O
approaches O
, O
enhances O
existing O
peak-calling O
ensembles O
, O
and O
results O
in O
epigenetic O
profiles O
of O
higher O
confidence O

999 O
Despite O
the O
vast O
morphological O
variation O
observed O
across O
phyla O
, O
animals O
share O
multiple O
basic O
developmental O
processes O
orchestrated O
by O
a O
common O
ancestral O
gene B-Gene
toolkit I-Gene

There O
is O
a O
more O
clear O
vision O
whereas O
'omics O
'omics O
technologies O
applied O
to O
unveil O
relevant O
epigenetic O
factors O
could O
play O
a O
significant O
role O
in O
the O
treatment O
of O
periodontal B-Disease
disease I-Disease
in O
a O
personalized O
mode O
, O
evidencing O
that O
public O
health O
approach O
should O
coexist O
with O
precision O
individualized O

Despite O
successes O
in O
identifying O
causes O
, O
it O
is O
often O
claimed O
that O
there O
are O
missing O
additional O
causes O
for O
even O
reasonably O
well-understood O
conditions O
such O
as O
lung B-Disease
cancer I-Disease
and O
coronary B-Disease
heart I-Disease
disease I-Disease


We O
highlight O
the O
important O
roles O
of O
gene-environment O
interactions O
and O
epigenetics O
as O
sources O
of O
phenotypic O
change O
and O
as O
a O
bridge O
between O
the O
life O
and O
social O
and O
behavioral O
sciences O
in O
the O
development O
of O
robust O
interdisciplinary O
analyses O

Methylation O
analysis O
of O
newborn O
blood O
DNA O
using O
an O
Illumina O
HumanMethylation450K O
array O
was O
performed O
in O
23 O
CP B-Disease
cases O
and O
21 O
unaffected O
controls O

681 O
Epigenetics B-Disease
is O
the O
field O
of O
science O
that O
deals O
with O
the O
study O
of O
changes O
in O
gene B-Gene
function O
that O
do O
not O
involve O
changes O
in O
DNA B-Gene
sequence O
and O
are O
heritable O
while O
epigenetics B-Disease
inheritance O
is O
the O
process O

g O

The O
field O
of O
epigenetics O
has O
seen O
remarkable O
growth O
in O
the O
past O
few O
years O
with O
significant O
advances O
in O
basic O
biology O
, O
contributions O
to O
human B-Disease
disease I-Disease
, O
as O
well O
as O
epigenomics O
technologies O

Existing O
methods O
based O
on O
short-read O
sequencing O
for O
the O
detection O
of O
modifications O
show O
difficulty O
in O
determining O
the O
modification O
patterns O
of O
single O
chromosomes O
or O
an O
entire O
transcript O
sequence O

41 O
 O
The O
inappropriate O
use O
of O
antibiotics B-Chemical
in O
man O
is O
driving O
to O
insurgence O
of O
pathogenic O
bacteria B-Species
resistant O
to O
multiple O
drugs O
( O
MDR B-Disease
) O
representing O
a O
challenge O
in O
critical O
illness O

Also O
, O
sequences O
flanking O
DMC B-Gene
were O
enriched O
in O
SNPs B-Gene
compared O
to O
all O
other O
CpGs B-Gene
, O
either O
methylated O
or O
unmethylated O
in O
the O
two O
subspecies B-Species


While O
the O
viruses B-Species
may O
differ O
in O
significant O
ways O
from O
each O
other O
and O
cellular O
chromatin O
, O
the O
role O
of O
epigenetics B-Gene
appears O
to O
be O
relatively O
similar O

1441Background O
and O
scope O
Neurodevelopmental B-Disease
disorders I-Disease
( O
NDDs B-Disease
) O
are O
defined O
by O
a O
wide O
variety O
of O
behavioural O
phenotypes O
, O
psychopathology O
and O
clinically O
informed O
categorical O
classifications O

From O
a O
conceptual O
point O
of O
view O
, O
intriguing O
similarities O
can O
be O
found O
between O
Darwin's B-Gene
( O
early O
) O
conception O
of O
habit O
and O
contemporary O
views O
on O
epigenetic B-Gene
inheritance I-Gene

276 O
Polycystic B-Disease
ovarian I-Disease
syndrome I-Disease
( O
PCOS B-Disease
) O
is O
a O
complex O
condition O
of O
ovarian O
dysfunction O
and O
metabolic O
abnormalities O
with O
widely O
varying O
clinical O
manifestations O
resulting O
from O
interference O
of O
the O
genome O
and O
the O
environment O
through O
integrative O
biological O
mechanisms O
with O
the O
emerging O
field O
of O

Availability O
and O
implementation O
 O
The O
EWAS B-Gene
software O
is O
freely O
available O
at O
http//www O
. O

However O
, O
translating O
and O
implementing O
genotype-phenotype O
data O
into O
gene-based O
medicine O
in O
CKD B-Disease
populations O
is O
still O
in O
an O
early O
phase O
and O
will O
require O
continuous O
research O
efforts O
with O
integrated O
approaches O
and O
intensified O
investigations O
that O
focus O
on O
the O
biological O
pathways O
, O
which O
causatively O
link O
a O

We O
propose O
10 O
recommendations O
for O
future O
prenatal B-Disease
pharmacoepigenetic O
studies O
considering O
both O
epidemiological O
and O
epigenetic O
perspectives O

most O

For O
these O
reasons O
chromatin O
biology O
and O
epigenetic O
research O
have O
a O
rich O
history O
of O
chasing O
discoveries O
in O
a O
variety O
of O
model O
organisms O
, O
including O
yeast B-Species
, O
flies B-Species
, O
plants B-Species
and O
humans B-Species

Contact O
 O
felipe O

Major O
conclusions O
 O
High-throughput O
omics O
approaches O
have O
been O
productive O
in O
genetic O
and O
epigenetic O
studies O
of O
CVID B-Disease
, O
leading O
to O
the O
identifications O
of O
several O
significantly O
associated O
loci O
of O
different O
variant O
types O
, O
as O
well O
as O
genes O
and O
pathways O
elucidating O
the O
shared O
genetic O
basis O
of O

We O
conclude O
by O
highlighting O
the O
potential O
for O
ongoing O
research O
on O
the O
epigenomics O
of O
marine B-Species
fishes I-Species
to O
reveal O
critical O
aspects O
of O
the O
interaction O
between O
organisms O
and O
their O
environments O

Furthermore O
, O
DMF-ChIP-seq O
was O
capable O
of O
processing O
the O
samples O
with O
as O
few O
as O
8 O
cells O
while O
maintaining O
a O
high O
signal-to-noise O
ratio O

Our O
findings O
provide O
a O
graphical O
and O
numerical O
synopsis O
of O
the O
past O
decade O
of O
epigenetic O
age O
estimation O
research O
and O
indicate O
areas O
where O
further O
attention O
could O
be O
focused O
in O
the O
coming O
years O

One O
well O
studied O
epigenetic O
mechanism O
is O
DNA B-Gene
methylation O
, O
the O
addition O
of O
a O
methyl B-Chemical
group I-Chemical
to O
cytosines B-Chemical
, O
which O
have O
the O
potential O
to O
alter O
gene B-Gene
expression I-Gene
depending O
on O
the O
genomic O
region O
in O
which O
it O
takes O
place O

We O
have O
found O
no O
evidence O
that O
this O
affected O
methylation O
calling O
, O
nor O
concordance O
of O
results O

This O
review O
summarizes O
our O
current O
knowledge O
on O
the O
role O
of O
the O
epigenetic O
machinery O
as O
a O
'filter' O
between O
genetic O
commitment O
and O
environmental O
signals O
in O
cell O
types O
that O
can O
alternatively O
promote O
skeletal O
muscle O
regeneration O
or O
fibro-adipogenic O
degeneration O

Using O
selected O
examples O
, O
we O
first O
recapitulate O
key O
findings O
supporting O
the O
role O
of O
adverse O
life O
events O
, O
alone O
or O
in O
combination O
with O
genetic O
risk O
, O
in O
epigenetic O
programming O
of O
neuropsychiatric B-Disease
systems I-Disease

and O

652 O
Unlike O
genetics O
, O
epigenetics O
involves O
the O
modification O
of O
genome O
without O
changes O
in O
DNA B-Gene
sequences O
, O
including O
DNA B-Gene
methylation O
, O
histone O
modification O
, O
chromatin O
remodeling O
and O
noncoding O
RNA B-Gene
regulation O


I O
outline O
the O
basic O
bioinformatic O
steps O
needed O
to O
process O
raw O
Illumina O
sequencing O
data O
and O
then O
describe O
the O
inital O
steps O
of O
the O
analysis O
of O
datasets O
, O
including O
an O
assessment O
of O
imprint O
control O
regions O

351 O
 O
Sequencing-based O
approaches O
now O
allow O
high-resolution O
, O
genome-scale O
investigation O
of O
cellular O
epigenetic O
landscapes O

The O
EpiMet O
project O
was O
registered O
under O
the O
ID#AAP-BMS_003_211 O

These O
readily O
available O
epigenetic O
clocks O
can O
be O
used O
for O
elephant B-Species
conservation O
efforts O
where O
accurate O
estimates O
of O
age O
are O
needed O
to O
predict O
demographic O
trends O

It O
is O
imperative O
that O
promising O
candidates O
are O
validated O
using O
these O
resources O
, O
and O
in O
subsequent O
prospective O
clinical B-Disease
trials I-Disease
, O
so O
that O
future O
biomarkers O
may O
be O
used O
in O
the O
clinic O
to O
personalize O
patient O
care O

As O
society O
progresses O
in O
understanding O
the O
epigenetic O
mechanisms O
of O
substance B-Disease
use I-Disease
and O
addiction B-Disease
, O
there O
is O
an O
opportunity O
to O
use O
these O
use O
this O
knowledge O
to O
enable O
medical O
, O
behavioral O
, O
and O
environmental O
interventions O
to O
alleviate O
the O
burden O
of O
addiction B-Disease

This O
reductionism O
about O
biosocial O
dynamics O
of O
disease O
, O
we O
argue O
, O
hampers O
the O
pursuit O
of O
the O
goals O
has O
given O
itself O
( O
in O
and O
beyond O
) O

Epigenetic O
can O
explain O
how O
environmental O
variables O
may O
affect O
gene B-Gene
expression I-Gene
without O
modifying O
the O
DNA B-Gene
sequence I-Gene


The O
percent O
methylation O
at O
each O
CpG B-Gene
site I-Gene
was O
determined O
, O
and O
then O
agglomerative O
hierarchical O
cluster O
analysis O
was O
used O
to O
create O
a O
model O
to O
indicate O
sample O
origin O

As O
the O
results O
of O
gene O
enrichment O
, O
pathways O
analysis O
showed O
that O
TAPBP B-Gene
, O
BDNF B-Gene
, O
and O
SORBS2 B-Gene
linked O
together O
by O
inflammatory O
pathways O

DNA O
methylation O
can O
change O
the O
activity O
of O
the O
DNA B-Gene
molecule O
without O
changing O
the O
sequence O

However O
, O
the O
relative O
contribution O
of O
each O
site O
to O
aging O
varies O
between O
individuals O
, O
leading O
to O
variable O
personal O
aging O
patterns O

474 O
Schizophrenia B-Disease
is O
a O
debilitating O
psychiatric O
disorder O
with O
a O
complex O
genetic O
architecture O
and O
limited O
understanding O
of O
its O
neuropathology O
, O
reflected O
by O
the O
lack O
of O
diagnostic O
measures O
and O
effective O
pharmacological O
treatments O

These O
imprinted O
genes O
play O
an O
important O
role O
in O
embryonic O
and O
extraembryonic O
growth O
and O
development O
, O
as O
well O
as O
in O
a O
variety O
of O
processes O
after O
birth O

Conclusions O
 O
Discoveries O
in O
neuroscience O
and O
epigenetics O
reveal O
synergistic O
mechanisms O
that O
support O
the O
integration O
of O
psychotherapy O
, O
psychopharmacology O
, O
and O
psychoeducation O
in O
practice O

Dysregulation O
in O
the O
deposition O
and O
maintenance O
of O
epigenetic O
features O
, O
which O
include O
histone B-Chemical
posttranslational I-Chemical
modifications I-Chemical
( O
PTMs O
) O
and O
histone B-Chemical
variants I-Chemical
, O
can O
result O
in O
the O
inappropriate O
expression O
or O
silencing O
of O
genes O
, O
often O
leading O
to O
diseased O
states O
, O

g O

However O
, O
interindividual O
variation O
in O
methylation O
can O
also O
be O
a O
consequence O
of O
DNA B-Chemical
sequence O
polymorphisms O
that O
result O
in O
methylation O
quantitative O
trait O
loci O
( O
methQTLs O
) O
and O
, O
potentially O
, O
the O
interaction O
between O
fixed O
genetic O
variation O
and O
environmental O
influences O

org O
/ O
10 O

In O
particular O
, O
DNA B-Gene
methylation I-Gene
assays O
are O
widely O
applied O
to O
formalin-fixed B-Chemical
, O
paraffin-embedded B-Chemical
archival O
tissue O
specimens O
as O
clinical O
pathology O
tests O

How O
can O
these O
two O
seemingly O
contradictory O
observations O
be O
reconciled O
? O
Here O
, O
we O
discuss O
how O
stochastic O
processes O
relate O
to O
gbM B-Gene
maintenance O
dynamics O

the O

and O
Stuart O
et O
al O

At O
the O
model O
's O
core O
was O
the O
modular O
assembly O
of O
regulators O
, O
operators O
, O
and O
structural O
genes B-Gene

Genome O
- O
wide O
association O
and O
gene O
mapping O
studies O
have O
supported O
the O
genetic O
background O
for O
SLE B-Disease
susceptibility O

So O
far O
, O
only O
few O
publications O
dealing O
with O
forensic O
age O
estimation O
address O
these O
confounding O
factors O

Evolutionary O
reasoning O
first O
articulated O
by O
G B-Gene

The O
late O
onset O
of O
such O
diseases B-Disease
in O
response O
to O
earlier O
transient O
experiences O
has O
led O
to O
the O
suggestion O
that O
developmental O
programming O
may O
have O
an O
epigenetic O
component O
, O
as O
epigenetic O
marks O
such O
as O
DNA B-Chemical
methylation I-Chemical
or O
histone B-Chemical
tail I-Chemical
modifications I-Chemical
could O
provide O

However O
, O
the O
extent O
to O
which O
environment-induced O
epigenetic O
changes O
are O
conserved O
between O
these O
tissues O
is O
unclear O

Specifically O
, O
complexification O
can O
be O
defined O
as O
producing O
, O
stabilizing O
, O
and O
normalizing O
novel O
experimental O
systems O
that O
are O
supposed O
to O
improve O
techno-scientific O
enactments O
of O
complexity O

In O
addition O
, O
profiling O
genome-wide O
methylation O
patterns O
using O
a O
hidden O
Markov O
model O
revealed O
abundant O
genomic O
regions O
in O
which O
CpGs B-Chemical
and O
CpHs B-Chemical
are O
differentially O
methylated O
in O
brain B-Species

529 O
Epigenetic O
control O
plays O
an O
important O
role O
in O
gene O
regulation O
through O
chemical B-Chemical
modifications I-Chemical
of O
DNA B-Gene
and O
post-translational O
modifications O
of O
histones B-Gene

Finally O
, O
they O
provide O
their O
perspective O
of O
using O
epigenetic O
drugs B-Chemical
for O
treating O
schizophrenia B-Disease

A O
set O
of O
25 O
miRNA B-Gene
master O
regulators O
was O
identified O
that O
likely O
contribute O
to O
the O
sexual O
dimorphic O
mRNA B-Gene
expression O

These O
conditions O
cannot O
be O
ignored O
by O
anyone O
but O
there O
are O
evidences O
that O
suggest O
that O
exercise O
, O
healthy O
diet O
and O
good O
routines O
may O
delay O
the O
Aging B-Disease
process O
significantly O

A O
recent O
study O
by O
Takahashi O
et O
al O

Our O
review O
shows O
that O
multigenerational O
persistence O
of O
epigenomic O
patterns O
is O
common O
in O
both O
plants B-Species
and O
animals B-Species
, O
but O
also O
highlights O
many O
knowledge O
gaps O
that O
remain O
to O
be O
filled O

An O
innovative O
analytical O
approach O
has O
been O
adopted O
to O
identify O
Stochastic B-Disease
Epigenetic I-Disease
Mutations I-Disease
(SEMs) O
in O
HCC B-Disease

Thus O
, O
the O
combination O
of O
the O
two O
enrichment-based O
methods O
provides O
a O
cost-effective O
alternative O
to O
WGBS B-Chemical

heat B-Disease

This O
heterogeneity O
confounds O
decisions O
regarding O
treatment O
and O
promotes O
disease B-Disease
relapse I-Disease


We O
demonstrate O
this O
approach O
by O
showing O
that O
hunger-related O
DNA B-Gene
methylation I-Gene
changes O
are O
found O
in O
ancient O
hunter-gatherers O

826 O
Epigenome O
editing O
has O
rapidly O
evolved O
in O
recent O
years O
, O
with O
diverse O
applications O
that O
include O
elucidating O
gene O
 B-Gene
regulation O
mechanisms O
, O
annotating O
coding O
and O
noncoding O
genome O
functions O
and O
programming O
cell O
state O
and O
lineage O
specification O

Today O
, O
clarification O
of O
this O
issue O
is O
more O
pressing O
than O
ever O
because O
profiling O
efforts O
and O
epigenome-wide O
association O
studies O
( O
EWAS O
) O
continuously O
provide O
comprehensive O
datasets O
depicting O
epigenomic O
differences O
between O
tissues O
and O
disease B-Disease
states I-Disease

Epigenetic O
Drug-Target B-Chemical
Network I-Chemical
( O
EP-DTN B-Chemical
) O
was O
constructed O
with O
the O
drugs O
associated O
with O
the O
proteins O
of O
EP-PPIN B-Gene

The O
carcinogenic O
effects O
of O
furan B-Chemical
have O
been O
attributed O
to O
genotoxic B-Disease
and O
non-genotoxic B-Disease
mechanisms O

Several O
machine O
learning O
and O
data O
mining O
techniques O
are O
presently O
applied O
for O
identifying O
cancer B-Disease
using O
gene B-Gene
expression I-Gene
data O

1218 O
The O
recent O
advent O
of O
genome O
and O
epigenome O
editing O
technologies O
has O
provided O
a O
new O
paradigm O
in O
which O
the O
landscape O
of O
the O
human B-Species
genome O
and O
epigenome O
can O
be O
precisely O
manipulated O
in O
their O
native O
context O

More O
effort O
is O
required O
to O
improve O
the O
selectivity O
, O
pharmacokinetics O
, O
and O
toxicity O
profiles O
of O
HDACIs B-Chemical
to O
achieve O
a O
better O
understanding O
of O
their O
efficacy O
in O
reducing O
addictive B-Disease
behavior I-Disease

As O
such O
, O
this O
range O
of O
NDDs B-Disease
displays O
a O
broad O
phenotypic O
diversity O
, O
which O
may O
be O
explained O
by O
a O
combination O
and O
interplay O
of O
underlying O
loss- O
and O
potential O
gain-of-function O
traits O

Despite O
the O
reproducible O
and O
accurate O
age O
predictions O
from O
DNA B-Chemical
methylation I-Chemical
data O
, O
these O
findings O
suggest O
they O
may O
have O
limited O
utility O
as O
currently O
designed O
in O
understanding O
the O
molecular O
biology O
of O
aging O
and O
may O
not O
be O
suitable O
as O
surrogate O
endpoints O
in O
studies O
of O
anti-aging O

methylation I-Chemical

13 O

However O
, O
when O
natural O
selection O
declines O
as O
midlife O
approaches O
, O
persistent O
, O
progressive O
, O
and O
specific O
DNA B-Gene
damage O
and O
misrepair O
changes O
the O
initial O
conditions O
of O
the O
regulatory O
process O
, O
thereby O
compromising O
morphostasis O
regulatory O
redundancy O
, O
instigating O
chaos O
, O
initiating O
senescence B-Disease
, O
and O

Using O
systematic O
search O
procedures O
the O
authors O
identified O
and O
reviewed O
41 O
studies O
of O
epigenetic O
mechanisms O
in O
psychiatric B-Disease
and O
behavioral O
phenotypes O
among O
humans B-Species

g O

This O
allows O
the O
end O
user O
to O
rapidly O
visualize O
track O
coverage O
at O
individual O
genomic O
loci O
or O
aggregated O
coverage O
profiles O
over O
sets O
of O
genomic O
loci O

Apart O
from O
this O
, O
the O
involvement O
of O
novel O
cellular O
and O
molecular O
mechanisms O
including O
the O
role O
of O
endothelin-receptor B-Chemical
antagonists I-Chemical
, O
Wnt B-Gene
signaling I-Gene
pathway I-Gene
, O
epigenetics O
and O
micro B-Gene
RNA I-Gene
is O
also O
discussed O
so O
that O
key O
molecular O
switches O
involved O
in O

We O
applied O
weighted O
gene B-Gene
correlation I-Gene
network I-Gene
analysis I-Gene
(WGCNA) O
and O
the O
Comb-p B-Gene
algorithm O
to O
find O
methylation O
modules O
and O
regions O
associated O
with O
incident O
CVD B-Disease
in O
the O

The O
aim O
of O
the O
present O
paper O
is O
to O
reveal O
a O
hidden O
history O
of O
epigenetics O
, O
by O
means O
of O
a O
multicenter O
approach O

As O
a O
key O
risk O
factor O
of O
gastric B-Disease
cancer I-Disease
, O
H B-Gene

Our O
detailed O
optimization O
protocol O
for O
efficient O
plasmid B-Chemical
delivery O
and O
measurement O
of O
single-cell O
plasmid B-Chemical
expression O
provides O
a O
comprehensive O
instruction O
for O
assessing O
both O
transient O
and O
sustained O
effects O
of O
epigenetic O
reprogramming O

generates O

Furthermore O
, O
epigenetic O
marks-DNA O
methylation B-Chemical
, O
histone B-Chemical
modifications O
, O
chromatin B-Chemical
remodeling O
, O
and O
microRNA B-Gene
- O
can O
be O
considered O
potential O
markers O
of O
cancer B-Disease
development O
and O
progression O


DNA O
methylation O
plays O
an O
important O
role O
in O
normal O
human B-Species
development O
and O
is O
associated O
with O
the O
regulation O
of O
gene B-Gene
expression O
, O
tumorigenesis B-Disease
, O
and O
other O
genetic O
and O
epigenetic O
diseases O

Methylation O
in O
blood O
correlated O
with O
that O
in O
lip O
/ O
palate O
at O
some O
regions O

In O
particular O
, O
we O
focus O
on O
three O
key O
computational O
topics O
 O
predicting O
enhancer O
locations O
, O
determining O
the O
cell-type-specific O
activity O
of O
enhancers O
, O
and O
linking O
enhancers O
to O
their O
target O
genes B-Gene

The O
molecular O
techniques O
span O
from O
classical O
polymerase B-Chemical
chain I-Chemical
reaction I-Chemical
(PCR) I-Chemical
to O
sequencing O
the O
nucleic O
acid O
composition O

With O
the O
characterization O
of O
the O
first O
loss O
of O
function O
phenotypes O
of O
the O
macroH2A B-Gene
histone I-Gene
variants I-Gene
, O
previously O
unrecognized O
epigenetic O
mechanisms O
have O
now O
moved O
into O
the O
spotlight O
of O
cancer B-Disease
research O

We O
then O
discuss O
candidate-gene O
investigations O
that O
have O
honed O
in O
on O
Th1 B-Gene
, O
Th2 B-Gene
, O
T B-Gene
regulatory I-Gene
, O
and O
innate O
genes O
of O
a O
priori O
interest O
in O
food B-Disease
allergy I-Disease

enrichment O

Multiple O
molecular O
epigenetic O
mechanisms O
exist O
, O
but O
methylation O
of O
DNA B-Chemical
so O
far O
has O
dominated O
the O
Ecological B-Disease
Epigenetic I-Disease
literature O

Results O
A O
total O
of O
181 O
DEGs B-Gene
were O
identified O

Powerful O
genetic O
and O
imaging O
approaches O
, O
combined O
with O
conservation O
of O
mammalian O
programs O
, O
have O
made O
zebrafish B-Species
a O
prominent O
model O
for O
the O
study O
of O
HSC B-Gene
production O

Here O
, O
we O
critically O
examine O
emerging O
evidence O
linking O
epigenetic O
mechanisms O
to O
the O
development O
or O
maintenance O
of O
chronic B-Disease
pain I-Disease
states O

These O
epigenetic O
mechanisms O
induce O
the O
expression O
of O
genes O
associated O
with O
transcriptional O
regulation O
, O
endometrial B-Disease
epithelial I-Disease
growth I-Disease
, O
angiogenesis O
, O
and O
stromal O
cell O
proliferation O
during O
the O
proliferative O
phase O

jetbrains O

DNA O
modification O
, O
mediated O
by O
restriction-modification O
systems O
, O
functions O
as O
an O
immune O
response O
against O
antagonistic O
external O
DNA O
, O
and O
bacteriophage-acquired O
methyltransferases B-Chemical
( O
MTase B-Gene
) O
and O
orphan O
MTases B-Gene
- O
those O
lacking O
the O
cognate O
restriction O
endonuclease O
- O
facilitate O
evolution O
of O
new O

Furthermore O
, O
BBA-seq O
data O
revealed O
that O
the O
correlation O
of O
methylation O
levels O
with O
age O
at O
neighboring O
CpG O
sites O
follows O
a O
bell-shaped O
curve O
, O
often O
associated O
with O
a O
binding O
site O

Finally O
, O
we O
discuss O
the O
role O
neutrophils B-Gene
play O
in O
adaptive O
pathologies O
with O
a O
focus O
on O
tumour B-Disease
initiation I-Disease
and O
progression O

Methods O
 O
In O
the O
German O
birth O
cohort O
KUNO-Kids O
we O
assessed O
when O
information O
for O
such O
scores O
may O
be O
best O
collected O
and O
how O
to O
calculate O
an O
adapted O
FLoSS B-Gene

While O
selective O
personalized O
therapies O
are O
conceptually O
impressive O
, O
the O
majority O
of O
cancer B-Disease
therapies O
have O
dismal O
outcome O

Ecological O
epigenetic O
studies O
are O
in O
their O
infancy O
, O
but O
it O
is O
paramount O
for O
the O
field O
to O
move O
forward O
to O
have O
detailed O
information O
about O
tissue O
and O
time O
dependence O
relationships O
in O
methylation O
to O
gain O
insights O
into O
if O
blood O
DNA B-Chemical
methylation O
patterns O
can O
be O
a O
reliable O
bioindicator O

1422 O
Lactate B-Chemical
, O
which O
is O
an O
end O
product O
of O
glycolysis O
, O
has O
traditionally O
been O
considered O
a O
metabolic O
waste O

393 O
Epigenetic O
enzymes O
regulate O
higher-order O
chromatin O
architecture O
and O
cell-type O
specific O
gene O
expression O

14 O
days O
) O

3 O
 O
Fibromyalgia B-Disease
is O
a O
disease O
characterized O
by O
chronic O
widespread O
pain O
with O
additional O
symptoms O
, O
such O
as O
joint O
stiffness O
, O
fatigue O
, O
sleep O
disturbance O
, O
cognitive O
dysfunction O
, O
and O
depression O

The O
high-resolution O
chromatographic O
separation O
along O
with O
sensitive O
MS B-Chemical
detection O
permits O
the O
identification O
and O
quantification O
of O
deoxyribonucleosides B-Chemical
with O
precision O
and O
reliability O

g O

Particularly O
, O
it O
facilitates O
novel O
interdisciplinary O
collaborations O
and O
attracts O
actors O
in O
health O
advocacy O
who O
are O
interested O
in O
non-deterministic O
readings O
of O
ACEs B-Gene
that O
counteract O
stigma O
and O
support O
positive O
health O
interventions O
and O
healing O

Here O
we O
discuss O
key O
features O
of O
the O
method O
and O
debunk O
misconceptions O
using O
empirical O
data O

Applied O
to O
single O
cell O
ATAC-seq O
, O
BROCKMAN O
readily O
distinguished O
cell O
types O
, O
treatments O
, O
batch O
effects O
, O
experimental O
artifacts O
, O
and O
cycling O
cells O

In O
this O
review O
, O
we O
introduce O
several O
examples O
of O
natural O
and O
induced O
epigenetic O
changes O
impacting O
on O
agronomic O
traits O
and O
discuss O
the O
methods O
for O
generating O
epigenomic O
diversity O
and O
site-specific O
epigenetic O
engineering O

Moreover O
, O
feasible O
suggestions O
on O
precision O
healthcare O
and O
healthy O
longevity O
are O
kindly O
proposed O
based O
on O
the O
comprehensive O
review O
of O
current O
studies O

The O
laboratory O
is O
also O
involved O
in O
a O
case O
control O
study O
of O
asbestos-associated B-Disease
mesothelioma I-Disease
, O
arsenic B-Chemical
exposure O
, O
cigarette B-Chemical
smoking O
and O
bladder B-Disease
cancer I-Disease

Research O
also O
suggests O
adverse O
early O
life O
experiences O
are O
associated O
with O
changes O
in O
gene O
expression O
of O
multiple O
known O
candidate O
genes O
, O
genes O
involved O
in O
DNA B-Chemical
transcription O
and O
translation O
, O
and O
genes O
necessary O
for O
brain O
circuitry O
development O
, O
with O
changes O
in O
gene O
expression O
reported O
in O
key O
brain O
structures O

gene B-Gene

This O
epigenetic O
toolkit O
can O
be O
easily O
altered O
with O
a O
large O
variety O
of O
epigenetic O
effectors O
and O
is O
a O
useful O
tool O
for O
researchers O
to O
use O
in O
understanding O
gene-specific O
epigenetic O
changes O
and O
their O
relation O
to O
gene B-Gene
expression O

Furthermore O
, O
the O
histologic O
diagnosis O
of O
dysplasia B-Disease
can O
be O
subjective O
and O
is O
thus O
prone O
to O
a O
considerable O
range O
of O
interpretation O

neural O

Plant O
DNA B-Gene
is O
normally O
highly O
methylated O
, O
although O
notable O
differences O
exist O
between O
species B-Species

We O
discuss O
the O
influences O
of O
the O
model O
and O
its O
broader O
theoretical O
framework O
on O
the O
first O
generation O
of O
synthetic O
biological O
circuits O
, O
which O
were O
predominantly O
transcriptional O
and O
posttranscriptional O
circuits O

However O
, O
over O
the O
past O
several O
years O
, O
these O
advances O
in O
the O
ability O
to O
measure O
genetic O
( O
or O
heritable O
) O
contributions O
to O
medical O
illness B-Disease
have O
been O
joined O
by O
advances O
in O
epigenetic O
( O
or O
acquired O
) O
contributions O
to O
common O
medical O
illnesses B-Disease

We O
performed O
systematic O
literature O
searches O
in O
five O
databases O

Epigenetic O
mechanisms O
such O
as O
DNA B-Chemical
methylation I-Chemical
are O
important O
factors O
that O
mediate O
the O
environmental O
effect O
in O
the O
genome O
by O
regulating O
gene B-Gene
expression I-Gene
and O
consequently O
its O
effect O
on O
the O
phenotype O
and O
the O
development O
of O
disease B-Disease

This O
review O
will O
cover O
recent O
findings O
from O
large-scale O
genome-wide O
association O
studies O
as O
well O
as O
newer O
epigenome-wide O
studies O

Although O
still O
in O
early O
development O
, O
epigenetic O
studies O
in O
SLE B-Disease
are O
expected O
to O
reveal O
novel O
therapeutic O
targets O
and O
disease O
biomarkers O
in O
autoimmunity O

Therefore O
, O
the O
integration O
of O
multi-omics O
data O
including O
epigenomics O
is O
now O
important O
for O
classifying O
primary O
brain B-Disease
tumors I-Disease
and O
predicting O
their O
biological O
behavior O

013 O
to O
0 O

To O
bolster O
the O
review O
of O
these O
topics O
, O
we O
include O
novel O
analyses O
to O
assess O
the O
effect O
of O
gbM B-Gene
on O
transcripts O

1447 O
 O
Our O
understanding O
of O
the O
minimal O
residual O
disease B-Disease
( O
MRD B-Disease
) O
in O
solid O
cancers B-Disease
indicates O
that O
it O
can O
persist O
in O
the O
system O
for O
years O
or O
even O
decades O

Considering O
its O
ubiquitous O
presence O
in O
divergent O
clinical B-Disease
pathologies I-Disease
, O
quantitative O
analysis O
of O
DNA B-Gene
CpG I-Gene
methylation I-Gene
both O
globally O
and O
at O
individual O
genes O
helps O
to O
elucidate O
the O
regulation O
of O
genes O
involved O
in O
pathophysiological B-Disease
conditions I-Disease

110 O
 O
The O
convened O
a O
research O
symposium O
, O
" O
Epigenetics O
and O
Epigenomics O
 O
Implications O
for O
Diabetes B-Disease
and O
Obesity B-Disease
" O
on O
17-19 O
November O
2017 O

interplay O

Investigative O
use O
of O
CCSs O
in O
biological O
and O
medical O
research O
shows O
promise O
in O
identifying O
the O
likelihood O
that O
a O
disease B-Disease
state I-Disease
is O
present O
or O
absent O
, O
as O
well O
as O
an O
ability O
to O
prospectively O
stratify O
individuals O
according O
to O
their O
likely O
response O
to O
medical O
intervention O

545 O
Cancer B-Disease
epigenetics O
is O
one O
of O
the O
most O
important O
research O
subjects O
in O
dissecting O
cancer B-Disease
mechanisms O
and O
therapeutic O
targets O
because O
the O
emergence O
and O
malignant O
transformation O
of O
various O
cancers B-Disease
are O
caused O
by O
unnatural O
expression O
of O
cancer-related O
genes B-Gene
attributed O
to O
their O
epigenetic O
errors O


However O
, O
due O
to O
the O
lack O
of O
efficient O
collection O
, O
standardized O
quality O
control O
, O
and O
analysis O
procedures O
, O
efficiently O
integrating O
and O
reusing O
these O
data O
remain O
considerable O
challenges O

Here O
, O
Li O
and O
colleagues O
begin O
to O
fill O
these O
gaps O
by O
identifying O
the O
loss O
of O
the O
DNA B-Chemical
hydroxymethylation I-Chemical
mark I-Chemical
5-hmC I-Chemical
in O
psoriasis B-Disease
and O
presenting O
compelling O
evidence O
for O
its O
potential O
contribution O
to O
disease O
manifestations O

14 O

The O
effect O
of O
genetic O
polymorphism O
has O
accrued O
considerable O
interest O
and O
population O
polymorphism O
leading O
to O
variation O
in O
drug B-Chemical
response I-Chemical
is O
being O
studied O
extensively O

of O

Substantial O
progress O
has O
been O
made O
in O
identifying O
the O
signaling O
pathways O
and O
transcriptional O
networks O
that O
orchestrate O
alterations O
of O
adipocyte O
gene B-Gene
expression I-Gene
linked O
to O
diverse O
phenotypes O

949 O
Intra-tumoral O
epigenetic O
heterogeneity O
is O
an O
indicator O
of O
tumor O
population O
fitness O
and O
is O
linked O
to O
the O
deregulation O
of O
transcription O

They O
report O
on O
the O
evidence O
of O
epigenetic O
alterations O
in O
schizophrenia B-Disease
and O
their O
relevance O
to O
pharmacological O
studies O

DNA O
methylation O
was O
measured O
in O
whole O
blood O



Finally O
, O
we O
review O
the O
methodological O
limitations O
that O
could O
hinder O
interpretation O
of O
epigenetic O
data O
in O
psychiatry B-Disease

1327Background O
Epigenetic B-Chemical
data I-Chemical
could O
help O
identify O
risk O
factors O
for O
orofacial B-Disease
clefts I-Disease
, O
either O
by O
revealing O
a O
causal O
role O
for O
epigenetic B-Chemical
mechanisms I-Chemical
in O
causing O
clefts B-Disease
or O
by O
capturing O
information O
about O
causal O
genetic B-Gene
or O
environmental O
factors O

Here O
, O
we O
examine O
current O
and O
future O
questions O
about O
the O
roles O
of O
DNA B-Gene
methylation I-Gene
mechanisms O
as O
causal O
factors O
in O
the O
processes O
of O
aging B-Disease
and O
cancer B-Disease
so O
that O
we O
may O
better O
understand O
if O
and O
how O
aging-associated B-Disease
epigenetic O
alterations O
lead O
to O
tumorigenesis B-Disease

Moreover O
, O
the O
authors O
discuss O
the O
characteristics O
of O
epigenetic O
regulation O
in O
the O
process O
of O
MI B-Disease
and O
cardiac O
repair O
including O
the O
methylating O
of O
DNA B-Chemical
, O
modification O
of O
histone B-Chemical
, O
remodeling O
of O
the O
chromatin B-Chemical
, O
and O
micro-RNA B-Gene
expression O
, O
mediating O
cellular O

Robust O
, O
high-throughput O
single-cell O
DNA B-Chemical
methylation I-Chemical
assays O
are O
now O
possible O
( O
sciMET O
) O
; O
however O
, O
the O
genome-wide O
nature O
of O
DNA B-Chemical
methylation I-Chemical
results O
in O
a O
high O
sequencing O
burden O
per O
cell O


Finally O
, O
genes O
; O
GRIK2 B-Gene
, O
TRAF1 B-Gene
, O
BICC1 B-Gene
, O
STAG1 B-Gene
were O
epigenetically O
sensitive O
to O
acute O
exercise O
demonstrating O
hypomethylation O
after O
a O
single O
bout O
of O
resistance O
exercise O
that O
was O
maintained O
22 O
weeks O
later O
with O
the O
largest O
increase O
in O
gene O
expression O
and O
muscle O

The O
average O
pairwise O
correlation O
coefficients O
between O
CpGs O
were O
enhanced O
after O
selection O
for O
the O
replication O
( O
e O

Greater O
extrinsic O
age O
acceleration O
was O
associated O
with O
taking O
fewer O
steps O
(regression O
coefficient O
(95% O
CI) O
- O
0 O

829 O
The O
immune O
system O
plays O
a O
dual O
role O
in O
human B-Species
health O
, O
functioning O
both O
as O
a O
protector O
against O
pathogens O
and O
, O
at O
times O
, O
as O
a O
contributor O
to O
disease B-Disease

917 O
Severe O
or O
chronic O
stress O
and O
trauma O
can O
have O
a O
detrimental O
impact O
on O
health O

of O
the O
co-occurrence O
of O
different O
epigenetic O
marks O
in O
different O
cell O
types O

Second O
, O
we O
show O
on O
this O
basis O
that O
epigenetics O
has O
progressively O
turned O
its O
main O
focus O
from O
biological O
problems O
regarding O
development O
, O
toward O
issues O
concerning O
evolution O

PAT-ChIP O
provides O
, O
for O
the O
first O
time O
, O
the O
chance O
to O
perform O
analyses O
of O
histone B-Chemical
modifications O
and O
transcription O
factor O
binding O
on O
a O
genome-wide O
scale O
using O
patient-derived O
FFPE O
samples O

617 O
To O
fully O
exploit O
the O
potentials O
of O
reprogramming O
the O
epigenome O
through O
CRISPR/dCas9 B-Gene
systems O
for O
epigenetic O
editing O
, O
there O
is O
a O
growing O
need O
for O
improved O
transfection O
methods O

In O
this O
review O
we O
describe O
recent O
advances O
in O
the O
field O
of O
cancer B-Disease
epigenomics O
concerning O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
and O
miRNAs B-Gene

The O
review O
identifies O
areas O
of O
future O
research O
in O
epigenetic O
responses O
to O
environmental O
temperature O
change O

tau O

It O
outperforms O
other O
methods O
in O
terms O
of O
interpreting O
and O
reproducing O
the O
identified O
cCREs O
clusters O

The O
studies O
of O
aDNA B-Gene
have O
shed O
light O
on O
the O
history O
of O
human O
migration O
, O
replacement O
of O
populations O
, O
interbreeding O
of O
Cro-Magnons B-Species
with O
Neanderthals B-Species
and O
Denisovans B-Species
, O
evolution O
of O
human O
pathogens O
, O
etc O

How O
can O
a O
memory O
persist O
beyond O
the O
lifetimes O
of O
its O
constitutive O
molecular O
building O
blocks O
? O
Epigenetics O
- O
changes O
in O
gene B-Gene
expression O
that O
do O
not O
alter O
the O
underlying O
DNA B-Gene
sequence O
- O
may O
be O
the O
answer O

As O
DNA B-Gene
binding O
transcription O
factors O
, O
they O
exhibit O
tremendous O
variability O
and O
complexity O
in O
their O
DNA B-Gene
recognition O
patterns O

135 O
Epigenetics O
is O
the O
study O
of O
changes O
in O
gene B-Gene
expression I-Gene
that O
occur O
without O
changes O
in O
DNA B-Gene
sequence I-Gene

155 O
 O
Interindividual O
variability O
is O
an O
inherent O
characteristic O
of O
biological O
systems O

10 O
) O
and O
1 O

albrecht@mpi-inf O

1259 O
Gestational B-Disease
diabetes I-Disease
mellitus I-Disease
( O
GDM B-Disease
) O
is O
the O
most O
common O
metabolic O
complication O
in O
pregnancy O
, O
which O
affects O
the O
future O
health O
of O
both O
the O
mother O
and O
the O
newborn O

We O
present O
PRISM O
, O
a O
tool O
for O
inferring O
the O
composition O
of O
epigenetically O
distinct O
subclones O
of O
a O
tumor B-Disease
solely O
from O
methylation O
patterns O
obtained O
by O
reduced O
representation O
bisulfite B-Chemical
sequencing I-Chemical

We O
hypothesized O
that O
the O
variation O
of O
SWI/SNF B-Gene
subunit I-Gene
expression O
in O
the O
human B-Species
population O
would O
contribute O
to O
variability O
in O
the O
efficiency O
of O
induced B-Disease
pluripotent I-Disease
stem I-Disease
cells I-Disease
(iPSC) I-Disease
reprogramming O

Moreover O
, O
combining O
the O
clustered O
epigenetic O
data O
with O
information O
on O
the O
expression O
status O
of O
associated O
genes B-Gene
we O
classify O
differences O
in O
epigenetic O
status O
of O
e O

The O
mechanisms O
underlying O
PCa B-Disease
progression O
and O
therapy O
resistance O
are O
multiple O
and O
include O
metabolic O
reprogramming O
, O
especially O
in O
relation O
to O
lipid B-Chemical
metabolism O
, O
as O
well O
as O
epigenetic O
remodelling O
, O
both O
of O
which O
enable O
cancer O
cells O
to O
adapt O
to O
dynamic O
changes O
in O
the O
tumour O

The O
methodology O
involves O
a O
thorough O
analysis O
of O
existing O
literature O
, O
including O
pertinent O
books O
, O
academic O
journals O
, O
and O
online O
resources O
, O
to O
provide O
a O
comprehensive O
overview O
of O
the O
role O
of O
epigenetic O
studies O
in O
IMF O
deposition O
in O
beef B-Species
cattle I-Species

few O

Moreover O
, O
we O
consider O
the O
Jensen-Shannon O
distance O
between O
sample-specific O
energy O
landscapes O
as O
a O
measure O
of O
epigenetic O
dissimilarity O
and O
demonstrate O
its O
effectiveness O
for O
discerning O
epigenetic O
differences O

Here O
we O
describe O
the O
guanidine B-Chemical
thiocyanate I-Chemical
method O
reported O
by O
Hossain B-Gene
with O
additional O
modifications O
resulting O
in O
high O
molecular O
weight O
DNA B-Gene
of O
high O
quality O
with O
an O
A260/280 B-Chemical
ratio I-Chemical
ranging O
between O
1 O

This O
emerging O
evidence O
, O
together O
with O
work O
examining O
related O
biological O
processes O
, O
begins O
to O
shed O
light O
on O
the O
epigenetic O
and O
, O
more O
broadly O
, O
molecular O
underpinnings O
of O
the O
long-hypothesized O
connection O
between O
and O

GeNemo O
is O
the O
first O
online O
search O
tool O
that O
accomplishes O
this O
goal O

Here O
, O
we O
introduce O
CFEA O
( O
http//www O

Finally O
, O
epigenetics O
offers O
multiple O
clinical O
applications O
, O
including O
powerful O
diagnostic O
and O
prognostic O
biomarkers O
as O
well O
as O
therapeutic O
targets O

254 O
Allergic B-Disease
disease I-Disease
development O
is O
affected O
by O
both O
genes B-Gene
and O
the O
environment O
, O
and O
epigenetic O
mechanisms O
are O
hypothesized O
to O
mediate O
these O
environmental O
effects O

819 O
The O
perinatal O
period O
is O
a O
window O
of O
susceptibility O
for O
later O
life O
disease B-Disease

mpg O

Expression O
of O
GSTM3 B-Gene
, O
DNA B-Chemical
methylation I-Chemical
, O
and O
histone B-Chemical
modification I-Chemical
were O
assessed O
by O
quantificational O
real-time O
PCR O
, O
Western B-Chemical
blot I-Chemical
, O
bisulfite-sequencing B-Chemical
PCR I-Chemical
, O
pyrosequencing B-Chemical
, O
and O
chromatin B-Chemical
immunoprecipitation I-Chemical
assay I-Chemical

Accelerated O
aging O
, O
calculated O
from O
the O
discrepancy O
between O
the O
chronological O
age O
and O
the O
epigenetic O
age O
, O
has O
shown O
to O
predict O
morbidity B-Disease
and I-Disease
mortality I-Disease
rate O

We O
introduce O
a O
schematic O
, O
analytically O
solvable O
mathematical O
model O
to O
compare O
the O
adaptive O
value O
of O
different O
schemes O
of O
inheritance O

Causal O
inference O
test O
( O
CIT O
) O
identified O
the O
causal O
regulation O
chains O

This O
includes O
DNA B-Gene
methylation O
, O
histone B-Chemical
modifications O
, O
chromatin B-Chemical
remodeling O
, O
microRNAs B-Gene
, O
and O
long B-Gene
non-coding I-Gene
RNAs I-Gene

These O
epigenetic O
mechanisms O
are O
involved O
in O
complex O
and O
dynamic O
processes O
that O
modulate O
post-stroke B-Disease
gene B-Gene
expression I-Gene
, O
cellular O
injury O
response O
, O
motor O
function O
, O
and O
cognitive O
ability O

On O
the O
other O
, O
however O
, O
the O
topology O
of O
his O
famous O
epigenetic O
landscape O
was O
anchored O
only O
in O
the O
genome B-Gene
, O
and O
the O
variation O
of O
the O
environment O
was O
treated O
as O
an O
external O
perturbation O

748 O
LINE-1 B-Gene
hypomethylation O
of O
cell-free O
DNA B-Gene
has O
been O
described O
as O
an O
epigenetic O
biomarker O
of O
human B-Species
aging O

774Objective O
In O
this O
review O
, O
we O
have O
highlighted O
the O
advances O
over O
the O
past O
year O
in O
genetics O
, O
genomics O
and O
epigenetics O
in O
the O
ï¬eld O
of O
osteoarthritis B-Disease
( O
OA B-Disease
) O

149 O
 O
Background O
 O
One O
of O
the O
fundamental O
assumptions O
of O
DNA B-Gene
methylation I-Gene
in O
clinical O
epigenetics O
is O
that O
DNA B-Gene
methylation I-Gene
status O
can O
change O
over O
time O
with O
or O
without O
interplay O
with O
environmental O
and O
clinical O
conditions O

Since O
then O
, O
the O
field O
has O
rapidly O
grown O

These O
findings O
give O
rise O
for O
further O
studies O
on O
factors O
that O
targets O
methylation O
of O
revealed O
genes B-Gene

The O
function O
of O
a O
number O
of O
rice B-Species
epigenetic O
regulators O
has O
been O
studied O
, O
many O
of O
which O
are O
found O
to O
be O
involved O
in O
a O
diverse O
range O
of O
developmental O
and O
stress-responsive O
pathways O

Transcriptome O
and O
proteome O
analyses O
revealed O
correlations O
with O
oxidation-reduction O
, O
metabolic O
, O
and O
immune O
response O
pathways O

691 O
The O
epigenetic O
landscape O
, O
which O
in O
part O
includes O
DNA B-Chemical
methylation I-Chemical
, O
chromatin O
organization O
, O
histone O
modifications O
, O
and O
noncoding O
RNA B-Gene
regulation O
, O
greatly O
contributes O
to O
the O
heterogeneity O
that O
makes O
developing O
effective O
therapies O
for O
lung B-Disease
cancer I-Disease
challenging O

Advances O
in O
our O
understanding O
of O
chromatin B-Gene
and O
gene B-Gene
regulatory O
mechanisms O
have O
had O
impact O
on O
drug B-Chemical
development O
, O
fueling O
excitement O
in O
the O
lay O
public O
about O
the O
prospects O
of O
applying O
this O
knowledge O
to O
address O
health B-Disease
issues I-Disease

These O
demethylating B-Chemical
agents I-Chemical
may O
induce O
T-cell B-Gene
attraction O
and O
enhance O
immune B-Gene
checkpoint I-Gene
inhibitor I-Gene
efficacy O
in O
mouse B-Species
models O

mapping O

991 O
years O

But O
is O
recovery O
of O
ovarian B-Species
fitness O
possible O
, O
even O
if O
only O
briefly O
prior O
to O
IVF B-Disease
? O
Alterations O
in O
gap O
junctions O
, O
bio-conductive O
features O
, O
and O
modulation O
of O
gene B-Gene
regulatory I-Gene
networks I-Gene
after O
PRP B-Chemical
use O
in O
other O
tissues O
are O
discussed O
here O
alongside O

The O
results O
reveal O
the O
existence O
of O
parallel O
accelerated O
regions O
( O
pARs O
) O
in O
distant O
hibernators B-Species

Although O
researchers O
have O
been O
focusing O
on O
DNA B-Gene
methylation O
when O
studying O
monozygotic B-Species
(MZ) I-Species
twins I-Species
, O
a O
great O
model O
in O
epigenetics O
research O
, O
interactions O
between O
genetics O
and O
epigenetics O
in O
chromatin B-Chemical
level O
are O
expected O
to O
be O
an O
imperative O
research O
trend O
in O
the O
future O

The O
epigenetic O
model O
of O
aging O
postulates O
that O
there O
are O
epigenetic O
marks O
of O
aging O
that O
increase O
with O
age O
, O
leading O
to O
a O
progressive O
derepression O
of O
DNA B-Gene
which O
in O
turn O
causes O
deregulated O
expression O
of O
genes O
that O
disrupt O
cell O
function O

7 O
years O
) O
from O
the O
Genetic O
Epidemiology O
Network O
of O
Arteriopathy B-Disease
( O
GENOA B-Gene
) O
study O
, O
we O
measured O
DNA B-Gene
methylation I-Gene
levels O
using O
Illumina B-Chemical
HumanMethylation I-Chemical
BeadChips I-Chemical

However O
, O
these O
elements O
have O
high O
mutational O
rates O
, O
particularly O
Alu B-Gene
sequences O
, O
which O
could O
lead O
to O
assay O
bias O
and O
masking O
of O
changes O
at O
a O
regional O
level O

90 O
Epigenetics O
is O
mainly O
comprised O
of O
features O
that O
regulate O
genomic O
interactions O
thereby O
playing O
a O
crucial O
role O
in O
a O
vast O
array O
of O
biological O
processes O

The O
goal O
of O
this O
paper O
is O
to O
review O
studies O
of O
the O
genetics O
of O
these O
stress-related O
psychiatric B-Disease
disorders I-Disease

, O
different O
enhancer O
sub-classes O
) O

Plant O
epigenomics O
expands O
, O
the O
potential O
for O
sustainable O
agriculture O
by O
implementing O
advanced O
epigenetic O
approaches O
becomes O
increasingly O
evident O

All O
epigenetic O
effects O
are O
considered O
in O
light O
of O
their O
persistent O
changes O
induced O
in O
the O
postsynaptic O
neurons O
including O
sensitization O
and O
desensitization O
, O
priming O
, O
and O
shift O
of O
neuronal O
phenotype O

As O
for O
other O
malignancies O
, O
aberrant O
DNA B-Gene
methylation I-Gene
has O
been O
shown O
to O
play O
a O
crucial O
role O
in O
the O
initiation O
and O
progression O
of O
bladder B-Disease
cancer I-Disease
, O
and O
thus O
holds O
great O
promise O
as O
a O
diagnostic O
and O
prognostic O
biological O
marker O

Epigenetic O
modifications O
can O
influence O
drug O
efficacy O
by O
altering O
gene B-Gene
expression I-Gene
via O
changing O
chromatin B-Chemical
structure I-Chemical

Age B-Disease
- I-Disease
associated I-Disease
DNA B-Gene
methylation I-Gene
changes O
provide O
a O
promising O
biomarker O
for O
the O
aging B-Disease
process I-Disease

If O
this O
is O
the O
case O
, O
an O
imperative O
exists O
to O
reconcile O
lifespan/longevity O
associated O
inherited O
epigenetic O
processes O
with O
the O
evolution O
of O
ageing O

This O
review O
provides O
a O
mechanism-based O
understanding O
and O
comparative O
overview O
of O
the O
most O
common O
techniques O
for O
detecting O
the O
status O
of O
epigenetic O
effects O
, O
including O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical
, O
for O
applicable O
approaches O
from O
low- O
to O
high-throughput O
scales O

Remarkable O
progress O
has O
been O
made O
over O
the O
last O
decade O
in O
developing O
methodologies O
to O
investigate O
DNA B-Gene
methylation I-Gene

One O
of O
the O
major O
discoveries O
from O
retinoblastoma B-Disease
sequencing O
studies O
is O
that O
some O
retinoblastoma B-Disease
tumors O
have O
stable O
genomes O

After O
mapping O
these O
events O
to O
known O
genes B-Gene
, O
significant O
enrichment O
of O
a O
subset O
of O
these O
pathways O
suggested O
that O
arsenic-mediated B-Chemical
methylation O
may O
be O
both O
specific O
and O
non-specific O

Furthermore O
, O
various O
diseases O
such O
as O
cancer B-Disease
have O
been O
found O
to O
be O
associated O
with O
epigenetic O
mechanisms O

Errors O
in O
this O
process O
can O
lead O
to O
transmission O
of O
epimutations O
through O
the O
germ-line O
, O
which O
have O
the O
potential O
to O
affect O
development O
and O
disease B-Disease
in O
the O
progeny O

Recent O
studies O
have O
investigated O
the O
role O
of O
an O
oxidized O
form O
of O
DNA B-Gene
methylation O
- O
5-hydroxymethylcytosine B-Chemical
( O
5hmC B-Chemical
) O
- O
in O
the O
epigenome O
, O
but O
its O
contribution O
to O
age-related B-Disease
DNA B-Gene
methylation O
remains O
unclear O

They O
also O
provided O
a O
capillary O
blood O
sample O
for O
DNA B-Chemical
extraction O
and O
analysis O
of O
four O
CpG B-Gene
sites I-Gene
via O
bisulfite O
conversion O
within O
Exon B-Gene
1 I-Gene
of O
TNF B-Gene

DNAm O
differences O
between O
patients O
with O
and O
without O
POD B-Disease
were O
examined O

1455 O
 O
Background O
 O
The O
impact O
of O
cell-composition O
effects O
in O
analysis O
of O
DNA B-Chemical
methylation I-Chemical
data O
is O
now O
widely O
appreciated O

Our O
understanding O
of O
the O
processes O
of O
memory O
T-cell B-Species
differentiation O
and O
maintenance O
of O
long-term O
immunity O
is O
continuously O
evolving O
, O
and O
recent O
advances O
highlight O
new O
regulatory O
networks O
and O
chromatin O
dynamic O
changes O
contributing O
to O
maintain O
T-cell B-Species
identity O
and O
impeding O
the O
reprogramming O
of O
specific O
T-cell B-Species

Here O
, O
we O
review O
some O
of O
the O
technological O
advances O
in O
this O
rapidly O
developing O
field O
, O
identify O
the O
conceptual O
challenges O
and O
discuss O
approaches O
that O
are O
needed O
to O
rigorously O
test O
the O
biological O
function O
of O
specific O
RNA B-Chemical
modifications I-Chemical

69 O
nm O
which O
helped O
us O
achieve O
two O
critical O
parameters O
for O
epigenomics O
monitoring O
 O
efficient O
nuclear O
uptake O
( O
98 O
% O
) O
without O
complex O
functionalization O
and O
no O
conformational O
nuclear O
changes O

In O
this O
article O
, O
epigenetic O
mechanisms O
including O
DNA B-Chemical
methylation I-Chemical
and O
acetylation B-Chemical
or O
methylation B-Chemical
of O
the O
histone B-Chemical
proteins I-Chemical
that O
package O
DNA B-Chemical
are O
described O
in O
the O
context O
of O
animal B-Species
learning O

Conclusions O
 O
Our O
findings O
provide O
insight O
into O
the O
epigenetic O
crosstalk O
regulating O
the O
CG B-Gene
methylation I-Gene
pattern I-Gene
in O
mammalian B-Species
oocytes O
and O
other O
cells O

However O
, O
the O
large O
and O
diverse O
bioinformatic O
and O
statistical O
methods O
, O
referring O
to O
the O
confounders O
of O
the O
statistical O
models O
, O
application O
of O
multiple-testing O
adjustment O
methods O
, O
questions O
regarding O
the O
correlation O
of O
DNAm B-Gene
across O
tissues O
, O
and O
sex-dependent O
differences O
in O
results O
, O
have O
raised O

The O
majority O
of O
current O
techniques O
are O
invasive O
and O
difficult O
to O
translate O
to O
what O
is O
happening O
within O
a O
human B-Species
brain O
in O
vivo O

1283 O
Epigenetic O
pharmacotherapies O
have O
emerged O
as O
a O
promising O
treatment O
option O
for O
substance O
use O
disorder B-Disease
(SUD) I-Disease
due O
to O
their O
ability O
to O
reverse O
maladaptive O
transcriptional O
and O
behavioral O
responses O
to O
drugs O
of O
abuse O

, O
CD3D B-Gene
, O
CD3E B-Gene
) O
, O
CTLA4 B-Gene
, O
and O
GZMA B-Gene

685 O
Genomic O
editing O
technology O
has O
been O
developed O
since O
2010 O
through O
the O
use O
of O
some O
techniques O
, O
such O
as O
the O
clustered O
regularly O
interspaced O
short O
palindromic O
repeat O
( O
CRISPR B-Gene
) O
DNA B-Chemical
sequences O
/ O
CRISPR-associated B-Gene
( O
Cas B-Gene
) O
type-9 O
method O
, O
or O
through O

listing O

Over O
600 O
questionnaires O
were O
completed O
, O
with O
391 O
included O
in O
the O
analysis O

Epigenetic O
functions O
result O
partly O
from O
modification O
of O
the O
nucleobases O
in O
DNA B-Gene
and O
RNA B-Gene
, O
and/or O
post-translational O
modifications O
of O
proteins O

Our O
review O
highlights O
that O
two O
molecular O
bearers O
of O
epigenetic O
information O
, O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical
, O
are O
key O
features O
for O
development O
in O
mollusk B-Species
species I-Species
, O
and O
both O
are O
sensitive O
to O
environmental O
conditions O
to O
which O
developing O
individuals O
are O
exposed O

S O

1426Background O
Hashimoto B-Disease
thyroiditis I-Disease
( O
HT B-Disease
), O
a O
prevalent O
autoimmune O
disorder O
, O
is O
not O
yet O
thoroughly O
understood O
, O
especially O
when O
it O
comes O
to O
the O
influence O
of O
epigenetics O
in O
its O
pathogenesis O

Therefore O
, O
it O
is O
not O
known O
if O
the O
parental O
effects O
are O
the O
result O
of O
developmental O
or O
phenotypic O
plasticity O
or O
if O
the O
altered O
phenotypes O
are O
durably O
passed O
to O
subsequent O
generations O

The O
Collection O
represents O
the O
gradual O
growth O
in O
our O
understanding O
of O
the O
overall O
process O
of O
how O
cancer B-Disease
progresses O
, O
along O
with O
the O
factors O
that O
play O
a O
decisive O
role O
in O
this O
progression O

1227 O
Metastable O
and O
somatically O
heritable O
patterns O
of O
DNA B-Chemical
methylation I-Chemical
provide O
an O
important O
level O
of O
genomic O
regulation O

This O
is O
mostly O
achieved O
through O
rhythmic O
regulation O
of O
myriad O
genes B-Gene
via O
dynamic O
epigenome O
changes O

Moreover O
, O
it O
has O
recently O
been O
demonstrated O
that O
epigenetic O
modifications O
are O
more O
susceptible O
to O
alterations O
induced O
by O
environmental O
factors O
than O
are O
DNA B-Chemical
sequences O
, O
and O
that O
some O
drugs O
commonly O
used O
reverse O
mental-stress O
induced O
alterations O
to O
histone B-Chemical
modifications O
in O
neural O
genes B-Gene

Given O
the O
lack O
of O
additional O
somatic O
mutation O
, O
the O
role O
of O
epigenetic O
regulation O
in O
cell O
specification O
, O
and O
our O
prior O
results O
of O
germline O
KMT2C B-Gene
variation O
in O
infant O
leukaemia B-Disease
patients O
, O
we O
hypothesized O
that O
germline O
dysfunction O
of O
KMT2C B-Gene
altered O
haematopoietic O

In O
order O
to O
accommodate O
these O
biological O
effects O
, O
we O
propose O
a O
hybrid O
Bayesian O
method O
to O
learn O
tissue-specific O
pairwise O
influence O
models O
amongst O
genes B-Gene
and O
to O
predict O
a O
gene's B-Gene
expression O
level O
as O
a O
nonlinear-function O
of O
its O
epigenetic O
and O
regulatory O
influences O

Accurate O
estimation O
of O
the O
epigenetic O
state O
has O
vast O
medical O
and O
biological O
implications O

power O

Gene O
expression O
is O
known O
to O
change O
in O
characteristic O
ways O
with O
age O
, O
and O
in O
particular O
DNA B-Chemical
methylation I-Chemical
changes O
in O
age-related O
ways O

EpiSAFARI O
employs O
a O
novel O
smoothing O
method O
for O
decreasing O
noise O
in O
signal O
profiles O
and O
accounts O
for O
technical O
factors O
such O
as O
sparse O
signals O
, O
mappability O
and O
nucleotide B-Chemical
content I-Chemical

However O
, O
such O
inferences O
still O
suffer O
from O
a O
lack O
of O
statistical O
resolution O
for O
recent O
, O
for O
example O
bottlenecks O
, O
events O
, O
and/or O
for O
populations O
with O
small O
nucleotide O
diversity O

Such O
long O
periods O
of O
different O
phenotypic O
states O
can O
be O
formed O
due O
to O
the O
existence O
of O
more O
than O
one O
stable O
state O
in O
the O
molecule O
concentration O
, O
where O
the O
different O
states O
are O
explored O
through O
molecular O
fluctuations O

Integrating O
the O
different O
components O
of O
the O
epigenome O
from O
these O
multiomics O
measures O
allows O
investigations O
of O
cis-regulatory O
elements O
on O
a O
genome-scale O

for O

In O
fact O
, O
it O
has O
been O
estimated O
that O
approximately O
45% O
of O
epigenetic O
researchers O
today O
identify O
cancer/oncology B-Disease
as O
their O
main O
area O
of O
focus O
vis-Ã -vis O
their O
epigenetic O
research O
efforts O

PROSPERO O
registration O
ID O
 O
CRD42020166675 O

178 O
Genetics B-Gene
and O
environmental O
factors O
have O
important O
roles O
in O
autoimmune B-Disease
diseases I-Disease
but O
neither O
has O
given O
us O
sufficient O
understanding O
of O
these O
mysterious O
diseases O

1200 O
There O
have O
been O
numerous O
genetic O
and O
epigenetic O
datasets O
generated O
for O
the O
study O
of O
complex O
disease O
including O
neurodegenerative B-Disease
disease I-Disease

Importantly O
, O
the O
only O
study O
to O
compare O
the O
effect O
of O
aging O
on O
DNA B-Gene
methylation I-Gene
in O
male O
and O
female O
mice B-Species
and O
humans B-Species
found O
that O
>95% O
of O
the O
age-related O
changes O
in O
DNA B-Gene
methylation I-Gene
in O
the O
hippocampus O
were O
sexually O
divergent O
, O
i O

DNA O
methylation O
is O
a O
well-characterised O
epigenetic O
mechanism O
, O
and O
a O
highly O
stable O
epigenetic O
marker O
, O
that O
is O
implicated O
in O
disease B-Disease
pathogenesis I-Disease

Conclusion O
 O
These O
analyses O
support O
the O
use O
of O
precision O
epigenetic O
methods O
as O
part O
of O
the O
initial O
diagnosis O
and O
care O
of O
stable O
CHD B-Disease
and O
can O
meaningfully O
reduce O
cost O

This O
review O
outlines O
the O
current O
understanding O
of O
epigenetic O
alterations O
observed O
in O
PDTC B-Disease
and O
ATC B-Disease
and O
explores O
the O
potential O
for O
exploiting O
this O
understanding O
in O
developing O
novel O
therapeutic O
strategies O

Here O
, O
we O
present O
a O
comprehensive O
discussion O
on O
how O
subtelomeres O
and O
ITSs O
might O
influence O
studies O
of O
human B-Species
telomere B-Gene
epigenetics O

This O
type O
of O
approach O
, O
involving O
genotypes O
, O
endophenotypes O
, O
epigenetics O
and O
brain O
functioning O
, O
could O
help O
to O
elucidate O
the O
interaction O
between O
these O
various O
levels O
and/or O
explain O
the O
underlying O
mechanisms O
of O
psychiatric B-Disease
disorders I-Disease

In O
summary O
, O
EpiProfile O
2 O

This O
paper O
attempts O
a O
general O
overview O
of O
currently O
available O
resources O
, O
together O
with O
remarks O
on O
their O
data O
mining O
and O
analysis O
capabilities O


Here O
we O
report O
an O
improved O
protocol O
using O
100-fold O
less O
genomic B-Chemical
DNA I-Chemical
than O
that O
commonly O
used O

Here O
, O
we O
review O
various O
factors O
governing O
epigenetic O
dysregulation O
of O
cancer B-Disease
stem I-Disease
cells I-Disease
ranging O
from O
the O
role O
of O
epigenetic O
mediators O
such O
as O
histone B-Chemical
and O
DNA B-Chemical
methyltransferases B-Chemical
, O
histone B-Chemical
deacetylases B-Chemical
, O
histone B-Chemical
methyltransferases B-Chemical

We O
also O
detected O
significant O
associations O
between O
key O
environmental O
variables O
and O
96 O
SMVs O
, O
including O
42 O
located O
in O
promoter O
regions O
or O
gene B-Gene
bodies I-Gene

Aberrant O
epigenetic O
modifications O
are O
associated O
with O
the O
development O
of O
many O
diseases B-Disease

Cytotoxic O
approaches O
are O
limited O
in O
potency O
and O
sustainability O
, O
however O
, O
since O
they O
require O
hematopoietic O
reserves O
sufficient O
to O
repeatedly O
mount O
recoveries O
from O
stress O
that O
destroys O
their O
counterparts O
, O
and O
such O
reserves O
are O
finite O

Intriguingly O
, O
these O
epigenetic O
changes O
triggered O
during O
early O
periods O
of O
hyperglycemic B-Disease
exposure O
and O
uncontrolled B-Disease
diabetes I-Disease
are O
not O
immediately O
corrected O
even O
after O
restoration O
of O
normoglycemia B-Disease
and O
metabolic O
balance O

The O
contribution O
of O
each O
epigenetic O
state O
in O
cCREs O
to O
gene B-Gene
regulation O
, O
inferred O
from O
a O
multivariate O
regression O
, O
was O
used O
to O
estimate O
epigenetic O
state O
regulatory O
potential O
( O
esRP O
) O
scores O
for O
each O
cCRE O
in O
each O
cell O
type O
, O
which O
were O
used O
to O
categorize O
dynamic O

( O

, O
explaining O
individual O
differences O
in O
health O
outcomes O
to O
interrupt O
optimistic O
biases O
about O
health O
exposures O
) O
; O
( O
2 O
) O
illuminate O
new O
approaches O
to O
targeted O
and O
tailored O
health O
promotion O
interventions O
( O
e O

Further O
, O
these O
comparative O
epigenomic O
studies O
have O
begun O
to O
show O
promise O
toward O
enhancing O
our O
understanding O
of O
how O
regulatory O
programs O
evolve O

In O
this O
review O
, O
we O
will O
discuss O
the O
main O
theory O
about O
epigenetic O
inheritance O
, O
present O
clinical O
evidence O
of O
its O
potential O
role O
in O
major O
psychiatric O
disorders O
, O
and O
how O
studies O
with O
patients O
and O
animal B-Species
models I-Species
have O
helped O
describe O
the O
epigenetic O
mechanisms O
and O
possible O
targets O
underlying O

In O
conclusion O
, O
inhibition O
of O
JMJD1 B-Gene
enzymatic O
activity O
through O
small O
molecules O
is O
predicted O
to O
be O
beneficial O
in O
many O
different O
cancers B-Disease
, O
but O
not O
in O
the O
few O
malignancies O
where O
JMJD1 B-Gene
proteins O
apparently O
exert O
tumor-suppressive O
functions O

Many O
epigenetic O
studies O
have O
been O
done O
using O
plants B-Species
, O
rodent B-Species
, O
and O
human B-Species
models O
, O
but O
fewer O
have O
focused O
on O
domestic O
livestock B-Species
species O

We O
show O
that O
DNA B-Gene
methylation I-Gene
differs O
substantially O
between O
naÃ¯ve O
and O
memory O
T B-Species
cells I-Species
, O
supporting O
the O
need O
for O
adjustment O
on O
these O
cell-types O

Here O
, O
we O
show O
that O
RVX-208 B-Chemical
, O
a O
clinically O
tested O
, O
BD2-selective O
BET B-Gene
inhibitor O
, O
dose-dependently O
reduced O
cocaine B-Chemical
conditioned O
place O
preference O
in O
male O
and O
female O
mice B-Species
, O
similar O
to O
the O
pan-BET O
inhibitor O
JQ1 B-Chemical

09 O
, O
p O
= O

This O
is O
further O
complicated O
by O
the O
antecedent O
nonleukemic O
state O
of O
clonal O
hematopoiesis O
that O
nevertheless O
is O
associated O
with O
an O
increased O
risk O
of O
developing O
a O
hematologic O
malignancy O
and O
with O
a O
greater O
risk O
of O
mortality O
from O
ischemic O
cardiovascular O
disease B-Disease

Recent O
progress O
in O
microarray O
platforms O
and O
next-generation O
sequencing O
approaches O
has O
allowed O
the O
characterization O
of O
abnormal O
epigenetic O
patterns O
genome O
wide O
in O
a O
large O
number O
of O
cancer B-Disease
cases O

The O
results O
obtained O
from O
these O
models O
were O
compared O
with O
each O
other O
and O
with O
the O
outcomes O
generated O
by O
other O
well-established O
epigenetic O
clocks O

Consequently O
, O
planarians B-Species
possess O
remarkable O
regenerative O
capabilities O

DNA O
methylation O
occurs O
as O
part O
of O
the O
typical O
gene B-Gene
silencing O
during O
latent O
infection O
by O
herpesviruses B-Species

Supplementary O
information O
 O
Supplementary O
data O
are O
available O
at O
Bioinformatics O
online O

Results O
 O
Childhood O
exposure O
to O
hunger O
was O
associated O
with O
CVD B-Disease
and O
depressive B-Disease
symptoms I-Disease
in O
later O
life O

The O
upstream O
clock O
mechanism(s) O
that O
control O
the O
timing O
of O
growth O
, O
development O
, O
and O
aging O
remain O
obscure O

a O
c O

Current O
technologies O
that O
not O
only O
read O
out O
the O
DNA B-Gene
sequence O
, O
but O
also O
determine O
how O
the O
DNA B-Gene
is O
modified O
in O
response O
to O
the O
environment O
, O
promise O
new O
insight O
into O
how O
puberty B-Disease
is O
regulated O
, O
including O
the O
identification O
and O
understanding O
of O
gene B-Gene
regulatory O
networks O
that O
control O

1341 O
The O
methylation O
status O
of O
the O
O(6)-methylguanine-DNA B-Chemical
methyltransferase I-Chemical
(MGMT) B-Gene
gene O
is O
an O
important O
predictive O
biomarker O
for O
benefit O
from O
alkylating B-Chemical
agent I-Chemical
therapy O
in O
glioblastoma B-Disease

One O
of O
the O
reasons O
for O
this O
may O
be O
the O
extreme O
complexity O
and O
variability O
of O
clinical O
presentation O
of O
food B-Disease
allergy I-Disease
, O
ranging O
from O
less O
severe O
forms O
such O
as O
oral B-Disease
allergy I-Disease
syndrome I-Disease
to O
full-blown O
anaphylaxis B-Disease

Genetic O
and O
epigenetic O
factors O
combine O
to O
alter O
both O
gene B-Gene
expression O
and O
drug B-Chemical
responses O
at O
both O
pharmacokinetic O
and O
pharmacodynamic O
levels O

Building O
on O
sociologist O
Thomas O
Lemke O
's O
Foucauldian O
" O
analytics O
of O
biopolitics O
" O
and O
on O
literature O
from O
the O
field O
of O
science O
and O
technology O
studies O
, O
we O
present O
two O
sociological O
trends O
that O
may O
impede O
the O
policy O
translation O
of O
epigenetics B-Gene
 O
molecularization O
and O
biomedicalization O

Epigenetic O
mechanisms O
are O
good O
candidates O
to O
explain O
the O
molecular O
links O
between O
the O
two O
phenomena O
, O
but O
recent O
reports O
have O
also O
revealed O
considerable O
differences O
, O
particularly O
regarding O
the O
loss O
of O
DNA B-Chemical
methylation I-Chemical
in O
the O
two O
processes O

The O
changes O
of O
methylation B-Chemical
levels O
can O
further O
lead O
to O
alterations O
of O
gene B-Gene
expression O
, O
and O
influence O
the O
risk O
of O
various O
complex O
human B-Species
diseases B-Disease

e O

Here O
, O
we O
review O
the O
current O
applications O
of O
these O
epigenetic O
editing O
tools O
in O
mammals B-Species
and O
shed O
light O
on O
biochemical B-Chemical
improvements O
that O
facilitate O
versatile O
applications O

Key O
to O
this O
are O
new O
discoveries O
about O
the O
fitness O
costs O
associated O
with O
DNA B-Gene
methylation I-Gene
, O
and O
new O
theories O
about O
how O
the O
fundamental O
biochemical O
mechanisms O
of O
DNA B-Gene
methylation I-Gene
introduction O
and O
maintenance O
could O
explain O
how O
new O
genome-wide O
patterns O
of O
methylation O
evolve O

The O
next O
challenge O
is O
to O
leverage O
these O
tools O
for O
improved O
patient O
outcomes O

Using O
Artificial O
Intelligence O
(AI) O
platforms/Machine O
Learning O
(ML) O
analysis O
, O
CpG B-Chemical
methylation I-Chemical
levels O
in O
a O
combination O
of O
230 O
significantly O
differentially-methylated O
CpG B-Chemical
loci O
in O
258 O
genes O
had O
a O
95% O
sensitivity O
and O
94 O

Although O
our O
minimized O
epigenetic O
clock O
yielded O
slightly O
higher O
age O
prediction O
errors O
compared O
to O
other O
epigenetic O
clocks O
, O
it O
still O
represents O
a O
viable O
alternative O
to O
the O
genome-wide O
epigenotyping O
array O

Conclusions O
 O
MSRE-HTPrimer O
, O
based O
on O
Primer3 B-Gene
, O
is O
a O
high-throughput O
pipeline O
and O
has O
no O
limitation O
on O
the O
number O
and O
size O
of O
target O
sequences O
for O
primer O
design O
and O
provides O
full O
flexibility O
to O
customize O
it O
for O
specific O
requirements O

Multiple O
studies O
have O
demonstrated O
the O
involvement O
of O
certain O
noncoding O
RNAs O
, O
particularly O
miR-140 B-Gene
, O
in O
OA B-Disease
development O
via O
modulation O
of O
key O
catabolic O
factors O

Based O
on O
recent O
studies O
, O
methodological O
developments O
are O
necessary O
to O
improve O
epigenetic O
research O

These O
studies O
have O
helped O
to O
unravel O
the O
epigenome O
-- O
a O
separate O
layer O
of O
regulatory O
information O
contained O
in O
eukaryotic B-Species
chromosomes O
that O
influences O
gene B-Gene
expression O
and O
phenotypes O
without O
involving O
changes O
to O
the O
underlying O
DNA B-Chemical
sequence O

In O
addition O
, O
we O
will O
describe O
how O
this O
knowledge O
is O
translated O
into O
the O
clinic O

1088 O
Systemic B-Disease
lupus I-Disease
erythematosus I-Disease
(SLE) O
is O
a O
chronic O
relapsing-remitting O
autoimmune O
disease O
affecting O
several O
organs O

In O
this O
review O
, O
we O
introduce O
the O
regulation O
of O
dynamic O
regulation O
of O
core-histone O
modifications O
and O
the O
emergence O
of O
an O
oocyte-type O
linker O
histone O
during O
transdifferentiation O

In O
multicellular O
organisms B-Species
, O
a O
single O
genome B-Gene
can O
give O
rise O
to O
tremendous O
variability O
across O
tissues O
at O
the O
single-cell O
level O
due O
to O
epigenetic O
differences O
in O
the O
genes B-Gene
that O
are O
expressed O

18 O
 O
is O
currently O
considered O
as O
the O
optimal O
treatment O
for O
inborn O
errors O
of O
metabolism O
( O
IEMs O
) O
, O
as O
it O
aims O
to O
permanently O
compensate O
for O
the O
primary O
genetic O
defect O

57 O
 O
is O
an O
intricate O
biological O
process O
that O
bridges O
gap O
between O
the O
genotype O
and O
the O
phenotype O

e O

They O
affect O
DNA B-Gene
methylation O
, O
histone B-Gene
modifications O
, O
chromatin B-Gene
remodeling O
, O
long O
noncoding O
RNAs O
, O
and O
microRNAs O

Progress O
in O
this O
area O
will O
likely O
require O
analysis O
of O
much O
larger O
sample O
sizes O
than O
have O
been O
reported O
to O
date O

In O
addition O
, O
we O
highlight O
the O
interaction O
of O
epigenetics O
with O
senescent O
physiology O
and O
environmental O
factors O
in O
regulating O
transcription O

Indeed O
, O
standard O
genomic O
approaches O
do O
not O
take O
into O
account O
the O
world O
of O
regulation O
of O
gene B-Gene
expression O
by O
modifications O
of O
the O
' O
epi O
' O
genome O

The O
main O
mechanisms O
in O
epigenetics O
are O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
and O
non-coding B-Chemical
RNAs I-Chemical
( O
ncRNAs B-Chemical
) O

Phytoestrogens O
and O
other O
phytochemicals O
have O
dramatic O
effects O
on O
cellular O
signaling O
events O
, O
so O
have O
the O
capacity O
to O
dramatically O
alter O
developmental O
and O
physiological O
events O

Of O
note O
, O
through O
targeting O
multiple O
omics O
aberrations O
, O
clinical O
outcome O
of O
NKTCL B-Disease
patients O
has O
been O
significantly O
improved O
by O
asparaginase-based B-Chemical
regimens O
, O
immune O
checkpoints O
inhibitors O
, O
and O
histone B-Chemical
deacetylation I-Chemical
inhibitors O

The O
hyper/hypo-methylation O
and O
modifications O
of O
chromosol O
and O
extrachromosomal O
DNA B-Gene
may O
result O
in O
alternations O
in O
proteins O
within O
inflammatory O
cells O
, O
which O
can O
be O
identified O
as O
disease-specific B-Disease
biomarkers O
and O
therapeutic O
targets O

4 O

To O
test O
this O
hypothesis O
, O
we O
established O
the O
epigenetic O
and O
transcriptomic O
profiles O
of O
immune O
cells O
from O
44 O
childhood B-Disease
cancer I-Disease
survivors I-Disease
( O
CCS O
, O
> O
16 O
years O
old O
) O
on O
full O
remission O
( O
> O
5 O
years O
) O
who O
had O
received O
chemotherapy B-Chemical
alone O
or O
in O

ZIP13 O
deficiency O
, O
which O
is O
associated O
with O
Spondylocheirodysplastic B-Disease
Ehlers-Danlos I-Disease
syndrome I-Disease
( O
SCD-EDS O
) O
, O
increases O
DNMT B-Gene
activity O
, O
leading O
to O
dysgenesis O
of O
dermis O
via O
improper O
gene O
expressions O

Here O
, O
we O
present O
a O
low-cost O
, O
efficient O
, O
simultaneous O
indexing O
and O
tagmentation-based O
ChIP-seq O
( O
itChIP-seq O
) O
method O
, O
compatible O
with O
both O
low O
cellular O
input O
and O
single O
cells O
for O
profiling O
chromatin O
states O

In O
this O
systematic O
review O
, O
we O
summarize O
all O
the O
available O
evidence O
of O
proven O
or O
hypothesized O
epigenetic O
mechanisms O
related O
to O
nephrolithiasis B-Disease


Methylation O
level O
for O
each O
CpG B-Gene
locus O
had O
an O
area O
under O
the O
receiver O
operating O
curve O
( O
AUC O
) O
â¥ O
0 O

However O
, O
existing O
implementations O
are O
numerous O
, O
and O
quality O
control O
and O
optimization O
require O
expensive O
external O
validation O

Accumulating O
recent O
data O
suggest O
that O
rapid O
and O
dynamic O
methylation B-Chemical
and O
demethylation B-Chemical
of O
specific O
genes O
in O
the O
brain O
may O
play O
a O
fundamental O
role O
in O
learning O
, O
memory O
formation O
, O
and O
behavioral O
plasticity O

The O
review O
will O
evaluate O
if O
the O
levels O
of O
DNA B-Gene
methylation I-Gene
are O
a O
possible O
risk O
factor O
for O
T2DM B-Disease

This O
chapter O
summarizes O
approaches O
that O
have O
been O
used O
to O
identify O
epigenetic O
regulators O
of O
HSC O
development O
in O
zebrafish B-Species
and O
highlights O
additional O
strategies O
that O
are O
likely O
to O
facilitate O
progress O
in O
this O
promising O
field O

A O
few O
interesting O
talks O
on O
replication O
added O
some O
insightful O
information O
on O
the O
controversial O
issue O
of O
histone B-Chemical
post-translational I-Chemical
modifications I-Chemical
as O
genuine O
epigenetic O
marks O
that O
are O
inherited O
through O
cell O
division O

It O
seems O
plausible O
that O
changes O
in O
epigenetic O
state O
may O
be O
induced O
by O
environmental O
exposures O
such O
as O
malnutrition O
, O
tobacco O
smoke O
, O
air O
pollutants O
, O
metals O
, O
organic O
chemicals B-Chemical
, O
other O
sources O
of O
oxidative O
stress O
, O
and O
the O
microbiome B-Species
, O
particularly O
if O
the O

However O
, O
with O
the O
exception O
of O
melanoma B-Disease
, O
most O
patients O
do O
not O
respond O
to O
immunotherapy O
alone O

We O
present O
ALEA O
, O
a O
computational O
toolbox O
for O
allele-specific O
epigenomics O
analysis O
, O
which O
incorporates O
allelic O
variation O
data O
within O
existing O
resources O
, O
allowing O
for O
the O
identification O
of O
significant O
associations O
between O
epigenetic O
modifications O
and O
specific O
allelic O
variants O
in O
human B-Species
and O
mouse B-Species
cells O

Then O
, O
promoter O
hypermethylation O
of O
SLC6A4 B-Gene
in O
LCLs B-Species
of O
BD B-Disease
patients O
was O
confirmed O
in O
a O
case-control O
analysis O

Each O
cell O
type O
carries O
a O
unique O
DNA B-Gene
modification O
profile O
consisting O
mainly O
of O
patterns O
of O
5-methylcytosine B-Chemical
in O
CpG B-Gene
dinucleotides O
, O
which O
are O
critical O
for O
establishing O
and O
maintaining O
cellular O
identity O
and O
which O
are O
frequently O
disturbed O
in O
cancer B-Disease

We O
describe O
EpiSAFARI O
, O
a O
computational O
method O
for O
sensitive O
detection O
of O
valleys O
from O
diverse O
types O
of O
epigenetic O
profiles O

742 O
 O
Arsenic B-Chemical
is O
a O
naturally O
occurring O
metal O
carcinogen O
found O
in O
the O
Earth O
's O
crust O

high O

In O
the O
imprinting O
loci O
where O
methylation O
of O
constituent O
alleles O
is O
known O
, O
our O
analysis O
detected O
the O
deviation O
toward O
the O
concordant O
linkage O
as O
expected O

735 O
The O
benefits O
of O
diploidy O
are O
considered O
to O
involve O
masking O
partially O
recessive O
mutations O
and O
increasing O
genetic O
diversity O

CG O
methylation O
is O
transmitted O
transgenerationally O
in O
plants B-Species
, O
opening O
the O
possibility O
that O
gbM B-Gene
may O
be O
shaped O
by O
adaptation O

The O
quantitative O
biomarkers O
of O
this O
process O
, O
as O
well O
as O
the O
correspondence O
to O
different O
biological O
clocks O
, O
remain O
largely O
an O
open O
problem O

The O
total O
number O
of O
epialleles O
, O
the O
epiallele O
DNAm B-Gene
patterns O
, O
and O
a O
noise O
hyperparameter O
are O
all O
automatically O
inferred O
from O
the O
data O

167 O
The O
field O
of O
epigenomics O
has O
rapidly O
progressed O
from O
the O
study O
of O
individual O
reference O
epigenomes O
to O
surveying O
epigenomic O
variation O
in O
populations O

This O
toolkit O
may O
have O
arisen O
as O
a O
means O
of O
navigating O
the O
genomic O
conflict O
that O
arose O
from O
the O
expansion O
of O
transposable B-Gene
elements I-Gene
within O
the O
ancestral O
eukaryotic B-Species
genome O

1145 O
Children O
have O
special O
rights O
for O
protection O
compared O
to O
adults O
in O
our O
society O

Both O
DNAm B-Gene
and O
gene B-Gene
expression I-Gene
profiles O
are O
known O
to O
be O
tissue- O
and O
development O
specific O

Studies O
in O
rodents B-Species
represent O
the O
second O
most O
common O
species O
used O
for O
epigenetic O
studies O
in O
toxicology O
, O
in O
vivo O
exposures O
being O
the O
most O
predominant O

Second O
, O
DEG B-Gene
from O
day O
7 O
to O
days O
13 O
and O
16 O
and O
DMG B-Gene
from O
day O
7 O
to O
day O
17 O
were O
determined O
in O
the O
TE B-Species
from O
IVP B-Species
vs O

To O
account O
for O
these O
non-linear O
epigenetic O
changes O
with O
age O
, O
we O
recently O
developed O
a O
formalism O
inspired O
by O
the O
Pacemaker B-Gene
model O
of O
evolution O
that O
accounts O
for O
varying O
rates O
of O
mutations O
with O
time O

Here O
, O
we O
review O
the O
most O
recent O
epigenetic O
inheritance O
examples O
in O
animal B-Species
models O
, O
outlining O
molecular O
details O
behind O
environmental O
sensing O
by O
the O
germline O
, O
and O
the O
functional O
relationships O
connecting O
epigenetic O
mechanisms O
and O
phenotypic O
traits O
after O
fertilization O

This O
review O
focuses O
on O
plant B-Species
variation O

0 O
Ã O
10-5 O
) O
, O
p O
= O

While O
in O
GE B-Disease
the O
genetic O
information O
is O
changed O
by O
directly O
modifying O
DNA B-Gene
, O
intervening O
in O
the O
epigenome O
requires O
modifying O
the O
configuration O
of O
DNA B-Gene
, O
for O
example O
, O
how O
it O
is O
folded O

However O
, O
we O
argue O
that O
adaptive O
responses O
to O
stress O
shift O
with O
age O

In O
healthy O
subjects O
(n O
= O
278 O
), O
epigenetic O
age O
calculated O
using O
the O
targeted O
clock O
was O
highly O
correlated O
with O
chronological O
age O
(Spearman O
correlation O
= O
0 O

bioconductor O

These O
online O
tools O
generate O
interactive O
graphical O
outputs O
of O
relevant O
chromosomal O
regions O
, O
showing O
genes O
, O
transcripts O
, O
and O
other O
genomic O
landmarks O
, O
and O
epigenetic O
features O
mapped O
by O
projects O
such O
as O
ENCODE B-Gene

However O
, O
all O
these O
epigenetic O
biomarkers O
should O
be O
validated O
in O
larger O
clinical O
studies O

In O
this O
study O
, O
we O
demonstrated O
that O
colocalize O
with O
in O
pluripotent O
stem O
cells O
, O
but O
not O
in O
brain O
cells O

However O
, O
the O
mechanism O
governing O
how O
these O
epigenetic O
marks O
accumulate O
at O
discrete O
immune O
gene B-Gene
loci I-Gene
has O
been O
poorly O
understood O
, O
until O
now O

This O
information O
may O
help O
to O
identify O
prognostic O
and O
predictive O
biomarkers O
as O
well O
as O
targetable O
vulnerabilities O

Revealing O
tumor B-Disease
clonal O
complexity O
in O
an O
integrative O
and O
quantitative O
manner O
facilitates O
improved O
mutational O
characterization O
, O
understanding O
, O
and O
therapeutic O
assignments O

By O
modifying O
the O
SunTag B-Chemical
framework O
of O
dCas9 B-Gene
tagged O
with O
five O
GCN4 B-Gene
moieties O
, O
each O
epigenetic O
writer O
is O
bound O
to O
scFv B-Gene
and O
target-specific O
sgRNA B-Gene
, O
and O
this O
system O
is O
able O
to O
modify O
multiple O
epigenetic O
marks O
in O
a O
target-specific O
manner O

Conclusion O
 O
Our O
results O
suggest O
that O
the O
model O
we O
used O
was O
a O
fitting O
model O
for O
the O
assessment O
of O
environmental O
stressors O
on O
candidate O
gene B-Gene
expression I-Gene

He O
received O
his O
medical O
degree O
from O
Jordan O
University O
of O
Science O
and O
Technology O
and O
completed O
his O
residency O
training O
in O
internal O
medicine O
at O
the O
University O
of O
Oklahoma O
Health O
Sciences O
Center O
, O
and O
his O
fellowship O
in O
rheumatology O
at O
the O
University O
of O
Michigan O

Moreover O
, O
we O
observed O
that O
TiO2 B-Chemical
nanotubes I-Chemical
promoted O
the O
osteogenic O
differentiation O
of O
hASCs B-Species
by O
upregulating O
methylation O
level O
of O
histone B-Chemical
H3 I-Chemical
at O
lysine B-Chemical
4 I-Chemical
( O
H3K4 B-Gene
) O
in O
the O
promoter O
regions O
of O
osteogenic O
genes O

Mechanistically O
, O
we O
discuss O
the O
increasingly O
well-understood O
molecular O
pathways O
responsible O
for O
epigenetic O
inheritance O
, O
with O
a O
focus O
on O
the O
unusual O
features O
of O
the O
germline O
epigenome O

Due O
to O
their O
intimacy O
with O
DNA B-Gene
, O
histones B-Chemical
have O
a O
central O
role O
in O
chromatin B-Chemical
structure O
and O
epigenetic O
regulation O

257 O
Our O
goal O
is O
to O
draw O
a O
line-hypothetical O
in O
its O
totality O
but O
experimentally O
supported O
at O
each O
individual O
step-connecting O
the O
ribosomal B-Gene
DNA I-Gene
and O
the O
phenomenon O
of O
transgenerational O
epigenetic O
inheritance O
of O
induced O
phenotypes O

However O
, O
the O
extent O
to O
which O
epigenetic O
factors O
( O
primarily O
methylation B-Chemical
at O
promoter O
regions O
) O
affect O
transcription O
of O
immune-related O
genes B-Gene
may O
vary O
across O
cancer B-Disease
types O

Based O
on O
the O
genomic O
and O
transcriptomic O
CHO B-Species
data O
currently O
available O
, O
we O
developed O
a O
customized O
oligonucleotide O
microarray O
covering O
19598 O
CpG B-Gene
islands I-Gene
( O
89 O
% O
of O
total O
bioinformatically O
identified O
CpG B-Gene
islands I-Gene
) O
in O
the O
CHO B-Species
genome O

Here O
, O
we O
describe O
an O
improved O
procedure O
for O
WGBS O
and O
original O
bioinformatic O
workflows O
applied O
to O
unravel O
tissue-specific O
variations O
of O
the O
methylome O
in O
relation O
to O
gene B-Gene
expression O
and O
accumulation O
of O
secondary O
metabolites O
in O
the O
medicinal O
plant O
Catharanthus B-Species
roseus I-Species

305 O
Recent O
advances O
in O
molecular O
biology O
and O
computational O
power O
have O
seen O
the O
biomedical O
sector O
enter O
a O
new O
era O
, O
with O
corresponding O
development O
of O
Bioinformatics O
as O
a O
major O
discipline O

749 O
 O
Tumor B-Disease
heterogeneity I-Disease
poses O
one O
of O
the O
greatest O
challenges O
to O
a O
successful O
treatment O
of O
cancer B-Disease


Post-translational O
events O
and O
microRNAs B-Gene
can O
be O
also O
regulated O
epigenetically O
and O
potentially O
participate O
in O
disease B-Disease
pathogenesis O

Multiplexed O
assays O
resolving O
multiple O
modalities O
in O
the O
same O
cell O
are O
required O
to O
overcome O
these O
shortcomings O
and O
have O
the O
potential O
to O
deliver O
unprecedented O
understanding O
of O
biology O
and O
disease B-Disease

We O
will O
provide O
a O
comprehensive O
introduction O
into O
the O
topic O
, O
describe O
in O
detail O
how O
ChIP-seq O
data O
are O
analyzed O
and O
elaborate O
on O
how O
to O
integrate O
ChIP-seq O
and O
RNA-seq O
data O
from O
a O
segregating O
disease B-Disease
animal B-Species
model O
for O
the O
identification O
of O
the O
epigenetic O
control O
of O

those O
due O
to O
mutations O
to O
the O
gene B-Gene
regulation I-Gene
network O
and O
those O
due O
to O
noise O
in O
gene B-Gene
expression I-Gene
dynamics O
were O
found O
to O
be O
proportional O
over O
a O
number O
of O
genes O

This O
method O
allows O
transcription O
factors O
that O
are O
functionally O
active O
in O
gene B-Gene
expression I-Gene
to O
be O
investigated O

Availability O
and O
implementation O
 O
http//deepblue O

SAR O
information O
of O
DNMT B-Gene
inhibitors O
( O
DNMTi B-Gene
) O
, O
stored O
in O
a O
public O
database O
, O
is O
surveyed O
to O
further O
illustrate O
concepts O
and O
generalities O
of O
activity O
landscape O
modeling O
with O
a O
special O
emphasis O
on O
structure-activity O
similarity O
( O
SAS O
) O
maps O

Expert O
opinion O
 O
Currently O
, O
we O
cannot O
fully O
contextualize O
the O
application O
of O
epigenetics O
to O
the O
field O
of O
drug B-Chemical
toxicology O
, O
as O
there O
are O
still O
many O
challenges O
to O
overcome O
before O
DNA B-Gene
methylation-based I-Gene
biomarkers O
can O
be O
effectively O
used O
in O
drug B-Chemical
development O

Although O
the O
recent O
high-throughput O
methods O
for O
DNA B-Gene
methylation I-Gene
analysis O
have O
various O
advantages O
, O
they O
require O
high O
levels O
of O
technical O
expertise O
, O
costly O
equipment O
, O
and O
reagents O

Finally O
, O
we O
show O
that O
several O
factors O
moderate O
the O
relationship O
between O
epigenetic O
ages O
and O
real O
ages O
, O
such O
as O
body O
weight O
, O
which O
increases O
epigenetic O
ageing O

Recent O
technological O
advances O
have O
enabled O
genome-wide O
profiling O
of O
DNAme B-Chemical
in O
large O
human B-Species
cohorts O

This O
latency O
in O
effect O
across O
time O
and O
conditions O
is O
associated O
with O
persistent O
development O
of O
complications O
in O
diabetes B-Disease
with O
prior O
history O
of O
poor O
glycemic O
control O
, O
termed O
as O
metabolic O
memory O
or O
legacy O
effect O

1313 O
 O
Exposure O
to O
trauma O
is O
one O
of O
the O
most O
important O
and O
prevalent O
risk O
factors O
for O
mental B-Disease
and O
physical B-Disease
ill-health I-Disease

This O
volume O
highlights O
the O
latest O
in O
laboratory O
and O
bioinformatic O
techniques O
used O
for O
the O
investigation O
of O
epigenetic O
phenomena O
in O
plants B-Species

Here O
, O
we O
report O
a O
genome-wide O
6mA O
map O
for O
the O
model O
industrial O
oleaginous O
microalga B-Species
Nannochloropsis I-Species
oceanica I-Species
produced O
by O
single-molecule O
real-time O
sequencing O

The O
role O
of O
epigenetics O
in O
normal O
embryonic O
development O
and O
the O
influence O
of O
biological O
and O
environmental O
factors O
altering O
behavior O
through O
epigenetic O
mechanisms O
and O
developmental O
programming O
are O
discussed O

Conclusions O
Our O
findings O
comprise O
a O
comprehensive O
benchmark O
for O
the O
quantitative O
accuracy O
of O
key O
methods O
for O
methylation O
analysis O
and O
demonstrate O
their O
applicability O
to O
the O
quantification O
of O
circulating O
tumour B-Disease
DNA B-Gene
biomarkers O
by O
using O
sample O
concentrations O
that O
are O
representative O
of O
typical O
clinical O
isolates O

We O
show O
that O
this O
information O
is O
paving O
the O
way O
towards O
a O
more O
complete O
understanding O
of O
the O
heritable O
basis O
underlying O
population O
epigenomic O
variation O

the O

Its O
detection O
is O
still O
based O
on O
methods O
with O
low O
sensitivity O
and O
although O
standard O
pathological O
and O
clinical O
variables O
provide O
important O
prognostic O
information O
, O
these O
parameters O
seem O
to O
be O
insufficient O
to O
accurately O
predict O
the O
behavior O
of O
these O
tumors O

The O
many O
attributes O
of O
marine B-Species
fish I-Species
species I-Species
, O
including O
their O
high O
diversity O
, O
variable O
life O
histories O
, O
high O
fecundity O
, O
impressive O
plasticity O
, O
and O
economic O
value O
provide O
unique O
opportunities O
for O
studying O
epigenetic O
mechanisms O
in O
an O
environmental O
context O

It O
leads O
to O
changes O
in O
gene B-Gene
expressions O
and O
the O
emergence O
of O
new O
traits O
in O
different O
organisms O
in O
many O
diseases O
such O
as O
cancer B-Disease

I O
show O
that O
Waddington's O
biology O
is O
best O
characterized O
as O
an O
asymmetric O
understanding O
of O
the O
causal O
role O
of O
genes B-Gene
and O
environment O
both O
in O
development O
and O
evolution O

1184 O
The O
development O
of O
the O
CRISPR-Cas9 B-Gene
system O
triggered O
a O
revolution O
in O
the O
field O
of O
genome O
engineering O

904 O
The O
Medical O
Research O
Council O
Clinical O
Sciences O
Centre O
Symposium O
on O
Epigenetic O
Regulation O
 O
From O
Mechanism O
to O
Intervention O
in O
London O
, O
UK O
, O
which O
was O
held O
on O
20-22 O
June O
2012 O
, O
attracted O
305 O
participants O
from O
around O
the O
globe O
and O
included O
37 O
speakers O
and O
85 O
selected O
poster O

Two O
broad O
categories O
of O
epigenetic O
modifications O
must O
be O
distinguished O

Epigenetic O
mechanisms O
play O
an O
important O
role O
in O
modulating O
the O
chromatin O
structure O
and O
regulating O
gene O
transcription O

730 O
Systemic B-Disease
lupus I-Disease
erythematosus I-Disease
(SLE) O
is O
a O
multisystem O
autoimmune O
disease O
in O
which O
immune O
disorders O
lead O
to O
autoreactive O
immune O
responses O
and O
cause O
inflammation O
and O
tissue O
damage O

Their O
children O
had O
higher O
cortisol B-Chemical
levels O
and O
differential O
methylation O
at O
candidate O
genes O
( O
NR3C1 B-Gene
, O
HTR3A B-Gene
and O
BNDF B-Gene
) O

For O
example O
, O
the O
lifespan O
of O
is O
about O
100 O
days O
and O
adults O
make O
about O
two O
million O
new O
every O
second O

The O
resulting O
catalogs O
of O
cCREs O
are O
useful O
resources O
for O
further O
studies O
of O
gene O
regulation O
in O
blood O
cells O
, O
indicated O
by O
high O
overlap O
with O
known O
functional O
elements O
and O
strong O
enrichment O
for O
human B-Species
genetic O
variants O
associated O
with O
blood B-Disease
cell I-Disease
phenotypes I-Disease

1112 O
Pyrosequencing O
is O
a O
technique O
that O
uses O
a O
sequencing-by-synthesis O
system O
which O
is O
designed O
to O
quantify O
single-nucleotide O
polymorphisms O
( O
SNPs O
) O

70 O
Epigenetics O
refers O
to O
structural O
modifications O
to O
genes B-Gene
that O
do O
not O
change O
the O
nucleotide O
sequence O
itself O
but O
instead O
control O
and O
regulate O
gene B-Gene
expression O

The O
conference O
brought O
together O
experts O
in O
human B-Species
nutrition O
who O
use O
nutrigenomic O
and O
metabolomic O
methods O
to O
better O
understand O
metabolic O
individuality O
and O
nutrition O
effects O
on O
health O

Numerous O
tumor O
suppressor O
genes O
have O
been O
reported O
to O
be O
partially O
or O
completely O
silenced O
due O
to O
hypermethylation O
of O
their O
promoters O
in O
single-locus O
studies O
, O
and O
the O
use O
of O
hypomethylating B-Chemical
agents I-Chemical
has O
been O
shown O
to O
restore O
the O
expression O
of O
many O
of O
these O
genes O
in O

Further O
work O
is O
needed O
to O
identify O
original O
key O
marks O
and O
their O
changes O
during O
development O
, O
throughout O
an O
individual O
's O
lifetime O
or O
over O
several O
generations O
, O
and O
to O
determine O
how O
to O
revert O
malprogramming O
with O
a O
view O
to O
prevention O
and O
treatment O

188 O
What O
is O
known O
and O
objective O
 O
There O
is O
increasing O
evidence O
that O
epigenetics O
plays O
a O
major O
role O
in O
the O
pathogenesis O
of O
the O
idiopathic B-Disease
mental I-Disease
disorders I-Disease

Several O
anticancer B-Disease
drugs O
targeting O
epigenetic-machinery O
such O
as O
HDAC B-Gene
inhibitors O
, O
and O
DNMT B-Gene
inhibitors O
have O
been O
developed O

Here O
we O
outline O
a O
general O
experimental O
approach O
for O
achieving O
this O
using O
crosses O
of O
epigenomically O
perturbed O
isogenic O
lines O
in O
mammalian B-Species
and O
plant B-Species
species O

The O
TERT-gene B-Gene
is O
highly O
expressed O
in O
chronic B-Disease
smokers I-Disease
and O
makes O
the O
role O
of O
epigenetics O
evident O

Finding O
associations O
between O
epigenetic O
variation O
and O
phenotype O
is O
a O
significant O
challenge O
in O
biomedical O
research O

We O
implemented O
eight O
downstream O
analysis O
modules O
that O
can O
perform O
multidimensional O
analyses O
to O
pathway O
enrichment O

Current O
tools O
for O
visualisation O
and O
data O
exploration O
represent O
and O
leverage O
these O
complex O
features O
only O
to O
a O
limited O
extent O

Patient O
tumor O
samples O
were O
profiled O
by O
Whole O
Exome O
Sequencing O
(WES) O
and O
RNA-seq O
on O
an O
Illumina B-Chemical
HiSeq I-Chemical
2500 I-Chemical
and O
methylation O
profiling O
was O
performed O
on O
the O
Illumina B-Chemical
Infinium I-Chemical
450K I-Chemical
array O

Ten O
articles O
met O
inclusion O
criteria O

We O
illustrate O
the O
usability O
of O
our O
maps O
for O
deriving O
biological O
hypotheses O

A O
key O
player O
of O
the O
epigenetic O
modifications O
is O
the O
DNA B-Gene
methylation I-Gene
, O
a O
process O
involving O
the O
covalent O
transfer O
of O
a O
methyl B-Chemical
group I-Chemical
to O
the O
C-5 O
position O
of O
the O
cytosine B-Chemical
ring I-Chemical
of O
DNA B-Gene
forming O
5-methylcytosine B-Chemical
( O

It O
then O
clusters O
nearby O
CpG B-Gene
sites I-Gene
with O
consistent O
change O
into O
regions O

We O
generated O
the O
workflow O
"CandiMeth" O
( O
Candidate O
Methylation O
) O
in O
the O
web-based O
environment O
Galaxy O

Analyses O
of O
publicly O
available O
genomic O
data O
( O
e O

As O
such O
, O
it O
is O
likely O
that O
a O
threshold O
for O
cumulative O
risk O
may O
exist O
that O
, O
if O
surpassed O
, O
culminates O
in O
a O
predisposition O
to O
disease B-Disease
and O
ultimately O
an O
observed O
phenotype O
in O
offspring O

driving O

Epigenetic O
aspects O
of O
cancer B-Disease
and O
cancer B-Disease
systems O
biology O
represent O
novel O
approaches O
to O
cancer B-Disease
aetiology O
and O
converge O
in O
the O
notion O
that O
cancer B-Disease
is O
characterized O
by O
a O
nonspecific O
progressive O
destabilization O
of O
multiple O
molecular O
pathways O

Many O
imprinted O
genes O
are O
clustered O
in O
the O
genome O
with O
the O
establishment O
and O
maintenance O
of O
imprinted O
gene O
expression O
governed O
by O
complex O
epigenetic O
mechanisms O

To O
date O
, O
characterizations O
of O
inter-individual O
DNAm B-Gene
variability O
and O
DNAm B-Gene
concordance O
across O
tissues O
have O
been O
largely O
performed O
in O
adult O
tissues O
and O
therefore O
are O
limited O
in O
their O
relevance O
to O
DNAm B-Gene
profiles O
from O
pediatric O
samples O

In O
light O
of O
these O
breakthroughs O
, O
now O
is O
a O
particularly O
opportune O
time O
to O
develop O
a O
framework O
that O
will O
guide O
and O
facilitate O
exceptional O
studies O
in O
Ecological B-Disease
Epigenetics I-Disease

DAC B-Chemical
- I-Chemical
activated O
FBW7 B-Gene
expression O
promoted O
Mcl-1 B-Gene
ubiquitination O
and O
degradation O
leading O
to O
a O
significant O
reduction O
in O
the O
half-life O
of O
Mcl-1 B-Gene
protein O

Higher O
GrimAgeAccel O
, O
b O
( O
SE O
) O
= O
- O
75 O

We O
found O
that O
the O
evidence O
of O
epigenetic O
effects O
remains O
uneven O
across O
agents O

Further O
, O
they O
describe O
the O
implications O
of O
epigenetic O
mechanisms O
in O
the O
etiopathogenesis O
of O
the O
disease B-Disease
and O
the O
effects O
of O
current O
antipsychotic B-Chemical
drugs O
on O
epigenetic O
processes O

Among O
the O
6958 O
CpG B-Gene
sites I-Gene
examined O
, O
smoking O
status O
was O
associated O
with O
methylation O
change O
for O
22 O
CpGs B-Gene
( O
false O
discovery O
rate O
q O
< O
0 O

931 O
There O
is O
increasing O
evidence O
documenting O
gene-by-environment O
( O
G O
Ã O
E O
) O
interactions O
for O
CVD B-Disease
related O
traits O

381 O
Saliva O
and O
buccal O
samples O
are O
popular O
for O
epigenome O
wide O
association O
studies O
(EWAS) O
due O
to O
their O
ease O
of O
collection O
compared O
and O
their O
ability O
to O
sample O
a O
different O
cell O
lineage O
compared O
to O
blood O

In O
this O
review O
, O
we O
summarize O
different O
computational O
methods O
such O
as O
machine O
learning O
and O
other O
bioinformatics O
tools O
, O
publicly O
available O
databases O
and O
resources O
to O
identify O
key O
modifications O
associated O
with O
epigenetic O
machinery O

Thereby O
, O
it O
combines O
compression O
, O
clustering O
and O
visualization O
of O
the O
data O
in O
a O
single O
tool O

Previous O
animal B-Species
studies O
have O
shown O
a O
link O
between O
the O
type O
of O
diet O
and O
expression O
or O
suppression O
of O
obesity B-Disease
genes O
, O
but O
there O
are O
very O
few O
human B-Species
studies O
that O
demonstrate O
the O
relationship O
between O
dietary O
intake O
and O
obesity B-Disease
gene B-Gene
expression O

g O

Apart O
from O
protein-coding O
genes O
, O
studies O
are O
uncovering O
the O
critical O
regulatory O
roles O
played O
by O
noncoding O
RNAs B-Gene
and O
noncoding O
regions O
of O
the O
genome O
during O
cancer B-Disease
progression O

3 O
Ã O
10-7 O
) O

Redistribution O
of O
BAF B-Gene
localization O
is O
a O
major O
driver O
of O
synovial B-Disease
sarcoma I-Disease
proliferation O
and O
presents O
a O
promising O
therapeutic O
target O

Additionally O
, O
this O
paper O
outlines O
the O
future O
trends O
of O
these O
technologies O
and O
their O
current O
technical O
limitations O

5 O
Early O
life O
adversity O
is O
associated O
with O
long-term O
effects O
on O
physical O
and O
mental O
health O
later O
in O
life O
, O
but O
the O
mechanisms O
are O
yet O
unclear O

Transgenerational O
epigenetics O
is O
suggesting O
a O
link O
between O
maternal O
behaviour O
and O
lifestyle O
during O
pregnancy O
and O
the O
subsequent O
well-being O
of O
their O
children O

1338 O
Post-transcriptional O
RNA B-Chemical
modifications O
can O
be O
dynamic O
and O
might O
have O
functions O
beyond O
fine-tuning O
the O
structure O
and O
function O
of O
RNA B-Chemical

Epigenetic O
profiling O
is O
likely O
to O
become O
a O
routine O
tool O
for O
the O
diagnosis O
of O
neurological B-Disease
and O
psychiatric B-Disease
disorders O
in O
the O
near O
future O

Symptoms O
occur O
in O
association O
with O
an O
inappropriate O
rise O
in O
heart O
rate O
in O
the O
absence O
of O
a O
fall O
in O
blood O
pressure O
with O
the O
assumption O
of O
standing O

We O
performed O
genome-wide O
DNA B-Chemical
methylation I-Chemical
analysis O
in O
male O
and O
female O
mouse B-Species
primordial O
germ O
cells O
at O
embryonic O
days O
10 O

Gestational O
length O
and O
birthweight O
were O
obtained O
from O
medical O
chart O
review O

Methylation O
of O
DNA B-Chemical
, O
chromatin O
remodeling O
, O
and O
histone O
modifications O
regulate O
the O
chromatin O
and O
access O
of O
transcription O
factors O
to O
DNA B-Chemical
and O
in O
turn O
gene O
transcription O

g O

Here O
we O
present O
EpiProfile O
2 O

ncbi O

Several O
of O
these O
potential O
epigenetic O
biomarkers O
detected O
in O
women's B-Disease
cancers I-Disease
, O
colorectal B-Disease
cancers I-Disease
, O
prostate B-Disease
, O
pancreatic B-Disease
, O
gastric B-Disease
, O
and O
lung B-Disease
cancers I-Disease
are O
discussed O

The O
current O
review O
discusses O
how O
epigenetics O
can O
cooperate O
with O
genetics O
to O
regulate O
development O
and O
allow O
for O
greater O
plasticity O
in O
response O
to O
environmental O
influences O

Consequently O
, O
many O
human B-Species
diseases O
are O
associated O
with O
aberrant O
DNA B-Gene
methylation O


25 O
In O
light O
of O
the O
post-genomic O
era O
, O
epigenetics O
brings O
about O
an O
opportunity O
to O
better O
understand O
how O
the O
molecular O
machinery O
works O
and O
is O
led O
by O
a O
complex O
dynamic O
set O
of O
mechanisms O
, O
often O
intricate O
and O

Recent O
studies O
have O
suggested O
various O
key O
factors O
and O
specific O
culture O
methods O
to O
improve O
the O
successful O
tissue O
differentiation O
and O
efficient O
generation O
of O
human B-Species
induced I-Species
pluripotent I-Species
stem I-Species
cells I-Species

In O
this O
study O
, O
we O
applied O
newly O
developed O
lmQCM O
algorithm O
to O
mine O
co-methylation O
clusters O
using O
methylome O
data O
from O
11 O
cancer B-Disease
types I-Disease
in O
TCGA O
database O
, O
and O
found O
frequent O
co-methylated O
gene B-Gene
clusters I-Gene
exist O
in O
these O
cancer B-Disease
types I-Disease

Hence O
, O
studies O
focusing O
on O
the O
epigenetic O
features O
of O
human B-Species
telomeres O
have O
to O
be O
carefully O
designed O
and O
interpreted O

In O
this O
review O
, O
we O
summarize O
the O
proposed O
mediation O
analysis O
methods O
with O
applications O
to O
epigenomic O
data O

A O
growing O
body O
of O
evidence O
identifies O
behavioral O
phenotypes O
associated O
with O
inter- O
, O
multi- O
, O
and O
transgenerational O
studies O
following O
a O
wide O
variety O
of O
parental O
exposures O

Examining O
the O
epigenome O
by O
age O
, O
we O
identified O
28,196 O
unique O
differentially O
methylated O
CpGs O
( O
DMCs O
) O
and O
8,613 O
differentially O
hydroxymethylated O
regions O
( O
DHMRs O
) O

Characterizing O
phenotypic O
consequences O
of O
rice B-Species
epigenomic O
variations O
and O
the O
underlining O
chromatin O
mechanism O
and O
identifying O
epialleles O
related O
to O
important O
agronomic O
traits O
may O
provide O
novel O
strategies O
to O
enhance O
agronomically O
favorable O
traits O
and O
grain O
productivity O
in O
rice B-Species

Moreover O
, O
epidemiological O
studies O
suggest O
an O
association O
between O
a O
high-fat O
diet O
, O
which O
can O
alter O
the O
availability O
of O
metabolites O
, O
and O
PCa B-Disease
progression O

emerged O

Alterations O
to O
the O
phenotype O
, O
due O
to O
exposure O
to O
environmental O
insults O
during O
sensitive O
periods O
of O
development O
, O
are O
mediated O
through O
alterations O
in O
epigenetic O
programming O
in O
affected O
tissues O

With O
proper O
selection O
, O
histone-modifying B-Gene
enzymes O
may O
constitute O
good O
targets O
for O
therapy O

Epigenetic O
factors O
have O
been O
suggested O
to O
play O
a O
key O
role O
in O
AUD B-Disease

023 O
, O
SE B-Gene
= O
0 O

Our O
consideration O
on O
near-neutrality O
expands O
in O
relation O
to O
the O
progress O
on O
molecular O
understanding O
of O
robustness O
and O
epigenetics O

Conclusions O
 O
Expression O
of O
GSTM3 B-Gene
might O
be O
regulated O
by O
epigenetic O
changes O
in O
lens O
tissue O

Finally O
, O
we O
will O
also O
consider O
in O
detail O
the O
knowledge O
on O
epigenetics O
in O
DS B-Disease
, O
particularly O
DNA B-Gene
methylation I-Gene

to O

Since O
the O
epigenetic O
status O
of O
telomeres B-Gene
could O
influence O
cancer B-Disease
cells I-Disease
proliferation O
, O
this O
pipeline O
might O
help O
design O
precise O
epigenetic O
treatments O
for O
specific O
cancer B-Disease
types O

Methodological O
shortcomings O
include O
the O
insufficient O
consideration O
of O
genetic B-Gene
variation O
and O
cell B-Species
mixture O
distribution O

Such O
a O
method O
can O
therefore O
facilitate O
the O
rapid O
generation O
of O
multiple O
genome O
wide O
epigenetic O
datasets O

The O
development O
of O
next-generation O
sequencing O
in O
routine O
clinical O
practice O
has O
led O
to O
an O
explosion O
in O
the O
identification O
of O
new O
AID B-Gene
genes I-Gene

The O
laboratory O
is O
involved O
in O
the O
development O
and O
application O
of O
technologies O
to O
analyze O
DNA B-Gene
methylation B-Chemical
, O
miRNAs B-Gene
and O
other O
epigenetic O
modifications O
quantitatively O
at O
high O
resolution O
at O
target O
loci O
and O
genome-wide O
using O
state-of-the-art O
sequencing O
technologies O
as O
well O
as O
the O
development O
of O


481 O
Human B-Species
longevity O
is O
a O
complex O
trait O
and O
increasingly O
we O
understand O
that O
both O
genes B-Gene
and O
lifestyle O
interact O
in O
the O
longevity O
phenotype O


Interactions O
of O
epigenetic O
molecular O
functions O
and O
drugs B-Chemical
are O
mutual O

1095 O
The O
final O
data-generation O
step O
of O
genome-wide O
profiling O
of O
any O
epigenetic O
parameter O
typically O
involves O
DNA B-Chemical
deep O
sequencing O
which O
yields O
large O
datasets O
that O
must O
then O
be O
computationally O
analyzed O
both O
individually O
and O
collectively O
to O
comprehensively O
describe O
the O
epigenetic O
programming O
that O
dictates O
cell O
fate O

These O
findings O
together O
with O
rapid O
development O
of O
immunotherapies O
open O
new O
avenues O
for O
cancer B-Disease
treatment O

Forty O
CpG O
sites O
showed O
significant O
association O
with O
PD B-Disease
at O
5% O
FDR O
correction O
, O
though O
the O
differences O
of O
the O
DNA B-Chemical
methylation I-Chemical
levels O
were O
relatively O
small O

during O

Early O
detection O
can O
decrease O
both O
morbidity O
and O
mortality O
associated O
with O
this O
neoplasm B-Disease

To O
translate O
this O
resulting O
state O
into O
a O
causal O
relationship O
with O
a O
subset O
of O
regulatory O
features O
, O
many O
experiments O
deploy O
an O
array O
of O
laboratory O
assays O
from O
multiple O
modalities O

In O
this O
paper O
we O
present O
details O
of O
a O
novel O
DMR O
caller O
, O
the O
Probe O
Lasso O
 O
a O
flexible O
window O
based O
approach O
that O
gathers O
neighbouring O
significant-signals O
to O
define O
clear O
DMR O
boundaries O
for O
subsequent O
in-depth O
analysis O

With O
these O
objectives O
in O
mind O
, O
we O
first O
show O
how O
Waddington B-Gene
introduced O
the O
term O
" O
epigenetics O
" O
in O
a O
biological O
context O
in O
order O
to O
solve O
a O
developmental O
problem O
, O
and O
we O
then O
build O
on O
this O
by O
presenting O
Nanney B-Gene
's O
, O
Riggs B-Gene
' O
and O

Conversely O
, O
a O
critical O
appraisal O
of O
how O
this O
emerging O
epigenetics O
knowledge O
is O
debated O
and O
employed O
can O
highlight O
the O
very O
processes O
that O
reinforce O
existing O
gender O
disparities O
in O
the O
social O
determinants O
of O
health O
framework O

1289/EHP2322 O

In O
multicellular O
organisms O
, O
such O
division O
is O
achieved O
through O
epigenetic B-Chemical
factors O
regulating O
cell O
differentiation O
during O
development O

1270 O
 O
Background O
 O
The O
biological O
mechanisms O
underlying O
frailty O
in O
older O
people O
are O
poorly O
understood O

The O
standard O
for O
technical O
validation O
of O
a O
lab O
developed O
test O
(LDT) O
in O
the O
USA O
comes O
from O
the O
Clinical B-Disease
Laboratory I-Disease
Improvement I-Disease
Amendments I-Disease
(CLIA) I-Disease

This O
pilot O
study O
was O
conducted O
to O
investigate O
the O
potential O
effects O
of O
timing O
of O
CD4+ B-Gene
T-cell I-Gene
processing O
from O
peripheral O
blood O
of O
atopic B-Disease
and O
non-atopic B-Disease
adults O
on O
their O
transcriptomic O
and O
epigenetic O
profiles O

We O
discuss O
some O
of O
the O
challenges O
in O
studying O
epigenetic O
mediation O
of O
pathogenesis O
and O
describe O
some O
unique O
opportunities O
for O
exploring O
these O
phenomena O

One O
JMJD B-Gene
subfamily O
consists O
of O
JMJD1A B-Gene
/ I-Gene
KDM3A I-Gene
, O
JMJD1B B-Gene
/ I-Gene
KDM3B I-Gene
, O
and O
JMJD1C B-Gene
/ I-Gene
KDM3C I-Gene
that O
are O
roughly O
50% O
identical O
at O
the O
amino O
acid O
level O

Early O
21st O
century O
bioarchaeology O
may O
also O
be O
enhanced O
from O
a O
renewed O
engagement O
with O
the O
concept O
of O
biological B-Disease
stress I-Disease

However O
, O
analyzing O
this O
data O
in O
terms O
of O
accuracy O
, O
sensitivity O
, O
and O
speed O
still O
remains O
an O
important O
challenge O


Differences O
in O
the O
genome-wide O
expression O
profile O
of O
microRNAs B-Gene
were O
found O
among O
multiple O
tissues O
, O
indicating O
the O
involvement O
of O
distinct O
processes O
in O
fibromyalgia B-Disease
pathogenesis O

Recent O
findings O
 O
Recent O
studies O
attempted O
to O
link O
epigenetic O
modifications O
with O
genetic O
or O
environmental O
risk O
factors O
for O
RA B-Disease

68 O
Genetic B-Gene
, O
epigenetic O
, O
and O
metabolic O
alterations O
are O
all O
hallmarks O
of O
cancer B-Disease

We O
performed O
maximum O
relevance O
maximum O
distance O
( O
MRMD O
) O
analysis O
to O
select O
key O
features O
and O
used O
the O
Extreme O
Gradient O
Boosting O
( O
XGBoost O
) O
algorithm O
to O
build O
our O
predictor O

Typical O
fluorescent O
assays O
quantify O
based O
on O
relative O
intensity O

The O
protocol O
outlined O
herein O
could O
be O
applied O
for O
delivery O
of O
adeno-associated B-Species
viruses I-Species
( O
AAV B-Species
) O
or O
lentiviruses B-Species
in O
both O
mice B-Species
and O
rats B-Species

Not O
only O
can O
epigenetic O
status O
influence O
drug O
response O
, O
but O
it O
can O
also O
be O
modulated O
by O
drugs O

For O
example O
, O
the O
24-nt O
siRNA-involved O
RNA-directed O
DNA O
methylation O
( O
RdDM O
) O
pathway O
is O
plant-specific O
because O
of O
the O
involvements O
of O
two O
plant-specific O
DNA-dependent O
RNA O
polymerases O
, O
Pol O
IV O
and O
Pol O
V O

We O
conducted O
a O
systematic O
review O
of O
all O
available O
literature O
and O
included O
156 O
publications O
across O
4 O
resource O
databases O

More O
specifically O
, O
the O
importance O
of O
epigenetic O
regulatory O
mechanisms O
for O
biological O
processes O
like O
speciation B-Disease
and O
embryogenesis O
has O
been O
well O
documented O
and O
revealed O
the O
direct O
link O
between O
epigenetic O
modifications O
and O
various O
diseases B-Disease

The O
advent O
of O
genome-scale O
analysis O
techniques O
, O
including O
the O
recently O
developed O
next-generation O
sequencing O
, O
has O
enabled O
an O
invaluable O
advance O
in O
the O
molecular O
mechanisms O
underlying O
tumor B-Disease
initiation I-Disease
, O
progression O
, O
and O
expansion O

com O
/ O
david-juan O
/ O
ChromDet B-Gene

The O
Inheritance O
of O
Acquired B-Disease
Characteristics I-Disease
) O

Animals O
were O
individually O
weighted O
from O
1 O
week O
after O
hatching O
, O
with O
weight O
records O
at O
7 O
, O
14 O
, O
21 O
, O
28 O
, O
35 O
and O
42 O
days O
of O
age O
( O
BW7 O
, O
BW14 O
, O
BW21 O
, O
BW28 O
, O
BW35 O
and O
BW42 O
, O
respectively O
) O

Epigenetic O
modifications O
defined O
as O
' O
heritable O
changes O
to O
the O
genome O
that O
do O
not O
involve O
changes O
in O
DNA B-Gene
sequence O
' O
have O
emerged O
as O
a O
new O
layer O
of O
biological O
regulation O
in O
CVD B-Disease
and O
could O
advance O
individualized O
risk O
assessment O
as O
well O
as O
devising O
and O
deploying O
tailored O

Here O
we O
consider O
how O
single-cell O
epigenomic O
technologies O
may O
address O
the O
current O
challenges O
faced O
by O
cancer B-Disease
clinicians O

Recent O
methodologies O
include O
many O
sequencing O
and O
analytical O
techniques O
to O
extrapolate O
different O
types O
of O
epigenetic O
data O

Several O
theoretical O
and O
experimental O
considerations O
suggest O
that O
cancer B-Disease
might O
be O
associated O
with O
the O
absence O
or O
impairment O
of O
the O
proper O
coherent O
dynamics O
in O
certain O
biological O
structures O
, O
most O
notably O
in O
the O
microtubules B-Chemical

Currently O
, O
climate O
change O
is O
one O
of O
the O
most O
important O
drivers O
of O
freshwater O
transformation O
and O
its O
effects O
include O
changes O
in O
the O
composition O
, O
biodiversity O
and O
functioning O
of O
freshwater O
ecosystems O

, O
MeDIP-seq O
and O
MRE-seq O
) O
, O
we O
can O
significantly O
increase O
the O
efficiency O
of O
whole O
DNA B-Chemical
methylome I-Chemical
profiling O

Here O
, O
we O
bring O
the O
increasing O
evidence O
that O
environmental O
exposures O
early O
in O
development O
are O
linked O
to O
diabetes B-Disease
through O
epigenetic O
modifications O

855 O
 O
Major O
mental O
diseases O
such O
as O
autism B-Disease
, O
bipolar B-Disease
disorder I-Disease
, O
schizophrenia B-Disease
, O
and O
major B-Disease
depressive I-Disease
disorder I-Disease
are O
debilitating O
illnesses O
with O
complex O
etiologies O

This O
research O
evaluated O
longitudinal O
changes O
in O
epigenetic O
age O
before O
and O
after O
exposure O
to O
work-related O
trauma B-Disease
among O
paramedicine O
students O

Recently O
, O
studies O
have O
demonstrated O
that O
these O
modifications O
are O
influenced O
not O
only O
by O
biological O
cues O
but O
also O
by O
mechanical O
and O
topographical O
signals O

By O
contrast O
, O
several O
epigenetic O
biomarkers O
and O
treatments O
are O
currently O
in O
use O
for O
personalized O
therapies O
in O
patients O
with O
cancer B-Disease

19 O
% O
and O
DNA B-Gene
integrity O
of O
purified O
MIC B-Species
is O
maintained O

Importantly O
, O
integrated O
epigenetic O
mechanisms O
were O
explored O
during O
male O
germ O
cell O
differentiation O
, O
which O
provides O
deep O
insight O
into O
the O
epigenetic O
processes O
associated O
with O
male O
germ O
cell O
differentiation O
and O
possibly O
improves O
treatment O
options O
to O
male O
infertility B-Disease
in O
animals B-Species
and O
humans B-Species

Even O
though O
the O
involvement O
of O
many O
genes B-Gene
are O
likely O
, O
up O
regulating O
and O
activation O
or O
down O
regulation O
and O
silencing O
of O
these O
genes B-Gene
by O
the O
environmental O
factors O
play O
a O
crucial O
role O
in O
contributing O
to O
their O
pathogenesis B-Disease


445 O
Diabetic B-Disease
retinopathy I-Disease
(DR) O
, O
which O
arises O
as O
a O
result O
of O
an O
increasing O
incidence O
of O
diabetes B-Disease
mellitus I-Disease
, O
has O
gradually O
become O
a O
common O
disease O

Traditional O
approaches O
to O
characterize O
epigenetic O
modifications O
of O
chromatin O
or O
the O
transcriptome O
of O
cells O
have O
often O
focused O
on O
blended O
responses O
of O
many O
cells O
in O
a O
tissue O
; O
however O
, O
such O
bulk O
measures O
lose O
spatial O
and O
temporal O
differences O
that O
occur O
from O
cell O
to O
cell O
, O
and O
cannot O

48 O
Advances O
in O
molecular O
biology O
technologies O
have O
allowed O
uncovering O
the O
role O
of O
epigenetic O
regulation O
in O
several O
complex O
diseases O
, O
such O
as O
cancer B-Disease
and O
neurodegenerative B-Disease
disorders O

However O
, O
the O
factors O
that O
determine O
the O
extent O
of O
somaclonal O
variation O
and O
the O
molecular O
changes O
underpinning O
this O
process O
remain O
poorly O
understood O

Imprinted O
genes O
also O
often O
exhibit O
parent-of-origin-dependent O
allele-specific O
methylation B-Chemical
(pd-ASM) O
, O
which O
causes O
parent-of-origin-dependent O
allele-specific O
expression O

Around O
40% O
of O
all O
cases O
are O
caused O
by O
a O
germline O
mutation O
in O
a O
susceptibility O
gene O
, O
half O
of O
which O
being O
found O
in O
an O
SDHx B-Gene
gene I-Gene
( O
SDHA B-Gene
, O
SDHB B-Gene
, O
SDHC B-Gene
, O
SDHD B-Gene
or O
SDHAF2 B-Gene
) O

We O
describe O
biomarker O
assays O
to O
validate O
the O
probes O
in O
specific O
cellular O
systems O
, O
and O
provide O
guidelines O
for O
their O
use O
in O
functional O
characterization O
of O
methyltransferases B-Chemical
including O
detailed O
protocols O
, O
examples O
, O
and O
controls O

In O
this O
preliminary O
study O
we O
identified O
190 O
lipid O
related O
CpG O
loci O
differentially O
methylated O
in O
hypercholesterolemic B-Disease
versus O
control O
individuals O

We O
also O
illustrate O
the O
application O
of O
HMM-DM O
using O
a O
real O
breast B-Disease
cancer I-Disease
dataset O

Here O
we O
review O
latest O
findings O
on O
chromatin B-Chemical
related O
mechanisms O
and O
hypothesize O
how O
their O
impairment O
might O
contribute O
to O
the O
altered O
epigenome O
of O
cancer B-Disease
cells I-Disease

Dysregulation O
of O
DNA B-Gene
methylation I-Gene
has O
been O
implicated O
in O
human B-Species
diseases O
, O
with O
regions O
such O
as O
repeat O
elements O
commonly O
altered O

, O
expression O
, O
copy O
number O
, O
methylation O
) O
from O
TCGA O
, O
GEO O
, O
ENCODE O
, O
and O
Human B-Species
Protein I-Species
Atlas I-Species
projects O
led O
to O
the O
following O
observations O
 O
( O
a O
) O
mda-9 B-Gene
expression O
correlates O
with O
both O
copy O
number O
and O
methylation O
level O
of O
an O
intronic O

hence O

Consequently O
, O
we O
detected O
many O
more O
differentially O
methylated O
regions O
( O
DMRs O
) O
with O
the O
pooled O
libraries O
and O
a O
significantly O
lower O
statistical O
power O
for O
regions O
from O
individual O
libraries O

1332 O
The O
Developmental O
Origins O
of O
Health O
and O
Disease B-Disease
and O
the O
related O
science O
of O
epigenetics O
redefines O
the O
meaning O
of O
what O
constitutes O
upstream O
approaches O
to O
significant O
social O
and O
public O
health O
problems O

Previous O
studies O
indicated O
that O
DNAm B-Gene
could O
also O
show O
positive O
correlations O
with O
gene O
expression O

Furthermore O
, O
from O
2000-2023 O
, O
the O
top O
five O
frequent O
research O
topics O
were O
diabetic B-Disease
retinopathy I-Disease
, O
522 O
; O
microribonucleic B-Chemical
acid I-Chemical
, O
469 O
; O
retinoblastoma B-Disease
, O
370 O
; O
apoptosis B-Disease
, O
268 O
; O
and O
epigenetics B-Chemical
, O
206 O

In O
addition O
, O
we O
introduce O
a O
novel O
genotype-independent O
test O
to O
detect O
methylation B-Chemical
imbalance O
between O
chromosomes O

architecture O

epigenetic O

As O
with O
the O
previous O
introduction O
of O
genetic O
research O
in O
psychiatry O
, O
there O
is O
also O
the O
problem O
of O
unrealistic O
expectations O
and O
new O
legal O
and O
ethical O
problems O

769 O
In O
this O
issue O
of O
the O
Biomedical O
Journal O
, O
we O
examine O
how O
far O
the O
explosion O
of O
epigenetic O
studies O
in O
recent O
years O
has O
translated O
to O
benefits O
for O
patients O
in O
the O
clinic O
, O
and O
we O
highlight O
an O
original O
study O
suggesting O
that O
increased O
vegetable O
intake O
protects O
against O
osteoporotic B-Disease

Results O
 O
Seven O
CpG B-Gene
sites I-Gene
were O
associated O
with O
dysmenorrhea B-Disease
and O
two O
with O
HMB B-Disease

This O
article O
is O
part O
of O
a O
Special O
Issue O
entitled O
SI O
 O
Neuroprotection B-Disease


Potential O
targets O
of O
disruption O
along O
putative O
adverse O
outcome O
pathways O
associated O
with O
the O
signaling O
pathways O
are O
identified O
, O
along O
with O
assays O
that O
show O
promise O
in O
evaluating O
the O
target O
in O
a O
screening O
and O
testing O
program O
such O
that O
in O
vitro O
methods O
are O
used O
where O
possible O
, O
and O
animal O
experiments O

Here O
, O
we O
present O
a O
colorimetric O
method O
of O
quantification O
of O
5-hmC B-Chemical
using O
Brassica B-Species
rapa I-Species
DNA O

Even O
when O
one O
only O
considers O
a O
single O
epigenetic O
modification O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
the O
last O
10 O
years O
have O
seen O
a O
wide O
array O
of O
technologies O
developed O

Our O
study O
highlights O
that O
placental O
post-processing O
techniques O
must O
be O
considered O
in O
the O
evaluation O
and O
interpretation O
of O
epigenetic O
studies O

1068 O
Characterization O
of O
the O
epigenetic O
profile O
of O
humans B-Species
since O
the O
initial O
breakthrough O
on O
the O
human B-Species
genome B-Gene
project O
has O
strongly O
established O
the O
key O
role O
of O
histone B-Chemical
modifications O
and O
DNA B-Chemical
methylation O

This O
article O
argues O
that O
social O
epigeneticists O
make O
far-reaching O
claims O
by O
selecting O
elements O
from O
research O
labelled O
epigenetics O
in O
biology O
while O
ignoring O
widely O
confirmed O
scientific O
facts O
in O
genetics O
and O
cell O
biology O
, O
such O
as O
the O
dependence O
of O
epigenetic O
marks O
on O
sequence-specific O
events O
, O
or O
the O

We O
also O
provide O
strong O
evidence O
that O
the O
Sandwich O
Model O
enhances O
student O
engagement O
and O
satisfaction O

The O
aim O
of O
this O
review O
is O
to O
describe O
the O
endogenous O
processes O
that O
surround O
the O
generation O
and O
removal O
of O
the O
most O
common O
types O
of O
DNA O
nucleobase O
modifications O
, O
namely O
, O
uracil B-Chemical
and O
certain O
epigenetic O
modifications O
, O
together O
with O
their O
role O
in O
the O
development O
of O

e O

1062 O
Numerous O
studies O
have O
shown O
that O
epigenetic O
age-an O
individual's O
degree O
of O
aging O
based O
on O
patterns O
of O
DNA B-Chemical
methylation-can O
be O
computed O
and O
is O
associated O
with O
an O
array O
of O
factors O
including O
diet O
, O
lifestyle O
, O
genetics O
, O
and O
disease B-Disease

This O
review O
aims O
to O
describe O
in O
detail O
the O
mechanisms O
of O
epigenetic O
regulation O
and O
the O
known O
findings O
involving O
the O
dysfunction O
of O
these O
mechanisms O
as O
a O
possible O
cause O
of O
various O
diseases B-Disease

506 O
Methylation B-Chemical
has O
frequently O
been O
implicated O
in O
gender O
determination O
in O
plants B-Species

The O
enormous O
information O
content O
that O
comes O
with O
the O
large O
variety O
of O
observed O
STR B-Gene
genotypes O
allows O
for O
genetic O
individualisation O
(with O
the O
exception O
of O
identical O
twins O
) O

004 O
; O
DNAm O
PAI-1 B-Gene
, O
b(SE) O
= O
- O
1 O

However O
, O
we O
are O
now O
discovering O
that O
the O
mechanisms O
that O
regulate O
how O
genes B-Gene
are O
expressed O
tell O
a O
much O
richer O
story O
than O
our O
DNA B-Gene
alone O

The O
aim O
of O
this O
article O
is O
to O
review O
the O
major O
epigenetic O
findings O
in O
motor B-Disease
neuron I-Disease
diseases I-Disease
and O
major O
hereditary O
muscular B-Disease
dystrophies I-Disease

In O
cancer B-Disease
epidemiology O
, O
epigenetic B-Gene
biomarkers O
offer O
advantages O
over O
other O
types O
of O
biomarkers O
because O
they O
are O
expressed O
against O
a O
person O
's O
genetic B-Gene
background O
and O
environmental O
exposure O
, O
and O
because O
epigenetic B-Gene
events O
occur O
early O
in O
cancer B-Disease
development O

) O
as O
related O
to O
its O
clinical O
manifestations O
, O
rather O
than O
genetic O
factors O

Large-scale O
numerical O
experiments O
show O
that O
adaptive O
SMCCA O
converges O
as O
fast O
as O
conventional O
SMCCA O

Among O
molecular O
mechanisms O
linking O
stress O
and O
aging O
, O
the O
present O
article O
reviews O
evidence O
on O
the O
role O
of O
epigenetics O
, O
biochemical O
processes O
that O
can O
be O
set O
into O
motion O
by O
stressors O
and O
in O
turn O
influence O
genomic O
function O
and O
complex O
phenotypes O
, O
including O
aging-related O
outcomes O

Second O
, O
these O
and O
other O
EDCs B-Chemical
are O
potent O
modulators O
of O
nuclear O
DNA B-Gene
epigenetics O
, O
including O
DNA B-Gene
methylation O
and O
histone B-Gene
modifications O

These O
clocks O
were O
developed O
using O
novel O
DNA B-Gene
methylation I-Gene
profiles O
of O
140 O
elephant B-Species
blood O
samples O
of O
known O
age O
, O
at O
loci O
that O
are O
highly O
conserved O
between O
mammalian B-Species
species I-Species
, O
using O
a O
custom O
Infinium B-Chemical
array I-Chemical
( O
HorvathMammalMethylChip40 B-Chemical
) O

Multiple O
methodological O
shortcomings O
are O
identified O
, O
including O
at O
the O
phenotypic O
level O
where O
construct O
validity O
of O
childhood B-Disease
SEP I-Disease
is O
highly O
inconsistent O
, O
with O
studies O
using O
a O
wide O
range O
of O
measures O

These O
results O
show O
the O
variations O
in O
chromatin B-Chemical
remodeling I-Chemical
protein O
expression O
have O
a O
strong O
impact O
on O
iPSC B-Species
reprogramming O

Conclusions O
 O
BROCKMAN O
and O
related O
approaches O
will O
help O
gain O
a O
mechanistic O
understanding O
of O
the O
trans O
determinants O
of O
chromatin O
variability O
between O
cells O
, O
treatments O
, O
and O
individuals O

The O
epigenetic O
heterogeneity O
among O
different O
subsets O
of O
T B-Species
cells I-Species
and O
among O
promoters O
or O
non-promoters O
of O
target O
genes B-Gene
should O
be O
furthermore O
clarified O
in O
acute O
or O
chronic O
lung B-Disease
diseases I-Disease
and O
cancers B-Disease

1392 O
Adversity O
during O
childhood O
has O
for O
long O
been O
known O
to O
increase O
the O
risk O
of O
developing O
mental O
health O
problems O
in O
adulthood O

The O
aims O
of O
this O
paper O
are O
to O
synthesize O
and O
report O
research O
findings O
from O
neuroscience O
and O
epigenetics O
that O
contribute O
to O
an O
emerging O
explanatory O
framework O
for O
advanced O
practice O
psychiatric O
nursing O

755 O
RNA B-Chemical
sequencing I-Chemical
( O
RNA-seq B-Chemical
) O
, O
chromatin B-Chemical
immunoprecipitation I-Chemical
sequencing I-Chemical
( O
ChIP-seq B-Chemical
) O
, O
and O
assay O
for O
transposase-accessible B-Chemical
chromatin I-Chemical
sequencing I-Chemical
( O
ATAC-seq B-Chemical
) O
are O
genome-wide O
techniques O
that O
provide O
information O
relative O

We O
suggest O
a O
three-step O
process O
for O
using O
epigenetics B-Chemical
in O
health B-Disease
promotion I-Disease
research O
that O
emphasizes O
integrating O
epigenetic B-Chemical
mechanisms O
into O
conceptual O
model O
development O
that O
then O
informs O
selection O
of O
intervention O
approaches O
and O
outcomes O

By O
combining O
each O
one O
of O
these O
principles O
with O
other O
genomic O
methodologies O
, O
a O
large O
range O
of O
approaches O
aimed O
at O
the O
analysis O
of O
methylation B-Chemical
from O
one O
specific O
CpG B-Gene
site I-Gene
to O
a O
large O
number O
of O
sequences O
on O
the O
genome O
scale O
and O
suitable O
for O
different O
research O
needs O

There O
are O
many O
copies O
of O
rRNA B-Gene
genes I-Gene
per O
genome O
that O
are O
under O
tight O
transcriptional O
control O
by O
epigenetic O
mechanisms O
serving O
to O
meet O
cellular O
needs O
in O
protein O
synthesis O

The O
advent O
of O
commercial O
, O
array-based O
methods O
to O
interrogate O
DNA B-Gene
methylation I-Gene
has O
led O
to O
a O
profusion O
of O
epigenetic O
studies O
in O
the O
literature O

Here O
, O
we O
review O
the O
role O
of O
key O
aberrant O
epigenetic O
processes O
- O
DNA B-Chemical
methylation I-Chemical
and O
post-translational O
modification O
of O
histones B-Chemical
- O
in O
tumour B-Disease
immunogenicity I-Disease
, O
as O
well O
as O
the O
effects O
of O
epigenetic O
modulation O
on O
antitumour B-Disease
immune I-Disease
cell I-Disease
function O

Fourteen O
DMRs O
correlated O
with O
differentially O
expressed O
genes O
in O
AT O
post O
bariatric O
surgery O
, O
including O
downregulation O
of O
PIK3AP1 B-Gene
in O
both O
SAT B-Species
and O
OVAT B-Species

BECs O
had O
greater O
inter-individual O
DNAm O
variability O
compared O
to O
PBMCs O
and O
highly O
the O
variable O
CpGs O
are O
more O
likely O
to O
be O
positively O
correlated O
between O
the O
matched O
tissues O
compared O
to O
less O
variable O
CpGs O

Finally O
, O
we O
demonstrated O
epihet O
utility O
on O
acute B-Disease
myeloid I-Disease
leukemia I-Disease

In O
exposed O
rats B-Species
, O
DNA B-Gene
methylation O
was O
higher O
in O
young O
and O
lower O
in O
mature O
animals O
then O
in O
controls O

Nevertheless O
, O
we O
also O
explored O
gene O
expression O
in O
sperm O
by O
a O
pathway O
analysis O
showing O
that O
genes O
were O
enriched O
for O
the O
pathway O
maps O
of O
bacterial O
infections O
in O
cystic B-Disease
fibrosis I-Disease
( O
CF B-Disease
) O
airways O
, O
glycolysis O
and O
gluconeogenesis O
p O

Here O
we O
propose O
a O
potential O
role O
of O
adult O
stem O
cells O
in O
maintaining O
epigenetic O
states O
provides O
a O
useful O
basis O
for O
formulating O
such O
epidemiologically-relevant O
concepts O

Sections O
of O
our O
DNA B-Gene
are O
constantly O
being O
turned O
on O
or O
off O
, O
marked O
for O
easy O
access O
, O
or O
secluded O
and O
hidden O
away O
, O
all O
in O
response O
to O
ongoing O
cellular O
activity O

The O
strongest O
predictor O
is O
the O
region O
coincident O
with O
PbRR9 B-Gene
, O
showing O
that O
this O
gene O
stands O
out O
against O
all O
genes O
in O
the O
genome O
in O
having O
the O
strongest O
sex-specific O
methylation O
pattern O

These O
EpiScores O
for O
protein O
levels O
can O
therefore O
be O
a O
valuable O
resource O
for O
disease B-Disease
prediction O
and O
risk O
stratification O

213 O
Epigenetic O
mechanisms O
are O
an O
underappreciated O
and O
often O
ignored O
component O
of O
an O
organism's O
response O
to O
environmental O
change O
and O
may O
underlie O
many O
types O
of O
phenotypic O
plasticity O

However O
, O
since O
epigenetic O
modification O
is O
an O
internal O
system O
based O
on O
attachment O
and O
detachment O
of O
chemical B-Chemical
residues O
on O
a O
DNA B-Gene
sequence O
, O
it O
is O
reversible O
and O
potentially O
treatable O

Here O
, O
we O
discuss O
the O
essentials O
of O
the O
computational O
methodology O
required O
for O
analyzing O
common O
single-cell O
epigenomic O
measurements O
for O
DNA B-Chemical
methylation O
using O
bisulfite B-Chemical
sequencing O
and O
open O
chromatin O
using O
ATAC-Seq B-Chemical

942 O
is O
an O
epigenetic O
modification O
with O
an O
established O
role O
in O
both O
normal O
cellular O
function O
and O

500 O
) O
per O
each O
additional O
marijuana B-Chemical
- I-Chemical
year I-Chemical

Class O
IIa O
histone B-Chemical
deacetylases I-Chemical
are O
a O
class O
of O
epigenetic O
regulators O
that O
possess O
a O
myriad O
of O
post-transcriptional O
modification O
sites O
that O
modulate O
their O
activity O
in O
response O
to O
oxidative B-Disease
stress I-Disease
, O
altered O
catecholamine B-Chemical
signalling O
or O
changes O
in O
the O
cellular O
metabolism O

Effects O
following O
parental O
exposure O
to O
drugs B-Chemical
of I-Chemical
abuse I-Chemical
are O
used O
as O
an O
example O
of O
the O
wide O
range O
of O
behavioral O
outcomes O
and O
the O
variability O
associated O
with O
these O
multiple O
generation O
studies O

245Contents O
Summary O
738 O
I O

Epigenetic O
changes O
following O
exposure O
to O
multiple O
stressors O
constitute O
another O
promising O
area O
of O
further O
research O

This O
chapter O
reviews O
traditional O
bisulfite B-Chemical
sequencing O
and O
shotgun B-Chemical
bisulfite I-Chemical
sequencing O
approaches O
, O
with O
a O
greater O
emphasis O
on O
shotgun B-Chemical
bisulfite I-Chemical
sequencing O
methods O
and O
data O
analysis O

The O
packaging O
and O
modifications O
around O
the O
genome O
have O
been O
shown O
to O
exert O
significant O
influence O
on O
cellular O
behaviour O
and O
, O
in O
turn O
, O
human B-Species
development O
and O
disease B-Disease

This O
package O
first O
introduces O
a O
binarized O
indexing O
strategy O
for O
clustering O
the O
cCREs O

Functional O
analysis O
revealed O
that O
these O
regions O
are O
linked O
with O
cell O
identities O

Next O
, O
we O
conduct O
a O
scoping O
review O
of O
postgenomic O
work O
in O
environmental O
epigenetics O
and O
DOHaD O
that O
looks O
at O
the O
role O
of O
race/ethnicity O
in O
human O
health O
( O
2000-2021 O
) O

The O
adaptation O
of O
the O
different O
schemes O
for O
processing O
variations O
is O
quantified O
for O
a O
range O
of O
fluctuating O
environments O
, O
following O
an O
approach O
that O
links O
quantitative O
genetics O
with O
stochastic O
control O
theory O

e O

 O

Unlike O
the O
existing O
chromatin O
segmentation O
approaches O
, O
EPIGENE B-Gene
uses O
a O
constrained O
, O
semi-supervised O
multivariate O
hidden O
Markov O
model O
( O
HMM O
) O
that O
models O
the O
observed O
combination O
of O
histone B-Chemical
modifications I-Chemical
using O
a O
product O
of O
independent O
Bernoulli O
random O
variables O
, O
to O
identify O
active O
TUs O

of O

The O
aim O
of O
this O
COST O
action O
launched O
in O
2020 O
is O
 O
( O
1 O
) O
to O
define O
standardized O
pipelines O
and O
methods O
used O
in O
the O
study O
of O
epigenetic O
mechanisms O
in O
plants B-Species
, O
( O
2 O
) O
update O
, O
share O
, O
and O
exchange O
findings O
in O
epigenetic O
responses O
to O
environmental O

89 O
) O

Release O

Recent O
research O
in O
this O
area O
has O
led O
to O
excitement O
and O
questions O
about O
medical O
applications O
of O
epigenetics O

The O
Nanopore O
sequencer O
is O
a O
single-molecule O
, O
long-read O
sequencer O
that O
can O
directly O
sequence O
RNA B-Chemical
as O
well O
as O
DNA B-Chemical

Very O
often O
, O
these O
experiments O
are O
based O
on O
the O
hypothesis O
that O
epigenetic O
memorization O
of O
events O
or O
conditions O
could O
be O
the O
basis O
of O
an O
altered O
response O
of O
the O
progeny O
upon O
encountering O
the O
same O
or O
a O
similar O
condition O

The O
change O
of O
structure O
is O
either O
open O
chromatin O
for O
" O
active O
" O
state O
or O
closed O
chromatin O
for O
" O
inactive O
" O
state O
, O
that O
regulates O
important O
biological O
phenomenon O
like O
chromatin O
condensation O
, O
gene B-Gene
expression O
, O
DNA B-Gene
repair O
, O
cellular O
development O
, O
differentiation O
and O
homeostasis O
, O

Because O
epigenetic O
alterations O
can O
be O
reversed O
by O
chemicals B-Chemical
and O
activate O
gene B-Gene
expression O
, O
epigenetic O
biomarkers O
potentially O
have O
numerous O
clinical O
applications O
in O
cancer B-Disease
intervention O
and O
treatment O
and O
significant O
implications O
in O
public O
health O

DNA O
methylation O
, O
cause O
cancer B-Disease

This O
Review O
highlights O
the O
complexity O
of O
neurodegenerative B-Disease
diseases I-Disease
and O
the O
variability O
in O
patient O
responses O
to O
pharmacotherapy O
, O
emphasizing O
the O
influence O
of O
genetic B-Gene
polymorphisms I-Gene
on O
the O
pharmacokinetics O
and O
pharmacodynamics O
of O
drugs B-Chemical
used O
to O
treat O
those O
conditions O

This O
paper O
provides O
a O
comprehensive O
review O
of O
the O
emerging O
analytical O
and O
experimental O
approaches O
of O
single-cell O
sequencing O
in O
various O
omics O
, O
focusing O
specifically O
on O
epigenomics O

This O
review O
will O
 O
( O
1 O
) O
provide O
a O
brief O
overview O
of O
the O
main O
evolutionary O
theories O
of O
ageing O
; O
( O
2 O
) O
discuss O
recent O
genetic O
evidence O
which O
has O
revealed O
alleles O
that O
have O
pleiotropic O
effects O
on O
fitness O
at O
different O
ages O
in O
; O
( O
3 O
) O
consider O

To O
understand O
current O
progress O
and O
trends O
in O
the O
inclusion O
of O
epigenetics B-Gene
in O
cancer B-Disease
epidemiology O
, O
we O
evaluated O
the O
published O
literature O
and O
the O
( O
) O
- O
supported O
research O
grant O
awards O
in O
this O
field O
to O
identify O
trends O
in O

Supplementary O
information O
 O
Supplementary O
data O
are O
available O
at O
Bioinformatics O
online O

) O
Heynh O

05 O

Network O
enrichment O
analysis O
shows O
CNR1 B-Gene
expression O
in O
the O
brain O
and O
its O
interacting O
genes O
involve O
different O
pathways O
such O
as O
Rap1 B-Gene
signalling O
, O
dopaminergic B-Disease
synapse I-Disease
, O
and O
relaxin B-Chemical
signalling O

It O
focuses O
on O
the O
biochemical O
mechanisms O
and O
epigenetic O
variants O
at O
the O
origin O
of O
disease O
, O
leading O
to O
novel O
biomedical O
means O
of O
assessing O
epigenetic O
susceptibility O
and O
reversing O
detrimental O
epigenetic O
variants O

We O
, O
first O
( O
I O
) O
, O
make O
the O
case O
that O
a O
broader O
ethical O
debate O
on O
EE B-Chemical
is O
due O
, O
provide O
scientific O
background O
on O
EE B-Chemical
, O
compile O
potential O
use-cases O
and O
recap O
previous O
debates O

The O
emerging O
field O
of O
epigenetics O
is O
also O
providing O
further O
insights O
into O
these O
mechanisms O

Aging O
and O
cancer B-Disease
demonstrate O
profound O
genome-wide O
DNA B-Gene
methylation I-Gene
changes O
, O
suggesting O
that O
nutrition O
may O
affect O
the O
aging O
process O
and O
cancer B-Disease
development O
through O
epigenetic O
mechanisms O

Moreover O
, O
combining O
molecular O
assays O
with O
network O
analysis O
of O
epigenomic O
data O
may O
aid O
in O
clarifying O
the O
multistage O
transition O
from O
a O
" O
pre-disease B-Disease
" O
to O
" O
disease B-Disease
" O
state O
, O
with O
the O
goal O
of O
improving O
primary O
prevention O
of O
lung B-Disease
diseases I-Disease
and O
its O

61 O
Epigenetic O
changes O
frequently O
occur O
in O
human B-Species
gastric I-Species
cancer B-Disease

In O
addition O
, O
we O
take O
the O
opportunity O
to O
describe O
the O
aims O
of O
EPI-CATCH B-Gene
, O
an O
international O
action O
consortium O
composed O
by O
researchers O
from O
28 O
countries O

This O
is O
the O
case O
in O
epigenome-wide O
association O
studies O
used O
as O
genome-wide O
screening O
of O
methylation O
changes O
to O
detect O
new O
candidate O
genes B-Gene
and O
regions O
associated O
with O
a O
specific O
disease B-Disease
or O
condition O

These O
individual O
differences O
are O
produced O
epigenetically O
by O
the O
two-way O
interaction O
between O
the O
brain O
and O
hormones O
, O
immune B-Disease
system I-Disease
mediators O
and O
the O
autonomic B-Disease
nervous I-Disease
system O

05 O
) O
, O
but O
none O
in O
HUVEC B-Species

Exposure O
to O
heavy O
metals O
, O
bioflavonoids O
, O
and O
endocrine O
disruptors O
, O
such O
as O
bisphenol B-Chemical
A I-Chemical
and O
phthalates B-Chemical
, O
has O
been O
shown O
to O
affect O
the O
epigenetic O
memory O
of O
an O
organism O

The O
quest O
for O
personalized O
medicine O
is O
a O
contemporary O
manifestation O
of O
this O
dream O

This O
review O
further O
outlines O
exciting O
future O
avenues O
of O
research O
to O
address O
the O
significance O
of O
epigenetic O
heterogeneity O
and O
the O
contributions O
of O
microfluidics O
technologies O
to O
single-cell O
isolation O
and O
analysis O

322 O
High-throughput O
single-cell O
measurements O
of O
DNA B-Chemical
methylomes O
can O
quantify O
methylation O
heterogeneity O
and O
uncover O
its O
role O
in O
gene O
regulation O

Therefore O
, O
it O
is O
of O
interest O
to O
consider O
the O
evolution O
of O
epigenetic O
processes O

683 O
Forensic O
geneticists O
are O
in O
a O
race O
to O
develop O
methods O
based O
on O
DNA B-Chemical
methylation I-Chemical
for O
various O
forensic O
applications O
, O
including O
age O
estimation O

1331Background O
Studies O
on O
DNA B-Gene
methylation I-Gene
following O
bariatric B-Disease
surgery I-Disease
have O
primarily O
focused O
on O
blood B-Species
cells I-Species
, O
while O
it O
is O
unclear O
to O
which O
extend O
it O
may O
reflect O
DNA B-Gene
methylation I-Gene
profiles O
in O
specific O
metabolically O
relevant O
organs O
such O
as O
adipose B-Species
tissue I-Species

517 O
Platform O
technologies O
for O
measurement O
of O
CpG B-Chemical
methylation O
at O
multiple O
loci O
across O
the O
genome O
have O
made O
ambitious O
epigenome-wide O
association O
studies O
affordable O
and O
practicable O

g O

( O
ii O
) O
Knockdown O
of O
GLDC B-Gene
increased O
cell O
proliferation O
, O
migration O
, O
invasion O
, O
colony O
formation O
and O
reduced O
apoptosis O

Although O
these O
drugs O
have O
the O
potential O
to O
be O
highly O
beneficial O
for O
patients O
, O
they O
act O
systemically O
and O
may O
have O
" O
off-target O
" O
effects O
in O
other O
cells O
such O
as O
the O
patients O
' O
sperm B-Species
or O
eggs B-Species

Some O
aging O
clocks O
that O
have O
been O
proposed O
include O
the O
suprachiasmatic B-Species
nucleus I-Species
, O
the O
hypothalamus B-Species
, O
involution O
of O
the O
thymus B-Species
, O
and O
cellular O
senescence O

About O
10% O
of O
the O
probes O
on O
the O
arrays O
were O
estimated O
to O
be O
useful O
for O
DNA B-Chemical
methylation I-Chemical
assay O
in O
the O
common B-Species
marmoset I-Species

Ethanol B-Chemical
exposure O
in O
adolescence O
alters O
memory O
and O
cognition O
, O
anxiety-like O
behavior O
, O
and O
ethanol B-Chemical
sensitivity O
as O
well O
as O
brain O
myelination O
and O
dendritic O
spine O
morphology O
, O
with O
effects O
lasting O
into O
adulthood O

The O
authors O
discuss O
the O
current O
evidence O
for O
transgenerational O
epigenetic O
inheritance O
and O
summarize O
the O
data O
linking O
epigenetics O
to O
cardiovascular B-Disease
disease I-Disease

Publications O
on O
epigenetic O
research O
in O
the O
atherosclerosis B-Disease
field O
have O
increased O
significantly O
every O
year O
, O
indicating O
that O
the O
study O
of O
epigenetic O
modifications O
plays O
an O
increasingly O
important O
role O
in O
understanding O
the O
pathology O
of O
atherosclerosis B-Disease

In O
this O
process O
, O
dorsal O
iris O
pigmented O
epithelial O
cells O
transdifferentiate O
into O
lens O
cells O

Understanding O
the O
dynamic O
interplay O
between O
epigenetic O
regulation O
and O
cellular O
programming O
is O
crucial O
for O
advancing O
mechanism O
and O
clinical O
management O
of O
obesity B-Disease

between O

Human O
population O
studies O
investigating O
these O
tend O
to O
use O
consensus O
sequences O
to O
target O
repeat O
elements O

Thus O
, O
the O
dysregulation O
of O
zinc B-Chemical
homeostasis O
can O
lead O
to O
epigenetic O
alterations O

Such O
cross-disciplinary O
synergisms O
hopefully O
will O
promote O
more O
complete O
understandings O
of O
health B-Disease
and O
stress B-Disease
in O
bioarchaeological O
science O

China O
and O
the O
USA B-Species
were O
the O
countries O
with O
the O
highest O
number O
of O
publications O
( O
1739 O
) O
and O
total O
citations O
( O
40533 O
) O
, O
respectively O

However O
, O
the O
specific O
factors O
related O
to O
epigenetic O
age O
deviation O
and O
the O
direction O
of O
association O
differed O
across O
tissues O

Availability O
and O
implementation O
 O
http//bioconductor O

1274 O
The O
assessment O
of O
expression O
and O
epigenomic O
status O
using O
sequencing O
based O
methods O
provides O
an O
unprecedented O
opportunity O
to O
identify O
and O
correlate O
allelic O
differences O
with O
epigenomic O
status O

These O
relationships O
have O
been O
studied O
in O
various O
autoimmune O
diseases O
, O
including O
multiple B-Disease
sclerosis I-Disease
( O
MS B-Disease
) O
, O
systemic B-Disease
sclerosis I-Disease
( O
SSc B-Disease
) O
, O
type B-Disease
1 I-Disease
diabetes I-Disease
( O
T1D B-Disease
) O
, O
Grave's B-Disease
disease I-Disease
( O
GD B-Disease
) O
, O

DNA O
methylation O
could O
not O
explain O
this O
association O

miRNA O
precursors O
, O
difficult O

Â© O
2022 O
Wiley O
Periodicals O
LLC O

The O
proposed O
procedure O
yielded O
the O
highest O
true O
positive O
rate O
, O
acceptable O
false O
discovery O
proportion O
level O
, O
and O
lower O
mean O
square O
error O

Epigenetics O
has O
taken O
center O
stage O
in O
the O
study O
of O
diseases O
such O
as O
cancer B-Disease
and O
diabetes B-Disease
, O
but O
its O
integration O
into O
the O
field O
of O
environmental O
health O
is O
still O
emerging O

However O
, O
the O
mechanisms O
involved O
in O
establishing O
and O
maintaining O
these O
epigenetic O
modifications O
during O
development O
remain O
unclear O

With O
this O
system O
, O
many O
novel O
biological O
questions O
can O
flexibly O
be O
posed O
and O
rapidly O
answered O

Similarly O
, O
the O
insulin-signaling B-Gene
pathway I-Gene
was O
differentially O
methylated O
in O
artery O
( O
Max O
F O
P O
= O
0 O

In O
this O
review O
, O
we O
focus O
on O
the O
epigenetic O
modification O
of O
immune O
cells O
' O
proliferation O
, O
recruitment O
, O
differentiation O
and O
function O
, O
providing O
an O
overview O
of O
the O
key O
genes O
which O
regulated O
by O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
, O
and O
non-coding O

Operating O
parameters O
must O
be O
established O
, O
performance O
characteristics O
determined O
, O
and O
guidelines O
set O
to O
ensure O
repeatability O
and O
accuracy O

The O
relationships O
between O
diet O
and O
nutrigenomic-metabolomic O
profiles O
, O
as O
well O
as O
between O
these O
profiles O
and O
health B-Disease
, O
are O
being O
elucidated O
, O
and O
this O
will O
dramatically O
alter O
clinical O
practice O
in O
nutrition O

g O

The O
purpose O
of O
this O
overview O
is O
to O
discuss O
the O
application O
of O
epigenetics B-Chemical
to O
toxicologic B-Chemical
pathology O
and O
its O
utility O
in O
preclinical O
or O
mechanistic O
based O
safety O
, O
efficacy O
, O
and O
carcinogenicity B-Disease
studies O

Methylation O
of O
5-methylcytosine B-Chemical
( O
5mC B-Chemical
) O
is O
widespread O
in O
both O
eukaryotes B-Species
and O
prokaryotes B-Species
, O
and O
it O
is O
a O
very O
important O
epigenetic O
modification O
event O
, O
which O
can O
regulate O
gene B-Gene
activity O
and O
influence O
a O
number O
of O
key O
processes O
such O
as O

These O
regions O
were O
frequently O
located O
in O
putative O
enhancers O
, O
and O
mCpHs O
within O
the O
enhancers O
increased O
in O
correlation O
with O
brain B-Species
age O

Mouse O
blood O
showed O
a O
general O
pattern O
of O
epigenome-wide O
hypermethylation O
and O
hypo-hydroxymethylation O
with O
age O

Pediatric O
AML B-Disease
(pAML) O
accounts O
for O
15-20% O
of O
all O
pediatric O
leukemias B-Disease
and O
differs O
considerably O
from O
adult O
AML B-Disease

Epigenetic O
changes O
are O
believed O
to O
be O
a O
result O
of O
changes O
in O
an O
organism's O
environment O
that O
result O
in O
fixed O
and O
permanent O
changes O
in O
most O
differentiated O
cells O

g O

He O
was O
honored O
in O
2006 O
with O
the O
Distinguished O
Achievement O
Award O
from O
the O
College O
of O
Engineering O
at O
the O
University O
of O
Wisconsin-Madison O

Exposure O
to O
EDCs B-Chemical
through O
the O
parents O
is O
concerning O
because O
if O
the O
resulting O
phenotype O
of O
the O
offspring O
is O
heritable O
and O
affects O
fitness O
then O
evolutionary O
consequences O
may O
be O
evident O

Methods O
 O
In O
113 O
youths O
aged O
8-16 O
years O
with O
wide O
variability O
in O
ELA O
, O
we O
examined O
associations O
of O
abuse O
( O
physical O
, O
sexual O
, O
emotional O
; O
indicating O
threat-related O
experiences O
) O
and O
neglect O
( O
emotional O
, O
physical O
; O
indicating O
deprivation-related O
experiences O
) O
with O
DNAm B-Gene

In O
this O
review O
, O
we O
highlight O
latest O
discoveries O
in O
the O
mechanistic O
understanding O
of O
epigenetically-induced O
drug B-Chemical
resistance O

The O
epigenetic O
studies O
in O
dental O
field O
have O
been O
mainly O
conducted O
in O
periodontology O
and O
have O
focused O
on O
DNA B-Gene
methylation I-Gene
analysis O

Infinium O
Human B-Species
Methylation O
BeadChip O
is O
an O
array O
platform O
for O
complex O
evaluation O
of O
DNA B-Gene
methylation O
at O
an O
individual O
CpG O
locus O
in O
the O
human B-Species
genome O
based O
on O
Illumina's O
bead O
technology O
and O
is O
one O
of O
the O
most O
common O
techniques O
used O
in O
epigenome-wide O

909 O
Motivation O
Human B-Species
epigenomic O
data O
has O
been O
generated O
by O
large O
consortia O
for O
thousands O
of O
cell O
types O
to O
be O
used O
as O
a O
reference O
map O
of O
normal O
and O
disease B-Disease
chromatin O
states O

Conversely O
, O
diets O
higher O
in O
glycemic O
load O
, O
fat O
, O
saturated O
fat O
, O
and O
Ï-6 B-Chemical
fatty I-Chemical
acids I-Chemical
demonstrate O
a O
positive O
association O
with O
epigenetic O
aging O

Meanwhile O
, O
data O
on O
the O
role O
of O
epigenetical O
factors O
in O
the O
manifestation O
of O
diseases B-Disease
have O
been O
emerging O

In O
conclusion O
, O
HCC B-Disease
showed O
a O
methylation O
profile O
completely O
deregulated O
and O
very O
far O
from O
adjacent O
non-cancerous O
liver O
tissues O

The O
epigenomic O
signature O
is O
frequently O
associated O
with O
a O
cell O
of O
origin O
, O
as O
well O
as O
with O
tumor B-Disease
stage O
and O
differentiation O
, O
which O
all O
reflect O
its O
high O
heterogeneity O
across O
and O
within O
various O
tumors B-Disease

Among O
the O
different O
combinations O
investigated O
, O
a O
combination O
of O
five O
imprinted O
genes O
comprising O
IGF2-H19 B-Gene
DMR I-Gene
, O
IG-DMR B-Gene
, O
ZAC B-Gene
, O
KvDMR B-Gene
, O
and O
PEG3 B-Gene
( O
AUC O
= O
0 O

In O
this O
paper O
, O
we O
review O
the O
important O
roles O
of O
epigenetic B-Disease
disorders I-Disease
in O
the O
pathogenesis O
of O
SLE B-Disease

There O
are O
many O
environmental O
factors O
involved O
in O
the O
pathogenesis O
of O
T1D B-Disease

Methods O
 O
Electronic O
and O
manual O
literature O
search O
of O
MEDLINE O
, O
EMBASE O
and O
PSYCHINFO O
, O
using O
a O
range O
of O
search O
terms O
around O
epigenetics O
, O
DNA B-Gene
methylation I-Gene
, O
histone B-Gene
modifications I-Gene
, O
psychoses B-Disease
, O
schizophrenia B-Disease
, O
bipolar B-Disease
disorder I-Disease
and O
environmental O
risks O

To O
make O
public O
epigenomic O
data O
conveniently O
available O
for O
analysis O
in O
R O
, O
we O
developed O
an O
R/Bioconductor O
package O
that O
connects O
to O
the O
DeepBlue O
Epigenomic O
Data O
Server O
, O
enabling O
users O
to O
quickly O
gather O
and O
transform O
epigenomic O
data O
from O
selected O
experiments O
for O
analysis O
in O

1254 O
The O
analysis O
of O
age-related O
methylation O
changes O
in O
patients O
with O
colorectal B-Disease
cancer I-Disease
indicates O
that O
tumors O
have O
their O
origins O
earlier O
in O
life O
than O
previously O
suspected O

Although O
there O
is O
still O
much O
to O
learn O
about O
the O
relationship O
between O
ageing O
, O
age-related O
diseases B-Disease
and O
DNAm B-Gene
, O
we O
now O
know O
how O
to O
interpret O
some O
of O
the O
effects O
caused O
by O
age O
in O
the O
form O
of O
changes O
in O
methylation B-Chemical
marks I-Chemical
at O
specific O
loci O

A O
literature O
review O
has O
been O
carried O
out O
using O
PubMed O
on O
the O
evidence O
published O
on O
the O
association O
between O
epigenetics B-Gene
and O
colorectal B-Disease
cancer I-Disease

In O
addition O
, O
the O
manuscript O
revisits O
the O
gradual O
degeneration O
of O
the O
nonalcoholic B-Disease
fatty I-Disease
liver I-Disease
disease I-Disease
to O
propose O
an O
integrative O
generalized O
mechanistic O
explanation O
for O
the O
involution O
and O
carcinogenesis O
of O
tissues O
associated O
with O
aging O

In O
this O
review O
, O
we O
discuss O
current O
progress O
in O
epigenetic O
studies O
of O
aDNA B-Gene
, O
including O
methodological O
approaches O
and O
promising O
research O
directions O
in O
this O
field O

In O
longitudinal O
epigenome-wide O
analyses O
, O
we O
examined O
whether O
experiencing O
abuse O
and O
neglect O
over O
an O
approximately O
2-year O
follow-up O
were O
each O
associated O
with O
change O
in O
DNAm B-Gene
from O
baseline O
to O
follow-up O

1171 O
Asthma B-Disease
is O
a O
complex O
and O
heterogeneous O
chronic O
inflammatory O
disease O
of O
the O
airways O

However O
, O
identifying O
subpopulation-level O
changes O
in O
a O
heterogeneous O
sample O
remains O
challenging O

In O
particular O
, O
we O
present O
findings O
in O
the O
context O
of O
hepatocellular B-Disease
carcinoma I-Disease
, O
fibrosis B-Disease
and O
non-alcoholic B-Disease
fatty I-Disease
liver I-Disease
disease I-Disease
, O
where O
there O
is O
urgent O
unmet O
need O
for O
new O
clinical O
interventions O
and O
biomarkers O

The O
opioid B-Chemical
peptide I-Chemical
dynorphins B-Chemical
play O
a O
critical O
role O
in O
neurological B-Disease
and O
psychiatric B-Disease
disorders I-Disease
, O
pain B-Disease
processing I-Disease
and O
stress O
, O
while O
their O
mutations O
cause O
profound O
neurodegeneration B-Disease
in O
the O
human B-Species
brain I-Species

 O

Supplementation O
of O
butyrate B-Chemical
is O
known O
to O
enhance O
cell O
specific O
productivities O
in O
CHO B-Species
cells O
and O
leads O
to O
alterations O
of O
epigenetic O
silencing O
events O

Such O
links O
would O
have O
diverse O
implications O
in O
basic O
research O
, O
in O
clinics O
, O
as O
well O
as O
for O
therapeutic O
studies O

lens O
transparency O
; O
retinal B-Disease
blood I-Disease
vessel I-Disease
calibre O
; O
corneal B-Species
endothelial I-Species
cell I-Species
counts O
) O
and O
so O
the O
eye O
may O
also O
be O
a O
uniquely O
useful O
site O
as O
a O
model O
of O
ageing O

We O
derived O
Horvath's B-Gene
DNA B-Chemical
methylation I-Chemical
age O
(DNAmAge) O
, O
Hannum's B-Gene
DNAmAge O
, O
PhenoAge O
, O
and O
GrimAge O
based O
on O
DNA B-Chemical
methylation I-Chemical
measured O
in O
peripheral O
blood O
samples O
from O
479 O
Australian B-Species
women O
in O
130 O
families O

At O
age O
79 O
years O
, O
sedentary O
behavior O
and O
physical O
activity O
were O
measured O
over O
7 O
days O
using O
an O
activPAL B-Chemical
activity I-Chemical
monitor I-Chemical

Epigenetic O
modifications O
are O
likely O
to O
be O
important O
in O
both O
suicidal B-Disease
ideation I-Disease
and O
behavior O

Recent O
epigenetic O
findings O
are O
beginning O
to O
increase O
our O
understanding O
of O
the O
molecular O
mechanisms O
that O
may O
contribute O
to O
the O
programming O
of O
obesity B-Disease

We O
also O
discuss O
the O
influence O
of O
diet O
in O
this O
scenario O

BS-Seeker3 O
is O
an O
accurate O
, O
versatile O
, O
ultra-fast O
pipeline O
for O
processing O
bisulfite-converted B-Chemical
reads O

Here O
, O
we O
aimed O
to O
provide O
a O
resource O
to O
the O
community O
to O
aid O
interpretation O
of O
blood-based O
DNA B-Chemical
methylation I-Chemical
results O
in O
the O
context O
of O
brain B-Species
tissue I-Species

However O
, O
the O
methylation O
detection O
on O
low-input O
samples O
is O
more O
accurate O
using O
ddPCR B-Chemical

, O
extrinsic O
and O
intrinsic O
epigenetic O
age O
acceleration O

The O
results O
showed O
that O
the O
majority O
of O
CpGs O
on O
Illumina O
HumanMethylation450 O
BeadChip O
probe O
set O
were O
longitudinally O
stable O
over O
the O
time O
period O
of O
three O
months O

Comment O
 O
There O
are O
two O
classes O
of O
epigenetic O
drugs O
undergoing O
trials O
for O
treating O
the O
idiopathic B-Disease
mental I-Disease
disorders I-Disease
 O
DNA B-Chemical
methyltransferase I-Chemical
and O
histone B-Chemical
deacetylase I-Chemical
inhibitors I-Chemical

The O
susceptible O
CpGs O
overlap O
with O
the O
Illumina B-Chemical
Infinium I-Chemical
HumanMethylation450 I-Chemical
BeadChip I-Chemical
array I-Chemical
content O

382 O
 O
Epigenetic O
changes O
during O
ageing O
have O
been O
characterized O
by O
multiple O
epigenetic O
clocks O
that O
allow O
the O
prediction O
of O
chronological O
age O
based O
on O
methylation O
status O

The O
reciprocal O
communication O
between O
brain B-Species
and O
body O
via O
the O
neuroendocrine B-Chemical
, O
autonomic B-Chemical
, O
metabolic B-Chemical
and O
immune B-Chemical
systems O
and O
the O
plasticity O
of O
brain B-Species
architecture O
provide O
the O
basis O
for O
devising O
better O
" O
top O
down O
" O
interventions O
that O
engage O
the O
whole O
person O
in O

Third O
, O
the O
possibility O
of O
epigenetic O
effects O
( O
inherited O
changes O
in O
gene B-Gene
expression I-Gene
) O
as O
a O
result O
of O
Famine B-Disease
has O
been O
discussed O
as O
a O
possible O
mechanism O
whereby O
Famine B-Disease
survivors O
might O
have O
passed O
on O
experiences O
of O
physical O
and O
psychological O
trauma B-Disease
to O
their O
children O

Androgen O
deprivation O
therapy O
is O
the O
primary O
treatment O
for O
patients O
that O
present O
with O
locally O
advanced O
or O
metastatic O
disease B-Disease

In O
this O
Review O
, O
we O
highlight O
the O
basic O
dynamic O
mechanisms O
underlying O
the O
synergy O
between O
immunotherapy O
and O
epigenetic O
therapies O
and O
detail O
current O
efforts O
to O
translate O
this O
knowledge O
into O
clinical O
benefit O
for O
patients O

746 O
Environmental O
stress O
is O
one O
of O
the O
most O
important O
factors O
affecting O
plant B-Species
growth O
and O
development O

We O
discuss O
the O
implications O
for O
understanding O
the O
benefits O
of O
diploidy O
, O
and O
the O
mechanisms O
shaping O
brain B-Disease
development O
, O
function O
, O
and O
disease B-Disease

We O
demonstrated O
that O
an O
in O
silico O
epigenetic O
panel O
can O
identify O
epigenetic O
modifiers O
in O
order O
to O
overcome O
epigenetic O
barriers O
to O
tissue-specific O
differentiation O

We O
demonstrated O
the O
superior O
performance O
of O
the O
proposed O
weighted O
epigenetic O
distance-based O
method O
over O
nonweighted O
versions O
and O
site-level O
EWAS B-Disease
(epigenome-wide I-Disease
association I-Disease
studies) I-Disease
methods O
in O
simulation O
studies O

This O
review O
describes O
the O
potential O
role O
of O
epigenetic O
processes O
, O
particularly O
DNA B-Chemical
methylation I-Chemical
, O
in O
the O
regulation O
of O
sexual O
differentiation O
of O
the O
hypothalamus B-Disease
by O
hormones O

These O
P-t-C O
draw O
on O
existing O
guidance O
on O
the O
return O
of O
genetic B-Disease
research I-Disease
results I-Disease
, O
while O
also O
integrating O
the O
research O
on O
and O
discussion O
of O
the O
issues O
associated O
with O
epigenetic B-Disease
data I-Disease
as O
well O
as O
the O
experience O
of O
a O

Our O
laboratory O
provides O
public O
access O
to O
plant B-Species
DNA B-Gene
methylation I-Gene
data O
via O
visualization O
tools O
available O
at O
our O
" O
Next-Gen O
Sequence O
" O
websites O
( O
http//mpss O

Pathway O
analysis O
showed O
that O
age-dependent O
methylations O
were O
especially O
involved O
in O
cellular O
signalling O
activities O
while O
demethylations O
particularly O
linked O
to O
functions O
of O
the O
extracellular O
matrix O
, O
all O
implicated O
in O
the O
aging O
process O
and O
age-related O
disease B-Disease
risk O

Specific O
enzymes O
, O
known O
as O
RNA-modifying B-Gene
proteins I-Gene
( O
RMPs B-Gene
) O
, O
are O
responsible O
for O
depositing O
, O
removing O
, O
and O
reading O
chemical B-Chemical
modifications I-Chemical
in O
RNA B-Gene

, O
H3K4me3 B-Gene
and O
H3K27ac B-Gene
) O
and O
could O
be O
characterized O
when O
the O
number O
of O
tissue O
samples O
is O
large O
( O
e O
) O

We O
also O
observed O
that O
aberrant O
enhancer O
hypermethylation O
was O
predictive O
of O
adverse O
prognosis O
in O
ccRCC B-Disease

Some O
pro-health O
interventions O
and O
recommendations O
are O
proposed O
, O
with O
the O
hope O
of O
guarantee O
the O
health O
of O
future O
generations O
and O
trying O
to O
combat O
the O
continuous O
increase O
in O
age-related B-Disease
diseases I-Disease
in O
human B-Species
populations I-Species

Early O
embryogenesis O
is O
a O
critical O
period O
of O
epigenetic O
regulation O
, O
and O
is O
sensitive O
to O
environmental O
factors O

Congenital O
heart O
diseases O
(CHD) O
are O
the O
most O
prominent O
congenital O
diseases B-Disease

004 O
; O
DNAm O
ADM O
, O
b O
( O
SE O
) O
= O
- O

Several O
CpGs B-Gene
were O
differentially O
methylated O
in O
artery B-Species
and O
placenta B-Species
when O
controlling O
the O
false O
discovery O
rate O
( O
q-value<0 O

com O
/ O
songlab O
/ O
chance O

1016 O
Alzheimer's B-Disease
disease I-Disease
( O
AD B-Disease
) O
is O
a O
progressive O
neurodegenerative O
disorder O
characterized O
by O
loss O
of O
memory O
and O
other O
cognitive O
functions O

These O
techniques O
open O
a O
new O
field O
for O
identifying O
useful O
new O
biomarkers O
and O
therapeutic O
targets O

54 O
Epigenetic O
editing O
refers O
to O
the O
locus-specific O
targeting O
of O
epigenetic O
enzymes O
to O
rewrite O
the O
local O
epigenetic O
landscape O
of O
an O
endogenous O
genomic O
site O
, O
often O
with O
the O
aim O
of O
transcriptional O
reprogramming O

1291 O
Accumulating O
evidence O
indicates O
a O
central O
role O
for O
epigenetic O
modifications O
in O
the O
progression O
of O
stroke B-Disease
pathology O

This O
study O
identifies O
a O
potential O
correlate O
or O
determinant O
of O
accelerated O
epigenetic O
aging-menarcheal O
age O

Using O
simulations O
and O
real O
data O
, O
we O
demonstrate O
that O
our O
method O
maximizes O
power O
while O
properly O
controlling O
the O
false O
positive O
rate O

BFCs O
, O
such O
as O
ascorbic B-Chemical
acid I-Chemical
, O
Î±-tocopherol B-Chemical
, O
polyunsaturated B-Chemical
fatty I-Chemical
acids I-Chemical
, O
trace B-Chemical
elements I-Chemical
, O
carnitines B-Chemical
, O
N-acetylcysteine B-Chemical
, O
and O
coenzyme B-Chemical
Q10 I-Chemical
, O
have O
been O
shown O
to O
improve O
male O

Whereas O
previously O
separate O
experiments O
were O
required O
to O
study O
either O
epigenetic O
marking O
, O
cfNOMe O
delivers O
reliable O
results O
for O
both O
, O
enabling O
more O
comprehensive O
and O
inexpensive O
epigenetic O
cfDNA O
profiling O

g O

Preliminary O
results O
from O
DNA B-Gene
methylation I-Gene
analysis O
technologies O
that O
may O
help O
in O
predicting O
response O
and O
efficacy O
of O
a O
drug B-Chemical
are O
discussed O

FBW7 B-Gene
is O
a O
tumor B-Disease
suppressor I-Disease
that O
functions O
as O
an O
Mcl-1 B-Gene
E3 O
ligase O
to O
degrade O
Mcl-1 B-Gene
by O
ubiquitination O

The O
coming O
of O
the O
epigenetic O
era O
in O
food B-Disease
allergies I-Disease
is O
to O
provide O
better O
understanding O
of O
pathogenesis O
of O
food B-Disease
allergy I-Disease
, O
as O
well O
as O
providing O
therapeutic O
and O
preventive O
strategies O
for O
this O
very O
common O
condition O

This O
epigenetic O
memory O
does O
not O
only O
affect O
transient O
gene B-Gene
expression O
but O
also O
represents O
long-lasting O
decisions O
on O
cellular O
fate O

OMP B-Gene
was O
identified O
and O
defined O
, O
originally O
, O
as O
being O
more O
common O
among O
low O
birth O
weight O
individuals O
conceived O
in O
vitro O
but O
we O
have O
also O
identified O
OMP B-Gene
individuals O
among O
colon B-Disease
cancer I-Disease
patients O
profiled O
by O
us O
, O
as O
well O
as O
multiple O
types O
of O
cancer B-Disease
patients O
in O

We O
describe O
how O
the O
chapters O
in O
this O
two-volume O
set O
present O
theory O
and O
research O
pertinent O
to O
the O
roles O
of O
evolutionary O
and O
ontogenetic O
processes O
in O
cognitive O
, O
emotional O
, O
and O
behavioral O
development O
across O
the O
life O
span O

Rather O
than O
isolated O
episodes O
, O
each O
transition O
builds O
upon O
the O
last O
and O
is O
influenced O
by O
consequential O
changes O
that O
occur O
in O
the O
transition O
before O
it O

437Background O
Epigenetics O
is O
changing O
the O
widely O
accepted O
linear O
conception O
of O
genome O
function O
by O
explaining O
how O
environmental O
and O
psychological O
factors O
regulate O
the O
activity O
of O
our O
genome O
without O
involving O
changes O
in O
the O
DNA B-Gene
sequence O

636 O
Epigenetic O
mechanisms O
may O
contribute O
to O
the O
pathogenesis O
of O
complex O
diseases B-Disease

In O
this O
article O
, O
we O
propose O
a O
graph O
neural O
network-based O
model O
for O
the O
extraction O
of O
molecular O
features O
, O
thus O
reducing O
the O
computational O
requirements O

advanced O

However O
, O
children O
and O
adults O
showed O
a O
large O
within-population O
variation O
in O
cellular O
heterogeneity O

Although O
the O
intrapartum O
period O
is O
relatively O
short O
compared O
to O
the O
complete O
perinatal O
period O
, O
there O
is O
emerging O
evidence O
that O
this O
time O
frame O
may O
be O
a O
critical O
formative O
phase O
for O
the O
human B-Species
genome B-Gene

646 O
 O
Epigenetics O
refers O
to O
heritable O
molecular O
determinants O
of O
phenotype O
independent O
of O
DNA B-Chemical
sequence O

Identification O
of O
their O
shared O
genes B-Gene
is O
just O
one O
small O
step O
in O
the O
link O
from O
genes B-Gene
to O
their O
physical O
and O
psychological O
profiles O

Herein O
, O
I O
review O
HDACis B-Chemical
and O
microRNAs B-Gene
for O
melanoma B-Disease

Epigenetic O
marks O
include O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
and O
a O
variety O
of O
non-coding O
RNAs O

Examination O
of O
the O
genetic O
underpinning O
of O
epigenetic O
conservation O
suggests O
that O
primary O
sequence O
conservation O
is O
a O
driving O
force O
behind O
epigenetic O
conservation O

We O
are O
able O
to O
( O
1 O
) O
improve O
the O
accuracy O
of O
demographic O
inference O
in O
recent O
times O
, O
( O
2 O
) O
uncover O
past O
demographic O
events O
hidden O
to O
SNP-based O
inference O
methods O
, O
and O
( O
3 O
) O
infer O
the O
hyper-mutable O
marker O
mutation O
rates O
under O
a O
finite O
site O
model O

The O
role O
of O
underlying O
epigenetic O
processes O
in O
generation O
of O
biological O
forms O
via O
similarity O
transformations O
is O
analyzed O
within O
the O
framework O
of O
D'Arcy B-Gene
Thompson I-Gene

CandiMeth O

946 O
Retinoblastoma B-Disease
is O
a O
rare O
pediatric O
cancer O
of O
the O
retina O

The O
objectives O
of O
this O
conference O
were O
to O
showcase O
the O
breadth O
of O
epigenetic O
research O
on O
environment O
and O
health O
across O
Canada O
and O
to O
provide O
the O
catalyst O
to O
develop O
collaborative O
Canadian O
epigenetic O
research O
opportunities O
, O
similar O
to O
existing O
international O
epigenetic O
initiatives O
in O
the O
US B-Species
and O
Europe B-Species

an O

Here O
, O
we O
review O
new O
studies O
showing O
evidence O
for O
diverse O
allele-specific O
expression O
and O
epigenetic O
states O
in O
mammalian B-Species
brain I-Species
cells I-Species
, O
which O
suggest O
that O
diploidy O
expands O
the O
landscape O
of O
gene B-Gene
regulatory I-Gene
and O
expression O
programs O
in O
cells O

We O
rank O
evaluated O
methods O
and O
discuss O
computational O
challenges O
associated O
with O
scATAC-seq O
analysis O
including O
inherently O
sparse O
data O
, O
determination O
of O
features O
, O
peak O
calling O
, O
the O
effects O
of O
sequencing O
coverage O
and O
noise O
, O
and O
clustering O
performance O

1020 O
A O
report O
of O
the O
6th O
Epigenomics O
of O
Common B-Disease
Diseases I-Disease
Conference O
held O
at O
the O
Wellcome O
Genome B-Gene
Campus I-Gene
in O
Hinxton O
, O
Cambridge O
, O
UK O
, O
on O
1-4 O
November O
2016 O

, O
enhancers O

In O
this O
article O
, O
I O
report O
from O
Select O
Biosciences O
Epigenetics O
Europe O
2010 O
industry O
conference O
held O
on O
14-15 O
September O
2010 O
at O
The O
Burlington O
Hotel O
, O
Dublin O
, O
Ireland O

149 O
years O
) O

05 O
) O
methylation O
changes O
in O
65 O
different O
CpG B-Gene
sites I-Gene
located O
in O
75 O
genes O
in O
CoA B-Disease
subjects O

Despite O
the O
very O
different O
organisms O
and O
biological O
processes O
investigated O
, O
the O
overarching O
question O
has O
been O
if O
and O
how O
an O
organism O
's O
epigenome O
registers O
and O
records O
external O
cues O
and O
relays O
this O
information O
to O
its O
progeny O

Vargas O
( O
2009 O

Summary O
 O
Enhancing O
our O
understanding O
of O
the O
way O
in O
which O
patients O
as O
genomic O
organisms O
interact O
with O
the O
perioperative O
environment O
requires O
a O
more O
sophisticated O
appreciation O
of O
the O
factors O
governing O
gene B-Gene
expression I-Gene
than O
has O
been O
the O
case O
to O
date O

This O
review O
investigated O
the O
possible O
causes O
and O
molecular O
mechanisms O
underlying O
male O
idiopathic O
infertility O
by O
extensive O
literature O
searches O
of O
 O
( O
i O
) O
causal O
gene B-Gene
mutations O
; O
( O
ii O
) O
proteome O
studies O
of O
spermatozoa O
from O
idiopathic O
infertile O
men O
; O
( O
iii O
) O
the O

There O
are O
limited O
studies O
in O
which O
epigenetic O
changes O
have O
been O
explored O
to O
address O
cancer B-Disease
disparities O
in O
various O
racial O
and O
ethnic O
populations O

Supplementary O
information O
 O
Supplementary O
data O
are O
available O
at O
Bioinformatics O
online O

Unlike O
genetic O
mutations O
, O
the O
ability O
to O
reprogram O
the O
epigenetic O
landscape O
in O
the O
cancer B-Disease
epigenome O
is O
one O
of O
the O
most O
promising O
target O
therapies O
in O
both O
treatment O
and O
reversibility O
of O
drug B-Chemical
resistance O

rRNA B-Gene
is O
a O
structural O
component O
of O
the O
most O
abundant O
cellular O
molecule O
, O
the O
ribosome B-Species


This O
information O
combined O
with O
the O
impact O
of O
polarity-related O
proteins O
on O
epigenetic O
mechanisms O
of O
cancer B-Disease
enables O
us O
to O
envision O
how O
to O
guide O
the O
choice O
of O
drugs O
specific O
for O
distinct O
epigenetic O
modifiers O
, O
in O
order O
to O
halt O
cancer B-Disease
development O
and O
counter O
the O
consequences O
of O
polarity O

Cancers O
are O
composed O
of O
numerous O
cell O
types O
and O
evolve O
over O
time O

While O
the O
biological O
mechanisms O
underlying O
this O
differential O
susceptibility O
are O
unknown O
, O
epigenetic O
changes O
have O
been O
proposed O
to O
underlie O
the O
relationship O
between O
exposure O
to O
traumatic O
stress O
and O
the O
susceptibility O
to O
develop O
PTSD B-Disease

Third O
, O
p300-dCas9 O
was O
guided O
to O
the O
native O
polyketide B-Chemical
synthase I-Chemical
( O
PKS B-Gene
) O
gene O
fuml B-Gene
, O
which O
increased O
production O
of O
the O
compound O
fumonisin B-Chemical
B2 I-Chemical
detected O
by O
HPLC O
and O
LC-MS O

Here O
, O
I O
describe O
a O
novel O
live-cell O
imaging O
system O
based O
on O
" O
Momiji B-Species
" I-Species
mice I-Species
for O
monitoring O
XCI B-Gene
at O
the O
single O
cell O
level O

433 O
is O
the O
most O
studied O
epigenetic O
mark O
in O
both O
and O

106 O
 O
Peripheral B-Disease
T-cell I-Disease
lymphoma I-Disease
( O
PTCL B-Disease
) O
is O
a O
rare O
and O
heterogeneous O
group O
of O
clinically O
aggressive O
diseases O
associated O
with O
poor O
prognosis O

This O
review O
is O
devoted O
to O
elucidate O
the O
recent O
mechanistic O
advances O
in O
regulation O
of O
genes O
by O
epigenetic O
modification O
and O
emphasizes O
their O
possible O
role O
related O
to O
reproductive O
infertility B-Disease

Therefore O
, O
in O
attempts O
to O
develop O
novel O
safer O
and O
more O
efficacious O
drugs O
, O
both O
nutritional O
requirements O
and O
epigenetic O
mechanisms O
need O
to O
be O
addressed O


We O
conclude O
that O
the O
widely-used O
constrained O
projection O
technique O
may O
not O
always O
be O
optimal O

We O
get O
strong O
indications O
that O
epigenetically O
induced O
changes O
in O
nucleosome-nucleosome O
interaction O
can O
cause O
chromatin O
to O
shift O
between O
different O
activity O
states O

Within O
the O
medical O
field O
, O
machine O
learning O
is O
promising O
in O
the O
development O
of O
assistive O
clinical O
tools O
for O
detection O
of O
e O

005 O

Furthermore O
, O
we O
show O
that O
epigenetic O
modules O
may O
act O
as O
a O
molecular O
readout O
of O
cumulative O
cardiovascular B-Disease
risk I-Disease
factor I-Disease
exposure O
, O
with O
implications O
for O
the O
improvement O
of O
clinical O
risk O
prediction O

Advances O
in O
epigenetics O
and O
epigenomics O
have O
influenced O
pharmacology O
, O
leading O
to O
the O
development O
of O
a O
new O
specialty O
, O
pharmacoepigenetics O
, O
the O
study O
of O
the O
epigenetic O
basis O
for O
the O
individual O
variation O
in O
drug O
response O

genetic O

These O
altered O
peaks O
are O
more O
likely O
to O
differ O
between O
individuals O
and O
, O
as O
such O
, O
could O
be O
relevant O
in O
the O
study O
of O
various O
human B-Species
phenotypes O

This O
memory O
is O
induced O
in O
the O
hematopoietic O
niche O
and O
propagated O
to O
daughter O
cells O
, O
generating O
epigenetically O
and O
metabolically O
reprogrammed O
innate O
immune O
cells O
that O
are O
greatly O
enhanced O
in O
their O
capacity O
to O
resolve O
inflammation B-Disease

While O
some O
of O
these O
appear O
to O
be O
corrected O
by O
normal O
germline-specific O
epigenetic O
reprogramming O
and O
are O
therefore O
not O
transmitted O
transgenerationally O
, O
others O
are O
not O
corrected O
and O
are O
transmitted O
over O
multiple O
subsequent O
generations O

The O
main O
reasons O
for O
restenosis O
after O
PCI O
are O
hyperplasia O
of O
vascular O
endothelial O
cells O
and O
smooth O
muscle O
cell O
migration O

In O
this O
review O
we O
focus O
on O
the O
global O
perspective O
of O
epigenetics O
and O
the O
use O
of O
recent O
next-generation O
sequencing O
platforms O
to O
interrogate O
epigenetic O
changes O
in O
the O
prostate B-Disease
cancer I-Disease
genome O

After O
treatment O
with O
inhibitor O
or O
inhibitor O
, O
had O
an O
increased O
expression O

Here O
, O
we O
resolve O
the O
DNA B-Chemical
methylome O
across O
CpG B-Gene
, O
CHG B-Gene
, O
and O
CHH-methylation B-Gene
contexts O
in O
the O
loblolly B-Species
pine I-Species
tree I-Species
( O
Pinus B-Species
taeda I-Species
) O
and O
construct O
epigenetic O
clocks O
capable O
of O
predicting O
ages O
in O
this O
species O
within O
6% O

More O
recent O
studies O
show O
epigenetic O
mechanisms O
implicated O
in O
the O
regulation O
of O
SLC6A2 B-Gene
expression O

Many O
biomolecular O
techniques O
based O
on O
PCR B-Chemical
have O
been O
developed O
to O
analyse O
DNA B-Chemical
methylation O
status O
, O
however O
a O
qualitative O
leap O
was O
made O
with O
the O
advent O
of O
next-generation O
sequencing O
( O
NGS O
) O

The O
major O
family O
of O
proteins O
that O
bind O
methylated B-Chemical
DNA B-Gene
is O
the O
methyl-CpG B-Gene
binding I-Gene
domain I-Gene
proteins I-Gene
, O
or O
the O
MBDs B-Gene

1058 O
Evidence O
from O
across O
the O
tree O
of O
life O
suggests O
that O
epigenetic O
inheritance O
is O
more O
common O
than O
previously O
thought O

In O
this O
mini-review O
we O
introduce O
the O
concept O
of O
epigenetic O
drivers O
of O
cancer B-Disease
and O
discuss O
how O
aberrant O
DNA B-Gene
methylation I-Gene
, O
histone B-Gene
modifications I-Gene
, O
and O
chromatin B-Gene
states I-Gene
are O
being O
targeted O
using O
drugs O
either O
in O
preclinical O
, O
or O
clinical O
development O
, O
and O
how O

Through O
a O
parameter O
sweep O
process O
, O
we O
identified O
the O
suitable O
hyperparameter O
values O
and O
built O
a O
VAE O
model O
to O
represent O
the O
epigenomics O
data O
and O
to O
further O
explore O
the O
biological O
regulation O

Using O
principles O
from O
statistical O
physics O
and O
information O
theory O
, O
we O
derive O
epigenetic O
energy O
landscapes O
from O
whole-genome O
bisulfite O
sequencing O
( O
WGBS O
) O
data O
that O
enable O
us O
to O
quantify O
methylation O
stochasticity O
genome-wide O
using O
Shannon B-Gene
's I-Gene
entropy O
, O
associating O
it O
with O
chromatin B-Chemical

Mn B-Chemical
appears O
to O
interfere O
with O
epigenetic O
processes O
, O
potentially O
leading O
to O
persistent O
changes O
in O
developmental O
programming O
, O
which O
warrants O
further O
study O

Here O
, O
we O
provide O
a O
brief O
overview O
of O
the O
major O
epigenetic O
mechanisms O
( O
ie O
, O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modifications I-Chemical
and O
chromatin B-Chemical
remodeling I-Chemical
, O
and O
non-coding B-Chemical
RNA I-Chemical
regulation I-Chemical
) O

5 O
% O
of O
these O
sites O
showing O
a O
change O
with O
age O

DL O
achieved O
an O
AUC O
( O
95% O
CI O
) O
= O
0 O

603 O
 O
All O
reproductively O
competent O
adults O
have O
gone O
through O
puberty O

g O

The O
pipeline O
has O
been O
validated O
using O
human B-Species
and O
hybrid O
mouse B-Species
ChIP-seq O
and O
RNA-seq O
data O

g O

However O
, O
differences O
in O
sequencing O
depth O
and O
signal-to-noise O
ratios O
in O
the O
data O
from O
different O
experiments O
can O
hinder O
our O
ability O
to O
identify O
real O
biological O
variation O
from O
raw O
epigenomic O
data O

They O
function O
in O
a O
highly O
orchestrated O
manner O
, O
regulating O
mitotically O
heritable O
differences O
in O
gene B-Gene
expression I-Gene
potential I-Gene
without O
altering O
the O
primary O
DNA B-Gene
sequence I-Gene

Current O
bisulfite B-Chemical
aligners O
provide O
pipelines O
for O
processing O
the O
reads O
by O
WGBS O
; O
however O
, O
few O
are O
able O
to O
analyze O
the O
BS-seqs O
in O
a O
reasonable O
timeframe O
that O
meets O
the O
needs O
of O
the O
rapid O
expansion O
of O
epigenome O
sequencing O
in O
biomedical O
research O

Our O
results O
show O
that O
neither O
genotypes O
and O
endophenotypes O
, O
nor O
brain O
mechanism O
, O
nor O
neuropsychological O
deviances O
have O
a O
one-to-one O
correlation O
with O
clinical O
categories O
as O
defined O
in O
even O
the O
dsm B-Disease
5 I-Disease

Recent O
advances O
in O
molecular O
genetics O
and O
epigenetic O
integrated O
diagnostics O
of O
brain B-Disease
tumors I-Disease
influence O
new O
strategies O
for O
targeted O
therapy O

Though O
believed O
to O
be O
infrequent O
, O
eMethSNPs O
could O
constitute O
a O
new O
category O
of O
mechanistically-based O
genetic O
biomarkers O
predisposing O
to O
essential B-Disease
hypertension I-Disease

In O
particular O
, O
pAML B-Disease
relapse O
is O
commonly O
caused O
by O
leukemia B-Disease
stem I-Disease
cells O
that O
resist O
therapy O

By O
projecting O
these O
EpiScores O
into O
an O
independent O
sample O
( O
Generation B-Species
Scotland I-Species
; O
n O
= O
9537 O
) O
and O
relating O
them O
to O
incident O
morbidities B-Disease
over O
a O
follow-up O
of O
14 O
years O
, O
we O
uncovered O
137 O
EpiScore-disease B-Disease
associations O

We O
discuss O
advances O
in O
the O
elucidation O
of O
the O
epigenetic O
mechanisms O
involved O
in O
long-term O
memory O
, O
focusing O
on O
the O
role O
of O
small O
RNAs O
, O
and O
in O
particular O
piwi-interacting B-Gene
RNAs I-Gene
( O
piRNAs B-Gene
) O
, O
in O
the O
epigenetic O
regulation O
underlying O
memory O
storage O

To O
better O
understand O
and O
address O
the O
drivers O
of O
health O
disparities O
and O
inform O
the O
development O
of O
effective O
interventions O
, O
integrative O
mechanistic O
studies O
examining O
the O
dynamic O
interplay O
of O
multiple O
factors O
across O
the O
life O
course O
and O
even O
between O
generations O
are O
needed O

On O
the O
basis O
of O
this O
reaction O
, O
an O
adenine B-Chemical
derivative I-Chemical
with O
a O
tethered O
bipyridine B-Chemical
moiety I-Chemical
has O
been O
designed O
for O
sequence-specific O
osmium B-Chemical
complex I-Chemical
formation O

HMEs O
were O
identified O
by O
applying O
a O
search O
pipeline O
built O
upon O
profile O
hidden O
Markov B-Gene
model I-Gene
(HMM) I-Gene
to O
proteomes O

In O
this O
review O
article O
, O
we O
aim O
to O
give O
a O
brief O
introduction O
to O
the O
basic O
molecular O
principals O
of O
epigenetics O
and O
provide O
a O
concise O
summary O
of O
the O
existing O
evidence O
for O
the O
role O
of O
epigenetic O
mechanisms O
in O
gastrointestinal B-Disease
health I-Disease
and I-Disease
disease I-Disease
, O
hepatology B-Disease
, O

Epigenetics O
is O
the O
alteration O
of O
heritable O
genes O
caused O
by O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
modification I-Chemical
, O
noncoding O
RNAs O
and O
chromatin O
remodeling O
without O
altering O
the O
DNA B-Chemical
sequence O

DNA O
methylation O
alterations O
also O
account O
for O
the O
histological O
heterogeneity O
and O
clinicopathological O
diversity O
of O
human B-Species
cancers B-Disease

Overall O
, O
Î²-values O
enable O
better O
imputation O
performances O
than O
M-values O

Furthermore O
such O
data O
may O
prove O
of O
use O
in O
providing O
identifying O
information O
, O
providing O
the O
possibility O
of O
a O
future O
forensic O
epigenome O

However O
, O
in O
silico O
methods O
can O
be O
implemented O
to O
conduct O
preliminary O
screening O
to O
save O
experimental O
resources O
and O
time O
, O
especially O
given O
the O
rapid O
accumulation O
of O
sequencing O
data O

A O
better O
understanding O
of O
the O
epigenetic O
basis O
of O
developmental O
programming O
and O
how O
these O
effects O
may O
be O
transmitted O
across O
generations O
is O
essential O
for O
the O
implementation O
of O
initiatives O
aimed O
at O
curbing O
the O
current O
obesity B-Disease
and O
diabetes B-Disease
crisis O

Epigenetics O
has O
now O
morphed O
from O
a O
phenomenon O
to O
a O
branch O
of O
science O
whose O
molecular O
underpinnings O
are O
well O
understood O

A O
deeper O
understanding O
of O
epigenetics O
may O
provide O
an O
answer O
to O
the O
continuing O
strong O
clinical O
impact O
of O
cardiovascular B-Disease
diseases I-Disease
by O
improving O
diagnostic O
capabilities O
, O
personalized O
medical O
approaches O
and O
the O
development O
of O
targeted O
therapeutic O
interventions O

Here O
, O
using O
a O
comprehensive O
genome-wide O
analysis O
of O
H3K27ac B-Chemical
mark O
and O
gene O
expression O
in O
mammary B-Species
epithelial I-Species
cells I-Species
undergoing O
EMT B-Disease
, O
we O
found O
that O
ERK B-Gene
signalling O
is O
essential O
for O
the O
epigenetic O
reprogramming O
underlying O
hallmark O
gene O
expression O
and O
phenotypic O
changes O

Differentially O
methylated O
CpGs O
were O
searched O
in O
the O
EWAS O
Catalog O
and O
associated O
traits O
identified O

Moreover O
, O
Listeria B-Species
monocytogenes I-Species
can O
indirectly O
induce O
H3 B-Gene
hyperacetylation O
leading O
to O
inflammation B-Disease
in O
human O
endothelial O
cells O
whereas O
Pseudomonas B-Species
aeruginosa I-Species
excretes O
QS B-Chemical
2-AA I-Chemical
to O
directly O
induce O
H3 B-Gene
deacetylation O
leading O
to O
bacterial O
persistence O
in O
human O

This O
understanding O
provides O
the O
basis O
for O
elucidating O
how O
the O
intricate O
interactions O
of O
the O
genome B-Gene
, O
epigenome B-Gene
, O
and O
transcriptome B-Gene
shape O
immune O
responses O
and O
maintain O
immune O
tolerance O
to O
self-antigens O

Because O
an O
individual's O
epigenetic O
patterns O
are O
established O
during O
early O
gestation O
and O
are O
changed O
and O
personalized O
by O
environmental O
factors O
during O
our O
lifetime O
, O
epigenetic O
mechanisms O
are O
quite O
important O
in O
the O
development O
of O
transgenerational O
and O
adult O
obesity B-Disease
as O
well O
as O
in O
the O
development O
of O
diabetes B-Disease

Obesity O
is O
often O
associated O
with O
overnutrition O
and O
a O
sedentary O
lifestyle O
, O
but O
clearly O
other O
factors O
also O
increase O
the O
susceptibility O
of O
metabolic B-Disease
disease I-Disease
states O

Conclusion O
 O
GLDC B-Gene
is O
a O
putative O
tumor O
suppressor O
gene O
involved O
in O
gastric B-Disease
cancer I-Disease
progression O
and O
hypermethylation O
of O
the O
GLDC B-Gene
promoter O
regulates O
its O
transcriptional O
silencing O

Selection O
operates O
on O
the O
phenotype O
, O
and O
its O
consequences O
are O
manifest O
in O
representation O
of O
the O
genotype B-Gene
in O
successive O
generations O

Analysis O
of O
epigenetic O
variations O
among O
different O
rice B-Species
varieties O
indicates O
that O
epigenetic O
modification O
may O
lead O
to O
inheritable O
phenotypic O
variation O

This O
review O
summaries O
the O
known O
reversible O
, O
post-translational O
modifications O
( O
PTMs O
) O
of O
class O
IIa O
histone B-Chemical
deacetylases I-Chemical
( O
HDACs B-Gene
) O
that O
ultimately O
drive O
transcriptional O
changes O
in O
homeostasis O
and O
disease B-Disease

221 O
Epigenetics O
plays O
a O
key O
role O
in O
cellular O
development O
and O
function O

However O
, O
the O
fixation O
process O
and O
the O
long O
storage O
duration O
lead O
to O
DNA B-Gene
fragmentation O
and O
hinder O
epigenome O
analysis O

Genome O
- O
wide O
association O
studies O
( O
GWAS O
) O
completed O
during O
the O
past O
few O
years O
have O
identified O
risk O
- O
associated O
single O
nucleotide O
polymorphisms O
that O
can O
be O
used O
as O
screening O
tools O
in O
epidemiologic O
studies O
of O
a O
variety O
of O
tumor B-Disease
types I-Disease

, O
does O
task-specific O
self-efficacy O
have O
an O
effect O
on O
GSE B-Gene
, O
or O
does O
GSE B-Gene
have O
an O
effect O
on O
task-specific O
self-efficacy O

Advances O
in O
the O
knowledge O
of O
AID B-Gene
further O
blur O
the O
limits O
between O
monogenic O
and O
multifactorial O
forms O
of O
these O
syndromes O
, O
and O
between O
autoinflammatory O
and O
autoimmune O
conditions O

chromatin O

1047 O
The O
early O
developmental O
phase O
is O
of O
critical O
importance O
for O
human B-Species
health O
and O
disease B-Disease
later O
in O
life O

layers O

1051 O
Epigenetic O
research O
has O
accelerated O
rapidly O
in O
the O
twenty-first O
century O
, O
generating O
justified O
excitement O
and O
hope O
, O
but O
also O
a O
degree O
of O
hype O

This O
will O
provide O
further O
opportunities O
to O
enhance O
our O
understanding O
of O
the O
biological O
embedding O
of O
prenatal B-Disease
stress I-Disease
exposure O

While O
our O
understanding O
of O
epigenetic O
mechanisms O
in O
vertebrates B-Species
is O
rapidly O
growing O
, O
our O
knowledge O
about O
invertebrates B-Species
remains O
lower O
, O
or O
is O
restricted O
to O
model O
organisms O

Recent O
studies O
have O
shed O
new O
light O
on O
the O
mechanisms O
underlying O
both O
promoter-specific O
hypermethylation O
and O
global O
hypomethylation O
in O
cancer B-Disease
cells O
and O
identified O
potential O
targets O
for O
biomarker O
discovery O
and O
therapeutic O
intervention O


535 O
Accumulating O
evidence O
, O
particularly O
from O
rodent O
and O
studies O
, O
shows O
that O
the O
environmental O
exposures O
and O
experience O
of O
a O
father O
prior O
to O
conception O
can O
modulate O
sperm O
and O
subsequent O
offspring O
phenotypes O

This O
will O
be O
helpful O
in O
the O
diagnosis O
and O
development O
of O
treatment O
for O
numerous O
diseases O
, O
including O
cancer B-Disease


Already O
, O
there O
is O
evidence O
to O
suggest O
that O
, O
in O
people O
with O
eating B-Disease
disorders I-Disease
, O
epigenetically O
informed O
interventions O
help O
reduce O
stigma O
and O
shame O
, O
and O
increase O
self-acceptance O
and O
hopes O
of O
recovery O

Although O
research O
in O
this O
area O
is O
still O
under O
investigation O
, O
available O
results O
suggest O
that O
DNA B-Gene
methylation O
associated O
with O
attachment-related O
dimensions O
might O
affect O
the O
development O
of O
stress B-Disease
regulation I-Disease
system I-Disease
and O
social-emotional O
capacities O
, O
thus O
contributing O
to O
the O
emerging O
phenotypic O
outcomes O

The O
role O
of O
epigenetic O
variation O
and O
inheritance O
in O
natural O
populations O
, O
however O
, O
remains O
poorly O
understood O

04e-16 O
) O
and O
predicts O
age O
from O
skin O
samples O
with O
a O
standard O
deviation O
of O
2 O

We O
introduce O
the O
R O
package O
MLML2R O
, O
which O
provides O
maximum O
likelihood O
estimates O
( O
MLE O
) O
of O
5-mC B-Chemical
and O
5-hmC B-Chemical
proportions O

P O

Conclusion O
 O
In O
order O
to O
make O
full O
use O
of O
machine O
learning O
algorithms O
, O
one O
should O
get O
familiar O
with O
the O
pros O
and O
cons O
of O
them O
, O
which O
will O
benefit O
from O
big O
data O
by O
choosing O
the O
most O
suitable O
method O
( O
s O
) O

Conserved O
DNA B-Gene
methylation I-Gene
is O
accompanied O
by O
conservation O
of O
other O
epigenetic O
marks O
including O
histone B-Chemical
modifications O

569 O
methylation O
is O
a O
heritable O
but O
reversible O
epigenetic O
mechanism O
of O
control O
over O
gene O
expression O

We O
conclude O
that O
DNA B-Gene
hydroxymethylation O
is O
a O
sensitive O
biosensor O
for O
many O
harmful O
environmental O
factors O
each O
of O
which O
specifically O
targets O
5hmC B-Chemical
in O
different O
organs O
, O
cell O
types O
, O
and O
DNA B-Gene
sequences O
and O
induces O
its O
changes O
through O
a O
specific O
metabolic O
pathway O

We O
describe O
some O
applications O
for O
the O
analysis O
and O
interpretation O
of O
these O
data O

Finally O
, O
we O
argued O
that O
the O
REAL O
model O
highlights O
important O
avenues O
for O
early O
intervention O
based O
on O
common O
and O
unique O
factors O
across O
childhood B-Disease
disorders I-Disease

224 O
Just O
as O
genome-wide O
association O
studies O
( O
GWAS B-Gene
) O
grew O
from O
the O
field O
of O
genetic O
epidemiology O
, O
so O
too O
do O
epigenome-wide O
association O
studies O
( O
EWAS B-Gene
) O
derive O
from O
the O
burgeoning O
field O
of O
epigenetic O
epidemiology O
, O
with O
both O
aiming O
to O
understand O
the O


g O

function-can O

In O
this O
chapter O
, O
we O
discuss O
how O
CRISPR/Cas9 B-Gene
and O
dCas9 B-Gene
have O
recently O
been O
engineered O
for O
epigenome O
editing O

MicroRNA O
(miRNA) O
, O
a O
member O
of O
noncoding O
RNAs O
superfamily O
, O
participates O
in O
RNA O
interference O
through O
a O
unique O
mechanism O

This O
improved O
control O
promises O
to O
revolutionize O
our O
understanding O
of O
epigenetic O
modifications O
in O
human O
health O
and O
disease B-Disease
states I-Disease

We O
discuss O
the O
role O
of O
genetics O
and O
epigenetics O
to O
the O
health O
disparities O
observed O
in O
rheumatic B-Disease
diseases I-Disease

human B-Species

Conceivably O
, O
newly O
developed O
precision O
epigenetic O
technologies O
could O
drive O
down O
these O
costs O

In O
particular O
, O
we O
examine O
whether O
we O
could O
identify O
separations O
between O
the O
female O
and O
male O
distributions O
of O
DNA B-Chemical
methylation I-Chemical
across O
hundred O
of O
thousands O
CpG B-Gene
sites I-Gene
in O
two O
independent O
cohorts O
, O
the O
Swedish B-Species
Adoption I-Species
Twin I-Species
study I-Species
and O
the O

1357 O
In O
this O
issue O
of O
Neuron O
, O
Aldiri B-Gene
et I-Gene
al I-Gene

These O
constitute O
the O
core O
techniques O
that O
are O
used O
in O
our O
laboratory O
for O
accurately O
surveying O
the O
epigenetics O
of O
retrotransposable B-Species
elements I-Species

841 O
Most O
of O
the O
studies O
characterizing O
DNA B-Gene
methylation I-Gene
patterns O
have O
been O
restricted O
to O
particular O
genomic O
loci O
in O
a O
limited O
number O
of O
human B-Species
samples O
and O
pathological B-Disease
conditions I-Disease

Recent O
findings O
 O
A O
growing O
number O
of O
loci B-Gene
have O
been O
identified O
, O
which O
are O
good O
candidate O
biomarkers O
for O
atherosclerosis B-Disease
and O
provide O
novel O
insights O
into O
the O
molecular O
changes O
taking O
place O
in O
the O
diseased O
vessel O

DNA O
methylation O
of O
six O
CpG B-Gene
sites I-Gene
was O
validated O
for O
the O
same O
21 O
cartilage B-Species
samples O
by O
pyrosequencing O

1245 O
 O
Background O
 O
The O
metabolic O
enzyme O
, O
glycine B-Chemical
dehydrogenase I-Chemical
( O
GLDC B-Gene
) O
, O
involved O
in O
glycine B-Chemical
metabolism O
, O
is O
known O
to O
be O
involved O
in O
non-ketotic B-Disease
hyperglycinemia I-Disease
but O
not O
in O
cancer B-Disease

The O
human B-Species
genome O
contains O
around O
28 O
million O
DNA B-Chemical
methylation I-Chemical
sites O
, O
many O
of O
which O
change O
with O
age O

Traditional O
methods O
used O
to O
identify O
functional O
DNA B-Gene
have O
relied O
on O
comparative O
genomics O
, O
conservation O
analysis O
and O
low O
throughput O
validation O
assays O

To O
fill O
this O
gap O
, O
we O
conducted O
a O
comparison O
study O
in O
which O
we O
processed O
cord O
blood O
samples O
from O
four O
newborns O
in O
duplicates O
using O
both O
the O
Illumina B-Chemical
HumanMethylationEPIC I-Chemical
BeadChip I-Chemical
and O
the O
Illumina B-Chemical
TruSeq I-Chemical
Methyl I-Chemical
Capture I-Chemical
EPIC I-Chemical

Expert O
opinion O
 O
There O
is O
growing O
evidence O
that O
pharmacoepigenetics O
has O
the O
potential O
to O
become O
an O
important O
element O
of O
personalized O
medicine O

cis-regulatory O

A O
number O
of O
natural O
products O
having O
diverse O
mechanism O
of O
action O
are O
used O
for O
drug O
discovery O

Then O
we O
discuss O
the O
potential O
of O
using O
targeted O
epigenetic O
pharmacotherapy O
, O
combined O
with O
psychosocial O
interventions O
, O
for O
future O
personalized O
medicine O
for O
patients O

These O
advances O
improve O
our O
understanding O
of O
the O
disease's B-Disease
complexity O
and O
guide O
us O
toward O
functional O
assessments O
of O
genetic/epigenetic O
outcomes O
and O
toward O
their O
translational O
and O
clinical O
applications O

org O
/ O
10 O

of O

Multinomial O
logistic O
regression O
was O
used O
to O
calculate O
relative O
risk O
ratios O
for O
being O
physically O
frail O
or O
pre-frail O
according O
to O
epigenetic B-Chemical
age I-Chemical
acceleration I-Chemical

Epigenetics O
is O
the O
study O
of O
processes O
that O
control O
gene B-Gene
expression O
and O
phenotype O
without O
alterations O
in O
the O
underlying O
DNA B-Gene
sequence O

tissue O

1222 O
Aim O
DNA B-Chemical
methylation I-Chemical
has O
proven O
to O
be O
a O
remarkably O
accurate O
biomarker O
for O
human B-Species
age O
, O
allowing O
the O
prediction O
of O
chronological O
age O
to O
within O
a O
couple O
of O
years O

751 O
Although O
new O
developments O
of O
surgery O
, O
chemotherapy B-Chemical
, O
radiotherapy B-Chemical
, O
and O
immunotherapy B-Chemical
treatments O
for O
cancer B-Disease
have O
improved O
patient O
survival O
, O
the O
emergence O
of O
chemoresistance O
in O
cancer B-Disease
has O
significant O
impacts O
on O
treatment O
effects O

One O
model O
that O
supports O
the O
transition O
from O
traditional O
lecturing O
towards O
active O
learning O
by O
maintaining O
a O
balance O
between O
instruction O
and O
self-learning O
is O
the O
'Sandwich B-Chemical
Model' I-Chemical

Conclusions O
 O
Our O
results O
show O
that O
DGW B-Gene
automatically O
recognises O
and O
aligns O
important O
genomic O
features O
such O
as O
transcription O
start O
sites O
and O
splicing O
sites O
from O
histone B-Chemical
marks I-Chemical

Here O
are O
presented O
the O
main O
advantages O
and O
disadvantages O
of O
different O
approaches O
to O
methylation B-Chemical
analysis O

In O
recent O
times O
various O
studies O
implicated O
that O
, O
aberrant O
epigenetic O
mechanisms O
are O
associated O
with O
reproductive B-Disease
infertility I-Disease

Mechanisms O
of O
epigenetics O
include O
DNA B-Chemical
methylation O
(and O
demethylation O
), O
histone O
modifications O
, O
and O
non-coding O
RNAs O
such O
as O
microRNAs O

Here O
, O
we O
perform O
a O
comparative O
analysis O
of O
spatial O
genetic O
and O
epigenetic O
variation O
based O
on O
8,459 O
single O
nucleotide O
polymorphisms O
( O
SNPs O
) O
and O
8,580 O
single O
methylation O
variants O
( O
SMVs O
) O
from O
eight O
populations O
of O
the O
Puerto B-Species
Rican I-Species
crested I-Species
anole I-Species
, O

Advances O
in O
genomics O
techniques O
are O
now O
driving O
the O
profiling O
of O
germline O
and O
zygotic O
epigenomes O
, O
thereby O
improving O
our O
understanding O
of O
MEI B-Gene
in O
diverse O
species B-Species

006 O
; O
FDR O
< O


To O
deliver O
the O
system O
, O
consisting O
of O
a O
dead O
( O
deactivated O
) O
version O
of O
Cas9 B-Gene
( O
dCas9 B-Gene
) O
fused O
with O
the O
catalytic O
domain O
of O
the O
DNA B-Chemical
methyltransferase I-Chemical
enzyme I-Chemical
3A I-Chemical
( O
DNMT3A B-Gene
) O
, O
a O
lentiviral O
vector O
is O
used O

Adverse O
effects O
observed O
in O
the O
OECD O
transgenerational O
assays O
could O
be O
used O
to O
inform O
future O
tests O
specifically O
designed O
to O
investigate O
the O
epigenetic O
mechanism O
of O
action O

Findings O

This O
study O
demonstrates O
an O
efficient O
multiplexed O
body O
fluid O
identification O
process O
utilizing O
methylation O
that O
can O
be O
easily O
implemented O
in O
forensic O
laboratories O

In O
this O
review O
, O
we O
discuss O
some O
of O
the O
most O
relevant O
advances O
in O
this O
field O

61 O
was O
selected O
with O
a O
specificity O
of O
90 O

More O
precise O
work O
is O
necessary O
to O
estimate O
the O
methylation O
level O
of O
each O
CpG B-Gene
site I-Gene
in O
the O
whole O
genome O

We O
found O
that O
both O
the O
epi(genetic) O
status O
of O
the O
explant O
and O
the O
regeneration O
protocol O
employed O
play O
critical O
roles O
in O
shaping O
the O
molecular O
and O
phenotypic O
landscape O
of O
clonal O
plants B-Species

Finally O
, O
our O
results O
indicate O
that O
cellular O
composition O
and O
DNA B-Chemical
sequence I-Chemical
variation O
are O
the O
strongest O
predictors O
of O
DNA B-Chemical
methylation O
, O
highlighting O
critical O
factors O
for O
medical O
epigenomics O
studies O

Since O
epigenetic O
data O
contains O
potentially O
identifiable O
information O
, O
similarly O
to O
genetic B-Gene
data I-Gene
, O
most O
raw O
files O
generated O
by O
these O
consortia O
are O
stored O
in O
controlled-access O
databases O

These O
mitotically O
stable O
and O
meiotically O
heritable O
changes O
are O
sensitive O
to O
environmental O
conditions O
especially O
during O
developmental O
periods O
, O
and O
they O
are O
essential O
to O
understanding O
how O
information O
in O
the O
DNA B-Gene
sequence I-Gene
is O
utilized O

Here O
, O
we O
analyzed O
quality O
metrics O
of O
394,043 O
CpG B-Gene
sites O
in O
two O
samples O
of O
568 O
and O
319 O
mentally B-Disease
healthy I-Disease
young O
adults O

We O
present O
an O
R O
package O
called O
MammalMethylClock O
for O
the O
construction O
, O
assessment O
, O
and O
application O
of O
epigenetic O
clocks O
in O
different O
mammalian B-Species
species I-Species

5 O
is O
currently O
the O
best O
for O
WGBS O
among O
the O
examined O
HCS B-Chemical
versions O

1453Background O
The O
combination O
of O
sodium B-Chemical
bisulfite I-Chemical
treatment O
with O
highly-parallel O
sequencing O
is O
a O
common O
method O
for O
quantifying O
DNA B-Gene
methylation I-Gene
across O
the O
genome O

1104 O
Elucidating O
the O
molecular O
basis O
of O
natural O
variation O
in O
complex O
traits O
is O
the O
key O
for O
their O
effective O
management O
in O
crops O
or O
natural O
systems O

In O
recent O
decades O
, O
the O
intake O
of O
methyl B-Chemical
group I-Chemical
compounds I-Chemical
has O
changed O
significantly O
due O
to O
, O
e O

A O
plausible O
initial O
application O
of O
rejuvenation O
in O
vivo O
would O
be O
preventing O
adult O
individuals O
from O
aging O
thus O
eliminating O
a O
major O
risk O
factor O
for O
end O
of O
life O
pathologies O

govern O

He O
also O
holds O
faculty O
appointments O
at O
the O
Center O
for O
Computational O
Medicine O
and O
Bioinformatics O
and O
the O
Graduate O
Program O
in O
Immunology B-Disease
at O
the O
University O
of O
Michigan O

This O
review O
focuses O
on O
the O
progress O
made O
in O
the O
field O
of O
prognostic O
and O
predictive O
biomarkers O
, O
highlighting O
the O
limitations O
, O
challenges O
, O
and O
also O
the O
opportunities O
associated O
with O
the O
application O
of O
genomics B-Gene
and O
epigenomics B-Gene
technologies O
in O
clinical O
practice O

672 O
Epigenetic O
sex O
differences O
and O
their O
resulting O
implications O
for O
human O
health O
have O
been O
studied O
for O
about O
a O
decade O

However O
, O
how O
transcriptional O
activities O
are O
molecularly O
controlled O
and O
which O
of O
the O
many O
known O
epigenomic O
features O
have O
causal O
roles O
remains O
unclear O

The O
recent O
explosion O
of O
epigenome-wide O
association O
studies O
has O
provided O
us O
with O
novel O
insights O
into O
psoriasis B-Disease
pathogenesis I-Disease
, O
and O
the O
mechanism O
of O
action O
of O
UVB B-Chemical
, O
methotrexate B-Chemical
, O
and O
anti-TNF B-Chemical
therapies I-Chemical
, O
as O
well O
as O
molecular O
signatures O
of O

The O
idea O
that O
aging O
is O
an O
epigenetic O
program O
has O
propitious O
implications O
for O
the O
feasibility O
of O
medical O
rejuvenation O

Results O
 O
Of O
the O
six O
associations O
examined O
, O
only O
two O
were O
statistically O
significant O
in O
initial O
models O
adjusted O
for O
age O
and O
sex O
alone O

Social O
epigenetics O
is O
an O
emerging O
area O
of O
research O
that O
aims O
to O
uncover O
biological O
pathways O
through O
which O
social O
experiences O
affect O
health O
outcomes O

Both O
implementations O
were O
tested O
with O
datasets O
from O
fluorescent O
qPCR B-Chemical
reactions O
, O
as O
well O
as O
pH-LAMP B-Chemical
experiments O
that O
have O
been O
optimized O
for O
on-chip O
amplifications O

bioapp O

The O
second O
body O
of O
theories O
employs O
the O
principle O
of O
the O
extraordinary O
plasticity O
of O
the O
( O
body-)organism O
and O
emphasizes O
the O
value O
of O
the O
( O
body-)organism-environment O
mutual O
interchange O
, O
known O
as O
' O
the O
epigenetic O
approach O
' O

These O
mechanisms O
are O
critical O
components O
in O
the O
normal O
development O
and O
growth O
of O
cells O

Personalized O
medicine-customized O
treatment O
tailored O
to O
the O
individual-offers O
a O
solution O

1386 O
Analyzing O
the O
conditions O
in O
which O
past O
individuals O
lived O
is O
key O
to O
understanding O
the O
environments O
and O
cultural O
transitions O
to O
which O
humans B-Species
had O
to O
adapt O

However O
, O
considerable O
progress O
in O
studying O
chromosome O
territories O
became O
possible O
only O
in O
the O
end O
of O
the O
XX O
century O
mainly O
due O
to O
advances O
in O
microscopy O
and O
molecular O
biology O

4 O
% O
specificity O
for O
newborn O
prediction O
of O
CP B-Disease

These O
saDMP's O
are O
enriched O
in O
CpG B-Chemical
islands O
and O
CpG B-Chemical
shores O
and O
located O
preferentially O
at O
5'UTRs O
, O
3'UTRs O
and O
enhancers O

genomic O

DNA O
demethylation O
augments O
STAT3 B-Gene
association O
at O
the O
Prdm1 B-Gene
promoter O
and O
a O
downstream O
enhancer O
, O
thus O
ensuring O
efficient O
gene O
expression O
and O
plasma B-Species
cell I-Species
differentiation O

Concurrent O
advances O
in O
genome-modulating O
technologies O
, O
like O
gene B-Gene
silencing I-Gene
and O
genome O
editing O
, O
are O
providing O
ability O
to O
understand O
in O
detail O
the O
process O
of O
cancer B-Disease
initiation I-Disease
, O
progression I-Disease
, O
and O
signaling O
as O
well O
as O
opening O
up O
avenues O
for O
therapeutic O
targeting O

Furthermore O
, O
gene O
expression O
in O
sperm O
cells O
is O
not O
significantly O
affected O
by O
extensive O
supplementation O
of O
methylating B-Chemical
micronutrients I-Chemical
and O
thus O
RNA B-Gene
molecules I-Gene
could O
not O
be O
established O
as O
the O
epigenetic O
mark O
in O
this O
feeding O
experiment O

A O
total O
of O
22 O
different O
epigenetic O
and O
transcriptional O
regulators O
of O
OCG B-Gene
were O
identified O
; O
key O
epigenetic O
regulators O
included O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
methylation I-Chemical
, O
histone B-Chemical
acetylation I-Chemical
, O
miRNAs B-Gene
and O
lncRNAs B-Gene

Fortunately O
, O
that O
scenario O
is O
now O
changing O
thanks O
to O
the O
growing O
availability O
of O
complete O
reference O
genome B-Gene
sequences I-Gene
along O
with O
the O
development O
of O
high-throughput O
DNA B-Gene
sequencing I-Gene
and O
bioinformatic O
methods O

Finally O
, O
we O
present O
some O
new O
frontiers O
in O
epigenetics O
with O
implications O
for O
human B-Species
health O

Epigenetics O
includes O
DNA B-Chemical
methylation I-Chemical
, O
noncoding O
RNA B-Gene
interference O
, O
and O
modifications O
of O

This O
regulatory O
mechanism O
is O
important O
in O
cellular O
differentiation O
and O
development O

We O
contrast O
the O
primarily O
independent O
efforts O
for O
these O
two O
categories O
of O
exposure O
, O
and O
potential O
explanations O
for O
these O
differences O

Induced O
proximity O
strategies O
involve O
bringing O
molecular O
effectors O
into O
spatial O
proximity O
with O
specific O
genomic O
regions O
to O
achieve O
the O
probing O
or O
manipulation O
of O
local O
epigenetic O
environments O
with O
increased O
proximity O

Recent O
developments O
start O
to O
exploit O
the O
epigenetic O
information O
on O
cfDNA B-Chemical
, O
which O
could O
have O
substantially O
wider O
applications O

The O
four O
tissue O
types O
( O
brain O
, O
blood O
, O
saliva O
, O
buccal O
) O
of O
samples O
from O
up O
to O
40 O
patients O
, O
including O
11 O
cases O
, O
were O
analyzed O
using O

Epigenetics O
is O
one O
possible O
mechanism O
through O
which O
these O
early O
life O
exposures O
can O
impact O
later O
life O
health O

These O
techniques O
return O
large O
, O
high O
dimensional O
data O
sets O
with O
visually O
complex O
structures O
, O
such O
as O
multi-modal O
peaks O
extended O
over O
large O
genomic B-Gene
regions I-Gene

We O
have O
generated O
a O
searchable O
database O
for O
the O
interpretation O
of O
data O
from O
blood-based O
EWAS O
analyses O
( O
http//epigenetics O

Thus O
, O
epigenetic O
modifications O
could O
mediate O
environmental O
signals O
and O
provide O
a O
link O
between O
susceptibility O
genes B-Gene
and O
environmental O
factors O
in O
the O
etiology O
of O
cancer B-Disease

The O
findings O
suggest O
that O
a O
number O
of O
prenatal O
adverse O
( O
e O

3 O
% O
of O
families O
, O
comparable O
to O
original O
FLoSS B-Disease
in O
elderly O

which O

There O
arises O
a O
question O
as O
to O
whether O
the O
aberrant O
epigenetic O
state O
after O
reprogramming O
leads O
to O
epigenetic O
defects O
in O
induced O
stem O
cells O
causing O
unpredictable O
long O
term O
effects O
in O
differentiated O
cells O

NCCN O
Clinical O
Practice O
Guidelines O
also O
recommended O
epigenetic O
drugs O
for O
PTCL B-Disease
subtypes O
as O
second-line O
therapy O

jp O
/ O
packages O
/ O
3 O

interview O

This O
article O
reviews O
several O
examples O
that O
illustrate O
well O
how O
different O
environmental O
pressures O
, O
particularly O
those O
imposed O
by O
pathogens O
and O
infectious B-Disease
diseases I-Disease
, O
have O
shaped O
the O
patterns O
of O
genetic O
and O
epigenetic O
variability O
currently O
observed O
in O
human B-Species
populations I-Species

111 O
Autoimmune B-Disease
diseases I-Disease
now O
include O
over O
100 O
conditions O
and O
are O
estimated O
to O
affect O
over O
20 O
million O
people O
in O
the O
United O
States O
or O
5% O
of O
the O
world O
population O
with O
numerous O
geographical O
differences O
coined O
as O
geoepidemiology O

, O
2017 O
) O

For O
epigenetic O
investigations O
of O
cytosine B-Chemical
methylation O
where O
regions O
of O
interest O
, O
such O
as O
specific O
gene B-Gene
promoters O
or O
CpG B-Gene
islands O
, O
have O
been O
identified O
and O
there O
is O
a O
need O
to O
examine O
significant O
numbers O
of O
samples O
with O
high O
quantitative O
accuracy O
, O
we O
have O
developed O
a O

In O
addition O
, O
the O
laboratory O
is O
also O
involved O
with O
the O
study O
of O
inherited O
susceptibility O
to O
brain B-Disease
tumors I-Disease
and O
pancreatic B-Disease
cancer I-Disease

Because O
epigenetics O
is O
reversible O
and O
susceptible O
to O
environmental O
factors O
, O
it O
could O
potentially O
be O
a O
promising O
direction O
for O
clinical O
medicine O
research O

84 O
, O
P O
< O
0 O

g O

Shortly O
after O
the O
study O
was O
published O
in O
1998 O
, O
the O
US O
CDC O
deemed O
ACEs B-Disease
an O
important O
public O
health O
target O
; O
however O
, O
it O
is O
only O
recently O
that O
ACEs B-Disease
feature O
prominently O
in O
scientific O
and O
public O
discourses O

242 O
methylation O
is O
a O
stable O
covalent O
epigenetic O
modification O
of O
primarily O
dinucleotides O
that O
has O
recently O
gained O
considerable O
attention O
for O
its O
use O
as O
a O
biomarker O
in O
different O
clinical O
settings O
, O
including O
diagnosis O
, O
prognosis O
and O
therapeutic O
response O
prediction O

Our O
overall O
goal O
is O
to O
aid O
scientists O
using O
these O
technologies O
in O
their O
favorite O
system O
of O
interest O

The O
clinical O
and O
forensic O
research O
on O
psychopathy B-Disease
is O
brought O
into O
conversation O
with O
the O
emerging O
field O
of O
epigenetics B-Gene
to O
highlight O
critical O
issues O
of O
( O
1 O
) O
clinical O
definition O
and O
diagnosis O
, O
( O
2 O
) O
assessment O
, O
( O
3 O
) O
aetiology O
of O
psychopathic B-Disease
phenotypes O
, O
and O

First O
, O
there O
is O
sufficient O
evidence O
that O
EDCs O
( O
including O
bisphenols B-Chemical
and I-Chemical
phthalates B-Chemical
) O
directly O
target O
mitochondrial O
function O
, O
and O
more O
direct O
evidence O
is O
needed O
to O
connect O
this O
to O
mtDNA B-Gene
methylation O

Finally O
, O
targeted O
therapy O
for O
CSCs O
by O
epigenetic O
drugs B-Chemical
is O
referred O
to O
, O
which O
is O
a O
new O
approach O
in O
overcoming O
resistance O
and O
recurrence O
of O
cancer B-Disease

1165 O
Age-associated O
DNA B-Chemical
methylation I-Chemical
reflects O
aspect O
of O
biological O
aging-therefore O
epigenetic O
clocks O
for O
mice B-Species
can O
elucidate O
how O
the O
aging O
process O
in O
this O
model O
organism O
is O
affected O
by O
specific O
treatments O
or O
genetic O
background O

1084 O
Evidence O
emerging O
from O
the O
study O
of O
epigenetics O
and O
epigenomics O
challenges O
notions O
of O
health O
by O
enhancing O
understanding O
of O
disease B-Disease
etiologies O
and O
improving O
awareness O
of O
new O
health O
risks O

Future O
research O
will O
need O
to O
investigate O
whether O
epigenetic O
age O
acceleration O
plays O
a O
causal O
role O
in O
the O
onset O
of O
physical B-Disease
frailty I-Disease

1097 O
Inherited O
epigenetic O
information O
has O
been O
observed O
to O
regulate O
a O
variety O
of O
complex O
organismal O
phenotypes O
across O
diverse O
taxa O
of O
life O

Indeed O
, O
metastasis B-Disease
accounts O
for O
the O
vast O
majority O
of O
cancer-related B-Disease
deaths O

Since O
their O
inception O
they O
have O
been O
used O
to O
infer O
knowledge O
about O
gene B-Gene
regulation O
and O
as O
methods O
of O
computation O

Various O
methods O
are O
available O
for O
the O
detection O
of O
DNA B-Gene
methylation I-Gene
changes O

993 O
 O
Background O
 O
Studies O
on O
DNA B-Gene
methylation I-Gene
have O
the O
potential O
to O
discover O
mechanisms O
of O
cardiovascular B-Disease
disease I-Disease
( O
CVD B-Disease
) O
risk O

Ignoring O
exposure O
misclassification O
increases O
type O
I O
error O
in O
mediation O
analysis O

The O
demand O
for O
comprehensively O
describing O
DNA B-Gene
methylation I-Gene
patterns I-Gene
spawns O
a O
diversity O
of O
DNA B-Gene
methylation I-Gene
profiling O
technologies O
that O
target O
its O
genomic O
distribution O

We O
searched O
PubMed O
, O
EMBASE O
, O
OVID/PsychInfo O
, O
and O
Google O
Scholar O
with O
the O
following O
inclusion O
criteria O
 O
( O
1 O
) O
systematic O
review O
or O
meta-analysis O
from O
a O
peer-reviewed O
journal O
; O
( O
2 O
) O
inclusion O
of O
a O
measure O
assessing O
early O
age O
of O
onset O
of O
depression B-Disease
; O
and O

Recent O
advances O
in O
the O
study O
of O
the O
epigenome O
have O
led O
to O
novel O
insights O
into O
the O
pathogenesis O
and O
potential O
therapeutic O
targets O
of O
various O
pathologic O
entities O
including O
inflammatory B-Disease
diseases I-Disease

867Background O
Differences O
in O
DNA B-Gene
methylation I-Gene
can O
arise O
as O
epialleles O
, O
which O
are O
loci O
that O
differ O
in O
chromatin O
state O
and O
are O
inherited O
over O
generations O

1035Motivation O
Deciphering O
relevant O
biological O
insights O
from O
epigenomic O
data O
can O
be O
a O
challenging O
task O

zoom O
in O
on O
the O
late O
occurring O
, O
subclonal O
subset O
of O
such O
mutations O
and O
define O
the O
molecular O
mechanism O
behind O
their O
enrichment O
in O
cancer B-Disease

Together O
with O
a O
growing O
understanding O
of O
our O
own O
evolutionary O
relationships O
to O
common O
ancestors O
, O
the O
epigenetic O
processes O
involved O
enforce O
a O
reexamination O
of O
what O
is O
regarded O
as O
a O
normal O
foot O
structure O

343 O
Asthma B-Disease
is O
a O
heterogeneous O
group O
of O
conditions O
that O
typically O
begin O
in O
early O
life O
and O
result O
in O
recurrent O
, O
reversible O
bronchial O
obstruction O

Further O
analysis O
reduced O
the O
number O
of O
CpG B-Gene
sites I-Gene
required O
for O
optimal O
determination O
of O
body O
fluid O
type O
to O
five O

Therefore O
, O
we O
reviewed O
the O
crucial O
studies O
in O
which O
varying O
epigenomic O
events O
were O
captured O
with O
immuno-oncology O
set-ups O

The O
PubMed O
, O
Web O
of O
Science O
, O
and O
Google O
Scholar O
databases O
were O
searched O
, O
and O
the O
original O
articles O
cited O
in O
reviews O
located O
through O
the O
search O
were O
also O
reviewed O

Many O
advances O
in O
medicine O
have O
been O
made O
to O
treat O
these O
conditions O
but O
there O
are O
still O
gaps O
, O
and O
an O
innovative O
and O
efficient O
therapy O
is O
needed O

296 O
 O
Purpose O
of O
review O
 O

0 O

treating O

Finally O
, O
strategies O
to O
address O
these O
challenges O
through O
the O
development O
of O
improved O
evidence-based O
epigenetic O
therapeutics O
and O
through O
combining O
pharmacological O
and O
behavioural O
approaches O
are O
presented O

2 O

Collectively O
, O
these O
studies O
provide O
evidence O
that O
phenotypes O
can O
be O
inherited O
in O
a O
DNA B-Chemical
-independent O
manner O
; O
the O
extent O
to O
which O
this O
process O
contributes O
to O
disease B-Disease
development O
, O
as O
well O
as O
the O
cellular O
and O
molecular O
regulation O
of O
this O
process O
, O
remain O
largely O
undefined O

More O
recently O
, O
disruptive O
technologies O
using O
innovative O
biochemistry O
came O
into O
play O

Advances O
in O
understanding O
of O
epigenomic O
regulation O
of O
adipogenesis O
have O
revealed O
critical O
roles O
of O
histone B-Chemical
methylation/demethylation I-Chemical
, O
histone B-Chemical
acetylation/deacetylation I-Chemical
, O
chromatin B-Chemical
remodeling I-Chemical
, O
DNA B-Chemical
methylation I-Chemical
, O
and O
microRNAs B-Gene
in O
adipocyte B-Species
differentiation O

The O
present O
work O
highlights O
substantial O
scopes O
and O
relevant O
discoveries O
related O
to O
the O
development O
of O
the O
term O
from O
its O
first O
notions O

These O
contributions O
were O
subdivided O
into O
3 O
categories O
 O
( O
a O
) O
quality O
control O
( O
QC O
) O
methods O
for O
DNA B-Gene
methylation I-Gene
data O
; O
( O
b O
) O
heritability O
estimates O
pretreatment O
and O
posttreatment O
with O
fenofibrate B-Chemical
; O
and O
( O
c O
) O
impact O
of O
drug O
response O
pretreatment O
and O

Some O
IEIs O
have O
no O
identified O
mutation(s) O
, O
while O
others O
with O
identical O
mutations O
can O
display O
heterogeneous O
presentations O


Silencing O
of O
the O
genes B-Gene
by O
hypermethylation B-Chemical
or O
induction O
of O
oncogenes B-Gene
by O
promoter O
hypomethylation B-Chemical
is O
a O
frequent O
mechanism O
in O
head B-Disease
and I-Disease
neck I-Disease
cancer I-Disease
and O
achieves O
increasing O
diagnostic O
and O
therapeutic O
importance O


1080 O
Genomic O
datasets O
are O
often O
interpreted O
in O
the O
context O
of O
large-scale O
reference O
databases O

Furthermore O
, O
we O
will O
assess O
whether O
DNA B-Gene
methylation I-Gene
is O
a O
plausible O
biomarker O
and O
therapeutic O
target O
for O
the O
treatment O
and O
management O
of O
T2DM B-Disease

It O
has O
also O
not O
been O
shown O
whether O
this O
epigenetic O
clock O
is O
unique O
to O
humans B-Species
or O
conserved O
in O
the O
more O
experimentally O
tractable O
mouse B-Species

Although O
further O
experimental O
research O
is O
needed O
in O
order O
to O
conclusively O
compare O
and O
contrast O
PRS B-Gene
and O
non-PRS O
activities O
regarding O
learning O
gain O
, O
we O
propose O
the O
usage O
of O
the O
Sandwich B-Chemical
Model I-Chemical
with O
a O
variety O
of O
in-class O
learning O
activities O
, O
both O
PRS B-Gene
and O
non-PRS-based O

256 O
Epigenetics O
is O
emerging O
as O
an O
important O
field O
in O
cancer B-Disease
epidemiology O
that O
promises O
to O
provide O
insights O
into O
gene B-Gene
regulation O
and O
facilitate O
cancer B-Disease
control O
throughout O
the O
cancer B-Disease
care O
continuum O

, O
M&M O
and O
methylCRF O
) O
, O
the O
combination O
of O
MeDIP-seq O
and O
MRE-seq O
produces O
genome-wide O
CpG O
methylation O
measurement O
at O
high O
coverage O
and O
high O
resolution O
, O
and O
robust O
predictions O
of O
differentially O
methylated O
regions O

383 O
Combinatorial O
patterns O
of O
epigenetic O
features O
reflect O
transcriptional O
states O
and O
functions O
of O
genomic O
regions O

Meanwhile O
, O
the O
discovery O
of O
new O
epigenetic O
marks O
continues O
, O
and O
there O
are O
many O
useful O
methods O
for O
epigenome O
analysis O
applicable O
to O
primary O
tumor B-Disease
samples O
, O
in O
addition O
to O
cancer B-Disease
cell I-Disease
lines O

Promising O
results O
are O
emerging O
from O
studies O
performed O
in O
peripheral O
blood O
DNA B-Gene
that O
could O
provide O
early O
biomarkers O
of O
the O
pathology B-Disease

Furthermore O
, O
we O
found O
a O
significant O
change O
in O
the O
four O
candidate O
genes O
' O
expression O
levels O
following O
UVC B-Chemical
treatment O
( O
TOP2B B-Gene
, O
RNF13 B-Gene
, O
PKNOX1 B-Gene
and O
CREB5 B-Gene
) O
and O
yet O
no O
changes O
were O
recorded O
in O
hypoxic O
conditions O

Recently O
, O
a O
growing O
number O
of O
epigenetic O
clocks O
have O
been O
developed O
in O
non-model O
animals O
and O
we O
here O
review O
these O
studies O

2014;180(2)127-128) O
, O
the O
research O
area O
of O
"-omics" O
includes O
genomics B-Gene
, O
proteomics B-Gene
, O
metabolomics B-Gene
, O
and O
nascent O
fields O
of O
scientific O
inquiry O
such O
as O
epigenomics B-Gene
and O
exposomics B-Gene

Conclusion O
and O
perspectives O
 O
Epigenetic O
mechanisms O
are O
emerging O
as O
key O
players O
in O
regulating O
transcriptional O
networks O
associated O
with O
key O
processes O
and O
functions O
of O
the O
cyclical O
endometrium B-Disease

Furthermore O
, O
critical O
research O
challenges O
are O
defined O
and O
the O
way O
forward O
is O
proposed O

Potential O
results O
include O
global O
methyl B-Chemical
cytosine I-Chemical
content O
, O
degree O
of O
methylation O
at O
specific O
loci O
, O
or O
genome-wide O
methylation O
maps O

We O
pay O
special O
attention O
to O
the O
risk O
of O
social O
discrimination O
and O
stigmatization O
as O
a O
consequence O
of O
inferring O
information O
related O
to O
lifestyle O
and O
environmental O
exposures O
potentially O
contained O
in O
epigenetic O
data O

These O
processes O
accumulate O
over O
the O
lifespan O

The O
integration O
and O
interpretation O
of O
the O
different O
datasets O
pose O
a O
critical O
challenge O
towards O
the O
holistic O
understanding O
of O
the O
complex O
biological O
processes O
that O
are O
involved O
in O
early O
development O

nih O

Evaluation O
of O
non-CpG O
site O
methylation O
has O
only O
been O
examined O
in O
a O
few O
studies O
, O
with O
about O
~0 O

These O
observations O
place O
chromatin B-Chemical
dysfunction O
at O
the O
top O
of O
the O
molecular O
pathways O
hierarchy O
that O
ushers O
in O
a O
sizeable O
proportion O
of O
NDDs B-Disease
and O
that O
manifest O
themselves O
through O
synaptic O
dysfunction O
and O
recurrent O
systemic O
clinical O
manifestation O

494 O
In O
this O
interview O
, O
Oskar B-Gene
Karlsson I-Gene
speaks O
with O
Storm B-Gene
Johnson I-Gene
, O
commissioning O
editor O
for O
Epigenomics O
, O
on O
his O
work O
to O
date O
in O
the O
field O
of O
toxicological B-Chemical
origins O
of O
disease B-Disease
and O
gene-environment O
interactions O

1305 O
Imprinting O
disorders O
are O
associated O
with O
mutations O
and O
epimutations O
affecting O
imprinted O
genes O
, O
that O
is O
those O
whose O
expression O
is O
restricted O
by O
parent O
of O
origin O

397 O
This O
article O
analyses O
attempts O
to O
enact O
complexity O
in O
postgenomic O
experimentations O
using O
the O
case O
of O
epigenetic O
research O
on O
biomarkers O
of O
psychosocial B-Disease
stress I-Disease

195 O
alterations O
have O
been O
widely O
studied O
as O
mediators O
of O
environmentally O
induced O

Despite O
intense O
research O
in O
this O
field O
, O
the O
molecular O
processes O
underlying O
the O
pathology O
of O
NAFLD B-Disease
remain O
poorly O
understood O

subclone O

Recent O
findings O
showed O
that O
drug O
response O
could O
be O
largely O
influenced O
by O
the O
presence O
of O
aberrant O
epigenetic O
marks O
of O
the O
whole O
genome O

Epigenetics O
has O
a O
broad O
impact O
on O
development O
, O
by O
controlling O
pluripotent O
and O
differentiated O
states O

1364 O
The O
recent O
development O
of O
next-generation O
sequencing O
(NGS) O
technologies O
has O
contributed O
to O
research O
into O
various O
biological O
processes O

Second O
, O
babies O
in O
utero O
during O
the O
Famine O
were O
reported O
to O
have O
accounted O
for O
an O
increase O
in O
first O
admissions O
when O
they O
reached O
the O
high-risk O
age O
for O
mental B-Disease
illness I-Disease
( O
1860-75 O
) O

These O
studies O
not O
only O
confirm O
the O
importance O
of O
epigenetic O
marks O
in O
developmental O
processes O
, O
but O
also O
highlight O
the O
significant O
diversity O
in O
epigenetic O
regulatory O
mechanisms O
across O
taxa O

1181 O
Embryonic O
heart O
development O
is O
an O
intricate O
process O
that O
mainly O
involves O
morphogens O
, O
, O
and O

We O
highlight O
the O
challenges O
and O
opportunities O
in O
this O
approach O

ac O

Furthermore O
, O
we O
summarize O
other O
potential O
sources O
of O
epigenetic O
variability O
, O
such O
as O
epigenetic O
drift O
and O
the O
epigenetic O
clock O
, O
as O
well O
as O
the O
current O
ongoing O
direction O
of O
the O
field O

82 O
Ã O
10-7 O
) O

When O
integrated O
with O
electronic O
health O
records O
, O
survey O
, O
census O
, O
and/or O
epidemiologic O
data O
, O
multiomics O
are O
anticipated O
to O
facilitate O
data-driven O
precision O
oral O
health O
, O
or O
the O
delivery O
of O
the O
right O
oral O
health O
intervention O
to O
the O
right O
individuals/populations O
at O
the O
right O
time O

In O
conclusion O
, O
the O
proposed O
MRF O
is O
a O
useful O
tool O
to O
identify O
novel O
mQTLs O
, O
especially O
for O
studies O
with O
limited O
sample O
sizes O

This O
contemporary O
neoliberal O
" O
regime O
of O
truth O
," O
to O
use O
a O
term O
from O
Michel O
Foucault O
, O
greatly O
influences O
the O
ways O
in O
which O
knowledge O
is O
being O
interpreted O
and O
implemented O

Recent O
findings O
 O
Epigenetic O
events O
are O
gene B-Gene
regulatory O
mechanisms O
that O
contribute O
to O
inflammation O
across O
inflammatory O
diseases B-Disease
and O
resemble O
shared O
mechanisms O
that O
may O
be O
used O
as O
disease B-Disease
biomarkers O
and O
treatment O
targets O

Evidence O
indicates O
that O
recurrent O
stressors O
, O
episodes O
of O
depression B-Disease
, O
and O
bouts O
of O
substance B-Chemical
abuse I-Chemical
can O
each O
show O
sensitization O
( O
increased O
reactivity O
upon O
repetition O
) O
and O
cross-sensitization O
to O
the O
others O
, O
and O
drive O
illness O
progression O
and O
treatment O
resistance O

Annual O
citations O
increased O
to O
a O
plateau O
in O
2000 O
and O
show O
a O
downward O
trend O
since O
2008 O

Since O
gametes O
and O
zygotes O
are O
in O
the O
process O
of O
resetting O
the O
genome O
in O
order O
to O
create O
embryonic O
stem O
cells O
that O
will O
each O
differentiate O
to O
create O
one O
of O
many O
specific O
tissue O
types O
, O
this O
phase O
of O
life O
is O
now O
viewed O
as O
a O
window O
of O
susceptibility O
to O
epigenetic O

In O
this O
regard O
, O
there O
is O
extensive O
epidemiologic O
and O
experimental O
data O
showing O
that O
early O
sub-optimal O
nutrition O
can O
have O
health O
consequences O
several O
decades O
later O


A O
more O
complete O
understanding O
of O
how O
and O
when O
epigenetic O
inheritance O
occurs O
will O
advance O
our O
understanding O
of O
numerous O
different O
aspects O
of O
biology O
ranging O
from O
how O
organisms O
cope O
with O
changing O
environments O
to O
human B-Disease
pathologies I-Disease
influenced O
by O
a O
parent O
's O
environment O

Curiously O
, O
only O
a O
fraction O
of O
rRNA B-Gene
genes I-Gene
is O
used O
even O
in O
the O
fast-growing O
cells O
, O
raising O
a O
question O
why O
unused O
copies O
of O
these O
genes B-Gene
have O
not O
been O
lost O
during O
evolution O

Further O
analysis O
of O
tumoral O
epigenetic O
alterations O
in O
hematopoietic O
CDRs B-Gene
points O
to O
sets O
of O
genes O
that O
are O
tightly O
regulated O
in O
leukemic B-Disease
transformations O
and O
commonly O
mutated O
in O
other O
tumors O

Since O
then O
, O
Aydan O
has O
been O
awarded O
Development O
's O
Outstanding O
Paper O
Prize O
for O
2022 O
and O
, O
most O
recently O
, O
a O
European O
Research O
Council O
Starting O
Grant O
Award O
for O
2023 O


CVDs O
such O
as O
congenital B-Disease
heart I-Disease
disease I-Disease
, O
cardiomyopathy B-Disease
, O
heart B-Disease
failure I-Disease
, O
cardiac B-Disease
fibrosis I-Disease
, O
hypertension B-Disease
, O
and O
atherosclerosis B-Disease
are O
now O
being O
viewed O
as O
much O
more O
complex O
and O
dynamic O
disorders O

Recent O
advances O
in O
genomic O
research O
provide O
evidence O
that O
focussing O
these O
efforts O
on O
individual O
variations O
in O
abilities O
to O
metabolize O
nutrients O
( O
nutrigenetics O
) O
and O
exploring O
the O
role O
of O
dietary O
compounds O
on O
gene B-Gene
expression I-Gene
( O
nutrigenomics O
and O
nutri-epigenomics O
) O
can O
lead O
to O

In O
mammals B-Species
, O
this O
chain O
of O
events O
occurs O
in O
neurons O
following O
peripheral O
axonal O
injury B-Disease
, O
however O
it O
fails O
upon O
axonal O
injury B-Disease
in O
the O
central O
nervous O
system O
, O
such O
as O
in O
the O
spinal O
cord O
and O
the O
brain O

Novel O
epigenetic-targeted O
drugs O
have O
shown O
good O
tolerance O
and O
therapeutic O
effects O
in O
the O
treatment O
of O
peripheral B-Disease
T-cell I-Disease
lymphoma I-Disease
as O
monotherapy O
or O
combination O
therapy O

947 O
Age-related B-Disease
macular I-Disease
degeneration I-Disease
( O
AMD B-Disease
) O
is O
an O
ocular O
disease O
and O
the O
main O
reason O
for O
sight O
loss O
in O
the O
elderly O
in O
the O
developed O
countries O

This O
kit O
could O
also O
be O
identified O
with O
the O
Fragment B-Chemical
CpG-plot O
, O
which O
summarizes O
the O
CpG B-Gene
content O
of O
the O
captured O
fragments O
, O
implying O
that O
the O
latter O
can O
be O
used O
as O
a O
tool O
to O
monitor O
data O
quality O

SigSeeker O
has O
been O
validated O
using O
established O
benchmarks O
for O
transcription O
factor O
binding O
and O
histone B-Chemical
modification I-Chemical
ChIP-Seq O
data O

693 O
 O
Background O
 O
The O
human B-Species
endometrium O
is O
a O
highly O
dynamic O
tissue O
whose O
function O
is O
mainly O
regulated O
by O
the O
ovarian O
steroid O
hormones O
estradiol B-Chemical
and O
progesterone B-Chemical

molecular O

It O
accurately O
recovers O
cell-type-specific O
latent O
methylation B-Chemical
components O
and O
their O
proportions O

premature O
adrenarche B-Disease
, O
atypical B-Disease
puberty I-Disease
, O
metabolic B-Disease
syndrome I-Disease
) O

Recent O
epigenome-wide O
association O
studies O
suggest O
a O
key O
role O
for O
epigenetic O
mechanisms O
in O
its O
development O
and O
course O

In O
the O
review O
, O
recent O
studies O
demonstrating O
the O
role O
of O
genetic O
and O
epigenetic O
factors O
in O
the O
etiology O
and O
pathogenesis O
of O
AD B-Disease
are O
discussed O

In O
addition O
to O
aging O
, O
smoking O
and O
diabetes B-Disease
, O
an O
increasing O
number O
of O
studies O
have O
found O
that O
genetic O
and O
epigenetic O
factors O
play O
an O
important O
role O
in O
ISR B-Disease

7 O
Ã O
10-18 O
) O

In O
particular O
, O
we O
employed O
an O
optimized O
method O
of O
using O
the O
inhibitor O
SCR7 B-Chemical
to O
markedly O
enhance O
the O
insertion O
efficiency O
induced O
by O
the O
long O
methylated O
repair O
template O
, O
contributing O
to O
the O
induction O
of O
stable O
methylation O
alterations O
through O
epigenetic O
recombination O
after O

GSE O
studies O
would O
also O
benefit O
from O
consideration O
of O
the O
theory O
of O
competence O
( O
concept O
of O
virtue O
) O
based O
on O
the O
perspective O
of O
healthy B-Disease
ego-development I-Disease

Evidences O
indicated O
that O
the O
main O
culprit O
behind O
COVID-19 B-Disease
deaths O
is O
the O
cytokine B-Disease
storm I-Disease
, O
which O
is O
illustrated O
by O
an O
uncontrolled O
over-production O
of O
soluble O
markers O
of O
inflammation O

DNA B-Gene
methylation I-Gene
changes O
at O
a O
discrete O
set O
of O
sites O
in O
the O
human B-Species
genome I-Species
are O
predictive O
of O
chronological O
and O
biological O
age O

300Background O
DNA B-Gene
methylation I-Gene
( O
DNAm B-Gene
) O
performs O
excellently O
in O
the O
discrimination O
of O
current O
and O
former O
smokers O
from O
never O
smokers O
, O
where O
AUCs O
> O
0 O

1011 O
Diabetic B-Disease
cardiomyopathy I-Disease
( O
DCM B-Disease
) O
is O
a O
critical O
complication O
that O
poses O
a O
significant O
threat O
to O
the O
health O
of O
patients O
with O
diabetes B-Disease

An O
increasing O
number O
of O
studies O
explored O
the O
role O
of O
different O
classes O
of O
toxicants O
in O
the O
occurrence O
and O
severity O
of O
thyroid B-Disease
diseases I-Disease
, O
but O
large O
epidemiological O
studies O
are O
limited O
and O
only O
a O
few O
animal B-Species
or O
in O
vitro O
studies O
have O
attempted O
to O
identify O
the O

Not O
surprisingly O
, O
tumor-associated O
aberrations O
in O
the O
miRNA B-Gene
or O
epigenetic O
machineries O
are O
widely O
distributed O
in O
human B-Species
cancer B-Disease
, O
and O
we O
are O
just O
starting O
to O
understand O
their O
relevance O
in O
diagnosis O
, O
prognosis O
or O
therapy O

Furthermore O
, O
if O
the O
objective O
is O
the O
detection O
of O
DNA B-Gene
methylation I-Gene
in O
subclonal O
tumor B-Disease
cell I-Disease
populations I-Disease
or O
in O
circulating O
tumor B-Disease
DNA I-Disease
or O
in O
any O
case O
of O
mosaicism O
, O
the O
importance O
of O
accuracy O
becomes O
critical O

Here O
, O
we O
asked O
whether O
one O
form O
of O
epigenetic O
potential O
( O
i O

97 O
( O
0 O

Anxiety B-Disease
disorders I-Disease
are O
among O
the O
most O
common O
mental O
disorders O
with O
a O
lifetime O
prevalence O
of O
over O
20% O

We O
show O
that O
this O
leads O
to O
a O
marginal O
but O
statistically O
significant O
improvement O
of O
cell-count O
estimates O
in O
whole O
blood B-Chemical
as O
well O
as O
in O
mixtures O
involving O
epithelial O
cell-types O

EpiCompare O
will O
then O
identify O
regions O
with O
specified O
epigenomic O
features O
, O
and O
provide O
a O
quality O
assessment O
of O
the O
predictions O

These O
erroneous O
beliefs O
can O
be O
overcome O
by O
using O
precise O
definitions O
, O
by O
raising O
the O
awareness O
about O
methodological O
pitfalls O
and O
by O
returning O
to O
the O
basic O
facts O
in O
molecular O
and O
cellular O
biology O

Our O
model O
, O
inspired O
from O
evolutionary O
models O
, O
is O
able O
to O
account O
for O
acceleration/deceleration O
in O
epigenetic O
changes O
by O
fitting O
an O
individual O
's O
model O
age O
, O
the O
epigenetic O
age O
, O
which O
is O
related O
to O
chronological O
age O
in O
a O
non-linear O
fashion O

This O
problem O
was O
reproduced O
multiple O
times O
with O
different O
WGBS O
libraries O
and O
likely O
to O
be O
associated O
with O
the O
low O
sequence O
diversity O
of O
bisulfite-converted B-Chemical
DNA I-Chemical

Approved O
and O
investigational O
drugs O
in O
the O
DrugBank B-Chemical
database O
included O
122 O
compounds O
that O
interacted O
with O
68 O
unique O
epigenetic O
enzymes O

889 O
With O
rapid O
technological O
advancements O
emerging O
epigenetic O
studies O
of O
complex O
traits O
have O
shifted O
from O
candidate O
gene B-Gene
analyses O
towards O
epigenome-wide O
association O
studies O
(EWAS) O

These O
provide O
a O
reasonable O
molecular O
mechanism O
for O
epigenetic O
modifying O
drugs B-Chemical
in O
the O
treatment O
of O
PTCL B-Disease

This O
feature O
emphasizes O
the O
importance O
to O
uncover O
the O
underlying O
causes O
of O
its O
malfunctions O
, O
necessitating O
an O
in-depth O
analysis O
in O
both O
pathological O
and O
physiological O
conditions O
to O
better O
understand O
the O
immune B-Disease
system I-Disease
and O
immune B-Disease
disorders I-Disease

Here O
we O
will O
discuss O
the O
relationship O
between O
canonical O
and O
non-canonical O
epigenetic O
mechanisms O
that O
govern O
gene B-Gene
expression O
and O
offer O
our O
perspective O
on O
whether O
(or O
not O
) O
epitranscriptomic O
modifications O
can O
be O
classified O
as O
epigenetic O
mechanisms O

This O
study O
will O
facilitate O
further O
epigenetic O
research O
in O
Tetrahymena B-Species

The O
enzymes O
within O
this O
family O
have O
multiple O
targets O
, O
including O
DNA B-Gene
and O
chromatin O
, O
and O
thus O
may O
be O
capable O
of O
modulating O
gene O
transcription O
in O
response O
to O
intracellular O
lipid B-Chemical
accumulation O
through O
alteration O
of O
the O
epigenome O

A O
search O
for O
publications O
on O
the O
Web O
of O
Science O
database O
in O
the O
field O
of O
atherosclerosis B-Disease
related O
to O
epigenetics O
was O
conducted O
from O
the O
earliest O
mention O
to O
31 O
December O
2020 O

We O
also O
assessed O
their O
level O
of O
concern O
regarding O
four O
emerging O
non-medical O
applications O
of O
epigenetic O
testing-i O

We O
also O
consider O
the O
nuanced O
relationships O
between O
the O
genome B-Gene
, O
the O
epigenome B-Gene
, O
and O
gene B-Gene
expression I-Gene

5 O
, O
13 O

We O
also O
discuss O
key O
mechanistic O
studies O
that O
investigate O
the O
mode O
of O
action O
of O
chromatin O
regulators O
, O
transcription O
factors O
and O
non-coding O
RNAs O
during O
preimplantation O
development O

This O
chapter O
briefly O
highlights O
different O
epigenetics O
databases O
( O
MethDB O
, O
REBASE O
, O
Pubmeth O
, O
MethPrimerDB O
, O
Histone O
Database O
, O
ChromDB O
, O
MeInfoText O
database O
, O
EpimiR O
, O
Methylome O
DB O
, O
and O
dbHiMo O
) O
, O
and O
tools O
( O
compEpiTools O
, O
CpGProD O
, O
MethBlAST O

The O
most O
different O
CpG O
site O
between O
control O
and O
POD B-Disease
was O
found O
at O
cg16526133 O
near O
the O
ADAMTS9 B-Gene
gene O
from O
the O
brain B-Species
tissue O
( O
p O
= O
8 O

Here O
, O
we O
provide O
a O
critical O
overview O
of O
different O
analytical O
methods O
that O
are O
suitable O
for O
biomarker O
validation O
, O
including O
general O
study O
design O
considerations O
, O
which O
might O
help O
to O
streamline O
epigenetic B-Chemical
marker O
development O

329Significance O
Methylation O
of O
cytosine B-Chemical
in O
DNA B-Chemical
is O
linked O
with O
gene B-Gene
regulation O
, O
and O
this O
has O
profound O
implications O
in O
development O
, O
normal O
biology O
, O
and O
disease B-Disease
conditions O
in O
many O
eukaryotic B-Species
organisms O

Drawing O
on O
ethnographic O
fieldwork O
conducted O
in O
Australia O
with O
researchers O
and O
clinicians O
in O
Indigenous O
health O
, O
we O
explore O
how O
some O
construct O
epigenetics B-Chemical
as O
useless O
knowledge O
and O
a O
distraction O
from O
implementing O
anti-colonial O
change O
, O
rather O
than O
a O
tool O
with O
which O
to O
enact O
change O

Diagnosis O
can O
be O
upheld O
by O
observing O
the O
cause O
of O
disease B-Disease
under O
the O
microscope O
or O
detecting O
the O
presence O
of O
nucleic B-Chemical
acid I-Chemical
and O
proteins B-Chemical
of O
the O
pathogens O

150 O
Asthma B-Disease
and O
allergic B-Disease
diseases I-Disease
are O
among O
the O
most O
prevalent O
chronic O
noncommunicable O
diseases O
of O
childhood O
, O
but O
the O
underlying O
pathogenetic O
mechanisms O
are O
poorly O
understood O

Therefore O
, O
application O
of O
diagnostic O
assays O
to O
detect O
epigenetic O
alterations O
will O
provide O
new O
insight O
into O
the O
characterization O
and O
treatment O
of O
neurodevelopmental B-Disease
disorders I-Disease

We O
also O
review O
epigenome-wide O
association O
studies O
that O
have O
been O
performed O
in O
various O
tissues O
examining O
relationships O
with O
osteoporosis B-Disease
and O
fracture O

616 O
Although O
epigenetic O
modifications O
have O
been O
intensely O
investigated O
over O
the O
last O
decade O
due O
to O
their O
role O
in O
crop O
adaptation O
to O
rapid O
climate O
change O
, O
it O
is O
unclear O
which O
epigenetic O
changes O
are O
heritable O
and O
therefore O
transmitted O
to O
their O
progeny O

These O
drug-induced B-Chemical
epigenetic O
adaptations O
mediate O
enduring O
changes O
in O
brain O
function O
which O
contribute O
to O
life-long O
, O
drug-related O
behavioral O
abnormalities O
that O
define O
addiction B-Disease

Epigenetic O
mechanisms O
such O
as O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical
influence O
gene O
expression O
by O
modulating O
the O
packaging O
of O
DNA B-Chemical
in O
the O
nucleus O

Epigenetic O
changes O
and O
metabolic O
rewiring O
are O
intertwined O
in O
cancer B-Disease

A O
significant O
positive O
association O
emerged O
between O
SEMs O
measured O
in O
peritumoral O
tissue O
and O
hepatitis B-Disease
B I-Disease
and/or O
C B-Disease
virus I-Disease
infection I-Disease
status O

Here O
, O
we O
are O
reviewing O
the O
works O
have O
been O
undertaken O
to O
utilize O
a O
portable O
sequencer O
, O
MinION B-Gene
, O
in O
various O
aspects O
of O
infectious B-Disease
disease I-Disease
management O

Many O
of O
these O
studies O
included O
multiple O
search O
terms O

We O
suggest O
three O
domains O
in O
which O
new O
understandings O
of O
epigenetics B-Gene
could O
inform O
innovations O
in O
health O
promotion O
research O
 O
( O
1 O
) O
increase O
the O
motivational O
potency O
of O
health O
communications O
( O

Results O
 O
Health-related O
autonomous O
motivation O
was O
weakly O
but O
positively O
associated O
with O
TNF B-Gene
methylation O
( O
Î² O
= O

A O
biologic O
definition O
of O
" O
healthy O
" O
exercise O
that O
links O
the O
metabolic O
transducers O
of O
physical O
activity O
with O
parallel O
processes O
that O
regulate O
growth O
will O
transform O
health O
policy O
and O
guidelines O
that O
promote O
optimal O
use O
of O
physical O
activity O

This O
article O
presents O
an O
overview O
of O
the O
key O
clinical O
features O
of O
neuroblastoma B-Disease
and O
current O
therapeutic O
approaches O

The O
techniques O
and O
general O
underlying O
principles O
described O
here O
should O
be O
applicable O
to O
other O
mammals B-Species
of O
interest O

86 O
 O
Purpose O
of O
review O
 O
The O
interplay O
between O
lipids B-Chemical
and O
epigenetic O
mechanisms O
has O
recently O
gained O
increased O
interest O
because O
of O
its O
relevance O
for O
common O
diseases B-Disease
and O
most O
notably O
atherosclerosis B-Disease

In O
vivo O
partial O
reprogramming O
holds O
great O
promise O
as O
a O
possible O
therapy O
, O
but O
several O
limitations O
remain O

The O
next O
steps O
include O
increasing O
the O
specificity O
for O
target O
genes B-Gene
, O
the O
development O
of O
biomarkers O
for O
dose O
and O
response O
studies O
, O
and O
establishing O
a O
strategy O
to O
select O
drugs B-Chemical
for O
combination O
therapy O

313 O
 O
X-chromosome B-Disease
inactivation I-Disease
( O
XCI B-Disease
) O
is O
an O
epigenetic O
phenomenon O
that O
equalizes O
the O
number O
of O
X-linked B-Gene
gene I-Gene
products I-Gene
between O
male O
and O
female O
eutherian B-Species
mammals I-Species
by O
inactivating O
one O
of O
the O
two O
X B-Gene
chromosomes I-Gene

This O
provides O
a O
rationale O
for O
the O
conservation O
of O
epigenotypes O
of O
interest O
, O
thus O
contributing O
to O
agrobiodiversity O
preservation O
through O
conservation O
and O
( O
epi O
) O
genetic O
monitoring O

In O
this O
review O
, O
we O
provide O
essential O
knowledge O
on O
the O
aberrant O
epigenetic O
modification O
involved O
in O
the O
pathogenesis O
of O
CHD B-Disease

In O
particular O
, O
epigenetic O
strategies O
might O
open O
interesting O
new O
perspectives O
in O
combination O
with O
conventional O
ones O

Recent O
findings O
on O
the O
subject O
matter O
have O
provided O
an O
insight O
into O
the O
mechanism O
of O
epigenetic O
modifications O
, O
thus O
this O
review O
aims O
to O
present O
an O
update O
on O
the O
latest O
studies O

905 O
Circadian O
rhythms O
play O
a O
central O
role O
in O
physiological O
and O
metabolic O
processes O

edu O

During O
the O
procedure O
, O
DNA B-Gene
binding I-Gene
proteins O
are O
covalently O
cross-linked O
to O
DNA B-Gene
, O
and O
the O
isolated O
chromatin O
is O
broken O
into O
pieces O
of O
300-500 O
bps O
in O
length O
on O
average O

Recently O
, O
epigenetics O
has O
become O
one O
of O
the O
fastest-growing O
areas O
of O
science O
and O
has O
now O
become O
a O
central O
issue O
in O
biologic O
studies O
of O
development O
and O
disease B-Disease
pathogenesis I-Disease

The O
structure O
of O
chromatin O
is O
subjected O
to O
a O
dynamic O
regulation O
through O
multiple O
epigenetic O
mechanisms O
, O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
posttranslational I-Chemical
modifications I-Chemical
( O
PTMs O
) O
, O
chromatin O
remodeling O
and O
noncoding O
RNAs O


Though O
very O
powerful O
, O
these O
methods O
are O
not O
without O
limitations O

To O
address O
these O
issues O
we O
performed O
comprehensive O
methylation O
analysis O
of O
imprinted B-Gene
genes I-Gene
in O
a O
research O
cohort O
of O
285 O
patients O
with O
clinical O
features O
of O
imprinting B-Disease
disorders I-Disease
, O
with O
or O
without O
a O
positive O
molecular O
diagnosis O

Yet O
the O
function O
and O
implication O
of O
negative O
definition O
for O
scientific O
discourse O
has O
thus O
far O
received O
scant O
attention O

1292 O
Fetal B-Chemical
hemoglobin I-Chemical
( O
HbF B-Chemical
) O
inhibits O
the O
root O
cause O
of O
sickle B-Disease
pathophysiology O
, O
sickle B-Disease
hemoglobin I-Disease
polymerization O

, O
schizophrenia B-Disease
, O
Williams B-Disease
syndrome I-Disease
, O
and O
autism B-Disease
spectrum I-Disease
disorders I-Disease
(comparison O
2 O
) O

The O
ability O
to O
epigenetically O
modify O
and O
regulate O
genomes O
has O
contributed O
greatly O
to O
the O
diversity O
of O
eukaryotes B-Species
observed O
today O

Therefore O
, O
this O
study O
explored O
whether O
differences O
in O
DNA B-Gene
methylation I-Gene
at O
age O
10 O
were O
associated O
with O
monozygotic B-Species
twin I-Species
discordance O
for O
psychotic B-Disease
symptoms I-Disease
at O
age O
12 O

We O
propose O
that O
advanced O
ancient O
DNA O
techniques O
should O
be O
applied O
to O
a O
wide O
range O
of O
past O
animals O
, O
so O
novel O
dynamics O
in O
animal O
evolution O
and O
adaption O
can O
be O
revealed O

We O
also O
analyze O
the O
methodologies O
that O
have O
been O
pivotal O
in O
uncovering O
these O
epigenetic O
regulations O
, O
i O

01 O
) O
relative O
to O
the O
control O
condition O
at O
the O
12-month O
follow-up O

Understanding O
the O
functions O
of O
chromatin O
in O
the O
context O
of O
the O
CNS B-Disease
will O
aid O
in O
the O
future O
development O
of O
pharmacological O
therapeutics O
aimed O
at O
alleviating O
devastating O
neurological B-Disease
disorders I-Disease

We O
found O
four O
genomic O
regions O
in O
blood O
differentially O
methylated O
in O
CLO B-Disease
compared O
to O
CLP B-Disease
, O
17 O
in O
CPO B-Disease
compared O
to O
CLP B-Disease
and O
294 O
in O
CPO B-Disease
compared O
to O
CLO B-Disease

454 O
Selection O
of O
agricultural O
animals O
for O
improved O
performance O
based O
on O
genetics O
has O
seen O
significant O
progress O
made O
over O
the O
past O
few O
decades O

The O
short-term O
response O
of O
cells O
to O
oxidative B-Chemical
stress I-Chemical
is O
well O
understood O
, O
but O
the O
mechanisms O
behind O
long-term O
consequences O
require O
further O
clarification O

Out O
of O
these O
, O
24 O
studies O
investigating O
12 O
different O
skeletal B-Disease
disorders I-Disease
were O
included O
in O
the O
review O

We O
selected O
CpGs O
reaching O
the O
Bonferroni-corrected O
significance O
level O
( O
2 O
[Formula O
see O
text O
] O
10-7 O
) O
or O
the O
top-ranked O
20 O
CpGs O
with O
the O
lowest O
P O
values O
if O
they O
did O
not O
reach O
this O
significance O
level O
in O
EWAS O
analysis O
associated O
with O
non-stroke B-Disease
CVD I-Disease
, O

373 O
methylation-based O
epigenetic O
signatures O
have O
become O
valuable O
biomarkers O

124 O
 O
The O
genetic O
code O
cannot O
alone O
explain O
the O
diversity O
of O
cellular O
and O
individual O
phenotypes O

This O
review O
summarizes O
the O
current O
evidences O
on O
the O
relationship O
between O
air O
pollution O
exposure O
, O
epigenetic O
alterations O
and O
cardiovascular B-Disease
impact I-Disease
, O
in O
view O
of O
present O
implications O
and O
future O
perspectives O

Besides O
a O
detailed O
protocol O
of O
sample O
preparation O
for O
the O
ChIP O
assay O
from O
primary O
human B-Species
monocyte-derived B-Species
macrophages I-Species
( O
MDM O
) O
[ O
an O
acceptable O
in O
vitro O
model O
for O
primary O
, O
human B-Species
macrophage I-Species
cells I-Species
] O
, O
we O
show O
that O
differences O
between O
various O
types O
of O


Changes O
in O
gene B-Gene
expression I-Gene
were O
evaluated O
using O
qRT-PCR O

Their O
diagnosis O
is O
challenging O
for O
two O
reasons O
 O
firstly O
, O
their O
clinical O
features O
, O
particularly O
prenatal O
and O
postnatal O
growth O
disturbance O
, O
are O
heterogeneous O
and O
partially O
overlapping O
; O
secondly O
, O
their O
underlying O
molecular O
defects O
include O
mutation O
, O
epimutation O
, O
copy O
number O
variation O
, O
and O
chromosomal O

g O

In O
this O
context O
, O
a O
novel O
workflow O
was O
developed O
to O
interrogate O
publicly O
available O
epidemiological O
transcriptomic O
and O
methylomic O
data O
to O
identify O
relevant O
pathway O
level O
changes O
in O
response O
to O
chemical O
exposure O
, O
using O
inorganic B-Chemical
arsenic I-Chemical
as O
a O
case O
study O

Array O
-based O
methods O
, O
such O
as O
the O
popular O
Illumina B-Chemical
GoldenGate I-Chemical
and O
Infinium B-Chemical
platforms O
, O
estimate O
the O
proportion O
of O
DNA B-Chemical
methylated O
at O
single-base O
resolution O
for O
thousands O
of O
CpG B-Gene
sites O
across O
the O
genome O

431 O
Epigenomics O
, O
the O
determination O
of O
epigenetic O
landscapes O
on O
a O
genome-wide O
scale O
, O
has O
progressed O
at O
an O
astounding O
rate O
over O
the O
past O
decade O

978 O
 O
Chromosome O
conformation O
capture O
techniques O
are O
producing O
a O
huge O
amount O
of O
data O
about O
the O
architecture O
of O
our O
genome O


In O
this O
review O
, O
we O
will O
describe O
the O
main O
genetic O
factors O
responsible O
for O
these O
diverse O
clinical O
phenotypes O
in O
neuroblastoma B-Disease
, O
the O
chronology O
of O
their O
discovery O
, O
and O
the O
impact O
on O
patient O
prognosis O

670 O
Tumor-derived O
DNA O
, O
found O
in O
body O
fluids O
( O
liquid O
biopsy O
) O
of O
cancer B-Disease
patients I-Disease
as O
part O
of O
cell-free O
DNA O
( O
cfDNA O
) O
, O
lends O
itself O
for O
noninvasive O
cancer B-Disease
detection I-Disease
and O
monitoring O

Using O
a O
case-study O
format O
, O
we O
present O
examples O
as O
to O
how O
the O
inclusion O
of O
genetic O
, O
environmental O
, O
and O
epigenetic O
data O
can O
augment O
social O
and O
behavioral O
health O
research O
by O
expanding O
the O
parameters O
of O
such O
studies O
, O
adding O
specificity O
to O
phenotypic O
assessments O
, O
and O
providing O
additional O

droit@crchuq O

Combinations O
of O
agents O
targeting O
DNA B-Chemical
methylation I-Chemical
and/or O
other O
epigenetic O
modifications O
may O
be O
a O
promising O
cancer B-Disease
treatment O

Elucidating O
the O
proteins O
that O
interact O
with O
chromatin-associated O
RNA B-Gene
or O
proteins O
is O
key O
to O
understanding O
fundamental O
epigenetic O
regulatory O
pathways O

proteins O

molecular O

Epigenetic O
diseases B-Disease
are O
illustrated O
by O
the O
array O
of O
multi-system O
disorders O
and O
neoplasias O
and O
investigations O
of O
these O
diseases O
have O
an O
impact O
on O
biomedical O
research O
and O
provide O
interesting O
models O
for O
functions O
and O
mechanisms O
of O
epigenetic O
gene B-Gene
control O

Innovative O
epigenetic O
therapy O
could O
be O
targeted O
to O
treat O
the O
disease B-Disease
in O
a O
precision O
epigenetics O
approach O

Exposure O
to O
opioids B-Chemical
causes O
long-term O
changes O
to O
brain O
regions O
involved O
in O
reward O
processing O
and O
motivation O
, O
leading O
vulnerable O
individuals O
to O
engage O
in O
pathological O
drug O
seeking O
and O
drug O
taking O
that O
can O
remain O
a O
lifelong O
struggle O

In O
this O
review O
, O
we O
cover O
the O
basics O
of O
DNA B-Gene
methylation I-Gene
establishment O
and O
control O
, O
and O
the O
methods O
used O
to O
examine O
it O

266 O
This O
chapter O
describes O
resources O
and O
technologies O
generated O
by O
the O
that O
may O
be O
useful O
to O
epigenomics O
researchers O
investigating O
a O
variety O
of O
diseases O
including O
cancer B-Disease

We O
found O
that O
some O
computed O
scores O
, O
unlike O
all O
6 O
experimental O
features O
, O
significantly O
contribute O
to O
the O
predictions O
of O
both O
models O

Conclusions O
and O
relevance O
 O
The O
studies O
highlighted O
in O
this O
special O
issue O
demonstrate O
important O
scientific O
progress O
in O
the O
complex O
integration O
of O
social O
determinants O
of O
health O
and O
health O
disparities O
with O
biological O
pathways O
and O
health O
outcomes O
to O
improve O
understanding O
of O
the O
mechanisms O
underlying O
health O
disparities O
among O

For O
example O
, O
miRNAs B-Gene
, O
which O
have O
been O
identified O
to O
govern O
many O
genes O
including O
drug B-Chemical
targets O
, O
are O
altered O
in O
disease B-Disease
development O
and O
after O
drug B-Chemical
administration O

, O

However O
finding O
, O
downloading O
and O
using O
the O
publicly O
available O
functional O
annotations O
require O
time O
, O
programming O
skills O
and O
IT O
infrastructure O

The O
use O
of O
epigenetic O
modifying O
drugs B-Chemical
to O
treat O
these O
diseases O
has O
been O
the O
interest O
in O
recent O
years O

MeDeCom O
is O
a O
new O
unsupervised O
tool O
for O
the O
exploratory O
study O
of O
the O
major O
sources O
of O
methylation B-Chemical
variation O
, O
which O
should O
lead O
to O
a O
deeper O
understanding O
and O
better O
biological O
interpretation O

insight O

Recent O
advances O
in O
genomics O
technology O
and O
epigenetics O
now O
offer O
methods O
to O
link O
genetic O
variants O
to O
gene B-Gene
regulatory I-Gene
elements I-Gene
embedded O
within O
non-coding O
regions O
, O
which O
have O
started O
to O
unravel O
the O
molecular O
mechanisms O
underlying O
the O
complex O
(epi)genetics O
of O
asthma B-Disease

Significantly O
altered O
DNA B-Gene
methylation I-Gene
was O
recorded O
for O
alcohol B-Chemical
abusers O
in O
MIR29B2CHG B-Gene

They O
account O
for O
substantial O
morbidity O
and O
mortality O
in O
NF1 B-Disease

Further O
applications O
about O
VAEs O
should O
focus O
on O
fine-grained O
subtypes O
identification O
for O
precision O
medicine O

Here O
, O
I O
summarize O
our O
current O
understanding O
of O
epigenetics B-Chemical
and O
it O
affects O
gene B-Gene
expression O
, O
with O
impacts O
on O
health B-Disease
and O
aging B-Disease

We O
describe O
here O
the O
adaptation O
of O
SILAC B-Chemical
to O
the O
analysis O
of O
histones B-Chemical
, O
in O
both O
standard O
and O
spike-in O
setups O

We O
also O
trained O
a O
prediction O
model O
that O
uses O
the O
average O
methylation O
level O
over O
genomic O
regions O

With O
this O
low O
starting O
material O
protocol O
, O
MBD-seq O
performed O
equally O
well O
, O
or O
better O
, O
than O
the O
protocol O
requiring O
ample O
starting O
material O
( O
> O
1 O
Âµg O
) O

These O
disparities O
are O
thought O
to O
be O
due O
to O
socioeconomic O
status O
, O
culture O
, O
diet O
, O
stress O
, O
the O
environment O
, O
and O
biology O

Despite O
significant O
advancements O
towards O
epigenomic O
profiling O
, O
it O
is O
challenging O
to O
understand O
how O
various O
epigenetic O
modifications O
such O
as O
chromatin O
modifications O
and O
DNA B-Chemical
methylation I-Chemical
regulate O
gene O
expression O

 O

However O
, O
the O
peculiar O
nature O
of O
early O
embryos O
in O
addition O
to O
their O
scarcity O
poses O
numerous O
technological O
challenges O
that O
are O
slowly O
being O
overcome O

We O
conclude O
by O
discussing O
the O
potential O
adaptive O
character O
of O
gbM B-Gene
and O
its O
implications O
for O
an O
updated O
view O
of O
the O
mechanisms O
of O
adaptation O
in O
plants B-Species

The O
magnitude O
of O
rejuvenation O
instigated O
by O
MPTR B-Gene
appears O
substantially O
greater O
than O
that O
achieved O
in O
previous O
transient O
reprogramming O
protocols O

The O
full O
exploitation O
of O
cutting O
edge O
epigenomics O
will O
be O
decisive O
to O
define O
whether O
epigenetics O
will O
contribute O
to O
lower O
the O
burden O
of O
cardiovascular B-Disease
diseases I-Disease

org/ O
packages/ O
/COCOA/ O
)/ O

DNA O
was O
bisulfite O
modified O
and O
DNA O
methylation O
was O
quantified O
using O
the O
Infinium B-Chemical
HumanMethylation450 I-Chemical
array O

These O
range O
from O
a O
single O
pathway/molecule O
defect O
such O
as O
abnormalities O
of O
the O
mitogen-activated B-Chemical
protein I-Chemical
kinase I-Chemical
pathway I-Chemical
, O
considered O
to O
be O
a O
hallmark O
of O
pilocytic B-Species
astrocytomas I-Species
, O
to O
alterations O
in O
the O
epigenome B-Chemical
as O
a O
critical O
component O
altered O

In O
this O
experimental O
method O
, O
cellular O
proteins O
are O
first O
anchored O
to O
a O
polyacrylamide B-Chemical
polymer O
instead O
of O
crosslinking O
them O
to O
protein O
and O
DNA B-Gene
, O
alleviating O
structural O
bias O

Epigenetics O
describes O
a O
mechanism O
for O
controlling O
gene O
expression O
and O
cellular O
processes O
without O
altering O
DNA B-Gene
sequences I-Gene

information O

Objective O
 O
To O
examine O
the O
effect O
of O
20 O
weeks O
of O
an O
internet-based O
parent-child O
interaction O
training O
( O
iPCIT O
) O
program O
on O
biomarkers O
associated O
with O
aging O
and O
chronic B-Disease
inflammation I-Disease
among O
preschoolers O
with O
developmental B-Disease
delay I-Disease
at O
12-month O
follow-up O

To O
elucidate O
the O
potential O
applications O
of O
these O
recently O
developed O
methods O
in O
transplantation B-Disease
research O

We O
report O
, O
for O
the O
first O
time O
in O
humans B-Species
, O
genome-wide O
DNA B-Gene
methylation I-Gene
( O
850,000 O
CpGs O
) O
and O
gene B-Gene
expression I-Gene
analysis O
after O
muscle B-Disease
hypertrophy I-Disease
( O
loading O
) O
, O
return O
of O
muscle B-Disease
mass I-Disease
to O
baseline O
( O
unloading O
) O
, O
followed O

We O
review O
concepts O
of O
population O
genetics O
and O
natural O
selection O
, O
current O
genome-wide O
genetic O
and O
epigenetic O
studies O
of O
several O
autoimmune B-Disease
diseases I-Disease
, O
and O
environmental O
exposures O
associated O
with O
disease O
risk O
in O
different O
populations O

Recent O
data O
have O
revealed O
atypical O
modes O
of O
transmission O
in O
several O
inherited O
AID B-Disease
, O
such O
as O
somatic O
mosaicism O
and O
digenism O

Materials O
& O
methods O
 O
To O
utilize O
bioinformatics O
analysis O
and O
' O
wet O
lab O
' O
methods O
to O
identify O
and O
verify O
differentially O
expressed O
genes O
in O
multiple O
targeted O
organs O
in O
SLE B-Disease

With O
the O
introduction O
of O
new O
gene B-Gene
expression O
and O
sequencing O
technologies O
there O
have O
been O
advances O
in O
the O
knowledge O
of O
the O
genetic O
landscape O
of O
acute B-Disease
leukemias I-Disease

Using O
cell-type-specific O
data O
from O
two O
separate O
studies O
, O
we O
discover O
epigenetic O
mechanisms O
underlying O
childhood B-Disease
food I-Disease
allergy I-Disease
and O
survival-associated O
, O
methylation-driven O
ncRNAs O
in O
non-small B-Disease
cell I-Disease
lung I-Disease
cancer I-Disease

Co O
- O
existing O
parental O
species B-Species
displayed O
highly O
distinct O
genetic O
( O
SNPs B-Gene
) O
and O
methylation O
patterns O
( O
37,000 O
differentially O
methylated O
cytosines B-Chemical
) O

O O
wing O
to O
recent O
advances O
in O
epigenomics O
, O
we O
also O
gained O
a O
better O
appreciation O
for O
the O
fact O
that O
different O
environmental O
cues O
can O
epigenetically O
reprogram O
adipocyte O
fate O
and O
function O
, O
mainly O
by O
altering O
methylation O
and O
histone O
modification O
patterns O

Epigenetic O
mechanisms O
including O
DNA B-Chemical
methylation I-Chemical
and O
histone B-Chemical
modifications I-Chemical
, O
at O
key O
stress O
response O
and O
neurotrophin B-Gene
genes I-Gene
, O
are O
increasingly O
implicated O
in O
mediating O
this O
risk O

Methods O
 O
Differentially O
expressed O
genes B-Gene
( O
DEGs B-Gene
) O
and O
their O
associated O
differentially O
expressed O
miRNAs B-Gene
and O
differentially O
methylated O
positions O
( O
DMPs B-Gene
) O
were O
identified O

Conclusions O
 O
The O
pipeline O
provides O
a O
group O
of O
integrated O
analytical O
methods O
wrapped O
into O
an O
easy-to-use O
interface O

Furthermore O
, O
the O
kinds O
of O
modifications O
for O
which O
detection O
methods O
are O
available O
are O
very O
limited O

Conclusion O
 O
Research O
on O
possible O
epigenetic O
mechanisms O
involved O
in O
postsurgical B-Disease
pain I-Disease
and O
chronic B-Disease
postsurgical I-Disease
pain I-Disease
in O
humans B-Species
is O
scarce O

Using O
the O
compressed O
data O
in O
the O
latent O
space O
, O
we O
found O
that O
the O
majority O
of O
histone B-Chemical
marks I-Chemical
were O
well O
clustered O
but O
not O
for O
tissues O
or O
cell O
types O

An O
online O
tool O
EpiCompare O
was O
developed O
to O
assist O
investigators O
in O
exploring O
the O
specificity O
of O
epigenomic O
features O
across O
selected O
tissue O
and O
cell O
types O

29 O
Mechanistically O
, O
how O
epigenetic O
states O
are O
inherited O
through O
cellular O
divisions O
remains O
an O
important O
open O
question O
in O
the O
field O
and O
beyond O

Differentially O
methylated O
loci O
were O
identified O
by O
fitting O
linear O
models O
with O
adjustment O
of O
age O
, O
sex O
, O
estimated O
cell O
type O
proportions O
, O
and O
repeat O
measurement O

While O
current O
techniques O
in O
the O
field O
are O
characterizing O
the O
average O
epigenomic O
features O
across O
large O
cell O
ensembles O
, O
the O
increasing O
interest O
in O
the O
epigenetics O
within O
complex O
and O
heterogeneous O
tissues O
is O
driving O
the O
development O
of O
single-cell O
epigenomics O

We O
demonstrated O
that O
nuclear O
localization O
signals O
( O
NLS O
) O
at O
both O
termini O
of O
fusion O
constructs O
is O
crucial O
for O
both O
proper O
nuclear O
import O
of O
such O
large O
constructs O
as O
well O
as O
for O
maximization O
of O
targeted O
DNA B-Chemical
methylation I-Chemical
activity O

Altogether O
, O
these O
epigenomes O
represent O
a O
powerful O
resource O
to O
develop O
a O
deeper O
understanding O
of O
the O
underlying O
molecular O
biology O
of O
thyroid B-Disease
function I-Disease
and O
provide O
contextual O
information O
of O
thyroid B-Disease
and O
human B-Species
epigenomic O
data O
for O
comparison O
and O
integration O
into O
future O
studies O

The O
present O
review O
is O
focused O
on O
the O
most O
recent O
knowledge O
of O
epigenetically O
active O
nutrients/diets O
including O
transgenerational O
inheritance O
and O
prenatal O
predispositions O
related O
to O
increased O
risk O
for O
cancer B-Disease
, O
metabolic B-Disease
syndrome I-Disease
, O
and O
neurodegenerative B-Disease
diseases I-Disease

The O
cells O
of O
the O
zygote O
and O
cleavage-stage O
embryo O
hold O
the O
potential O
to O
form O
all O
cell O
lineages O
of O
the O
embryonic O
and O
extra-embryonic O
tissues O
, O
with O
gradual O
fate O
restriction O
occurring O
from O
the O
time O
of O
compaction O
and O
blastocyst O
formation O

Recent O
advances O
in O
the O
study O
of O
DNA B-Gene
and O
its O
alterations O
have O
considerably O
increased O
our O
understanding O
of O
the O
function O
of O
epigenetics B-Gene
in O
regulating O
energy O
metabolism O
and O
expenditure O
in O
obesity B-Disease
and O
metabolic B-Disease
diseases I-Disease

In O
this O
review O
, O
we O
examine O
the O
nature O
of O
epigenetic O
modifications O
in O
several O
well-studied O
autoimmune O
, O
allergic O
, O
and/or O
inflammatory O
disorders O
of O
the O
skin O
including O
systemic B-Disease
lupus I-Disease
erythematosus I-Disease
, O
vitiligo B-Disease
, O
systemic B-Disease
sclerosis I-Disease
, O
alopecia B-Disease
areata I-Disease

Additional O
studies O
inclusive O
of O
diverse O
populations O
and O
other O
psychosocial O
stressors O
are O
needed O

Yet O
, O
these O
data O
are O
scattered O
throughout O
the O
literature O
with O
no O
central O
organization O

Our O
new O
model O
produced O
highly O
accurate O
chronological O
age O
predictions O
, O
comparable O
to O
a O
state-of-the-art O
epiclock B-Gene

Our O
ability O
to O
connect O
biological O
embedding O
to O
the O
epigenetic O
landscape O
in O
its O
complexity O
is O
challenging O
and O
complicated O
by O
the O
influence O
of O
multiple O
factors O

However O
, O
when O
the O
parents O
experienced O
lead B-Chemical
stress O
environment O
, O
their O
biomass O
allocation O
strategies O
disappeared O
, O
and O
they O
prefer O
to O
grow O
in O
favourable O
patches O
to O
avoid O
lead-contaminated B-Chemical
patches O

Deciphering O
the O
precise O
contribution O
of O
epigenetic O
factors O
to O
autoimmunity O
, O
and O
in O
particular O
to O
lupus B-Disease
, O
has O
become O
an O
active O
research O
area O

The O
serotonin B-Chemical
transporter I-Chemical
gene O
(SLC6A4) B-Gene
is O
a O
stress-related O
gene O
which O
has O
well-documented O
implications O
for O
behavioral O
and O
socio-emotional O
development O
and O
which O
has O
been O
shown O
to O
be O
susceptible O
to O
transcriptional O
regulation O
via O
epigenetic O
mechanisms O

In O
this O
paper O
we O
employ O
the O
following O
cognitive O
tests O
 O
1 O

Moreover O
, O
interactions O
between O
the O
host O
epigenome O
and O
the O
microbiome B-Species
are O
increasingly O
recognized O
, O
and O
interventions O
of O
the O
microbiome B-Species
could O
contribute O
to O
modulation O
of O
the O
epigenome O
with O
a O
potential O
effect O
on O
the O
overall O
goal O
of O
prevention O
of O
allergic B-Disease
diseases I-Disease

10 O

239Background O
Lung B-Disease
cancer I-Disease
is O
one O
of O
the O
most O
malignant O
tumors O
, O
causing O
over O
1,000,000 O
deaths O
each O
year O
worldwide O

The O
role O
of O
epigenetic O
regulation O
is O
further O
supported O
by O
studies O
examining O
fear B-Disease
conditioning I-Disease
in O
rodent B-Species
models O

For O
microarrays O
analysis O
, O
fold O
of O
change O
was O
calculated O
comparing O
hypercholesterolemic B-Disease
vs O
control O
group O

Interactions O
between O
genetics B-Gene
and O
epigenetics B-Gene
are O
multifaceted O
and O
epigenetic B-Gene
variation O
stands O
at O
the O
crossroad O
between O
genetic B-Gene
and O
environmental O
variance O
, O
which O
make O
these O
mechanisms O
prominent O
in O
the O
processes O
of O
adaptive O
evolution O

We O
applied O
the O
framework O
to O
two O
representative O
neurodegenerative O
diseases O
, O
Alzheimer's B-Disease
disease I-Disease
( O
AD B-Disease
) O
and O
Down B-Disease
syndrome I-Disease
( O
DS B-Disease
) O
, O
using O
DNA B-Chemical
methylation I-Chemical
datasets O
from O
public O
sources O
( O
Gene B-Gene
Expression I-Gene
Omnibus I-Gene
, O
GEO O
accession O
ID O

, O
HOX B-Gene
genes O
) O
as O
being O
epigenetically O
regulated O

With O
error-corrected O
methylation O
patterns O
, O
PRISM O
focuses O
on O
a O
short O
individual O
genomic O
region O
harboring O
dichotomous O
patterns O
that O
can O
be O
split O
into O
fully O
methylated O
and O
unmethylated O
patterns O

These O
emergent O
findings O
call O
into O
question O
the O
effectiveness O
of O
early-life O
obesity B-Disease
interventions O
that O
focus O
exclusively O
on O
the O
mother O

Some O
of O
the O
effects O
of O
both O
the O
and O
on O
seem O
to O
be O
mediated O
by O

Our O
findings O
suggest O
that O
the O
epigenetic O
age O
of O
the O
newborn O
should O
be O
seen O
as O
a O
characteristic O
of O
a O
specific O
tissue O
, O
and O
less O
as O
a O
general O
characteristic O
of O
the O
child O
itself O


Even O
in O
the O
very O
different O
politico-economic O
and O
epistemic O
context O
of O
contemporary O
postgenomic O
science O
, O
these O
trends O
echo O
deeply O
held O
beliefs O
in O
Western O
thinking O
which O
claimed O
that O
different O
environments O
shape O
different O
bodies O
and O
then O
used O
this O
logic O
to O
argue O
for O
essential O
differences O
between O
Europeans B-Species
and O

However O
, O
the O
range O
of O
DNA B-Gene
methylation I-Gene
profiling O
techniques O
can O
make O
selecting O
the O
appropriate O
protocol O
a O
challenge O

Evidence O
indicates O
epigenetic O
marks O
function O
in O
combinations O
, O
whereby O
a O
given O
modification O
has O
distinct O
effects O
on O
local O
genome O
control O
, O
depending O
on O
which O
additional O
modifications O
are O
locally O
present O

1459 O
 O
The O
American O
Society O
for O
Parenteral O
and O
Enteral O
Nutrition O
( O
A O

Troubleshooting O
steps O
for O
common O
problems O
are O
discussed O

Archer O
about O
his O
experiences O
in O
academia O
, O
struggles O
he O
has O
faced O
, O
and O
thoughts O
on O
addressing O
racial O
bias O

Assessing O
the O
methylation O
status O
of O
each O
of O
these O
sites O
will O
be O
required O
to O
understand O
fully O
the O
role O
of O
DNA B-Gene
methylation O
in O
health O
and O
disease B-Disease

1 O
), O
among O
which O
152 O
exhibited O
hypomethylation O
and O
131 O
demonstrated O
hypermethylation O

412 O
continues O
to O
emerge O
as O
an O
important O
target O
class O
for O
discovery O
and O
research O

Although O
the O
published O
literature O
on O
this O
subject O
seems O
promising O
, O
the O
overall O
strength O
of O
evidence O
is O
limited O
by O
the O
small O
number O
of O
studies O
evaluating O
individual O
skeletal B-Disease
disorders I-Disease
, O
and O
also O
by O
deficiencies O
in O
key O
aspects O
of O
study O
design O

Eligible O
participants O
included O
children O
recruited O
within O
3 O
months O
of O
their O
third O
birthday O
who O
had O
a O
Child B-Disease
Behavior I-Disease
Checklist I-Disease
Externalizing I-Disease
Problems I-Disease
T I-Disease
score I-Disease
greater O
than O
60 O
and O
provided O
saliva O
in O
at O
least O
1 O
study O
wave O

Result O
& O
conclusion O
 O
A O
multimolecule O
drug O
consisting O
of O
sulmazole B-Chemical
, O
clofibrate B-Chemical
, O
colchicine B-Chemical
, O
furazolidone B-Chemical
, O
nadolol B-Chemical
, O
eticlopride B-Chemical
and O
felbinac B-Chemical
is O
proposed O
to O
target O
on O
novel O
biomarkers O
for O
promoting O
hepatogenesis B-Disease
and O

Results O

Our O
analyses O
yielded O
1880 O
likely O
causal O
genes B-Gene
for O
blood B-Disease
pressure I-Disease
, O
tens O
of O
which O
are O
targets O
of O
the O
available O
licensed O
drugs B-Chemical

The O
interest O
in O
epigenetics O
is O
also O
true O
for O
studies O
of O
drug B-Chemical
metabolism O
and O
transport O

Following O
global O
demethylation O
and O
sex O
determination O
, O
CpG B-Chemical
sites I-Chemical
switched O
to O
de O
novo O
methylation O
in O
males O
, O
but O
the O
X-linked O
genes B-Gene
appeared O
resistant O
to O
the O
wave O
of O
de O
novo O
methylation O

1018 O
The O
future O
of O
medicine O
is O
discussed O
in O
the O
context O
of O
epigenetic O
influences O
during O
the O
entire O
life O
course O
and O
the O
lived O
experiences O
of O
each O
person O
, O
avoiding O
as O
much O
as O
possible O
the O
" O
medicalization O
" O
of O
the O
individual O
and O
taking O
a O
more O
humanistic O
view O

Consequently O
, O
this O
cohort O
can O
be O
a O
vital O
tool O
for O
researchers O
seeking O
to O
validate O
observational O
results O
from O
human B-Species
population O
studies O
and O
perform O
detailed O
mechanistic O
studies O
in O
a O
controlled O
cell O
culture O
environment O

DNA O
methyltransferase B-Gene
and O
histone B-Gene
deacetylase I-Gene
, O
that O
regulate O
epigenetic O
patterns O
are O
active O
in O
clinical O
settings O


Emerging O
work O
in O
the O
field O
of O
epigenetics O
also O
suggests O
that O
translational O
studies O
that O
integrate O
numerous O
unbiased O
genome-wide O
approaches O
will O
help O
to O
further O
unravel O
the O
genetics O
of O
stress-related B-Disease
psychiatric I-Disease
disorders I-Disease

On O
the O
other O
hand O
, O
the O
characterization O
of O
early O
epigenetic O
predictors O
of O
asthma B-Disease
points O
to O
a O
potential O
role O
of O
epigenetic O
mechanisms O
in O
regulating O
the O
inception O
of O
, O
and O
the O
susceptibility O
to O
, O
this O
disease O

Through O
a O
structured O
review O
of O
recent O
studies O
exploring O
epigenetic O
and O
social O
mechanisms O
of O
obesity B-Disease
risk I-Disease
transmission O
, O
we O
argue O
that O
the O
role O
of O
the O
father O
in O
influencing O
the O
obesity B-Disease
risk I-Disease
of O
children O
during O
early O
life O
is O
underappreciated O

The O
endocrine O
pancreas B-Species
is O
no O
exception O

e O

In O
this O
review O
, O
we O
suggest O
that O
the O
difficulties O
may O
be O
exaggerated O
and O
we O
explore O
how O
cellular O
heterogeneity O
may O
be O
embraced O
with O
appropriate O
study O
designs O
and O
analytical O
tools O

7 O
to O
12 O

Recent O
discoveries O
have O
highlighted O
the O
significance O
of O
epigenetics O
in O
bridging O
the O
gap O
between O
multiple O
risk O
factors O
that O
contribute O
to O
ADs B-Disease
and O
expanding O
our O
understanding O
of O
the O
pathomechanisms O
underlying O
ADs B-Disease

Epigenetics O
may O
well O
constitute O
this O
missing O
link O
to O
include O
DNA B-Gene
methylation I-Gene
, O
histone B-Gene
changes I-Gene
, O
and O
microRNA B-Gene
which O
contribute O
to O
the O
epigenome O
characterizing O
specific O
diseases B-Disease

1207 O
With O
technological O
advances O
in O
high-throughput O
sequencing O
, O
high O
resolution O
mass-spectrometry O
, O
and O
multi-omics O
data O
integrative O
tools O
and O
data O
repositories O
, O
the O
omics O
research O
in O
life O
sciences O
are O
evolving O
from O
single-omics O
strategy O
to O
multi-omics O
strategy O

The O
first O
critical O
step O
towards O
solving O
these O
issues O
is O
understanding O
the O
epigenomic O
events O
that O
play O
a O
significant O
role O
in O
the O
regulation O
of O
specific O
biomolecules O
in O
the O
context O
of O
the O
immune O
population O
present O
in O
the O
tumor B-Disease
immune I-Disease
microenvironment I-Disease
(TIME) O
during O
various O
treatments O
and O
responses O

However O
, O
the O
pathogenesis O
of O
autoimmune B-Disease
diseases I-Disease
has O
not O
been O
clearly O
elucidated O

g O

Our O
model O
allows O
for O
variations O
to O
be O
inherited O
, O
randomly O
produced O
, O
or O
environmentally O
induced O
, O
and O
, O
irrespectively O
, O
to O
be O
either O
transmitted O
or O
not O
during O
reproduction O

5 O
Ã O
10-5 O
), O
p O
= O

Taken O
together O
with O
other O
recent O
cases O
with O
mutations O
of O
HIST1H1E B-Gene
in O
intellectual B-Disease
disability I-Disease
, O
the O
evidence O
supporting O
the O
link O
to O
causality O
in O
disease O
is O
strong O

Thus O
far O
, O
these O
mechanisms O
include O
permanent O
structural O
changes O
to O
the O
organ O
caused O
by O
suboptimal O
levels O
of O
an O
important O
factor O
during O
a O
critical O
developmental O
period O
, O
changes O
in O
gene B-Gene
expression I-Gene
caused O
by O
epigenetic O
modifications O
( O
including O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical

Thus O
, O
various O
epitranscriptomic O
signatures O
have O
been O
identified O
to O
play O
specific O
roles O
during O
stem O
cell O
differentiation O
towards O
the O
neuronal O
and O
glial O
lineages O
, O
axonal O
guidance O
, O
synaptic O
plasticity O
, O
thus O
leading O
to O
the O
development O
of O
the O
mature O
brain O
tissue O

A O
systematic O
search O
was O
conducted O
in O
MEDLINE O
, O
Scopus O
, O
Web O
of O
Science O
, O
Cochrane O
Central O
database O
, O
EMBASE O
, O
and O
CINHAL O

development O
of O
their O
therapeutics O

Results O
 O

Five O
decades O
ago O
, O
it O
was O
considered O
soon O
to O
be O
eradicated O
, O
but O
the O
adaptation O
of O
pathogens O
to O
environmental O
pressure O
, O
such O
as O
antimicrobials B-Chemical
, O
encouraged O
the O
emergence O
and O
reemergence O
of O
infectious B-Disease
disease I-Disease

Therefore O
, O
advanced O
epigenetic O
therapeutics O
are O
required O
to O
develop O
target-specific O
epigenetic O
modifications O
to O
reverse O
gene B-Gene
expression I-Gene
pattern I-Gene

However O
, O
supporting O
empirical O
data O
are O
still O
largely O
missing O

methylation I-Gene

1039 O
An O
understanding O
towards O
genetics B-Gene
and O
epigenetics B-Gene
is O
essential O
to O
cope O
up O
with O
the O
paradigm O
shift O
which O
is O
underway O

csv O
files O
that O
are O
included O
within O
this O
software O
package O
, O
can O
be O
found O
on O
Zenodo O
at O
https//doi O

The O
genome-wide O
analyses O
of O
synonymous O
and O
nonsynonymous O
substitutions O
at O
protein-coding O
regions O
show O
prevalence O
of O
very O
weak O
selection O

Examples O
include O
contrasting O
analyses O
across O
different O
tissues O
or O
diseases B-Disease

132 O
Epigenetics O
, O
a O
field O
that O
links O
genetics O
and O
environmental O
influences O
on O
the O
expression O
of O
phenotypic O
traits O
, O
offers O
to O
increase O
our O
understanding O
of O
the O
development O
and O
trajectory O
of O
disease B-Disease
and O
psychological O
disorders O
beyond O

Archer O
and O
not O
the O
or O
the O
government O

This O
parameter O
is O
directly O
related O
to O
the O
reset O
coefficient O
( O
Î½ B-Gene
) O
and O
the O
epigenetic B-Chemical
coefficient O
of O
transmissibility O
( O
1-Î½ B-Gene
) O

While O
genome-wide O
DNA B-Chemical
methylation I-Chemical
profiles O
enable O
robust O
age-predictors O
by O
integration O
of O
many O
age-associated O
CG B-Gene
dinucleotides I-Gene
(CpGs) O
, O
there O
are O
various O
alternative O
approaches O
for O
targeted O
measurements O
at O
specific O
CpGs B-Gene
that O
better O
support O
standardized O
and O
cost-effective O
high-throughput O
analysis O

5 O
is O
the O
best O
among O
the O
examined O
versions O

Global O
epigenome O
research O
projects O
have O
emphasized O
the O
importance O
of O
epigenetic O
research O
for O
understanding O
human B-Species
health O
and O
disease O
, O
and O
current O
international O
consortia O
show O
an O
improved O
interest O
in O
the O
importance O
of O
oral O
health O
with O
systemic O
health O

Epigenetic O
modifications O
such O
as O
DNA B-Chemical
methylation I-Chemical
, O
histone B-Chemical
posttranslational I-Chemical
modifications O
and O
associated O
changes O
in O
chromatin B-Chemical
architecture I-Chemical
have O
been O
implicated O
in O
breast B-Disease
cancer I-Disease
pathogenesis O

These O
compounds O
stimulate O
hyphal O
branching O
in O
arbuscular B-Species
mycorrhizal I-Species
fungi I-Species
( O
AMF B-Species
) O
and O
seed O
germination O
of O
root O
parasitic O
plants O

Understanding O
the O
global O
change O
in O
DNA B-Gene
methylation I-Gene
during O
atherosclerosis B-Disease
remains O
a O
challenge O

Genes O
associated O
with O
many O
pathophysiological O
features O
of O
these O
vascular O
complications O
( O
e O

Recent O
discoveries O
of O
5-methylcytosine B-Chemical
( O
5mC B-Chemical
) O
oxidation O
derivatives O
including O
5-hydroxymethylcytosine B-Chemical
( O
5hmC B-Chemical
) O
, O
5-formylcytsine B-Chemical
( O
5fC B-Chemical
) O
and O
5-carboxycytosine B-Chemical
( O
5caC B-Chemical
) O
in O
mammalian B-Species
genome O
further O

By O
adopting O
this O
perspective O
, O
this O
paper O
draws O
attention O
to O
the O
role O
of O
exaptation O
in O
the O
evolution O
of O
epigenetics O
in O
the O
RNA B-Chemical
world O
and O
addresses O
the O
role O
of O
epigenetics O
in O
the O
later O
evolution O
of O
developmental O
processes O
such O
as O
cellular O
differentiation O
, O
learning O
, O

There O
might O
be O
transgenerational O
effects O
associated O
with O
epigenetic O
modifications O
of O
gametes O
and O
studies O
suggest O
the O
importance O
of O
alterations O
in O
epigenetic O
modification O
at O
early O
and O
late O
stages O
of O
gametogenesis O

996 O
Biological O
embedding O
occurs O
when O
life O
experience O
alters O
biological O
processes O
to O
affect O
later O
life O
health O
and O
well-being O

However O
, O
there O
is O
every O
possibility O
that O
blood O
testing O
for O
the O
presence O
of O
methylated B-Chemical
DNA I-Chemical
will O
become O
an O
integral O
part O
of O
the O
clinical O
follow-up O
of O
such O
patients O

This O
process O
, O
commonly O
referred O
to O
as O
biological O
embedding O
, O
may O
cause O
abnormal O
cognitive O
and O
behavioral O
functioning O
, O
including O
impaired O
learning O
, O
memory O
, O
and O
depressive- O
and O
anxiety-like O
behaviors O
, O
as O
well O
as O
neuropsychiatric B-Disease
outcomes I-Disease
in O
later O
life O

google O

The O
ways O
in O
which O
epigenetic O
modifications O
fix O
the O
effects O
of O
early O
environmental O
events O
, O
leading O
to O
sustained O
responses O
to O
transient O
stimuli O
, O
modified O
gene B-Gene
expression I-Gene
patterns I-Gene
and O
altered O
phenotypes O
in O
later O
life O
, O
is O
a O
topic O
of O
considerable O
interest O

In O
this O
review O
, O
we O
describe O
how O
underlying O
genetics O
may O
confer O
susceptibility O
to O
elevated O
Mn B-Chemical
concentrations O
and O
how O
the O
epigenetic O
effects O
of O
Mn B-Chemical
may O
explain O
the O
association O
between O
Mn B-Chemical
exposure O
early O
in O
life O
and O
its O
toxic O
effects O
later O
in O
life O

Here O
, O
we O
summarize O
the O
experimental O
techniques O
that O
were O
exploited O
to O
determine O
5-mrC B-Chemical
in O
mRNA B-Gene
and O
the O
computational O
procedures O
implemented O
for O
RNA B-Gene
bisulfite I-Gene
sequencing I-Gene
data O
analysis O

The O
implication O
is O
, O
therefore O
, O
that O
sublethal O
adverse O
conditions O
which O
alter O
the O
developmental O
trajectory O
of O
these O
cells O
may O
have O
long-term O
implications O
for O
the O
health O
and O
development O
of O
the O
resulting O
offspring O

Dr O
Jirtle O
was O
also O
given O
the O
in O
2019 O
at O
the O
50th O
annual O
meeting O
of O
the O

686 O
years O

The O
software O
is O
distributed O
under O
the O
MIT O
License O
and O
is O
accompanied O
by O
example O
files O
and O
data O

Recent O
significant O
technological O
advancement O
in O
the O
study O
of O
could O
break O
through O
the O
barrier O
of O
the O
mysterious O
black O
box O
of O
toxicity O

Meta-analytic O
support O
and O
replicated O
findings O
are O
evident O
for O
several O
genetic O
risk O
factors O
; O
however O
, O
extant O
research O
suggests O
the O
effects O
are O
pleiotropic O


Low O
-volume O
automated O
nanoliter O
dispensers O
ensure O
accuracy O
of O
pipetting O
within O
volume O
ranges O
that O
are O
difficult O
to O
achieve O
manually O

Therefore O
, O
the O
epigenetic O
diversity O
has O
been O
proposed O
as O
a O
new O
resource O
for O
future O
crop O
breeding O
, O
which O
will O
be O
hereinafter O
referred O
to O
as O
epibreeding O

As O
a O
resource O
to O
the O
community O
, O
we O
have O
developed O
a O
tool O
, O
POWEREDBiSeq O
, O
which O
utilizes O
our O
simulation O
framework O
to O
predict O
study-specific O
power O
for O
the O
identification O
of O
DNAm B-Gene
differences O
between O
groups O
, O
taking O
into O
account O
user-defined O
read O
depth O
filtering O
parameters O
and O
the O
minimum O
sample O
size O

- O
and O
they O
will O
be O
the O
subject O
of O
this O
comprehensive O
review O

577 O
Over O
the O
past O
decade O
, O
awareness O
of O
the O
importance O
of O
epigenetic O
alterations O
in O
the O
pathogenesis O
of O
rheumatic B-Disease
diseases I-Disease
has O
grown O
in O
parallel O
with O
a O
general O
recognition O
of O
the O
fundamental O
role O
of O
epigenetics O
in O
the O
regulation O
of O
gene B-Gene
expression I-Gene

Jirtle O
was O
presented O
the O
Linus B-Chemical
Pauling I-Chemical
Award I-Chemical
from O
the O
Institute O
of O
Functional O
Medicine O
in O
2014 O

500 O
bjectivesO O
To O
identify O
epigenetic O
and O
transcriptional O
factors O
controlling O
( O
CGO O
) O
, O
that O
have O
been O
shown O
to O
play O
a O
role O
in O
the O
pathogenesis O
of O

In O
this O
paper O
, O
we O
reviewed O
recent O
research O
on O
lactate-induced B-Chemical
histone O
modifications O
and O
provided O
a O
new O
vision O
about O
the O
metabolic O
effect O
of O
glycolysis B-Chemical

Among O
epigenetic O
marks O
, O
DNA B-Chemical
methylation I-Chemical
is O
one O
of O
the O
best O
studied O

Dysregulated O
epigenetic O
candidates O
identified O
include O
the O
Aurora B-Gene
group O
, O
KMT2D B-Gene
, O
PTEN B-Gene
, O
RASSF1A B-Gene
, O
multiple O
non-coding O
RNAs O
( O
ncRNA B-Gene
) O
, O
and O
the O
SWI/SNF B-Gene
chromatin-remodeling I-Gene
complex I-Gene

Dr O
Pfeifer O
received O
a O
PhD O
degree O
from O
the O
University O
of O
Frankfurt O
, O
Germany O

The O
dynamic O
nature O
of O
the O
epigenome O
makes O
it O
an O
ideal O
tool O
to O
investigate O
the O
relationship O
between O
inherited O
genetic O
mutations O
associated O
with O
schizophrenia B-Disease
and O
altered O
gene B-Gene
regulation O
throughout O
the O
course O
of O
brain O
development O

Thus O
, O
preserving O
a O
sustainable O
environment O
means O
placing O
the O
prospect O
of O
a O
longer O
human O
life O
in O
a O
logic O
of O
better O
quality O
of O
life O
, O
of O
â O
sustainable O
health O
â O
, O
but O
it O
is O
also O
a O
matter O
of O
public O
policy O

Together O
, O
these O
techniques O
are O
rapidly O
becoming O
a O
powerful O
tool O
in O
studies O
of O
cellular O
plasticity O
and O
diversity O
, O
as O
seen O
in O
stem B-Species
cells I-Species
and O
cancer B-Disease

For O
example O
, O
pathways O
related O
to O
activation O
and O
proliferation O
of O
helper O
and O
cytotoxic O
T O
cells O
appear O
to O
be O
more O
highly O
enriched O
in O
kidney B-Disease
, O
skin B-Disease
, O
head O
and O
neck O
, O
and O
esophageal B-Disease
cancers O
compared O
to O
those O
of O
lung B-Disease
, O
colorectal B-Disease
, O
and O

In O
the O
near O
future O
, O
this O
information O
will O
be O
used O
to O
generate O
novel O
biomarkers O
of O
relevance O
to O
diagnosis O
, O
prognosis O
, O
and O
chemotherapeutic O
response O

1233 O
Epigenetics O
is O
the O
field O
of O
research O
that O
examines O
alterations O
in O
gene B-Gene
expression I-Gene
caused O
by O
mechanisms O
other O
than O
changes O
in O
DNA B-Gene
sequence I-Gene

The O
PubMed O
and O
EMBASE O
databases O
were O
searched O
up O
to O
30th O
April O
2020 O
; O
references O
of O
included O
articles O
and O
pertinent O
review O
articles O
were O
also O
screened O
to O
identify O
eligible O
studies O
